id,generic_name,company_name,presentation,update_type,update_date,availability,related_info,resolved_note,reason_for_shortage,therapeutic_category,status,change_date,date_discontinued,ndc,availability_status
1,Abciximab (ReoPro) Injection,"Janssen Biotech, Inc.",2mg/mL (NDC 57894-200-01),Revised,8/15/19,,Janssen has made a business decision to discontinue manufacture of the drug product.,,,Cardiovascular,To be Discontinued,8/15/19,8/15/19,57894-200-01,discontinued
2,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 25 mg (NDC 50419-863-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-863-51,discontinued
3,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 50 mg (NDC 50419-861-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-861-51,discontinued
4,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 100 mg (NDC 50419-862-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-862-51,discontinued
5,Acarbose (Precose) Tablets,Bayer,Unit Dose 50 mg (NDC 50419-861-48),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-861-48,discontinued
6,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 200mg Capsules 100s (NDC 40076-991-55),New,12/21/18,,,,,Anti-Infective,To be Discontinued,12/21/18,12/21/18,40076-991-55,discontinued
7,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 400mg Tablets 100s (NDC 40076-949-55),New,12/21/18,,,,,Anti-Infective,To be Discontinued,12/21/18,12/21/18,40076-949-55,discontinued
8,Acyclovir (Zovirax) Tablets and Capsules,Mylan Pharmaceuticals Inc.,Acyclovir (Zovirax) 800mg Tablets 100s (NDC 40076-945-55),New,12/21/18,,,,,Anti-Infective,To be Discontinued,12/21/18,12/21/18,40076-945-55,discontinued
9,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 100 count (NDC 0093-8940-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8940-01,discontinued
10,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 500 count (NDC 0093-8940-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8940-05,discontinued
11,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 100 count (NDC 0093-8943-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8943-01,discontinued
12,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 500 count (NDC 0093-8943-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8943-05,discontinued
13,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 100 count (NDC 0093-8947-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8947-01,discontinued
14,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 500 count, (NDC 0093-8947-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8947-05,discontinued
15,Albuterol Sulfate and Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,0.3 mg mg/3 mL and 0.5 mg/3 mL (NDC 0591-3817-39),New,7/3/19,,This product discontinuation is a business related decision.,,,Pulmonary/Allergy,To be Discontinued,7/3/19,7/3/19,0591-3817-39,discontinued
16,Alogliptin Tablets,Perrigo Company PLC,"12.5mg, 30 Tablets (NDC 45802-0103-65)",Revised,12/10/19,On backorder – expected release the week of late December/early January,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,45802-0103-65,not available
17,Alogliptin Tablets,Perrigo Company PLC,"25mg, 30 Tablets (NDC 45802-0150-65)",Revised,12/10/19,On backorder – expected release the week of 12/16/2019,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,45802-0150-65,not available
18,Alogliptin Tablets,Perrigo Company PLC,"6.25mg, 30 Tablets (NDC 45802-0087-65)",Revised,12/10/19,On backorder – expected release the week of 01/27/2020,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,45802-0087-65,not available
19,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"6.25 mg, 30 Tablets (NDC 64764-625-30)",New,8/15/19,Product available.,,,,Endocrinology/Metabolism,Current,,,64764-625-30,available
20,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"12.5 mg, 30 Tablets (NDC 64764-125-30)",New,8/15/19,Product available.,,,,Endocrinology/Metabolism,Current,,,64764-125-30,available
21,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"25 mg, 30 Tablets (NDC 64764-250-30)",New,8/15/19,Product available.,,,,Endocrinology/Metabolism,Current,,,64764-250-30,available
22,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) Pharmacy Bulk Package in 1,000 mL plastic container, catalog S4500, (NDC 0264-4500-00)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-4500-00,
23,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) in 1,000mL glass container, catalog S3200-SS, (NDC 0264-3200-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,9/24/19,0264-3200-55,
24,Amino Acids,B. Braun Medical Inc.,"10% FreAmine III (Amino Acid Injection) in 1,000mL glass container, catalog S9010-SS, (NDC 0264-9010-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9010-55,
25,Amino Acids,B. Braun Medical Inc.,"TrophAmine (10% Amino Acid Injection) in 500mL glass container, catalog S9341-SS, (NDC 0264-9341-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9341-55,
26,Amino Acids,B. Braun Medical Inc.,"TrophAmine (6% Amino Acid Injection) in 500mL glass container, catalog S9361-SS, (NDC 0264-9361-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9361-55,
27,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-4178-03,
28,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (NDC 0409-4179-05)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-4179-05,
29,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-7172-17,
30,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (NDC 0409-7171-17),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-7171-17,
31,Amino Acids,Baxter Healthcare,"PREMASOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B0009 10% 1000 mL (NDC 0338-1130-04), 2B0010 10% 2000 mL (NDC 0338-1130-06),
2B0012 10% 500 mL (NDC 0338-1130-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-1130-04,
32,Amino Acids,Baxter Healthcare,"10% TRAVASOL (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 1B6624 10% 1000 mL (NDC 0338-0644-04),
1B6623 10% 500 mL (NDC 0338-0644-03),
1B6626P 10% 2000 mL (NDC 0338-0644-06)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0644-04,
33,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0502-06,
34,Amino Acids,Baxter Healthcare,"20% PROSOL - sulfite-free (Amino Acid) Injection, 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Code 2B6186 (NDC 0338-0499-06)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0499-06,
35,Amino Acids,Baxter Healthcare,CLINIMIX E sulfite-free (Amino Acid with Electrolytes in Dextrose with Calcium) Injection in CLARITY Dual Chamber Container,Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,,
36,Amino Acids,Baxter Healthcare,CLINIMIX sulfite-free (Amino Acid in Dextrose) Injection in CLARITY Dual Chamber Container,Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,,
37,Amino Acids,Baxter Healthcare,SYNTHAMIN 17 without Electrolytes - 10% Amino Acids Intravenous Infusion 3000 mL. Product code FKB6642.  Pack factor 3  (NDC 0338-9575-03),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9575-03,
38,Amino Acids,Baxter Healthcare,"CLINIMIX N9G15E-Solution for Infusion, 1000 mL (2.75% Amino Acid in 7.5% Glucose with Electrolytes). Product code FKB6669C - Pack factor of 8 (NDC 0338-9570-08)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9570-08,
39,Amino Acids,Baxter Healthcare,"CLINIMIX N9G20E-Solution for Infusion, 1000 mL  (2.75% Amino Acid in 10% Glucose with Electrolytes) Product code FKB6670C - Pack factor of 8 
(NDC 0338-9566-08)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9566-08,
40,Amino Acids,Baxter Healthcare,"CLINIMIX N14G30E-Solution for Infusion, 2000 mL (4.25% Amino Acid in 15% Dextrose with Electrolytes) Product code FKB6654V - Pack factor of 4 (NDC 0338-9587-04)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9587-04,
41,"Aminophylline Injection, USP","Hospira, Inc.",250 mg/10mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5921-01),Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Pulmonary/Allergy,Current,,,0409-5921-01,limited availability
42,"Aminophylline Injection, USP","Hospira, Inc.",500 mg/20mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5922-01),Reverified,12/20/19,Available,,,Other,Pulmonary/Allergy,Current,,,0409-5922-01,available
43,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-60,discontinued
44,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-09,discontinued
45,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-05,discontinued
46,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-15,discontinued
47,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-30,discontinued
48,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-2610-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2610-01,discontinued
49,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 1000 count bottle (NDC 0378-2610-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2610-10,discontinued
50,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 100 count bottle (NDC 0378-2625-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2625-01,discontinued
51,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 1000 count bottle (NDC 0378-2625-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2625-10,discontinued
52,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-2650-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2650-01,discontinued
53,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 1000 count bottle (NDC 0378-2650-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2650-10,discontinued
54,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"75 mg, 100 count bottle (NDC 0378-2675-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2675-01,discontinued
55,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-2685-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2685-01,discontinued
56,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 100 count bottle (NDC 0378-2695-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2695-01,discontinued
57,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,2.5 mg/10 mg (NDC 0093-7370-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7370-01,discontinued
58,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/10 mg (NDC 0093-7371-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7371-01,discontinued
59,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/20 mg (NDC 0093-7372-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7372-01,discontinued
60,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/40 mg (NDC 0093-7670-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7670-01,discontinued
61,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/20 mg (NDC 0093-7373-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7373-01,discontinued
62,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/40 mg (NDC 0093-7671-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7671-01,discontinued
63,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/20 mg tablets (NDCs 0093-7027-56 and 0093-7027-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
64,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/40 mg tablets (NDCs 0093-7028-56 and 0093-7028-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
65,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7029-56 and 0093-7029-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
66,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7030-56 and 0093-7030-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
67,Amoxicillin (Moxatag) Extended Release Tablets,"Pragma Pharmaceuticals, LLC",775 mg tablets (NDCs 69442-030-10 and NDCs 69442-030-30),New,12/19/18,,"The last batches will expire September 30, 2019.",,,Anti-Infective,To be Discontinued,12/19/18,12/19/18,,discontinued
68,Amoxicillin Powder for Suspension,Teva Pharmaceuticals,"125 mg/5 mL powder for suspension (NDCs 0093-4150-73, 0093-4150-79 and 0093-4150-80)",New,6/3/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,6/3/19,6/3/19,,discontinued
69,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-950-01,limited availability
70,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-951-01,limited availability
71,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-952-01,limited availability
72,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-953-01,limited availability
73,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-954-01,limited availability
74,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-955-01,limited availability
75,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",New,9/12/19,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-956-01,limited availability
76,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0864-01,available
77,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0853-01,available
78,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0842-01,available
79,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0831-01,available
80,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0110-01,available
81,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0112-01,available
82,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0115-01,available
83,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0120-01,available
84,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0130-01,available
85,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0105-01,available
86,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,57844-0117-01,available
87,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4541-01,not available
88,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4542-01,not available
89,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4543-01,not available
90,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4544-01,not available
91,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4545-01,not available
92,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4546-01,not available
93,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/26/19,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4547-01,not available
94,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",New,9/12/19,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,13107-0068-01,limited availability
95,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",New,9/12/19,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,13107-0070-01,limited availability
96,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",New,9/12/19,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,13107-0072-01,limited availability
97,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",New,9/12/19,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,13107-0073-01,limited availability
98,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",New,9/12/19,Product under allocation,Stocks available to support customer demand,,Demand increase for the drug,Psychiatry,Current,,,13107-0074-01,limited availability
99,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0776-02,available
100,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0777-02,available
101,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0775-02,available
102,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0972-02,available
103,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0973-02,available
104,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0974-02,available
105,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,12/16/19,Product is Available,,,,Psychiatry,Current,,,0555-0971-02,available
106,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Reverified,12/16/19,Allocating inventory,Rolling backorders into December 2019; Expected recovery March 2020,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,0172-5240-60,limited availability
107,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Reverified,12/16/19,Allocating inventory,Rolling backorders into December 2019; Expected recovery March 2020,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,0172-5241-60,limited availability
108,Anagrelide Hydrochloride Capsules,Shire US Inc. now part of Takeda,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Reverified,12/2/19,Available,Takeda is actively working to mitigate a recent unexpected increase in demand for the product.,,Demand increase for the drug,Hematology,Current,,,54092-063-01,available
109,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,12/13/19,Estimated availability: January 2020,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,13668-453-01,not available
110,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,12/13/19,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,13668-462-01,available
111,Aprepitant (Emend) Capsules,Merck Sharp & Dohme Corp.,40-mg capsules unit-of-use package of 1 (NDC 0006-0464-10),New,12/3/18,,,,,Gastroenterology,To be Discontinued,12/3/18,12/3/18,0006-0464-10,discontinued
112,Aprepitant (Emend) Capsules,Merck Sharp & Dohme Corp.,40-mg capsules unit-of-use package of 5 (NDC 0006-0464-05),New,12/3/18,,,,,Gastroenterology,To be Discontinued,12/3/18,12/3/18,0006-0464-05,discontinued
113,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 5 vial carton (NDC 57902-249-05)",Revised,12/9/19,Available.  For further information and to sign up for supply alerts by Jazz Pharmaceuticals please visit Erwinazesupply.com https://erwinazesupply.com/,,,Other,Hematology;Oncology;Pediatric,Current,,,57902-249-05,available
114,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 1 vial (NDC 57902-249-01)",Revised,12/9/19,Available.  For further information and to sign up for supply alerts by Jazz Pharmaceuticals please visit Erwinazesupply.com https://erwinazesupply.com/,,,Other,Hematology;Oncology;Pediatric,Current,,,57902-249-01,available
115,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 10 mL, 10PK (NDC 67457-698-10)",New,9/24/19,,,,,Anesthesia,To be Discontinued,9/24/19,9/24/19,67457-698-10,discontinued
116,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 5 mL, 10 PK (NDC 67457-699-05)",New,9/24/19,,,,,Anesthesia,To be Discontinued,9/24/19,9/24/19,67457-699-05,discontinued
117,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,12/20/19,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,63323-580-20,available
118,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3339-1, Old NDC 0548-3339-00)",Reverified,12/16/19,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,76329-3339-1,available
119,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-1630-10,not available
120,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-9630-05,not available
121,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-4910-34,not available
122,Atropine Sulfate Injection,"Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-4911-34,not available
123,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25
(NDC 00517-0401-25)",Reverified,11/27/19,Limited Availability,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,00517-0401-25,limited availability
124,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Reverified,11/27/19,Limited Availability,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,00517-1010-25,limited availability
125,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,12/13/19,"January 2020, has inventory",,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0641-6006-10,available
126,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,12/13/19,Availability limited to product already in pharmacies until resumption of manufacturing in January 2020 and distribution in February 2020,Currently qualifying alternate supplier of inactive ingredient,,Shortage of an inactive ingredient,Ophthalmology,Current,,,24208-825-55,limited availability
127,Avelox® (moxifloxacin HCl) Tablets,Bayer,Bottles of 30 Tablets (NDC 50419-530-01),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Anti-Infective,To be Discontinued,2/1/19,2/1/19,50419-530-01,discontinued
128,Azacitidine Injection,Teva Pharmaceuticals,100 mg/1 unit (NDC 0591-2897-49),New,10/30/19,,The product has not been marketed for an extended period of time. Teva made a business decision to discontinue this product.,,,Oncology,To be Discontinued,10/30/19,10/30/19,0591-2897-49,discontinued
129,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/19,,,,,Ophthalmology,Resolved,9/11/19,,17478-307-03,
130,Bacitracin Ophthalmic Ointment,Perrigo Pharmaceuticals,Bacitracin Ophthalmic Ointment 3.5 g (NDC 0574-4022-35),Reverified,12/10/19,On backorder. Expected release early January 2020,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0574-4022-35,not available
131,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Reverified,12/16/19,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of NULOJIX via the US NULOJIX Distribution Program, initiated 15-Feb-2017. Starting in August 2018, the restrictions of the NDP will be eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient.  For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,0003-0371-13,limited availability
132,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-08),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,69202-780-08,discontinued
133,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-88),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,69202-780-88,discontinued
134,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-08),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,23594-780-08,discontinued
135,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-88),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,23594-780-88,discontinued
136,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"5 mg, 30 count bottle (NDC 29300-126-13)",Revised,6/14/19,,,Available,,Cardiovascular,Resolved,6/14/19,,29300-126-13,
137,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"5 mg, 100 count bottle (NDC 29300-126-01)",Revised,6/14/19,,,Available,,Cardiovascular,Resolved,6/14/19,,29300-126-01,
138,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"10 mg, 30 count bottle (NDC 29300-127-13)",Revised,6/14/19,,,Available,,Cardiovascular,Resolved,6/14/19,,29300-127-13,
139,Bisoprolol Fumarate Tablets,Unichem Pharmaceuticals (USA) Inc.,"10 mg, 100 count bottle (NDC 29300-127-01)",Revised,6/14/19,,,Available,,Cardiovascular,Resolved,6/14/19,,29300-127-01,
140,Bosentan Tablets,"Janssen Research and Development, LLC",62.5 mg tablets (NDC 10148-625-60),New,10/15/19,,,,,Cardiovascular,To be Discontinued,10/15/19,10/15/19,10148-625-60,discontinued
141,Bosentan Tablets,"Janssen Research and Development, LLC",125 mg tablets (NDC 10148-125-60),New,10/15/19,,,,,Cardiovascular,To be Discontinued,10/15/19,10/15/19,10148-125-60,discontinued
142,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/19,,,,,Gastroenterology,To be Discontinued,12/23/19,12/23/19,0093-7445-01,discontinued
143,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,12/13/19,"Temporary back-order, additional lots available end of December/January 2020",,,Demand increase for the drug,Cardiovascular,Current,,,0641-6008-10,limited availability
144,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured in the October - November 2019 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6007-10,available
145,"Bumetanide Injection, USP","Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1412-04,not available
146,"Bumetanide Injection, USP","Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: November 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1412-10,not available
147,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-461-57,not available
148,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-463-57,not available
149,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-17,not available
150,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-37,not available
151,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-17,not available
152,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-37,not available
153,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,12/20/19,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-462-31,not available
154,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-460-37,available
155,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Reverified,12/20/19,Next Delivery: February 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-01,not available
156,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Reverified,12/20/19,Next Delivery: March 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-17,not available
157,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: May 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9043-01,not available
158,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Reverified,12/20/19,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-01,not available
159,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Reverified,12/20/19,Next Delivery: March 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-17,not available
160,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Reverified,12/20/19,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9046-01,not available
161,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: June 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-10,not available
162,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-30,limited availability
163,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Reverified,12/20/19,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-10,not available
164,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Reverified,12/20/19,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-29,not available
165,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Reverified,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: June 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1752-50,limited availability
166,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Reverified,12/20/19,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1755-50,not available
167,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Reverified,12/20/19,Available,All Bupivacaine presentations are on intermittent back order and will be released as the product becomes available.  Product will ship into the wholesalers.,,Demand increase for the drug,Anesthesia,Current,,,63323-465-57,available
168,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-467-57,available
169,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-17,available
170,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-37,available
171,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
172,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-17,available
173,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-37,available
174,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-466-31,not available
175,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-17,available
176,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-37,available
177,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Revised,11/7/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-167-10,available
178,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Revised,11/7/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-168-30,available
179,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Revised,11/7/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-169-10,available
180,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Revised,12/11/19,Currently backordered,Next shipment TBD,,Demand increase for the drug,Anesthesia,Current,,,55150-170-30,not available
181,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-171-10,available
182,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-172-30,available
183,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Revised,12/11/19,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-249-50,available
184,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Revised,12/11/19,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-250-50,available
185,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1159-01,not available
186,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-1159-02,available
187,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-1160-01,available
188,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1162-01,not available
189,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1162-02,limited availability
190,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1163-01,limited availability
191,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,12/20/19,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1165-01,not available
192,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-1165-02,available
193,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL); Glass Ampul (NDC 00409-3613-01),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-3613-01,available
194,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,12/20/19,Next Delivery and Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1559-10,not available
195,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1559-30,not available
196,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1587-50,not available
197,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1560-10,not available
198,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1560-29,not available
199,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: May 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1610-50,not available
200,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: June 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1582-10,not available
201,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1582-29,not available
202,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL); Glass Ampul (NDC 00409- 1761-02),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-,available
203,"Bupivacaine Hydrochloride Injection, USP",Baxter Healthcare,"Bupivacaine HCL in 8.25% Dextrose lnjection, USP (7.5 mg/mL) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,12/11/19,Available,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,,Anesthesia,Current,,,36000-092-10,available
204,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-717-05,available
205,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-719-10,available
206,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-718-05,available
207,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),New,9/12/18,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-720-10,available
208,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 30 count bottle (NDC 0378-0923-93)",New,5/2/19,,,,,Analgesia/Addiction,To be Discontinued,5/2/19,5/2/19,0378-0923-93,discontinued
209,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"8 mg, 30 count bottle (NDC 0378-0924-93)",New,5/2/19,,,,,Analgesia/Addiction,To be Discontinued,5/2/19,5/2/19,0378-0924-93,discontinued
210,Bupropion Hydrochloride (Zyban) Tablets,GlaxoSmithKline,150 mg  (NDC 0173-0556-01),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately July 2019.,,,Psychiatry,To be Discontinued,6/28/19,6/28/19,0173-0556-01,discontinued
211,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 90 count bottle (NDC 0378-2008-77)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2008-77,discontinued
212,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"300 mg, 500 count bottle (NDC 0378-2009-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2009-05,discontinued
213,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 100 (NDC 69238-1117-01)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1117-01,available
214,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 500 (NDC 69238-1117-05)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1117-05,available
215,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 100 (NDC 69238-1118-01)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1118-01,available
216,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 500 (NDC 69238-1118-05)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1118-05,available
217,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 60 (NDC 69238-1118-06)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1118-06,available
218,Buspirone HCl Tablets,Amneal Pharmaceutical,"30mg, 60 (NDC 69238-1119-06)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1119-06,available
219,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 100 (NDC 69238-1115-01)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1115-01,available
220,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 500 (NDC 69238-1115-05)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1115-05,available
221,Buspirone HCl Tablets,Amneal Pharmaceutical,"7.5mg, 100 (NDC 69238-1116-01)",Reverified,12/17/19,Available,,,Other,Psychiatry,Current,,,69238-1116-01,available
222,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 60 count bottle (NDC 64380-743-03)",Revised,5/16/19,Currently out of stock. Re-supply by the first week of June 2019.,,,Demand increase for the drug,Psychiatry,Current,,,64380-743-03,not available
223,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 180 count bottle (NDC 64380-743-18)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-743-18,available
224,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 100 count bottle (NDC 16729-200-01)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-200-01,available
225,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 500 count bottle (NDC 16729-200-16)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-200-16,available
226,Buspirone HCl Tablets,Accord Healthcare Inc.,"7.5 mg, 100 count bottle (NDC 16729-201-01)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-201-01,available
227,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 100 count bottle (NDC 16729-202-01)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-202-01,available
228,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 500 count bottle (NDC 16729-202-16)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-202-16,available
229,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 60 count bottle (NDC 16729-203-12)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-203-12,available
230,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 100 count bottle (NDC 16729-203-01)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-203-01,available
231,Buspirone HCl Tablets,Accord Healthcare Inc.,"30 mg, 60 count bottle (NDC 16729-289-12)",Revised,12/11/19,"Sufficient stocks available to support customer demand; Product not on allocation effective Dec 1, 2019",,,Demand increase for the drug,Psychiatry,Current,,,16729-289-12,available
232,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0115-1690-01)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1690-01,not available
233,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 500 count bottle (NDC 0115-1690-02)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1690-02,not available
234,Buspirone HCl Tablets,Impax Laboratories,"5 mg, 1000 count bottle (NDC 0115-1690-03)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1690-03,not available
235,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0115-1691-01)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1691-01,not available
236,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 500 count bottle (NDC 0115-1691-02)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1691-02,not available
237,Buspirone HCl Tablets,Impax Laboratories,"10 mg, 1000 count bottle (NDC 0115-1691-03)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1691-03,not available
238,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 60 count bottle (NDC 0115-1692-13)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1692-13,not available
239,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 180 count bottle (NDC 0115-1692-19)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1692-19,not available
240,Buspirone HCl Tablets,Impax Laboratories,"15 mg, 500 count bottle (NDC 0115-1692-02)",Reverified,1/29/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0115-1692-02,not available
241,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 49884-725-01)",Reverified,11/26/19,Available,"Manufactured and marketed by Par Pharmaceutical. For product availability inquiries, call 1-800-828-9393, option # 5 then option # 2",,Demand increase for the drug,Psychiatry,Current,,,49884-725-01,available
242,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 500 count bottle (NDC 49884-725-05)",Reverified,11/26/19,Available,"Manufactured and marketed by Par Pharmaceutical. For product availability inquiries, call 1-800-828-9393, option # 5 then option # 2",,Demand increase for the drug,Psychiatry,Current,,,49884-725-05,available
243,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-1140-01)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1140-01,available
244,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-1140-05)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1140-05,available
245,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, unit-dose blister pack, 100 count (NDC 51079-985-20)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,51079-985-20,available
246,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 0378-1145-01)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1145-01,available
247,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-1150-01)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1150-01,available
248,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-1150-05)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1150-05,available
249,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, unit-dose blister pack, 100 count (NDC 51079-986-20)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,51079-986-20,available
250,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 60 count bottle (NDC 0378-1165-91)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1165-91,available
251,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 180 count bottle (NDC 0378-1165-80)",Reverified,11/26/19,Unavailable. Re-supply: November 2019,,,Other,Psychiatry,Current,,,0378-1165-80,not available
252,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 500 count bottle (NDC 0378-1165-05)",Reverified,11/26/19,Unavailable. Re-supply: November 2019,,,Other,Psychiatry,Current,,,0378-1165-05,not available
253,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, unit-dose blister pack, 100 count (NDC 51079-960-20)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,51079-960-20,available
254,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 60 count bottle (NDC 0378-1175-91)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-1175-91,available
255,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, unit-dose blister pack, 100 count (NDC 51079-994-20)",Reverified,11/26/19,Available,,,Other,Psychiatry,Current,,,51079-994-20,available
256,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 100 count bottle (NDC 64380-741-06)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-741-06,available
257,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 500 count bottle (NDC 64380-741-07)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-741-07,available
258,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 1000 count bottle (NDC 64380-741-08)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-741-08,available
259,Buspirone HCl Tablets,Strides Pharma Inc.,"7.5 mg, 100 count bottle (NDC 64380-787-06)",Revised,5/16/19,Currently out of stock. Re-supply by the first week of June 2019.,,,Demand increase for the drug,Psychiatry,Current,,,64380-787-06,not available
260,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 100 count bottle (NDC 64380-742-06)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-742-06,available
261,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 500 count bottle (NDC 64380-742-07)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-742-07,available
262,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 1000 count bottle (NDC 64380-742-08)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-742-08,available
263,Buspirone HCl Tablets,Strides Pharma Inc.,"30 mg, 60 count bottle (NDC 64380-744-03)",Revised,5/16/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,64380-744-03,available
264,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0093-0053-01)",Revised,12/16/19,Available,,,,Psychiatry,Current,,,0093-0053-01,available
265,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 500 count bottle (NDC 0093-0053-05)",Revised,12/16/19,Available,,,,Psychiatry,Current,,,0093-0053-05,available
266,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0093-0054-01)",Revised,12/16/19,Available,,,,Psychiatry,Current,,,0093-0054-01,available
267,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 500 count bottle (NDC 0093-0054-05)",Revised,12/16/19,Available,,,Increase in demand,Psychiatry,Current,,,0093-0054-05,available
268,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 100 count bottle (NDC 0093-1003-01)",Revised,12/16/19,Available,,,Increase in demand,Psychiatry,Current,,,0093-1003-01,available
269,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 500 count bottle (NDC 0093-1003-05)",Revised,12/16/19,Available,,,Increase in demand,Psychiatry,Current,,,0093-1003-05,available
270,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 60 count bottle (NDC 0093-5200-06)",Revised,12/16/19,Available,,,Increase in demand,Psychiatry,Current,,,0093-5200-06,available
271,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 500 count bottle (NDC 0093-5200-05)",Revised,12/16/19,Available,,,Increase in demand,Psychiatry,Current,,,0093-5200-05,available
272,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 100 count bottle (NDC 68382-180-01)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-180-01,available
273,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 500 count bottle (NDC 68382-180-05)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-180-05,available
274,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 100 count bottle (NDC 68382-181-01)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-181-01,available
275,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 500 count bottle (NDC 68382-181-05)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-181-05,available
276,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 100 count bottle (NDC 68382-182-01)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-182-01,available
277,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 500 count bottle (NDC 68382-182-05)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-182-05,available
278,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 60 count bottle (NDC 68382-183-14)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-183-14,available
279,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 500 count bottle (NDC 68382-183-05)",Revised,12/18/19,Available,,,Demand increase for the drug,Psychiatry,Current,,,68382-183-05,available
280,Calcitriol Injection USP 1MCG /ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,12/2/19,Available,,,Other,Endocrinology/Metabolism,Current,,,17478-931-01,available
281,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); Ansyr Plastic Syringe (NDC 00409-1631-10),Reverified,12/20/19,Next Delivery: April 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,00409-1631-10,not available
282,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4928-34),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,00409-4928-34,not available
283,"Calcium Chloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Calcium Chloride Inj. USP, 10%, 10mL Luer-Jet Prefilled Syringe, (NDC 0548-3304-00), new (NDC 76329-3304-1)",Revised,11/6/19,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Gastroenterology;Pediatric,Current,,,0548-3304-00,limited availability
284,"Calcium Chloride Injection, USP","Medefil, Inc.","Calcium Chloride Inj. USP, 10%, 10mL Prefilled Syringe, (NDC 64253-900-36)",Revised,12/11/19,Available,Check wholesaler for inventory,,Other,Gastroenterology;Pediatric,Current,,,64253-900-36,available
285,"Calcium Chloride Injection, USP",American Regent/Luitpold,"10% Calcium Chloride Injection, USP, 1 gram/10mL (100mg/mL), single dose vial, (NDC 0517-6710-01)",Reverified,11/27/19,Limited availability.,,,Requirements related to complying with good manufacturing practices,Gastroenterology;Pediatric,Current,,,0517-6710-01,limited availability
286,"Capreomycin Injection, USP",Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,12/2/19,Available,,,Delay in shipping of the drug,Anti-Infective,Current,,,17478-080-50,available
287,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,100 mg capsules (NDC 29033-019-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-019-12,discontinued
288,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,200 mg capsules (NDC 29033-020-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-020-12,discontinued
289,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,300 mg capsules (NDC 29033-004-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-004-12,discontinued
290,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 25/100 mg (NDC 0378-0088-01)",Revised,7/12/19,,,,,Neurology,Resolved,7/12/19,,0378-0088-01,
291,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 50/200 mg (NDC 0378-0094-01)",Revised,7/12/19,,,,,Neurology,Resolved,7/12/19,,0378-0094-01,
292,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa (50 mg of carbidopa and 200 mg of levodopa)  (SINEMET CR 50-200) sustained-release tablets, (NDC 0006-3919-68)bottles of 100",New,7/17/19,,To be discontinued on or near November 2019.,,,Neurology,To be Discontinued,7/17/19,7/17/19,0006-3919-68,discontinued
293,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa  (25 mg of carbidopa and 100 mg of levodopa) (SINEMET CR 25-100 ) sustained-release tablets, (NDC 0006-3918-68) bottles of 100",New,7/17/19,,To be discontinued on or near February 2020.,Available,,Neurology,To be Discontinued,7/17/19,,0006-3918-68,discontinued
294,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 100CT; (NDC 1672907901),Revised,7/12/19,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/19,,1672907901,
295,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  25-100 mg (NDC  62756-461-88 ),Revised,7/12/19,,,Available,,Neurology,Resolved,7/12/19,,62756-461-88,
296,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 1000CT; (NDC 1672907917),Revised,7/12/19,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/19,,1672907917,
297,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 100CT; (NDC 1672907801),Revised,7/12/19,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/19,,1672907801,
298,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 1000CT; (NDC 1672907817),Revised,7/12/19,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/19,,1672907817,
299,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  50-200 (NDC 62756-457-88),Revised,7/12/19,,,Available,,Neurology,Resolved,7/12/19,,62756-457-88,
300,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg/5 mL oral solution (NDCs 64376-612-16 and 64376-612-40),Revised,9/11/19,,,,,Pulmonary/Allergy,To be Discontinued,9/11/19,9/11/19,,discontinued
301,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg tablets (NDC 64376-605-01),Revised,9/11/19,,,,,Pulmonary/Allergy,To be Discontinued,9/11/19,9/11/19,64376-605-01,discontinued
302,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/18,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/18,3/20/18,10122-326-10,discontinued
303,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg 30 count bottle (NDC 0037-2250-30)",Reverified,11/26/19,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,0037-2250-30,available
304,"Carisoprodol Tablets, USP",Ingenus Pharmaceuticals LLC,"350 mg, 100 count tablets (NDC 50742-656-01)",Reverified,9/19/19,Available,Distributed by Ingenus Pharmaceuticals LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,50742-656-01,available
305,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 16714-510-01)",Reverified,10/1/19,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,16714-510-01,available
306,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 16714-510-02)",Reverified,10/1/19,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,16714-510-02,available
307,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 16714-510-03)",Reverified,10/1/19,Available,Distributed by Northstar Rx LLC,,,Analgesia/Addiction;Musculoskeletal,Current,,,16714-510-03,available
308,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 61442-451-01)",Reverified,10/1/19,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,61442-451-01,available
309,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 61442-451-05)",Reverified,10/1/19,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,61442-451-05,available
310,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 61442-451-10)",Reverified,10/1/19,Available,"Distributed by Carlsbad Technology, Inc.",,,Analgesia/Addiction;Musculoskeletal,Current,,,61442-451-10,available
311,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 59746-705-01)",Reverified,10/1/19,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,59746-705-01,not available
312,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 59746-705-05)",Reverified,10/1/19,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,59746-705-05,not available
313,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 59746-705-05)",Reverified,10/1/19,Unavailable,Distributed by Jubilant Cadista; Stopped distribution,,,Analgesia/Addiction;Musculoskeletal,Current,,,59746-705-05,not available
314,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 100 count (NDC 0591-5513-01)",Reverified,12/16/19,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,0591-5513-01,available
315,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 500 count (NDC 0591-5513-05)",Reverified,12/16/19,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,0591-5513-05,available
316,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 1000 count (NDC 0591-5513-10)",Reverified,12/16/19,Available,,,,Analgesia/Addiction;Musculoskeletal,Current,,,0591-5513-10,available
317,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 50228-109-01)",Reverified,9/23/19,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,50228-109-01,available
318,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 50228-109-05)",Reverified,9/23/19,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,50228-109-05,available
319,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 50228-109-10)",Reverified,9/23/19,Available,Labeler: ScieGen,,Other,Analgesia/Addiction;Musculoskeletal,Current,,,50228-109-10,available
320,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 60429-508-10)",Reverified,9/23/19,Available,Labeler: GSMS (Golden State Medical Supply),,Other,Analgesia/Addiction;Musculoskeletal,Current,,,60429-508-10,available
321,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 42543-700-01)",Reverified,9/23/19,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,42543-700-01,not available
322,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 42543-700-05)",Reverified,9/23/19,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,42543-700-05,not available
323,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 42543-700-10)",Reverified,9/23/19,Unavailable,"Labeler: Vensun, stopped distribution",,Other,Analgesia/Addiction;Musculoskeletal,Current,,,42543-700-10,not available
324,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,4/26/19,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,00603-2582-21,discontinued
325,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,4/26/19,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,00603-2582-28,discontinued
326,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,4/26/19,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,,Analgesia/Addiction;Musculoskeletal,Current,,,00603-2582-32,discontinued
327,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg, 30 count bottle (NDC 0037-2250-30); 100 count bottle (NDC 0037-2250-10)",Reverified,11/26/19,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,0037-2250-30,available
328,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 350 mg, 100 count bottle (NDC 0037-2001-01)",Reverified,11/26/19,Available,Distributed by Meda Pharmaceuticals,,Available,Analgesia/Addiction;Musculoskeletal,Current,,,0037-2001-01,available
329,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-21,discontinued
330,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-28,discontinued
331,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-32,discontinued
332,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),New,3/12/19,Available,,,,Anti-Infective,Current,,,66288-1100-1,available
333,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),New,3/13/19,Available,,,,Anti-Infective,Current,,,66288-1300-1,available
334,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,11/27/19,Available,,,,Anti-Infective,Current,,,60505-6143-04,available
335,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Revised,12/20/19,Available. On allocation. Estimated availability March,,,Manufacturing delay,Anti-Infective,Current,,,25021-101-10,limited availability
336,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,11/27/19,Available,,,,Anti-Infective,Current,,,60505-6142-05,available
337,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Revised,12/20/19,Available. On allocation. Estimated availability January,,,Manufacturing delay,Anti-Infective,Current,,,25021-102-99,limited availability
338,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Revised,12/20/19,Available. On allocation,,,Manufacturing delay,Anti-Infective,Current,,,25021-100-10,limited availability
339,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,12/11/19,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,00264-3105-11,limited availability
340,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,12/11/19,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,0264-3103-11,limited availability
341,Cefazolin Injection,WG Critical Care,500mg Cefazolin SDV (NDC 44567-706-25),Revised,11/4/19,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-706-25,available
342,Cefazolin Injection,WG Critical Care,1g Cefazolin SDV (NDC 44567-707-25),Revised,11/4/19,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-707-25,available
343,Cefazolin Injection,WG Critical Care,10g Cefazolin PBP (NDC 44567-708-10),Revised,11/4/19,On backorder - Product continues to be manufactured with monthly releases.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-708-10,limited availability
344,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,00409-0805-01,not available
345,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01),Reverified,12/20/19,Available,,,Other,Anti-Infective,Current,,,00409-2585-01,available
346,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,00409-0806-01,not available
347,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,12/13/19,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0143-9923-90,available
348,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,12/13/19,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0143-9924-90,available
349,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,12/13/19,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9983-03,not available
350,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,12/18/19,Available,,,,Anti-Infective,Current,,,0781-3450-95,available
351,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,12/18/19,Available,,,,Anti-Infective,Current,,,0781-3451-96,available
352,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,12/18/19,Limited availablity until February 2020,,,,Anti-Infective,Current,,,0781-3452-95,limited availability
353,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Reverified,12/11/19,Available,,,,Anti-Infective,Current,,,0338-3503-41,available
354,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Reverified,12/11/19,Product on allocation for existing customers,,,Demand increase for the drug,Anti-Infective,Current,,,0338-3508-41,limited availability
355,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (10 vials) (NDC 60505-6146-04),Reverified,11/27/19,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6146-04,available
356,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-6146-00),Reverified,11/27/19,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6146-00,available
357,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (10 vials) (NDC 60505-6147-04),Reverified,11/27/19,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6147-04,available
358,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (1 vial) (NDC 60505-6147-00),Reverified,11/27/19,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6147-00,available
359,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-0834-00),Revised,3/1/19,,"Product was manufactured by Hospira, no longer distributed by Apotex",,,Anti-Infective;Pediatric,To be Discontinued,3/1/19,3/1/19,60505-0834-00,discontinued
360,Cefepime Injection,B. Braun Medical Inc.,Cefepime 1 g (NDC 0264-3193-11),Reverified,12/11/19,Product on allocation to contracted custormers,,,Other,Anti-Infective;Pediatric,Current,,,0264-3193-11,limited availability
361,Cefepime Injection,B. Braun Medical Inc.,Cefepime 2 g (NDC 0264-3195-11),Reverified,12/11/19,Product on allocation to contracted customers,,,Other,Anti-Infective;Pediatric,Current,,,0264-3195-11,limited availability
362,Cefepime Injection,Sagent Pharmaceuticals,1 g vial (NDC 25021-121-20),Reverified,12/20/19,Available,,,,Anti-Infective;Pediatric,Current,,,25021-121-20,available
363,Cefepime Injection,Sagent Pharmaceuticals,2 g vial (NDC 25021-122-50),Reverified,12/20/19,Available,,,,Anti-Infective;Pediatric,Current,,,25021-122-50,available
364,Cefepime Injection,"Fresenius Kabi USA, LLC","1 g single dose vial, sterile powder (NDC 63323-326-20)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-326-20,available
365,Cefepime Injection,"Fresenius Kabi USA, LLC","2 g single dose vial, sterile powder (NDC 63323-340-20)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-340-20,available
366,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 1 gram/50mL, GALAXY Container (NDC 0338-1301-41)",Reverified,12/11/19,Available,,,,Anti-Infective;Pediatric,Current,,,0338-1301-41,available
367,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 2 gram/100mL, GALAXY Container (NDC 0338-1301-48)",Reverified,12/11/19,On allocation,,,Other,Anti-Infective;Pediatric,Current,,,0338-1301-48,limited availability
368,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0218-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,00409-0218-01,not available
369,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0217-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,00409-0217-01,not available
370,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose Glass Fliptop Vial (NDC 00409-0219-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,00409-0219-01,not available
371,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose Glass Fliptop Vial (NDC 00409-0220-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,00409-0220-01,not available
372,Cefepime Injection,WG Critical Care,1 g vial (NDC 44567-0240-10),Reverified,11/4/19,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,44567-0240-10,available
373,Cefepime Injection,WG Critical Care,2 g vial (NDC 44567-0241-10),Reverified,11/4/19,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,44567-0241-10,available
374,Cefepime Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak Pharmacy Bulk Package (NDC 66288-8100-1),Revised,3/27/19,Available,,,,Anti-Infective;Pediatric,Current,,,66288-8100-1,available
375,Cefotaxime Sodium Injection,Apollo Pharmaceuticals Inc.,"2g/vial, (NDC 21586-012-2)",New,8/28/19,Available,"Apollo in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,21586-012-2,available
376,Cefotaxime Sodium Injection,Apollo Pharmaceuticals Inc.,"1g/vial, (NDC 21586-011-2)",New,8/28/19,Available,"Apollo in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,21586-011-2,available
377,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,12/13/19,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9930-10,not available
378,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,12/13/19,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9931-25,not available
379,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,12/13/19,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9933-25,not available
380,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,12/13/19,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9935-01,not available
381,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,12/11/19,Product available,,,Other,Anti-Infective,Current,,,00264-3173-11,available
382,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,12/11/19,Product available,,,Other,Anti-Infective,Current,,,00264-3175-11,available
383,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Reverified,12/20/19,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0385-10,available
384,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Reverified,12/20/19,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0386-20,available
385,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Reverified,12/20/19,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,63323-0396-61,not available
386,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Revised,1/10/18,Available,,,,Anti-Infective,Current,,,52565-0053-10,available
387,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 1g Vial 10 (NDC 52565-0052-10),Revised,1/10/18,Available,,,,Anti-Infective,Current,,,52565-0052-10,available
388,"Cefoxitin for Injection, USP",Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Reverified,11/27/19,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0759-05,discontinued
389,"Cefoxitin for Injection, USP",Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Reverified,11/27/19,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0760-05,discontinued
390,"Cefoxitin for Injection, USP",Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Reverified,11/27/19,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0761-04,discontinued
391,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Reverified,12/20/19,Backordered.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,63323-341-25,not available
392,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Reverified,12/20/19,Backordered.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,63323-342-25,not available
393,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Reverified,12/20/19,On backorder. Product continues to be manufactured with monthly releases. Estimated availability Feb-2020,,,Demand increase for the drug,Anti-Infective,Current,,,25021-111-99,not available
394,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Reverified,12/20/19,Available. On allocation,,,Manufacturing delay,Anti-Infective,Current,,,25021-109-10,limited availability
395,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Reverified,12/20/19,On allocation. Product continues to be manufactured with monthly releases. Estimated availability Jan-2020,,,Demand increase for the drug,Anti-Infective,Current,,,25021-110-20,limited availability
396,"Cefoxitin for Injection, USP",WG Critical Care,1 g (NDC 44567-245-25),Revised,11/4/19,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-245-25,not available
397,"Cefoxitin for Injection, USP",WG Critical Care,2 g (NDC 44567-246-25),Revised,11/4/19,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-246-25,not available
398,"Cefoxitin for Injection, USP",WG Critical Care,10 g (NDC 44567-247-10),Revised,11/4/19,On backorder.  Next release December.,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-247-10,not available
399,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,12/13/19,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9878-25,available
400,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,12/13/19,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9877-25,available
401,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,12/13/19,Available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9876-10,available
402,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0412-00,discontinued
403,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0413-00,discontinued
404,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0425-00,discontinued
405,Cetirizine Hydrochloride,Torrent Pharma Inc.,5 mg/5 mL oral syrup (NDC 13668-596-07),New,4/24/19,,,,,Pulmonary/Allergy,To be Discontinued,4/24/19,4/24/19,13668-596-07,discontinued
406,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-251-10,discontinued
407,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-252-10,discontinued
408,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,25 mg (NDC 43547-253-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-253-10,discontinued
409,Chloroquine Phosphate Tablets,"Rising Pharmaceuticals, Inc.",500 mg (NDC 64980-178-02),Revised,3/25/16,,,Available,,Anti-Infective;Pediatric,Resolved,3/25/15,,64980-178-02,
410,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0150-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-0150-01,discontinued
411,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0162-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-0162-01,discontinued
412,Chlorpheniramine Maleate; Hydrocodone Bitartrate; Pseudoephedrine Hydrochloride Oral Solution,"Paddock Laboratories, LLC",4 mg/5 mL; 5 mg/5 mL; 60 mg/5 mL (NDC 0574-1103-16),New,6/12/19,,,,,Pulmonary/Allergy,To be Discontinued,6/12/19,6/12/19,0574-1103-16,discontinued
413,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0197-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0197-01,discontinued
414,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0210-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0210-01,discontinued
415,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 50 count bottle (NDC 0378-1743-89)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-1743-89,discontinued
416,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1000 mg, 50 count bottle (NDC 0378-1745-89)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-1745-89,discontinued
417,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",300 mg per 2 mL (150 mg per mL); SDV; (NDC 63323-282-02),New,5/10/19,,3 & 6 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-02,discontinued
418,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",600 mg per 4 mL (150 mg per mL); SDV; (NDC 63323-282-04),New,5/10/19,,6 & 8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-04,discontinued
419,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",900 mg per 6 mL (150 mg per mL); SDV; (NDC 63323-282-06),New,5/10/19,,3 & 5 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-06,discontinued
420,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",9 grams per Pharmacy Bulk Package (150 mg per mL); (NDC 63323-282-60),New,5/10/19,,8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-60,discontinued
421,Clindamycin Phosphate and Benzoyl Peroxide (Duac) Topical Gel,GlaxoSmithKline,10 mg; 50 mg  (NDC 0145-2371-05),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately November 2019.,,,Dermatology,To be Discontinued,6/28/19,6/28/19,0145-2371-05,discontinued
422,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-65),New,6/10/19,,,,,Reproductive,To be Discontinued,6/10/19,6/10/19,0093-0041-65,discontinued
423,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-03),New,6/10/19,,,,,Reproductive,To be Discontinued,6/10/19,6/10/19,0093-0041-03,discontinued
424,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-77,discontinued
425,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-01,discontinued
426,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-10,discontinued
427,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-77,discontinued
428,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-01,discontinued
429,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-10,discontinued
430,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-01,discontinued
431,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-05,discontinued
432,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-01,discontinued
433,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-05,discontinued
434,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-10,discontinued
435,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-01,discontinued
436,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-05,discontinued
437,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-10,discontinued
438,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-01,discontinued
439,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-02,discontinued
440,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-01,discontinued
441,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-02,discontinued
442,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-01,discontinued
443,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-05,discontinued
444,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-10,discontinued
445,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-01,discontinued
446,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-05,discontinued
447,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-10,discontinued
448,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-10,discontinued
449,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-101-10,discontinued
450,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-01,discontinued
451,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-10,discontinued
452,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-01,discontinued
453,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-01,discontinued
454,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-10,discontinued
455,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-01,discontinued
456,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-10,discontinued
457,"Cycloserine Capsules, USP",Purdue GMP Center,250mg capsules blister pack x 30 (NDC 13845-1202-2),Revised,4/17/19,,,Available,,Anti-Infective,Resolved,4/17/19,,13845-1202-2,
458,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/19,,,Available,,Other;Pediatric,Resolved,9/3/19,,51754-1007-1,
459,Daclatasvir Tablets,Bristol Myers Squibb Co.,60 mg tablets (NDC 0003-0215-01),Revised,1/4/19,,Planned cease distribution is June 2019.,,,Antiviral,To be Discontinued,1/4/19,1/4/19,0003-0215-01,discontinued
460,Daclatasvir Tablets,Bristol Myers Squibb Co.,30 mg tablets (NDC 0003-0213-01),Revised,1/4/19,,Planned cease distribution is June 2019.,,,Antiviral,To be Discontinued,1/4/19,1/4/19,0003-0213-01,discontinued
461,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 30, (NDC 10370-171-11)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-171-11,discontinued
462,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 90 (NDC 10370-171-09)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-171-09,discontinued
463,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 10370-170-11)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-170-11,discontinued
464,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 90 (NDC 10370-170-09)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-170-09,discontinued
465,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-0063-28,discontinued
466,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4505-6,
467,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4504-6,
468,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",500 mg; Single Dose Glass Fliptop Vial (NDC 00409-2336-10),Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,00409-2336-10,
469,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",2 g; Single Dose Glass Fliptop Vial (NDC 00409-2337-25),Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,00409-2337-25,
470,"Deferoxamine Mesylate for Injection, USP","Fresenius Kabi USA, LLC","500 mg per vial, 10 mL vial (NDC 63323-597-10)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,63323-597-10,
471,Delavirdine Mesylate (RESCRIPTOR) Tablets,ViiV Healthcare,200 mg tablets; bottles of 180 tablets (NDC 49702-225-17),New,6/26/19,,This decision is business-related and the anticipated final date for availability to patients is January 2020.,,,Antiviral,To be Discontinued,6/26/19,6/26/19,49702-225-17,discontinued
472,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-4017-01)",New,5/2/19,,,,,Pulmonary/Allergy,To be Discontinued,5/2/19,5/2/19,0378-4017-01,discontinued
473,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-4017-05)",New,5/2/19,,,,,Pulmonary/Allergy,To be Discontinued,5/2/19,5/2/19,0378-4017-05,discontinued
474,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/14,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/14,,50458-196-15,discontinued
475,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/26/19,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-423-12,available
476,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/26/19,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-422-54,available
477,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/26/19,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-421-30,available
478,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/26/19,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-420-10,available
479,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,10/7/19,Currently available,Check wholesalers for inventory,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-237-01,available
480,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,10/7/19,Backordered — next shipment anticipated late Oct. 2019.,Intermittent availability expected.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-238-05,not available
481,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,10/7/19,Backordered — next shipment anticipated late Oct. 2019.,Intermittent availability expected.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-239-30,not available
482,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",New,2/8/19,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,70069-021-25,available
483,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-05,available
484,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-516-10,available
485,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-30,available
486,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Delay in manufacturing,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-01,available
487,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Reverified,12/20/19,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-506-01,available
488,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Revised,12/13/19,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6145-25,available
489,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Revised,12/13/19,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6146-25,available
490,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Revised,12/13/19,"Available, additional lots manufactured Jan/feb 2020.",,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-0367-25,available
491,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,10 mg 100 Count (NDC 0093-5277-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5277-01,discontinued
492,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg 100 Count (NDC 0093-5275-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5275-01,discontinued
493,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,5 mg 100 Count (NDC 0093-5276-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5276-01,discontinued
494,Dexrazoxane Injection,Gland Pharma,500 mg per vial (NDC 72266-101-01,Reverified,12/10/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Oncology;Pediatric,Current,,,72266-101-01,available
495,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",250 mg per vial (NDC 0143-9247-01),Reverified,12/13/19,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9247-01,available
496,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9248-01),Reverified,12/13/19,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the June 2019 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9248-01,not available
497,Dexrazoxane Injection,Mylan Institutional,250 mg Kit (NDC 67457-207-25),Revised,12/20/19,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-207-25,available
498,Dexrazoxane Injection,Mylan Institutional,500 mg Kit (NDC 67457-208-50),Revised,12/20/19,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-208-50,available
499,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 250 mg; Single Dose Vial (NDC 00013-8717-62),Reverified,12/20/19,Available,,,Other,Oncology;Pediatric,Current,,,00013-8717-62,available
500,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 500 mg; Single Dose Vial (NDC 00013-8727-89),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Oncology;Pediatric,Current,,,00013-8727-89,not available
501,Dexrazoxane Injection,Clinigen Healthcare Ltd,Totect® (Dexrazoxane) for injection; 1 vial (500 mg)(NDC 66220-110-01),Revised,5/10/19,Available,,,Available,Oncology;Pediatric,Current,,,66220-110-01,available
502,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1070-01,discontinued
503,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1071-01,discontinued
504,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1072-01,discontinued
505,Dextrose 25% Injection,"Hospira, Inc.",250 mg/mL (25%); Ansyr Plastic Syringe (NDC 0409-1775-10),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-1775-10,limited availability
506,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0062-30,
507,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-10,
508,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-9147-30,
509,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-02,
510,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-03,
511,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-04,
512,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-02,
513,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-03,
514,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-02,
515,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-03,
516,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-09,
517,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-25,
518,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-53,
519,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-55,
520,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-61,
521,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-06,
522,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-11,
523,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-13,
524,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-20,
525,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-23,
526,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-36,
527,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-37,
528,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 100mL 
(NDC 63323-624-61)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-61,
529,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 250mL 
(NDC 63323-624-74)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-74,
530,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-41)
Quad Pack (NDC 0338-0017-11)
Multi Pack (NDC 0338-0017-31)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-41,
531,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-48)
Quad Pack (NDC 0338-0017-18
Multi Pack (NDC 0338-0017-38)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-48,
532,Dextrose 5% Injection Bags,"Hospira, Inc.",50 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-66),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,00409-7100-66,
533,Dextrose 5% Injection Bags,"Hospira, Inc.",100 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-67),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,00409-7100-67,
534,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 500mL 
(NDC 63323-624-75)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-75,
535,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 1000mL 
(NDC 63323-624-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-10,
536,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 50 mL,  Product code 2B0040 (NDC 0338-0551-11)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0551-11,
537,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 100 mL,  Product code 2B0041 (NDC 0338-0551-18)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0551-18,
538,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","DEXTROSE INJECTION, USP, 50%, [500 mg / mL](NDC 76329-3301-1)",Reverified,12/16/19,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,76329-3301-1,limited availability
539,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); LifeShield Abboject Glass Syringe (NDC 0409-4902-34),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,0409-4902-34,not available
540,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Single Dose Glass Fliptop Vial (NDC 0409-6648-02),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,0409-6648-02,not available
541,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Ansyr Plastic Syringe (NDC 0409-7517-16),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: June 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-7517-16,not available
542,"Diazepam Injection, USP","Beloteca, Inc.","Diazepam Injection, USP 10 mg/2 mL (5 mg/mL) Prefilled Single-dose Syringe with Luer Lock (NDC 69339-136-32)",Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,69339-136-32,
543,"Diazepam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1273-32),Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,00409-1273-32,
544,"Diazepam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-3213-12),Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,00409-3213-12,
545,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/18,4/4/18,0378-0355-01,discontinued
546,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,10 mg capsules in bottles of 100 (NDC 58914-012-10),New,3/29/19,,Product discontinued October 2017,,,Gastroenterology,To be Discontinued,3/29/19,3/29/19,58914-012-10,discontinued
547,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,20 mg tablets in bottles of 100 (NDC 58914-013-10),New,3/29/19,,Product discontinued December 2016,,,Gastroenterology,To be Discontinued,3/29/19,3/29/19,58914-013-10,discontinued
548,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 100s (NDC 0378-1610-01),Reverified,11/26/19,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,0378-1610-01,not available
549,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 500s (NDC 0378-1610-05),Reverified,11/26/19,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,0378-1610-05,not available
550,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 100s (NDC 0378-1620-01),Reverified,11/26/19,Available,,,Other,Gastroenterology,Current,,,0378-1620-01,available
551,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 500s (NDC 0378-1620-05),Reverified,11/26/19,Out of Stock. Resupply is Q4 2019.,,,Other,Gastroenterology,Current,,,0378-1620-05,not available
552,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (100 count bottles) (NDC 0527-0586-01)",Revised,9/12/19,Available,,,,Gastroenterology,Current,,,0527-0586-01,available
553,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (1000 count bottles) (NDC 0527-0586-10)",Revised,9/12/19,Available,,,,Gastroenterology,Current,,,0527-0586-10,available
554,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (100 count bottles) (NDC 0527-1282-01)",Revised,9/12/19,Available,,,,Gastroenterology,Current,,,0527-1282-01,available
555,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (1000 count bottles) (NDC 0527-1282-10)",Revised,9/12/19,Available,,,,Gastroenterology,Current,,,0527-1282-10,available
556,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 100 count (NDC 0591-0794-01),Reverified,12/16/19,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,0591-0794-01,available
557,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 1000 count (NDC 0591-0794-10),Reverified,12/16/19,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,0591-0794-10,available
558,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 100 count (NDC 0591-0795-01),Reverified,12/16/19,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,0591-0795-01,available
559,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 1000 count (NDC 0591-0795-10),Reverified,12/16/19,Available,Cannot support additional business currently.,,,Gastroenterology,Current,,,0591-0795-10,available
560,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 1000s (NDC 0143-3126-10)",Reverified,12/13/19,Available,,,,Gastroenterology,Current,,,0143-3126-10,available
561,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 100s (NDC 0143-3126-01)",Reverified,12/13/19,Available,,,,Gastroenterology,Current,,,0143-3126-01,available
562,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 1000s (NDC 0143-1227-10)",Reverified,12/13/19,Available,,,,Gastroenterology,Current,,,0143-1227-10,available
563,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 100s (NDC 0143-1227-01)",Reverified,12/13/19,Available,,,,Gastroenterology,Current,,,0143-1227-01,available
564,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0588-01,discontinued
565,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0589-01,discontinued
566,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0590-01,discontinued
567,Diethylpropion Hydrochloride Controlled-Release Tablets,Teva Pharmaceuticals,75 mg tablets (NDC 0591-0782-01),New,6/11/19,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/19,6/11/19,0591-0782-01,discontinued
568,Diethylpropion Hydrochloride Tablets,Teva Pharmaceuticals,25 mg tablets (NDC 0591-0783-01),New,6/11/19,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/19,6/11/19,0591-0783-01,discontinued
569,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/19,,,,,Ophthalmology,Resolved,10/15/19,,0065-9204-07,
570,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,12/13/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6013-10,available
571,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,12/13/19,Temporarily backorderd. Additional lots available end of December 2019 and additional product manufactured Jan/Feb 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6014-10,not available
572,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,12/13/19,Temporarily backorderd. Additional lots available end of December 2019 and additional product manufactured Jan/Feb 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6015-10,not available
573,Diltiazem Hydrochloride,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,,,Demand increase for the drug,Cardiovascular,Current,,,00409-4350-03,limited availability
574,Diltiazem Hydrochloride,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1171-01,not available
575,Diltiazem Hydrochloride,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1171-02,limited availability
576,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-10,available
577,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0817-10,available
578,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0817-25,available
579,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0817-26,available
580,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,12/2/19,Unavailable. Estimated recovery Dec 2019,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-25,not available
581,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-26,available
582,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,12/2/19,Unavailable. Estimated recovery Dec 2019,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-05,not available
583,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05)",Revised,12/2/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0817-05,available
584,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,60 mg (NDC 0378-6060-01),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-6060-01,available
585,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,90 mg (NDC 0378-6090-01),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-6090-01,available
586,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,120 mg (NDC 0378-6120-01),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-6120-01,available
587,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5220-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5220-01,discontinued
588,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-5220-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5220-05,discontinued
589,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 100 count bottle (NDC 0378-5280-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5280-01,discontinued
590,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 500 count bottle (NDC 0378-5280-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5280-05,discontinued
591,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 100 count bottle (NDC 0378-5340-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5340-01,discontinued
592,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 500 count bottle (NDC 0378-5340-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5340-05,discontinued
593,Diphenhydramine Injection,"Hospira, Inc.",50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Pediatric;Pulmonary/Allergy,Current,,,00409-2290-31,not available
594,Diphenhydramine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL vial (NDC 0641-0376-25)",Reverified,12/13/19,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,0641-0376-25,available
595,Diphenhydramine Injection,Mylan Institutional,500 mg / 10mL(NDC 67457-124-10),Reverified,11/26/19,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,67457-124-10,available
596,Diphenhydramine Injection,"Fresenius Kabi USA, LLC","50 mg per vial, Single dose, Amber vial (NDC 63323-664-01)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,63323-664-01,available
597,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4140-01,discontinued
598,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4141-01,discontinued
599,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",Reverified,12/16/19,Availability and estimated duration of supply interruption is unknown,,,Other,Analgesia/Addiction,Current,,,0093-5035-01,unclear
600,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",Reverified,12/16/19,Availability and estimated duration of supply interruption is unknown,,,Other,Analgesia/Addiction,Current,,,0093-5036-01,unclear
601,Disulfiram Tablets,"Alvogen, Inc.","250 mg, 30 count (NDC 47781-607-30)",Revised,11/20/19,Next delivery: February 2020,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,47781-607-30,not available
602,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 500 (NDC 10370-511-50),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-511-50,discontinued
603,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 100 (NDC 10370-511-10),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-511-10,discontinued
604,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 100 (NDC 10370-510-10),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-510-10,discontinued
605,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 500 (NDC 10370-510-50),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-510-50,discontinued
606,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Reverified,12/20/19,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2346-32,available
607,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Reverified,12/20/19,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2347-32,available
608,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: May 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-3724-32,not available
609,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Reverified,12/20/19,Next Delivery: March 2020; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-20,not available
610,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Reverified,12/20/19,Next Delivery and Estimated Recovery: December 2019,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-54,not available
611,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Reverified,12/20/19,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-01,available
612,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Reverified,12/20/19,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-02,available
613,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,12/11/19,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,0338-1073-02,available
614,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-21)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/19,4/9/19,0603-0150-21,discontinued
615,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-32)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/19,4/9/19,0603-0150-32,discontinued
616,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,12/11/19,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
617,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,12/20/19,Available,,,Other,Cardiovascular,Current,,,00409-7809-22,available
618,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7809-24,limited availability
619,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7810-22,limited availability
620,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-5820-01,limited availability
621,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,12/20/19,Next Delivery and Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-9104-20,not available
622,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,12/20/19,Available,,,,Ophthalmology,Current,,,17478-605-10,available
623,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,12/20/19,"Limit availability / Recovery expected Q1, 2020","Manufacturer interruption production issues.  Marketed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,50383-233-10,limited availability
624,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,12/20/19,Available,"Marketed by Akorn, Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,17478-604-30,available
625,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Reverified,12/18/19,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,61314-030-02,available
626,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,12/13/19,Intermittent backorders through Q1 2020. Estimated availability: Late January 2020/February 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Valeant Pharmaceuticals North America at pharcs@valeant.com",,Other,Ophthalmology,Current,,,24208-486-10,limited availability
627,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,0591-2482-79,not available
628,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,,discontinued
629,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Reverified,12/13/19,Available,Available,,Other,Ophthalmology,Current,,,65862-0947-60,available
630,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0591-2481-79,discontinued
631,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0093-7618-43,discontinued
632,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/18,4/20/18,0591-2481-79,not available
633,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/18,4/20/18,0093-7618-43,not available
634,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,12/2/19,"Limit availability / Recovery expected Q1, 2020","Manufacturer interruption production issues. Distributed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,50383-232-10,limited availability
635,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Reverified,6/1/18,Product is available,"For additional information please contact: Merck National Service Center, Telephone Number: 1-800-672-6372",,Demand increase for the drug,Ophthalmology,Current,,,0006-3519-36,available
636,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,12/13/19,Currently on backorder. Estimated availability: January 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Bausch Health US, LLC at pharcs@bauschhealth.com",,Other,Ophthalmology,Current,,,24208-485-10,not available
637,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Reverified,12/18/19,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,61314-019-10,available
638,Doxycycline Capsules,Teva Pharmaceuticals,50 mg capsules (NDC 0591-0410-01),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-0410-01,discontinued
639,Doxycycline Capsules,Teva Pharmaceuticals,75 mg capsules (NDC 0591-2404-01),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-2404-01,discontinued
640,Doxycycline Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-0411-50),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-0411-50,discontinued
641,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,50 mg  (NDC 0591-5535-50),New,10/15/19,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/19,10/15/19,0591-5535-50,discontinued
642,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,100 mg (NDCs 0591-5440-50 and 0591-5440-05),New,10/15/19,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/19,10/15/19,,discontinued
643,Doxycycline Hyclate Delayed Release Tablets,Mylan Pharmaceuticals Inc.,150 mg tablets (NDC 0378-3030-01),New,9/9/19,,,,,Anti-Infective,To be Discontinued,9/9/19,9/9/19,0378-3030-01,discontinued
644,Dronabinol Capsules,"Endo Pharmaceuticals, Inc.","2.5 mg capsules (NDC 498840-867-02), 5 mg capsules (NDC 498840-868-02), 10 mg capsules (NDC 498840-869-02)",New,2/7/19,,,,,Gastroenterology,To be Discontinued,2/7/19,2/7/19,498840-867-02,discontinued
645,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,12/20/19,Next delivery and Estimated recovery: Q3 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Ophthalmology,Current,,,0046-1065-05,not available
646,Eflornithine Hydrochloride (Vaniqa) Cream,Allergan,13.9% (NDC 0023-4857-45),Revised,6/12/19,,,,,Dermatology,Resolved,6/12/19,,0023-4857-45,
647,Emedastine Difumarate (Emadine) 0.05% Ophthalmic Solution,Novartis,Emadine (emedastine difumarate) 0.05% ophthalmic solution 5mL in 1 Bottle (NDC 0065-0325-05),New,1/29/19,,Novartis Pharmaceuticals has made a business decision to permanently discontinue this product.,,,Ophthalmology;Pulmonary/Allergy,To be Discontinued,1/29/19,1/29/19,0065-0325-05,discontinued
648,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,12/13/19,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9786-10,not available
649,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,12/13/19,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9787-10,not available
650,"Enalaprilat Injection, USP","Hospira, Inc.",1.25 mg/mL; Single Dose Glass Fliptop Vial (NDC 00409-2122-01),Reverified,12/20/19,Next Delivery: March 2020;  Estimated Recovery: June 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2122-01,not available
651,"Enalaprilat Injection, USP","Hospira, Inc.",2.5 mg/2 mL (1.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2122-02),Reverified,12/20/19,Next Delivery: March 2020;  Estimated Recovery: June 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2122-02,not available
652,Epinastine Hydrochloride (Elestat®) Ophthalmic Solution,Allergan,5 mL in 10 mL bottle (NDC 00023-9201-05),New,8/19/19,,,,,Ophthalmology,To be Discontinued,8/19/19,8/19/19,00023-9201-05,discontinued
653,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pulmonary/Allergy,Current,,,00409-4921-34,limited availability
654,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","1:10,000, 10mL Luer-Jet Prefilled Syringe
(NDC 76329-3316-1)(old NDC 0548-3316-00)",Reverified,12/16/19,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,76329-3316-1,limited availability
655,"Epinephrine Injection, Auto-Injector",Mylan Specialty,"0.3 mg (EpiPen® NDC 49502-500-02, pack of 2; NDC 49502-500-01, individual) (Authorized Generic NDC 49502-102-02, pack of 2; NDC 49502-102-01, individual)",Reverified,11/26/19,Available,"Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,Manufacturing delays,Pulmonary/Allergy,Current,,,49502-500-02,available
656,"Epinephrine Injection, Auto-Injector",Mylan Specialty,0.15 mg (EpiPen® NDC 49502-501-02) (Authorized Generic NDC 49502-101-02),Reverified,11/26/19,Available,"Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,Manufacturing delays,Pulmonary/Allergy,Current,,,49502-501-02,available
657,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,12/13/19,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1695-49,limited availability
658,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,12/13/19,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1694-49,limited availability
659,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,12/13/19,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-023-01,available
660,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,12/13/19,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-022-01,available
661,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,12/13/19,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-021-01,available
662,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,12/16/19,Available,,,,Pulmonary/Allergy,Current,,,0093-5986-27,available
663,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3442-20,available
664,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3448-20,available
665,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,12/16/19,Available,,,,Pulmonary/Allergy,Current,,,0093-5985-27,available
666,Epirubicin Hydrochloride Injection,Teva Pharmaceuticals,2 mg/1 mL  (NDCs 45963-608-60 and 45963-608-68),New,7/17/19,,This product discontinuation is a business related decision.  Anticipated discontinuance time is first quarter of the year 2020.,,,Oncology,To be Discontinued,7/17/19,7/17/19,,discontinued
667,Epirubicin Hydrochloride Injection,Cipla Limited,2 mg/1 mL  (NDCs 25021-203-25 and 59923-701-25),New,7/17/19,,Anticipated unavailability of product is September 2019.,,,Oncology,To be Discontinued,7/17/19,7/17/19,,discontinued
668,Eprosartan Mesylate Tablets,Mylan Pharmaceuticals Inc.,Eprosartan Mesylate 600mg T 30s (NDC 0378-6629-93),Reverified,11/26/19,Out of stock. Resupply TBD,,,Other,Cardiovascular,Current,,,0378-6629-93,not available
669,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,0.75 mg/mL (NDCs 0085-1136-02 and 0085-1136-03),New,11/18/19,,The following presentation will continue to be available: 0.75 mg/mL (NDC 0085-1136-01 ),,,Cardiovascular,To be Discontinued,11/18/19,11/18/19,,discontinued
670,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,2 mg/mL (NDCs 0085-1177-03 and 0085-1177-05),New,11/18/19,,The following presentations will continue to be available: 2 mg/mL (NDCs 0085-1177-01 and 0085-1177-02),,,Cardiovascular,To be Discontinued,11/18/19,11/18/19,,discontinued
671,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single Dose Glass Fliptop Vial (NDC 00409-6482-01),Revised,12/20/19,Available,,,Other,Anti-Infective,Current,,,00409-6482-01,available
672,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single-dose ADD-Vantage® Vial (NDC 00409-6476-44),Revised,12/20/19,Available,,,Other,Anti-Infective,Current,,,00409-6476-44,available
673,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,12/2/19,Limited availability.,"Expected availability Dec, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,17478-070-35,limited availability
674,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-01),Revised,12/2/19,On backorder,"Expected availability Oct 1, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,not available
675,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,12/2/19,No longer distributing,,,,Ophthalmology,Current,,,17478-824-35,discontinued
676,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,12/2/19,No longer distributing,,,,Ophthalmology,Current,,,17478-824-01,discontinued
677,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Reverified,12/13/19,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,24208-910-55,available
678,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Reverified,12/13/19,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,24208-910-19,available
679,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-50,available
680,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-35,available
681,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-39,available
682,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Lexapro oral solution 240 mL bottle 5 mg/5mL (NDC 0456-2101-08),New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0456-2101-08,discontinued
683,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Escitalopram Oxalate oral solution 240 mL bottle (NDC 0591-4151-38),New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-4151-38,discontinued
684,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 6 blister pack in 1 carton (NDC 0603-7625-17)",New,5/10/19,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/19,5/10/19,0603-7625-17,discontinued
685,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 3 blister pack in 1 carton (NDC 0603-7625-49)",New,5/10/19,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/19,5/10/19,0603-7625-49,discontinued
686,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,8/1/19,,,Available,,Medical Imaging;Oncology,Resolved,8/1/19,,67684-1901-1,
687,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,7/31/19,,,,,Medical Imaging;Oncology,Resolved,7/31/19,,67684-1901-1,
688,"Ethosuximide Oral Solution, USP",Teva Pharmaceuticals,"250 mg/5mL, 474 mL Bottle (NDC 0093-9660-16)",New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-9660-16,discontinued
689,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ USP 20MG/ML 5ML (NDC 16729-114-31),Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,16729-114-31,
690,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ USP 20MG/ML (Nova Plus) 5ML (NDC 16729-262-31),Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,16729-262-31,
691,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ. USP 20MG/ML 25 ML (NDC 16729-114-08),Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,16729-114-08,
692,Etoposide Injection,Accord Healthcare Inc.,ETOPOSIDE INJ. USP 20MG/ML 50 ML (NDC 16729-114-11),Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,16729-114-11,
693,Etoposide Injection,"Fresenius Kabi USA, LLC","100 mg per 5 mL, 20 mg per mL, MDV (NDC 63323-104-05)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,63323-104-05,
694,Etoposide Injection,"Fresenius Kabi USA, LLC","500 mg per 25 mL, 20 mg per mL, MDV (NDC 63323-104-25)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,63323-104-25,
695,Etoposide Injection,"Fresenius Kabi USA, LLC","1 gram per 50 mL, 20 mg per mL, MDV (NDC 63323-104-50)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,63323-104-50,
696,Etoposide Injection,Teva Pharmaceuticals,100 mg/5 mL Multiple-dose Vials (NDC 0703-5653-01),Revised,8/16/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/19,8/16/19,0703-5653-01,discontinued
697,Etoposide Injection,Teva Pharmaceuticals,500 mg/25 mL Multiple-dose Vials (NDC 0703-5656-01),Revised,8/16/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/19,8/16/19,0703-5656-01,discontinued
698,Etoposide Injection,Teva Pharmaceuticals,1 gram/50 mL Multiple-dose Vials (NDC 0703-5657-01),Revised,8/16/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,8/16/19,8/16/19,0703-5657-01,discontinued
699,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 5 mL vial (NDC 0143-9510-01)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,0143-9510-01,
700,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 25 mL vial (NDC 0143-9511-01)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,0143-9511-01,
701,Etoposide Injection,West-Ward Pharmaceuticals,"20 mg/mL, 50 mL vial (NDC 0143-9512-01)",Revised,6/12/19,,,,,Oncology,Resolved,6/12/19,,0143-9512-01,
702,Etoposide Phosphate (Etopophos) Injection,Bristol Myers Squibb Co.,Etopophos Injection 100 mg (1VL) 10.6 mL US (NDC 0015-3404-20),Revised,6/12/19,, ,,,Oncology,Resolved,6/12/19,,0015-3404-20,
703,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/18,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/18,4/3/18,0310-6520-04,discontinued
704,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 45mg 90s (NDC 10370-209-09),New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,10370-209-09,discontinued
705,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 135mg 90s (NDC 10370-210-09),New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,10370-210-09,discontinued
706,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"45 mg, 90 count bottle (NDC 0378-2589-77)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-2589-77,discontinued
707,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"135 mg, 90 count bottle (NDC 0378-2590-77)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-2590-77,discontinued
708,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-55,available
709,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-1276-32,not available
710,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,12/20/19,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-32,not available
711,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,12/20/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-35,available
712,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,12/20/19,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-38,discontinued
713,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-22,limited availability
714,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,12/20/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-25,available
715,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,12/20/19,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-28,not available
716,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-31,limited availability
717,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-61,limited availability
718,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,12/13/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6024-10,available
719,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,12/13/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6025-10,available
720,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,12/13/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6026-05,available
721,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,12/13/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6027-25,available
722,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,12/13/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6028-25,available
723,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,12/13/19,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6029-25,not available
724,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,12/13/19,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6030-01,not available
725,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-02,available
726,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-25,available
727,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-05,available
728,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-20,available
729,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/18,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/18,5/23/18,0378-5036-05,discontinued
730,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0555-0997-02,
731,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-01,
732,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-02,
733,Flumazenil Injection,Mylan,"1 mg in 10 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-444-10)",Revised,7/19/19,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,7/19/19,7/19/19,67457-444-10,discontinued
734,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/19,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/19,12/16/19,67457-447-53,discontinued
735,Fluorescein Injection,Novartis,Fluorescite (fluorescein injection) 10% 5 mL vial (NDC 0065-0092-65),Reverified,12/11/19,Available,,,Other,Ophthalmology,Current,,,0065-0092-65,available
736,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 10%, 100 mg/mL in a 5 mL single use vial (NDC 17478-253-10)",Revised,12/2/19,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,17478-253-10,available
737,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 25%, 250 mg/mL in a 2 mL single use vial (NDC 17478-250-20)",Revised,12/2/19,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,17478-250-20,available
738,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Altafluor Solution Fluorescein sodium 0.25% and Benoxinate HCl 0.4%, 5 mL bottle (NDC 59390-0218-05)",Revised,12/10/19,,,,,Ophthalmology,Resolved,12/10/19,,59390-0218-05,
739,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Flurox Solution  Fluorescein sodium 2.5mg (0.25%), benoxinate hydrochloride 4mg (0.4%), 5mL bottle (NDC 54799-508-05)",Revised,12/11/19,,,,,Ophthalmology,Resolved,12/11/19,,54799-508-05,
740,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,10/23/19,Available,,,,Ophthalmology,Current,,,,available
741,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,10/23/19,Available,,,,Ophthalmology,Current,,,17238-900-30,available
742,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,12/2/19,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,17478-404-01,not available
743,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,12/2/19,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,17478-403-03,not available
744,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-01,discontinued
745,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-10,discontinued
746,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-01,discontinued
747,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-10,discontinued
748,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-01,discontinued
749,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-10,discontinued
750,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-31,discontinued
751,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 28 count bottle (NDC 0378-5410-28)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-5410-28,discontinued
752,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"20 mg, 28 count bottle (NDC 0378-5420-28)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-5420-28,discontinued
753,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-6004-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6004-01,discontinued
754,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 500 count bottle (NDC 0378-6004-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6004-05,discontinued
755,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 100 count bottle (NDC 0378-6009-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6009-01,discontinued
756,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 500 count bottle (NDC 0378-6009-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6009-05,discontinued
757,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6074-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6074-01,discontinued
758,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6074-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6074-05,discontinued
759,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6097-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6097-01,discontinued
760,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6097-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6097-05,discontinued
761,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 15mg C 100s (NDC 0378-4415-01),Reverified,11/26/19,Out of Stock. Resupply is Q4 2019.,,,Other,Psychiatry,Current,,,0378-4415-01,not available
762,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 30mg C 100s (NDC 0378-4430-01),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,Other,Psychiatry,Current,,,0378-4430-01,not available
763,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-0076-01)",New,5/2/19,,,,,Rheumatology,To be Discontinued,5/2/19,5/2/19,0378-0076-01,discontinued
764,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0093-01)",New,5/2/19,,,,,Rheumatology,To be Discontinued,5/2/19,5/2/19,0378-0093-01,discontinued
765,"Flutamide Capsules, USP",Teva Pharmaceuticals,125 mg 180 count (NDC 0591-2466-18),New,6/10/19,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,6/10/19,6/10/19,0591-2466-18,discontinued
766,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 30 count bottle (NDC 0378-5121-93)",New,5/2/19,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5121-93,discontinued
767,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5121-01)",New,5/2/19,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5121-01,discontinued
768,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,12/6/19,On backorder. Estimated availability January 2020,,,Shortage of an active ingredient,Psychiatry,Current,,,10370-175-11,not available
769,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,12/16/19,On backorder. Estimated availability January 2020,,,Shortage of an active ingredient,Psychiatry,Current,,,10370-176-11,not available
770,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0228-2848-03,available
771,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0228-2849-03,available
772,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 100 (NDC 0603-3162-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-21,discontinued
773,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 1000 (NDC 0603-3162-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-32,discontinued
774,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 2500 (NDC 0603-3162-30)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-30,discontinued
775,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 100 count (NDC 0093-4443-01)",New,12/6/18,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2636-11 Gabapentin Tablets, 600mg, 100 count.",,,,Neurology,To be Discontinued,12/6/18,12/6/18,0093-4443-01,discontinued
776,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 500 count (NDC 0093-4443-05)",New,12/6/18,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2636-50 Gabapentin Tablets, 600mg, 500 count.",,,,Neurology,To be Discontinued,12/6/18,12/6/18,0093-4443-05,discontinued
777,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 600 mg, 1000 count (NDC 0093-4443-10)",New,12/6/18,This was a business-related decision to discontinue manufacturing these products.,,,,Neurology,To be Discontinued,12/6/18,12/6/18,0093-4443-10,discontinued
778,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 800 mg, 100 count (NDC 0093-4444-01)",New,12/6/18,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2637-11 Gabapentin Tablets, 800mg, 100 count.",,,,Neurology,To be Discontinued,12/6/18,12/6/18,0093-4444-01,discontinued
779,Gabapentin Tablets,Teva Pharmaceuticals,"Gabapentin Tablets USP, 800 mg, 500 count (NDC 0093-4444-05)",New,12/6/18,"This was a business-related decision to discontinue manufacturing these products. TEVA is replacing this same strength product under NDC 0228-2637-50 Gabapentin Tablets, 600mg, 500 count.",,,,Neurology,To be Discontinued,12/6/18,12/6/18,0093-4444-05,discontinued
780,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 5 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-81)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-81,discontinued
781,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 10 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-82)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-82,discontinued
782,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 15 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-83)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-83,discontinued
783,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 20 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-84)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-84,discontinued
784,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 10 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-36)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-36,discontinued
785,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 15 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-37)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-37,discontinued
786,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 20 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-38)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-38,discontinued
787,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 50 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-58)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-58,discontinued
788,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 100 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-11)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-11,discontinued
789,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,4 mg tablets (NDCs 50458-396-60 and 10147-0881-6),New,10/29/18,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/18,10/29/18,,discontinued
790,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,8 mg tablets (NDCs 50458-397-60 and 10147-0882-6),New,10/29/18,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/18,10/29/18,,discontinued
791,Galantamine Hydrobromide Tablets,Janssen Pharmaceuticals,12 mg tablets (NDCs 50458-398-60 and 10147-0883-6),New,10/29/18,,The last batches will be distributed April 2019.,,,Neurology,To be Discontinued,10/29/18,10/29/18,,discontinued
792,Gemcitabine Hydrochloride Injection,Mylan,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/19,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/19,12/16/19,67457-462-01,discontinued
793,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,12/18/19,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-07,unclear
794,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,12/18/19,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-05,unclear
795,Glimepiride Tablets,Teva Pharmaceuticals,1 mg 100 Count (NDC 0093-7254-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7254-01,discontinued
796,Glimepiride Tablets,Teva Pharmaceuticals,2 mg 100 Count (NDC 0093-7255-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7255-01,discontinued
797,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 100 Count (NDC 0093-7256-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7256-01,discontinued
798,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 250 Count (NDC 0093-7256-52),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7256-52,discontinued
799,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1061-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1061-01,discontinued
800,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-1062-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1062-01,discontinued
801,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"3 mg, 100 count bottle (NDC 0378-1063-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1063-01,discontinued
802,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"4 mg, 100 count bottle (NDC 0378-1065-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1065-01,discontinued
803,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",New,6/12/19,Available,,,Other,Cardiovascular,Current,,,42806-048-01,available
804,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",New,6/12/19,Available,,,Other,Cardiovascular,Current,,,42806-296-01,available
805,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-1160-01),Reverified,11/26/19,Unavailable. Estimated recovery: Q1 2020.,,,Other,Cardiovascular,Current,,,0378-1160-01,not available
806,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-1190-01),Reverified,11/26/19,Unavailable. Estimated recovery: Q1 2020.,,,Other,Cardiovascular,Current,,,0378-1190-01,not available
807,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Reverified,12/16/19,"Available, however limited supply until mid December 2019",,,Shortage of an active ingredient,Cardiovascular,Current,,,0591-0444-01,limited availability
808,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Reverified,12/16/19,Available,,,,Cardiovascular,Current,,,0591-0453-01,available
809,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,12/17/19,Available,,,Other,Cardiovascular,Current,,,65162-711-03,available
810,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,12/17/19,Available,,,Other,Cardiovascular,Current,,,65162-713-03,available
811,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0351-01,
812,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0257-01,
813,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0214-01,
814,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0327-01,
815,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0334-01,
816,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0355-01,
817,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-01,
818,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-10,
819,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-080-01,
820,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-081-01,
821,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9101,
822,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9101,
823,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9113,
824,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9201,
825,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9201,
826,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
827,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9801,
828,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
829,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9610,
830,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9610,
831,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9601,
832,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9601,
833,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9613,
834,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9701,
835,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9701,
836,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9713,
837,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9301,
838,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium BP 2,000 IU/L  in 0.9% w/v Sodium Chloride IV Infusion in VIAFLEX container  (1,000 units / 500 mL)  Product code FKB0953G (NDC 0338-9556-20)",Revised,12/11/19,Available,Baxter Healthcare Corporation in conjunction with FDA has initiated temporary importation of Heparin IV Infusion into the U.S. market to address drug shortages.,,,Hematology,Current,,,0338-9556-20,available
839,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,12/11/19,Available,,,,Hematology,Current,,,0338-0433-04,available
840,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,12/11/19,Unavailable,,,Other,Hematology,Current,,,0338-0431-03,not available
841,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Reverified,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,00409-7620-03,limited availability
842,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Reverified,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,00409-7620-59,limited availability
843,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  AHB0953U  (NDC 0338-0424-18)",New,12/11/19,Available,,,,Hematology,Current,,,0338-0424-18,available
844,Hydrochlorothiazide (Microzide) Capsules,Allergan Sales LLC,12.5 mg (NDC 52544-622-01),New,10/22/19,,"The authorized generic, Hydrochlorothiazide Capsules, USP, 12.5 mg remains commercially available.",,,Cardiovascular,To be Discontinued,10/22/19,10/22/19,52544-622-01,discontinued
845,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2025-01,discontinued
846,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2012-01,discontinued
847,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-1012-01,discontinued
848,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/18,6/5/18,0574-1105-16,discontinued
849,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-12,discontinued
850,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-24,discontinued
851,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-01,discontinued
852,"Hydrocortisone Butyrate Cream USP, 0.1%",Teva Pharmaceuticals,"Hydrocortisone Butyrate Cream USP, 0.1% (Lipophilic), 45 g/Tube, (NDC 0472-0490-45)",New,12/21/18,,This was a business-related decision to discontinue manufacturing these products.,,,Dermatology,To be Discontinued,12/21/18,12/21/18,0472-0490-45,discontinued
853,"Hydrocortisone Butyrate Cream USP, 0.1%",Teva Pharmaceuticals,"Hydrocortisone Butyrate Cream USP, 0.1% (Lipophilic), 60 g/Tube, (NDC 0472-0490-60)",New,12/21/18,,This was a business-related decision to discontinue manufacturing these products.,,,Dermatology,To be Discontinued,12/21/18,12/21/18,0472-0490-60,discontinued
854,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"5 mg, bottle of 50 (NDC 0603-3899-19)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3899-19,discontinued
855,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"10 mg, bottle of 100 (NDC 0603-3900-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3900-21,discontinued
856,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"20 mg, bottle of 100 (NDC 0603-3901-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3901-21,discontinued
857,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"32 mg, 100 count (NDC 0591-3631-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3631-01,discontinued
858,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"16 mg, 100 count (NDC 0591-3630-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3630-01,discontinued
859,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"12 mg, 100 count (NDC 0591-3739-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3739-01,discontinued
860,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"8 mg, 100 count (NDC 0591-3629-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3629-01,discontinued
861,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Reverified,12/20/19,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-06,available
862,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Reverified,12/20/19,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-11,available
863,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-852-25,available
864,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-853-25,available
865,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-854-10,available
866,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Reverified,12/20/19,Backordered.  Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-10,not available
867,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-15,available
868,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-50,available
869,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,12/13/19,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-0121-25,available
870,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,12/13/19,Temporarily on backorder.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-2341-41,not available
871,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1283-05,available
872,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1283-10,not available
873,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1312-10,not available
874,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1283-31,available
875,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1312-30,available
876,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,12/20/19,Next Delivery and Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1304-31,not available
877,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2552-01,limited availability
878,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,12/20/19,Next Delivery: April 2020; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-3356-01,not available
879,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2540-01,not available
880,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-3365-01,available
881,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2634-01,limited availability
882,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-05,available
883,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-50,available
884,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Revised,12/2/19,Unavailable. Estimataed recovery Dec 2019,"Expected availability Dec, 2019",,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-01,not available
885,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Revised,12/2/19,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-05,available
886,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Revised,12/2/19,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-50,available
887,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Reverified,12/20/19,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-05,unclear
888,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Reverified,12/20/19,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-10,unclear
889,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Reverified,12/20/19,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-010-10,not available
890,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Reverified,12/20/19,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-011-10,not available
891,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,12/16/19,Available,,,Other,Analgesia/Addiction,Current,,,,available
892,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,12/16/19,Available,,,Other,Analgesia/Addiction,Current,,,0703-0113-03,available
893,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,12/16/19,Available,,,Other,Analgesia/Addiction,Current,,,0703-0018-01,available
894,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,0517-1767-01,
895,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-104-01,
896,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-247-02,
897,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
898,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-243-01,
899,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
900,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-309-01,
901,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-310-01,
902,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-105-01,
903,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0555-0324-02,available
904,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0555-0323-02,available
905,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0555-0323-04,available
906,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0555-0302-02,available
907,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Reverified,12/16/19,Available,,,Other,Psychiatry,Current,,,0555-0302-04,available
908,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Reverified,12/18/19,Limited monthly supply through September due to increase in demand.  Working to increase production to meet current demand.,,,Demand increase for the drug,Psychiatry,Current,,,0185-0674-01,limited availability
909,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Reverified,12/18/19,Limited monthly supply through September due to increase in demand.  Working to increase production to meet current demand.,,,Demand increase for the drug,Psychiatry,Current,,,0185-0674-05,limited availability
910,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,12/13/19,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1803-01,limited availability
911,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,12/13/19,Expected to be on allocation until sometime in 1Q20.,,,OIther,Psychiatry,Current,,,00115-1803-02,limited availability
912,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,12/13/19,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1804-01,limited availability
913,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,12/13/19,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1804-02,limited availability
914,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Reverified,12/20/19,Next delivery and Estimated recovery: July 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Psychiatry,Current,,,0069-5410-66,not available
915,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Reverified,12/20/19,Available,,,Other,Psychiatry,Current,,,0069-5420-66,available
916,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),New,11/15/19,Available,,,Other,Psychiatry,Current,,,14539-674-01,available
917,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),New,11/15/19,Available,,,Other,Psychiatry,Current,,,14539-674-05,available
918,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),New,11/15/19,Available,,,Other,Psychiatry,Current,,,14539-675-01,available
919,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),New,11/15/19,Available,,,Other,Psychiatry,Current,,,14539-675-05,available
920,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,1 gram/20 mL; 1 gram/10 mL  (NDCs 0703-4100-48 and 0703-4100-58),New,10/18/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/19,10/18/19,,discontinued
921,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,3 gram/60 mL; 1 gram/10 mL (NDC 0703-4100-68 ),New,10/18/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/19,10/18/19,0703-4100-68,discontinued
922,"Imipenem and Cilastatin for Injection, USP",Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,12/18/17,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,0006-3516-59,available
923,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-349-25,available
924,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,12/20/19,Available,Check wholesaler inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-322-25,available
925,"Imipenem and Cilastatin for Injection, USP","Hospira, Inc.",500 mg/500 mg; Single Dose Glass Fliptop Vial (NDC 00409-3507-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,00409-3507-01,not available
926,"Imipenem and Cilastatin for Injection, USP","Hospira, Inc.",250 mg/250 mg; Single Dose Glass Fliptop Vial (NDC 00409-3508-01),Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,00409-3508-01,not available
927,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-01,discontinued
928,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-10,discontinued
929,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-01,discontinued
930,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-05,discontinued
931,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4350-01,discontinued
932,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4351-01,discontinued
933,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4352-01,discontinued
934,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01),New,9/12/19,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-1168-01,discontinued
935,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01),New,9/12/19,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-1133-01,discontinued
936,Isocarboxazid Tablets,Validus Pharmaceuticals LLC,10mg (NDC 30698-032-01),Reverified,12/10/19,"Due to the current critical shortage of Isocarboxazid Tablets in the United States (US) market, Validus Pharmaceuticals LLC is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Isocarboxazid Tablets. Validus has initiated temporary importation of another manufacturer’s Isocarboxazid Tablets into the U.S. market.  This product is manufactured and marketed in Denmark by MediLink. MediLink's Marplan is commercially available under a new NDC 72604-032-01.",,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,30698-032-01,available
937,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 100 (NDC 0603-4110-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-21,discontinued
938,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 500 (NDC 0603-4110-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-28,discontinued
939,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 1000 (NDC 0603-4110-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-32,discontinued
940,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 100 (NDC 0603-4111-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-21,discontinued
941,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 500 (NDC 0603-4111-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-28,discontinued
942,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 1000 (NDC 0603-4111-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-32,discontinued
943,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"120 mg, bottle of 100 (NDC 0603-4112-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4112-21,discontinued
944,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Reverified,12/13/19,Inventory is currently available.,,,,Anesthesia,Current,,,0143-9509-10,available
945,Ketamine Injection,Mylan Institutional,200 mg / 20 mL (NDC 67457-181-20),Reverified,11/26/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-181-20,available
946,Ketamine Injection,Mylan Institutional,500 mg / 10 mL (NDC 67457-001-10),Reverified,11/26/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-001-10,available
947,Ketamine Injection,Mylan Institutional,1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/26/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-108-10,available
948,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,12/20/19,Next Delivery: February 2020; Estimated Recovery: June 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-2051-05,not available
949,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,12/20/19,Next Delivery: January 2020; Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-2053-10,not available
950,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Reverified,12/13/19,Inventory is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9508-10,available
951,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Reverified,12/16/19,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,42023-113-10,available
952,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Reverified,12/16/19,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,42023-115-10,available
953,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Reverified,12/16/19,Product is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,42023-114-10,available
954,Ketoconazole Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0261-01)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-0261-01,discontinued
955,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-10,discontinued
956,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,11/25/19,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-10,available
957,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,11/25/19,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-11,available
958,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,11/25/19,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-01,discontinued
959,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,11/25/19,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-10,discontinued
960,Ketoprofen Capsules,Mylan Pharmaceuticals Inc.,"200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/26/19,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/16,,0378-8200-01,available
961,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-01,discontinued
962,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3193-01,not available
963,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-01,not available
964,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,12/16/19,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-05,not available
965,Ketorolac Tromethamine Injection,Gland Pharma,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,70860-700-01,available
966,Ketorolac Tromethamine Injection,Gland Pharma,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,70860-701-01,available
967,Ketorolac Tromethamine Injection,Gland Pharma,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Analgesia/Addiction,Current,,,70860-701-02,available
968,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,12/20/19,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,25021-700-01,not available
969,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,12/20/19,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-02,not available
970,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,12/20/19,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-01,not available
971,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Revised,12/20/19,Next Delivery: August 2020; Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2287-23,not available
972,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2287-31,not available
973,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Revised,12/20/19,Next Delivery: August 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2287-61,not available
974,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-3793-01,available
975,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-3795-01,available
976,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-3796-01,available
977,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/18,Available,,,Other,Analgesia/Addiction,Current,,,69543-0386-25,available
978,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Revised,12/13/19,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6041-25,unclear
979,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Revised,12/13/19,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6042-25,unclear
980,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Revised,12/13/19,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6043-25,unclear
981,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,12/20/19,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-161-01,available
982,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-01,not available
983,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-02,not available
984,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",New,12/12/19,Unavailable (anticipated delivery in January 2020),FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,0338-0072-25,not available
985,Ketorolac Tromethamine Injection,Gland Pharma,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,12/16/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-118-25,available
986,Ketorolac Tromethamine Injection,Gland Pharma,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,12/16/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,72266-119-25,available
987,Labetalol Hydrochloride Injection,Gland Pharma,"5mg/mL, 20 mL vial (NDC 72266-102-01)",Reverified,12/11/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-102-01,available
988,Labetalol Hydrochloride Injection,Gland Pharma,"5 mg/mL, 40 mL vial (NDC 72266-103-01)",Reverified,12/11/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-103-01,available
989,Labetalol Hydrochloride Injection,"Hospira, Inc.",100 mg/20 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-20),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: February 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2267-20,not available
990,Labetalol Hydrochloride Injection,"Hospira, Inc.",200 mg/40 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-54),Reverified,12/20/19,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2267-54,not available
991,Labetalol Hydrochloride Injection,"Hospira, Inc.",20 mg/4 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2339-34),Reverified,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2339-34,limited availability
992,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (100mg/20mL) Multi-Dose vial (NDC 17478-420-20),Revised,12/2/19,Available,,,Other,Cardiovascular,Current,,,17478-420-20,available
993,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (200mg/40mL) Multi-Dose vial (NDC 17478-420-40 ),Revised,12/2/19,Available,,,Other,Cardiovascular,Current,,,17478-420-40,available
994,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 20 mL multidose vial (NDC 0143-9622-01)",Revised,12/13/19,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9622-01,not available
995,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 40 mL multidose vial (NDC 0143-9623-01)",Revised,12/13/19,Currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9623-01,available
996,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5180-91,discontinued
997,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5168-93,discontinued
998,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5169-91,discontinued
999,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5170-93,discontinued
1000,Lamotrigine Tablets,Teva Pharmaceuticals,25 mg tablets (NDCs 0093-0032-05 and 0093-0039-01),New,12/21/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,12/21/18,12/21/18,,discontinued
1001,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 100 (NDC 69097-148-07),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-07,discontinued
1002,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 500 (NDC NDC 69097-148-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-12,discontinued
1003,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 1000 (NDC 69097-148-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-15,discontinued
1004,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 100 (NDC 69097-149-07),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-07,discontinued
1005,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 500 (NDC 69097-149-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-12,discontinued
1006,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 1000 (NDC 69097-149-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-15,discontinued
1007,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 60 (NDC 69097-151-03),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-03,discontinued
1008,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 500 (NDC 69097-151-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-12,discontinued
1009,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 1000 (NDC 69097-151-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-15,discontinued
1010,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 60 (NDC 69097-152-03),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-03,discontinued
1011,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 500 (NDC 69097-152-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-12,discontinued
1012,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 1000 (NDC 69097-152-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-15,discontinued
1013,Lamotrigine Tablets,Teva Pharmaceuticals,100 mg (NDCs 0093-0463-01 and 0093-0463-05),New,10/15/19,,This product is being discontinued due to a business decision.,,,Neurology,To be Discontinued,10/15/19,10/15/19,,discontinued
1014,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/18,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,59212-245-55,discontinued
1015,Latanoprost Ophthalmic Solution 0.005%,Sandoz,2.5 mL Bottle (NDC 61314-547-01),Reverified,12/18/19,Available,,,,Ophthalmology,Current,,,61314-547-01,available
1016,Latanoprost Ophthalmic Solution 0.005%,Pfizer Pharmaceuticals,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 59762-0333-2)",Reverified,12/20/19,Next Delivery: December 2019;  Estimated Recovery: March 2020,Limited Supply Available.  Please check with your wholesaler for available inventory,,Demand increase for the drug,Ophthalmology,Current,,,59762-0333-2,not available
1017,Latanoprost Ophthalmic Solution 0.005%,Bausch Health,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 24208-463-25)",Reverified,12/13/19,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,,Ophthalmology,Current,,,24208-463-25,available
1018,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 5 count bottle (NDC 70785-011-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-011-05,discontinued
1019,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 30 count bottle (NDC 70785-011-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-011-30,discontinued
1020,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200mg tablets 5 count bottle (NDC 70785-021-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-021-05,discontinued
1021,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 30 count bottle (NDC 70785-021-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-021-30,discontinued
1022,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 90 count bottle (NDC 70785-021-90),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-021-90,discontinued
1023,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 5 count bottle (NDC 70785-022-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-05,discontinued
1024,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 30 count bottle (NDC 70785-022-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-30,discontinued
1025,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 90 count bottle (NDC 70785-022-90),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-90,discontinued
1026,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,12/2/19,Available,,,Other,Antiviral,Current,,,0006-5004-01,available
1027,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,12/2/19,Available,,,Other,Antiviral,Current,,,0006-5003-01,available
1028,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Reverified,12/20/19,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-828-50,limited availability
1029,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,12/20/19,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,63323-710-50,available
1030,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,12/20/19,Backordered. Next release January 2020.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,63323-711-00,not available
1031,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Reverified,12/20/19,Backordered. Estimated availability May-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-813-10,not available
1032,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Reverified,12/20/19,Backordered. Estimated availability May-2021,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-814-30,not available
1033,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Reverified,12/20/19,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-815-30,limited availability
1034,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Reverified,12/20/19,On allocation. Estimated availability Mar-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-816-30,limited availability
1035,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,12/16/19,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5140-01,available
1036,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,12/16/19,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5145-01,available
1037,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,Lupron Depot 3.75 mg PDS kit (NDC 0074-3641-03),Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3641-03,available
1038,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot Ped, 3Month, 11.25 mg kit (NDC 0074-3379-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3379-03,available
1039,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot Ped, 3Month, 30 mg kit (NDC 0074-9694-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-9694-03,available
1040,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 3Month, 11.25 mg PDS kit (NDC 0074-3663-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3663-03,available
1041,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 3Month, 22.5 mg PDS kit (NDC 0074-3346-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3346-03,available
1042,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 4Month, 30 mg PDS kit (NDC 0074-3683-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3683-03,available
1043,Leuprolide Acetate (Lupron Depot; Lupron Depot Ped) Injection,Abbvie,"Lupron Depot, 6Month 45 mg PDS kit (NDC 0074-3473-03)",Revised,12/17/19,Available,,,Other,Endocrinology/Metabolism;Oncology,Current,12/9/19,12/9/19,0074-3473-03,available
1044,Leuprolide Acetate Injection,Sandoz,Leuprolide Acetate Injection 1mg/0.2ml (14mg/2.8ml)(NDC 0781-4003-32),Revised,5/10/19,,,Available,,Oncology,Resolved,5/10/19,,0781-4003-32,
1045,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 500 mg 60 ct. bottle; (NDC 69102-200-60)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-200-60,discontinued
1046,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 750 mg 60 ct. bottle; (NDC 69102-201-60)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-201-60,discontinued
1047,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,500mg (NDC 0591-3635-60),New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/19,6/7/19,0591-3635-60,discontinued
1048,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,750mg (NDC 0591-3699-60),New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/19,6/7/19,0591-3699-60,discontinued
1049,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Revised,11/27/19,"Backorder, Estimated Resupply February 2020",,,Demand increase for the drug,Neurology,Current,,,60505-3280-06,not available
1050,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Revised,11/27/19,"Backorder, Estimated Resupply February 2020",,,Demand increase for the drug,Neurology,Current,,,60505-3517-06,not available
1051,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Revised,12/3/19,"Back-order, Estimated re-supply: TBD",,,Demand increase for the drug,Neurology,Current,,,4733557386,not available
1052,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Revised,12/3/19,"Back-order, Estimated re-supply: TBD",,,Demand increase for the drug,Neurology,Current,,,4733557686,not available
1053,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Reverified,12/17/19,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,68180-117-07,limited availability
1054,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Reverified,12/17/19,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,68180-118-07,limited availability
1055,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-598-66,available
1056,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-599-66,available
1057,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0345-06,not available
1058,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0345-50,not available
1059,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0346-06,not available
1060,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0346-50,not available
1061,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Revised,12/13/19,Available,,,,Neurology,Current,,,13668-014-12,available
1062,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Revised,12/13/19,Available,,,,Neurology,Current,,,13668-015-12,available
1063,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Revised,12/13/19,Available,,,,Neurology,Current,,,13668-016-12,available
1064,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Revised,12/13/19,Available,,,,Neurology,Current,,,13668-016-05,available
1065,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Revised,12/13/19,Available,,,Shortage of Active Ingredient,Neurology,Current,,,13668-017-60,available
1066,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-594-40,available
1067,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-595-40,available
1068,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-596-40,available
1069,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Reverified,12/3/19,Available,,,,Neurology,Current,,,50474-597-66,available
1070,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Reverified,12/13/19,Available,,,,Neurology,Current,,,65862024508,available
1071,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Reverified,12/13/19,Available,,,,Neurology,Current,,,65862024608,available
1072,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Reverified,12/13/19,Available,,,,Neurology,Current,,,65862031560,available
1073,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Reverified,12/13/19,Available,,,,Neurology,Current,,,65862024708,available
1074,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1075,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1076,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1077,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1078,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1079,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Reverified,12/17/19,Available,,,,Neurology,Current,,,,available
1080,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Reverified,12/17/19,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
1081,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Reverified,12/17/19,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
1082,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Reverified,12/17/19,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
1083,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Reverified,12/17/19,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
1084,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053612,available
1085,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053605,available
1086,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053712,available
1087,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053705,available
1088,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053812,available
1089,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053805,available
1090,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0221-15,not available
1091,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0222-15,not available
1092,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0222-11,not available
1093,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0223-15,not available
1094,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0224-06,not available
1095,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Revised,11/26/19,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,0378-5613-78,not available
1096,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Revised,11/26/19,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,0378-5613-05,not available
1097,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Revised,11/26/19,"Unavailable, recovery in January 2020",,,Shortage of active ingredient,Neurology,Current,,,0378-5615-05,not available
1098,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Revised,11/26/19,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5615-78,available
1099,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Revised,11/26/19,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5617-78,available
1100,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Revised,11/26/19,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5617-05,available
1101,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Revised,11/26/19,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5619-91,available
1102,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 500 mg (120 count; (NDC 69102-104-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-104-01,discontinued
1103,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 750 mg (120 count; (NDC 69102-102-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-102-01,discontinued
1104,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 1000 mg 60 count; (NDC  69102-103-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-103-01,discontinued
1105,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (17.5 mL)(NDC 67457-600-20),New,6/25/19,,,,,Oncology,To be Discontinued,6/25/19,6/25/19,67457-600-20,discontinued
1106,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (25 mL)(NDC 67457-601-30),New,6/25/19,,,,,Oncology,To be Discontinued,6/25/19,6/25/19,67457-601-30,discontinued
1107,Levonorgestrel and Ethinyl Estradiol Tablets 0.1mg/0.02mg,Mylan Pharmaceuticals Inc.,"0.1mg/0.02mg Tablets, NDC (0378-7298-53)",New,1/2/19,,,,,Reproductive,To be Discontinued,1/2/19,1/2/19,,discontinued
1108,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-26,discontinued
1109,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-30,discontinued
1110,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,12/11/19,Available,,,,Cardiovascular,Current,,,0338-0409-03,available
1111,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,12/11/19,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
1112,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Revised,12/11/19,Product available,,,Other,Cardiovascular,Current,,,00264-9598-20,available
1113,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Revised,12/11/19,Product available,,,Other,Cardiovascular,Current,,,00264-9594-20,available
1114,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Revised,12/11/19,Product on allocation to contracted customers,,,Other,Cardiovascular,Current,,,00264-9594-10,limited availability
1115,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,available
1116,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,12/11/19,Currently on backorder,Next shipment expected Jan. 2020,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,not available
1117,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,available
1118,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-161-02,available
1119,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-162-05,available
1120,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-163-30,available
1121,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-164-02,available
1122,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-165-05,available
1123,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-31,not available
1124,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,12/20/19,Next Delivery: April 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-9137-05,not available
1125,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1.5%; 20mL Sterile Pack Amp (NDC 0409-4056-01),Revised,12/20/19,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,0409-4056-01,discontinued
1126,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4713-32,available
1127,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4276-01,available
1128,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4279-02,not available
1129,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02),Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4276-02,available
1130,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1%; 30 mL Sterile Pack vial (NDC 0409-4270-01),Revised,12/20/19,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,0409-4270-01,discontinued
1131,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4282-01,available
1132,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4282-02,available
1133,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,12/20/19,Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4904-34,not available
1134,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,12/20/19,Next Delivery: January 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4903-34,not available
1135,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: January 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-2066-05,limited availability
1136,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4277-01,available
1137,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4277-02,available
1138,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4283-01,available
1139,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-1323-05,not available
1140,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverfied,12/16/19,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Anesthesia;Pediatric,Current,,,76329-3390-1,limited availability
1141,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,11/27/19,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00517-0625-25,discontinued
1142,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,12/20/19,Backordered. Next release date not available at this time.,All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-97,not available
1143,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,12/20/19,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-91,not available
1144,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0202-02,available
1145,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0208-05,available
1146,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-17,available
1147,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-27,available
1148,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-57,available
1149,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,12/20/19,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-10,not available
1150,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,12/20/19,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-20,not available
1151,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,12/20/19,No release date available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-50,not available
1152,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-27,available
1153,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-07,available
1154,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0496-97,not available
1155,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4275-01,limited availability
1156,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (50 mg/mL); Glass Ampul (NDC 0409-4712-01),Revised,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4712-01,not available
1157,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4278-01,limited availability
1158,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,12/20/19,Next Delivery and  Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4713-02,not available
1159,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0484-57,not available
1160,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0491-57,available
1161,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,12/20/19,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-02,not available
1162,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-10,available
1163,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-27,available
1164,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,12/20/19,Backordered. Next release December 2019.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-57,not available
1165,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-27,available
1166,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,12/20/19,Backordered. No release expectations at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-80,not available
1167,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,12/20/19,Backordered. No release expectations at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-89,not available
1168,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-57,available
1169,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-37,available
1170,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,12/20/19,Next Delivery and Estimated Recovery: February 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4776-01,not available
1171,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-251-10,available
1172,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-252-20,available
1173,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-254-10,available
1174,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-255-20,available
1175,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,12/13/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9595-25,available
1176,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,12/13/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9594-25,available
1177,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,12/13/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9577-10,available
1178,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,12/13/19,Available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9575-10,available
1179,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/18,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,65282-1605-1,available
1180,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0482-17,not available
1181,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0487-17,not available
1182,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,12/20/19,Available,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0488-17,available
1183,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,12/20/19,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0489-17,not available
1184,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,12/20/19,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-0996-01,discontinued
1185,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,00409-3177-01,available
1186,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,00409-3178-01,available
1187,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,00409-3178-02,limited availability
1188,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-3178-03,limited availability
1189,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-1209-01,available
1190,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3181-01,available
1191,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-3182-01,not available
1192,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,12/20/19,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3182-02,available
1193,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-3182-03,limited availability
1194,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,12/20/19,Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-3183-01,not available
1195,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,12/20/19,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-7263-01,discontinued
1196,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3611-01,discontinued
1197,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3612-01,discontinued
1198,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1/4 (NDC 0456-0040-01),New,12/6/18,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/18,12/6/18,0456-0040-01,discontinued
1199,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1/2 (NDC 0456-0045-01),New,12/6/18,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/18,12/6/18,0456-0045-01,discontinued
1200,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-1 (NDC 0456-0050-01),New,12/6/18,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/18,12/6/18,0456-0050-01,discontinued
1201,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-2 (NDC 0456-0055-01),New,12/6/18,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/18,12/6/18,0456-0055-01,discontinued
1202,Liotrix (Thyrolar) Tablets,Allergan,Thyrolar-3 (NDC 0456-0060-01),New,12/6/18,,"The company has made a business decision to discontinue manufacturing of Thyrolar® (Liotrix tablets, USP) ¼, ½, 1, 2 and 3 grains",,,Endocrinology/Metabolism,To be Discontinued,12/6/18,12/6/18,0456-0060-01,discontinued
1203,Lisinopril (Prinivil) Tablets,Merck Sharp & Dohme Corp.,"5-mg tablets, unit-of-use bottle/90 (NDC 0006-0019-54)",New,3/11/19,,To be discontinued on or near April 2019.,,,Cardiovascular,To be Discontinued,3/11/19,,0006-0019-54,discontinued
1204,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/18,4/11/18,0378-2072-01,discontinued
1205,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,12/20/19,Next delivery: January 2020 Estimated Recovery: December 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-1539-31,not available
1206,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,12/20/19,Available,,,Other,Neurology,Current,,,00409-1985-30,available
1207,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,12/20/19,Available,,,Other,Neurology,Current,,,00409-6778-02,available
1208,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,12/20/19,Available,,,Other,Neurology,Current,,,00409-6779-02,available
1209,"Lorazepam Injection, USP","Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-6780-02,limited availability
1210,"Lorazepam Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,12/16/19,Available,,,Other,Neurology,Current,,,76329-8261-1,available
1211,"Lorazepam Injection, USP",Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Revised,12/2/19,Available,,,Demand increase for the drug,Neurology,Current,,,17478-040-01,available
1212,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6001-25,available
1213,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6000-10,available
1214,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6003-25,available
1215,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
1216,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6044-25,available
1217,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6046-10,available
1218,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6045-25,available
1219,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
1220,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1394-10,discontinued
1221,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1395-10,discontinued
1222,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1396-10,discontinued
1223,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1397-10,discontinued
1224,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",New,11/25/19,"Out of stock, estimated availability in January/February 2020",Additional lots are scheduled for release in the January/February timeframe. Product will be made available as it is released.,,Other,Psychiatry,Current,,,0527-1394-01,not available
1225,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/19,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1394-10,not available
1226,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",New,11/25/19,Allocating inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,0527-1395-01,limited availability
1227,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/19,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1395-10,not available
1228,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",New,11/25/19,Allocating Inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,0527-1396-01,limited availability
1229,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/19,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1396-10,not available
1230,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",New,11/25/19,Allocating Inventory,Additional lots are scheduled for release in the January/February timeframe.,,Other,Psychiatry,Current,,,0527-1397-01,limited availability
1231,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/19,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1397-10,not available
1232,Loxapine Capsules,Mylan,"5 mg, 100 count bottle (NDC 0378-7005-01)",New,11/25/19,End Q1 2020,,,Other,Psychiatry,Current,,,0378-7005-01,not available
1233,Loxapine Capsules,Mylan,"10 mg, 100 count bottle (NDC 0378-7010-01)",New,11/25/19,End Q1 2020,,,Other,Psychiatry,Current,,,0378-7010-01,not available
1234,Loxapine Capsules,Mylan,"25 mg, 100 count bottle (NDC 0378-7025-01)",New,11/25/19,End Q1 2020,,,Other,Psychiatry,Current,,,0378-7025-01,not available
1235,Loxapine Capsules,Mylan,"50 mg, 100 count bottle (NDC 0378-7050-01)",New,11/25/19,End Q1 2020,,,Other,Psychiatry,Current,,,0378-7050-01,not available
1236,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Reverified,12/16/19,Product is available,,,,Psychiatry,Current,,,0591-0369-01,available
1237,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Reverified,12/16/19,Availability and estimated duration of supply interruption is unknown,,,Other,Psychiatry,Current,,,0591-0370-01,unclear
1238,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Reverified,12/16/19,Product is available,,,,Psychiatry,Current,,,0591-0371-01,available
1239,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Reverified,12/16/19,Product is available,,,,Psychiatry,Current,,,0591-0372-01,available
1240,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-01,discontinued
1241,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-10,discontinued
1242,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-01,discontinued
1243,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-10,discontinued
1244,Megestrol Acetate (Megace) Oral Suspension,"Endo Pharmaceuticals, Inc.",MEGACE®ES 625mg/5ml Suspension (NDC 63481-160-38),New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,8/21/19,8/21/19,63481-160-38,discontinued
1245,Megestrol Acetate (Megace) Oral Suspension,Bristol Myers Squibb Co.,40 mg/mL Oral Suspension (NDC 00015-508-42),New,5/6/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/6/19,5/6/19,00015-508-42,discontinued
1246,Mesna Injection,Teva Pharmaceuticals,100 mg/mL (NDC 0703-4805-03),New,6/21/19,,This product discontinuation is a business related decision.,,,Oncology,To be Discontinued,6/21/19,6/21/19,0703-4805-03,discontinued
1247,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"10mg, 100 count (NDC 49884-0258-01)",New,7/12/19,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/19,7/12/19,49884-0258-01,discontinued
1248,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"20mg, 100 count (NDC 49884-0259-01)",New,7/12/19,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/19,7/12/19,49884-0259-01,discontinued
1249,Metformin Hydrochloride (Glucophage XR) Tablets Extended Release,Bristol Myers Squibb Co.,"500mg 100/bottle, (NDC 0087-6063-13)",New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6063-13,discontinued
1250,Metformin Hydrochloride (Glucophage XR) Tablets Extended Release,Bristol Myers Squibb Co.,750mg 100/bottle (NDC 0087-6064-13),New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6064-13,discontinued
1251,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"500mg 100/bottle, (NDC  0087-6060-05)",New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6060-05,discontinued
1252,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"500mg 500/bottle, (NDC 0087-6060-10)",New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6060-10,discontinued
1253,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"850mg 100/bottle, (NDC 0087-6070-05)",New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6070-05,discontinued
1254,Metformin Hydrochloride (Glucophage) Tablets,Bristol Myers Squibb Co.,"1000mg 100/bottle, (NDC 0087-6071-11)",New,2/27/19,,This was a business-related decision to discontinue manufacturing these products,,,Endocrinology/Metabolism,To be Discontinued,2/27/19,2/27/19,0087-6071-11,discontinued
1255,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 750 mg per tablet, (NDC 0093-7212-01), 100 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7212-01,discontinued
1256,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-01), 100 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7267-01,discontinued
1257,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-10), 1000 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7267-10,discontinued
1258,Methadone Hydrochloride Injection,Mylan Institutional,Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Reverified,11/26/19,Available,,,Other,Analgesia/Addiction;Anesthesia,Current,,,67457-217-20,available
1259,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,12/11/19,Backordered. Estimated recovery February/March 2020,,,Other,Analgesia/Addiction;Anesthesia,Current,,,17478-380-20,not available
1260,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.","Robaxin® 500mg, 100 Tablets (NDC 52244-429-10)",New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction;Musculoskeletal,To be Discontinued,8/21/19,8/21/19,52244-429-10,discontinued
1261,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","500 mg, 100 ct (NDC 69584-611-10); 500 ct (NDC 69584-611-50); 1000 ct (NDC 69584-611-90)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,69584-611-10,
1262,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","750 mg, 100 ct (NDC 69584-612-10); 500 ct (NDC 69584-612-50); 1000 ct (NDC 69584-612-90)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,69584-612-10,
1263,Methocarbamol Tablets,"Solco Healthcare US, LLC","500 mg, 100 ct (NDC 43547-0405-10); 500 ct (NDC 43547-0405-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,43547-0405-10,
1264,Methocarbamol Tablets,"Solco Healthcare US, LLC","750 mg, 100 ct (NDC 43547-0226-10); 500 ct (NDC 43547-0226-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,43547-0226-10,
1265,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 70010-754-01); 500 ct (NDC 70010-754-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,70010-754-01,
1266,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 70010-770-01); 500 ct (NDC 70010-770-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,70010-770-01,
1267,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 500 mg, 100 ct (NDC 60429-118-01); 500 ct (NDC 60429-118-05) Distributed by Virus Pharmaceuticals: 500 mg, 100 ct (NDC 69543-134-10); 500 ct (NDC 69543-134-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,60429-118-01,
1268,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 750 mg, 100 ct (NDC 60429-119-01); 500 ct (NDC 60429-119-05) Distributed by Virtus Pharmaceuticals: 750 mg, 100 ct (NDC 69543-135-10); 500 ct (NDC 69543-135-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,60429-119-01,
1269,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 31722-533-01); 500 ct (NDC 31722-533-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,31722-533-01,
1270,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 31722-534-01); 500 ct (NDC 31722-534-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,31722-534-01,
1271,Methocarbamol Tablets,Bayshore Pharmaceuticals,"500 mg, 100 ct (NDC 76385-123-01); 500 ct (NDC 76385-123-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,76385-123-01,
1272,Methocarbamol Tablets,Bayshore Pharmaceuticals,"750 mg, 100 ct (NDC 76385-124-01); 500 ct (NDC 76385-124-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,76385-124-01,
1273,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 2 mL vial (NDC 0143-9519-10)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,0143-9519-10,
1274,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML (NDC 00703-3678-01),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3678-01,
1275,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML Premier label  (NDC 00703-3678-81),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3678-81,
1276,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X10ML (NDC 00703-3675-01),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3675-01,
1277,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML SDV 10X2ML (NDC 00703-3671-03),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3671-03,
1278,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","1 gram per vial, 50 mL vial, SDV (NDC 63323-122-50)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,63323-122-50,
1279,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","250 mg per 10 mL, vial (NDC 63323-123-10)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,63323-123-10,
1280,Methotrexate Sodium Injection,"Hospira, Inc.",50 mg/2 mL (25 mg/mL); Glass Fliptop Vial (NDC 61703-0350-38),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,61703-0350-38,
1281,Methotrexate Sodium Injection,"Hospira, Inc.",1 g/40 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 61703-0408-41),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,61703-0408-41,
1282,Methotrexate Sodium Injection,Mylan Institutional,1000 mg/40 mL (NDC 67457-480-40),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,67457-480-40,
1283,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 2mL (NDC 16729-277-30),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-30,
1284,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 40 mL (NDC 16729-277-35),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-35,
1285,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 10 mL (NDC 16729-277-03),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-03,
1286,Methotrexate Sodium Injection,Mylan,"250 mg in 10 mL (25 mg/mL), single dose vial (NDC 67457-466-10)",New,12/16/19,,Expected Discontinuation April 2020,,,Dermatology;Oncology;Pediatric;Rheumatology,To be Discontinued,12/16/19,12/16/19,67457-466-10,discontinued
1287,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 36 count (NDC 67253-320-36)",New,9/13/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/19,9/13/19,67253-320-36,discontinued
1288,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 100 count (NDC 67253-320-10)",New,9/13/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/19,9/13/19,67253-320-10,discontinued
1289,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"2.5 mg, 100 count (NDC  64376-603-01)",New,7/18/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/19,7/18/19,64376-603-01,discontinued
1290,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"5 mg, 60 count (NDC 64376-604-61)",New,7/18/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/19,7/18/19,64376-604-61,discontinued
1291,Methyclothiazide Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-0160-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0160-01,discontinued
1292,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-05),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2932-05,discontinued
1293,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-01),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2932-01,discontinued
1294,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-10),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2931-10,discontinued
1295,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-01),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2931-01,discontinued
1296,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
1297,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
1298,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
1299,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
1300,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,250 mg (NDC 0378-0611-01),Reverified,11/26/19,Unavailable. Estimated recovery: Q1 2020,,,Other,Cardiovascular,Current,,,0378-0611-01,not available
1301,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,500 mg (NDC 0378-0421-01),Reverified,11/26/19,Unavailable. Estimated recovery: Q1 2020,,,Other,Cardiovascular,Current,,,0378-0421-01,not available
1302,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",20 mg (NDC 24478-074-01),Revised,8/9/19,,,,,Pediatric;Psychiatry,Resolved,8/9/19,,24478-074-01,
1303,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",30 mg (NDC 24478-075-01),Revised,8/9/19,,,,,Pediatric;Psychiatry,Resolved,8/9/19,,24478-075-01,
1304,Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets,"Tris Pharma, Inc.",40 mg (NDC 24478-076-01),Revised,8/9/19,,,,,Pediatric;Psychiatry,Resolved,8/9/19,,24478-076-01,
1305,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",300 mg/60 mL (NDC 24478-321-02),Reverified,12/13/19,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,24478-321-02,available
1306,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",600 mg/120mL (NDC 24478-322-04),Reverified,12/13/19,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,24478-322-04,available
1307,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",750 mg/150 mL (NDC 24478-323-05),Reverified,12/13/19,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,24478-323-05,available
1308,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",900 mg/180 mL (NDC 24478-324-06),Reverified,12/13/19,Available,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,Other,Pediatric;Psychiatry,Current,,,24478-324-06,available
1309,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,36 mg 30 count (NDC 0591-2717-30),New,5/17/19,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-2717-30,discontinued
1310,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,54 mg 30 count (NDC 0591-2718-30),New,5/17/19,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-2718-30,discontinued
1311,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,5 mg 100 count (NDC 0591-5882-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5882-01,discontinued
1312,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,10 mg 100 count (NDC 0591-5883-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5883-01,discontinued
1313,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,20 mg 100 count (NDC 0591-5884-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5884-01,discontinued
1314,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0591-0790-01,discontinued
1315,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,23155-240-41,
1316,"Metoclopramide Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3414-01),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,00409-3414-01,
1317,"Metoclopramide Injection, USP","Fresenius Kabi USA, LLC","10 mg per 2 mL, single use, prefilled syringe (NDC 76045-101-20)",Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,76045-101-20,
1318,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-04),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,0703-4502-04,
1319,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-84),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,0703-4502-84,
1320,"Metoprolol Tartrate Injection, USP",Gland Pharma,"1 mg/mL, 5 mL vial (NDC 72266-122-25)",Reverified,12/16/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-122-25,available
1321,"Metoprolol Tartrate Injection, USP",Gland Pharma,1 mg/mL 5mL vial (NDC 70860-300-05 and 70860-300-41),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Cardiovascular,Current,,,70860-300-05,available
1322,"Metoprolol Tartrate Injection, USP",Gland Pharma,5 mg per 5 mL Single Dose Vial (NDC 47781-587-17),Reverified,12/16/19,Available,Distributed by Alvogen Inc. (Company Contact Information:  973-532-7840),,Available,Cardiovascular,Current,,,47781-587-17,available
1323,"Metoprolol Tartrate Injection, USP",Baxter Healthcare,1 mg/mL - 5 mL Sterile Single Use Glass Vial (10 x 5 mL). For Intravenous Use (NDC 36000-033-10),Reverified,12/11/19,Available,,,,Cardiovascular,Current,,,36000-033-10,available
1324,"Metoprolol Tartrate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 5 mL, SDV, PF (NDC 63323-660-05)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Manufacturing delays,Cardiovascular,Current,,,63323-660-05,available
1325,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1mg/mL – 10mL vials, (NDC 0143-9660-10)",Reverified,12/13/19,Available,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9660-10,available
1326,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1mg/mL – 5ml vials (NDC 0143-9873-25),Reverified,12/13/19,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9873-25,not available
1327,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1778-05),Reverified,12/20/19,Available,,,Other,Cardiovascular,Current,,,00409-1778-05,available
1328,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1778-35),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1778-35,not available
1329,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Glass Ampul (NDC 00409-2285-05),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-2285-05,not available
1330,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
1331,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
1332,"Metronidazole Injection, USP",Baxter Healthcare,"Metronidazole Injection, USP, 500 mg/100 mL, in VIAFLEX Plus Container (NDC 0338-1055-48)",Reverified,12/11/19,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
1333,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-24),Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,00409-7811-24,limited availability
1334,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-37),Reverified,12/20/19,Available,,,Other,Anti-Infective,Current,,,00409-7811-37,available
1335,"Metronidazole Injection, USP",B. Braun Medical Inc.,Metronidazole Injection 500mg (5mg/mL) 100mL D5353-5224 (NDC 0264-5535-32),Revised,1/22/19,Product available for contracted  customers,,,Manufacturing interruptions and demand increase,Anti-Infective,Current,,,0264-5535-32,limited availability
1336,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2469-15,discontinued
1337,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2470-15,discontinued
1338,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2471-15,discontinued
1339,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0093-7206-56),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0093-7206-56,discontinued
1340,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0591-1117-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1117-30,discontinued
1341,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 1000 count bottle (NDC 0591-1117-10),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1117-10,discontinued
1342,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0093-7207-56),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0093-7207-56,discontinued
1343,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0591-1118-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1118-30,discontinued
1344,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 1000 count bottle (NDC 0591-1118-10),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1118-10,discontinued
1345,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,45 mg 30 count bottle (NDC 0591-1119-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1119-30,discontinued
1346,Modafinil Tablets,Par Pharmaceutical,"100 mg, bottle of 30 (NDC 49884-534-11)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/19/19,4/19/19,49884-534-11,discontinued
1347,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,7.5 mg; 12.5 mg tablets (NDC 0093-5213-01),New,11/6/18,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/18,11/6/18,0093-5213-01,discontinued
1348,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,15 mg; 12.5 mg tablets (NDC 0093-5214-01),New,11/6/18,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/18,11/6/18,0093-5214-01,discontinued
1349,Moexipril Hydrochloride/Hydrochlorothiazide Tablets,Teva Pharmaceuticals,15 mg; 25 mg tablets (NDC 0093-5215-01),New,11/6/18,,This product discontinuation is a business-related decision.,,,Cardiovascular,To be Discontinued,11/6/18,11/6/18,0093-5215-01,discontinued
1350,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 15 gram tube  (NDC 0085-3149-01),New,7/29/19,,,,,Dermatology,To be Discontinued,7/29/19,7/29/19,0085-3149-01,discontinued
1351,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 50 gram tube  (NDC 0085-3149-03),New,7/29/19,,,,,Dermatology,To be Discontinued,7/29/19,7/29/19,0085-3149-03,discontinued
1352,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/18,3/20/18,0378-5201-93,discontinued
1353,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,20 mg/0.8 mg; 30 capsules per bottle (NDC 60793-430-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-430-20,discontinued
1354,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,30 mg/1.2 mg; 30 capsules per bottle (NDC 60793-431-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-431-20,discontinued
1355,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,50 mg/2 mg; 30 capsules per bottle (NDC 60793-433-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-433-20,discontinued
1356,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,60 mg/2.4 mg; 30 capsules per bottle (NDC 60793-434-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-434-20,discontinued
1357,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,80 mg/3.2 mg; 30 capsules per bottle (NDC 60793-435-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-435-20,discontinued
1358,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,100 mg/4 mg; 30 capsules per bottle (NDC 60793-437-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-437-20,discontinued
1359,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"15 mg, bottle of 100 (NDC 60951-652-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-652-70,discontinued
1360,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"30 mg, bottle of 100 (NDC 60951-653-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-653-70,discontinued
1361,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"60 mg, bottle of 100 (NDC 60951-655-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-655-70,discontinued
1362,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"100 mg, bottle of 100 (NDC 60951-658-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-658-70,discontinued
1363,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"200 mg, bottle of 100 (NDC 60951-659-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-659-70,discontinued
1364,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2658-01,discontinued
1365,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2659-01,discontinued
1366,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2660-01,discontinued
1367,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2661-01,discontinued
1368,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2662-01,discontinued
1369,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-452-01,available
1370,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-454-01,available
1371,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-455-01,available
1372,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Reverified,12/20/19,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-458-01,available
1373,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-451-01,available
1374,"Morphine Sulfate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS,Revised,12/16/19,Available,,,,Analgesia/Addiction,Current,,,,available
1375,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6125-25,available
1376,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,available
1377,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6127-25,available
1378,"Morphine Sulfate Injection, USP","Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,12/20/19,Next Delivery: March 2020; Estimated Recovery: April 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1135-02,not available
1379,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1890-01,available
1380,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1890-11,not available
1381,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1891-01,available
1382,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1891-11,not available
1383,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1892-01,available
1384,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1892-11,not available
1385,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1893-01,available
1386,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1893-11,not available
1387,"Morphine Sulfate Injection, USP","Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-3814-12,available
1388,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-3815-12,limited availability
1389,"Morphine Sulfate Injection, USP","Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,12/20/19,Available,,,Other,Analgesia/Addiction,Current,,,00409-1134-03,available
1390,"Morphine Sulfate Injection, USP","Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1134-05,not available
1391,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-004-10,available
1392,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-005-10,available
1393,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-006-10,available
1394,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syring (NDC 76045-007-10)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-007-10,not available
1395,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-008-10,not available
1396,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",1mg/mL 30mL PCA glass vial (NDC 0409-2029-02),Reverified,12/16/19,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Analgesia/Addiction,Current,,,0409-2029-02,not available
1397,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",5mg/mL 30mL PCA GLASS VIAL (CII)(NDC 0409-6028-04),New,10/2/19,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,10/2/19,10/2/19,0409-6028-04,discontinued
1398,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6019-10,available
1399,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6020-10,available
1400,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6039-01,available
1401,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,12/13/19,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6040-01,available
1402,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Revised,12/20/19,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0434-82,not available
1403,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Revised,12/20/19,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0422-83,not available
1404,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Revised,12/20/19,Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0421-53,not available
1405,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,12/11/19,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5646-1,available
1406,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,12/11/19,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5649-1,available
1407,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,12/11/19,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5650-2,available
1408,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,12/11/19,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5647-0,available
1409,Mupirocin Calcium Nasal Ointment,GlaxoSmithKline,2% Nasal Ointment 1 gram tube Package of 10 (NDC 0029152611),Revised,12/13/19,,,,,Anti-Infective,To be Discontinued,12/13/19,12/13/19,0029152611,discontinued
1410,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3124-95,discontinued
1411,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3125-95,discontinued
1412,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3126-95,discontinued
1413,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9124-95,discontinued
1414,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9224-92,discontinued
1415,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9225-92,discontinued
1416,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3128-92,discontinued
1417,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3129-92,discontinued
1418,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 60 gm (NDC 40085-201-60),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-201-60,discontinued
1419,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 90 gm (NDC 40085-201-90),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-201-90,discontinued
1420,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 45 gm (NDC 40085-203-45),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-203-45,discontinued
1421,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 60 gm (NDC 40085-203-60),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-203-60,discontinued
1422,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Reverified,12/20/19,Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1463-01,not available
1423,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Reverified,12/20/19,Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1465-01,not available
1424,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Reverified,12/20/19,Limited Supply Available. Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1464-01,limited availability
1425,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Reverified,12/20/19,Limited Supply Available. Next Delivery: June 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1467-01,limited availability
1426,Naratriptan Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg  (NDC 0378-4450-59),New,7/17/19,,,,,Neurology,To be Discontinued,7/17/19,7/17/19,0378-4450-59,discontinued
1427,Nebivolol Hydrochloride and Valsartan (BYVALSAN) Tablets,Allergan,"5 mg, 80 mg per tablet; (NDCs 0023-5874-90; 0023-5874-84; 0023-5874-32; 0023-5874-31; 0023-5874-30; 0023-5874-07)",New,12/19/18,,,,,Cardiovascular,To be Discontinued,12/19/18,12/19/18,,discontinued
1428,Nelarabine (Arranon) Injection,Novartis,250 mg/50 mL (NDC 0078-0683-06),Reverified,12/11/19,Available,,,Demand increase for the drug,Hematology,Current,,,0078-0683-06,available
1429,"Neomycin and Polymyxin B Sulfates Solution For Irrigation, USP",Teva Pharmaceuticals,"40 mg and 200,000 units (1 mL ampule) (NDC 0591-2190-45)",New,6/10/19,,Discontinuation of the manufacture of the drug.,,,Anti-Infective;Urology,To be Discontinued,6/10/19,6/10/19,0591-2190-45,discontinued
1430,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/18,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/18,2/5/18,65847-205-25,discontinued
1431,Nevirapine Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg tablets (NDC 0378-6950-77),New,1/31/19,,,,,Antiviral,To be Discontinued,1/31/19,1/31/19,0378-6950-77,discontinued
1432,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 100 count bottle (NDC 10370-677-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-677-01,discontinued
1433,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 500 count bottle (NDC 10370-677-05)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-677-05,discontinued
1434,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 100 count bottle (NDC 10370-678-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-678-01,discontinued
1435,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 500 count bottle (NDC 10370-678-05)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-678-05,discontinued
1436,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"90 mg, 100 count bottle (NDC 10370-679-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-679-01,discontinued
1437,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 500 count (NDC 45963-152-50)",New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/19,6/7/19,45963-152-50,discontinued
1438,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 100 count (NDC 45963-152-02)",New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/19,6/7/19,45963-152-02,discontinued
1439,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"150 mg, 60 count bottle (NDC 0378-5150-91)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-5150-91,discontinued
1440,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"300 mg, 30 count bottle (NDC 0378-5300-93)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-5300-93,discontinued
1441,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/18,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/18,2/23/18,52544-235-28,discontinued
1442,Norethindrone Acetate and Ethinyl Estradiol plus Ferrous Fumarate Chewable Tablets 0.1mg/0.02mg + 75mg (Minastrin 24Fe),Mylan Pharmaceuticals Inc.,"0.1mg/0.02mg + 75mg Tablets, NDC (0378-7315-53)",New,1/2/19,,,,,Reproductive,To be Discontinued,1/2/19,1/2/19,,discontinued
1443,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate) (NDC 0023-5970-05) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,0023-5970-05,discontinued
1444,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0010-05) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,0430-0010-05,discontinued
1445,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0482-14) 72 Carton in 1 Case > 5 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,0430-0482-14,discontinued
1446,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 0430-0482-95) 30 Tray in 1 Case > 6 Carton in 1 Tray > 1 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,0430-0482-95,discontinued
1447,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 54868-6161-0) 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,54868-6161-0,discontinued
1448,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)(NDC 68180-897-13) 5 Pouch in 1 Carton > 1 Blister Pack in 1 Pouch > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,68180-897-13,discontinued
1449,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)( NDC 68180-898-13) 72 Carton in 1 Case > 5 Cello Pack in 1 Carton > 1 Blister Pack in 1 Cello Pack > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,68180-898-13,discontinued
1450,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Allergan,"Norethindrone, Ethinyl Estradiol Tablet (0.4 mg norethindrone / 0.035 mg ethinyl estradiol) Ferrous Fumarate Placebo Tablet (75 mg ferrous fumarate)( NDC68180-899-13) 5 Blister Pack in 1 Carton > 1 Kit in 1 Blister Pack",New,1/11/19,,The company has made a business decision to discontinue manufacturing of these items,,,Reproductive,To be Discontinued,1/11/19,1/11/19,,discontinued
1451,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Mylan Pharmaceuticals Inc.,"0.02 mg norethindrone acetate / 1 mg ethinyl estradiol / 75 mg ferrous fumarate; 28 tablets per blister pack, 3 blisters per carton (NDC 0378-7301-53)",New,5/23/19,,,,,Reproductive,To be Discontinued,5/23/19,5/23/19,0378-7301-53,discontinued
1452,Normosol-M and 5% Dextrose Injection,"ICU Medical, Inc.",Normosol-M and 5% Dextrose Injection (NDC 0409-7965-03),New,12/6/18,,Discontinuation of the manufacture of the drug.,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,To be Discontinued,12/6/18,12/6/18,0409-7965-03,discontinued
1453,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 15 g (NDC 0603-7818-74)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-74,discontinued
1454,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 30 g (NDC 0603-7818-78)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-78,discontinued
1455,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 60 g (NDC 0603-7818-88)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-88,discontinued
1456,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 USP units per gram, 15 g (NDC 0472-0163-15)",New,11/15/19,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/19,11/15/19,0472-0163-15,discontinued
1457,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 units per gram, 30 g (NDC 0472-0163-30)",New,11/15/19,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/19,11/15/19,0472-0163-30,discontinued
1458,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 473 mL bottles (NDC 60432-0537-16)",Reverified,12/10/19,Available,,,Other,Anti-Infective;Pediatric,Current,,,60432-0537-16,available
1459,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 60 mL bottles (NDC 60432-0537-60)",Reverified,12/10/19,Available,,,Other,Anti-Infective;Pediatric,Current,,,60432-0537-60,available
1460,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 50 unit dose cups/ case (NDC 66689-037-50)",Revised,11/13/19,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,66689-037-50,available
1461,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 100 unit dose cups/ case (NDC 66689-037-99)",Revised,11/13/19,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,66689-037-99,available
1462,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 60 mL Bottle (NDC 66689-008-02)",Revised,11/13/19,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,66689-008-02,available
1463,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 480 mL Bottle (NDC 66689-008-16)",Revised,11/13/19,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,66689-008-16,available
1464,Nystatin Oral Suspension,"Pharmaceutical Associates, Inc","Nystatin Oral Suspension, USP 500,000 Units/5 mL 5 mL Unit Dose Cups Case of 40 – 5 mL UDC (NDC 00121-4810-40); Case of 100 – 5 mL UDC (NDC 00121-4810-00); 2 oz. Bottles (NDC 00121-0810-02); 16 oz. Bottles (NDC 00121-0810-16)",New,1/8/19,Product availability will be limited as we resume production.,Resolution of product quality and manufacturing concerns.,,Requirements related to complying with good manufacturing practices,Anti-Infective;Pediatric,Current,,,00121-4810-40,limited availability
1465,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,500mg/50 ML x 1 vial (NDC 0002-8926-01),New,10/2/19,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/19,10/2/19,0002-8926-01,discontinued
1466,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,190mg/19 ML x 1 vial (NDC 0002-7190-01),New,10/2/19,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/19,10/2/19,0002-7190-01,discontinued
1467,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 30 count bottle (NDC 0378-1413-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1413-93,discontinued
1468,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 90 count bottle (NDC 0378-1413-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1413-77,discontinued
1469,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 30 count bottle (NDC 0378-1422-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1422-93,discontinued
1470,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 90 count bottle (NDC 0378-1422-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1422-77,discontinued
1471,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 30 count bottle (NDC 0378-1425-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1425-93,discontinued
1472,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 90 count bottle (NDC 0378-1425-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1425-77,discontinued
1473,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"5mg, 30 ct. (NDC 65852-0741-30)",Revised,12/13/19,Temporarily discontinued,,,,Cardiovascular,Current,,,65852-0741-30,discontinued
1474,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 30 ct. (NDC 65862-0742-30)",Revised,12/13/19,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,65862-0742-30,discontinued
1475,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 90 ct. (NDC 65862-0742-90)",Revised,12/13/19,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,65862-0742-90,discontinued
1476,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg, 30 ct. (NDC 65862-0743-30)",Revised,12/13/19,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,65862-0743-30,discontinued
1477,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg., 90 ct. (NDC 65862-0743-90)",Revised,12/13/19,Temporarily discontinued,,,API Supply Issue,Cardiovascular,Current,,,65862-0743-90,discontinued
1478,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"5mg, Bottle of 30 counts (NDC 62332-131-30)",Reverified,12/18/19,Available,,,,Cardiovascular,Current,,,62332-131-30,available
1479,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 30 counts (NDC 62332-132-30)",Reverified,12/18/19,Available,,,,Cardiovascular,Current,,,62332-132-30,available
1480,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 90 counts (NDC 62332-132-90)",Reverified,12/18/19,Available,,,,Cardiovascular,Current,,,62332-132-90,available
1481,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 30 counts (NDC 62332-133-30)",Reverified,12/18/19,Available,,,,Cardiovascular,Current,,,62332-133-30,available
1482,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 90 counts (NDC 62332-133-90)",Reverified,12/18/19,Available,,,,Cardiovascular,Current,,,62332-133-90,available
1483,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,5mg (NDC 68462-0436-30),Revised,12/12/19,Temporarily on backorder. Supply available mid-December 2019,,,API shortage,Cardiovascular,Current,,,68462-0436-30,limited availability
1484,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-30),Revised,12/12/19,Available,,,API shortage,Cardiovascular,Current,,,68462-0437-30,available
1485,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-90),Revised,12/12/19,Available,,,API shortage,Cardiovascular,Current,,,68462-0437-90,available
1486,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-30),Revised,12/12/19,Temporarily on backorder. Estimated availability: mid-December 2019,,,API shortage,Cardiovascular,Current,,,68462-0438-30,not available
1487,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-90),Revised,12/12/19,Available,,,API shortage,Cardiovascular,Current,,,68462-0438-90,available
1488,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil  5mg T 30s (NDC 0378-7012-93),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,,Cardiovascular,Current,,,0378-7012-93,not available
1489,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 30s (NDC 0378-7112-93),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,0378-7112-93,not available
1490,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 90s (NDC 0378-7112-77),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,0378-7112-77,not available
1491,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 30s (NDC 0378-7124-93),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,,Cardiovascular,Current,,,0378-7124-93,not available
1492,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 90s (NDC 0378-7124-77),Reverified,11/26/19,Out of Stock. Resupply is Q1 2020.,,,Other,Cardiovascular,Current,,,0378-7124-77,not available
1493,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 30T (NDC 1672-9320-10)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9320-10,available
1494,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 90T (NDC 1672-9320-15)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9320-15,available
1495,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 30T (NDC 1672-9321-10)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9321-10,available
1496,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 90T (NDC 1672-9321-15)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9321-15,available
1497,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 30T (NDC 1672-9322-10)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9322-10,available
1498,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 90T (NDC 1672-9322-15)",Revised,12/11/19,Stocks available to support current customer demand,,,Limited API availability,Cardiovascular,Current,,,1672-9322-15,available
1499,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,5mg tablet (NDC 13668-248-30),Reverified,12/13/19,Available,,,,Cardiovascular,Current,,,13668-248-30,available
1500,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-30),Reverified,12/13/19,Available,,,,Cardiovascular,Current,,,13668-249-30,available
1501,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-90),Reverified,12/13/19,Available,,,,Cardiovascular,Current,,,13668-249-90,available
1502,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-30),Reverified,12/13/19,Available,,,,Cardiovascular,Current,,,13668-250-30,available
1503,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-90),Reverified,12/13/19,Available,,,,Cardiovascular,Current,,,13668-250-90,available
1504,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","5mg, 30 Unit (NDC 65597-101-30)",Reverified,12/10/19,Available,,,Other,Cardiovascular,Current,,,65597-101-30,available
1505,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 30 Unit (NDC 65597-103-30)",Reverified,12/10/19,Available,,,Other,Cardiovascular,Current,,,65597-103-30,available
1506,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 90 Unit (NDC 65597-103-90)",Reverified,12/10/19,Available,,,Other,Cardiovascular,Current,,,65597-103-90,available
1507,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 30 Unit (NDC 65597-104-30)",Reverified,12/10/19,Available,,,Other,Cardiovascular,Current,,,65597-104-30,available
1508,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 90 Unit (NDC 65597-104-90)",Reverified,12/10/19,Available,,,Other,Cardiovascular,Current,,,65597-104-90,available
1509,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 30 Tabs (NDC 67877-0446-30),New,3/12/19,Availability: TBD,,,Other,Cardiovascular,Current,,,67877-0446-30,unclear
1510,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 90 Tabs (NDC 67877-0446-90),New,3/12/19,Availability: TBD,,,Other,Cardiovascular,Current,,,67877-0446-90,unclear
1511,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 30 Tabs (NDC 67877-0447-30),New,3/12/19,Availability: TBD,,,Other,Cardiovascular,Current,,,67877-0447-30,unclear
1512,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 90 Tabs (NDC 67877-0447-90),New,3/12/19,Availability: TBD,,,Other,Cardiovascular,Current,,,67877-0447-90,unclear
1513,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 5mg 30 Tabs (NDC 67877-0445-30),New,3/12/19,Availability: TBD,,,Other,Cardiovascular,Current,,,67877-0445-30,unclear
1514,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-3082-28,discontinued
1515,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,"900 mg/1 unit capsule, liquid filled (NDC 49884-019-08)",New,5/10/19,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/19,5/10/19,49884-019-08,discontinued
1516,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,900mg/1 unit capsule (NDC 0254-3010-08),New,5/10/19,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/19,5/10/19,0254-3010-08,discontinued
1517,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-56), (30 count Bottle)",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,0093-5294-56,discontinued
1518,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC (0093-5294-98) (90 count Bottle)",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,,discontinued
1519,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-10) (1000 count Bottle )",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,0093-5294-10,discontinued
1520,Ondansetron Hydrochloride Injection,Gland Pharma,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,12/16/19,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-123-25,available
1521,Ondansetron Hydrochloride Injection,Gland Pharma,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,12/16/19,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-124-01,available
1522,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,12/11/19,Available,For IV or IM injection,,,Gastroenterology,Current,,,36000-012-25,available
1523,Ondansetron Hydrochloride Injection,Gland Pharma,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,70860-776-02,available
1524,Ondansetron Hydrochloride Injection,Gland Pharma,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,12/16/19,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,70860-777-20,available
1525,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-373-02,available
1526,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Reverified,12/20/19,Backordered.  Next release January 2020.,,,Demand increase for the drug,Gastroenterology,Current,,,63323-374-20,not available
1527,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,76045-103-20,available
1528,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,11/27/19,Available,,,Available,Gastroenterology,Current,,,60505-6130-05,available
1529,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Revised,11/20/19,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-549-31,available
1530,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Revised,11/20/19,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-41,available
1531,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Revised,11/20/19,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-42,available
1532,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,10/9/19,Inventory is currently available.,Additional lots are scheduled for manufacturing in the October – November 2019 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0143-9890-01,available
1533,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,12/11/19,"Currently on backorder, next shipment expected Dec. 2019",Intermittent availability expected,,Demand increase for the drug,Gastroenterology,Current,,,55150-125-02,not available
1534,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Revised,11/20/19,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-547-41,available
1535,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Reverified,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: December 2019,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,00409-4759-01,limited availability
1536,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,10/9/19,Inventory is currently available,Additional lots are scheduled for manufacturing in the October – November 2019 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6078-25,available
1537,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Reverified,12/20/19,Available,,,Other,Gastroenterology,Current,,,00409-4755-03,available
1538,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,00409-1120-12,not available
1539,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,12/11/19,"Currently on backorder, next shipment expected Dec. 2019",Intermittent availability expected,,Demand increase for the drug,Gastroenterology,Current,,,55150-126-20,not available
1540,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION,20 mL Vials, (NDC 0703-7226-03)",New,10/12/18,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/18,10/12/18,0703-7226-03,discontinued
1541,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION, 20 mL Vial, (NDC 0703-7226-01)",New,10/12/18,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/18,10/12/18,0703-7226-01,discontinued
1542,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION, 2 mL Vial, (NDC 0703-7221-04)",New,10/12/18,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/18,10/12/18,0703-7221-04,discontinued
1543,Ondansetron Hydrochloride Injection,Teva Pharmaceuticals,"EQ 2MG BASE/ML, INJECTION, SOLUTION,  2 mL Vial, (NDC 0703-7221-01)",New,10/12/18,,This was a business-related decision to discontinue manufacturing these products,,,Gastroenterology,To be Discontinued,10/12/18,10/12/18,0703-7221-01,discontinued
1544,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,12/20/19,Available,,,,Gastroenterology,Current,,,25021-782-20,available
1545,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,12/20/19,Available,,,,Gastroenterology,Current,,,25021-777-02,available
1546,Orphenadrine Citrate Injection,Teva Pharmaceuticals,30mg/mL injection (NDCs 0591-3222-47 and 0591-3222-02),New,10/25/18,,This product discontinuation is a business-related decision.,,,Analgesia/Addiction,To be Discontinued,10/25/18,10/25/18,,discontinued
1547,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6605-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6605-01,discontinued
1548,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6605-05)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6605-05,discontinued
1549,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6610-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6610-01,discontinued
1550,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6610-05)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6610-05,discontinued
1551,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100 count bottle (NDC 0378-6615-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6615-01,discontinued
1552,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0093-5206-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5206-01,discontinued
1553,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0093-5207-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5207-01,discontinued
1554,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"15 mg, 100 count bottle (NDC 0093-5208-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5208-01,discontinued
1555,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,30 mg/1 unit (NDC 0228-2879-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2879-11,discontinued
1556,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,15 mg/1 unit (NDC 0228-2878-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2878-11,discontinued
1557,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/1 unit (NDC 0228-2876-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2876-11,discontinued
1558,Oxymorphone Hydrochloride,Teva Pharmaceuticals,5 mg/1 unit (NDC 0093-5861-01),New,6/10/19,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/19,6/10/19,0093-5861-01,discontinued
1559,Oxymorphone Hydrochloride,Teva Pharmaceuticals,10 mg/1 unit (NDC 0093-5862-01),New,6/10/19,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/19,6/10/19,0093-5862-01,discontinued
1560,"Oxytocin (Pitocin) Synthetic Injection, USP",Par Pharmaceutical,Pitocin Single Pack 10 mL Vial (NDC 42023-116-01),New,11/1/19,,Par has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,11/1/19,11/1/19,42023-116-01,discontinued
1561,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,12/20/19,Available,Check wholesalers for inventory,,Delay in manufacturing,Reproductive,Current,,,63323-012-10,available
1562,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,12/20/19,Backordered.  Next release January 2020.,,,Delay in manufacturing,Reproductive,Current,,,63323-012-30,not available
1563,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory for both NDC's,,Delay in manufacturing,Reproductive,Current,,,63323-012-01,not available
1564,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,12/16/19,Available,,,,Reproductive,Current,,,42023-130-06,available
1565,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,12/16/19,"On backorder at this time due to increased demand, new material will be released in January 2020",,,,Reproductive,Current,,,42023-116-25,not available
1566,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,12/16/19,"On backorder at this time due to increased demand, new material will be released in January 2020.",,,,Reproductive,Current,,,42023-116-02,not available
1567,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/19,,19-Dec,,,Oncology,To be Discontinued,11/22/19,11/22/19,67457-449-17,discontinued
1568,"Paclitaxel Injection, USP",HQ Specialty Pharma,30 mg/5 mL (NDC 44567-504-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-504-1,discontinued
1569,"Paclitaxel Injection, USP",HQ Specialty Pharma,100 mg/16.7 mL (NDC 44567-505-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-505-1,discontinued
1570,"Paclitaxel Injection, USP",HQ Specialty Pharma,300 mg/50 mL (6 mg/mL)(NDC 44567-506-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-506-1,discontinued
1571,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Revised,12/13/19,Available,,,Demand increase for the drug,Gastroenterology,Current,,,0143-9284-10,available
1572,Pantoprazole Sodium for Injection,Aurobindo Pharma,"40 mg, 10 vials (NDC 55150-202-10)",Reverified,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,55150-202-10,available
1573,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Reverified,12/20/19,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-0923-55,not available
1574,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Reverified,12/20/19,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-0923-60,not available
1575,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Reverified,12/20/19,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-2001-10,not available
1576,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-2001-25,not available
1577,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Reverified,12/20/19,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-4001-10,not available
1578,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Reverified,12/20/19,Next delivery: December 2019; Estimated recovery: March 2020,Please check with wholesaler for available inventory. Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-4001-25,not available
1579,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",New,10/29/19,Available,,,,Gastroenterology,Current,,,62756-129-44,available
1580,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,12/18/19,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0202-1,unclear
1581,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,12/18/19,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0203-1,unclear
1582,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,12/18/19,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0204-1,unclear
1583,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,12/18/19,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0205-1,unclear
1584,Pegademase bovine (Adagen) Injection,"Leadiant Biosciences, Inc.",ADAGEN (pegademase bovine) Injection 250 units per mL (NDC 57665-001-01),New,1/18/19,,"The discontinuation of the manufacture of Adagen is due to the permanent shortage of the active ingredient. The discontinuation of the product is not due to product quality, safety, or efficacy concerns. Based on the demand in mid-January 2019, the inventory is estimated to runout by late-March 2019. Physicians can continue to treat ADA-SCID patients with another approved treatment for ADA-SCID.",,,Other;Pediatric,To be Discontinued,1/18/19,1/18/19,57665-001-01,discontinued
1585,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4347-01,discontinued
1586,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4348-01,discontinued
1587,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/18,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4349-01,discontinued
1588,PEGINTRON (peginterferon alfa-2b) Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b) 50 mcg per 0.5 mL; box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,9/12/19,,To be discontinued on or near May 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,00085-4353-01,discontinued
1589,Penicillamine (Depen) Titratable Tablets,Mylan Pharmaceuticals Inc.,"Penicillamine tablets, 250 mg (NDC 0037-4401-01)",Revised,10/1/19,,,,,Endocrinology/Metabolism;Gastroenterology;Inborn Errors;Pediatric;Renal;Rheumatology,Resolved,10/1/19,,0037-4401-01,
1590,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/19,,,,,Anti-Infective,Resolved,9/13/19,,63323-877-15,
1591,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-01,discontinued
1592,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-05,discontinued
1593,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD) therapy (Dianeal and Extraneal),Reverified,12/11/19,Available.  Please see link.,,,,Pediatric;Renal,Current,,,,available
1594,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal),Reverified,12/11/19,Available. Please see link.,,,,Pediatric;Renal,Current,,,,available
1595,Peritoneal Dialysis Solutions,Fresenius Medical Care North America,Peritoneal Dialysis Solutions (Delflex and Stay Safe),New,8/8/14,Available,,,Other,Pediatric;Renal,Current,,,,available
1596,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/19,,,,,Neurology,To be Discontinued,11/25/19,11/25/19,16571-330-16,discontinued
1597,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-0493-25,
1598,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-2555-45,
1599,"Physostigmine Salicylate Injection, USP",Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,12/2/19,Available,,,Other,Neurology,Current,,,17478-510-02,available
1600,Pimozide (Orap) Tablets,Teva Pharmaceuticals,1 mg tablet (NDC 57844-151-01),New,12/18/18,,This was a business-related decision to discontinue manufacturing this product.,,,Psychiatry,To be Discontinued,12/18/18,12/18/18,57844-151-01,discontinued
1601,Pimozide (Orap) Tablets,Teva Pharmaceuticals,2 mg tablet (NDC 57844-198-01),New,12/18/18,,This was a business-related decision to discontinue manufacturing this product.,,,Psychiatry,To be Discontinued,12/18/18,12/18/18,57844-198-01,discontinued
1602,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-9210-95) Novaplus",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-9210-95,available
1603,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-9214-95) Novaplus",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-9214-95,available
1604,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-9213-95) Novaplus",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-9213-95,available
1605,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 0781-9350-95) Novaplus",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-9350-95,discontinued
1606,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 2.25 g/50 mL, frozen IV bag (NDC 0206-8860-02)",Reverified,12/20/19,Available,,,,Anti-Infective;Pediatric,Current,,,0206-8860-02,available
1607,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g/50 mL, frozen IV bag (NDC 0206-8861-02)",Reverified,12/20/19,Available,,,,Anti-Infective;Pediatric,Current,,,0206-8861-02,available
1608,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g/100 mL, frozen IV bag (NDC 0206-8862-02)",Reverified,12/20/19,Next Delivery and Estimated Recovery: December 2019,,,,Anti-Infective;Pediatric,Current,,,0206-8862-02,not available
1609,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"3.375 g, single dose vial, box of 10 (NDC 67457-522-37)",Reverified,11/26/19,Available,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,67457-522-37,available
1610,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 55150-119-30)",Reverified,12/10/19,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,55150-119-30,available
1611,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 55150-120-30)",Reverified,12/10/19,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,55150-120-30,available
1612,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 55150-121-50)",Reverified,12/10/19,Available,Marketed by AuroMedics Pharma LLC. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,55150-121-50,available
1613,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 63323-309-20)",Reverified,12/16/19,Available,"Marketed by Fresenius Kabi USA, LLC. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,63323-309-20,available
1614,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","3.375 g, single dose vial, box of 10 (NDC 63323-983-21)",Revised,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-983-21,available
1615,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","4.5 g, single dose vial, box of 10 (NDC 63323-0982-52)",Revised,12/20/19,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-0982-52,available
1616,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 63323-304-74)",Reverified,12/16/19,Available,"Marketed by Fresenius Kabi USA, LLC. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,63323-304-74,available
1617,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3374-02) ADD-Vantage",Reverified,12/18/19,Next Delivery: September 2019; Estimated Recovery: October 2019,Marketed by Hospira. Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,0409-3374-02,not available
1618,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn 2.25 g, single dose vial, box of 10 (NDC 0206-8852-16)",Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,0206-8852-16,not available
1619,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g, single dose vial, box of 10 (NDC 0206-8854-16)",Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,0206-8854-16,not available
1620,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g, single dose vial, box of 10 (NDC 0206-8855-16)",Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,0206-8855-16,not available
1621,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 40.5 g, pharmacy bulk vial (NDC 0206-8859-10)",Reverified,12/20/19,Next Delivery and Estimated Recovery: March 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective;Pediatric,Current,,,0206-8859-10,not available
1622,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 25021-164-30)",Reverified,12/10/19,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,,Anti-Infective;Pediatric,Current,,,25021-164-30,available
1623,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 25021-165-30)",Reverified,12/10/19,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,,Anti-Infective;Pediatric,Current,,,25021-165-30,available
1624,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 25021-166-48)",Reverified,12/10/19,Available,"Marketed by Sagent Pharmaceuticals. To order, contact Sagent at 1-866-625-1618.",,Manufacturing delay,Anti-Infective;Pediatric,Current,,,25021-166-48,available
1625,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 44567-801-10)",Reverified,12/16/19,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,44567-801-10,available
1626,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 44567-802-10)",Reverified,12/16/19,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,44567-802-10,available
1627,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 44567-803-10)",Reverified,12/16/19,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,44567-803-10,available
1628,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 44567-804-01)",Reverified,12/16/19,Available,"Marketed by WG Critical Care. Product continues to be manufactured, please check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,44567-804-01,available
1629,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-3114-95)",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-3114-95,available
1630,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-3113-95)",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-3113-95,available
1631,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-3110-95)",Reverified,12/18/19,Available,,,,Anti-Infective;Pediatric,Current,,,0781-3110-95,available
1632,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"4.5 g, single dose vial, box of 10 (NDC 67457-523-45)",Reverified,11/26/19,Available,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,67457-523-45,available
1633,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 0781-3344-95)",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-3344-95,discontinued
1634,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"2.25 g, single dose vial, box of 10 (NDC 67457-521-22)",Reverified,11/26/19,Available,,,,Anti-Infective;Pediatric,Current,,,67457-521-22,available
1635,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 0781-3350-95)",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-3350-95,discontinued
1636,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 0781-3367-95)",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-3367-95,discontinued
1637,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 0781-9367-95) Novaplus",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-9367-95,discontinued
1638,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 0781-9344-95) Novaplus",Reverified,12/16/19,Permanently discontinued,"Marketed by Sandoz, Inc.",,,Anti-Infective;Pediatric,Current,,,0781-9344-95,discontinued
1639,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 39822-0123-2)",Revised,12/11/19,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,39822-0123-2,limited availability
1640,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 39822-0127-6)",Revised,12/11/19,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,39822-0127-6,limited availability
1641,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 39822-0139-7)",Revised,12/11/19,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. To order, contact X-GEN at 1-866-390-4411",,,Anti-Infective;Pediatric,Current,,,39822-0139-7,limited availability
1642,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 39822-0125-4)",Revised,12/11/19,Available - Less than one year dating,"Marketed by X-GEN Pharmaceuticals, Inc. Check wholesalers for inventory.",,,Anti-Infective;Pediatric,Current,,,39822-0125-4,limited availability
1643,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial, box of 10 (NDC 64679-012-01)",Revised,12/12/19,Stock sold out and new batches on backorder until week of 12/23/2019,,,,Anti-Infective;Pediatric,Current,,,64679-012-01,not available
1644,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial (NDC 64679-012-02)",Revised,12/12/19,Stock sold out and new batches on backorder until week of 12/23/2019,,,,Anti-Infective;Pediatric,Current,,,64679-012-02,not available
1645,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial, box of 10 (NDC 64679-034-01)",Revised,12/12/19,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,64679-034-01,limited availability
1646,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial (NDC 64679-034-02)",Revised,12/12/19,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,64679-034-02,limited availability
1647,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 61990-0120-2)",Revised,12/11/19,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,61990-0120-2,available
1648,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"13.5 g, pharmacy bulk vial (NDC 61990-0140-2)",Revised,12/11/19,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,61990-0140-2,available
1649,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 61990-0150-2)",Revised,12/11/19,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,61990-0150-2,available
1650,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 70860-121-30)",Reverified,12/16/19,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,70860-121-30,available
1651,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 70860-122-50)",Reverified,12/16/19,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,70860-122-50,available
1652,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 70860-123-99)",Reverified,12/16/19,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,70860-123-99,available
1653,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3378-13) ADD-Vantage",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-3378-13,available
1654,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3379-04) ADD-Vantage",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-3379-04,available
1655,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3383-02)",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-3383-02,available
1656,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3385-13)",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-3385-13,available
1657,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3390-04)",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-3390-04,available
1658,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"13.5 g, pharmacy bulk bottle (NDC 0409-2999-14)",Reverified,12/18/19,Available,Marketed by Hospira.,,,Anti-Infective;Pediatric,Current,,,0409-2999-14,available
1659,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","2.25 g, single-dose vial (NDC 63323-981-21)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-981-21,not available
1660,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial, box of 10 (NDC 64679-056-01)",Revised,12/12/19,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,64679-056-01,limited availability
1661,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial (NDC 64679-056-02)",Revised,12/12/19,"Stock sold out. Product has arrived, will be available for sale wk of 12/9/19",,,,Anti-Infective;Pediatric,Current,,,64679-056-02,limited availability
1662,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial (NDC 64679-0679-01)",Revised,12/12/19,No backorder,,,,Anti-Infective;Pediatric,Current,,,64679-0679-01,available
1663,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial, box of 10 (NDC 64679-0679-02)",Revised,12/12/19,No backorder,,,,Anti-Infective;Pediatric,Current,,,64679-0679-02,available
1664,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 61990-0110-2)",Revised,12/11/19,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,61990-0110-2,available
1665,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 61990-0130-2)",Revised,12/11/19,Available,Marketed by Apollo Pharmaceuticals Inc. Check wholesalers for inventory.,,,Anti-Infective;Pediatric,Current,,,61990-0130-2,available
1666,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 70860-120-20)",Reverified,12/16/19,Available,"To order, contact Athenex at 855-273-0154",,,Anti-Infective;Pediatric,Current,,,70860-120-20,available
1667,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","2.25 g, single dose vial, box of 10 (NDC 60505-6156-4)",Reverified,10/30/19,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,60505-6156-4,available
1668,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","3.375 g, single dose vial, box of 10 (NDC 60505-6157-4)",Reverified,10/30/19,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,60505-6157-4,available
1669,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","4.5 g, single dose vial, box of 10 (NDC 60505-6159-4)",Reverified,10/30/19,Available,"Marketed by Apotex Corp. To order, contact Apotex at 800-706-5575.",,,Anti-Infective;Pediatric,Current,,,60505-6159-4,available
1670,"Polyethylene Glycol 3350 Powder, for Oral Solution",Perrigo Pharmaceuticals,"Polyethylene Glycol Powder for solution 17G  (NDC 0574-0412-07, 0574-0412-05, 0574-0412-02)",New,12/6/18,,,,,Gastroenterology,To be Discontinued,12/6/18,12/6/18,0574-0412-07,discontinued
1671,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-51,limited availability
1672,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-01,limited availability
1673,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Revised,12/20/19,Limited Supply Available. Next Delivery and Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-25,limited availability
1674,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Revised,12/20/19,Next Delivery: February 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-25,not available
1675,"Potassium Acetate Injection, USP","Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,12/10/19,On allocation due to increased demand.,"Please check with wholesaler for availability. Additional production underway. Direct shipment to hospitals at 200 vials max per week are available from Exela. Customer Service # 828-758-5474, then press #2",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,51754-2001-4,limited availability
1676,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14),Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7075-14,
1677,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26)
(ICU Medical NDC 0990-7075-26)",Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7075-26,
1678,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.45% NaCl (NDC 0409-9257-39),Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-9257-39,
1679,Potassium Chloride Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL); Single Dose Glass Fliptop Vial (NDC 00409-6635-01),Revised,6/21/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00409-6635-01,
1680,Potassium Chloride Injection,Baxter Healthcare,30 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0673-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0673-04,
1681,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 5 mL vials, (NDC 63323-0965-05)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,63323-0965-05,
1682,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 10 mL vials, (NDC 63323-0965-10)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,63323-0965-10,
1683,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 15 mL vials, (NDC 63323-0965-15)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,63323-0965-15,
1684,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 20 mL vials, (NDC 63323-0965-20)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,63323-0965-20,
1685,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","2 mEq/mL, 30 mL vials, (NDC 63323-0967-30)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,63323-0967-30,
1686,Potassium Chloride Injection,B. Braun Medical Inc.,250mL Potassium Chloride Injection Concentrate (2 mEq K/mL)(NDC 0264-1940-20),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0264-1940-20,
1687,Potassium Chloride Injection,Baxter Healthcare,10 mEq/100 mL in sterile water (NDC 00338-0709-48),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0709-48,
1688,Potassium Chloride Injection,Baxter Healthcare,20 mEq/100 mL in sterile water (NDC 00338-0705-48),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0705-48,
1689,Potassium Chloride Injection,Baxter Healthcare,40 mEq/100 mL in sterile water (NDC 00338-0703-48),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0703-48,
1690,Potassium Chloride Injection,Baxter Healthcare,20 mEq/50 mL in sterile water (NDC 00338-0703-41),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0703-41,
1691,Potassium Chloride Injection,Baxter Healthcare,10 mEq/50 mL in sterile water (NDC 00338-0705-41),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0705-41,
1692,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0811-04,
1693,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0803-04,
1694,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0691-04,
1695,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0675-04,
1696,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0683-04,
1697,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0695-04,
1698,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0671-04,
1699,Potassium Chloride Injection,Baxter Healthcare,"20 mEq/L in 5% dextrose and 0.45% sodium chloride, 500 mL (NDC 00338-0671-03)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0671-03,
1700,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0704-34,
1701,Potassium Chloride Injection,Baxter Healthcare,40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0807-04,
1702,Potassium Chloride Injection,Baxter Healthcare,"20 mEq/L in 5% dextrose and 0.2% sodium chloride, 500 mL (NDC 00338-0663-03)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0663-03,
1703,Potassium Chloride Injection,Baxter Healthcare,20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0663-04,
1704,Potassium Chloride Injection,Baxter Healthcare,10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0669-04,
1705,Potassium Chloride Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6651-06),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00409-6651-06,
1706,Potassium Chloride Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00409-6653-05,
1707,Potassium Chloride Injection,"ICU Medical, Inc.","10 mEq/100 mL (Legacy Hospira NDC 0409-7074-26)
(ICU Medical NDC 0990-7074-26)",Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7074-26,
1708,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/50 mL (NDC 0409-7077-14),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7077-14,
1709,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/100 mL (NDC 0409-7077-26),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7077-26,
1710,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL (NDC 0409-7116-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7116-09,
1711,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.9% NaCl (NDC 0409-7115-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7115-09,
1712,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dextrose (NDC 0409-7905-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7905-09,
1713,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% Dex/Lact Ringers (NDC 0409-7111-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7111-09,
1714,Potassium Chloride Injection,"ICU Medical, Inc.","10 mEq/ 500 mL in 5% dex 0.45% NaCl
(NDC 0409-7902-03)",Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7902-03,
1715,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/1000 mL in 5% dex& 0.225% NaCl
(NDC 0409-7901-09)",Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7901-09,
1716,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7902-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7902-09,
1717,Potassium Chloride Injection,"ICU Medical, Inc.",30 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7903-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7903-09,
1718,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7904-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7904-09,
1719,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/1000 mL in 5% dex & 0.45% NaCl (NDC 0409-7993-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7993-09,
1720,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7107-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7107-09,
1721,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7109-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7109-09,
1722,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol per 5 mL, Potassium 22 mEq per 5 mL,single dose vial (NDC 63323-086-05)",Revised,5/23/19,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/19,,63323-086-05,
1723,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol per 15 mL, Potassium 66 mEq per 15 mL, single dose vial (NDC 63323-086-15)",Revised,5/23/19,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/19,,63323-086-15,
1724,Potassium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 150 mmol per 50 mL, Potassium 220 mEq per 50 mL, single dose vial (NDC 63323-086-50)",Revised,5/23/19,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/23/19,,63323-086-50,
1725,Potassium Phosphate Injection,"Hospira, Inc.",Phosphorus 45mM per 15mL; Single Dose Glass Fliptop Vial (NDC 00409-7295-01),Revised,5/29/19,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,5/29/19,,00409-7295-01,
1726,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.25 mg tablets (NDCs 0597-0184-61 and 0597-0184-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,,discontinued
1727,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.125 mg tablets (NDC 0597-0183-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,0597-0183-90,discontinued
1728,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.5 mg tablets (NDCs 0597-0185-61 and 0597-0185-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,,discontinued
1729,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.75 mg tablets (NDC 0597-0101-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,0597-0101-90,discontinued
1730,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",1 mg tablets (NDCs 0597-0190-61 and 0597-0190-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,,discontinued
1731,Pramipexole Dihydrochloride (Mirapex) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",1.5 mg tablets (NDCs 0597-0191-61 and 0597-0191-90),New,11/6/18,,This product discontinuation is a business related decision.,,,Neurology,To be Discontinued,11/6/18,11/6/18,,discontinued
1732,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-05,
1733,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-10,
1734,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-10,
1735,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-15,
1736,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-05,
1737,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-10,
1738,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-15,
1739,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-15,
1740,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-05,
1741,"Primaquine Phosphate Tablet, EQ 15mg Base",Sanofi,"Primaquine; Film-coated tablet, 15 mg/1 unit, bottles of 100, (NDC 0024-1596-01)",Revised,12/10/19,,,,,Anti-Infective,Resolved,12/10/19,,0024-1596-01,
1742,"Primaquine Phosphate Tablet, EQ 15mg Base",Bayshore Pharmaceuticals,"Primaquine Phosphate USP,  26.3 mg (15mg base)Tablets, (NDC 76385-102-01), 100 Count Bottle",Revised,12/10/19,,,,,Anti-Infective,Resolved,12/10/19,,76385-102-01,
1743,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-21)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/19,4/9/19,0603-5371-21,discontinued
1744,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-28)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/19,4/9/19,0603-5371-28,discontinued
1745,"Procainamide Hydrochloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",100 mg/1 mL injection; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3399-5),Reverified,12/16/19,Available,,,Other,Cardiovascular;Renal,Current,,,76329-3399-5,available
1746,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/10 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1902-01)",Reverified,12/20/19,Available,,,Other,Cardiovascular;Renal,Current,,,00409-1902-01,available
1747,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1903-01)",Reverified,12/20/19,Next Delivery and Estimated Recovery: January 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Renal,Current,,,00409-1903-01,not available
1748,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","500 mg/mL, 2 mL (NDC 14789-900-02)",New,10/19/17,Available,,,Other,Cardiovascular;Renal,Current,,,14789-900-02,available
1749,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","100 mg/mL, 10 mL (NDC 14789-900-10)",New,10/19/17,Available,,,Other,Cardiovascular;Renal,Current,,,14789-900-10,available
1750,"Progesterone Injection, USP",Teva Pharmaceuticals,50MG 1X10ML (NDC 0591-3128-79),Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,0591-3128-79,
1751,"Progesterone Injection, USP","Fresenius Kabi USA, LLC","500 mg per 10 mL, MDV (NDC 63323-0261-10)",Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,63323-0261-10,
1752,"Progesterone Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL (NDC 0143-9725-01)",Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,0143-9725-01,
1753,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,55150-306-10,
1754,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0928-25,available
1755,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0929-25,available
1756,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1495-35,available
1757,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Revised,12/13/19,On backorder.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1496-35,not available
1758,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6084-25,available
1759,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6085-25,available
1760,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Revised,12/13/19,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6082-25,available
1761,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Revised,12/13/19,On backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6083-25,not available
1762,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,12/11/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5525-3,available
1763,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,12/11/19,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5550-6,available
1764,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-01,discontinued
1765,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-01,discontinued
1766,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-04,discontinued
1767,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-04,discontinued
1768,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 12.5mg Bx12 (NDC 40085-218-12),New,12/13/18,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/18,12/13/18,40085-218-12,discontinued
1769,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 25mg Bx12 (NDC 40085-219-12),New,12/13/18,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/18,12/13/18,40085-219-12,discontinued
1770,Promethazine Suppository,Mylan Pharmaceuticals Inc.,Promethazine Suppositories 50mg Bx12,New,12/13/18,,A business decision was made to discontinue manufacture of the drug product,,,Anesthesia;Gastroenterology;Pediatric;Pulmonary/Allergy,To be Discontinued,12/13/18,12/13/18,,discontinued
1771,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,5 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0527-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0527-40,discontinued
1772,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,10 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0530-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0530-40,discontinued
1773,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,20 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0532-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0532-40,discontinued
1774,Quinidine Gluconate Injection,Eli Lilly and Co.,"QUINIDINE GLUCONATE, 80 mg/1 mL,10 mL/vial Injectable (NDC 0002-1407-01)",Revised,9/19/19,,Discontinuation of the manufacture of the drug. The product distribution has ceased given the product's labeled expiry of March 2019. FDA and CDC are developing a strategy to ensure continued access to essential medicine for the treatment of severe malaria in the United States.,,,Anti-Infective;Cardiovascular,To be Discontinued,9/19/19,9/19/19,0002-1407-01,discontinued
1775,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 30 count bottle (NDC 0378-6709-93)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-93,discontinued
1776,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 90 count bottle (NDC 0378-6709-77)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-77,discontinued
1777,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 500 count bottle (NDC 0378-6709-05)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-05,discontinued
1778,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 2ml vial; 10 pack; (NDC 67457-397-99)",Revised,12/19/19,Unavailable.,,,,Gastroenterology,Current,,,67457-397-99,not available
1779,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 6 mL vial; 1 pack; (NDC 67457-398-62)",Revised,12/19/19,Unavailable.,,,,Gastroenterology,Current,,,67457-398-62,not available
1780,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (10x2mL SD vials)(NDC 68382-422-02),Reverified,12/18/19,Available,,,Other,Gastroenterology,Current,,,68382-422-02,available
1781,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (6mL MD vial)(NDC 68382-423-06),Reverified,12/18/19,Unavailable,,,Other,Gastroenterology,Current,,,68382-423-06,not available
1782,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 2ML VIAL (NDC 52565-101-01),Reverified,10/29/19,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,52565-101-01,not available
1783,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 40ML VIAL (NDC 52565-096-01),Reverified,10/29/19,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,52565-096-01,not available
1784,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 6ML VIAL (NDC 52565-102-01),Reverified,10/29/19,Unavailable,,,Demand increase for the drug,Gastroenterology,Current,,,52565-102-01,not available
1785,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","1 mg per vial, SDV (NDC 63323-723-03)",Reverified,12/20/19,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,63323-723-03,available
1786,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","2 mg per vial, SDV (NDC 63323-724-05)",Reverified,12/20/19,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,63323-724-05,available
1787,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","5 mg per vial, SDV (NDC 63323-725-10)",Reverified,12/20/19,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,63323-725-10,available
1788,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,1 mg (NDC 67457-198-03),Reverified,11/26/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,67457-198-03,available
1789,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,2 mg (NDC 67457-198-05),Reverified,11/26/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,67457-198-05,available
1790,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,5 mg (NDC 67457-198-10),Reverified,11/26/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,67457-198-10,available
1791,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/18,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/18,2/2/18,0781-5149-01,discontinued
1792,Ribavirin (Rebetol) Oral Solution,Merck Sharp & Dohme Corp.,40 mg/mL (NDC 0085-1318-01),New,4/16/19,,To be discontinued on or near June 2019.,,,Antiviral,To be Discontinued,4/16/19,4/16/19,0085-1318-01,discontinued
1793,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","200 mg (NDCs 66435-101-14, 66435-101-16, 66435-101-18, 66435-101-42, 66435-101-56, 66435-101-70, 66435-101-84, 66435-102-16, 66435-102-95, 54738-950-16)",New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1794,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",400 mg (NDCs 66435-103-56 and 66435-103-95),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1795,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","600 mg (NDCs 66435-104-56, 66435-104-92, 54738-952-56)",New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1796,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",600 mg dose pack (NDCs 66435-108-56 and 66435-108-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1797,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",800 mg dose pack (NDCs 66435-105-56 and 66435-105-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1798,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1000 mg dose pack (NDCs 66435-106-56 and 66435-106-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1799,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1200 mg dose pack (NDCs 66435-107-56 and 66435-107-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
1800,Risedronate Sodium Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 1 count blister card (NDC 0378-4150-32)",New,5/2/19,,,,,Other,To be Discontinued,5/2/19,5/2/19,0378-4150-32,discontinued
1801,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/19,,,,,Musculoskeletal,To be Discontinued,12/9/19,12/9/19,0430-0471-15,discontinued
1802,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-60,discontinued
1803,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-10,discontinued
1804,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-60,discontinued
1805,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-50,discontinued
1806,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-60,discontinued
1807,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-50,discontinued
1808,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-10,discontinued
1809,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-60,discontinued
1810,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-50,discontinued
1811,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-10,discontinued
1812,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-60,discontinued
1813,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-50,discontinued
1814,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-10,discontinued
1815,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-60,discontinued
1816,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-50,discontinued
1817,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-10,discontinued
1818,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-330-50,discontinued
1819,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-320-50,discontinued
1820,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-300-50,discontinued
1821,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-302-50,discontinued
1822,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-50,discontinued
1823,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-01,discontinued
1824,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 9 count bottle (NDC 0378-3701-59)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-3701-59,discontinued
1825,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 9 count bottle (NDC 0378-3702-59)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-3702-59,discontinued
1826,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-05,available
1827,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-10,available
1828,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 0.25 mg, 100 count bottles (NDC 0007-4890-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4890-20,discontinued
1829,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) QUIP Tablets, 0.5 mg, 100 count bottles (NDC 0007-4891-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4891-20,discontinued
1830,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 1 mg, 100 count bottles (NDC 0007-4892-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4892-20,discontinued
1831,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 2 mg, 100 count bottles (NDC 0007-4893-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4893-20,discontinued
1832,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 3 mg, 100 count bottles (NDC 0007-4895-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4895-20,discontinued
1833,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 4 mg, 100 count bottles (NDC 0007-4896-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4896-20,discontinued
1834,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) Tablets, 5 mg, 100 count bottles (NDC 0007-4894-20)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4894-20,discontinued
1835,Ropinirole Hydrochloride (Requip) Tablets,GlaxoSmithKline,"Ropinirole Hydrochloride (Requip) XL Tablets, 2 mg, 30 count bottles (NDC 0007-4885-13)",New,12/19/18,,A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.,,,Neurology,To be Discontinued,12/19/18,12/19/18,0007-4885-13,discontinued
1836,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,4 mg  (NDC 0007-4887-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4887-13,discontinued
1837,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,6 mg  (NDC 0007-4883-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4883-13,discontinued
1838,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,8 mg  (NDC 0007-4888-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4888-13,discontinued
1839,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,12 mg  (NDC 0007-4882-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4882-13,discontinued
1840,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,12/20/19,Available,,,,Anesthesia,Current,,,25021-671-82,available
1841,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,12/20/19,Available,,,,Anesthesia,Current,,,25021-671-87,available
1842,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-9300-10,available
1843,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-9300-20,available
1844,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-9301-30,available
1845,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: February 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9302-20,limited availability
1846,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-9303-10,available
1847,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,12/20/19,Available,,,Other,Anesthesia,Current,,,00409-9303-20,available
1848,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Reverified,12/2/19,Available,,,Other,Anesthesia,Current,,,17478-0081-30,available
1849,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-195-20,available
1850,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Revised,12/11/19,Currently on backorder,Next shipment expected Feb. 2020,,Demand increase for the drug,Anesthesia,Current,,,55150-196-99,not available
1851,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-197-20,available
1852,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-198-30,available
1853,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-199-20,available
1854,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Revised,12/11/19,Short-dated product available exp. Aug. 2020,Next shipment TBD,,Demand increase for the drug,Anesthesia,Current,,,55150-200-10,limited availability
1855,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Revised,12/11/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-201-20,available
1856,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-10,not available
1857,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-20,available
1858,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-286-20,available
1859,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-287-20,available
1860,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,,available
1861,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-20,available
1862,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-61,available
1863,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-63,not available
1864,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-65,not available
1865,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-64,not available
1866,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,12/20/19,Backordered. Next release January 2020.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-286-00,not available
1867,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-286-63,available
1868,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-13,available
1869,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-285-23,available
1870,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-286-35,available
1871,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-286-23,available
1872,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-287-21,available
1873,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-11,available
1874,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,12/20/19,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-21,available
1875,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,12/20/19,Backordered. Next release date not available at this time.,,,Manufacturing Delay,Anesthesia,Current,,,63323-286-31,not available
1876,Sacrosidase (Sucraid) Oral Solution,"QOL Medical, LLC","8,500 I.U./mL 118 mL per bottle, 2 bottles/box  (NDC  67871-111-04)",Revised,5/6/19,,,Available,,Gastroenterology;Inborn Errors,Resolved,5/6/19,,67871-111-04,
1877,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/18,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/18,2/6/18,0004-0245-15,discontinued
1878,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/19,Unavailable,,,Other,Pulmonary/Allergy,Current,,,63256-100-30,not available
1879,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 10 count (NDC 10019-553-03),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,10019-553-03,
1880,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 24 count (NDC 10019-553-04),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,10019-553-04,
1881,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 4 count (NDC 66758-208-54),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,66758-208-54,
1882,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 4-Count Pack (NDC 45802-580-84)",Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-84,
1883,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 10-Count Pack (NDC 45802-580-46)",Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-46,
1884,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 24-Count Pack (NDC 45802-580-62)",Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-62,
1885,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 4s (NDC 0378-6470-99),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-99,
1886,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 10s (NDC 0378-6470-97),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-97,
1887,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-44,
1888,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0338-01,
1889,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-4190-68,
1890,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0336-21,
1891,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,70954-168-10,
1892,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/18,,,,,Antiviral,To be Discontinued,5/23/18,5/23/18,59676-225-28,discontinued
1893,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0093-7152-98,discontinued
1894,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
1895,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
1896,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
1897,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
1898,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/18,,,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0006-0726-31,discontinued
1899,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Revised,9/18/19,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/15,,0270-0556-15,available
1900,"Sodium Acetate Injection, USP","Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Revised,12/20/19,Backordered. Next release January 2020.,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,63323-0032-00,not available
1901,"Sodium Acetate Injection, USP","Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,00409-3299-05,limited availability
1902,"Sodium Acetate Injection, USP","Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Revised,12/20/19,Limited Supply Available. Next Delivery: January 2020; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,00409-3299-06,limited availability
1903,"Sodium Acetate Injection, USP","Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: March 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Total Parenteral Nutrition,Current,,,00409-7299-73,limited availability
1904,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6609-02,not available
1905,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Infant; 5 mEq/10 mL (4.2%; 0.5 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-5534-34),Revised,12/20/19,Next Delivery: February 2020; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-5534-34,not available
1906,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",44.6 mEq/50 mL (7.5%; 0.9 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4916-34),Revised,12/20/19,Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-4916-34,not available
1907,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); Single Dose Glass Fliptop Vial (NDC 0409-6625-02),Revised,12/20/19,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6625-02,available
1908,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-6637-34),Revised,12/20/19,Next Delivery: December 2019; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6637-34,not available
1909,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Pediatric; 10 mEq/10 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4900-34),Revised,12/20/19,Limited Supply Available. Next Delivery: December 2019; Estimated Recovery: August 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-4900-34,limited availability
1910,"Sodium Bicarbonate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,12/16/19,Intermittent supply,"IMS is releasing product, but market demand continues to exceed our capacity",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0548-3352-00,limited availability
1911,"Sodium Bicarbonate Injection, USP","Athenex Pharmaceutical Division, LLC (Athenex)","Sodium Bicarbonate Injection, 8.4% (1mEq/mL), 10mL per vial, 10 vials per carton (NDC 71456-001-01)",Reverified,12/16/19,Available,"Due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States (US) market, Athenex Pharmaceutical Division, LLC (Athenex) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Sodium Bicarbonate Injection. Athenex has initiated temporary importation of another manufacturer’s 8.4% Sodium Bicarbonate Injection (1 mEq/mL) 10 mL into the U.S. market. This product is manufactured and marketed in Australia by Phebra Pty Ltd (Phebra).",,Available,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,71456-001-01,available
1912,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-083-05,available
1913,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-089-50,available
1914,"Sodium Bicarbonate Injection, USP","Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,12/13/19,Available direct or through Premier's ProvideGx program at this time and through CIVICA Rx program in Q1 2020.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,51754-5001-1,available
1915,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-11,
1916,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-21,
1917,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-31,
1918,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-01,
1919,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-41,
1920,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-23,
1921,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL VIAFLEX Plastic Container.  Single pack (NDC 0338-0049-48, product code 2B1307)Quad Pack (NDC 0338-0049-18, product code 2B1302) Multi Pack (NDC 0338-0049-38, product code 2B1309)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-48,
1922,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container.  Single Pack (NDC 0338-0049-41, product code 2B1306) Quad Pack (NDC 0338-0049-11, product code 2B1301) Multi Pack (NDC 0338-0049-31, product code 2B1308)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-41,
1923,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack (NDC 0338-0049-10). Product code 2B1300",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-10,
1924,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 50mL (NDC 63323-623-53)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-53,
1925,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 100mL (NDC 63323-623-61)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-61,
1926,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 250mL (NDC 63323-623-74)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-74,
1927,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 500mL (NDC 63323-623-75)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-75,
1928,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 1000mL (NDC 63323-623-76)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-76,
1929,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0042  (NDC 0338-0553-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0553-11,
1930,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0043 (NDC 0338-0553-18)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0553-18,
1931,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 100mL fill in 150mL PAB S8004-5264 (NDC 0264-1800-32),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-32,
1932,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 50mL fill in 100mL PAB S8004-5384 (NDC 0264-1800-31),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-31,
1933,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 25mL fill in 100mL PAB S8004-5410 (NDC 0264-1800-36),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-36,
1934,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-66),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-66,
1935,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-67),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-67,
1936,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL (Dual Pack); ADD-Vantage Flexible Container (NDC 00409-7101-02),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-02,
1937,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride in Waiter for Injection, 100 mL, in VIAFLEX Container Product code ABB1307U (NDC 0338-9525-72)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9525-72,
1938,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 1000 mL.  Product code JB1324 (NDC 00338-9612-12)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-9612-12,
1939,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-50,
1940,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-30,
1941,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-16,
1942,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus 1,000 mL Product Code 9999-00, (NDC 0264-9999-00)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-9999-00,
1943,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus container sizes: 500 mL (NDC 0264-9999-10),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-9999-10,
1944,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-13)
(ICU Medical NDC 0990-7984-13)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-13,
1945,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container-4 pack (Legacy Hospira NDC 0409-7984-37)
(ICU Medical NDC 0990-7984-37)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-37,
1946,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 250mL bag, PVC/DEHP-free (NDC 00264-7800-20)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-20,
1947,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 500mL bag, PVC/DEHP-free (NDC 00264-7800-10)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-10,
1948,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 1000mL bag, PVC/DEHP-free (NDC 00264-7800-00)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-00,
1949,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",150mL flexible container (NDC 0409-7983-61),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-61,
1950,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL Vis-IV container, PVC/DEHP-free (NDC 0409-7983-25)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-25,
1951,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL flexible container (Legacy Hospira NDC 0409-7983-02)
(ICU Medical NDC 0990-7983-02)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-02,
1952,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",250mL flexible container 2 port (NDC 0409-7983-53),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-53,
1953,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container 2 port (NDC 0409-7983-55),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-55,
1954,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container (NDC 0409-7983-03),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-03,
1955,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",1000mL flexible container (NDC 0409-7983-09),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-09,
1956,Sodium Chloride 0.9% Injection Bags,Fresenius Medical Care North America,1000ml (NDC 49230-300-10),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,49230-300-10,
1957,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-11,
1958,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-36,
1959,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-20,
1960,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-06,
1961,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-02,
1962,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-03,
1963,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-04,
1964,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-04,
1965,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-06,
1966,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-02,
1967,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,12/20/19,Available,Check Wholesaler Inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0187-30,available
1968,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-61,available
1969,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,12/20/19,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-63,available
1970,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,12/20/19,Next Delivery and Estimated Recovery: April 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,00409-1141-02,not available
1971,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,63323-186-02,available
1972,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,63323-186-10,available
1973,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Reverified,12/20/19,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,63323-186-20,available
1974,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Reverified,12/20/19,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,63323-186-00,not available
1975,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Reverified,12/20/19,Available,,,Other,Other,Current,,,00409-4888-10,available
1976,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Reverified,12/20/19,Available,,,Other,Other,Current,,,00409-4888-12,available
1977,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Reverified,12/20/19,Available,,,Other,Other,Current,,,00409-4888-20,available
1978,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Reverified,12/20/19,Available,,,Demand increase for the drug,Other,Current,,,00409-4888-50,available
1979,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,12/13/19,Inventory is currently available.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,0641-0497-25,available
1980,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,12/11/19,Available,Check wholesalers for inventory,,Available,Other,Current,,,64253-202-30,available
1981,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,00409-1918-32,not available
1982,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Reverified,12/20/19,Next Delivery and Estimated Recovery: August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,00409-1918-33,not available
1983,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Reverified,12/20/19,Next Delivery and Estimated Recovery:  August 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,00409-1918-35,not available
1984,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/mL, 5 mL, Sodium 20 mEq/5mL vials (NDC 63323-170-05)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/19,,63323-170-05,
1985,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL (NDC 63323-170-15)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/19,,63323-170-15,
1986,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5123-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5123-01,discontinued
1987,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5124-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5124-01,discontinued
1988,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"160 mg, 100 count bottle (NDC 0378-5125-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5125-01,discontinued
1989,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-11,discontinued
1990,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-50,discontinued
1991,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-11,discontinued
1992,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-50,discontinued
1993,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-11,discontinued
1994,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-50,discontinued
1995,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 100 (NDC 0603-5763-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-21,discontinued
1996,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 500 (NDC 0603-5763-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-28,discontinued
1997,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 1000 (NDC 0603-5763-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-32,discontinued
1998,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 2500 (NDC 0603-5763-30)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-30,discontinued
1999,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 100 (NDC 0603-5764-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5764-21,discontinued
2000,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 500 (NDC 0603-5764-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5764-28,discontinued
2001,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 100 (NDC 0603-5765-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5765-21,discontinued
2002,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 500 (NDC 0603-5765-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5765-28,discontinued
2003,Stavudine (Zerit) Powder for Oral Solution,Bristol Myers Squibb Co.,1mg/mL (NDC 0003-1968-01),New,10/15/18,,,,,Antiviral,To be Discontinued,10/15/18,10/15/18,0003-1968-01,discontinued
2004,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/18,,,,,Antiviral,To be Discontinued,4/30/18,4/30/18,0378-5041-91,discontinued
2005,Stavudine Capsules,Mylan Pharmaceuticals Inc.,40 mg  (NDC0378-5043-91),New,7/17/19,,,,,Antiviral,To be Discontinued,7/17/19,7/17/19,,discontinued
2006,Sterile Talc Powder,Lymol Medical Corp.,Sterile Talc Powder (NDC 63256-200-05),Revised,6/12/19,,,,,Pulmonary/Allergy,Resolved,6/12/19,,63256-200-05,
2007,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 2 grams, in a 50 mL single-dose vial (NDC 62327-222-02)",Revised,6/12/19,,,,,Pulmonary/Allergy,Resolved,6/12/19,,62327-222-02,
2008,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 3 grams, in a 10 mL single-dose vial (NDC 62327-333-03)",Revised,6/12/19,,,,,Pulmonary/Allergy,Resolved,6/12/19,,62327-333-03,
2009,Sterile Talc Powder,Novatech SA,"STERITALC® (talc), powder, for intrapleural use 4 grams, in a 50 mL single-dose vial (NDC 62327-444-04)",Revised,6/12/19,,,,,Pulmonary/Allergy,Resolved,6/12/19,,62327-444-04,
2010,Sterile Water,"Hospira, Inc.",10 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-10,
2011,Sterile Water,"Fresenius Kabi USA, LLC","Single dose vial, 5 mL fill (NDC 63323-185-05)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-05,
2012,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 250mL EXCEL container (NDC  0264-7850-20),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-20,
2013,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP (For Drug Diluent Use Only), 1000 mL VIAFLEX Plastic Container. Product code 2B0304X (NDC 0338-0013-04)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-04,
2014,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 1000 mL (NDC 0409-7990-09),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7990-09,
2015,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 10 mL fill (NDC 63323-185-10)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-10,
2016,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 20 mL fill (NDC 63323-185-20)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-20,
2017,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 50 mL fill (NDC 63323-185-50)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-50,
2018,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, tear top vial, 100 mL (NDC 63323-185-00)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-00,
2019,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.   Product code 2B0306 (NDC 0338-0013-06)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-06,
2020,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 3000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.  Product code 2B0307  (NDC 0338-0013-08)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-08,
2021,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 5000 mL VIAFLEX Plastic Container, Pharmacy Bulk Package. Product code 2B0309 (NDC 0338-0013-29)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-29,
2022,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 500mL EXCEL container (NDC  0264-7850-10),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-10,
2023,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 1,000mL EXCEL container  (NDC 0264-7850-00)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-00,
2024,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 2,000mL Titan container (NDC  0264-7385-50)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7385-50,
2025,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 3,000mL Titan container (NDC  0264-7385-60)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7385-60,
2026,Sterile Water,"Hospira, Inc.",20 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,8/2/19,, ,,,Other,Resolved,8/2/19,,00409-4887-20,
2027,Sterile Water,"Hospira, Inc.",50 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-50,
2028,Sterile Water,"Hospira, Inc.",100 mL; Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-99,
2029,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 2000 mL (NDC 0409-7118-07),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7118-07,
2030,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 1000 mL (NDC 0409-7973-05),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-05,
2031,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-08),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-08,
2032,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-07),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-07,
2033,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation USP, 1000 mL Aqualite ™ Plastic Pour Bottle (NDC 0409-7139-09)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7139-09,
2034,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 500 mL (NDC 0409-6139-03)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-6139-03,
2035,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP 1500 mL (NDC 0409-7139-36)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7139-36,
2036,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 250 mL (NDC 0409-6139-22)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-6139-22,
2037,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3005-25,
2038,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3010-25,
2039,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3020-25,
2040,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0641-6147-25,
2041,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/18,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/18,2/27/18,63481-367-06,discontinued
2042,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0703-7351-01,discontinued
2043,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"0.5 mg, 100s (NDC 0378-2045-01)",Revised,11/26/19,Available,,,,Transplant,Current,,,0378-2045-01,available
2044,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100s (NDC 0378-2046-01)",Revised,11/26/19,Unavailable. Estimated recovery: November 2019,,,,Transplant,Current,,,0378-2046-01,not available
2045,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-2047-01)",Revised,11/26/19,Unavailable. Estimated recovery: December 2019,,,,Transplant,Current,,,0378-2047-01,not available
2046,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Reverified,12/12/19,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,1672904101,limited availability
2047,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Reverified,12/12/19,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,1672904201,limited availability
2048,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Reverified,12/12/19,Shortage duration from July 2019 to May 2020. We would be temporarily discontinuing this product until May 2020. We will allocate any product we do have available based on API availability,,,Limited API availability,Transplant,Current,,,1672904301,limited availability
2049,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3075-3,available
2050,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3075-1,available
2051,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3010-3,available
2052,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3010-1,available
2053,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3040-3,available
2054,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Revised,8/12/19,Available,,,,Transplant,Current,,,68992-3040-1,available
2055,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,12/2/19,Available,Product available on allocation.,,Demand increase for the drug,Transplant,Current,,,64338-721-06,available
2056,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,12/2/19,"Currently, we do not distribute this product strength and NDC. We are evaluating options to potentially re-launch this product strength.",,,,Transplant,Current,,,64380-720-06,not available
2057,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,12/2/19,"Currently, we do not distribute this product strength and NDC. We are evaluating options to potentially re-launch this product strength.",,,,Transplant,Current,,,64380-722-06,not available
2058,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Reverified,12/18/19,Available,,,,Transplant,Current,,,0781-2102-01,available
2059,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Reverified,12/18/19,Available,,,,Transplant,Current,,,0781-2103-04,available
2060,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Reverified,12/18/19,Available,,,,Transplant,Current,,,0781-2104-01,available
2061,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0607-73,limited availability
2062,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0657-73,limited availability
2063,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0617-73,limited availability
2064,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0647-73,limited availability
2065,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0677-73,limited availability
2066,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-0687-73,limited availability
2067,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-1230-50,limited availability
2068,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Revised,6/21/19,Available; product under allocation,,,,Transplant,Current,,,0469-1330-50,limited availability
2069,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-30),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-525-30,available
2070,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-525-01,available
2071,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-05),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-525-05,available
2072,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg unit dose (NDC 55111-525-78),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-525-78,available
2073,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-30),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-526-30,available
2074,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/7/19,Available,Releasing product as it beceomes available,,,Transplant,Current,,,55111-526-01,available
2075,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-05),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-526-05,available
2076,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg unit dose (NDC 55111-526-78),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-526-78,available
2077,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-30),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-527-30,available
2078,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-527-01,available
2079,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-05),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-527-05,available
2080,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg unit dose (NDC 55111-527-78),Reverified,11/7/19,Available,Releasing product as it becomes available,,,Transplant,Current,,,55111-527-78,available
2081,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/18,4/16/18,00409-1941-01,discontinued
2082,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Reverified,12/10/19,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,71647-001-01,available
2083,Technetium Tc99m Succimer Injection (DMSA),GE Healthcare,DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection (NDC 17156-525-01),Revised,12/20/19,,,,,Medical Imaging,To be Discontinued,12/20/19,12/20/19,17156-525-01,discontinued
2084,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/18,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/18,3/6/18,0597-0127-37,discontinued
2085,Testosterone Buccal System,"Endo Pharmaceuticals, Inc.","Striant® 30 mg, 6 blister cards, 60 buccal system  (NDC 52244-030-60)",New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,8/21/19,8/21/19,52244-030-60,discontinued
2086,Testosterone Gel 1%,Par Pharmaceutical,"2.5 g, 30 packets (NDC 49884-418-72)",New,4/29/19,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/19,4/29/19,49884-418-72,discontinued
2087,Testosterone Gel 1%,Par Pharmaceutical,"5 g, 30 packets (NDC 49884-510-72)",New,4/29/19,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/19,4/29/19,49884-510-72,discontinued
2088,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,50 mg (NDC 0378-0616-01),Revised,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-0616-01,available
2089,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0618-01),Revised,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-0618-01,available
2090,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0612-01),Revised,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-0612-01,available
2091,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,25 mg (NDC 0378-0614-01),Revised,11/26/19,Available,,,Other,Psychiatry,Current,,,0378-0614-01,available
2092,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1001-01)",Revised,11/26/19,Unavailable. Estimated re-supply: March 2020.,,,Other,Psychiatry,Current,,,0378-1001-01,not available
2093,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-2002-01)",Revised,11/26/19,Unavailable. Estimated re-supply: March 2020.,,,Other,Psychiatry,Current,,,0378-2002-01,not available
2094,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-3005-01)",Revised,11/26/19,Available,,,,Psychiatry,Current,,,0378-3005-01,available
2095,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-5010-01)",Revised,11/26/19,Available,,,,Psychiatry,Current,,,0378-5010-01,available
2096,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,8/15/19,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,70954-014-10,available
2097,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,8/15/19,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,70954-015-10,available
2098,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,8/15/19,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,70954-016-10,available
2099,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,8/15/19,Available ; Will cater to the entire market demand,,,Other,Psychiatry,Current,,,70954-017-10,available
2100,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count (NDC 0378-0055-01)",Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-0055-01,available
2101,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count (NDC 0378-0221-01)",Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-0221-01,available
2102,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 100 count (NDC 0378-0715-01)",Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-0715-01,available
2103,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0724-19,discontinued
2104,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0722-19,discontinued
2105,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0217-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0217-01,discontinued
2106,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0551-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0551-01,discontinued
2107,Tolbutamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0215-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0215-01,discontinued
2108,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"2 mg, blisters (NDC 0009-5190-04)",New,10/1/19,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/19,10/1/19,0009-5190-04,discontinued
2109,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"4 mg, blisters (NDC 0009-5191-04)",New,10/1/19,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/19,10/1/19,0009-5191-04,discontinued
2110,Tositumomab and Iodine I 131 Tositumomab (Bexxar),GlaxoSmithKline,,Revised,2/18/14,,,"BEXXAR (Tositumomab and Iodine I 131 Tositumomab) is being discontinued.  The product discontinuation is not related to product safety or any FDA action.   BEXXAR will no longer be available effective February 20, 2014.",,Oncology,To Be Discontinued,2/18/14,2/18/14,,discontinued
2111,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-543-90,discontinued
2112,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-542-90,discontinued
2113,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-541-30,discontinued
2114,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-3,discontinued
2115,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-1,discontinued
2116,"Triamcinolone Acetonide (Triesence) Injection, Suspension",Novartis,Triesence (Triamcinolone acetonide injectable suspension) Vial 40mg/mL 1mL in 1 vial (NDC 0065-0534-01),Revised,12/11/19,Unavailable. Estimated Shortage Duration: December 2019,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0065-0534-01,not available
2117,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-80,discontinued
2118,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-16,discontinued
2119,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-028-80,discontinued
2120,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-30),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately October 2019.,,,Cardiovascular,To be Discontinued,6/28/19,6/28/19,0007-3650-30,discontinued
2121,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-01,discontinued
2122,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-05,discontinued
2123,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-01,discontinued
2124,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-05,discontinued
2125,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-00,discontinued
2126,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-03,discontinued
2127,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-00,discontinued
2128,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-03,discontinued
2129,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-2401-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2401-01,
2130,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-2402-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2402-01,
2131,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-2405-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2405-01,
2132,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-2410-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2410-01,
2133,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-8028-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8028-01,
2134,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0832-0494-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0494-11,
2135,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-8032-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8032-01,
2136,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0832-0495-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0495-11,
2137,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-8034-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8034-01,
2138,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0832-0496-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0496-11,
2139,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-8036-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8036-01,
2140,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0832-0497-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0497-11,
2141,Trifluridine Ophthalmic Solution,Sandoz,Trifluridine 1% 7.5 mL (NDC 61314-044-75),Revised,12/18/19,"Limited supply available, on allocation, release of recently received stock expected end-4Q2019.",,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-044-75,limited availability
2142,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 gram  (NDCs 0093-7259-98 and 0093-7259-56),New,11/15/19,,This product is being discontinued due to a business decision.,,,Antiviral,To be Discontinued,11/15/19,11/15/19,,discontinued
2143,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,500 mg tablets (NDCs 45963-558-30 and 45963-558-08),New,2/21/19,,,,,Antiviral,To be Discontinued,2/21/19,2/21/19,,discontinued
2144,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 G tablets (NDCs 45963-559-30 and 45963-559-08),New,2/21/19,,,,,Antiviral,To be Discontinued,2/21/19,2/21/19,,discontinued
2145,Valsartan Tablets,Amneal Pharmaceutical,"40 mg, 30 ct bottle (NDC 65162-837-03); 60 ct bottle (NDC 65162-837-06); 500 ct bottle (NDC 65162-837-50)",New,8/16/18,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,65162-837-03,not available
2146,Valsartan Tablets,Amneal Pharmaceutical,"80 mg, 90 ct bottle (NDC 65162-838-09); 500 ct bottle (NDC 65162-838-50); 1000 ct bottle (NDC 65162-838-11)",New,8/16/18,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,65162-838-09,not available
2147,Valsartan Tablets,Amneal Pharmaceutical,"160 mg, 90 ct bottle (NDC 65162-839-09); 500 ct bottle (NDC 65162-839-50); 1000 ct bottle (NDC 65162-839-11)",New,8/16/18,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,65162-839-09,not available
2148,Valsartan Tablets,Amneal Pharmaceutical,"320 mg, 90 ct bottle (NDC 65162-840-09); 500 ct bottle (NDC 65162-840-50); 1000 ct bottle (NDC 65162-840-11)",New,8/16/18,"Estimated release September 7, 2018",,,Other,Cardiovascular,Current,,,65162-840-09,not available
2149,Valsartan Tablets,Camber Pharmaceuticals Inc.,40 mg (NDC 31722-745-30),Reverified,12/17/19,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,31722-745-30,discontinued
2150,Valsartan Tablets,Camber Pharmaceuticals Inc.,80 mg (NDC 31722-746-90),Reverified,12/17/19,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,31722-746-90,discontinued
2151,Valsartan Tablets,Camber Pharmaceuticals Inc.,160 mg (NDC 31722-746-90),Reverified,12/17/19,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,31722-746-90,discontinued
2152,Valsartan Tablets,Camber Pharmaceuticals Inc.,320 mg (NDC 31722-748-90),Reverified,12/17/19,Currently not marketing this product,Subject to nationwide voluntary recall,,Shortage of an active ingredient,Cardiovascular,Current,,,31722-748-90,discontinued
2153,Valsartan Tablets,Ohm Laboratories Inc.,40 mg (NDC 51660-140-30),New,8/3/18,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,51660-140-30,unclear
2154,Valsartan Tablets,Ohm Laboratories Inc.,80 mg (NDC 51660-141-90),New,8/3/18,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,51660-141-90,unclear
2155,Valsartan Tablets,Ohm Laboratories Inc.,160 mg (NDC 51660-142-90),New,8/3/18,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,51660-142-90,unclear
2156,Valsartan Tablets,Ohm Laboratories Inc.,320 mg (NDC 51660-143-90),New,8/3/18,Manufacturing resumes from September  2018 dependent on API supplies.,Manufacturing stopped temporarily and currently not supplying.,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,51660-143-90,unclear
2157,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 40mg x 30's Bottle Pack (NDC 33342006207),Reverified,6/11/19,Available,,,Available,Cardiovascular,Current,,,33342006207,available
2158,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 80mg x 90's Bottle Pack (NDC 33342006310),Reverified,6/11/19,Available,,,Available,Cardiovascular,Current,,,33342006310,available
2159,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 160mg x 30's Bottle Pack (NDC 33342006410),Reverified,6/11/19,Available,,,Available,Cardiovascular,Current,,,33342006410,available
2160,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 320mg x 30's Bottle Pack (NDC 33342006510),Reverified,6/11/19,Available,,,Available,Cardiovascular,Current,,,33342006510,available
2161,Valsartan Tablets,"Solco Healthcare US, LLC",40mg 30’s (NDC 43547-0367-03),Revised,12/13/19,Currently not marketing this product,,,Other,Cardiovascular,Current,,,43547-0367-03,discontinued
2162,Valsartan Tablets,"Solco Healthcare US, LLC",160mg 90’s (NDC 43547-0369-09),Revised,12/13/19,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,43547-0369-09,discontinued
2163,Valsartan Tablets,"Solco Healthcare US, LLC",80mg 90’s (NDC 43547-0368-09),Revised,12/13/19,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,43547-0368-09,discontinued
2164,Valsartan Tablets,"Solco Healthcare US, LLC",320mg 90’s (NDC 43547-0370-09),Revised,12/13/19,Currently not marketing this product,"Valsartan tablets are the subject of a nationwide voluntary recall for all lots, which was announced on July 13, 2018.",,Other,Cardiovascular,Current,,,43547-0370-09,discontinued
2165,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 40 mg. - 30/Bottle (NDC 65862-0570-30),Revised,12/13/19,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,65862-0570-30,discontinued
2166,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 80 mg. - 90/Bottle (NDC 65862-0571-90),Revised,12/13/19,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,65862-0571-90,discontinued
2167,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 160 mg. - 90/Bottle (NDC 65862-0572-90),Revised,12/13/19,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,65862-0572-90,discontinued
2168,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 320 mg. - 90/Bottle (NDC 65862-0573-90 ),Revised,12/13/19,Temporarily discontinued,,,Demand increase for the drug,Cardiovascular,Current,,,65862-0573-90,discontinued
2169,Valsartan Tablets,Mylan Pharmaceuticals Inc.,40 mg (30’s) (NDC 0378-5807-93),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-5807-93,available
2170,Valsartan Tablets,Mylan Pharmaceuticals Inc.,160 mg (90’s) (NDC 0378-5814-77),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-5814-77,available
2171,Valsartan Tablets,Mylan Pharmaceuticals Inc.,80 mg (90’s) (NDC 0378-5813-77),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-5813-77,available
2172,Valsartan Tablets,Mylan Pharmaceuticals Inc.,320 mg (90’s) (NDC 0378-5815-77),Reverified,11/26/19,Available,,,Other,Cardiovascular,Current,,,0378-5815-77,available
2173,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",40 mg (30's) (NDC 59746-0360-30),Revised,6/17/19,Available,,,Other,Cardiovascular,Current,,,59746-0360-30,available
2174,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",80 mg (90's) (NDC 59746-0361-90),Revised,6/17/19,Available,,,Other,Cardiovascular,Current,,,59746-0361-90,available
2175,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",160 mg (90's) (NDC 59746-0362-90),Revised,6/17/19,Available,,,Other,Cardiovascular,Current,,,59746-0362-90,available
2176,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",320 mg (90's) (NDC 59746-0363-90),Revised,6/17/19,Available,,,Other,Cardiovascular,Current,,,59746-0363-90,available
2177,Valsartan Tablets,Teva Pharmaceuticals,"Valsartan Tablets, USP 40mg, 90 count, (NDC 0591-2167-19)",New,8/3/18,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,8/3/18,8/3/18,0591-2167-19,discontinued
2178,Valsartan Tablets,Torrent Pharma Inc.,40 mg (NDC 13668-067-30),Reverified,12/13/19,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,13668-067-30,not available
2179,Valsartan Tablets,Torrent Pharma Inc.,80 mg (NDC 13668-068-90),Reverified,12/13/19,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,13668-068-90,not available
2180,Valsartan Tablets,Torrent Pharma Inc.,160 mg (NDC 13668-069-90),Reverified,12/13/19,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,13668-069-90,not available
2181,Valsartan Tablets,Torrent Pharma Inc.,320 mg (NDC 13668-070-90),Reverified,12/13/19,Unavailable,Subject to nationwide voluntary recall,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,13668-070-90,not available
2182,Valsartan Tablets,Novartis,DIOVAN® scored tablets 40mg 30s 1 bottle of 30 tablets (NDC 0078-0423-15),Reverified,12/11/19,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,0078-0423-15,available
2183,Valsartan Tablets,Novartis,DIOVAN® tablets 80mg 1 bottle of 90 tablets (NDC 0078-0358-34),Reverified,12/11/19,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,0078-0358-34,available
2184,Valsartan Tablets,Novartis,DIOVAN® tablets 160mg 1 bottle of 90 tablets (NDC 0078-0359-34),Reverified,12/11/19,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,0078-0359-34,available
2185,Valsartan Tablets,Novartis,DIOVAN® tablets 320mg 1 bottle of 90 count (NDC 0078-0360-34),Reverified,12/11/19,Available,Novartis’ Diovan Tablets are readily available and currently not in shortage,,Demand increase for the drug,Cardiovascular,Current,,,0078-0360-34,available
2186,Valsartan Tablets,Novartis,Valsartan Tablets 40 mg 1 bottle of 90 tablets (NDC 0781-5607-31),Reverified,12/11/19,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,0781-5607-31,discontinued
2187,Valsartan Tablets,Novartis,Valsartan Tablets 80 mg 1 bottle of 90 tablets (NDC 0781-5608-92),Reverified,12/11/19,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,0781-5608-92,discontinued
2188,Valsartan Tablets,Novartis,Valsartan Tablets 160 mg 1 bottle of 90 tablets (NDC 0781-5618-92),Reverified,12/11/19,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,0781-5618-92,discontinued
2189,Valsartan Tablets,Novartis,Valsartan Tablets 320 mg 1 bottle of 90 tablets (NDC 0781-5619-92),Reverified,12/11/19,Manufacture of the drug  has been discontinued,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,0781-5619-92,discontinued
2190,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 30 counts (NDC 62332-044-30),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-044-30,limited availability
2191,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 90 counts (NDC 62332-044-90),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-044-90,limited availability
2192,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 500 counts (NDC 62332-044-71),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-044-71,limited availability
2193,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 30 counts (NDC 62332-045-30),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-045-30,limited availability
2194,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 90 counts (NDC 62332-045-90),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-045-90,limited availability
2195,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 500 counts (NDC 62332-045-71),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-045-71,limited availability
2196,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 30 counts (NDC 62332-046-30),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-046-30,limited availability
2197,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 90 counts (NDC 62332-046-90),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-046-90,limited availability
2198,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 500 counts (NDC 62332-046-71),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-046-71,limited availability
2199,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 30 count (NDC 62332-047-30),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-047-30,limited availability
2200,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 90 count (NDC 62332-047-90),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-047-90,limited availability
2201,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 500 counts (NDC 62332-047-71),Revised,12/18/19,Product available to existing customers.,,,Other,Cardiovascular,Current,,,62332-047-71,limited availability
2202,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,Levitra® (vardenafil HCL) tablets 2.5 mg tablet strength (NDC 0173-0828-13),New,5/15/18,,"Bayer will continue to market the 5 mg, 10 mg and 20 mg tablet strengths.",,,Other;Reproductive,To be Discontinued,5/15/18,5/15/18,0173-0828-13,discontinued
2203,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,"5mg, 30 count (NDC 0173-0829-13)",New,7/25/19,,Bayer will continue to market the 10 mg and 20 mg tablet strengths.,,,Reproductive,To be Discontinued,7/25/19,7/25/19,0173-0829-13,discontinued
2204,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"120mg, 100 count, (NDC 0093-3043-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3043-01,discontinued
2205,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 500 count, (NDC 0093-3044-05)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3044-05,discontinued
2206,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 100 count, (NDC 0093-3044-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3044-01,discontinued
2207,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 100 count, (NDC 0093-3045-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3045-01,discontinued
2208,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 500 count, (NDC 0093-3045-05)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3045-05,discontinued
2209,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"100 mg capsule, 100 count bottle (NDC 0378-6201-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6201-01,discontinued
2210,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 100 count bottle (NDC 0378-6202-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6202-01,discontinued
2211,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 500 count bottle (NDC 0378-6202-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6202-05,discontinued
2212,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 100 count bottle (NDC 0378-6203-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6203-01,discontinued
2213,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 500 count bottle (NDC 0378-6203-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6203-05,discontinued
2214,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-0512-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0512-01,discontinued
2215,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-0772-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0772-01,discontinued
2216,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-0772-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0772-05,discontinued
2217,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC",10 mg per 10 mL (1 mg per mL); MDV (NDC 63323-0278-10),Revised,12/20/19,Available on allocation for direct and drop ship orders.  Please contact customer service (888)-386-1300.  Next release January 2020.,Check wholesalers for inventory,,Manufacturing delays,Oncology,Current,,,63323-0278-10,limited availability
2218,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,"Vincasar PFS -- vincristine sulfate injection, solution, 1 MG/ 1 ML (NDC 0703-4402-11)",New,7/5/19,,Teva made a business decion to discontinue the product.,,,Oncology,To be Discontinued,7/5/19,7/5/19,0703-4402-11,discontinued
2219,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,VINCASAR PFS (vincristine sulfate injection USP) 2 mg/2 mL Vial (1 mg/mL) (NDC 0703-4412-11),New,3/20/19,,Teva made a business decision to discontinue this product size (2mL).,,,Oncology,To be Discontinued,3/20/19,,0703-4412-11,discontinued
2220,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",1 mg/mL Single Dose Glass Fliptop Vial (NDC 61703-0309-06),Reverified,12/20/19,Next Delivery: December 2019; Estimated Recovery: January 2020,"Shortage per manufacturer: Manufacturing delay. Product available to order and being released for direct shipment to health care providers to meet patient needs. Please contact Pfizer Supply Continuity Team between 7:00am – 6:00pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]), for additional support.",,Other,Oncology,Current,,,61703-0309-06,not available
2221,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",2 mg/2 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 61703-0309-16),Reverified,12/20/19,Next Delivery and Estimated Recovery: December 2019,"Shortage per manufacturer: Manufacturing delay. November deliveries received. Please check with wholesaler for available inventory. Product available to order for direct shipment to health care providers to meet patient needs. Please contact Pfizer Supply Continuity Team between 7:00am – 6:00pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]), for additional support.",,Other,Oncology,Current,,,61703-0309-16,not available
2222,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","10 mg/mL Single Dose Glass, Vial (NDC 64370-532-01)",New,11/8/19,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,11/8/19,11/8/19,64370-532-01,discontinued
2223,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","50 mg/5mL Single Dose Glass, Vial (NDC 64370-532-02)",New,11/8/19,,"Limited availability; distribution to end December 31, 2019. Discontinuation of the manufacture of the drug.",,,Oncology,To be Discontinued,11/8/19,11/8/19,64370-532-02,discontinued
2224,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/18,4/16/18,61703-0341-06,discontinued
2225,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/18,4/16/18,61703-0341-09,discontinued
2226,Zoledronic Acid (Zometa) Injection,Novartis,Zometa (zoledronic acid) VIAL 4mg/5mL 5mL in 1 Vial (NDC 0078-0387-25),New,10/29/18,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/5mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. There are therapeutic equivalents available.",,,Oncology,To be Discontinued,10/29/18,10/29/18,0078-0387-25,discontinued
2227,Zoledronic Acid (Zometa) Injection,Novartis,Zometa (zoledronic acid) VIAL 4mg/100mL 100mL in 1 Vial (NDC 0078-0590-61),New,10/29/18,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/100mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.There are therapeutic equivalents available.",,,Oncology,To be Discontinued,10/29/18,10/29/18,0078-0590-61,discontinued
2228,Zoledronic Acid Injection,Teva Pharmaceuticals,"0.8 mg/mL, 4 mg 5 mL/Vial (NDC 45963-440-55)",New,5/1/19,,Discontinuation of the manufacture of the drug.,,,Musculoskeletal;Oncology,To be Discontinued,5/1/19,5/1/19,45963-440-55,discontinued
2229,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/18,,,Available,,Psychiatry,Resolved,11/21/18,,0037-6010-30,
2230,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,6.25 mg tablets (NDC 0228-3481-11),New,2/22/19,,,,,Psychiatry,To be Discontinued,2/22/19,2/22/19,0228-3481-11,discontinued
2231,Zolpidem Tartrate Tablets,Wockhardt,5 mg  (NDCs 64679-0714-01 and 64679-0714-04),New,7/18/19,,,,,Psychiatry,To be Discontinued,7/18/19,7/18/19,,discontinued
2232,Zolpidem Tartrate Tablets,Wockhardt,10 mg  (NDCs 64679-0715-01 and 64679-0715-04),New,7/18/19,,,,,Psychiatry,To be Discontinued,7/18/19,7/18/19,,discontinued
2233,Abacavir Sulfate and Lamivudine Tablets,Teva Pharmaceuticals,600 mg and 300 mg  (NDC 0093-5382-56),New,10/2/20,,,,,Antiviral,To be Discontinued,10/2/20,10/2/20,0093-5382-56,discontinued
2234,Abciximab (ReoPro) Injection,"Janssen Biotech, Inc.",2mg/mL (NDC 57894-200-01),Revised,8/15/19,,Janssen has made a business decision to discontinue manufacture of the drug product.,,,Cardiovascular,To be Discontinued,8/15/19,8/15/19,57894-200-01,discontinued
2235,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/20,,,,,Oncology,To be Discontinued,6/5/20,6/5/20,57894-155-12,discontinued
2236,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 25 mg (NDC 50419-863-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-863-51,discontinued
2237,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 50 mg (NDC 50419-861-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-861-51,discontinued
2238,Acarbose (Precose) Tablets,Bayer,Bottles of 100 Tablets 100 mg (NDC 50419-862-51),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-862-51,discontinued
2239,Acarbose (Precose) Tablets,Bayer,Unit Dose 50 mg (NDC 50419-861-48),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Endocrinology/Metabolism,To be Discontinued,2/1/19,2/1/19,50419-861-48,discontinued
2240,Acetaminophen/Tramadol Hydrochloride (Ultracet) Tablets,Janssen Pharmaceuticals,325 mg/1 unit || 37.5 mg/1 unit (NDC 50458-650-60),New,4/1/20,,"The Company has made a business decision to permanently discontinue Ultracet. Product should be maintained on the formularies until the last batch produced expires (31 Oct 2022), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-650-60,discontinued
2241,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/20,,Endo has made a business decision to permanently discontinue the drug product.,,,Pulmonary/Allergy,To be Discontinued,6/2/20,6/2/20,52244-404-10,discontinued
2242,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 100 count (NDC 0093-8940-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8940-01,discontinued
2243,"Acyclovir Capsules, USP",Teva Pharmaceuticals,"200 mg, 500 count (NDC 0093-8940-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8940-05,discontinued
2244,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 100 count (NDC 0093-8943-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8943-01,discontinued
2245,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"400 mg, 500 count (NDC 0093-8943-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8943-05,discontinued
2246,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 100 count (NDC 0093-8947-01)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8947-01,discontinued
2247,"Acyclovir Tablets, USP",Teva Pharmaceuticals,"800 mg, 500 count, (NDC 0093-8947-05)",New,3/21/19,,Teva made a business decision to discontinue product.,,,Antiviral,To be Discontinued,3/21/19,3/21/19,0093-8947-05,discontinued
2248,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/20,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/20,7/27/20,0074-6347-02,discontinued
2249,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/20,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/20,7/27/20,0074-9374-02,discontinued
2250,Albuterol Sulfate and Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,0.3 mg mg/3 mL and 0.5 mg/3 mL (NDC 0591-3817-39),New,7/3/19,,This product discontinuation is a business related decision.,,,Pulmonary/Allergy,To be Discontinued,7/3/19,7/3/19,0591-3817-39,discontinued
2251,Alfentanil Injection,"Hospira, Inc.",1 mg/2 mL (500 mcg/mL) Glass Ampul (NDC 00409-2266-02),New,3/25/20,,Discontinuation of the manufacture of the drug. Current supply exhausted.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/25/20,3/25/20,00409-2266-02,discontinued
2252,Alfentanil Injection,"Hospira, Inc.",2.5 mg/5 mL (500 mcg/mL) Glass Ampul (NDC 00409-2266-05),New,3/25/20,,Discontinuation of the manufacture of the drug. Current supply expected to deplete by May/June 2020 timeframe.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/25/20,3/25/20,00409-2266-05,discontinued
2253,Alogliptin Tablets,Perrigo Company PLC,"12.5mg, 30 Tablets (NDC 45802-0103-65)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,45802-0103-65,
2254,Alogliptin Tablets,Perrigo Company PLC,"25mg, 30 Tablets (NDC 45802-0150-65)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,45802-0150-65,
2255,Alogliptin Tablets,Perrigo Company PLC,"6.25mg, 30 Tablets (NDC 45802-0087-65)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,45802-0087-65,
2256,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"6.25 mg, 30 Tablets (NDC 64764-625-30)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,64764-625-30,
2257,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"12.5 mg, 30 Tablets (NDC 64764-125-30)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,64764-125-30,
2258,Alogliptin Tablets,Takeda Pharmaceuticals USA Inc.,"25 mg, 30 Tablets (NDC 64764-250-30)",Revised,10/5/20,,,,,Endocrinology/Metabolism,Resolved,10/5/20,,64764-250-30,
2259,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/20,,,,,Antiviral;Neurology,To be Discontinued,7/16/20,7/16/20,,discontinued
2260,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),New,5/21/20,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,76310-017-50,limited availability
2261,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) Pharmacy Bulk Package in 1,000 mL plastic container, catalog S4500, (NDC 0264-4500-00)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-4500-00,
2262,Amino Acids,B. Braun Medical Inc.,"15% Amino Acid (Plenamine) in 1,000mL glass container, catalog S3200-SS, (NDC 0264-3200-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,9/24/19,0264-3200-55,
2263,Amino Acids,B. Braun Medical Inc.,"10% FreAmine III (Amino Acid Injection) in 1,000mL glass container, catalog S9010-SS, (NDC 0264-9010-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9010-55,
2264,Amino Acids,B. Braun Medical Inc.,"TrophAmine (10% Amino Acid Injection) in 500mL glass container, catalog S9341-SS, (NDC 0264-9341-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9341-55,
2265,Amino Acids,B. Braun Medical Inc.,"TrophAmine (6% Amino Acid Injection) in 500mL glass container, catalog S9361-SS, (NDC 0264-9361-55)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0264-9361-55,
2266,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-4178-03,
2267,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (NDC 0409-4179-05)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-4179-05,
2268,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-7172-17,
2269,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (NDC 0409-7171-17),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0409-7171-17,
2270,Amino Acids,Baxter Healthcare,"PREMASOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B0009 10% 1000 mL (NDC 0338-1130-04), 2B0010 10% 2000 mL (NDC 0338-1130-06),
2B0012 10% 500 mL (NDC 0338-1130-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-1130-04,
2271,Amino Acids,Baxter Healthcare,"10% TRAVASOL (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 1B6624 10% 1000 mL (NDC 0338-0644-04),
1B6623 10% 500 mL (NDC 0338-0644-03),
1B6626P 10% 2000 mL (NDC 0338-0644-06)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0644-04,
2272,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0502-06,
2273,Amino Acids,Baxter Healthcare,"20% PROSOL - sulfite-free (Amino Acid) Injection, 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion.  Product Code 2B6186 (NDC 0338-0499-06)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-0499-06,
2274,Amino Acids,Baxter Healthcare,CLINIMIX E sulfite-free (Amino Acid with Electrolytes in Dextrose with Calcium) Injection in CLARITY Dual Chamber Container,Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,,
2275,Amino Acids,Baxter Healthcare,CLINIMIX sulfite-free (Amino Acid in Dextrose) Injection in CLARITY Dual Chamber Container,Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,,
2276,Amino Acids,Baxter Healthcare,SYNTHAMIN 17 without Electrolytes - 10% Amino Acids Intravenous Infusion 3000 mL. Product code FKB6642.  Pack factor 3  (NDC 0338-9575-03),Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9575-03,
2277,Amino Acids,Baxter Healthcare,"CLINIMIX N9G15E-Solution for Infusion, 1000 mL (2.75% Amino Acid in 7.5% Glucose with Electrolytes). Product code FKB6669C - Pack factor of 8 (NDC 0338-9570-08)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9570-08,
2278,Amino Acids,Baxter Healthcare,"CLINIMIX N9G20E-Solution for Infusion, 1000 mL  (2.75% Amino Acid in 10% Glucose with Electrolytes) Product code FKB6670C - Pack factor of 8 
(NDC 0338-9566-08)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9566-08,
2279,Amino Acids,Baxter Healthcare,"CLINIMIX N14G30E-Solution for Infusion, 2000 mL (4.25% Amino Acid in 15% Dextrose with Electrolytes) Product code FKB6654V - Pack factor of 4 (NDC 0338-9587-04)",Revised,9/24/19,,,,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,9/24/19,,0338-9587-04,
2280,"Aminophylline Injection, USP","Hospira, Inc.",250 mg/10mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5921-01),Reverified,11/20/20,Available,,,Other,Pulmonary/Allergy,Current,,,0409-5921-01,available
2281,"Aminophylline Injection, USP","Hospira, Inc.",500 mg/20mL (25 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-5922-01),Reverified,11/20/20,Available,,,Other,Pulmonary/Allergy,Current,,,0409-5922-01,available
2282,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-60,discontinued
2283,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-09,discontinued
2284,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-05,discontinued
2285,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-15,discontinued
2286,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-30,discontinued
2287,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-2610-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2610-01,discontinued
2288,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 1000 count bottle (NDC 0378-2610-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2610-10,discontinued
2289,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 100 count bottle (NDC 0378-2625-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2625-01,discontinued
2290,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"25 mg, 1000 count bottle (NDC 0378-2625-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2625-10,discontinued
2291,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-2650-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2650-01,discontinued
2292,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 1000 count bottle (NDC 0378-2650-10)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2650-10,discontinued
2293,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"75 mg, 100 count bottle (NDC 0378-2675-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2675-01,discontinued
2294,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-2685-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2685-01,discontinued
2295,Amitriptyline Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 100 count bottle (NDC 0378-2695-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2695-01,discontinued
2296,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,2.5 mg/10 mg (NDC 0093-7370-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7370-01,discontinued
2297,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/10 mg (NDC 0093-7371-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7371-01,discontinued
2298,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/20 mg (NDC 0093-7372-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7372-01,discontinued
2299,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,5 mg/40 mg (NDC 0093-7670-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7670-01,discontinued
2300,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/20 mg (NDC 0093-7373-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7373-01,discontinued
2301,Amlodipine Besylate and Benazepril Hydrochloride Capsules,Teva Pharmaceuticals,10 mg/40 mg (NDC 0093-7671-01),New,6/5/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,6/5/19,6/5/19,0093-7671-01,discontinued
2302,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/20 mg tablets (NDCs 0093-7027-56 and 0093-7027-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
2303,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",5 mg/40 mg tablets (NDCs 0093-7028-56 and 0093-7028-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
2304,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7029-56 and 0093-7029-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
2305,Amlodipine Besylate and Olmesartan Medoxomil Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",10 mg/20 mg tablets (NDCs 0093-7030-56 and 0093-7030-98),New,3/11/19,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,3/11/19,3/11/19,,discontinued
2306,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Reverified,11/19/20,Available,,,,Psychiatry,Current,3/9/20,,0591-5714-01,available
2307,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Reverified,11/19/20,On backorder,Recovery March 2021,,Other,Psychiatry,Current,3/9/20,,0591-5713-01,not available
2308,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Reverified,11/19/20,Available,,,,Psychiatry,Current,3/9/20,,0591-5715-01,available
2309,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 100 tablets (NDC 0591-5716-01)",Reverified,11/19/20,Available,,,,Psychiatry,Current,3/9/20,,0591-5716-01,available
2310,Amoxicillin Powder for Suspension,Teva Pharmaceuticals,"125 mg/5 mL powder for suspension (NDCs 0093-4150-73, 0093-4150-79 and 0093-4150-80)",New,6/3/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,6/3/19,6/3/19,,discontinued
2311,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-950-01,limited availability
2312,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-951-01,limited availability
2313,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-952-01,limited availability
2314,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-953-01,limited availability
2315,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-954-01,limited availability
2316,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-955-01,limited availability
2317,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Reverified,10/13/20,Available; allocating inventory.,Product is on allocation to its current committed customers.,,Shortage of an active ingredient,Psychiatry,Current,,,68382-956-01,limited availability
2318,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,11/13/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0864-01,available
2319,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,11/13/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0853-01,available
2320,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,11/13/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0842-01,available
2321,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,11/13/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0831-01,available
2322,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,57844-0110-01,available
2323,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,57844-0112-01,available
2324,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,57844-0115-01,available
2325,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,57844-0120-01,available
2326,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,57844-0130-01,available
2327,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,57844-0105-01,available
2328,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,57844-0117-01,available
2329,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4541-01,not available
2330,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4542-01,not available
2331,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4543-01,not available
2332,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4544-01,not available
2333,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4545-01,not available
2334,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4546-01,not available
2335,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Mylan Pharmaceuticals Inc.,30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/10/20,Out of Stock – Resupply TBD,,,Other,Psychiatry,Current,,,0378-4547-01,not available
2336,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Reverified,9/25/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0068-01,available
2337,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Reverified,9/25/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0070-01,available
2338,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Reverified,9/25/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0072-01,available
2339,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Reverified,9/25/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0073-01,available
2340,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Reverified,9/25/20,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0074-01,available
2341,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0776-02,available
2342,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0777-02,available
2343,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0775-02,available
2344,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0972-02,available
2345,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0973-02,available
2346,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0974-02,available
2347,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0555-0971-02,available
2348,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Reverified,11/19/20,"Limited inventory, on allocation",,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,0172-5240-60,limited availability
2349,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Reverified,11/19/20,"Limited inventory, on allocation",,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,0172-5241-60,limited availability
2350,Anagrelide Hydrochloride Capsules,Shire US Inc. now part of Takeda,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Reverified,10/27/20,Available,Takeda is actively working to mitigate a recent unexpected increase in demand for the product.,,Demand increase for the drug,Hematology,Current,,,54092-063-01,available
2351,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Reverified,9/14/20,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,13668-453-01,available
2352,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Reverified,9/14/20,Available and shipping,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,13668-462-01,available
2353,Anastrozole Tablets,Apotex Corp.,1 mg tablets (NDC 60505-2985-3),New,1/21/20,,,,,Oncology,To be Discontinued,1/21/20,1/21/20,60505-2985-3,discontinued
2354,Argatroban Injection,Novartis,"250 mg/2.5 mL (100 mg/mL), single dose vial (NDC 0078-0930-61)",New,1/15/20,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue the product Argatroban Injection, Vial 250 mg/2.5 mL.",,,Hematology,To be Discontinued,1/15/20,1/15/20,0078-0930-61,discontinued
2355,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 5 vial carton (NDC 57902-249-05)",Revised,11/6/20,Available,,,Other,Hematology;Oncology;Pediatric,Current,,,57902-249-05,available
2356,Asparaginase Erwinia Chrysanthemi (Erwinaze),"Jazz Pharmaceuticals, Inc.","ERWINAZE 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial 1 vial (NDC 57902-249-01)",Revised,11/6/20,Available,,,Other,Hematology;Oncology;Pediatric,Current,,,57902-249-01,available
2357,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/20,,"Business decision made by the applicant, BIPI. BIPI will no longer be supplying the market with AGGRENOX capsules after June 11, 2020.",,,Cardiovascular,To be Discontinued,5/26/20,5/26/20,0597-0001-60,discontinued
2358,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 10 mL, 10PK (NDC 67457-698-10)",New,9/24/19,,,,,Anesthesia,To be Discontinued,9/24/19,9/24/19,67457-698-10,discontinued
2359,"Atracurium Besylate Injection, USP",Mylan Institutional,"10 mg/mL, 5 mL, 10 PK (NDC 67457-699-05)",New,9/24/19,,,,,Anesthesia,To be Discontinued,9/24/19,9/24/19,67457-699-05,discontinued
2360,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,11/16/20,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,63323-580-20,available
2361,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3339-1, Old NDC 0548-3339-00)",Reverified,10/30/20,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,76329-3339-1,available
2362,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Reverified,11/20/20,Limited Supply Available. Next Delivery: December 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-1630-10,limited availability
2363,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Reverified,11/20/20,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-9630-05,available
2364,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Reverified,11/20/20,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-4910-34,available
2365,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Reverified,11/20/20,Available,,,Other,Anesthesia;Neurology;Pediatric,Current,,,0409-4911-34,available
2366,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Revised,7/10/20,Limited Availability,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,00517-1010-25,limited availability
2367,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,8/20/20,Available,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0641-6006-10,available
2368,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Revised,7/10/20,Limited availability,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Other,Anesthesia;Neurology;Pediatric,Current,,,00517-0401-25,limited availability
2369,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,7/22/20,Availability limited to product already in pharmacies until resumption of manufacturing in the second half of 2020,Currently qualifying alternate supplier of inactive ingredient,,Shortage of an inactive ingredient,Ophthalmology,Current,,,24208-825-55,limited availability
2370,Avelox® (moxifloxacin HCl) Tablets,Bayer,Bottles of 30 Tablets (NDC 50419-530-01),New,2/1/19,,Business decision to discontinue marketing in the US.,,,Anti-Infective,To be Discontinued,2/1/19,2/1/19,50419-530-01,discontinued
2371,"AVYCAZ® (ceftazidime and avibactam) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",New,2/26/20,Currently unavailable.  Duration of the shortage is yet to be determined.,,,Other,Anti-Infective,Current,,,0456-2700-01,not available
2372,"AVYCAZ® (ceftazidime and avibactam) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",New,2/26/20,Currently unavailable.  Duration of the shortage is yet to be determined.,,,Other,Anti-Infective,Current,,,0456-2700-10,not available
2373,Azacitidine Injection,Teva Pharmaceuticals,100 mg/1 unit (NDC 0591-2897-49),New,10/30/19,,The product has not been marketed for an extended period of time. Teva made a business decision to discontinue this product.,,,Oncology,To be Discontinued,10/30/19,10/30/19,0591-2897-49,discontinued
2374,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/19,,,,,Ophthalmology,Resolved,9/11/19,,17478-307-03,
2375,Azithromycin Tablets,Aurobindo Pharma,250mg 6x3 Blister Pack/ Carton (NDC 65862064163),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,65862064163,available
2376,Azithromycin Tablets,Lupin,250 mg – Carton of 3 Blister Cards (6 Tablets per Blister Card) (NDC  6818016013),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,6818016013,available
2377,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; Unit Dose package of 50 (NDC 0069-4061-89),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-4061-89,available
2378,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; Unit Dose package of 50 (NDC 0069-3070-86),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-3070-86,available
2379,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; bottle of 30 (NDC 0069-3060-30),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-3060-30,available
2380,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 250 mg tablets; boxes of 3 (Z-PAKS of 6) (NDC 0069-3060-75),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-3060-75,available
2381,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; bottles of 30 (NDC 0069-3070-30),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-3070-30,available
2382,Azithromycin Tablets,Pfizer Pharmaceuticals,Zithromax 500 mg tablets; boxes of 3 (TRI-PAKS of 3 tablets) (NDC 0069-3070-75),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0069-3070-75,available
2383,Azithromycin Tablets,Pfizer Pharmaceuticals,250 mg tablets; Blister of 3x6 (NDC 59762-2198-3),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,59762-2198-3,available
2384,Azithromycin Tablets,Pfizer Pharmaceuticals,250 mg tablets; Bottle of 30 (NDC 59762-2198-7),Reverified,11/20/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,59762-2198-7,available
2385,Azithromycin Tablets,Sandoz,600 mg 30 count bottle (NDC 0781-5793-31),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-5793-31,available
2386,Azithromycin Tablets,Sandoz,500 mg 30 count bottle (NDC 0781-8090-31),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-8090-31,available
2387,Azithromycin Tablets,Sandoz,500 mg 3 count unit dose (NDC 0781-8090-03),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-8090-03,available
2388,Azithromycin Tablets,Sandoz,250 mg 30 count bottle (NDC 0781-8089-31),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-8089-31,available
2389,Azithromycin Tablets,Sandoz,250 mg 6 count unit dose (NDC 0781-8089-26),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-8089-26,available
2390,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"600 mg, 30/bottle (NDC 51224-222-30)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-222-30,available
2391,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, 30/bottle (NDC 51224-122-30)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-122-30,available
2392,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, 30/bottle (NDC 51224-022-30)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-022-30,available
2393,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, Cartons of 1 blister card, 3 tablets per blister card (NDC 51224-122-03)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-122-03,available
2394,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"500 mg, Cartons of 3 blister card, 3 tablets per blister card (NDC 51224-122-09)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-122-09,available
2395,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, Cartons of 1 blister card, 6 tablets per blister card (NDC 51224-022-06)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-022-06,available
2396,Azithromycin Tablets,CSPC Ouyi Pharmaceutical Co. Ltd.,"250 mg, Cartons of 3 blister cards, 6 tablets per blister card (NDC 51224-022-18)",Revised,8/20/20,Available,"Distributed by TAGI Pharma Inc at 1-815-624-7685, or Toll-free 1-855-225-8244",,Demand increase for the drug,Anti-Infective,Current,,,51224-022-18,available
2397,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 30 count (NDC 50111-787-10),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-787-10,available
2398,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 6 x 1 blister pack (NDC 50111-787-51),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-787-51,available
2399,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 3 x 1 blister pack (NDC 50111-788-55),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-788-55,available
2400,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 30 count (NDC 50111-788-10),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-788-10,available
2401,Azithromycin Tablets,Teva Pharmaceuticals,600  mg 30 count (NDC 50111-789-10),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-789-10,available
2402,Azithromycin Tablets,Teva Pharmaceuticals,250  mg 18 3 x 6 blister pack (NDC 50111-787-66),Reverified,11/19/20,Available,,,Demand increase for the drug,Anti-Infective,Current,,,50111-787-66,available
2403,Azithromycin Tablets,Teva Pharmaceuticals,500  mg 3 x 3 blister pack (NDC 50111-788-67),Reverified,11/19/20,Available,,,,Anti-Infective,Current,,,50111-788-67,available
2404,Azithromycin Tablets,Wockhardt,250 MG 3X6T (NDC 64679-0961-05),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-0961-05,not available
2405,Azithromycin Tablets,Wockhardt,250 mg 30T (NDC 64679-961-01),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-961-01,not available
2406,Azithromycin Tablets,Wockhardt,250 mg Unit dose package of 100  (NDC 64679-961-02),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-961-02,not available
2407,Azithromycin Tablets,Wockhardt,250 mg Cartons of 3 blister cards (6 tablets per blister card) (NDC 64679-961-05),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-961-05,not available
2408,Azithromycin Tablets,Wockhardt,250 mg 500-ct bottle (NDC 64679-961-07),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-961-07,not available
2409,Azithromycin Tablets,Wockhardt,"500 mg 500 mg, 30T (NDC 64679-0964-01)",Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-0964-01,not available
2410,Azithromycin Tablets,Wockhardt,"500 mg 500 mg, 3X3T (NDC 64679-0964-05)",Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-0964-05,not available
2411,Azithromycin Tablets,Wockhardt,500 mg Unit dose package of 100  (NDC 64679-964-02),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-964-02,not available
2412,Azithromycin Tablets,Wockhardt,500 mg Cartons of 3 blister cards (3 tablets per blister card) (NDC 64679-964-05),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-964-05,not available
2413,Azithromycin Tablets,Wockhardt,500 mg 500-ct bottle (NDC 64679-964-07),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-964-07,not available
2414,Azithromycin Tablets,Wockhardt,600 mg Bottles of 30 (NDC 64679-962-01),Reverified,4/23/20,Unavailable,,,Requirements related to complying with good manufacturing practices & demand increase for the drug,Anti-Infective,Current,,,64679-962-01,not available
2415,Azithromycin Tablets,Bionpharma Inc.,250 mg bottles of 30 (NDC 69452-171-13),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-171-13,available
2416,Azithromycin Tablets,Bionpharma Inc.,250 mg Carton of 6 (1 Card of 6 Tablets) (NDC 69452-171-04),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-171-04,available
2417,Azithromycin Tablets,Bionpharma Inc.,250 mg Carton of 18 (3 Cards of 6 Tablets) (NDC 69452-171-73),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-171-73,available
2418,Azithromycin Tablets,Bionpharma Inc.,500 mg bottles of 30 (NDC 69452-172-13),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-172-13,available
2419,Azithromycin Tablets,Bionpharma Inc.,500 mg Carton of 3 (1 Card of 3 Tablets) (NDC 69452-172-74),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-172-74,available
2420,Azithromycin Tablets,Bionpharma Inc.,500 mg Carton of 9 (3 Cards of 3 Tablets) (NDC 69452-172-72),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,69452-172-72,available
2421,Azithromycin Tablets,Alembic Pharmaceuticals,250 mg bottles of 30 (NDC 62332-251-30),Revised,8/21/20,Available,,,Other,Anti-Infective,Current,,,62332-251-30,available
2422,Azithromycin Tablets,Alembic Pharmaceuticals,250 mg carton of 3 blister cards (6 tablets per blister card) (NDC 62332-251-06),Revised,8/21/20,Available,,,Other,Anti-Infective,Current,,,62332-251-06,available
2423,Azithromycin Tablets,Alembic Pharmaceuticals,500 mg bottle of 30 (NDC 62332-252-30),Revised,8/21/20,Available,,,Other,Anti-Infective,Current,,,62332-252-30,available
2424,Azithromycin Tablets,Alembic Pharmaceuticals,500 mg carton of 3 blister cards (3 tablets per blister card) (NDC 62332-252-03),Revised,8/21/20,Available,,,Other,Anti-Infective,Current,,,62332-252-03,available
2425,Azithromycin Tablets,HEC Pharm USA Inc.,500 mg carton of 1 blister card (3 tablets per blister card) (NDC 0527-2750-17),New,4/22/20,Available,"HEC and its distributor Lannett Company, Inc. in conjunction with FDA has initiated a temporary importation of German approved Azithromycin tablets into the U.S. market to address drug shortage. To place an order, please contact Lannett at (215) 333-9000.",,,Anti-Infective,Current,,,0527-2750-17,available
2426,Azithromycin Tablets,Aurobindo Pharma,500mg 1x3 Blister Pack/Carton (NDC 65862064264),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,65862064264,available
2427,Azithromycin Tablets,Lupin,250 mg Bottle of 30’s (NDC 6818016006),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,6818016006,available
2428,Azithromycin Tablets,Lupin,500 mg Carton of 3 Blister Cards (3 Tablets per Blister Card) (NDC 6818016113),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,6818016113,available
2429,Azithromycin Tablets,Lupin,"Azithromycin Tablets, 500 mg Bottle of 30's (NDC 6818016106)",Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,6818016106,available
2430,Azithromycin Tablets,Lupin,"Azithromycin Tablets, 600 mg Bottle of 30’s (NDC 6818016206)",Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,6818016206,available
2431,Azithromycin Tablets,Aurobindo Pharma,250mg 30 count bottles (NDC 65862064130),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,65862064130,available
2432,Azithromycin Tablets,Aurobindo Pharma,250mg 1x6 Blister Pack/ Carton (NDC 65862064169),Reverified,10/2/20,Available,,,,Anti-Infective,Current,,,65862064169,available
2433,Azithromycin Tablets,Aurobindo Pharma,500mg 3x3 Blister Pack/ Carton (NDC 65862064290),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,65862064290,available
2434,Azithromycin Tablets,Aurobindo Pharma,500mg 30 count bottles (NDC 65862064230),Revised,8/20/20,Available,,,,Anti-Infective,Current,,,65862064230,available
2435,Bacitracin Ophthalmic Ointment,Perrigo Pharmaceuticals,Bacitracin Ophthalmic Ointment 3.5 g (NDC 0574-4022-35),Revised,4/29/20,,,Available,,Ophthalmology,Resolved,4/29/20,,0574-4022-35,
2436,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Reverified,12/16/19,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of NULOJIX via the US NULOJIX Distribution Program, initiated 15-Feb-2017. Starting in August 2018, the restrictions of the NDP will be eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient.  For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,0003-0371-13,limited availability
2437,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-08),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,69202-780-08,discontinued
2438,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 69202-780-88),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,69202-780-88,discontinued
2439,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-08),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,23594-780-08,discontinued
2440,Benzyl Alcohol (Ulesfia) Lotion 5%,Shionogi Inc.,Ulesfia (benzyl alcohol) lotion 5% (50 mg/g of lotion) Bottles (NDC 23594-780-88),New,9/18/19,,"Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.",,,Dermatology,To be Discontinued,9/18/19,9/18/19,23594-780-88,discontinued
2441,Bethanechol Chloride Tablets,Teva Pharmaceuticals,10 mg  (NDC 50111-324-01),New,5/1/20,,,,,Urology,To be Discontinued,5/1/20,5/1/20,50111-324-01,discontinued
2442,Bethanechol Chloride Tablets,Teva Pharmaceuticals,5 mg  (NDC 50111-323-01),New,5/1/20,,,,,Urology,To be Discontinued,5/1/20,5/1/20,50111-323-01,discontinued
2443,Bethanechol Chloride Tablets,Teva Pharmaceuticals,25 mg  (NDC 50111-325-01),New,5/1/20,,,,,Urology,To be Discontinued,5/1/20,5/1/20,50111-325-01,discontinued
2444,Bethanechol Chloride Tablets,Teva Pharmaceuticals,50 mg  (NDC 50111-326-01),New,5/1/20,,,,,Urology,To be Discontinued,5/1/20,5/1/20,50111-326-01,discontinued
2445,Bethanechol Chloride Tablets,Teva Pharmaceuticals,5 mg capsules (NDC 51285-697-02),New,1/13/20,,,,,Urology,To be Discontinued,1/13/20,1/13/20,51285-697-02,discontinued
2446,Bethanechol Chloride Tablets,Teva Pharmaceuticals,10 mg capsules (NDC 51285-690-02),New,1/13/20,,,,,Urology,To be Discontinued,1/13/20,1/13/20,51285-690-02,discontinued
2447,Betrixaban (Bevyxxa) Capsules,"Portola Pharmaceuticals, Inc.",40 mg capsules (NDC 69853-0202-1),New,5/1/20,,,,,Hematology,To be Discontinued,5/1/20,5/1/20,69853-0202-1,discontinued
2448,Betrixaban (Bevyxxa) Capsules,"Portola Pharmaceuticals, Inc.",80 mg capsules (NDC 69853-0201-1),New,5/1/20,,,,,Hematology,To be Discontinued,5/1/20,5/1/20,69853-0201-1,discontinued
2449,Bosentan Tablets,"Janssen Research and Development, LLC",62.5 mg tablets (NDC 10148-625-60),New,10/15/19,,,,,Cardiovascular,To be Discontinued,10/15/19,10/15/19,10148-625-60,discontinued
2450,Bosentan Tablets,"Janssen Research and Development, LLC",125 mg tablets (NDC 10148-125-60),New,10/15/19,,,,,Cardiovascular,To be Discontinued,10/15/19,10/15/19,10148-125-60,discontinued
2451,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/19,,,,,Gastroenterology,To be Discontinued,12/23/19,12/23/19,0093-7445-01,discontinued
2452,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6008-10,not available
2453,"Bumetanide Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6007-10,not available
2454,"Bumetanide Injection, USP","Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1412-04,limited availability
2455,"Bumetanide Injection, USP","Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-1412-10,available
2456,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,11/16/20,Backordered.  Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-461-57,not available
2457,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-463-57,not available
2458,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-17,not available
2459,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-37,not available
2460,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-17,not available
2461,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-37,not available
2462,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,11/16/20,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-462-31,not available
2463,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-460-37,available
2464,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-01,not available
2465,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-17,not available
2466,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9043-01,not available
2467,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-01,not available
2468,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-17,not available
2469,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9046-01,not available
2470,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-10,not available
2471,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-30,not available
2472,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-10,not available
2473,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-29,not available
2474,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1752-50,not available
2475,"Bupivacaine Hydrochloride and Epinephrine Injection, USP","Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Reverified,11/20/20,Next Delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1755-50,not available
2476,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-465-57,available
2477,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-467-57,available
2478,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-17,available
2479,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-37,available
2480,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Reverified,11/16/20,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
2481,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-17,available
2482,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-37,available
2483,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Reverified,11/16/20,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-466-31,not available
2484,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-17,available
2485,"Bupivacaine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-37,available
2486,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-167-10,available
2487,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Revised,11/20/20,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-168-30,not available
2488,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-169-10,available
2489,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Revised,11/20/20,Currently on backorder - next shipment anticipated end of Nov 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-170-30,not available
2490,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Revised,11/20/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,55150-171-10,available
2491,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-172-30,available
2492,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Revised,11/20/20,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-249-50,available
2493,"Bupivacaine Hydrochloride Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Revised,11/20/20,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-250-50,not available
2494,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1159-01,available
2495,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1159-02,available
2496,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1160-01,available
2497,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1162-01,available
2498,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1162-02,available
2499,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1163-01,available
2500,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1165-01,available
2501,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1165-02,available
2502,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-3613-01,available
2503,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1559-10,available
2504,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1559-30,available
2505,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1587-50,available
2506,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1560-10,available
2507,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1560-29,available
2508,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1610-50,available
2509,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1582-10,available
2510,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1582-29,available
2511,"Bupivacaine Hydrochloride Injection, USP","Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-,available
2512,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-717-05,available
2513,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-719-10,available
2514,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),New,9/12/19,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-718-05,available
2515,"Bupivacaine Hydrochloride Injection, USP","Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),New,9/12/18,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-720-10,available
2516,"Bupivacaine Hydrochloride Injection, USP",Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,10/28/20,Stocked out - recovery TBD,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,Manufacturing Delay,Anesthesia,Current,,,36000-092-10,not available
2517,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 30 count bottle (NDC 0378-0923-93)",New,5/2/19,,,,,Analgesia/Addiction,To be Discontinued,5/2/19,5/2/19,0378-0923-93,discontinued
2518,Buprenorphine Hydrochloride Sublingual Tablets,Mylan Pharmaceuticals Inc.,"8 mg, 30 count bottle (NDC 0378-0924-93)",New,5/2/19,,,,,Analgesia/Addiction,To be Discontinued,5/2/19,5/2/19,0378-0924-93,discontinued
2519,Bupropion Hydrochloride (Zyban) Tablets,GlaxoSmithKline,150 mg  (NDC 0173-0556-01),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately July 2019.,,,Psychiatry,To be Discontinued,6/28/19,6/28/19,0173-0556-01,discontinued
2520,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 90 count bottle (NDC 0378-2008-77)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2008-77,discontinued
2521,Bupropion Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"300 mg, 500 count bottle (NDC 0378-2009-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-2009-05,discontinued
2522,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 100 (NDC 69238-1117-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1117-01,
2523,Buspirone HCl Tablets,Amneal Pharmaceutical,"10mg, 500 (NDC 69238-1117-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1117-05,
2524,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 100 (NDC 69238-1118-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1118-01,
2525,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 500 (NDC 69238-1118-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1118-05,
2526,Buspirone HCl Tablets,Amneal Pharmaceutical,"15mg, 60 (NDC 69238-1118-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1118-06,
2527,Buspirone HCl Tablets,Amneal Pharmaceutical,"30mg, 60 (NDC 69238-1119-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1119-06,
2528,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 100 (NDC 69238-1115-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1115-01,
2529,Buspirone HCl Tablets,Amneal Pharmaceutical,"5mg, 500 (NDC 69238-1115-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1115-05,
2530,Buspirone HCl Tablets,Amneal Pharmaceutical,"7.5mg, 100 (NDC 69238-1116-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,69238-1116-01,
2531,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"5 mg, 100 count bottle (NDC 23155-023-01",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-023-01,
2532,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"5 mg, 500 count bottle (NDC 23155-023-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-023-05,
2533,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"10 mg, 100 count bottle (NDC 23155-024-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-024-01,
2534,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"10 mg, 500 count bottle (NDC 23155-024-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-024-05,
2535,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 60 count bottle (NDC 23155-025-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-025-06,
2536,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 100 count bottle (NDC 23155-025-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-025-01,
2537,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 180 count bottle (NDC 23155-025-08)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-025-08,
2538,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"15 mg, 500 count bottle (NDC 23155-025-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-025-05,
2539,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"30 mg, 60 count bottle (NDC 23155-097-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-097-06,
2540,Buspirone HCl Tablets,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,"30 mg, 500 count bottle (NDC 23155-097-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,23155-097-05,
2541,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 60 count bottle (NDC 64380-743-03)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-743-03,
2542,Buspirone HCl Tablets,Strides Pharma Inc.,"15 mg, 180 count bottle (NDC 64380-743-18)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-743-18,
2543,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 100 count bottle (NDC 16729-200-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-200-01,
2544,Buspirone HCl Tablets,Accord Healthcare Inc.,"5 mg, 500 count bottle (NDC 16729-200-16)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-200-16,
2545,Buspirone HCl Tablets,Accord Healthcare Inc.,"7.5 mg, 100 count bottle (NDC 16729-201-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-201-01,
2546,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 100 count bottle (NDC 16729-202-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-202-01,
2547,Buspirone HCl Tablets,Accord Healthcare Inc.,"10 mg, 500 count bottle (NDC 16729-202-16)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-202-16,
2548,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 60 count bottle (NDC 16729-203-12)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-203-12,
2549,Buspirone HCl Tablets,Accord Healthcare Inc.,"15 mg, 100 count bottle (NDC 16729-203-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-203-01,
2550,Buspirone HCl Tablets,Accord Healthcare Inc.,"30 mg, 60 count bottle (NDC 16729-289-12)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,16729-289-12,
2551,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 49884-725-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,49884-725-01,
2552,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 500 count bottle (NDC 49884-725-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,49884-725-05,
2553,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-1140-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1140-01,
2554,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-1140-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1140-05,
2555,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"5 mg, unit-dose blister pack, 100 count (NDC 51079-985-20)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,51079-985-20,
2556,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"7.5 mg, 100 count bottle (NDC 0378-1145-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1145-01,
2557,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-1150-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1150-01,
2558,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-1150-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1150-05,
2559,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"10 mg, unit-dose blister pack, 100 count (NDC 51079-986-20)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,51079-986-20,
2560,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 60 count bottle (NDC 0378-1165-91)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1165-91,
2561,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 180 count bottle (NDC 0378-1165-80)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1165-80,
2562,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 500 count bottle (NDC 0378-1165-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1165-05,
2563,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"15 mg, unit-dose blister pack, 100 count (NDC 51079-960-20)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,51079-960-20,
2564,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 60 count bottle (NDC 0378-1175-91)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0378-1175-91,
2565,Buspirone HCl Tablets,Mylan Pharmaceuticals Inc.,"30 mg, unit-dose blister pack, 100 count (NDC 51079-994-20)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,51079-994-20,
2566,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 100 count bottle (NDC 64380-741-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-741-06,
2567,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 500 count bottle (NDC 64380-741-07)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-741-07,
2568,Buspirone HCl Tablets,Strides Pharma Inc.,"5 mg, 1000 count bottle (NDC 64380-741-08)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-741-08,
2569,Buspirone HCl Tablets,Strides Pharma Inc.,"7.5 mg, 100 count bottle (NDC 64380-787-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-787-06,
2570,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 100 count bottle (NDC 64380-742-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-742-06,
2571,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 500 count bottle (NDC 64380-742-07)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-742-07,
2572,Buspirone HCl Tablets,Strides Pharma Inc.,"10 mg, 1000 count bottle (NDC 64380-742-08)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-742-08,
2573,Buspirone HCl Tablets,Strides Pharma Inc.,"30 mg, 60 count bottle (NDC 64380-744-03)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,64380-744-03,
2574,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0093-0053-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-0053-01,
2575,Buspirone HCl Tablets,Teva Pharmaceuticals,"5 mg, 500 count bottle (NDC 0093-0053-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-0053-05,
2576,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0093-0054-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-0054-01,
2577,Buspirone HCl Tablets,Teva Pharmaceuticals,"10 mg, 500 count bottle (NDC 0093-0054-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-0054-05,
2578,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 100 count bottle (NDC 0093-1003-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-1003-01,
2579,Buspirone HCl Tablets,Teva Pharmaceuticals,"15 mg, 500 count bottle (NDC 0093-1003-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-1003-05,
2580,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 60 count bottle (NDC 0093-5200-06)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-5200-06,
2581,Buspirone HCl Tablets,Teva Pharmaceuticals,"30 mg, 500 count bottle (NDC 0093-5200-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,0093-5200-05,
2582,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 100 count bottle (NDC 68382-180-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-180-01,
2583,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"5 mg, 500 count bottle (NDC 68382-180-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-180-05,
2584,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 100 count bottle (NDC 68382-181-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-181-01,
2585,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"10 mg, 500 count bottle (NDC 68382-181-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-181-05,
2586,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 100 count bottle (NDC 68382-182-01)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-182-01,
2587,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"15 mg, 500 count bottle (NDC 68382-182-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-182-05,
2588,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 60 count bottle (NDC 68382-183-14)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-183-14,
2589,Buspirone HCl Tablets,Zydus Pharmaceuticals USA Inc.,"30 mg, 500 count bottle (NDC 68382-183-05)",Revised,1/16/20,,,Available,,Psychiatry,Resolved,1/16/20,,68382-183-05,
2590,Busulfan Injection,Teva Pharmaceuticals,6 mg/mL  (NDC 45963-640-77),New,5/6/20,,,,,Hematology,To be Discontinued,5/6/20,5/6/20,45963-640-77,discontinued
2591,Calcitriol Injection USP 1MCG /ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,12/2/19,Available,,,Other,Endocrinology/Metabolism,Current,,,17478-931-01,available
2592,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); Ansyr Plastic Syringe (NDC 00409-1631-10),Reverified,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric,Current,,,00409-1631-10,limited availability
2593,"Calcium Chloride Injection, USP","Hospira, Inc.",1 g/10 mL (100 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4928-34),Reverified,11/20/20,Available,,,Other,Gastroenterology;Pediatric,Current,,,00409-4928-34,available
2594,"Calcium Chloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Calcium Chloride Inj. USP, 10%, 10mL Luer-Jet Prefilled Syringe, (NDC 0548-3304-00), new (NDC 76329-3304-1)",Reverified,10/30/20,Available,,,Demand increase for the drug,Gastroenterology;Pediatric,Current,,,0548-3304-00,available
2595,"Calcium Chloride Injection, USP","Medefil, Inc.","Calcium Chloride Inj. USP, 10%, 10mL Prefilled Syringe, (NDC 64253-900-36)",Reverified,5/8/20,Available,Check wholesaler for inventory,,Other,Gastroenterology;Pediatric,Current,,,64253-900-36,available
2596,"Calcium Chloride Injection, USP",American Regent/Luitpold,"10% Calcium Chloride Injection, USP, 1 gram/10mL (100mg/mL), single dose vial, (NDC 0517-6710-10)",Reverified,9/29/20,Available,,,,Gastroenterology;Pediatric,Current,,,0517-6710-10,available
2597,"Capreomycin Injection, USP",Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,7/15/20,Available,"Available until 2Q 2021. After that, no further supply will be available",,Shortage of an active ingredient,Anti-Infective,Current,,,17478-080-50,available
2598,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,100 mg capsules (NDC 29033-019-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-019-12,discontinued
2599,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,200 mg capsules (NDC 29033-020-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-020-12,discontinued
2600,Carbamazepine Extended Release Capsules,Mylan Pharmaceuticals Inc.,300 mg capsules (NDC 29033-004-12),New,6/19/19,,,,,Neurology,To be Discontinued,6/19/19,6/19/19,29033-004-12,discontinued
2601,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 25/100 mg (NDC 0378-0088-01)",Revised,7/12/19,,,,,Neurology,Resolved,7/12/19,,0378-0088-01,
2602,Carbidopa and Levodopa Extended Release Tablets,Mylan Pharmaceuticals Inc.,"Carbidopa and Levodopa Extended Release Tablets, 50/200 mg (NDC 0378-0094-01)",Revised,7/12/19,,,,,Neurology,Resolved,7/12/19,,0378-0094-01,
2603,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa (50 mg of carbidopa and 200 mg of levodopa)  (SINEMET CR 50-200) sustained-release tablets, (NDC 0006-3919-68)bottles of 100",New,7/17/19,,To be discontinued on or near November 2019.,,,Neurology,To be Discontinued,7/17/19,7/17/19,0006-3919-68,discontinued
2604,Carbidopa and Levodopa Extended Release Tablets,Merck Sharp & Dohme Corp.,"Carbidopa levodopa  (25 mg of carbidopa and 100 mg of levodopa) (SINEMET CR 25-100 ) sustained-release tablets, (NDC 0006-3918-68) bottles of 100",New,7/17/19,,To be discontinued on or near February 2020.,Available,,Neurology,To be Discontinued,7/17/19,,0006-3918-68,discontinued
2605,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 100CT; (NDC 1672907901),Revised,7/12/19,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/19,,1672907901,
2606,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  25-100 mg (NDC  62756-461-88 ),Revised,7/12/19,,,Available,,Neurology,Resolved,7/12/19,,62756-461-88,
2607,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 50MG/200MG 1000CT; (NDC 1672907917),Revised,7/12/19,,,Stocks available to support current customer demand,,Neurology,Resolved,7/12/19,,1672907917,
2608,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 100CT; (NDC 1672907801),Revised,7/12/19,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/19,,1672907801,
2609,Carbidopa and Levodopa Extended Release Tablets,Accord Healthcare Inc.,CARBIDOPA & LEVODOPA ER TABLETS 25MG/100MG 1000CT; (NDC 1672907817),Revised,7/12/19,,,Due to manufacturing constraints; we estimate the delay to continue until January 2020,,Neurology,Resolved,7/12/19,,1672907817,
2610,Carbidopa and Levodopa Extended Release Tablets,Sun Pharmaceutical Industries Inc.,Carbidopa and Levodopa Extended Release Tablets  50-200 (NDC 62756-457-88),Revised,7/12/19,,,Available,,Neurology,Resolved,7/12/19,,62756-457-88,
2611,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg/5 mL oral solution (NDCs 64376-612-16 and 64376-612-40),Revised,9/11/19,,,,,Pulmonary/Allergy,To be Discontinued,9/11/19,9/11/19,,discontinued
2612,Carbinoxamine Maleate,"Endo Pharmaceuticals, Inc.",4 mg tablets (NDC 64376-605-01),Revised,9/11/19,,,,,Pulmonary/Allergy,To be Discontinued,9/11/19,9/11/19,64376-605-01,discontinued
2613,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/18,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/18,3/20/18,10122-326-10,discontinued
2614,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-21,discontinued
2615,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-28,discontinued
2616,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),New,3/18/19,,Endo has made a business decision to permanently discontinue Carisoprodol 350mg tablets.,,,Musculoskeletal,To be Discontinued,3/18/19,3/18/19,00603-2582-32,discontinued
2617,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg 30 count bottle (NDC 0037-2250-30)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0037-2250-30,
2618,"Carisoprodol Tablets, USP",Ingenus Pharmaceuticals LLC,"350 mg, 100 count tablets (NDC 50742-656-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,50742-656-01,
2619,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 100 count (NDC 0591-5513-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0591-5513-01,
2620,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 500 count (NDC 0591-5513-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0591-5513-05,
2621,"Carisoprodol Tablets, USP",Teva Pharmaceuticals,"350 mg, 1000 count (NDC 0591-5513-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0591-5513-10,
2622,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 50228-109-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,50228-109-01,
2623,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 50228-109-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,50228-109-05,
2624,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 50228-109-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,50228-109-10,
2625,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 60429-508-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,60429-508-10,
2626,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 100 count (NDC 42543-700-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,42543-700-01,
2627,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 500 count (NDC 42543-700-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,42543-700-05,
2628,"Carisoprodol Tablets, USP","ScieGen Pharmaceuticals, Inc.","350 mg, 1000 count (NDC 42543-700-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,42543-700-10,
2629,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100’s count bottle (NDC 00603-2582-21),Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,00603-2582-21,
2630,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",500's count bottle (NDC 00603-2582-28),Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,00603-2582-28,
2631,"Carisoprodol Tablets, USP","Endo Pharmaceuticals, Inc.",100's count bottle (NDC 00603-2582-32),Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,00603-2582-32,
2632,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 250 mg, 30 count bottle (NDC 0037-2250-30); 100 count bottle (NDC 0037-2250-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0037-2250-30,
2633,"Carisoprodol Tablets, USP",Mylan Specialty,"Soma, 350 mg, 100 count bottle (NDC 0037-2001-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,0037-2001-01,
2634,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 16714-510-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,16714-510-01,
2635,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 16714-510-02)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,16714-510-02,
2636,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 16714-510-03)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,16714-510-03,
2637,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 61442-451-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,61442-451-01,
2638,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 61442-451-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,61442-451-05,
2639,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 61442-451-10)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,61442-451-10,
2640,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 100 tablets (NDC 59746-705-01)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,59746-705-01,
2641,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 500 tablets (NDC 59746-705-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,59746-705-05,
2642,"Carisoprodol Tablets, USP","Orient Pharma Co., Ltd","350 mg, 1000 tablets (NDC 59746-705-05)",Revised,5/19/20,,,,,Analgesia/Addiction;Musculoskeletal,Resolved,5/19/20,,59746-705-05,
2643,"Carisoprodol, Aspirin, and Codeine Phosphate Tablets USP",Ingenus Pharmaceuticals LLC,200 mg/325 mg/16 mg (NDC 50742-256-01),New,9/1/20,,,,,Musculoskeletal,To be Discontinued,9/1/20,9/1/20,50742-256-01,discontinued
2644,Caspofungin Acetate Injection,Mylan Institutional,50 mg (NDC 67457-831-50),New,7/23/20,,,,,Anti-Infective;Pediatric,To be Discontinued,7/23/20,7/23/20,67457-831-50,discontinued
2645,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: February 2021,,,Demand increase for the drug,Anti-Infective,Current,,,00409-2585-01,limited availability
2646,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,60505-6143-04,available
2647,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,11/20/20,Available,,,,Anti-Infective,Current,,,66288-1100-1,available
2648,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,11/20/20,Available,,,,Anti-Infective,Current,,,66288-1300-1,available
2649,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,10/22/20,Available,,,,Anti-Infective,Current,,,25021-101-10,available
2650,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Revised,10/28/20,Available,,,,Anti-Infective,Current,,,0338-3503-41,available
2651,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Revised,10/28/20,Product on allocation for existing customers,,,Other,Anti-Infective,Current,,,0338-3508-41,limited availability
2652,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,60505-6142-05,available
2653,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,10/22/20,Available,,,,Anti-Infective,Current,,,25021-102-99,available
2654,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,10/22/20,Available,,,,Anti-Infective,Current,,,25021-100-10,available
2655,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,9/8/20,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,00264-3105-11,limited availability
2656,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,9/8/20,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,0264-3103-11,limited availability
2657,Cefazolin Injection,WG Critical Care,500mg Cefazolin SDV (NDC 44567-706-25),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-706-25,available
2658,Cefazolin Injection,WG Critical Care,1g Cefazolin SDV (NDC 44567-707-25),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-707-25,available
2659,Cefazolin Injection,WG Critical Care,10g Cefazolin PBP (NDC 44567-708-10),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-708-10,available
2660,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,00409-0805-01,discontinued
2661,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Revised,10/2/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/20,10/2/20,00409-0805-01,discontinued
2662,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Revised,10/2/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/20,10/2/20,00409-0806-01,discontinued
2663,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,7/22/20,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9923-90,available
2664,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,7/22/20,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9924-90,available
2665,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,7/22/20,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9983-03,available
2666,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-3450-95,available
2667,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-3451-96,available
2668,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,11/13/20,Available,,,,Anti-Infective,Current,,,0781-3452-95,available
2669,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/20,,,,,Anti-Infective,To be Discontinued,7/9/20,7/9/20,0781-2176-60,discontinued
2670,Cefepime Injection,"Hospira, Inc.",1g; Single Dose Vial (NDC 00409-9566-01),Reverified,11/20/20,Available,,,Other,Anti-Infective;Pediatric,Current,,,00409-9566-01,available
2671,Cefepime Injection,"Hospira, Inc.",2g; Single Dose Vial (NDC 00409-9735-01),Reverified,11/20/20,Available,,,Other,Anti-Infective;Pediatric,Current,,,00409-9735-01,available
2672,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (10 vials) (NDC 60505-6146-04),Reverified,11/13/20,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6146-04,available
2673,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-6146-00),Reverified,11/13/20,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6146-00,available
2674,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (10 vials) (NDC 60505-6147-04),Reverified,11/13/20,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6147-04,available
2675,Cefepime Injection,Apotex Corp.,Cefepime for Injection 2 g (1 vial) (NDC 60505-6147-00),Reverified,11/13/20,Available,,,,Anti-Infective;Pediatric,Current,,,60505-6147-00,available
2676,Cefepime Injection,Apotex Corp.,Cefepime for Injection 1 g (1 vial) (NDC 60505-0834-00),Revised,3/1/19,,"Product was manufactured by Hospira, no longer distributed by Apotex",,,Anti-Infective;Pediatric,To be Discontinued,3/1/19,3/1/19,60505-0834-00,discontinued
2677,Cefepime Injection,B. Braun Medical Inc.,Cefepime 1 g (NDC 0264-3193-11),Reverified,9/9/20,Product on allocation to contracted custormers,,,Other,Anti-Infective;Pediatric,Current,,,0264-3193-11,limited availability
2678,Cefepime Injection,B. Braun Medical Inc.,Cefepime 2 g (NDC 0264-3195-11),Reverified,9/9/20,Product on allocation to contracted customers,,,Other,Anti-Infective;Pediatric,Current,,,0264-3195-11,limited availability
2679,Cefepime Injection,Sagent Pharmaceuticals,1 g vial (NDC 25021-121-20),Revised,10/22/20,Available.,,,,Anti-Infective;Pediatric,Current,,,25021-121-20,available
2680,Cefepime Injection,Sagent Pharmaceuticals,2 g vial (NDC 25021-122-50),Revised,10/22/20,On Allocation. Estimated availability Nov 2020,,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,25021-122-50,limited availability
2681,Cefepime Injection,"Fresenius Kabi USA, LLC","1 g single dose vial, sterile powder (NDC 63323-326-20)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-326-20,available
2682,Cefepime Injection,"Fresenius Kabi USA, LLC","2 g single dose vial, sterile powder (NDC 63323-340-20)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,63323-340-20,available
2683,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 1 gram/50mL, GALAXY Container (NDC 0338-1301-41)",Reverified,10/28/20,Available,,,,Anti-Infective;Pediatric,Current,,,0338-1301-41,available
2684,Cefepime Injection,Baxter Healthcare,"Cefepime Injection, 2 gram/100mL, GALAXY Container (NDC 0338-1301-48)",Reverified,10/28/20,Available,,,,Anti-Infective;Pediatric,Current,,,0338-1301-48,available
2685,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0218-01),Revised,8/25/20,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/20,8/25/20,00409-0218-01,discontinued
2686,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose ADD-Vantage Glass Vial (NDC 00409-0217-01),Revised,8/25/20,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/20,8/25/20,00409-0217-01,discontinued
2687,Cefepime Injection,"Hospira, Inc.",Maxipime 1 g; Single Dose Glass Fliptop Vial (NDC 00409-0219-01),Revised,8/25/20,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/20,8/25/20,00409-0219-01,discontinued
2688,Cefepime Injection,"Hospira, Inc.",Maxipime 2 g; Single Dose Glass Fliptop Vial (NDC 00409-0220-01),Revised,8/25/20,,Discontinuation of the manufacture of the drug,,,Anti-Infective;Pediatric,To be Discontinued,8/25/20,8/25/20,00409-0220-01,discontinued
2689,Cefepime Injection,WG Critical Care,1 g vial (NDC 44567-0240-10),Reverified,11/18/20,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,44567-0240-10,available
2690,Cefepime Injection,WG Critical Care,2 g vial (NDC 44567-0241-10),Reverified,11/18/20,Available,Please check wholesalers and distributors for inventory.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,44567-0241-10,available
2691,Cefepime Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak Pharmacy Bulk Package (NDC 66288-8100-1),Reverified,11/20/20,Available,,,,Anti-Infective;Pediatric,Current,,,66288-8100-1,available
2692,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Revised,11/16/20,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,21586-012-2,available
2693,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Revised,11/16/20,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact FFF Enterprises at 1-800-843-7477",,Other,Anti-Infective;Pediatric,Current,,,21586-011-2,available
2694,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Revised,7/22/20,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9930-10,not available
2695,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Revised,7/22/20,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9931-25,not available
2696,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Revised,7/22/20,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9933-25,not available
2697,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Revised,7/22/20,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9935-01,not available
2698,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,11/10/20,Available,,,,Anti-Infective,Current,,,52565-0053-10,available
2699,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 1g Vial 10 (NDC 52565-0052-10),Revised,3/31/20,,Low volume available; short-dated product; Teligent has made a business decision to discontinue manufacture of this presentation.,,,Anti-Infective,To be Discontinued,3/31/20,3/31/20,52565-0052-10,discontinued
2700,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,8/28/20,Product not available,,,Other,Anti-Infective,Current,,,00264-3173-11,not available
2701,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,8/28/20,Product not available,,,Other,Anti-Infective,Current,,,00264-3175-11,not available
2702,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Revised,11/16/20,8 mos expiry available by request. Next release December 2020.,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0385-10,limited availability
2703,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Revised,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0386-20,available
2704,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Revised,11/16/20,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,63323-0396-61,not available
2705,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,7/22/20,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9878-25,available
2706,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,7/22/20,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9877-25,available
2707,"Cefoxitin for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,7/22/20,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9876-10,available
2708,"Cefoxitin for Injection, USP",Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Reverified,11/13/20,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0759-05,discontinued
2709,"Cefoxitin for Injection, USP",Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Reverified,11/13/20,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0760-05,discontinued
2710,"Cefoxitin for Injection, USP",Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Reverified,11/13/20,Product is temporarily discontinued,Product manufactured by Hospira,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,60505-0761-04,discontinued
2711,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,63323-341-25,available
2712,"Cefoxitin for Injection, USP","Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delays,Anti-Infective,Current,,,63323-342-25,available
2713,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,10/22/20,Available,,,,Anti-Infective,Current,,,25021-111-99,available
2714,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,10/22/20,On backorder. Estimated availability Dec 2020,,,Manufacturing delay,Anti-Infective,Current,,,25021-109-10,not available
2715,"Cefoxitin for Injection, USP",Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,10/22/20,On allocation. Estimated availability Nov 2020,,,Manufacturing delay,Anti-Infective,Current,,,25021-110-20,limited availability
2716,"Cefoxitin for Injection, USP",WG Critical Care,1 g (NDC 44567-245-25),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-245-25,available
2717,"Cefoxitin for Injection, USP",WG Critical Care,2 g (NDC 44567-246-25),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-246-25,available
2718,"Cefoxitin for Injection, USP",WG Critical Care,10 g (NDC 44567-247-10),Reverified,11/18/20,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-247-10,available
2719,"Cefoxitin for Injection, USP",B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,9/8/20,Available,,,Other,Anti-Infective,Current,,,00264-3125-11,available
2720,"Cefoxitin for Injection, USP",B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,9/8/20,Available,,,Other,Anti-Infective,Current,,,0264-3123-11,available
2721,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0412-00,discontinued
2722,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0413-00,discontinued
2723,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0425-00,discontinued
2724,Cetirizine Hydrochloride,Torrent Pharma Inc.,5 mg/5 mL oral syrup (NDC 13668-596-07),New,4/24/19,,,,,Pulmonary/Allergy,To be Discontinued,4/24/19,4/24/19,13668-596-07,discontinued
2725,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-251-10,discontinued
2726,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-252-10,discontinued
2727,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,25 mg (NDC 43547-253-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-253-10,discontinued
2728,Chloroquine Phosphate Tablets,Natco Pharma Limited,"250 mg, 50 count bottle (NDC 64980-177-50); distributed by Rising Pharmaceuticals, to order contact: 201-961-9000",Revised,5/8/20,,,Available,,Anti-Infective,Resolved,5/8/20,,64980-177-50,
2729,Chloroquine Phosphate Tablets,Natco Pharma Limited,"500 mg, 25 count bottle (NDC 64980-178-02); distributed by Rising Pharmaceuticals, to order contact: 201-961-9000",Revised,5/8/20,,,Available,,Anti-Infective,Resolved,5/8/20,,64980-178-02,
2730,Chlorothiazide (Diuril) Oral Suspension,Bausch Health,250 mg/5 mL (50 mg/mL) 237 mL (NDC 65649-311-12),New,8/12/20,Product availability is planned for 18-Sep-2020.,"Distributor-Salix Pharmaceuticals, Inc.: 1-800-321-4576",,Shortage of an inactive ingredient,Cardiovascular;Pediatric,Current,,,65649-311-12,not available
2731,Chlorothiazide Injection,Mylan Institutional,500 mg (NDC 67457-263-30),New,4/8/20,,Expected discontinuation May 2020,,,Cardiovascular,To be Discontinued,4/8/20,4/8/20,67457-263-30,discontinued
2732,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0150-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-0150-01,discontinued
2733,Chlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0162-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-0162-01,discontinued
2734,Chlorpheniramine Maleate; Hydrocodone Bitartrate; Pseudoephedrine Hydrochloride Oral Solution,"Paddock Laboratories, LLC",4 mg/5 mL; 5 mg/5 mL; 60 mg/5 mL (NDC 0574-1103-16),New,6/12/19,,,,,Pulmonary/Allergy,To be Discontinued,6/12/19,6/12/19,0574-1103-16,discontinued
2735,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0197-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0197-01,discontinued
2736,Chlorpropamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0210-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0210-01,discontinued
2737,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 50 count bottle (NDC 0378-1743-89)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-1743-89,discontinued
2738,Ciprofloxacin Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1000 mg, 50 count bottle (NDC 0378-1745-89)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-1745-89,discontinued
2739,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Reverified,11/19/20,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,0703-2045-03,available
2740,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Reverified,11/19/20,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,0703-2056-03,available
2741,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Reverified,11/19/20,Product is available,"Teva is experiencing a significant increase in demand, due in part to the pandemic",,Demand increase for the drug,Anesthesia,Current,,,0703-2033-03,available
2742,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),New,4/8/20,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,70069-141-10,limited availability
2743,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),New,4/8/20,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,70069-161-10,limited availability
2744,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),New,4/8/20,Limited supply available. Please contact wholesaler for availability. Somerset is ramping up production to meet increased demand.,,,Demand increase for the drug,Anesthesia,Current,,,70069-151-10,limited availability
2745,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/22/20,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,71288-712-06,not available
2746,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/22/20,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,71288-713-21,not available
2747,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/22/20,"Backordered. Next Delivery: July 2020, August 2020 and November 2020.",Prioritized manufacturing and increased production due to overall demand.,,Demand increase for the drug,Anesthesia,Current,,,71288-712-11,not available
2748,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,11/16/20,Backordered. Next release Q2 - 2021.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-416-05,not available
2749,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-417-10,available
2750,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,11/16/20,Backordered. Next release Q2 2021.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-418-20,not available
2751,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Reverified,11/13/20,Available,,,,Anesthesia,Current,,,0781-3150-95,available
2752,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Reverified,11/13/20,Available,,,,Anesthesia,Current,,,0781-3152-95,available
2753,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Reverified,11/13/20,Available,,,,Anesthesia,Current,,,0781-3153-95,available
2754,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: December 2020,,,Demand increase for the drug,Anesthesia,Current,,,00409-1098-02,limited availability
2755,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-1103-01,limited availability
2756,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-1208-01,limited availability
2757,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,11/19/20,Product available,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,0074-4378-05,available
2758,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,11/19/20,Product available,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,0074-4380-10,available
2759,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,11/19/20,Limited availability,Please check with your wholesaler for available inventory,,Demand increase for the drug,Anesthesia,Current,,,0074-4382-20,limited availability
2760,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Reverified,11/20/20,Available,Check wholesaler for inventory,,Demand increase for the drug,Anesthesia,Current,,,,available
2761,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 pledgets (NDC 0009-3116-14),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3116-14,discontinued
2762,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 mL applicator bottle (NDC 0009-3116-02),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3116-02,discontinued
2763,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 60 g tube (NDC 0009-3331-01),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3331-01,discontinued
2764,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 30 g tube (NDC 0009-3331-02),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3331-02,discontinued
2765,"Clindamycin Injection, USP",Mylan Institutional,6 mL / vial (NDC 67457-816-06),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,67457-816-06,discontinued
2766,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",300 mg per 2 mL (150 mg per mL); SDV; (NDC 63323-282-02),New,5/10/19,,3 & 6 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-02,discontinued
2767,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",600 mg per 4 mL (150 mg per mL); SDV; (NDC 63323-282-04),New,5/10/19,,6 & 8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-04,discontinued
2768,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",900 mg per 6 mL (150 mg per mL); SDV; (NDC 63323-282-06),New,5/10/19,,3 & 5 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-06,discontinued
2769,"Clindamycin Injection, USP","Fresenius Kabi USA, LLC",9 grams per Pharmacy Bulk Package (150 mg per mL); (NDC 63323-282-60),New,5/10/19,,8 months dating available for direct or drop ship orders by request. Check wholesalers for inventory,,,Anti-Infective,To Be Discontinued,5/10/19,5/10/19,63323-282-60,discontinued
2770,Clindamycin Phosphate and Benzoyl Peroxide (Duac) Topical Gel,GlaxoSmithKline,10 mg; 50 mg  (NDC 0145-2371-05),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately November 2019.,,,Dermatology,To be Discontinued,6/28/19,6/28/19,0145-2371-05,discontinued
2771,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-65),New,6/10/19,,,,,Reproductive,To be Discontinued,6/10/19,6/10/19,0093-0041-65,discontinued
2772,Clomiphene Citrate,Teva Pharmaceuticals,50 mg/1 unit tablet (NDC 0093-0041-03),New,6/10/19,,,,,Reproductive,To be Discontinued,6/10/19,6/10/19,0093-0041-03,discontinued
2773,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-77,discontinued
2774,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-01,discontinued
2775,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-10,discontinued
2776,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-77,discontinued
2777,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-01,discontinued
2778,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-10,discontinued
2779,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-01,discontinued
2780,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-05,discontinued
2781,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-01,discontinued
2782,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-05,discontinued
2783,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-10,discontinued
2784,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-01,discontinued
2785,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-05,discontinued
2786,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-10,discontinued
2787,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-01,discontinued
2788,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-02,discontinued
2789,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-01,discontinued
2790,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-02,discontinued
2791,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-01,discontinued
2792,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-05,discontinued
2793,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-10,discontinued
2794,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-01,discontinued
2795,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-05,discontinued
2796,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-10,discontinued
2797,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-10,discontinued
2798,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-101-10,discontinued
2799,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-01,discontinued
2800,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-10,discontinued
2801,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-01,discontinued
2802,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-01,discontinued
2803,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-10,discontinued
2804,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-01,discontinued
2805,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-10,discontinued
2806,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-113-06,available
2807,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-108-06,available
2808,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,,available
2809,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-105-06,available
2810,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-103-06,available
2811,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-102-06,available
2812,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,10/28/20,Available,,,,Renal,Current,,,24571-111-06,available
2813,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,10/28/20,Available,,,,Renal,Current,,,24571-116-06,available
2814,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,10/28/20,Available,,,,Renal,Current,,,24571-117-06,available
2815,Coumadin Tablets,Bristol Myers Squibb Co.,1 mg (NDC 0056-0169-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0169-70,discontinued
2816,Coumadin Tablets,Bristol Myers Squibb Co.,1 mg (NDC 0056-0169-75),New,4/24/20,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0169-75,discontinued
2817,Coumadin Tablets,Bristol Myers Squibb Co.,2 mg (NDC 056-0170-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,056-0170-70,discontinued
2818,Coumadin Tablets,Bristol Myers Squibb Co.,2 mg (NDC 0056-0170-75),New,4/24/20,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0170-75,discontinued
2819,Coumadin Tablets,Bristol Myers Squibb Co.,2 1/2 mg (NDC 0056-0176-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0176-70,discontinued
2820,Coumadin Tablets,Bristol Myers Squibb Co.,2 1/2 mg (NDC 0056-0176-75),New,4/24/20,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0176-75,discontinued
2821,Coumadin Tablets,Bristol Myers Squibb Co.,3 mg (NDC 0056-0188-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0188-70,discontinued
2822,Coumadin Tablets,Bristol Myers Squibb Co.,3 mg (NDC 0056-0188-75),New,4/24/20,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0188-75,discontinued
2823,Coumadin Tablets,Bristol Myers Squibb Co.,4 mg (NDC 0056-0168-70),New,4/24/20,,Projection Cease of Commercialization: 1Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0168-70,discontinued
2824,Coumadin Tablets,Bristol Myers Squibb Co.,4 mg (NDC 0056-0168-75),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0168-75,discontinued
2825,Coumadin Tablets,Bristol Myers Squibb Co.,5 mg (NDC 0056-0172-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0172-70,discontinued
2826,Coumadin Tablets,Bristol Myers Squibb Co.,5 mg (NDC 0056-0172-75),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0172-75,discontinued
2827,Coumadin Tablets,Bristol Myers Squibb Co.,6 mg (NDC 0056-0189-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0189-70,discontinued
2828,Coumadin Tablets,Bristol Myers Squibb Co.,6 mg (NDC 0056-0189-75),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0189-75,discontinued
2829,Coumadin Tablets,Bristol Myers Squibb Co.,7 1/2  mg (NDC 0056-0173-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0173-70,discontinued
2830,Coumadin Tablets,Bristol Myers Squibb Co.,7 1/2 mg (NDC 0056-0173-75),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0173-75,discontinued
2831,Coumadin Tablets,Bristol Myers Squibb Co.,10 mg (NDC 0056-0174-70),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0174-70,discontinued
2832,Coumadin Tablets,Bristol Myers Squibb Co.,10 mg (NDC 0056-0174-75),New,4/24/20,,Projection Cease of Commercialization: 2Q 2020,,,Hematology,To be Discontinued,4/24/20,4/24/20,0056-0174-75,discontinued
2833,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-02,available
2834,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-05,available
2835,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0395-15,available
2836,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-02,available
2837,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-05,available
2838,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-02,available
2839,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-05,available
2840,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-15,available
2841,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/20,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-01,available
2842,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/20,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-03,available
2843,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",New,11/9/20,Product available for existing clients/business,"Distributed by Bausch + Lomb, a division of Bausch Health US, LLC – 1-800-321-4576",,Other,Ophthalmology,Current,,,24208-735-01,limited availability
2844,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",New,11/9/20,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,17478-097-12,not available
2845,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",New,11/9/20,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,17478-097-02,not available
2846,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",New,11/9/20,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,17478-097-10,not available
2847,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",New,11/9/20,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,17478-100-02,not available
2848,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",New,11/9/20,Not available/ Estimated availability March 2021,Manufacturing Delays,,Other,Ophthalmology,Current,,,17478-100-12,not available
2849,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (NDC 54482-020-01)",New,10/27/20,Shortage anticipated from November 2020; Estimated shortage duration:  Unknown,"For more information please contact 1-866-634-2765, Leadiant@tmac.com, or go to  www.leadiant.com",,Delay in manufacturing,Ophthalmology,Current,,,54482-020-01,unclear
2850,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/19,,,Available,,Other;Pediatric,Resolved,9/3/19,,51754-1007-1,
2851,Darifenacin Extended-release Tablets,Teva Pharmaceuticals,"7.5 mg, 30 count bottle (NDC 0591-4375-30)",New,6/26/20,,Discontinuation of manufacturing,,,Urology,To be Discontinued,6/26/20,6/26/20,0591-4375-30,discontinued
2852,Darifenacin Extended-release Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC 0591-4380-30)",New,6/26/20,,Discontinuation of manufacturing,,,Urology,To be Discontinued,6/26/20,6/26/20,0591-4380-30,discontinued
2853,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/20,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/20,6/17/20,0591-4375-19,discontinued
2854,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/20,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/20,6/17/20,,discontinued
2855,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-15,discontinued
2856,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-23,discontinued
2857,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-00,discontinued
2858,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-96,discontinued
2859,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-15,discontinued
2860,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-23,discontinued
2861,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-00,discontinued
2862,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-96,discontinued
2863,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 30, (NDC 10370-171-11)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-171-11,discontinued
2864,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 15 mg Bottle of 90 (NDC 10370-171-09)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-171-09,discontinued
2865,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 10370-170-11)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-170-11,discontinued
2866,Darifenacin Hydrobromide Tablets,Par Pharmaceutical,"Extended-Release Tablet, 7.5 mg Bottle of 90 (NDC 10370-170-09)",New,10/30/19,,Par has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,10/30/19,10/30/19,10370-170-09,discontinued
2867,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-0063-28,discontinued
2868,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3516-56,discontinued
2869,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3517-56,discontinued
2870,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3515-56,discontinued
2871,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4505-6,
2872,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4504-6,
2873,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",500 mg; Single Dose Glass Fliptop Vial (NDC 00409-2336-10),Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,00409-2336-10,
2874,"Deferoxamine Mesylate for Injection, USP","Hospira, Inc.",2 g; Single Dose Glass Fliptop Vial (NDC 00409-2337-25),Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,00409-2337-25,
2875,"Deferoxamine Mesylate for Injection, USP","Fresenius Kabi USA, LLC","500 mg per vial, 10 mL vial (NDC 63323-597-10)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,63323-597-10,
2876,Delavirdine Mesylate (RESCRIPTOR) Tablets,ViiV Healthcare,200 mg tablets; bottles of 180 tablets (NDC 49702-225-17),New,6/26/19,,This decision is business-related and the anticipated final date for availability to patients is January 2020.,,,Antiviral,To be Discontinued,6/26/19,6/26/19,49702-225-17,discontinued
2877,"Demeclocycline Hydrochloride Tablets, USP",Teva Pharmaceuticals,150 mg 100 count (NDC 0555-0701-02),New,4/21/20,,Teva had evaluated the market and decided to discontinue the product.,,,Anti-Infective,To be Discontinued,4/21/20,4/21/20,0555-0701-02,discontinued
2878,"Demeclocycline Hydrochloride Tablets, USP",Teva Pharmaceuticals,300 mg 48 count (NDC 0555-0702-84),New,4/21/20,,Teva had evaluated the market and decided to discontinue the product.,,,Anti-Infective,To be Discontinued,4/21/20,4/21/20,0555-0702-84,discontinued
2879,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-4017-01)",New,5/2/19,,,,,Pulmonary/Allergy,To be Discontinued,5/2/19,5/2/19,0378-4017-01,discontinued
2880,Desloratadine Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-4017-05)",New,5/2/19,,,,,Pulmonary/Allergy,To be Discontinued,5/2/19,5/2/19,0378-4017-05,discontinued
2881,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/14,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/14,,50458-196-15,discontinued
2882,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/10/20,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-423-12,available
2883,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/10/20,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-422-54,available
2884,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/10/20,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-421-30,available
2885,Dexamethasone Sodium Phosphate Injection,Mylan Institutional,Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/10/20,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-420-10,available
2886,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,11/20/20,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-237-01,not available
2887,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,11/20/20,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-238-05,not available
2888,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-239-30,available
2889,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,9/11/20,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,70069-021-25,available
2890,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,11/16/20,"3, 4, 5 month expiry available by request.  Next release November 2020.",Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-05,limited availability
2891,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-516-10,available
2892,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-30,available
2893,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-01,available
2894,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-506-01,available
2895,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Reverified,9/17/20,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6145-25,not available
2896,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Reverified,9/17/20,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6146-25,not available
2897,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Reverified,9/17/20,This presentation is temporarily on backorder.,Shortage duration is unknown at this time.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-0367-25,not available
2898,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),10 mg/1 mL SDV (NDC 55150-304-25),Revised,11/20/20,Initial availability targeted for end of November 2020,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-304-25,not available
2899,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-305-10,available
2900,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Reverified,10/23/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-106-10,available
2901,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Reverified,10/23/20,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-109-10,available
2902,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Revised,8/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9532-25,available
2903,Dexmedetomidine Injection,Sandoz,"200 mcg/2 mL (100 mcg/mL) vial, box of 10 (NDC 0781-3297-95)",New,4/13/20,,Permanent Discontinuation,,,Anesthesia,To be Discontinued,4/13/20,4/13/20,0781-3297-95,discontinued
2904,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Revised,11/3/20,Available,,,,Anesthesia,Current,,,16729-239-93,available
2905,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Revised,11/3/20,Available,,,,Anesthesia,Current,,,16729-432-93,available
2906,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Revised,11/20/20,Currently on backorder - next shipment anticipated end of Nov 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-209-02,not available
2907,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,10/28/20,Available,,,,Anesthesia,Current,,,0338-9555-24,available
2908,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,10/28/20,Available,,,,Anesthesia,Current,,,0338-9557-12,available
2909,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,10/28/20,Available,,,,Anesthesia,Current,,,43066-555-24,available
2910,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,10/28/20,Available,,,,Anesthesia,Current,,,43066-557-12,available
2911,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,11/16/20,Backordered. Next release December 2020.,,,Demand increase for the drug,Anesthesia,Current,,,63323-671-20,not available
2912,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,11/16/20,Backordered. Next release December 2020.,,,Demand increase for the drug,Anesthesia,Current,,,63323-671-50,not available
2913,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,11/16/20,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-671-00,not available
2914,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-421-02,available
2915,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Revised,11/18/20,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-600-04,available
2916,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Revised,11/18/20,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-601-04,available
2917,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Revised,11/18/20,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-602-24,available
2918,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Revised,11/18/20,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-603-24,available
2919,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,10/27/20,Available,"Distributed by Athenex. To order, contact Athenex at 855-273-0154.",,Demand increase for the drug,Anesthesia,Current,,,70860-605-03,available
2920,Dexmedetomidine Injection,Mylan Institutional,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Reverified,11/10/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-251-02,available
2921,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,11/5/20,Available,Please check wholesalers for supply,,,Anesthesia,Current,,,42023-146-25,available
2922,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-20,available
2923,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-50,available
2924,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-10,available
2925,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1638-02,available
2926,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,10/27/20,"Currently on backorder, estimated to continue until Dec 2020.",,,Demand increase for the drug,Anesthesia,Current,,,71225-126-05,not available
2927,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,10/27/20,"Currently on backorder, estimated to continue until Dec 2020.",,,Demand increase for the drug,Anesthesia,Current,,,71225-126-06,not available
2928,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,10 mg 100 Count (NDC 0093-5277-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5277-01,discontinued
2929,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg 100 Count (NDC 0093-5275-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5275-01,discontinued
2930,Dexmethylphenidate Hydrochloride Tablets,Teva Pharmaceuticals,5 mg 100 Count (NDC 0093-5276-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-5276-01,discontinued
2931,Dexrazoxane Injection,Gland Pharma,500 mg per vial (NDC 72266-101-01); distributed by Fosun Pharma USA Inc.,Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,72266-101-01,
2932,Dexrazoxane Injection,Gland Pharma,"500 mg per vial (NDC 51991-942-98); distributed by Breckenridge Pharmaceutical, Inc.",New,2/26/20,,,,,Oncology;Pediatric,Resolved,2/26/20,,51991-942-98,
2933,Dexrazoxane Injection,Gland Pharma,"500 mg per vial (NDC 47781-578-07); distributed by Alvogen, Inc.",New,2/26/20,,,,,Oncology;Pediatric,Resolved,2/26/20,,47781-578-07,
2934,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",250 mg per vial (NDC 0143-9247-01); distributed by West-Ward,Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,0143-9247-01,
2935,Dexrazoxane Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9248-01); distributed by West-Ward,Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,0143-9248-01,
2936,Dexrazoxane Injection,Mylan Institutional,250 mg Kit (NDC 67457-207-25),Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,67457-207-25,
2937,Dexrazoxane Injection,Mylan Institutional,500 mg Kit (NDC 67457-208-50),Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,67457-208-50,
2938,Dexrazoxane Injection,Pfizer Pharmaceuticals,Zinecard 250 mg; Single Dose Vial (NDC 0013-8717-62),Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,0013-8717-62,
2939,Dexrazoxane Injection,Clinigen Healthcare Ltd,Totect® (Dexrazoxane) for injection; 1 vial (500 mg)(NDC 66220-110-01); distributed by Cumberland Pharmaceuticals,Revised,2/26/20,,,Available,,Oncology;Pediatric,Resolved,2/26/20,,66220-110-01,
2940,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1070-01,discontinued
2941,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1071-01,discontinued
2942,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1072-01,discontinued
2943,Dextrose 25% Injection,"Hospira, Inc.",250 mg/mL (25%); Ansyr Plastic Syringe (NDC 0409-1775-10),Reverified,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-1775-10,available
2944,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0062-30,
2945,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-10,
2946,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-9147-30,
2947,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-02,
2948,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-03,
2949,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-04,
2950,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-02,
2951,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-03,
2952,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-02,
2953,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-03,
2954,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-09,
2955,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-25,
2956,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-53,
2957,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-55,
2958,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-61,
2959,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-06,
2960,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-11,
2961,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-13,
2962,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-20,
2963,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-23,
2964,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-36,
2965,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-37,
2966,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 100mL 
(NDC 63323-624-61)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-61,
2967,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 250mL 
(NDC 63323-624-74)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-74,
2968,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-41)
Quad Pack (NDC 0338-0017-11)
Multi Pack (NDC 0338-0017-31)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-41,
2969,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL, in VIAFLEX Plastic Container: Single Pack (NDC 0338-0017-48)
Quad Pack (NDC 0338-0017-18
Multi Pack (NDC 0338-0017-38)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-48,
2970,Dextrose 5% Injection Bags,"Hospira, Inc.",50 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-66),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,00409-7100-66,
2971,Dextrose 5% Injection Bags,"Hospira, Inc.",100 mL (5%); ADD-Vantage Flexible Container (NDC 00409-7100-67),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,00409-7100-67,
2972,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 500mL 
(NDC 63323-624-75)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-75,
2973,Dextrose 5% Injection Bags,"Fresenius Kabi USA, LLC","5% Dextrose Injection, USP, 1000mL 
(NDC 63323-624-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,63323-624-10,
2974,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 50 mL,  Product code 2B0040 (NDC 0338-0551-11)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0551-11,
2975,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in MINI-BAG Plus container, 100 mL,  Product code 2B0041 (NDC 0338-0551-18)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0551-18,
2976,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","DEXTROSE INJECTION, USP, 50%, [500 mg / mL](NDC 76329-3301-1)",Reverified,10/30/20,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,76329-3301-1,available
2977,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); LifeShield Abboject Glass Syringe (NDC 0409-4902-34),Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,0409-4902-34,limited availability
2978,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Single Dose Glass Fliptop Vial (NDC 0409-6648-02),Revised,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,9/23/19,,0409-6648-02,available
2979,Dextrose 50% Injection,"Hospira, Inc.",25 g/50 mL (50%; 0.5 g/mL); Ansyr Plastic Syringe (NDC 0409-7517-16),Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-7517-16,limited availability
2980,"Diazepam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1273-32),Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,00409-1273-32,
2981,"Diazepam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-3213-12),Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,00409-3213-12,
2982,"Diazepam Injection, USP","Beloteca, Inc.","Diazepam Injection, USP 10 mg/2 mL (5 mg/mL) Prefilled Single-dose Syringe with Luer Lock (NDC 69339-136-32)",Revised,12/17/19,,,,,Neurology,Resolved,12/17/19,,69339-136-32,
2983,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/18,4/4/18,0378-0355-01,discontinued
2984,Diclofenac Sodium Topical Gel,"Endo Pharmaceuticals, Inc.",1% topical gel (NDC 49884-935-47),New,2/13/20,,,,,Analgesia/Addiction,To be Discontinued,2/13/20,2/13/20,49884-935-47,discontinued
2985,Diclofenac Sodium Topical Solution,Apotex Corp.,2% topical solution (NDC 60505-0399-5),New,5/6/20,,,,,Analgesia/Addiction,To be Discontinued,5/6/20,5/6/20,60505-0399-5,discontinued
2986,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,10 mg capsules in bottles of 100 (NDC 58914-012-10),New,3/29/19,,Product discontinued October 2017,,,Gastroenterology,To be Discontinued,3/29/19,3/29/19,58914-012-10,discontinued
2987,Dicyclomine Hydrochloride (BENTYL®) Capsule & Tablet,Allergan Sales LLC,20 mg tablets in bottles of 100 (NDC 58914-013-10),New,3/29/19,,Product discontinued December 2016,,,Gastroenterology,To be Discontinued,3/29/19,3/29/19,58914-013-10,discontinued
2988,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 1000s (NDC 0143-3126-10)",Reverified,7/22/20,Available,,,,Gastroenterology,Current,,,0143-3126-10,available
2989,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Caps, USP, 10mg 100s (NDC 0143-3126-01)",Reverified,7/22/20,Available,,,,Gastroenterology,Current,,,0143-3126-01,available
2990,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 1000s (NDC 0143-1227-10)",Reverified,7/22/20,Available,,,,Gastroenterology,Current,,,0143-1227-10,available
2991,Dicyclomine Oral Tablets/Capsules,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dicyclomine HCl Tabs, USP, 20mg 100s (NDC 0143-1227-01)",Reverified,7/22/20,Available,,,,Gastroenterology,Current,,,0143-1227-01,available
2992,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 100s (NDC 0378-1610-01),Reverified,11/10/20,Available,,,Other,Gastroenterology,Current,,,0378-1610-01,available
2993,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 10mg C 500s (NDC 0378-1610-05),Reverified,11/10/20,Available,,,Other,Gastroenterology,Current,,,0378-1610-05,available
2994,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 100s (NDC 0378-1620-01),Reverified,11/10/20,Out of Stock. Resupply TBD.,,,Other,Gastroenterology,Current,,,0378-1620-01,not available
2995,Dicyclomine Oral Tablets/Capsules,Mylan Pharmaceuticals Inc.,Dicyclomine HCl 20mg T 500s (NDC 0378-1620-05),Reverified,11/10/20,Out of Stock. Resupply TBD.,,,Other,Gastroenterology,Current,,,0378-1620-05,not available
2996,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (100 count bottles) (NDC 0527-0586-01)",Reverified,11/12/20,Available,,,,Gastroenterology,Current,,,0527-0586-01,available
2997,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Capsules USP, 10 mg (1000 count bottles) (NDC 0527-0586-10)",Reverified,11/12/20,Available,,,,Gastroenterology,Current,,,0527-0586-10,available
2998,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (100 count bottles) (NDC 0527-1282-01)",Reverified,11/12/20,Available,,,,Gastroenterology,Current,,,0527-1282-01,available
2999,Dicyclomine Oral Tablets/Capsules,"Lannett Company, Inc.","Dicyclomine Hydrochloride Tablets USP, 20 mg (1000 count bottles) (NDC 0527-1282-10)",Reverified,11/12/20,Available,,,,Gastroenterology,Current,,,0527-1282-10,available
3000,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 100 count (NDC 0591-0794-01),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,0591-0794-01,available
3001,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 10MG CAPSULES 1000 count (NDC 0591-0794-10),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,0591-0794-10,available
3002,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 100 count (NDC 0591-0795-01),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,0591-0795-01,available
3003,Dicyclomine Oral Tablets/Capsules,Teva Pharmaceuticals,DICYCLOMINE HCL 20MG TABLETS 1000 count (NDC 0591-0795-10),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,0591-0795-10,available
3004,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0588-01,discontinued
3005,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0589-01,discontinued
3006,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0590-01,discontinued
3007,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Cpasules, 125 mg (NDC 0087-6671-17)",New,2/24/20,,"This discontinnuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6671-17,discontinued
3008,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 200 mg (NDC 0087-6672-17)",New,2/24/20,,"This discontinuation is due to a marketing decision. Discontinuation date: February 14, 2020",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6672-17,discontinued
3009,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 250 mg (NDC 0087-6673-17)",New,2/24/20,,"This discontinuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6673-17,discontinued
3010,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,"VIDEX EC Capsules, 400 mg (NDC 0087-6674-17)",New,2/24/20,,"This discontinuation is due to a marketing decision. Discontinuation date: November 20, 2019",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6674-17,discontinued
3011,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,VIDEX PED PWD 2 g (1 bottle) 4 oz (NDC 0087-6632-41),New,2/24/20,,"This discontinuation is due to a marketing decision. Discontinuation date: March 31, 2020",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6632-41,discontinued
3012,Didanosine Delayed-Release Capsules USP,Bristol Myers Squibb Co.,VIDEX PED PWD 4 g (1 bottle) 8 oz (NDC 0087-6633-41),New,2/24/20,,"This discontinuation is due to a marketing decision. Discontinuation date: May 31, 2019",,,Antiviral,To be Discontinued,2/24/20,2/24/20,0087-6633-41,discontinued
3013,Diethylpropion Hydrochloride Controlled-Release Tablets,Teva Pharmaceuticals,75 mg tablets (NDC 0591-0782-01),New,6/11/19,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/19,6/11/19,0591-0782-01,discontinued
3014,Diethylpropion Hydrochloride Tablets,Teva Pharmaceuticals,25 mg tablets (NDC 0591-0783-01),New,6/11/19,,This product discontinuation is a business related decision.,,,Endocrinology/Metabolism,To be Discontinued,6/11/19,6/11/19,0591-0783-01,discontinued
3015,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/19,,,,,Ophthalmology,Resolved,10/15/19,,0065-9204-07,
3016,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-05,available
3017,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-10,available
3018,Diltiazem Hydrochloride,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-25,available
3019,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,7/22/20,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6013-10,available
3020,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,7/22/20,Product is currently on allocation.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6014-10,limited availability
3021,Diltiazem Hydrochloride,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,7/22/20,This presentation is temporarily on backorder,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6015-10,not available
3022,Diltiazem Hydrochloride,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-4350-03,available
3023,Diltiazem Hydrochloride,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Reverified,11/20/20,Next Delivery and Estimated Recovery: February 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-1171-01,not available
3024,Diltiazem Hydrochloride,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-1171-02,available
3025,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,2/7/20,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-10,not available
3026,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10)",Revised,2/7/20,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/20,2/7/20,17478-0817-10,discontinued
3027,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25)",Revised,2/7/20,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/20,2/7/20,17478-0817-25,discontinued
3028,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26)",Revised,2/7/20,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/20,2/7/20,17478-0817-26,discontinued
3029,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,2/7/20,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-25,not available
3030,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,2/7/20,Backorder. Estimated recovery March 2020,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-26,not available
3031,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,2/7/20,Backorder. Estimated recovery March 2020.,,,Demand increase for the drug,Cardiovascular,Current,,,17478-0937-05,not available
3032,Diltiazem Hydrochloride,Akorn Pharmaceuticals,"Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05)",Revised,2/7/20,,This product discontinuation is a business related decision.,,,Cardiovascular,To be Discontinued,2/7/20,,17478-0817-05,discontinued
3033,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,60 mg (NDC 0378-6060-01),Revised,2/20/20,,,,,Cardiovascular,Resolved,2/20/20,,0378-6060-01,
3034,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,90 mg (NDC 0378-6090-01),Revised,2/20/20,,,,,Cardiovascular,Resolved,2/20/20,,0378-6090-01,
3035,Diltiazem Hydrochloride ER (Twice-a-Day) Capsules,Mylan Pharmaceuticals Inc.,120 mg (NDC 0378-6120-01),Revised,2/20/20,,,,,Cardiovascular,Resolved,2/20/20,,0378-6120-01,
3036,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5220-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5220-01,discontinued
3037,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-5220-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5220-05,discontinued
3038,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 100 count bottle (NDC 0378-5280-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5280-01,discontinued
3039,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"180 mg, 500 count bottle (NDC 0378-5280-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5280-05,discontinued
3040,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 100 count bottle (NDC 0378-5340-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5340-01,discontinued
3041,Diltiazem Hydrochloride Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"240 mg, 500 count bottle (NDC 0378-5340-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-5340-05,discontinued
3042,Dimercaprol (Bal in Oil) Injection USP,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,11/10/20,Product is currently on backorder. Estimated shortage duration is until Jan 2021,Estimated recovery 1Q2021,,Other,Hematology;Other,Current,,,17478-526-03,not available
3043,Diphenhydramine Injection,"Hospira, Inc.",50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Pediatric;Pulmonary/Allergy,Current,,,00409-2290-31,discontinued
3044,Diphenhydramine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL vial (NDC 0641-0376-25)",Revised,7/22/20,Inventory is currently available,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,0641-0376-25,available
3045,Diphenhydramine Injection,Mylan Institutional,500 mg / 10mL(NDC 67457-124-10),Reverified,11/10/20,Available,,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,67457-124-10,available
3046,Diphenhydramine Injection,"Fresenius Kabi USA, LLC","50 mg per vial, Single dose, Amber vial (NDC 63323-664-01)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Pediatric;Pulmonary/Allergy,Current,,,63323-664-01,available
3047,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4140-01,discontinued
3048,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4141-01,discontinued
3049,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",New,11/20/20,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/20,11/20/20,0093-5035-01,discontinued
3050,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",New,11/20/20,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/20,11/20/20,0093-5036-01,discontinued
3051,Disulfiram Tablets,"Alvogen, Inc.","250 mg, 30 count (NDC 47781-607-30)",Revised,8/24/20,,,,,Analgesia/Addiction,Resolved,8/24/20,8/24/20,47781-607-30,
3052,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 500 (NDC 10370-511-50),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-511-50,discontinued
3053,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,500 mg Bottle of 100 (NDC 10370-511-10),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-511-10,discontinued
3054,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 100 (NDC 10370-510-10),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-510-10,discontinued
3055,Divalproex Sodium Extended-Release Tablets,Par Pharmaceutical,250 mg Bottle of 500 (NDC 10370-510-50),New,10/31/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,10/31/19,10/31/19,10370-510-50,discontinued
3056,Dobutamine Hydrochloride Injection,Pfizer Pharmaceuticals,500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),New,4/3/20,,Discontinuation of the manufacture of the drug.,,,Cardiovascular;Pediatric;Renal,To be Discontinued,4/3/20,4/3/20,00409-2025-54,discontinued
3057,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,10/28/20,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,0338-1073-02,available
3058,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,11/20/20,Next Delivery: January 2021; Estimated Recovery: June 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2346-32,not available
3059,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: October 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2347-32,not available
3060,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: May 2021,Check Wholesaler for Availablility Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-3724-32,not available
3061,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-20,discontinued
3062,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-54,discontinued
3063,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,11/20/20,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-01,available
3064,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,11/20/20,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-02,available
3065,Docetaxel Injection,Teva Pharmaceuticals,20 mg/mL  (NDC 45963-790-56),New,3/31/20,,,,,Oncology,To be Discontinued,3/31/20,3/31/20,45963-790-56,discontinued
3066,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-21)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/19,4/9/19,0603-0150-21,discontinued
3067,"Docusate Sodium Capsules, USP",Par Pharmaceutical,"100mg, count bottle (NDC 0603-0150-32)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,4/9/19,4/9/19,0603-0150-32,discontinued
3068,Donepezil Hydrochloride Tablets,Teva Pharmaceuticals,23mg tablets (NDCs 0228-4529-03 and 0228-4529-09),New,2/13/20,,,,,Neurology,To be Discontinued,2/13/20,2/13/20,,discontinued
3069,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,11/20/20,Next Delivery: February 2021; Estimated Recovery: September 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7809-22,not available
3070,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: May 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7809-24,not available
3071,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,11/20/20,Limited Supply Available. Next Delivery: March 2021; Estimated Recovery: September 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7810-22,limited availability
3072,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-5820-01,available
3073,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-9104-20,available
3074,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,10/28/20,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
3075,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,6/8/20,Available,,,,Ophthalmology,Current,,,17478-605-10,available
3076,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,6/8/20,Limit availability / Recovery expected July 2020.,"Manufacturer interruption production issues.  Marketed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,50383-233-10,limited availability
3077,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,6/8/20,Available,"Marketed by Akorn, Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,Other,Ophthalmology,Current,,,17478-604-30,available
3078,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Reverified,11/13/20,Supply Available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,61314-030-02,available
3079,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,6/9/20,Available,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Valeant Pharmaceuticals North America at pharcs@valeant.com",,Other,Ophthalmology,Current,,,24208-486-10,available
3080,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,0591-2482-79,not available
3081,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,,discontinued
3082,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Reverified,9/25/20,Available,Available,,Other,Ophthalmology,Current,,,65862-0947-60,available
3083,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0591-2481-79,discontinued
3084,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0093-7618-43,discontinued
3085,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/18,4/20/18,0591-2481-79,not available
3086,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,4/20/18,4/20/18,0093-7618-43,not available
3087,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,10/14/20,Available,"Manufacturer interruption production issues. Distributed by Hi-Tech Pharmacal Co., Inc. To order, contact Akorn Customer Service (1-800-932-5676)",,,Ophthalmology,Current,,,50383-232-10,available
3088,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Reverified,6/1/18,Product is available,"For additional information please contact: Merck National Service Center, Telephone Number: 1-800-672-6372",,Demand increase for the drug,Ophthalmology,Current,,,0006-3519-36,available
3089,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,12/13/19,Currently on backorder. Estimated availability: January 2020,"Marketed by Bausch & Lomb Inc. To order, contact Bausch & Lomb, a division of Bausch Health US, LLC at pharcs@bauschhealth.com",,Other,Ophthalmology,Current,,,24208-485-10,not available
3090,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Reverified,11/13/20,Supply available,"Labeled under Sandoz Inc. To order, contact Sandoz Inc. at 1-800-525-8747",,Demand increase for the product,Ophthalmology,Current,,,61314-019-10,available
3091,Doxorubicin Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg/mL, 10 mL single-dose vial (NDC 63323-883-10)",New,3/5/20,,Product available. Check wholesalers for inventory or contact Customer Service to place a direct order. 10 mL will be discontinued when inventory is depleted.,,,Oncology;Pediatric,To Be Discontinued,3/5/20,3/5/20,63323-883-10,discontinued
3092,Doxycycline Capsules,Teva Pharmaceuticals,50 mg capsules (NDC 0591-0410-01),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-0410-01,discontinued
3093,Doxycycline Capsules,Teva Pharmaceuticals,75 mg capsules (NDC 0591-2404-01),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-2404-01,discontinued
3094,Doxycycline Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-0411-50),New,4/29/19,,This product discontinuation is a business related decision.,,,Anti-Infective,To be Discontinued,4/29/19,4/29/19,0591-0411-50,discontinued
3095,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,50 mg  (NDC 0591-5535-50),New,10/15/19,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/19,10/15/19,0591-5535-50,discontinued
3096,Doxycycline Hyclate Capsules,Teva Pharmaceuticals,100 mg (NDCs 0591-5440-50 and 0591-5440-05),New,10/15/19,,This product is being discontinued due to a business decision.,,,Anti-Infective,To be Discontinued,10/15/19,10/15/19,,discontinued
3097,Doxycycline Hyclate Delayed Release Tablets,Mylan Pharmaceuticals Inc.,150 mg tablets (NDC 0378-3030-01),New,9/9/19,,,,,Anti-Infective,To be Discontinued,9/9/19,9/9/19,0378-3030-01,discontinued
3098,Doxycycline Hyclate Injection,"Fresenius Kabi USA, LLC",100 mg per vial; amber vial; preservative free; lyophilized powder (NDC 63323-130-11),Revised,10/23/20,Backordered.  Next release expected November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Anti-Infective,Current,,,63323-130-11,not available
3099,Doxycycline Hyclate Injection,Mylan Institutional,100 mg (Lyophilizate in Vials)(NDC 67457-437-10),Revised,11/10/20,Available,Increased supply in 2020 to meet increased demand,,Demand increase for the drug,Anti-Infective,Current,,,67457-437-10,available
3100,Dronabinol Capsules,"Endo Pharmaceuticals, Inc.","2.5 mg capsules (NDC 498840-867-02), 5 mg capsules (NDC 498840-868-02), 10 mg capsules (NDC 498840-869-02)",New,2/7/19,,,,,Gastroenterology,To be Discontinued,2/7/19,2/7/19,498840-867-02,discontinued
3101,Dutasteride Capsules,Apotex Corp.,0.5 mg capsules (NDCs 60505-3877-9 and 60505-3877-3),New,1/7/20,,,,,Urology,To be Discontinued,1/7/20,1/7/20,,discontinued
3102,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,11/20/20,Available,,,Other,Ophthalmology,Current,,,0046-1065-05,available
3103,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),New,10/27/20,,"Pfizer anticipates stock available through May 1st, 2021.",,,Ophthalmology,To be Discontinued,10/27/20,10/27/20,0046-1065-05,discontinued
3104,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,7/22/20,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9786-10,available
3105,"Enalaprilat Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,7/22/20,Inventory is currently available.,Additional lots will be scheduled for manufacturing Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9787-10,available
3106,"Enalaprilat Injection, USP","Hospira, Inc.",1.25 mg/mL; Single Dose Glass Fliptop Vial (NDC 00409-2122-01),New,3/24/20,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,,3/24/20,00409-2122-01,discontinued
3107,"Enalaprilat Injection, USP","Hospira, Inc.",2.5 mg/2 mL (1.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2122-02),New,3/24/20,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,,3/24/20,00409-2122-02,discontinued
3108,Entecavir Tablets,Teva Pharmaceuticals,0.5mg tablets (NDCs 0093-5786-98 and 0093-5786-56),New,2/14/20,,,,,Antiviral,To be Discontinued,2/14/20,2/14/20,,discontinued
3109,Entecavir Tablets,Teva Pharmaceuticals,1mg tablets (NDC 0093-5787-56),New,2/14/20,,,,,Antiviral,To be Discontinued,2/14/20,2/14/20,0093-5787-56,discontinued
3110,Epinastine Hydrochloride (Elestat®) Ophthalmic Solution,Allergan,5 mL in 10 mL bottle (NDC 00023-9201-05),New,8/19/19,,,,,Ophthalmology,To be Discontinued,8/19/19,8/19/19,00023-9201-05,discontinued
3111,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,11/20/20,Available,,,,Cardiovascular;Pulmonary/Allergy,Current,,,00409-4921-34,available
3112,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","1:10,000, 10mL Luer-Jet Prefilled Syringe
(NDC 76329-3316-1)(old NDC 0548-3316-00)",Reverified,10/30/20,Available,,,,Cardiovascular;Pulmonary/Allergy,Current,,,76329-3316-1,available
3113,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,11/19/20,Available,,,,Pulmonary/Allergy,Current,,,0093-5986-27,available
3114,"Epinephrine Injection, Auto-Injector",Mylan Specialty,"0.3 mg (EpiPen® NDC 49502-500-02, pack of 2; NDC 49502-500-01, individual) (Authorized Generic NDC 49502-102-02, pack of 2; NDC 49502-102-01, individual)",Reverified,11/10/20,Available,"Production output from Mylan’s manufacturing partner Meridian Medical Technologies, a Pfizer company, has improved in recent months. Supplies are routinely shipping and, as a result, are more consistently available at the pharmacy level. In the event patients experience difficulty accessing product, they can continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,,Pulmonary/Allergy,Current,,,49502-500-02,available
3115,"Epinephrine Injection, Auto-Injector",Mylan Specialty,0.15 mg (EpiPen® NDC 49502-501-02) (Authorized Generic NDC 49502-101-02),Reverified,11/10/20,Available,"Production output from Mylan’s manufacturing partner Meridian Medical Technologies, a Pfizer company, has improved in recent months. Supplies are routinely shipping and, as a result, are more consistently available at the pharmacy level. In the event patients experience difficulty accessing product, they can continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.",,,Pulmonary/Allergy,Current,,,49502-501-02,available
3116,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,6/1/20,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1695-49,limited availability
3117,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,6/1/20,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1694-49,limited availability
3118,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,6/15/20,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-023-01,available
3119,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,6/15/20,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-022-01,available
3120,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,6/15/20,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-021-01,available
3121,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3442-20,available
3122,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3448-20,available
3123,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,11/19/20,Available,,,,Pulmonary/Allergy,Current,,,0093-5985-27,available
3124,Epirubicin Hydrochloride Injection,Teva Pharmaceuticals,2 mg/1 mL  (NDCs 45963-608-60 and 45963-608-68),New,7/17/19,,This product discontinuation is a business related decision.  Anticipated discontinuance time is first quarter of the year 2020.,,,Oncology,To be Discontinued,7/17/19,7/17/19,,discontinued
3125,Epirubicin Hydrochloride Injection,Cipla Limited,2 mg/1 mL  (NDCs 25021-203-25 and 59923-701-25),New,7/17/19,,Anticipated unavailability of product is September 2019.,,,Oncology,To be Discontinued,7/17/19,7/17/19,,discontinued
3126,Eprosartan Mesylate Tablets,Mylan Pharmaceuticals Inc.,Eprosartan Mesylate 600mg T 30s (NDC 0378-6629-93),Revised,3/16/20,,Mylan has made a business decision to discontinue this product.,,,Cardiovascular,To be Discontinued,3/16/20,3/16/20,0378-6629-93,discontinued
3127,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,0.75 mg/mL (NDCs 0085-1136-02 and 0085-1136-03),New,11/18/19,,The following presentation will continue to be available: 0.75 mg/mL (NDC 0085-1136-01 ),,,Cardiovascular,To be Discontinued,11/18/19,11/18/19,,discontinued
3128,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,2 mg/mL (NDCs 0085-1177-03 and 0085-1177-05),New,11/18/19,,The following presentations will continue to be available: 2 mg/mL (NDCs 0085-1177-01 and 0085-1177-02),,,Cardiovascular,To be Discontinued,11/18/19,11/18/19,,discontinued
3129,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,20 mg/10ml (2 mg/ml)(NDC 0085-1177-01),New,10/21/20,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1177-01,discontinued
3130,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,75 mg/100ml (0.75 mg/ml)(NDC 0085-1136-01),New,10/21/20,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1136-01,discontinued
3131,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,200 mg/100ml (2 mg/ml)(NDC 0085-1177-02),New,10/21/20,,Discontinued,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1177-02,discontinued
3132,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/20,,Discontinuation of drug manufacturing,,,Neurology,To be Discontinued,7/2/20,7/2/20,0781-5405-01,discontinued
3133,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",25 mg tablets (NDC 50242-062-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-062-01,discontinued
3134,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",100 mg tablets (NDC 50242-063-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-063-01,discontinued
3135,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",150 mg tablets (NDC 50242-064-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-064-01,discontinued
3136,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single Dose Glass Fliptop Vial (NDC 00409-6482-01),Reverified,11/20/20,Available,,,Other,Anti-Infective,Current,,,00409-6482-01,available
3137,"Erythromycin Lactobionate for Injection, USP","Hospira, Inc.",500 mg Single-dose ADD-Vantage® Vial (NDC 00409-6476-44),Reverified,11/20/20,Available,,,Other,Anti-Infective,Current,,,00409-6476-44,available
3138,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,12/2/19,Limited availability.,"Expected availability Dec, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,17478-070-35,limited availability
3139,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-01),Revised,12/2/19,On backorder,"Expected availability Oct 1, 2019",,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,,not available
3140,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,12/2/19,No longer distributing,,,,Ophthalmology,Current,,,17478-824-35,discontinued
3141,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,12/2/19,No longer distributing,,,,Ophthalmology,Current,,,17478-824-01,discontinued
3142,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Reverified,12/13/19,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,24208-910-55,available
3143,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Reverified,12/13/19,Available,"Distributed by: Bausch & Lomb Incorporated, a division of  Bausch Health Americas, Inc, Bridgewater, NJ 08807 USA",,Demand increase for the drug,Ophthalmology,Current,,,24208-910-19,available
3144,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-50,available
3145,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-35,available
3146,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,12/10/19,Available and shipping,,,Demand increase for the drug,Ophthalmology,Current,,,00574-4024-39,available
3147,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Lexapro oral solution 240 mL bottle 5 mg/5mL (NDC 0456-2101-08),New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0456-2101-08,discontinued
3148,Escitalopram (Lexapro) 5 mg/5 mL Oral Solution,Allergan Sales LLC,Escitalopram Oxalate oral solution 240 mL bottle (NDC 0591-4151-38),New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-4151-38,discontinued
3149,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400 mg  (NDC 0555-0923-02),New,9/28/20,,,,,Anti-Infective,To be Discontinued,9/28/20,9/28/20,0555-0923-02,discontinued
3150,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 6 blister pack in 1 carton (NDC 0603-7625-17)",New,5/10/19,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/19,5/10/19,0603-7625-17,discontinued
3151,Ethinyl Estradiol and Levonorgestrel (Myzilra),"Endo Pharmaceuticals, Inc.","0.03mg, 0.04mg, 0.03mg, 0.05mg, 0.075mg, 0.125mg; 3 blister pack in 1 carton (NDC 0603-7625-49)",New,5/10/19,,Discontinued due to business reasons.,,,Reproductive,To be Discontinued,5/10/19,5/10/19,0603-7625-49,discontinued
3152,Ethinyl Estradiol; Norgestrel Tablets,Teva Pharmaceuticals,0.05 mg; 0.5mg  (NDC 52544-848-28),New,5/8/20,,,,,Reproductive,To be Discontinued,5/8/20,5/8/20,52544-848-28,discontinued
3153,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,8/1/19,,,Available,,Medical Imaging;Oncology,Resolved,8/1/19,,67684-1901-1,
3154,Ethiodized Oil (Lipiodol) Injection,Guerbet LLC,Box of one 10 mL ampoule (NDC 67684-1901-1),Revised,7/31/19,,,,,Medical Imaging;Oncology,Resolved,7/31/19,,67684-1901-1,
3155,"Ethosuximide Oral Solution, USP",Teva Pharmaceuticals,"250 mg/5mL, 474 mL Bottle (NDC 0093-9660-16)",New,5/17/19,,Teva made a business decision to discontinue this product.,,,Neurology,To be Discontinued,5/17/19,5/17/19,0093-9660-16,discontinued
3156,Etomidate (Amidate) Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL) Abboject Glass Syringe (NDC 00409-8060-29),New,3/24/20,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,3/24/20,3/24/20,00409-8060-29,discontinued
3157,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 10 mL vial (NDC 55150-221-10)",Revised,11/20/20,Currently on backorder - next shipment anticipated mid Dec 20,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,55150-221-10,not available
3158,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial (NDC 55150-222-10)",Revised,11/20/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,55150-222-10,available
3159,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 70860-652-10)",Reverified,10/27/20,Unavailable,Distributed by Athenex Pharmaceutical. To contact: 855-273-0154.,,,Anesthesia,Current,,,70860-652-10,not available
3160,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 70860-652-20)",Reverified,10/27/20,Unavailable,Distributed by Athenex Pharmaceutical. To contact: 855-273-0154.,,,Anesthesia,Current,,,70860-652-20,not available
3161,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",Reverified,10/27/20,Available,Distributed by Fosun Pharma. To contact: 866-611-3762,,,Anesthesia,Current,,,72266-146-10,available
3162,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",Reverified,10/27/20,Available,Distributed by Fosun Pharma. To contact: 866-611-3762,,,Anesthesia,Current,,,72266-147-10,available
3163,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",Revised,9/9/20,Available,,,,Anesthesia,Current,,,0143-9506-10,available
3164,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",Revised,9/9/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9507-10,not available
3165,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",Revised,9/9/20,TBD,,,,Anesthesia,Current,,,0143-9310-10,unclear
3166,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",Revised,9/9/20,TBD,,,,Anesthesia,Current,,,0143-9311-10,unclear
3167,Etomidate Injection,Mylan Institutional,"2 mg/mL, 10 mL vial (NDC 67457-902-10)",Revised,11/10/20,Available,,,Other,Anesthesia,Current,,,67457-902-10,available
3168,Etomidate Injection,Mylan Institutional,"2 mg/mL, 20 mL vial (NDC 67457-903-20)",Revised,11/10/20,Available,,,,Anesthesia,Current,,,67457-903-20,available
3169,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-6695-01,available
3170,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",Reverified,11/20/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-6695-02,available
3171,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL syringe (NDC 0409-8060-29)",Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia,Current,,,0409-8060-29,discontinued
3172,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/18,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/18,4/3/18,0310-6520-04,discontinued
3173,Ezetimibe Tablets,Apotex Corp.,10 mg (NDC 60505-2945-9) || (NDC 60505-2945-3) || (NDC 60505-2945-5),New,7/31/20,,To be discontinued due to API supply issues.,,,Cardiovascular,To be Discontinued,7/31/20,7/31/20,60505-2945-9,discontinued
3174,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Reverified,11/10/20,Available,,,Demand increase for the drug,Gastroenterology,Current,,,67457-433-22,available
3175,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Reverified,10/28/20,Available,,,,Gastroenterology,Current,,,0338-5197-41,available
3176,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6022-25,available
3177,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6023-25,not available
3178,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6021-10,not available
3179,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-739-12,not available
3180,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-738-09,available
3181,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/16/20,Backordered. Next release Q4 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-738-20,not available
3182,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [40 mg / 4 ml] 10PK (NDC 67457-448-43),Reverified,11/10/20,Available,,,Demand increase for the drug,Gastroenterology,Current,,,67457-448-43,available
3183,Famotidine Injection,Mylan Institutional,Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Reverified,11/10/20,Available,,,Demand increase for the drug,Gastroenterology,Current,,,67457-457-20,available
3184,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Reverified,11/19/20,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,0172-5728-60,not available
3185,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Reverified,11/19/20,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,0172-5728-80,not available
3186,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Reverified,11/19/20,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,0172-5728-70,not available
3187,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Reverified,11/19/20,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,0172-5729-60,not available
3188,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Reverified,11/19/20,"On backorder, expected recovery in Q4, 2020","This product is on allocation, however we are satisfying historical committed customer demand.",,Demand increase for the drug,Gastroenterology,Current,,,0172-5729-70,not available
3189,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Reverified,9/25/20,Available,,,,Gastroenterology,Current,,,65862-859-01,available
3190,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Reverified,9/25/20,Available,,,,Gastroenterology,Current,,,65862-860-01,available
3191,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),New,5/4/20,Available,,,,Gastroenterology,Current,,,62332-001-31,available
3192,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),New,5/4/20,Available,,,,Gastroenterology,Current,,,62332-001-91,available
3193,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),New,5/4/20,Available,,,,Gastroenterology,Current,,,62332-002-31,available
3194,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),New,5/4/20,Available,,,,Gastroenterology,Current,,,62332-002-71,available
3195,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),New,5/4/20,Available,,,,Gastroenterology,Current,,,62332-002-91,available
3196,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),New,5/4/20,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,61442-121-01,limited availability
3197,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),New,5/4/20,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,61442-121-10,limited availability
3198,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),New,5/4/20,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,61442-122-01,limited availability
3199,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),New,5/4/20,"We do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can.","We are still shipping products. However, we are limited due to manufacturing capabilities, as well as limited resources such as active ingredient.",,Demand increase for the drug and shortage of an active ingredient,Gastroenterology,Current,,,61442-122-10,limited availability
3200,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 45mg 90s (NDC 10370-209-09),New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,10370-209-09,discontinued
3201,Fenofibric Acid Delayed-Release Capsules,Par Pharmaceutical,Fenofibric Acid Delayed-Release Capsules 135mg 90s (NDC 10370-210-09),New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,10370-210-09,discontinued
3202,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"45 mg, 90 count bottle (NDC 0378-2589-77)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-2589-77,discontinued
3203,Fenofibric Acid Delayed-Release Capsules,Mylan Pharmaceuticals Inc.,"135 mg, 90 count bottle (NDC 0378-2590-77)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-2590-77,discontinued
3204,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 00409-2304-02),New,11/16/20,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,00409-2304-02,discontinued
3205,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Glass Ampul (NDC 00409-2304-01),New,11/16/20,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,00409-2304-01,discontinued
3206,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,100 ug/1 h (NDC 50458-094-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-094-05,discontinued
3207,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,75 ug/1 h (NDC 50458-093-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-093-05,discontinued
3208,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,50 ug/1 h (NDC 50458-092-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-092-05,discontinued
3209,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,25 ug/1 h (NDC 50458-091-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-091-05,discontinued
3210,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,100 ug/1 unit (NDC 50458-106-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-106-05,discontinued
3211,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,75 ug/1 unit (NDC 50458-105-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-105-05,discontinued
3212,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,50 ug/1 unit (NDC 50458-104-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-104-05,discontinued
3213,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,25 ug/1 unit (NDC 50458-102-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-102-05,discontinued
3214,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,12.5 ug/1 unit (NDC 50458-101-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-101-05,discontinued
3215,"Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film",Janssen Pharmaceuticals,12.5 ug/1 h (NDC 50458-090-05),New,4/1/20,,"The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-090-05,discontinued
3216,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-20,available
3217,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-50,available
3218,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Reverified,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-01,available
3219,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Reverified,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-02,available
3220,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Reverified,11/16/20,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-05,available
3221,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,11/20/20,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-1276-32,not available
3222,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,11/20/20,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-32,available
3223,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,11/20/20,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-35,available
3224,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-38,discontinued
3225,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,11/20/20,Available,,,,Analgesia/Addiction;Pediatric,Current,,,00409-9094-22,available
3226,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,11/20/20,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-25,available
3227,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,11/20/20,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-28,available
3228,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,11/20/20,Limited Supply Available.,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-31,limited availability
3229,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: February 2021,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9094-61,limited availability
3230,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,7/22/20,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6024-10,not available
3231,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,7/22/20,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6025-10,not available
3232,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,7/22/20,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6026-05,not available
3233,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6027-25,available
3234,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6028-25,not available
3235,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6029-25,not available
3236,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6030-01,not available
3237,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-02,available
3238,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-25,available
3239,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-05,available
3240,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-20,available
3241,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,12/2/19,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-55,available
3242,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/18,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/18,5/23/18,0378-5036-05,discontinued
3243,Finasteride Tablets,Teva Pharmaceuticals,"1mg tablet (NDC 45963-600-03, 45963-600-09)",New,9/18/20,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/20,9/18/20,45963-600-03,discontinued
3244,Finasteride Tablets,Teva Pharmaceuticals,5mg tablet (NDC 45963-500-02),New,9/18/20,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-02,discontinued
3245,Finasteride Tablets,Teva Pharmaceuticals,5 mg 30 CT (NDC 45963-500-30),New,9/18/20,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-30,discontinued
3246,Finasteride Tablets,Teva Pharmaceuticals,5 mg 90 CT (NDC 45963-500-08),New,9/18/20,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-08,discontinued
3247,"Floxuridine for Injection, USP","Fresenius Kabi USA, LLC",500 mg per vial (NDC 63323-145-07_,New,9/30/20,,"Discontinued: May 30, 2019",,,Oncology,To be Discontinued,9/30/20,9/30/20,63323-145-07,discontinued
3248,"Floxuridine for Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Reverified,10/9/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the Late October 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,0143-9270-01,not available
3249,"Fludarabine Phosphate for Injection, USP","Hospira, Inc.",50 mg Single Dose Glass Fliptop Vial (NDC 61703-0344-18),New,2/10/20,,Discontinuation of the manufacture of the drug due to Active Pharmaceutical Ingredient Supplier market exit. Current supply expected to exhaust August 2020.,,,Oncology,To be Discontinued,2/10/20,2/10/20,61703-0344-18,discontinued
3250,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0555-0997-02,
3251,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-01,
3252,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-02,
3253,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/19,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/19,12/16/19,67457-447-53,discontinued
3254,Flumazenil Injection,Mylan,"1 mg in 10 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-444-10)",Revised,7/19/19,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,7/19/19,7/19/19,67457-444-10,discontinued
3255,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 10%, 100 mg/mL in a 5 mL single use vial (NDC 17478-253-10)",Revised,12/2/19,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,17478-253-10,available
3256,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR® (fluorescein injection, USP) 25%, 250 mg/mL in a 2 mL single use vial (NDC 17478-250-20)",Revised,12/2/19,Available,Continue to allocate available inventory,,Shortage of an active ingredient,Ophthalmology,Current,,,17478-250-20,available
3257,Fluorescein Injection,Novartis,Fluorescite (fluorescein injection) 10% 5 mL vial (NDC 0065-0092-65),Reverified,12/11/19,Available,,,Other,Ophthalmology,Current,,,0065-0092-65,available
3258,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Altafluor Solution Fluorescein sodium 0.25% and Benoxinate HCl 0.4%, 5 mL bottle (NDC 59390-0218-05)",Revised,12/10/19,,,,,Ophthalmology,Resolved,12/10/19,,59390-0218-05,
3259,Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution,Altaire,"Flurox Solution  Fluorescein sodium 2.5mg (0.25%), benoxinate hydrochloride 4mg (0.4%), 5mL bottle (NDC 54799-508-05)",Revised,12/11/19,,,,,Ophthalmology,Resolved,12/11/19,,54799-508-05,
3260,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Reverified,2/13/20,Available,,,,Ophthalmology,Current,,,,available
3261,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Reverified,2/12/20,Available,,,,Ophthalmology,Current,,,17238-900-30,available
3262,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,12/2/19,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,17478-404-01,not available
3263,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,12/2/19,On backorder,Availability Q12020,,Other,Ophthalmology,Current,,,17478-403-03,not available
3264,Fluorouracil Injection,Teva Pharmaceuticals,5g/100mL injection (NDC 0703-3019-12),Revised,2/20/20,,,,,Oncology,To be Discontinued,2/20/20,2/20/20,0703-3019-12,discontinued
3265,Fluorouracil Injection,Teva Pharmaceuticals,2.5g/50mL injection (NDC 0703-3018-12),Revised,2/20/20,,Actively selling. Remaining inventory estimated to last until April 2020,,,Oncology,To be Discontinued,2/20/20,2/20/20,0703-3018-12,discontinued
3266,Fluorouracil Injection,Teva Pharmaceuticals,50mg/1mL injection (NDC 0703-3015-13),Revised,2/20/20,,Actively selling. Remaining inventory estimated to last until April 2020,,,Oncology,To be Discontinued,2/20/20,2/20/20,0703-3015-13,discontinued
3267,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 28 count bottle (NDC 0378-5410-28)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-5410-28,discontinued
3268,Fluoxetine Capsules,Mylan Pharmaceuticals Inc.,"20 mg, 28 count bottle (NDC 0378-5420-28)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-5420-28,discontinued
3269,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-01,discontinued
3270,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-10,discontinued
3271,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-01,discontinued
3272,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-10,discontinued
3273,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-01,discontinued
3274,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-10,discontinued
3275,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-31,discontinued
3276,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-6004-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6004-01,discontinued
3277,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 500 count bottle (NDC 0378-6004-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6004-05,discontinued
3278,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 100 count bottle (NDC 0378-6009-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6009-01,discontinued
3279,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"2.5 mg, 500 count bottle (NDC 0378-6009-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6009-05,discontinued
3280,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6074-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6074-01,discontinued
3281,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6074-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6074-05,discontinued
3282,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6097-01)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6097-01,discontinued
3283,Fluphenazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6097-05)",New,5/2/19,,,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0378-6097-05,discontinued
3284,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 15mg C 100s (NDC 0378-4415-01),Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-4415-01,available
3285,Flurazepam Hydrochloride Capsules,Mylan Pharmaceuticals Inc.,Flurazepam HCl 30mg C 100s (NDC 0378-4430-01),Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-4430-01,available
3286,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"50 mg, 100 count bottle (NDC 0378-0076-01)",New,5/2/19,,,,,Rheumatology,To be Discontinued,5/2/19,5/2/19,0378-0076-01,discontinued
3287,Flurbiprofen Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100 count bottle (NDC 0378-0093-01)",New,5/2/19,,,,,Rheumatology,To be Discontinued,5/2/19,5/2/19,0378-0093-01,discontinued
3288,"Flutamide Capsules, USP",Teva Pharmaceuticals,125 mg 180 count (NDC 0591-2466-18),New,6/10/19,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,6/10/19,6/10/19,0591-2466-18,discontinued
3289,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 30 count bottle (NDC 0378-5121-93)",New,5/2/19,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5121-93,discontinued
3290,Fluvastatin Sodium Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5121-01)",New,5/2/19,,,,,Endocrinology/Metabolism;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5121-01,discontinued
3291,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,4/7/20,On backorder. Estimated availability end of April 2020,,,Delay in shipping of the drug,Psychiatry,Current,,,10370-175-11,not available
3292,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,4/7/20,On backorder. Estimated availability end of April 2020,,,Delay in shipping of the drug,Psychiatry,Current,,,10370-176-11,not available
3293,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0228-2848-03,available
3294,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0228-2849-03,available
3295,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 100 (NDC 0603-3162-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-21,discontinued
3296,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 1000 (NDC 0603-3162-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-32,discontinued
3297,"Folic Acid Tablets, USP",Par Pharmaceutical,"1 mg, bottle of 2500 (NDC 0603-3162-30)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology;Reproductive,To be Discontinued,4/19/19,4/19/19,0603-3162-30,discontinued
3298,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,10/28/20,Available,,,,Cardiovascular,Current,,,36000-284-25,available
3299,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,10/28/20,Available,,,,Cardiovascular,Current,,,36000-282-25,available
3300,"Furosemide Injection, USP",Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,10/28/20,Available,,,,Cardiovascular,Current,,,36000-283-25,available
3301,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,11/6/20,Available,,,,Cardiovascular,Current,,,23155-473-41,available
3302,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,11/6/20,Available,,,,Cardiovascular,Current,,,23155-473-42,available
3303,"Furosemide Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,11/6/20,Available,,,,Cardiovascular,Current,,,23155-473-44,available
3304,"Furosemide Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,0409-6102-02,available
3305,"Furosemide Injection, USP","Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,0409-6102-04,available
3306,"Furosemide Injection, USP","Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,0409-6102-10,available
3307,"Furosemide Injection, USP","Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,0409-1639-10,available
3308,"Furosemide Injection, USP","Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,0409-9631-04,available
3309,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-02,available
3310,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-04,available
3311,"Furosemide Injection, USP","Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-10,available
3312,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,11/20/20,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-322-25,not available
3313,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,11/20/20,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-323-25,not available
3314,"Furosemide Injection, USP",AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL single-dose vial (NDC 55150--324-25),Reverified,11/20/20,Backordered — next shipments anticipated Jan 21,Intermittent availability expected.,,Delay in shipping of the drug,Cardiovascular,Current,,,55150--324-25,not available
3315,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 5 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-81)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-81,discontinued
3316,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 10 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-82)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-82,discontinued
3317,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 15 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-83)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-83,discontinued
3318,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Vials 20 mL single-dose vials, rubber stoppered, in individual cartons of 10, 2 cartons per Box (NDC 50419-188-84)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-84,discontinued
3319,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 10 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-36)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-36,discontinued
3320,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 15 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-37)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-37,discontinued
3321,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Single-Dose Pre-Filled Syringes 20 mL pre-filled disposable syringe, Boxes of 5 (NDC 50419-188-38)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-38,discontinued
3322,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 50 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-58)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-58,discontinued
3323,Gadopentetate Dimeglumine (Magnevist) Injection,Bayer,"Pharmacy Bulk Package 100 mL Pharmacy Bulk Package, rubber stoppered, 10 per box (NDC 50419-188-11)",New,7/17/19,,"Business decision to discontinue marketing in the US. Product discontinuation is not related to product quality, safety, or efficacy.",,,Medical Imaging,To be Discontinued,7/17/19,7/17/19,50419-188-11,discontinued
3324,Gemcitabine Hydrochloride Injection,Apotex Corp.,"200 mg/5.26 mL (38 mg/mL), single dose vial (NDC 60505-6113-6)",New,1/8/20,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/20,1/8/20,60505-6113-6,discontinued
3325,Gemcitabine Hydrochloride Injection,Apotex Corp.,"1 g/26.3 mL (38 mg/mL), single dose vial (NDC 60505-6114-0)",New,1/8/20,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/20,1/8/20,60505-6114-0,discontinued
3326,Gemcitabine Hydrochloride Injection,Apotex Corp.,"2 g/52.6 mL (38 mg/mL), single dose vial (NDC 60505-6115-2)",New,1/8/20,,Apotex made a business decision to discontinue this product.,,,Oncology,To be Discontinued,1/8/20,1/8/20,60505-6115-2,discontinued
3327,Gemcitabine Hydrochloride Injection,Mylan Institutional,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/19,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/19,12/16/19,67457-462-01,discontinued
3328,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"1 g, single dose vial (NDC 45963-619-59)",New,1/16/20,,Actively selling; Remaining inventory estimated to last through April 2020,,,Oncology,To be Discontinued,1/16/20,1/16/20,45963-619-59,discontinued
3329,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"200 mg/5.26 mL (38 mg/mL), single dose vial (NDC 45963-623-57)",New,1/16/20,,Actively selling; Remaining inventory estimated to last through March 2020,,,Oncology,To be Discontinued,1/16/20,1/16/20,45963-623-57,discontinued
3330,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"1 g/26.3 mL (38 mg/mL), single dose vial (NDC 45963-624-58)",New,1/16/20,,Actively selling; Remaining inventory estimated to last through July 2020,,,Oncology,To be Discontinued,1/16/20,1/16/20,45963-624-58,discontinued
3331,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"2 g/52.6 mL (38 mg/mL), single dose vial (NDC 45963-636-60)",New,1/16/20,,Actively selling; Remaining inventory estimated to last through March 2020,,,,To be Discontinued,1/16/20,1/16/20,45963-636-60,discontinued
3332,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"200 mg, single dose vial (NDC 45963-612-57)",New,1/7/20,,,,,Oncology,To be Discontinued,1/7/20,1/7/20,45963-612-57,discontinued
3333,Gemcitabine Hydrochloride Injection,Teva Pharmaceuticals,"2 g, single dose vial (NDC 45963-620-60)",New,1/7/20,,,,,Oncology,To be Discontinued,1/7/20,1/7/20,45963-620-60,discontinued
3334,Gemcitabine Hydrochloride Injection,Mylan Institutional,"200 mg, single dose vial (NDC 67457-464-20)",New,6/26/20,,Expected discontinuation December 2020,,,Oncology,To be Discontinued,6/26/20,6/26/20,67457-464-20,discontinued
3335,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,11/5/20,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-07,unclear
3336,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,11/5/20,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-05,unclear
3337,Glimepiride Tablets,Teva Pharmaceuticals,1 mg 100 Count (NDC 0093-7254-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7254-01,discontinued
3338,Glimepiride Tablets,Teva Pharmaceuticals,2 mg 100 Count (NDC 0093-7255-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7255-01,discontinued
3339,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 100 Count (NDC 0093-7256-01),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7256-01,discontinued
3340,Glimepiride Tablets,Teva Pharmaceuticals,4 mg 250 Count (NDC 0093-7256-52),New,5/17/19,,Teva made a business decision to discontinue this product.,,,Endocrinology/Metabolism,To be Discontinued,5/17/19,5/17/19,0093-7256-52,discontinued
3341,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/20,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/20,5/28/20,0591-0460-10,discontinued
3342,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/20,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/20,5/28/20,0591-0461-10,discontinued
3343,Glycopyrrolate (Seebri Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,"15.6mcg  (NDCs 63402-815-06, 63402-815-12, and 63402-815-60)",New,3/10/20,,,,,Pulmonary/Allergy,To be Discontinued,3/10/20,3/10/20,,discontinued
3344,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1061-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1061-01,discontinued
3345,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-1062-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1062-01,discontinued
3346,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"3 mg, 100 count bottle (NDC 0378-1063-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1063-01,discontinued
3347,Guanfacine Hydrochloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"4 mg, 100 count bottle (NDC 0378-1065-01)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-1065-01,discontinued
3348,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",New,6/12/19,Available,,,Other,Cardiovascular,Current,,,42806-048-01,available
3349,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",New,6/12/19,Available,,,Other,Cardiovascular,Current,,,42806-296-01,available
3350,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-1160-01),Reverified,11/10/20,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,0378-1160-01,not available
3351,Guanfacine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-1190-01),Reverified,11/10/20,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,0378-1190-01,not available
3352,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Reverified,11/19/20,Available,,,Other,Cardiovascular,Current,,,0591-0444-01,available
3353,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Reverified,11/19/20,Available,,,,Cardiovascular,Current,,,0591-0453-01,available
3354,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-711-03,available
3355,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-713-03,available
3356,Guanidine Hydrochloride Tablets,Merck Sharp & Dohme Corp.,125 mg tablets (NDC 0085-0492-01),New,9/28/20,,To be discontinued on or near October 2020.,,,Neurology,To be Discontinued,9/28/20,9/28/20,0085-0492-01,discontinued
3357,Haloperidol Lactate (Haldol) Injection,"Janssen Biotech, Inc.","5 mg/mL, 10 ampule in 1 box, > 1 mL in 1 ampule, (NDC 50458-255-01)",New,11/13/20,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/20,11/13/20,50458-255-01,discontinued
3358,Haloperidol Lactate Injection,Patriot Pharmaceuticals,"5 mg/mL, 10 ampule in 1 box,> 1 mL in 1 ampule, (NDC 10147-0911-1)",New,11/13/20,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/20,11/13/20,10147-0911-1,discontinued
3359,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0351-01,
3360,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0257-01,
3361,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0214-01,
3362,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0327-01,
3363,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0334-01,
3364,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0355-01,
3365,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-01,
3366,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-10,
3367,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-080-01,
3368,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-081-01,
3369,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9101,
3370,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9101,
3371,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9113,
3372,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9201,
3373,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9201,
3374,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
3375,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9801,
3376,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
3377,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9610,
3378,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9610,
3379,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9601,
3380,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9601,
3381,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9613,
3382,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9701,
3383,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9701,
3384,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9713,
3385,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9301,
3386,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Reverified,10/28/20,Available,,,,Hematology,Current,,,0338-0433-04,available
3387,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Reverified,10/28/20,Unavailable,Product code 2B0953 was replaced with code AHB0953U,,Other,Hematology,Current,,,0338-0431-03,not available
3388,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: July 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Hematology,Current,,,00409-7620-03,limited availability
3389,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Revised,11/20/20,Available,,,Other,Hematology,Current,,,00409-7620-59,available
3390,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Reverified,10/28/20,Available,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,0338-0424-18,available
3391,Heparin Sodium and Sodium Chloride 0.9% Injection,Sagent Pharmaceuticals,1000 units/mL 10mL pack 25 (NDC 25021-400-10),Reverified,10/22/20,Available.,,,,Hematology,Current,,,25021-400-10,available
3392,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Reverified,10/23/20,Expected availability February 2021,,,Other,Hematology,Current,,,63323-519-77,not available
3393,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Reverified,10/23/20,Expected availability February 2021,,,Other,Hematology,Current,,,63323-519-10,not available
3394,"Hydralazine Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,10/23/20,Backordered.  Next release expected November 2020.,Check wholesaler for inventory,,Manufacturing Delay,Cardiovascular,Current,,,63323-614-01,not available
3395,"Hydralazine Hydrochloride Injection, USP",Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,11/3/20,Not available,Not available,,Other,Cardiovascular,Current,,,17478-934-01,not available
3396,"Hydralazine Hydrochloride Injection, USP",Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,11/3/20,On allocation / Recovery expected March 2021,Manufacturer interruption production issues.,,Other,Cardiovascular,Current,,,17478-934-15,limited availability
3397,"Hydralazine Hydrochloride Injection, USP",Mylan Institutional,20 mg / 1 ml] 25PK (NDC 67457-291-01),Reverified,11/10/20,Intermittent supply,,,Demand increase for the drug,Cardiovascular,Current,,,67457-291-01,limited availability
3398,"Hydralazine Hydrochloride Injection, USP","X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,9/9/20,Not available and no plans to manufacture at this time.,,,Other,Cardiovascular,Current,,,39822-0500-4,discontinued
3399,Hydrochlorothiazide (Microzide) Capsules,Allergan Sales LLC,12.5 mg (NDC 52544-622-01),New,10/22/19,,"The authorized generic, Hydrochlorothiazide Capsules, USP, 12.5 mg remains commercially available.",,,Cardiovascular,To be Discontinued,10/22/19,10/22/19,52544-622-01,discontinued
3400,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2025-01,discontinued
3401,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2012-01,discontinued
3402,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-1012-01,discontinued
3403,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/18,6/5/18,0574-1105-16,discontinued
3404,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-12,discontinued
3405,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-24,discontinued
3406,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-01,discontinued
3407,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Revised,11/20/20,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,59762-0073-1,unclear
3408,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Revised,11/20/20,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,59762-0074-1,unclear
3409,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Revised,11/20/20,Next Delivery: December 2020; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism,Current,,,59762-0075-1,unclear
3410,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Revised,11/20/20,Available,,,Other,Endocrinology/Metabolism,Current,,,0009-0044-01,available
3411,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Revised,11/20/20,Next Delivery and Estimated Recovery: October 2020,,,Other,Endocrinology/Metabolism,Current,,,0009-0012-01,not available
3412,"Hydrocortisone Tablets, USP",Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Revised,11/20/20,Available,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0009-0031-01,available
3413,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 42543-140-50)",Reverified,10/5/20,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,42543-140-50,available
3414,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 42543-141-01)",Reverified,10/5/20,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,42543-141-01,available
3415,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 42543-142-01)",Reverified,10/5/20,Available,ANDA Holder: Strides Pharma,,Other,Endocrinology/Metabolism,Current,,,42543-142-01,available
3416,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"5 mg, bottle of 50 (NDC 0603-3899-19)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3899-19,discontinued
3417,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"10 mg, bottle of 100 (NDC 0603-3900-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3900-21,discontinued
3418,"Hydrocortisone Tablets, USP",Par Pharmaceutical,"20 mg, bottle of 100 (NDC 0603-3901-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Pulmonary/Allergy,To be Discontinued,4/19/19,4/19/19,0603-3901-21,discontinued
3419,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 64380-970-25)",New,10/5/20,Available,,,,Endocrinology/Metabolism,Current,,,64380-970-25,available
3420,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 64380-971-06)",New,10/5/20,Available,,,,Endocrinology/Metabolism,Current,,,64380-971-06,available
3421,"Hydrocortisone Tablets, USP","Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 64380-972-06)",New,10/5/20,Available,,,,Endocrinology/Metabolism,Current,,,64380-972-06,available
3422,"Hydrocortisone Tablets, USP",Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),New,5/15/20,Unavailable,,,Limited API availability,Endocrinology/Metabolism,Current,,,00115-1697-01,not available
3423,"Hydrocortisone Tablets, USP",Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),New,5/15/20,Limited availability,,,Limited API availability,Endocrinology/Metabolism,Current,,,00115-1700-01,limited availability
3424,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"32 mg, 100 count (NDC 0591-3631-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3631-01,discontinued
3425,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"16 mg, 100 count (NDC 0591-3630-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3630-01,discontinued
3426,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"12 mg, 100 count (NDC 0591-3739-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3739-01,discontinued
3427,"Hydromorphone Hydrochloride Extended-Release Tablets, CII",Teva Pharmaceuticals,"8 mg, 100 count (NDC 0591-3629-01)",New,6/20/19,,This was a business-related decision to discontinue manufacturing these products.,,,Analgesia/Addiction,To be Discontinued,6/20/19,6/20/19,0591-3629-01,discontinued
3428,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,11/16/20,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-06,available
3429,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,11/16/20,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-11,available
3430,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-852-25,available
3431,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-853-25,available
3432,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-854-10,available
3433,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-10,available
3434,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-15,available
3435,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,11/16/20,Backorderd. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-50,not available
3436,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,7/22/20,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-0121-25,available
3437,"Hydromorphone Hydrochloride Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-2341-41,not available
3438,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Revised,11/16/20,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-05,unclear
3439,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,11/16/20,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-10,unclear
3440,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,11/16/20,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-010-10,not available
3441,"Hydromorphone Hydrochloride Injection, USP","Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,11/16/20,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-011-10,not available
3442,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,11/19/20,Available,,,,Analgesia/Addiction,Current,,,,available
3443,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,11/19/20,Available,,,,Analgesia/Addiction,Current,,,0703-0113-03,available
3444,"Hydromorphone Hydrochloride Injection, USP",Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,11/19/20,Available,,,,Analgesia/Addiction,Current,,,0703-0018-01,available
3445,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1283-05,available
3446,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1283-10,discontinued
3447,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1312-10,discontinued
3448,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1283-31,available
3449,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,11/20/20,Next Delivery and Estimated Recovery: November 2020,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-1312-30,not available
3450,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1304-31,available
3451,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-2552-01,available
3452,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-3356-01,discontinued
3453,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2540-01,discontinued
3454,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-3365-01,available
3455,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-01,available
3456,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-05,available
3457,"Hydromorphone Hydrochloride Injection, USP","Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-50,available
3458,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Revised,12/2/19,Unavailable. Estimataed recovery Dec 2019,"Expected availability Dec, 2019",,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-01,not available
3459,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Revised,12/2/19,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-05,available
3460,"Hydromorphone Hydrochloride Injection, USP",Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Revised,12/2/19,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-50,available
3461,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 500 count bottle (NDC 0591-3041-05)",Revised,6/26/20,,,"Distributed by Actavis Pharma (Teva);  500 count bottle: on backorder, recovery to be determined.",,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,0591-3041-05,
3462,Hydroxychloroquine Sulfate Tablets,Sandoz,"200 mg, 100 count bottle (NDC 16714-753-01)",Revised,6/26/20,,,Northstar Rx label; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,16714-753-01,
3463,Hydroxychloroquine Sulfate Tablets,Alkaloida Chemical Co. Zrt.,"200 mg, 100 count bottle (NDC 57664-761-88); 500 count bottle (NDC 57664-761-13)",Revised,6/26/20,,,Distributed by Sun Pharmaceutical. Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,57664-761-88,
3464,Hydroxychloroquine Sulfate Tablets,Amneal Pharmaceutical,"200 mg, 100 count bottle (NDC 69238-1544-1)",Revised,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,69238-1544-1,
3465,Hydroxychloroquine Sulfate Tablets,Appco Pharma LLC,"200 mg, 100 count bottle (NDC 43598-721-01); 500 count bottle (NDC 43598-721-05)",Revised,6/26/20,,,Distributed by Dr. Reddy’s Laboratories Inc.; Limited supply subject to allocation; duration to be determined,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,43598-721-01,
3466,Hydroxychloroquine Sulfate Tablets,Concordia Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 66993-057-02); 500 count bottle (NDC 66993-057-04)",Revised,6/26/20,,,Distributed by Prasco Laboratories; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,66993-057-02,
3467,Hydroxychloroquine Sulfate Tablets,Concordia Pharmaceuticals Inc.,"Plaquenil 200 mg, 100 count bottle (NDC 59212-562-10)",Revised,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,59212-562-10,
3468,Hydroxychloroquine Sulfate Tablets,Laurus Labs Limited,"200 mg, 100 count bottle (NDC42385-927-01); 500 count bottle (NDC 42385-927-05)",Revised,6/26/20,,,Distributed by Rising Pharmaceuticals; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,42385-927-05,
3469,Hydroxychloroquine Sulfate Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0373-01)",Revised,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,0378-0373-01,
3470,Hydroxychloroquine Sulfate Tablets,Sandoz,"200 mg, 100 count bottle (NDC 0781-5994-01); 500 count bottle (NDC 0781-5994-05)",Revised,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,0781-5994-01,
3471,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 100 count bottle (NDC 0591-3041-01)",Revised,6/26/20,,,Distributed by Actavis Pharma (Teva); 100 count bottle: Limited supply subject to allocation; duration to be determined.,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,0591-3041-01,
3472,Hydroxychloroquine Sulfate Tablets,Zydus Pharmaceuticals USA Inc.,"200 mg, 100 count bottle (NDC 68382-096-01); 500 count bottle (NDC 68382-096-05)",Revised,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,68382-096-01,
3473,Hydroxychloroquine Sulfate Tablets,Zydus Pharmaceuticals USA Inc.,"200 mg, 100 count bottle (NDC 16714-110-01)",Revised,6/26/20,,,Northstar Rx label; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,16714-110-01,
3474,Hydroxychloroquine Sulfate Tablets,Ipca Laboratories Limited,"200 mg, 100 count bottle (NDC 76385-144-01)",New,6/26/20,,,Distributed by Bayshore Pharmaceuticals; Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,76385-144-01,
3475,Hydroxychloroquine Sulfate Tablets,Accord Healthcare Inc.,"200 mg, 500 count bottle (NDC 16729-485-16)",New,6/26/20,,,Available,,Anti-Infective;Other;Rheumatology,Resolved,6/26/20,,16729-485-16,
3476,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-309-01,
3477,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-310-01,
3478,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-105-01,
3479,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,0517-1767-01,
3480,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-104-01,
3481,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-247-02,
3482,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
3483,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-243-01,
3484,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
3485,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Reverified,10/1/20,"Product is on back order, estimated release not sooner than December 2020",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,24208-800-60,not available
3486,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,11/20/20,Next delivery and Estimated recovery: January 2021,Shortage per manufacturer: Manufacturing Delay,,Other,Psychiatry,Current,,,0069-5410-66,not available
3487,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,11/20/20,Available,,,Other,Psychiatry,Current,,,0069-5420-66,available
3488,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Reverified,11/6/20,Available,,,,Psychiatry,Current,,,14539-674-01,available
3489,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Reverified,11/6/20,Available,,,,Psychiatry,Current,,,14539-674-05,available
3490,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Reverified,11/6/20,Available,,,,Psychiatry,Current,,,14539-675-01,available
3491,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Reverified,11/6/20,Available,,,,Psychiatry,Current,,,14539-675-05,available
3492,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0555-0324-02,available
3493,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0555-0323-02,available
3494,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0555-0323-04,available
3495,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0555-0302-02,available
3496,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Reverified,11/19/20,Available,,,Other,Psychiatry,Current,,,0555-0302-04,available
3497,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Reverified,11/13/20,Supply Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0674-01,available
3498,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Reverified,11/13/20,Supply Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0674-05,available
3499,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Reverified,2/20/20,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1803-01,limited availability
3500,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Reverified,2/20/20,Expected to be on allocation until sometime in 1Q20.,,,OIther,Psychiatry,Current,,,00115-1803-02,limited availability
3501,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Reverified,2/20/20,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1804-01,limited availability
3502,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Reverified,2/20/20,Expected to be on allocation until sometime in 1Q20.,,,Other,Psychiatry,Current,,,00115-1804-02,limited availability
3503,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,1 gram/20 mL; 1 gram/10 mL  (NDCs 0703-4100-48 and 0703-4100-58),New,10/18/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/19,10/18/19,,discontinued
3504,Ifosfamide/Mesna Kit,Teva Pharmaceuticals,3 gram/60 mL; 1 gram/10 mL (NDC 0703-4100-68 ),New,10/18/19,,This product is being discontinued due to a business decision.,,,Oncology,To be Discontinued,10/18/19,10/18/19,0703-4100-68,discontinued
3505,"Imipenem and Cilastatin for Injection, USP",Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,12/18/17,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,0006-3516-59,available
3506,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-349-25,available
3507,"Imipenem and Cilastatin for Injection, USP","Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,11/16/20,Available,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-322-25,available
3508,Indacterol Maleate (Arcapta Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,75mcg  (NDCs 63402-675-06 and 63402-675-30),New,3/10/20,,,,,Pulmonary/Allergy,To be Discontinued,3/10/20,3/10/20,,discontinued
3509,Indacterol Maleate and Glycopyrrolate (Utibron Neohaler) Inhalation Powder,Sunovion Pharmaceuticals Inc.,"15.6mcg; 27.5mcg  (NDCs 63402-681-06, 63402-681-12, and 63402-681-60)",New,3/10/20,,,,,Pulmonary/Allergy,To be Discontinued,3/10/20,3/10/20,,discontinued
3510,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,"400 mg capsules, unit-of-use bottles of 180 (with desiccant)(NDC 0006-0573-62)",New,3/31/20,,To be discontinued on or near August 2020.,,,Antiviral,To be Discontinued,3/31/20,3/31/20,0006-0573-62,discontinued
3511,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,200 mg capsules (NDC 0006-0571-43),New,9/21/20,,,,,Antiviral,To be Discontinued,9/21/20,9/21/20,0006-0571-43,discontinued
3512,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-01,discontinued
3513,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-10,discontinued
3514,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-01,discontinued
3515,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-05,discontinued
3516,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4350-01,discontinued
3517,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4351-01,discontinued
3518,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/19,,To be discontinued in 2022,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-4352-01,discontinued
3519,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01),New,9/12/19,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-1168-01,discontinued
3520,INTRON A (Interferon alfa-2b) Recombinant for Injection,Merck Sharp & Dohme Corp.,INTRON A Solution for Injection (Interferon alfa-2b) 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01),New,9/12/19,,To be discontinued in 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,0085-1133-01,discontinued
3521,Isocarboxazid Tablets,Validus Pharmaceuticals LLC,10mg (NDC 30698-032-01),Revised,1/10/20,,,,,Psychiatry,Resolved,1/10/20,,30698-032-01,
3522,Isoniazid Tablets,Teva Pharmaceuticals,300 mg 1000 count (NDC 0555-0071-05),New,10/27/20,,Teva made a business decision to discontinue the 1000 count presentation. The other presentations of Isoniazid Tablets product remain active.,,,Anti-Infective,To be Discontinued,10/27/20,10/27/20,0555-0071-05,discontinued
3523,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 100 (NDC 0603-4110-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-21,discontinued
3524,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 500 (NDC 0603-4110-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-28,discontinued
3525,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"30 mg, bottle of 1000 (NDC 0603-4110-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4110-32,discontinued
3526,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 100 (NDC 0603-4111-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-21,discontinued
3527,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 500 (NDC 0603-4111-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-28,discontinued
3528,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"60 mg, bottle of 1000 (NDC 0603-4111-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4111-32,discontinued
3529,"Isosorbide Mononitrate Extended-Release Tablets, USP",Par Pharmaceutical,"120 mg, bottle of 100 (NDC 0603-4112-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-4112-21,discontinued
3530,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the July - August 2020 timeframe.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9509-10,not available
3531,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9508-10,available
3532,Ketamine Injection,Mylan Institutional,200 mg / 20 mL (NDC 67457-181-20),Reverified,11/10/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-181-20,available
3533,Ketamine Injection,Mylan Institutional,500 mg / 10 mL (NDC 67457-001-10),Reverified,11/10/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-001-10,available
3534,Ketamine Injection,Mylan Institutional,1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/10/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-108-10,available
3535,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-2051-05,available
3536,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,11/20/20,Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-2053-10,not available
3537,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,7/28/20,Backordered due to increased demand.  Expected recovered date is September 2020.,,,Demand increase for the drug,Anesthesia,Current,,,42023-113-10,not available
3538,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,7/28/20,Available,Please check wholesalers for supply,,Demand increase for the drug,Anesthesia,Current,,,42023-115-10,available
3539,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,7/28/20,Available,Please check wholesalers for supply,,Demand increase for the drug,Anesthesia,Current,,,42023-114-10,available
3540,Ketoconazole Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100 count bottle (NDC 0378-0261-01)",New,5/2/19,,,,,Anti-Infective,To be Discontinued,5/2/19,5/2/19,0378-0261-01,discontinued
3541,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-10,discontinued
3542,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Reverified,9/28/20,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-10,available
3543,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Reverified,9/28/20,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-11,available
3544,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Reverified,9/28/20,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-01,discontinued
3545,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Reverified,9/28/20,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-10,discontinued
3546,Ketoprofen Capsules,Mylan Pharmaceuticals Inc.,"200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/10/20,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/16,,0378-8200-01,available
3547,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3193-01,not available
3548,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-01,not available
3549,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,11/19/20,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-05,not available
3550,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-01,discontinued
3551,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Reverified,9/28/20,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-021-01,available
3552,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Reverified,9/28/20,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-022-01,available
3553,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,7/22/20,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6041-25,unclear
3554,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,7/22/20,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6042-25,unclear
3555,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,7/22/20,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6043-25,unclear
3556,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/18,Available,,,Other,Analgesia/Addiction,Current,,,69543-0386-25,available
3557,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,9/28/20,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-700-01,not available
3558,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,9/28/20,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-01,not available
3559,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,9/28/20,"Backordered, next shipment in November","Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-02,not available
3560,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,10/22/20,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,25021-700-01,not available
3561,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,10/22/20,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-02,not available
3562,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,10/22/20,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-01,not available
3563,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-23,discontinued
3564,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Reverified,11/20/20,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2287-31,not available
3565,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Reverified,11/20/20,Next Delivery and Estimated Recovery: January 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2287-61,not available
3566,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Reverified,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3793-01,limited availability
3567,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Reverified,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-3795-01,available
3568,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Reverified,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-3796-01,available
3569,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,11/16/20,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-161-01,not available
3570,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,11/16/20,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-01,not available
3571,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,11/16/20,Backordered. Next release November 2020.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-02,not available
3572,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Revised,10/28/20,Available,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,,Analgesia/Addiction,Current,,,0338-0072-25,available
3573,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,11/16/20,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-107-10,available
3574,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,11/16/20,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-104-10,available
3575,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,11/16/20,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-105-20,available
3576,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Revised,10/28/20,"Stocked out, Recovery mid-November 2020",FOR INTRAVENOUS AND INTRAMUSCULAR USE. 15 mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,0338-0069-10,not available
3577,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,9/28/20,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-118-25,available
3578,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,9/28/20,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,72266-119-25,available
3579,Labetalol Hydrochloride Injection,Gland Pharma,"5mg/mL, 20 mL vial (NDC 72266-102-01)",Reverified,12/11/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-102-01,available
3580,Labetalol Hydrochloride Injection,Gland Pharma,"5 mg/mL, 40 mL vial (NDC 72266-103-01)",Reverified,12/11/19,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-103-01,available
3581,Labetalol Hydrochloride Injection,"Hospira, Inc.",100 mg/20 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-20),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-2267-20,available
3582,Labetalol Hydrochloride Injection,"Hospira, Inc.",200 mg/40 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2267-54),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-2267-54,available
3583,Labetalol Hydrochloride Injection,"Hospira, Inc.",20 mg/4 mL (5 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2339-34),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-2339-34,available
3584,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (100mg/20mL) Multi-Dose vial (NDC 17478-420-20),Revised,12/2/19,Available,,,Other,Cardiovascular,Current,,,17478-420-20,available
3585,Labetalol Hydrochloride Injection,Akorn Pharmaceuticals,5mg/mL (200mg/40mL) Multi-Dose vial (NDC 17478-420-40 ),Revised,12/2/19,Available,,,Other,Cardiovascular,Current,,,17478-420-40,available
3586,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 20 mL multidose vial (NDC 0143-9622-01)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the July - August 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9622-01,not available
3587,Labetalol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 40 mL multidose vial (NDC 0143-9623-01)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9623-01,available
3588,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5180-91,discontinued
3589,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5168-93,discontinued
3590,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5169-91,discontinued
3591,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5170-93,discontinued
3592,Lamotrigine Tablets,Teva Pharmaceuticals,100 mg (NDCs 0093-0463-01 and 0093-0463-05),New,10/15/19,,This product is being discontinued due to a business decision.,,,Neurology,To be Discontinued,10/15/19,10/15/19,,discontinued
3593,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 100 (NDC 69097-148-07),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-07,discontinued
3594,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 500 (NDC NDC 69097-148-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-12,discontinued
3595,Lamotrigine Tablets,Cipla Limited,25 mg bottles of 1000 (NDC 69097-148-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-148-15,discontinued
3596,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 100 (NDC 69097-149-07),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-07,discontinued
3597,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 500 (NDC 69097-149-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-12,discontinued
3598,Lamotrigine Tablets,Cipla Limited,100 mg bottles of 1000 (NDC 69097-149-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-149-15,discontinued
3599,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 60 (NDC 69097-151-03),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-03,discontinued
3600,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 500 (NDC 69097-151-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-12,discontinued
3601,Lamotrigine Tablets,Cipla Limited,150 mg bottles of 1000 (NDC 69097-151-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-151-15,discontinued
3602,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 60 (NDC 69097-152-03),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-03,discontinued
3603,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 500 (NDC 69097-152-12),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-12,discontinued
3604,Lamotrigine Tablets,Cipla Limited,200 mg bottles of 1000 (NDC 69097-152-15),New,9/20/19,,,,,Neurology,To be Discontinued,9/20/19,9/20/19,69097-152-15,discontinued
3605,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/18,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,59212-245-55,discontinued
3606,Latanoprost Ophthalmic Solution 0.005%,Sandoz,2.5 mL Bottle (NDC 61314-547-01),Revised,4/6/20,,,,,Ophthalmology,Resolved,4/6/20,,61314-547-01,
3607,Latanoprost Ophthalmic Solution 0.005%,Pfizer Pharmaceuticals,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 59762-0333-2)",Revised,4/6/20,,,,,Ophthalmology,Resolved,4/6/20,,59762-0333-2,
3608,Latanoprost Ophthalmic Solution 0.005%,Bausch Health,"2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle (NDC 24208-463-25)",Revised,4/6/20,,,,,Ophthalmology,Resolved,4/6/20,,24208-463-25,
3609,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 5 count bottle (NDC 70785-011-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-011-05,discontinued
3610,Lesinurad (ZURAMPIC) Tablets,Ironwood Pharmaceuticals Inc.,ZURAMPIC® (lesinurad) 200 mg tablets 30 count bottle (NDC 70785-011-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-011-30,discontinued
3611,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200mg tablets 5 count bottle (NDC 70785-021-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-021-05,discontinued
3612,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 30 count bottle (NDC 70785-021-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,Endocrinology/Metabolism,To be Discontinued,4/15/19,4/15/19,70785-021-30,discontinued
3613,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/200 mg tablets 90 count bottle (NDC 70785-021-90),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-021-90,discontinued
3614,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 5 count bottle (NDC 70785-022-05),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-05,discontinued
3615,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 30 count bottle (NDC 70785-022-30),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-30,discontinued
3616,Lesinurad/Allopurinol (DUZALLO®) Tablets,Ironwood Pharmaceuticals Inc.,200/300 mg tablets 90 count bottle (NDC 70785-022-90),New,4/15/19,,"Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.",,,,To be Discontinued,4/15/19,4/15/19,70785-022-90,discontinued
3617,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,12/2/19,Available,,,Other,Antiviral,Current,,,0006-5004-01,available
3618,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,12/2/19,Available,,,Other,Antiviral,Current,,,0006-5003-01,available
3619,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Reverified,10/22/20,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-828-50,not available
3620,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,11/19/20,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5140-01,available
3621,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,11/19/20,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5145-01,available
3622,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Reverified,11/16/20,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,63323-710-50,available
3623,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Reverified,11/16/20,Available,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,63323-711-00,available
3624,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Reverified,10/22/20,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-813-10,not available
3625,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Reverified,10/22/20,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-814-30,not available
3626,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Reverified,10/22/20,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-815-30,not available
3627,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Reverified,10/22/20,Backordered. Estimated availability Dec-2020,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-816-30,not available
3628,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",New,5/15/20,Backordered. Next release July 2020.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,63323-631-50,not available
3629,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",New,7/16/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9555-01,available
3630,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",New,7/16/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9554-01,available
3631,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",New,7/16/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9553-01,available
3632,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",New,7/16/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9552-01,available
3633,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,11/18/20,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-223-05,available
3634,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,11/18/20,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-303-30,available
3635,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,11/18/20,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-453-45,available
3636,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,11/18/20,Available,Call customer service: 1-888-FENSOLVI,,,Endocrinology/Metabolism;Oncology,Current,,,62935-153-50,available
3637,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,11/18/20,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-753-75,available
3638,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,11/3/20,On backorder. Units expected to be received by November. Further replenishment expected to be received in December,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,0074-9694-03,not available
3639,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,11/3/20,On backorder; Additional lots coming in late November 2020,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3346-03,not available
3640,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,11/3/20,On backorder. Units expected in October,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,0074-3473-03,not available
3641,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,11/3/20,Available; Additional Units expected to release by mid-November,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3642-03,limited availability
3642,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,11/3/20,On backorder. Units expected to be released by mid-November,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,0074-3683-03,not available
3643,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,11/3/20,Available; Additional units released early October 2020,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3641-03,available
3644,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,11/3/20,On backorder. Next units expected to release by mid-November,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,0074-3663-03,not available
3645,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,11/3/20,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2282-03,available
3646,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,11/3/20,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2440-03,available
3647,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,11/3/20,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2108-03,available
3648,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,11/3/20,On backorder. Units expected to be released in December,,,Delay in shipping of the drug,Endocrinology/Metabolism;Oncology,Current,,,0074-3779-03,not available
3649,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,500mg (NDC 0591-3635-60),New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/19,6/7/19,0591-3635-60,discontinued
3650,"Levetiracetam Extended-Release Oral Tablets, USP",Teva Pharmaceuticals,750mg (NDC 0591-3699-60),New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Neurology,To be Discontinued,6/7/19,6/7/19,0591-3699-60,discontinued
3651,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Reverified,11/13/20,Available,,,Demand increase for the drug,Neurology,Current,,,60505-3280-06,available
3652,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Reverified,11/13/20,Available,,,Demand increase for the drug,Neurology,Current,,,60505-3517-06,available
3653,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Reveriifed,5/5/20,"Back-order, Estimated re-supply: TBD",,,Shortage of active ingredient,Neurology,Current,,,4733557386,not available
3654,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Reveriifed,5/5/20,"Back-order, Estimated re-supply: TBD",,,Shortage of active ingredient,Neurology,Current,,,4733557686,not available
3655,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Reverified,4/30/20,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,68180-117-07,limited availability
3656,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Reverified,4/30/20,Continuous production but will be on/off backorder,,,Shortage of active ingredient,Neurology,Current,,,68180-118-07,limited availability
3657,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Revised,4/21/20,Available,,,,Neurology,Current,,,50474-598-66,available
3658,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Revised,4/21/20,Available,,,,Neurology,Current,,,50474-599-66,available
3659,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0345-06,not available
3660,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0345-50,not available
3661,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0346-06,not available
3662,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0346-50,not available
3663,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 500 mg 60 ct. bottle; (NDC 69102-200-60)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-200-60,discontinued
3664,"Levetiracetam Extended-Release Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra XR) Extended-Release Tablets, 750 mg 60 ct. bottle; (NDC 69102-201-60)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-201-60,discontinued
3665,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Reverified,2/18/20,Available,,,,Neurology,Current,,,13668-014-12,available
3666,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Reverified,2/18/20,Available,,,,Neurology,Current,,,13668-015-12,available
3667,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Reverified,2/18/20,Available,,,,Neurology,Current,,,13668-016-12,available
3668,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Reverified,2/18/20,Available,,,,Neurology,Current,,,13668-016-05,available
3669,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Reverified,2/18/20,Available,,,Shortage of Active Ingredient,Neurology,Current,,,13668-017-60,available
3670,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Revised,4/21/20,Available,,,,Neurology,Current,,,50474-594-40,available
3671,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Revised,4/21/20,Available,,,,Neurology,Current,,,50474-595-40,available
3672,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Revised,4/21/20,Available,,,,Neurology,Current,,,50474-596-40,available
3673,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Revised,4/21/20,Available,,,,Neurology,Current,,,50474-597-66,available
3674,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Reverified,9/25/20,Available,,,,Neurology,Current,,,65862024508,available
3675,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Reverified,9/25/20,Available,,,,Neurology,Current,,,65862024608,available
3676,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Reverified,9/25/20,Available,,,,Neurology,Current,,,65862031560,available
3677,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Reverified,9/25/20,Available,,,,Neurology,Current,,,65862024708,available
3678,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3679,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3680,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3681,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3682,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3683,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Reverified,4/30/20,Available,,,,Neurology,Current,,,,available
3684,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Reverified,4/30/20,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
3685,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Reverified,4/30/20,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
3686,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Reverified,4/30/20,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
3687,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Reverified,4/30/20,Will remain on backorder for few months,"Due to shortage, API is being allocated between the different strengths",,Shortage of active Ingredient,Neurology,Current,,,,not available
3688,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053612,available
3689,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053605,available
3690,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053712,available
3691,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053705,available
3692,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053812,available
3693,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Reverified,12/17/19,Available,,,,Neurology,Current,,,31722053805,available
3694,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0221-15,not available
3695,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0222-15,not available
3696,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0222-11,not available
3697,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0223-15,not available
3698,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Reverified,12/11/19,Long-term backorder for all skus. No estimated release date at this time.,,,,Neurology,Current,,,43547-0224-06,not available
3699,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5613-78,available
3700,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5613-05,available
3701,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5615-05,available
3702,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5615-78,available
3703,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5617-78,available
3704,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5617-05,available
3705,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Reverified,11/10/20,Available,,,Shortage of active ingredient,Neurology,Current,,,0378-5619-91,available
3706,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 500 mg (120 count; (NDC 69102-104-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-104-01,discontinued
3707,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 750 mg (120 count; (NDC 69102-102-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-102-01,discontinued
3708,"Levetiracetam Oral Tablets, USP",Lotus Pharmaceutical Co. Ltd.,"Levetiracetam (Roweepra) Tablets, 1000 mg 60 count; (NDC  69102-103-01)",New,9/3/19,,The discontinuation of this product is a business decision.,,,Neurology,To be Discontinued,9/3/19,9/3/19,69102-103-01,discontinued
3709,Levocetirizine Dihydrochloride Tablets,Apotex Corp.,5 mg tablets (NDCs 60505-3713-9 and 60505-3713-5),New,1/21/20,,,,,Pulmonary/Allergy,To be Discontinued,1/21/20,1/21/20,,discontinued
3710,Levofloxacin Tablets,Sandoz,250 mg 100 count bottle (NDC 0781-5790-01),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5790-01,discontinued
3711,Levofloxacin Tablets,Sandoz,250 mg 50 count bottle (NDC 0781-5790-50),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5790-50,discontinued
3712,Levofloxacin Tablets,Sandoz,500 mg 50 count bottle (NDC 0781-5791-50),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5791-50,discontinued
3713,Levofloxacin Tablets,Sandoz,500 mg 100 count bottle (NDC 0781-5791-01),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5791-01,discontinued
3714,Levofloxacin Tablets,Sandoz,750 mg 20 count bottle (NDC 0781-5792-20),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5792-20,discontinued
3715,Levofloxacin Tablets,Sandoz,750 mg 50 count bottle (NDC 0781-5792-50),New,2/26/20,,Sandoz Inc. has made a business decision to discontinue Levofloxacin Tablets.,,,Anti-Infective,To be Discontinued,2/26/20,2/26/20,0781-5792-50,discontinued
3716,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (17.5 mL)(NDC 67457-600-20),New,6/25/19,,,,,Oncology,To be Discontinued,6/25/19,6/25/19,67457-600-20,discontinued
3717,Levoleucovorin Calcium Injection,Mylan Pharmaceuticals Inc.,10 mg/1 mL (25 mL)(NDC 67457-601-30),New,6/25/19,,,,,Oncology,To be Discontinued,6/25/19,6/25/19,67457-601-30,discontinued
3718,Levoleucovorin Calcium Injection,Teva Pharmaceuticals,10 mg/ml (NDC 45963-762-57),New,5/20/20,,Teva made a business decision to discontinue the manufacturing of this product.,,,Oncology,To be Discontinued,5/20/20,5/20/20,45963-762-57,discontinued
3719,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-26,discontinued
3720,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-30,discontinued
3721,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,9/23/20,Available,,,,Cardiovascular,Current,,,0338-0409-03,available
3722,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,9/23/20,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
3723,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Revised,9/10/20,Product available,,,Other,Cardiovascular,Current,,,00264-9598-20,available
3724,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Revised,9/10/20,Product available,,,Other,Cardiovascular,Current,,,00264-9594-20,available
3725,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Revised,9/10/20,Product available,,,Other,Cardiovascular,Current,,,00264-9594-10,available
3726,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,available
3727,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,11/20/20,Available,Next shipment expected Jan. 2020,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,available
3728,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,available
3729,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-161-02,available
3730,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-162-05,available
3731,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,11/20/20,Currently on backorder - next shipment anticipated mid Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-163-30,not available
3732,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-164-02,available
3733,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-165-05,available
3734,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,11/20/20,Next Delivery and Estimated Recovery: August 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-9137-05,not available
3735,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1.5%; 20mL Sterile Pack Amp (NDC 0409-4056-01),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,0409-4056-01,discontinued
3736,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4713-32,available
3737,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4276-01,available
3738,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4279-02,available
3739,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4276-02,available
3740,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",1%; 30 mL Sterile Pack vial (NDC 0409-4270-01),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,0409-4270-01,discontinued
3741,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4282-01,available
3742,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4282-02,available
3743,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4904-34,limited availability
3744,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: May 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4903-34,limited availability
3745,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-2066-05,available
3746,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4277-01,available
3747,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4277-02,available
3748,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4283-01,available
3749,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,11/20/20,Next Delivery and Estimated Recovery: July 2021,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-1323-05,not available
3750,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverified,10/30/20,Available,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,76329-3390-1,available
3751,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,7/8/20,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00517-0625-25,discontinued
3752,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-97,available
3753,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,11/16/20,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-91,not available
3754,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0202-02,available
3755,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0208-05,available
3756,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-17,available
3757,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-27,available
3758,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-57,available
3759,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-10,not available
3760,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-20,not available
3761,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-50,not available
3762,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-27,available
3763,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-07,available
3764,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0496-97,available
3765,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,11/20/20,Next Delivery: January 2021; Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4275-01,not available
3766,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (50 mg/mL); Glass Ampul (NDC 0409-4712-01),Revised,11/20/20,Next Delivery: September 2022; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4712-01,not available
3767,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4278-01,available
3768,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-31,not available
3769,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,11/16/20,Not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0484-57,not available
3770,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0491-57,available
3771,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-02,available
3772,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-10,available
3773,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-27,available
3774,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,11/16/20,Backordered. Next release December 2019.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-57,not available
3775,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-27,available
3776,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-80,not available
3777,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,11/16/20,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-89,not available
3778,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-57,available
3779,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,11/16/20,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-37,available
3780,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4713-02,not available
3781,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4776-01,available
3782,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-251-10,available
3783,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,11/20/20,Currently on backorder - next shipment anticipated in Jan 21,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-252-20,not available
3784,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,11/20/20,Currently on backorder,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,55150-254-10,not available
3785,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,11/20/20,Currently on backorder - next shipment anticipated in Jan 21,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-255-20,not available
3786,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Reverified,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9595-25,available
3787,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9594-25,available
3788,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9577-10,available
3789,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9575-10,available
3790,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/18,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,65282-1605-1,available
3791,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% MDV 1000mg/50mL (NDC 55150-025-650),New,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-025-650,available
3792,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-0996-01,discontinued
3793,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,00409-3177-01,available
3794,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3178-01,limited availability
3795,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,00409-3178-02,limited availability
3796,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3178-03,available
3797,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-1209-01,available
3798,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,11/20/20,Limited Supply Available.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3181-01,limited availability
3799,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3182-01,available
3800,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3182-02,available
3801,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3182-03,available
3802,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,11/20/20,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-3183-01,available
3803,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-7263-01,discontinued
3804,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,11/16/20,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0482-17,not available
3805,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,11/16/20,Backordered. Next release December 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0487-17,not available
3806,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,11/16/20,Available,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0488-17,available
3807,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,11/16/20,Backorered. Next release December 2020.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0489-17,not available
3808,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3611-01,discontinued
3809,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3612-01,discontinued
3810,Lisinopril (Prinivil) Tablets,Merck Sharp & Dohme Corp.,"5-mg tablets, unit-of-use bottle/90 (NDC 0006-0019-54)",New,3/11/19,,To be discontinued on or near April 2019.,,,Cardiovascular,To be Discontinued,3/11/19,,0006-0019-54,discontinued
3811,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/18,4/11/18,0378-2072-01,discontinued
3812,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (ndc 0054-3527-63),Revised,5/18/20,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,,not available
3813,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,11/20/20,Next Delivery and Estimated Recovery: January 2021,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-1539-31,not available
3814,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,11/20/20,Available,,,,Neurology,Current,,,00409-1985-30,available
3815,"Lorazepam Injection, USP","Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,11/20/20,Available,,,Other,Neurology,Current,,,00409-6778-02,available
3816,"Lorazepam Injection, USP","Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,11/20/20,Next Delivery and Estimated Recovery: February 2023,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-6779-02,not available
3817,"Lorazepam Injection, USP","Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,11/20/20,Next Delivery and Estimated Recovery: February 2023,Shortage per manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-6780-02,not available
3818,"Lorazepam Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,10/30/20,Available,,,Other,Neurology,Current,,,76329-8261-1,available
3819,"Lorazepam Injection, USP",Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Revised,12/2/19,Available,,,Demand increase for the drug,Neurology,Current,,,17478-040-01,available
3820,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6001-25,available
3821,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Revised,7/22/20,This presentation is temporarily on backorder,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6000-10,not available
3822,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6003-25,available
3823,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
3824,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6044-25,available
3825,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6046-10,not available
3826,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6045-25,available
3827,"Lorazepam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
3828,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1394-10,discontinued
3829,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1395-10,discontinued
3830,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1396-10,discontinued
3831,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1397-10,discontinued
3832,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,11/12/20,Allocating Inventory. Additional lots are scheduled for release in the January timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,0527-1394-01,limited availability
3833,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",Revised,11/12/20,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1394-10,not available
3834,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,11/12/20,Allocating Inventory. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,0527-1395-01,limited availability
3835,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",Revised,11/12/20,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1395-10,not available
3836,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,11/12/20,Unavailable. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,0527-1396-01,limited availability
3837,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",Revised,11/12/20,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1396-10,not available
3838,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,11/12/20,Allocating Inventory. Additional lots are scheduled for release in the December timeframe. Product will be made available as it is released (allocating inventory).,Manufacturing capacity constraint,,Other,Psychiatry,Current,,,0527-1397-01,limited availability
3839,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",Revised,11/12/20,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1397-10,not available
3840,Loxapine Capsules,Mylan,"5 mg, 100 count bottle (NDC 0378-7005-01)",Reverified,11/9/20,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,0378-7005-01,not available
3841,Loxapine Capsules,Mylan,"10 mg, 100 count bottle (NDC 0378-7010-01)",Reverified,11/9/20,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,0378-7010-01,not available
3842,Loxapine Capsules,Mylan,"25 mg, 100 count bottle (NDC 0378-7025-01)",Reverified,11/9/20,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,0378-7025-01,not available
3843,Loxapine Capsules,Mylan,"50 mg, 100 count bottle (NDC 0378-7050-01)",Reverified,11/9/20,Unavailable. Re-supply TBD.,,,Other,Psychiatry,Current,,,0378-7050-01,not available
3844,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Reverified,11/19/20,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,0591-0369-01,not available
3845,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Reverified,11/19/20,Available,,,,Psychiatry,Current,,,0591-0370-01,available
3846,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Reverified,11/19/20,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,0591-0371-01,not available
3847,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Reverified,11/19/20,"On backorder, (recovery expected Jan 2021)",Cannot support additional business currently.,,Other,Psychiatry,Current,,,0591-0372-01,not available
3848,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-01,discontinued
3849,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-10,discontinued
3850,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-01,discontinued
3851,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-10,discontinued
3852,"Medroxyprogesterone Acetate (Depo-Provera) Injection, Suspension",Pfizer Pharmaceuticals,"400 mg/mL, 1 carton containing one 2.5 mL vial (NDC 0009-0626-01)",New,10/27/20,,Discontinuation of the manufacturing of the drug.,,,Reproductive,To be Discontinued,10/27/20,10/27/20,0009-0626-01,discontinued
3853,Medroxyprogesterone Acetate (Provera) Tablet,Pfizer Pharmaceuticals,"10 mg, bottles of 500 (NDC 0009-0050-11)",New,2/12/20,,Discontinuation of the manufacture of the drug.,,,Reproductive,To be Discontinued,2/12/20,2/12/20,0009-0050-11,discontinued
3854,Megestrol Acetate (Megace) Oral Suspension,"Endo Pharmaceuticals, Inc.",MEGACE®ES 625mg/5ml Suspension (NDC 63481-160-38),New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,8/21/19,8/21/19,63481-160-38,discontinued
3855,Megestrol Acetate (Megace) Oral Suspension,Bristol Myers Squibb Co.,40 mg/mL Oral Suspension (NDC 00015-508-42),New,5/6/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/6/19,5/6/19,00015-508-42,discontinued
3856,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/20,,"Additional products remain available:   
NDC 58914-501-56 (30 suppositories in 1 box); NDC 58914-501-33 (3 suppositories in 1 box); NDC 59762-0118-3",,,Gastroenterology,To be Discontinued,7/30/20,7/30/20,58914-501-42,discontinued
3857,Mesna Injection,Teva Pharmaceuticals,100 mg/mL (NDC 0703-4805-03),New,6/21/19,,This product discontinuation is a business related decision.,,,Oncology,To be Discontinued,6/21/19,6/21/19,0703-4805-03,discontinued
3858,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"10mg, 100 count (NDC 49884-0258-01)",New,7/12/19,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/19,7/12/19,49884-0258-01,discontinued
3859,"Metaproterenol Sulfate Tablets, USP",Par Pharmaceutical,"20mg, 100 count (NDC 49884-0259-01)",New,7/12/19,,Business decision to discontinue marketing in the US.,,,Pulmonary/Allergy,To be Discontinued,7/12/19,7/12/19,49884-0259-01,discontinued
3860,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 750 mg per tablet, (NDC 0093-7212-01), 100 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7212-01,discontinued
3861,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-01), 100 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7267-01,discontinued
3862,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,"Metformin Hydrochloride Tablet Extended Release, 500 mg per tablet, (NDC 0093-7267-10), 1000 count per bottle",New,7/22/19,,Teva made a business decision to discontinue the drug product.,,,Endocrinology/Metabolism,To be Discontinued,7/22/19,7/22/19,0093-7267-10,discontinued
3863,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/20,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/20,6/24/20,2037-577-10,discontinued
3864,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/20,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/20,6/24/20,62037-571-01,discontinued
3865,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 100 (NDC 42806-213-01)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-213-01,discontinued
3866,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 500 (NDC 42806-213-05)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-213-05,discontinued
3867,Metformin Hydrochloride Tablets,Sandoz,"500 mg, bottle count 1000 (NDC 42806-213-10)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-213-10,discontinued
3868,Metformin Hydrochloride Tablets,Sandoz,"850 mg, bottle count 100 (NDC 42806-215-01)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-215-01,discontinued
3869,Metformin Hydrochloride Tablets,Sandoz,"850 mg, bottle count 500 (NDC 42806-215-05)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-215-05,discontinued
3870,Metformin Hydrochloride Tablets,Sandoz,"1000 mg, bottle count 500 (NDC 42806-221-05)",New,4/15/20,,Business decision to discontinue.,,,Endocrinology/Metabolism,To be Discontinued,4/15/20,4/15/20,42806-221-05,discontinued
3871,Methadone Hydrochloride Injection,Mylan Institutional,Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Reverified,11/10/20,Available,Short dated inventory,,Other,Analgesia/Addiction;Anesthesia,Current,,,67457-217-20,available
3872,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,2/18/20,Backordered. Estimated recovery March 2020,,,Other,Analgesia/Addiction;Anesthesia,Current,,,17478-380-20,not available
3873,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.","Robaxin® 500mg, 100 Tablets (NDC 52244-429-10)",New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction;Musculoskeletal,To be Discontinued,8/21/19,8/21/19,52244-429-10,discontinued
3874,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.",750 mg tablets (NDC 52244-449-10),New,10/27/20,,,,,Analgesia/Addiction,To be Discontinued,10/27/20,10/27/20,52244-449-10,discontinued
3875,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","500 mg, 100 ct (NDC 69584-611-10); 500 ct (NDC 69584-611-50); 1000 ct (NDC 69584-611-90)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,69584-611-10,
3876,Methocarbamol Tablets,"Oxford Pharmaceuticals, LLC","750 mg, 100 ct (NDC 69584-612-10); 500 ct (NDC 69584-612-50); 1000 ct (NDC 69584-612-90)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,69584-612-10,
3877,Methocarbamol Tablets,"Solco Healthcare US, LLC","500 mg, 100 ct (NDC 43547-0405-10); 500 ct (NDC 43547-0405-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,43547-0405-10,
3878,Methocarbamol Tablets,"Solco Healthcare US, LLC","750 mg, 100 ct (NDC 43547-0226-10); 500 ct (NDC 43547-0226-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,43547-0226-10,
3879,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 70010-754-01); 500 ct (NDC 70010-754-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,70010-754-01,
3880,Methocarbamol Tablets,Granules Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 70010-770-01); 500 ct (NDC 70010-770-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,70010-770-01,
3881,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 500 mg, 100 ct (NDC 60429-118-01); 500 ct (NDC 60429-118-05) Distributed by Virus Pharmaceuticals: 500 mg, 100 ct (NDC 69543-134-10); 500 ct (NDC 69543-134-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,60429-118-01,
3882,Methocarbamol Tablets,"AustarPharma, LLC","Distributed by Golden State Medical Supply, Inc.: 750 mg, 100 ct (NDC 60429-119-01); 500 ct (NDC 60429-119-05) Distributed by Virtus Pharmaceuticals: 750 mg, 100 ct (NDC 69543-135-10); 500 ct (NDC 69543-135-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,60429-119-01,
3883,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"500 mg, 100 ct (NDC 31722-533-01); 500 ct (NDC 31722-533-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,31722-533-01,
3884,Methocarbamol Tablets,Camber Pharmaceuticals Inc.,"750 mg, 100 ct (NDC 31722-534-01); 500 ct (NDC 31722-534-05)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,31722-534-01,
3885,Methocarbamol Tablets,Bayshore Pharmaceuticals,"500 mg, 100 ct (NDC 76385-123-01); 500 ct (NDC 76385-123-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,76385-123-01,
3886,Methocarbamol Tablets,Bayshore Pharmaceuticals,"750 mg, 100 ct (NDC 76385-124-01); 500 ct (NDC 76385-124-50)",Revised,12/13/19,,,,,Analgesia/Addiction,Resolved,12/13/19,,76385-124-01,
3887,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 2 mL vial (NDC 0143-9519-10)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,0143-9519-10,
3888,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML (NDC 00703-3678-01),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3678-01,
3889,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X40ML Premier label  (NDC 00703-3678-81),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3678-81,
3890,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML 1X10ML (NDC 00703-3675-01),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3675-01,
3891,Methotrexate Sodium Injection,Teva Pharmaceuticals,25MG/ML SDV 10X2ML (NDC 00703-3671-03),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,00703-3671-03,
3892,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","1 gram per vial, 50 mL vial, SDV (NDC 63323-122-50)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,63323-122-50,
3893,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","250 mg per 10 mL, vial (NDC 63323-123-10)",Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,63323-123-10,
3894,Methotrexate Sodium Injection,"Hospira, Inc.",50 mg/2 mL (25 mg/mL); Glass Fliptop Vial (NDC 61703-0350-38),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,61703-0350-38,
3895,Methotrexate Sodium Injection,"Hospira, Inc.",1 g/40 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 61703-0408-41),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,61703-0408-41,
3896,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 2mL (NDC 16729-277-30),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-30,
3897,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 40 mL (NDC 16729-277-35),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-35,
3898,Methotrexate Sodium Injection,Accord Healthcare Inc.,25 mg/mL; 10 mL (NDC 16729-277-03),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,16729-277-03,
3899,Methotrexate Sodium Injection,Mylan Institutional,1000 mg/40 mL (NDC 67457-480-40),Revised,12/17/19,,,,,Oncology,Resolved,12/17/19,,67457-480-40,
3900,Methotrexate Sodium Injection,Mylan,"250 mg in 10 mL (25 mg/mL), single dose vial (NDC 67457-466-10)",Revised,3/3/20,,Expected Discontinuation March 2020,,,Dermatology;Oncology;Pediatric;Rheumatology,To be Discontinued,12/16/19,12/16/19,67457-466-10,discontinued
3901,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 36 count (NDC 67253-320-36)",New,9/13/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/19,9/13/19,67253-320-36,discontinued
3902,"Methotrexate Tablets, USP","Endo Pharmaceuticals, Inc.","Methotrexate Sodium 2.5 mg Tablet, 100 count (NDC 67253-320-10)",New,9/13/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Dermatology;Oncology;Rheumatology,To be Discontinued,9/13/19,9/13/19,67253-320-10,discontinued
3903,Methscopolamine Bromide Tablets,Par Pharmaceutical,"5 mg tablets, bottle of 60 (NDC 64376-604-61)",New,1/27/20,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,1/27/20,1/27/20,64376-604-61,discontinued
3904,Methscopolamine Bromide Tablets,Par Pharmaceutical,"2.5 mg tablets, bottle of 100 (NDC 64376-603-01)",New,1/27/20,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,1/27/20,1/27/20,64376-603-01,discontinued
3905,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"2.5 mg, 100 count (NDC  64376-603-01)",New,7/18/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/19,7/18/19,64376-603-01,discontinued
3906,"Methscopolamine Bromide, Tablets, USP",Par Pharmaceutical,"5 mg, 60 count (NDC 64376-604-61)",New,7/18/19,,Par has made a business decision to permanently discontinue the drug product.,,,Gastroenterology,To be Discontinued,7/18/19,7/18/19,64376-604-61,discontinued
3907,Methyclothiazide Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-0160-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0160-01,discontinued
3908,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-05),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2932-05,discontinued
3909,Methyldopa Tablets,Teva Pharmaceuticals,500 mg/1 unit (NDC 0093-2932-01),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2932-01,discontinued
3910,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-10),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2931-10,discontinued
3911,Methyldopa Tablets,Teva Pharmaceuticals,250 mg/1 unit (NDC 0093-2931-01),New,6/10/19,,"The discontinuation of these products is a business decision and not related to product quality, safety or efficacy.",,,Cardiovascular,To be Discontinued,6/10/19,6/10/19,0093-2931-01,discontinued
3912,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
3913,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
3914,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
3915,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Reverified,12/13/19,Limited availability; Estimated shortage until March 2020,,,API procurement delay,Cardiovascular,Current,,,,limited availability
3916,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,250 mg (NDC 0378-0611-01),Reverified,11/10/20,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,0378-0611-01,not available
3917,Methyldopa Tablets,Mylan Pharmaceuticals Inc.,500 mg (NDC 0378-0421-01),Reverified,11/10/20,Unavailable. Estimated recovery TBD.,,,Other,Cardiovascular,Current,,,0378-0421-01,not available
3918,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",300 mg/60 mL (NDC 24478-321-02),Revised,10/7/20,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/20,,24478-321-02,
3919,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",600 mg/120mL (NDC 24478-322-04),Revised,10/7/20,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/20,,24478-322-04,
3920,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",750 mg/150 mL (NDC 24478-323-05),Revised,10/7/20,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/20,,24478-323-05,
3921,Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension,"Tris Pharma, Inc.",900 mg/180 mL (NDC 24478-324-06),Revised,10/7/20,,"Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product",,,Pediatric;Psychiatry,Resolved,10/7/20,,24478-324-06,
3922,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,36 mg 30 count (NDC 0591-2717-30),New,5/17/19,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-2717-30,discontinued
3923,"Methylphenidate Hydrochloride Extended-Release Tablets, USP CII",Teva Pharmaceuticals,54 mg 30 count (NDC 0591-2718-30),New,5/17/19,,Teva made a business related decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-2718-30,discontinued
3924,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,5 mg 100 count (NDC 0591-5882-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5882-01,discontinued
3925,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,10 mg 100 count (NDC 0591-5883-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5883-01,discontinued
3926,"Methylphenidate Hydrochloride Tablets, USP CII",Teva Pharmaceuticals,20 mg 100 count (NDC 0591-5884-01),New,5/17/19,,Teva made a business decision to discontinue the product.,,,Pediatric;Psychiatry,To be Discontinued,5/17/19,5/17/19,0591-5884-01,discontinued
3927,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0591-0790-01,discontinued
3928,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg  (NDC 0591-0790-21),New,8/17/20,,,,,Rheumatology,To be Discontinued,8/17/20,8/17/20,0591-0790-21,discontinued
3929,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,23155-240-41,
3930,"Metoclopramide Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3414-01),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,00409-3414-01,
3931,"Metoclopramide Injection, USP","Fresenius Kabi USA, LLC","10 mg per 2 mL, single use, prefilled syringe (NDC 76045-101-20)",Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,76045-101-20,
3932,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-04),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,0703-4502-04,
3933,"Metoclopramide Injection, USP",Teva Pharmaceuticals,5 mg/ 1 ml (NDC 0703-4502-84),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,0703-4502-84,
3934,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,5 mg per 5 mL Single Dose Vial (NDC 47781-587-17),Reverified,10/27/20,Available,Distributed by Alvogen Inc. (Company Contact Information:  973-532-7840),,Available,Cardiovascular,Current,,,47781-587-17,available
3935,"Metoprolol Tartrate Injection, USP",Baxter Healthcare,1 mg/mL - 5 mL Sterile Single Use Glass Vial (10 x 5 mL). For Intravenous Use (NDC 36000-033-10),Reverified,9/23/20,Available,,,,Cardiovascular,Current,,,36000-033-10,available
3936,"Metoprolol Tartrate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 5 mL, SDV, PF (NDC 63323-660-05)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delays,Cardiovascular,Current,,,63323-660-05,available
3937,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1mg/mL – 10mL vials, (NDC 0143-9660-10)",Reverified,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9660-10,available
3938,"Metoprolol Tartrate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1mg/mL – 5ml vials (NDC 0143-9873-25),Reverified,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9873-25,available
3939,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1778-05),Reverified,11/20/20,Available,,,Other,Cardiovascular,Current,,,00409-1778-05,available
3940,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1778-35),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,00409-1778-35,discontinued
3941,"Metoprolol Tartrate Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL); Glass Ampul (NDC 00409-2285-05),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,00409-2285-05,discontinued
3942,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,"1 mg/mL, 5 mL vial (NDC 72266-122-25)",Reverified,10/27/20,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Cardiovascular,Current,,,72266-122-25,available
3943,"Metoprolol Tartrate Injection, USP",Gland Pharma Limited,1 mg/mL 5mL vial (NDC 70860-300-05 and 70860-300-41),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Cardiovascular,Current,,,70860-300-05,available
3944,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
3945,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
3946,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 100 bottle (NDC 0025-1831-31),New,10/20/20,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/20,10/20/20,0025-1831-31,discontinued
3947,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 50 bottle (NDC 0025-1831-50),New,10/20/20,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/20,10/20/20,0025-1831-50,discontinued
3948,"Metronidazole Injection, USP",Baxter Healthcare,"Metronidazole Injection, USP, 500 mg/100 mL, in VIAFLEX Plus Container (NDC 0338-1055-48)",Reverified,9/23/20,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
3949,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-24),Reverified,11/20/20,Available,,,Other,Anti-Infective,Current,,,00409-7811-24,available
3950,"Metronidazole Injection, USP","Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 00409-7811-37),Reverified,11/20/20,Available,,,Other,Anti-Infective,Current,,,00409-7811-37,available
3951,"Metronidazole Injection, USP",B. Braun Medical Inc.,Metronidazole Injection 500mg (5mg/mL) 100mL D5353-5224 (NDC 0264-5535-32),Reverified,9/8/20,Product available for contracted  customers,,,Manufacturing interruptions and demand increase,Anti-Infective,Current,,,0264-5535-32,limited availability
3952,"Midazolam Injection, USP",Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),New,4/2/20,Limited supply. On allocation for 2020.,Cannot supply market demand.,,Other,Anesthesia;Neurology,Current,,,17478-0524-10,limited availability
3953,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-10,available
3954,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0001-20,available
3955,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-12,available
3956,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-25,available
3957,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-25,available
3958,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-10,available
3959,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0002-10,available
3960,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Revised,11/16/20,8 month dating (expiry 7/31/2021) available by request.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-02,limited availability
3961,"Midazolam Injection, USP","Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-05,available
3962,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Revised,10/23/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6056-10,available
3963,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Revised,10/23/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6057-25,available
3964,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Revised,10/23/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,0641-6059-25,available
3965,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Revised,10/23/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6061-25,available
3966,"Midazolam Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Revised,10/23/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6060-10,available
3967,"Midazolam Injection, USP","Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,11/20/20,Available,,,,Anesthesia;Neurology,Current,,,00409-2305-17,available
3968,"Midazolam Injection, USP","Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,11/20/20,Available,,,,Anesthesia;Neurology,Current,,,00409-2305-05,available
3969,"Midazolam Injection, USP","Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,11/20/20,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2308-01,available
3970,"Midazolam Injection, USP","Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,11/20/20,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2596-05,available
3971,"Midazolam Injection, USP","Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,11/20/20,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2308-02,available
3972,"Midazolam Injection, USP","Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,11/20/20,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2596-03,available
3973,"Midazolam Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,11/20/20,Available,,,,Anesthesia;Neurology,Current,,,00409-2587-05,available
3974,"Midazolam Injection, USP","Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,11/20/20,Next delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,00409-2306-62,not available
3975,"Midazolam Injection, USP","Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,11/20/20,Next delivery and Estimated Recovery: June 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,00409-2307-60,not available
3976,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Revised,11/6/20,On backorder – increase demand due to Covid-19; resupply date end of November 2020,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,23155-601-42,not available
3977,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Revised,11/6/20,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,23155-601-41,available
3978,"Midazolam Injection, USP",Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Revised,11/6/20,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,23155-600-41,available
3979,"Midazolam Injection, USP",Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Revised,10/27/20,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-10,available
3980,"Midazolam Injection, USP",Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Revised,10/27/20,No stock available. Resupply December 2020,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-05,not available
3981,"Midazolam Injection, USP",Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Revised,10/27/20,"No stock available, Resupply July 2020",Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-17,not available
3982,"Midazolam Injection, USP",Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Revised,10/27/20,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-91,available
3983,"Midazolam Injection, USP",Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Revised,10/27/20,"No stock available, Resupply December 2020","Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-600-02,not available
3984,"Midazolam Injection, USP",Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Revised,10/27/20,Stock available. Additional resupply June 2020,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-588-68,available
3985,Miglitol Tablets,"Hospira, Inc.",25 mg (NDC 0009-5012-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5012-01,discontinued
3986,Miglitol Tablets,"Hospira, Inc.",50 mg (NDC 0009-5013-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5013-01,discontinued
3987,Miglitol Tablets,"Hospira, Inc.",100 mg (NDC 0009-5014-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5014-01,discontinued
3988,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,55 mg 30 count (NDC 00093-7741-56),New,3/24/20,,Estimated Inventory Depletion: June 2020,,,Anti-Infective,To be Discontinued,3/24/20,3/24/20,00093-7741-56,discontinued
3989,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,115 mg 30 count (NDC 00093-2133-56),New,3/24/20,,Estimated Inventory Depletion: April 2020,,,Anti-Infective,To be Discontinued,3/24/20,3/24/20,00093-2133-56,discontinued
3990,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,65 mg 30 count (NDC 00093-2134-56),New,3/24/20,,Estimated Inventory Depletion: May 2020,,,Anti-Infective,To be Discontinued,3/24/20,3/24/20,00093-2134-56,discontinued
3991,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,105 mg 30 count (NDC 00093-7743-56),New,3/24/20,,No Inventory Remains,,,Anti-Infective,To be Discontinued,3/24/20,3/24/20,00093-7743-56,discontinued
3992,"Minocycline Hydrochloride Extended-Release Tablets, USP",Teva Pharmaceuticals,80 mg 30 count (NDC 00093-7742-56),New,3/24/20,,No Inventory Remains,,,Anti-Infective,To be Discontinued,3/24/20,3/24/20,00093-7742-56,discontinued
3993,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2469-15,discontinued
3994,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2470-15,discontinued
3995,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2471-15,discontinued
3996,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0093-7206-56),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0093-7206-56,discontinued
3997,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 30 count bottle (NDC 0591-1117-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1117-30,discontinued
3998,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,15 mg 1000 count bottle (NDC 0591-1117-10),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1117-10,discontinued
3999,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0093-7207-56),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0093-7207-56,discontinued
4000,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 30 count bottle (NDC 0591-1118-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1118-30,discontinued
4001,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,30 mg 1000 count bottle (NDC 0591-1118-10),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1118-10,discontinued
4002,"Mirtazapine Tablets, USP",Teva Pharmaceuticals,45 mg 30 count bottle (NDC 0591-1119-30),New,5/2/19,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To be Discontinued,5/2/19,5/2/19,0591-1119-30,discontinued
4003,Misoprostol Tablets,Teva Pharmaceuticals,"100 mcg, 120 count (NDC 0172-4430-59)",New,8/11/20,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/20,8/11/20,0172-4430-59,discontinued
4004,Misoprostol Tablets,Teva Pharmaceuticals,"100 mcg, 60 count (NDC 0172-4430-49)",New,8/11/20,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/20,8/11/20,0172-4430-49,discontinued
4005,Misoprostol Tablets,Teva Pharmaceuticals,"200 mcg, 100 count (NDC 0172-4431-60)",New,8/11/20,,Business decision to discontinue. The product has been unavailable since May 2011.,,,Gastroenterology,To be Discontinued,8/11/20,8/11/20,0172-4431-60,discontinued
4006,Modafinil Tablets,Par Pharmaceutical,"100 mg, bottle of 30 (NDC 49884-534-11)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/19/19,4/19/19,49884-534-11,discontinued
4007,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 15 gram tube  (NDC 0085-3149-01),New,7/29/19,,,,,Dermatology,To be Discontinued,7/29/19,7/29/19,0085-3149-01,discontinued
4008,Mometasone Furoate (Elocon) Topical Cream,Merck Sharp & Dohme Corp.,0.1% 50 gram tube  (NDC 0085-3149-03),New,7/29/19,,,,,Dermatology,To be Discontinued,7/29/19,7/29/19,0085-3149-03,discontinued
4009,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
4010,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
4011,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
4012,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/18,3/20/18,0378-5201-93,discontinued
4013,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,20 mg/0.8 mg; 30 capsules per bottle (NDC 60793-430-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-430-20,discontinued
4014,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,30 mg/1.2 mg; 30 capsules per bottle (NDC 60793-431-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-431-20,discontinued
4015,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,50 mg/2 mg; 30 capsules per bottle (NDC 60793-433-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-433-20,discontinued
4016,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,60 mg/2.4 mg; 30 capsules per bottle (NDC 60793-434-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-434-20,discontinued
4017,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,80 mg/3.2 mg; 30 capsules per bottle (NDC 60793-435-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-435-20,discontinued
4018,Morphine Sulfate and Naltrexone Hydrochloride (EMBEDA®) Extended-Release Capsules,Pfizer Pharmaceuticals,100 mg/4 mg; 30 capsules per bottle (NDC 60793-437-20),New,10/7/19,,Stop sale date 15Nov2019.  Anticipated unavailability of product is early 2020.,,,Analgesia/Addiction,To be Discontinued,10/7/19,10/7/19,60793-437-20,discontinued
4019,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"15 mg, bottle of 100 (NDC 60951-652-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-652-70,discontinued
4020,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"30 mg, bottle of 100 (NDC 60951-653-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-653-70,discontinued
4021,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"60 mg, bottle of 100 (NDC 60951-655-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-655-70,discontinued
4022,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"100 mg, bottle of 100 (NDC 60951-658-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-658-70,discontinued
4023,Morphine Sulfate Extended-Release Tablets,Par Pharmaceutical,"200 mg, bottle of 100 (NDC 60951-659-70)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Analgesia/Addiction,To be Discontinued,4/19/19,4/19/19,60951-659-70,discontinued
4024,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2658-01,discontinued
4025,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2659-01,discontinued
4026,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2660-01,discontinued
4027,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2661-01,discontinued
4028,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2662-01,discontinued
4029,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-452-01,available
4030,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-454-01,available
4031,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-455-01,available
4032,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,11/16/20,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-458-01,not available
4033,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,11/16/20,Backordered. Next release December 2020.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-451-01,not available
4034,"Morphine Sulfate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS (NDC 76329-1911-1),Reverified,10/30/20,Available,,,,Analgesia/Addiction,Current,,,76329-1911-1,available
4035,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6125-25,available
4036,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,available
4037,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6127-25,available
4038,"Morphine Sulfate Injection, USP","Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1135-02,discontinued
4039,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1890-01,available
4040,"Morphine Sulfate Injection, USP","Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1890-11,discontinued
4041,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1891-01,available
4042,"Morphine Sulfate Injection, USP","Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1891-11,discontinued
4043,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1892-01,available
4044,"Morphine Sulfate Injection, USP","Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1892-11,discontinued
4045,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1893-01,available
4046,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1893-11,discontinued
4047,"Morphine Sulfate Injection, USP","Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-3814-12,available
4048,"Morphine Sulfate Injection, USP","Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-3815-12,available
4049,"Morphine Sulfate Injection, USP","Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1134-03,available
4050,"Morphine Sulfate Injection, USP","Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,11/20/20,Available,,,Other,Analgesia/Addiction,Current,,,00409-1134-05,available
4051,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-004-10,available
4052,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-005-10,available
4053,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-006-10,available
4054,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syring (NDC 76045-007-10)",Revised,11/16/20,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-007-10,not available
4055,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,11/16/20,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-008-10,not available
4056,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",1mg/mL 30mL PCA glass vial (NDC 0409-2029-02),Revised,4/30/20,,,,,Analgesia/Addiction,To be Discontinued,4/30/20,4/30/20,0409-2029-02,discontinued
4057,"Morphine Sulfate Injection, USP","ICU Medical, Inc.",5mg/mL 30mL PCA GLASS VIAL (CII)(NDC 0409-6028-04),New,10/2/19,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,10/2/19,10/2/19,0409-6028-04,discontinued
4058,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,7/22/20,This presentation is temporarily on backorder .,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6019-10,not available
4059,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,7/22/20,This presentation is temporarily on backorder .,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6020-10,not available
4060,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6039-01,available
4061,"Morphine Sulfate Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6040-01,available
4062,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-11)",Revised,10/8/20,Backordered. Next release October 2020.,Check wholesalers for inventory,,Other,Analgesia/Addiction,Current,,,76045-004-11,not available
4063,"Morphine Sulfate Injection, USP","Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-11)",Revised,10/8/20,Availble,Check wholesalers for inventory,,Available,Analgesia/Addiction,Current,,,76045-004-11,available
4064,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,11/20/20,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0434-82,not available
4065,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,11/20/20,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0422-83,not available
4066,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,11/20/20,Next Delivery and Estimated Recovery: September 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0421-53,not available
4067,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,9/23/20,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5646-1,available
4068,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,9/23/20,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5649-1,available
4069,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,9/23/20,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5650-2,available
4070,Multi-Vitamin Infusion (Adult and Pediatric),Baxter Healthcare,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,9/23/20,Available,"For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition.",,,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5647-0,available
4071,Mupirocin Calcium Nasal Ointment,GlaxoSmithKline,2% Nasal Ointment 1 gram tube Package of 10 (NDC 0029152611),Revised,12/13/19,,,,,Anti-Infective,To be Discontinued,12/13/19,12/13/19,0029152611,discontinued
4072,Mycophenolic Acid Delayed Release Tablets,Teva Pharmaceuticals,180mg tablets (NDC 0093-7031-89),New,3/11/20,,,,,Transplant,To be Discontinued,3/11/20,3/11/20,0093-7031-89,discontinued
4073,Mycophenolic Acid Delayed Release Tablets,Teva Pharmaceuticals,360mg tablets (NDC 0093-7032-89),New,3/11/20,,,,,Transplant,To be Discontinued,3/11/20,3/11/20,0093-7032-89,discontinued
4074,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (100 ct) (NDC 50742-178-01),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-178-01,discontinued
4075,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (1000 ct) (NDC 50742-178-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-178-10,discontinued
4076,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (100 ct) (NDC 50742-179-01 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-179-01,discontinued
4077,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (1000 ct) (NDC 50742-179-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-179-10,discontinued
4078,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (100 ct) (NDC 50742-180-01 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-180-01,discontinued
4079,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (1000 ct) (NDC 50742-180-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-180-10,discontinued
4080,Nadolol Tablets,Teva Pharmaceuticals,"20 mg, 100 count (NDC 0591-2694-01)",New,8/11/20,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/20,8/11/20,0591-2694-01,discontinued
4081,Nadolol Tablets,Teva Pharmaceuticals,"40 mg, 100 count (NDC 0591-2697-01)",New,8/11/20,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/20,8/11/20,0591-2697-01,discontinued
4082,Nadolol Tablets,Teva Pharmaceuticals,"80 mg, 100 count (NDC 0591-2685-01)",New,8/11/20,,Business decision to discontinue. The 20 mg and 80 mg tablets have been unavailable since Mar 2016 and the 40 mg tablets have been unavailable since Dec 2015,,,Cardiovascular,To be Discontinued,8/11/20,8/11/20,0591-2685-01,discontinued
4083,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3124-95,discontinued
4084,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3125-95,discontinued
4085,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3126-95,discontinued
4086,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9124-95,discontinued
4087,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9224-92,discontinued
4088,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9225-92,discontinued
4089,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3128-92,discontinued
4090,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3129-92,discontinued
4091,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 60 gm (NDC 40085-201-60),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-201-60,discontinued
4092,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 1% 90 gm (NDC 40085-201-90),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-201-90,discontinued
4093,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 45 gm (NDC 40085-203-45),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-203-45,discontinued
4094,Naftifine Hydrochloride Cream,Mylan Pharmaceuticals Inc.,Naftifine HCl Cream 2% 60 gm (NDC 40085-203-60),New,5/15/19,,Discontinuation of the manufacture of the drug,,,Dermatology,To be Discontinued,5/15/19,5/15/19,40085-203-60,discontinued
4095,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,00409-1463-01,not available
4096,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,00409-1465-01,limited availability
4097,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: November 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,00409-1464-01,limited availability
4098,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage of an active ingredient,,Other,Analgesia/Addiction,Current,,,00409-1467-01,not available
4099,Naratriptan Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg  (NDC 0378-4450-59),New,7/17/19,,,,,Neurology,To be Discontinued,7/17/19,7/17/19,0378-4450-59,discontinued
4100,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Reverified,11/19/20,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,0093-7178-01,unclear
4101,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Reverified,11/19/20,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,0093-1024-06,unclear
4102,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Reverified,11/19/20,Availability is unknown at this time.,API availabliity,,Other,Psychiatry,Current,,,0093-7113-06,unclear
4103,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Reverified,11/19/20,Availablity is unknown at this time.,API availability,,Other,Psychiatry,Current,,,0093-1025-06,unclear
4104,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Reverified,11/19/20,Availability is unknown at this time.,API availability,,Other,Psychiatry,Current,,,0093-1026-06,unclear
4105,Nelarabine (Arranon) Injection,Novartis,250 mg/50 mL (NDC 0078-0683-06),Revised,1/7/20,,,,,Hematology,Resolved,1/7/20,,0078-0683-06,
4106,"Neomycin and Polymyxin B Sulfates Solution For Irrigation, USP",Teva Pharmaceuticals,"40 mg and 200,000 units (1 mL ampule) (NDC 0591-2190-45)",New,6/10/19,,Discontinuation of the manufacture of the drug.,,,Anti-Infective;Urology,To be Discontinued,6/10/19,6/10/19,0591-2190-45,discontinued
4107,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/18,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/18,2/5/18,65847-205-25,discontinued
4108,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/20,,,,,Antiviral,To be Discontinued,5/29/20,5/29/20,0597-0046-60,discontinued
4109,Nevirapine Extended Release Tablets,Sandoz,"400 mg, bottle of 30 tablets (NDC 0781-5893-31)",New,1/24/20,,,,,Antiviral,To be Discontinued,1/24/20,1/24/20,0781-5893-31,discontinued
4110,Nevirapine Extended Release Tablets,Sandoz,"400 mg, bottle of 500 tablets (NDC 0781-5893-05)",New,1/24/20,,,,,Antiviral,To be Discontinued,1/24/20,1/24/20,0781-5893-05,discontinued
4111,Nevirapine Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg tablets (NDC 0378-6950-77),New,1/31/19,,,,,Antiviral,To be Discontinued,1/31/19,1/31/19,0378-6950-77,discontinued
4112,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 500 count (NDC 45963-152-50)",New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/19,6/7/19,45963-152-50,discontinued
4113,"Nifedipine Extended-Release Tablet, USP",Teva Pharmaceuticals,"Nifedipine extended-release tablets, 90 mg, 100 count (NDC 45963-152-02)",New,6/7/19,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,6/7/19,6/7/19,45963-152-02,discontinued
4114,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 100 count bottle (NDC 10370-677-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-677-01,discontinued
4115,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"30mg, 500 count bottle (NDC 10370-677-05)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-677-05,discontinued
4116,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 100 count bottle (NDC 10370-678-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-678-01,discontinued
4117,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"60mg, 500 count bottle (NDC 10370-678-05)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-678-05,discontinued
4118,"Nifedipine Extended-Release Tablet, USP",Par Pharmaceutical,"90 mg, 100 count bottle (NDC 10370-679-01)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/15/19,4/15/19,10370-679-01,discontinued
4119,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"150 mg, 60 count bottle (NDC 0378-5150-91)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-5150-91,discontinued
4120,Nizatidine Capsules,Mylan Pharmaceuticals Inc.,"300 mg, 30 count bottle (NDC 0378-5300-93)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-5300-93,discontinued
4121,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/9/20,,,,,Gastroenterology,To be Discontinued,3/9/20,3/9/20,68462-0425-60,discontinued
4122,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/9/20,,,,,Gastroenterology,To be Discontinued,3/9/20,3/9/20,68462-0426-30,discontinued
4123,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Reverified,11/19/20,Supply Interruption,Duration of the supply interruption is unknown at this time.,,Other,Gastroenterology,Current,3/27/20,,0591-3138-30,unclear
4124,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Reverified,11/19/20,Supply Interruption,Duration of the supply interruption is unknown at this time.,,Other,Gastroenterology,Current,3/27/20,,0591-3137-60,unclear
4125,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/20,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/20,,68462-0426-30,not available
4126,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/20,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/20,,68462-0425-60,not available
4127,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/18,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/18,2/23/18,52544-235-28,discontinued
4128,Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Tablets,Mylan Pharmaceuticals Inc.,"0.02 mg norethindrone acetate / 1 mg ethinyl estradiol / 75 mg ferrous fumarate; 28 tablets per blister pack, 3 blisters per carton (NDC 0378-7301-53)",New,5/23/19,,,,,Reproductive,To be Discontinued,5/23/19,5/23/19,0378-7301-53,discontinued
4129,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 15 g (NDC 0603-7818-74)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-74,discontinued
4130,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 30 g (NDC 0603-7818-78)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-78,discontinued
4131,"Nystatin Cream, USP",Par Pharmaceutical,"100,000 USP units per gram, 60 g (NDC 0603-7818-88)",New,4/15/19,,Par has made a business decision to permanently discontinue the drug product.,,,Dermatology,To be Discontinued,4/15/19,4/15/19,0603-7818-88,discontinued
4132,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 USP units per gram, 15 g (NDC 0472-0163-15)",New,11/15/19,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/19,11/15/19,0472-0163-15,discontinued
4133,"Nystatin Cream, USP",Teva Pharmaceuticals,"100,000 units per gram, 30 g (NDC 0472-0163-30)",New,11/15/19,,Teva made a business decision to discontinue the product.,,,Dermatology,To be Discontinued,11/15/19,11/15/19,0472-0163-30,discontinued
4134,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 473 mL bottles (NDC 60432-0537-16)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,60432-0537-16,
4135,Nystatin Oral Suspension,Wockhardt,"Nystatin Oral Solution 100,000 units/1mL; 60 mL bottles (NDC 60432-0537-60)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,60432-0537-60,
4136,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 50 unit dose cups/ case (NDC 66689-037-50)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,66689-037-50,
4137,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 500,000 units/5 ml; 5mL unit dose cup; 100 unit dose cups/ case (NDC 66689-037-99)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,66689-037-99,
4138,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 60 mL Bottle (NDC 66689-008-02)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,66689-008-02,
4139,Nystatin Oral Suspension,"VistaPharm, Inc.","Nystatin Oral Suspension, USP 100,000 units/ml; 480 mL Bottle (NDC 66689-008-16)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,66689-008-16,
4140,Nystatin Oral Suspension,"Pharmaceutical Associates, Inc","Nystatin Oral Suspension, USP 500,000 Units/5 mL 5 mL Unit Dose Cups Case of 40 – 5 mL UDC (NDC 00121-4810-40); Case of 100 – 5 mL UDC (NDC 00121-4810-00); 2 oz. Bottles (NDC 00121-0810-02); 16 oz. Bottles (NDC 00121-0810-16)",Revised,5/6/20,,,,,Anti-Infective;Pediatric,Resolved,5/6/20,,00121-4810-40,
4141,Ocriplasmin (Jetrea) Injection,"Thrombogenics, Inc.",1.25 mg/ml (NDC 24856-002-01),New,4/24/20,,ThromboGenics has decided for business reasons to discontinue manufacture of the drug product for the United States.,,,Ophthalmology,To be Discontinued,4/24/20,4/24/20,24856-002-01,discontinued
4142,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/20,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/20,7/15/20,,discontinued
4143,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/20,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/20,7/15/20,,discontinued
4144,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,500mg/50 ML x 1 vial (NDC 0002-8926-01),New,10/2/19,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/19,10/2/19,0002-8926-01,discontinued
4145,Olaratumab (Lartruvo) Injection,Eli Lilly and Co.,190mg/19 ML x 1 vial (NDC 0002-7190-01),New,10/2/19,,Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.,,,Oncology,To be Discontinued,10/2/19,10/2/19,0002-7190-01,discontinued
4146,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 30 count bottle (NDC 0378-1413-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1413-93,discontinued
4147,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"20mg/12.5mg, 90 count bottle (NDC 0378-1413-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1413-77,discontinued
4148,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 30 count bottle (NDC 0378-1422-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1422-93,discontinued
4149,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/12.5mg, 90 count bottle (NDC 0378-1422-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1422-77,discontinued
4150,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 30 count bottle (NDC 0378-1425-93)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1425-93,discontinued
4151,Olmesartan Medoxomil and Hydrochlorothiazide Tablets,Mylan Pharmaceuticals Inc.,"40mg/25mg, 90 count bottle (NDC 0378-1425-77)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-1425-77,discontinued
4152,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"5mg, 30 ct. (NDC 65852-0741-30)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,65852-0741-30,
4153,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 30 ct. (NDC 65862-0742-30)",Revised,3/5/20,,,,API Supply Issue,Cardiovascular,Resolved,3/5/20,,65862-0742-30,
4154,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"20mg, 90 ct. (NDC 65862-0742-90)",Revised,3/5/20,,,,API Supply Issue,Cardiovascular,Resolved,3/5/20,,65862-0742-90,
4155,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg, 30 ct. (NDC 65862-0743-30)",Revised,3/5/20,,,,API Supply Issue,Cardiovascular,Resolved,3/5/20,,65862-0743-30,
4156,Olmesartan Medoxomil Tablets,Aurobindo Pharma,"40mg., 90 ct. (NDC 65862-0743-90)",Revised,3/5/20,,,,API Supply Issue,Cardiovascular,Resolved,3/5/20,,65862-0743-90,
4157,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"5mg, Bottle of 30 counts (NDC 62332-131-30)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,62332-131-30,
4158,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 30 counts (NDC 62332-132-30)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,62332-132-30,
4159,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"20mg, Bottle of 90 counts (NDC 62332-132-90)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,62332-132-90,
4160,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 30 counts (NDC 62332-133-30)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,62332-133-30,
4161,Olmesartan Medoxomil Tablets,Alembic Pharmaceuticals,"40mg, Bottle of 90 counts (NDC 62332-133-90)",Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,62332-133-90,
4162,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,5mg (NDC 68462-0436-30),Revised,3/5/20,,,,API shortage,Cardiovascular,Resolved,3/5/20,,68462-0436-30,
4163,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-30),Revised,3/5/20,,,,API shortage,Cardiovascular,Resolved,3/5/20,,68462-0437-30,
4164,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,20mg (NDC 68462-0437-90),Revised,3/5/20,,,,API shortage,Cardiovascular,Resolved,3/5/20,,68462-0437-90,
4165,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-30),Revised,3/5/20,,,,API shortage,Cardiovascular,Resolved,3/5/20,,68462-0438-30,
4166,Olmesartan Medoxomil Tablets,Glenmark Pharmaceuticals,40mg (NDC 68462-0438-90),Revised,3/5/20,,,,API shortage,Cardiovascular,Resolved,3/5/20,,68462-0438-90,
4167,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil  5mg T 30s (NDC 0378-7012-93),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,0378-7012-93,
4168,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 30s (NDC 0378-7112-93),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,0378-7112-93,
4169,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 20mg T 90s (NDC 0378-7112-77),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,0378-7112-77,
4170,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 30s (NDC 0378-7124-93),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,0378-7124-93,
4171,Olmesartan Medoxomil Tablets,Mylan Pharmaceuticals Inc.,Olmesartan Medoxomil 40mg T 90s (NDC 0378-7124-77),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,0378-7124-77,
4172,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 30T (NDC 1672-9320-10)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9320-10,
4173,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"5mg, 90T (NDC 1672-9320-15)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9320-15,
4174,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 30T (NDC 1672-9321-10)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9321-10,
4175,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"20mg, 90T (NDC 1672-9321-15)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9321-15,
4176,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 30T (NDC 1672-9322-10)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9322-10,
4177,Olmesartan Medoxomil Tablets,Accord Healthcare Inc.,"40mg, 90T (NDC 1672-9322-15)",Revised,3/5/20,,,,Limited API availability,Cardiovascular,Resolved,3/5/20,,1672-9322-15,
4178,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,5mg tablet (NDC 13668-248-30),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,13668-248-30,
4179,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-30),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,13668-249-30,
4180,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,20mg tablet (NDC 13668-249-90),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,13668-249-90,
4181,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-30),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,13668-250-30,
4182,Olmesartan Medoxomil Tablets,Torrent Pharma Inc.,40mg tablet (NDC 13668-250-90),Revised,3/5/20,,,,,Cardiovascular,Resolved,3/5/20,,13668-250-90,
4183,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","5mg, 30 Unit (NDC 65597-101-30)",Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,65597-101-30,
4184,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 30 Unit (NDC 65597-103-30)",Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,65597-103-30,
4185,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","20mg, 90 Unit (NDC 65597-103-90)",Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,65597-103-90,
4186,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 30 Unit (NDC 65597-104-30)",Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,65597-104-30,
4187,Olmesartan Medoxomil Tablets,"Daiichi Sankyo, Inc.","40mg, 90 Unit (NDC 65597-104-90)",Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,65597-104-90,
4188,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 30 Tabs (NDC 67877-0446-30),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,67877-0446-30,
4189,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 20mg 90 Tabs (NDC 67877-0446-90),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,67877-0446-90,
4190,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 30 Tabs (NDC 67877-0447-30),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,67877-0447-30,
4191,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 40mg 90 Tabs (NDC 67877-0447-90),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,67877-0447-90,
4192,Olmesartan Medoxomil Tablets,Alkem Laboratories,Olmesartan Medoxomil 5mg 30 Tabs (NDC 67877-0445-30),Revised,3/5/20,,,,Other,Cardiovascular,Resolved,3/5/20,,67877-0445-30,
4193,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 5mL in 1 bottle (NDC 0065-0272-11),New,2/26/20,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/20,2/26/20,0065-0272-11,discontinued
4194,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 2.5mL in 1 bottle (NDC 0065-0272-25),New,2/26/20,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/20,2/26/20,0065-0272-25,discontinued
4195,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pataday 2mg/mL 2.5mL in 1 bottle (NDC 61314-272-25),New,2/26/20,,The product will be available via OTC.,,,Ophthalmology,To be Discontinued,2/26/20,2/26/20,61314-272-25,discontinued
4196,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pazeo Ophthalmic Solution 7mg/mL 2.5mL in 1 bottle (NDC 0065-4273-25),New,8/11/20,,"Discontinuation of this product is not due to manufacturing, product quality, safety, or efficacy concerns.",,,Ophthalmology,To be Discontinued,8/11/20,8/11/20,0065-4273-25,discontinued
4197,Olopatadine Hydrochloride Ophthalmic Solution,Novartis,Pazeo Ophthalmic Solution 7mg/mL 5mL in 1 bottle (NDC 0065-4273-27),New,8/11/20,,"Discontinuation of this product is not due to manufacturing, product quality, safety, or efficacy concerns.",,,Ophthalmology,To be Discontinued,8/11/20,8/11/20,0065-4273-27,discontinued
4198,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-3082-28,discontinued
4199,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,"900 mg/1 unit capsule, liquid filled (NDC 49884-019-08)",New,5/10/19,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/19,5/10/19,49884-019-08,discontinued
4200,Omega-3-Acid Ethyl Esters,Par Pharmaceutical,900mg/1 unit capsule (NDC 0254-3010-08),New,5/10/19,,Par has made a business decision to discontinue the drug product.,,,Gastroenterology,To be Discontinued,5/10/19,5/10/19,0254-3010-08,discontinued
4201,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-56), (30 count Bottle)",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,0093-5294-56,discontinued
4202,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC (0093-5294-98) (90 count Bottle)",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,,discontinued
4203,Omeprazole Delayed-Release 40 mg Capsules,Teva Pharmaceuticals,"Omeprazole 40 mg Capsule, Delayed Release Pellets (NDC 0093-5294-10) (1000 count Bottle )",New,7/17/19,,Teva made a business decision to discontinue product.,,,Gastroenterology,To be Discontinued,7/17/19,7/17/19,0093-5294-10,discontinued
4204,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,10/27/20,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-123-25,available
4205,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,10/27/20,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-124-01,available
4206,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,9/23/20,Available,For IV or IM injection,,,Gastroenterology,Current,,,36000-012-25,available
4207,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Gastroenterology,Current,,,70860-776-02,available
4208,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,10/27/20,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,70860-777-20,available
4209,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Reverified,11/6/20,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-549-31,available
4210,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Reverified,11/6/20,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-41,available
4211,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Reverified,11/6/20,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-42,available
4212,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Revised,11/16/20,7 months expiry (expiry 6/30/2021) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-373-02,limited availability
4213,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-374-20,available
4214,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,76045-103-20,available
4215,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0143-9890-01,available
4216,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,11/20/20,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,55150-125-02,not available
4217,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Reverified,11/6/20,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-547-41,available
4218,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Reverified,11/20/20,Available,,,Other,Gastroenterology,Current,,,00409-4759-01,available
4219,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,7/22/20,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6078-25,not available
4220,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Reverified,11/20/20,Available,,,Other,Gastroenterology,Current,,,00409-4755-03,available
4221,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology,Current,,,00409-1120-12,discontinued
4222,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,11/20/20,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,55150-126-20,not available
4223,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,11/13/20,Available,,,Available,Gastroenterology,Current,,,60505-6130-05,available
4224,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,10/22/20,Available,,,,Gastroenterology,Current,,,25021-782-20,available
4225,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,10/22/20,Available,,,,Gastroenterology,Current,,,25021-777-02,available
4226,Oxalaplatin Injection,Gland Pharma Limited,"50 mg/10 mL, 10 vials per pack (NDC 72266-125-10)",New,9/28/20,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/20,9/28/20,72266-125-10,discontinued
4227,Oxalaplatin Injection,Gland Pharma Limited,"100 mg/20 mL, 10 vials per pack (NDC 72266-126-10)",New,9/28/20,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/20,9/28/20,72266-126-10,discontinued
4228,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"5 mg, 100 count bottle (NDC 0093-5206-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5206-01,discontinued
4229,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"10 mg, 100 count bottle (NDC 0093-5207-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5207-01,discontinued
4230,Oxybutynin Chloride Extended-Release Tablets,Impax Laboratories,"15 mg, 100 count bottle (NDC 0093-5208-01)",New,3/29/19,,"Distributed by Teva Pharmaceuticals, 1-800-545-8800. Teva made a business decision to discontinue product.",,,Neurology;Pediatric;Urology,To be Discontinued,3/29/19,3/29/19,0093-5208-01,discontinued
4231,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-6605-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6605-01,discontinued
4232,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 500 count bottle (NDC 0378-6605-05)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6605-05,discontinued
4233,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-6610-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6610-01,discontinued
4234,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 500 count bottle (NDC 0378-6610-05)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6610-05,discontinued
4235,Oxybutynin Chloride Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100 count bottle (NDC 0378-6615-01)",New,5/2/19,,,,,Neurology;Pediatric;Urology,To be Discontinued,5/2/19,5/2/19,0378-6615-01,discontinued
4236,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,30 mg/1 unit (NDC 0228-2879-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2879-11,discontinued
4237,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,15 mg/1 unit (NDC 0228-2878-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2878-11,discontinued
4238,Oxycodone Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/1 unit (NDC 0228-2876-11),New,11/7/19,,Teva made a business decision to discontinue manufacture of the drug product.,,,Analgesia/Addiction;Anesthesia,To be Discontinued,11/7/19,11/7/19,0228-2876-11,discontinued
4239,Oxymorphone Hydrochloride,Teva Pharmaceuticals,5 mg/1 unit (NDC 0093-5861-01),New,6/10/19,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/19,6/10/19,0093-5861-01,discontinued
4240,Oxymorphone Hydrochloride,Teva Pharmaceuticals,10 mg/1 unit (NDC 0093-5862-01),New,6/10/19,,Business related decision to discontinue these products,,,Analgesia/Addiction;Anesthesia,To be Discontinued,6/10/19,6/10/19,0093-5862-01,discontinued
4241,"Oxytocin (Pitocin) Synthetic Injection, USP",Par Pharmaceutical,Pitocin Single Pack 10 mL Vial (NDC 42023-116-01),New,11/1/19,,Par has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,11/1/19,11/1/19,42023-116-01,discontinued
4242,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,11/16/20,Available,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,63323-012-10,available
4243,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,11/16/20,Available,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,63323-012-30,available
4244,"Oxytocin Injection, USP Synthetic","Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,11/16/20,8 month expiry dating available by request. Next release November 2020.,Check wholesalers for inventory.,,Delay in manufacturing,Reproductive,Current,,,63323-012-01,not available
4245,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,3/30/20,Available,,,,Reproductive,Current,,,42023-130-06,available
4246,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,3/30/20,Available,,,,Reproductive,Current,,,42023-116-25,available
4247,"Oxytocin Injection, USP Synthetic",Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,3/30/20,Available,,,,Reproductive,Current,,,42023-116-02,available
4248,"Paclitaxel Injection, USP",HQ Specialty Pharma,30 mg/5 mL (NDC 44567-504-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-504-1,discontinued
4249,"Paclitaxel Injection, USP",HQ Specialty Pharma,100 mg/16.7 mL (NDC 44567-505-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-505-1,discontinued
4250,"Paclitaxel Injection, USP",HQ Specialty Pharma,300 mg/50 mL (6 mg/mL)(NDC 44567-506-1),New,7/3/19,,Distributed by WG Critical Care. Discontinuance: no longer commercially viable,,,Oncology,To be Discontinued,7/3/19,7/3/19,44567-506-1,discontinued
4251,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/19,,19-Dec,,,Oncology,To be Discontinued,11/22/19,11/22/19,67457-449-17,discontinued
4252,"Paclitaxel Injection, USP","Fresenius Kabi USA, LLC",30 mg/5 mL (6 mg/mL) MDV (NDC 63323-763-05),Revised,3/30/20,,Product available. Check wholesalers for inventory or contact Customer Service to place a direct order. Product will be discontinued when inventory is depleted.,,,Oncology,To be Discontinued,3/6/20,3/6/20,63323-763-05,discontinued
4253,"Paclitaxel Injection, USP",Mylan Institutional,"30 mg in 5 mL (6 mg/mL), multi-dose vial (NDC 67457-471-52)",Revised,3/30/20,,Expected discontinuation October 2020 (short dating),,,Oncology,To be Discontinued,3/30/20,3/30/20,67457-471-52,discontinued
4254,"Paclitaxel Injection, USP",Mylan Institutional,"300 mg in 50 mL (6 mg/mL), multi-dose vial (NDC 67457-434-51)",Revised,3/30/20,,Expected discontinuation October 2020 (short dating),,,Oncology,To be Discontinued,3/30/20,3/30/20,67457-434-51,discontinued
4255,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Reverified,7/22/20,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0143-9284-10,available
4256,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",New,10/29/19,Available,,,,Gastroenterology,Current,,,62756-129-44,available
4257,Pantoprazole Sodium for Injection,Aurobindo Pharma,"40 mg, 10 vials (NDC 55150-202-10)",Reverified,9/25/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,55150-202-10,available
4258,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,11/20/20,Limited Supply Available.  Next Delivery: November 2020; Estimated Recovery: December 2020,,,Other,Gastroenterology,Current,,,0008-0923-55,limited availability
4259,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: May 2021,,,Other,Gastroenterology,Current,,,0008-0923-60,not available
4260,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,11/20/20,Available,,,Other,Gastroenterology,Current,,,0008-2001-10,available
4261,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,11/20/20,Available,,,Other,Gastroenterology,Current,,,0008-2001-25,available
4262,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: November 2020,,,Other,Gastroenterology,Current,,,0008-4001-10,not available
4263,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,11/20/20,Next Delivery: December 2020; Estimated Recovery: April 2021,,,Other,Gastroenterology,Current,,,0008-4001-25,not available
4264,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,11/13/20,Available,,,,Gastroenterology,Current,,,0781-3232-95,available
4265,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,1/28/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0202-1,unclear
4266,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,1/28/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0203-1,unclear
4267,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,1/28/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0204-1,unclear
4268,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,1/28/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0205-1,unclear
4269,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4347-01,discontinued
4270,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4348-01,discontinued
4271,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/18,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4349-01,discontinued
4272,PEGINTRON (peginterferon alfa-2b) Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b) 50 mcg per 0.5 mL; box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,9/12/19,,To be discontinued on or near May 2021,,,Antiviral;Oncology,To be Discontinued,9/12/19,9/12/19,00085-4353-01,discontinued
4273,Penicillamine (Depen) Titratable Tablets,Mylan Pharmaceuticals Inc.,"Penicillamine tablets, 250 mg (NDC 0037-4401-01)",Revised,10/1/19,,,,,Endocrinology/Metabolism;Gastroenterology;Inborn Errors;Pediatric;Renal;Rheumatology,Resolved,10/1/19,,0037-4401-01,
4274,Penicillin V Potassium Tablets,Sandoz,"500 mg, 100 tablets (NDC 0781-1655-01)",New,3/19/20,,,,,Anti-Infective,To be Discontinued,3/19/20,3/19/20,0781-1655-01,discontinued
4275,Penicillin V Potassium Tablets,Sandoz,"500 mg, 1000 tablets (NDC 0781-1655-10)",New,3/19/20,,,,,Anti-Infective,To be Discontinued,3/19/20,3/19/20,0781-1655-10,discontinued
4276,Penicillin V Potassium Tablets,Sandoz,"250 mg, 100 tablets (NDC 0781-1205-01)",New,3/19/20,,,,,Anti-Infective,To be Discontinued,3/19/20,3/19/20,0781-1205-01,discontinued
4277,Penicillin V Potassium Tablets,Sandoz,"250 mg, 1000 tablets (NDC 0781-1205-10)",New,3/19/20,,,,,Anti-Infective,To be Discontinued,3/19/20,3/19/20,0781-1205-10,discontinued
4278,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/19,,,,,Anti-Infective,Resolved,9/13/19,,63323-877-15,
4279,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-01,discontinued
4280,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-05,discontinued
4281,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal),Revised,3/2/20,,,,,Pediatric;Renal,Resolved,3/2/20,,,
4282,Peritoneal Dialysis Solutions,Fresenius Medical Care North America,Peritoneal Dialysis Solutions (Delflex and Stay Safe),Revised,3/2/20,,,,,Pediatric;Renal,Resolved,3/2/20,,,
4283,Peritoneal Dialysis Solutions,Baxter Healthcare,Peritoneal Dialysis Solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD) therapy (Dianeal and Extraneal),Revised,3/2/20,,,,,Pediatric;Renal,Resolved,3/2/20,,,
4284,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/19,,,,,Neurology,To be Discontinued,11/25/19,11/25/19,16571-330-16,discontinued
4285,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-0493-25,
4286,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-2555-45,
4287,"Physostigmine Salicylate Injection, USP",Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,12/2/19,Available,,,Other,Neurology,Current,,,17478-510-02,available
4288,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,4/24/20,Currently Unavailable; Estimated Resupply: 2Q 2021,Finished Goods can be manufactured upon receipt of API.,,Shortage of an active ingredient,Cardiovascular,Current,,,62559-560-01,not available
4289,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,4/24/20,Currently Unavailable; Estimated Resupply: 2Q 2021,Finished Goods can be manufactured upon receipt of API.,,Shortage of an active ingredient,Cardiovascular,Current,,,62559-561-01,not available
4290,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,11/18/20,Available,,,,Cardiovascular,Current,,,76385-131-01,available
4291,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,11/18/20,Available,,,,Cardiovascular,Current,,,76385-132-01,available
4292,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",New,2/21/20,No product available. Product can be manufactured upon availability of API. Concrete estimated release dates cannot be provided at this moment.,,,Shortage of active ingredient,Cardiovascular,Current,,,57664-655-88,not available
4293,Pindolol Tablets,Mylan Pharmaceuticals Inc.,Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Revised,11/17/20,Unavailable. Re-supply Q1 2021.,,,,Cardiovascular,Current,,,0378-0052-01,not available
4294,Pindolol Tablets,Mylan Pharmaceuticals Inc.,Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Revised,11/17/20,Unavailable. Re-supply Q1 2021.,,,,Cardiovascular,Current,,,0378-0127-01,not available
4295,Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets,Sandoz,500mg;15mg tablets (NDC 0781-5626-60),New,2/10/20,,,,,Endocrinology/Metabolism,To be Discontinued,2/10/20,2/10/20,0781-5626-60,discontinued
4296,Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets,Sandoz,850mg;15mg tablets (NDC 0781-5627-60),New,2/10/20,,,,,Endocrinology/Metabolism,To be Discontinued,2/10/20,2/10/20,0781-5627-60,discontinued
4297,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial, box of 10 (NDC 64679-034-01",Revised,2/21/20,,,,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-034-01,
4298,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"2.25 g, single dose vial, box of 10 (NDC 61990-0110-2)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,61990-0110-2,
4299,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"4.5 g, single dose vial, box of 10 (NDC 61990-0130-2)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,61990-0130-2,
4300,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 70860-120-20); distributed by Athenex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,70860-120-20,
4301,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"3.375 g, single dose vial, box of 10 (NDC 61990-0120-2)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,61990-0120-2,
4302,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"13.5 g, pharmacy bulk vial (NDC 61990-0140-1)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,61990-0140-1,
4303,Piperacillin and Tazobactam (Zosyn) Injection,Apollo Pharmaceuticals Inc.,"40.5 g, pharmacy bulk vial (NDC 61990-0150-1)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,61990-0150-1,
4304,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 70860-121-30); distributed by Athenex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,70860-121-30,
4305,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 70860-122-50); distributed by Athenex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,70860-122-50,
4306,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 70860-123-99); distributed by Athenex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,70860-123-99,
4307,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3378-13) ADD-Vantage; distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3378-13,
4308,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3379-04) ADD-Vantage; distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3379-04,
4309,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3383-02); distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3383-02,
4310,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0409-3385-13); distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3385-13,
4311,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0409-3390-04); distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3390-04,
4312,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"13.5 g, pharmacy bulk bottle (NDC 0409-2999-14); distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-2999-14,
4313,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","2.25 g, single-dose vial (NDC 63323-981-21)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,63323-981-21,
4314,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial, box of 10 (NDC 64679-056-01)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-056-01,
4315,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"3.375 g, single dose vial (NDC 64679-056-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-056-02,
4316,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial, box of 10 (NDC 64679-679-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-679-02,
4317,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","2.25 g, single dose vial, box of 10 (NDC 60505-6156-4); distributed by Apotex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,60505-6156-4,
4318,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","3.375 g, single dose vial, box of 10 (NDC 60505-6157-4); distributed by Apotex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,60505-6157-4,
4319,Piperacillin and Tazobactam (Zosyn) Injection,"Qilu Tianhe Pharmaceutical Co., Ltd.","4.5 g, single dose vial, box of 10 (NDC 60505-6159-4); distributed by Apotex",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,60505-6159-4,
4320,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-9210-95) Novaplus",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-9210-95,
4321,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-9214-95) Novaplus",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-9214-95,
4322,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-9213-95) Novaplus",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-9213-95,
4323,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"3.375 g, single dose vial, box of 10 (NDC 67457-522-37)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,67457-522-37,
4324,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"4.5 g, single dose vial, box of 10 (NDC 67457-523-45)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,67457-523-45,
4325,Piperacillin and Tazobactam (Zosyn) Injection,Mylan Institutional,"2.25 g, single dose vial, box of 10 (NDC 67457-521-22)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,67457-521-22,
4326,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 2.25 g/50 mL, frozen IV bag (NDC 0206-8860-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0206-8860-02,
4327,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 3.375 g/50 mL, frozen IV bag (NDC 0206-8861-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0206-8861-02,
4328,Piperacillin and Tazobactam (Zosyn) Injection,Pfizer Pharmaceuticals,"Zosyn; 4.5 g/100 mL, frozen IV bag (NDC 0206-8862-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0206-8862-02,
4329,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 55150-119-30); distributed by AuroMedics Pharma LLC",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,55150-119-30,
4330,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 55150-120-30); distributed by AuroMedics Pharma LLC",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,55150-120-30,
4331,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 55150-121-50); distributed by AuroMedics Pharma LLC",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,55150-121-50,
4332,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 63323-309-20); distributed by Fresenius Kabi",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,63323-309-20,
4333,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","3.375 g, single dose vial, box of 10 (NDC 63323-983-21)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,63323-983-21,
4334,Piperacillin and Tazobactam (Zosyn) Injection,"Fresenius Kabi USA, LLC","4.5 g, single dose vial, box of 10 (NDC 63323-982-52)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,63323-982-52,
4335,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 63323-304-74); distributed by Fresenius Kabi",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,63323-304-74,
4336,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0409-3374-02) ADD-Vantage; distributed by Hospira",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0409-3374-02,
4337,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"2.25 g, single dose vial, box of 10 (NDC 25021-164-30); distributed by Sagent Pharmaceuticals",Reverified,10/9/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,25021-164-30,
4338,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"3.375 g, single dose vial, box of 10 (NDC 25021-165-30); distributed by Sagent Pharmaceuticals",Reverified,10/9/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,25021-165-30,
4339,Piperacillin and Tazobactam (Zosyn) Injection,Aurobindo Pharma,"4.5 g, single dose vial, box of 10 (NDC 25021-166-48); distributed by Sagent Pharmaceuticals",Reverified,10/9/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,25021-166-48,
4340,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"2.25 g, single dose vial, box of 10 (NDC 44567-801-10); distributed by WG Critical Care",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,44567-801-10,
4341,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"3.375 g, single dose vial, box of 10 (NDC 44567-802-10); distributed by WG Critical Care",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,44567-802-10,
4342,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"4.5 g, single dose vial, box of 10 (NDC 44567-803-10); distributed by WG Critical Care",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,44567-803-10,
4343,Piperacillin and Tazobactam (Zosyn) Injection,Istituto Biochimico Italiano SpA,"40.5 g, pharmacy bulk bottle (NDC 44567-804-01); distributed by WG Critical Care",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,44567-804-01,
4344,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"4.5 g, single dose vial, box of 10 (NDC 0781-3114-95)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-3114-95,
4345,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"3.375 g, single dose vial, box of 10 (NDC 0781-3113-95)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-3113-95,
4346,Piperacillin and Tazobactam (Zosyn) Injection,Sandoz,"2.25 g, single dose vial, box of 10 (NDC 0781-3110-95)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,0781-3110-95,
4347,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial, box of 10 (NDC 64679-012-01)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-012-01,
4348,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"4.5 g, single dose vial (NDC 64679-012-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-012-02,
4349,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"40.5 g, pharmacy bulk vial (NDC 64679-679-01)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-679-01,
4350,Piperacillin and Tazobactam (Zosyn) Injection,Wockhardt,"2.25 g, single dose vial (NDC 64679-034-02)",Revised,2/21/20,,,Available,,Anti-Infective;Pediatric,Resolved,2/21/20,,64679-034-02,
4351,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Reverified,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-51,available
4352,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Reverified,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-01,available
4353,"Potassium Acetate Injection, USP","Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Reverified,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-25,available
4354,"Potassium Acetate Injection, USP","Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Reverified,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-25,available
4355,"Potassium Acetate Injection, USP","Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,12/10/19,On allocation due to increased demand.,"Please check with wholesaler for availability. Additional production underway. Direct shipment to hospitals at 200 vials max per week are available from Exela. Customer Service # 828-758-5474, then press #2",,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,51754-2001-4,limited availability
4356,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14),Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7075-14,
4357,Potassium Chloride Injection,Baxter Healthcare,30 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0673-04),Revised,6/21/19,,,Available,,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00338-0673-04,
4358,Potassium Chloride Injection,"ICU Medical, Inc.",30 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7903-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7903-09,
4359,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex& 0.45% NaCl (NDC 0409-7904-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7904-09,
4360,Potassium Chloride Injection,"ICU Medical, Inc.",10 mEq/1000 mL in 5% dex & 0.45% NaCl (NDC 0409-7993-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7993-09,
4361,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7107-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7107-09,
4362,Potassium Chloride Injection,"ICU Medical, Inc.",40 mEq/1000 mL in 5% dex & 0.9% NaCl (NDC 0409-7109-09),Revised,6/21/19,,,Available,Other,Gastroenterology;Endocrinology/Metabolism;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7109-09,
4363,Potassium Chloride Injection,"ICU Medical, Inc.",20 mEq/1000 mL in 0.45% NaCl (NDC 0409-9257-39),Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-9257-39,
4364,Potassium Chloride Injection,"ICU Medical, Inc.","20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26)
(ICU Medical NDC 0990-7075-26)",Revised,6/21/19,,,Available,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,0409-7075-26,
4365,Potassium Chloride Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL); Single Dose Glass Fliptop Vial (NDC 00409-6635-01),Revised,6/21/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,6/21/19,,00409-6635-01,
4366,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",4.5 mg tablets (NDC 10370-255-11),New,1/27/20,,,,,Neurology,To be Discontinued,1/27/20,1/27/20,10370-255-11,discontinued
4367,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-05,
4368,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-10,
4369,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-10,
4370,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-15,
4371,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-05,
4372,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-10,
4373,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-15,
4374,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-15,
4375,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-05,
4376,"Primaquine Phosphate Tablet, EQ 15mg Base",Sanofi,"Primaquine; Film-coated tablet, 15 mg/1 unit, bottles of 100, (NDC 0024-1596-01)",Revised,12/10/19,,,,,Anti-Infective,Resolved,12/10/19,,0024-1596-01,
4377,"Primaquine Phosphate Tablet, EQ 15mg Base",Bayshore Pharmaceuticals,"Primaquine Phosphate USP,  26.3 mg (15mg base)Tablets, (NDC 76385-102-01), 100 Count Bottle",Revised,12/10/19,,,,,Anti-Infective,Resolved,12/10/19,,76385-102-01,
4378,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-21)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/19,4/9/19,0603-5371-21,discontinued
4379,"Primidone Tablets, USP",Par Pharmaceutical,"50mg, count bottle (NDC 0603-5371-28)",New,4/9/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Neurology,To be Discontinued,4/9/19,4/9/19,0603-5371-28,discontinued
4380,Prinivil Tablets,Merck Sharp & Dohme Corp.,"10-mg tablets, unit-of-use bottle/90 (NDC0006-0106-54)",New,2/20/20,,To be discontinued on or near March 2020.,,,Cardiovascular,To be Discontinued,2/20/20,2/20/20,,discontinued
4381,Prinivil Tablets,Merck Sharp & Dohme Corp.,"20-mg tablets, unit-of-use bottle/90 (NDC 0006-0207-54)",New,2/20/20,,To be discontinued on or near March 2020.,,,Cardiovascular,To be Discontinued,2/20/20,2/20/20,0006-0207-54,discontinued
4382,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/10 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1902-01)",Reverified,11/20/20,Available,,,Other,Cardiovascular;Renal,Current,,,00409-1902-01,available
4383,"Procainamide Hydrochloride Injection, USP","Hospira, Inc.","1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1903-01)",Reverified,11/20/20,Available,,,Other,Cardiovascular;Renal,Current,,,00409-1903-01,available
4384,"Procainamide Hydrochloride Injection, USP","Amphastar Pharmaceuticals, Inc./IMS",100 mg/1 mL injection; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3399-5),Reverified,10/30/20,Available,,,Other,Cardiovascular;Renal,Current,,,76329-3399-5,available
4385,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","500 mg/mL, 2 mL (NDC 14789-900-02)",New,10/19/17,Available,,,Other,Cardiovascular;Renal,Current,,,14789-900-02,available
4386,"Procainamide Hydrochloride Injection, USP","Nexus Pharmaceuticals, Inc.","100 mg/mL, 10 mL (NDC 14789-900-10)",New,10/19/17,Available,,,Other,Cardiovascular;Renal,Current,,,14789-900-10,available
4387,"Progesterone Injection, USP",Teva Pharmaceuticals,50MG 1X10ML (NDC 0591-3128-79),Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,0591-3128-79,
4388,"Progesterone Injection, USP","Fresenius Kabi USA, LLC","500 mg per 10 mL, MDV (NDC 63323-0261-10)",Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,63323-0261-10,
4389,"Progesterone Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL (NDC 0143-9725-01)",Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,0143-9725-01,
4390,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,55150-306-10,
4391,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0928-25,available
4392,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Revised,7/22/20,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0929-25,available
4393,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1495-35,available
4394,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1496-35,available
4395,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6084-25,available
4396,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Revised,7/22/20,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6085-25,available
4397,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6082-25,available
4398,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Revised,7/22/20,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6083-25,available
4399,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,12/11/19,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5525-3,available
4400,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,12/11/19,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5550-6,available
4401,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-01,discontinued
4402,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-01,discontinued
4403,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-04,discontinued
4404,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-04,discontinued
4405,Promethazine Suppository,Teva Pharmaceuticals,"25 mg/1 unit, (NDC 0591-2992-39 )",New,4/28/20,,"Teva evaluated the market and decided to discontinue the product. For Promethazine Hydrochloride 25 mg/1 unit, NDC 0591-2992-39, allocations are being made based on customer Rx trends. Product availability is anticipated until May, 2020",,,Anesthesia;Pulmonary/Allergy,To be Discontinued,4/28/20,4/28/20,0591-2992-39,discontinued
4406,Promethazine Suppository,Teva Pharmaceuticals,"12.5 mg/1 unit, (NDC 0591-2985-39)",New,4/28/20,,"Teva evaluated the market and decided to discontinue the product. For Promethazine Hydrochloride 25 mg/1 unit, NDC 0591-2992-39, allocations are being made based on customer Rx trends. Product availability is anticipated until May, 2020",,,Anesthesia;Pulmonary/Allergy,To be Discontinued,4/28/20,4/28/20,0591-2985-39,discontinued
4407,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,11/16/20,Shipping / Check wholesaler inventory,,,,Anesthesia,Current,,,63323-269-10,unclear
4408,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,11/16/20,Shipping / Check wholesaler inventory,,,Demand increase for the drug,Anesthesia,Current,,,63323-269-29,unclear
4409,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,11/16/20,Allocating to wholesalers / Check wholesaler inventory,COVID-19 demand,,Demand increase for the drug,Anesthesia,Current,,,63323-269-50,limited availability
4410,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,11/16/20,Allocating to wholesalers / Check wholesaler inventory,COVID-19 demand,,Demand increase for the drug,Anesthesia,Current,,,63323-269-65,limited availability
4411,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,10/22/20,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,25021-608-20,limited availability
4412,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Reverified,11/19/20,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-68,limited availability
4413,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: March 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-30,limited availability
4414,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,11/20/20,Limited Supply Available. Next Delivery and Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-33,limited availability
4415,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-24,limited availability
4416,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,43598-265-58,limited availability
4417,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,43598-265-20,limited availability
4418,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,43598-548-21,limited availability
4419,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,43598-548-50,limited availability
4420,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Reverified,11/19/20,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-51,limited availability
4421,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Reverified,11/19/20,Limited supply available. Next Delivery and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-95,limited availability
4422,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,10/22/20,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,250-21-608-50,limited availability
4423,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,10/22/20,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,25021-608-51,limited availability
4424,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",New,7/23/20,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6194-10,available
4425,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",New,7/23/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the August – September 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6195-20,not available
4426,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",New,7/23/20,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing in the August – September 2020 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6196-10,not available
4427,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times,,Demand increase for the drug,Anesthesia,Current,,,43598-549-10,limited availability
4428,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times.,,Demand increase for the drug,Anesthesia,Current,,,43598-549-52,limited availability
4429,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Reverified,11/13/20,"Limited supply, resupply TBD",Manufacturer extended lead times.,,Demand increase for the drug,Anesthesia,Current,,,43598-265-25,limited availability
4430,"Pyrazinamide Tablets, USP",DAVA Pharmaceuticals Inc.,"500 mg, Bottle of 100 (NDC 67253-660-10)",New,4/20/20,,Distributed by Par Pharmaceuticals.,,,Anti-Infective,To be Discontinued,4/20/20,4/20/20,67253-660-10,discontinued
4431,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,5 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0527-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0527-40,discontinued
4432,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,10 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0530-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0530-40,discontinued
4433,Quinapril Hydrochloride (Accupril) Tablets,Pfizer Pharmaceuticals,20 mg tablets; 10 x 10 unit dose blisters (NDC 0071-0532-40),New,11/12/19,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,11/12/19,11/12/19,0071-0532-40,discontinued
4434,Quinidine Gluconate Injection,Eli Lilly and Co.,"QUINIDINE GLUCONATE, 80 mg/1 mL,10 mL/vial Injectable (NDC 0002-1407-01)",Revised,9/19/19,,Discontinuation of the manufacture of the drug. The product distribution has ceased given the product's labeled expiry of March 2019. FDA and CDC are developing a strategy to ensure continued access to essential medicine for the treatment of severe malaria in the United States.,,,Anti-Infective;Cardiovascular,To be Discontinued,9/19/19,9/19/19,0002-1407-01,discontinued
4435,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 30 count bottle (NDC 0378-6709-93)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-93,discontinued
4436,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 90 count bottle (NDC 0378-6709-77)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-77,discontinued
4437,Rabeprazole Sodium Delayed-Release Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 500 count bottle (NDC 0378-6709-05)",New,5/2/19,,,,,Gastroenterology,To be Discontinued,5/2/19,5/2/19,0378-6709-05,discontinued
4438,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 2ml vial; 10 pack; (NDC 67457-397-99)",Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,67457-397-99,discontinued
4439,"Ranitidine Injection, USP",Mylan Institutional,"Ranitidine Injection 25 mg/mL, 6 mL vial; 1 pack; (NDC 67457-398-62)",Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,67457-398-62,discontinued
4440,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (10x2mL SD vials)(NDC 68382-422-02),Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,68382-422-02,discontinued
4441,"Ranitidine Injection, USP",Zydus Pharmaceuticals USA Inc.,Ranitidine HCl Injection 25mg/mL (6mL MD vial)(NDC 68382-423-06),Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,68382-423-06,discontinued
4442,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 2ML VIAL (NDC 52565-101-01),Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,52565-101-01,discontinued
4443,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 40ML VIAL (NDC 52565-096-01),Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,52565-096-01,discontinued
4444,"Ranitidine Injection, USP","Teligent Pharma, Inc.",ZANTAC INJECTABLE 25MG/ML 6ML VIAL (NDC 52565-102-01),Revised,4/3/20,,,,,Gastroenterology,To be Discontinued,4/3/20,4/3/20,52565-102-01,discontinued
4445,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 60 count bottle (NDC 68462-248-60),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-248-60,discontinued
4446,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 100 count bottle (NDC 68462-248-01),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-248-01,discontinued
4447,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,150mg 500 count bottle (NDC 68462-248-05),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-248-05,discontinued
4448,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 30 count bottle (NDC 68462-249-30),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-249-30,discontinued
4449,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 100 count bottle (NDC 68462-249-01),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-249-01,discontinued
4450,Ranitidine Tablets/Capsules,Glenmark Pharmaceuticals,300mg 250 count bottle (NDC 68462-249-20),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,68462-249-20,discontinued
4451,Ranitidine Tablets/Capsules,Appco Pharma LLC,150mg 60 count bottle (NDC 62559-690-60),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,62559-690-60,discontinued
4452,Ranitidine Tablets/Capsules,Appco Pharma LLC,150mg 500 count bottle (NDC 62559-690-05),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,62559-690-05,discontinued
4453,Ranitidine Tablets/Capsules,Appco Pharma LLC,300mg 30 count bottle (NDC 62559-691-30),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,62559-691-30,discontinued
4454,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",150mg 60 count bottle (NDC 5511112960),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,5511112960,discontinued
4455,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",150mg 500 count bottle (NDC 5511112905),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,5511112905,discontinued
4456,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",300mg 30 count bottle (NDC 5511113030),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,5511113030,discontinued
4457,Ranitidine Tablets/Capsules,"Dr. Reddy's Laboratories, Inc.",300mg 100 count bottle (NDC 5511113001),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,5511113001,discontinued
4458,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"150 mg, Bottle of 60 capsules (NDC 70954-001-20)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,70954-001-20,discontinued
4459,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"150 mg, Bottle of 500 capsules (NDC 70954-001-40)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,70954-001-40,discontinued
4460,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"300 mg, Bottle of 30 capsules (NDC 70954-002-10)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,70954-002-10,discontinued
4461,Ranitidine Tablets/Capsules,Novitium Pharma LLC,"300 mg, Bottle of 100 capsule (NDC 70954-002-40)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,70954-002-40,discontinued
4462,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,150 mg 60’s count bottle (NDC 27241-109-06),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,27241-109-06,discontinued
4463,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,150 mg 500’s count bottle (NDC 27241-109-50),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,27241-109-50,discontinued
4464,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,300 mg 30’s count bottle (NDC 27241-110-03),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,27241-110-03,discontinued
4465,Ranitidine Tablets/Capsules,Ajanta Pharma USA Inc,300 mg 100’s count bottle (NDC 27241-110-10),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,27241-110-10,discontinued
4466,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 60 count bottle (NDC 64380-0803-03)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0803-03,discontinued
4467,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 100 count bottle (NDC 64380-0803-06)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0803-06,discontinued
4468,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 500 count bottle (NDC 64380-0803-07)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0803-07,discontinued
4469,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"150 mg, 1000 count bottle (NDC 64380-0803-08)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0803-08,discontinued
4470,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 30 count bottle (NDC 64380-0804-04)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0804-04,discontinued
4471,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 100 count bottle (NDC 64380-0804-06)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0804-06,discontinued
4472,Ranitidine Tablets/Capsules,Strides Pharma Inc.,"300 mg, 250 count bottle (NDC 64380-0804-38)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,64380-0804-38,discontinued
4473,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 60 count (NDC 65162-253-06)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-06,discontinued
4474,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 100 count (NDC 65162-253-10)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-10,discontinued
4475,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 180 count (NDC 65162-253-18)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-18,discontinued
4476,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 500 count (NDC 65162-253-50)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-50,discontinued
4477,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 1000 count (NDC 65162-253-11)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-11,discontinued
4478,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"150 mg, 1000 count (NDC 65162-253-11)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-253-11,discontinued
4479,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 30 count (NDC 65162-254-03)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-254-03,discontinued
4480,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 100 count (NDC 65162-254-10)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-254-10,discontinued
4481,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 250 count (NDC 65162-254-25)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,65162-254-25,discontinued
4482,Ranitidine Tablets/Capsules,Amneal Pharmaceutical,"300 mg, 250 count (NDC 53746-254-02)",Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,53746-254-02,discontinued
4483,Ranitidine Tablets/Capsules,Sandoz,150 mg 500 ct bottle (NDC 0781-2855-05),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,0781-2855-05,discontinued
4484,Ranitidine Tablets/Capsules,Sandoz,150 mg 60 ct bottle (NDC 0781-2855-60),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,0781-2855-60,discontinued
4485,Ranitidine Tablets/Capsules,Sandoz,300 mg 30 ct bottle (NDC 0781-2865-31),Revised,4/3/20,,,,,Gastroenterology;Pediatric,To be Discontinued,4/3/20,4/3/20,0781-2865-31,discontinued
4486,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,150 mg / 300 mg (NDC 0172-4357-49) and (NDC 0172-4358-46),New,4/30/20,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/20,4/30/20,0172-4357-49,discontinued
4487,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,150 mg/1 unit (NDC 0172-4357-70),New,4/30/20,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/20,4/30/20,0172-4357-70,discontinued
4488,Ranitidine Tablets/Capsules,Teva Pharmaceuticals,300 mg/1 unit (NDC 0172-4358-60),New,4/30/20,,Teva made a business decision to discontinue these products. Teva has not marketed the subject products for an extended period of time.,,,Gastroenterology;Pediatric,To be Discontinued,4/30/20,4/30/20,0172-4358-60,discontinued
4489,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,7/6/20,7/6/20,45963-418-50,discontinued
4490,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,7/6/20,7/6/20,45963-419-50,discontinued
4491,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","1 mg per vial, SDV (NDC 63323-723-03)",Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,63323-723-03,
4492,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","2 mg per vial, SDV (NDC 63323-724-05)",Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,63323-724-05,
4493,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,"Fresenius Kabi USA, LLC","5 mg per vial, SDV (NDC 63323-725-10)",Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,63323-725-10,
4494,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,1 mg (NDC 67457-198-03),Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,67457-198-03,
4495,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,2 mg (NDC 67457-198-05),Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,67457-198-05,
4496,Remifentanil (Ultiva) Lyophilized Powder for Solution Injection,Mylan Institutional,5 mg (NDC 67457-198-10),Revised,3/2/20,,,,,Analgesia/Addiction;Pediatric,Resolved,3/2/20,,67457-198-10,
4497,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/18,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/18,2/2/18,0781-5149-01,discontinued
4498,Ribavirin (Rebetol) Oral Solution,Merck Sharp & Dohme Corp.,40 mg/mL (NDC 0085-1318-01),New,4/16/19,,To be discontinued on or near June 2019.,,,Antiviral,To be Discontinued,4/16/19,4/16/19,0085-1318-01,discontinued
4499,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","200 mg (NDCs 66435-101-14, 66435-101-16, 66435-101-18, 66435-101-42, 66435-101-56, 66435-101-70, 66435-101-84, 66435-102-16, 66435-102-95, 54738-950-16)",New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4500,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",400 mg (NDCs 66435-103-56 and 66435-103-95),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4501,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC","600 mg (NDCs 66435-104-56, 66435-104-92, 54738-952-56)",New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4502,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",600 mg dose pack (NDCs 66435-108-56 and 66435-108-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4503,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",800 mg dose pack (NDCs 66435-105-56 and 66435-105-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4504,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1000 mg dose pack (NDCs 66435-106-56 and 66435-106-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4505,Ribavirin Capsules and Tablets,"Kadmon Pharmaceuticals, LLC",1200 mg dose pack (NDCs 66435-107-56 and 66435-107-99),New,7/12/19,,,,,Antiviral,To Be Discontinued,7/12/19,7/12/19,,discontinued
4506,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0510-30,discontinued
4507,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0508-60,discontinued
4508,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0509-60,discontinued
4509,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0088-0576-41,discontinued
4510,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",New,3/25/20,On allocation with intermittent supply.,,,Demand increase for the drug,Anti-Infective,Current,3/25/20,,0088-2102-24,limited availability
4511,Risedronate Sodium Tablets,Mylan Pharmaceuticals Inc.,"150 mg, 1 count blister card (NDC 0378-4150-32)",New,5/2/19,,,,,Other,To be Discontinued,5/2/19,5/2/19,0378-4150-32,discontinued
4512,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/19,,,,,Musculoskeletal,To be Discontinued,12/9/19,12/9/19,0430-0471-15,discontinued
4513,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-60,discontinued
4514,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-10,discontinued
4515,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-60,discontinued
4516,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-50,discontinued
4517,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-60,discontinued
4518,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-50,discontinued
4519,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-10,discontinued
4520,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-60,discontinued
4521,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-50,discontinued
4522,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-10,discontinued
4523,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-60,discontinued
4524,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-50,discontinued
4525,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-10,discontinued
4526,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-60,discontinued
4527,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-50,discontinued
4528,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-10,discontinued
4529,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-330-50,discontinued
4530,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-320-50,discontinued
4531,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-300-50,discontinued
4532,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-302-50,discontinued
4533,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-50,discontinued
4534,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-01,discontinued
4535,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"1.5 mg capsules, 60 count (NDC 0591-3208-60)",New,3/10/20,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/20,3/10/20,0591-3208-60,discontinued
4536,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"3 mg capsules, 60 count (NDC 0591-3209-60)",New,3/10/20,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/20,3/10/20,0591-3209-60,discontinued
4537,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"4.5 mg capsules, 60 count (NDC 0591-3210-60)",New,3/10/20,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/20,3/10/20,0591-3210-60,discontinued
4538,Rivastigmine Tartrate Capsules,Teva Pharmaceuticals,"6 mg capsules, 60 count (NDC 0591-3211-60)",New,3/10/20,,Discontinuation of the manufacture of the drug.,,,Neurology,To be Discontinued,3/10/20,3/10/20,0591-3211-60,discontinued
4539,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 9 count bottle (NDC 0378-3701-59)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-3701-59,discontinued
4540,Rizatriptan Benzoate Orally Disintegrating Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 9 count bottle (NDC 0378-3702-59)",New,5/2/19,,,,,Neurology;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-3702-59,discontinued
4541,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-05,available
4542,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-10,available
4543,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,4 mg  (NDC 0007-4887-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4887-13,discontinued
4544,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,6 mg  (NDC 0007-4883-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4883-13,discontinued
4545,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,8 mg  (NDC 0007-4888-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4888-13,discontinued
4546,Ropinirole Hydrochloride Extended Release (Requip XL) Tablets,GlaxoSmithKline,12 mg  (NDC 0007-4882-13),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.,,,Neurology,To be Discontinued,6/28/19,6/28/19,0007-4882-13,discontinued
4547,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Reverified,10/22/20,Available,,,,Anesthesia,Current,,,25021-652-82,available
4548,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Reverified,10/22/20,Available,,,,Anesthesia,Current,,,25021-652-87,available
4549,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,10/22/20,Available,,,,Anesthesia,Current,,,25021-671-82,available
4550,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,10/22/20,Available,,,,Anesthesia,Current,,,25021-671-87,available
4551,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Reverified,12/2/19,Available,,,Other,Anesthesia,Current,,,17478-0081-30,available
4552,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: January 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9300-10,not available
4553,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: February 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9300-20,not available
4554,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-9301-30,available
4555,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-9302-20,available
4556,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-9303-10,available
4557,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,11/20/20,Limited Supply Available. Next Delivery: January 2021; Estimated Recovery: February 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9303-20,limited availability
4558,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-195-20,available
4559,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-196-99,available
4560,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-197-20,available
4561,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-198-30,available
4562,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Revised,11/20/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-199-20,available
4563,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Revised,11/20/20,Currently on backorder - next shipment anticipated late Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-200-10,not available
4564,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Revised,11/20/20,Currently on backorder - next shipment anticipated late Dec 20,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-201-20,not available
4565,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-10,available
4566,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-20,available
4567,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-20,available
4568,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-20,available
4569,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,available
4570,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-20,available
4571,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-61,available
4572,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-63,available
4573,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-65,available
4574,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-64,available
4575,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-00,available
4576,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-63,available
4577,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-13,available
4578,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-23,available
4579,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-35,available
4580,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-23,available
4581,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-21,available
4582,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,11/16/20,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-11,available
4583,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,11/16/20,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-21,available
4584,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,11/16/20,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-286-31,available
4585,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/18,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/18,2/6/18,0004-0245-15,discontinued
4586,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/19,Unavailable,,,Other,Pulmonary/Allergy,Current,,,63256-100-30,not available
4587,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 10 count (NDC 10019-553-03),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,10019-553-03,
4588,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 24 count (NDC 10019-553-04),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,10019-553-04,
4589,Scopolamine Transdermal System,GlaxoSmithKline,Transderm (Scopolamine) 1.5 mg Patch 4 count (NDC 66758-208-54),Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,66758-208-54,
4590,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 4-Count Pack (NDC 45802-580-84)",Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-84,
4591,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 10-Count Pack (NDC 45802-580-46)",Revised,12/11/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-46,
4592,Scopolamine Transdermal System,Perrigo Pharmaceuticals,"Scopolamine Transdermal System, 1mg/3days 24-Count Pack (NDC 45802-580-62)",Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,45802-580-62,
4593,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 4s (NDC 0378-6470-99),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-99,
4594,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 10s (NDC 0378-6470-97),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-97,
4595,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-44,
4596,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-01)",Revised,7/10/20,Unavailable,Northstar Rx label. Product Distributed by: McKesson (972-446-4800),,Other,Psychiatry,Current,,,16714-601-01,not available
4597,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,20mg/ml (NDC 64980-409-06),Revised,7/10/20,Currently available,Distributed by Rising Pharmaceuticals Contact Rising Pharmaceuticals : +1 (201) 961-9000,,Other,Psychiatry,Current,,,64980-409-06,available
4598,"Sertraline Hydrochloride Oral Solution, USP",Pfizer Pharmaceuticals,"Sertraline Hydrochloride 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 59762-0067-1)",Reverified,11/20/20,Available,,,Other,Psychiatry,Current,,,59762-0067-1,available
4599,"Sertraline Hydrochloride Oral Solution, USP",Pfizer Pharmaceuticals,"Zoloft (sertraline hydrochloride) 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 0049-0050-01)",Reverified,11/20/20,Available,,,Other,Psychiatry,Current,,,0049-0050-01,available
4600,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",New,7/10/20,Available,Northstar Rx label. Product Distributed by: McKesson (972-446-4800 ),,Demand increase for the drug,Psychiatry,Current,,,16714-601-02,available
4601,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,8/31/20,Available,,,,Pediatric;Psychiatry,Current,,,16729-215-10,available
4602,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,8/31/20,Available,,,,Pediatric;Psychiatry,Current,,,16729-215-15,available
4603,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,8/31/20,Limited supply/out of stock. Cannot supoort monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,16729-215-16,limited availability
4604,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,8/31/20,Limited supply/out of stock. Cannot supoort monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,16729-216-15,limited availability
4605,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,8/31/20,Limited supply / out of stock.  Cannot support monthly demand.  Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,16729-216-16,limited availability
4606,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,8/31/20,Limited supply / out of stock.  Cannot support monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,16729-217-15,limited availability
4607,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,8/31/20,Limited supply / out of stock.  Cannot support monthly demand. Estimated shortage duration: 90 days.,API delivery has been delayed due to the impacts caused by COVID-19. Manufacturing and Packaging utilization and allocation process remains active.,,Other,Pediatric;Psychiatry,Current,,,16729-217-16,limited availability
4608,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-011-30,available
4609,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-011-01,available
4610,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-011-05,available
4611,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-012-30,available
4612,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-012-01,available
4613,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-012-05,available
4614,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-013-30,available
4615,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-013-01,available
4616,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Reverified,8/31/20,Available,Sufficient quantities available for current and future demand increases.,,,Pediatric;Psychiatry,Current,,,65862-013-05,available
4617,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-611-01,available
4618,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-611-04,available
4619,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-611-05,available
4620,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-611-06,available
4621,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-612-01,available
4622,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-612-04,available
4623,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-612-05,available
4624,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-612-06,available
4625,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-613-01,available
4626,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-613-04,available
4627,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-613-05,available
4628,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Reverified,8/31/20,Available,Northstar Rx label. Product distributed by: McKesson (972-446-4800),,,Pediatric;Psychiatry,Current,,,16714-613-06,available
4629,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,0049-4960-30,available
4630,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,0049-4900-30,available
4631,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,0049-4900-41,available
4632,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,0049-4910-30,available
4633,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,0049-4910-41,available
4634,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,25 mg; Bottle of 30 tablets (NDC 59762-6347-1),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,59762-6347-1,available
4635,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 30 tablets (NDC 59762-6443-1),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,59762-6443-1,available
4636,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 100 tablets (NDC 59762-6443-2),Reverified,11/20/20,Next Delivery and Estimated Recovery: March 2022,,,Demand increase for the drug,Pediatric;Psychiatry,Current,,,59762-6443-2,not available
4637,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,50 mg; Bottle of 500 tablets (NDC 59762-6443-3),Reverified,11/20/20,Next Delivery and Estimated Recovery: March 2022,,,Other,Pediatric;Psychiatry,Current,,,59762-6443-3,not available
4638,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 30 tablets (NDC 59762-5160-1),Reverified,11/20/20,Available,,,Other,Pediatric;Psychiatry,Current,,,59762-5160-1,available
4639,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 100 tablets (NDC 59762-5160-2),Reverified,11/20/20,Available,,,Demand Increase for the drug,Pediatric;Psychiatry,Current,,,59762-5160-2,available
4640,Sertraline Hydrochloride Tablets,Pfizer Pharmaceuticals,100 mg; Bottle of 500 tablets (NDC 59762-5160-3),Reverified,11/20/20,Next Delivery and Estimated Recovery: March 2022,,,Other,Pediatric;Psychiatry,Current,,,59762-5160-3,not available
4641,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-351-06,limited availability
4642,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-351-09,limited availability
4643,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-351-03,limited availability
4644,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-352-06,limited availability
4645,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-352-09,limited availability
4646,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-352-02,limited availability
4647,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-352-05,limited availability
4648,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-353-06,limited availability
4649,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-353-09,limited availability
4650,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-353-02,limited availability
4651,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Reverified,9/1/20,"Continuous production but due to increase in demand and API shortage, product is/will be on/off backorder for few months.",,,Shortage of an active ingredient.,Pediatric;Psychiatry,Current,,,68180-353-05,limited availability
4652,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-833-02,available
4653,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-833-05,available
4654,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-833-12,available
4655,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-834-02,available
4656,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-834-12,available
4657,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-835-02,available
4658,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,9/2/20,Available,Distributed by Cipla USA Inc.,,,Pediatric;Psychiatry,Current,,,69097-835-12,available
4659,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-30,available
4660,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-60,available
4661,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-90,available
4662,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-01,available
4663,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-18,available
4664,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-212-05,available
4665,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-30,available
4666,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-60,available
4667,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-90,available
4668,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-01,available
4669,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-18,available
4670,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-213-05,available
4671,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-30,available
4672,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-60,available
4673,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-90,available
4674,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-01,available
4675,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-18,available
4676,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,9/2/20,Available,Distributed by Exellan,,,Pediatric;Psychiatry,Current,,,76282-214-05,available
4677,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0338-01,
4678,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-4190-68,
4679,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0336-21,
4680,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,70954-168-10,
4681,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/18,,,,,Antiviral,To be Discontinued,5/23/18,5/23/18,59676-225-28,discontinued
4682,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/18,,,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0006-0726-31,discontinued
4683,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0093-7152-98,discontinued
4684,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
4685,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
4686,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
4687,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
4688,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Revised,9/18/19,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/15,,0270-0556-15,available
4689,"Sodium Acetate Injection, USP","Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,63323-0032-00,available
4690,"Sodium Acetate Injection, USP","Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Reverified,11/20/20,Available,,,Other,Total Parenteral Nutrition,Current,,,00409-3299-05,available
4691,"Sodium Acetate Injection, USP","Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Reverified,11/20/20,Available,,,Other,Total Parenteral Nutrition,Current,,,00409-3299-06,available
4692,"Sodium Acetate Injection, USP","Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Reverified,11/20/20,Available,,,Other,Total Parenteral Nutrition,Current,,,00409-7299-73,available
4693,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6609-02,discontinued
4694,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Infant; 5 mEq/10 mL (4.2%; 0.5 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-5534-34),Revised,11/20/20,Next Delivery and Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-5534-34,not available
4695,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",44.6 mEq/50 mL (7.5%; 0.9 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4916-34),Revised,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-4916-34,available
4696,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); Single Dose Glass Fliptop Vial (NDC 0409-6625-02),Revised,11/20/20,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6625-02,available
4697,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",50 mEq/50 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-6637-34),Revised,11/20/20,Limited Supply Available. Next Delivery: November 2020; Estimated Recovery: December 2020,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6637-34,limited availability
4698,"Sodium Bicarbonate Injection, USP","Hospira, Inc.",Pediatric; 10 mEq/10 mL (8.4%; 1 mEq/mL); LifeShield Abboject Glass Syringe (NDC 0409-4900-34),Revised,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-4900-34,discontinued
4699,"Sodium Bicarbonate Injection, USP","Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,10/30/20,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0548-3352-00,available
4700,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,11/16/20,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-083-05,available
4701,"Sodium Bicarbonate Injection, USP","Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-089-50,not available
4702,"Sodium Bicarbonate Injection, USP","Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,12/13/19,Available direct or through Premier's ProvideGx program at this time and through CIVICA Rx program in Q1 2020.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,51754-5001-1,available
4703,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-11,
4704,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-21,
4705,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-31,
4706,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-01,
4707,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-41,
4708,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0042  (NDC 0338-0553-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0553-11,
4709,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container, VIAFLEX Plastic Container Product code 2B0043 (NDC 0338-0553-18)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0553-18,
4710,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride in Waiter for Injection, 100 mL, in VIAFLEX Container Product code ABB1307U (NDC 0338-9525-72)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9525-72,
4711,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 1000 mL.  Product code JB1324 (NDC 00338-9612-12)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-9612-12,
4712,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 100mL fill in 150mL PAB S8004-5264 (NDC 0264-1800-32),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-32,
4713,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 50mL fill in 100mL PAB S8004-5384 (NDC 0264-1800-31),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-31,
4714,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,0.9% Sodium Chloride Injection USP 25mL fill in 100mL PAB S8004-5410 (NDC 0264-1800-36),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-1800-36,
4715,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-66),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-66,
4716,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL (5-Pack); ADD-Vantage Flexible Container (NDC 00409-7101-67),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-67,
4717,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL (Dual Pack); ADD-Vantage Flexible Container (NDC 00409-7101-02),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00409-7101-02,
4718,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 100 mL VIAFLEX Plastic Container.  Single pack (NDC 0338-0049-48, product code 2B1307)Quad Pack (NDC 0338-0049-18, product code 2B1302) Multi Pack (NDC 0338-0049-38, product code 2B1309)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-48,
4719,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container.  Single Pack (NDC 0338-0049-41, product code 2B1306) Quad Pack (NDC 0338-0049-11, product code 2B1301) Multi Pack (NDC 0338-0049-31, product code 2B1308)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-41,
4720,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack (NDC 0338-0049-10). Product code 2B1300",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-0049-10,
4721,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 50mL (NDC 63323-623-53)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-53,
4722,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 100mL (NDC 63323-623-61)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-61,
4723,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 250mL (NDC 63323-623-74)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-74,
4724,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 500mL (NDC 63323-623-75)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-75,
4725,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, 0.9%, 1000mL (NDC 63323-623-76)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,63323-623-76,
4726,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus container sizes: 500 mL (NDC 0264-9999-10),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-9999-10,
4727,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-13)
(ICU Medical NDC 0990-7984-13)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-13,
4728,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container-4 pack (Legacy Hospira NDC 0409-7984-37)
(ICU Medical NDC 0990-7984-37)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-37,
4729,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 250mL bag, PVC/DEHP-free (NDC 00264-7800-20)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-20,
4730,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 500mL bag, PVC/DEHP-free (NDC 00264-7800-10)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-10,
4731,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"0.9% NaCl 1000mL bag, PVC/DEHP-free (NDC 00264-7800-00)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00264-7800-00,
4732,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",150mL flexible container (NDC 0409-7983-61),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-61,
4733,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL Vis-IV container, PVC/DEHP-free (NDC 0409-7983-25)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-25,
4734,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","250mL flexible container (Legacy Hospira NDC 0409-7983-02)
(ICU Medical NDC 0990-7983-02)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-02,
4735,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",250mL flexible container 2 port (NDC 0409-7983-53),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-53,
4736,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container 2 port (NDC 0409-7983-55),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-55,
4737,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",500mL flexible container (NDC 0409-7983-03),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-03,
4738,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",1000mL flexible container (NDC 0409-7983-09),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7983-09,
4739,Sodium Chloride 0.9% Injection Bags,Fresenius Medical Care North America,1000ml (NDC 49230-300-10),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,49230-300-10,
4740,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,"Sodium Chloride 0.9% w/v Intravenous Infusion BP in the Ecoflac® plus 1,000 mL Product Code 9999-00, (NDC 0264-9999-00)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0264-9999-00,
4741,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-50,
4742,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-30,
4743,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-16,
4744,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-02,
4745,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-03,
4746,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-04,
4747,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-04,
4748,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-06,
4749,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-02,
4750,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-23,
4751,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-11,
4752,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-36,
4753,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-20,
4754,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-06,
4755,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,11/16/20,Backordered. Next release November 2020.,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0187-30,not available
4756,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,11/16/20,Backordered. Next release November 2020.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-61,not available
4757,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,11/16/20,Backordered. Next release January 2021.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-63,not available
4758,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,11/20/20,Next Delivery: November 2020; Estimated Recovery: December 2020,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,00409-1141-02,not available
4759,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-32,discontinued
4760,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Reverified,11/20/20,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,00409-1918-33,not available
4761,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Reverified,11/20/20,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-35,discontinued
4762,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,7/22/20,Inventory is currently available.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,0641-0497-25,available
4763,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,63323-186-02,available
4764,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,63323-186-10,available
4765,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Reverified,11/16/20,Available,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,63323-186-20,available
4766,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Reverified,11/16/20,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,63323-186-00,not available
4767,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Reverified,11/20/20,Available,,,Other,Other,Current,,,00409-4888-10,available
4768,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Reverified,11/20/20,Available,,,Other,Other,Current,,,00409-4888-12,available
4769,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Reverified,11/20/20,Available,,,Other,Other,Current,,,00409-4888-20,available
4770,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Reverified,11/20/20,Available,,,Demand increase for the drug,Other,Current,,,00409-4888-50,available
4771,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,12/11/19,Available,Check wholesalers for inventory,,Available,Other,Current,,,64253-202-30,available
4772,"Sodium Lactate Injection, USP","Hospira, Inc.",50 mEq/10 mL (5 mEq/10 mL); Single Dose Plastic Fliptop Vial (NDC 00409-6664-02),New,1/9/20,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism;Gastroenterology,To be Discontinued,1/9/20,1/9/20,00409-6664-02,discontinued
4773,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/mL, 5 mL, Sodium 20 mEq/5mL vials (NDC 63323-170-05)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/19,,63323-170-05,
4774,Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL (NDC 63323-170-15)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Resolved,8/7/19,,63323-170-15,
4775,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/20,,Other Somatropin Recombinant (Humatrope) Injection products will continue to be available to treat patients.  The product distribution will continue until end of December 2020.,,,Hematology,To be Discontinued,7/7/20,7/7/20,0002-7335-11,discontinued
4776,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-5123-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5123-01,discontinued
4777,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-5124-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5124-01,discontinued
4778,Sotalol Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"160 mg, 100 count bottle (NDC 0378-5125-01)",New,5/2/19,,,,,Cardiovascular;Pediatric,To be Discontinued,5/2/19,5/2/19,0378-5125-01,discontinued
4779,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-11,discontinued
4780,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-50,discontinued
4781,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-11,discontinued
4782,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-50,discontinued
4783,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-11,discontinued
4784,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-50,discontinued
4785,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 100 (NDC 0603-5763-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-21,discontinued
4786,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 500 (NDC 0603-5763-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-28,discontinued
4787,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 1000 (NDC 0603-5763-32)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-32,discontinued
4788,"Spironolactone Tablets, USP",Par Pharmaceutical,"25 mg, bottle of 2500 (NDC 0603-5763-30)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5763-30,discontinued
4789,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 100 (NDC 0603-5764-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5764-21,discontinued
4790,"Spironolactone Tablets, USP",Par Pharmaceutical,"50 mg, bottle of 500 (NDC 0603-5764-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5764-28,discontinued
4791,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 100 (NDC 0603-5765-21)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5765-21,discontinued
4792,"Spironolactone Tablets, USP",Par Pharmaceutical,"100 mg, bottle of 500 (NDC 0603-5765-28)",New,4/19/19,,Par has made a business decision to permanently discontinue the drug product.,,,Cardiovascular,To be Discontinued,4/19/19,4/19/19,0603-5765-28,discontinued
4793,Stavudine Capsules,Mylan Pharmaceuticals Inc.,40 mg  (NDC0378-5043-91),New,7/17/19,,,,,Antiviral,To be Discontinued,7/17/19,7/17/19,,discontinued
4794,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/18,,,,,Antiviral,To be Discontinued,4/30/18,4/30/18,0378-5041-91,discontinued
4795,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3005-25,
4796,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3010-25,
4797,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3020-25,
4798,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0641-6147-25,
4799,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 500mL EXCEL container (NDC  0264-7850-10),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-10,
4800,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 1,000mL EXCEL container  (NDC 0264-7850-00)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-00,
4801,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 2,000mL Titan container (NDC  0264-7385-50)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7385-50,
4802,Sterile Water,B. Braun Medical Inc.,"Sterile Water for Injection in 3,000mL Titan container (NDC  0264-7385-60)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7385-60,
4803,Sterile Water,"Hospira, Inc.",20 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,8/2/19,, ,,,Other,Resolved,8/2/19,,00409-4887-20,
4804,Sterile Water,"Hospira, Inc.",50 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-50,
4805,Sterile Water,"Hospira, Inc.",100 mL; Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-99,
4806,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 2000 mL (NDC 0409-7118-07),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7118-07,
4807,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 1000 mL (NDC 0409-7973-05),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-05,
4808,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-08),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-08,
4809,Sterile Water,"ICU Medical, Inc.",Sterile Water for Irrigation 2000 mL (NDC 0409-7973-07),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7973-07,
4810,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation USP, 1000 mL Aqualite ™ Plastic Pour Bottle (NDC 0409-7139-09)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7139-09,
4811,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 500 mL (NDC 0409-6139-03)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-6139-03,
4812,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP 1500 mL (NDC 0409-7139-36)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7139-36,
4813,Sterile Water,"ICU Medical, Inc.","Sterile Water for Irrigation, USP, Aqualite 250 mL (NDC 0409-6139-22)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-6139-22,
4814,Sterile Water,"Hospira, Inc.",10 mL; Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00409-4887-10,
4815,Sterile Water,"Fresenius Kabi USA, LLC","Single dose vial, 5 mL fill (NDC 63323-185-05)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-05,
4816,Sterile Water,B. Braun Medical Inc.,Sterile Water for Injection in 250mL EXCEL container (NDC  0264-7850-20),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0264-7850-20,
4817,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP (For Drug Diluent Use Only), 1000 mL VIAFLEX Plastic Container. Product code 2B0304X (NDC 0338-0013-04)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-04,
4818,Sterile Water,"ICU Medical, Inc.",Sterile Water for Injection 1000 mL (NDC 0409-7990-09),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0409-7990-09,
4819,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 10 mL fill (NDC 63323-185-10)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-10,
4820,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 20 mL fill (NDC 63323-185-20)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-20,
4821,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, plastic vial, 50 mL fill (NDC 63323-185-50)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-50,
4822,Sterile Water,"Fresenius Kabi USA, LLC","Single dose, tear top vial, 100 mL (NDC 63323-185-00)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,63323-185-00,
4823,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.   Product code 2B0306 (NDC 0338-0013-06)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-06,
4824,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 3000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package.  Product code 2B0307  (NDC 0338-0013-08)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-08,
4825,Sterile Water,Baxter Healthcare,"Sterile Water for Injection, USP in 5000 mL VIAFLEX Plastic Container, Pharmacy Bulk Package. Product code 2B0309 (NDC 0338-0013-29)",Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0338-0013-29,
4826,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,00591-0796-01,available
4827,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,00591-0796-10,available
4828,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Reverified,11/19/20,Available,,,,Gastroenterology,Current,,,00591-0796-05,available
4829,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Revised,11/20/20,Available,,,Other,Gastroenterology,Current,,,0013-0101-10,available
4830,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20),Revised,11/20/20,Available,,,Other,Gastroenterology,Current,,,0013-0101-20,available
4831,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Revised,11/20/20,Next Delivery and Estimated Recovery: December 2020,,,Other,Gastroenterology,Current,,,0013-0102-50,not available
4832,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20),Revised,11/20/20,Available,,,Other,Gastroenterology,Current,,,0013-0102-20,available
4833,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Revised,11/20/20,Next Delivery: March 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-0104-1,unclear
4834,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Revised,11/20/20,Next Delivery: January 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-0104-6,unclear
4835,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Revised,11/20/20,Next Delivery: March 2021; Estimated Recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-5000-1,unclear
4836,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Revised,11/20/20,Next Delivery: January 2021; Estimated recovery: TBD,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-5000-6,unclear
4837,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/18,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/18,2/27/18,63481-367-06,discontinued
4838,Sumatriptan Succinate (Imitrex) Injection,GlaxoSmithKline,"6 mg, single dose vial (NDC 0173-0449-02)",New,4/3/20,,A business decision was made to discontinue manufacture of the drug product. The anticipated date that GSK will cease distribution of the product is approximately August 2020.,,,Neurology,To be Discontinued,4/3/20,4/3/20,0173-0449-02,discontinued
4839,Sumatriptan Succinate Injection,Mylan Institutional,"6 mg/0.5 mL, single-dose vial (NDC 67457-880-05)",New,2/21/20,,Expected discontinuation August 2020 (short dating),,,Neurology,To be Discontinued,2/21/20,2/21/20,67457-880-05,discontinued
4840,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0703-7351-01,discontinued
4841,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/13/20,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,55111-525-01,limited availability
4842,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/13/20,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,55111-526-01,limited availability
4843,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/13/20,Can only supply contracted customers,Manufacturer extended lead times.,,Demand increase for the drug,Transplant,Current,,,55111-527-01,limited availability
4844,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"0.5 mg, 100s (NDC 0378-2045-01)",Reverified,11/10/20,Available,,,,Transplant,Current,,,0378-2045-01,available
4845,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100s (NDC 0378-2046-01)",Reverified,11/10/20,Available,,,,Transplant,Current,,,0378-2046-01,available
4846,Tacrolimus Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-2047-01)",Reverified,11/10/20,Available,,,,Transplant,Current,,,0378-2047-01,available
4847,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Revised,9/14/20,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,1672904101,limited availability
4848,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Revised,9/14/20,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,1672904201,limited availability
4849,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Revised,9/14/20,Limited supply availability. Product will be allocated until Q1 2021,,,Limited API availability,Transplant,Current,,,1672904301,limited availability
4850,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3075-3,available
4851,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3075-1,available
4852,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3010-3,available
4853,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3010-1,available
4854,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3040-3,available
4855,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Reverified,9/30/20,Available,,,,Transplant,Current,,,68992-3040-1,available
4856,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,11/9/20,Available,,,,Transplant,Current,,,64338-721-06,available
4857,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,11/9/20,Available,,,,Transplant,Current,,,64380-720-06,available
4858,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,11/9/20,Available,,,,Transplant,Current,,,64380-722-06,available
4859,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Revised,11/13/20,Intermittent supply until Feb/Mar 2021,,,Demand increase for the drug,Transplant,Current,,,0781-2102-01,limited availability
4860,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Revised,11/13/20,Intermittent supply until Feb/Mar 2021,,,Demand increase for the drug,Transplant,Current,,,0781-2103-04,limited availability
4861,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Revised,11/13/20,Available,,,Demand increase for the drug,Transplant,Current,,,0781-2104-01,available
4862,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0607-73,available
4863,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0657-73,available
4864,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0617-73,available
4865,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0647-73,available
4866,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0677-73,available
4867,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-0687-73,available
4868,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-1230-50,available
4869,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Reverified,9/11/20,Available,,,,Transplant,Current,,,0469-1330-50,available
4870,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Reverified,9/9/20,Available,,,,Transplant,Current,,,54288-135-01,available
4871,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/18,4/16/18,00409-1941-01,discontinued
4872,Technetium Tc99m Succimer Injection (DMSA),GE Healthcare,DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection (NDC 17156-525-01),Revised,12/20/19,,,,,Medical Imaging,To be Discontinued,12/20/19,12/20/19,17156-525-01,discontinued
4873,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Reverified,12/10/19,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,71647-001-01,available
4874,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/18,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/18,3/6/18,0597-0127-37,discontinued
4875,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg child-resistent sachets, 5 count (NDC 0085-3004-03)",New,1/23/20,,To be discontinued on or near March 2020.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-3004-03,discontinued
4876,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg child-resistent sachets, 14 count (NDC 0085-3004-04)",New,1/23/20,,To be discontinued on or near March 2020.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-3004-04,discontinued
4877,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg child-resistent sachets, 5 count (NDC 0085-1519-03)",New,1/23/20,,To be discontinued on or near Jun 2020.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-1519-03,discontinued
4878,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg child-resistent sachets, 14 count (NDC 0085-1519-04)",New,1/23/20,,Discontinued in 2018.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-1519-04,discontinued
4879,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg child-resistent sachets, 5 count (NDC 0085-1425-03)",New,1/23/20,,To be discontinued on or near Aug 2020.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-1425-03,discontinued
4880,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg child-resistent sacehts, 14 count (NDC 0085-1430-04)",New,1/23/20,,Discontinued in 2018.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0085-1430-04,discontinued
4881,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg, 5 capsules (NDC 0781-2691-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2691-75,discontinued
4882,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"5 mg, 14 capsules (NDC 0781-2691-44)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2691-44,discontinued
4883,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg, 5 capsules (NDC 0781-2692-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2692-75,discontinued
4884,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"20 mg, 14 capsules (NDC 0781-2692-44)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2692-44,discontinued
4885,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"100 mg, 5 capsules (NDC 0781-2693-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2693-75,discontinued
4886,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"100 mg, 14 capsules (MDC 0781-2693-44)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,,discontinued
4887,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg, 5 capsules (NDC 0781-2694-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2694-75,discontinued
4888,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"140 mg, 14 capsules (NDC 0781-2694-44)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2694-44,discontinued
4889,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg, 5 capsules (NDC 0781-2695-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2695-75,discontinued
4890,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"180 mg, 14 capsules (NDC 0781-2695-44)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2695-44,discontinued
4891,Temozolomide (TEMODAR) Capsules,Merck Sharp & Dohme Corp.,"250 mg, 5 capsules (NDC 0781-2696-75)",New,1/23/20,,Authorized generic distributed by Sandoz 609-627-8500. All authorized generic presentations will be discontinued as of 31 December 2019.,,,Oncology,To be Discontinued,1/23/20,1/23/20,0781-2696-75,discontinued
4892,Temozolomide Capsules,Teva Pharmaceuticals,5 mg  (NDCs 0093-7599-41 and 0093-7599-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,,discontinued
4893,Temozolomide Capsules,Teva Pharmaceuticals,20 mg  (NDCs 0093-7600-41 and 0093-7600-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,,discontinued
4894,Temozolomide Capsules,Teva Pharmaceuticals,100 mg  (NDCs 0093-7601-41 and 0093-7601-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,,discontinued
4895,Temozolomide Capsules,Teva Pharmaceuticals,140 mg (NDCs 0093-7638-41 and 0093-7638-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,,discontinued
4896,Temozolomide Capsules,Teva Pharmaceuticals,180 mg (NDCs 0093-7639-41 and 0093-7639-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,,discontinued
4897,Temozolomide Capsules,Teva Pharmaceuticals,250 mg (NDC 0093-7602-57),New,5/8/20,,,,,Oncology,To be Discontinued,5/8/20,5/8/20,0093-7602-57,discontinued
4898,Testosterone Buccal System,"Endo Pharmaceuticals, Inc.","Striant® 30 mg, 6 blister cards, 60 buccal system  (NDC 52244-030-60)",New,8/21/19,,Endo has made a business decision to permanently discontinue the drug product.,,,Reproductive,To be Discontinued,8/21/19,8/21/19,52244-030-60,discontinued
4899,Testosterone Gel 1%,Par Pharmaceutical,"2.5 g, 30 packets (NDC 49884-418-72)",New,4/29/19,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/19,4/29/19,49884-418-72,discontinued
4900,Testosterone Gel 1%,Par Pharmaceutical,"5 g, 30 packets (NDC 49884-510-72)",New,4/29/19,,Par has made a business decision to discontinue the drug product.,,,Reproductive,To be Discontinued,4/29/19,4/29/19,49884-510-72,discontinued
4901,Testosterone Topical Gel,"Endo Pharmaceuticals, Inc.",50mg/5g topical gel (NDC 0254-1012-11),New,4/3/20,,,,,Reproductive,To be Discontinued,4/3/20,4/3/20,0254-1012-11,discontinued
4902,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"100 mg, 100 count (NDC 50111-0483-01)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0483-01,discontinued
4903,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"100 mg, 500 count (NDC 50111-0483-02)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0483-02,discontinued
4904,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 100 count (NDC 50111-0482-01)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0482-01,discontinued
4905,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 500 count (NDC 50111-0482-02)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0482-02,discontinued
4906,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"200 mg, 100 count (NDC 50111-0482-03)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0482-03,discontinued
4907,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 100 count (NDC 50111-0459-01)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0459-01,discontinued
4908,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 500 count (NDC 50111-0459-02)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0459-02,discontinued
4909,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"300 mg, 1000 count (NDC 50111-0459-03)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0459-03,discontinued
4910,Theophylline Extended Release Tablets and Capsules,Teva Pharmaceuticals,"450 mg, 100 count (NDC 50111-0518-01)",New,8/11/20,,"Business decision to discontinue. The both 100 mg presentations, both 200 mg presentation and 300 mg 100 count have been unavailable since Dec 2015. The 300 mg 100 count, 300 mg 500 count and 450 mg presentations have been unavailable since Jan 2016.",,,Pulmonary/Allergy,To be Discontinued,8/11/20,8/11/20,50111-0518-01,discontinued
4911,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0612-01),Revised,1/7/20,,,,,Psychiatry,Resolved,1/7/20,,0378-0612-01,
4912,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,25 mg (NDC 0378-0614-01),Revised,1/7/20,,,,,Psychiatry,Resolved,1/7/20,,0378-0614-01,
4913,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,50 mg (NDC 0378-0616-01),Revised,1/7/20,,,,,Psychiatry,Resolved,1/7/20,,0378-0616-01,
4914,Thioridazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0618-01),Revised,1/7/20,,,,,Psychiatry,Resolved,1/7/20,,0378-0618-01,
4915,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"1 mg, 100 count bottle (NDC 0378-1001-01)",Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-1001-01,available
4916,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"2 mg, 100 count bottle (NDC 0378-2002-01)",Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-2002-01,available
4917,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100 count bottle (NDC 0378-3005-01)",Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-3005-01,available
4918,Thiothixene Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100 count bottle (NDC 0378-5010-01)",Reverified,11/10/20,Available,,,Other,Psychiatry,Current,,,0378-5010-01,available
4919,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,5/20/20,Available,,,,Psychiatry,Current,,,70954-014-10,available
4920,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,5/20/20,Available,,,,Psychiatry,Current,,,70954-015-10,available
4921,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,5/20/20,Available,,,,Psychiatry,Current,,,70954-016-10,available
4922,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,5/20/20,Available,,,,Psychiatry,Current,,,70954-017-10,available
4923,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.25% timolol equivalent gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-814-25)",New,5/29/20,"New lots TIMOPTIC-XE® of 0.25% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,24208-814-25,unclear
4924,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.5% timolol equivalent, gel forming solution 5 mL in a 7.5 mL bottle (NDC 24208-816-05)",New,5/29/20,"New lots TIMOPTIC-XE® of 0.5% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,24208-816-05,limited availability
4925,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% timolol gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-818-25)",New,5/29/20,"New lots  of 0.25% solution available not sooner than January 2021, conditional to manufacturing capacity",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,24208-818-25,limited availability
4926,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, equivalent and 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-819-05)",New,5/29/20,"New lots  of 0.5% solution available not sooner than January 2021, conditional to manufacturing capacity.",Product is on back order due to manufacturing interruptions; capacity impacted due to COVID-19 Pandemic,,Other,Ophthalmology,Current,,,24208-819-05,not available
4927,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,"Timolol Maleate Ophthalmic Gel Forming Solution 0.5%, 5 mL bottle (NDC 61314-225-05)",Revised,11/13/20,Supply not available,,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-225-05,not available
4928,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,Timolol Maleate Ophthalmic Gel Forming Solution 0.25% 5 mL bottle (NDC 61314-224-05),Revised,11/13/20,Limited Short dated material available,,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-224-05,limited availability
4929,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-227-05,available
4930,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-227-10,available
4931,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-227-15,available
4932,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-226-05,available
4933,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-226-10,available
4934,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,11/13/20,Supply Available,,,API shortage,Ophthalmology,Current,,,61314-226-15,available
4935,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Reverified,10/1/20,Available,,,,Ophthalmology,Current,,,60505-1005-04,available
4936,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Reverified,10/1/20,Available,,,,Ophthalmology,Current,,,60505-1005-01,available
4937,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",New,5/29/20,Available,,,Other,Ophthalmology,Current,,,24208-004-01,available
4938,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",New,5/29/20,"Back-order, Estimated availability June 2020",,,Other,Ophthalmology,Current,,,24208-004-03,not available
4939,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",New,5/29/20,Available,Distributed under Oceanside Pharmaceuticals,,Other,Ophthalmology,Current,,,68682-045-25,available
4940,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",New,5/29/20,Available,Distributed under Oceanside Pharmaceuticals,,Other,Ophthalmology,Current,,,68682-045-50,available
4941,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-513-05,available
4942,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-513-01,available
4943,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-513-15,available
4944,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-514-05,available
4945,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-514-01,available
4946,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Reverified,9/14/20,Available,Distributed through Rising Pharmaceuticals,,Demand increase for the drug,Ophthalmology,Current,,,64980-514-15,available
4947,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,10/14/20,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,60758-802-05,available
4948,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,10/14/20,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,60758-802-10,available
4949,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,10/14/20,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,60758-801-05,available
4950,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,10/14/20,Available,"Distributed by Pacific Pharma, Inc.",,,Ophthalmology,Current,,,60758-801-10,available
4951,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,9/14/20,Available,,,Other,Ophthalmology,Current,,,17478-0288-10,available
4952,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,9/14/20,Available,,,Other,Ophthalmology,Current,,,17478-0288-11,available
4953,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,9/14/20,Available,,,Other,Ophthalmology,Current,,,17478-0288-12,available
4954,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"5 mg, 100 count (NDC 0378-0055-01)",Reverified,11/10/20,Available,,,Other,Cardiovascular,Current,,,0378-0055-01,available
4955,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"10 mg, 100 count (NDC 0378-0221-01)",Reverified,11/10/20,Available,,,Other,Cardiovascular,Current,,,0378-0221-01,available
4956,Timolol Maleate Tablets,Mylan Pharmaceuticals Inc.,"20 mg, 100 count (NDC 0378-0715-01)",Reverified,11/10/20,Available,,,Other,Cardiovascular,Current,,,0378-0715-01,available
4957,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0724-19,discontinued
4958,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0722-19,discontinued
4959,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Reverified,11/16/20,Backordered.  Next release expected November 2020.,Delay in manufacturing,,Other,Anti-Infective;Pediatric,Current,,,63323-303-51,not available
4960,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Reverified,11/16/20,Backordered.  Next release expected November 2020.,Delay in manufacturing,,Other,Anti-Infective;Pediatric,Current,,,63323-303-55,not available
4961,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",New,8/24/20,Available,XGen continues to manufacture at full capacity.  Plans are underway to increase production.  Timeline TBD.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,39822-0412-1,available
4962,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",New,8/24/20,Available,XGen continues to manufacture at full capacity.  Plans are underway to increase production.  Timeline TBD.,,Demand increase for the drug,Anti-Infective;Pediatric,Current,,,39822-0412-6,available
4963,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100 count bottle (NDC 0378-0217-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0217-01,discontinued
4964,Tolazamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0551-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0551-01,discontinued
4965,Tolbutamide Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100 count bottle (NDC 0378-0215-01)",New,5/2/19,,,,,Endocrinology/Metabolism,To be Discontinued,5/2/19,5/2/19,0378-0215-01,discontinued
4966,Tolcapone Tablets,"Endo Pharmaceuticals, Inc.",100mg tablets (NDC 49884-254-09),New,10/5/20,,,,,Neurology,To be Discontinued,10/5/20,10/5/20,49884-254-09,discontinued
4967,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"2 mg, blisters (NDC 0009-5190-04)",New,10/1/19,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/19,10/1/19,0009-5190-04,discontinued
4968,Tolterodine Tartrate (Detrol LA) Extended Release Capsules,Pfizer Pharmaceuticals,"4 mg, blisters (NDC 0009-5191-04)",New,10/1/19,,Discontinuation of the manufacture of the drug.,,,Urology,To be Discontinued,10/1/19,10/1/19,0009-5191-04,discontinued
4969,Tositumomab and Iodine I 131 Tositumomab (Bexxar),GlaxoSmithKline,,Revised,2/18/14,,,"BEXXAR (Tositumomab and Iodine I 131 Tositumomab) is being discontinued.  The product discontinuation is not related to product safety or any FDA action.   BEXXAR will no longer be available effective February 20, 2014.",,Oncology,To Be Discontinued,2/18/14,2/18/14,,discontinued
4970,Tramadol Hydrochloride (Ultram) Tablets,Janssen Pharmaceuticals,50 mg/1 unit (NDC 50458-659-60),New,4/1/20,,"The Company has made a business decision to permanently discontinue Ultram tablets. Product should be maintained on the formularies until the last batch produced expires (30 Sept 2022), in order to maintain continuity of the reimbursement process.",,,Analgesia/Addiction,To be Discontinued,4/1/20,4/1/20,50458-659-60,discontinued
4971,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-543-90,discontinued
4972,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-542-90,discontinued
4973,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-541-30,discontinued
4974,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-3,discontinued
4975,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-1,discontinued
4976,Trazodone Tablets,Accord Healthcare Inc.,"50 mg tablets, bottle of 100 (NDC 16729-299-01); bottle of 1000 (NDC 16729-299-17)",New,4/20/20,,,,,Psychiatry,To be Discontinued,4/20/20,4/20/20,16729-299-01,discontinued
4977,Trazodone Tablets,Accord Healthcare Inc.,"100 mg tablets, bottle of 100 (NDC 16729-300-01); bottle of 1000 (NDC 16729-300-17)",New,4/20/20,,,,,Psychiatry,To be Discontinued,4/20/20,4/20/20,16729-300-01,discontinued
4978,Trazodone Tablets,Accord Healthcare Inc.,"150 mg tablets, bottle of 100 (NDC 16729-301-01); bottle of 1000 (NDC 16729-301-17)",New,4/20/20,,,,,Psychiatry,To be Discontinued,4/20/20,4/20/20,16729-301-01,discontinued
4979,Trazodone Tablets,Accord Healthcare Inc.,"300 mg tablets, bottle of 100 (NDC 16729-302-01)",New,4/20/20,,,,,Psychiatry,To be Discontinued,4/20/20,4/20/20,16729-302-01,discontinued
4980,"Triamcinolone Acetonide (Triesence) Injection, Suspension",Novartis,Triesence (Triamcinolone acetonide injectable suspension) Vial 40mg/mL 1mL in 1 vial (NDC 0065-0543-01),Revised,9/22/20,Available,There are no therapeutic equivalents.,,,Ophthalmology,Current,,,0065-0543-01,available
4981,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-80,discontinued
4982,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-16,discontinued
4983,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-028-80,discontinued
4984,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-30),New,6/28/19,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately October 2019.,,,Cardiovascular,To be Discontinued,6/28/19,6/28/19,0007-3650-30,discontinued
4985,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-22),New,11/16/20,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately December 2020.,,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,0007-3650-22,discontinued
4986,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-01,discontinued
4987,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-05,discontinued
4988,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-01,discontinued
4989,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-05,discontinued
4990,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-00,discontinued
4991,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-03,discontinued
4992,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-00,discontinued
4993,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-03,discontinued
4994,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-8028-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8028-01,
4995,Trifluoperazine Hydrochloride Tablets,Sandoz,1 mg 100 count bottle (NDC 0832-0494-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0494-11,
4996,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-8032-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8032-01,
4997,Trifluoperazine Hydrochloride Tablets,Sandoz,2 mg 100 count bottle (NDC 0832-0495-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0495-11,
4998,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-8034-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8034-01,
4999,Trifluoperazine Hydrochloride Tablets,Sandoz,5 mg 100 count bottle (NDC 0832-0496-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0496-11,
5000,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-8036-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0781-8036-01,
5001,Trifluoperazine Hydrochloride Tablets,Sandoz,10 mg 100 count bottle (NDC 0832-0497-11),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0832-0497-11,
5002,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-2401-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2401-01,
5003,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-2402-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2402-01,
5004,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-2405-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2405-01,
5005,Trifluoperazine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-2410-01),Revised,12/10/19,,,,,Psychiatry,Resolved,12/10/19,,0378-2410-01,
5006,Trifluridine Ophthalmic Solution,Sandoz,Trifluridine 1% 7.5 mL (NDC 61314-044-75),Reverified,11/13/20,Short-dated supply available; Fresh supply expected for delivery by end of October,,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-044-75,limited availability
5007,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 gram  (NDCs 0093-7259-98 and 0093-7259-56),New,11/15/19,,This product is being discontinued due to a business decision.,,,Antiviral,To be Discontinued,11/15/19,11/15/19,,discontinued
5008,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,500 mg tablets (NDCs 45963-558-30 and 45963-558-08),New,2/21/19,,,,,Antiviral,To be Discontinued,2/21/19,2/21/19,,discontinued
5009,Valacyclovir Hydrochloride Tablets,Teva Pharmaceuticals,1 G tablets (NDCs 45963-559-30 and 45963-559-08),New,2/21/19,,,,,Antiviral,To be Discontinued,2/21/19,2/21/19,,discontinued
5010,Valsartan Tablets,Amneal Pharmaceutical,"40 mg, 30 ct bottle (NDC 65162-837-03); 60 ct bottle (NDC 65162-837-06); 500 ct bottle (NDC 65162-837-50)",Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,65162-837-03,
5011,Valsartan Tablets,Amneal Pharmaceutical,"80 mg, 90 ct bottle (NDC 65162-838-09); 500 ct bottle (NDC 65162-838-50); 1000 ct bottle (NDC 65162-838-11)",Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,65162-838-09,
5012,Valsartan Tablets,Amneal Pharmaceutical,"160 mg, 90 ct bottle (NDC 65162-839-09); 500 ct bottle (NDC 65162-839-50); 1000 ct bottle (NDC 65162-839-11)",Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,65162-839-09,
5013,Valsartan Tablets,Amneal Pharmaceutical,"320 mg, 90 ct bottle (NDC 65162-840-09); 500 ct bottle (NDC 65162-840-50); 1000 ct bottle (NDC 65162-840-11)",Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,65162-840-09,
5014,Valsartan Tablets,Camber Pharmaceuticals Inc.,40 mg (NDC 31722-745-30),Revised,3/4/20,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/20,,31722-745-30,
5015,Valsartan Tablets,Camber Pharmaceuticals Inc.,80 mg (NDC 31722-746-90),Revised,3/4/20,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/20,,31722-746-90,
5016,Valsartan Tablets,Camber Pharmaceuticals Inc.,160 mg (NDC 31722-746-90),Revised,3/4/20,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/20,,31722-746-90,
5017,Valsartan Tablets,Camber Pharmaceuticals Inc.,320 mg (NDC 31722-748-90),Revised,3/4/20,,,,Shortage of an active ingredient,Cardiovascular,Resolved,3/4/20,,31722-748-90,
5018,Valsartan Tablets,Ohm Laboratories Inc.,40 mg (NDC 51660-140-30),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,51660-140-30,
5019,Valsartan Tablets,Ohm Laboratories Inc.,80 mg (NDC 51660-141-90),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,51660-141-90,
5020,Valsartan Tablets,Ohm Laboratories Inc.,160 mg (NDC 51660-142-90),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,51660-142-90,
5021,Valsartan Tablets,Ohm Laboratories Inc.,320 mg (NDC 51660-143-90),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,51660-143-90,
5022,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 40mg x 30's Bottle Pack (NDC 33342006207),Revised,3/4/20,,,,Available,Cardiovascular,Resolved,3/4/20,,33342006207,
5023,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 80mg x 90's Bottle Pack (NDC 33342006310),Revised,3/4/20,,,,Available,Cardiovascular,Resolved,3/4/20,,33342006310,
5024,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 160mg x 30's Bottle Pack (NDC 33342006410),Revised,3/4/20,,,,Available,Cardiovascular,Resolved,3/4/20,,33342006410,
5025,Valsartan Tablets,Macleods Pharmaceuticals Limited,Valsartan Tablets 320mg x 30's Bottle Pack (NDC 33342006510),Revised,3/4/20,,,,Available,Cardiovascular,Resolved,3/4/20,,33342006510,
5026,Valsartan Tablets,"Solco Healthcare US, LLC",40mg 30’s (NDC 43547-0367-03),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,43547-0367-03,
5027,Valsartan Tablets,"Solco Healthcare US, LLC",160mg 90’s (NDC 43547-0369-09),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,43547-0369-09,
5028,Valsartan Tablets,"Solco Healthcare US, LLC",80mg 90’s (NDC 43547-0368-09),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,43547-0368-09,
5029,Valsartan Tablets,"Solco Healthcare US, LLC",320mg 90’s (NDC 43547-0370-09),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,43547-0370-09,
5030,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 40 mg. - 30/Bottle (NDC 65862-0570-30),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,65862-0570-30,
5031,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 80 mg. - 90/Bottle (NDC 65862-0571-90),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,65862-0571-90,
5032,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 160 mg. - 90/Bottle (NDC 65862-0572-90),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,65862-0572-90,
5033,Valsartan Tablets,Aurobindo Pharma,Valsartan Tablets USP 320 mg. - 90/Bottle (NDC 65862-0573-90 ),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,65862-0573-90,
5034,Valsartan Tablets,Mylan Pharmaceuticals Inc.,40 mg (30’s) (NDC 0378-5807-93),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,0378-5807-93,
5035,Valsartan Tablets,Mylan Pharmaceuticals Inc.,160 mg (90’s) (NDC 0378-5814-77),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,0378-5814-77,
5036,Valsartan Tablets,Mylan Pharmaceuticals Inc.,80 mg (90’s) (NDC 0378-5813-77),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,0378-5813-77,
5037,Valsartan Tablets,Mylan Pharmaceuticals Inc.,320 mg (90’s) (NDC 0378-5815-77),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,0378-5815-77,
5038,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",40 mg (30's) (NDC 59746-0360-30),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,59746-0360-30,
5039,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",80 mg (90's) (NDC 59746-0361-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,59746-0361-90,
5040,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",160 mg (90's) (NDC 59746-0362-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,59746-0362-90,
5041,Valsartan Tablets,"Jubilant Cadista Pharmaceuticals, Inc.",320 mg (90's) (NDC 59746-0363-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,59746-0363-90,
5042,Valsartan Tablets,Teva Pharmaceuticals,"Valsartan Tablets, USP 40mg, 90 count, (NDC 0591-2167-19)",New,8/3/18,,This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,8/3/18,8/3/18,0591-2167-19,discontinued
5043,Valsartan Tablets,Torrent Pharma Inc.,40 mg (NDC 13668-067-30),Revised,1/16/20,,,,,Cardiovascular,To be Discontinued,1/16/20,1/16/20,13668-067-30,discontinued
5044,Valsartan Tablets,Torrent Pharma Inc.,80 mg (NDC 13668-068-90),Revised,1/16/20,,,,,Cardiovascular,To be Discontinued,1/16/20,1/16/20,13668-068-90,discontinued
5045,Valsartan Tablets,Torrent Pharma Inc.,160 mg (NDC 13668-069-90),Revised,1/16/20,,,,,Cardiovascular,To be Discontinued,1/16/20,1/16/20,13668-069-90,discontinued
5046,Valsartan Tablets,Torrent Pharma Inc.,320 mg (NDC 13668-070-90),Revised,1/16/20,,,,,Cardiovascular,To be Discontinued,1/16/20,1/16/20,13668-070-90,discontinued
5047,Valsartan Tablets,Novartis,DIOVAN® scored tablets 40mg 30s 1 bottle of 30 tablets (NDC 0078-0423-15),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,0078-0423-15,
5048,Valsartan Tablets,Novartis,DIOVAN® tablets 80mg 1 bottle of 90 tablets (NDC 0078-0358-34),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,0078-0358-34,
5049,Valsartan Tablets,Novartis,DIOVAN® tablets 160mg 1 bottle of 90 tablets (NDC 0078-0359-34),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,0078-0359-34,
5050,Valsartan Tablets,Novartis,DIOVAN® tablets 320mg 1 bottle of 90 count (NDC 0078-0360-34),Revised,3/4/20,,,,Demand increase for the drug,Cardiovascular,Resolved,3/4/20,,0078-0360-34,
5051,Valsartan Tablets,Novartis,Valsartan Tablets 40 mg 1 bottle of 90 tablets (NDC 0781-5607-31),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,0781-5607-31,
5052,Valsartan Tablets,Novartis,Valsartan Tablets 80 mg 1 bottle of 90 tablets (NDC 0781-5608-92),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,0781-5608-92,
5053,Valsartan Tablets,Novartis,Valsartan Tablets 160 mg 1 bottle of 90 tablets (NDC 0781-5618-92),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,0781-5618-92,
5054,Valsartan Tablets,Novartis,Valsartan Tablets 320 mg 1 bottle of 90 tablets (NDC 0781-5619-92),Revised,3/4/20,,,,Discontinuation of the manufacture of the drug,Cardiovascular,Resolved,3/4/20,,0781-5619-92,
5055,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 30 counts (NDC 62332-044-30),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-044-30,
5056,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 90 counts (NDC 62332-044-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-044-90,
5057,Valsartan Tablets,Alembic Pharmaceuticals,40 mg bottle of 500 counts (NDC 62332-044-71),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-044-71,
5058,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 30 counts (NDC 62332-045-30),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-045-30,
5059,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 90 counts (NDC 62332-045-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-045-90,
5060,Valsartan Tablets,Alembic Pharmaceuticals,80 mg bottle of 500 counts (NDC 62332-045-71),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-045-71,
5061,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 30 counts (NDC 62332-046-30),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-046-30,
5062,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 90 counts (NDC 62332-046-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-046-90,
5063,Valsartan Tablets,Alembic Pharmaceuticals,160 mg bottle of 500 counts (NDC 62332-046-71),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-046-71,
5064,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 30 count (NDC 62332-047-30),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-047-30,
5065,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 90 count (NDC 62332-047-90),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-047-90,
5066,Valsartan Tablets,Alembic Pharmaceuticals,320 mg bottle of 500 counts (NDC 62332-047-71),Revised,3/4/20,,,,Other,Cardiovascular,Resolved,3/4/20,,62332-047-71,
5067,Vardenafil Hydrochloride (Levitra) Tablets,Bayer,Levitra® (vardenafil HCL) tablets 2.5 mg tablet strength (NDC 0173-0828-13),New,5/15/18,,"Bayer will continue to market the 5 mg, 10 mg and 20 mg tablet strengths.",,,Other;Reproductive,To be Discontinued,5/15/18,5/15/18,0173-0828-13,discontinued
5068,Vardenafil Hydrochloride Tablets,Bayer,"Levitra 5 mg, 30 count (NDC 0173-0829-13)",Revised,9/1/20,,Bayer will continue to market the 20 mg tablet strength.,,,Reproductive,To be Discontinued,7/25/19,7/25/19,0173-0829-13,discontinued
5069,Vardenafil Hydrochloride Tablets,Bayer,Levitra 10 mg (NDC 0173-0830-13),Revised,9/1/20,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/20,9/1/20,0173-0830-13,discontinued
5070,Vardenafil Hydrochloride Tablets,Bayer,Staxyn 10 mg (NDC 0173-0822-04),Revised,9/1/20,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/20,9/1/20,0173-0822-04,discontinued
5071,Vecuronium Bromide for Injection,Teva Pharmaceuticals,10 mg* 10 X 10 mL *1 mg/mL when reconstituted to 10 mL (NDC 0703-2914-03),Reverified,11/19/20,Available. We are satisfying historical committed customer demand.,,,,Anesthesia,Current,,,0703-2914-03,available
5072,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1632-01,available
5073,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,11/20/20,Available,,,Other,Anesthesia,Current,,,00409-1634-01,available
5074,Vecuronium Bromide for Injection,Mylan Institutional,Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Revised,10/14/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-438-10,available
5075,Vecuronium Bromide for Injection,Mylan Institutional,Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Revised,10/14/20,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-475-20,available
5076,Vecuronium Bromide for Injection,Gland Pharma Limited,10 mg/vial (NDC 63323-781-10),Reverified,10/27/20,Currently on backorder; estimate shortage thru Q4 2020.,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,Demand increase for the drug,Anesthesia,Current,,,63323-781-10,not available
5077,Vecuronium Bromide for Injection,Gland Pharma Limited,20 mg/vial (NDC 63323-782-20),Reverified,10/27/20,Currently on backorder; estimate shortage thru Q4 2020.,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,Demand increase for the drug,Anesthesia,Current,,,63323-782-20,not available
5078,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Revised,9/17/20,Available,,,Demand increase of the drug,Anesthesia,Current,,,47335-931-44,available
5079,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Revised,9/17/20,Available,,,Demand increase of the drug,Anesthesia,Current,,,47335-932-44,available
5080,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Revised,11/20/20,Currently on backorder - next shipment anticipated end of Oct 20,Production increase in response to increased demand.,,Demand increase for the drug,Anesthesia,Current,,,55150-235-10,not available
5081,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Revised,11/20/20,Currently on backorder - next shipment anticipated Jan 21,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,55150-236-20,not available
5082,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"120mg, 100 count, (NDC 0093-3043-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3043-01,discontinued
5083,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 500 count, (NDC 0093-3044-05)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3044-05,discontinued
5084,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"180mg, 100 count, (NDC 0093-3044-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3044-01,discontinued
5085,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 100 count, (NDC 0093-3045-01)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3045-01,discontinued
5086,Verapamil HCl Extended-Release Tablets,Teva Pharmaceuticals,"240mg, 500 count, (NDC 0093-3045-05)",New,2/22/19,,This was a business-related decision to discontinue manufacturing these products,,,Cardiovascular,To be Discontinued,2/22/19,2/22/19,0093-3045-05,discontinued
5087,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"100 mg capsule, 100 count bottle (NDC 0378-6201-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6201-01,discontinued
5088,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 100 count bottle (NDC 0378-6202-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6202-01,discontinued
5089,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"200 mg capsule, 500 count bottle (NDC 0378-6202-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6202-05,discontinued
5090,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 100 count bottle (NDC 0378-6203-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6203-01,discontinued
5091,Verapamil Hydrochloride Extended-Release Tablets and Capsules,Mylan Pharmaceuticals Inc.,"300 mg capsule, 500 count bottle (NDC 0378-6203-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-6203-05,discontinued
5092,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"80 mg, 100 count bottle (NDC 0378-0512-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0512-01,discontinued
5093,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 100 count bottle (NDC 0378-0772-01)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0772-01,discontinued
5094,Verapamil Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,"120 mg, 500 count bottle (NDC 0378-0772-05)",New,5/2/19,,,,,Cardiovascular,To be Discontinued,5/2/19,5/2/19,0378-0772-05,discontinued
5095,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC",10 mg per 10 mL (1 mg per mL); MDV (NDC 63323-0278-10),Revised,3/3/20,Available,,,,Oncology,Resolved,,,63323-0278-10,available
5096,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,"Vincasar PFS -- vincristine sulfate injection, solution, 1 MG/ 1 ML (NDC 0703-4402-11)",New,7/5/19,,Teva made a business decion to discontinue the product.,,,Oncology,To be Discontinued,7/5/19,7/5/19,0703-4402-11,discontinued
5097,"Vincristine Sulfate (VINCASAR PFS) Injection, USP",Teva Pharmaceuticals,VINCASAR PFS (vincristine sulfate injection USP) 2 mg/2 mL Vial (1 mg/mL) (NDC 0703-4412-11),New,3/20/19,,Teva made a business decision to discontinue this product size (2mL).,,,Oncology,To be Discontinued,3/20/19,,0703-4412-11,discontinued
5098,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",1 mg/mL Single Dose Glass Fliptop Vial (NDC 61703-0309-06),Revised,1/30/20,,,,,Oncology,Resolved,1/30/20,,61703-0309-06,
5099,"Vincristine Sulfate Injection, USP (Preservative-Free)","Hospira, Inc.",2 mg/2 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 61703-0309-16),Revised,1/30/20,,,,,Oncology,Resolved,1/30/20,,61703-0309-16,
5100,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","10 mg/mL Single Dose Glass, Vial (NDC 64370-532-01)",New,11/8/19,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,11/8/19,11/8/19,64370-532-01,discontinued
5101,Vinorelbine Tartrate Injection,"Pierre Fabre Pharmaceuticals, Inc.","50 mg/5mL Single Dose Glass, Vial (NDC 64370-532-02)",New,11/8/19,,"Limited availability; distribution to end December 31, 2019. Discontinuation of the manufacture of the drug.",,,Oncology,To be Discontinued,11/8/19,11/8/19,64370-532-02,discontinued
5102,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/18,4/16/18,61703-0341-06,discontinued
5103,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/18,4/16/18,61703-0341-09,discontinued
5104,Zoledronic Acid Injection,Teva Pharmaceuticals,"0.8 mg/mL, 4 mg 5 mL/Vial (NDC 45963-440-55)",New,5/1/19,,Discontinuation of the manufacture of the drug.,,,Musculoskeletal;Oncology,To be Discontinued,5/1/19,5/1/19,45963-440-55,discontinued
5105,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/18,,,Available,,Psychiatry,Resolved,11/21/18,,0037-6010-30,
5106,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,6.25 mg tablets (NDC 0228-3481-11),New,2/22/19,,,,,Psychiatry,To be Discontinued,2/22/19,2/22/19,0228-3481-11,discontinued
5107,Zolpidem Tartrate Extended Release Tablets,Teva Pharmaceuticals,12.5 mg  (NDC 0228-3482-11),New,5/1/20,,,,,Psychiatry,To be Discontinued,5/1/20,5/1/20,0228-3482-11,discontinued
5108,Zolpidem Tartrate Tablets,Wockhardt,5 mg  (NDCs 64679-0714-01 and 64679-0714-04),New,7/18/19,,,,,Psychiatry,To be Discontinued,7/18/19,7/18/19,,discontinued
5109,Zolpidem Tartrate Tablets,Wockhardt,10 mg  (NDCs 64679-0715-01 and 64679-0715-04),New,7/18/19,,,,,Psychiatry,To be Discontinued,7/18/19,7/18/19,,discontinued
5110,Abacavir Sulfate and Lamivudine Tablets,Teva Pharmaceuticals,600 mg and 300 mg  (NDC 0093-5382-56),New,10/2/20,,,,,Antiviral,To be Discontinued,10/2/20,10/2/20,0093-5382-56,discontinued
5111,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/20,,,,,Oncology,To be Discontinued,6/5/20,6/5/20,57894-155-12,discontinued
5112,Acetazolamide Injection,"Mylan Institutional, a Viatris company","500 mg, Lyophilisate in Single Dose Vials 1PK (NDC 67457-853-50)",Reverified,11/29/21,Available,,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,67457-853-50,available
5113,Acetazolamide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9503-01),Reverified,10/12/21,Inventory is currently available.,Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,0143-9503-01,available
5114,Acetazolamide Injection,"X-GEN Pharmaceuticals, Inc.",500mg per vial (NDC 39822-0190-1),Revised,7/8/21,Available,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Ophthalmology,Current,,,39822-0190-1,available
5115,Acitretin Capsules,GlaxoSmithKline,25 mg (NDC 0145-0091-25),New,4/23/21,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately September 2021.,,,Dermatology,To be Discontinued,4/23/21,4/23/21,0145-0091-25,discontinued
5116,Acitretin Capsules,GlaxoSmithKline,10 mg (NDC 0145-0090-25),New,4/23/21,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately September 2021.,,,Dermatology,To be Discontinued,4/23/21,4/23/21,0145-0090-25,discontinued
5117,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/20,,Endo has made a business decision to permanently discontinue the drug product.,,,Pulmonary/Allergy,To be Discontinued,6/2/20,6/2/20,52244-404-10,discontinued
5118,Acyclovir Ointment 5%,"Tolmar Pharmaceuticals, Inc.",15 mg (NDC 63646-300-15),New,12/15/20,,,,,Dermatology,To be Discontinued,12/15/20,12/15/20,63646-300-15,discontinued
5119,Acyclovir Ointment 5%,"Tolmar Pharmaceuticals, Inc.",30 mg (NDC 63646-300-30),New,12/15/20,,,,,Dermatology,To be Discontinued,12/15/20,12/15/20,63646-300-30,discontinued
5120,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/20,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/20,7/27/20,0074-6347-02,discontinued
5121,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/20,,The company has discontinued manufacture of these products based on a market assessment and product demand.,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,7/27/20,7/27/20,0074-9374-02,discontinued
5122,Adapalene/Benzoyl Peroxide Topical Gel,Teva Pharmaceuticals,0.1/2.5% PMP 45 g (NDC 0472-0310-38),New,1/27/21,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,1/27/21,1/27/21,0472-0310-38,discontinued
5123,"Albuterol Sulfate Aerosol, Metered","Endo Pharmaceuticals, Inc.",90 mcg  (NDC 0254-1007-52),New,7/6/21,,,,,Pulmonary/Allergy,To be Discontinued,7/6/21,7/6/21,0254-1007-52,discontinued
5124,Alprostadil Suppository,"Mylan Specialty, a Viatris Company",125 mcg (NDC 0037-8110-06),New,6/14/21,,,,,Urology,To be Discontinued,6/14/21,6/14/21,0037-8110-06,discontinued
5125,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 12oz, (NDC 0135-0094-41)",New,8/6/21,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/21,8/6/21,0135-0094-41,discontinued
5126,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 6oz, (NDC 0135-0094-42)",New,8/6/21,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/21,8/6/21,0135-0094-42,discontinued
5127,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Chewable Tablet, Regular Strength, 80 mg/1, 14.2 mg/1, 100ct Bottle, (NDC 0135-0096-26)",New,8/6/21,,This product discontinuation is a business-related decision.,,,Gastroenterology,To be Discontinued,8/6/21,8/6/21,0135-0096-26,discontinued
5128,Amantadine Hydrochloride Capsules,Teva Pharmaceuticals,100 mg capsules (NDC 0591-4930-01 & 0591-4930-05),New,1/4/21,,A business decision was made to discontinue this presentation.,,,Antiviral;Neurology,To be Discontinued,1/4/21,1/4/21,0591-4930-01,discontinued
5129,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/20,,,,,Antiviral;Neurology,To be Discontinued,7/16/20,7/16/20,,discontinued
5130,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),New,5/21/20,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,76310-017-50,limited availability
5131,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 1,000mL S4500 (NDC 00264-4500-00)",Reverified,8/9/21,Product on allocation to contracted customers,,,Other,Gastroenterology,Current,9/24/19,,00264-4500-00,limited availability
5132,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (Legacy Hospira NDC 0409-7171-17)(ICU Medical NDC 0990-7171-17),Reverified,11/10/21,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,0409-7171-17,limited availability
5133,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17) (ICU Medical NDC 0990-7172-17),Reverified,11/10/21,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,0409-7172-17,limited availability
5134,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03)",Reverified,11/10/21,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,0409-4178-03,not available
5135,Amino Acids,"ICU Medical, Inc.","AMINOSYN II 10%, Sulfite-Free, (Pediatric Formula) 1000 mL (Legacy Hospira NDC 0409-4179-05) (ICU Medical NDC 0990-4179-05)",Reverified,11/10/21,Available to contracted customers only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Gastroenterology,Current,,,0409-4179-05,limited availability
5136,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion. Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Reverified,11/23/21,Available,,,,Gastroenterology,Current,,,0338-0502-06,available
5137,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-60,discontinued
5138,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-09,discontinued
5139,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0185-0144-05,discontinued
5140,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-15,discontinued
5141,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Amiodarone HCl Tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0245-0145-30,discontinued
5142,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",10 mg (NDCs 0378-2610-01 and 0378-2610-10),New,8/2/21,,,,,Psychiatry,To be Discontinued,8/2/21,8/2/21,,discontinued
5143,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",25 mg (NDCs 0378-2625-01 and 0378-2625-10),New,8/2/21,,,,,Psychiatry,To be Discontinued,8/2/21,8/2/21,,discontinued
5144,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Revised,11/8/21,Available,,,,Psychiatry,Current,3/9/20,,0591-5714-01,available
5145,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Revised,11/8/21,On backorder,Recovery Dec 2021,,Other,Psychiatry,Current,3/9/20,,0591-5713-01,not available
5146,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Revised,11/8/21,Available,,,,Psychiatry,Current,3/9/20,,0591-5715-01,available
5147,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 30 tablets (NDC 00591-5716-30)",Revised,11/8/21,Available,Recovery Oct 2021,,,Psychiatry,Current,3/9/20,,00591-5716-30,available
5148,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-950-01,discontinued
5149,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-951-01,discontinued
5150,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-952-01,discontinued
5151,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-953-01,discontinued
5152,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-954-01,discontinued
5153,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-955-01,discontinued
5154,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Revised,7/12/21,,Availability and Estimated Shortage Duration (Discontinuance): January 2022,,,Psychiatry,To be Discontinued,7/12/21,7/12/21,68382-956-01,discontinued
5155,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Reverified,11/16/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0864-01,available
5156,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Reverified,11/16/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0853-01,available
5157,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Reverified,11/16/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0842-01,available
5158,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Reverified,11/16/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,0185-0831-01,available
5159,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0110-01,available
5160,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0112-01,available
5161,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0115-01,available
5162,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Reverified,11/8/21,Currently unavailable. Expected resupply end of September and product recovery October 2021,,,,Psychiatry,Current,,,57844-0120-01,not available
5163,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0130-01,available
5164,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0105-01,available
5165,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,57844-0117-01,available
5166,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4541-01,not available
5167,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4542-01,not available
5168,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4543-01,not available
5169,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4544-01,not available
5170,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4545-01,not available
5171,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4546-01,not available
5172,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Reverified,11/29/21,Out of Stock/Unavailable,,,Other,Psychiatry,Current,,,0378-4547-01,not available
5173,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Reverified,11/10/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0068-01,available
5174,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Reverified,11/10/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0070-01,available
5175,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Reverified,11/10/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0072-01,available
5176,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Reverified,11/10/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0073-01,available
5177,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Reverified,11/10/21,Available,,,Demand increase for the drug,Psychiatry,Current,,,13107-0074-01,available
5178,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0776-02,available
5179,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0777-02,available
5180,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0775-02,available
5181,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0972-02,available
5182,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0973-02,available
5183,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0974-02,available
5184,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Reverified,11/8/21,Available,,,,Psychiatry,Current,,,0555-0971-02,available
5185,Ampicillin for Injection,"Mylan Institutional, a Viatris company",250 mg (NDC 67457-353-10),New,9/23/21,,,,,Anti-Infective,To be Discontinued,9/23/21,9/23/21,67457-353-10,discontinued
5186,Ampicillin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-350-10),New,9/23/21,,,,,Anti-Infective,To be Discontinued,9/23/21,9/23/21,67457-350-10,discontinued
5187,"Ampicillin for Injection, USP","Hospira, Inc.",250 mg/vial; Single Dose Vial (powder) (NDC 00409-3719-01),New,12/14/20,,Discontinuation of the manufacture of the drug,,,Antiviral,To be Discontinued,12/14/20,12/14/20,00409-3719-01,discontinued
5188,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Revised,7/20/21,,,,,Hematology,Resolved,7/20/21,,0172-5240-60,
5189,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Revised,7/20/21,,,,,Hematology,Resolved,7/20/21,,0172-5241-60,
5190,Anagrelide Hydrochloride Capsules,Takeda Pharmaceuticals USA Inc.,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Revised,7/20/21,,,Available,,Hematology,Resolved,7/20/21,,54092-063-01,
5191,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,7/20/21,,,Available,,Hematology,Resolved,7/20/21,,13668-453-01,
5192,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,7/20/21,,,Available,,Hematology,Resolved,7/20/21,,13668-462-01,
5193,Asenapine (Saphris®) Sublingual Tablets,Allergan,5 mg (NDC 0456-2405-63),New,3/3/21,,The company has made a business decision to discontinue manufacturing this product. All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,3/3/21,3/3/21,0456-2405-63,discontinued
5194,Asenapine (Saphris®) Sublingual Tablets,Allergan,10 mg (NDC 0456-2410-63),New,3/3/21,,The company has made a business decision to discontinue manufacturing this product. All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,3/3/21,3/3/21,0456-2410-63,discontinued
5195,Asenapine Maleate (Saphris®) Sublingual Tablets,Allergan,Box of 100 (10 blisters with 10 tablets) (NDC 00456-2405-63),New,2/8/21,,The company has made a business decision to discontinue manufacturing this product.  All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,2/8/21,2/8/21,00456-2405-63,discontinued
5196,Asenapine Maleate (Saphris®) Sublingual Tablets,Allergan,Box of 100 (10 blisters with 10 tablets) (NDC 0456-2410-63),New,2/8/21,,The company has made a business decision to discontinue manufacturing this product.  All other Saphris® SKU’s remain available.,,,Psychiatry,To be Discontinued,2/8/21,2/8/21,0456-2410-63,discontinued
5197,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/20,,"Business decision made by the applicant, BIPI. BIPI will no longer be supplying the market with AGGRENOX capsules after June 11, 2020.",,,Cardiovascular,To be Discontinued,5/26/20,5/26/20,0597-0001-60,discontinued
5198,Atazanavir Capsules,Bristol Myers Squibb Co.,150mg (NDC 0003-3624-12),New,4/28/21,,"Product available until December 31, 2021.",,,Antiviral,To be Discontinued,4/28/21,4/28/21,0003-3624-12,discontinued
5199,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Reverified,5/19/21,Available,"American Regent is currently releasing the 0.4mg/mL, 1 mL vial, NDC 00517-0401-25",,Other,Anesthesia;Neurology;Pediatric,Current,,,00517-0401-25,available
5200,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-525-08)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-525-08,available
5201,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 20 mL multi-dose vial, pack of 10 (NDC 16729-512-43)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-512-43,available
5202,Atropine Sulfate Injection,Accord Healthcare Inc.,"1 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-526-08)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-526-08,available
5203,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.05 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-483-03)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-483-03,available
5204,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 10 mL prefilled syringe, pack of 10 (NDC 16729-484-45)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-484-45,available
5205,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-484-90)",New,9/10/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-484-90,available
5206,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,11/23/21,5 month expiry (4/2022 expiry) dating available  by request.,Check wholesaler inventory,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,63323-580-20,limited availability
5207,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3340-1),Revised,11/2/21,Backorder due to the increase in demands,,,,Anesthesia;Neurology;Pediatric,Current,,,76329-3340-1,not available
5208,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe
(NDC 0409-1630-10)",Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-1630-10,limited availability
5209,Atropine Sulfate Injection,"Hospira, Inc.","0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe
(NDC 0409-9630-05)",Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-9630-05,limited availability
5210,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-4910-34,not available
5211,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Revised,11/18/21,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,0409-4911-34,available
5212,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Reverified,5/19/21,Available,"American Regent is currently releasing the 1mg/mL, 1 mL vial, (NDC 00517-1010-25)",,Other,Anesthesia;Neurology;Pediatric,Current,,,00517-1010-25,available
5213,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0641-6006-10,available
5214,Atropine Sulfate Ophthalmic Ointment,Bausch Health,"1% (10 mg/g), 3.5 g tube (NDC 24208-825-55)",Revised,9/20/21,,,Available,,Ophthalmology,Resolved,9/20/21,,24208-825-55,
5215,Azacitidine for Injection,"Meitheal Pharmaceuticals, Inc.",100 mg per vial (NDC 71288-115-30),New,10/7/21,Available,Check wholesalers for inventory,,,Oncology,Current,,,71288-115-30,available
5216,Azacitidine for Injection,Teva Pharmaceuticals,100 mg/vial Lyophilized Powder (NDC 68001-0313-56),Reverified,11/8/21,No supply disruption - we are meeting current demand.,Product is manufactured and labeled for Blue Point Laboratories,,,Oncology,Current,,,68001-0313-56,available
5217,Azacitidine for Injection,Breckenridge Pharmaceutical,100 mg per vial (NDC 51991-797-98),Reverified,9/29/21,Available,,,,Oncology,Current,,,51991-797-98,available
5218,Azacitidine for Injection,Cipla Limited,100 mg per vial (NDC 69097-805-40),Revised,6/8/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,69097-805-40,available
5219,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94)",Revised,10/1/21,Available,"Distributed by Sandoz, Inc. Contact number 800-525-8747",,,Oncology,Current,,,0781-3253-94,available
5220,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94)",Revised,10/1/21,Available,"NOVAPLUS labeling. Distributed by Sandoz, Inc. Contact number 800-525-8747",,,Oncology,Current,,,0781-9253-94,available
5221,Azacitidine for Injection,Celgene Corporation,"VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01)",Revised,10/1/21,Available,,,,Oncology,Current,,,59572-102-01,available
5222,Azacitidine for Injection,"Fresenius Kabi USA, LLC","100 mg per vial, single dose vial, PF, (NDC 63323-771-39)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,63323-771-39,available
5223,Azacitidine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg per vial, (NDC 0143-9606-01)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,0143-9606-01,available
5224,Azacitidine for Injection,"Dr. Reddy's Laboratories, Inc.","100 mg per vial, (NDC 43598-305-62)",Revised,11/8/21,Low inventory,Partial shipments on allocation through December,,Demand increase for the drug,Oncology,Current,,,43598-305-62,limited availability
5225,Azacitidine for Injection,Armas Pharmaceuticals Inc,100 mg per vial (NDC 72485-201-01),Reverified,5/19/21,Limited availability,Additional lots are manufactured. Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,72485-201-01,limited availability
5226,Azacitidine for Injection,Accord Healthcare Inc.,100 mg per vial (NDC 16729-306-10),Revised,6/10/21,Limited availability.,,,Shortage of an active ingredient,Oncology,Current,,,16729-306-10,limited availability
5227,Azacitidine for Injection,"Mylan Institutional, a Viatris company",100 mg per vial (NDC 67457-254-30),Reverified,11/29/21,Unavailable,,,Other,Oncology,Current,,,67457-254-30,not available
5228,Azithromycin (Azasite) Ophthalmic Solution 1%,Akorn Pharmaceuticals,Azasite (Azithromycin Ophthalmic Solution) 1% 2.5 mL in 5 mL bottle (NDC 17478-307-03),Revised,9/11/19,,,,,Ophthalmology,Resolved,9/11/19,,17478-307-03,
5229,Azithromycin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-860-50),New,4/26/21,,,,,Anti-Infective,To be Discontinued,4/26/21,4/26/21,67457-860-50,discontinued
5230,Bacitracin Ophthalmic Ointment,Padagis US LLC,3.5 g (NDC 0574-4022-35),New,9/10/21,,,,,Ophthalmology,To be Discontinued,9/10/21,9/10/21,0574-4022-35,discontinued
5231,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Revised,2/25/21,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of Nulojix via the US NULOJIX Distribution Program, initiated 2/15/2017. Starting in August 2018, the restrictions of the NDP were eased to allow for expansion of use to appropriate new patients if the treating physician determines that Nulojix is the best treatment option for the patient. For further information, contact BMS Medical Information.",Increased demand for the drug exacerbated by a delay in transition to a more efficient manufacturing process.,,Demand increase for the drug,Transplant,Current,,,0003-0371-13,limited availability
5232,Benzonatate Capsules,Pfizer Pharmaceuticals,Tessalon 100 mg perles; Bottle of 100 (NDC 0069-0122-01),New,6/8/21,,Discontinuation of the manufacture of the drug.,,,Pulmonary/Allergy,To be Discontinued,6/8/21,6/8/21,0069-0122-01,discontinued
5233,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/19,,,,,Gastroenterology,To be Discontinued,12/23/19,12/23/19,0093-7445-01,discontinued
5234,Bumetanide Injection,"Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: March 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-1412-04,limited availability
5235,Bumetanide Injection,"Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-1412-10,limited availability
5236,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6008-10,available
5237,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and available in the October  - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6007-10,not available
5238,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 100 Tablets (NDC 14539-700-01),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-700-01,discontinued
5239,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 500 Tablets (NDC 14539-700-05),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-700-05,discontinued
5240,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",0.5 mg 1000 Tablets (NDC 14539-700-10),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-700-10,discontinued
5241,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 100 Tablets (NDC 14539-701-01),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-701-01,discontinued
5242,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 500 Tablets (NDC 14539-701-05),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-701-05,discontinued
5243,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",1 mg 1000 Tablets (NDC 14539-701-10),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-701-10,discontinued
5244,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 100 Tablets (NDC 14539-702-01),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-702-01,discontinued
5245,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 500 Tablets (NDC 14539-702-05),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-702-05,discontinued
5246,Bumetanide Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",2 mg 1000 Tablets (NDC 14539-702-10),New,2/18/21,,,,,Renal,To be Discontinued,2/18/21,2/18/21,14539-702-10,discontinued
5247,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-461-57,not available
5248,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,11/23/21,Backordered.  Next release January 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-463-57,not available
5249,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-17,not available
5250,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-37,not available
5251,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-17,not available
5252,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-37,not available
5253,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,11/23/21,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-462-31,not available
5254,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-460-37,not available
5255,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-01,not available
5256,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-17,not available
5257,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9043-01,not available
5258,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-01,not available
5259,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-17,not available
5260,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Revised,11/18/21,Next Delivery and Estimated Recovery: April 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9046-01,not available
5261,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Revised,11/18/21,Limited Supply Available. Next Delivery: February 2022; Estimated Recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-10,limited availability
5262,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-30,limited availability
5263,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Revised,11/18/21,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: May 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-10,limited availability
5264,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-29,limited availability
5265,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1752-50,not available
5266,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: May 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1755-50,not available
5267,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-167-10,available
5268,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-168-30,available
5269,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-169-10,available
5270,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-170-30,available
5271,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-171-10,available
5272,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-172-30,available
5273,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-249-50,available
5274,Bupivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-250-50,available
5275,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1159-01,not available
5276,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1159-02,not available
5277,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-1160-01,not available
5278,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1162-01,not available
5279,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1162-02,limited availability
5280,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-1163-01,available
5281,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-1165-01,available
5282,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-1165-02,available
5283,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-3613-01,limited availability
5284,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1559-10,not available
5285,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1559-30,limited availability
5286,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-1587-50,limited availability
5287,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1560-10,not available
5288,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1560-29,not available
5289,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,11/18/21,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1610-50,limited availability
5290,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-1582-10,available
5291,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,11/18/21,Limited Supply Available.,,,Demand increase for the drug,Anesthesia,Current,,,00409-1582-29,limited availability
5292,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-465-57,available
5293,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-467-57,available
5294,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-17,available
5295,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Revised,11/23/21,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-37,not available
5296,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Revised,11/23/21,Backordered.  Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
5297,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-17,available
5298,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-37,not available
5299,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Revised,11/23/21,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-466-31,not available
5300,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-17,available
5301,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Revised,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-37,available
5302,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-,limited availability
5303,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,11/23/21,Stocked out - recovery TBD,SPINAL 0.75% - Sterile Hyperbaric Solution for Spinal Anesthesia,,Manufacturing Delay,Anesthesia,Current,,,36000-092-10,not available
5304,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),Reverified,5/19/21,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-717-05,available
5305,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),Reverified,5/19/21,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-719-10,available
5306,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),Reverified,5/19/21,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-718-05,available
5307,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),Reverified,5/19/21,Available,"Areva Pharmaceuticals Inc., in conjunction with FDA, has initiated temporary importation of Bupivacaine Hydrochloride Injection USP (Preservative free, Latex free) 0.25% and 0.5% into the US market to address drug shortage.  Importation will begin mid-September 2019.  Product is available via authorized distributors (McKesson, Cardinal Health, Amerisource Bergen) . All orders must be placed with your authorized wholesalers.  Please call Areva Pharmaceutical Customer Service at  812-399-3599,  Option # 1 or email us at customerservice@arevapharma.com if you would like drop shipments.",,,Anesthesia,Current,,,59923-720-10,available
5308,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","HCl 0.75% & Dextrose 8.25%, Injectable spinal (NDC 73293-0002)",New,6/21/21,Available,"Drug Product is distributed by HUONS USA, please contact Tel : (949)656-6751 or E-mail: jmchoi@huonsglobal.com for supply related inquires.",,,Anesthesia,Current,,,73293-0002,available
5309,Busulfan Injection,American Regent/Luitpold,6 mg/mL  (NDC 0517-0920-08),New,8/6/21,,,,,Hematology,To be Discontinued,8/6/21,8/6/21,0517-0920-08,discontinued
5310,Busulfan Injection,Apotex Corp.,6mg/mL (NDCs 60505-6177-0 and 60505-6177-8),New,10/15/21,,,,,Hematology,To be Discontinued,10/15/21,10/15/21,,discontinued
5311,Calcitriol Injection 1MCG/ML,Akorn Pharmaceuticals,"Calcitriol Injection USP, 1 mcg/mL, 1 mL ampule  (NDC 17478-931-01)",Revised,10/6/21,,,Available,,Endocrinology/Metabolism,Resolved,10/6/21,,17478-931-01,
5312,Calcium Disodium Versenate Injection,Bausch Health,1000 mg/5 mL (200 mg/mL) (NDC 99207-240-05),Reverified,10/25/21,Not currently available. Estimated Shortage duration TBD,,,Requirements related to complying with good manufacturing practices,Other,Current,,,99207-240-05,not available
5313,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","1,000 mg calcium gluconate per 10 mL (100 mg/mL), single dose vial (NDC 63323-360-01, 1 vial; NDC 63323-360-19, 25 vials)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-01,available
5314,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","5,000 mg calcium gluconate per 50 mL (100 mg/mL), single dose vial (NDC 63323-360-03, 1 vial; NDC 63323-360-59, 25 vials)",Revised,11/23/21,Available,Check wholesaler for inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-03,available
5315,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","10,000 mg calcium gluconate per 100 mL (100 mg/mL), pharmacy bulk package vial (NDC 63323-360-05, 1 vial; NDC 63323-360-61, 20 vials)",Revised,11/23/21,Backordered. Next release January 2022,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-05,not available
5316,Calcium Gluconate Injection,HQ Specialty Pharma,1000 mg/50 mL (20 mg/mL) single-dose bag (NDC 44567-620-24),Revised,6/22/21,Available,Marketed by WG Critical Care,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,44567-620-24,available
5317,Calcium Gluconate Injection,HQ Specialty Pharma,2000 mg/100 mL (20 mg/mL) single-dose bag (NDC 44567-621-24),Revised,6/22/21,Available,Marketed by WG Critical Care,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,44567-621-24,available
5318,Capreomycin Injection,Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,5/5/21,,,,,Anti-Infective,To be Discontinued,5/5/21,5/5/21,17478-080-50,discontinued
5319,Captopril Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg; 25mg; 50mg; 100mg (NDC 0378-3007-10; 0378-3007-01; 0378-3012-10; 0378-3012-01; 0378-3017-10; 0378-3017-01; 0378-3022-01),New,8/9/21,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,8/9/21,8/9/21,0378-3007-10,discontinued
5320,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/15mg 100s Tabs (NDC 00378-0081-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,8/9/21,8/9/21,00378-0081-01,discontinued
5321,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/25mg 100s Tabs (NDC 00378-0083-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,8/9/21,8/9/21,00378-0083-01,discontinued
5322,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/15mg 100s Tabs (NDC 00378-0084-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,8/9/21,8/9/21,00378-0084-01,discontinued
5323,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/25mg 100s Tabs (NDC 00378-0086-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,8/9/21,8/9/21,00378-0086-01,discontinued
5324,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"50/12.5/200 mg, Bottle of 100 Tablets (NDC 64679-0782-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,64679-0782-04,discontinued
5325,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"75/18.75/200 mg, Bottle of 100 Tablets (NDC 64679-0783-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,64679-0783-04,discontinued
5326,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"100/25/200 mg, Bottle of 100 Tablets (NDC64679-0784-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,,discontinued
5327,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"125/31.25/200 mg, Bottle of 100 Tablets (NDC 64679-0785-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,64679-0785-04,discontinued
5328,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"150/37.5/200 mg, Bottle of 100 Tablets (NDC 64679-0786-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,64679-0786-04,discontinued
5329,"Carbidopa, Levodopa and Entacapone, Tablets",Wockhardt,"200/50/200 mg, Bottle of 100 Tablets (NDC 64679-0787-04)",New,3/3/21,,The discontinuation of the product was a result of a business decision.,,,Neurology,To be Discontinued,3/3/21,3/3/21,64679-0787-04,discontinued
5330,Carboplatin Injection,Ingenus Pharmaceuticals LLC,450 mg/45 mL (NDC 50742-448-45),New,4/7/21,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/21,4/7/21,50742-448-45,discontinued
5331,Carboplatin Injection,Ingenus Pharmaceuticals LLC,600 mg/60 mL (10 mg/mL)(NDC 50742-447-60),New,4/7/21,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/21,4/7/21,50742-447-60,discontinued
5332,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/18,,The decision to discontinue the 0.2 mg/mL in 5% Dextrose formulation was business related.  Other formulations of Cardene IV remain available.,,,Cardiovascular,To be Discontinued,3/20/18,3/20/18,10122-326-10,discontinued
5333,"Carisoprodol, Aspirin, and Codeine Phosphate Tablets USP",Ingenus Pharmaceuticals LLC,200 mg/325 mg/16 mg (NDC 50742-256-01),New,9/1/20,,,,,Musculoskeletal,To be Discontinued,9/1/20,9/1/20,50742-256-01,discontinued
5334,Caspofungin Acetate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",50 mg (NDC 67457-831-50),New,7/23/20,,,,,Anti-Infective;Pediatric,To be Discontinued,7/23/20,7/23/20,67457-831-50,discontinued
5335,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,11/18/21,Available,,,Other,Anti-Infective,Current,,,00409-2585-01,available
5336,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,10/27/21,Available,,,,Anti-Infective,Current,,,60505-6142-05,available
5337,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,10/22/21,Available,,,,Anti-Infective,Current,,,25021-102-99,available
5338,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,10/22/21,Available,,,,Anti-Infective,Current,,,25021-100-10,available
5339,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,7/15/21,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,00264-3105-11,limited availability
5340,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,7/15/21,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,0264-3103-11,limited availability
5341,Cefazolin Injection,WG Critical Care,500mg SDV (NDC 44567-706-25),Reverified,8/31/21,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-706-25,available
5342,Cefazolin Injection,WG Critical Care,1g SDV (NDC 44567-707-25),Reverified,8/31/21,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-707-25,available
5343,Cefazolin Injection,WG Critical Care,10g PBP (NDC 44567-708-10),Reverified,8/31/21,Available,Please check wholesalers for available inventory.,,Demand increase for the drug,Anti-Infective,Current,,,44567-708-10,available
5344,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,00409-0805-01,discontinued
5345,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Revised,10/2/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/20,10/2/20,00409-0805-01,discontinued
5346,Cefazolin Injection,"Hospira, Inc.",10 g Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-0806-01),Revised,10/2/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/2/20,10/2/20,00409-0806-01,discontinued
5347,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,10/12/21,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9923-90,available
5348,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,10/12/21,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9924-90,available
5349,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,10/12/21,Inventory is currently available,Product will be made available as it is released.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9983-03,available
5350,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,11/16/21,Available,,,,Anti-Infective,Current,,,0781-3450-95,available
5351,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,11/16/21,Available,,,,Anti-Infective,Current,,,0781-3451-96,available
5352,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,11/16/21,Available,,,,Anti-Infective,Current,,,0781-3452-95,available
5353,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,10/27/21,Available,,,,Anti-Infective,Current,,,60505-6143-04,available
5354,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,10/22/21,Available,,,,Anti-Infective,Current,,,25021-101-10,available
5355,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Reverified,11/23/21,Available,,,,Anti-Infective,Current,,,0338-3503-41,available
5356,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Reverified,11/23/21,Available,,,,Anti-Infective,Current,,,0338-3508-41,available
5357,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,11/18/21,Available,,,,Anti-Infective,Current,,,66288-1100-1,available
5358,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,11/18/21,Available,,,,Anti-Infective,Current,,,66288-1300-1,available
5359,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/20,,,,,Anti-Infective,To be Discontinued,7/9/20,7/9/20,0781-2176-60,discontinued
5360,Cefdinir Powder for Suspension,Sandoz,125 mg/5 mL (NDCs 0781-6077-46 and 0781-6077-61),New,10/29/21,,,,,Anti-Infective,To be Discontinued,10/29/21,10/29/21,,discontinued
5361,Cefdinir Powder for Suspension,Sandoz,250 mg/5 mL (NDCs 0781-6078-46 and 0781-6078-61),New,10/29/21,,,,,Anti-Infective,To be Discontinued,10/29/21,10/29/21,,discontinued
5362,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Reverified,10/14/21,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact Direct Success at Distribution@DSuccess.com or 1-877-404-3338.",,Other,Anti-Infective;Pediatric,Current,,,21586-012-2,available
5363,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Reverified,10/14/21,Available,"SteriMax in conjunction with FDA has initiated a temporary importation of Cefotaxime sodium for Injection, BP into the U.S. market to address drug shortage. To place an order, please contact Direct Success at Distribution@DSuccess.com or 1-877-404-3338.",,Other,Anti-Infective;Pediatric,Current,,,21586-011-2,available
5364,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,10/12/21,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9930-10,not available
5365,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,10/12/21,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9931-25,not available
5366,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,10/12/21,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9933-25,not available
5367,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,10/12/21,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9935-01,not available
5368,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Reverified,5/19/21,Product not available; Expected recovery: December 2021,,,Other,Anti-Infective,Current,,,00264-3173-11,not available
5369,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Reverified,5/19/21,Product not available; Expected recovery: December 2021,,,Other,Anti-Infective,Current,,,00264-3175-11,not available
5370,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Reverified,11/23/21,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0385-10,available
5371,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Reverified,11/23/21,Available,Check wholesalers for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0386-20,available
5372,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Reverified,11/23/21,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,63323-0396-61,not available
5373,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,10/13/21,Discontinued,,,,Anti-Infective,Current,,,52565-0053-10,discontinued
5374,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),New,3/25/21,,Business decision to discontinue manufacture of the product,,,Anti-Infective,To be Discontinued,3/25/21,3/25/21,52565-0053-10,discontinued
5375,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,0143-9878-25,
5376,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,0143-9877-25,
5377,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,0143-9876-10,
5378,Cefoxitin for Injection,Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Revised,11/18/21,,,,,Anti-Infective,Resolved,11/18/21,,60505-0759-05,
5379,Cefoxitin for Injection,Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Revised,11/18/21,,,,,Anti-Infective,Resolved,11/18/21,,60505-0761-04,
5380,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,63323-341-25,
5381,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,63323-342-25,
5382,Cefoxitin for Injection,Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,25021-111-99,
5383,Cefoxitin for Injection,Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,25021-109-10,
5384,Cefoxitin for Injection,Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,25021-110-20,
5385,Cefoxitin for Injection,WG Critical Care,1 g (NDC 44567-245-25),Revised,11/18/21,Available,,Available,,Anti-Infective,Resolved,11/18/21,,44567-245-25,available
5386,Cefoxitin for Injection,WG Critical Care,2 g (NDC 44567-246-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,44567-246-25,
5387,Cefoxitin for Injection,WG Critical Care,10 g (NDC 44567-247-10),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,44567-247-10,
5388,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,00264-3125-11,
5389,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,11/18/21,,0264-3123-11,
5390,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0412-00,discontinued
5391,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0413-00,discontinued
5392,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",Revised,2/8/21,The product is available through direct distribution from the manufacturer. Please contact your wholesaler or customer service.,,,Regulatory delay,Anti-Infective,Current,,,0456-2700-01,unclear
5393,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",Revised,2/8/21,The product is available through direct distribution from the manufacturer.  Please contact your wholesaler or customer service.,,,Regulatory delay,Anti-Infective,Current,,,0456-2700-10,unclear
5394,Ceftolozane and Tazobactam (Zerbaxa) Injection,Merck Sharp & Dohme Corp.,Supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial. Vials are supplied in cartons containing 10 vials (NDC 67919-030-01),Reverified,11/15/21,"unavailable, resupply expected approximately December 2021",,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,67919-030-01,not available
5395,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/18,,No longer manufacturing product,,,Anti-Infective;Pediatric,To be Discontinued,3/20/18,3/20/18,24987-0425-00,discontinued
5396,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 1000 count (NDC 0555-0033-05)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0033-05,available
5397,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 100 count (NDC 0555-0033-02)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0033-02,available
5398,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 100 count (NDC 0555-0159-02)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0159-02,available
5399,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 500 count (NDC 0555-0158-04)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0158-04,available
5400,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 500 count (NDC 0555-0159-04)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0159-04,available
5401,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 100 count (NDC 0555-0158-02)",Reverified,11/8/21,Available,This product is on allocation.,,,Neurology;Psychiatry,Current,,,0555-0158-02,available
5402,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","10mg, 100ct (NDC 42806-562-01)",Revised,11/18/21,Available,,,,Neurology;Psychiatry,Current,,,42806-562-01,available
5403,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","25mg, 100ct (NDC 42806-563-01)",Revised,11/18/21,Available,,,,Neurology;Psychiatry,Current,,,42806-563-01,available
5404,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","5mg, 100ct (NDC 42806-564-01)",New,11/18/21,Available,,,,Neurology;Psychiatry,Current,,,42806-564-01,available
5405,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-251-10,discontinued
5406,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/19,,"Product discontinuation as per business decision, non-safety related. Distributed by Solco Healthcare U.S., LLC. 
For additional information, please contact : 
Solco Healthcare US
email: chris.keith@solcohealthcare.com",,,Neurology;Psychiatry,To be Discontinued,11/19/19,11/19/19,43547-252-10,discontinued
5407,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal® (Chloroprocaine HCl Injection, USP) 5mL ampules 50 mg/5 mL (10 mg/mL) Catalog D7055 (NDC 0264-7055-05)",New,5/17/21,Product available,,,Other,Anesthesia,Current,,,0264-7055-05,available
5408,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 1% (300 mg per 30 mL) (10 mg per mL); MDV; (NDC 63323-475-37),Revised,11/23/21,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-475-37,available
5409,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 2% (600 mg per 30 mL) (20 mg per mL); MDV; (NDC 63323-476-37),Revised,11/23/21,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-476-37,available
5410,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 2% (400 mg per 20 mL) (20 mg per mL); SDV; (NDC 63323-477-27),Revised,11/23/21,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-477-27,available
5411,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 3% (600 mg per 20 mL) (30 mg per mL); SDV; (NDC 63323-478-27),Revised,11/23/21,Backordered. Next release December 2021.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-478-27,not available
5412,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% (20 mg/mL), 20 mL vial (NDC 0143-9209-10)",New,5/17/21,Inventory is currently available.,Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9209-10,available
5413,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","3% (30 mg/mL), 20 mL vial (NDC 0143-9210-10)",New,5/17/21,This presentation is temporarily on backorder.,Additional lots will be available in the June 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9210-10,not available
5414,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/5 mL Single Dose Vial, Package of 10 vials (NDC 55150-284-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,55150-284-10,
5415,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,,
5416,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0703-2045-03,
5417,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0703-2056-03,
5418,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0703-2033-03,
5419,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),Revised,7/27/21,,,,,Anesthesia,Resolved,7/27/21,,70069-141-10,
5420,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),Revised,7/27/21,,,,,Anesthesia,Resolved,7/27/21,,70069-161-10,
5421,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),Revised,7/27/21,,,,,Anesthesia,Resolved,7/27/21,,70069-151-10,
5422,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,71288-712-06,
5423,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,71288-713-21,
5424,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,71288-712-11,
5425,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,63323-416-05,
5426,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,63323-417-10,
5427,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,63323-418-20,
5428,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0781-3150-95,
5429,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0781-3152-95,
5430,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0781-3153-95,
5431,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,00409-1098-02,
5432,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,00409-1103-01,
5433,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,00409-1208-01,
5434,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0074-4378-05,
5435,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0074-4380-10,
5436,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,7/27/21,,0074-4382-20,
5437,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 pledgets (NDC 0009-3116-14),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3116-14,discontinued
5438,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical solution 1 x 60 mL applicator bottle (NDC 0009-3116-02),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3116-02,discontinued
5439,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 60 g tube (NDC 0009-3331-01),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3331-01,discontinued
5440,Cleocin-T 1%,Pfizer Pharmaceuticals,Topical gel 1 x 30 g tube (NDC 0009-3331-02),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,0009-3331-02,discontinued
5441,"Clindamycin and Benzoyl Peroxide Gel, 1%/5%","Tolmar Pharmaceuticals, Inc.",45g jar (NDC 0781-7263-68); 35g pump (NDC 0781-7275-43); 50g jar (NDC 0781-7287-50); 50g pump (NDC 0781-7291-46),New,9/30/21,,"A business decision was made to discontinue manufacture of the drug product. Distributed by: Sandoz, Inc.. Sandoz Customer Service Number: 1-800-525-8747",,,Dermatology,To be Discontinued,9/30/21,9/30/21,0781-7263-68,discontinued
5442,Clindamycin Injection,"Mylan Institutional, a Viatris company",6 mL/vial (NDC 67457-816-06),New,10/23/20,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/23/20,10/23/20,67457-816-06,discontinued
5443,Clindamycin Injection,"Mylan Institutional, a Viatris company","150 mg/1 mL; 4 mL in 1 vial, Single dose; 25 vial/carton (NDC 67457-815-04)",New,1/8/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,1/8/21,1/8/21,67457-815-04,discontinued
5444,Clindamycin Injection,"Mylan Institutional, a Viatris company",300 mg/ 2 mL; Solution in Single Dose Vials (containing preservatives) (NDC 67457-814-02),New,6/1/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,6/1/21,6/1/21,67457-814-02,discontinued
5445,"Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%","Tolmar Pharmaceuticals, Inc.",45 g tube (NDC 0781-7161-19),New,9/30/21,,"A business decision was made to discontinue manufacture of the drug product. Distributed by: Sandoz, Inc.. Sandoz Customer Service Number: 1-800-525-8747",,,Dermatology,To be Discontinued,9/30/21,9/30/21,0781-7161-19,discontinued
5446,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",30mL (NDC 52565-018-29),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-018-29,discontinued
5447,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",60mL (NDC 52565-018-59),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-018-59,discontinued
5448,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-039-15),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-039-15,discontinued
5449,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-039-30),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-039-30,discontinued
5450,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",45g (NDC 52565-039-45),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-039-45,discontinued
5451,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-039-60),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-039-60,discontinued
5452,Clobetasol Propionate Topical Foam,Ingenus Pharmaceuticals LLC,0.05% (NDCs 50742-304-01 and 50742-304-50),New,11/16/21,,,,,Dermatology,To be Discontinued,11/16/21,11/16/21,,discontinued
5453,Clobetasol Propionate Topical Solution 0.05%,"Tolmar Pharmaceuticals, Inc.",25 mL (NDC 63646-500-25),New,12/8/20,,,,,Dermatology,To be Discontinued,12/8/20,12/8/20,63646-500-25,discontinued
5454,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",25 mL bottle (NDC 63646-500-25),New,11/1/21,,,,,Dermatology,To be Discontinued,11/1/21,11/1/21,63646-500-25,discontinued
5455,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",50 mL bottle (NDC 63646-500-50),New,11/1/21,,,,,Dermatology,To be Discontinued,11/1/21,11/1/21,63646-500-50,discontinued
5456,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-77,discontinued
5457,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-01,discontinued
5458,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1910-10,discontinued
5459,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-77,discontinued
5460,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-01,discontinued
5461,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1912-10,discontinued
5462,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-01,discontinued
5463,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric,To be Discontinued,5/8/18,5/8/18,0378-1914-05,discontinued
5464,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-01,discontinued
5465,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-05,discontinued
5466,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0063-10,discontinued
5467,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-01,discontinued
5468,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-05,discontinued
5469,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-8018-10,discontinued
5470,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-01,discontinued
5471,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-752-02,discontinued
5472,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-01,discontinued
5473,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Northstar Rx LLC",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,16714-469-02,discontinued
5474,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-01,discontinued
5475,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-05,discontinued
5476,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0185-0064-10,discontinued
5477,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-01,discontinued
5478,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-05,discontinued
5479,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/18,,"Sandoz Inc. has made a business decision to permanently discontinue Clonazepam Tablets, marketed by Sandoz",,,Neurology;Pediatric,To be Discontinued,6/5/18,6/5/18,0781-5567-10,discontinued
5480,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.1 mg tablets (NDC 0597-0006-01),New,1/6/21,,,,,Cardiovascular,To be Discontinued,1/6/21,1/6/21,0597-0006-01,discontinued
5481,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.2 mg tablets (NDC 0597-0007-01),New,1/6/21,,,,,Cardiovascular,To be Discontinued,1/6/21,1/6/21,0597-0007-01,discontinued
5482,Clonidine Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",0.3 mg tablets (NDC 0597-0011-01),New,1/6/21,,,,,Cardiovascular,To be Discontinued,1/6/21,1/6/21,0597-0011-01,discontinued
5483,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-101-10,discontinued
5484,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-01,discontinued
5485,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-102-10,discontinued
5486,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-01,discontinued
5487,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-01,discontinued
5488,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-105-10,discontinued
5489,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-01,discontinued
5490,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-106-10,discontinued
5491,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/19,,A commercial decision has been made to discontinue the sale of the product.,,,Psychiatry,To be Discontinued,11/22/19,11/22/19,18860-104-10,discontinued
5492,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-113-06,limited availability
5493,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-108-06,limited availability
5494,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,,limited availability
5495,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-105-06,limited availability
5496,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-103-06,limited availability
5497,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-102-06,limited availability
5498,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-111-06,limited availability
5499,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-116-06,limited availability
5500,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,11/23/21,Available on allocation,,,,Renal,Current,,,24571-117-06,limited availability
5501,Cortisone Acetate Tablets,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg, bottles of 100 (NDC 0143-9700-01)",Reverified,11/2/21,Currently Unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient,Endocrinology/Metabolism;Rheumatology,Current,,,0143-9700-01,not available
5502,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-02,available
5503,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-05,available
5504,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0395-15,available
5505,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-02,available
5506,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-05,available
5507,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-02,available
5508,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-05,available
5509,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-15,available
5510,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/20,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-01,available
5511,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/20,Available,"Product distributed by Sandoz. Company Contact Information:
800-525-8747",,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-03,available
5512,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",Revised,6/24/21,On backorder. Estimated availability: Mid-September 2021,"Distributed by Bausch + Lomb, a division of Bausch Health US, LLC – 1-800-321-4576",,Other,Ophthalmology,Current,,,24208-735-01,not available
5513,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-12,not available
5514,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-02,not available
5515,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-10,not available
5516,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",Revised,6/24/21,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,17478-100-02,not available
5517,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",Revised,6/24/21,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,17478-100-12,not available
5518,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (NDC 54482-020-01)",Revised,12/21/20,In shortage; Estimated shortage duration:  Unknown,"Delay in manufacturing. For more information please contact 1-866-634-2765, Leadiant@tmac.com, or go to  www.leadiant.com",,Other,Ophthalmology,Current,,,54482-020-01,limited availability
5519,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/19,,,Available,,Other;Pediatric,Resolved,9/3/19,,51754-1007-1,
5520,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), vial (NDC 67457-452-20)",New,5/21/21,,,,,Oncology;Pediatric,To be Discontinued,5/21/21,5/21/21,67457-452-20,discontinued
5521,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), vial (NDC 67457-455-52)",New,5/21/21,,,,,Oncology;Pediatric,To be Discontinued,5/21/21,5/21/21,67457-455-52,discontinued
5522,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), vial (NDC 67457-454-50)",New,5/21/21,,,,,Oncology;Pediatric,To be Discontinued,5/21/21,5/21/21,67457-454-50,discontinued
5523,Cytarabine Injection,"Fresenius Kabi USA, LLC","2 g/20 mL (100 mg/mL), single dose vial (NDC 63323-120-20)",New,9/24/21,Backordered.  Next release October 2021.,Manufacturing delay.  Check wholesaler inventory,,Other,Oncology;Pediatric,Current,,,63323-120-20,not available
5524,Cytarabine Injection,"Hospira, Inc.","100 mg/5 mL (20 mg/mL), single dose vial (NDC 61703-305-38)",Revised,11/18/21,Available,,,Other,Oncology;Pediatric,Current,,,61703-305-38,available
5525,Cytarabine Injection,"Hospira, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 61703-319-22)",Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,61703-319-22,limited availability
5526,Cytarabine Injection,"Hospira, Inc.","500 mg/25 mL (20 mg/mL), multiple dose vial (NDC 61703-304-36)",Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,61703-304-36,limited availability
5527,Cytarabine Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 61703-303-46)",Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Oncology;Pediatric,Current,,,61703-303-46,limited availability
5528,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 71288-109-20)",New,9/24/21,"Currently, no inventory",Manufacturing delay,,Other,Oncology;Pediatric,Current,,,71288-109-20,not available
5529,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), single dose vial (NDC 67457-452-20)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-452-20,not available
5530,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), single dose vial (NDC 67457-455-52)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-455-52,not available
5531,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 67457-454-50)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-454-50,not available
5532,Cytotec (Misoprostol) Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 0025-1451-20),New,6/11/21,,Discontinuation of the manufacture of the drug.,,,Gastroenterology,To be Discontinued,6/11/21,,0025-1451-20,discontinued
5533,"Dacarbazine for Injection, USP","Hospira, Inc.",200 mg Single Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0327-22),New,1/14/21,,Discontinuation of the manufacture of the drug,,,Oncology,To be Discontinued,1/14/21,1/14/21,61703-0327-22,discontinued
5534,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 10x20mL (NDC 00703-5075-03),New,10/20/21,Limited quantities are available,,,Other,Oncology,Current,,,00703-5075-03,limited availability
5535,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 1x20mL (NDC 00703-5075-01),New,10/20/21,Limited quantities are available,,,Other,Oncology,Current,,,00703-5075-01,limited availability
5536,Dacarbazine Injection,"Fresenius Kabi USA, LLC","100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10)",Reverified,11/23/21,Backordered. Next release November 2021.,,,Manufacturing delay,Oncology,Current,,,63323-127-10,not available
5537,Dacarbazine Injection,"Fresenius Kabi USA, LLC","200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20)",Reverified,11/23/21,Backordered. Next release November 2021.,,,Manufacturing delay,Oncology,Current,,,63323-128-20,not available
5538,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",200 mg/vial (NDC 0143-9245-10),Revised,10/27/21,This presentation is temporarily on backorder.,Additional lots will be available in the beginning of November 2021.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,0143-9245-10,not available
5539,Daptomycin Injection,Merck Sharp & Dohme Corp.,500 mg (NDC 67919-011-01),New,10/8/21,,,,,Anti-Infective,To be Discontinued,10/8/21,10/8/21,67919-011-01,discontinued
5540,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/20,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/20,6/17/20,0591-4375-19,discontinued
5541,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/20,,Discontinuance of Manufacturing,,,Urology,To be Discontinued,6/17/20,6/17/20,,discontinued
5542,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-15,discontinued
5543,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-23,discontinued
5544,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-00,discontinued
5545,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0171-96,discontinued
5546,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-15,discontinued
5547,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-23,discontinued
5548,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-00,discontinued
5549,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/20,,Allergan has made a business decision to permanently discontinue the drug product.,,,Urology,To be Discontinued,6/4/20,6/4/20,0430-0170-96,discontinued
5550,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary.",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-0063-28,discontinued
5551,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3516-56,discontinued
5552,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3517-56,discontinued
5553,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/20,,Teva had evaluated the market and made a business decision to discontinue the product.,,,Hematology,To be Discontinued,7/20/20,7/20/20,00093-3515-56,discontinued
5554,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","500 mg per vial, Single use vial, Carton of 4 vials (NDC 52609-4505-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4505-6,
5555,"Deferoxamine Mesylate for Injection, USP","ApoPharma USA, Inc.","2 g per vial, Single use vial, Carton of 4 vials (NDC 52609-4504-6)",Revised,9/10/19,,,,,Hematology,Resolved,9/10/19,,52609-4504-6,
5556,Desmopressin Acetate Nasal Spray,Ferring,"1.5 mg/mL, (NDC 0053-6871-00)",Revised,5/14/21,Unavailable,,,Other,Hematology,Current,,,0053-6871-00,not available
5557,Desmopressin Acetate Nasal Spray,Apotex Corp.,10 mcg/0.1mL (NDC 60505-0815-0),Reverified,6/24/21,Available,,,,Hematology,Current,,,60505-0815-0,available
5558,Desmopressin Acetate Nasal Spray,Ferring,10 mcg/0.1mL (NDCs 55566-2500-0 and 69918-501-05),New,5/14/21,Unavailable,,,Other,Hematology,Current,,,,not available
5559,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/14,,Product will be delisted. Last distribution March 2015.,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,10/8/14,,50458-196-15,discontinued
5560,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,11/29/21,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-423-12,available
5561,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,11/29/21,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-422-54,available
5562,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,11/29/21,Intermittent supply,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-421-30,limited availability
5563,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,11/29/21,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-420-10,available
5564,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),4 mg/1 mL SDV (NDC 55150-237-01),Revised,11/5/21,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-237-01,not available
5565,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,11/5/21,Backordered — next shipment TBD,Sporadic availability expected.,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-238-05,not available
5566,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),120 mg/30 mL MDV (NDC 55150-239-30),Revised,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-239-30,not available
5567,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,5/19/21,Currently in Stock (we have capacity constraint but product available at this time). Estimated Release Dates: Released Product Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,70069-021-25,available
5568,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,11/23/21,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-05,available
5569,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-516-10,not available
5570,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,11/23/21,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-30,available
5571,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,11/23/21,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-01,available
5572,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-506-01,not available
5573,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6145-25,available
5574,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6146-25,available
5575,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-0367-25,available
5576,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Revised,11/23/21,8 month expiry (7/2022 expiry) dating available by request.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-106-10,limited availability
5577,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Revised,11/23/21,8 month expiry (7/2022 expiry) dating available by request.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-109-10,limited availability
5578,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),10 mg/1 mL SDV (NDC 55150-304-25),Revised,11/5/21,Currently on backorder - next shipment anticipated early Nov,Check wholesalers for inventory,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-304-25,not available
5579,Dexamethasone Sodium Phosphate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-305-10,not available
5580,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9532-25,available
5581,Dexmedetomidine Injection,Amneal Pharmaceutical,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1388-8 box of 20; NDC 70121-1388-1 individual)",New,4/6/21,Available,,,,Anesthesia,Current,,,70121-1388-8,available
5582,Dexmedetomidine Injection,Amneal Pharmaceutical,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1389-7 box of 10; NDC 70121-1389-1 individual)",New,4/6/21,Available,,,,Anesthesia,Current,,,70121-1389-7,available
5583,Dexmedetomidine Injection,Gland Pharma Limited,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-976-58)",Reverified,11/5/21,Inventory available,Marketed by Dr. Reddy’s Laboratories Inc. Check wholesalers for inventory.,,,Anesthesia,Current,,,43598-976-58,available
5584,Dexmedetomidine Injection,Gland Pharma Limited,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-975-58)",Reverified,11/5/21,Inventory available,Marketed by Dr. Reddy’s Laboratories Inc. Check wholesalers for inventory..,,,Anesthesia,Current,,,43598-975-58,available
5585,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200mcg/50mL, single dose bag (NDC 55150-296-10)",Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-296-10,available
5586,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"400mcg/100mL, single dose bag (NDC 55150-297-10)",Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-297-10,available
5587,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.2 mg / 50 ml (Solution in Single Use Vials/Bottles), 20PK (NDC 67457-924-50)",Revised,11/29/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-924-50,available
5588,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.4 mg / 100 ml (Solution in Single Use Vials/Bottles), 10PK (NDC 67457-925-10)",Revised,11/29/21,Available,,,Demand increase for the drug,,Current,,,67457-925-10,available
5589,Dexmedetomidine Injection,Par Pharmaceutical,"200 mcg/50 mL (4 mcg/mL), 50 mL single dose vial, box of 25 (NDC 42023-186-20)",Reverified,11/3/21,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-186-20,unclear
5590,Dexmedetomidine Injection,Par Pharmaceutical,"400 mcg/100 mL (4 mcg/mL), 100 mL single dose vial, box of 10 (NDC 42023-187-10)",Reverified,11/3/21,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-187-10,unclear
5591,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Revised,9/13/21,Available,,,,Anesthesia,Current,,,16729-239-93,available
5592,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Revised,9/13/21,Available,,,,Anesthesia,Current,,,16729-432-93,available
5593,Dexmedetomidine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-209-02,available
5594,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,11/23/21,Available,,,,Anesthesia,Current,,,0338-9555-24,available
5595,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,11/23/21,Available,,,,Anesthesia,Current,,,0338-9557-12,available
5596,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,11/23/21,Available,,,,Anesthesia,Current,,,43066-555-24,available
5597,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,11/23/21,Available,,,,Anesthesia,Current,,,43066-557-12,available
5598,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,11/23/21,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-671-20,not available
5599,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,11/23/21,5 month expiry (4/2022 expiry) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-671-50,limited availability
5600,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,11/23/21,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-671-00,not available
5601,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-421-02,available
5602,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Reverified,8/31/21,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-600-04,available
5603,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Reverified,8/31/21,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-601-04,available
5604,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Reverified,8/31/21,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-602-24,available
5605,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Reverified,8/31/21,Available,Distributed by WG Critical Care. Please contact WG Critical Care at 888-493-0861.,,Demand increase for the drug,Anesthesia,Current,,,44567-603-24,available
5606,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,11/5/21,Available,"Distributed by Athenex. To order, contact Athenex at 855-273-0154.",,Demand increase for the drug,Anesthesia,Current,,,70860-605-03,available
5607,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Revised,11/29/21,Short dated stock (4/2022 expiry) available by request. Additional manufacturer in progress.,,,Demand increase for the drug,Anesthesia,Current,,,67457-251-02,limited availability
5608,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,11/3/21,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-146-25,unclear
5609,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Reverified,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,,Anesthesia,Current,,,0409-1660-20,limited availability
5610,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Reverified,11/18/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-50,available
5611,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery; July 2022,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-10,limited availability
5612,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Reverified,11/18/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,0409-1638-02,available
5613,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,5/20/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,71225-126-05,available
5614,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,5/20/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,71225-126-06,available
5615,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1070-01,discontinued
5616,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1071-01,discontinued
5617,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Neurology;Pediatric;Psychiatry,To be Discontinued,5/8/18,5/8/18,0378-1072-01,discontinued
5618,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container.  Product code 2B0062Q  (NDC 0338-0017-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-02,
5619,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container.  Product code 2B0063Q  (NDC 0338-0017-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-03,
5620,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLEX Plastic Container. Product code 2B0064X  (NDC 0338-0017-04)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-04,
5621,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL AVIVA Container.  Product code 6E0062 (NDC 0338-6346-02)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-02,
5622,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL AVIVA Container. Product code 6E0063  (NDC 0338-6346-03)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-6346-03,
5623,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-02),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-02,
5624,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-03),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-03,
5625,Dextrose 5% Injection Bags,"ICU Medical, Inc.",1000 mL (NDC 0409-7922-09),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-09,
5626,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL VisIV™ Container (NDC 0409-7922-25),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-25,
5627,Dextrose 5% Injection Bags,"ICU Medical, Inc.",250 mL (NDC 0409-7922-53),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-53,
5628,Dextrose 5% Injection Bags,"ICU Medical, Inc.",500 mL (NDC 0409-7922-55),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-55,
5629,Dextrose 5% Injection Bags,"ICU Medical, Inc.",150 mL (NDC 0409-7922-61),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7922-61,
5630,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL VisIV™ Container (NDC 0409-7923-06),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-06,
5631,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL VisIV™ Container (NDC 0409-7923-11),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-11,
5632,Dextrose 5% Injection Bags,"ICU Medical, Inc.",50 mL (NDC 0409-7923-13),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-13,
5633,Dextrose 5% Injection Bags,"ICU Medical, Inc.","25 mL, Quad Pack (NDC 0409-7923-20)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-20,
5634,Dextrose 5% Injection Bags,"ICU Medical, Inc.",100 mL (NDC 0409-7923-23),Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-23,
5635,Dextrose 5% Injection Bags,"ICU Medical, Inc.","50 mL, Quad Pack (NDC 0409-7923-36)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-36,
5636,Dextrose 5% Injection Bags,"ICU Medical, Inc.","100 mL, Quad Pack (NDC 0409-7923-37)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0409-7923-37,
5637,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL, in VIAFLEX Plastic Container. Quad Pack.  Product code 2B0080  (NDC 0338-0017-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0017-10,
5638,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, in VIAFLEX Plastic Container.  Single Pack. Product code EZPB0041 (NDC 0338-9147-30)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-9147-30,
5639,Dextrose 5% Injection Bags,Baxter Healthcare,"5% Dextrose Injection, USP, in VIAFLO container Product codes:  UE0062D (250mL, NDC 0338-0062-30); UE0063D (500mL, NDC 0338-0066-20); UE0064D (1000mL, NDC 0338-0070-10)",Revised,9/23/19,,,,,Gastroenterology;Other;Pediatric,Resolved,9/23/19,,0338-0062-30,
5640,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction;Rheumatology,To be Discontinued,4/4/18,4/4/18,0378-0355-01,discontinued
5641,Diclofenac Sodium Topical Solution,"Teligent Pharma, Inc.",1.5% 60mL bottle (NDC 52565-002-59),New,2/18/21,,Long-term back order with no date of return; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,2/18/21,2/18/21,52565-002-59,discontinued
5642,Diclofenac Sodium Topical Solution,"Teligent Pharma, Inc.",1.5% 150mL bottle (NDC 51565-002-05),New,2/18/21,,Long-term back order with no date of return; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To be Discontinued,2/18/21,2/18/21,51565-002-05,discontinued
5643,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0588-01,discontinued
5644,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0589-01,discontinued
5645,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/18,,This was a business-related decision to discontinue manufacturing these products,,,Antiviral,To be Discontinued,5/9/18,5/9/18,0555-0590-01,discontinued
5646,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",15g (NDC 52565-063-15),New,7/6/21,,,,,Dermatology,To be Discontinued,7/6/21,7/6/21,52565-063-15,discontinued
5647,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",30g (NDC 52565-063-30),New,7/6/21,,,,,Dermatology,To be Discontinued,7/6/21,7/6/21,52565-063-30,discontinued
5648,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",60g (NDC 52565-063-60),New,7/6/21,,,,,Dermatology,To be Discontinued,7/6/21,7/6/21,52565-063-60,discontinued
5649,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/19,,,,,Ophthalmology,Resolved,10/15/19,,0065-9204-07,
5650,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) Ampule (NDC 0515-260-10),Revised,10/6/21,Available,,,Delay in shipping of the drug,Cardiovascular,Current,,,0515-260-10,available
5651,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) vial (NDC 70515-261-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-261-10,available
5652,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) ampoule (NDC 70515-262-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-262-10,available
5653,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) vial (NDC 70515-263-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-263-10,available
5654,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","250 mcg/mL, 2 mL  (NDC 0641-1410-35)",New,6/4/21,This presentation is on backorder.,Product recovery is undetermined at this time.,,Other,Cardiovascular,Current,,,0641-1410-35,not available
5655,Digoxin Injection,Sandoz,500mcg/2 mL; 10 ampules (NDC 0781-3059-95),Reverified,11/16/21,Available; Intermittent Backorder,,,Demand increase for the drug,Cardiovascular,Current,,,0781-3059-95,limited availability
5656,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1171-02),New,6/8/21,,,,,Cardiovascular,To be Discontinued,6/8/21,6/8/21,0409-1171-02,discontinued
5657,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-05,available
5658,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-10,available
5659,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-301-25,available
5660,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6013-10,available
5661,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,10/12/21,Inventory is currently available,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6014-10,available
5662,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6015-10,available
5663,Diltiazem Hydrochloride Injection,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Reverified,11/18/21,Available,,,Other,Cardiovascular,Current,,,00409-4350-03,available
5664,Diltiazem Hydrochloride Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01),Revised,3/23/21,,,,,Cardiovascular,To be Discontinued,3/23/21,3/23/21,00409-1171-01,discontinued
5665,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,00409-1171-02,discontinued
5666,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,2/12/21,On backorder. Expected release: April 2021,,,,Cardiovascular,Current,,,17478-0937-10,not available
5667,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,2/12/21,Available,,,,Cardiovascular,Current,,,17478-0937-25,available
5668,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,2/12/21,Discontinued,,,,Cardiovascular,Current,,,17478-0937-26,discontinued
5669,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,2/12/21,Available,,,,Cardiovascular,Current,,,17478-0937-05,available
5670,Dimercaprol (Bal in Oil) Injection,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,6/29/21,,,Available,,Hematology;Other,Resolved,6/29/21,,17478-526-03,
5671,"Diphenhydramine Hydrochloride Injection, USP",Pfizer Pharmaceuticals,50 mg/mL Carpuject™ Luer Lock Glass Syringe (NDC 00409-2290-31),New,12/28/20,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To be Discontinued,12/28/20,12/28/20,00409-2290-31,discontinued
5672,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 100 mg capsules, bottle of 100 (NDC 0025-2732-31)",Reverified,11/18/21,Next Delivery and Estimated Recovery: January 2022,Manufacturing Delay. Please contact Pfizer Customer Service for assistance.,,Other,Cardiovascular,Current,,,0025-2732-31,not available
5673,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 150 mg capsules, bottle of 100 (NDC 0025-2742-31)",Reverified,11/18/21,Next Delivery and Estimated Recovery: January 2022,Manufacturing Delay. Please contact Pfizer Customer Service for assistance.,,Other,Cardiovascular,Current,,,0025-2742-31,not available
5674,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 59762-0386-1)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: March 2022,Shortage per Manufacturer: Manufacturing delay,,Other,Cardiovascular,Current,,,59762-0386-1,not available
5675,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 59762-0400-1)",Reverified,11/18/21,Next Delivery and Estimated Recovery: February 2022,Greenstone label,,,Cardiovascular,Current,,,59762-0400-1,not available
5676,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 0093-3127-01)",Reverified,11/8/21,Available,,,,Cardiovascular,Current,,,0093-3127-01,available
5677,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 0093-3129-01)",Reverified,11/8/21,Available,,,,Cardiovascular,Current,,,0093-3129-01,available
5678,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 100 mg capsules; bottle of 100 (NDC 0025-2752-31)",Reverified,11/18/21,Next Delivery: January 2022; Estimated Recovery: February 2022,Shortage per Manufacturer: Manufacturing delay,,Other,Cardiovascular,Current,,,0025-2752-31,not available
5679,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 150 mg capsules; bottle of 100 (NDC 0025-2762-31)",Reverified,11/18/21,Next Delivery: January 2022; Estimated Recovery: February 2022,,,,Cardiovascular,Current,,,0025-2762-31,not available
5680,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4140-01,discontinued
5681,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-4141-01,discontinued
5682,Disulfiram Tablets,Teva Pharmaceuticals,"250 mg, 100 count (NDC 0093-5035-01)",New,11/20/20,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/20,11/20/20,0093-5035-01,discontinued
5683,Disulfiram Tablets,Teva Pharmaceuticals,"500 mg, 100 count (NDC 0093-5036-01)",New,11/20/20,,Teva made a business decision to discontinue the product.,,,Analgesia/Addiction,To be Discontinued,11/20/20,11/20/20,0093-5036-01,discontinued
5684,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,11/23/21,Available,,,,Cardiovascular;Pediatric;Renal,Current,,,0338-1073-02,available
5685,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,11/18/21,Available,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2346-32,available
5686,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2347-32,limited availability
5687,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,11/18/21,Limited Supply Available. Next Delivery: January 2022; Estimated Recovery: March 2022,,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-3724-32,limited availability
5688,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-20,discontinued
5689,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-54,discontinued
5690,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,11/18/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-01,not available
5691,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-02,limited availability
5692,Docetaxel Injection,Ingenus Pharmaceuticals LLC,20 mg/2 mL (10 mg/mL)(NDC 50742-428-02),New,4/7/21,,Discontinued manufacturing due to lack of commercial viability in the market,,,Oncology,To be Discontinued,4/7/21,4/7/21,50742-428-02,discontinued
5693,Dofetilide Capsules,Pfizer Pharmaceuticals,125 mcg (0.125 mg) capsules; Bottle of 60 (NDC 59762-0037-2),New,5/21/21,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/21,5/21/21,59762-0037-2,discontinued
5694,Dofetilide Capsules,Pfizer Pharmaceuticals,250 mcg (0.25 mg) capsules; Bottle of 60 (NDC 59762-0038-2),New,5/21/21,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/21,5/21/21,59762-0038-2,discontinued
5695,Dofetilide Capsules,Pfizer Pharmaceuticals,500 mcg (0.5 mg) capsules; Bottle of 60 (NDC 59762-0039-2),New,5/21/21,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/21/21,5/21/21,59762-0039-2,discontinued
5696,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 5 mL vial (NDC 0143-9252-25)",Reverified,10/12/21,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9252-25,available
5697,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 10 mL vial (NDC 0143-9254-25)",Reverified,10/12/21,This presentation is currently available.,Additional lots are scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9254-25,available
5698,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,11/18/21,Available,,,Other,Cardiovascular,Current,,,00409-7809-22,available
5699,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,11/18/21,Next Delivery and Estimated Recovery: February 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-7809-24,not available
5700,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,11/18/21,Next Delivery: March 2022; Estimated Recovery: April 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-7810-22,not available
5701,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,11/18/21,Available,,,Other,Cardiovascular,Current,,,00409-5820-01,available
5702,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,11/18/21,Available,,,Other,Cardiovascular,Current,,,00409-9104-20,available
5703,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-03), 3200 mcg/mL (250 mL bag) Product code 2B0846 (NDC 0338-1009-02)",Reverified,11/23/21,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
5704,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,17478-605-10,
5705,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,50383-233-10,
5706,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,17478-604-30,
5707,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,61314-030-02,
5708,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,24208-486-10,
5709,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,0591-2482-79,
5710,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing this product.,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,,discontinued
5711,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,65862-0947-60,
5712,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0591-2481-79,discontinued
5713,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/18,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/20/18,4/20/18,0093-7618-43,discontinued
5714,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",Revised,4/29/21,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/29/21,4/29/21,0591-2481-79,discontinued
5715,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",Revised,4/29/21,,This was a business-related decision to discontinue manufacturing these products,,,Ophthalmology,To be Discontinued,4/29/21,4/29/21,0093-7618-43,discontinued
5716,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,61314-019-10,
5717,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,50383-232-10,
5718,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"TRUSOPT® dorzolamide hydrochloride ophthalmic solution 2%, 10 mL in an 18 mL capacity bottle (NDC 0006-3519-36)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,0006-3519-36,
5719,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,5/10/21,,24208-485-10,
5720,Doxycycline Hyclate Powder for Suspension,"Hospira, Inc.",25mg/5mL (NDC 0069-0970-65),New,11/15/21,,,,,Anti-Infective,To be Discontinued,11/15/21,11/15/21,0069-0970-65,discontinued
5721,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Pfizer Pharmaceuticals,6.25 mg package for 0.125% (NDC 0046-1065-05),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,0046-1065-05,discontinued
5722,Efavirenz Tablets,"Mylan Specialty, a Viatris Company",600 mg (NDC 0378-2233-93),New,11/2/21,,,,,Antiviral,To be Discontinued,11/2/21,11/2/21,0378-2233-93,discontinued
5723,Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate (Atripla) Tablets,"Gilead Sciences, LLC",600 mg; 200 mg; 300 mg (NDC 15584-0101-1),New,2/4/21,,Date of permanent discontinuation of manufacture is July 2021.  Product expected to be available until December 2021.,,,Antiviral,To be Discontinued,2/4/21,2/4/21,15584-0101-1,discontinued
5724,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Revised,10/12/21,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9786-10,available
5725,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Revised,10/12/21,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9787-10,available
5726,Enoxaparin Sodium Injection,Teva Pharmaceuticals,30 mg/0.3mL (NDCs 0703-8530-21 and 0703-8530-23),New,1/28/21,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5727,Enoxaparin Sodium Injection,Teva Pharmaceuticals,40 mg/0.4 mL (NDCs 0703-8540-21 and 0703-8540-23),New,1/28/21,,Product expected to be available until October 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5728,Enoxaparin Sodium Injection,Teva Pharmaceuticals,60 mg/0.6 mL (NDCs 0703-8560-21 and 0703-8560-23),New,1/28/21,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5729,Enoxaparin Sodium Injection,Teva Pharmaceuticals,80 mg/0.8 mL (NDCs 0703-8680-21 and 0703-8680-23),New,1/28/21,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5730,Enoxaparin Sodium Injection,Teva Pharmaceuticals,100 mg/1 mL (NDCs 0703-8580-21 and 0703-8580-23),New,1/28/21,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5731,Enoxaparin Sodium Injection,Teva Pharmaceuticals,120 mg/0.8 mL (NDCs 0703-8610-21 and 0703-8610-23),New,1/28/21,,Product expected to be available until August 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5732,Enoxaparin Sodium Injection,Teva Pharmaceuticals,150 mg/1 mL (NDCs 0703-8510-21 and 0703-8510-23),New,1/28/21,,Product expected to be available until December 2021,,,Hematology,To be Discontinued,1/28/21,1/28/21,,discontinued
5733,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4933-01) (old NDC 00409-4921-34, pack of 10; NDC 0409-4921-20, individual)",Revised,11/18/21,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,0409-4933-01,unclear
5734,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","0.1mg/mL, 10mL, (NDC 76329-3316-1)",Revised,11/2/21,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,76329-3316-1,not available
5735,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.3 mg EpiPen® (NDC 49502-500-02); Authorized Generic (NDC 49502-102-02),Reverified,11/29/21,Available,Product is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,49502-500-02,available
5736,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.15 mg EpiPen® (NDC 49502-501-02); Authorized Generic (NDC 49502-101-02),Reverified,11/29/21,Available,Product is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,49502-501-02,available
5737,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,4/28/21,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1695-49,limited availability
5738,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Reverified,12/14/20,On allocation to current customers.,,,Manufacturing delays,Pulmonary/Allergy,Current,,,0115-1694-49,limited availability
5739,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,1/27/21,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-023-01,available
5740,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,1/27/21,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-022-01,available
5741,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,1/27/21,Available,AUVI-Q is readily available and not currently in shortage.,,,Pulmonary/Allergy,Current,,,60842-021-01,available
5742,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,11/8/21,Limited inventory on allocation.  Expected recovery mid-November.,,,,Pulmonary/Allergy,Current,,,0093-5986-27,limited availability
5743,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 0781-3442-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3442-20,available
5744,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 0781-3448-20)",Reverified,12/17/19,Available,,,,Pulmonary/Allergy,Current,,,0781-3448-20,available
5745,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,11/8/21,Limited inventory on allocation.  Expected recovery mid-October.,,,,Pulmonary/Allergy,Current,,,0093-5985-27,limited availability
5746,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,20 mg/10ml (2 mg/ml)(NDC 0085-1177-01),New,10/21/20,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1177-01,discontinued
5747,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,75 mg/100ml (0.75 mg/ml)(NDC 0085-1136-01),New,10/21/20,,To be discontinued on or near October 2020.,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1136-01,discontinued
5748,Eptifibatide (Integrilin) Injection,Merck Sharp & Dohme Corp.,200 mg/100ml (2 mg/ml)(NDC 0085-1177-02),New,10/21/20,,Discontinued,,,Cardiovascular,To be Discontinued,10/21/20,10/21/20,0085-1177-02,discontinued
5749,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/20,,Discontinuation of drug manufacturing,,,Neurology,To be Discontinued,7/2/20,7/2/20,0781-5405-01,discontinued
5750,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",25 mg tablets (NDC 50242-062-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-062-01,discontinued
5751,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",100 mg tablets (NDC 50242-063-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-063-01,discontinued
5752,Erlotinib Hydrochloride Tablets,"Astellas Pharma Global Development, Inc.",150 mg tablets (NDC 50242-064-01),New,9/29/20,,,,,Oncology,To be Discontinued,9/29/20,9/29/20,50242-064-01,discontinued
5753,Erythromycin Ethylsuccinate Powder for Suspension,"Endo Pharmaceuticals, Inc.",200 mg/5 mL  (NDC 0254-1020-47),New,2/8/21,,,,,Anti-Infective,To be Discontinued,2/8/21,2/8/21,0254-1020-47,discontinued
5754,Erythromycin Ethylsuccinate Powder for Suspension,"Endo Pharmaceuticals, Inc.",400 mg/5 mL (NDC 0254-1021-47),New,2/8/21,,,,,Anti-Infective,To be Discontinued,2/8/21,2/8/21,0254-1021-47,discontinued
5755,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,17478-070-35,
5756,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC17478-070-31),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,,
5757,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-824-35)(Premier),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,17478-824-35,
5758,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g  tube (unit dose) (NDC 17478-824-01)(Premier),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,17478-824-01,
5759,Erythromycin Ophthalmic Ointment,Bausch Health,3.5 g in 1 Tube (NDC 24208-910-55),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,24208-910-55,
5760,Erythromycin Ophthalmic Ointment,Bausch Health,1 g in cartons of 50 (NDC 24208-910-19),Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,24208-910-19,
5761,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"1 gram, 50-count (NDC 00574-4024-50)",Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,00574-4024-50,
5762,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 1-count (NDC 00574-4024-35)",Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,00574-4024-35,
5763,Erythromycin Ophthalmic Ointment,Perrigo Company PLC,"3.5 gram, 24-count (NDC 00574-4024-39)",Revised,5/19/21,,,Available,,Ophthalmology,Resolved,5/19/21,,00574-4024-39,
5764,Esomeprazole Sodium for Injection,"Mylan Institutional, a Viatris company","40 mg vial, box of 10 (NDC 67457-392-99)",New,9/16/21,,,,,Gastroenterology;Pediatric,To be Discontinued,9/16/21,9/16/21,67457-392-99,discontinued
5765,Estradiol (Alora) Patch,Allergan,(NDC 0023-5885-12),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0023-5885-12,discontinued
5766,Estradiol (Alora) Patch,Allergan,(NDC 0023-5886-15),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0023-5886-15,discontinued
5767,Estradiol (Alora) Patch,Allergan,(NDC 0023-5887-17),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0023-5887-17,discontinued
5768,Estradiol (Alora) Patch,Allergan,(NDC 0023-5888-11),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0023-5888-11,discontinued
5769,Ethacrynic Acid Tablets,"Endo Pharmaceuticals, Inc.",25 mg/1 (NDC 49884-276-01),New,12/17/20,,Discontinued due to business reasons,,,Cardiovascular;Renal,To be Discontinued,12/17/20,12/17/20,49884-276-01,discontinued
5770,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400 mg  (NDC 0555-0923-02),New,9/28/20,,,,,Anti-Infective,To be Discontinued,9/28/20,9/28/20,0555-0923-02,discontinued
5771,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400mg  (NDC 0555-0923-02),New,11/5/21,,,,,Anti-Infective,To be Discontinued,11/5/21,11/5/21,0555-0923-02,discontinued
5772,Etomidate Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",20 mg/10mL carton of 10 (NDC 23155-160-41),Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,23155-160-41,
5773,Etomidate Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",40 mg/20 mL carton of 10 (NDC 23155-160-42),Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,23155-160-42,
5774,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 10 mL vial (NDC 55150-221-10)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,55150-221-10,
5775,Etomidate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"40 mg/mL, 20 mL vial (NDC 55150-222-20)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,55150-222-20,
5776,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",Revised,4/22/21,,,Distributed by Fosun Pharma; Available,,Anesthesia,Resolved,4/22/21,4/22/21,72266-146-10,
5777,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",Revised,4/22/21,,,Distributed by Fosun Pharma; Available,,Anesthesia,Resolved,4/22/21,4/22/21,72266-147-10,
5778,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0143-9506-10,
5779,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0143-9507-10,
5780,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0143-9310-10,
5781,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0143-9311-10,
5782,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 10 mL vial (NDC 67457-902-10)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,67457-902-10,
5783,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 20 mL vial (NDC 67457-903-20)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,67457-903-20,
5784,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0409-6695-01,
5785,Etomidate Injection,Pfizer Pharmaceuticals,"Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",Revised,4/22/21,,,Available,,Anesthesia,Resolved,4/22/21,,0409-6695-02,
5786,Etoposide Injection,Accord Healthcare Inc.,20mg/mL (NDC 16729-262-31),New,2/16/21,,Last lot of this NDC available in the market currently expires in October 2021.,,,Oncology,To be Discontinued,2/16/21,2/16/21,16729-262-31,discontinued
5787,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/18,,"The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018.  There are currently 2 other delivery options for exenatide-extended-release:  the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).",,,Endocrinology/Metabolism,To be Discontinued,4/3/18,4/3/18,0310-6520-04,discontinued
5788,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 70860-751-02 and 41)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,70860-751-02,
5789,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","200 mg per 20 mL(10 mg per mL), multiple dose vial with preservatives, (NDC 70860-751-20 and 41)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,70860-751-20,
5790,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,67457-433-22,
5791,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0338-5197-41,
5792,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0641-6022-25,
5793,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0641-6023-25,
5794,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0641-6021-10,
5795,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,63323-739-12,
5796,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,63323-738-09,
5797,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,63323-738-20,
5798,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [40 mg / 4 ml] 10PK (NDC 67457-448-43),Revisee,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,67457-448-43,
5799,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,67457-457-20,
5800,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0172-5728-60,
5801,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0172-5728-80,
5802,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0172-5728-70,
5803,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0172-5729-60,
5804,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,0172-5729-70,
5805,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,65862-859-01,
5806,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,65862-860-01,
5807,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,62332-001-31,
5808,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,62332-001-91,
5809,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,62332-002-31,
5810,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,62332-002-71,
5811,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,62332-002-91,
5812,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,61442-121-01,
5813,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,61442-121-10,
5814,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,61442-122-01,
5815,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,11/10/21,,61442-122-10,
5816,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40 mg (NDC 55111-796-30),New,11/22/21,,,,,Rheumatology,To be Discontinued,11/22/21,11/22/21,55111-796-30,discontinued
5817,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80 mg (NDC 55111-797-30),New,11/22/21,,,,,Rheumatology,To be Discontinued,11/22/21,11/22/21,55111-797-30,discontinued
5818,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",20 mg/2 mL (10 mg/mL); Glass Ampul (NDC 00409-2304-02),New,11/16/20,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,00409-2304-02,discontinued
5819,"Fenoldopam Mesylate (Corlopam) Injection, USP","Hospira, Inc.",10 mg/mL (10 mg/mL); Glass Ampul (NDC 00409-2304-01),New,11/16/20,,"Discontinuation of the manufacture of the ampul, equivalent vial available.",,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,00409-2304-01,discontinued
5820,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) Single Dose Simplist PFS  (NDC 63323-808-11),Reverified,11/23/21,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-808-11,available
5821,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 1 mL vial
(NDC 0641-6247-25)",New,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6247-25,available
5822,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Reverified,11/23/21,Backordered. Next release January 2022.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-20,not available
5823,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-50,not available
5824,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Reverified,11/23/21,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-01,available
5825,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Reverified,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-02,not available
5826,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Reverified,11/23/21,Available,Check wholesalers for inventory.,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-05,available
5827,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,11/18/21,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-1276-32,not available
5828,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-32,not available
5829,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,11/18/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-35,available
5830,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-38,discontinued
5831,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9094-22,limited availability
5832,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,11/18/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-25,available
5833,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,11/18/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-28,available
5834,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: March 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9094-31,limited availability
5835,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9094-61,limited availability
5836,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,10/12/21,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6024-10,not available
5837,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,10/12/21,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6025-10,not available
5838,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,10/12/21,Currently not available,Inventory available in vial presentations.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6026-05,not available
5839,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6027-25,available
5840,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6028-25,available
5841,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and available in the November - December 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6029-25,not available
5842,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6030-01,available
5843,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,2/12/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-02,available
5844,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-25,discontinued
5845,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,2/12/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-05,available
5846,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-20,discontinued
5847,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-55,discontinued
5848,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/18,,The discontinuation of this product is a business decision,,,Urology,To be Discontinued,5/23/18,5/23/18,0378-5036-05,discontinued
5849,Finasteride Tablets,Teva Pharmaceuticals,5 mg 30 CT (NDC 45963-500-30),New,9/18/20,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-30,discontinued
5850,Finasteride Tablets,Teva Pharmaceuticals,5 mg 90 CT (NDC 45963-500-08),New,9/18/20,,"Teva’s Finasteride 5 mg Tablets marketed under NDC 0093-7355-56, NDC 0093-7355-05 & NDC 0093-7355-98 are not affected by this discontinuation.",,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-08,discontinued
5851,Finasteride Tablets,Teva Pharmaceuticals,"1mg tablet (NDC 45963-600-03, 45963-600-09)",New,9/18/20,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/20,9/18/20,45963-600-03,discontinued
5852,Finasteride Tablets,Teva Pharmaceuticals,5mg tablet (NDC 45963-500-02),New,9/18/20,,This product discontinuation is a business related decision.,,,Urology,To be Discontinued,9/18/20,9/18/20,45963-500-02,discontinued
5853,Floxuridine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Revised,10/12/21,This presentation is temporarily on backorder.,,,Other,Oncology,Current,,,0143-9270-01,not available
5854,"Floxuridine for Injection, USP","Fresenius Kabi USA, LLC",500 mg per vial (NDC 63323-145-07_,New,9/30/20,,"Discontinued: May 30, 2019",,,Oncology,To be Discontinued,9/30/20,9/30/20,63323-145-07,discontinued
5855,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0555-0997-02,
5856,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-01,
5857,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,8/7/19,,0115-7033-02,
5858,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/19,,Expected Discontinuation April 2020,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,12/16/19,12/16/19,67457-447-53,discontinued
5859,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-054-15),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-054-15,discontinued
5860,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-054-30),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-054-30,discontinued
5861,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-054-60),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-054-60,discontinued
5862,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-040-15),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-040-15,discontinued
5863,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-040-30),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-040-30,discontinued
5864,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-040-60),New,6/21/21,,Discontinuation of the manufacture of the drug,,,,To be Discontinued,6/21/21,6/21/21,52565-040-60,discontinued
5865,Fluocinonide Topical Solution,Teva Pharmaceuticals,0.5 mg/mL  (NDC 0472-0829-02),New,8/3/21,,,,,Dermatology,To be Discontinued,8/3/21,8/3/21,0472-0829-02,discontinued
5866,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,6/4/21,,17478-404-01,
5867,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,6/4/21,,17478-403-03,
5868,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,6/4/21,,,
5869,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,6/4/21,,17238-900-30,
5870,Fluorometholone Ophthalmic Ointment,Abbvie,FML (flourometholone) Ointment 0.1% 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0316-04),New,9/13/21,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/21,9/13/21,0023-0316-04,discontinued
5871,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-01,discontinued
5872,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2823-10,discontinued
5873,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-01,discontinued
5874,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2822-10,discontinued
5875,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-01,discontinued
5876,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-10,discontinued
5877,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Fluoxetine Capsules.,,,Psychiatry,To be Discontinued,2/23/18,2/23/18,0781-2824-31,discontinued
5878,Fluoxetine Tablets,Allergan Pharmaceuticals International Limited,"Fluoxetine (Sarafem) Tablets, 10 mg (NDC 0430-0210-14)",New,12/22/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/22/20,12/22/20,0430-0210-14,discontinued
5879,Fluoxetine Tablets,Allergan Pharmaceuticals International Limited,"Fluoxetine (Sarafem) Tablets, 20 mg (NDC 0430-0220-14)",New,12/22/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/22/20,12/22/20,0430-0220-14,discontinued
5880,Fluticasone Inhalational Powder,GlaxoSmithKline,"100 mcg, 28 blisters (NDC 0173-0602-00)",New,4/23/21,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/21,4/23/21,0173-0602-00,discontinued
5881,Fluticasone Inhalational Powder,GlaxoSmithKline,"250 mcg, 28 blisters (NDC 0173-0601-00)",New,4/23/21,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately July 2021. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/21,4/23/21,0173-0601-00,discontinued
5882,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,1/15/21,Product available,,,Delay in shipping of the drug,Psychiatry,Current,,,10370-175-11,available
5883,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,1/15/21,On backorder. Estimated availability February 2021,,,Delay in shipping of the drug,Psychiatry,Current,,,10370-176-11,not available
5884,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Reverified,11/8/21,Product is available,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,0228-2848-03,available
5885,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Reverified,11/8/21,Available,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,0228-2849-03,available
5886,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","100 mg/2 mL, package of 25 vials (NDC 67457-516-25)",New,9/3/21,,,,,Neurology;Pediatric,To be Discontinued,9/3/21,9/3/21,67457-516-25,discontinued
5887,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","500 mg/10 mL, package of 10 vials (NDC 67457-517-01)",New,8/4/21,,,,,Neurology;Pediatric,To be Discontinued,8/4/21,8/4/21,67457-517-01,discontinued
5888,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",20 mg/2mL vial (NDC 70860-302-41 and 70860-302-02),New,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-302-41,available
5889,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",40 mg/4mL vial (NDC 70860-302-42 and 70860-302-04),New,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-302-42,available
5890,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",100 mg/10mL vial (NDC 70860-302-43 and 70860-302-10),New,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,,Cardiovascular,Current,,,70860-302-43,available
5891,Furosemide Injection,Gland Pharma Limited,"2 mL in 1 vial, 25 vials/carton (NDC 25021-311-02)",Reverified,7/16/21,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-02,available
5892,Furosemide Injection,Gland Pharma Limited,"4 mL in 1 vial, 25 vials/carton (NDC 25021-311-04)",Reverified,7/16/21,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-04,available
5893,Furosemide Injection,Gland Pharma Limited,"10 mL in 1 vial, 25 vials/carton (NDC 25021-311-10)",Reverified,7/16/21,Available,Marketing partner: Sagent Pharmaceuticals,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-10,available
5894,Furosemide Injection,Sagent Pharmaceuticals,20 mg/2 mL single-dose vial (NDC 25021-311-02),Reverified,10/22/21,Available,,,,Cardiovascular,Current,,,25021-311-02,available
5895,Furosemide Injection,Sagent Pharmaceuticals,40 mg/4 mL single-dose vial (NDC25021-311-04),Reverified,10/22/21,Available,,,,Cardiovascular,Current,,,,available
5896,Furosemide Injection,Sagent Pharmaceuticals,100 mg/10 mL single-dose vial (NDC 25021-311-10),Reverified,10/22/21,Available,,,,Cardiovascular,Current,,,25021-311-10,available
5897,Furosemide Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-02,available
5898,Furosemide Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-04,not available
5899,Furosemide Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-10,available
5900,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,11/5/21,"Currently on backorder, next shipment TBD",Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-322-25,not available
5901,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,11/5/21,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-323-25,available
5902,Furosemide Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),100 mg/10 mL single-dose vial (NDC 55150-324-25),Reverified,11/5/21,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-324-25,available
5903,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,11/23/21,Available,,,,Cardiovascular,Current,,,36000-284-25,available
5904,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,11/23/21,Available,,,,Cardiovascular,Current,,,36000-282-25,available
5905,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,11/23/21,Available,,,,Cardiovascular,Current,,,36000-283-25,available
5906,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,10/13/21,Available,,,,Cardiovascular,Current,,,23155-473-41,available
5907,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,10/13/21,Available,,,,Cardiovascular,Current,,,23155-473-42,available
5908,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,10/13/21,Available,,,,Cardiovascular,Current,,,23155-473-44,available
5909,Furosemide Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Other,Cardiovascular,Current,,,0409-6102-02,limited availability
5910,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Cardiovascular,Current,,,0409-6102-04,limited availability
5911,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Revised,11/18/21,Available,,,Other,Cardiovascular,Current,,,0409-6102-10,available
5912,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Revised,11/18/21,Limited Supply Available.,,,Demand increase for the drug,Cardiovascular,Current,,,0409-1639-10,limited availability
5913,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Revised,11/18/21,Limited Supply Available.,,,Demand increase for the drug,Cardiovascular,Current,,,0409-9631-04,limited availability
5914,Furosemide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",80mg (NDC 0378-0232-05),New,4/7/21,,,,,Cardiovascular,To be Discontinued,4/7/21,4/7/21,0378-0232-05,discontinued
5915,Gemcitabine Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg, single dose vial (NDC 67457-464-20)",New,6/26/20,,Expected discontinuation December 2020,,,Oncology,To be Discontinued,6/26/20,6/26/20,67457-464-20,discontinued
5916,Gemcitabine Hydrochloride Injection,Mylan Institutional,"1 g, single dose vial (NDC 67457-462-01)",New,12/16/19,,Expected Discontinuation March/April 2020,,,Oncology,To be Discontinued,12/16/19,12/16/19,67457-462-01,discontinued
5917,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Reverified,11/10/21,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-07,unclear
5918,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Reverified,11/10/21,Estimated recovery to be determined.,License to manufacture and distribute FACTIVE is under legal dispute.,,Other,Anti-Infective,Current,,,44004-321-05,unclear
5919,Gentamicin Sulfate and Prednisolone Acetate Ophthalmic Ointment,Abbvie,PRED-G- gentamicin sulfate 0.3% and prednisolone acetate 0.6% ointment 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0066-04),New,9/13/21,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/21,9/13/21,0023-0066-04,discontinued
5920,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","80 mg per 2 mL (40 mg per mL), MDV, (NDC 63323-010-02)",Revised,11/23/21,Backordered. Next release January 2022.,Check wholesaler inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-010-02,not available
5921,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","800 mg per 20 mL (40 mg per mL), MDV, (NDC 63323-010-20)",Revised,11/23/21,Available,Check wholesaler inventory,,,Anti-Infective,Current,,,63323-010-20,available
5922,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Pediatric SDV, (NDC 63323-173-02)",Revised,11/23/21,Available,Check wholesaler inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-173-02,available
5923,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL); 2 mL Single Dose Glass Fliptop Vial (NDC 00409-1207-03),Revised,11/18/21,Next Delivery: December 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anti-Infective,Current,,,00409-1207-03,not available
5924,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL) Single Dose Glass Fliptop Vial NovaPlus (NDC 00409-1207-25),Revised,11/18/21,Available,,,Other,Anti-Infective,Current,,,00409-1207-25,available
5925,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/20,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/20,5/28/20,0591-0460-10,discontinued
5926,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/20,,"Teva had evaluated the market and made decision to discontinue the product. No inventory remains for Glipizide 5 mg tablets 100 count NDC: 0591-0460-01. For the remaining presentations, allocations are being made based on customer Rx trends.",,,Endocrinology/Metabolism,To be Discontinued,5/28/20,5/28/20,0591-0461-10,discontinued
5927,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",1 mg (NDC 0378-1160-01),Reverified,11/29/21,Unavailable,,,Other,Cardiovascular,Current,,,0378-1160-01,not available
5928,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",2 mg (NDC 0378-1190-01),Reverified,11/29/21,Unavailable,,,Other,Cardiovascular,Current,,,0378-1190-01,not available
5929,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Revised,11/8/21,Available,,,,Cardiovascular,Current,,,0591-0444-01,available
5930,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Revised,11/8/21,On backorder,Recovery: December 2021,,,Cardiovascular,Current,,,0591-0453-01,not available
5931,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-711-03,available
5932,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-713-03,available
5933,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",Reverified,2/23/21,Available,,,Other,Cardiovascular,Current,,,42806-048-01,available
5934,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",Reverified,2/23/21,Available,,,Other,Cardiovascular,Current,,,42806-296-01,available
5935,Guanidine Hydrochloride Tablets,Merck Sharp & Dohme Corp.,125 mg tablets (NDC 0085-0492-01),New,9/28/20,,To be discontinued on or near October 2020.,,,Neurology,To be Discontinued,9/28/20,9/28/20,0085-0492-01,discontinued
5936,Haloperidol Lactate (Haldol) Injection,"Janssen Biotech, Inc.","5 mg/mL, 10 ampule in 1 box, > 1 mL in 1 ampule, (NDC 50458-255-01)",New,11/13/20,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/20,11/13/20,50458-255-01,discontinued
5937,Haloperidol Lactate Injection,Patriot Pharmaceuticals,"5 mg/mL, 10 ampule in 1 box,> 1 mL in 1 ampule, (NDC 10147-0911-1)",New,11/13/20,,Product discontinuation as per business decision,,,Psychiatry,To be Discontinued,11/13/20,11/13/20,10147-0911-1,discontinued
5938,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0351-01,
5939,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0257-01,
5940,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0214-01,
5941,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0327-01,
5942,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0334-01,
5943,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0378-0355-01,
5944,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-01,
5945,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-079-10,
5946,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-080-01,
5947,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,11/20/19,,68382-081-01,
5948,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9101,
5949,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9101,
5950,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9113,
5951,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9201,
5952,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9201,
5953,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
5954,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9801,
5955,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9213,
5956,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9610,
5957,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9610,
5958,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9601,
5959,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9601,
5960,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9613,
5961,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9701,
5962,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9701,
5963,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-13-9713,
5964,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/19,,,,,Psychiatry,Resolved,11/20/19,,0781-83-9301,
5965,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,11/23/21,Available,,,Manufacturing Delay,Hematology,Current,,,0338-0433-04,available
5966,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,11/23/21,Unavailable,Product code 2B0953 was replaced with code AHB0953U,,Other,Hematology,Current,,,0338-0431-03,not available
5967,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Hematology,Current,,,00409-7620-03,limited availability
5968,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Hematology,Current,,,00409-7620-59,limited availability
5969,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Revised,11/23/21,Available,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,0338-0424-18,available
5970,Heparin Sodium and Sodium Chloride 0.9% Injection,Sagent Pharmaceuticals,1000 units/mL 10mL pack 25 (NDC 25021-400-10),Revised,10/22/21,On backorder.,,,Demand increase for the drug,Hematology,Current,,,25021-400-10,not available
5971,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Revised,11/23/21,Available,Check wholesaler for inventory,,Other,Hematology,Current,,,63323-519-77,available
5972,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Revised,11/23/21,Backordered. Next release January 2022.,Check wholesaler for inventory,,Other,Hematology,Current,,,63323-519-10,not available
5973,Histrelin Acetate Implant,"Endo Pharmaceuticals, Inc.",Vantas 50 mg Implantation Kit (NDC 67979-500-01),Revised,9/21/21,,Endo has made a business decision to discontinue manufacture of this product.,,,Oncology,To be Discontinued,9/21/21,9/21/21,67979-500-01,discontinued
5974,Hydralazine Hydrochloride Injection,American Regent/Luitpold,20mg/ml SDV ( NDC 0517 - 0901-25 ),Revised,6/29/21,,,Available,,Cardiovascular,Resolved,6/29/21,,0517,
5975,Hydralazine Hydrochloride Injection,"Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,6/29/21,,,Available,,Cardiovascular,Resolved,6/29/21,,63323-614-01,
5976,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,6/29/21,,,,,Cardiovascular,Resolved,6/29/21,,17478-934-01,
5977,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,6/29/21,,,,,Cardiovascular,Resolved,6/29/21,,17478-934-15,
5978,Hydralazine Hydrochloride Injection,"Mylan Institutional, a Viatris company",20 mg / 1 ml] 25PK (NDC 67457-291-01),Revised,6/29/21,,,,,Cardiovascular,Resolved,6/29/21,,67457-291-01,
5979,Hydralazine Hydrochloride Injection,"X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,6/29/21,,,,,Cardiovascular,Resolved,6/29/21,,39822-0500-4,
5980,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2025-01,discontinued
5981,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-2012-01,discontinued
5982,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,0378-1012-01,discontinued
5983,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,6/5/18,6/5/18,0574-1105-16,discontinued
5984,Hydrocodone/Homatropine Tablets,Lupin,5/1.5 mg (NDC 43386-0118-03),New,12/28/20,,This discontinuation is a business decision. We have no plans to re-enter the market at this time.,,,Pulmonary/Allergy,To be Discontinued,12/28/20,12/28/20,43386-0118-03,discontinued
5985,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-12,discontinued
5986,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-24,discontinued
5987,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/19,,,,,Other;Urology,To be Discontinued,11/25/19,11/25/19,59741-301-01,discontinued
5988,Hydrocortisone Tablets,Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Reverified,11/18/21,Available,,,Other,Endocrinology/Metabolism,Current,,,59762-0073-1,available
5989,Hydrocortisone Tablets,Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Reverified,11/18/21,Available,,,Other,Endocrinology/Metabolism,Current,,,59762-0074-1,available
5990,Hydrocortisone Tablets,Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Reverified,11/18/21,Available,,,Other,Endocrinology/Metabolism,Current,,,59762-0075-1,available
5991,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Reverified,11/18/21,Available,,,Other,Endocrinology/Metabolism,Current,,,0009-0044-01,available
5992,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Reverified,11/18/21,Available,,,Other,Endocrinology/Metabolism,Current,,,0009-0012-01,available
5993,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Reverified,11/18/21,Available,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0009-0031-01,available
5994,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","5 mg, 50 count bottles (NDC 64380-970-25)",Reverified,11/2/21,Available,,,,Endocrinology/Metabolism,Current,,,64380-970-25,available
5995,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","10 mg, 100 count bottles (NDC 64380-971-06)",Reverified,11/2/21,Available,,,,Endocrinology/Metabolism,Current,,,64380-971-06,available
5996,Hydrocortisone Tablets,"Vensun Pharmaceuticals, Inc.","20 mg, 100 count bottles (NDC 64380-972-06)",Reverified,11/2/21,Available,,,,Endocrinology/Metabolism,Current,,,64380-972-06,available
5997,Hydrocortisone Tablets,Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),Reverified,5/24/21,Available,,,,Endocrinology/Metabolism,Current,,,00115-1697-01,available
5998,Hydrocortisone Tablets,Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),Reverified,5/24/21,Available,,,,Endocrinology/Metabolism,Current,,,00115-1700-01,available
5999,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-121-11)",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-121-11,available
6000,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-010-11)",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-010-11,available
6001,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-06,available
6002,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-11,not available
6003,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-852-25,not available
6004,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-853-25,not available
6005,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-854-10,available
6006,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-10,available
6007,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-15,available
6008,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-50,available
6009,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-05)",Revised,11/23/21,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-05,unclear
6010,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,11/23/21,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-10,unclear
6011,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,11/23/21,Backordered. Next release date not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-010-10,not available
6012,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,11/23/21,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-011-10,not available
6013,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,11/8/21,Available,,,,Analgesia/Addiction,Current,,,,available
6014,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,11/8/21,Available,,,,Analgesia/Addiction,Current,,,0703-0113-03,available
6015,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,11/8/21,Available,,,,Analgesia/Addiction,Current,,,0703-0018-01,available
6016,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-0121-25,available
6017,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Reverified,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-2341-41,available
6018,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1283-05,limited availability
6019,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1283-10,discontinued
6020,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1312-10,discontinued
6021,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Reverified,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1283-31,available
6022,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1312-30,limited availability
6023,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Reverified,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1304-31,available
6024,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Reverified,11/18/21,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-2552-01,not available
6025,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-3356-01,discontinued
6026,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2540-01,discontinued
6027,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-3365-01,discontinued
6028,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Reverified,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-01,available
6029,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Reverified,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-05,available
6030,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-2634-50,not available
6031,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Reverified,5/19/21,Available,,,,Analgesia/Addiction,Current,,,17478-0540-01,available
6032,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Reverified,5/19/21,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-05,available
6033,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Reverified,5/19/21,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-50,available
6034,Hydroxocobalamin Injection,SERB SA,"Hydroxocobalamin Injection (Cyanokit) intravenous powder for solution for injection, 5 gram, vial, (NDC 11704-0370-01)",Reverified,11/12/21,Available,Product Is distributed by Meridian Medical Technologies.  Contact number: 1-800-638-8093,Other,Other,Endocrinology/Metabolism,Current,,,11704-0370-01,available
6035,Hydroxocobalamin Injection,Teva Pharmaceuticals,"Hydroxocobalamin Injection 1000MCG/ML, 1X30ML(NDC 0591-2888-30)",Reverified,11/8/21,Available,,,Other,Endocrinology/Metabolism,Current,,,0591-2888-30,available
6036,Hydroxychloroquine Sulfate Tablets,Teva Pharmaceuticals,"200 mg, 500 count bottle (NDC 0591-3041-05)",New,12/7/20,,Teva made a business decision to discontinue this product.,,,Anti-Infective;Rheumatology,To be Discontinued,12/7/20,12/7/20,0591-3041-05,discontinued
6037,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-309-01,
6038,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,55150-310-01,
6039,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-105-01,
6040,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,0517-1767-01,
6041,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,71225-104-01,
6042,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-247-02,
6043,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
6044,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,64011-243-01,
6045,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,8/2/19,,66993-038-01,
6046,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Revised,9/8/21,"Unavailable, Resupply expected February 2022",,,Other,Ophthalmology,Current,,,24208-800-60,not available
6047,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0555-0324-02,
6048,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0555-0323-02,
6049,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0555-0323-04,
6050,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0555-0302-02,
6051,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0555-0302-04,
6052,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0185-0674-01,
6053,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0185-0674-05,
6054,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,00115-1803-01,
6055,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,00115-1803-02,
6056,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,00115-1804-01,
6057,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,00115-1804-02,
6058,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,14539-674-01,
6059,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,14539-674-05,
6060,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,14539-675-01,
6061,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,14539-675-05,
6062,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0069-5410-66,
6063,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,2/17/21,,,,,Psychiatry,Resolved,2/17/21,,0069-5420-66,
6064,Imipenem and Cilastatin for Injection,Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Reverified,11/15/21,Product is available,"For additional information, please contact: Merck National Service Center at 1-800-672-6372",,Demand increase for the drug,Anti-Infective,Current,,,0006-3516-59,available
6065,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-349-25,available
6066,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Reverified,11/23/21,Available,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-322-25,available
6067,Indinavir (CRIXIVAN) Capsules,Merck Sharp & Dohme Corp.,200 mg capsules (NDC 0006-0571-43),New,9/21/20,,,,,Antiviral,To be Discontinued,9/21/20,9/21/20,0006-0571-43,discontinued
6068,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-01,discontinued
6069,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0143-10,discontinued
6070,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-01,discontinued
6071,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-0147-05,discontinued
6072,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4350-01)",New,4/23/21,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0085-4350-01,discontinued
6073,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4351-01)",New,4/23/21,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0085-4351-01,discontinued
6074,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01)",New,4/23/21,,To be discontinued on or near March 2022,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0085-4352-01,discontinued
6075,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Solution for Injection (Interferon alfa-2b), 18 million IU multidose vial (22.8 million IU per 3.8 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01)",New,4/23/21,,To be discontinued on or near July 2021,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0085-1168-01,discontinued
6076,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Solution for Injection (Interferon alfa-2b), 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01)",New,4/23/21,,To be discontinued on or near June 2021,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0085-1133-01,discontinued
6077,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200), 10x50mL vial, (NDC 0270-1314-30)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1314-30,discontinued
6078,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200M), 10x20mL vial, (NDC 0270-1411-25)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1411-25,discontinued
6079,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x150mL bottle, (NDC 0270-1317-09)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1317-09,discontinued
6080,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x50mL bottle, (NDC 0270-1317-05)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1317-05,discontinued
6081,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250 PBP),  10x200mL bottle, (NDC 0270-1317-41)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1317-41,discontinued
6082,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300), 10x75mL bottle, (NDC 0270-1315-47)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1315-47,discontinued
6083,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 6x500mL bottle, (NDC 0270-1315-98)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1315-98,discontinued
6084,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 10x200mL bottle, (NDC 0270-1315-41)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1315-41,discontinued
6085,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 6x500mL bottle, (NDC 0270-1316-98)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1316-98,discontinued
6086,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 10x200mL bottle, (NDC 0270-1316-41)",New,7/1/21,,Bracco continues to manufacture/provide customers with a variety of ISOVUE products.,,,Medical Imaging,To be Discontinued,7/1/21,7/1/21,0270-1316-41,discontinued
6087,Ipratropium Bromide Inhalation Solution,Teva Pharmaceuticals,"0.5 mg/2.5 mL  (NDCs 0591-3798-30, 0591-3798-60, and 0591-3798-83)",New,12/15/20,,,,,Pulmonary/Allergy,To be Discontinued,12/15/20,12/15/20,,discontinued
6088,Isoniazid Injection,Sandoz,10 mL (100 mg/mL) Multiple dose vial (NDC 0781-3056-70),Reverified,11/16/21,Unavailable. Estimated recovery: TBD,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,0781-3056-70,not available
6089,Isoniazid Tablets,Teva Pharmaceuticals,300 mg 1000 count (NDC 0555-0071-05),New,10/27/20,,Teva made a business decision to discontinue the 1000 count presentation. The other presentations of Isoniazid Tablets product remain active.,,,Anti-Infective,To be Discontinued,10/27/20,10/27/20,0555-0071-05,discontinued
6090,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9509-10,available
6091,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9508-10,not available
6092,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,7/7/21,Product Available – Please Check Wholesalers for Availability,,,,Anesthesia,Current,,,42023-113-10,unclear
6093,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,7/7/21,Product Available – Please Check Wholesalers for Availability,,,,Anesthesia,Current,,,42023-115-10,unclear
6094,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,7/7/21,Product Available – Please Check Wholesalers for Availability,,,Demand increase for the drug,Anesthesia,Current,,,42023-114-10,unclear
6095,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),200 mg / 20 mL (NDC 67457-181-20),Reverified,11/5/21,Available,Mylan label; Sporadic availability expected.,,,Anesthesia,Current,,,67457-181-20,available
6096,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),500 mg / 10 mL (NDC 67457-001-10),Reverified,11/5/21,Currently on backorder - next shipment anticipated in November,Sporadic availability expected.,,,Anesthesia,Current,,,67457-001-10,not available
6097,Ketamine Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1000 mg / 10 mL (NDC 67457-108-10),Reverified,11/5/21,Currently on backorder - next shipment anticipated in November,Mylan label; Sporadic availability expected.,,,Anesthesia,Current,,,67457-108-10,not available
6098,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Revised,11/18/21,Limited Supply Available. Next Delivery: April 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-2051-05,limited availability
6099,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Revised,11/18/21,Next Delivery and Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-2053-10,not available
6100,Ketoprofen Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,11/29/21,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,12/23/16,,0378-8200-01,available
6101,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,11/8/21,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3193-01,not available
6102,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,11/8/21,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-01,not available
6103,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,11/8/21,Unavailable,This was a business-related decision to discontinue manufacturing these products,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-05,not available
6104,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-10,discontinued
6105,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,1/19/21,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-10,available
6106,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,1/19/21,Available,"Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.",,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-11,available
6107,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-01,available
6108,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,1/19/21,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-10,discontinued
6109,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/19,,Avet is no longer marketing the 25 mg strength,,,Analgesia/Addiction;Rheumatology,To be Discontinued,11/25/19,11/25/19,23155-020-01,discontinued
6110,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-021-01,available
6111,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-022-01,available
6112,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,11/5/21,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-118-25,available
6113,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,11/5/21,Available,Distributed by Fosun Pharma USA Inc. (Company Contact Information:  833-291-9645),,Available,Analgesia/Addiction,Current,,,72266-119-25,available
6114,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Reverified,11/23/21,Limited Supply,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,0338-0072-25,limited availability
6115,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,11/23/21,Backordered. Next release January 2022.,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-107-10,not available
6116,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,11/23/21,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-104-10,available
6117,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,11/23/21,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-105-20,available
6118,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Reverified,11/23/21,Limited Supply,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 15 mg/mL (1 mL fill volume/ 2 mL container),,,Analgesia/Addiction,Current,,,0338-0069-10,limited availability
6119,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,10/12/21,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6041-25,unclear
6120,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,10/12/21,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6042-25,unclear
6121,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,10/12/21,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6043-25,unclear
6122,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-700-01,available
6123,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-01,available
6124,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-02,available
6125,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,10/22/21,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,25021-700-01,not available
6126,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,10/22/21,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-02,not available
6127,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,10/22/21,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-01,not available
6128,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-23,discontinued
6129,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-31,discontinued
6130,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-61,discontinued
6131,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Reverified,11/18/21,Next Delivery: December 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3793-01,not available
6132,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3795-01,limited availability
6133,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Reverified,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-3796-01,available
6134,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/18,Available,,,Other,Analgesia/Addiction,Current,,,69543-0386-25,available
6135,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-161-01,not available
6136,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-01,not available
6137,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,11/23/21,Backordered.  Next release December 2021.,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,12/4/15,,63323-162-02,not available
6138,Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection,Sun Pharmaceutical Industries Inc.,5 Vial Kit (NDC 45567-0030-1),Revised,11/16/21,Currently unavailable. Distribution is anticipated in late December 2021 to early January 2022.,Issues that led the shortage have been addressed but the timing for complete market recovery is unknown at this time.,,Other,Medical Imaging,Current,,,45567-0030-1,not available
6139,Lamivudine and Tenofovir Disoproxil Fumarate Tablets,"Celltrion, Inc.",300 mg; 300 mg (NDC 72606-002-01),New,9/1/21,,,,,Antiviral,To be Discontinued,9/1/21,9/1/21,72606-002-01,discontinued
6140,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5180-91,discontinued
6141,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5168-93,discontinued
6142,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5169-91,discontinued
6143,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/18,,,,,Antiviral,To be Discontinued,3/16/18,3/16/18,0378-5170-93,discontinued
6144,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/18,,"A business decision was made to discontinue manufacture and supply of the Lanoxin 187.5 mcg (0.1875 mg) strength tablets.  All existing lots on the market are good through expiry. The anticipated final date of availability for sale is June 30, 2018 (NDC 59212-245-55).",,,Cardiovascular,To be Discontinued,5/22/18,5/22/18,59212-245-55,discontinued
6145,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,480 mg injection (NDC 0006-5004-01),Revised,9/14/21,,,Available,,Antiviral,Resolved,9/14/21,9/14/21,0006-5004-01,
6146,Letermovir (Prevymis) Injection,Merck Sharp & Dohme Corp.,240 mg injection (NDC 0006-5003-01),Revised,9/14/21,,,Available,,Antiviral,Resolved,9/14/21,9/14/21,0006-5003-01,
6147,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,11/8/21,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5140-01,not available
6148,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,11/8/21,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,0703-5145-01,not available
6149,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,11/23/21,Available,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,9/25/13,,63323-710-50,available
6150,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,11/23/21,Backordered. Next release December 2021.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,63323-711-00,not available
6151,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Revised,10/22/21,Backordered. Estimated availability December 2021,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-813-10,not available
6152,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Revised,10/22/21,Available,,,Manufacturing delay,Oncology;Pediatric,Current,9/25/13,,25021-814-30,available
6153,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Revised,10/22/21,Available.,,,,Oncology;Pediatric,Current,9/25/13,,25021-815-30,available
6154,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Revised,10/22/21,Available.,,,,Oncology;Pediatric,Current,9/25/13,,25021-816-30,available
6155,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Revised,10/22/21,Available,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-828-50,available
6156,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9555-01,available
6157,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9554-01,available
6158,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9553-01,available
6159,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9552-01,not available
6160,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-10)",Revised,11/23/21,Backordered. Next release January 2022.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,63323-631-10,not available
6161,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",Revised,11/23/21,Backordered. Next release January 2022.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,63323-631-50,not available
6162,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",100 mg vial (NDC 67457-528-10),Reverified,11/29/21,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-528-10,limited availability
6163,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",200 mg vial (NDC 67457-529-20),Reverified,11/29/21,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-529-20,limited availability
6164,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",350 mg vial (NDC 67457-530-35),Reverified,11/29/21,Intermittent Supply,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-530-35,limited availability
6165,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,7/29/21,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-223-05,available
6166,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,7/29/21,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-303-30,available
6167,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,7/29/21,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-453-45,available
6168,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,7/29/21,Available,Call customer service: 1-888-FENSOLVI,,,Endocrinology/Metabolism;Oncology,Current,,,62935-153-50,available
6169,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,7/29/21,Available,Call customer service: 1-877-ELIGARD,,,Endocrinology/Metabolism;Oncology,Current,,,62935-753-75,available
6170,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-9694-03,available
6171,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3346-03,available
6172,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3473-03,available
6173,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3642-03,available
6174,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,11/8/21,Not Available; Next replenishment anticipated January 2022,,,Other,Endocrinology/Metabolism;Oncology,Current,,,0074-3683-03,not available
6175,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3641-03,available
6176,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3663-03,available
6177,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2282-03,available
6178,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2440-03,available
6179,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2108-03,available
6180,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,11/8/21,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3779-03,available
6181,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 500 mg (60 ct. bottle)(NDC 60505-3280-06),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,60505-3280-06,
6182,"Levetiracetam Extended-Release Oral Tablets, USP",Apotex Corp.,Levetiracetam Extended-Release Tablets 750 mg (60 ct. bottle)(NDC 60505-3517-06),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,60505-3517-06,
6183,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,500mg tablet 60 count bottle (NDC 4733557386),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,4733557386,
6184,"Levetiracetam Extended-Release Oral Tablets, USP",Sun Pharmaceutical Industries Inc.,750mg tablet 60 count bottle (NDC 4733557686),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,4733557686,
6185,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,500mg  60 count bottle (NDC 68180-117-07),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,68180-117-07,
6186,"Levetiracetam Extended-Release Oral Tablets, USP",Lupin,750mg 60 count bottle (NDC 68180-118-07),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,68180-118-07,
6187,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,500mg extended-release (NDC 50474-598-66),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-598-66,
6188,"Levetiracetam Extended-Release Oral Tablets, USP",UCB Inc.,750mg extended-release (NDC 50474-599-66),Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-599-66,
6189,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 60’s (NDC 43547-0345-06)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0345-06,
6190,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 500mg, 500’s (NDC 43547-0345-50)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0345-50,
6191,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 60’s (NDC 43547-0346-06)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0346-06,
6192,"Levetiracetam Extended-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam ER Tablets, 750mg, 500’s (NDC 43547-0346-50)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0346-50,
6193,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"250MG, (NDC 50474-594-40)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-594-40,
6194,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"500MG, (NDC 50474-595-40)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-595-40,
6195,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"750MG, (NDC 50474-596-40)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-596-40,
6196,"Levetiracetam Immediate-Release Oral Tablets, USP",UCB Inc.,"1000MG, (NDC 50474-597-66)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,50474-597-66,
6197,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"250mg, 120 count (NDC 65862024508)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,65862024508,
6198,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"500mg , 120 count (NDC 65862024608)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,65862024608,
6199,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"1000mg, 60 count (NDC 65862031560)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,65862031560,
6200,"Levetiracetam Immediate-Release Oral Tablets, USP",Aurobindo Pharma,"750mg, 120 count (NDC 65862024708)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,65862024708,
6201,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 90 Count Bottes (68180-112-09)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6202,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 120 Count Bottes (68180-112-16)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6203,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 250 mg – 500 Count Bottes (68180-112-02)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6204,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 90 Count Bottes (68180-113-09)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6205,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 90 Count Bottes (68180-114-09)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6206,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 500 Count Bottes (68180-114-02)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6207,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 120 Count Bottes (68180-113-16)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6208,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 500 mg – 500 Count Bottes (68180-113-02)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6209,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 750 mg – 120 Count Bottes (68180-114-16)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6210,"Levetiracetam Immediate-Release Oral Tablets, USP",Lupin,"Levetiracetam Tablets, 1000 mg – 60 Count Bottes (68180-115-07)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,,
6211,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 120 count (NDC 31722053612)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053612,
6212,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"250mg, 500 count (NDC 31722053605)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053605,
6213,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 120 count (NDC 31722053712)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053712,
6214,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"500mg, 500 count (NDC 31722053705)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053705,
6215,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 120 count (NDC 31722053812)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053812,
6216,"Levetiracetam Immediate-Release Oral Tablets, USP",Camber Pharmaceuticals Inc.,"750mg, 500 count (NDC 31722053805)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,31722053805,
6217,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 250mg – 120’s (NDC 43547-0221-15)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0221-15,
6218,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 120’s (NDC 43547-0222-15)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0222-15,
6219,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 500mg – 1000’s (NDC 43547-0222-11)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0222-11,
6220,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 750mg – 120’s (NDC 43547-0223-15)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0223-15,
6221,"Levetiracetam Immediate-Release Oral Tablets, USP","Solco Healthcare US, LLC","Levetiracetam Tablets, 1000mg – 60’s (NDC 43547-0224-06)",Revised,3/16/21,,,Long-term backorder for all skus. No estimated release date at this time.,,Neurology,Resolved,3/16/21,,43547-0224-06,
6222,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 120 count (NDC 0378-5613-78)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5613-78,
6223,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 250 mg, 500 count (NDC 0378-5613-05)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5613-05,
6224,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 500 count (NDC 0378-5615-05)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5615-05,
6225,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 500 mg, 120 count (NDC 0378-5615-78)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5615-78,
6226,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 120 count (NDC 0378-5617-78)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5617-78,
6227,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 750 mg, 500 count (NDC 0378-5617-05)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5617-05,
6228,"Levetiracetam Immediate-Release Oral Tablets, USP",Mylan Pharmaceuticals Inc.,"Levetiracetam Tablets, 1000 mg, 60 count (NDC 0378-5619-91)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,0378-5619-91,
6229,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"250mg, 120 count bottle (NDC 13668-014-12)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,13668-014-12,
6230,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"500mg, 120 count bottle (NDC 13668-015-12)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,13668-015-12,
6231,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 120 count bottle (NDC 13668-016-12)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,13668-016-12,
6232,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"750 mg, 500 count bottle (NDC 13668-016-05)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,13668-016-05,
6233,"Levetiracetam Immediate-Release Oral Tablets, USP",Torrent Pharma Inc.,"1000 mg, 60 count bottle (NDC 13668-017-60)",Revised,3/16/21,,,,,Neurology,Resolved,3/16/21,,13668-017-60,
6234,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-26,discontinued
6235,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/18,,This was a business-related decision to discontinue manufacturing these products,,,Anesthesia,To be Discontinued,4/27/18,4/27/18,0591-3012-30,discontinued
6236,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,11/23/21,Available,,,Demand increase for the drug,Cardiovascular,Current,,,0338-0409-03,available
6237,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,11/23/21,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
6238,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9598-20,available
6239,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9594-20,available
6240,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9594-10,available
6241,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Ampoule (NDC 55150-158-72),Revised,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,available
6242,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Ampoule (NDC 55150-159-74),Revised,11/5/21,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,available
6243,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Ampoule (NDC 55150-160-72),Revised,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,available
6244,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,11/5/21,Currently on backorder - next shipment anticipated early Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-161-02,not available
6245,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,11/5/21,Currently on backorder - next shipment anticipated in November,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-162-05,not available
6246,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,11/5/21,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-163-30,available
6247,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-164-02,not available
6248,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,11/5/21,Available,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-165-05,available
6249,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Reverified,11/23/21,Not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0484-57,not available
6250,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0491-57,available
6251,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-02,not available
6252,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-10,not available
6253,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Reverified,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-27,not available
6254,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Reverified,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-57,not available
6255,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-27,available
6256,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-80,not available
6257,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-89,not available
6258,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Reverified,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-57,not available
6259,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-37,available
6260,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,11/18/21,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-9137-05,available
6261,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,11/18/21,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4713-32,available
6262,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4276-01,not available
6263,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (1%; 10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,11/18/21,Next Delivery: March 2022; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4279-02,not available
6264,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","500 mg/50 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02; NDC 0409-4276-17, individual)",Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4276-02,not available
6265,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,11/18/21,Next Delivery: May 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4282-01,not available
6266,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4282-02,not available
6267,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4904-34,limited availability
6268,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4903-34,limited availability
6269,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-2066-05,not available
6270,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4277-01,not available
6271,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,11/18/21,Next Delivery: March 2022; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4277-02,not available
6272,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (4%; 40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,11/18/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4283-01,not available
6273,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (2%; 20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-1323-05,not available
6274,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)
(old NDC 0548-3390-00)",Reverified,11/2/21,Available,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,76329-3390-1,available
6275,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,3/30/21,Unavailable-No product available for release. No plan to manufacture.,"American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection, USP",,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00517-0625-25,discontinued
6276,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-97,available
6277,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-91,available
6278,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0202-02,available
6279,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0208-05,available
6280,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-17,available
6281,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-27,available
6282,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Reverified,11/23/21,Backordred. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-57,not available
6283,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)
discontinued",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-10,not available
6284,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-20,not available
6285,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-50,not available
6286,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Reverified,11/23/21,Backordered. Next release November 2021.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-27,not available
6287,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Reverified,11/23/21,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-07,available
6288,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Reverified,11/23/21,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0496-97,not available
6289,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,11/18/21,Unavailable. Next Delivery and Estimated Recovery: January 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4275-01,not available
6290,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/2 mL (5%; 50 mg/mL) and 7.5% Dextrose; Glass Ampul (NDC 0409-4712-01),Revised,11/18/21,Unavailable. Next Delivery: September 2022; Estimated Recovery: December 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4712-01,not available
6291,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,11/18/21,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4278-01,not available
6292,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,11/18/21,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4713-02,available
6293,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Reverified,11/23/21,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-31,not available
6294,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,11/5/21,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-251-10,not available
6295,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-252-20,not available
6296,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,11/5/21,Currently on backorder - next shipment anticipated end of Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-254-10,not available
6297,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,11/5/21,Currently on backorder - next shipment anticipated end of Nov,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-255-20,not available
6298,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9595-25,not available
6299,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9594-25,available
6300,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9577-10,available
6301,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9575-10,available
6302,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),New,6/14/18,"Currently available, in stock Production is ongoing",,,Other,Anesthesia,Current,,,65282-1605-1,available
6303,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (1.5%; 15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,11/18/21,Available,,,Other,Anesthesia;Pediatric,Current,,,0409-4776-01,available
6304,Lidocaine Hydrochloride (Xylocaine) Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),2% MDV 1000mg/50mL (NDC 55150-256-50),Revised,11/5/21,Currently on backorder - next shipment anticipated end of Nov,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-256-50,not available
6305,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-0996-01,discontinued
6306,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Reverified,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3177-01,limited availability
6307,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Reverified,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: March 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3178-01,limited availability
6308,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3178-02,not available
6309,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3178-03,not available
6310,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Reverified,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-1209-01,limited availability
6311,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Reverified,11/18/21,Next Delivery and Estimated Recovery: July 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3181-01,not available
6312,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-01,not available
6313,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-02,not available
6314,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-03,not available
6315,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3183-01,not available
6316,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-7263-01,discontinued
6317,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0482-17,not available
6318,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Reverified,11/23/21,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0487-17,not available
6319,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Reverified,11/23/21,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0488-17,not available
6320,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Reverified,11/23/21,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0489-17,not available
6321,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3611-01,discontinued
6322,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/18,,The discontinuation of this product is a business decision,,,Endocrinology/Metabolism,To be Discontinued,3/28/18,3/28/18,0378-3612-01,discontinued
6323,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (20 grams per 100 mL) (NDC 63323--820-00)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323--820-00,not available
6324,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (50 grams per 250 mL) (NDC 63323--820-74)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323--820-74,not available
6325,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (100 grams per 500 mL) (NDC 63323-820-50)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323-820-50,not available
6326,Lipid Injection,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20%, PBP (0.2 grams per mL) (200 grams per 1000 mL) (NDC 63323-820-10)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323-820-10,not available
6327,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 100 mL, Product Code EADB9520, (NDC 0338-954-005)",Revised,11/23/21,Available,NDC 0338-954-005,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-005,available
6328,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 1000 mL, Product Code EADB9524, (NDC 0338-954-008)",Revised,11/23/21,Available,NDC 0338-954-008,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-008,available
6329,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 250 mL, Product Code EADB9521, (NDC 0338-954-006)",Revised,11/23/21,Available,NDC 0338-954-006,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-006,available
6330,Lipid Injection,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 500 mL, Product Code EADB9523, (NDC 0338-954-007)",Revised,11/23/21,Available,NDC 0338-954-007,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-007,available
6331,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 100 mL, Product Code 2B6061, (NDC 0338-051-958)",Revised,11/23/21,"Limited Supply, on Allocation; Recovery Q4",NDC 0338-051-958. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-958,limited availability
6332,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 250 mL, Product Code 2B6062, (NDC 0338-051-909)",Revised,11/23/21,"Limited Supply on Allocation, Recovery Q4",NDC 0338-051-909. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-909,limited availability
6333,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 1000 mL, Pharmacy Bulk Package, Product Code 2B6064, (NDC 0338-051-914)",New,10/26/21,Limited Supply on Allocation,NDC 0338-051-914. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-914,limited availability
6334,Lipid Injection,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 500 mL, Product Code 2B6063, (NDC 0338-051-913)",New,10/26/21,Limited Supply on Allocation,NDC 0338-051-913. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-913,limited availability
6335,Lipid Injection,Baxter Healthcare,"Intralipid 30% IV Fat Emulsion, 500 mL, Pharmacy Bulk Package, Product Code 2B6065, (NDC 0338-052-013)",New,10/26/21,Limited Supply on Allocation,NDC 0338-052-013. Fresenius is the NDA holder and Baxter is the distributor.,,Demand Increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-052-013,limited availability
6336,Lipid Injection,B. Braun Medical Inc.,"Nutrilipid (20% IV Fat Emulsion) in 1,000mL Bag Catalog S4600 (NDC 00264-4460-00)",New,10/27/21,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,00264-4460-00,limited availability
6337,Lipid Injection,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 500mL Bag Catalog S4601 (NDC 0264-4460-10),New,10/27/21,"Product on back order, next release expected end Nov 2021",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0264-4460-10,not available
6338,Lipid Injection,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 250mL Bag Catalog S4603 (NDC 00264-4460-30),New,10/27/21,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,00264-4460-30,limited availability
6339,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05),New,4/11/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,4/11/18,4/11/18,0378-2072-01,discontinued
6340,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (NDC 0054-3527-63),Reverified,11/5/21,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,0054-3527-63,not available
6341,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-1539-31,discontinued
6342,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Reverified,11/18/21,Available,,,Other,Neurology,Current,,,00409-1985-30,available
6343,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Reverified,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Neurology,Current,,,00409-6778-02,limited availability
6344,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-6779-02,discontinued
6345,Lorazepam Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-6780-02,discontinued
6346,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,11/2/21,Available,,,Other,Neurology,Current,,,76329-8261-1,available
6347,Lorazepam Injection,Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Reverified,5/19/21,Available,,,Demand increase for the drug,Neurology,Current,,,17478-040-01,available
6348,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6001-25,available
6349,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6000-10,available
6350,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6003-25,available
6351,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
6352,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6044-25,available
6353,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6046-10,available
6354,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6045-25,available
6355,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,available
6356,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1394-10,discontinued
6357,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1395-10,discontinued
6358,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1396-10,discontinued
6359,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,11/25/19,11/25/19,0527-1397-10,discontinued
6360,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,6/21/21,Available,,,,Psychiatry,Current,,,0527-1394-01,available
6361,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",Revised,6/21/21,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1394-10,not available
6362,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,6/21/21,Available,,,,Psychiatry,Current,,,0527-1395-01,available
6363,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",Revised,6/21/21,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1395-10,not available
6364,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,6/21/21,Available,,,Other,Psychiatry,Current,,,0527-1396-01,available
6365,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",Revised,6/21/21,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1396-10,not available
6366,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,6/21/21,Available,,,,Psychiatry,Current,,,0527-1397-01,available
6367,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",Revised,6/21/21,Unavailable,,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,0527-1397-10,not available
6368,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-7005-01)",Reverified,11/29/21,Unavailable,,,Other,Psychiatry,Current,,,0378-7005-01,not available
6369,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-7010-01)",Reverified,11/29/21,Unavailable,,,Other,Psychiatry,Current,,,0378-7010-01,not available
6370,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","25 mg, 100 count bottle (NDC 0378-7025-01)",Reverified,11/29/21,Unavailable,,,Other,Psychiatry,Current,,,0378-7025-01,not available
6371,Loxapine Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","50 mg, 100 count bottle (NDC 0378-7050-01)",Reverified,11/29/21,Unavailable,,,Other,Psychiatry,Current,,,0378-7050-01,not available
6372,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Revised,11/8/21,Available,,,,Psychiatry,Current,,,0591-0369-01,available
6373,Loxapine Capsules,Teva Pharmaceuticals,"10 mg, 100 count bottle (NDC 0591-0370-01)",Revised,11/8/21,Recovery: Feb 2022,January 2022 recovery,,Other,Psychiatry,Current,,,0591-0370-01,unclear
6374,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Revised,11/8/21,Available,,,,Psychiatry,Current,,,0591-0371-01,available
6375,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Revised,11/8/21,Available,,,,Psychiatry,Current,,,0591-0372-01,available
6376,Mannitol Injection,"Fresenius Kabi USA, LLC",25% (12.5 grams per 50 mL)(250 mg per mL) Single dose vial (NDC 63323-024-25),Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,63323-024-25,not available
6377,Mannitol Injection,"Hospira, Inc.",12.5 g/50 mL (25%); Single Dose Glass Fliptop Vial (NDC 0409-4031-01),Revised,11/18/21,Limited Supply Available. Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Renal,Current,,,0409-4031-01,limited availability
6378,Mannitol Injection,Baxter Healthcare,"10% OSMITROL Injection (10% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5613Q (NDC 0338-0535-03)",New,9/29/21,Available,,,,Renal,Current,,,0338-0535-03,available
6379,Mannitol Injection,Baxter Healthcare,"20% OSMITROL Injection (20% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5633Q (NDC 0338-0357-03); 250 mL Viaflex Plastic Container Product Code 2D5632Q (NDC 0338-0357-02)",New,9/29/21,Available,,,,Renal,Current,,,0338-0357-03,available
6380,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 500 mL (Legacy Hospira NDC 0409-7715-03)(ICU Medical NDC 0990-7715-03)",Revised,11/10/21,On allocation,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Renal,Current,,,0409-7715-03,limited availability
6381,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 250 mL (Legacy Hospira NDC 0409-7715-02)(ICU Medical NDC 0990-7715-02)",Revised,11/10/21,On allocation,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical.",,Other,Renal,Current,,,0409-7715-02,limited availability
6382,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-01,discontinued
6383,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-012-10,discontinued
6384,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-01,discontinued
6385,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/18,,This discontinuation is due to a business decision.,,,Gastroenterology,To be Discontinued,2/28/18,2/28/18,42806-014-10,discontinued
6386,"Medroxyprogesterone Acetate (Depo-Provera) Injection, Suspension",Pfizer Pharmaceuticals,"400 mg/mL, 1 carton containing one 2.5 mL vial (NDC 0009-0626-01)",New,10/27/20,,Discontinuation of the manufacturing of the drug.,,,Reproductive,To be Discontinued,10/27/20,10/27/20,0009-0626-01,discontinued
6387,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",7.5 mg tablets (NDCs 0597-0029-01 and 0597-0029-94),New,11/1/21,,,,,Analgesia/Addiction,To be Discontinued,11/1/21,11/1/21,,discontinued
6388,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",15 mg tablets (NDCs 0597-0030-01 and 0597-0030-56),New,11/1/21,,,,,Analgesia/Addiction,To be Discontinued,11/1/21,11/1/21,,discontinued
6389,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 1% (500 mg per 50 mL), (10 mg per mL), MDV, (NDC 63323-0283-57)",Revised,11/23/21,Available,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0283-57,available
6390,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 2% (1,000 mg per 50 mL), (20 mg per mL), MDV, (NDC 63323-0296-57)",Revised,11/23/21,Available,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0296-57,available
6391,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1% (300 mg per 30 mL), (10 mg per mL), SDV, (NDC 63323-0260-37)",Revised,11/23/21,Available,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0260-37,available
6392,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1.5% (450 mg per 30 mL), (15 mg per mL), SDV, (NDC 63323-0293-37)",Revised,11/23/21,Available,,,Manufacturing delay,Anesthesia,Current,,,63323-0293-37,available
6393,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 2% (400 mg per 20 mL), (20 mg per mL), SDV, (NDC 63323-0294-27)",Revised,11/23/21,Backordered. Next release December 2021.,,,Manufacturing delay,Anesthesia,Current,,,63323-0294-27,not available
6394,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1036-30),Reverified,11/18/21,Next Delivery and estimated recovery: May 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-1036-30,not available
6395,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1067-20),Reverified,11/18/21,Next Delivery and estimated recovery: April 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-1067-20,not available
6396,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1041-30),Reverified,11/18/21,Next Delivery and estimated recovery: June 2022,Shortage per manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-1041-30,not available
6397,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 0409-1038-50),Reverified,11/18/21,Available,,,Other,Anesthesia,Current,,,0409-1038-50,available
6398,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/20,,"Additional products remain available:   
NDC 58914-501-56 (30 suppositories in 1 box); NDC 58914-501-33 (3 suppositories in 1 box); NDC 59762-0118-3",,,Gastroenterology,To be Discontinued,7/30/20,7/30/20,58914-501-42,discontinued
6399,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/20,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/20,6/24/20,2037-577-10,discontinued
6400,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/20,,Teva made a business decision to discontinue the product.,,,Endocrinology/Metabolism,To be Discontinued,6/24/20,6/24/20,62037-571-01,discontinued
6401,Methadone Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Revised,6/8/21,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,6/8/21,,67457-217-20,
6402,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,6/8/21,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,6/8/21,,17478-380-20,
6403,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 5 mg tablets; bottle of 100 (NDC 60793-104-01),New,11/5/21,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism,To be Discontinued,11/5/21,11/5/21,60793-104-01,discontinued
6404,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 10 mg tablets; bottle of 100 (NDC 60793-105-01),New,11/5/21,,Discontinuation of the manufacture of the drug.,,,Endocrinology/Metabolism,To be Discontinued,11/5/21,11/5/21,60793-105-01,discontinued
6405,"Methocarbamol Tablet, USP","Endo Pharmaceuticals, Inc.",750 mg tablets (NDC 52244-449-10),New,10/27/20,,,,,Analgesia/Addiction,To be Discontinued,10/27/20,10/27/20,52244-449-10,discontinued
6406,Methohexital Sodium (Brevital) Injection,Par Pharmaceutical,"500 mg/vial, 50 mL multiple dose vial, box of 1 (NDC 42023-105-01)",Revised,11/15/21,,,Available,,Anesthesia,Resolved,11/15/21,,42023-105-01,
6407,Methoxsalen Capsules,Teva Pharmaceuticals,10mg  (NDC 45963-325-50),New,3/22/21,,,,,Dermatology,To be Discontinued,3/22/21,3/22/21,45963-325-50,discontinued
6408,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Revised,2/5/21,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,limited availability
6409,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Revised,2/5/21,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,limited availability
6410,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Revised,2/5/21,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,limited availability
6411,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Revised,2/5/21,Limited availability,,,API procurement delay,Cardiovascular,Current,,,,limited availability
6412,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",250 mg (NDC 0378-0611-01),Revised,10/8/21,,,,,Cardiovascular,To be Discontinued,10/8/21,10/8/21,0378-0611-01,discontinued
6413,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",500 mg (NDC 0378-0421-01),Revised,10/8/21,,,,,Cardiovascular,To be Discontinued,10/8/21,10/8/21,0378-0421-01,discontinued
6414,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0591-0790-01,discontinued
6415,"Metoclopramide Injection, USP",Heritage Pharma,10mg/2mL (NDC 23155-240-41),Revised,10/18/19,,,,,Gastroenterology,Resolved,10/18/19,,23155-240-41,
6416,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-01",New,7/6/21,,Discontinued due to business reasons.,,,Gastroenterology,To be Discontinued,7/6/21,7/6/21,49884-0689-01,discontinued
6417,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-05)",New,7/6/21,,Discontinued due to business reasons.,,,Gastroenterology,To be Discontinued,7/6/21,7/6/21,49884-0689-05,discontinued
6418,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
6419,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,12/16/19,12/16/19,,discontinued
6420,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 100 bottle (NDC 0025-1831-31),New,10/20/20,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/20,10/20/20,0025-1831-31,discontinued
6421,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,250 mg tablets 1 x 50 bottle (NDC 0025-1831-50),New,10/20/20,,Discontinuation of the manufacture of the drug.,,,,To be Discontinued,10/20/20,10/20/20,0025-1831-50,discontinued
6422,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 100 bottle (NDC 0025-1821-31),New,10/13/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/13/21,10/13/21,0025-1821-31,discontinued
6423,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 50 bottle (NDC 0025-1821-50),New,10/13/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/13/21,10/13/21,0025-1821-50,discontinued
6424,Midazolam Injection,Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),Revised,10/22/21,Available,,,,Anesthesia;Neurology,Current,,,17478-0524-10,available
6425,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-10,available
6426,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0001-20,available
6427,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-12,available
6428,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-25,available
6429,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-25,available
6430,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-10,available
6431,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0002-10,available
6432,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-02,available
6433,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-05,available
6434,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Reverified,10/12/21,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6056-10,available
6435,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Reverified,10/12/21,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6057-25,available
6436,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Reverified,10/12/21,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,0641-6059-25,available
6437,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Reverified,10/12/21,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6061-25,available
6438,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Reverified,10/12/21,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6060-10,available
6439,Midazolam Injection,"Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2305-17,not available
6440,Midazolam Injection,"Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2305-05,limited availability
6441,Midazolam Injection,"Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2308-01,limited availability
6442,Midazolam Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: February 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2596-05,limited availability
6443,Midazolam Injection,"Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,11/18/21,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2308-02,available
6444,Midazolam Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,11/18/21,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2596-03,available
6445,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Revised,10/13/21,Available,,,Other,Anesthesia;Neurology,Current,,,23155-601-42,available
6446,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Revised,10/13/21,Available,,,Other,Anesthesia;Neurology,Current,,,23155-601-41,available
6447,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Revised,10/13/21,Available; On allocation due to increased demand,,,Other,Anesthesia;Neurology,Current,,,23155-600-41,limited availability
6448,Midazolam Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2587-05,limited availability
6449,Midazolam Injection,"Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,00409-2306-62,discontinued
6450,Midazolam Injection,"Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,00409-2307-60,discontinued
6451,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Reverified,11/5/21,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-10,available
6452,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Reverified,11/5/21,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-05,available
6453,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Reverified,11/5/21,No stock available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-17,not available
6454,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Reverified,11/5/21,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-91,available
6455,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Reverified,11/5/21,Available,"Marketing partner: Athenex Pharmaceutical Division, LLC.",,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-600-02,available
6456,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Reverified,11/5/21,Available,Marketing partner: Alvogen Inc.,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-588-68,available
6457,Miglitol Tablets,"Hospira, Inc.",25 mg (NDC 0009-5012-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5012-01,discontinued
6458,Miglitol Tablets,"Hospira, Inc.",50 mg (NDC 0009-5013-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5013-01,discontinued
6459,Miglitol Tablets,"Hospira, Inc.",100 mg (NDC 0009-5014-01),New,11/17/20,,,,,Endocrinology/Metabolism,To be Discontinued,11/17/20,11/17/20,0009-5014-01,discontinued
6460,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2469-15,discontinued
6461,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2470-15,discontinued
6462,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/18,,This product discontinuation is a business related decision,,,Psychiatry,To be Discontinued,5/29/18,5/29/18,0591-2471-15,discontinued
6463,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 59762-5008-2),Reverified,11/18/21,Next Delivery: December 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Gastroenterology,Current,,,59762-5008-2,not available
6464,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 60 (NDC 43386-160-06),Revised,4/30/21,Available,,,Other,Gastroenterology,Current,,,43386-160-06,available
6465,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 120 (NDC 43386-160-12),Revised,4/30/21,Available,,,Other,Gastroenterology,Current,,,43386-160-12,available
6466,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 60 (NDC 43386-161-06),Revised,4/30/21,Available,,,Other,Gastroenterology,Current,,,43386-161-06,available
6467,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 100 (NDC 43386-161-01),Revised,4/30/21,Available,,,Other,Gastroenterology,Current,,,43386-161-01,available
6468,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 59762-5007-1),Reverified,11/18/21,Next Delivery: November 2021; Esimtated Recovery: January 2022,,,Other,Gastroenterology,Current,,,59762-5007-1,not available
6469,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 59762-5007-2),Reverified,11/18/21,Next Delivery and Estimated Recovery: March 2022,,,Other,Gastroenterology,Current,,,59762-5007-2,not available
6470,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 59762-5008-1),Reverified,11/18/21,Next Delivery and Estimated Recovery: January 2022,,,Other,Gastroenterology,Current,,,59762-5008-1,not available
6471,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; 10x10 blister (NDC 0025-1451-34),Reverified,11/18/21,Available,,,Other,Gastroenterology,Current,,,0025-1451-34,available
6472,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 0025-1451-60),Reverified,11/18/21,Available,,,Demand increase for the drug,Gastroenterology,Current,,,0025-1451-60,available
6473,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 0025-1461-31),Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Gastroenterology,Current,,,0025-1461-31,not available
6474,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 0025-1461-60),Reverified,11/18/21,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Gastroenterology,Current,,,0025-1461-60,unclear
6475,Mometasone Furoate Monohydrate Nasal Spray,Merck Sharp & Dohme Corp.,50 mcg (NDC 0085-1288-01),New,6/9/21,,,,,Pulmonary/Allergy,To be Discontinued,6/9/21,6/9/21,0085-1288-01,discontinued
6476,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
6477,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
6478,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,7/28/20,7/28/20,,discontinued
6479,Montelukast Sodium Chewable Tablet,Sandoz,"4 mg  (NDCs 0781-5554-05, 0781-5554-06, 0781-5554-13, 0781-5554-31, 0781-5554-64, 0781-5554-92)",New,10/12/21,,,,,Pulmonary/Allergy,To be Discontinued,10/12/21,10/12/21,,discontinued
6480,Montelukast Sodium Chewable Tablet,Sandoz,"5 mg  (NDCs 0781-5555-05, 0781-5555-06, 0781-5555-13, 0781-5555-31, 0781-5555-64, 0781-5555-92)",New,10/12/21,,,,,Pulmonary/Allergy,To be Discontinued,10/12/21,10/12/21,,discontinued
6481,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/18,,The discontinuation of this product is a business decision,,,Pediatric;Pulmonary/Allergy,To be Discontinued,3/20/18,3/20/18,0378-5201-93,discontinued
6482,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2658-01,discontinued
6483,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2659-01,discontinued
6484,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2660-01,discontinued
6485,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2661-01,discontinued
6486,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Analgesia/Addiction,To be Discontinued,5/8/18,5/8/18,0378-2662-01,discontinued
6487,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-452-01,not available
6488,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-454-01,not available
6489,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,11/23/21,7 month expiry (6/2022 expiry) dating available by request.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-455-01,limited availability
6490,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,11/23/21,7 month expiry (6/2022 expiry) dating available by request.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-458-01,limited availability
6491,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,11/23/21,Backordered. Next release January 2022.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-451-01,not available
6492,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",Morphine Sulfate 1 mg/mL 30 mg in 30 mL PUMP-JET®  SUITABLE FOR USE WITH COMPATIBLE I.V. INFUSION PUMPS (NDC 76329-1911-1),Reverified,11/2/21,Available,,,,Analgesia/Addiction,Current,,,76329-1911-1,available
6493,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6125-25,available
6494,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,available
6495,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6127-25,available
6496,Morphine Sulfate Injection,"Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1135-02,discontinued
6497,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1890-01,limited availability
6498,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1890-11,discontinued
6499,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1891-01,not available
6500,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1891-11,discontinued
6501,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1892-01,available
6502,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1892-11,discontinued
6503,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1893-01,available
6504,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1893-11,discontinued
6505,Morphine Sulfate Injection,"Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,11/18/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3814-12,not available
6506,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,11/18/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3815-12,not available
6507,Morphine Sulfate Injection,"Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1134-03,available
6508,Morphine Sulfate Injection,"Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,11/18/21,Available,,,Other,Analgesia/Addiction,Current,,,00409-1134-05,available
6509,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,11/23/21,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-004-10,unclear
6510,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,11/23/21,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-10,unclear
6511,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-006-10,available
6512,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syringe (NDC 76045-007-10)",Revised,11/23/21,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-007-10,not available
6513,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,11/23/21,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-008-10,available
6514,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6019-10,not available
6515,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,10/12/21,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing in the October - November 2021 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6020-10,not available
6516,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6039-01,available
6517,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6040-01,available
6518,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-004-11)",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-004-11,available
6519,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-005-11)",Revised,11/23/21,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-11,available
6520,Moxifloxacin (Moxeza) Ophthalmic Solution,Novartis,"5mg/mL, 3mL in 1 bottle, (NDC 0065-0006-03)",New,7/2/21,,Novartis Pharmaceuticals has made a business decision to permanently discontinue Moxeza (moxifloxacin hydrochloride) Solution 5mg/mL.,,,Ophthalmology,To be Discontinued,7/2/21,7/2/21,0065-0006-03,discontinued
6521,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0434-82,discontinued
6522,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0422-83,discontinued
6523,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0421-53,discontinued
6524,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,11/16/21,Limited supply on allocation,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5646-1,limited availability
6525,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,11/16/21,Limited supply on allocation,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5649-1,limited availability
6526,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,11/16/21,Stocked out; Recovery TBD,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5650-2,not available
6527,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,11/16/21,Stocked out; Recovery TBD,"Drug Product is distributed by Baxter Healthcare, please contact 888-229-0001 for supply related inquires.  For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition",,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5647-0,not available
6528,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (100 ct) (NDC 50742-178-01),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-178-01,discontinued
6529,Nadolol Tablets,Ingenus Pharmaceuticals LLC,20 mg (1000 ct) (NDC 50742-178-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-178-10,discontinued
6530,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (100 ct) (NDC 50742-179-01 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-179-01,discontinued
6531,Nadolol Tablets,Ingenus Pharmaceuticals LLC,40 mg (1000 ct) (NDC 50742-179-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-179-10,discontinued
6532,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (100 ct) (NDC 50742-180-01 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-180-01,discontinued
6533,Nadolol Tablets,Ingenus Pharmaceuticals LLC,80 mg (1000 ct) (NDC 50742-180-10 ),New,9/11/20,,Product Discontinuation,,,Cardiovascular,To be Discontinued,9/11/20,9/11/20,50742-180-10,discontinued
6534,Nafcillin Injection,Pfizer Pharmaceuticals,1 g; Single Dose Vial (Powder)(NDC 0409-3713-01),New,10/20/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/21,10/20/21,0409-3713-01,discontinued
6535,Nafcillin Injection,Pfizer Pharmaceuticals,2 g; Single Dose Vial (Powder)(NDC 0409-3714-01),New,10/20/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/21,10/20/21,0409-3714-01,discontinued
6536,Nafcillin Injection,Pfizer Pharmaceuticals,10 g per Pharmacy Bulk Package; Pharmacy Bulk Vial (Powder)(NDC 0409-3715-01),New,10/20/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,10/20/21,10/20/21,0409-3715-01,discontinued
6537,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3124-95,discontinued
6538,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3125-95,discontinued
6539,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3126-95,discontinued
6540,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9124-95,discontinued
6541,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9224-92,discontinued
6542,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-9225-92,discontinued
6543,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3128-92,discontinued
6544,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,12/23/19,12/23/19,0781-3129-92,discontinued
6545,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,6/28/21,,00409-1463-01,
6546,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,6/28/21,,00409-1465-01,
6547,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,6/28/21,,00409-1464-01,
6548,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,6/28/21,,00409-1467-01,
6549,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Revised,11/17/21,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,0093-7178-01,not available
6550,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Revised,11/17/21,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,0093-1024-06,not available
6551,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Revised,11/17/21,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,0093-7113-06,not available
6552,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Revised,11/17/21,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,0093-1025-06,not available
6553,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Revised,11/17/21,Estimated availability in 4Q 2021 to 1Q 2022,,,Regulatory delay,Psychiatry,Current,,,0093-1026-06,not available
6554,"Neomycin Sulfate, Polymyxin B Sulfate and Hydrocortisone Acetate Cream",Pfizer Pharmaceuticals,"CORTISPORIN (neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate cream); Tube of 7.5 g cream (NDC 61570-032-75)",New,3/9/21,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,3/9/21,3/9/21,61570-032-75,discontinued
6555,"Neomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone Ointment",Pfizer Pharmaceuticals,"Cortisporin (neomycin sulfate, polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment); Tube of 1/2 oz ointment with applicator tip (NDC 61570-031-50)",New,3/9/21,,Discontinuation of the manufacture of the drug.,,,Dermatology,To be Discontinued,3/9/21,3/9/21,61570-031-50,discontinued
6556,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/18,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To be Discontinued,2/5/18,2/5/18,65847-205-25,discontinued
6557,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/20,,,,,Antiviral,To be Discontinued,5/29/20,5/29/20,0597-0046-60,discontinued
6558,Nevirapine Oral Suspension,"Boehringer Ingelheim Pharmaceuticals, Inc.",50mg/5mL (NDC 0597-0047-24),New,10/1/21,,,,,Antiviral,To be Discontinued,10/1/21,10/1/21,0597-0047-24,discontinued
6559,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Revised,11/8/21,Supply Interruption. Relaunch Mar-Apr 2022,,,Other,Gastroenterology,Current,3/27/20,,0591-3138-30,limited availability
6560,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Revised,11/8/21,Supply Interruption. Relaunch Mar-Apr 2022,,,Other,Gastroenterology,Current,3/27/20,,0591-3137-60,limited availability
6561,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/20,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/20,,68462-0426-30,not available
6562,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/20,Unavailable,This was a business-related decision to discontinue manufacturing these products.,,,Gastroenterology,Current,3/27/20,,68462-0425-60,not available
6563,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/18,,"An authorized generic of the product is currently available as Nora-BE, NDC 52544-629-28.",,,Reproductive,To be Discontinued,2/23/18,2/23/18,52544-235-28,discontinued
6564,Norethindrone Acetate/Ethinyl Estradiol (Femhrt) Tablets,Allergan,Femhrt (NDC 0430-0145-14),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0430-0145-14,discontinued
6565,Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate Kit,Allergan,Tilia Fe (NDC 51862-284-03),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,51862-284-03,discontinued
6566,Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate Kit,Allergan,ESTROSTEP Fe (NDC 0430-0005-31),New,3/24/21,,The company has made a business decision to discontinue the product.,,,Reproductive,To be Discontinued,3/24/21,3/24/21,0430-0005-31,discontinued
6567,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7521-17),New,12/17/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/20,12/17/20,0603-7521-17,discontinued
6568,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7521-49),New,12/17/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/20,12/17/20,0603-7521-49,discontinued
6569,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7525-17),New,12/17/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/20,12/17/20,0603-7525-17,discontinued
6570,Norethindrone/Ethinyl Estradiol Kit,"Endo Pharmaceuticals, Inc.",(NDC 0603-7525-49),New,12/17/20,,Discontinued due to business reasons,,,Reproductive,To be Discontinued,12/17/20,12/17/20,0603-7525-49,discontinued
6571,Nystatin and Triamcinolone Acetonide Topical Cream,Sandoz,"100,000 units per gram; 0.1%  (NDCs 0168-0081-15, 0168-0081-30, and 0168-0081-60)",New,4/21/21,,,,,Dermatology,To be Discontinued,4/21/21,4/21/21,,discontinued
6572,Nystatin Topical Cream,Sandoz,"100,000 units per gram  (NDCs 0168-0054-15 and 0168-0054-30)",New,4/21/21,,,,,Dermatology,To be Discontinued,4/21/21,4/21/21,,discontinued
6573,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/20,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/20,7/15/20,,discontinued
6574,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/20,,The product distribution will continue until end of December 2020.,,,Psychiatry,To be Discontinued,7/15/20,7/15/20,,discontinued
6575,Olopatadine Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"0.2%, 2.5 mL Bottle (NDC 0093-7684-32)",New,4/27/21,,Rx to OTC Switch. Current Rx customers on allocation through May 2021.,,,Ophthalmology,To be Discontinued,4/27/21,4/27/21,0093-7684-32,discontinued
6576,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/18,,"Estimated product availability until January 1, 2019. The product discontinuation is voluntary",,,Antiviral,To be Discontinued,5/22/18,5/22/18,0074-3082-28,discontinued
6577,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Demand increase for the drug,Gastroenterology,Current,,,70860-776-02,available
6578,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Reverified,11/5/21,Available,"Marketed by Athenex. To order, contact Athenex at 855-273-0154",,Available,Gastroenterology,Current,,,70860-777-20,available
6579,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Reverified,9/3/21,Available,,,,Gastroenterology,Current,,,25021-782-20,available
6580,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Reverified,9/3/21,Available,,,,Gastroenterology,Current,,,25021-777-02,available
6581,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Reverified,11/5/21,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,55150-125-02,not available
6582,Ondansetron Hydrochloride Injection,Heritage Pharma,"4mg/2mL, 10 (NDC 23155-547-41 )",Reverified,10/13/21,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-547-41,available
6583,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Revised,11/18/21,Available,,,Other,Gastroenterology,Current,,,00409-4759-01,available
6584,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0641-6078-25,available
6585,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Revised,11/18/21,Available,,,Other,Gastroenterology,Current,,,00409-4755-03,available
6586,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Revised,10/6/21,,Discontinuation of the manufacture of the drug,,,Gastroenterology,To be Discontinued,10/6/21,10/6/21,00409-1120-12,discontinued
6587,Ondansetron Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Reverified,11/5/21,On long term backorder,On long term backorder,,Delay in shipping of the drug,Gastroenterology,Current,,,55150-126-20,not available
6588,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Reverified,11/23/21,Available,Check wholesalers for inventor,,Demand increase for the drug,Gastroenterology,Current,,,63323-373-02,available
6589,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Reverified,11/23/21,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,63323-374-20,not available
6590,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,76045-103-20,available
6591,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0143-9890-01,available
6592,Ondansetron Hydrochloride Injection,Heritage Pharma,"Inj4mg/2mL, 25 (NDC 23155-549-31)",Reverified,10/13/21,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-549-31,available
6593,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-41),Reverified,10/13/21,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-41,available
6594,Ondansetron Hydrochloride Injection,Heritage Pharma,PPRx4mg/2mL (NDC 23155-548-42),Reverified,10/13/21,Product is available,,,Demand increase for the drug,Gastroenterology,Current,,,23155-548-42,available
6595,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Reverified,11/5/21,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-123-25,available
6596,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Reverified,11/5/21,Available,Distributed by Fosun Pharma USA Inc. Company Contact Information:  833-291-9645,,Available,Gastroenterology,Current,,,72266-124-01,available
6597,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Reverified,11/23/21,Available,For IV or IM injection,,,Gastroenterology,Current,,,36000-012-25,available
6598,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Reverified,10/27/21,Available,,,Available,Gastroenterology,Current,,,60505-6130-05,available
6599,Oxalaplatin Injection,Gland Pharma Limited,"50 mg/10 mL, 10 vials per pack (NDC 72266-125-10)",New,9/28/20,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/20,9/28/20,72266-125-10,discontinued
6600,Oxalaplatin Injection,Gland Pharma Limited,"100 mg/20 mL, 10 vials per pack (NDC 72266-126-10)",New,9/28/20,,"50 mg/10 mL and 100 mg/20 mL, 1 vial per packs (NDCs 72266-161-01 and 72266-162-01, respectively) will continue to be available; Gland Pharma Limited, Distributed by Fosun Pharma USA Inc. (Company Contact Information: 833-291-9645)",,,Oncology,To be Discontinued,9/28/20,9/28/20,72266-126-10,discontinued
6601,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial;  (NDC 63323-012-10),Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,63323-012-10,
6602,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,63323-012-30,
6603,Oxytocin Injection (Synthetic),"Fresenius Kabi USA, LLC",10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,63323-012-01,
6604,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,42023-130-06,
6605,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,42023-116-25,
6606,Oxytocin Injection (Synthetic),Par Pharmaceutical,"Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,6/10/21,,,Available,,Reproductive,Resolved,6/10/21,,42023-116-02,
6607,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"Abraxane® 100 mg, single dose vial (NDC 68817-134-50)",Revised,11/15/21,Limited supply. Temporarily on allocation through January 2022.,Manufacturing delay,,Other,Oncology,Current,,,68817-134-50,limited availability
6608,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/19,,19-Dec,,,Oncology,To be Discontinued,11/22/19,11/22/19,67457-449-17,discontinued
6609,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",Revised,8/26/21,Out of Stock,Expected to be back in stock by October 2021.,,Other,Gastroenterology,Current,,,62756-129-44,not available
6610,Pantoprazole Sodium for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"40 mg, 10 vials (NDC 55150-202-10)",Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology,Current,,,55150-202-10,available
6611,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,11/18/21,Available,,,Other,Gastroenterology,Current,,,0008-0923-55,available
6612,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-0923-60,limited availability
6613,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,11/18/21,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-2001-10,not available
6614,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,11/18/21,Next Delivery and Estimated Recovery: February 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-2001-25,not available
6615,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,11/18/21,Available,,,Other,Gastroenterology,Current,,,0008-4001-10,available
6616,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0008-4001-25,limited availability
6617,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Gastroenterology,Current,,,0143-9284-10,available
6618,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,11/16/21,Available,,,Demand increase for the drug,Gastroenterology,Current,,,0781-3232-95,available
6619,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Reverified,12/11/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0202-1,unclear
6620,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Reverified,12/11/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0203-1,unclear
6621,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Reverified,12/11/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0204-1,unclear
6622,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Reverified,12/11/20,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0205-1,unclear
6623,Paricalcitol Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",(Solution in Multi Dose Vials) [0.01 mg / 2 ml](NDC 67457-389-25),New,1/29/21,,,,,Endocrinology/Metabolism,To be Discontinued,1/29/21,1/29/21,67457-389-25,discontinued
6624,Paricalcitol Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",(Solution in Single Dose Vials) [0.002 mg / 1 ml],New,1/29/21,,,,,Endocrinology/Metabolism,To be Discontinued,1/29/21,1/29/21,,discontinued
6625,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4347-01,discontinued
6626,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/18,,This presentation will be discontinued on or near December 2019. For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4348-01,discontinued
6627,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/18,,This presentation will be discontinued on or near December 2018.  For additional information please contact the Merck National Service Center Telephone Number: 1-800-672-6372,,,Oncology,To be Discontinued,2/28/18,2/28/18,0085-4349-01,discontinued
6628,Peginterferon alfa-2b Injection,Merck Sharp & Dohme Corp.,"PEGINTRON injection (peginterferon alfa-2b), 50 mcg per 0.5 mL; A box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs (NDC 00085-4353-01)",New,4/23/21,,To be discontinued on or near May 2021,,,Antiviral,To be Discontinued,4/23/21,4/23/21,00085-4353-01,discontinued
6629,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/19,,,,,Anti-Infective,Resolved,9/13/19,,63323-877-15,
6630,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-01,discontinued
6631,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/18,,The discontinuation of this product is a business decision,,,Cardiovascular,To be Discontinued,5/8/18,5/8/18,0378-0357-05,discontinued
6632,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/19,,,,,Neurology,To be Discontinued,11/25/19,11/25/19,16571-330-16,discontinued
6633,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 2 mL vial (NDC 0641-0493-25)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-0493-25,
6634,"Phenytoin Sodium Injection, USP","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 5 mL vial (NDC 0641-2555-45)",Revised,9/3/19,,,Available,,Neurology,Resolved,9/3/19,,0641-2555-45,
6635,Physostigmine Salicylate Injection,Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Revised,10/25/21,Unavailable. Expected to release Q4 2022.,,,Other,Neurology,Current,,,17478-510-02,not available
6636,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",New,2/21/20,No product available. Product can be manufactured upon availability of API. Concrete estimated release dates cannot be provided at this moment.,,,Shortage of active ingredient,Cardiovascular,Current,,,57664-655-88,not available
6637,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Reverified,11/29/21,Available,,,,Cardiovascular,Current,,,0378-0052-01,available
6638,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Reverified,11/29/21,Available,,,,Cardiovascular,Current,,,0378-0127-01,available
6639,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,11/18/20,Available,,,,Cardiovascular,Current,,,76385-131-01,available
6640,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,11/18/20,Available,,,,Cardiovascular,Current,,,76385-132-01,available
6641,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,6/22/21,Available,,,,Cardiovascular,Current,,,62559-560-01,available
6642,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,6/22/21,Available,,,,Cardiovascular,Current,,,62559-561-01,available
6643,Pindolol Tablets,"Nostrum Laboratories, Inc.","5 mg, Bottle of 100 tablets (NDC 29033-028-01)",New,11/30/20,"Currently Available; Predicted Shortage duration: 2 months, January and February 2021
Resupply: March 2021",,,Shortage of an active ingredient,Cardiovascular,Current,,,29033-028-01,limited availability
6644,Pindolol Tablets,"Nostrum Laboratories, Inc.","10 mg, Bottle of 100 tablets (NDC 29033-029-01)",New,11/30/20,"Currently available; Predicted Shortage duration: 1 month, February 2021
Resupply: March 2021",,,Shortage of an active ingredient,Cardiovascular,Current,,,29033-029-01,limited availability
6645,Pioglitazone/Metformin HCl (ACTOPLUS MET®) Tablets,Takeda Pharmaceuticals USA Inc.,15mg/500mg tablet (NDC 64764-0155-60),New,10/18/21,,Business reasons for discontinuation,,,Endocrinology/Metabolism,To be Discontinued,10/18/21,10/18/21,64764-0155-60,discontinued
6646,Piroxicam Capsules,Pfizer Pharmaceuticals,10 mg capsules; Bottles of 100 (NDC 59762-0140-1),New,8/10/21,,Stock anticipated to be available through February 2022,,,Analgesia/Addiction,To be Discontinued,8/10/21,8/10/21,59762-0140-1,discontinued
6647,Piroxicam Capsules,Pfizer Pharmaceuticals,20 mg capsules; Bottles of 100 (NDC 59762-0145-1),New,8/10/21,,Stock anticipated to be available through June 2022,,,Analgesia/Addiction,To be Discontinued,8/10/21,8/10/21,59762-0145-1,discontinued
6648,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3294-51)",Reverified,11/18/21,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-51,not available
6649,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Reverified,11/18/21,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-01,not available
6650,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial NovaPlus (NDC 00409-3294-25)",Reverified,11/18/21,Next Delivery: May 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-3294-25,not available
6651,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/mL (2 mEq/mL), Single Dose Plastic Fliptop Vial NovaPlus (NDC 00409-8183-25)",Reverified,11/18/21,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-25,not available
6652,Potassium Acetate Injection,"Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,10/8/21,Available. Direct shipments to hospitals at 200 vials max per week. Order via on-line portal at www.exelapharma.com,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,51754-2001-4,limited availability
6653,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,(2 mEq K /mL) 250mL bulk package Catalog# S9402-11(NDC 0264-1940-20),New,11/2/21,Product on allocation to contracted customers.,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0264-1940-20,limited availability
6654,Potassium Chloride Concentrate Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL) Single Dose Glass Fliptop Vial (NDC 0409-6635-01),Reverified,11/18/21,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-6635-01,not available
6655,Potassium Chloride Concentrate Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 0409-6651-06),Reverified,11/18/21,Next Delivery: January 2022; Estimated Recovery: April 2022,,,Demand Increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-6651-06,not available
6656,Potassium Chloride Concentrate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Reverified,11/18/21,Next Delivery: November 2021 and Estimated Recovery: February 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-6653-05,not available
6657,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","60 mEq per 30 mL (2 mEq per mL), Multi dose, plastic vial, (NDC 63323-967-30)",Reverified,11/23/21,Backordered. Next release January 2022.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-967-30,not available
6658,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","10 mEq per 5 mL(2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-05)",Reverified,11/23/21,Backordered. Next release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-05,not available
6659,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","20 mEq per 10 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-10)",Reverified,11/23/21,Backordered. Next  release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-10,not available
6660,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","40 mEq per 20 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-20)",Reverified,11/23/21,Backordered. Next release December 2021.,,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-20,not available
6661,Pravastatin Sodium (Pravachol) Tablets,Bristol Myers Squibb Co.,20mg (NDC 0003-5178-05),New,3/24/21,,"Last batch expiry is October 31, 2021.",,,Cardiovascular,To be Discontinued,3/24/21,3/24/21,0003-5178-05,discontinued
6662,Pravastatin Sodium (Pravachol) Tablets,Bristol Myers Squibb Co.,40mg (NDC 0003-5194-10),New,3/24/21,,"Last batch expiry is October 31, 2021.",,,Cardiovascular,To be Discontinued,3/24/21,3/24/21,0003-5194-10,discontinued
6663,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-05,
6664,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-10,
6665,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-10,
6666,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-15,
6667,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-05,
6668,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-10,
6669,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,61314-637-15,
6670,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,11980-180-15,
6671,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,10/31/19,,60758-119-05,
6672,Procardia Capsules,Pfizer Pharmaceuticals,10 mg capsule; Bottle of 100 (NDC 0069-2600-66),New,5/10/21,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,5/10/21,5/10/21,0069-2600-66,discontinued
6673,"Progesterone Injection, USP",AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),500 mg/10 mL multiple dose vial (NDC 55150-306-10),Revised,9/23/19,,,,,Endocrinology/Metabolism,Resolved,9/23/19,,55150-306-10,
6674,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 10 mL pre-filled syringe, (NDC 0270-1111-16)",New,6/1/21,,"Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM  bottles.  All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70",,,Medical Imaging,To be Discontinued,6/1/21,6/1/21,0270-1111-16,discontinued
6675,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 17 mL pre-filled syringe, (NDC 0270-111-45)",New,6/1/21,,"Bracco offers ProHance® products in a variety of packaging options including both single-dose vials and ProHance® MultiPackTM  bottles.  All of these options are available: ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 5 mL Vial, NDC 0270-1111-04; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 10mL Vial, NDC 0270-1111-01; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 15 mL Vial, NDC 0270-1111-02; ProHance® (Gadoteridol) Injection, 279.3 mg/mL - 5 x 20 mL Vial, NDC 0270-1111-03; ProHance® MultiPackTM (Gadoteridol) Injection, 279.3 mg/mL - 5 x 50 mL Bottle, NDC 0270-1111-70",,,Medical Imaging,To be Discontinued,6/1/21,6/1/21,0270-111-45,discontinued
6676,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0928-25,available
6677,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0929-25,available
6678,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1495-35,available
6679,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1496-35,available
6680,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6084-25,available
6681,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Reverified,10/12/21,Inventory is currently available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6085-25,available
6682,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6082-25,available
6683,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Reverified,10/12/21,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6083-25,available
6684,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,2/25/21,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5525-3,available
6685,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,2/25/21,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5550-6,available
6686,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-01,discontinued
6687,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-01,discontinued
6688,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2191-04,discontinued
6689,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/19,,Teva made a business decision to discontinue this product.,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,12/19/19,12/19/19,0703-2201-04,discontinued
6690,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-269-65,available
6691,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,9/3/21,Available. On Allocation,,,Demand increase due to Covid-19,Anesthesia,Current,,,25021-608-20,limited availability
6692,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Revised,11/8/21,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-68,limited availability
6693,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: May 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-30,limited availability
6694,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-33,limited availability
6695,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: January 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-24,limited availability
6696,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Revised,11/8/21,Pack size discontinued,,,,Anesthesia,Current,,,43598-265-58,discontinued
6697,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Revised,11/8/21,No current supply,Partial shipments on allocation April-December 2021,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-265-20,not available
6698,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Revised,11/8/21,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-548-21,limited availability
6699,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Revised,11/8/21,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-548-50,limited availability
6700,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Revised,11/8/21,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-51,limited availability
6701,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Revised,11/8/21,Limited supply available. Next Delivery ETA Late November 2021 and Estimated Recovery: TBD,Supply chain has been impacted by shipping delays due to COVID-19,,Other,Anesthesia,Current,,,0591-2136-95,limited availability
6702,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,11/23/21,Available,Check wholesaler inventory,,,Anesthesia,Current,,,63323-269-10,available
6703,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,11/23/21,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-269-29,available
6704,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,11/23/21,Available,Check wholesaler inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-269-50,available
6705,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,9/3/21,Available,,,,Anesthesia,Current,,,250-21-608-50,available
6706,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,9/3/21,Available,,,,Anesthesia,Current,,,25021-608-51,available
6707,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0209-10),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,00069-0209-10,limited availability
6708,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0234-20),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,00069-0234-20,limited availability
6709,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0248-10),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,00069-0248-10,limited availability
6710,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6194-10,available
6711,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",Revised,10/12/21,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing.   Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6195-20,not available
6712,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",Revised,10/12/21,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0641-6196-10,not available
6713,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Revised,11/8/21,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-549-10,limited availability
6714,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Revised,11/8/21,Allocating to Wholesalers,Check Wholesaler Inventory,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-549-52,limited availability
6715,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Revised,11/8/21,No current supply,Partial shipments on allocation April-December 2021,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-265-25,not available
6716,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL (10 mg per mL), single dose vial, preservative free,  (NDC 63323-229-05)",Reverified,11/23/21,Available,Check wholesaler inventory,,,Hematology,Current,,,63323-229-05,available
6717,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","250 mg per 25 mL (10 mg per mL), single dose vial, preservative free, (NDC 63323-229-30)",Reverified,11/23/21,Available,Check wholesaler inventory,,,Hematology,Current,,,63323-229-30,available
6718,Rabeprazole Sodium Delayed Release Tablets,Teva Pharmaceuticals,20mg  (NDC 0093-0064-56 ),New,1/22/21,,,,,Gastroenterology,To be Discontinued,1/22/21,1/22/21,0093-0064-56,discontinued
6719,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,7/6/20,7/6/20,45963-418-50,discontinued
6720,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,7/6/20,7/6/20,45963-419-50,discontinued
6721,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/18,,,,,Endocrinology/Metabolism,To be Discontinued,2/2/18,2/2/18,0781-5149-01,discontinued
6722,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0510-30,discontinued
6723,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0508-60,discontinued
6724,Rifampin Capsules,"Lannett Company, Inc.",150 mg )NDC 0527-1393-30),New,2/2/21,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/21,2/2/21,0527-1393-30,discontinued
6725,Rifampin Capsules,"Lannett Company, Inc.",150 mg (NDC 0527-1393-01),New,2/2/21,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/21,2/2/21,0527-1393-01,discontinued
6726,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-30),New,2/2/21,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/21,2/2/21,0527-1315-30,discontinued
6727,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-06),New,2/2/21,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/21,2/2/21,0527-1315-06,discontinued
6728,Rifampin Capsules,"Lannett Company, Inc.",300 mg (NDC 0527-1315-01),New,2/2/21,,Lannett has made a business decision to discontinue the drug product.,,,Anti-Infective,To be Discontinued,2/2/21,2/2/21,0527-1315-01,discontinued
6729,Rifampin Injection,"Fresenius Kabi USA, LLC","600 mg per vial, PF, Lyophilized powder (NDC 63323-351-20)",Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesaler inventory,,,Anti-Infective,Current,,,63323-351-20,not available
6730,Rifampin Injection,Sanofi,"600 mg/10 mL, Lyophilized powder (NDC 0068-0597-01)",Revised,6/22/21,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,0068-0597-01,available
6731,Rifampin Injection,"Mylan Institutional, a Viatris company","600 mg, (Lyophilizate in Single Dose Vials) (NDC 67457-445-60)",Reverified,11/29/21,Available,,,Demand increase for the drug,Anti-Infective,Current,,,67457-445-60,available
6732,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0068-0509-60,discontinued
6733,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/20,,,,,Anti-Infective,To be Discontinued,6/15/20,6/15/20,0088-0576-41,discontinued
6734,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",Revised,6/22/21,Available,,,Demand increase for the drug,Anti-Infective,Current,3/25/20,,0088-2102-24,available
6735,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/19,,,,,Musculoskeletal,To be Discontinued,12/9/19,12/9/19,0430-0471-15,discontinued
6736,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-60,discontinued
6737,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-595-10,discontinued
6738,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-60,discontinued
6739,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-594-50,discontinued
6740,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-60,discontinued
6741,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-50,discontinued
6742,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-593-10,discontinued
6743,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-60,discontinued
6744,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-50,discontinued
6745,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-592-10,discontinued
6746,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-60,discontinued
6747,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-50,discontinued
6748,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-591-10,discontinued
6749,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-60,discontinued
6750,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-50,discontinued
6751,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-590-10,discontinued
6752,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-330-50,discontinued
6753,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-320-50,discontinued
6754,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-300-50,discontinued
6755,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-302-50,discontinued
6756,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-50,discontinued
6757,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/18,,"Janssen has made a business decision to discontinue all Risperidone Tablet strengths, Risperdal 0.25 mg and various Risperdal pack sizes.",,,Pediatric;Psychiatry,To be Discontinued,5/24/18,5/24/18,50458-301-01,discontinued
6758,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-05,available
6759,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,11/2/18,,70860-651-10,available
6760,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Revised,2/12/21,Available,,,Other,Anesthesia,Current,,,17478-0081-30,available
6761,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Reverified,11/18/21,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9300-10,not available
6762,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Reverified,11/18/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9300-20,not available
6763,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-9301-30,not available
6764,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Reverified,11/18/21,Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Anesthesia,Current,,,00409-9302-20,not available
6765,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Reverified,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-9303-10,available
6766,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Reverified,11/18/21,Available,,,Other,Anesthesia,Current,,,00409-9303-20,available
6767,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-195-20,available
6768,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-196-99,available
6769,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Reverified,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-197-20,not available
6770,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Reverified,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-198-30,not available
6771,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Reverified,11/5/21,"Currently on backorder, next shipment TBD",Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-199-20,not available
6772,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 10 mL Single Dose Vials (NDC 55150-200-10),Reverified,11/5/21,Currently on backorder - next shipment TBD,Sporadic availability expected.,,Demand increase for the drug,Anesthesia,Current,,,55150-200-10,not available
6773,Ropivacaine Hydrochloride Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),1% 20 mL Single Dose Vials (NDC 55150-201-20),Reverified,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-201-20,available
6774,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-10,available
6775,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-20,available
6776,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-20,not available
6777,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-20,available
6778,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,,available
6779,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-20,available
6780,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-61,not available
6781,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,11/23/21,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-63,not available
6782,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-285-65,not available
6783,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-64,available
6784,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-00,available
6785,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,11/23/21,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-286-63,available
6786,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-13,available
6787,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,11/23/21,Backordered. Next release April 2021.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-285-23,not available
6788,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-35,available
6789,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,11/23/21,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-286-23,available
6790,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-21,available
6791,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,11/23/21,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-11,available
6792,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,11/23/21,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-21,available
6793,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,11/23/21,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-286-31,available
6794,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Reverified,9/3/21,Available,,,,Anesthesia,Current,,,25021-652-82,available
6795,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Reverified,9/3/21,Available,,,,Anesthesia,Current,,,25021-652-87,available
6796,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Reverified,9/3/21,Available,,,,Anesthesia,Current,,,25021-671-82,available
6797,Ropivacaine Hydrochloride Injection,Sagent Pharmaceuticals,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Reverified,9/3/21,Available,,,,Anesthesia,Current,,,25021-671-87,available
6798,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.2%, 40 mg/20 mL (2 mg/mL) single dose vial (NDC 43066-015-10)",New,12/22/20,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,43066-015-10,available
6799,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 100 mg/20 mL (5 mg/mL) single dose vial (NDC 43066-019-10)",New,12/22/20,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,43066-019-10,available
6800,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 150 mg/30 mL (5 mg/mL) single dose vial (NDC 43066-023-10)",New,12/22/20,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,43066-023-10,available
6801,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"1%, 200 mg/20 mL (10 mg/mL) single dose vial (NDC 43066-027-10)",New,12/22/20,Available,Distributed by Baxter Healthcare; Contact Baxter Healthcare: 1-888-229-0001,,,Anesthesia,Current,,,43066-027-10,available
6802,Rosiglitasone Tablets,GlaxoSmithKline,2 mg (NDC 0173-0861-18),New,4/23/21,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product.,,,Endocrinology/Metabolism,To be Discontinued,4/23/21,4/23/21,0173-0861-18,discontinued
6803,Rosiglitasone Tablets,GlaxoSmithKline,4 mg (NDC 0173-0863-13),New,4/23/21,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product.,,,Endocrinology/Metabolism,To be Discontinued,4/23/21,4/23/21,0173-0863-13,discontinued
6804,Salmeterol Xinafoate Inhalational Powder,GlaxoSmithKline,"50 mcg, 28 blisters (NDC 0173-0520-00)",New,4/23/21,,This product discontinuation is a business-related decision. GSK has ceased distribution of this product. The 60-blister presentation will continue to be available.,,,Pulmonary/Allergy,To be Discontinued,4/23/21,4/23/21,0173-0520-00,discontinued
6805,Samarium SM 153 Lexidronam  (Quadramet) Injection,Lantheus Medical Imaging INC,150mCi (NDC 11994-016-01),New,10/28/21,,Manufacturing is discontinued.  Please contact 800-362-2668 for additional information.,,,Oncology,To be Discontinued,10/28/21,10/28/21,11994-016-01,discontinued
6806,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/18,,"Roche intends to stop-shipping Saquinavir Mesylate (Invirase) 200 mg Capsules on March 31, 2018 with product availability continuing until the September 2018 expiry date.  Saquinavir Mesylate (Invirase) 500mg Tablets are still available.",,,Antiviral,To be Discontinued,2/6/18,2/6/18,0004-0245-15,discontinued
6807,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Reverified,12/11/19,Unavailable,,,Other,Pulmonary/Allergy,Current,,,63256-100-30,not available
6808,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,12/11/19,,0378-6470-44,
6809,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,20mg/ml (NDC 64980-409-06),Revised,4/13/21,,,Distributed by Rising Pharmaceuticals Contact Rising Pharmaceuticals : +1 (201) 961-9000,,Psychiatry,Resolved,4/13/21,,64980-409-06,
6810,"Sertraline Hydrochloride Oral Solution, USP","Upjohn US 1 LLC, a Viatris Company","Sertraline Hydrochloride 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 59762-0067-1)",Revised,4/13/21,,,"Greenstone label. To order, contact Pfizer at 800-553-4535.",,Psychiatry,Resolved,4/13/21,,59762-0067-1,
6811,"Sertraline Hydrochloride Oral Solution, USP","Upjohn US 1 LLC, a Viatris Company","Zoloft (sertraline hydrochloride) 60 mL (20 mg/mL) oral concentrate, with 12% alcohol; bottle with calibrated dropper (NDC 0049-0050-01)",Revised,4/13/21,,,"Pfizer label. To order, contact Pfizer at 800-553-4535.",,Psychiatry,Resolved,4/13/21,,0049-0050-01,
6812,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",Revised,4/13/21,,,Northstar Rx label. Product Distributed by McKesson:  +1 (972) 446-4800,,Psychiatry,Resolved,4/13/21,,16714-601-02,
6813,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-215-10,
6814,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-215-15,
6815,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-215-16,
6816,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-216-15,
6817,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-216-16,
6818,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-217-15,
6819,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16729-217-16,
6820,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-011-30,
6821,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-011-01,
6822,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-011-05,
6823,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-012-30,
6824,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-012-01,
6825,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-012-05,
6826,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-013-30,
6827,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-013-01,
6828,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,65862-013-05,
6829,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-611-01,
6830,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-611-04,
6831,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-611-05,
6832,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-611-06,
6833,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-612-01,
6834,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-612-04,
6835,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-612-05,
6836,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-612-06,
6837,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-613-01,
6838,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-613-04,
6839,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-613-05,
6840,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,16714-613-06,
6841,Sertraline Hydrochloride Tablets,Viatris,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,0049-4960-30,
6842,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,0049-4900-30,
6843,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,0049-4900-41,
6844,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,0049-4910-30,
6845,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,0049-4910-41,
6846,Sertraline Hydrochloride Tablets,Viatris,25 mg; Bottle of 30 tablets (NDC 59762-6347-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,59762-6347-1,
6847,Sertraline Hydrochloride Tablets,Viatris,50 mg; Bottle of 30 tablets (NDC 59762-6443-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,59762-6443-1,
6848,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 30 tablets (NDC 59762-5160-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,59762-5160-1,
6849,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 100 tablets (NDC 59762-5160-2); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,3/15/21,,59762-5160-2,
6850,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-351-06,
6851,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-351-09,
6852,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-351-03,
6853,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-352-06,
6854,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-352-09,
6855,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-352-02,
6856,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-352-05,
6857,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-353-06,
6858,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-353-09,
6859,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-353-02,
6860,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,68180-353-05,
6861,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-833-02,
6862,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-833-05,
6863,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-833-12,
6864,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-834-02,
6865,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-834-12,
6866,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-835-02,
6867,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,69097-835-12,
6868,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-30,
6869,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-60,
6870,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-90,
6871,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-01,
6872,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-18,
6873,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-212-05,
6874,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-30,
6875,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-60,
6876,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-90,
6877,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-01,
6878,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-18,
6879,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-213-05,
6880,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-30,
6881,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-60,
6882,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-90,
6883,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-01,
6884,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-18,
6885,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,3/9/21,,76282-214-05,
6886,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0338-01,
6887,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/19,, ,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-4190-68,
6888,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,0069-0336-21,
6889,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,10/24/19,,70954-168-10,
6890,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/18,,,,,Antiviral,To be Discontinued,5/23/18,5/23/18,59676-225-28,discontinued
6891,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0093-7152-98,discontinued
6892,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
6893,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
6894,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
6895,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/18,,Product discontinuation will occur the second quarter of 2018.  This was a business-related decision to discontinue manufacturing these products.,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,,discontinued
6896,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/18,,,,,Cardiovascular,To be Discontinued,2/6/18,2/6/18,0006-0726-31,discontinued
6897,Simvastatin Tablets,Merck Sharp & Dohme Corp.,80 mg (NDCs 0006-0543-31 and 0006-0543-54),New,7/27/21,,,,,Cardiovascular,To be Discontinued,7/27/21,7/27/21,,discontinued
6898,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Reverified,7/16/21,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,12/17/15,,0270-0556-15,available
6899,Sodium Acetate Injection,"Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-05),Reverified,11/18/21,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,00409-3299-05,not available
6900,Sodium Acetate Injection,"Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-3299-06),Reverified,11/18/21,Next Delivery: March 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,00409-3299-06,not available
6901,Sodium Acetate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-7299-73),Reverified,11/18/21,Next Delivery: December 2021; Estimated Recovery: June 2022,,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,00409-7299-73,not available
6902,Sodium Acetate Injection,"Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,63323-0032-00,not available
6903,Sodium Acetate Injection,Milla Pharmaceuticals,100 mEq/50 mL (2 mEq/mL) (NDC 69784-230-20),New,9/1/21,Available,"Distributed by Woodward Pharma Services LLC Contact Information:
Phone: 248-308-1120
Fax: 248-480-0153
Email: info@woodwardphrma.com",,Other,Total Parenteral Nutrition,Current,,,69784-230-20,available
6904,Sodium Acetate Injection,Milla Pharmaceuticals,200 mEq/100 mL (2 mEq/mL) (NDC 69784-231-20),New,9/1/21,Available,"Distributed by Woodward Pharma Services LLC Contact Information:
Phone: 248-308-1120
Fax: 248-480-0153
Email: info@woodwardphrma.com",,Other,Total Parenteral Nutrition,Current,,,69784-231-20,available
6905,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial (4.2% Concentration) (NDC 0409-5555-02),Revised,11/2/21,Next Delivery and Estimated Recovery: November 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-5555-02,not available
6906,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial Novaplus®  (4.2% Concentration) (NDC 0409-5555-01),Revised,11/2/21,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-5555-01,available
6907,Sodium Bicarbonate Injection,"Hospira, Inc.",44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (7.5% concentration) (NDC 0409-4916-14) (old NDC 0409-4916-34),Revised,11/18/21,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-4916-14,available
6908,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) (NDC 0409-6625-14) (old NDC 0409-6625-02),Revised,11/18/21,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6625-14,available
6909,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Vial Novaplus® (8.4% concentration) (NDC 0409-6625-35),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6625-35,limited availability
6910,Sodium Bicarbonate Injection,"Hospira, Inc.",Pediatric 10 mEq/10 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-4900-14) (old NDC 0409-4900-34),Revised,11/18/21,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-4900-14,available
6911,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,11/23/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-083-05,available
6912,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-089-50,not available
6913,Sodium Bicarbonate Injection,"Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,11/2/21,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6609-02,discontinued
6914,Sodium Bicarbonate Injection,"Hospira, Inc.",Infant 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe (4.2% Concentration) (NDC 0409-5534-14) (old NDC 0409-5534-34),Revised,11/2/21,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-5534-14,available
6915,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-6637-14) (old NDC 0409-6637-34),Revised,11/2/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2021,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0409-6637-14,limited availability
6916,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Revised,11/2/21,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,11/16/16,,0548-3352-00,available
6917,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate Inj. USP, 8.4%, 50mL (NDC 51754-5001-1)",Revised,5/6/21,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,51754-5001-1,available
6918,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-11,
6919,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL flexible container (Legacy Hospira NDC 0409-7984-23)
(ICU Medical NDC 0990-7984-23)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-23,
6920,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-21,
6921,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-31,
6922,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-01,
6923,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,76297-001-41,
6924,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","100 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-11)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-11,
6925,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL flexible container (Legacy Hospira NDC 0409-7984-36)
(ICU Medical NDC 0990-7984-36)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-36,
6926,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.",25 mL flexible container (NDC 0409-7984-20),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-20,
6927,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","50 mL Vis-IV container, PVC/DEHP-free (NDC 0409-7984-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0409-7984-06,
6928,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 250 mL, in VIAFLEX Container.   Product code FZB1322 (NDC 0338-9517-50)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-50,
6929,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 500 mL, in VIAFLEX Container.   Product code FZB1323 (NDC 0338-9517-30)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-30,
6930,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"0.9% Sodium Chloride Injection, 1,000 mL, in VIAFLEX Container.   Product code FZB1324 (NDC 0338-9517-16)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9517-16,
6931,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,250 mL Product code 2B1322Q (NDC 00338-0049-02),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-02,
6932,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,500 mL  Product code 2B1323Q (NDC 00338-0049-03),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-03,
6933,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1323D (NDC 0338-9543-04)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-04,
6934,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,1000 mL Product code 2B1324X (NDC 00338-0049-04),Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,00338-0049-04,
6935,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL Non-PVC, Dripless Access Container (DAC)  VIAFLO Container  Product code UE1324D (NDC 0338-9543-06)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-06,
6936,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL, Non-PVC, Dripless Access Container (DAC) VIAFLO Container Product code UE1322D (NDC 0338-9543-02)",Revised,11/13/19,,,,,Gastroenterology;Other;Pediatric,Resolved,11/13/19,,0338-9543-02,
6937,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0088-61),Revised,11/23/21,Backordered. Next release December 2021.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-61,not available
6938,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,11/23/21,Backordered. Next release January 2022.,Check wholesalers for inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-63,not available
6939,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Reverified,11/18/21,Limited Supply Available. Next Delivery: March 2022; Estimated Recovery: August 2022,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,00409-1141-02,limited availability
6940,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0187-30),Revised,11/23/21,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0187-30,not available
6941,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Revised,11/23/21,Backordered. Next release Q1-2022.,Check wholesalers for inventory,,Increase in Demand,Other,Current,,,63323-186-02,not available
6942,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Revised,11/23/21,Backordered. Next release January 2022.,Check wholesalers for inventory,,Manufacturing delay,Other,Current,,,63323-186-10,not available
6943,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Revised,11/23/21,Backordered. Next release not available at this time.,,,Manufacturing delay,Other,Current,,,63323-186-20,not available
6944,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Revised,11/23/21,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,63323-186-00,not available
6945,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: December 2022,,,Demand increase for the drug,Other,Current,,,00409-4888-10,limited availability
6946,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Other,Current,,,00409-4888-12,not available
6947,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Revised,11/18/21,Limited Supply Available. Next Delivery and Estimated Recovery: December 2021,,,Demand increase for the drug,Other,Current,,,00409-4888-20,limited availability
6948,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Revised,11/18/21,Limited Supply Available. Next Delivery: November 2021; Estimated Recovery: July 2022,,,Demand increase for the drug,Other,Current,,,00409-4888-50,limited availability
6949,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Reverified,2/23/21,Available,Check wholesalers for inventory,,Available,Other,Current,,,64253-202-30,available
6950,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Reverified,10/12/21,This presentation is temporarily on backorder.  Recovery is TBD at this time.,Additional lots will be scheduled for manufacturing as needed.  Product will be made available as it is released.,,Demand increase for the drug,Other,Current,,,0641-0497-25,not available
6951,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-32,discontinued
6952,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-33,discontinued
6953,"Sodium Chloride Injection USP, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Revised,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-35,discontinued
6954,Sodium Phosphates Injection,"Hospira, Inc.","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 0409-7391-72)",Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: April 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7391-72,not available
6955,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/5 mL, Sodium 20 mEq/5 mL, vial (NDC 63323-170-05)",Revised,11/23/21,Backordered. Next release December 2021.,Manufacturing delay. Check wholesaler for inventory.,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-170-05,not available
6956,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 63323-170-15)",Revised,11/23/21,Backordered. Next release December 2021.,Manufacturing delay. Check wholesaler for inventory.,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-170-15,not available
6957,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/20,,Other Somatropin Recombinant (Humatrope) Injection products will continue to be available to treat patients.  The product distribution will continue until end of December 2020.,,,Hematology,To be Discontinued,7/7/20,7/7/20,0002-7335-11,discontinued
6958,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-11,discontinued
6959,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2803-50,discontinued
6960,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-11,discontinued
6961,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2672-50,discontinued
6962,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-11,discontinued
6963,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/18,,"This product discontinuation is a business related decision and not related to product quality, safety or efficacy.",,,Renal,To be Discontinued,5/22/18,5/22/18,0228-2673-50,discontinued
6964,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/18,,,,,Antiviral,To be Discontinued,4/30/18,4/30/18,0378-5041-91,discontinued
6965,Sterile Water,American Regent/Luitpold,5 mL vial (NDC 00517-3005-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3005-25,
6966,Sterile Water,American Regent/Luitpold,10 mL vial (NDC 00517-3010-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3010-25,
6967,Sterile Water,American Regent/Luitpold,20 mL vial (NDC 00517-3020-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,00517-3020-25,
6968,Sterile Water,West-Ward Pharmaceuticals,10 mL Single Dose Vial (NDC 0641-6147-25),Revised,8/2/19,,,,,Other,Resolved,8/2/19,,0641-6147-25,
6969,Sterile Water for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mL vial (NDC 0641-6147-10),New,11/23/21,This presentation is temporarily on backorder.,Additional lots have been manufactured and will be available in the December 2021 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Other,Current,11/23/21,11/23/21,0641-6147-10,not available
6970,Sterile Water for Injection,"Hospira, Inc.",10 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),New,11/23/21,Limited Supply. Next delivery: December 2021; Estimated recovery: December 2022,,,Demand increase for the drug,Other,Current,11/23/21,11/23/21,00409-4887-10,limited availability
6971,Sterile Water for Injection,"Hospira, Inc.",20 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),New,11/23/21,Next delivery: December 2021; Estimated recovery: April 2022,,,Demand increase for the drug,Other,Current,11/23/21,11/23/21,00409-4887-20,not available
6972,Sterile Water for Injection,"Hospira, Inc.",50 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),New,11/23/21,Next delivery: December 2021; Estimated recovery: June 2022,,,Demand increase for the drug,Other,Current,11/23/21,11/23/21,00409-4887-50,not available
6973,Sterile Water for Injection,"Hospira, Inc.",100 mL Single Dose Glass Fliptop Vial (NDC 00409-4887-99),New,11/23/21,Next delivery: December 2021; Estimated recovery: December 2022,,,Demand increase for the drug,Other,Current,11/23/21,11/23/21,00409-4887-99,not available
6974,Sterile Water for Injection,"Fresenius Kabi USA, LLC",10 mL Vial (NDC 63323-0185-10),New,11/23/21,TBD,,,TBD,Other,Current,11/23/21,11/23/21,63323-0185-10,unclear
6975,Sterile Water for Injection,"Fresenius Kabi USA, LLC",20 mL Vial (NDC 63323-0185-20),New,11/23/21,TBD,,,TBD,Other,Current,11/23/21,11/23/21,63323-0185-20,unclear
6976,Sterile Water for Injection,"Fresenius Kabi USA, LLC",50 mL Vial (NDC 63323-0185-50),New,11/23/21,TBD,,,TBD,Other,Current,11/23/21,11/23/21,63323-0185-50,unclear
6977,Succimer (Chemet) Capsules,Recordati Rare Diseases,100 mg capsules (NDC 55292-201-11),Revised,9/14/21,,,Available,,Hematology,Resolved,9/14/21,9/14/21,55292-201-11,
6978,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide S.O.P. (sulfacetamide sodium 10% and prednisolone acetate 0.2%) 1 TUBE in 1 CARTON 3.5 g in 1 TUBE (NDC 0023-0313-04),New,9/13/21,,Discontinuation of the manufacture of the drug,,,Ophthalmology,To be Discontinued,9/13/21,9/13/21,0023-0313-04,discontinued
6979,Sulfasalazine Tablets,Chartwell Pharma,500 mg tablets; Bottle of 100 (NDC 23155-019-01),Reverified,9/14/21,"Product being allocated.  Distributed by Avet. For inquiries, call Customer Service number 1-855-228-9470",,,Other,Gastroenterology,Current,,,23155-019-01,limited availability
6980,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Reverified,11/18/21,Available,,,Other,Gastroenterology,Current,,,0013-0101-10,available
6981,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20/0013-0101-30),Reverified,11/18/21,Available,,,Other,Gastroenterology,Current,,,0013-0101-20,available
6982,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Reverified,11/18/21,Next Delivery: November 2021; Estimated Recovery: December 2021,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,0013-0102-50,not available
6983,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20/0013-0102-60),Reverified,11/18/21,Available,,,Other,Gastroenterology,Current,,,0013-0102-20,available
6984,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Reverified,11/18/21,Next Delivery: January 2022; Estimated recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-0104-1,not available
6985,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Reverified,11/18/21,Next Delivery: December 2021; Estimated recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-0104-6,not available
6986,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Reverified,11/18/21,Next Delivery: January 2022; Estimated Recovery: April 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-5000-1,not available
6987,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Reverified,11/18/21,Next Delivery: December 2021; Estimated recovery: March 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology,Current,,,59762-5000-6,not available
6988,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Reverified,11/8/21,Available,This product is on allocation.,,,Gastroenterology,Current,,,00591-0796-01,available
6989,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Reverified,11/8/21,Available,This product is on allocation.,,,Gastroenterology,Current,,,00591-0796-10,available
6990,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Reverified,11/8/21,Available,This product is on allocation.,,,Gastroenterology,Current,,,00591-0796-05,available
6991,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/18,,A business decision has been made to discontinue Sumavel DosePro 6 mg/0.5mL.,,,Neurology,To be Discontinued,2/27/18,2/27/18,63481-367-06,discontinued
6992,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/19,,,,,Neurology,To be Discontinued,12/5/19,12/5/19,0703-7351-01,discontinued
6993,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","0.5 mg, 100s (NDC 0378-2045-01)",Reverified,11/29/21,Available,,,,Transplant,Current,,,0378-2045-01,available
6994,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100s (NDC 0378-2046-01)",Reverified,11/29/21,Available,,,,Transplant,Current,,,0378-2046-01,available
6995,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100s (NDC 0378-2047-01)",Reverified,11/29/21,Available,,,,Transplant,Current,,,0378-2047-01,available
6996,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Reverified,6/8/21,Limited supply availability. Product will be allocated until Q3 2021,,,Limited API availability,Transplant,Current,,,1672904101,limited availability
6997,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Reverified,6/8/21,Limited supply availability. Product will be allocated until Q3 2021,,,Limited API availability,Transplant,Current,,,1672904201,limited availability
6998,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Reverified,6/8/21,Product is available,,,,Transplant,Current,,,1672904301,available
6999,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3075-3,available
7000,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3075-1,available
7001,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3010-3,available
7002,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3010-1,available
7003,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3040-3,available
7004,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Reverified,6/14/21,Available,,,,Transplant,Current,,,68992-3040-1,available
7005,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Reverified,11/2/21,Available,,,,Transplant,Current,,,64338-721-06,available
7006,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Reverified,11/2/21,Available,,,,Transplant,Current,,,64380-720-06,available
7007,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Reverified,11/2/21,Available,,,,Transplant,Current,,,64380-722-06,available
7008,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Reverified,11/16/21,Available,,,Demand increase for the drug,Transplant,Current,,,0781-2102-01,available
7009,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Reverified,11/16/21,Available,,,Demand increase for the drug,Transplant,Current,,,0781-2103-04,available
7010,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Reverified,11/16/21,Available,,,Demand increase for the drug,Transplant,Current,,,0781-2104-01,available
7011,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0607-73,available
7012,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0657-73,available
7013,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0617-73,available
7014,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0647-73,available
7015,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0677-73,available
7016,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-0687-73,available
7017,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-1230-50,available
7018,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Reverified,6/9/21,Available,,,,Transplant,Current,,,0469-1330-50,available
7019,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Reverified,11/8/21,Available,,,,Transplant,Current,,,55111-525-01,available
7020,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Reverified,11/8/21,Available,,,,Transplant,Current,,,55111-526-01,available
7021,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Reverified,11/8/21,Available,,,,Transplant,Current,,,55111-527-01,available
7022,Tacrolimus Capsules,Ascend Laboratories LLC.,0.5 mg 100’s count (NDC 67877-278-01),Revised,6/9/21,Available,,,,Transplant,Current,,,67877-278-01,available
7023,Tacrolimus Capsules,Ascend Laboratories LLC.,1 mg 100’s count (NDC 67877-279-01),Revised,6/9/21,Available,,,,Transplant,Current,,,67877-279-01,available
7024,Tacrolimus Capsules,Ascend Laboratories LLC.,5 mg 100’s count (NDC 67877-280-01),Revised,6/9/21,Available,,,,Transplant,Current,,,67877-280-01,available
7025,Tacrolimus Capsules,Glenmark Pharmaceuticals,0.5 mg 100 count bottles (NDC 68462-685-01),Revised,6/10/21,Available,,,,Transplant,Current,,,68462-685-01,available
7026,Tacrolimus Capsules,Glenmark Pharmaceuticals,1 mg 100 count bottles (NDC 68462-686-01),Revised,6/10/21,Available,,,,Transplant,Current,,,68462-686-01,available
7027,Tacrolimus Capsules,Glenmark Pharmaceuticals,5 mg 100 count bottles (NDC 68462-687-01),Revised,6/10/21,Available,,,,Transplant,Current,,,68462-687-01,available
7028,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Reverified,6/8/21,Available,,,,Transplant,Current,,,54288-135-01,available
7029,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To be Discontinued,4/16/18,4/16/18,00409-1941-01,discontinued
7030,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Revised,1/7/21,Available,"Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug.  Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. This product is marketed in Germany and is manufactured in Dresden, Germany by ROTOP Pharmaka GmbH for Theragnostics.",,Other,Medical Imaging,Current,,,71647-001-01,available
7031,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/18,,"Discontinuation is the result of a business decision made by Boehringer lngelheim Pharmaceuticals, Inc. All other strengths of Twynsta® tablets are still available.",,,Cardiovascular,To be Discontinued,3/6/18,3/6/18,0597-0127-37,discontinued
7032,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 100 mg; child-resistant sachets, 5 count (NDC 0085-1366-03)",New,4/23/21,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/21,4/23/21,0085-1366-03,discontinued
7033,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 100 mg; child-resistent sachets, 14-count (NDC 0085-1366-04)",New,4/23/21,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/21,4/23/21,0085-1366-04,discontinued
7034,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 140 mg, child-resistant sachets, 14-count (NDC 0085-1425-04)",New,4/23/21,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/21,4/23/21,0085-1425-04,discontinued
7035,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 180 mg; child-resistent sachets, 5 count (NDC 0085-1430-03)",New,4/23/21,,To be discontinued on or near October 2021,,,Oncology,To be Discontinued,4/23/21,4/23/21,0085-1430-03,discontinued
7036,Temozolomide Capsules,Merck Sharp & Dohme Corp.,"TEMODAR Capsules, 250 mg; child-resistent sachets, 5 count (NDC 0085-1417-02)",New,4/23/21,,To be discontinued on or near April 2022,,,Oncology,To be Discontinued,4/23/21,4/23/21,0085-1417-02,discontinued
7037,Teprotumumab-trbw,Horizon Therapeutics,500 mg lyophilized powder (NDC 75987-130-15),Revised,3/31/21,Product available.,Manufacturing delays due to limited capacity at manufacturing facility,,Other,Ophthalmology,Current,,,75987-130-15,available
7038,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100 count bottle (NDC 0378-1001-01)",Reverified,11/29/21,Available,,,Other,Psychiatry,Current,,,0378-1001-01,available
7039,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg, 100 count bottle (NDC 0378-2002-01)",Reverified,11/29/21,Available,,,Other,Psychiatry,Current,,,0378-2002-01,available
7040,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-3005-01)",Reverified,11/29/21,Available,,,Other,Psychiatry,Current,,,0378-3005-01,available
7041,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-5010-01)",Reverified,11/29/21,Available,,,Other,Psychiatry,Current,,,0378-5010-01,available
7042,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,4/27/21,Available,,,,Psychiatry,Current,,,70954-014-10,available
7043,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,4/27/21,Available,,,,Psychiatry,Current,,,70954-015-10,available
7044,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,4/27/21,Available,,,,Psychiatry,Current,,,70954-016-10,available
7045,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,4/27/21,Available,,,,Psychiatry,Current,,,70954-017-10,available
7046,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,"Timolol Maleate Ophthalmic Gel Forming Solution 0.5%, 5 mL bottle (NDC 61314-225-05)",Revised,10/4/21,,,Available,,Ophthalmology,Resolved,10/4/21,,61314-225-05,
7047,Timolol Maleate Ophthalmic Gel Forming Solution,Sandoz,Timolol Maleate Ophthalmic Gel Forming Solution 0.25% 5 mL bottle (NDC 61314-224-05),Revised,10/4/21,,,Available,,Ophthalmology,Resolved,10/4/21,,61314-224-05,
7048,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.25% timolol equivalent gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-814-25)",Revised,10/4/21,,,,,Ophthalmology,Resolved,10/4/21,,24208-814-25,
7049,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","TIMOPTIC-XE®, 0.5% timolol equivalent, gel forming solution 5 mL in a 7.5 mL bottle (NDC 24208-816-05)",Revised,10/4/21,,,,,Ophthalmology,Resolved,10/4/21,,24208-816-05,
7050,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% timolol gel forming solution, 5 mL in a 7.5 mL bottle (NDC 24208-818-25)",Revised,10/4/21,,,,,Ophthalmology,Resolved,10/4/21,,24208-818-25,
7051,Timolol Maleate Ophthalmic Gel Forming Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Gel Forming Solution, equivalent and 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-819-05)",Revised,10/4/21,,,,,Ophthalmology,Resolved,10/4/21,,24208-819-05,
7052,Timolol Maleate Ophthalmic Gel Forming Solution,Alembic Pharmaceuticals,Timolol GFS 0.25 % - 5 mL fill (NDC 62332-545-05),Revised,10/4/21,,,Available,,Ophthalmology,Resolved,10/4/21,,62332-545-05,
7053,Timolol Maleate Ophthalmic Gel Forming Solution,Alembic Pharmaceuticals,Timolol GFS 0.5 % - 5 mL fill (NDC 62332-546-05),Revised,10/4/21,,,Available,,Ophthalmology,Resolved,10/4/21,,62332-546-05,
7054,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.25%, 5 mL in a 7.5 mL bottle (NDC 24208-812-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,24208-812-05,
7055,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-813-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,24208-813-05,
7056,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 10 mL in a 10 mL bottle (NDC 24208-813-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,24208-813-10,
7057,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.",Authorized Generic Timolol Maleate Ophthalmic Solution 0.5% 5 mL in a 7.5 mL bottle (NDC 68682-813-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,68682-813-05,
7058,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE® (timolol maleate) Sterile Ophthalmic Solution, 0.25% 0.3 mL in 60 individual doses (NDC 0187-1498-25)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,0187-1498-25,
7059,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE®  (timolol maleate) Sterile Ophthalmic Solution, 0.5% 0.3 mL in 60 individual doses (NDC 0187-1496-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,0187-1496-05,
7060,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,24208-004-01,
7061,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,24208-004-03,
7062,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,68682-045-25,
7063,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,68682-045-50,
7064,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-513-05,
7065,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-513-01,
7066,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-513-15,
7067,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-514-05,
7068,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-514-01,
7069,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,64980-514-15,
7070,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60758-802-05,
7071,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60758-802-10,
7072,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60758-801-05,
7073,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60758-801-10,
7074,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,17478-0288-10,
7075,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,17478-0288-11,
7076,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,17478-0288-12,
7077,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-227-05,
7078,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-227-10,
7079,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-227-15,
7080,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-226-05,
7081,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-226-10,
7082,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,61314-226-15,
7083,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60505-1005-04,
7084,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,4/16/21,,60505-1005-01,
7085,Tipranavir Oral Solution,"Boehringer Ingelheim Pharmaceuticals, Inc.",100mg/mL (NDC 0597-0002-01),New,6/29/21,,,,,Antiviral,To be Discontinued,6/29/21,6/29/21,0597-0002-01,discontinued
7086,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",2 mg  (NDC 49884-611-53),New,6/30/21,,,,,Neurology,To be Discontinued,6/30/21,6/30/21,49884-611-53,discontinued
7087,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",4 mg (NDC 49884-719-53),New,6/30/21,,,,,Neurology,To be Discontinued,6/30/21,6/30/21,49884-719-53,discontinued
7088,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",6 mg (NDC 49884-765-53),New,6/30/21,,,,,Neurology,To be Discontinued,6/30/21,6/30/21,49884-765-53,discontinued
7089,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0724-19,discontinued
7090,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/19,,,,,Neurology,To be Discontinued,11/21/19,11/21/19,0378-0722-19,discontinued
7091,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,4/12/21,,63323-303-51,
7092,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,4/12/21,,63323-303-55,
7093,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,4/12/21,,39822-0412-1,
7094,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,4/12/21,,39822-0412-6,
7095,Tocilizumab Injection,"Genentech, Inc","200mg/10mL, (NDC 50242-0136-01)",Reverified,11/1/21,Available,,,Demand increase for the drug,Rheumatology,Current,,,50242-0136-01,available
7096,Tocilizumab Injection,"Genentech, Inc","400mg/20mL, (NDC 50242-0137-01)",Reverified,11/1/21,Available,,,Demand increase for the drug,Rheumatology,Current,,,50242-0137-01,available
7097,Tocilizumab Injection,"Genentech, Inc","80mg/4mL, (NDC 50242-0135-01)",Reverified,11/1/21,Available,,,Demand increase for the drug,Rheumatology,Current,,,50242-0135-01,available
7098,Tolcapone Tablets,"Endo Pharmaceuticals, Inc.",100mg tablets (NDC 49884-254-09),New,10/5/20,,,,,Neurology,To be Discontinued,10/5/20,10/5/20,49884-254-09,discontinued
7099,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-543-90,discontinued
7100,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-542-90,discontinued
7101,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/18,,This discontinuation is due to a business decision.,,,Cardiovascular,To be Discontinued,4/18/18,4/18/18,16252-541-30,discontinued
7102,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-3,discontinued
7103,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/19,,Apotex has decided to Discontinue the manufacture of the drug,,,Hematology,To be Discontinued,12/4/19,12/4/19,60505-3638-1,discontinued
7104,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-80,discontinued
7105,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-029-16,discontinued
7106,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/18,,"The discontinuation of this product is a business decision and not related to product quality, safety or efficacy",,,Dermatology,To be Discontinued,3/20/18,3/20/18,40085-028-80,discontinued
7107,Triamcinolone Acetonide Injectable Suspension,Novartis,"40mg/mL vial, 1mL in 1 vial (NDC 0065-0543-01)",Revised,11/23/21,Availability through wholesalers: Not available. Estimated Duration of Supply Shortage: November 2021,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0065-0543-01,not available
7108,Triamcinolone Hexacetonide Injectable suspension,Medexus,"Hexatrione 2% (triamcinolone hexacetonide) Injectable suspension, 20mg/ml, 2-mL glass ampoule (NDC 59137-570-01)",Reverified,10/8/21,Available,"Medexus in conjunction with FDA has initiated a temporary importation of Triamcinolone Hexacetonide (Hexatrione 2%) injectable suspension, to the U.S. market to address drug shortage. To place an order, please contact Medexus at 1-855-336-3322, Option # 9.",,,Rheumatology,Current,,,59137-570-01,available
7109,Triamterene and Hydrochlorothiazide (Dyazide) Capsules,GlaxoSmithKline,25 mg; 37.5 mg (NDC 0007-3650-22),New,11/16/20,,This product discontinuation is a business related decision.  The anticipated date that GSK will cease distribution of the product is approximately December 2020.,,,Cardiovascular,To be Discontinued,11/16/20,11/16/20,0007-3650-22,discontinued
7110,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-01,discontinued
7111,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5068-05,discontinued
7112,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-01,discontinued
7113,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,0781-5067-05,discontinued
7114,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-00,discontinued
7115,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0216-03,discontinued
7116,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-00,discontinued
7117,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/18,,Sandoz Inc. has made a business decision to permanently discontinue Triamterene and Hydrochlorothiazide tablets.,,,Cardiovascular,To be Discontinued,2/23/18,2/23/18,68001-0215-03,discontinued
7118,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, 100 count bottle (NDC 61570-079-01)",New,12/14/20,,Discontinuation of the manufacturing of the drug.,,,Gastroenterology,To be Discontinued,12/14/20,12/14/20,61570-079-01,discontinued
7119,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 30 (NDC 43386-660-03)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-03,not available
7120,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 100 (NDC 43386-660-24)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-24,not available
7121,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 500 (NDC 43386-660-26)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-26,not available
7122,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, bottle of 100 (NDC 61570-079-01)",Reverified,11/18/21,Discontinued,,,Discontinuation of the manufacture of the drug.,Gastroenterology,Current,,,61570-079-01,discontinued
7123,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",Revised,10/26/21,Unavailable,,,Shortage of an active ingredient.,Gastroenterology,Current,,,53489-376-01,not available
7124,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",New,10/26/21,,Non-Availability of Active Ingredient.,,,Gastroenterology,To be Discontinued,10/26/21,10/26/21,53489-376-01,discontinued
7125,Ursodiol (Actigall) Capsules,Allergan Sales LLC,300 mg (NDC 0023-6145-01),New,1/15/21,,,,,Urology,To be Discontinued,1/15/21,1/15/21,0023-6145-01,discontinued
7126,Valacyclovir Tablets,GlaxoSmithKline,"500 mg, 100-count unit dose pack (NDC 0173-0933-56)",New,4/23/21,,This product discontinuation is a business-related decision. The anticipated date that GSK will cease distribution of the product is approximately November 2021. 30-count and 90-count bottles will continue to be available.,,,Antiviral,To be Discontinued,4/23/21,4/23/21,0173-0933-56,discontinued
7127,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9785-10)",Revised,10/12/21,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0143-9785-10,available
7128,Valproate Sodium Injection,"Fresenius Kabi USA, LLC",500 mg per 5 mL (100 mg per mL) (NDC 63323-494-05),Reverified,11/23/21,Available,Check wholesaler for inventory,,Manufacturing delays,Neurology,Current,,,63323-494-05,available
7129,Vancomycin Hydrochloride for Injection,"Mylan Institutional, a Viatris company",Vancomycin Hydrochloride Injection (Lyophilisate in Single Dose Vials) [250 mg] (NDC 67457-822-99),New,7/26/21,,,,,Anti-Infective,To be Discontinued,7/26/21,7/26/21,67457-822-99,discontinued
7130,Vardenafil Hydrochloride Tablets,Bayer,Levitra 20mg (NDC 0173-0831-13),New,4/8/21,,"Discontinue distribution April 30, 2021.  Discontinuation of the manufacture of the drug.",,,Other;Reproductive,To be Discontinued,4/8/21,4/8/21,0173-0831-13,discontinued
7131,Vardenafil Hydrochloride Tablets,Bayer,Levitra 10 mg (NDC 0173-0830-13),Revised,9/1/20,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/20,9/1/20,0173-0830-13,discontinued
7132,Vardenafil Hydrochloride Tablets,Bayer,Staxyn 10 mg (NDC 0173-0822-04),Revised,9/1/20,,Discontinuation of the manufacture of the drug.,,,Other;Reproductive,To be Discontinued,9/1/20,9/1/20,0173-0822-04,discontinued
7133,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5),New,7/16/21,Available,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,60505-4765-5,available
7134,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6),New,7/16/21,Available,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,60505-4766-6,available
7135,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0),New,7/16/21,Estimated Date Available; TBD,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,60505-4767-0,unclear
7136,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5),New,7/16/21,Estimated Date Available; TBD,"Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,,Analgesia/Addiction,Current,,,60505-4766-5,unclear
7137,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 0.5 mg; bottle of 56 (NDC 0069-0468-56),Reverified,11/18/21,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,0069-0468-56,unclear
7138,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 1 mg; bottle of 56 (NDC 0069-0469-56),Reverified,11/18/21,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,0069-0469-56,unclear
7139,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Starting wallet; 0.5 mg 1x11 1 mg FCT 3x14 BLS WL US (NDC 0069-0471-03),Reverified,11/18/21,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,0069-0471-03,unclear
7140,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Continuing wallet; 1 mg FCT 4x14 BLS WL US (NDC 0069-0469-03),Reverified,11/18/21,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Other,Analgesia/Addiction,Current,,,0069-0469-03,unclear
7141,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"0.5 mg, 56 ‘s count bottle pack (NDC 49884-155-76)",New,9/22/21,Available,More batches will be available by end of September or Early October.,,,Analgesia/Addiction,Current,,,49884-155-76,available
7142,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"1 mg, 56 ‘s count bottle pack (NDC 49884-156-76)",New,9/22/21,Available,More batches will be available by end of September or Early October.,,,Analgesia/Addiction,Current,,,49884-156-76,available
7143,Vecuronium Bromide for Injection,Teva Pharmaceuticals,10 mg* 10 X 10 mL *1 mg/mL when reconstituted to 10 mL (NDC 0703-2914-03),Reverified,11/8/21,Backordered – Estimated date of availability TBD,,,,Anesthesia,Current,,,0703-2914-03,not available
7144,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Revised,11/18/21,Next Delivery: November 2021; Estimated Recovery: July 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1632-01,not available
7145,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,11/18/21,Next Delivery: January 2022; Estimated Recovery: June 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1634-01,not available
7146,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Reverified,11/29/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-438-10,available
7147,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Reverified,11/29/21,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-475-20,available
7148,Vecuronium Bromide for Injection,Gland Pharma Limited,10 mg/vial (NDC 63323-781-10),Reverified,10/20/21,Available,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,,Anesthesia,Current,,,63323-781-10,available
7149,Vecuronium Bromide for Injection,Gland Pharma Limited,20 mg/vial (NDC 63323-782-20),Reverified,10/20/21,Available,Distributed by marketing partner: Fresenius Kabi  LLC (888-386-1300),,,Anesthesia,Current,,,63323-782-20,available
7150,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Reverified,10/22/21,Available,,,Demand increase of the drug,Anesthesia,Current,,,47335-931-44,available
7151,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Reverified,10/22/21,Available,,,Demand increase of the drug,Anesthesia,Current,,,47335-932-44,available
7152,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Revised,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-235-10,available
7153,Vecuronium Bromide for Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Revised,11/5/21,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-236-20,available
7154,Vibramycin Hyclate (Doxycycline Hyclate) for Suspension,Pfizer Pharmaceuticals,25 mg/5 mL oral suspension; 1 x 60 mL bottle (NDC 0069-0970-65),New,11/16/21,,Discontinuation of the manufacture of the drug.,,,Anti-Infective,To be Discontinued,11/16/21,11/16/21,0069-0970-65,discontinued
7155,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To be Discontinued,4/16/18,4/16/18,61703-0341-06,discontinued
7156,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/18,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,4/16/18,4/16/18,61703-0341-09,discontinued
7157,Vitamin A Palmitate (Aquasol A) Injection,"Casper Pharma, LLC","50,000 USP units/mL (15 mg retinol), single dose vial (NDC 61703-418-18)",New,10/21/21,Anticipated availability: January 2022,Delay is due to manufacturing delays at the contract manufacturing facility.,,Manufacturing delay,Endocrinology/Metabolism;Gastroenterology,Current,,,61703-418-18,not available
7158,Zinc Acetate Capsules,Teva Pharmaceuticals,"25 mg, bottle of 250 (NDC 57844-215-52)",Revised,5/18/21,,,Available,,Other;Pediatric,Resolved,5/18/21,,57844-215-52,
7159,Zinc Acetate Capsules,Teva Pharmaceuticals,"50 mg, bottle of 250 (NDC 57844-208-52)",Revised,5/18/21,,,Available,,Other;Pediatric,Resolved,5/18/21,,57844-208-52,
7160,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/18,,,Available,,Psychiatry,Resolved,11/21/18,,0037-6010-30,
7161,Abiraterone Acetate Tablets,"Janssen Research and Development, LLC",250 mg tablets (NDC 57894-155-12),New,6/5/20,,,,,Oncology,To be Discontinued,,,57894-155-12,discontinued
7162,Acetaminophen (Ofirmev) Injection,Mallinckrodt,"OFIRMEV® (Acetaminophen) Injection 1 g/100 mL (10 mg/mL), (NDC 43825-102-01, 43825-102-03)",New,6/9/22,,,,,Analgesia/Addiction,To be Discontinued,,,43825-102-01,discontinued
7163,Acetazolamide Injection,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)",500 mg (NDC 23155-313-31),Revised,6/17/22,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,23155-313-31,available
7164,Acetazolamide Injection,"Mylan Institutional, a Viatris company","500 mg, Lyophilisate in Single Dose Vials 1PK (NDC 67457-853-50)",Revised,6/17/22,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,67457-853-50,available
7165,Acetazolamide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9503-01),Revised,6/17/22,This presentation is temporarily on backorder.,,,,Cardiovascular;Ophthalmology,Resolved,,,0143-9503-01,not available
7166,Acetazolamide Injection,"X-GEN Pharmaceuticals, Inc.",500mg per vial (NDC 39822-0190-1),Revised,6/17/22,Available,,,,Cardiovascular;Ophthalmology,Resolved,,,39822-0190-1,available
7167,Acetic Acid Otic Solution,Wockhardt Bio A.G.,"2% 15ml, (NDC 60432-741-15)",New,6/22/22,,,,,Anti-infective,To be Discontinued,,,60432-741-15,discontinued
7168,Acrivastine and Pseudoephedrine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.","Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)",New,6/2/20,,,,,Pulmonary/Allergy,To be Discontinued,,,52244-404-10,discontinued
7169,Adalimumab (Humira) Pre-filled Syringe,Abbvie,10 mg/0.2 mL pre-filled syringe (NDC 0074-6347-02),New,7/27/20,,,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,,,0074-6347-02,discontinued
7170,Adalimumab (Humira) Pre-filled Syringe,Abbvie,20 mg/0.4 mL pre-filled syringe (NDC 0074-9374-02),New,7/27/20,,,,,Dermatology;Gastroenterology;Ophthalmology;Rheumatology,To be Discontinued,,,0074-9374-02,discontinued
7171,Adefovir Dipivoxil Tablets,"Gilead Sciences, Inc.",10mg  (NDC 61958-0501-1),New,8/1/22,,,,,Antiviral,To Be Discontinued,8/1/22,8/1/22,61958-0501-1,discontinued
7172,Adenosine Injection,Hospira,90 mg/30 mL (3 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1932-02),New,6/28/22,,,,,Cardiovascular,To be Discontinued,,,0409-1932-02,discontinued
7173,Adenosine Injection,Teva,NDC 0703-8776-01 (60 mg/20 mL (3 mg/mL)),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiovascular,To be Discontinued,8/11/22,8/11/22,0703-8776-01,discontinued
7174,Adenosine Injection,Teva,NDC 0703-8777-01 (90 mg/30 mL (3 mg/mL)),New,8/11/22,,Product is  available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Cardiovascular,To be Discontinued,8/11/22,8/11/22,0703-8777-01,discontinued
7175,Adenosine Injection,Hospira,60 mg/20 mL (3 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1932-01),New,9/12/22,,Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,9/12/22,9/12/22,0409-1932-01,discontinued
7176,"Albuterol Sulfate Aerosol, Metered","Endo Pharmaceuticals, Inc.",90 mcg  (NDC 0254-1007-52),New,7/6/21,,,,,Pulmonary/Allergy,To be Discontinued,,,0254-1007-52,discontinued
7177,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,150 mg / 12.5 mg (NDC 70839-112-30),New,12/16/21,,,,,Cardiovascular,To be Discontinued,,,70839-112-30,discontinued
7178,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,150 mg / 25 mg (NDC 70839-125-30),New,12/16/21,,,,,Cardiovascular,To be Discontinued,,,70839-125-30,discontinued
7179,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,300 mg / 12.5 mg (NDC 70839-312-30),New,12/16/21,,,,,Cardiovascular,To be Discontinued,,,70839-312-30,discontinued
7180,Aliskiren and Hydrochlorothiazide Tablets,Noden Pharma,300 mg / 25 mg; (NDC 70839-325-30),New,12/16/21,,,,,Cardiovascular,To be Discontinued,,,70839-325-30,discontinued
7181,Alprostadil Injection,Teva,NDC 0703-1501-02 (500 mcg/mL 1 mL Single Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Pediatric; Cardiovascular,To be Discontinued,8/11/22,8/11/22,0703-1501-02,discontinued
7182,Alprostadil Suppository,"Mylan Specialty, a Viatris Company",125 mcg (NDC 0037-8110-06),New,6/14/21,,,,,Urology,To be Discontinued,,,0037-8110-06,discontinued
7183,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 12oz, (NDC 0135-0094-41)",New,8/6/21,,,,,Gastroenterology,To be Discontinued,,,0135-0094-41,discontinued
7184,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Liquid Regular Strength, 95 mg/15mL, 358 mg/15mL, Mint 6oz, (NDC 0135-0094-42)",New,8/6/21,,,,,Gastroenterology,To be Discontinued,,,0135-0094-42,discontinued
7185,Aluminum Hydroxide and Magnesium Carbonate (Gaviscon Regular Strength),GlaxoSmithKline,"Gaviscon Chewable Tablet, Regular Strength, 80 mg/1, 14.2 mg/1, 100ct Bottle, (NDC 0135-0096-26)",New,8/6/21,,,,,Gastroenterology,To be Discontinued,,,0135-0096-26,discontinued
7186,Amantadine Hydrochloride Capsules,Sandoz,100 mg capsules  (NDCs 0781-2320-01 and 0781-2320-05),New,7/16/20,,,,,Antiviral;Neurology,To be Discontinued,,,,discontinued
7187,Ambrisentan Tablets,Par Pharmaceutical,"5 mg (NDC 49884-353-11, 49884-353-62 )",New,12/23/21,,,,,Cardiovascular,To be Discontinued,,,49884-353-11,discontinued
7188,Ambrisentan Tablets,Par Pharmaceutical,"10 mg (NDC 49884-354-11, 49884-354-62)",New,12/23/21,,,,,Cardiovascular,To be Discontinued,,,49884-354-11,discontinued
7189,Amifostine Injection,"Clinigen, Inc.",ETHYOL® (amifostine) for injection: 3 x 500 mg vials (NDC 76310-017-50),Reverified,5/16/22,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,Other,Oncology;Other,Current,,,76310-017-50,limited availability
7190,Amikacin Sulfate Injection,Teva,"NDC 0703-9032-03 (500 mg/2 mL (250 mg/mL), 10 x 2 mL Single Dose Vials)",New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Anti-infective,To be Discontinued,8/11/22,8/11/22,0703-9032-03,discontinued
7191,Amikacin Sulfate Injection,Teva,"NDC 0703-9040-03  (1 g/4 mL (250 mg/mL), 10 x 4 mL Vials)",New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Anti-infective,To be Discontinued,8/11/22,8/11/22,0703-9040-03,discontinued
7192,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 2,000mL S4505 (NDC 00264-4500-05)",New,6/8/22,Available,,,,Gastroenterology,Current,,,00264-4500-05,available
7193,Amino Acids,B. Braun Medical Inc.,"Plenamine 15% Amino Acids Injection 1,000mL S4500 (NDC 00264-4500-00)",Revised,6/8/22,Available,,,,Gastroenterology,Current,,,00264-4500-00,available
7194,Amino Acids,"ICU Medical, Inc.",Aminosyn II 15% Sulfite-Free BLK PK 2000 mL (Legacy Hospira NDC 0409-7171-17)(ICU Medical NDC 0990-7171-17),Reverified,10/3/22,Unavailable,,,Other,Gastroenterology,Current,,,0409-7171-17,not available
7195,Amino Acids,"ICU Medical, Inc.",Aminosyn II 10% Sulfite-Free BLK PK 2000 mL (NDC 0409-7172-17) (ICU Medical NDC 0990-7172-17),Reverified,10/3/22,Unavailable,,,Other,Gastroenterology,Current,,,0409-7172-17,not available
7196,Amino Acids,"ICU Medical, Inc.","AMINOSYN™-PF 7%, Sulfite-Free, 500 mL (NDC 0409-4178-03) (ICU Medical NDC 0990-4178-03)",Reverified,10/3/22,Available,,,,Gastroenterology,Current,,,0409-4178-03,available
7197,Amino Acids,"ICU Medical, Inc.","AMINOSYN-PF 10%  Sulfite-Free  (Pediatric Formula) 1000 mL   (Legacy Hospira NDC 0409-4179-05) (ICU Medical NDC 0990-4179-05)""""",,10/3/22,Unavailable,,,Other,Gastroenterology,Current,,,0409-4179-05,not available
7198,Amino Acids,Baxter Healthcare,"15% CLINISOL - sulfite-free (Amino Acid) Injection in VIAFLEX Plastic Container. Pharmacy Bulk Package. Not for Direct Infusion. Product Codes: 2B6189 15% 2000 mL (NDC 0338-0502-06), 2B6187 15% 500 mL (NDC 0338-0502-03)",Reverified,9/28/22,Available,,,,Gastroenterology,Current,,,0338-0502-06,available
7199,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 60 count bottle (NDC 0185-0144-60)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0185-0144-60,discontinued
7200,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 90 count bottle (NDC 0185-0144-09)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0185-0144-09,discontinued
7201,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 200 mg, 500 count bottle (NDC 0185-0144-05)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0185-0144-05,discontinued
7202,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 500 count bottle (NDC 0245-0145-15)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0245-0145-15,discontinued
7203,Amiodarone Tablets,Sandoz,"Amiodarone hydrochloride tablets, 400 mg, 30 count bottle (NDC 0245-0145-30)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0245-0145-30,discontinued
7204,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",10 mg (NDCs 0378-2610-01 and 0378-2610-10),New,8/2/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7205,Amitriptyline Hydrochloride Tablets,"Mylan Specialty, a Viatris Company",25 mg (NDCs 0378-2625-01 and 0378-2625-10),New,8/2/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7206,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.","10mg (NDCs 0603-2212-02, 0603-2212-16, 0603-2212-21, and 0603-2212-32)",New,12/16/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7207,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.","25mg (NDCs 0603-2213-02, 0603-2213-21, 0603-2213-30, and 0603-2213-32)",New,12/16/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7208,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",50mg (NDCs 0603-2214-21 and 0603-2214-32),New,12/16/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7209,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",75mg (NDCs 0603-2215-21 and 0603-2215-25),New,12/16/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7210,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",100mg (NDCs 0603-2216-21 and 0603-2216-25),New,12/16/21,,,,,Psychiatry,To be Discontinued,,,,discontinued
7211,Amitriptyline Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",150mg (NDC 0603-2217-21),New,12/16/21,,,,,Psychiatry,To be Discontinued,,,0603-2217-21,discontinued
7212,Amoxapine Tablets,Teva Pharmaceuticals,"50 mg, 100 tablets (NDC 0591-5714-01)",Revised,10/5/22,Available,,,,Psychiatry,Current,,,0591-5714-01,available
7213,Amoxapine Tablets,Teva Pharmaceuticals,"25 mg, 100 tablets (NDC 0591-5713-01)",Revised,10/5/22,"Backorder, Recovery expected Nov-22",,,Other,Psychiatry,Current,,,0591-5713-01,not available
7214,Amoxapine Tablets,Teva Pharmaceuticals,"100 mg, 100 tablets (NDC 0591-5715-01)",Revised,10/5/22,Product is Available,,,,Psychiatry,Current,,,0591-5715-01,available
7215,Amoxapine Tablets,Teva Pharmaceuticals,"150 mg, 30 tablets (NDC 00591-5716-30)",Revised,10/5/22,Allocation,,,,Psychiatry,Current,,,00591-5716-30,limited availability
7216,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,12.5  mg 100 count (NDC 0555-0776-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0776-02,
7217,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,15  mg 100 count (NDC 0555-0777-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0777-02,
7218,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,7.5  mg 100 count (NDC 0555-0775-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0775-02,
7219,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,10  mg 100 count (NDC 0555-0972-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0972-02,
7220,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,20 mg 100 count (NDC 0555-0973-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0973-02,
7221,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,30 mg 100 count (NDC 0555-0974-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0974-02,
7222,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,5 mg 100 count (NDC 0555-0971-02),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0555-0971-02,
7223,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"5 mg, 100 Count Bottle (NDC 68382-950-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-950-01,discontinued
7224,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"7.5 mg, 100 Count Bottle (NDC 68382-951-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-951-01,discontinued
7225,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"10 mg, 100 Count Bottle (NDC 68382-952-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-952-01,discontinued
7226,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"12.5 mg, 100 Count Bottle (NDC 68382-953-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-953-01,discontinued
7227,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"15 mg, 100 Count Bottle (NDC 68382-954-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-954-01,discontinued
7228,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"20 mg, 100 Count Bottle (NDC 68382-955-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-955-01,discontinued
7229,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Nesher Pharmaceuticals (USA) LLC,"30 mg, 100 Count Bottle (NDC 68382-956-01)",Revised,7/12/21,,,,,Psychiatry,To be Discontinued,,,68382-956-01,discontinued
7230,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"30 mg, 100 Count Bottle (NDC 0185-0864-01)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0185-0864-01,
7231,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"20 mg, 100 Count Bottle (NDC 0185-0853-01)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0185-0853-01,
7232,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"10 mg, 100 Count Bottle (NDC 0185-0842-01)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0185-0842-01,
7233,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Sandoz,"5 mg, 100 Count Bottle (NDC 0185-0831-01)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0185-0831-01,
7234,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 10mg 100 (NDC 57844-0110-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0110-01,
7235,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 12.5mg 100 (NDC 57844-0112-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0112-01,
7236,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 15mg 100 (NDC 57844-0115-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0115-01,
7237,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 20mg 100 (NDC 57844-0120-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0120-01,
7238,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 30mg 100 (NDC 57844-0130-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0130-01,
7239,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 5mg 100 (NDC 57844-0105-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0105-01,
7240,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Teva Pharmaceuticals,Adderall(R) Tablets 7.5mg 100 (NDC 57844-0117-01),Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,57844-0117-01,
7241,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",5mg [1.25/1.25/1.25/1.25mg] 100s (NDC 0378-4541-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4541-01,
7242,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",7.5mg [1.875/1.875/1.875/1.875mg] 100s (NDC 0378-4542-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4542-01,
7243,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",10mg [2.5/2.5/2.5/2.5mg] 100s (NDC 0378-4543-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4543-01,
7244,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg [3.125/3.125/3.125/3.125mg] 100s (NDC 0378-4544-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4544-01,
7245,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",15mg [3.75/3.75/3.75/3.75mg] 100s (NDC 0378-4545-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4545-01,
7246,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",20mg [5/5/5/5mg] 100s (NDC 0378-4546-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4546-01,
7247,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",30mg [7.5/7.5/7.5/7.5mg] 100s (NDC 0378-4547-01),Revised,5/31/22,,,,,Psychiatry,Resolved,,,0378-4547-01,
7248,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 5 mg, 100 (NDC 13107-0068-01)",Revised,5/31/22,,,,,Psychiatry,Resolved,,,13107-0068-01,
7249,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 10 mg, 100 (NDC 13107-0070-01)",Revised,5/31/22,,,,,Psychiatry,Resolved,,,13107-0070-01,
7250,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 15 mg, 100 (NDC 13107-0072-01)",Revised,5/31/22,,,,,Psychiatry,Resolved,,,13107-0072-01,
7251,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 20 mg, 100 (NDC 13107-0073-01)",Revised,5/31/22,,,,,Psychiatry,Resolved,,,13107-0073-01,
7252,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,Aurobindo Pharma,"Amphetamine Mixed Salts Tablets C-II 30 mg, 100 (NDC 13107-0074-01)",Revised,5/31/22,,,,,Psychiatry,Resolved,,,13107-0074-01,
7253,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","5 mg, 100 count (NDC 0527-1500-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1500-37,
7254,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","7.5 mg, 100 count (NDC 0527-1501-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1501-37,
7255,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","10 mg, 100 count (NDC 0527-1502-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1502-37,
7256,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","12.5 mg, 100 count (NDC 0527-1503-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1503-37,
7257,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","15 mg, 100 count (NDC 0527-1504-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1504-37,
7258,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","20 mg, 100 count (NDC 0527-1505-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1505-37,
7259,Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets,"Lannett Company, Inc.","30 mg, 100 count (NDC 0527-1506-37)",Revised,5/31/22,,,Available,,Psychiatry,Resolved,,,0527-1506-37,
7260,"Amphetamine Oral Suspension, Extended Release","Tris Pharma, Inc.",Amphetamine (Dyanavel XR) EQ 2.5MG BASE/ML (NDC 27808-102-01),Revised,8/26/22,,,,,Psychiatry,Resolved,8/26/22,,27808-102-01,
7261,Ampicillin for Injection,"Mylan Institutional, a Viatris company",250 mg (NDC 67457-353-10),New,9/23/21,,,,,Anti-Infective,To be Discontinued,,,67457-353-10,discontinued
7262,Ampicillin for Injection,"Mylan Institutional, a Viatris company",500 mg (NDC 67457-350-10),New,9/23/21,,,,,Anti-Infective,To be Discontinued,,,67457-350-10,discontinued
7263,Ampicillin for Injection,Pfizer,1 g; Single Dose Vial (Powder) (NDC 0409-3726-01),New,7/29/22,,Supply expected to exhaust 01Aug2022; Discontinuation of the manufacture of the drug.,,,,To Be Discontinued,7/29/22,7/29/22,0409-3726-01,discontinued
7264,Ampicillin for Injection,Pfizer,2 g; Single Dose Vial (Powder) (NDC 0409-3720-01,New,7/29/22,,Discontinuation of the manufacture of the drug.,,,,To Be Discontinued,7/29/22,7/29/22,0409-3720-01,discontinued
7265,Ampicillin for Injection,Pfizer,500 mg; Single Dose Vial (Powder) (NDC 0409-3718-01),New,6/22/22,,,,,Antibiotic,To be Discontinued,,,0409-3718-01,discontinued
7266,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,1 MG 100 Capsules (NDC 0172-5240-60),Revised,7/20/21,,,,,Hematology,Resolved,,,0172-5240-60,
7267,Anagrelide Hydrochloride Capsules,Teva Pharmaceuticals,0.5 MG 100 Capsules (NDC 0172-5241-60),Revised,7/20/21,,,,,Hematology,Resolved,,,0172-5241-60,
7268,Anagrelide Hydrochloride Capsules,Takeda Pharmaceuticals USA Inc.,"AGRYLIN 0.5 mg Capsule,100 capsules in 1 bottle (NDC 54092-063-01)",Revised,7/20/21,,,Available,,Hematology,Resolved,,,54092-063-01,
7269,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,0.5 mg per capsule Bottles of 100 (NDC 13668-453-01),Revised,7/20/21,,,Available,,Hematology,Resolved,,,13668-453-01,
7270,Anagrelide Hydrochloride Capsules,Torrent Pharma Inc.,"1 mg per capsule, Bottles of 100 (NDC 13668-462-01)",Revised,7/20/21,,,Available,,Hematology,Resolved,,,13668-462-01,
7271,Aspirin/Dipyridamole (Aggrenox) Extended Release Capsules,"Boehringer Ingelheim Pharmaceuticals, Inc.",25mg/200mg capsules (NDC 0597-0001-60),New,5/26/20,,,,,Cardiovascular,To be Discontinued,,,0597-0001-60,discontinued
7272,Atropine Sulfate Injection,American Regent/Luitpold,"0.4 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-0401-25)",Revised,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,00517-0401-25,available
7273,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC",8 mg per 20 mL (0.4 mg per mL); MDV; (NDC 63323-580-20),Reverified,9/14/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,63323-580-20,available
7274,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS",0.1 mg/mL; 10 mL Luer-Jet Prefilled Syringe (NDC 76329-3340-1),Reverified,8/12/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,76329-3340-1,available
7275,Atropine Sulfate Injection,"Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); Ansyr Plastic Syringe(NDC 0409-1630-10),Revised,9/30/22,Next Delivery: November 2022; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-1630-10,not available
7276,Atropine Sulfate Injection,"Hospira, Inc.",0.25 mg/5 mL (0.05 mg/mL); Ansyr Plastic Syringe(NDC 0409-9630-05),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0409-9630-05,not available
7277,Atropine Sulfate Injection,"Hospira, Inc.",0.5 mg/5 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4910-34),Revised,9/30/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,0409-4910-34,available
7278,Atropine Sulfate Injection,"Hospira, Inc.","1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4911-34, pack of 10; NDC 0409-4911-11, individual)",Revised,9/30/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,0409-4911-34,available
7279,Atropine Sulfate Injection,American Regent/Luitpold,"1 mg/mL, 1 mL single-dose vial, package of 25 (NDC 00517-1010-25)",Revised,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,00517-1010-25,available
7280,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.4 mg/mL, 20 mL vial (NDC 0641-6006-10)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Anesthesia;Neurology;Pediatric,Current,,,0641-6006-10,available
7281,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-525-08)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-525-08,available
7282,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.4 mg/mL, 20 mL multi-dose vial, pack of 10 (NDC 16729-512-43)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-512-43,available
7283,Atropine Sulfate Injection,Accord Healthcare Inc.,"1 mg/mL, 1 mL single dose vial, pack of 25 (NDC 16729-526-08)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-526-08,available
7284,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.05 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-483-03)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-483-03,available
7285,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 10 mL prefilled syringe, pack of 10 (NDC 16729-484-45)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-484-45,available
7286,Atropine Sulfate Injection,Accord Healthcare Inc.,"0.1 mg/mL, 5 mL prefilled syringe, pack of 10 (NDC 16729-484-90)",Reverified,4/6/22,Available,,,,Anesthesia;Neurology;Pediatric,Current,,,16729-484-90,available
7287,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94)",Revised,10/1/21,Available,,,,Oncology,Current,,,0781-3253-94,available
7288,Azacitidine for Injection,Celgene Corporation,"100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94)",Revised,10/1/21,Available,,,,Oncology,Current,,,0781-9253-94,available
7289,Azacitidine for Injection,Celgene Corporation,"VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01)",Revised,10/1/21,Available,,,,Oncology,Current,,,59572-102-01,available
7290,Azacitidine for Injection,"Fresenius Kabi USA, LLC","100 mg per vial, single dose vial, PF, (NDC 63323-771-39)",Reverified,9/14/22,Available,,,Demand increase for the drug,Oncology,Current,,,63323-771-39,available
7291,Azacitidine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg per vial, (NDC 0143-9606-01)",Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Oncology,Current,,,0143-9606-01,available
7292,Azacitidine for Injection,"Dr. Reddy's Laboratories, Inc.","100 mg per vial, (NDC 43598-305-62)",Revised,3/4/22,Approximately 2 months of inventory on hand,,,Demand increase for the drug,Oncology,Current,,,43598-305-62,limited availability
7293,Azacitidine for Injection,Armas Pharmaceuticals Inc,100 mg per vial (NDC 72485-201-01),Reverified,5/19/21,Limited availability,,,Demand increase for the drug,Oncology,Current,,,72485-201-01,limited availability
7294,Azacitidine for Injection,Accord Healthcare Inc.,100 mg per vial (NDC 16729-306-10),Revised,6/10/21,Limited availability.,,,Shortage of an active ingredient,Oncology,Current,,,16729-306-10,limited availability
7295,Azacitidine for Injection,"Mylan Institutional, a Viatris company",100 mg per vial (NDC 67457-254-30),Reverified,9/28/22,Unavailable,,,Other,Oncology,Current,,,67457-254-30,not available
7296,Azacitidine for Injection,Cipla Limited,100 mg per vial (NDC 69097-805-40),Revised,6/8/21,Available,,,Demand increase for the drug,Oncology,Current,,,69097-805-40,available
7297,Azacitidine for Injection,Teva Pharmaceuticals,100 mg/vial Lyophilized Powder (NDC 68001-0313-56),Reverified,10/5/22,"Backorder, Recovery expected TBD",Product is manufactured and labeled for Blue Point Laboratories,,,Oncology,Current,,,68001-0313-56,not available
7298,Azacitidine for Injection,Breckenridge Pharmaceutical,100 mg per vial (NDC 51991-797-98),Reverified,2/18/22,Available,,,,Oncology,Current,,,51991-797-98,available
7299,Azacitidine for Injection,"Meitheal Pharmaceuticals, Inc.",100 mg per vial (NDC 71288-115-30),New,10/7/21,Available,,,,Oncology,Current,,,71288-115-30,available
7300,Azithromycin (Azasite) Ophthalmic Solution 1%,Thea Pharma Inc.,"Azasite (Azithromycin Ophthalmic Solution) 1% (NDC 82584-307-03), 2.5mL",Revised,6/3/22,On backorder.,,,Other,Ophthalmology,Current,,,82584-307-03,not available
7301,Bacitracin Ophthalmic Ointment,Padagis US LLC,3.5 g (NDC 0574-4022-35),New,9/10/21,,,,,Ophthalmology,To be Discontinued,,,0574-4022-35,discontinued
7302,Bacteriostatic 0.9% Sodium Chloride Injection,"Fresenius Kabi USA, LLC","0.9% (90 mg per 10 mL), (9mg/mL), Multiple Dose Plastic Vial, 30 mL (NDC 63323-924-30)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Increase in demand,Gastroenterology;Other;Pediatric,Current,,,63323-924-30,not available
7303,Bacteriostatic 0.9% Sodium Chloride Injection,"Fresenius Kabi USA, LLC","0.9% (90 mg per 10 mL), (9mg/mL), Multiple Dose Plastic Vial, 10 mL, (NDC 63323-924-10)",Revised,9/14/22,Available,Check wholesaler inventory,,Increase in demand,Gastroenterology;Other;Pediatric,Current,,,63323-924-10,available
7304,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",10 mL Multiple Dose LifeShield™ Plastic Fliptop Vial (NDC 00409-1966-12),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,00409-1966-12,not available
7305,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",20 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-1966-05),Revised,9/12/22,Available,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,00409-1966-05,available
7306,Bacteriostatic 0.9% Sodium Chloride Injection,"Hospira, Inc.",30 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-1966-07),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,00409-1966-07,not available
7307,Bacteriostatic Water for Injection,"Hospira, Inc.",30 mL Multiple Dose Plastic Fliptop Vial (NDC 00409-3977-03),Reverified,9/12/22,Next Delivery: October 2022; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Other,Current,,,00409-3977-03,not available
7308,Belatacept (Nulojix) Lyophilized Powder for Injection,Bristol Myers Squibb Co.,20cc vial 250mg lyophilized powder per vial for IV infusion (NDC 0003-0371-13),Revised,2/25/21,"No disruption to existing patients is anticipated. Until further notice, BMS will continue to limit distribution of Nulojix via the US NULOJIX Distribution Program, initiated 2/15/2017. Starting in August 2018, the restrictions of the NDP were eased to al",,,Demand increase for the drug,Transplant,Current,,,0003-0371-13,limited availability
7309,Belladonna and Opium Suppositories,Padagis US LLC,16.2mg/60 mg suppository (NDC: 0574-7040),New,8/3/22,Currently out of stock. No estimated release date available.,Manufacturing delay due to active ingredient shortage,,"Regulatory delay, shortage of active ingredient",Urology,Current,,,,not available
7310,Belladonna and Opium Suppositories,Padagis US LLC,"Belladonna and Opium Suppositories, 16.2mg/30 mg (NDC 0574-7045)",New,8/3/22,Currently out of stock. No estimated release date available.,Manufacturing delay due to active ingredient shortage,,"Regulatory delay, shortage of active ingredient",Urology,Current,,,0574-7045,not available
7311,Benzonatate Capsules,Pfizer Pharmaceuticals,Tessalon 100 mg perles; Bottle of 100 (NDC 0069-0122-01),New,6/8/21,,,,,Pulmonary/Allergy,To be Discontinued,,,0069-0122-01,discontinued
7312,Betamethasone Valerate Topical Foam,Ingenus Pharmaceuticals LLC,0.12% (NDCs 50742-315-01 and 50742-315-50),New,11/30/21,,,,,Dermatology,To be Discontinued,,,,discontinued
7313,Bivalirudin in 0.9% Sodium Chloride Injection,Baxter,250 mg/50 mL (NDC 0338-9572-24),New,7/12/22,,Discontinuation of the manufacture of the drug.,,,Hematology,To be Discontinued,7/12/22,7/12/22,0338-9572-24,discontinued
7314,Bivalirudin in 0.9% Sodium Chloride Injection,Baxter,500 mg/100 mL (NDC 0338-9576-12),New,7/12/22,,Discontinuation of the manufacture of the drug.,,,Hemtology,To be Discontinued,7/12/22,7/12/22,0338-9576-12,discontinued
7315,Bleomycin Injection,Teva,NDC 0703-3154-01 (15 Units/Single Dose Vial),New,8/11/22,,Product is available with an expected supply duration until SEPT 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-3154-01,discontinued
7316,Bleomycin Injection,Teva,NDC 0703-3155-01 (30 Units/Single Dose Vial),New,8/11/22,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-3155-01,discontinued
7317,"Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup",Wockhardt Bio A.G.,4 Fl Oz (118ml) (NDC 60432-275-04),New,8/26/22,,Discontinuing the manufacture of the product due to business reasons,,,Pulmonary/Allergy; Gastroenterology,To be Discontinued,8/26/22,8/26/22,60432-275-04,discontinued
7318,"Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup",Wockhardt Bio A.G.,1 pint (475ml) (NDC 60432-275-16),New,8/26/22,,Discontinuing the manufacture of the product due to business reasons,,,Pulmonary/Allergy; Gastroenterology,To be Discontinued,8/26/22,8/26/22,60432-275-16,discontinued
7319,Budesonide Capsules,Teva Pharmaceuticals,3 mg capsules (NDC 0093-7445-01),New,12/23/19,,,,,Gastroenterology,To be Discontinued,,,0093-7445-01,discontinued
7320,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 4 mL vial (NDC 0641-6008-10)",Revised,8/26/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6008-10,available
7321,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.25 mg/mL, 10 mL vial (NDC 0641-6007-10)",Revised,8/26/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6007-10,available
7322,Bumetanide Injection,"Hospira, Inc.",1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04),Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-1412-04,not available
7323,Bumetanide Injection,"Hospira, Inc.",2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10),Revised,9/12/22,Next Delivery and Estimated Recovery: February 2025,,,Demand increase for the drug,Cardiovascular,Current,,,00409-1412-10,not available
7324,Bumetanide Injection,Pfizer,1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1412-04),New,7/19/22,,Stock anticipated to be available through September 2022,,,Cardiology; Renal,To be Discontinued,7/19/22,7/19/22,0409-1412-04,discontinued
7325,Bumetanide Injection,Pfizer,2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1412-10),New,7/19/22,,Stock anticipated to be available through August 2022,,,Cardiology; Renal,To be Discontinued,7/19/22,7/19/22,0409-1412-10,discontinued
7326,Bumetanide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",1mg/4mL vial (NDC 70860-405-04),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-405-04,available
7327,Bumetanide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",2.5mg/10mL vial (NDC 70860-406-10),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-406-10,available
7328,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-461-57),Revised,9/14/22,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-461-57,not available
7329,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine w/EPI 0.5% (250 mg per 50 mL) (5 mg per mL) MDV (NDC 63323-463-57),Revised,9/14/22,Backordered.  Next release October 2022.,,,Demand increase for the drug,Anesthesia,Current,,,63323-463-57,not available
7330,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.25% (25 mg per 10 mL) (2.5 mg per mL) SDV (NDC 63323-468-17),Revised,9/14/22,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-17,not available
7331,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI .25% (75 mg per 30 mL) (2.5 mg per mL) SDV (NDC 63323-468-37),Revised,9/14/22,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-37,not available
7332,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (50 mg per 10 mL) (5 mg per mL) SDV (NDC 63323-462-17),Revised,9/14/22,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-17,not available
7333,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) SDV (NDC 63323-462-37),Revised,9/14/22,Backordered.  Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-37,not available
7334,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF w/EPI 0.5% (150 mg per 30 mL) (5 mg per mL) Sterile-Pak, SDV (NDC 63323-462-31)",Revised,9/14/22,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-462-31,not available
7335,Bupivacaine Hydrochloride and Epinephrine Injection,"Fresenius Kabi USA, LLC",Sensorcaine MPF w/EPI 0.75% (225 mg per 30 mL) (7.5 mg per mL)  SDV  (NDC 63323-460-37),Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-460-37,not available
7336,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-01),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-01,not available
7337,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9042-17),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9042-17,not available
7338,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9043-01),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9043-01,not available
7339,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-01),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-01,not available
7340,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-9045-17),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9045-17,not available
7341,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-9046-01),Revised,9/12/22,Next Delivery: April 2023; Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-9046-01,not available
7342,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-10)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-10,not available
7343,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1746-30)",Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1746-30,not available
7344,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-10)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: January 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-10,not available
7345,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000); Single Dose Glass Fliptop Vial (NDC 00409-1749-29)",Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1749-29,not available
7346,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1752-50)",Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1752-50,not available
7347,Bupivacaine Hydrochloride and Epinephrine Injection,"Hospira, Inc.","Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-1755-50)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1755-50,limited availability
7348,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.25% (125 mg per 50 mL) (2.5 mg per mL) MDV (NDC 63323-465-57),Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-465-57,not available
7349,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Sensorcaine 0.5% (250 mg per 50 mL) (5 mg per mL)                    MDV (NDC 63323-467-57),Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-467-57,not available
7350,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (25 mg per 10 mL) (2.5 mg per mL) MPF,         SDV (NDC 63323-464-17)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-17,not available
7351,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine MPF 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF, SDV (NDC 63323-464-37)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-37,not available
7352,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.25% (75 mg per 30 mL) (2.5 mg per mL) MPF,             Sterile-Pak, SDV (NDC 63323-464-31)",Revised,9/14/22,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
7353,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (50 mg per 10 mL) (5 mg per mL)  MPF,                 SDV  (NDC 63323-466-17)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-466-17,not available
7354,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                 SDV (NDC 63323-466-37)",Revised,9/14/22,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-37,available
7355,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.5% (150 mg per 30 mL) (5 mg per mL) MPF,                Sterile-Pak, SDV (NDC 63323-466-31)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-466-31,not available
7356,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (75 mg per 10 mL) (7.5 mg per mL) MPF,             SDV (NDC 63323-472-17)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia,Current,,,63323-472-17,not available
7357,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine 0.75% (225 mg per 30 mL) (7.5 mg per mL) MPF,     SDV (NDC 63323-472-37)",Revised,9/14/22,4 month expiry (12/2022 & 1/2023 expiry) dating available by request.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-472-37,unclear
7358,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 10 mL Single Dose Vials (NDC 55150-167-10),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-167-10,not available
7359,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 30 mL Single Dose Vials (NDC 55150-168-30),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-168-30,not available
7360,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 10 mL Single Dose Vials (NDC 55150-169-10),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-169-10,not available
7361,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 30 mL Single Dose Vials (NDC 55150-170-30),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-170-30,not available
7362,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 10 mL Single Dose Vials (NDC 55150-171-10),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-171-10,not available
7363,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 30 mL Single Dose Vials (NDC 55150-172-30),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-172-30,not available
7364,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.25% 50 mL Multiple Dose Vials (NDC 55150-249-50),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-249-50,not available
7365,Bupivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 50 mL Multiple Dose Vials (NDC 55150-250-50),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-250-50,not available
7366,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",25 mg/10 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-01),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: December 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1159-01,not available
7367,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/30 mL (2.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1159-02),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1159-02,not available
7368,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1160-01),Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1160-01,not available
7369,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-01),Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1162-01,not available
7370,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1162-02),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: July 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1162-02,not available
7371,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1163-01),Revised,9/12/22,Limited Supply Available. Next Delivery: March 2023; Estimated Recovery: July 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1163-01,limited availability
7372,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",75 mg/10 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-01),Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1165-01,not available
7373,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",225 mg/30 mL (7.5 mg/mL); Single Dose Glass Teartop Vial (NDC 00409-1165-02),Revised,9/12/22,Next Delivery: December 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1165-02,not available
7374,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409-3613-01),Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-3613-01,not available
7375,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 25 mg/10 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-10),Revised,9/12/22,Next Delivery and Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1559-10,not available
7376,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/30 mL (2.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1559-30),Revised,9/12/22,Next Delivery and Estimated Recovery: May 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1559-30,not available
7377,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 125 mg/50 mL (2.5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1587-50),Revised,9/12/22,Next Delivery and Estimated Recovery: June 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-1587-50,not available
7378,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-10),Revised,9/12/22,Next Delivery and Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,00409-1560-10,not available
7379,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1560-29),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-1560-29,not available
7380,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1610-50),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1610-50,not available
7381,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 75 mg/10 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-10),Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-1582-10,not available
7382,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine 225 mg/30 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1582-29),Revised,9/12/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,00409-1582-29,available
7383,Bupivacaine Hydrochloride Injection,"Hospira, Inc.",Marcaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose); Glass Ampul (NDC 00409- 1761-02),Revised,9/12/22,Next Delivery and Estimated Recovery: TBD,,,Demand increase for the drug,Anesthesia,Current,,,00409-,unclear
7384,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 5 mL single-dose ampules (NDC 59923-717-05),Revised,12/9/21,Available,,,,Anesthesia,Current,,,59923-717-05,available
7385,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.25% 10 mL single-dose ampules (NDC 59923-719-10),Revised,12/9/21,Available,,,,Anesthesia,Current,,,59923-719-10,available
7386,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 5 mL single-dose ampules (NDC 59923-718-05),Revised,12/9/21,Available,,,,Anesthesia,Current,,,59923-718-05,available
7387,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.",0.5% 10 mL single-dose ampules (NDC 59923-720-10),Revised,12/9/21,Available,,,,Anesthesia,Current,,,59923-720-10,available
7388,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Spinal, USP (7.5 mg/mL in 8.25% dextrose) 2 mL Single Dose Ampule (10 x 2 mL)(NDC 36000-092-10)",Reverified,9/28/22,Stocked out - recovery TBD,,,Manufacturing Delay,Anesthesia,Current,,,36000-092-10,not available
7389,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","HCl 0.75% & Dextrose 8.25%, Injectable spinal (NDC 73293-0002)",New,6/21/21,Available,,,,Anesthesia,Current,,,73293-0002,available
7390,Busulfan Injection,American Regent/Luitpold,6 mg/mL  (NDC 0517-0920-08),New,8/6/21,,,,,Hematology,To be Discontinued,,,0517-0920-08,discontinued
7391,Busulfan Injection,Apotex Corp.,6mg/mL (NDCs 60505-6177-0 and 60505-6177-8),New,10/15/21,,,,,Hematology,To be Discontinued,,,,discontinued
7392,Calcitonin Salmon Nasal Spray,"Endo Pharmaceuticals, Inc.",200 IU/spray (NDC 49884-161-11),New,8/29/22,,,,,Musculoskeletal,To be Discontinued,8/29/22,8/29/22,49884-161-11,discontinued
7393,Calcium Disodium Versenate Injection,Bausch Health,1000 mg/5 mL (200 mg/mL) (NDC 99207-240-05),Reverified,10/25/21,Not currently available. Estimated Shortage duration TBD,,,Requirements related to complying with good manufacturing practices,Other,Current,,,99207-240-05,not available
7394,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","1,000 mg calcium gluconate per 10 mL (100 mg/mL), single dose vial (NDC 63323-360-01, 1 vial; NDC 63323-360-19, 25 vials)",Revised,9/14/22,Available,Check wholesaler inventory,,Available,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-01,available
7395,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","5,000 mg calcium gluconate per 50 mL (100 mg/mL), single dose vial (NDC 63323-360-03, 1 vial; NDC 63323-360-59, 25 vials)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-03,not available
7396,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","10,000 mg calcium gluconate per 100 mL (100 mg/mL), pharmacy bulk package vial (NDC 63323-360-05, 1 vial; NDC 63323-360-61, 20 vials)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,63323-360-05,not available
7397,Calcium Gluconate Injection,HQ Specialty Pharma,1000 mg/50 mL (20 mg/mL) single-dose bag (NDC 44567-620-24),Reverified,5/3/22,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,44567-620-24,available
7398,Calcium Gluconate Injection,HQ Specialty Pharma,2000 mg/100 mL (20 mg/mL) single-dose bag (NDC 44567-621-24),Reverified,5/3/22,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,44567-621-24,available
7399,Calcium Gluconate Injection,HQ Specialty Pharma,1000mg/100mL (10mg/mL) Calcium Gluconate single-dose bag (NDC 44567-0622-24),Reverified,5/3/22,Available,,,,Cardiovascular;Endocrinology/Metabolism;Gastroenterology;Other;Pediatric;Pulmonary/Allergy,Current,,,44567-0622-24,available
7400,Capreomycin Injection,Akorn Pharmaceuticals,"Capastat Sulfate (Capreomycin for Injection USP) Eq to 1 g Capreomycin activity, 10mL (NDC 17478-080-50)",Revised,5/5/21,,,,,Anti-Infective,To be Discontinued,,,17478-080-50,discontinued
7401,Captopril Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",12.5mg; 25mg; 50mg; 100mg (NDC 0378-3007-10; 0378-3007-01; 0378-3012-10; 0378-3012-01; 0378-3017-10; 0378-3017-01; 0378-3022-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,,,0378-3007-10,discontinued
7402,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/15mg 100s Tabs (NDC 00378-0081-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,,,00378-0081-01,discontinued
7403,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 25mg/25mg 100s Tabs (NDC 00378-0083-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,,,00378-0083-01,discontinued
7404,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/15mg 100s Tabs (NDC 00378-0084-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,,,00378-0084-01,discontinued
7405,Captopril/Hydrochlorothiazide Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Captopril/HCTZ 50mg/25mg 100s Tabs (NDC 00378-0086-01),New,8/9/21,,,,,Cardiovascular,To be Discontinued,,,00378-0086-01,discontinued
7406,Carbamazepine Oral Suspension,Wockhardt Bio A.G.,"100mg/5ml 450mL, (NDC 60432-129-16)",New,6/22/22,,,,,Neurology; Pediatric,To be Discontinued,,,60432-129-16,discontinued
7407,Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose,"Chiesi USA, Inc.",Cardene IV (nicardipine hydrochloride) 0.2 mg/mL in 5% Dextrose (NDC 10122-326-10),New,3/20/18,,,,,Cardiovascular,To be Discontinued,,,10122-326-10,discontinued
7408,Caspofungin Acetate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",50 mg (NDC 67457-831-50),New,7/23/20,,,,,Anti-Infective;Pediatric,To be Discontinued,,,67457-831-50,discontinued
7409,Cefazolin Injection,"Hospira, Inc.",1g Single-dose ADD-Vantage Vial (NDC 00409-2585-01,Reverified,9/12/22,Available,,,Other,Anti-Infective,Current,,,00409-2585-01,available
7410,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 2 g (25 vials) (NDC 60505-6231-05),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,60505-6231-05,available
7411,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 1 g (25 vials) (NDC 60505-6142-05),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,60505-6142-05,available
7412,Cefazolin Injection,Sagent Pharmaceuticals,10g 10 vials (NDC 25021-102-99),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,25021-102-99,available
7413,Cefazolin Injection,Sagent Pharmaceuticals,500mg 25 vials (NDC 25021-100-10),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,25021-100-10,available
7414,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 2 gram/50 mL in DUPLEX Catalog 3105-11 (NDC 00264-3105-11),Reverified,6/10/22,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,00264-3105-11,limited availability
7415,Cefazolin Injection,B. Braun Medical Inc.,Cefazolin Injection 1 gram/50 mL in DUPLEX Catalog 3103-11 (NDC 0264-3103-11),Reverified,6/10/22,Product on allocation to contracted customers,,,Other,Anti-Infective,Current,,,0264-3103-11,limited availability
7416,Cefazolin Injection,WG Critical Care,500mg SDV (NDC 44567-706-25),Reverified,10/3/22,Available,,,Demand increase for the drug,Anti-Infective,Current,,,44567-706-25,available
7417,Cefazolin Injection,WG Critical Care,1g SDV (NDC 44567-707-25),Reverified,10/3/22,Available,,,Demand increase for the drug,Anti-Infective,Current,,,44567-707-25,available
7418,Cefazolin Injection,WG Critical Care,10g PBP (NDC 44567-708-10),Reverified,10/3/22,Available,,,Demand increase for the drug,Anti-Infective,Current,,,44567-708-10,available
7419,Cefazolin Injection,"Hospira, Inc.",1g Single Dose Glass Fliptop Vial (NDC 00409-0805-01),Reverified,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,00409-0805-01,discontinued
7420,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9923-90),Reverified,4/8/22,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,0143-9923-90,available
7421,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9924-90),Reverified,4/8/22,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,0143-9924-90,available
7422,Cefazolin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mg/ 100 mL vial (NDC 0143-9983-03),Reverified,4/8/22,Inventory is currently available,,,Demand increase for the drug,Anti-Infective,Current,,,0143-9983-03,available
7423,Cefazolin Injection,Sandoz,Cefazolin Na Injection 500 mg (NDC 0781-3450-95),Reverified,10/3/22,Available,,,,Anti-Infective,Current,,,0781-3450-95,available
7424,Cefazolin Injection,Sandoz,Cefazolin Na Injection 1 g (NDC 0781-3451-96),Reverified,10/3/22,Available,,,,Anti-Infective,Current,,,0781-3451-96,available
7425,Cefazolin Injection,Sandoz,Cefazolin Na Injection 10 g (NDC 0781-3452-95),Reverified,10/3/22,Available,,,,Anti-Infective,Current,,,0781-3452-95,available
7426,Cefazolin Injection,Sagent Pharmaceuticals,1g 25 vials (NDC 25021-101-10),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,25021-101-10,available
7427,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 1 gram/50 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3503)(NDC 0338-3503-41)",Revised,9/28/22,Available,,,,Anti-Infective,Current,,,0338-3503-41,available
7428,Cefazolin Injection,Baxter Healthcare,"Cefazolin Injection, USP, 2 gram/100 mL, in GALAXY Plastic Container. Frozen Premix. (Product code 2G3508)(NDC 0338-3508-41)",Revised,9/28/22,Available,,,Manufacturing Delay,Anti-Infective,Current,,,0338-3508-41,available
7429,Cefazolin Injection,Apotex Corp.,Cefazolin for Injection 10 g (10 vials) (NDC 60505-6143-04),Reverified,8/22/22,Available,,,,Anti-Infective,Current,,,60505-6143-04,available
7430,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",100 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1100-1),Reverified,10/6/22,Available,,,,Anti-Infective,Current,,,66288-1100-1,available
7431,Cefazolin Injection,"Samson Medical Technologies, L.L.C.",300 gram SmartPak® Pharmacy Bulk Package (NDC 66288-1300-1),Reverified,10/6/22,Available,,,,Anti-Infective,Current,,,66288-1300-1,available
7432,Cefdinir Capsules,Sandoz,300 mg capsules  (NDC 0781-2176-60),New,7/9/20,,,,,Anti-Infective,To be Discontinued,,,0781-2176-60,discontinued
7433,Cefdinir Powder for Suspension,Sandoz,125 mg/5 mL (NDCs 0781-6077-46 and 0781-6077-61),New,10/29/21,,,,,Anti-Infective,To be Discontinued,,,,discontinued
7434,Cefdinir Powder for Suspension,Sandoz,250 mg/5 mL (NDCs 0781-6078-46 and 0781-6078-61),New,10/29/21,,,,,Anti-Infective,To be Discontinued,,,,discontinued
7435,Cefixime Oral Capsules,Ascend Laboratories LLC.,400 mg (50’s HDPE Bottle pack)(NDC 67877-584-50),Revised,3/16/22,"Currently unavailable, Estimated recovery: June/July 2022",,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,67877-584-50,not available
7436,Cefixime Oral Capsules,Lupin,400 mg Bottle of 50 capsules (NDC 68180-423-08),Reverified,7/12/22,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,68180-423-08,limited availability
7437,Cefixime Oral Capsules,Lupin,400 mg Unit dose Package of 10 (1 blister of 10 capsules) (NDC 68180-423-11),Reverified,7/12/22,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,68180-423-11,limited availability
7438,Cefotaxime Sodium Injection,"SteriMax, Inc.","2g/vial, (NDC 21586-012-2)",Reverified,10/14/21,Available,,,Other,Anti-Infective;Pediatric,Current,,,21586-012-2,available
7439,Cefotaxime Sodium Injection,"SteriMax, Inc.","1g/vial, (NDC 21586-011-2)",Reverified,10/14/21,Available,,,Other,Anti-Infective;Pediatric,Current,,,21586-011-2,available
7440,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg/ 10 mL vial (NDC 0143-9930-10),Reverified,4/8/22,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9930-10,not available
7441,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1 g/ 10 mL vial (NDC 0143-9931-25),Reverified,4/8/22,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9931-25,not available
7442,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2 g/ 10 mL vial (NDC 0143-9933-25),Reverified,4/8/22,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9933-25,not available
7443,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 g/ 100 mL vial (NDC 0143-9935-01),Reverified,4/8/22,Currently unavailable,,,Delays due to manufacturing issues.,Anti-Infective;Pediatric,Current,,,0143-9935-01,not available
7444,Cefotetan Disodium Injection,B. Braun Medical Inc.,1 gram/50 mL in DUPLEX (NDC 00264-3173-11),Revised,6/9/22,,,,,Anti-Infective,To be Discontinued,,,00264-3173-11,discontinued
7445,Cefotetan Disodium Injection,B. Braun Medical Inc.,2 gram/50 mL in DUPLEX (NDC 00264-3175-11),Revised,6/9/22,,,,,Anti-Infective,To be Discontinued,,,00264-3175-11,discontinued
7446,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",1 g SDV (NDC 63323-0385-10),Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0385-10,not available
7447,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",2 g SDV (NDC 63323-0386-20),Revised,9/14/22,Available,Check wholesaler for inventory,,Manufacturing delay,Anti-Infective,Current,,,63323-0386-20,available
7448,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC",10 g PBP (NDC 63323-0396-61),Revised,9/14/22,No release date available at this time.,,,Manufacturing delay,Anti-Infective,Current,,,63323-0396-61,not available
7449,Cefotetan Disodium Injection,"Teligent Pharma, Inc.",Cefotan 2g Vial 10 (NDC 52565-0053-10),Reverified,10/13/21,Discontinued,,,,Anti-Infective,Current,,,52565-0053-10,discontinued
7450,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",1g vial (NDC 0143-9878-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,0143-9878-25,
7451,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",2g vial (NDC 0143-9877-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,0143-9877-25,
7452,Cefoxitin for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10g vial (NDC 0143-9876-10),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,0143-9876-10,
7453,Cefoxitin for Injection,Apotex Corp.,1 g (25 vials) (NDC 60505-0759-05),Revised,11/18/21,,,,,Anti-Infective,Resolved,,,60505-0759-05,
7454,Cefoxitin for Injection,Apotex Corp.,2 g (25 vials) (NDC 60505-0760-05),Revised,11/18/21,,,,,Anti-Infective,Resolved,,,60505-0760-05,
7455,Cefoxitin for Injection,Apotex Corp.,10 g (10 vials) (NDC 60505-0761-04),Revised,11/18/21,,,,,Anti-Infective,Resolved,,,60505-0761-04,
7456,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",1 g per vial; SDV; (NDC 63323-341-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,63323-341-25,
7457,Cefoxitin for Injection,"Fresenius Kabi USA, LLC",2 grams per vial; SDV; (NDC 63323-342-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,63323-342-25,
7458,Cefoxitin for Injection,Sagent Pharmaceuticals,"10 g, package of 10 vials (NDC 25021-111-99)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,25021-111-99,
7459,Cefoxitin for Injection,Sagent Pharmaceuticals,"1 g, package of 10 vials (NDC 25021-109-10)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,25021-109-10,
7460,Cefoxitin for Injection,Sagent Pharmaceuticals,"2 g, package of 10 vials (NDC 25021-110-20)",Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,25021-110-20,
7461,Cefoxitin for Injection,WG Critical Care,1 g (NDC 44567-245-25),Revised,11/18/21,Available,,Available,,Anti-Infective,Resolved,,,44567-245-25,available
7462,Cefoxitin for Injection,WG Critical Care,2 g (NDC 44567-246-25),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,44567-246-25,
7463,Cefoxitin for Injection,WG Critical Care,10 g (NDC 44567-247-10),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,44567-247-10,
7464,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 2 gram/50 mL in DUPLEX Catalog 3125-11 (NDC NDC 00264-3125-11),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,00264-3125-11,
7465,Cefoxitin for Injection,B. Braun Medical Inc.,Cefoxitin Injection 1 gram/50 mL in DUPLEX Catalog 3123-11 (NDC 0264-3123-11),Revised,11/18/21,,,Available,,Anti-Infective,Resolved,,,0264-3123-11,
7466,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 1g Bag 24 x 50mL (NDC 24987-0412-00),New,3/20/18,,,,,Anti-Infective;Pediatric,To be Discontinued,,,24987-0412-00,discontinued
7467,Ceftazidime (Fortaz) Injection,"Teligent Pharma, Inc.",Ceftazidime (Fortaz) Premix Sol Frozen 2g Bag 24 x 50mL (NDC 24987-0413-00),New,3/20/18,,,,,Anti-Infective;Pediatric,To be Discontinued,,,24987-0413-00,discontinued
7468,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution 1 Single-use vials (NDC 0456-2700-01)",Revised,2/7/22,,,Available,,Anti-Infective,Resolved,,,0456-2700-01,
7469,"Ceftazidime and Avibactam (AVYCAZ®) for Injection, 2 grams/0.5 grams",Allergan Sales LLC,"2 g/1, .5 g/1 powder for solution Carton containing 10 vials  (NDC 0456-2700-10)",Revised,2/7/22,,,Available,,Anti-Infective,Resolved,,,0456-2700-10,
7470,Ceftolozane and Tazobactam (Zerbaxa) Injection,Merck Sharp & Dohme Corp.,Supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial. Vials are supplied in cartons containing 10 vials (NDC 67919-030-01),Revised,3/14/22,,,Available,,Anti-Infective,Resolved,,,67919-030-01,
7471,Cefuroxime Sodium (Zinacef) Injection,"Teligent Pharma, Inc.",Cefuroxime Sodium (Zinacef) Premix Sol Frozen 1.5g Bag 24 x 50mL (NDC 24987-0425-00),New,3/20/18,,,,,Anti-Infective;Pediatric,To be Discontinued,,,24987-0425-00,discontinued
7472,Cetirizine Hydrochloride Solution,Torrent Pharma Inc.,"Oral Solution, 1 mg/mL 120 mL (NDC 1366859607) and 480 mL (NDC 1366859611)",New,6/9/22,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,1366859607,discontinued
7473,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 500 count (NDC 0555-0159-04)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0159-04,available
7474,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 100 count (NDC 0555-0158-02)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0158-02,available
7475,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 1000 count (NDC 0555-0033-05)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0033-05,available
7476,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"10 mg, 100 count (NDC 0555-0033-02)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0033-02,available
7477,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"25 mg, 100 count (NDC 0555-0159-02)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0159-02,available
7478,Chlordiazepoxide Hydrochloride Capsules,Teva Pharmaceuticals,"5 mg, 500 count (NDC 0555-0158-04)",Reverified,10/5/22,Available,,,,Neurology;Psychiatry,Current,,,0555-0158-04,available
7479,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","10mg, 100ct (NDC 42806-562-01)",Reverified,3/8/22,Available,,,,Neurology;Psychiatry,Current,,,42806-562-01,available
7480,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","25mg, 100ct (NDC 42806-563-01)",Reverified,3/8/22,Available,,,,Neurology;Psychiatry,Current,,,42806-563-01,available
7481,Chlordiazepoxide Hydrochloride Capsules,"Epic Pharma, LLC","5mg, 100ct (NDC 42806-564-01)",Reverified,3/8/22,Available,,,,Neurology;Psychiatry,Current,,,42806-564-01,available
7482,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,5 mg (NDC 43547-251-10),New,11/19/19,,,,,Neurology;Psychiatry,To be Discontinued,,,43547-251-10,discontinued
7483,"Chlordiazepoxide Hydrochloride USP, Capsules",Bausch Health,10 mg (NDC 43547-252-10),New,11/19/19,,,,,Neurology;Psychiatry,To be Discontinued,,,43547-252-10,discontinued
7484,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal® (Chloroprocaine HCl Injection, USP) 5mL ampules 50 mg/5 mL (10 mg/mL) Catalog D7055 (NDC 0264-7055-05)",New,5/17/21,Product available,,,Other,Anesthesia,Current,,,0264-7055-05,available
7485,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 1% (300 mg per 30 mL) (10 mg per mL); MDV; (NDC 63323-475-37),Revised,9/14/22,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-475-37,available
7486,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nescacaine 2% (600 mg per 30 mL) (20 mg per mL); MDV; (NDC 63323-476-37),Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-476-37,not available
7487,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 2% (400 mg per 20 mL) (20 mg per mL); SDV; (NDC 63323-477-27),Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-477-27,not available
7488,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC",Nesacaine 3% (600 mg per 20 mL) (30 mg per mL); SDV; (NDC 63323-478-27),Revised,9/14/22,Available,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-478-27,available
7489,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% (20 mg/mL), 20 mL vial (NDC 0143-9209-10)",Revised,4/8/22,Inventory is currently available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9209-10,available
7490,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","3% (30 mg/mL), 20 mL vial (NDC 0143-9210-10)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9210-10,available
7491,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"10 mg/5 mL Single Dose Vial, Package of 10 vials (NDC 55150-284-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,55150-284-10,
7492,Cisatracurium Besylate Injection,AuroMedics Pharma LLC (mfd. by Aurobindo Pharma Ltd.),"20 mg / 10 mL Multiple-Dose Vial, Package of 10 vials (ndc 55150-286-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,,
7493,Cisatracurium Besylate Injection,Teva Pharmaceuticals,200 mg/20 mL (10 mg/mL) Single-dose vials (NDC 0703-2045-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0703-2045-03,
7494,Cisatracurium Besylate Injection,Teva Pharmaceuticals,20 mg/10 mL (2 mg/mL) Multiple-dose vials (NDC 0703-2056-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0703-2056-03,
7495,Cisatracurium Besylate Injection,Teva Pharmaceuticals,10 mg/5 mL (2 mg/mL) Single-dose vials (NDC 0703-2033-03),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0703-2033-03,
7496,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/mL 10 vials (NDC 70069-141-10),Revised,7/27/21,,,,,Anesthesia,Resolved,,,70069-141-10,
7497,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",2mg/ml 10 vials (NDC 70069-161-10),Revised,7/27/21,,,,,Anesthesia,Resolved,,,70069-161-10,
7498,Cisatracurium Besylate Injection,"Somerset Therapeutics, LLC",10mg/mL 10 vials (NDC 70069-151-10),Revised,7/27/21,,,,,Anesthesia,Resolved,,,70069-151-10,
7499,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",10 mg per 5 mL single dose vial (NDC 71288-712-06),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,71288-712-06,
7500,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",200 mg per 20 mL single dose vial (NDC 71288-713-21),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,71288-713-21,
7501,Cisatracurium Besylate Injection,"Meitheal Pharmaceuticals, Inc.",20 mg per 10 mL  multi dose vial (NDC 71288-712-11),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,71288-712-11,
7502,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","10 mg (base) per 5 mL (2 mg per mL), Single dose vial, PF, (NDC 63323-416-05)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,63323-416-05,
7503,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","20 mg per 10 mL (2 mg per mL), Multiple dose vial, (NDC 63323-417-10)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,63323-417-10,
7504,Cisatracurium Besylate Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), Single dose vial, PF, (NDC 63323-418-20)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,63323-418-20,
7505,Cisatracurium Besylate Injection,Sandoz,2mg/ml; 5mL (NDC 0781-3150-95),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0781-3150-95,
7506,Cisatracurium Besylate Injection,Sandoz,2mg/mL; 10mL (NDC 0781-3152-95),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0781-3152-95,
7507,Cisatracurium Besylate Injection,Sandoz,1-mg/mL; 20mL (NDC 0781-3153-95_,Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0781-3153-95,
7508,Cisatracurium Besylate Injection,"Hospira, Inc.",10mg/5mL (2mg/mL) Single Dose Vial (NDC 00409-1098-02),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,00409-1098-02,
7509,Cisatracurium Besylate Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose Vial (NDC 00409-1103-01),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,00409-1103-01,
7510,Cisatracurium Besylate Injection,"Hospira, Inc.",20mg/10mL (2mg/mL) Multi-Dose Vial (NDC 00409-1208-01),Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,00409-1208-01,
7511,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 5 mL Single-dose vial (NDC 0074-4378-05, 0074-4378-24, 0074-4378-36)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0074-4378-05,
7512,Cisatracurium Besylate Injection,Abbvie,"2 mg/mL, 10 mL Multiple-dose vial (NDC 0074-4380-10, 0074-4380-79, 0074-4380-81)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0074-4380-10,
7513,Cisatracurium Besylate Injection,Abbvie,"10 mg/mL, 20 mL Single-dose vial (NDC 0074-4382-20, 0074-4382-91, 0074-4382-93)",Revised,7/27/21,,,Available,,Anesthesia,Resolved,,,0074-4382-20,
7514,Cladribine Injection,Mylan Laboratories Ltd.,1 mg/mL (NDC 67457-450-10),New,5/20/22,,,,,Oncology,To be Discontinued,,,67457-450-10,discontinued
7515,"Clindamycin and Benzoyl Peroxide Gel, 1%/5%","Tolmar Pharmaceuticals, Inc.",45g jar (NDC 0781-7263-68); 35g pump (NDC 0781-7275-43); 50g jar (NDC 0781-7287-50); 50g pump (NDC 0781-7291-46),New,9/30/21,,,,,Dermatology,To be Discontinued,,,0781-7263-68,discontinued
7516,"Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%","Tolmar Pharmaceuticals, Inc.",45 g tube (NDC 0781-7161-19),New,9/30/21,,,,,Dermatology,To be Discontinued,,,0781-7161-19,discontinued
7517,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",30mL (NDC 52565-018-29),New,6/21/21,,,,,,To be Discontinued,,,52565-018-29,discontinued
7518,Clindamycin Phosphate Topical Solution 1%,"Teligent Pharma, Inc.",60mL (NDC 52565-018-59),New,6/21/21,,,,,,To be Discontinued,,,52565-018-59,discontinued
7519,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-039-15),New,6/21/21,,,,,,To be Discontinued,,,52565-039-15,discontinued
7520,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-039-30),New,6/21/21,,,,,,To be Discontinued,,,52565-039-30,discontinued
7521,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",45g (NDC 52565-039-45),New,6/21/21,,,,,,To be Discontinued,,,52565-039-45,discontinued
7522,Clobetasol Propionate Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-039-60),New,6/21/21,,,,,,To be Discontinued,,,52565-039-60,discontinued
7523,Clobetasol Propionate Topical Foam,Ingenus Pharmaceuticals LLC,0.05% (NDCs 50742-304-01 and 50742-304-50),New,11/16/21,,,,,Dermatology,To be Discontinued,,,,discontinued
7524,Clobetasol Propionate Topical Solution 0.05%,Wockhardt,25 mL (NDC 6432-133-25) || 50 mL (NDC 60432-133-50),New,6/13/22,,,,,Dermatology,To be Discontinued,,,6432-133-25,discontinued
7525,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",25 mL bottle (NDC 63646-500-25),New,11/1/21,,,,,Dermatology,To be Discontinued,,,63646-500-25,discontinued
7526,"Clobetasol Propionate Topical Solution, 0.05%","Tolmar Pharmaceuticals, Inc.",50 mL bottle (NDC 63646-500-50),New,11/1/21,,,,,Dermatology,To be Discontinued,,,63646-500-50,discontinued
7527,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg  (90s)(NDC 0378-1910-77),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1910-77,discontinued
7528,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (100s)(NDC 0378-1910-01),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1910-01,discontinued
7529,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 0.5mg (1000s)(NDC 0378-1910-10),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1910-10,discontinued
7530,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (90s)(NDC 0378-1912-77),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1912-77,discontinued
7531,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (100s)(NDC 0378-1912-01),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1912-01,discontinued
7532,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 1mg (1000s)(NDC 0378-1912-10),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1912-10,discontinued
7533,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (100s)(NDC 0378-1914-01),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1914-01,discontinued
7534,Clonazepam Tablets,Mylan Pharmaceuticals Inc.,Clonazepam Tablets 2mg (500s)(NDC 0378-1914-05),New,5/8/18,,,,,Neurology;Pediatric,To be Discontinued,,,0378-1914-05,discontinued
7535,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0185-0063-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0063-01,discontinued
7536,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0185-0063-05)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0063-05,discontinued
7537,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0185-0063-10)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0063-10,discontinued
7538,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 0781-8018-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-8018-01,discontinued
7539,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 0781-8018-05)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-8018-05,discontinued
7540,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 1000 count bottle (NDC 0781-8018-10)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-8018-10,discontinued
7541,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-752-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,16714-752-01,discontinued
7542,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-752-02)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,16714-752-02,discontinued
7543,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 100 count bottle (NDC 16714-469-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,16714-469-01,discontinued
7544,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 0.5 mg, 500 count bottle (NDC 16714-469-02)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,16714-469-02,discontinued
7545,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0185-0064-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0064-01,discontinued
7546,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0185-0064-05)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0064-05,discontinued
7547,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0185-0064-10)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0185-0064-10,discontinued
7548,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 100 count bottle (NDC 0781-5567-01)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-5567-01,discontinued
7549,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 500 count bottle (NDC 0781-5567-05)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-5567-05,discontinued
7550,Clonazepam Tablets,Sandoz,"Clonazepam tablets, 1 mg, 1000 count bottle (NDC 0781-5567-10)",New,6/5/18,,,,,Neurology;Pediatric,To be Discontinued,,,0781-5567-10,discontinued
7551,Clonidine Hydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.1mg  (NDC 10370-257-02),New,11/30/21,,,,,Psychiatry,To be Discontinued,,,10370-257-02,discontinued
7552,Clonidine Hydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.1mg  (NDC 10370-257-02),New,3/22/22,,,,,Cardiovascular,To be Discontinued,,,10370-257-02,discontinued
7553,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","12.5 mg tablet, 100 CT Bottle (NDC 18860-101-10)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-101-10,discontinued
7554,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablets, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-102-01)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-102-01,discontinued
7555,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","25 mg tablet, 100  CT bottle (NDC 18860-102-10)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-102-10,discontinued
7556,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-104-01)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-104-01,discontinued
7557,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-105-01)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-105-01,discontinued
7558,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","150 mg Tablet, 100 CT Bottle (NDC 18860-105-10)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-105-10,discontinued
7559,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablet, 8 Blister Pack In 1 Carton > 6 Tablets in 1 Blister Pack (NDC 18860-106-01)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-106-01,discontinued
7560,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","200 mg Tablets, 100 CT Bottle (NDC 18860-106-10)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-106-10,discontinued
7561,Clozapine (FazaClo® ) Orally Disintegrating Tablets,"Jazz Pharmaceuticals, Inc.","100 mg Tablet, 100 CT Bottle (NDC 18860-104-10)",New,11/22/19,,,,,Psychiatry,To be Discontinued,,,18860-104-10,discontinued
7562,Codeine Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension,Aytu BioPharma,"14.7 mg of codeine (equivalent to 20 mg codeine phosphate); and chlorpheniramine polistirex, which contains 2.8 mg of chlorpheniramine (equivalent to 4 mg chlorpheniramine maleate) per 5 mL (NDCs 69654-480-01 and 69654-480-02)",New,6/13/22,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
7563,Conivaptan Hydrochloride (Vaprisol) in 5% Dextrose Plastic Container,Cumberland Pharmaceuticals Inc.,20 mg/100 mL (NDC 66220-160-10),New,3/14/22,Next delivery April 2022.  Estimated recovery 3Q 2022.,,,Other,Cardiovascular,Current,,,66220-160-10,not available
7564,"Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated",Pfizer,Conjugated estrogens 0.45 mg/bazedoxifene 20 mg; 2 blisters of 15 each (NDC 0008-1123-12),New,9/21/22,Next Delivery and Estimated Recovery: Late Q3 2023,Shortage per Manufacturer: Manufacturing Delay,,,Reproductive,Current,,,0008-1123-12,not available
7565,"Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated",Pfizer,Conjugated estrogens 0.45 mg/bazedoxifene 20 mg; blister of 7 each (US Sample) (NDC 63539-122-07),New,9/21/22,Next Delivery and Estimated Recovery: Late Q3 2023,Shortage per Manufacturer: Manufacturing Delay,,,Reproductive,Current,,,63539-122-07,not available
7566,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BK0/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON-PVC. (NDC 24571-113-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-113-06,
7567,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK0/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-108-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-108-06,
7568,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/0/1.2 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (DC 24571-114-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,,
7569,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-105-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-105-06,
7570,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/3.5 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-103-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-103-06,
7571,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol BGK2/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-102-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-102-06,
7572,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,"PrismaSol B22GK4/0 Replacement Solution for Continuous Renal Replacement Therapy, NON PVC. (NDC 24571-111-06)",Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-111-06,
7573,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM BK4/2.5 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-116-06),Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-116-06,
7574,Continuous Renal Replacement Therapy (CRRT) Solutions,Baxter Healthcare,PHOXILLUM B22K4/0 Replacement Solution for Continuous Renal Replacement Therapy (NDC 24571-117-06),Reverified,9/28/22,,,Available,,Renal,Resolved,9/19/22,,24571-117-06,
7575,Cortisone Acetate Tablets,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg, bottles of 100 (NDC 0143-9700-01)",Reverified,4/8/22,Currently Unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient,Endocrinology/Metabolism;Rheumatology,Current,,,0143-9700-01,not available
7576,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 2ML (NDC 0065-0359-02)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-02,available
7577,Cyclopentolate Ophthalmic Solution,Alcon,"CYCLOMYDRIL 0.2%, 1% 5ML (NDC 0065-0359-05)",New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0359-05,available
7578,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 0.5% 15ML (NDC 0065-0395-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0395-15,available
7579,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 2ML (NDC 0065-0396-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-02,available
7580,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 1% 5ML (NDC 0065-0396-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0396-05,available
7581,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 2ML (NDC 0065-0397-02),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-02,available
7582,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 5ML (NDC 0065-0397-05),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-05,available
7583,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOGYL 2% 15ML (NDC 0065-0397-15),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,0065-0397-15,available
7584,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 15ML (NDC 61314-396-01),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-01,available
7585,Cyclopentolate Ophthalmic Solution,Alcon,CYCLOPENTOLATE HCL 1% 2ML (NDC 61314-396-03),New,11/9/20,Available,,,Shortage of an active ingredient,Ophthalmology,Current,,,61314-396-03,available
7586,Cyclopentolate Ophthalmic Solution,Bausch & Lomb Incorporated,"Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%, 2 mL bottle (NDC 24208-735-01) and 15 mL bottle (NDC 24208-735-06)",Revised,6/24/21,On backorder. Estimated availability: Mid-September 2021,,,Other,Ophthalmology,Current,,,24208-735-01,not available
7587,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 15mL 1 Bottle (NDC 17478-097-12)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-12,not available
7588,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 2mL, 1 Bottle (NDC 17478-097-02)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-02,not available
7589,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl 2% Oph Sol 20mg/mL, 5mL 1 Bottle/EA (NDC 17478-097-10)",Revised,6/24/21,On backorder. Estimated availability: September 2021,,,Other,Ophthalmology,Current,,,17478-097-10,not available
7590,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Opht Sol 1% 10mg/mL, 2mL, 1 Bottle (NDC 17478-100-02)",Revised,6/24/21,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,17478-100-02,not available
7591,Cyclopentolate Ophthalmic Solution,Akorn Pharmaceuticals,"Cyclopentolate HCl Ophth 1% 10mg/mL, 15mL, 1 Bottle (NDC 17478-100-12)",Revised,6/24/21,On backorder. Estimated availability: August 2021,,,Other,Ophthalmology,Current,,,17478-100-12,not available
7592,Cysteamine Hydrochloride Ophthalmic Solution,"Leadiant Biosciences, Inc.","0.44%, 15 mL bottle (old NDC 54482-020-01) (NEW NDC 54482-020-02)",Revised,6/8/22,,,"NDC 54482-020-01 has been discontinued and replaced by NDC 54482-020-02, which is available.",,Ophthalmology,Resolved,,,54482-020-01,
7593,Cysteine Hydrochloride Injection,"Exela Pharma Sciences, LLC",Elcys (Cysteine Hydrochloride injection) 500mg/10ml Single-dose vials (NDC 51754-1007-1) Packaged as 10 per carton (NDC 51754-1007-3),Revised,9/3/19,,,Available,,Other;Pediatric,Resolved,,,51754-1007-1,
7594,Cytarabine Injection,"Fresenius Kabi USA, LLC","2 g/20 mL (100 mg/mL), single dose vial (NDC 63323-120-20)",Revised,9/14/22,Backordered. Next release October 2022.,,,,Oncology;Pediatric,Current,,,63323-120-20,not available
7595,Cytarabine Injection,"Hospira, Inc.","100 mg/5 mL (20 mg/mL), single dose vial (NDC 61703-305-38)",Reverified,9/12/22,Available,,,,Oncology;Pediatric,Current,,,61703-305-38,available
7596,Cytarabine Injection,"Hospira, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 61703-319-22)",Reverified,9/12/22,Available,,,Other,Oncology;Pediatric,Current,,,61703-319-22,available
7597,Cytarabine Injection,"Hospira, Inc.","500 mg/25 mL (20 mg/mL), multiple dose vial (NDC 61703-304-36)",Reverified,9/12/22,Available,,,Other,Oncology;Pediatric,Current,,,61703-304-36,available
7598,Cytarabine Injection,"Hospira, Inc.","1,000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 61703-303-46)",Reverified,9/12/22,Available,,,Other,Oncology;Pediatric,Current,,,61703-303-46,available
7599,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","2 g/20 mL (100 mg/mL), single dose vial (NDC 71288-109-20)",Reverified,5/18/22,"Currently, no inventory",,,Other,Oncology;Pediatric,Current,,,71288-109-20,not available
7600,Cytarabine Injection,"Mylan Institutional, a Viatris company","2 g/20 mL (100 mg/mL), single dose vial (NDC 67457-452-20)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-452-20,not available
7601,Cytarabine Injection,"Mylan Institutional, a Viatris company","100 mg/5 mL (20 mg/mL), single dose vial (NDC 67457-455-52)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-455-52,not available
7602,Cytarabine Injection,"Mylan Institutional, a Viatris company","1000 mg/50 mL (20 mg/mL), pharmacy bulk vial (NDC 67457-454-50)",Reverified,11/10/21,Unavailable,,,,Oncology;Pediatric,Current,,,67457-454-50,not available
7603,Cytotec (Misoprostol) Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 0025-1451-20),New,6/11/21,,,,,Gastroenterology,To be Discontinued,,,0025-1451-20,discontinued
7604,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",200 mg/vial (NDC 0143-9245-10),Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Oncology,Current,,,0143-9245-10,available
7605,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 10x20mL (NDC 00703-5075-03),Reverified,10/5/22,Backordered – Est date of availability TBD,,,Demand increase for the drug,Oncology,Current,,,00703-5075-03,not available
7606,Dacarbazine Injection,Teva Pharmaceuticals,200 mg 1x20mL (NDC 00703-5075-01),Reverified,10/5/22,Backordered – Est date of availability TBD,,,Demand increase for the drug,Oncology,Current,,,00703-5075-01,not available
7607,Dacarbazine Injection,"Fresenius Kabi USA, LLC","100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10)",Reverified,9/14/22,Available,,,Manufacturing delay,Oncology,Current,,,63323-127-10,available
7608,Dacarbazine Injection,"Fresenius Kabi USA, LLC","200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20)",Reverified,9/14/22,Available,,,Manufacturing delay,Oncology,Current,,,63323-128-20,available
7609,Dacarbazine Injection,Teva,NDC 0703-5075-03 (200 mg 10 X 20 mL Single-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-5075-03,discontinued
7610,Dacarbazine Injection,Teva,NDC 0703-5075-01 (200 mg 1 X 20 mL Single-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-5075-01,discontinued
7611,Daptomycin Injection,"Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc.",500 mg (NDC 67919-012-01),New,8/2/22,,,,,Anti-Infective,To Be Discontinued,8/2/22,8/2/22,67919-012-01,discontinued
7612,Daptomycin Injection,Pfizer,350 mg lyophilized; 15 mL Single-dose vial (NDC 0409-5933-01),New,7/26/22,,Supply expected to exhaust 01Sep2022; Replaced with NDC 0409-0120-01; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,7/26/22,7/26/22,0409-5933-01,discontinued
7613,Daptomycin Injection,Pfizer,500 mg lyophilized; 15 mL Single-dose vial (NDC 0409-2757-01),New,7/26/22,,Supply expected to exhaust 01Oct2022; Replaced with NDC 0409-0122-01; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,7/26/22,7/26/22,0409-2757-01,discontinued
7614,Daptomycin Injection,"Fresenius Kabi USA, LLC",350mg (NDC 63323-585-15),New,5/17/22,,,,,Anti-Infective,To be Discontinued,,,63323-585-15,discontinued
7615,Daptomycin Injection,"Fresenius Kabi USA, LLC","500mg (NDCs 63323-371-10, 63323-371-19, and 63323-871-15)",New,5/17/22,,,,,Anti-Infective,To be Discontinued,,,,discontinued
7616,Daptomycin Injection,Merck Sharp & Dohme Corp.,500 mg (NDC 67919-011-01),New,10/8/21,,,,,Anti-Infective,To be Discontinued,,,67919-011-01,discontinued
7617,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"Extended release, 7.5 mg, 90 count bottle (NDC 0591-4375-19)",New,6/17/20,,,,,Urology,To be Discontinued,,,0591-4375-19,discontinued
7618,Darifenacin Hydrobromide Tablets,Teva Pharmaceuticals,"15 mg, 30 count bottle (NDC: 0591-4380-30)",New,6/17/20,,,,,Urology,To be Discontinued,,,,discontinued
7619,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 30 (NDC 0430-0171-15)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0171-15,discontinued
7620,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of  90 (NDC 0430-0171-23)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0171-23,discontinued
7621,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg , 337500 TABLETS in 1 DRUM (NDC 0430-0171-00)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0171-00,discontinued
7622,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 15 mg, Bottle of 7 (NDC 0430-0171-96)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0171-96,discontinued
7623,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of 30 (NDC 0430-0170-15)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0170-15,discontinued
7624,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg Bottle of  90 (NDC 0430-0170-23)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0170-23,discontinued
7625,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, 337500 TABLETS in 1 DRUM (NDC 0430-0170-00)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0170-00,discontinued
7626,Darifenacin Hydrobromide Tablets,Allergan,"Extended-Release Tablet, 7.5 mg, Bottle of 7 (NDC 0430-0170-96)",New,6/4/20,,,,,Urology,To be Discontinued,,,0430-0170-96,discontinued
7627,Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets,Abbvie,"200mg; 8.33mg; 50mg; 33.33 tablets, (NDC 0074-0063-28)",New,5/22/18,,,,,Antiviral,To be Discontinued,,,0074-0063-28,discontinued
7628,Daunorubicin Hydrochloride Injection,Teva,"20 mg/4 mL, 10 Single Dose Vial Tray (NDC 0703-5233-13)",New,8/11/22,,Product is temporarily unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-5233-13,discontinued
7629,Daunorubicin Hydrochloride Injection (Novaplus®* Label),Teva Pharmaceuticals,"5 mg/mL, 20 mg 4 mL/Vial x 10 (NDC 0703-5233-93)",New,9/13/22,,Product has not been marketed for at least 5 years,,,Oncology,To be Discontinued,9/13/22,9/13/22,0703-5233-93,discontinued
7630,Deferasirox Tablets,Teva Pharmaceuticals,180 mg/1 (NDC 00093-3516-56),New,7/20/20,,,,,Hematology,To be Discontinued,,,00093-3516-56,discontinued
7631,Deferasirox Tablets,Teva Pharmaceuticals,90 mg/1 (NDC 00093-3517-56),New,7/20/20,,,,,Hematology,To be Discontinued,,,00093-3517-56,discontinued
7632,Deferasirox Tablets,Teva Pharmaceuticals,360 mg/1 (NDC 00093-3515-56),New,7/20/20,,,,,Hematology,To be Discontinued,,,00093-3515-56,discontinued
7633,Desmopressin Acetate Injection,Teva,NDC 0703-5051-03 (4 mcg/mL 10 x 1 mL  Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Hematology; Endocrinology,To be Discontinued,8/11/22,8/11/22,0703-5051-03,discontinued
7634,Desmopressin Acetate Injection,Teva,NDC 0703-5054-01 (4 mcg/mL 10 mL Muti Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Hematology; Endocrinology,To be Discontinued,8/11/22,8/11/22,0703-5054-01,discontinued
7635,Desmopressin Acetate Nasal Spray,Ferring,10 mcg/0.1mL (NDCs 55566-2500-0 and 69918-501-05),New,5/14/21,Unavailable,,,Other,Hematology,Current,,,,not available
7636,Desmopressin Acetate Nasal Spray,Apotex Corp.,10 mcg/0.1mL (NDC 60505-0815-0),Reverified,8/22/22,Available,,,,Hematology,Current,,,60505-0815-0,available
7637,Desmopressin Acetate Nasal Spray,Ferring,"1.5 mg/mL, (NDC 0053-6871-00)",Revised,5/14/21,Unavailable,,,Other,Hematology,Current,,,0053-6871-00,not available
7638,Desogestrel and Ethinyl Estradiol Tablets (ORTHO-CEPT),Janssen Pharmaceuticals,ORTHO-CEPT (NDC 50458-196-15),Revised,10/8/14,,,,Discontinuation of the manufacture of the drug.,,To Be Discontinued,,,50458-196-15,discontinued
7639,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection SDV [4 mg / 1 ml] 25PK (NDC 67457-423-12),Reverified,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-423-12,available
7640,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [20 mg / 5 ml] 25PK (NDC 67457-422-54),Reverified,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-422-54,available
7641,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [120 mg / 30 ml] 25 PK (NDC 67457-421-30),Reverified,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-421-30,available
7642,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris company",Dexamethasone Sodium Phosphate Injection MDV [100 mg / 10 ml] 10PK (NDC 67457-420-10),Reverified,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,67457-420-10,available
7643,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),4 mg/1 mL SDV (NDC 55150-237-01),Revised,9/28/22,On long term backorder,,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-237-01,not available
7644,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),20 mg/5 mL MDV  (NDC 55150-238-05),Revised,9/28/22,On long term backorder,,,Delay in shipping of the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-238-05,not available
7645,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),120 mg/30 mL MDV (NDC 55150-239-30),Revised,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-239-30,available
7646,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Injection USP, 10 mg/mL, 1 mL Single Dose Vial (Preservative Free)(NDC 70069-021-25)",Reverified,4/20/22,Available,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,70069-021-25,available
7647,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",20 mg per 5 mL (4 mg per mL); MDV;  Amber vial (NDC 63323-165-05),Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-05,available
7648,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",100 mg per 10 mL (10 mg per mL); MDV;  Amber Vial (NDC 63323-516-10),Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-516-10,available
7649,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",120 mg per 30 mL (4 mg per mL); MDV; Amber Vial (NDC 63323-165-30),Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-30,available
7650,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",4 mg per mL (4 mg per mL); SDV; Amber Vial (NDC 63323-165-01),Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-165-01,available
7651,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC",10 mg per mL (10 mg per mL); SDV; Preservative Free; Amber Vial (NDC 63323-506-01),Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,63323-506-01,not available
7652,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6145-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6145-25,not available
7653,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 5 mL vial (NDC 0641-6146-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-6146-25,not available
7654,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-0367-25)",Revised,4/8/22,Inventory is currently available,,,Other,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,0641-0367-25,available
7655,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-106-10)",Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-106-10,available
7656,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose Simplist syringe, preservative free (NDC 76045-109-10)",Revised,9/14/22,Available,Check wholesalers for inventory.,,Increase in demand,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,76045-109-10,available
7657,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),10 mg/1 mL SDV (NDC 55150-304-25),Revised,9/28/22,Available,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-304-25,available
7658,Dexamethasone Sodium Phosphate Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),100 mg/10 mL MDV (contains preservative)(NDC 55150-305-10),Revised,9/28/22,Backordered — next shipment TBD,,,Demand increase for the drug,Dermatology;Endocrinology/Metabolism;Gastroenterology;Hematology;Neurology;Oncology;Ophthalmology;Other;Pulmonary/Allergy;Rheumatology,Current,,,55150-305-10,not available
7659,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"200mcg/50mL, single dose bag (NDC 55150-296-10)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-296-10,available
7660,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"400mcg/100mL, single dose bag (NDC 55150-297-10)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-297-10,available
7661,Dexmedetomidine Injection,Amneal Pharmaceutical,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1388-8 box of 20; NDC 70121-1388-1 individual)",Reverified,4/7/22,Available,,,,Anesthesia,Current,,,70121-1388-8,available
7662,Dexmedetomidine Injection,Amneal Pharmaceutical,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single-dose bottle (NDC 70121-1389-7 box of 10; NDC 70121-1389-1 individual)",Reverified,4/7/22,Available,,,,Anesthesia,Current,,,70121-1389-7,available
7663,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.2 mg / 50 ml (Solution in Single Use Vials/Bottles), 20PK (NDC 67457-924-50)",Revised,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-924-50,available
7664,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","0.4 mg / 100 ml (Solution in Single Use Vials/Bottles), 10PK (NDC 67457-925-10)",Revised,9/28/22,Available,,,Demand increase for the drug,,Current,,,67457-925-10,available
7665,Dexmedetomidine Injection,Par Pharmaceutical,"200 mcg/50 mL (4 mcg/mL), 50 mL single dose vial, box of 25 (NDC 42023-186-20)",Reverified,9/21/22,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-186-20,unclear
7666,Dexmedetomidine Injection,Par Pharmaceutical,"400 mcg/100 mL (4 mcg/mL), 100 mL single dose vial, box of 10 (NDC 42023-187-10)",Reverified,9/21/22,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-187-10,unclear
7667,Dexmedetomidine Injection,Gland Pharma Limited,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-976-58)",Reverified,9/28/22,Inventory available,,,,Anesthesia,Current,,,43598-976-58,available
7668,Dexmedetomidine Injection,Gland Pharma Limited,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 43598-975-58)",Reverified,9/28/22,Inventory available,,,,Anesthesia,Current,,,43598-975-58,available
7669,Dexmedetomidine Injection,Hong Kong King Friend Industrial Co. Ltd.,"200 mcg/2 mL (100 mcg/mL) single dose vial, box of 25 (NDC 71288-505-03)",Reverified,4/7/22,Available,,,,Anesthesia,Current,,,71288-505-03,available
7670,Dexmedetomidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mcg/mL, 2 mL vial (NDC 0143-9532-25)",Reverified,4/8/22,Inventory is currently available,,,Demand increase for the drug,Anesthesia,Current,,,0143-9532-25,available
7671,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-239-93)",Reverified,4/21/22,Available,,,,Anesthesia,Current,,,16729-239-93,available
7672,Dexmedetomidine Injection,Accord Healthcare Inc.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 16729-432-93), Novaplus",Reverified,4/21/22,Available,,,,Anesthesia,Current,,,16729-432-93,available
7673,Dexmedetomidine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 55150-209-02)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-209-02,available
7674,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 0338-9555-24)",Reverified,9/28/22,Available,,,,Anesthesia,Current,,,0338-9555-24,available
7675,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 0338-9557-12)",Reverified,9/28/22,Available,,,,Anesthesia,Current,,,0338-9557-12,available
7676,Dexmedetomidine Injection,Baxter Healthcare,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 24 (NDC 43066-555-24), Novaplus",Reverified,9/28/22,Available,,,,Anesthesia,Current,,,43066-555-24,available
7677,Dexmedetomidine Injection,Baxter Healthcare,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bag, box of 12 (NDC 43066-557-12), Novaplus",Reverified,9/28/22,Available,,,,Anesthesia,Current,,,43066-557-12,available
7678,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 63323-671-20)",Reverified,9/14/22,Backordered. Next release September 2022.,,,Demand increase for the drug,Anesthesia,Current,,,63323-671-20,not available
7679,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 25 (NDC 63323-671-50)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-671-50,available
7680,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 63323-671-00)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-671-00,available
7681,Dexmedetomidine Injection,"Fresenius Kabi USA, LLC","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 63323-421-02)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-421-02,available
7682,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/4 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-600-04)",Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,44567-600-04,available
7683,Dexmedetomidine Injection,HQ Specialty Pharma,"1000 mcg/10 mL (100 mcg/mL), multi-dose vial, box of 4 (NDC 44567-601-04)",Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,44567-601-04,available
7684,Dexmedetomidine Injection,HQ Specialty Pharma,"200 mcg/50 mL (4 mcg/mL), single dose bag, box of 24 (NDC 44567-602-24)",Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,44567-602-24,available
7685,Dexmedetomidine Injection,HQ Specialty Pharma,"400 mcg/100 mL (4 mcg/mL), box of 24 (NDC 44567-603-24)",Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,44567-603-24,available
7686,Dexmedetomidine Injection,Jiangsu Hengrui Medicine Co. Ltd.,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 70860-605-03)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,70860-605-03,available
7687,Dexmedetomidine Injection,"Mylan Institutional, a Viatris company","200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 67457-251-02)",Revised,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-251-02,available
7688,Dexmedetomidine Injection,Par Pharmaceutical,"100 mcg/mL, 2 mL single dose vial, box of 25 (NDC 42023-146-25)",Reverified,9/21/22,Par Product Available – Please Check Wholesalers,,,,Anesthesia,Current,,,42023-146-25,unclear
7689,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"80 mcg/20 mL (4 mcg/mL) in 0.9% sodium chloride, single dose vial, box of 10 (NDC 0409-1660-20)",Revised,9/12/22,Depleted. Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-1660-20,not available
7690,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/50 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 20 (NDC 0409-1660-50)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia,Current,,,0409-1660-50,limited availability
7691,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"400 mcg/100 mL (4 mcg/mL) in 0.9% sodium chloride, single dose bottle, box of 10 (NDC 0409-1660-10)",Revised,9/12/22,Available,,,Other,Anesthesia,Current,,,0409-1660-10,available
7692,Dexmedetomidine Injection,Pfizer Pharmaceuticals,"200 mcg/2 mL (100 mcg/mL), single dose vial, box of 25 (NDC 0409-1638-02)",Revised,9/12/22,Available,,,Other,Anesthesia,Current,,,0409-1638-02,available
7693,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 50 mL single dose bottle, box of 20 (NDC 71225-126-05)",Revised,6/1/22,Available,,,,Anesthesia,Current,,,71225-126-05,available
7694,Dexmedetomidine Injection,Slayback Pharma,"4 mcg/mL in 0.9% sodium chloride, 100 mL single dose bottle, box of 10 (NDC 71225-126-06)",Revised,6/1/22,Available,,,,Anesthesia,Current,,,71225-126-06,available
7695,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"5 mg, 100s (NDC 0378-1070-01)",New,5/8/18,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,0378-1070-01,discontinued
7696,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"10 mg, 100s (NDC 0378-1071-01)",New,5/8/18,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,0378-1071-01,discontinued
7697,Dextroamphetamine Sulfate Extended-Release Capsules,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-1072-01)",New,5/8/18,,,,,Neurology;Pediatric;Psychiatry,To be Discontinued,,,0378-1072-01,discontinued
7698,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 250 mL Viaflex Plastic Container. Product Code 2B0162Q (NDC 0338-0023-02)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0023-02,available
7699,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 500 mL Viaflex Plastic Container. Product Code 2B0163Q (NDC 0338-0023-03)",Revised,9/28/22,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0023-03,available
7700,Dextrose 10% Injection,Baxter Healthcare,"10% Dextrose Injection, 1000 mL Viaflex Plastic Container. Product Code 2B0164X (NDC 0338-0023-04)",Revised,9/28/22,Available,,,Manufacturing Delay,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0023-04,available
7701,Dextrose 10% Injection,B. Braun Medical Inc.,10% 1000 mL Excel Bag L5200 (NDC 0264-7520-00),New,3/1/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-00,available
7702,Dextrose 10% Injection,B. Braun Medical Inc.,10% 500 mL Excel Bag L5201 (NDC 0264-7520-10),New,3/1/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-10,available
7703,Dextrose 10% Injection,B. Braun Medical Inc.,10% 250 mL Excel Bag L5202 (NDC 0264-7520-20),New,3/1/22,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-20,limited availability
7704,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (25 grams per 250 mL) (NDC 63323-824-74)",Reverified,9/14/22,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-824-74,not available
7705,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (50 grams per 500 mL) (NDC 63323-824-75)",Reverified,9/14/22,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-824-75,not available
7706,Dextrose 10% Injection,"Fresenius Kabi USA, LLC","10% Dextrose Injection, Single dose freeflex bag, (100 mg per mL), (100 grams per 1,000 mL) (NDC 63323-824-76)",Reverified,9/14/22,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-824-76,not available
7707,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 250 mL (Legacy Hospira NDC 0409-7930-02), (ICU Medical NDC 0990-7930-02)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7930-02,limited availability
7708,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7930-03), (ICU Medical NDC 0990-7930-03)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7930-03,limited availability
7709,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 1000 mL (Legacy Hospira NDC 0409-7930-09), (ICU Medical NDC 0990-7930-09)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7930-09,limited availability
7710,Dextrose 10% Injection,"ICU Medical, Inc.","10% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7938-19) (ICU Medical NDC 0990-7938-19)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7938-19,limited availability
7711,Dextrose 25% Injection,"Hospira, Inc., a Pfizer Company","2.5 g/10 mL (250 mg/mL), plastic syringe, 10 per bundle (NDC 0409-1775-10)",Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-1775-10,not available
7712,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",50 mL; ADD-Vantage Flexible Container (Case of 50)(NDC 0409-7100-66),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7100-66,limited availability
7713,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",100 mL; ADD-Vantage Flexible Container (Case of 50)(NDC 0409-7100-67),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7100-67,limited availability
7714,Dextrose 5% Injection,"Hospira, Inc., a Pfizer Company",250 mL; ADD-Vantage Flexible Container (Case of 24)(NDC 0409-7100-02),Revised,9/12/22,Available,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7100-02,available
7715,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (5 grams per 100 mL) (NDC 63323-624-61)",Revised,9/14/22,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-624-61,not available
7716,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (12.5 grams per 250 mL) (NDC 63323-624-74)",Revised,9/14/22,Backordered. Next release September 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-624-74,not available
7717,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (25 grams per 500 mL) (NDC 63323-624-75)",Revised,9/14/22,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-624-75,not available
7718,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (50 grams per 1,000 mL) (NDC 63323-624-10)",Revised,9/14/22,Available,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-624-10,available
7719,Dextrose 5% Injection,"Fresenius Kabi USA, LLC","5% Dextrose Injection, Single dose freeflex bag, (50 mg per mL), (2.5 grams per 50 mL) (NDC 63323-624-50)",Revised,9/14/22,Backordered. Next release October 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,63323-624-50,not available
7720,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 250 mL (Legacy Hospira NDC 0409-7922-02) (ICU Medical NDC 0990-7922-02)",Reverified,10/3/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-02,available
7721,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 150 mL (Legacy Hospira NDC 0409-7922-61) (ICU Medical NDC 0990-7922-61)",Reverified,10/3/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-61,available
7722,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL (Legacy Hospira NDC 0409-7923-13) (ICU Medical NDC 0990-7923-13)",Reverified,10/3/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-13,available
7723,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 25 mL 4-1 (Legacy Hospira NDC 0409-7923-20) (ICU Medical NDC 0990-7923-20)",Reverified,10/3/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-20,available
7724,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL (Legacy Hospira NDC 0409-7923-23) (ICU Medical NDC 0990-7923-23)",Reverified,10/3/22,Allocated to Contracted Customers Only,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-23,limited availability
7725,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL 4-1 (Legacy Hospira NDC 0409-7923-36) (ICU Medical NDC 0990-7923-36)",Reverified,10/3/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-36,available
7726,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL 4-1 (Legacy Hospira NDC 0409-7923-37) (ICU Medical NDC 0990-7923-37)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-37,limited availability
7727,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 25 mL VIAFLEX Plastic Container Quad Pack, Product Code 2B0080, (NDC 0338-0017-10)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-10,available
7728,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Product Code 2B0086, (NDC 0338-0017-41)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-41,available
7729,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B0081, (NDC 0338-0017-11)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-11,available
7730,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B0088, (NDC 0338-0017-31)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-31,available
7731,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Product Code 2B0087, (NDC 0338-0017-48)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-48,available
7732,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B0082, (NDC 0338-0017-18)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-18,available
7733,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B0089, (NDC 0338-0017-38)",Revised,9/28/22,"Limited Supply, Recovery late Sept 2022",,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-38,limited availability
7734,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL MINI-BAG Plus Container. Quad Pack, Product Code 2B0040, (NDC 0338-0551-11)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0551-11,available
7735,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 50 mL MINI-BAG Plus Container, Product Code EZPB0040, (NDC 0338-9143-30)",Revised,9/28/22,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-9143-30,limited availability
7736,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, Product Code EZPB0041, (NDC 0338-9147-30)",Revised,9/28/22,Available on allocation,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-9147-30,limited availability
7737,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 100 mL MINI-BAG Plus Container, Product Code 2B0041, (NDC 0338-0551-18)",Revised,9/28/22,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0551-18,available
7738,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 1000 mL VIAFLO Plastic Container, Product Code UE0064D, (NDC 0338-0070-10)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0070-10,available
7739,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLEX Plastic Container, Product Code 2B0062Q, (NDC 0338-0017-02)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-02,available
7740,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 250 mL VIAFLO Plastic Container, Product Code UE0062D, (NDC 0338-0062-30)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0062-30,available
7741,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLEX Plastic Container, Product Code 2B0063Q, (NDC 0338-0017-03)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0017-03,available
7742,Dextrose 5% Injection,Baxter Healthcare,"5% Dextrose Injection, USP, 500 mL VIAFLO Plastic Container, Product Code UE0063D, (NDC 0338-0066-20)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0338-0066-20,available
7743,Dextrose 5% Injection,B. Braun Medical Inc.,5% 500 mL Excel Bag L5101 (NDC 0264-7510-10),New,2/16/22,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7510-10,limited availability
7744,Dextrose 5% Injection,B. Braun Medical Inc.,5% 1000 mL Excel Bag L5100 (NDC 0264-7510-00),New,2/16/22,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7510-00,limited availability
7745,Dextrose 5% Injection,B. Braun Medical Inc.,5% 250 mL Excel Bag L5102 (NDC 0264-7510-20),New,2/16/22,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7510-20,limited availability
7746,Dextrose 5% Injection,B. Braun Medical Inc.,5% 100 mL PAB Bag S5104-5264 (NDC 0264-1510-32),New,2/16/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-1510-32,available
7747,Dextrose 5% Injection,B. Braun Medical Inc.,5% 50 mL PAB Bag S5104-5364 (NDC 0264-1510-31),New,2/16/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-1510-31,available
7748,Dextrose 5% Injection,B. Braun Medical Inc.,10% 1000 mL Excel Bag L5200 (NDC 0264-7520-00),New,2/16/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-00,available
7749,Dextrose 5% Injection,B. Braun Medical Inc.,10% 500 mL Excel Bag L5201 (NDC 0264-7520-10),New,2/16/22,Product available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-10,available
7750,Dextrose 5% Injection,B. Braun Medical Inc.,10% 250 mL Excel Bag L5202 (NDC 0264-7520-20),New,2/16/22,Product on allocation for contracted customers,,,Other,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0264-7520-20,limited availability
7751,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7922-03) (ICU Medical NDC 0990-7922-03)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-03,available
7752,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 500 mL (Legacy Hospira NDC 0409-7922-55) (ICU Medical NDC 0990-7922-55)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-55,available
7753,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 50 mL VisIV™ Container (Legacy Hospira NDC 0409-7923-06) (ICU Medical NDC 0990-7923-06)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-06,available
7754,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 100 mL VisIV™ Container (Legacy Hospira NDC 0409-7923-11) (ICU Medical NDC 0990-7923-11)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7923-11,available
7755,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 250 mL VisIV™ Container (Legacy Hospira NDC 0409-7922-25) (ICU Medical NDC 0990-7922-25)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-25,available
7756,Dextrose 5% Injection,"ICU Medical, Inc.","5% Dextrose Injection, USP, 1000 mL (Legacy Hospira NDC 0409-7922-09) (ICU Medical NDC 0990-7922-09)",Reverified,10/3/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Other;Pediatric,Current,,,0409-7922-09,available
7757,Dextrose 50% Injection,"Amphastar Pharmaceuticals, Inc./IMS","25 g/50 mL (0.5 g/mL), syringe, 10 per carton (NDC 76329-3302-1) (old NDC 76329-3301-1)",Reverified,8/12/22,Backorder due to increase in demand,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,76329-3302-1,not available
7758,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), plastic syringe, 10 per bundle (NDC 0409-7517-16)",Revised,9/30/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-7517-16,limited availability
7759,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), glass syringe, 10 per bundle (NDC 0409-4902-34)",Revised,9/30/22,Next Delivery: October 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-4902-34,not available
7760,Dextrose 50% Injection,"Hospira, Inc.","25 g/50 mL (0.5 g/mL), single dose vial, 25 per tray (NDC 0409-6648-02)",Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: July 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6648-02,not available
7761,Diazepam Oral Solution (Concentrate),"Lannett Company, Inc.",5 mg/mL (NDC 0527-1768-36),New,1/5/22,,,,,Neurology,To be Discontinued,,,0527-1768-36,discontinued
7762,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel - 10mg 2 Syrg per pack, (NDC 68682-652-20)",Revised,9/22/22,Available,Estimated availability September 2022,,,Neurology,Current,,,68682-652-20,available
7763,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel – 2.5mg 2 Syrg per pack, (NDC 68682-650-20)",Revised,9/22/22,Currently unavailable,Estimated availability: TBD,,,Neurology,Current,,,68682-650-20,not available
7764,Diazepam Rectal Gel,Bausch Health,Diastat Rectal Gel 2.5mg (NDC  66490-650-20),Revised,9/22/22,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,66490-650-20,discontinued
7765,Diazepam Rectal Gel,Bausch Health,Diastat Acudial 10 mg (NDC 0187-0658-20),Revised,9/22/22,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,0187-0658-20,discontinued
7766,Diazepam Rectal Gel,Bausch Health,Diastat Acudial 20 mg (NDC 0187-0659-20),Revised,9/22/22,No longer available,No plans to manufacture.  All volumes converted to generic version,,,Neurology,Current,,,0187-0659-20,discontinued
7767,Diazepam Rectal Gel,Bausch Health,"Diazepam Rectal Gel - 20mg 2 Syrg per pack, (NDC 68682-655-20)",Revised,9/22/22,Available,,,,Neurology,Current,,,68682-655-20,available
7768,Diclofenac Sodium Extended Release Tablets,Mylan Pharmaceuticals Inc.,100 mg (NDC 0378-0355-01),New,4/4/18,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,0378-0355-01,discontinued
7769,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 200 mg, 30 count bottles (NDC 0555-0588-01)",New,5/9/18,,,,,Antiviral,To be Discontinued,,,0555-0588-01,discontinued
7770,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 250 mg, 30 count bottles (NDC 0555-0589-01)",New,5/9/18,,,,,Antiviral,To be Discontinued,,,0555-0589-01,discontinued
7771,Didanosine Delayed-Release Capsules USP,Teva Pharmaceuticals,"Didanosine Delayed-Release Capsules, USP, 400 mg, 30 count bottles (NDC 0555-0590-01)",New,5/9/18,,,,,Antiviral,To be Discontinued,,,0555-0590-01,discontinued
7772,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",15g (NDC 52565-063-15),New,7/6/21,,,,,Dermatology,To be Discontinued,,,52565-063-15,discontinued
7773,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",30g (NDC 52565-063-30),New,7/6/21,,,,,Dermatology,To be Discontinued,,,52565-063-30,discontinued
7774,"Diflorasone Diacetate Ointment, 0.05%","Teligent Pharma, Inc.",60g (NDC 52565-063-60),New,7/6/21,,,,,Dermatology,To be Discontinued,,,52565-063-60,discontinued
7775,Diflunisal Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","500 mg, Bottle of 60 (NDC 14539-673-06)",Revised,9/7/22,"Product is available, on allocation",,,Demand increase for the drug,Analgesia/Addiction,Current,,,14539-673-06,limited availability
7776,Diflunisal Tablets,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","500 mg, Bottle of 100 (NDC 14539-673-01)",Revised,9/7/22,"Product is available, on allocation",,,Demand increase for the drug,Analgesia/Addiction,Current,,,14539-673-01,limited availability
7777,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 100 (NDC 0093-9222-01)",Revised,10/5/22,Available,,,Other,Analgesia/Addiction,Current,,,0093-9222-01,available
7778,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 500 (NDC 0093-9222-05)",Revised,10/5/22,"Backorder, Recovery expected Jan-23",,,Other,Analgesia/Addiction,Current,,,0093-9222-05,not available
7779,Diflunisal Tablets,Teva Pharmaceuticals,"500 mg, Bottle of 60 (NDC 0093-9222-06)",Revised,10/5/22,Available,,,Other,Analgesia/Addiction,Current,,,0093-9222-06,available
7780,Difluprednate (Durezol) Ophthalmic Emulsion,Novartis,0.05% 5mL in 8mL bottle (NDC 0065-9204-07),Revised,10/15/19,,,,,Ophthalmology,Resolved,,,0065-9204-07,
7781,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) Ampule (NDC 0515-260-10),Revised,10/6/21,Available,,,Delay in shipping of the drug,Cardiovascular,Current,,,0515-260-10,available
7782,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Adult (500mcg in 2ml) vial (NDC 70515-261-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-261-10,available
7783,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) ampoule (NDC 70515-262-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-262-10,available
7784,Digoxin Injection,Covis Pharma,Lanoxin (digoxin) Injection Pediatric (100mcg in 1ml) vial (NDC 70515-263-10),Revised,10/6/21,Available,,,,Cardiovascular,Current,,,70515-263-10,available
7785,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","250 mcg/mL, 2 mL  (NDC 0641-1410-35)",Reverified,4/8/22,Inventory is currently available,,,Other,Cardiovascular,Current,,,0641-1410-35,available
7786,Digoxin Injection,Sandoz,500mcg/2 mL; 10 ampules (NDC 0781-3059-95),Reverified,10/3/22,"Unavailable, resupply Q4 2022/Q1 2023",,,Shortage of an active ingredient,Cardiovascular,Current,,,0781-3059-95,not available
7787,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-1171-02),New,6/8/21,,,,,Cardiovascular,To be Discontinued,,,0409-1171-02,discontinued
7788,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",New,4/8/22,,,,,Cardiovascular,To be Discontinued,,,17478-0937-25,discontinued
7789,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",New,4/8/22,,,,,Cardiovascular,To be Discontinued,,,17478-0937-26,discontinued
7790,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",New,4/8/22,,,,,Cardiovascular,To be Discontinued,,,17478-0937-05,discontinued
7791,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",25 mg/5mL vial (NDC 70860-301-05),Reverified,9/28/22,On allocation,,,,Cardiovascular,Current,,,70860-301-05,limited availability
7792,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",50 mg/10mL vial (NDC 70860-301-10),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-301-10,available
7793,Diltiazem Hydrochloride Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",125 mg/25mL vial (NDC 70860-301-25),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-301-25,available
7794,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 5 mL vial  (NDC 0641-6013-10)",Revised,8/26/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6013-10,available
7795,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial (NDC 0641-6014-10)",Revised,8/26/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6014-10,available
7796,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 30 mL vial (NDC 0641-6015-10)",Revised,8/26/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-6015-10,available
7797,Diltiazem Hydrochloride Injection,"Hospira, Inc.",100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-4350-03,limited availability
7798,Diltiazem Hydrochloride Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,00409-1171-02,discontinued
7799,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10)",Revised,4/8/22,"On allocation, then discontinued.",,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,17478-0937-10,discontinued
7800,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25)",Revised,4/8/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,17478-0937-25,discontinued
7801,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26)",Revised,4/8/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,17478-0937-26,discontinued
7802,Diltiazem Hydrochloride Injection,Akorn Pharmaceuticals,"Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05)",Revised,4/8/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,17478-0937-05,discontinued
7803,Dimercaprol (Bal in Oil) Injection,Akorn Pharmaceuticals,"3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03)",Revised,6/29/21,,,Available,,Hematology;Other,Resolved,,,17478-526-03,
7804,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 59762-0386-1)",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,59762-0386-1,available
7805,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 59762-0400-1)",Reverified,9/12/22,Next Delivery & Recovery: October 2022,,,,Cardiovascular,Current,,,59762-0400-1,not available
7806,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"100 mg capsules, bottle of 100 (NDC 0093-3127-01)",Reverified,10/5/22,Product is Available,,,,Cardiovascular,Current,,,0093-3127-01,available
7807,Disopyramide Phosphate (Norpace) Capsules,Teva Pharmaceuticals,"150 mg capsules, bottle of 100 (NDC 0093-3129-01)",Reverified,10/5/22,"Backorder, Recovery expected March 2023",,,,Cardiovascular,Current,,,0093-3129-01,not available
7808,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 100 mg capsules, bottle of 100 (NDC 0025-2732-31)",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,0025-2732-31,available
7809,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace CR, 150 mg capsules, bottle of 100 (NDC 0025-2742-31)",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,0025-2742-31,available
7810,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 100 mg capsules; bottle of 100 (NDC 0025-2752-31)",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,0025-2752-31,available
7811,Disopyramide Phosphate (Norpace) Capsules,Pfizer Pharmaceuticals,"Norpace IR, 150 mg capsules; bottle of 100 (NDC 0025-2762-31)",Reverified,9/12/22,Next Delivery and Estimated Recovery: September 2022,,,,Cardiovascular,Current,,,0025-2762-31,not available
7812,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"250 mg, 100s (NDC 0378-4140-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-4140-01,discontinued
7813,Disulfiram Tablets,Mylan Pharmaceuticals Inc.,"500 mg, 100s (NDC 0378-4141-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-4141-01,discontinued
7814,Dobutamine Hydrochloride Injection,Baxter Healthcare,"250 mg/250 mL (NDC 0338-1073-02) Product code 2B0791, 500 mg/250 mL (NDC 0338-1075-02) Product code 2B0792, 1000 mg/250 mL (NDC 0338-1077-02) Product code 2B0793",Reverified,9/28/22,"Limited Supply on Allocation, Recovery Q4",Third-Party Supplier Issue,,Third-Party Supplier Issue,Cardiovascular;Pediatric;Renal,Current,,,0338-1073-02,limited availability
7815,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/250 mL (1 mg/mL); Flexible Container (NDC 00409-2346-32),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2346-32,not available
7816,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/250 mL (2 mg/mL); Flexible Container (NDC 00409-2347-32),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2347-32,not available
7817,Dobutamine Hydrochloride Injection,"Hospira, Inc.",1000 mg/250 mL (4 mg/mL); Flexible Container (NDC 00409-3724-32),Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-3724-32,not available
7818,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-20),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-20,discontinued
7819,Dobutamine Hydrochloride Injection,"Hospira, Inc.",500 mg/40 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2025-54),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular;Pediatric;Renal,Current,,,00409-2025-54,discontinued
7820,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-01),Revised,9/12/22,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-01,limited availability
7821,Dobutamine Hydrochloride Injection,"Hospira, Inc.",250 mg/20 mL (12.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2344-02),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pediatric;Renal,Current,,,00409-2344-02,limited availability
7822,Dofetilide Capsules,Pfizer Pharmaceuticals,125 mcg (0.125 mg) capsules; Bottle of 60 (NDC 59762-0037-2),New,5/21/21,,,,,Cardiovascular,To be Discontinued,,,59762-0037-2,discontinued
7823,Dofetilide Capsules,Pfizer Pharmaceuticals,250 mcg (0.25 mg) capsules; Bottle of 60 (NDC 59762-0038-2),New,5/21/21,,,,,Cardiovascular,To be Discontinued,,,59762-0038-2,discontinued
7824,Dofetilide Capsules,Pfizer Pharmaceuticals,500 mcg (0.5 mg) capsules; Bottle of 60 (NDC 59762-0039-2),New,5/21/21,,,,,Cardiovascular,To be Discontinued,,,59762-0039-2,discontinued
7825,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 5 mL vial (NDC 0143-9252-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9252-25,not available
7826,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg/mL, 10 mL vial (NDC 0143-9254-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9254-25,not available
7827,Dopamine Hydrochloride Injection,"Hospira, Inc.","400 mg/250 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-22)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Cardiovascular,Current,,,00409-7809-22,limited availability
7828,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/500 mL (1,600 mcg/mL); Flexible Container (NDC 00409-7809-24)",Revised,9/12/22,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,00409-7809-24,not available
7829,Dopamine Hydrochloride Injection,"Hospira, Inc.","800 mg/250 mL (3,200 mcg/mL); Flexible Container (NDC 00409-7810-22)",Revised,9/12/22,Next Delivery and Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,00409-7810-22,not available
7830,Dopamine Hydrochloride Injection,"Hospira, Inc.",200 mg/5 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-5820-01),Revised,9/12/22,Available,,,Other,Cardiovascular,Current,,,00409-5820-01,available
7831,Dopamine Hydrochloride Injection,"Hospira, Inc.",400 mg/10 mL (40 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9104-20),Revised,9/12/22,Available,,,Demand increase for the drug,Cardiovascular,Current,,,00409-9104-20,available
7832,Dopamine Hydrochloride Injection,Baxter Healthcare,"800 mcg/mL (250 mL bag) Product code 2B0832 (NDC 0338-1005-02), 800 mcg/mL (500 mL bag)  Product code 2B0833 (NDC 0338-1005-03), 1600 mcg/mL (250 mL bag) Product code 2B0842 (NDC 0338-1007-02), 1600 mcg/mL (500 mL bag) Product code 2B0843 (NDC 0338-1007-0",Revised,8/12/22,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
7833,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 17478-605-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,17478-605-10,
7834,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 50383-233-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,50383-233-10,
7835,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Akorn Pharmaceuticals,"Cosopt-PF® dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 0.2 mL single use, 60 count (NDC 17478-604-30)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,17478-604-30,
7836,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 61314-030-02)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,61314-030-02,
7837,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 24208-486-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,24208-486-10,
7838,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Aurobindo Pharma,"Dorzolamide HCl and Timolol Maleate (Cosopt® PF) Ophthalmic Solution 2%/0.5% Preservative Free, 2mL single use container (NDC 65862-0947-60)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,65862-0947-60,
7839,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL and Timolol maleate 6.8 mg/mL, 10 mL (NDC 0591-2482-79)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,0591-2482-79,
7840,Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide Hydrochloride and Timolol Maleate 20 mg and 5 mg/mL, 10 mL (0591-2482-79)",New,4/20/18,,,,,Ophthalmology,To be Discontinued,,,,discontinued
7841,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0591-2481-79)",New,4/20/18,,,,,Ophthalmology,To be Discontinued,,,0591-2481-79,discontinued
7842,Dorzolamide Hydrochloride Ophthalmic Solution,Teva Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 0093-7618-43)",New,4/20/18,,,,,Ophthalmology,To be Discontinued,,,0093-7618-43,discontinued
7843,Dorzolamide Hydrochloride Ophthalmic Solution,Sandoz,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 61314-019-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,61314-019-10,
7844,Dorzolamide Hydrochloride Ophthalmic Solution,Akorn Pharmaceuticals,"Dorzolamide hydrochloride 22.3 mg/mL, 10 mL (NDC 50383-232-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,50383-232-10,
7845,Dorzolamide Hydrochloride Ophthalmic Solution,Merck Sharp & Dohme Corp.,"Trusopt® Dorzolamide hydrochloride ophthalmic solution 2%, for topical ophthalmic use 10ml, (NDC 0006-3519-36)",New,4/11/22,,,,,Ophthalmology,To be Discontinued,,,0006-3519-36,discontinued
7846,Dorzolamide Hydrochloride Ophthalmic Solution,Bausch Health,"Dorzolamide hydrochloride USP 2%, 10 mL (NDC 24208-485-10)",Revised,5/10/21,,,Available,,Ophthalmology,Resolved,,,24208-485-10,
7847,Doxepin Hydrochloride Oral Solution,Wockhardt Bio A.G.,"10gm/mL, 118 mL (NDC 60432-651-04)",New,7/26/22,,Discontinuing the manufacture of the product due to business reasons,,,Neurology,To Be Discontinued,7/26/22,7/26/22,60432-651-04,discontinued
7848,Doxercalciferol Injection,Hospira,4 mcg/2 mL (2 mcg/mL) Multiple-Dose Vial (NDC 00409-1330-01),New,9/12/22,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To be Discontinued,9/12/22,9/12/22,00409-1330-01,discontinued
7849,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",50mg  (NDC 49884-726-01),New,6/28/22,,,,,Anti-Infective,To be Discontinued,,,49884-726-01,discontinued
7850,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",100mg  (NDCs 49884-0727-03 and 49884-0727-04),New,6/28/22,,,,,Anti-Infective,To be Discontinued,,,,discontinued
7851,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",150mg  (NDC 49884-0305-02),New,6/28/22,,,,,Anti-Infective,To be Discontinued,,,49884-0305-02,discontinued
7852,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",50mg (NDC 49884-726-01),New,1/31/22,,,,,Anti-Infective,To be Discontinued,,,49884-726-01,discontinued
7853,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",100mg (NDCs 49884-727-03 and 49884-727-04),New,1/31/22,,,,,Anti-Infective,To be Discontinued,,,,discontinued
7854,Doxycycline Capsules,"Endo Pharmaceuticals, Inc.",150mg (NDC 49884-305-02),New,1/31/22,,,,,Anti-Infective,To be Discontinued,,,49884-305-02,discontinued
7855,Doxycycline Hyclate Powder for Suspension,"Hospira, Inc.",25mg/5mL (NDC 0069-0970-65),New,11/15/21,,,,,Anti-Infective,To be Discontinued,,,0069-0970-65,discontinued
7856,Doxycycline Hyclate Tablets,Teva Pharmaceuticals,"75 mg tablets, 60 count (NDC 0591-6100-60)",Revised,6/22/22,,,,,Anti-Infective,To be Discontinued,,,0591-6100-60,discontinued
7857,Doxycycline Hyclate Tablets,Teva Pharmaceuticals,150mg  (NDC 0591-6125-60),New,6/21/22,,,,,Anti-Infective,To be Discontinued,,,0591-6125-60,discontinued
7858,Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution,Fera Pharmaceuticals,Phospholine Iodide 0.125% echothiophate iodide for ophthalmic solution 5ml (NDC 48102-053-05),Revised,6/1/22,"Available starting June 1st, 2022 through limited distribution by AllianceRx Walgreens Prime Specialty Pharmacy.",,,Delay in manufacturing,Ophthalmology,Current,,,48102-053-05,limited availability
7859,Efavirenz Capsules,Bristol-Myers Squibb Co.,50mg (NDC 0056-0470-30),New,9/28/22,,"Product available until March 31, 2023.",,,Antiviral,To be Discontinued,9/28/22,9/28/22,0056-0470-30,discontinued
7860,Efavirenz Capsules,Bristol-Myers Squibb Co.,200mg (NDC 0056-0474-92),New,9/28/22,,"Product available until March 31, 2023.",,,Antiviral,To be Discontinued,9/28/22,9/28/22,0056-0474-92,discontinued
7861,Efavirenz Tablets,"Mylan Specialty, a Viatris Company",600 mg (NDC 0378-2233-93),New,11/2/21,,,,,Antiviral,To be Discontinued,,,0378-2233-93,discontinued
7862,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2.5mg/2mL, vial (NDC 0143-9786-10)",Reverified,4/8/22,This presentation is currently available.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9786-10,available
7863,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1.25mg/mL, vial  (NDC 0143-9787-10)",Reverified,4/8/22,This presentation is currently available.,,,Demand increase for the drug,Cardiovascular,Current,,,0143-9787-10,available
7864,"Epinephrine Injection, 0.1 mg/mL","Hospira, Inc.",1 mg/10 mL (0.1 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4933-01),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular;Pulmonary/Allergy,Current,,,0409-4933-01,not available
7865,"Epinephrine Injection, 0.1 mg/mL","Amphastar Pharmaceuticals, Inc./IMS","0.1mg/mL, 10mL, (NDC 76329-3316-1)",Reverified,8/12/22,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular;Pulmonary/Allergy,Current,,,76329-3316-1,not available
7866,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.3 mg EpiPen® (NDC 49502-500-02); Authorized Generic (NDC 49502-102-02),Reverified,9/28/22,Available,,,,Pulmonary/Allergy,Current,,,49502-500-02,available
7867,"Epinephrine Injection, Auto-Injector","Mylan Specialty, a Viatris Company",0.15 mg EpiPen® (NDC 49502-501-02); Authorized Generic (NDC 49502-101-02),Reverified,9/28/22,Available,,,,Pulmonary/Allergy,Current,,,49502-501-02,available
7868,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)",Revised,10/3/22,Available,,,,Pulmonary/Allergy,Current,,,0115-1695-49,available
7869,"Epinephrine Injection, Auto-Injector",Impax Laboratories,"0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)",Revised,10/3/22,Available,,,,Pulmonary/Allergy,Current,,,0115-1694-49,available
7870,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)",Reverified,1/27/21,Available,,,,Pulmonary/Allergy,Current,,,60842-023-01,available
7871,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)",Reverified,1/27/21,Available,,,,Pulmonary/Allergy,Current,,,60842-022-01,available
7872,"Epinephrine Injection, Auto-Injector",Kaleo,"Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)",Reverified,1/27/21,Available,,,,Pulmonary/Allergy,Current,,,60842-021-01,available
7873,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)",Reverified,10/5/22,Available,,,,Pulmonary/Allergy,Current,,,0093-5986-27,available
7874,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.3 mg single-dose, pre-filled syringes (NDC 78670-130-02))",Revised,5/19/22,Available,,,,Pulmonary/Allergy,Current,,,78670-130-02,available
7875,"Epinephrine Injection, Auto-Injector",Adamis Pharmaceuticals Corporation,"Carton containing two SYMJEPI (epinephrine injection, USP) 0.15 mg single-dose, pre-filled syringes (NDC 78670-131-02)",Revised,5/19/22,Available,,,,Pulmonary/Allergy,Current,,,78670-131-02,available
7876,"Epinephrine Injection, Auto-Injector",Teva Pharmaceuticals,"0.15 MG Epinephrine Injection, USP auto-injector (NDC 0093-5985-27)",Reverified,10/5/22,Available,,,,Pulmonary/Allergy,Current,,,0093-5985-27,available
7877,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,NDC 0703-9258-09 ( 2 x 50 mL vials Sterile Diluent),New,9/12/22,,Product is available with an expected supply duration until AUG' 2022.  No future production expected for an extended period.,,,,To be Discontinued,9/12/22,9/12/22,0703-9258-09,discontinued
7878,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,"NDC 0703-1985-01 (0.5 mg/vial (500,000 ng))",New,9/12/22,,Product is unavailable and no future production expected for an extended period.,,,,To be Discontinued,9/12/22,9/12/22,0703-1985-01,discontinued
7879,Epoprostenol Sodium for Injection and Sterile Diluent for Epoprostenol Sodium for Injection,Teva,"NDC 0703-1995-01 (1.5 mg/vial (1,500,000 ng))",New,9/12/22,,Product is unavailable and no future production expected for an extended period.,,,,To be Discontinued,9/12/22,9/12/22,0703-1995-01,discontinued
7880,Eptifibatide Injection,Teva Pharmaceuticals,"0.75 mg/mL, 75 mg, 100 mL/Vial (NDC 0703-1179-01)",New,9/13/22,,Product has not been marketed for at least 5 years,,,Cardiovascular,To be Discontinued,9/13/22,9/13/22,0703-1179-01,discontinued
7881,Ergotamine Tartrate and Caffeine (Cafergot) Tablets,Sandoz,1mg/100mg (NDC 0781-5405-01),New,7/2/20,,,,,Neurology,To be Discontinued,,,0781-5405-01,discontinued
7882,Ertapenem Injection,"Merck Sharp & Dohme Corp. a subsidiary of Merck and Co., Inc.",1g (NDC 0006-3843-71),New,8/2/22,,,,,Anti-Infective,To Be Discontinued,8/2/22,8/2/22,0006-3843-71,discontinued
7883,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35),Revised,8/1/22,Unavailable. Estimated availability 1Q2023.,New manufacturing site being qualified.,,Discontinuation of manufacture of the drug (from existing site).,Ophthalmology; Pediatric,Current,,,17478-070-35,not available
7884,Erythromycin Ophthalmic Ointment,Akorn Pharmaceuticals,Erythromycin Ophthalmic Ointment 0.5%: 1 g tube (unit dose) (NDC17478-070-31),Revised,8/1/22,Unavailable. Estimated availability 1Q2023.,New manufacturing site being qualified.,,Discontinuation of manufacture of the drug (from existing site).,Ophthalmology; Pediatric,Current,,,,not available
7885,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 1 gram, 50-count (00574-4024-50)",Revised,8/1/22,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,available
7886,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 1-count (00574-4024-35)",Revised,8/1/22,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,available
7887,Erythromycin Ophthalmic Ointment,Bausch Health,"Erythromycin Ophthalmic Ointment USP, 0.5% 3.5 g in 1 tube (NDC 24208-910-55)",Revised,8/1/22,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,24208-910-55,limited availability
7888,Erythromycin Ophthalmic Ointment,Padagis US LLC,"Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 24-count (00574-4024-39)",Revised,8/1/22,Available and shipping,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,,available
7889,Erythromycin Ophthalmic Ointment,Bausch Health,"Erythromycin Ophthalmic Ointment USP, 0.5% 1 g in carton of 50 (NDC 24208-910-19)",Revised,8/1/22,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,24208-910-19,limited availability
7890,Esomeprazole Sodium for Injection,"Mylan Institutional, a Viatris company","40 mg vial, box of 10 (NDC 67457-392-99)",New,9/16/21,,,,,Gastroenterology;Pediatric,To be Discontinued,,,67457-392-99,discontinued
7891,Ethambutol Hydrochloride Tablets,Teva Pharmaceuticals,400mg  (NDC 0555-0923-02),New,11/5/21,,,,,Anti-Infective,To be Discontinued,,,0555-0923-02,discontinued
7892,Etomidate Injection,"Avet Pharmaceuticals, Inc.",20 mg/10mL carton of 10 (NDC 23155-160-41),New,10/5/22,Product available upon request,,,,Anesthesia,Current,,,23155-160-41,limited availability
7893,Etomidate Injection,"Avet Pharmaceuticals, Inc.",40 mg/20 mL carton of 10 (NDC 23155-160-42),New,10/5/22,Product available upon request,,,,Anesthesia,Current,,,23155-160-42,limited availability
7894,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 20 mL vial (NDC 25021-674-20)",New,10/5/22,Available,Marketed by Sagent,,,Anesthesiology,Current,,,25021-674-20,available
7895,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 72572-160-10)",New,10/5/22,Pending information,Distributed by Civica,,,Anesthesiology,Current,,,72572-160-10,unclear
7896,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 72572-161-10)",New,10/5/22,Pending information,Distributed by Civica,,,Anesthesiology,Current,,,72572-161-10,unclear
7897,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 10 mL vial (NDC 65219-445-10)",New,10/5/22,Available,Marketed by Fresenius Kabi,,,Anesthesiology,Current,,,65219-445-10,available
7898,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 20 mL vial (NDC 65219-447-20)",New,10/5/22,Available,Marketed by Fresenius Kabi,,,Anesthesiology,Current,,,65219-447-20,available
7899,Etomidate Injection,"Caplin Steriles, Ltd.","2 mg/mL, 10 mL vial (NDC 25021-674-10)",New,10/5/22,Available,Marketed by Sagent,,,Anesthesiology,Current,,,25021-674-10,available
7900,Etomidate Injection,"Eugia US, LLC (formerly AuroMedics Pharma LLC) [mfd. by Eugia Pharma Specialties, Ltd.)","2 mg/mL, 10 mL vial (NDC 55150-221-10)",New,10/5/22,Currently on backorder,Next shipment anticipated in Oct.,,Other,Anesthesiology,Current,,,55150-221-10,not available
7901,Etomidate Injection,"Eugia US, LLC (formerly AuroMedics Pharma LLC) [mfd. by Eugia Pharma Specialties, Ltd.)","2 mg/mL, 20 mL vial (NDC 55150-222-10)",New,10/5/22,Currently on backorder,Next shipment TBD,,Other,Anesthesiology,Current,,,55150-222-10,not available
7902,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 10 mL vial (NDC 72266-146-10)",New,10/5/22,Pending information,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesiology,Current,,,72266-146-10,unclear
7903,Etomidate Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-147-10)",New,10/5/22,Pending information,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesiology,Current,,,72266-147-10,unclear
7904,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9506-10)",New,10/5/22,Currently on backorder,,,Demand increase for the drug,Anesthesiology,Current,,,0143-9506-10,not available
7905,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9507-10)",New,10/5/22,Currently on backorder,,,Demand increase for the drug,Anesthesiology,Current,,,0143-9507-10,not available
7906,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 10 mL vial (NDC 0143-9310-10), Novaplus",New,10/5/22,Pending information,,,,Anesthesiology,Current,,,0143-9310-10,unclear
7907,Etomidate Injection,"Hikma Pharmaceuticals, LLC (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9311-10), Novaplus",New,10/5/22,Pending information,,,,Anesthesiology,Current,,,0143-9311-10,unclear
7908,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 10 mL vial (NDC 67457-902-10)",New,10/5/22,Q1 2023,,,Demand increase for the drug,Anesthesiology,Current,,,67457-902-10,unclear
7909,Etomidate Injection,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg/mL, 20 mL vial (NDC 67457-903-20)",New,10/5/22,Available,,,,Anesthesiology,Current,,,67457-903-20,available
7910,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, 2 mg/mL, 10 mL vial (NDC 0409-6695-01)",New,10/5/22,Next delivery: March 2023; Estimated recovery: December 2023,Manufacturing Delay,,Other,Anesthesiology,Current,,,0409-6695-01,not available
7911,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, 2 mg/mL, 20 mL vial (NDC 0409-6695-02)",New,10/5/22,Next delivery: February 2023; Estimated recovery: March 2023,Manufacturing Delay,,Other,Anesthesiology,Current,,,0409-6695-02,not available
7912,Etoposide (Toposar) Injection,Teva,NDC 0703-5653-01 (100 mg/5 mL (20 mg/mL) 5 mL Multiple-dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-5653-01,discontinued
7913,Etoposide (Toposar) Injection,Teva,NDC 0703-5656-01 (500 mg/25 mL (20 mg/mL) 25 mL Multiple-dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-5656-01,discontinued
7914,Etoposide (Toposar) Injection,Teva,DC 0703-5657-01 (1 gram/50 mL (20 mg/mL) 50 mL Multiple-dose Vial ),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,,discontinued
7915,Exenatide (BYDUREON) Extended Release for Injectable Suspension,AstraZeneca,"BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use;  Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)",New,4/3/18,,,,,Endocrinology/Metabolism,To be Discontinued,,,0310-6520-04,discontinued
7916,Famotidine Injection,Baxter Healthcare,"Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41)",Reverified,9/28/22,"Stocked Out, Recovery Q4",,Available,,Gastroenterology,Resolved,,,0338-5197-41,not available
7917,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 2 mL vial (NDC 0641-6022-25)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0641-6022-25,
7918,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 4 mL vial (NDC 0641-6023-25)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0641-6023-25,
7919,Famotidine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6021-10)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0641-6021-10,
7920,Famotidine Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,63323-739-12,
7921,Famotidine Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,63323-738-09,
7922,Famotidine Injection,"Fresenius Kabi USA, LLC","200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,63323-738-20,
7923,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,67457-457-20,
7924,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 70860-751-02 and 41)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,70860-751-02,
7925,Famotidine Injection,"Athenex Pharmaceutical Division, LLC (Athenex)","200 mg per 20 mL(10 mg per mL), multiple dose vial with preservatives, (NDC 70860-751-20 and 41)",Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,70860-751-20,
7926,Famotidine Injection,"Mylan Institutional, a Viatris company",Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,67457-433-22,
7927,Famotidine Tablets,Teva Pharmaceuticals,20 MG 100 Count (NDC 0172-5728-60),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0172-5728-60,
7928,Famotidine Tablets,Teva Pharmaceuticals,20 MG 1000 Count (NDC 0172-5728-80),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0172-5728-80,
7929,Famotidine Tablets,Teva Pharmaceuticals,20 MG 500 Count (NDC 0172-5728-70),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0172-5728-70,
7930,Famotidine Tablets,Teva Pharmaceuticals,40 MG 100 Count (NDC 0172-5729-60),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0172-5729-60,
7931,Famotidine Tablets,Teva Pharmaceuticals,40 MG 500 Count (NDC 0172-5729-70),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,0172-5729-70,
7932,Famotidine Tablets,Aurobindo Pharma,20 mg - 100/Bottle (NDC 65862-859-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,65862-859-01,
7933,Famotidine Tablets,Aurobindo Pharma,40 mg - 100/Bottle (NDC 65862-860-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,65862-860-01,
7934,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 100 counts (NDC 62332-001-31),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,62332-001-31,
7935,Famotidine Tablets,Alembic Pharmaceuticals,20 mg Bottle of 1000 counts (NDC 62332-001-91),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,62332-001-91,
7936,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 100 counts (NDC 62332-002-31),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,62332-002-31,
7937,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 500 counts (NDC 62332-002-71),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,62332-002-71,
7938,Famotidine Tablets,Alembic Pharmaceuticals,40 mg Bottle of 1000 counts (NDC 62332-002-91),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,62332-002-91,
7939,Famotidine Tablets,"Carlsbad Technology, Inc.",20mg 100 count (NDC 61442-121-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,61442-121-01,
7940,Famotidine Tablets,"Carlsbad Technology, Inc.",20 mg 1000 count (NDC 61442-121-10),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,61442-121-10,
7941,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 100 count (NDC 61442-122-01),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,61442-122-01,
7942,Famotidine Tablets,"Carlsbad Technology, Inc.",40 mg 1000 count (NDC 61442-122-10),Revised,11/10/21,,,Available,,Gastroenterology,Resolved,,,61442-122-10,
7943,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40 mg (NDC 55111-796-30),New,11/22/21,,,,,Rheumatology,To be Discontinued,,,55111-796-30,discontinued
7944,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80 mg (NDC 55111-797-30),New,11/22/21,,,,,Rheumatology,To be Discontinued,,,55111-797-30,discontinued
7945,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",40mg  (NDC NDC 55111-796-30),New,11/30/21,,,,,Rheumatology,To be Discontinued,,,55111-796-30,discontinued
7946,Febuxostat Tablets,"Dr. Reddy's Laboratories, Inc.",80mg  (NDC NDC 55111-797-30),New,11/30/21,,,,,Rheumatology,To be Discontinued,,,55111-797-30,discontinued
7947,Febuxostat Tablets,"Mylan, A Viatris company",40mg T 30s (NDC 0378-3925-93),New,9/21/22,,,,,Rheumatology,To be Discontinued,9/21/22,9/21/22,0378-3925-93,discontinued
7948,Febuxostat Tablets,"Mylan, A Viatris company",80mg T 30s (NDC 0378-3926-93),New,9/21/22,,,,,Rheumatology,To be Discontinued,9/21/22,,0378-3926-93,discontinued
7949,Fenoldopam Mesylate (Corlopam) Injection,Pfizer,20 mg/2 mL (10 mg/mL) Single Dose Vial (NDC 00409-3373-02),New,8/30/22,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/22,8/30/22,00409-3373-02,discontinued
7950,Fenoldopam Mesylate (Corlopam) Injection,Pfizer,10 mg/mL (10 mg/mL) Single Dose Vial (NDC 00409-3373-01),New,8/30/22,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/22,8/30/22,00409-3373-01,discontinued
7951,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) Single Dose Simplist PFS  (NDC 63323-808-11),Revised,9/14/22,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-808-11,available
7952,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 1 mL vial
(NDC 0641-6247-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6247-25,not available
7953,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","1,000 mcg per 20 mL (50 mcg per mL) (0.05 mg per mL)  SDV (NDC 63323-806-20)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-20,not available
7954,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC","2,500 mcg per 50 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-50)",Revised,9/14/22,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-50,available
7955,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",50 mcg per 1 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-01),Revised,9/14/22,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-01,available
7956,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",100 mcg per 2 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-02),Revised,9/14/22,Available,Check wholesalers for inventory,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-02,available
7957,Fentanyl Citrate (Sublimaze) Injection,"Fresenius Kabi USA, LLC",250 mcg per 5 mL (50 mcg per mL) (0.05 mg per mL) SDV (NDC 63323-806-05),Revised,9/14/22,Backordered. Next release not available at this time.,,,Increase in demand,Analgesia/Addiction;Pediatric,Current,,,63323-806-05,not available
7958,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1276-32),Revised,9/12/22,Next Delivery and Estimated Recovery: February 2025,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-1276-32,not available
7959,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-32),Revised,9/12/22,Next Delivery and Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-32,not available
7960,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-35),Revised,9/12/22,Limited Supply Available. Next Delivery: January 2023; Estimated Recovery: May 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9093-35,limited availability
7961,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",1000 mcg/20 mL (50 mcg/mL); Glass Ampul (NDC 00409-9093-38),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Pediatric,Current,,,00409-9093-38,discontinued
7962,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",100 mcg/2 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-22),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-22,limited availability
7963,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",250 mcg/5 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-25),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-25,not available
7964,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.",500 mcg/10 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-28),Revised,9/12/22,Limited Supply Available. Next Delivery: December 2022; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-28,limited availability
7965,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","1,000 mcg/20 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-31)",Revised,9/12/22,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-31,limited availability
7966,Fentanyl Citrate (Sublimaze) Injection,"Hospira, Inc.","2,500 mcg/50 mL (50 mcg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9094-61)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,00409-9094-61,limited availability
7967,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 2 mL ampul (NDC 0641-6024-10),Revised,4/8/22,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6024-10,not available
7968,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 5 mL ampul (NDC 0641-6025-10),Revised,4/8/22,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6025-10,not available
7969,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL ampul (NDC 0641-6026-05),Revised,4/8/22,Currently not available,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6026-05,not available
7970,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 2 mL vial
(NDC 0641-6027-25)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6027-25,available
7971,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL 5 mL vial
(NDC 0641-6028-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6028-25,not available
7972,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",50 mcg/mL 20 mL vial (NDC 0641-6029-25),Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6029-25,not available
7973,Fentanyl Citrate (Sublimaze) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mcg/mL  50 mL vial
(NDC 0641-6030-01)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Pediatric,Current,,,0641-6030-01,available
7974,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule 10 pack (NDC 17478-0030-02),Revised,2/12/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-02,available
7975,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,2 mL ampule; 25 pack (NDC 17478-0030-25),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-25,discontinued
7976,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 10 pack (NDC 17478-0030-05),Revised,2/12/21,Available,,,Other,Analgesia/Addiction;Pediatric,Current,,,17478-0030-05,available
7977,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,20 mL ampule (NDC 17478-0030-20),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-20,discontinued
7978,Fentanyl Citrate (Sublimaze) Injection,Akorn Pharmaceuticals,5 mL ampule 25 pack (NDC 17478-0030-55),Revised,2/12/21,Discontinued,,,,Analgesia/Addiction;Pediatric,Current,,,17478-0030-55,discontinued
7979,Finasteride Tablets,Mylan Pharmaceuticals Inc.,5 mg tablet (NDC 0378-5036-05)(NDC 0378-5036-77)(NDC 0378-5036-93),New,5/23/18,,,,,Urology,To be Discontinued,,,0378-5036-05,discontinued
7980,Floxuridine for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",500 mg per vial (NDC 0143-9270-01),Reverified,4/8/22,This presentation is temporarily on backorder.,,,Other,Oncology,Current,,,0143-9270-01,not available
7981,Fluconazole (Diflucan) Tablets,"Hospira, Inc.",50 mg tablets; Bottle of 30 (NDC 00049-3410-30),New,9/15/22,,Stock anticipated to be available through October 2022; Discontinuation of the manufacture of the drug,,,Anti-Infective,To be Discontinued,9/15/22,9/15/22,00049-3410-30,discontinued
7982,Fludarabine Phosphate Injection,Areva Pharmaceuticals,50 mg/2 mL (NDC 59923-604-02),New,10/3/22,Product anticipated mid/late October 2022,,,,Oncology,Current,,,59923-604-02,not available
7983,Fludarabine Phosphate Injection,Teva Pharmaceuticals,"Lyophilized Powder for Injection, 50 mg /vial (NDC 45963-0609-55, 1 Single-Dose Vial)",Reverified,10/5/22,Available,,,Other,Oncology,Current,,,45963-0609-55,available
7984,Fludarabine Phosphate Injection,"Fresenius Kabi USA, LLC","50 mg per 2 mL (25 mg per mL), Single dose vial, PF (NDC: 63323-192-02)",Reverified,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase,Oncology,Current,,,,not available
7985,Fludrocortisone Acetate Tablets,Teva Pharmaceuticals,"0.1 mg, 100 count bottle (NDC 0555-0997-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,,,0555-0997-02,
7986,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 100 count bottle (NDC 0115-7033-01)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,,,0115-7033-01,
7987,Fludrocortisone Acetate Tablets,Impax Laboratories,"0.1 mg, 500 count bottle (NDC 0115-7033-02)",Revised,8/7/19,,,Available,,Endocrinology/Metabolism,Resolved,,,0115-7033-02,
7988,Flumazenil Injection,Mylan,"0.5 mg in 5 mL (0.1 mg/mL), multi-dose vial, 10 vials (NDC 67457-447-53)",New,12/16/19,,,,,Analgesia/Addiction;Neurology;Pediatric,To be Discontinued,,,67457-447-53,discontinued
7989,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-054-15),New,6/21/21,,,,,,To be Discontinued,,,52565-054-15,discontinued
7990,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-054-30),New,6/21/21,,,,,,To be Discontinued,,,52565-054-30,discontinued
7991,Fluocinonide Gel 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-054-60),New,6/21/21,,,,,,To be Discontinued,,,52565-054-60,discontinued
7992,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",15g (NDC 52565-040-15),New,6/21/21,,,,,,To be Discontinued,,,52565-040-15,discontinued
7993,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",30g (NDC 52565-040-30),New,6/21/21,,,,,,To be Discontinued,,,52565-040-30,discontinued
7994,Fluocinonide Ointment 0.05%,"Teligent Pharma, Inc.",60g (NDC 52565-040-60),New,6/21/21,,,,,,To be Discontinued,,,52565-040-60,discontinued
7995,Fluocinonide Topical Solution,Teva Pharmaceuticals,0.5 mg/mL  (NDC 0472-0829-02),New,8/3/21,,,,,Dermatology,To be Discontinued,,,0472-0829-02,discontinued
7996,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR ((fluorescein injection, USP) 10% (NDC 17478-253-10), 5mL",Revised,10/4/22,Currently available,,,Other,Ophthalmology,Current,,,17478-253-10,available
7997,Fluorescein Injection,Akorn Pharmaceuticals,"AK-FLUOR ((fluorescein injection, USP) 25% (NDC 17478-250-20), 2mL",Revised,10/4/22,On backorder.,,,Other,Ophthalmology,Current,,,17478-250-20,not available
7998,Fluorescein Injection,Alcon,Fluorescite 5 mL in vial (NDC 0065-0092-65),New,5/2/22,Available,,,,Ophthalmology,Current,,,0065-0092-65,available
7999,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 1.0 mg 100 sterile strips (NDC 17478-404-01),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,,,17478-404-01,
8000,Fluorescein Strips,Akorn Pharmaceuticals,Ful-Glo 0.6 mg 300 sterile strips (NDC 17478-403-03),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,,,17478-403-03,
8001,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 100 Strips per box (ndc 17238-900-11),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,,,,
8002,Fluorescein Strips,HUB Pharmaceuticals,BIOGLO Fluorescein Sodium Ophthalmic Strips USP 300 Strips per box (NDC 17238-900-30),Revised,6/4/21,,,Available,,Ophthalmology,Resolved,,,17238-900-30,
8003,Fluorometholone Ophthalmic Ointment,Abbvie,FML (flourometholone) Ointment 0.1% 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0316-04),New,9/13/21,,,,,Ophthalmology,To be Discontinued,,,0023-0316-04,discontinued
8004,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 100 count bottle (NDC 0781-2823-01)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2823-01,discontinued
8005,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 10 mg, 1000 count bottle (NDC 0781-2823-10)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2823-10,discontinued
8006,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 100 count bottle (NDC 0781-2822-01)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2822-01,discontinued
8007,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 20 mg, 1000 count bottle (NDC 0781-2822-10)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2822-10,discontinued
8008,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 100 count bottle (NDC 0781-2824-01)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2824-01,discontinued
8009,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 1000 count bottle (NDC 0781-2824-10)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2824-10,discontinued
8010,Fluoxetine Capsules,Sandoz,"Fluoxetine capsules, 40 mg, 30 count bottle (NDC 0781-2824-31)",New,2/23/18,,,,,Psychiatry,To be Discontinued,,,0781-2824-31,discontinued
8011,Flurazepam Hydrochloride Capsules,"Rising Pharma Holdings, Inc.",15mg C 100s (NDC 0378-4415-01),New,8/3/22,Anticipated availability: August 2023.,Delay is due to manufacturing delays at the contract manufacturing facility.,,,Neurology; Other,Current,,,0378-4415-01,not available
8012,Flurazepam Hydrochloride Capsules,"Rising Pharma Holdings, Inc.",30mg C 100s (NDC 0378-4430-01),New,8/3/22,Anticipated availability: August 2023.,Delay is due to manufacturing delays at the contract manufacturing facility.,,,Neurology; Other,Current,,,0378-4430-01,not available
8013,Fluvoxamine ER Capsules,Par Pharmaceutical,100 mg. 30’s count (NDC 10370-175-11),Revised,5/24/22,"A limited inventory will be available in June, July and August 2022. Estimated recovery September 2022",,,Delay in shipping of the drug,Psychiatry,Current,,,10370-175-11,limited availability
8014,Fluvoxamine ER Capsules,Par Pharmaceutical,150 mg. 30’s count (NDC 10370-176-11),Revised,5/24/22,"A limited inventory will be available in June, July and August 2022. Estimate recovery October 2022",,,Delay in shipping of the drug,Psychiatry,Current,,,10370-176-11,limited availability
8015,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03)",Revised,10/5/22,Allocation,,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,0228-2848-03,limited availability
8016,Fluvoxamine ER Capsules,Teva Pharmaceuticals,"Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03)",Revised,10/5/22,"Backorder, Recovery expected Oct-22",,,Requirements related to complying with good manufacturing practices,Psychiatry,Current,,,0228-2849-03,not available
8017,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","100 mg/2 mL, package of 25 vials (NDC 67457-516-25)",New,9/3/21,,,,,Neurology;Pediatric,To be Discontinued,,,67457-516-25,discontinued
8018,Fosphenytoin Sodium Injection,"Mylan Institutional, a Viatris company","500 mg/10 mL, package of 10 vials (NDC 67457-517-01)",New,8/4/21,,,,,Neurology;Pediatric,To be Discontinued,,,67457-517-01,discontinued
8019,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",20 mg/2mL vial (NDC 70860-302-41 and 70860-302-02),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-302-41,available
8020,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",40 mg/4mL vial (NDC 70860-302-42 and 70860-302-04),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-302-42,available
8021,Furosemide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",100 mg/10mL vial (NDC 70860-302-43 and 70860-302-10),Reverified,9/28/22,Available,,,,Cardiovascular,Current,,,70860-302-43,available
8022,Furosemide Injection,Sagent Pharmaceuticals,20 mg/2 mL single-dose vial (NDC 25021-311-02),Reverified,8/22/22,Backorder. Estimated availability Aug 2022,,,,Cardiovascular,Current,,,25021-311-02,not available
8023,Furosemide Injection,Sagent Pharmaceuticals,40 mg/4 mL single-dose vial (NDC25021-311-04),Reverified,8/22/22,Backorder. Estimated availability July 2022,,,,Cardiovascular,Current,,,,not available
8024,Furosemide Injection,Sagent Pharmaceuticals,100 mg/10 mL single-dose vial (NDC 25021-311-10),Reverified,8/22/22,Available,,,,Cardiovascular,Current,,,25021-311-10,available
8025,Furosemide Injection,Gland Pharma Limited,"2 mL in 1 vial, 25 vials/carton (NDC 25021-311-02)",Reverified,7/1/22,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-02,available
8026,Furosemide Injection,Gland Pharma Limited,"4 mL in 1 vial, 25 vials/carton (NDC 25021-311-04)",Reverified,7/1/22,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-04,available
8027,Furosemide Injection,Gland Pharma Limited,"10 mL in 1 vial, 25 vials/carton (NDC 25021-311-10)",Reverified,7/1/22,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-10,available
8028,Furosemide Injection,"Hospira, Inc., a Pfizer Company","100 mg/10 mL (10 mg/mL) syringe, bundle of 10 (NDC 0409-1639-10)",New,9/28/22,,,,,Cardiovascular,To be Discontinued,9/28/22,9/28/22,0409-1639-10,discontinued
8029,Furosemide Injection,"Hospira, Inc., a Pfizer Company","100 mg/10 mL (10 mg/mL) syringe, individual (NDC 0409-1639-21)",New,9/28/22,,,,,Cardiovascular,To be Discontinued,9/28/22,9/28/22,0409-1639-21,discontinued
8030,Furosemide Injection,"Hospira, Inc., a Pfizer Company","40 mg/4 mL (10 mg/mL) syringe, bundle of 10 (NDC 0409-9631-04)",New,9/28/22,,,,,Cardiovascular,To be Discontinued,9/28/22,9/28/22,0409-9631-04,discontinued
8031,Furosemide Injection,"Hospira, Inc., a Pfizer Company","40 mg/4 mL (10 mg/mL) syringe, individual (NDC 0409-9631-14)",New,9/28/22,,,,,Cardiovascular,To be Discontinued,9/28/22,9/28/22,0409-9631-14,discontinued
8032,Furosemide Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-02)",Revised,9/14/22,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-02,available
8033,Furosemide Injection,"Fresenius Kabi USA, LLC","40 mg per 4 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-04)",Revised,9/14/22,Available,Check wholesalers for inventory.,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-04,available
8034,Furosemide Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), Amber, single dose vial (NDC 63323-280-10)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Cardiovascular,Current,,,63323-280-10,not available
8035,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),20 mg/2 mL single-dose vial (NDC 55150-322-25),Reverified,9/28/22,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-322-25,not available
8036,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),40 mg/4 mL single-dose vial (NDC 55150-323-25),Reverified,9/28/22,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-323-25,not available
8037,Furosemide Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),100 mg/10 mL single-dose vial (NDC 55150-324-25),Reverified,9/28/22,"Currently on backorder, next shipment TBD",,,Delay in shipping of the drug,Cardiovascular,Current,,,55150-324-25,not available
8038,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 10 mL Single Dose Glass Vial (25 x 10 mL) (NDC 36000-284-25)",Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,36000-284-25,available
8039,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 2 mL Single Dose Glass Vial (25 x 2 mL)(NDC 36000-282-25)",Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,36000-282-25,available
8040,Furosemide Injection,Baxter Healthcare,"Furosemide Injection, USP, 10 mg/mL - 4 mL Single Dose Glass Vial (25 x 4 mL)(NDC 36000-283-25)",Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,36000-283-25,available
8041,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,20 mg/mL (NDC 23155-473-41),Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,23155-473-41,available
8042,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,40 mg/4mL (NDC 23155-473-42),Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,23155-473-42,available
8043,Furosemide Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,100 mg/10mL (NDC 23155-473-44),Reverified,8/26/22,Available,,,,Cardiovascular,Current,,,23155-473-44,available
8044,Furosemide Injection,"Hospira, Inc.",20 mg/2 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-02),Revised,9/28/22,Available,,,Other,Cardiovascular,Current,,,0409-6102-02,available
8045,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-6102-04),Revised,9/28/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,0409-6102-04,limited availability
8046,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL): Single Dose Glass Fliptop Vial (NDC 0409-6102-10),Revised,9/28/22,Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Cardiovascular,Current,,,0409-6102-10,not available
8047,Furosemide Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL; Ansyr Plastic syringe (NDC 0409-1639-10),Revised,9/28/22,Unavailable,,,,Cardiovascular,Current,,,0409-1639-10,not available
8048,Furosemide Injection,"Hospira, Inc.",40 mg/4 mL (10 mg/mL); Ansyr Plastic syringe (NDC 0409-9631-04),Revised,9/28/22,Unavailable,,,,Cardiovascular,Current,,,0409-9631-04,not available
8049,Furosemide Oral Solution,Wockhardt,"10 mg/mL, 60mL (NDC 60432-0613-60)",New,4/11/22,,,,,Cardiovascular,To be Discontinued,,,60432-0613-60,discontinued
8050,"Furosemide Oral Solution, 10 mg/mL",Wockhardt Bio AG/Morton Grove Pharmaceuticals,"10 mg/mL, 4 oz. (NDC 60432-613-04)",New,5/19/22,,,,,Cardiovascular,To be Discontinued,,,60432-613-04,discontinued
8051,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 7 Tablets in 1 Blister Pack (NDC 44004-321-07)",Revised,6/8/22,,,,,Anti-Infective,To be Discontinued,,,44004-321-07,discontinued
8052,Gemifloxacin Mesylate (Factive) Tablets,"LG Chem, Ltd.","320mg, 5 Tablets in 1 Blister Pack (NDC 44004-321-05)",Revised,6/8/22,,,,,Anti-Infective,To be Discontinued,,,44004-321-05,discontinued
8053,Gentamicin and Prednisolone Acetate Ophthalmic Suspension,Abbvie,"PRED G® (gentamicin and prednisolone acetate ophthalmic suspension) NDC 0023-0106-05/ 1 Bottle, Dropper in 1 Carton> 5 mL in 1 Bottle, Dropper, (NDC 0023-0106-10) / 1 Bottle, Dropper in 1 Carton> 10 mL in 1 Bottle, Dropper",New,6/9/22,,,,,Ophthalmology,To be Discontinued,,,0023-0106-05,discontinued
8054,Gentamicin Sulfate and Prednisolone Acetate Ophthalmic Ointment,Abbvie,PRED-G- gentamicin sulfate 0.3% and prednisolone acetate 0.6% ointment 1 TUBE in 1 CARTON  3.5 g in 1 TUBE (NDC 0023-0066-04),New,9/13/21,,,,,Ophthalmology,To be Discontinued,,,0023-0066-04,discontinued
8055,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","80 mg per 2 mL (40 mg per mL), MDV, (NDC 63323-010-02)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Anti-Infective,Current,,,63323-010-02,not available
8056,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","800 mg per 20 mL (40 mg per mL), MDV, (NDC 63323-010-20)",Revised,9/14/22,Backordered. Next release October 2022.,,,Demand increase for the drug,Anti-Infective,Current,,,63323-010-20,not available
8057,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","20 mg per 2 mL (10 mg per mL), Pediatric SDV, (NDC 63323-173-02)",Revised,9/14/22,Available,Check wholesaler inventory,,Demand increase for the drug,Anti-Infective,Current,,,63323-173-02,available
8058,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL); 2 mL Single Dose Glass Fliptop Vial (NDC 00409-1207-03),Revised,9/12/22,Next Delivery: December 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anti-Infective,Current,,,00409-1207-03,not available
8059,Gentamicin Sulfate Injection,"Hospira, Inc.",80 mg/2 mL (40 mg/mL) Single Dose Glass Fliptop Vial NovaPlus (NDC 00409-1207-25),Revised,9/12/22,Next Delivery: December 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anti-Infective,Current,,,00409-1207-25,not available
8060,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 60 mg/50 mL, (NDC 0338-0507-41)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0507-41,available
8061,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 80 mg/50 mL, (NDC 0338-0509-41)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0509-41,available
8062,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 80mg/100 mL, (NDC 0338-0503-48)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0503-48,available
8063,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 100 mg/50 mL, (NDC 0338-0511-41)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0511-41,available
8064,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 100 mg/100 mL, (NDC 0338-0505-48)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0505-48,available
8065,Gentamicin Sulfate Injection,Baxter,"Gentamicin Sulfate in 0.9% Sodium Chloride Injection, 120 mg/100 mL, (NDC 0338-0507-48)",Revised,8/31/22,Available,,,,Anti-Infective,Current,,,0338-0507-48,available
8066,Gentamicin Sulfate Solution,Abbvie,GENOPTIC® (gentamicin sulfate) Ophthalmic solution/drops (NDC 60758-188-05) -- 5 mL in 10 mL bottle,New,6/9/22,,,,,Ophthalmology,To be Discontinued,,,60758-188-05,discontinued
8067,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 10 mg/1 unit (NDC 10370-746-01),New,2/9/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,10370-746-01,discontinued
8068,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 10 mg/1 unit (NDC 10370-746-05),New,2/9/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,10370-746-05,discontinued
8069,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 5 mg/1 unit (NDC 10370-745-01),New,2/9/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,10370-745-01,discontinued
8070,Glipizide Tablets,"Endo Pharmaceuticals, Inc.",Extended-release 5 mg/1 unit (NDC 10370-745-05),New,2/9/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,10370-745-05,discontinued
8071,Glipizide Tablets,Teva Pharmaceuticals,"5mg tablets (NDC 0591-0460-10), (NDC 0591-0460-05), (NDC 0591-0460-01)",New,5/28/20,,,,,Endocrinology/Metabolism,To be Discontinued,,,0591-0460-10,discontinued
8072,Glipizide Tablets,Teva Pharmaceuticals,"10mg tablets, (NDC 0591-0461-10), (NDC 0591-0461-01), (NDC 0591-0461-05)",New,5/28/20,,,,,Endocrinology/Metabolism,To be Discontinued,,,0591-0461-10,discontinued
8073,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,1.25 mg/250 mg 100 Count (NDC 00228-2751-11),New,9/6/22,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/22,9/6/22,00228-2751-11,discontinued
8074,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg/500 mg 100 Count (NDC 00228-2752-11),New,9/6/22,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/22,9/6/22,00228-2752-11,discontinued
8075,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,2.5 mg/500 mg 500 Count (NDC 00228-2752-50),New,9/6/22,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/22,9/6/22,00228-2752-50,discontinued
8076,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/500 mg 100 Count (NDC 00228-2753-11),New,9/6/22,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/22,9/6/22,00228-2753-11,discontinued
8077,Glyburide and Metformin Hydrochloride Tablets,Teva Pharmaceuticals,5 mg/500 mg 500 Count (NDC 00228-2753-50),New,9/6/22,,Discontinuation of the manufacture of the drug.,,,Endocrinology,To be Discontinued,9/6/22,9/6/22,00228-2753-50,discontinued
8078,Granisetron Hydrochloride Injection,Teva Pharmauceuticals,"1 mg/mL, 1 mg, 1 mL/Vial (NDC 0703-7971-03)",New,9/13/22,,Product has not been marketed for at least 5 years,,,Gastroenterology,To be Discontinued,9/13/22,9/13/22,0703-7971-03,discontinued
8079,Granisetron Hydrochloride Injection,Teva Pharmaceuticals,"1 mg/mL, 4 mg, 4 mL/Vial (NDC 0703-7973-01)",New,9/13/22,,Product has not been marketed for at least 5 years,,,Gastroenterology,To be Discontinued,9/13/22,9/13/22,0703-7973-01,discontinued
8080,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 1 mg, 100 Count (NDC 42806-048-01)",Reverified,2/23/21,Available,,,Other,Cardiovascular,Current,,,42806-048-01,available
8081,Guanfacine Hydrochloride Tablets,"Epic Pharma, LLC","Guanfacine Tablets 2 mg, 100 Count (NDC 42806-296-01)",Reverified,2/23/21,Available,,,Other,Cardiovascular,Current,,,42806-296-01,available
8082,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",1 mg (NDC 0378-1160-01),Reverified,12/8/21,Unavailable,,,Other,Cardiovascular,Current,,,0378-1160-01,not available
8083,Guanfacine Hydrochloride Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",2 mg (NDC 0378-1190-01),Reverified,12/8/21,Unavailable,,,Other,Cardiovascular,Current,,,0378-1190-01,not available
8084,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,1mg tablets 100 count bottle (NDC 0591-0444-01),Revised,10/5/22,"Backorder, Recovery expected Nov-22",,,,Cardiovascular,Current,,,0591-0444-01,not available
8085,Guanfacine Hydrochloride Tablets,Teva Pharmaceuticals,2 mg tablets 100 count bottle (NDC 0591-0453-01),Revised,10/5/22,Allocation,,,,Cardiovascular,Current,,,0591-0453-01,limited availability
8086,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,1 mg bottles of 30 (NDC 65162-711-03); 1 mg bottles of 100 (NDC 65162-711-10),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-711-03,available
8087,Guanfacine Hydrochloride Tablets,Amneal Pharmaceutical,2 mg bottles of 30 (NDC 65162-713-03); 2 mg bottles of 100 (NDC 65162-713-10); 2 mg bottles of 500 (NDC 65162-713-50),Reverified,8/17/20,Available,,,Other,Cardiovascular,Current,,,65162-713-03,available
8088,Haloperidol Decanoate Injection,Teva,NDC 0703-7133-01 (500 mg/5 mL (100 mg/mL) 5 mL Multiple Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/22,8/11/22,0703-7133-01,discontinued
8089,Haloperidol Decanoate Injection,Teva,NDC 0703-7131-03 (100 mg/mL 10 x 1 mL Single Dose Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/22,8/11/22,0703-7131-03,discontinued
8090,Haloperidol Decanoate Injection,Teva,NDC 0703-7121-03 (50 mg/mL 10 x 1 mL Single Dose Vials),New,8/11/22,,Product is available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/22,8/11/22,0703-7121-03,discontinued
8091,Haloperidol Decanoate Injection,Teva,NDC 0703-7123-01 (250 mg/5 mL (50 mg/mL) 5 mL Multiple Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Psychiatry,To be Discontinued,8/11/22,8/11/22,0703-7123-01,discontinued
8092,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,0.5 mg (NDC 0378-0351-01) and (NDC 0378-0351-10),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0351-01,
8093,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,1 mg (NDC 0378-0257-01) and (NDC 0378-0257-10),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0257-01,
8094,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0214-01) and (NDC 0378-0214-10),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0214-01,
8095,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,5 mg (NDC 0378-0327-01) and (NDC 0378-0327-10),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0327-01,
8096,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-0334-01),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0334-01,
8097,Haloperidol Tablets,Mylan Pharmaceuticals Inc.,20 mg (NDC 0378-0355-01),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0378-0355-01,
8098,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 100 CT (NDC 68382-079-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,,,68382-079-01,
8099,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 5MG 1000 CT (NDC 68382-079-10),Revised,11/20/19,,,Available,,Psychiatry,Resolved,,,68382-079-10,
8100,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 10MG 100 CT (NDC 68382-080-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,,,68382-080-01,
8101,Haloperidol Tablets,Zydus Pharmaceuticals USA Inc.,HALOPERIDOL TAB 20MG 100 CT (NDC 68382-081-01),Revised,11/20/19,,,Available,,Psychiatry,Resolved,,,68382-081-01,
8102,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-13-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9101,
8103,Haloperidol Tablets,Sandoz,0.5 mg 100 count bottle (NDC 0781-83-9101),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9101,
8104,Haloperidol Tablets,Sandoz,0.5 mg 100 count unit dose (NDC 0781-13-9113),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9113,
8105,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-13-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9201,
8106,Haloperidol Tablets,Sandoz,1 mg 100 count bottle (NDC 0781-83-9201),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9201,
8107,Haloperidol Tablets,Sandoz,1 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9213,
8108,Haloperidol Tablets,Sandoz,2 mg 100 count bottle (NDC 0781-13-9801),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9801,
8109,Haloperidol Tablets,Sandoz,2 mg 100 count unit dose (NDC 0781-13-9213),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9213,
8110,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-13-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9610,
8111,Haloperidol Tablets,Sandoz,5 mg 1000 count bottle (NDC 0781-83-9610),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9610,
8112,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-13-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9601,
8113,Haloperidol Tablets,Sandoz,5 mg 100 count bottle (NDC 0781-83-9601),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9601,
8114,Haloperidol Tablets,Sandoz,5 mg 100 count unit dose (NDC 0781-13-9613),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9613,
8115,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-13-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9701,
8116,Haloperidol Tablets,Sandoz,10 mg 100 count bottle (NDC 0781-83-9701),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9701,
8117,Haloperidol Tablets,Sandoz,10 mg 100 count unit dose (NDC 0781-13-9713),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-13-9713,
8118,Haloperidol Tablets,Sandoz,20 mg 100 count bottle (NDC 0781-83-9301),Revised,11/20/19,,,,,Psychiatry,Resolved,,,0781-83-9301,
8119,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 2,000 USP units in 1000 mL.  Product code 2B0944  (NDC 0338-0433-04)",Revised,9/28/22,Available,,,Manufacturing Delay,Hematology,Current,,,0338-0433-04,available
8120,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection in VIAFLEX Plus Plastic Container: 1,000 USP units in 500 mL.  Product code 2B0953 (NDC 0338-0431-03)",Revised,9/28/22,Unavailable,,,Other,Hematology,Current,,,0338-0431-03,not available
8121,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","1,000 Units/500 mL (2 Units/mL); Flexible Container (NDC 00409-7620-03)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Hematology,Current,,,00409-7620-03,limited availability
8122,Heparin Sodium and Sodium Chloride 0.9% Injection,"Hospira, Inc.","2,000 Units/1000 mL (2 Units/mL); Flexible Container (NDC 00409-7620-59)",Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Hematology,Current,,,00409-7620-59,limited availability
8123,Heparin Sodium and Sodium Chloride 0.9% Injection,Baxter Healthcare,"Heparin Sodium and 0.9% Sodium Chloride Injection, 1,000 units / 500 mL (2 units / mL) in VIAFLEX Plastic Container.  Product code AHB0953U (NDC 0338-0424-18)",Revised,9/28/22,Limited Supply Recovery Q4,,,Manufacturing Delay,Hematology,Current,,,0338-0424-18,limited availability
8124,Heparin Sodium and Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"1,000 USP units in 500 mL. Product code P8721 (NDC 0264-9872-10)",Revised,3/25/22,Available. On 100% allocation.,,,Demand increase for the drug,Hematology,Current,,,0264-9872-10,limited availability
8125,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","1,000 Units/500 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-77)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Other,Hematology,Current,,,63323-519-77,not available
8126,Heparin Sodium and Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","2,000 Units/1000 mL; (2 units/mL); Single dose, freeflex bag; (NDC 63323-519-10)",Revised,9/14/22,Available,Check wholesaler for inventory,,Other,Hematology,Current,,,63323-519-10,available
8127,Histrelin Acetate Implant,"Endo Pharmaceuticals, Inc.",Vantas 50 mg Implantation Kit (NDC 67979-500-01),Revised,9/21/21,,,,,Oncology,To be Discontinued,,,67979-500-01,discontinued
8128,Hydralazine Hydrochloride Injection,American Regent/Luitpold,20mg/ml SDV ( NDC 0517 - 0901-25 ),Revised,6/29/21,,,Available,,Cardiovascular,Resolved,,,0517,
8129,Hydralazine Hydrochloride Injection,"Fresenius Kabi USA, LLC","20 mg per mL, SDV (NDC 63323-614-01)",Revised,6/29/21,,,Available,,Cardiovascular,Resolved,,,63323-614-01,
8130,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 10) (NDC 17478-934-01)",Revised,6/29/21,,,,,Cardiovascular,Resolved,,,17478-934-01,
8131,Hydralazine Hydrochloride Injection,Akorn Pharmaceuticals,"20 mg/mL, 1mL single dose vial  (box of 25) (NDC 17478-934-15)",Revised,6/29/21,,,,,Cardiovascular,Resolved,,,17478-934-15,
8132,Hydralazine Hydrochloride Injection,"Mylan Institutional, a Viatris company",20 mg / 1 ml] 25PK (NDC 67457-291-01),Revised,6/29/21,,,,,Cardiovascular,Resolved,,,67457-291-01,
8133,Hydralazine Hydrochloride Injection,"X-GEN Pharmaceuticals, Inc.",20 mg/mL per vial (NDC 39822-0500-4),Revised,6/29/21,,,,,Cardiovascular,Resolved,,,39822-0500-4,
8134,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,20 mg/25 mg (NDC 0378-2025-01),New,5/22/18,,,,,Cardiovascular,To be Discontinued,,,0378-2025-01,discontinued
8135,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,12.5 mg/ 20 mg (NDC 0378-2012-01),New,5/22/18,,,,,Cardiovascular,To be Discontinued,,,0378-2012-01,discontinued
8136,Hydrochlorothiazide and Lisinopril Tablets,Mylan Pharmaceuticals Inc.,10 mg/ 12.5 mg (NDC 0378-1012-01),New,5/22/18,,,,,Cardiovascular,To be Discontinued,,,0378-1012-01,discontinued
8137,Hydrochlorothiazide and Spironolactone (Aldactazide) Tablets,Pfizer,50 mg tablet; bottle of 100 (NDC 0025-1021-31),New,9/8/22,,Supply expected to exhaust mid September 2022,,,Cardiovascular,To be Discontinued,9/8/22,9/8/22,0025-1021-31,discontinued
8138,Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution,Perrigo Pharmaceuticals,Hydrocodone Bitartrate (5 mg/5 mL) and Homatropine Methylbromide (1.5 mg/5 mL)(NDC 0574-1105-16),New,6/5/18,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,0574-1105-16,discontinued
8139,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 12 suppositories (NDC 59741-301-12),New,11/25/19,,,,,Other;Urology,To be Discontinued,,,59741-301-12,discontinued
8140,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 24 suppositories (NDC 59741-301-24),New,11/25/19,,,,,Other;Urology,To be Discontinued,,,59741-301-24,discontinued
8141,Hydrocortisone Acetate Suppository,Torrent Pharma Inc.,Boxes of 100 suppositories (NDC 59741-301-01),New,11/25/19,,,,,Other;Urology,To be Discontinued,,,59741-301-01,discontinued
8142,Hydrocortisone Tablets,Pfizer Pharmaceuticals,5 mg tablet; bottle of 50 (NDC 59762-0073-1),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,59762-0073-1,
8143,Hydrocortisone Tablets,Pfizer Pharmaceuticals,10 mg tablet; bottle of 100 (NDC 59762-0074-1),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,59762-0074-1,
8144,Hydrocortisone Tablets,Pfizer Pharmaceuticals,20 mg tablet; bottle of 100 (NDC 59762-0075-1),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,59762-0075-1,
8145,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 20 mg tablet; bottle of 100 (NDC 0009-0044-01),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,0009-0044-01,
8146,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 5 mg tablet; bottle of 50 (NDC 0009-0012-01),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,0009-0012-01,
8147,Hydrocortisone Tablets,Pfizer Pharmaceuticals,Cortef 10 mg tablet; bottle of 100 (NDC 0009-0031-01),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,0009-0031-01,
8148,Hydrocortisone Tablets,Amneal Pharmaceutical,100mg/100 count (NDC 00115-1697-01),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,00115-1697-01,
8149,Hydrocortisone Tablets,Amneal Pharmaceutical,20mg/100 count (NDC 00115-1700-01),Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,00115-1700-01,
8150,Hydrocortisone Tablets,Strides Pharma Inc.,"5 mg, 50 count bottles (NDC 64380-970-25)",Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,64380-970-25,
8151,Hydrocortisone Tablets,Strides Pharma Inc.,"10 mg, 100 count bottles (NDC 64380-971-06)",Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,64380-971-06,
8152,Hydrocortisone Tablets,Strides Pharma Inc.,"20 mg, 100 count bottles (NDC 64380-972-06)",Revised,6/8/22,,,Available,,Endocrinology/Metabolism,Resolved,,,64380-972-06,
8153,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-121-11)",Revised,8/12/22,Available,,,,Analgesia/Addiction,Current,,,76045-121-11,available
8154,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe, MicroVault packaging (NDC 76045-010-11)",Revised,8/12/22,Available,,,,Analgesia/Addiction,Current,,,76045-010-11,available
8155,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)                                                                                           Microvault",Revised,8/12/22,Available,,,,Analgesia/Addiction,Current,,,76045-009-06,available
8156,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-11)                                                                                                                                                                                     Microvault",Revised,8/12/22,Available,,,,Analgesia/Addiction,Current,,,76045-009-11,available
8157,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","1 mg per 1 mL, Single dose vial, (NDC 63323-852-25)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-852-25,available
8158,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-853-25)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-853-25,not available
8159,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-854-10)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-854-10,not available
8160,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-10,available
8161,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-15)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-15,available
8162,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL, Single dose vial, high potency formulation (HPF), (NDC 63323-851-50)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-50,available
8163,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 0.5 mg per 0.5 mL, prefilled syringe (NDC 76045-009-06)",Revised,9/14/22,Check wholesalers for inventory,Check wholesalers for inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-06,unclear
8164,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 1 mg per 1 mL, prefilled syringe (NDC 76045-009-10)                                                                                                                                       Blister pack",Revised,9/14/22,Check wholesalers for inventory,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-009-10,unclear
8165,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 2 mg per 1 mL, prefilled syringe (NDC 76045-010-10)",Revised,9/14/22,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-010-10,not available
8166,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Dilaudid) 4 mg per 1 mL, prefilled syringe (NDC 76045-011-10)",Revised,9/14/22,Backordered. Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-011-10,not available
8167,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC0703-0110-03),Reverified,10/5/22,Available,,,,Analgesia/Addiction,Current,,,,available
8168,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1ML (NDC 0703-0113-03),Reverified,10/5/22,Available,,,,Analgesia/Addiction,Current,,,0703-0113-03,available
8169,Hydromorphone Hydrochloride Injection,Teva Pharmaceuticals,10 MG/1 ML (NDC 0703-0018-01),Reverified,10/5/22,Available,,,,Analgesia/Addiction,Current,,,0703-0018-01,available
8170,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 1 mL vial (NDC 0641-0121-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-0121-25,not available
8171,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0641-2341-41)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-2341-41,not available
8172,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",0.5 mg/0.5 mL (1 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-05),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1283-05,limited availability
8173,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/1 mL); iSecure Luer Lock Glass Syringe (NDC 00409-1283-10),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1283-10,discontinued
8174,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1312-10),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1312-10,discontinued
8175,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1283-31),Revised,9/12/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-1283-31,available
8176,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1312-30),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-1312-30,limited availability
8177,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1304-31),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-1304-31,available
8178,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",1 mg/1 mL (1 mg/mL); Glass Ampul (NDC 00409-2552-01),Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-2552-01,not available
8179,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Glass Ampul (NDC 00409-3356-01),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-3356-01,discontinued
8180,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",4 mg/1 mL (4 mg/mL); Glass Ampul (NDC 00409-2540-01),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2540-01,discontinued
8181,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",2 mg/1 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3365-01),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-3365-01,discontinued
8182,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-01),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-01,available
8183,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",50 mg/5 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-05),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-2634-05,available
8184,Hydromorphone Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-2634-50),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-2634-50,limited availability
8185,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)",Reverified,5/19/21,Available,,,,Analgesia/Addiction,Current,,,17478-0540-01,available
8186,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)",Reverified,5/19/21,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-05,available
8187,Hydromorphone Hydrochloride Injection,Akorn Pharmaceuticals,"10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)",Reverified,5/19/21,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,17478-0540-50,available
8188,Hydroxocobalamin Injection,SERB SA,"Hydroxocobalamin Injection (Cyanokit) intravenous powder for solution for injection, 5 gram, vial, (NDC 11704-0370-01)",Revised,1/20/22,,,Available,,Endocrinology/Metabolism;Other,Resolved,,,11704-0370-01,
8189,Hydroxocobalamin Injection,Teva Pharmaceuticals,"Hydroxocobalamin Injection 1000MCG/ML, 1X30ML(NDC 0591-2888-30)",Revised,1/21/22,,,Available,,Endocrinology/Metabolism,Resolved,,,0591-2888-30,
8190,Hydroxyprogesterone Caproate Injection,American Regent/Luitpold,"Hydroxyprogesterone Caproate Injection, USP 250mg/mL 1mL Single Dose Vial (NDC 0517-1767-01)",Revised,8/2/19,,,,,Reproductive,Resolved,,,0517-1767-01,
8191,Hydroxyprogesterone Caproate Injection,Slayback Pharma,"Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml (NDC 71225-104-01)",Revised,8/2/19,,,,,Reproductive,Resolved,,,71225-104-01,
8192,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single dose auto-injector 1.1mL for subcutaneous injection: (NDC 64011-247-02),Revised,8/2/19,,,,,Reproductive,Resolved,,,64011-247-02,
8193,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,,,66993-038-01,
8194,Hydroxyprogesterone Caproate Injection,"AMAG Pharmaceuticals, Inc.",Multi-dose vial 5mL for intramuscular injection: (NDC 64011-243-01),Revised,8/2/19,,,,,Reproductive,Resolved,,,64011-243-01,
8195,Hydroxyprogesterone Caproate Injection,Prasco Laboratories,Single-dose vial 1mL for intramuscular injection: (NDC 66993-038-01),Revised,8/2/19,,,,,Reproductive,Resolved,,,66993-038-01,
8196,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),Hydroxyprogesterone Caproate Injection USP 250 mg/1 mL single-dose vial (NDC 55150-309-01),Revised,8/2/19,,,,,Reproductive,Resolved,,,55150-309-01,
8197,Hydroxyprogesterone Caproate Injection,AuroMedics Pharma LLC (mfd. by Eugia Pharmaceutical Specialities Ltd.),"Hydroxyprogesterone Caproate Injection USP 1,250 mg/5 mL multiple-dose vial (NDC 55150-310-01)",Revised,8/2/19,,,,,Reproductive,Resolved,,,55150-310-01,
8198,Hydroxyprogesterone Caproate Injection,Slayback Pharma,Hydroxyprogesterone Caproate Injection 250 mg/ 1 ml (NDC 71225-105-01),Revised,8/2/19,,,,,Reproductive,Resolved,,,71225-105-01,
8199,Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert,"Bausch Health Americas, Inc.","Lacrisert, 5 mg per ophthalmic insert, 60 unit dose blister pack (NDC 24208-800-60)",Revised,12/3/21,"Unavailable, Resupply expected July 2023",,,Other,Ophthalmology,Current,,,24208-800-60,not available
8200,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,100 mg 100 count (NDC 0555-0324-02),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0555-0324-02,
8201,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 100 count (NDC 0555-0323-02),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0555-0323-02,
8202,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,25 mg 500 count (NDC 0555-0323-04),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0555-0323-04,
8203,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 100 count (NDC 0555-0302-02),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0555-0302-02,
8204,Hydroxyzine Pamoate Oral Capsules,Teva Pharmaceuticals,50 mg 500 count (NDC 0555-0302-04),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0555-0302-04,
8205,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 100 count (NDC 0185-0674-01),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0185-0674-01,
8206,Hydroxyzine Pamoate Oral Capsules,Sandoz,25 mg 500 count (NDC 0185-0674-05),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0185-0674-05,
8207,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01),Revised,2/17/21,,,,,Psychiatry,Resolved,,,00115-1803-01,
8208,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02),Revised,2/17/21,,,,,Psychiatry,Resolved,,,00115-1803-02,
8209,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01),Revised,2/17/21,,,,,Psychiatry,Resolved,,,00115-1804-01,
8210,Hydroxyzine Pamoate Oral Capsules,Impax Laboratories,Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02),Revised,2/17/21,,,,,Psychiatry,Resolved,,,00115-1804-02,
8211,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0069-5410-66,
8212,Hydroxyzine Pamoate Oral Capsules,Pfizer Pharmaceuticals,Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66),Revised,2/17/21,,,,,Psychiatry,Resolved,,,0069-5420-66,
8213,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01),Revised,2/17/21,,,,,Psychiatry,Resolved,,,14539-674-01,
8214,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05),Revised,2/17/21,,,,,Psychiatry,Resolved,,,14539-674-05,
8215,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01),Revised,2/17/21,,,,,Psychiatry,Resolved,,,14539-675-01,
8216,Hydroxyzine Pamoate Oral Capsules,Heritage Pharma,Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05),Revised,2/17/21,,,,,Psychiatry,Resolved,,,14539-675-05,
8217,Hyoscyamine Sulfate Injection,"Meda Pharmaceuticals Inc, A Viatris company","Levsin® Injection, 0.5mg, (NDC 0037-9001-05)",New,9/13/22,,Product will be available until stock out or expiry (October 2023).,,,Anesthesia; Gastroenterology; Urology,To be Discontinued,9/13/22,9/13/22,0037-9001-05,discontinued
8218,Ibutilide Fumarate Injection,"Mylan Institutional, a Viatris company","1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 67457-366-10)",Revised,9/28/22,Unavailable,Re-supply October 2022.,,Other,Cardiovascular,Current,,,67457-366-10,not available
8219,Ibutilide Fumarate Injection,Pfizer Pharmaceuticals,"1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 0009-3794-01)",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,0009-3794-01,available
8220,Ibutilide Fumarate Injection,Pfizer Pharmaceuticals,"1 mg/10 mL (0.1 mg/mL), single dose vial (NDC 0009-3794-22), Novaplus",Reverified,9/12/22,Available,,,Other,Cardiovascular,Current,,,0009-3794-22,available
8221,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4155-11 (10 mg/10 mL (1 mg/mL) 10 mL Single Dose Vial),New,8/11/22,,Product is available with an expected supply duration until JUN' 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4155-11,discontinued
8222,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4156-11 (20 mg/20 mL (1 mg/mL) 20 mL Single Dose Vial),New,8/11/22,,Product is available with an expected supply duration until JUL' 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4156-11,discontinued
8223,Idarubicin Hydrochloride Injection,Teva,NDC 0703-4154-11 (5 mg/5 mL (1 mg/mL) 5 mL Single Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4154-11,discontinued
8224,Ifosfamide Injection,Teva,NDC 0703-3427-11 (1 g/20 mL (50 mg/mL) Single Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-3427-11,discontinued
8225,Ifosfamide Injection,Teva,NDC 0703-3429-11 (3 g/60 mL (50 mg/mL) Single Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-3429-11,discontinued
8226,Imipenem and Cilastatin for Injection,HQ Specialty Pharma,"500 mg per vial, single dose vial, sterile powder (NDC 44567-0705-10)",Revised,6/8/22,,,Available,,Anti-Infective,Resolved,,,44567-0705-10,
8227,Imipenem and Cilastatin for Injection,Merck Sharp & Dohme Corp.,500 mg  imipenem  equivalent  and  500 mg  cilastatin  equivalent  and  20 mg  sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3516-59),Revised,6/8/22,,,Available,,Anti-Infective,Resolved,,,0006-3516-59,
8228,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","250 mg/250 mg per vial, single dose vial, sterile powder (NDC 63323-349-25)",Revised,6/8/22,,,Available,,Anti-Infective,Resolved,,,63323-349-25,
8229,Imipenem and Cilastatin for Injection,"Fresenius Kabi USA, LLC","500 mg/500 mg per vial, single dose vial, sterile powder (NDC  63323-322-25)",Revised,6/8/22,,,Available,,Anti-Infective,Resolved,,,63323-322-25,
8230,Imipramine Tablets,Sandoz,10 mg 100 ct (NDC 0781-1762-01),New,2/28/22,,,,,Psychiatry,To be Discontinued,,,0781-1762-01,discontinued
8231,Imipramine Tablets,Sandoz,25 mg 100 ct (NDC 0781-1764-01),New,2/28/22,,,,,Psychiatry,To be Discontinued,,,0781-1764-01,discontinued
8232,Imipramine Tablets,Sandoz,25 mg 1000 ct (NDC 0781-1764-10),New,2/28/22,,,,,Psychiatry,To be Discontinued,,,0781-1764-10,discontinued
8233,Imipramine Tablets,Sandoz,50 mg 100 ct (NDC 0781-1766-01),New,2/28/22,,,,,Psychiatry,To be Discontinued,,,0781-1766-01,discontinued
8234,Imipramine Tablets,Sandoz,50 mg 1000 ct (NDC 0781-1766-10),New,2/28/22,,,,,Psychiatry,To be Discontinued,,,0781-1766-10,discontinued
8235,Indigotindisulfonate Sodium Injection,American Regent,Indigo Carmine injection 5mL ampule (NDC 0517-0375-05),Revised,8/24/22,"Out of Stock, no plans to manufacture until sometime in 2023",,,Shortage of an active ingredient,Medical Imaging,Current,,,0517-0375-05,not available
8236,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 100s (NDC 0378-0143-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-0143-01,discontinued
8237,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"25 mg, 1000s (NDC 0378-0143-10)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-0143-10,discontinued
8238,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 100s (NDC 0378-0147-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-0147-01,discontinued
8239,Indomethacin Capsules,Mylan Pharmaceuticals Inc.,"50 mg, 500s (NDC 0378-0147-05)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-0147-05,discontinued
8240,Indomethacin Injection,Hospira,1 mg Single Dose Vial (NDC 0409-1113-01),New,8/15/22,,Limited supply available. Product expected to exhaust by November 2022,,,Pediatric; Cardiovascular,To be Discontinued,8/15/22,8/15/22,0409-1113-01,discontinued
8241,Indomethacin Injection,Navinta LLC,1 mg per vial (NDC 68382-470-01),New,8/17/22,,Navinta has made a business decision to discontinue this product.,,,Pediatric; Cardiovascular,To be Discontinued,8/17/22,8/17/22,68382-470-01,discontinued
8242,Insulin Lispro (Humalog Mix50/50),Eli Lilly and Company,"Humalog (Insulin Lispro) Mix50/50, 10ml vial (NDC 0002-7512-01)",New,6/30/22,,,,,,To be Discontinued,,,0002-7512-01,discontinued
8243,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4350-01)",New,4/23/21,,,,,Antiviral,To be Discontinued,,,0085-4350-01,discontinued
8244,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4351-01)",New,4/23/21,,,,,Antiviral,To be Discontinued,,,0085-4351-01,discontinued
8245,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,"INTRON A Powder for Injection (Interferon alfa-2b), 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01)",New,4/23/21,,,,,Antiviral,To be Discontinued,,,0085-4352-01,discontinued
8246,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01),New,9/12/19,,,,,Antiviral;Oncology,To be Discontinued,,,0085-4350-01,discontinued
8247,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent ((NDC 0085-4351-01)),New,9/12/19,,,,,Antiviral;Oncology,To be Discontinued,,,0085-4351-01,discontinued
8248,"Interferon alfa-2b, Recombinant for Injection",Merck Sharp & Dohme Corp.,INTRON A Powder for Injection (Interferon alfa-2b) 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01),New,9/12/19,,,,,Antiviral;Oncology,To be Discontinued,,,0085-4352-01,discontinued
8249,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 100 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-10)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-383-10,available
8250,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 200 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-70)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-383-70,available
8251,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 50 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-05)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-383-05,available
8252,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 320 mg Iodine/mL: 150 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-383-50)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-383-50,available
8253,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 270 mg Iodine/mL: 100 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-381-10)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-381-10,available
8254,Iodixanol Injection,"JIANGSU HENGRUI PHARMACEUTICALS CO LTD (ANDA holder); Fresenius Kabi USA, LLC (marketing and US distribution partner)","Iodixanol Injection, USP, 270 mg Iodine/mL: 150 mL in single-dose polypropylene bottle, boxes of 10 (NDC 65219-381-50)",Revised,7/18/22,Available,,,Other,Medical Imaging,Current,,,65219-381-50,available
8255,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-23), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8256,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-62), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8257,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-66), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8258,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-67), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8259,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-16), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8260,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-19), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Drug Shortage Resolved.  Product Available as of August 26, 2022.",,,Other,Medical Imaging,Current,,,,available
8261,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-21), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8262,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-16), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of October 2022.,,,Other,Medical Imaging,Current,,,,not available
8263,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-19), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,not available
8264,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-21), 320 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order October 10, 2022.",,,Other,Medical Imaging,Current,,,,not available
8265,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-64), 320 mg/1 mL, INJECTION, SOLUTION, IV 10 BOTTLE, PLASTIC in 1 BOX > 100 mL in 1 BOTTLE, PLASTIC",Revised,9/2/22,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8266,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2223-17), 320 mg/1 mL, VISIPAQUE INJECTION, SOLUTION, IV VISIPAQUE 320mgI/ml USB 10x100 VIAL ml USA",Revised,9/2/22,"Backordered. Product will be available for order September 22, 2022.",,,Other,Medical Imaging,Current,,,,not available
8267,Iodixanol Injection,GE Healthcare,"Iodixanol (Visipaque) Injection NDC (0407-2222-17), 270 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,not available
8268,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-98), 350 mg/1 mL, OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 350mgI/ml USB PH10x500ml USA",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8269,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-72), 350 mg/1 mL OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 350mgI/ml USB IBP 10x500ml USA",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8270,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-88), OMNIPAQUE 350 mg/1 mL, INJECTION, SOLUTION, IV  10 BOTTLE, PLASTIC in 1 BOX > 500 mL in 1 BOTTLE, PLASTIC",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8271,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-48), 350 mg/1 mL, INJECTION, SOLUTION, IV 10 BOTTLE, PLASTIC in 1 BOX > 500 mL in 1 BOTTLE, PLASTIC",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8272,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-10), 240 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, IV OMNIPAQUE 240mgI/ml VIAL10x 10 ml USA",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8273,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-20), 240 mg/1 mL, OMNIPAQUE INJECTION,  SOLUTION, IV OMNIPAQUE 240mgI/ml VIAL10x 20 ml USA",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8274,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-89), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order October 30, 2022.",,,Other,Medical Imaging,Current,,,,not available
8275,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-91), 350 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, IV OMNIPAQUE 350mgI/ml USB 10x100 ml USA",Revised,9/2/22,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8276,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1411-10), 180 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, ORAL OMNIPAQUE 180mgI/ml VIAL10x 10 ml USA",Revised,9/2/22,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8277,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-68), 300 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8278,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1411-20), 180 mg/1 mL, OMNIPAQUE INJECTION, SOLUTION, ORAL OMNIPAQUE 180mgI/ml VIAL10x 20 ml USA",Revised,9/2/22,"Product available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8279,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-72),300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,not available
8280,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-89), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,not available
8281,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-48), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,not available
8282,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1416-12), 12 mg/1 mL, SOLUTION, ORAL",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8283,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1415-09), 9 mg/1 mL, SOLUTION, ORAL",Revised,9/2/22,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,not available
8284,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-34), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8285,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-30), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,not available
8286,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-35), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8287,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-33), 240 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8288,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-53), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8289,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-10), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8290,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-94), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8291,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-93), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8292,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-95), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8293,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1412-38), 240 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8294,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1401-52), 140 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 05, 2022.",,,Other,Medical Imaging,Current,,,,not available
8295,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-86), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8296,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-87), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of August.,,,Other,Medical Imaging,Current,,,,not available
8297,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-88), 300 mg/1 mL, INJECTION, SOLUTION, IT",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8298,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-42), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8299,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-90), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,8/12/22,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,not available
8300,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-85), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8301,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-84), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,"Product Available as of July 1, 2022.",,,Other,Medical Imaging,Current,,,,available
8302,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-82), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of September.,,,Other,Medical Imaging,Current,,,,not available
8303,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-87), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8304,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-86), 350 mg/1 mL, INJECTION, SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8305,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-59), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8306,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-65), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8307,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-61), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order October 30, 2022.",,,Other,Medical Imaging,Current,,,,not available
8308,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-63), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,"Backordered. Product will be available for order September 5, 2022.",,,Other,Medical Imaging,Current,,,,not available
8309,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-62), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8310,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-66), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8311,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1414-76), 350 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of 2022.,,,Other,Medical Imaging,Current,,,,not available
8312,Iohexol Injection,GE Healthcare,"Iohexol (Omnipaque) NDC (0407-1413-69), 300 mg/1 mL, INJECTION,  SOLUTION, IV",Revised,9/2/22,Backordered. Product availability is likely to be impacted until the end of January 2023.,,,Other,Medical Imaging,Current,,,,not available
8313,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  350, 6 X 500 ML (NDC 0270-9350-06)",Reverified,9/9/22,"Estimated Availability: October 4, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9350-06,not available
8314,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 350, 10 X 200 ML (NDC 0270-7350-20)",Reverified,9/9/22,"Estimated Availability: September 26, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7350-20,not available
8315,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 300, 6 X 500 ML (NDC 0270-9300-06)",Reverified,9/9/22,"Estimated Availability: September 29, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9300-06,not available
8316,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 400, 9 X 500 ML (NDC 0270-9400-01)",Reverified,9/9/22,"Estimated Availability: September 9, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9400-01,not available
8317,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 350, 9 X 500 ML (NDC 0270-9350-09)",Reverified,9/9/22,"Estimated Availability: September 6, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9350-09,not available
8318,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  350, 30 X 150 ML (NDC 0270-7350-15)",Reverified,9/9/22,"Estimated Availability: September 21, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7350-15,not available
8319,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  400, 6 X 500 ML (NDC 0270-9400-06)",Reverified,9/9/22,"Estimated Availability: October 11, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9400-06,not available
8320,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  300, 56 X 100 ML (NDC 0270-7300-10)",Reverified,9/9/22,"Estimated Availability: September 13, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7300-10,not available
8321,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON)  250, 56 X 100 ML (NDC 0270-7250-10)",Reverified,9/9/22,"Estimated Availability: September 2, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7250-10,not available
8322,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 56 X 100 ML (NDC 0270-7400-16)",Reverified,9/9/22,"Estimated Availability: September 16, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7400-16,not available
8323,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 30 X 200 ML (NDC 0270-7400-20)",Reverified,9/9/22,"Estimated Availability: September 7, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7400-20,not available
8324,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  300, 10 X 200 ML (NDC 0270-7300-20)",Reverified,9/9/22,"Estimated Availability: September 1, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7300-20,not available
8325,Iomeprol Injection,Bracco,"Iomeprol injection (IOMERON)  400, 6 X 500 ML (NDC 0270-9400-03)",Reverified,9/9/22,"Estimated Availability: September 15, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-9400-03,not available
8326,Iomeprol injection,Bracco,"Iomeprol injection (IOMERON) 400, 10 X 100 ML (NDC 0270-7400-10)",Reverified,9/9/22,"Estimated Availability: September 14, 2022","Bracco, in conjunction with FDA, has initiated a temporary importation of Iomeron® (iomeprol injection) into the U.S. market to address drug shortages.  To place an order, please contact Bracco Customer Service at 1-877-272-2269 or at Bracco.otc@diag.bracco.com. For more information see Bracco’s website: https://imaging.bracco.com/us-en/products/ct-ct-colonography/iomeron",,Other,Medical Imaging,Current,,,0270-7400-10,not available
8327,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200), 10x50mL vial, (NDC 0270-1314-30)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1314-30,discontinued
8328,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 41% (Isovue 200M), 10x20mL vial, (NDC 0270-1411-25)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1411-25,discontinued
8329,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x150mL bottle, (NDC 0270-1317-09)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1317-09,discontinued
8330,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250),  10x50mL bottle, (NDC 0270-1317-05)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1317-05,discontinued
8331,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 51% (IsoVue 250 PBP),  10x200mL bottle, (NDC 0270-1317-41)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1317-41,discontinued
8332,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300), 10x75mL bottle, (NDC 0270-1315-47)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1315-47,discontinued
8333,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 6x500mL bottle, (NDC 0270-1315-98)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1315-98,discontinued
8334,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 61% (IsoVue 300 PBP), 10x200mL bottle, (NDC 0270-1315-41)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1315-41,discontinued
8335,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 6x500mL bottle, (NDC 0270-1316-98)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1316-98,discontinued
8336,Iopamidol (Isovue) Injection,Bracco Diagnostics,"Iopamidol Injection 76% (IsoVue 370 PBP), 10x200mL bottle, (NDC 0270-1316-41)",New,7/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1316-41,discontinued
8337,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 50 mL in 1 VIAL, GLASS (NDC 50419-344-05)",Reverified,9/28/22,"Product availability is likely impacted until end of 2022, expect stock in Q1 2023","Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-344-05,limited availability
8338,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 50 mL in 1 VIAL, GLASS (NDC 50419-346-05)",Reverified,9/28/22,"Product availability is likely impacted until end of 2022, expect stock in Q1 2023","Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-346-05,limited availability
8339,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 100 mL in 1 VIAL, GLASS  (NDC 50419-346-10)",Reverified,9/28/22,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-346-10,available
8340,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 370 mg Iodine per mL: 10 VIAL, GLASS in 1 CARTON; > 150 mL in 1 VIAL, GLASS  (NDC 50419-346-15)",Reverified,9/28/22,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-346-15,available
8341,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 100 mL in 1 VIAL, GLASS (NDC 50419-344-10)",Reverified,9/28/22,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-344-10,available
8342,Iopromide (Ultravist) Injection,Bayer HealthCare Pharmaceuticals Inc.,"ULTRAVIST Injection; 300 mg Iodine per mL; 10 VIAL, GLASS in 1 CARTON; > 150 mL in 1 VIAL, GLASS  (NDC 50419-344-15)",Reverified,9/28/22,Product available,"Bayer, in conjunction with FDA has initiated a temporary importation of foreign labeled Ultravist (Iopromide) Injection into the U.S. market to address drug shortage. To place an order contact clscricustomerlogistics@bayer.com or call 1-724-940-7890.",,Demand increase,Medical Imaging,Current,,,50419-344-15,available
8343,Isoniazid Injection,Sandoz,10 mL (100 mg/mL) Multiple dose vial (NDC 0781-3056-70),Revised,10/4/22,Available,,,,Anti-Infective,Current,,,0781-3056-70,available
8344,IV Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid (20% IV Fat Emulsion) in 1,000mL Bag Catalog S4600 (NDC 00264-4460-00)",Revised,9/9/22,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,00264-4460-00,limited availability
8345,IV Fat Emulsion,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 500mL Bag Catalog S4601 (NDC 0264-4460-10),Revised,9/9/22,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0264-4460-10,limited availability
8346,IV Fat Emulsion,B. Braun Medical Inc.,Nutrilipid (20% IV Fat Emulsion) in 250mL Bag Catalog S4603 (NDC 00264-4460-30),Revised,9/9/22,"Product available, on allocation to contracted customers",,,Other,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,00264-4460-30,limited availability
8347,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (20 grams per 100 mL) (NDC 63323--820-00)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323--820-00,available
8348,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (50 grams per 250 mL) (NDC 63323--820-74)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323--820-74,available
8349,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20% (0.2 grams per mL) (100 grams per 500 mL) (NDC 63323-820-50)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323-820-50,available
8350,IV Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid injectable emulsion, USP, 20%, PBP (0.2 grams per mL) (200 grams per 1000 mL) (NDC 63323-820-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,63323-820-10,available
8351,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 100 mL, Product Code EADB9520, (NDC 0338-954-005)",Revised,9/28/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-005,available
8352,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 1000 mL, Product Code EADB9524, (NDC 0338-954-008)",Revised,9/28/22,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-008,available
8353,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 250 mL, Product Code EADB9521, (NDC 0338-954-006)",Revised,9/28/22,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-006,available
8354,IV Fat Emulsion,Baxter Healthcare,"Clinolipid 20% (Lipid Injectable Emulsion, USP) 500 mL, Product Code EADB9523, (NDC 0338-954-007)",Revised,9/28/22,Available,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-954-007,available
8355,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 100 mL, Product Code 2B6061, (NDC 0338-051-958)",Revised,9/28/22,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-958,limited availability
8356,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 250 mL, Product Code 2B6062, (NDC 0338-051-909)",Revised,9/28/22,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-909,limited availability
8357,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 1000 mL, Pharmacy Bulk Package, Product Code 2B6064, (NDC 0338-051-914)",Revised,9/28/22,Limited Supply; Recovery November,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-914,limited availability
8358,IV Fat Emulsion,Baxter Healthcare,"Intralipid 20% IV Fat Emulsion, 500 mL, Product Code 2B6063, (NDC 0338-051-913)",Revised,9/28/22,"Limited Supply on Allocation, Recovery late Sep",,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-051-913,limited availability
8359,IV Fat Emulsion,Baxter Healthcare,"Intralipid 30% IV Fat Emulsion, 500 mL, Pharmacy Bulk Package, Product Code 2B6065, (NDC 0338-052-013)",Revised,9/28/22,Available on allocation,,,Demand increase,Endocrinology/Metabolism;Gastroenterology;Total Parenteral Nutrition,Current,,,0338-052-013,limited availability
8360,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 10 mL vial (NDC 0143-9508-10)",Revised,6/3/22,This presentation is currently available.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9508-10,available
8361,Ketamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9509-10)",Revised,6/3/22,This presentation is temporarily on backorder.,,,,Anesthesia,Current,,,0143-9509-10,not available
8362,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),200 mg / 20 mL (NDC 67457-181-20),Revised,9/28/22,Available,,,,Anesthesia,Current,,,67457-181-20,available
8363,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),500 mg / 10 mL (NDC 67457-001-10),Revised,9/28/22,Available,,,,Anesthesia,Current,,,67457-001-10,available
8364,Ketamine Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1000 mg / 10 mL (NDC 67457-108-10),Revised,9/28/22,"Currently on backorder, next shipment Late November 2022",,,,Anesthesia,Current,,,67457-108-10,not available
8365,Ketamine Injection,"Hospira, Inc.",500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2051-05),Reverified,9/12/22,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-2051-05,limited availability
8366,Ketamine Injection,"Hospira, Inc.",500 mg/10 mL (50 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-2053-10),Reverified,9/12/22,Next Delivery and Estimated Recovery: February 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,00409-2053-10,not available
8367,Ketamine Injection,Par Pharmaceutical,"10 mg/mL, 20 mL MDV (NDC 42023-113-10)",Revised,8/12/22,Contact customer service at 1-800-828-9393,,,Demand increase,Anesthesia,Current,,,42023-113-10,unclear
8368,Ketamine Injection,Par Pharmaceutical,"100 mg/mL, 5 mL MDV (NDC 42023-115-10)",Revised,8/12/22,Releases to be intermittent – Please check wholesalers for inventory,,,Demand increase,Anesthesia,Current,,,42023-115-10,limited availability
8369,Ketamine Injection,Par Pharmaceutical,"50 mg/mL, 10 mL MDV (NDC 42023-114-10)",Revised,8/12/22,Releases to be intermittent – Please check wholesalers for inventory,,,Demand increase for the drug,Anesthesia,Current,,,42023-114-10,limited availability
8370,Ketoprofen Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","200 mg Extended-Release Capsules, bottle of 100 (NDC 0378-8200-01)",Reverified,9/28/22,Available,,,Other,Analgesia/Addiction;Rheumatology,Current,,,0378-8200-01,available
8371,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",New,11/25/19,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,23155-020-01,discontinued
8372,Ketoprofen Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0093-3193-01)",Reverified,4/29/22,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3193-01,not available
8373,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 100 count bottle (NDC 0093-3195-01)",Reverified,4/29/22,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-01,not available
8374,Ketoprofen Capsules,Teva Pharmaceuticals,"75 mg, 500 count bottle (NDC 0093-3195-05)",Reverified,4/29/22,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction;Rheumatology,Current,,,0093-3195-05,not available
8375,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",New,11/25/19,,,,,Analgesia/Addiction;Rheumatology,To be Discontinued,,,23155-020-10,discontinued
8376,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 69336-127-10)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-10,available
8377,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 69336-127-11)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,69336-127-11,available
8378,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 100 count bottle (NDC 23155-020-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-01,available
8379,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","25 mg, 1000 count bottle (NDC 23155-020-10)",Revised,1/19/21,Unavailable - Discontinuation of the manufacture of the drug,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-020-10,discontinued
8380,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","50 mg, 100 count bottle (NDC 23155-021-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-021-01,available
8381,Ketoprofen Capsules,"Avet Pharmaceuticals, Inc. (formerly Heritage Pharma)","75 mg, 100 count bottle (NDC 23155-022-01)",Revised,1/19/21,Available,,,,Analgesia/Addiction;Rheumatology,Current,,,23155-022-01,available
8382,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-107-10)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,76045-107-10,not available
8383,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose, Simplist Syringe, (NDC 76045-104-10)",Revised,9/14/22,Available,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,76045-104-10,available
8384,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","60 mg per 2 mL, Single Dose, Simplist Syringe, (NDC 76045-105-20)",Revised,9/14/22,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-105-20,available
8385,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 30 mg/ mL.  Single dose glass flip top vial - 25 units per carton (NDC 0338-0072-25)",Revised,9/28/22,Available,,,,Analgesia/Addiction,Current,,,0338-0072-25,available
8386,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine Injection, USP, 15 mg/mL. Single dose glass flip top vial. 10 units per carton (NDC 0338-0069-10)",Reverified,9/28/22,Available,,,,Analgesia/Addiction,Current,,,0338-0069-10,available
8387,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 1 mL vial (NDC 72266-118-25)",Reverified,9/28/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-118-25,available
8388,Ketorolac Tromethamine Injection,Gland Pharma Limited,"30 mg/mL, 2 mL vial (NDC 72266-119-25)",Reverified,9/28/22,Available,,,Available,Analgesia/Addiction,Current,,,72266-119-25,available
8389,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","15 mg/mL, 1 mL vial (NDC 0641-6041-25)",Reverified,4/8/22,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6041-25,unclear
8390,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 1 mL vial (NDC 0641-6042-25)",Reverified,4/8/22,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6042-25,unclear
8391,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","30 mg/mL, 2 mL vial (NDC 0641-6043-25)",Reverified,4/8/22,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6043-25,unclear
8392,Ketorolac Tromethamine Injection,Virtus Pharmaceuticals,30MG/ML (NDC 69543-0386-25),New,3/26/18,Available,,,Other,Analgesia/Addiction,Current,,,69543-0386-25,available
8393,Ketorolac Tromethamine Injection,Gland Pharma Limited,15 mg/mL vial (NDC 70860-700-01 and 70860-700-02),Reverified,9/12/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-700-01,available
8394,Ketorolac Tromethamine Injection,Gland Pharma Limited,30 mg/mL vial (NDC 70860-701-01 and 70860-701-03),Reverified,9/12/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-01,available
8395,Ketorolac Tromethamine Injection,Gland Pharma Limited,60 mg/mL vial (NDC 70860-701-02 and 70860-701-04),Reverified,9/12/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-02,available
8396,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 15MG/ML 25X1ML (NDC 25021-700-01),Reverified,8/22/22,Backordered. Estimated availability TBD,,,Manufacturing delays,Analgesia/Addiction,Current,,,25021-700-01,not available
8397,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X2ML (NDC 25021-701-02),Reverified,8/22/22,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-02,not available
8398,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE INJECTION 30MG/ML 25X1ML (NDC 25021-701-01),Reverified,8/22/22,Backordered. Estimated availability TBD,,,Manufacturing delay,Analgesia/Addiction,Current,,,25021-701-01,not available
8399,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-2287-23),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-23,discontinued
8400,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-31),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-31,discontinued
8401,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-2287-61),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-2287-61,discontinued
8402,Ketorolac Tromethamine Injection,"Hospira, Inc.",15 mg/mL (15 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3793-01),Revised,9/12/22,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3793-01,limited availability
8403,Ketorolac Tromethamine Injection,"Hospira, Inc.",30 mg/mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3795-01),Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-3795-01,not available
8404,Ketorolac Tromethamine Injection,"Hospira, Inc.",60 mg/2 mL (30 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3796-01),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,00409-3796-01,limited availability
8405,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","15 mg per mL, Single Dose Amber Vial, (NDC 63323-161-01)",Revised,9/14/22,Available,Check wholesaler for inventory,,Manufacturing delays,Analgesia/Addiction,Current,,,63323-161-01,available
8406,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-01)",Revised,9/14/22,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,,,63323-162-01,available
8407,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","30 mg per mL, Single Dose Amber Vial, (NDC 63323-162-02)",Revised,9/14/22,Available,Check wholesaler for inventory.,,Manufacturing delays,Analgesia/Addiction,Current,,,63323-162-02,available
8408,Lactulose Solution,Wockhardt Bio AG/Morton Grove Pharmaceuticals,"10 g/15 mL- (NDC 60432-037-08) [8 oz (237 mL)], (NDC 60432-037-32) [32 oz (946 mL)], (NDC 60432-038-16) [16 oz (473 mL)] and (NDC 60432-038-64) [64 oz (1892 mL)]",New,5/26/22,,,,,Gastroenterology,To be Discontinued,,,60432-037-08,discontinued
8409,Lactulose Solution,Torrent Pharma Inc.,10 g/15 mL (ORAL) 8 oz (NDC 13668580-08) || 16 oz. (NDC 13668-580-10) || 32 oz (NDC 13668-580-12),New,6/9/22,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,13668580-08,discontinued
8410,Lactulose Solution,Torrent Pharma Inc.,10 g / 15 mL (ORAL-RECTAL) 8 oz (NDC 13668-574-08) || 16 oz (NDC 13668-574-10) || 32 oz (NDC 13668-574-12),New,6/9/22,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,13668-574-08,discontinued
8411,Lamivudine and Tenofovir Disoproxil Fumarate Tablets,"Celltrion, Inc.",300 mg; 300 mg (NDC 72606-002-01),New,9/1/21,,,,,Antiviral,To be Discontinued,,,72606-002-01,discontinued
8412,Lamivudine and Zidovudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine and Zidovudine Tablets 150mg and 300mg (NDC 0378-5180-91),New,3/16/18,,,,,Antiviral,To be Discontinued,,,0378-5180-91,discontinued
8413,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 100mg (NDC 0378-5168-93),New,3/16/18,,,,,Antiviral,To be Discontinued,,,0378-5168-93,discontinued
8414,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 150mg (NDC 0378-5169-91),New,3/16/18,,,,,Antiviral,To be Discontinued,,,0378-5169-91,discontinued
8415,Lamivudine Tablets,Mylan Pharmaceuticals Inc.,Lamivudine Tablets 300mg (NDC 0378-5170-93),New,3/16/18,,,,,Antiviral,To be Discontinued,,,0378-5170-93,discontinued
8416,Lanoxin (digoxin) Tablets,Concordia Pharmaceuticals Inc.,Lanoxin (digoxin) 187.5 mcg (0.1875 mg) tablets; 100-count bottles (NDC 59212-245-55),New,5/22/18,,,,,Cardiovascular,To be Discontinued,,,59212-245-55,discontinued
8417,Leucovorin Calcium for Injection,Teva,NDC 0703-5140-01 (100 mg/vial Single-Dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Pediatric,To be Discontinued,8/11/22,8/11/22,0703-5140-01,discontinued
8418,Leucovorin Calcium for Injection,Teva,NDC 0703-5145-01 (350 mg/vial Single-Dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Pediatric,To be Discontinued,8/11/22,8/11/22,0703-5145-01,discontinued
8419,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-10)",Revised,9/14/22,Backordered. Next release not available at this time.,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,63323-631-10,not available
8420,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL) Single dose amber vial, liquid (NDC 63323-631-50)",Revised,9/14/22,Available,Check Wholesaler Inventory,,Manufacturing Delay,Oncology;Pediatric,Current,,,63323-631-50,available
8421,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",100 mg vial (NDC 67457-528-10),Reverified,9/28/22,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-528-10,available
8422,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",200 mg vial (NDC 67457-529-20),Reverified,9/28/22,Available,,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-529-20,available
8423,Leucovorin Calcium Lyophilized Powder for Injection,"Mylan Institutional, a Viatris company",350 mg vial (NDC 67457-530-35),Reverified,9/28/22,Unavailable,Re-supply in September 2022.,,Demand increase for the drug,Oncology;Pediatric,Current,,,67457-530-35,not available
8424,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,500mg vial (NDC 25021-828-50),Revised,8/22/22,Backordered. Estimated availability Oct 2022,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-828-50,not available
8425,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",200 mg SDV (NDC 63323-710-50),Revised,9/14/22,Backordered. Next release September 2022.,Check Wholesaler Inventory,,Demand increase for the drug,Oncology;Pediatric,Current,,,63323-710-50,not available
8426,Leucovorin Calcium Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC",500 mg SDV (NDC 63323-711-00),Revised,9/14/22,Backordered. Next release September 2022.,Check Wholesaler Inventory,,Manufacturing delay,Oncology;Pediatric,Current,,,63323-711-00,not available
8427,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,50 mg vial (NDC 25021-813-10),Revised,8/22/22,Available.,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-813-10,available
8428,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,100mg vial (NDC 25021-814-30),Revised,8/22/22,Backordered. Estimated availability Oct 2022,,,Manufacturing delay,Oncology;Pediatric,Current,,,25021-814-30,not available
8429,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,200mg vial (NDC 25021-815-30),Revised,8/22/22,Available.,,,,Oncology;Pediatric,Current,,,25021-815-30,available
8430,Leucovorin Calcium Lyophilized Powder for Injection,Sagent Pharmaceuticals,350mg vial (NDC 25021-816-30),Revised,8/22/22,Available,,,,Oncology;Pediatric,Current,,,25021-816-30,available
8431,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,"100mg/vial, 20mL (NDC 0703-5140-01)",Reverified,10/5/22,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0703-5140-01,not available
8432,Leucovorin Calcium Lyophilized Powder for Injection,Teva Pharmaceuticals,350mg/vial 30mL (NDC 0703-5145-01),Reverified,10/5/22,Backordered – Estimated date of availability TBD,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0703-5145-01,not available
8433,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg, 10 mL vial (NDC 0143-9555-01)",Revised,1/13/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9555-01,not available
8434,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg, 20 mL vial (NDC 0143-9554-01)",Revised,1/13/22,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9554-01,available
8435,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","200 mg, 30 mL vial (NDC 0143-9553-01)",Revised,1/13/22,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9553-01,available
8436,Leucovorin Calcium Lyophilized Powder for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","350 mg, 50 mL vial (NDC 0143-9552-01)",Revised,1/13/22,Inventory is currently available.,,,Demand increase for the drug,Oncology;Pediatric,Current,,,0143-9552-01,available
8437,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 22.5 mg (NDC 62935-223-05),Reverified,1/12/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,62935-223-05,available
8438,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 30 mg (NDC 62935-303-30),Reverified,1/12/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,62935-303-30,available
8439,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 45 mg (NDC 62935-453-45),Reverified,1/12/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,62935-453-45,available
8440,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Fensolvi 45 mg (NDC 62935-153-50),Reverified,1/12/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,62935-153-50,available
8441,Leuprolide Acetate Injection,"Tolmar Pharmaceuticals, Inc.",Eligard 7.5 mg Kit (NDC 62935-753-75),Reverified,1/12/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,62935-753-75,available
8442,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 30mg (NDC 0074-9694-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-9694-03,available
8443,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 22.5 mg PDS Kit (NDC 0074-3346-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3346-03,available
8444,Leuprolide Acetate Injection,Abbvie,Lupron Depot 6 Months 45mg PDS Kit (NDC 0074-3473-03),Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3473-03,available
8445,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 7.5 mg PDS Kit (NDC 0074-3642-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3642-03,available
8446,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 4 Months 30 mg PDS Kit (NDC 0074-3683-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3683-03,available
8447,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 1 Month 3.75 mg PDS Kit (NDC 0074-3641-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3641-03,available
8448,Leuprolide Acetate Injection,Abbvie,"Lupron Depot, 3 Months 11.25 mg PDS Kit (NDC 0074-3663-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3663-03,available
8449,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 11.25 mg PDS Kit (NDC 0074-2282-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2282-03,available
8450,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 15 mg PDS Kit (NDC 0074-2440-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2440-03,available
8451,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 1 Month 7.5 mg PDS Kit (NDC 0074-2108-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-2108-03,available
8452,Leuprolide Acetate Injection,Abbvie,"Lupron Depot PED, 3 Months, 11.25mg (NDC 0074-3779-03)",Revised,10/3/22,Available,,,,Endocrinology/Metabolism;Oncology,Current,,,0074-3779-03,available
8453,Levoleucovorin Calcium Pentahydrate Injection,Ingenus Pharmaceuticals LLC,10 mg/1mL (NDC 50742-494-17),New,12/10/21,,,,,Oncology;Pediatric,To be Discontinued,,,50742-494-17,discontinued
8454,Levoleucovorin Calcium Pentahydrate Injection,Ingenus Pharmaceuticals LLC,10 mg 1mL (NDC 50742-495-25),New,12/10/21,,,,,Oncology;Pediatric,To be Discontinued,,,50742-495-25,discontinued
8455,Levoleucovorin Injection,Sandoz,175 mg/17.5 mL (10 mg/mL) (NDC 0781-3201-94 ),New,5/5/22,,,,,Oncology;Pediatric,To be Discontinued,,,0781-3201-94,discontinued
8456,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 5 mL (NDC 0591-3012-26)",New,4/27/18,,,,,Anesthesia,To be Discontinued,,,0591-3012-26,discontinued
8457,Lidocaine HCl Topical Jelly,Teva Pharmaceuticals,"Lidocaine HCl Topical Jelly, 20 mg/1 mL (2%), 30 mL (NDC 0591-3012-30)",New,4/27/18,,,,,Anesthesia,To be Discontinued,,,0591-3012-30,discontinued
8458,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/500 mL (4mg/mL) in VIAFLEX Plus container. Product code 2B0973 (NDC 0338-0409-03)",Reverified,8/26/22,Available on allocation,,,,Cardiovascular,Current,,,0338-0409-03,limited availability
8459,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,Baxter Healthcare,"Lidocaine Hydrochloride and 5% Dextrose Injection USP, 2 gram/250 mL (8mg/mL) in VIAFLEX Plus container. Product code 2B0962 (NDC 0338-0411-02)",Reverified,8/26/22,Available on allocation,,,Demand increase,Cardiovascular,Current,,,0338-0411-02,limited availability
8460,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.8% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5982 (NDC 00264-9598-20),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9598-20,available
8461,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 250mL Excel Plastic container P5942 (NDC 00264-9594-20),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9594-20,available
8462,Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags,B. Braun Medical Inc.,0.4% Lidocaine Hydrochloride and 5% Dextrose in 500mL Excel Plastic container P5941 (NDC 00264-9594-10),Reverified,5/6/21,Product available,,,Other,Cardiovascular,Current,,,00264-9594-10,available
8463,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 2 mL Ampoule (NDC 55150-158-72),Revised,9/28/22,Currently on backorder - next shipment anticipated Mid Oct,,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,not available
8464,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 5 mL Ampoule (NDC 55150-159-74),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,not available
8465,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 2 mL Ampoule (NDC 55150-160-72),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,not available
8466,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 2 mL Single Dose Vial (NDC 55150-161-02),Revised,9/28/22,Currently on backorder - next shipment anticipated End Oct,,,Demand increase for the drug,Anesthesia,Current,,,55150-161-02,not available
8467,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 5 mL Single Dose Vial (NDC 55150-162-05),Revised,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-162-05,available
8468,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 30 mL Single Dose Vial (NDC 55150-163-30),Revised,9/28/22,Currently on backorder - next shipment anticipated Mid Oct,,,Demand increase for the drug,Anesthesia,Current,,,55150-163-30,not available
8469,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 2 mL Single Dose Vial (NDC 55150-164-02),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-164-02,not available
8470,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 5 mL Single Dose Vial (NDC 55150-165-05),Revised,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-165-05,available
8471,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-02),Revised,9/30/22,Next Delivery: October 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4713-02,not available
8472,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL, 50 mL vial (NDC 63323-0484-57)",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0484-57,not available
8473,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 0.5% - MPF injection, APP 5 mg/mL, 50 mL vial (NDC 63323-0491-57)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0491-57,not available
8474,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 2 mL vial (NDC 63323-0201-02)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-02,not available
8475,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1% Lidocaine 1% injection 10 mg/mL, 10 mL vial (NDC 63323-0201-10)",Revised,9/14/22,Backordered. Next release September 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0201-10,not available
8476,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 20 mL vial (NDC 63323-0485-27)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-27,not available
8477,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% injection 10 mg/mL, 50 mL vial (NDC 63323-0485-57)",Revised,9/14/22,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0485-57,not available
8478,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL vial (NDC 63323-0492-27)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-27,not available
8479,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-80,not available
8480,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-89,not available
8481,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 5 mL vial (NDC 63323-0492-57)",Revised,9/14/22,Backordered. Next release November 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-57,not available
8482,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial (NDC 63323-0492-37)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-37,not available
8483,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 1% - MPF injection 10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0492-31,not available
8484,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); Ansyr Plastic Syringe (NDC 0409-9137-05),Revised,9/30/22,Next Delivery: November 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-9137-05,not available
8485,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",20 mg/2 mL (1%; 10 mg/mL); Glass Ampul (NDC 0409-4713-32),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: November 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4713-32,not available
8486,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","200 mg/20 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-01, pack of 25; NDC 0409-4276-16, individual)",Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4276-01,not available
8487,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/30 mL (1%; 10 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4279-02),Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4279-02,not available
8488,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","500 mg/50 mL (1%; 10 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4276-02; NDC 0409-4276-17, individual)",Revised,9/30/22,Next Delivery: October 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4276-02,not available
8489,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",40 mg/2 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-01),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4282-01,not available
8490,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/10 mL (2%; 20 mg/mL); Glass Ampul (NDC 0409-4282-02),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: February 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4282-02,not available
8491,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",50 mg/5 mL (1%; 10 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4904-34),Revised,9/30/22,Available,,,,Anesthesia;Pediatric,Current,,,0409-4904-34,available
8492,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); LifeShield Abboject Glass Syringe (NDC 0409-4903-34),Revised,9/30/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4903-34,limited availability
8493,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",100 mg/5 mL (2%; 20 mg/mL); Single Dose Glass Fliptop Vial (NDC 0409-2066-05),Revised,9/30/22,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-2066-05,not available
8494,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","400 mg/20 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-01, pack of 25; NDC 0409-4277-16, individual)",Revised,9/30/22,Limited Supply Available. Next Delivery: January 2023; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4277-01,limited availability
8495,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.","1,000 mg/50 mL (2%; 20 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4277-02)",Revised,9/30/22,Next Delivery and Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4277-02,not available
8496,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",200 mg/5 mL (4%; 40 mg/mL); Glass Ampul (NDC 0409-4283-01),Revised,9/30/22,Next Delivery: November 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4283-01,not available
8497,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",Xylocaine Cardiac 100 mg/5 mL (2%; 20 mg/mL); Ansyr Plastic Syringe (NDC 0409-1323-05),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-1323-05,not available
8498,Lidocaine Hydrochloride (Xylocaine) Injection,"Amphastar Pharmaceuticals, Inc./IMS","2%, 5mL Luer-Jet Prefilled Syringe (NDC 76329-3390-1)(old NDC 0548-3390-00)",Reverified,8/12/22,Backordered due to the increase in demands,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,76329-3390-1,not available
8499,Lidocaine Hydrochloride (Xylocaine) Injection,American Regent/Luitpold,"1%, 50 mL vial package of 25 (NDC 00517-0625-25)",Reverified,3/30/21,Unavailable-No product available for release. No plan to manufacture.,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00517-0625-25,discontinued
8500,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 10 mL ampule (NDC 63323-0493-97)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-97,not available
8501,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL, 20 mL ampule (NDC 63323-0493-91)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0493-91,not available
8502,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% Lidocaine 2% injection 20 mg/mL, 2 mL vial (NDC 63323-0202-02)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0202-02,not available
8503,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Lidocaine 2% injection 20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0208-05,not available
8504,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-17)",Revised,9/14/22,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-17,not available
8505,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 20 mL vial (NDC 63323-0486-27)",Revised,9/14/22,Backordered. Next release October 2022.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-27,not available
8506,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-57)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-57,not available
8507,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 10 mL vial (NDC 63323-0486-10)discontinued",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-10,not available
8508,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection NDC discontinued 20 mg/mL, 20 mL vial (NDC 63323-0486-20)-NDC discontinued",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-20,not available
8509,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% injection 20 mg/mL, 50 mL vial (NDC 63323-0486-50)-NDC discontinued",Revised,9/14/22,Not available at this time.,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0486-50,not available
8510,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 2 mL vial (NDC 63323-0495-27)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-27,not available
8511,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 5 mL vial (NDC 63323-0495-07)",Revised,9/14/22,Backordered. Next release November 2022.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0495-07,not available
8512,Lidocaine Hydrochloride (Xylocaine) Injection,"Fresenius Kabi USA, LLC","Xylocaine 2% - MPF injection 20 mg/mL, 10 mL ampule (NDC 63323-0496-97)",Revised,9/14/22,Backordered. Next release date not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,63323-0496-97,not available
8513,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Multiple Dose Plastic Fliptop Vial (NDC 0409-4275-01),Revised,9/30/22,Next Delivery: April 2023; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Pediatric,Current,,,0409-4275-01,not available
8514,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",250 mg/50 mL (0.5%; 5 mg/mL); Single Dose Glass Teartop Vial (NDC 0409-4278-01),Revised,9/30/22,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4278-01,not available
8515,Lidocaine Hydrochloride (Xylocaine) Injection,"Hospira, Inc.",300 mg/20 mL (1.5%; 15 mg/mL); Glass Ampul (NDC 0409-4776-01),Revised,9/30/22,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-4776-01,not available
8516,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 10 mL Multi Dose Vial (NDC 55150-251-10),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-251-10,not available
8517,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 20 mL Multi Dose Vial (NDC 55150-252-20),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-252-20,not available
8518,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 10 mL Multi Dose Vial (NDC 55150-254-10),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-254-10,not available
8519,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% 20 mL Multi Dose Vial (NDC 55150-255-20),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-255-20,not available
8520,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 5 mL vial, Preservative Free (NDC 0143-9595-25)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9595-25,not available
8521,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 5 mL vial, Preservative Free (NDC 0143-9594-25)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9594-25,not available
8522,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1% 50 mL vial, Preserved (NDC 0143-9577-10)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9577-10,not available
8523,Lidocaine Hydrochloride (Xylocaine) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2% 50 mL vial, Preserved (NDC 0143-9575-10)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia,Current,,,0143-9575-10,not available
8524,Lidocaine Hydrochloride (Xylocaine) Injection,"Spectra Medical Devices, Inc.",1% 5 mL ampule (NDC 65282-1605-1),Revised,1/7/22,Available,,,Other,Anesthesia,Current,,,65282-1605-1,available
8525,Lidocaine Hydrochloride (Xylocaine) Injection,"Huons Co., Ltd. (South Korea)","Methylparaben Free Lidocaine HCl Injection, USP 1% 50mg/5mL (Vial) (NDC 73293-0001-2)",New,9/6/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,73293-0001-2,available
8526,Lidocaine Hydrochloride (Xylocaine) Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),2% MDV 1000mg/50mL (NDC 55150-256-50),Revised,9/28/22,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-256-50,not available
8527,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","0.5% w/EPI 1:100,000; 1.8 mL Carpule (NDC 00409-0996-01)",Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-0996-01,discontinued
8528,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2.5 g/50 mL (0.5%; 1:200,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3177-01)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3177-01,not available
8529,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","200 mg/20 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-01)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3178-01,not available
8530,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","300 mg/30 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 00409-3178-02)",Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,00409-3178-02,not available
8531,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","500 mg/50 mL (1%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3178-03)",Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3178-03,not available
8532,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","75 mg/5 mL (1.5%; 1:200,000); Glass Ampul (NDC 0409-1209-01)",Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-1209-01,not available
8533,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","450 mg/30 mL (1.5%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3181-01)",Revised,9/12/22,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3181-01,limited availability
8534,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-01)",Revised,9/12/22,Limited Supply Available. Next Delivery: October 2022; Estimated Recovery: May 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-01,limited availability
8535,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","600 mg/30 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-02)",Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-02,not available
8536,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","1 g/50 mL (2%; 1:100,000); Multiple Dose Glass Fliptop Vial (NDC 0409-3182-03)",Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: June 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3182-03,not available
8537,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","400 mg/20 mL (2%; 1:200,000); Single Dose Glass Fliptop Vial (NDC 0409-3183-01)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Pediatric,Current,,,0409-3183-01,not available
8538,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Hospira, Inc.","2% w/EPI 1:50,000; 1.8mL syringe (NDC 00409-7263-01)",Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Pediatric,Current,,,00409-7263-01,discontinued
8539,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100 mg MDV (NDC 63323-0482-17)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0482-17,not available
8540,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 100mg SDV, MPF (NDC 63323-0487-17)",Revised,9/14/22,Backordered. Next release August 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0487-17,not available
8541,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 150 mg, SDV, MPF (NDC 63323-0488-17)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0488-17,not available
8542,Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine,"Fresenius Kabi USA, LLC","Xylocaine w/EPI 10 mL, 200 mg, SDV, MPF (NDC 63323-0489-17)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory.,,Manufacturing delay,Anesthesia;Pediatric,Current,,,63323-0489-17,not available
8543,Lindane Shampoo 1%,Wockhardt Bio A.G.,"60 mL, (NDC 60432-834-60)",New,6/22/22,,,,,Other,To be Discontinued,,,60432-834-60,discontinued
8544,Linezolid Injection,Teva Pharmaceuticals,"600 mg/300 mL, 300 mL/Bag (NDC 0703-9060-33)",New,9/13/22,,Product has not been marketed for at least 5 years,,,Anti-Infective,To be Discontinued,9/13/22,9/13/22,0703-9060-33,discontinued
8545,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 5mcg tablets (NDC 0378-3611-01),New,3/28/18,,,,,Endocrinology/Metabolism,To be Discontinued,,,0378-3611-01,discontinued
8546,Liothyronine Sodium Tablets,Mylan Pharmaceuticals Inc.,Liothyronine Sodium 25mcg tablets (NDC 0378-3612-01),New,3/28/18,,,,,Endocrinology/Metabolism,To be Discontinued,,,0378-3612-01,discontinued
8547,Lisinopril Tablets,Mylan Pharmaceuticals Inc.,2.5 mg (NDC 0378-2072-01); 5 mg (NDC 0378-2073-01); 5 mg (NDC 0378-2073-10); 10 mg (NDC 0378-2074-01); 10 mg (NDC 0378-2074-10); 20 mg (NDC 0378-2075-01); 20 mg (NDC 0378-2075-10); 30 mg (NDC 0378-2077-01); 40 mg (NDC 0378-2076-01; 40 mg (NDC 0378-2076-05,New,4/11/18,,,,,Cardiovascular,To be Discontinued,,,0378-2072-01,discontinued
8548,Lithium Oral Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",8 mEq/5 mL 500 mL bottle (NDC 0054-3527-63),Reverified,10/6/22,"Unavailable, Estimated Shortage: TBD",,,Shortage of an active ingredient,Psychiatry,Current,,,0054-3527-63,not available
8549,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6001-25,not available
8550,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6000-10,not available
8551,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6003-25,not available
8552,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,not available
8553,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6044-25,not available
8554,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6046-10,not available
8555,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6045-25,not available
8556,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)",Reverified,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Neurology,Current,,,0641-6002-10,not available
8557,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-1539-31,discontinued
8558,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; Carpuject Luer Lock Glass Syringe  (NDC 00409-1985-30),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023,,,Demand increase for the drug,Neurology,Current,,,00409-1985-30,limited availability
8559,Lorazepam Injection,"Hospira, Inc.",2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02),Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Neurology,Current,,,00409-6778-02,not available
8560,Lorazepam Injection,"Hospira, Inc.",4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-6779-02,discontinued
8561,Lorazepam Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Neurology,Current,,,00409-6780-02,discontinued
8562,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc./IMS","LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)",Reverified,8/12/22,Backorder due to the increase in demands,,,Other,Neurology,Current,,,76329-8261-1,not available
8563,Lorazepam Injection,Akorn Pharmaceuticals,Lorazepam Injection 2 mg/mL (NDC 17478-040-01),Reverified,5/19/21,Available,,,Demand increase for the drug,Neurology,Current,,,17478-040-01,available
8564,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 1000 count bottle (NDC 0527-1394-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,,,0527-1394-10,discontinued
8565,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 1000 count bottle (NDC 0527-1395-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,,,0527-1395-10,discontinued
8566,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 1000 count bottle (NDC 0527-1396-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,,,0527-1396-10,discontinued
8567,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 1000 count bottle (NDC 0527-1397-10)",New,11/25/19,,,,,Psychiatry,To be Discontinued,,,0527-1397-10,discontinued
8568,Loxapine Capsules,"Lannett Company, Inc.","5 mg, 100 count bottle (NDC 0527-1394-01)",Revised,6/13/22,,,Available,,Psychiatry,Resolved,,,0527-1394-01,
8569,Loxapine Capsules,"Lannett Company, Inc.","10 mg, 100 count bottle (NDC 0527-1395-01)",Revised,6/13/22,,,Available,,Psychiatry,Resolved,,,0527-1395-01,
8570,Loxapine Capsules,"Lannett Company, Inc.","25 mg, 100 count bottle (NDC 0527-1396-01)",Revised,6/13/22,,,Available,Other,Psychiatry,Resolved,,,0527-1396-01,
8571,Loxapine Capsules,"Lannett Company, Inc.","50 mg, 100 count bottle (NDC 0527-1397-01)",Revised,6/13/22,,,Available,,Psychiatry,Resolved,,,0527-1397-01,
8572,Loxapine Capsules,Teva Pharmaceuticals,"5 mg, 100 count bottle (NDC 0591-0369-01)",Revised,6/14/22,,,Available,,Psychiatry,Resolved,,,0591-0369-01,
8573,Loxapine Capsules,Teva Pharmaceuticals,"25 mg, 100 count bottle (NDC 0591-0371-01)",Revised,6/14/22,,,Available,,Psychiatry,Resolved,,,0591-0371-01,
8574,Loxapine Capsules,Teva Pharmaceuticals,"50 mg, 100 count bottle (NDC 0591-0372-01)",Revised,6/14/22,,,Available,,Psychiatry,Resolved,,,0591-0372-01,
8575,Lutetium Lu 177 Dotatate (LUTATHERA) Injection,"Advanced Accelerator Applications USA, Inc.","Lutathera® (lutetium Lu 177 dotatate) injection, for intravenous use 10 mCi/mL; Colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 dotatate (NDC 69488-003-01)",Revised,8/1/22,,,Available,,Oncology,Resolved,8/1/22,,69488-003-01,
8576,Mannitol Injection,B. Braun Medical Inc.,20% 500 mL Excel Bag L5781 (NDC 0264-7578-20),New,6/10/22,Product on allocation for contracted customers,,,Other,Renal,Current,,,0264-7578-20,limited availability
8577,Mannitol Injection,"Fresenius Kabi USA, LLC",25% (12.5 grams per 50 mL)(250 mg per mL) Single dose vial (NDC 63323-024-25),Revised,9/14/22,Backordered. Next release October 2022.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,63323-024-25,not available
8578,Mannitol Injection,"Hospira, Inc.",12.5 g/50 mL (25%); Single Dose Glass Fliptop Vial (NDC 0409-4031-01),Reverified,9/12/22,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Renal,Current,,,0409-4031-01,not available
8579,Mannitol Injection,Baxter Healthcare,"10% OSMITROL Injection (10% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5613Q (NDC 0338-0535-03)",Revised,8/26/22,Available,,,,Renal,Current,,,0338-0535-03,available
8580,Mannitol Injection,Baxter Healthcare,"20% OSMITROL Injection (20% Mannitol Injection, USP) 500 mL Viaflex Plastic Container Product Code 2D5633Q (NDC 0338-0357-03); 250 mL Viaflex Plastic Container Product Code 2D5632Q (NDC 0338-0357-02)",Revised,8/26/22,Available,,,,Renal,Current,,,0338-0357-03,available
8581,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 500 mL (Legacy Hospira NDC 0409-7715-03)(ICU Medical NDC 0990-7715-03)",Reverified,10/3/22,On allocation,,,Other,Renal,Current,,,0409-7715-03,limited availability
8582,Mannitol Injection,"ICU Medical, Inc.","20% Mannitol Injection, USP 250 mL (Legacy Hospira NDC 0409-7715-02)(ICU Medical NDC 0990-7715-02)",Reverified,10/3/22,On allocation,,,Other,Renal,Current,,,0409-7715-02,limited availability
8583,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 100 count (NDC 42806-012-01)",New,2/28/18,,,,,Gastroenterology,To be Discontinued,,,42806-012-01,discontinued
8584,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"12.5mg tablets, 1000 count (NDC 42806-012-10)",New,2/28/18,,,,,Gastroenterology,To be Discontinued,,,42806-012-10,discontinued
8585,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 100 count (NDC 42806-014-01)",New,2/28/18,,,,,Gastroenterology,To be Discontinued,,,42806-014-01,discontinued
8586,Meclizine Hydrochloride Tablets,Epic Pharmaceuticals,"25mg tablets, 1000 count (NDC 42806-014-10)",New,2/28/18,,,,,Gastroenterology,To be Discontinued,,,42806-014-10,discontinued
8587,Medroxyprogesterone Acetate Injectable Suspension,Teva,NDC 0703-6801-01 (150 mg/mL 1 mL Single-Dose Vial),New,8/11/22,,Product is currently  unavailable and no future production expected for an extended period.,,,Reproductive,To be Discontinued,8/11/22,8/11/22,0703-6801-01,discontinued
8588,Medroxyprogesterone Acetate Injectable Suspension,Teva,NDC 0703-6801-04 (150 mg/mL  25 x 1 mL Single-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Reproductive,To be Discontinued,8/11/22,8/11/22,0703-6801-04,discontinued
8589,Megestrol Acetate Oral Suspension,Wockhardt Bio AG/Morton Grove Pharmaceuticals,"40 mg/mL (NDC 60432-126-08) [8 oz (240 mL)], (NDC 60432-126-16) [1 Pint (480 mL)]",New,5/26/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,60432-126-08,discontinued
8590,Megestrol Acetate Suspension,Par Pharmaceutical,"125mg/1ml, 150ml Bottle (NDC 49884-230-69)",New,12/1/21,,,,,Endocrinology/Metabolism,To be Discontinued,,,49884-230-69,discontinued
8591,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",7.5 mg tablets (NDCs 0597-0029-01 and 0597-0029-94),New,11/1/21,,,,,Analgesia/Addiction,To be Discontinued,,,,discontinued
8592,Meloxicam Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",15 mg tablets (NDCs 0597-0030-01 and 0597-0030-56),New,11/1/21,,,,,Analgesia/Addiction,To be Discontinued,,,,discontinued
8593,Memantine Hydrochloride Extended-Release Capsules,"ANI Pharmaceuticals, Inc.",14mg tablets(NDCs 43975-264-03 and 43975-264-09),New,4/8/22,,,,,Neurology,To be Discontinued,,,,discontinued
8594,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 1% (500 mg per 50 mL), (10 mg per mL), MDV, (NDC 63323-0283-57)",Revised,9/14/22,Available,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0283-57,available
8595,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine) 2% (1,000 mg per 50 mL), (20 mg per mL), MDV, (NDC 63323-0296-57)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0296-57,not available
8596,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1% (300 mg per 30 mL), (10 mg per mL), SDV, (NDC 63323-0260-37)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,,Anesthesia,Current,,,63323-0260-37,not available
8597,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 1.5% (450 mg per 30 mL), (15 mg per mL), SDV, (NDC 63323-0293-37)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler inventory,,Manufacturing delay,Anesthesia,Current,,,63323-0293-37,not available
8598,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","(Polocaine MPF) 2% (400 mg per 20 mL), (20 mg per mL), SDV, (NDC 63323-0294-27)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Manufacturing delay,Anesthesia,Current,,,63323-0294-27,not available
8599,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",300 mg/30 mL (10 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1036-30),Revised,6/10/22,,,,,Anesthesia,To be Discontinued,,,0409-1036-30,discontinued
8600,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1067-20),Revised,6/10/22,,,,,Anesthesia,To be Discontinued,,,0409-1067-20,discontinued
8601,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial (NDC 0409-1041-30),Revised,6/10/22,,,,,Anesthesia,To be Discontinued,,,0409-1041-30,discontinued
8602,Mepivacaine Hydrochloride Injection,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 0409-1038-50),Revised,6/10/22,,,,,Anesthesia,To be Discontinued,,,0409-1038-50,discontinued
8603,Mesalamine (CANASA®)  Suppositories,Allergan,"1 gm, Rectal Suppositories, 42 suppositories in 1 box (NDC 58914-501-42)",New,7/30/20,,,,,Gastroenterology,To be Discontinued,,,58914-501-42,discontinued
8604,Metaxalone Tablets,Pfizer Pharmaceuticals,Skelaxin 800 mg tablet; Bottle of 100 (NDC 60793-136-01),New,2/25/22,,,,,Musculoskeletal,To be Discontinued,,,60793-136-01,discontinued
8605,Metaxalone Tablets,Pfizer Pharmaceuticals,Skelaxin 800 mg tablet; Bottle of 500 (NDC 60793-136-05),New,2/25/22,,,,,Musculoskeletal,To be Discontinued,,,60793-136-05,discontinued
8606,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,750mg tablets (NDC 2037-577-10) and (NDC 62037-577-01 ),New,6/24/20,,,,,Endocrinology/Metabolism,To be Discontinued,,,2037-577-10,discontinued
8607,Metformin Hydrochloride Extended Release Tablets,Teva Pharmaceuticals,500mg tablets (NDC 62037-571-01) and (NDC 62037-571-10),New,6/24/20,,,,,Endocrinology/Metabolism,To be Discontinued,,,62037-571-01,discontinued
8608,Methadone Hydrochloride Injection,"Mylan Pharmaceuticals Inc., a Viatris Company",Methadone Hydrochloride Injection (Solution in Multi Dose Vials) [200 mg / 20 ml](NDC 67457-217-20),Revised,6/8/21,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,,,67457-217-20,
8609,Methadone Hydrochloride Injection,Akorn Pharmaceuticals,"Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) , 20 mL multidose vials (NDC 17478-380-20)",Revised,6/8/21,,,Available,,Analgesia/Addiction;Anesthesia,Resolved,,,17478-380-20,
8610,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 5 mg tablets; bottle of 100 (NDC 60793-104-01),New,11/5/21,,,,,Endocrinology/Metabolism,To be Discontinued,,,60793-104-01,discontinued
8611,Methimazole Tablets,Pfizer Pharmaceuticals,Tapazole 10 mg tablets; bottle of 100 (NDC 60793-105-01),New,11/5/21,,,,,Endocrinology/Metabolism,To be Discontinued,,,60793-105-01,discontinued
8612,Methocarbamol Injection,"Mylan Specialty, a Viatris Company",100 mg/mL (NDC 67457-273-10),New,5/9/22,,,,,Analgesia/Addiction,To be Discontinued,,,67457-273-10,discontinued
8613,Methohexital Sodium (Brevital) Injection,Par Pharmaceutical,"500 mg/vial, 50 mL multiple dose vial, box of 1 (NDC 42023-105-01)",Revised,11/15/21,,,Available,,Anesthesia,Resolved,,,42023-105-01,
8614,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 100s (16729-03-001),Revised,4/7/22,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,unclear
8615,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 250 mg 500s (16729-03-016),Revised,4/7/22,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,unclear
8616,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 100s (16729-03-101),Revised,4/7/22,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,unclear
8617,Methyldopa Tablets,Accord Healthcare Inc.,Methyldopa 500 mg 500s (16729-03-116),Revised,4/7/22,No additional lots are anticipated at this time.,,,API procurement delay,Cardiovascular,Current,,,,unclear
8618,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",250 mg (NDC 0378-0611-01),Revised,10/8/21,,,,,Cardiovascular,To be Discontinued,,,0378-0611-01,discontinued
8619,Methyldopa Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",500 mg (NDC 0378-0421-01),Revised,10/8/21,,,,,Cardiovascular,To be Discontinued,,,0378-0421-01,discontinued
8620,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0045-01 (400 mg/10 mL (40 mg/mL) 10 mL Multiple-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0045-01,discontinued
8621,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0043-01 (200 mg/5 mL (40 mg/mL) 5 mL Multiple-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0043-01,discontinued
8622,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0063-01 (400 mg/5 mL (80 mg/mL) 5 mL Multiple-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0063-01,discontinued
8623,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0031-01 (40 mg/mL 1 mL Single-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0031-01,discontinued
8624,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0031-04 (40 mg/mL 25 x 1 mL Single-Dose Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0031-04,discontinued
8625,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0051-01 (80 mg/mL 1 mL Single-Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0051-01,discontinued
8626,Methylprednisolone Acetate Injectable Suspension,Teva,NDC 0703-0051-04 (80 mg/mL 25 x 1 mL Single-Dose Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Rheumatology,To be Discontinued,8/11/22,8/11/22,0703-0051-04,discontinued
8627,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","400 mg/5 mL (80 mg/mL), 5 mL multiple dose vial, box of 1 (NDC 42023-240-01)",New,6/16/22,Available,,,,Rheumatology,Current,,,42023-240-01,available
8628,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,40MG/ML 1X10ML (NDC 25021-820-010),Reverified,8/22/22,Available,,,,Rheumatology,Current,,,25021-820-010,available
8629,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,40MG/ML 1X5ML (NDC 25021-820-05),Reverified,8/22/22,Backorder. Estimated availability June 2022,,,,Rheumatology,Current,,,25021-820-05,not available
8630,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,80MG/ML 1x5ML (NDC 25021-821-05),Reverified,8/22/22,Available,,,,Rheumatology,Current,,,25021-821-05,available
8631,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"40mg/mL, 1 single-dose vial (NDC 70121-1573-01)",New,12/15/21,Unavailable,,,Increase in demand,Rheumatology,Current,,,70121-1573-01,not available
8632,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"40 mg/mL, 25 single-dose vials (NDC 70121-1573-05)",New,12/15/21,Unavailable,,,Increase in demand,Rheumatology,Current,,,70121-1573-05,not available
8633,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"80 mg/mL, 1 single-dose vials (NDC 70121-1574-01)",New,12/15/21,Unavailable,,,Increase in demand,Rheumatology,Current,,,70121-1574-01,not available
8634,Methylprednisolone Acetate Injection,Amneal Pharmaceutical,"80 mg/mL, 25 single-dose vials (NDC 70121-1574-05)",New,12/15/21,Unavailable,,,Increase in demand,Rheumatology,Current,,,70121-1574-05,not available
8635,Methylprednisolone Acetate Injection,Northstar,"40mg/ml, 1ml/1 vial X 25 (NDC 16714-088-25)",New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-088-25,limited availability
8636,Methylprednisolone Acetate Injection,Northstar,"40mg/ml, 1ml/1 vial (NDC 16714-088-01)",New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-088-01,limited availability
8637,Methylprednisolone Acetate Injection,Northstar,200mg/5ml (40mg/ml) (NDC 16714-089-01),New,12/15/21,Out of Stock,,,Other,Rheumatology,Current,,,16714-089-01,not available
8638,Methylprednisolone Acetate Injection,Northstar,"80mg/ml, 1ml/1 vial X 25 (NDC 16714-472-25)",New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-472-25,limited availability
8639,Methylprednisolone Acetate Injection,Northstar,"80mg/ml, 1ml/1 vial (NDC 16714-472-01)",New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-472-01,limited availability
8640,Methylprednisolone Acetate Injection,Northstar,"400mg/5ml (80mg/ml), 5ml/1 vial (NDC 16714-473-01)",New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-473-01,limited availability
8641,Methylprednisolone Acetate Injection,Northstar,400mg/10ml (40mg/ml) (NDC 16714-090-01),New,12/15/21,Available; Product on allocation,,,Other,Rheumatology,Current,,,16714-090-01,limited availability
8642,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,400 mg/10 mL (40 mg/mL) 10 mL Multiple-Dose Vial (NDC 0703-0045-01),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0045-01,not available
8643,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,400 mg/5 mL (80 mg/mL) 5 mL Multiple-Dose Vial(NDC 0703-0063-01),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0063-01,not available
8644,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,200 mg/5 mL (40 mg/mL) 5 mL Multiple-Dose Vial(NDC 0703-0043-01),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0043-01,not available
8645,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,40 mg/mL 1 mL Single-Dose Vial (NDC 0703-0031-01),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0031-01,not available
8646,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,80 mg/mL 1 mL Single-Dose Vial(NDC 0703-0051-01),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0051-01,not available
8647,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,40 mg/mL 25 x 1 mL Single-Dose Vial (NDC 0703-0031-04 40),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0031-04,not available
8648,Methylprednisolone Acetate Injection,Teva Pharmaceuticals,80 mg/mL 25 x 1 mL Single-Dose Vial(NDC 0703-0051-04),Reverified,10/5/22,Backordered; Estimated duration TBD,,,Other,Rheumatology,Current,,,0703-0051-04,not available
8649,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,20 mg/mL; Multidose Vial (NDC 0009-0274-01),Revised,9/12/22,Next Delivery and Estimated Recovery: December 2022,,,Other,Rheumatology,Current,,,0009-0274-01,not available
8650,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-02),Revised,9/12/22,Next Delivery and Estimated Recovery: November 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-0280-02,not available
8651,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-03),Revised,9/12/22,Limited Supply Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Rheumatology,Current,,,0009-0280-03,limited availability
8652,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-51),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-0280-51,not available
8653,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Multidose Vial (NDC 0009-0280-52),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-0280-52,not available
8654,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Multidose Vial (NDC 0009-0306-02),Revised,9/12/22,Available,,,Other,Rheumatology,Current,,,0009-0306-02,available
8655,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Multidose Vial (NDC 0009-0306-12),Revised,9/12/22,Next Delivery and Estimated Recovery: September 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-0306-12,not available
8656,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial (NDC 0009-3073-01),Revised,9/12/22,Limited Supply Next Delivery: December 2022; Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3073-01,limited availability
8657,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial (NDC 0009-3073-03),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Rheumatology,Current,,,0009-3073-03,not available
8658,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,40 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3073-22),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3073-22,not available
8659,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3073-23),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3073-23,not available
8660,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial (NDC 0009-3475-01),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3475-01,not available
8661,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial (NDC 0009-3475-03),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: July 2023,,,Demand increase for the drug,Rheumatology,Current,,,0009-3475-03,not available
8662,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3475-22),Revised,9/12/22,Next Delivery and Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3475-22,not available
8663,Methylprednisolone Acetate Injection,Pfizer Pharmaceuticals,80 mg/mL; Single-dose Vial NovaPlus (NDC 0009-3475-23),Revised,9/12/22,Next Delivery: February 2023; Estimated Recovery: July 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Rheumatology,Current,,,0009-3475-23,not available
8664,Methylprednisolone Tablets,Pfizer,32 mg tablet; Bottle of 25 (NDC 0009-0176-01),New,9/12/22,,Discontinuation of the manufacture of the drug.,,,Rheumatology,To be Discontinued,9/12/22,9/12/22,0009-0176-01,discontinued
8665,Methylprednisolone Tablets,Teva Pharmaceuticals,4 mg tablets (NDC 0591-0790-01),New,12/5/19,,,,,Neurology,To be Discontinued,,,0591-0790-01,discontinued
8666,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-01",New,7/6/21,,,,,Gastroenterology,To be Discontinued,,,49884-0689-01,discontinued
8667,Metoclopramide Tablets,Par Pharmaceutical,"10 mg, 500S (NDC 49884-0689-05)",New,7/6/21,,,,,Gastroenterology,To be Discontinued,,,49884-0689-05,discontinued
8668,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,50 mg tablets (NDCs 0591-0462-01 and 0591-0462-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,,,,discontinued
8669,Metoprolol Tartrate Tablets,Teva Pharmaceuticals,100 mg tablets (NDCs 0591-0463-01 and 0591-0463-10),New,12/16/19,,,,,Cardiovascular,To be Discontinued,,,,discontinued
8670,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 100 bottle (NDC 0025-1821-31),New,10/13/21,,,,,Anti-Infective,To be Discontinued,,,0025-1821-31,discontinued
8671,Metronidazole (Flagyl) Tablets,Pfizer Pharmaceuticals,500 mg tablets 1 x 50 bottle (NDC 0025-1821-50),New,10/13/21,,,,,Anti-Infective,To be Discontinued,,,0025-1821-50,discontinued
8672,Metronidazole Injection,B. Braun Medical Inc.,500 mg/100 mL (5 mg/mL) NDC 0264-5535-32 (Product code D5353-5224),New,1/13/22,Available. On allocation.,,,Demand increase for the drug,Anti-Infective,Current,,,0264-5535-32,limited availability
8673,Metronidazole Injection,Baxter Healthcare,"500 mg/100 mL in VIAFLEX Plastic Container. Product Code 2B3421, (NDC 0338-1055-48)",Reverified,8/26/22,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
8674,Metronidazole Injection,Sagent Pharmaceuticals,5mg/ml 500mg per 100mL bag in 24 pack (NDC 25021-113-82),Reverified,8/12/22,Available,,,Demand increase for the drug,Anti-Infective,Current,,,25021-113-82,available
8675,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-7811-37),Reverified,9/12/22,Available,,,Other,Anti-Infective,Current,,,0409-7811-37,available
8676,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-7811-24),Revised,8/17/22,,Discontinuation of the manufacture of the drug. Replaced with NDC 00409-0152-24,,,Anti-Infective,To be Discontinued,8/17/22,8/17/22,0409-7811-24,discontinued
8677,Metronidazole Injection,"Hospira, Inc.",500 mg/100 mL (5 mg/mL); Flexible Container (NDC 0409-0152-24),Reverified,9/12/22,Available,,,Other,Anti-Infective,Current,,,0409-0152-24,available
8678,Metronidazole Injection,Gland Pharma Limited,100 mL Single Dose Bag (NDC 47335-993-01),New,4/11/22,Lots are anticipated in April; with additional inventory arriving in May.,,,Other,Anti-Infective,Current,,,47335-993-01,limited availability
8679,Midazolam Injection,WG Critical Care,50mg/50mL (1mg/mL) in 0.9% Sodium Chloride single-dose bag  (NDC 44567-610-10),Reverified,10/3/22,Available,,,,Anesthesia;Neurology,Current,,,44567-610-10,available
8680,Midazolam Injection,WG Critical Care,100mg/100mL (1mg/mL) in 0.9% Sodium Chloride single-dose bag  (NDC 44567-611-10),Reverified,10/3/22,Available,,,,Anesthesia;Neurology,Current,,,44567-611-10,available
8681,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,50 mg/10mL vial (NDC 23155-601-42),Reverified,8/23/22,Available,,,Other,Anesthesia;Neurology,Current,,,23155-601-42,available
8682,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,25 mg/5mL vial (NDC 23155-601-41),Reverified,8/23/22,Available,,,Other,Anesthesia;Neurology,Current,,,23155-601-41,available
8683,Midazolam Injection,Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals,2 mg/2mL vial (NDC 23155-600-41),Reverified,8/23/22,Available; On allocation due to increased demand,,,Other,Anesthesia;Neurology,Current,,,23155-600-41,limited availability
8684,Midazolam Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2587-05),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2587-05,not available
8685,Midazolam Injection,"Hospira, Inc.",2 mg/2 mL (1 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2306-62),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,00409-2306-62,discontinued
8686,Midazolam Injection,"Hospira, Inc.",5 mg/mL CARPUJECT™ Luer Lock Glass Syringe (NDC 00409-2307-60),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Anesthesia;Neurology,Current,,,00409-2307-60,discontinued
8687,Midazolam Injection,Akorn Pharmaceuticals,10 ML Vial - Pack of 10 (NDC 17478-0524-10),Revised,10/22/21,Available,,,,Anesthesia;Neurology,Current,,,17478-0524-10,available
8688,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-10,available
8689,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0001-20)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0001-20,available
8690,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-12,not available
8691,Midazolam Injection,"Fresenius Kabi USA, LLC","1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0411-25,available
8692,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-25,available
8693,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-10,available
8694,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 1 mL prefilled syringe, 24 count (NDC 76045-0002-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,76045-0002-10,available
8695,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-02,available
8696,Midazolam Injection,"Fresenius Kabi USA, LLC","5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia;Neurology,Current,,,63323-0412-05,available
8697,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 10 mL vial, 10 count (NDC 00641-6056-10)",Revised,8/26/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6056-10,available
8698,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 2 mL vial, 25 count (NDC 00641-6057-25)",Revised,8/26/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6057-25,available
8699,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","1 mg/mL, 5 mL vial, 10 count (NDC 0641-6059-25)",Revised,8/26/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,0641-6059-25,available
8700,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 1 mL vial, 25 count (NDC 00641-6061-25)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6061-25,not available
8701,Midazolam Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","5 mg/mL, 10 mL vial, 10 count (NDC 00641-6060-10)",Revised,8/26/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00641-6060-10,not available
8702,Midazolam Injection,"Hospira, Inc.",2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-17),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: April 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2305-17,not available
8703,Midazolam Injection,"Hospira, Inc.",5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2305-05),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia;Neurology,Current,,,00409-2305-05,limited availability
8704,Midazolam Injection,"Hospira, Inc.",5 mg/mL (5 mg/mL)  Single Dose Glass Fliptop Vial (NDC 00409-2308-01),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2308-01,limited availability
8705,Midazolam Injection,"Hospira, Inc.",50 mg/10 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-05),Revised,9/12/22,Available,,,Other,Anesthesia;Neurology,Current,,,00409-2596-05,available
8706,Midazolam Injection,"Hospira, Inc.",10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial (NDC 00409-2308-02),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2308-02,limited availability
8707,Midazolam Injection,"Hospira, Inc.",25 mg/5 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial (NDC 00409-2596-03),Revised,9/12/22,Next Delivery and Estimated Recovery: January 2023,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,00409-2596-03,not available
8708,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 70860-601-10),Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-10,available
8709,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 70860-601-05),Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-601-05,available
8710,Midazolam Injection,Gland Pharma Limited,25 mg per 5 mL Multi-Dose Vial (NDC 47781-589-17),Reverified,9/12/22,No stock available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-17,not available
8711,Midazolam Injection,Gland Pharma Limited,50 mg per 10 mL Multi-Dose Vial (NDC 47781-589-91),Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-589-91,available
8712,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 70860-600-02),Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,70860-600-02,available
8713,Midazolam Injection,Gland Pharma Limited,2 mg per 2 mL Single Dose Vial (NDC 47781-588-68),Reverified,9/12/22,Available,,,Demand increase for the drug,Anesthesia;Neurology,Current,,,47781-588-68,available
8714,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",15mg tablets (NDC 0591-2469-15),New,5/29/18,,,,,Psychiatry,To be Discontinued,,,0591-2469-15,discontinued
8715,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",30mg tablets (NDC 0591-2470-15),New,5/29/18,,,,,Psychiatry,To be Discontinued,,,0591-2470-15,discontinued
8716,Mirtazapine Orally Disintegrating Tablets,"Actavis LLC, an indirect wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.",45mg tablets (NDC 0591-2471-15),New,5/29/18,,,,,Psychiatry,To be Discontinued,,,0591-2471-15,discontinued
8717,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 59762-5008-2),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,59762-5008-2,
8718,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; 10x10 blister (NDC 0025-1451-34),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,0025-1451-34,
8719,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 0025-1451-60),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,0025-1451-60,
8720,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 100 (NDC 0025-1461-31),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,0025-1461-31,
8721,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 0025-1461-60),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,0025-1461-60,
8722,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 60 (NDC 43386-160-06),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,43386-160-06,
8723,Misoprostol Tablets,Lupin,100-mcg tablets Bottles of 120 (NDC 43386-160-12),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,43386-160-12,
8724,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 60 (NDC 43386-161-06),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,43386-161-06,
8725,Misoprostol Tablets,Lupin,200-mcg tablets Bottles of 100 (NDC 43386-161-01),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,43386-161-01,
8726,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 60 (NDC 59762-5007-1),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,59762-5007-1,
8727,Misoprostol Tablets,Pfizer Pharmaceuticals,100 mcg tablets; Bottle of 120 (NDC 59762-5007-2),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,59762-5007-2,
8728,Misoprostol Tablets,Pfizer Pharmaceuticals,200 mcg tablets; Bottle of 60 (NDC 59762-5008-1),Revised,3/11/22,,,Available,,Gastroenterology,Resolved,,,59762-5008-1,
8729,Mitoxantrone Injection,Teva,NDC 0703-4685-01 (20 mg/10 mL (2 mg/mL) Multiple Dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/22,8/11/22,0703-4685-01,discontinued
8730,Mitoxantrone Injection,Teva,NDC 0703-4680-01 (25 mg/12.5 mL (2 mg/mL) Multiple Dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/22,8/11/22,0703-4680-01,discontinued
8731,Mitoxantrone Injection,Teva,NDC 0703-4686-01 (30 mg/15 mL (2 mg/mL) Multiple Dose Vial),New,8/11/22,,Product is unavailable and no future production expected for an extended period.,,,Oncology; Neurology,To be Discontinued,8/11/22,8/11/22,0703-4686-01,discontinued
8732,Mometasone Furoate Monohydrate Nasal Spray,Merck Sharp & Dohme Corp.,50 mcg (NDC 0085-1288-01),New,6/9/21,,,,,Pulmonary/Allergy,To be Discontinued,,,0085-1288-01,discontinued
8733,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,4 mg  (NDCs 0093-7424-98 and 0093-7424-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
8734,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,5 mg  (NDCs 0093-7425-98 and 0093-7425-56),New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
8735,Montelukast Sodium Chewable Tablet,Teva Pharmaceuticals,"10 mg (NDCs 0093-7426-10, 0093-7426-56, and 0093-7426-98)",New,7/28/20,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
8736,Montelukast Sodium Chewable Tablet,Sandoz,"4 mg  (NDCs 0781-5554-05, 0781-5554-06, 0781-5554-13, 0781-5554-31, 0781-5554-64, 0781-5554-92)",New,10/12/21,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
8737,Montelukast Sodium Chewable Tablet,Sandoz,"5 mg  (NDCs 0781-5555-05, 0781-5555-06, 0781-5555-13, 0781-5555-31, 0781-5555-64, 0781-5555-92)",New,10/12/21,,,,,Pulmonary/Allergy,To be Discontinued,,,,discontinued
8738,Montelukast Sodium Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0378-5201-93),New,3/20/18,,,,,Pediatric;Pulmonary/Allergy,To be Discontinued,,,0378-5201-93,discontinued
8739,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"15 mg, 100s (NDC 0378-2658-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-2658-01,discontinued
8740,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"30 mg, 100s (NDC 0378-2659-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-2659-01,discontinued
8741,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"60 mg, 100s (NDC 0378-2660-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-2660-01,discontinued
8742,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"100 mg, 100s (NDC 0378-2661-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-2661-01,discontinued
8743,Morphine Sulfate Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"200 mg, 100s (NDC 0378-2662-01)",New,5/8/18,,,,,Analgesia/Addiction,To be Discontinued,,,0378-2662-01,discontinued
8744,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single dose vial, (NDC 63323-452-01)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-452-01,not available
8745,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single dose vial, (NDC 63323-454-01)",Revised,9/14/22,Backordered. Next release October 2022.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-454-01,not available
8746,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single dose vial, (NDC 63323-455-01)",Revised,9/14/22,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-455-01,available
8747,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single dose vial, (NDC 63323-458-01)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-458-01,not available
8748,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single dose vial, (NDC 63323-451-01)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-451-01,not available
8749,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc./IMS","30 mg/30 mL (1 mg/1 mL) Single-Dose (Preservative-Free PCA Vial), (NDC 76329-1912-1)",Reverified,8/12/22,Backorder in the U.S. due to a manufacturing delay,,,,Analgesia/Addiction,Current,,,76329-1912-1,not available
8750,Morphine Sulfate Injection,"Hospira, Inc.",250 mg/10 mL (25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1135-02),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1135-02,discontinued
8751,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1890-01),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-1890-01,available
8752,Morphine Sulfate Injection,"Hospira, Inc.",2 mg/mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1890-11),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1890-11,discontinued
8753,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1891-01),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-1891-01,available
8754,Morphine Sulfate Injection,"Hospira, Inc.",4 mg/mL (4 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1891-11),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1891-11,discontinued
8755,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1892-01),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-1892-01,available
8756,Morphine Sulfate Injection,"Hospira, Inc.",8 mg/mL (8 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1892-11),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1892-11,discontinued
8757,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); Carpuject Luer Lock Glass Syringe (NDC 00409-1893-01),Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1893-01,not available
8758,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/mL (10 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1893-11),Revised,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,00409-1893-11,discontinued
8759,Morphine Sulfate Injection,"Hospira, Inc.",5 mg/10 mL (0.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3814-12),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-3814-12,available
8760,Morphine Sulfate Injection,"Hospira, Inc.",10 mg/10 mL (1 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-3815-12),Revised,9/12/22,Available,,,Other,Analgesia/Addiction,Current,,,00409-3815-12,available
8761,Morphine Sulfate Injection,"Hospira, Inc.","1,000 mg/20 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-03)",Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1134-03,limited availability
8762,Morphine Sulfate Injection,"Hospira, Inc.","2,500 mg/50 mL (50 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1134-05)",Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction,Current,,,00409-1134-05,not available
8763,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe (NDC 76045-004-10)",Revised,9/14/22,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-004-10,unclear
8764,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe (NDC 76045-005-10)",Revised,9/14/22,Check wholesalers for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-10,unclear
8765,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","5 mg per 1 mL, Single-use prefilled syringe (NDC 76045-006-10)",Revised,9/14/22,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-006-10,available
8766,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","8 mg per 1 mL, Single-use prefilled syringe (NDC 76045-007-10)",Revised,9/14/22,Backordered.  Next release date not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-007-10,not available
8767,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","10 mg per 1 mL, Single-use prefilled syringe (NDC 76045-008-10)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-008-10,not available
8768,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","4 mg/mL, 1 mL vial (NDC 0641-6125-25)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6125-25,available
8769,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","8 mg/mL, 1 mL vial (NDC 0641-6126-25)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,available
8770,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 1 mL vial (NDC 0641-6127-25)",Revised,4/8/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6127-25,not available
8771,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 1 mg/mL, 10 mL ampul (NDC 0641-6019-10)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6019-10,available
8772,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Duramorph (Preservative-Free) 0.5 mg/mL, 10 mL ampul (NDC 0641-6020-10)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6020-10,available
8773,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 10 mg/mL, 20 mL ampul (NDC 0641-6039-01)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6039-01,available
8774,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Infumorph (Preservative-free Morphine Sulfate Sterile Solution) 25 mg/mL, 20 mL ampul (NDC 0641-6040-01)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6040-01,available
8775,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","2 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-004-11)",Revised,9/14/22,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-004-11,available
8776,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","4 mg per 1 mL, Single-use prefilled syringe, micro vault packaging (NDC 76045-005-11)",Revised,9/14/22,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-11,available
8777,Moxifloxacin (Moxeza) Ophthalmic Solution,Novartis,"5mg/mL, 3mL in 1 bottle, (NDC 0065-0006-03)",New,7/2/21,,,,,Ophthalmology,To be Discontinued,,,0065-0006-03,discontinued
8778,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 10 mL Single Dose Dual Glass Fliptop Vials (NDC 61703-0434-82),Reverified,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0434-82,discontinued
8779,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Adult; 2 x 50 mL Pharmacy Bulk Package Dual Glass Fliptop Vials (NDC 61703-0422-83),Reverified,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0422-83,discontinued
8780,Multi-Vitamin Infusion (Adult and Pediatric),"Hospira, Inc.",MVI Pediatric; Single Dose Glass Fliptop Vial (NDC 61703-0421-53),Reverified,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,61703-0421-53,discontinued
8781,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)",Reverified,7/1/22,Available on allocation,,,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5646-1,limited availability
8782,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)",Reverified,7/1/22,Available on allocation,,,Demand increase for the drug,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5649-1,limited availability
8783,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5650-2)",Reverified,7/1/22,Stocked out; Recovery TBD,,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5650-2,not available
8784,Multi-Vitamin Infusion (Adult and Pediatric),Sandoz,"INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)",Reverified,7/1/22,Stocked out; Recovery TBD,,,Other,Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,54643-5647-0,not available
8785,Nafcillin Injection,Pfizer Pharmaceuticals,1 g; Single Dose Vial (Powder)(NDC 0409-3713-01),New,10/20/21,,,,,Anti-Infective,To be Discontinued,,,0409-3713-01,discontinued
8786,Nafcillin Injection,Pfizer Pharmaceuticals,2 g; Single Dose Vial (Powder)(NDC 0409-3714-01),New,10/20/21,,,,,Anti-Infective,To be Discontinued,,,0409-3714-01,discontinued
8787,Nafcillin Injection,Pfizer Pharmaceuticals,10 g per Pharmacy Bulk Package; Pharmacy Bulk Vial (Powder)(NDC 0409-3715-01),New,10/20/21,,,,,Anti-Infective,To be Discontinued,,,0409-3715-01,discontinued
8788,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-3124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-3124-95,discontinued
8789,Nafcillin Sodium Injection,Sandoz,2 gram vial packaged in 10s (NDC 0781-3125-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-3125-95,discontinued
8790,Nafcillin Sodium Injection,Sandoz,Pharmacy Bulk Package bottle (NDC 0781-3126-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-3126-95,discontinued
8791,Nafcillin Sodium Injection,Sandoz,1 gram vial packaged in 10s (NDC 0781-9124-95),New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-9124-95,discontinued
8792,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9224-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-9224-92,discontinued
8793,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-9225-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-9225-92,discontinued
8794,Nafcillin Sodium Injection,Sandoz,"1 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3128-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-3128-92,discontinued
8795,Nafcillin Sodium Injection,Sandoz,"2 gram ADD-Vantage Vial, packed in 10s (NDC 0781-3129-92)",New,12/23/19,,,,,Anti-Infective,To be Discontinued,,,0781-3129-92,discontinued
8796,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",10 mg/mL; 1 mL Glass Ampul (NDC 00409-1463-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,,,00409-1463-01,
8797,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",20 mg/mL; 1 mL Glass Ampul (NDC 00409-1465-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,,,00409-1465-01,
8798,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1464-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,,,00409-1464-01,
8799,Nalbuphine Hydrochloride Injection,"Hospira, Inc.",200 mg/10 mL (20 mg/mL); 10 mL Multiple Dose Glass Fliptop Vial (NDC 00409-1467-01),Revised,6/28/21,,,Available,,Analgesia/Addiction,Resolved,,,00409-1467-01,
8800,Naratriptan Hydrochloride Tablets,GlaxoSmithKline,1 mg 9-count blisterpack (NDC 0173-0561-00),New,4/7/22,,,,,Neurology,To be Discontinued,,,0173-0561-00,discontinued
8801,Naratriptan Hydrochloride Tablets,GlaxoSmithKline,2.5 mg 9-count blisterpack (NDC 0173-0562-00),New,4/7/22,,,,,Neurology,To be Discontinued,,,0173-0562-00,discontinued
8802,Nebivolol Hydrochloride Tablets,Abbvie,"BYSTOLIC® (nebivolol) tablets, NDC 0456-1420-30 (30 tablets in 1 bottle)",New,6/9/22,,,,,Cardiovascular,To be Discontinued,,,0456-1420-30,discontinued
8803,Nedocromil Sodium Ophthalmic Solution,Allergan,2% (NDC 0023-8842-05),New,5/18/22,,,,,Ophthalmology,To be Discontinued,,,0023-8842-05,discontinued
8804,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,50 mg 100 Tablets (NDC 0093-7178-01),Revised,6/10/22,,,Available,,Psychiatry,Resolved,,,0093-7178-01,
8805,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,100 mg 60 Tablets (NDC 0093-1024-06),Revised,6/10/22,,,Available,,Psychiatry,Resolved,,,0093-1024-06,
8806,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,150 mg 60 Tablets (NDC 0093-7113-06),Revised,6/10/22,,,Available,,Psychiatry,Resolved,,,0093-7113-06,
8807,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,200 mg 60 Tablets (NDC 0093-1025-06),Revised,6/10/22,,,Available,,Psychiatry,Resolved,,,0093-1025-06,
8808,Nefazodone Hydrochloride Tablets,Teva Pharmaceuticals,250 mg 60 Tablets (NDC 0093-1026-06),Revised,6/10/22,,,Available,,Psychiatry,Resolved,,,0093-1026-06,
8809,Nesiritide Powder (NATRECOR) for Injection,Janssen Pharmaceuticals,1.5 mg (NDC 65847-205-25),New,2/5/18,,,,,Cardiovascular,To be Discontinued,,,65847-205-25,discontinued
8810,Nevirapine (Viramune) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.",200 mg tablets (NDC 0597-0046-60),New,5/29/20,,,,,Antiviral,To be Discontinued,,,0597-0046-60,discontinued
8811,Nevirapine Oral Suspension,"Boehringer Ingelheim Pharmaceuticals, Inc.",50mg/5mL (NDC 0597-0047-24),New,10/1/21,,,,,Antiviral,To be Discontinued,,,0597-0047-24,discontinued
8812,Nizatidine Capsules,Teva Pharmaceuticals,"300 mg, 30 count bottle (NDC 0591-3138-30)",Reverified,9/21/22,"Backorder, Recovery expected TBD",,,Other,Gastroenterology,Current,,,0591-3138-30,not available
8813,Nizatidine Capsules,Teva Pharmaceuticals,"150 mg, 60 count bottle (NDC 0591-3137-60)",Reverified,9/21/22,Available,,,Other,Gastroenterology,Current,,,0591-3137-60,available
8814,Nizatidine Capsules,Glenmark Pharmaceuticals,"300 mg, 30 count bottle (NDC 68462-0426-30)",New,3/27/20,Unavailable,,,,Gastroenterology,Current,,,68462-0426-30,not available
8815,Nizatidine Capsules,Glenmark Pharmaceuticals,"150 mg, 60 count bottle (NDC 68462-0425-60)",New,3/27/20,Unavailable,,,,Gastroenterology,Current,,,68462-0425-60,not available
8816,Norepinephrine Bitartrate Injection,Teva,NDC 0703-1153-03 (4 mg/4 mL (1 mg/mL) 10 Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiology,To be Discontinued,8/11/22,8/11/22,0703-1153-03,discontinued
8817,Norepinephrine Bitartrate Injection,Teva,NDC 0703-1153-83 (4 mg/4 mL (1 mg/mL) 10 Vials) PREMIERProRx®,New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Cardiology,To be Discontinued,8/11/22,8/11/22,0703-1153-83,discontinued
8818,Norethindrone (NOR QD) Tablets,Allergan,"Nor QD, 0.35 mg norethindrone, Tablets, (NDC  52544-235-28)",New,2/23/18,,,,,Reproductive,To be Discontinued,,,52544-235-28,discontinued
8819,Nystatin and Triamcinolone Acetonide Cream,Teva Pharmaceuticals,"0.1%  (NDCs 0472-0150-15, 0472-0150-30, 0472-0150-60)",New,4/8/22,,,,,Dermatology,To be Discontinued,,,,discontinued
8820,Nystatin and Triamcinolone Acetonide Ointment,Teva Pharmaceuticals,"0.1%  (NDCs 0472-0155-15, 0472-0155-30, 0472-0155-60)",New,4/8/22,,,,,Dermatology,To be Discontinued,,,,discontinued
8821,Nystatin Ointment,Sandoz,15 g tube (NDC 0168-0007-15 ),New,6/3/22,,,,,Dermatology,To be Discontinued,,,0168-0007-15,discontinued
8822,Nystatin Ointment,Sandoz,30 g tube (NDC 0168-0007-30 ),New,6/3/22,,,,,Dermatology,To be Discontinued,,,0168-0007-30,discontinued
8823,Octreotide Acetate Injection,Teva,NDC 0703-3343-01 (5000 mcg/5 mL (1000 mcg/mL) 5 mL Multiple Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/22,8/11/22,0703-3343-01,discontinued
8824,Octreotide Acetate Injection,Teva,"NDC 0703-3321-04 (500 mcg/mL, 25 x 1 mL Single Dose Vials)",New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/22,8/11/22,0703-3321-04,discontinued
8825,Octreotide Acetate Injection,Teva,NDC 0703-3333-01 (1000 mcg/5 mL (200 mcg/mL) 5 mL Multiple Dose Vial),New,8/11/22,,Product is available with an expected supply duration until JUL 2022.  No future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/22,8/11/22,0703-3333-01,discontinued
8826,Octreotide Acetate Injection,Teva,NDC 0703-3311-04 (100 mcg/mL 1 mL Single Dose Vial 25 Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/22,8/11/22,0703-3311-04,discontinued
8827,Octreotide Acetate Injection,Teva,NDC 0703-3301-04 (50 mcg/mL 1 mL Single Dose Vial 25 Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Endocrinology; Oncology,To be Discontinued,8/11/22,8/11/22,0703-3301-04,discontinued
8828,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,12mg/50mg per capsule (NDC Package Code 0002-3234-30),New,7/15/20,,,,,Psychiatry,To be Discontinued,,,,discontinued
8829,Olanzapine and Fluoxetine (Symbyax) Capsules,Eli Lilly and Co.,6mg/50mg per capsule (NDC Package Code 0002-3233-30),New,7/15/20,,,,,Psychiatry,To be Discontinued,,,,discontinued
8830,Olopatadine Hydrochloride Nasal Spray,Novartis Pharmaceuticals,"PATANASE (olopatadine hydrochloride) nasal spray, 665 mcg  (NDC 0078-0834-30) 1 BOTTLE in 1 CARTON (0078-0834-30) > 240 SPRAY, METERED in 1 BOTTLE",New,6/21/22,,,,,Pulmonary/Allergy,To be Discontinued,,,0078-0834-30,discontinued
8831,Olopatadine Hydrochloride Nasal Spray,Novartis Pharmaceuticals,"Olopatadine hydrochloride nasal spray, 665 mcg (NDC 61314 320-01) 1 BOTTLE in 1 CARTON (61314-320-01) > 30500 uL in 1 BOTTLE",New,6/21/22,,,,,Pulmonary/Allergy,To be Discontinued,,,61314,discontinued
8832,Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets,Abbvie,212.5mg; 75mg; 50mg (NDC 0074-3082-28),New,5/22/18,,,,,Antiviral,To be Discontinued,,,0074-3082-28,discontinued
8833,Omeprazole and Sodium Bicarbonate Powder for Suspension,Endo Pharmaceuticals. Inc.,40mg and 1680mg  (NDC 49884-269-11),New,6/28/22,,,,,Gastroenterology,To be Discontinued,,,49884-269-11,discontinued
8834,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",20mg and 1680mg  (NDC 49884-268-11),New,6/28/22,,,,,Gastroenterology,To be Discontinued,,,49884-268-11,discontinued
8835,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",20mg; 1680mg  (NDCs 49884-268-52 and 49884-268-11),New,2/2/22,,,,,Gastroenterology,To be Discontinued,,,,discontinued
8836,Omeprazole and Sodium Bicarbonate Powder for Suspension,"Endo Pharmaceuticals, Inc.",40mg; 1680mg (NDCs 49884-269-11 and 49884-269-52),New,2/2/22,,,,,Gastroenterology,To be Discontinued,,,,discontinued
8837,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, amber vial, 4 mg per 2 mL (NDC 63323-373-02)",Revised,4/25/22,Available,,Available,,Gastroenterology,Resolved,,,63323-373-02,available
8838,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Multi dose, amber vial, 40 mg per 20 mL (NDC 63323-374-20)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,63323-374-20,
8839,Ondansetron Hydrochloride Injection,"Fresenius Kabi USA, LLC","Single dose, Simplist syringe, 4 mg per 2 mL (NDC 76045-103-20)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,76045-103-20,
8840,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 20 mL vial (NDC 0143-9890-01)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,0143-9890-01,
8841,Ondansetron Hydrochloride Injection,Heritage Pharma,"2 mg/mL , 20 mL vials (NDC 23155-549-31)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,23155-549-31,
8842,Ondansetron Hydrochloride Injection,Heritage Pharma,"PPRX 2 mg/mL , 2 mL Vial, 25 pack (NDC 23155-548-42)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,23155-548-42,
8843,Ondansetron Hydrochloride Injection,Heritage Pharma,"PPRX 2 mg/mL , 2 mL Vial, 10 pack (NDC 23155-548-41)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,23155-548-41,
8844,Ondansetron Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"2 mg/mL, 2 mL vial, 25 count (NDC 55150-125-02)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,55150-125-02,
8845,Ondansetron Hydrochloride Injection,Heritage Pharma,"2 mg/mL , 2 mL Vial (NDC 23155-547-41)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,23155-547-41,
8846,Ondansetron Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-4759-01),Revised,4/25/22,,,,,Gastroenterology,Resolved,,,00409-4759-01,
8847,Ondansetron Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","2 mg/mL, 2 mL vial (NDC 0641-6078-25)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,0641-6078-25,
8848,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-4755-03),Revised,4/25/22,,,,,Gastroenterology,Resolved,,,00409-4755-03,
8849,Ondansetron Hydrochloride Injection,"Hospira, Inc.",4 mg/2 mL (2 mg/mL); iSecure Luer Lock Glass Syringe (NDC 00409-1120-12),Revised,10/6/21,,,,,Gastroenterology,To be Discontinued,,,00409-1120-12,discontinued
8850,Ondansetron Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"2 mg/mL, 20 mL vial, 1 count (NDC 55150-126-20)",Revised,4/25/22,,,,,Gastroenterology,Resolved,,,55150-126-20,
8851,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 2mL vial (NDC 70860-776-02),Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,70860-776-02,
8852,Ondansetron Hydrochloride Injection,Gland Pharma Limited,2 mg/mL 20mL vial (NDC 70860-777-20),Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,70860-777-20,
8853,Ondansetron Hydrochloride Injection,Apotex Corp.,Ondansetron 2mg/mL 2mL vials Box of 25 vials (NDC 60505-6130-05),Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,60505-6130-05,
8854,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,40mg/20mL EA 1 Vial (NDC 25021-782-20),Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,25021-782-20,
8855,Ondansetron Hydrochloride Injection,Sagent Pharmaceuticals,4mg/2mL PK 25 Vials (NDC 25021-777-02),Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,25021-777-02,
8856,Ondansetron Hydrochloride Injection,Baxter Healthcare,"Ondansetron Injection, USP (2 mg/mL) 2 mL Single Use Glass Vial (25 x 2 mL) (NDC 36000-012-25)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,36000-012-25,
8857,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 2 mL vial (NDC 72266-123-25)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,72266-123-25,
8858,Ondansetron Hydrochloride Injection,Gland Pharma Limited,"2 mg/mL, 20 mL vial (NDC 72266-124-01)",Revised,4/25/22,,,Available,,Gastroenterology,Resolved,,,72266-124-01,
8859,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 50 mg/10 mL vial (NDCs 0024-0590-10),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,,discontinued
8860,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 100 mg/20 mL vial (NDC 0024-0591-20),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0024-0591-20,discontinued
8861,Oxaliplatin Injection,Sanofi-Aventis,Eloxatin 200 mg/40 mL vial (NDC 0024-0592-40),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0024-0592-40,discontinued
8862,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Oxaliplatin 50 mg/10 mL vial (NDC 0955-1725-10),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0955-1725-10,discontinued
8863,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Oxaliplatin 100 mg/20 mL vial (NDC 0955-1727-20),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0955-1727-20,discontinued
8864,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Premier Oxaliplatin 50 mg/10 mL vial (NDC 0955-1731-10),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0955-1731-10,discontinued
8865,Oxaliplatin Injection,Sanofi-Aventis,Winthrop Premier Oxaliplatin 100 mg/20 mL vial (NDC 0955-1733-20),New,9/8/22,,,,,Oncology,To be Discontinued,9/8/22,9/8/22,0955-1733-20,discontinued
8866,Oxcarbazepine Oral Suspension,Novartis Pharmaceuticals Corporation,300mg/5mL (NDC 0781-6270-43),New,8/8/22,,,,,Neurology,To Be Discontinued,8/8/22,8/8/22,0781-6270-43,discontinued
8867,Oxybutynin Chloride Syrup,Wockhardt,"5mg/5mL, 473mL (NDC 60432-0092-16)",New,4/11/22,,,,,Urology,To be Discontinued,,,60432-0092-16,discontinued
8868,Oxytocin Injection,Fresenius Kabi,100 USP Units per 10 mL (10 USP units per mL); Multiple dose vial; (NDC 63323-012-10),New,9/23/22,Currently unavailable.  Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,63323-012-10,not available
8869,Oxytocin Injection,Fresenius Kabi,300 USP Units per 30 mL (10 USP Units per mL); Multiple dose vial; (NDC 63323-012-30),New,9/23/22,Currently unavailable. Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,63323-012-30,not available
8870,Oxytocin Injection,Fresenius Kabi,10 USP Units per mL (10 USP units per mL); (NDC 63323-012-01)( NDC 63323-0012-11),New,9/23/22,Currently unavailable.  Next release October 2022.,,,Manufacturing delay,Anesthesia; Urology; Other,Current,,,63323-012-01,not available
8871,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of six 50 mL Pharmacy Bulk Packages, each containing 10 units of oxytocin per mL (total = 500 units of oxytocin per vial), (NDC 42023-130-06)",Revised,10/3/22,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,42023-130-06,limited availability
8872,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin, (NDC 42023-116-25)",Revised,10/3/22,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,42023-116-25,limited availability
8873,Oxytocin Injection,Par Pharmaceuticals,"Pitocin: Packages of twenty-five 10 mL multiple-dose vial, each containing 10 units of oxytocin per mL (total = 100 units of oxytocin per vial) (NDC 42023-116-02)",Revised,10/3/22,Limited availability,Limited supply due to low market share,,,Anesthesia; Urology; Other,Current,,,42023-116-02,limited availability
8874,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"100 mg, single dose vial (NDC 24979-710-51)",New,5/27/22,No supply constraint or anticipated shortage,,,,Oncology,Current,,,24979-710-51,available
8875,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"100 mg, single dose vial (NDC 60505-6230-4)",New,5/27/22,No supply constraint or anticipated shortage,,,,Oncology,Current,,,60505-6230-4,available
8876,Paclitaxel Injection (protein-bound particles),Bristol Myers Squibb Co.,"Abraxane® 100 mg, single dose vial (NDC 68817-134-50)",Revised,5/27/22,No longer on allocation; recovery to normal inventory levels in progress.,,,Other,Oncology,Current,,,68817-134-50,available
8877,"Paclitaxel Injection, USP",Mylan Institutional,"100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17)",New,11/22/19,,,,,Oncology,To be Discontinued,,,67457-449-17,discontinued
8878,Pantoprazole Sodium for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"40 mg, 10 vials (NDC 55150-202-10)",Reverified,9/28/22,Available,,,Demand increase for the drug,Gastroenterology,Current,,,55150-202-10,available
8879,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-0923-55)",Revised,9/12/22,Available,,,Other,Gastroenterology,Current,,,0008-0923-55,available
8880,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-0923-60)",Revised,9/12/22,Available,,,Other,Gastroenterology,Current,,,0008-0923-60,available
8881,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-2001-10; Amerinet)",Revised,9/12/22,Next Delivery and Estimated Recovery: February 2025,,,Other,Gastroenterology,Current,,,0008-2001-10,not available
8882,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-2001-25; Amerinet)",Revised,9/12/22,Next Delivery and Estimated Recovery: February 2025,,,Other,Gastroenterology,Current,,,0008-2001-25,not available
8883,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 10 vials (NDC 0008-4001-10; PremierPro)",Revised,9/12/22,Limited Supply Next Delivery and Estimated Recovery: October 2022,Demand increase for the drug,,Other,Gastroenterology,Current,,,0008-4001-10,limited availability
8884,Pantoprazole Sodium for Injection,Pfizer Pharmaceuticals,"40 mg, 25 vials (NDC 0008-4001-25; PremierPro)",Revised,9/12/22,Available,,,Other,Gastroenterology,Current,,,0008-4001-25,available
8885,Pantoprazole Sodium for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","40 mg, 10 vials (NDC 0143-9284-10)",Revised,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Gastroenterology,Current,,,0143-9284-10,available
8886,Pantoprazole Sodium for Injection,Sun Pharmaceutical Industries Inc.,"40 mg, 10 vials (NDC 62756-129-44)",Revised,4/5/22,Available,,,Other,Gastroenterology,Current,,,62756-129-44,available
8887,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 72572-550-10)",Reverified,10/3/22,Available,Marketed by Civica,,,Gastroenterology,Current,,,72572-550-10,available
8888,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 65219-433-15)",Reverified,10/3/22,Limited Supply,Marketed by Fresenius Kabi,,Demand increase for the drug,Gastroenterology,Current,,,65219-433-15,limited availability
8889,Pantoprazole Sodium for Injection,Sandoz,"40 mg, 10 vials (NDC 0781-3232-95)",Reverified,10/3/22,Limited Availability,,,Demand increase for the drug,Gastroenterology,Current,,,0781-3232-95,limited availability
8890,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges),Revised,12/6/21,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0202-1,unclear
8891,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,50mcg   Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges),Revised,12/6/21,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0203-1,unclear
8892,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,75mcg   Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges),Revised,12/6/21,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0204-1,unclear
8893,Parathyroid Hormone (Natpara) Injection,Takeda Pharmaceuticals USA Inc.,100mcg   Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges),Revised,12/6/21,To be determined.  Takeda is actively working to resolve the issue and resume supply.  Updates will be provided on an ongoing basis.,,,Requirements related to complying with good manufacturing processes,Endocrinology/Metabolism,Current,,,68875-0205-1,unclear
8894,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4347-01)",New,2/28/18,,,,,Oncology,To be Discontinued,,,0085-4347-01,discontinued
8895,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4348-01)",New,2/28/18,,,,,Oncology,To be Discontinued,,,0085-4348-01,discontinued
8896,Peginterferon alfa-2b (Sylatron),Merck Sharp & Dohme Corp.,"SYLATRON (peginterferon alfa-2b) A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-4349-01)",New,2/28/18,,,,,Oncology,To be Discontinued,,,0085-4349-01,discontinued
8897,Pentamidine Isethionate (Nebupent) For Inhalation Solution,"Fresenius Kabi USA, LLC","300 mg per vial, SDV, PF (NDC 63323-877-15)",Revised,9/13/19,,,,,Anti-Infective,Resolved,,,63323-877-15,
8898,Pentostatin Injection,"Hospira, Inc.","10 mg, single dose vial (NDC 0409-0801-01)",Reverified,9/12/22,Available,,,Other,Oncology,Current,,,0409-0801-01,available
8899,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 100s (NDC 0378-0357-01)",New,5/8/18,,,,,Cardiovascular,To be Discontinued,,,0378-0357-01,discontinued
8900,Pentoxifylline Extended-Release Tablets,Mylan Pharmaceuticals Inc.,"400 mg, 500s (NDC 0378-0357-05)",New,5/8/18,,,,,Cardiovascular,To be Discontinued,,,0378-0357-05,discontinued
8901,Phenobarbital Oral Solution,Torrent Pharma Inc.,1 pint 473mL (NDC 16571-330-16),New,11/25/19,,,,,Neurology,To be Discontinued,,,16571-330-16,discontinued
8902,Physostigmine Salicylate Injection,Akorn Pharmaceuticals,"Physostigmine Salicylate Injection, USP  1mg/mL (10amps/box, 2mL each) (NDC 17478-510-02)",Reverified,1/21/22,Unavailable. Expected to release Q4 2022.,,,Other,Neurology,Current,,,17478-510-02,not available
8903,Pindolol Tablets,Sun Pharmaceutical Industries Inc.,"Pindolol Tablets, 5mg and 10mg (100 count bottles)(NDC 57664-655-88, 57664-656-88)",Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,57664-655-88,
8904,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 5mg Tabs 100s (NDC 0378-0052-01),Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,0378-0052-01,
8905,Pindolol Tablets,"Mylan Pharmaceuticals Inc., a Viatris Company",Pindolol 10mg Tabs 100s (NDC 0378-0127-01),Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,0378-0127-01,
8906,Pindolol Tablets,Bayshore Pharmaceuticals,5 mg/ 100 count (NDC 76385-131-01),Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,76385-131-01,
8907,Pindolol Tablets,Bayshore Pharmaceuticals,10 mg/ 100 count (NDC 76385-132-01),Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,76385-132-01,
8908,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","5 mg: Bottles of 100 tablets, (NDC 62559-560-01)",Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,62559-560-01,
8909,Pindolol Tablets,"ANI Pharmaceuticals, Inc.","10 mg; Bottles of 100 tablets, (NDC 62559-561-01)",Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,62559-561-01,
8910,Pindolol Tablets,"Nostrum Laboratories, Inc.","5 mg, Bottle of 100 tablets (NDC 29033-028-01)",Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,29033-028-01,
8911,Pindolol Tablets,"Nostrum Laboratories, Inc.","10 mg, Bottle of 100 tablets (NDC 29033-029-01)",Revised,1/11/22,,,Available,,Cardiovascular,Resolved,,,29033-029-01,
8912,Pioglitazone Hydrochloride Tablets,Sandoz,15 mg/1 (NDC 0781-5420-64),New,1/10/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,0781-5420-64,discontinued
8913,Pioglitazone Hydrochloride Tablets,Sandoz,30 mg/1 (NDC 0781-5421-10),New,1/10/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,0781-5421-10,discontinued
8914,Pioglitazone Hydrochloride Tablets,Sandoz,45 mg/1 (NDC 0781-5422-10),New,1/10/22,,,,,Endocrinology/Metabolism,To be Discontinued,,,0781-5422-10,discontinued
8915,Pioglitazone/Metformin HCl (ACTOPLUS MET®) Tablets,Takeda Pharmaceuticals USA Inc.,15mg/500mg tablet (NDC 64764-0155-60),New,10/18/21,,,,,Endocrinology/Metabolism,To be Discontinued,,,64764-0155-60,discontinued
8916,Piroxicam Capsules,Pfizer Pharmaceuticals,10 mg capsules; Bottles of 100 (NDC 59762-0140-1),New,8/10/21,,,,,Analgesia/Addiction,To be Discontinued,,,59762-0140-1,discontinued
8917,Piroxicam Capsules,Pfizer Pharmaceuticals,20 mg capsules; Bottles of 100 (NDC 59762-0145-1),New,8/10/21,,,,,Analgesia/Addiction,To be Discontinued,,,59762-0145-1,discontinued
8918,Polymyxin B Sulfate and Trimethoprim Sulfate Ophthalmic Solution,"Allergan Sales, LLC","10,000 units/mL; 1 mg/mL (NDC 0023-7824-10)",New,8/8/22,,,,,Ophthalmology,To Be Discontinued,8/8/22,8/8/22,0023-7824-10,discontinued
8919,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3294-51)",Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-3294-51,not available
8920,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/20 mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 00409-8183-01)",Revised,9/12/22,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-8183-01,not available
8921,Potassium Acetate Injection,"Hospira, Inc.","100 mEq/50 mL (2 mEq/mL), Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3294-25), Novaplus",Revised,9/12/22,Next Delivery and Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-3294-25,not available
8922,Potassium Acetate Injection,"Hospira, Inc.","40 mEq/20 mL (2 mEq/mL), Single Dose Plastic Fliptop Vial (NDC 0409-8183-25), Novaplus",Revised,9/12/22,Next Delivery: November 2022; Estimated Recovery: March 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-8183-25,not available
8923,Potassium Acetate Injection,"Exela Pharma Sciences, LLC",Potassium Acetate Inj. 40mEq (2mEq/ml) 20mL (NDC 51754-2001-4),Revised,5/16/22,Product shipped to and available in wholesalers. Additional shipment end of May 2022. Increased supply available in mid-June.,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,51754-2001-4,available
8924,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,Concentrated Potassium Chloride Injection USP 250 mL Plastic Bag P9402 (NDC 0264-1944-20),Revised,9/14/22,Backordered.  Next release not available at this time.,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0264-1944-20,not available
8925,Potassium Chloride Concentrate Injection,"Hospira, Inc.",10 mEq/5 mL (2 mEq/mL) Single Dose Glass Fliptop Vial (NDC 0409-6635-01),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-6635-01,not available
8926,Potassium Chloride Concentrate Injection,"Hospira, Inc.",20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 0409-6651-06),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand Increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-6651-06,not available
8927,Potassium Chloride Concentrate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial (NDC 00409-6653-05),Revised,9/12/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-6653-05,available
8928,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","60 mEq per 30 mL (2 mEq per mL), Multi dose, plastic vial, (NDC 63323-967-30)",Revised,9/14/22,Available,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-967-30,available
8929,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","10 mEq per 5 mL(2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-05)",Revised,9/14/22,Available,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-05,available
8930,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","20 mEq per 10 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-10)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-10,not available
8931,Potassium Chloride Concentrate Injection,"Fresenius Kabi USA, LLC","40 mEq per 20 mL (2 mEq per mL), Single dose, plastic vial, (NDC 63323-965-20)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Manufacturing delays,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-965-20,not available
8932,Potassium Chloride Concentrate Injection,B. Braun Medical Inc.,(2 mEq K /mL) 250mL bulk package Catalog# S9402-11(NDC 0264-1940-20),Revised,9/14/22,Inventory depleted.,,,Discontinuation of manufacturing,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0264-1940-20,not available
8933,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 20 mEq/50 mL (Legacy Hospira NDC 0409-7077-14) (ICU Medical NDC 0990-7077-14)",Reverified,10/3/22,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7077-14,limited availability
8934,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 10 mEq/100 mL (Legacy Hospira NDC 0409-7074-26) (ICU Medical NDC 0990-7074-26)",Reverified,10/3/22,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7074-26,limited availability
8935,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 10 mEq/50 mL (Legacy Hospira NDC 0409-7075-14) (ICU Medical NDC 0990-7075-14)",Reverified,10/3/22,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7075-14,limited availability
8936,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 20 mEq/100 mL (Legacy Hospira NDC 0409-7075-26) (ICU Medical NDC 0990-7075-26)",Reverified,10/3/22,Allocation,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7075-26,limited availability
8937,Potassium Chloride Concentrate Injection,"ICU Medical, Inc.","Potassium Chloride Injection, 40 mEq/100 mL (Legacy Hospira NDC 0409-7077-26) (ICU Medical NDC 0990-7077-26)",Reverified,10/3/22,Available,,,Demand Increase for the Drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7077-26,available
8938,Potassium Chloride Concentrate Injection,Baxter Healthcare,10 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0826 (NDC 0338-0709-48),Reverified,9/28/22,Available on allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0338-0709-48,limited availability
8939,Potassium Chloride Concentrate Injection,Baxter Healthcare,10 mEq/50 mL in VIAFLEX Plastic Container; Product Code 2B0821 (NDC 0338-0705-41),Reverified,9/28/22,Available on allocation,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0338-0705-41,limited availability
8940,Potassium Chloride Concentrate Injection,Baxter Healthcare,20 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0827 (NDC 0338-0705-48),Reverified,9/28/22,Limited Supply on Allocation; Recovery late June 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0338-0705-48,limited availability
8941,Potassium Chloride Concentrate Injection,Baxter Healthcare,20 mEq/50 mL in VIAFLEX Plastic Container; Product Code 2B0822 (NDC 0338-0703-41),Reverified,9/28/22,Limited Supply on Allocation; Recovery mid-July 2022,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0338-0703-41,limited availability
8942,Potassium Chloride Concentrate Injection,Baxter Healthcare,40 mEq/100 mL in VIAFLEX Plastic Container; Product Code 2B0824 (NDC 0338-0703-48),Reverified,9/28/22,Available on allocation,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0338-0703-48,limited availability
8943,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",29.8 g/L (20 mEq) 50 mL (NDC 14789-107-08),New,2/2/22,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,14789-107-08,limited availability
8944,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",29.8 g/L (40 mEq) 100 mL (NDC 14789-107-16),New,2/2/22,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,14789-107-16,limited availability
8945,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",14.9 g/L (20 mEq) 100 mL (NDC 14789-108-16),New,2/2/22,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,14789-108-16,limited availability
8946,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",14.9 g/L (10 mEq) 50 mL (NDC 14789-108-08),New,2/2/22,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,14789-108-08,limited availability
8947,Potassium Chloride Concentrate Injection,"Nexus Pharmaceuticals, Inc.",7.45 g/L ( 10 mEq) 100 mL (NDC 14789-109-16),New,2/2/22,Backordered. Available early March 2022.,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,14789-109-16,limited availability
8948,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.375mg (NDC 10370-251-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-251-11,discontinued
8949,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",0.75mg (NDC 10370-252-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-252-11,discontinued
8950,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",1.5mg (NDC 10370-253-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-253-11,discontinued
8951,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",2.25mg (NDC 10370-305-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-305-11,discontinued
8952,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",3mg (NDC 10370-254-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-254-11,discontinued
8953,Pramipexole Dihydrochloride Extended Release Tablets,"Endo Pharmaceuticals, Inc.",3.75mg (NDC 10370-306-11),New,12/16/21,,,,,Neurology,To be Discontinued,,,10370-306-11,discontinued
8954,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (Pred Forte) (NDC 11980-180-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,11980-180-05,
8955,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,11980-180-10,
8956,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,10 mL in 15 mL bottle (NDC 60758-119-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,60758-119-10,
8957,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (NDC 60758-119-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,60758-119-15,
8958,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 5mL in 1 bottle (NDC 61314-637-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,61314-637-05,
8959,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 10mL in 1 bottle (NDC 61314-637-10),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,61314-637-10,
8960,Prednisolone Acetate 1% Ophthalmic Suspension,Novartis,Prednisolone Acetate Suspension 1% 15mL in 1 bottle (NDC 61314-637-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,61314-637-15,
8961,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,15 mL in 15 mL bottle (Pred Forte) (NDC 11980-180-15),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,11980-180-15,
8962,Prednisolone Acetate 1% Ophthalmic Suspension,Allergan,5 mL in 10 mL bottle (NDC 60758-119-05),Revised,10/31/19,,,,,Ophthalmology,Resolved,,,60758-119-05,
8963,Prednisolone Sodium Phosphate Oral Solution,Wockhardt Bio AG/Morton Grove Pharmaceuticals,15 mg/5mL (NDC 60432-212-08) (8 fl oz.),New,5/26/22,,,,,Dermatology;Endocrinology/Metabolism;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,60432-212-08,discontinued
8964,Procainamide Hydrochloride Injection,Pfizer,"1,000 mg/2 mL (500 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1903-01)",New,8/30/22,,Discontinuation of the manufacture of the drug.,,,Cardiology,To be Discontinued,8/30/22,8/30/22,0409-1903-01,discontinued
8965,Procardia Capsules,Pfizer Pharmaceuticals,10 mg capsule; Bottle of 100 (NDC 0069-2600-66),New,5/10/21,,,,,Cardiovascular,To be Discontinued,,,0069-2600-66,discontinued
8966,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 10 mL pre-filled syringe, (NDC 0270-1111-16)",New,6/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-1111-16,discontinued
8967,ProHance® (Gadoteridol) Injection,Bracco Diagnostics,"279.3 mg/mL, 5 x 17 mL pre-filled syringe, (NDC 0270-111-45)",New,6/1/21,,,,,Medical Imaging,To be Discontinued,,,0270-111-45,discontinued
8968,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL vial (NDC 0641-0928-25)",Reverified,4/8/22,Inventory is currently available.,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0928-25,available
8969,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL ,1 mL vial (NDC 0641-0929-25)",Reverified,4/8/22,Inventory is currently available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-0929-25,available
8970,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","25 mg/mL, 1 mL ampul (NDC 0641-1495-35)",Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1495-35,available
8971,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","50 mg/mL, 1 mL ampul (NDC 0641-1496-35)",Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-1496-35,available
8972,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL vial (NDC 0641-6084-25)",Reverified,4/8/22,Inventory is currently available.,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6084-25,available
8973,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL ,1 mL vial (NDC 0641-6085-25)",Reverified,4/8/22,Inventory is currently available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6085-25,available
8974,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 25 mg/mL, 1 mL ampul (NDC 0641-6082-25)",Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6082-25,available
8975,Promethazine (Phenergan) Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","PHENERGAN Injection 50 mg/mL, 1 mL ampul (NDC 0641-6083-25)",Reverified,4/8/22,Inventory is currently available.,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,0641-6083-25,available
8976,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","25 mg/mL, Carton of 25 ampuls (NDC 39822-5525-3)",Reverified,2/25/21,Available,,,Demand increase for the drug,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5525-3,available
8977,Promethazine (Phenergan) Injection,"X-GEN Pharmaceuticals, Inc.","50 mg/mL, Carton of 25 ampuls (NDC 39822-5550-6)",Reverified,2/25/21,Available,,,Other,Analgesia/Addiction;Gastroenterology;Pediatric;Pulmonary/Allergy,Current,,,39822-5550-6,available
8978,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01)",New,12/19/19,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,0703-2191-01,discontinued
8979,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01)",New,12/19/19,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,0703-2201-01,discontinued
8980,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04)",New,12/19/19,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,0703-2191-04,discontinued
8981,"Promethazine Hydrochloride Injection, Solution",Teva Pharmaceuticals,"50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)",New,12/19/19,,,,,Anesthesia;Gastroenterology;Pulmonary/Allergy,To be Discontinued,,,0703-2201-04,discontinued
8982,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",150mg (NDCs 0603-5448-21 and 0603-5448-25),New,2/2/22,,,,,Cardiovascular,To be Discontinued,,,,discontinued
8983,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",225mg (NDCs 0603-5449-21 and 0603-5449-25),New,2/2/22,,,,,Cardiovascular,To be Discontinued,,,,discontinued
8984,Propafenone Hydrochloride Tablets,"Endo Pharmaceuticals, Inc.",300mg (NDC 0603-5450-21),New,2/2/22,,,,,Cardiovascular,To be Discontinued,,,0603-5450-21,discontinued
8985,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0209-10),Revised,9/12/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Demand increase for the drug,Anesthesia,Current,,,00069-0209-10,limited availability
8986,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0234-20),Revised,9/12/22,Available,,,Other,Anesthesia,Current,,,00069-0234-20,available
8987,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Use Vial (containing 0.005% edetate disodium EDTA) (NDC 00069-0248-10),Revised,9/12/22,Available,,,,Anesthesia,Current,,,00069-0248-10,available
8988,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 20 mL vial (NDC 0641-6194-10)",Reverified,4/8/22,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,0641-6194-10,not available
8989,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 50 mL vial (NDC 0641-6195-20",Reverified,4/8/22,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,0641-6195-20,not available
8990,Propofol Injectable Emulsion,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","10 mg/mL, 100 mL vial (NDC 0641-6196-10",Reverified,4/8/22,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Anesthesia,Current,,,0641-6196-10,not available
8991,Propofol Injectable Emulsion,Avet Pharmaceuticals,200 mg/20mL (pack 10) (NDC 23155-235-41),New,9/7/22,Available,,,,Anesthesia,Current,,,23155-235-41,available
8992,Propofol Injectable Emulsion,Avet Pharmaceuticals,200 mg/20mL (pack of 20) (NDC 23155-235-44),New,9/7/22,Available,,,,Anesthesia,Current,,,23155-235-44,available
8993,Propofol Injectable Emulsion,Avet Pharmaceuticals,500 mg/50 mL (pack of 20) (NDC 23155-345-42),New,9/7/22,Available,,,,Anesthesia,Current,,,23155-345-42,available
8994,Propofol Injectable Emulsion,Avet Pharmaceuticals,"1,000 mg/100 mL (pack of 10) (NDC 23155-345-13)",New,9/7/22,Available,,,,Anesthesia,Current,,,23155-345-13,available
8995,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Reverified,10/5/22,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,0591-2136-68,available
8996,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Reverified,10/5/22,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,0591-2136-51,available
8997,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Reverified,10/5/22,Available,Market Exit - Estimated Run Out TBD,,Discontinuance of Manufacturing,Anesthesia,Current,,,0591-2136-95,available
8998,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, 10ct (NDC 43598-549-10)",Reverified,9/19/22,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-549-10,limited availability
8999,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","1000mg/100mL vial, individual (NDC 43598-549-52)",Reverified,9/19/22,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-549-52,limited availability
9000,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, 25ct (NDC 43598-265-25)",Reverified,9/19/22,No current supply,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-265-25,not available
9001,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","1000 mg per 100 mL (10 mg per mL), single patient use only, 100 mL (NDC 63323-269-65)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-269-65,available
9002,Propofol Injectable Emulsion,Sagent Pharmaceuticals,200mg per 20ml (NDC 25021-608-20),Reverified,8/22/22,Available,,,Demand increase due to Covid-19,Anesthesia,Current,,,25021-608-20,available
9003,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 10X100ML VL (NDC 0591-2136-68),Revised,3/14/22,,,,,Anesthesia,To be Discontinued,,,0591-2136-68,discontinued
9004,Propofol Injectable Emulsion,"Hospira, Inc.",200 mg/20 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-30),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-30,limited availability
9005,Propofol Injectable Emulsion,"Hospira, Inc.",500 mg/50 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-33),Revised,9/12/22,Available,,,Other,Anesthesia,Current,,,00409-4699-33,available
9006,Propofol Injectable Emulsion,"Hospira, Inc.",1000 mg/100 mL (10 mg/mL) Single Dose/Single Patient Use Glass Fliptop Vial (NDC 00409-4699-24),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: November 2023,,,Demand increase for the drug,Anesthesia,Current,,,00409-4699-24,limited availability
9007,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",200mg/20mL  10ct (NDC 43598-265-58),Reverified,9/19/22,Pack size discontinued,,,,Anesthesia,Current,,,43598-265-58,discontinued
9008,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","200mg/20mL vial, individual (NDC 43598-265-20)",Reverified,9/19/22,No current supply,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-265-20,not available
9009,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.",500mg/50mL  20ct (NDC 43598-548-21),Reverified,9/19/22,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-548-21,limited availability
9010,Propofol Injectable Emulsion,"Dr. Reddy's Laboratories, Inc.","500mg/50mL vial, individual (NDC 43598-548-50)",Reverified,9/19/22,Allocating to Wholesalers,,,Demand increase for the drug.  Manufacturer extended lead times.,Anesthesia,Current,,,43598-548-50,limited availability
9011,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 20X50ML VL (NDC 0591-2136-51),Revised,3/14/22,,,,,Anesthesia,To be Discontinued,,,0591-2136-51,discontinued
9012,Propofol Injectable Emulsion,Teva Pharmaceuticals,10MG/ML 25X20ML VL (NDC 0591-2136-95),Revised,3/14/22,,,,,Anesthesia,To be Discontinued,,,0591-2136-95,discontinued
9013,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","100 mg per 10 mL (10 mg per mL), single patient use only, 10 mL (NDC 63323-269-10)",Reverified,9/14/22,Available,,,,Anesthesia,Current,,,63323-269-10,available
9014,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","200 mg per 20 mL (10 mg per mL), single patient use only, 20 mL (NDC 63323-269-29)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-269-29,available
9015,Propofol Injectable Emulsion,"Fresenius Kabi USA, LLC","500 mg per 50 mL (10 mg per mL), single patient use only, 50 mL (NDC 63323-269-50)",Reverified,9/14/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,63323-269-50,available
9016,Propofol Injectable Emulsion,Sagent Pharmaceuticals,500mg per 50ml (NDC 250-21-608-50),Reverified,8/22/22,Available,,,,Anesthesia,Current,,,250-21-608-50,available
9017,Propofol Injectable Emulsion,Sagent Pharmaceuticals,1000mg per 100ml (NDC 25021-608-51),Reverified,8/22/22,Available,,,,Anesthesia,Current,,,25021-608-51,available
9018,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","50 mg per 5 mL (10 mg per mL), single dose vial, preservative free,  (NDC 63323-229-05)",Revised,9/14/22,Available,Check wholesaler inventory,,,Hematology,Current,,,63323-229-05,available
9019,Protamine Sulfate Injection,"Fresenius Kabi USA, LLC","250 mg per 25 mL (10 mg per mL), single dose vial, preservative free, (NDC 63323-229-30)",Revised,9/14/22,Available,Check wholesaler inventory,,,Hematology,Current,,,63323-229-30,available
9020,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,500 mg  (NDC 45963-418-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,,,45963-418-50,discontinued
9021,Ranolazine Extended Release Tablets,Teva Pharmaceuticals,1000 mg  (NDC 45963-419-50),New,7/6/20,,,,,Cardiovascular,To be Discontinued,,,45963-419-50,discontinued
9022,Remifentanil Injection,"Mylan, a Viatris Company",1 mg (NDC 67457-198-03),Revised,9/28/22,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,67457-198-03,available
9023,Remifentanil Injection,"Mylan, a Viatris Company",2 mg (NDC 67457-198-05),Revised,9/28/22,Unavailable,Re-supply in December 2022.,,Demand increase for the drug,Analgesia/Addiction,Current,,,67457-198-05,not available
9024,Remifentanil Injection,"Mylan, a Viatris Company",5 mg (NDC 67457-198-10),Revised,9/28/22,Unavailable,Re-supply in January 2023.,,Demand increase for the drug,Analgesia/Addiction,Current,,,67457-198-10,not available
9025,Remifentanil Injection,Hikma Pharmaceuticals,1 mg/vial (NDC 0143-9391-10),Revised,8/26/22,This presentation is on backorder. Product will be available September 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9391-10,not available
9026,Remifentanil Injection,Hikma Pharmaceuticals,2 mg/Vial (NDC 0143-9392-10),Revised,8/26/22,This presentation is on backorder. Product will be available September 2022,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9392-10,not available
9027,Remifentanil Injection,Hikma Pharmaceuticals,5 mg/mL (NDC 0143-9393-10),Revised,8/26/22,Currently available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9393-10,available
9028,Remifentanil Injection,Fresenius Kabi USA,"1 mg per vial, SDV (NDC 63323-723-03)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-723-03,not available
9029,Remifentanil Injection,Fresenius Kabi USA,"2 mg per vial, SDV (NDC 63323-724-05)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-724-05,not available
9030,Remifentanil Injection,Fresenius Kabi USA,"5 mg per vial, SDV (NDC 63323-725-10)",Revised,9/14/22,Available,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-725-10,available
9031,Repaglinide Tablets,Sandoz,1mg tablets (NDC 0781-5149-01),New,2/2/18,,,,,Endocrinology/Metabolism,To be Discontinued,,,0781-5149-01,discontinued
9032,Rifampin (Rifadin) Capsules,Sanofi-Aventis,150 mg capsules (NDC 0068-0510-30),New,6/15/20,,,,,Anti-Infective,To be Discontinued,,,0068-0510-30,discontinued
9033,Rifampin (Rifadin) Capsules,Sanofi-Aventis,300 mg capsules (NDC 0068-0508-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,,,0068-0508-60,discontinued
9034,Rifampin Capsules,Akorn Pharmaceuticals,150 mg Bottles of 30 (NDC 61748-015-30),New,9/12/22,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/22,9/12/22,61748-015-30,discontinued
9035,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 30 (NDC 61748-018-30),New,9/12/22,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/22,9/12/22,61748-018-30,discontinued
9036,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 60 (NDC 61748-018-60),New,9/12/22,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/22,9/12/22,61748-018-60,discontinued
9037,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 100 (NDC 61748-018-01),New,9/12/22,,Discontinuation of manufacture of the drug.,,,,To be Discontinued,9/12/22,9/12/22,61748-018-01,discontinued
9038,Rifampin Capsules,"Epic Pharma, LLC",150 mg (NDC 42806-801-30),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-801-30,available
9039,Rifampin Capsules,"Epic Pharma, LLC",150 mg (NDC 42806-801-01),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-801-01,available
9040,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-30),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-799-30,available
9041,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-60),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-799-60,available
9042,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-01),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-799-01,available
9043,Rifampin Capsules,"Epic Pharma, LLC",300 mg (NDC 42806-799-05),Revised,1/11/22,Available,,,Other,Anti-Infective,Current,,,42806-799-05,available
9044,Rifampin Capsules,Lupin,150 mg - Bottles of 30 (NDC 68180-658-06),Reverified,7/15/22,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,68180-658-06,limited availability
9045,Rifampin Capsules,Lupin,300 mg - Bottles of 30 (NDC 68180-659-06),Reverified,7/15/22,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,68180-659-06,limited availability
9046,Rifampin Capsules,Lupin,300 mg - Bottles of 60 (NDC 68180-659-07),Reverified,7/15/22,Limited quantities available. More quantities will be available in coming weeks/months.,,,Shortage of an active ingredient.,Anti-Infective,Current,,,68180-659-07,limited availability
9047,Rifampin Capsules,Akorn Pharmaceuticals,150 mg Bottles of 30 (NDC 61748-015-30),Revised,9/12/22,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,61748-015-30,not available
9048,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 30 (NDC 61748-018-30),Revised,9/12/22,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,61748-018-30,not available
9049,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 60 (NDC 61748-018-60),Revised,9/12/22,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,61748-018-60,not available
9050,Rifampin Capsules,Akorn Pharmaceuticals,300 mg Bottles of 100 (NDC 61748-018-01),Revised,9/12/22,Unavailable,Discontinuation of manufacture of the drug.,,Other,Anti-Infective,Current,,,61748-018-01,not available
9051,Rifampin Injection,"Fresenius Kabi USA, LLC","600 mg per vial, PF, Lyophilized powder (NDC 63323-351-20)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,,Anti-Infective,Current,,,63323-351-20,not available
9052,Rifampin Injection,Sanofi,"600 mg/10 mL, Lyophilized powder (NDC 0068-0597-01)",Revised,6/22/21,Available,,,Requirements related to complying with good manufacturing practices,Anti-Infective,Current,,,0068-0597-01,available
9053,Rifampin Injection,"Mylan Institutional, a Viatris company","600 mg, (Lyophilizate in Single Dose Vials) (NDC 67457-445-60)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anti-Infective,Current,,,67457-445-60,available
9054,Rifampin/Isoniazid (Rifamate) Capsules,Sanofi-Aventis,150 mg/300 mg capsules (NDC 0068-0509-60),New,6/15/20,,,,,Anti-Infective,To be Discontinued,,,0068-0509-60,discontinued
9055,Rifampin/Isoniazid/Pyrazinamide (Rifater) Tablets,Sanofi-Aventis,150 mg/300 mg/120 mg tablets (NDC 0088-0576-41),New,6/15/20,,,,,Anti-Infective,To be Discontinued,,,0088-0576-41,discontinued
9056,Rifapentine Tablets,Sanofi,"Rifapentine (Piftin) Tablets, 150 mg (NDC 0088-2102-24)",Revised,6/22/22,Intermittent supply,,,Demand increase for the drug,Anti-Infective,Current,,,0088-2102-24,limited availability
9057,Risankizumab-rzaa Injection,Abbvie,75 mg/0.83 mL Prefilled Syringe (NDC numbers 0074-2042-01 and 0074-2042-02),New,9/20/22,,,,,Rheumatology,To be Discontinued,9/20/22,9/20/22,,discontinued
9058,Risedronate Sodium Tablets,Allergan Sales LLC,30 mg (NDC 0430-0470-15),New,5/9/22,,,,,Musculoskeletal,To be Discontinued,,,0430-0470-15,discontinued
9059,Risedronate Tablets,Allergan Sales LLC,5 mg tablets (NDC 0430-0471-15),New,12/9/19,,,,,Musculoskeletal,To be Discontinued,,,0430-0471-15,discontinued
9060,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-595-60,discontinued
9061,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 4 mg (NDC 50458-595-10),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-595-10,discontinued
9062,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-594-60,discontinued
9063,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 3 mg (NDC 50458-594-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-594-50,discontinued
9064,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-593-60,discontinued
9065,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-593-50,discontinued
9066,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 2 mg (NDC 50458-593-10),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-593-10,discontinued
9067,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-592-60,discontinued
9068,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-592-50,discontinued
9069,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 1 mg (NDC 50458-592-10),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-592-10,discontinued
9070,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-591-60,discontinued
9071,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-591-50,discontinued
9072,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.5 mg (NDC 50458-591-10),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-591-10,discontinued
9073,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-60),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-590-60,discontinued
9074,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-590-50,discontinued
9075,Risperidone Tablets,Janssen Pharmaceuticals,Risperidone 0.25 mg (NDC 50458-590-10),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-590-10,discontinued
9076,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 3 mg (NDC 50458-330-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-330-50,discontinued
9077,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 2 mg (NDC 50458-320-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-320-50,discontinued
9078,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 1 mg (NDC 50458-300-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-300-50,discontinued
9079,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.5 mg (NDC 50458-302-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-302-50,discontinued
9080,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-50),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-301-50,discontinued
9081,Risperidone Tablets,Janssen Pharmaceuticals,Risperdal 0.25 mg (NDC 50458-301-01),New,5/24/18,,,,,Pediatric;Psychiatry,To be Discontinued,,,50458-301-01,discontinued
9082,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 5mL vial (NDC 70860-651-05),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,,,70860-651-05,available
9083,Rocuronium Bromide Injection,"Athenex Pharmaceutical Division, LLC (Athenex)",10 mg/mL 10mL vial (NDC 70860-651-10),Revised,11/2/18,Available,,,Available,Anesthesia,Resolved,,,70860-651-10,available
9084,Ropivacaine Hydrochloride Injection,Akorn Pharmaceuticals,"0.5% 5mg/mL, 30mL, 1 Vial (NDC 17478-0081-30)",Revised,2/12/21,Available,,,Other,Anesthesia,Current,,,17478-0081-30,available
9085,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",20 mg/10 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-10),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/12/22,00409-9300-10,discontinued
9086,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",40 mg/20 mL (2 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9300-20),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/8/22,00409-9300-20,discontinued
9087,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/30 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9301-30),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/8/22,00409-9301-30,discontinued
9088,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",150 mg/20 mL (7.5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9302-20),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/8/22,00409-9302-20,discontinued
9089,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",100 mg/10 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-10),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/8/22,00409-9303-10,discontinued
9090,Ropivacaine Hydrochloride Injection,"Hospira, Inc.",200 mg/20 mL (10 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-9303-20),Revised,9/8/22,,Discontinuation of the manufacture of the drug,,,Anesthesia,To be Discontinued,9/8/22,9/8/22,00409-9303-20,discontinued
9091,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.2% 20 mL Single Dose Vials (NDC 55150-195-20),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-195-20,not available
9092,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.2% 100 mL Single Dose Infusion Bottles (NDC 55150-196-99),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-196-99,not available
9093,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 20 mL Single Dose Vials (NDC 55150-197-20),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-197-20,not available
9094,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.5% 30 mL Single Dose Vials (NDC 55150-198-30),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-198-30,not available
9095,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),0.75% 20 mL Single Dose Vials (NDC 55150-199-20),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-199-20,not available
9096,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 10 mL Single Dose Vials (NDC 55150-200-10),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-200-10,not available
9097,Ropivacaine Hydrochloride Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),1% 20 mL Single Dose Vials (NDC 55150-201-20),Reverified,9/28/22,Long-term backorder,,,Shortage of active ingredient,Anesthesia,Current,,,55150-201-20,not available
9098,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-10)",Revised,9/14/22,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-10,available
9099,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-285-20)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,63323-285-20,not available
9100,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-286-20)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,63323-286-20,not available
9101,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-287-20)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-20,not available
9102,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Plastic Ampule, Sterile-Pak (63323-288-10)",Revised,9/14/22,Backordered. Next release not available at this time.,,,Available,Anesthesia,Current,,,,not available
9103,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Plastic Ampule, Sterile-Pak (NDC 63323-288-20)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-20,not available
9104,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Free Flex Bag (NDC 63323-285-61)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-61,not available
9105,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Free Flex Bag (NDC 63323-285-63)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-63,not available
9106,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (200 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-285-65)",Revised,9/14/22,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-285-65,available
9107,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (400 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-285-64)",Revised,9/14/22,Available,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-64,available
9108,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (500 mg per 100 mL), Single Dose Infusion Bottle (NDC 63323-286-00)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-00,not available
9109,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (1,000 mg per 200 mL), Single Dose Infusion Bottle (NDC 63323-286-63)",Revised,9/14/22,Available,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-286-63,available
9110,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (20 mg per 10 mL), Single Dose Vial (NDC 63323-285-13)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-285-13,not available
9111,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","2 mg per mL / 0.2% (40 mg per 20 mL), Single Dose Vial (NDC 63323-285-23)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Manufacturing delays,Anesthesia,Current,,,63323-285-23,not available
9112,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Single Dose Vial (NDC 63323-286-35)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-286-35,not available
9113,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (100 mg per 20 mL), Single Dose Vial (NDC 63323-286-23)",Revised,9/14/22,Backordered. Next release September 2022.,,,Manufacturing delays,Anesthesia,Current,,,63323-286-23,not available
9114,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","7.5 mg per mL / 0.75% (150 mg per 20 mL), Single Dose Vial (NDC 63323-287-21)",Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-287-21,not available
9115,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (100 mg per 10 mL), Single Dose Vial (NDC 63323-288-11)",Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler for inventory,,Available,Anesthesia,Current,,,63323-288-11,not available
9116,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","10 mg per mL / 1% (200 mg per 20 mL), Single Dose Vial (NDC 63323-288-21)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler for inventory,,Manufacturing Delay,Anesthesia,Current,,,63323-288-21,not available
9117,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","5 mg per mL / 0.5% (150 mg per 30 mL), Sterile-Pack, Single Dose Vial (NDC 63323-286-31)",Revised,9/14/22,Backordered. Next release not available at this time.,,,,Anesthesia,Current,,,63323-286-31,not available
9118,Ropivacaine Hydrochloride Injection,InfoRLife SA,0.2% 2mg/mL 10x100mL (NDC 25021-671-82),Revised,4/25/22,Available,,,,Anesthesia,Current,,,25021-671-82,available
9119,Ropivacaine Hydrochloride Injection,InfoRLife SA,0.2% 2mg/mL 10x200mL (NDC 25021-671-87),Revised,4/25/22,Available,,,,Anesthesia,Current,,,25021-671-87,available
9120,Ropivacaine Hydrochloride Injection,InfoRLife SA,500 mg per 100 mL (5 mg per mL 0.5%) (NDC 25021-652-82 ),Revised,4/25/22,Available,,,,Anesthesia,Current,,,25021-652-82,available
9121,Ropivacaine Hydrochloride Injection,InfoRLife SA,"1,000 mg per 200 mL (5 mg per mL 0.5%) (NDC 25021-652-87)",Revised,4/25/22,Backordered. Estimated availability TBD,,,,Anesthesia,Current,,,25021-652-87,not available
9122,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 1 vial (NDC 70069-064-01)",New,4/20/22,Available,,,,Anesthesia,Current,,,70069-064-01,available
9123,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 10 vials (NDC 70069-064-10)",New,4/20/22,Available,,,,Anesthesia,Current,,,70069-064-10,available
9124,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","0.5% (5 mg/mL), 30 mL, 25 vials (NDC 70069-064-25)",New,4/20/22,Available,,,,Anesthesia,Current,,,70069-064-25,available
9125,Ropivacaine Hydrochloride Injection,InfoRLife SA,"0.2% 2mg/mL 10x100mL (NDC 25021-671-66), Novaplus",New,4/25/22,Available,,,,Anesthesia,Current,,,25021-671-66,available
9126,Ropivacaine Hydrochloride Injection,InfoRLife SA,"0.2% 2mg/mL 10x200mL (NDC 25021-671-67), Novaplus",New,4/25/22,Available,,,,Anesthesia,Current,,,25021-671-67,available
9127,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.2%, 40 mg/20 mL (2 mg/mL) single dose vial (NDC 43066-015-10)",Revised,9/28/22,Limited Supply Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,43066-015-10,limited availability
9128,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 100 mg/20 mL (5 mg/mL) single dose vial (NDC 43066-019-10)",Revised,9/28/22,Limited supply. Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,43066-019-10,limited availability
9129,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"0.5%, 150 mg/30 mL (5 mg/mL) single dose vial (NDC 43066-023-10)",Revised,9/28/22,Available:  Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,43066-023-10,unclear
9130,Ropivacaine Hydrochloride Injection,Caplin Steriles Limited,"1%, 200 mg/20 mL (10 mg/mL) single dose vial (NDC 43066-027-10)",Revised,9/28/22,Limited supply. Recovery Q1 2023,,,Demand increase,Anesthesia,Current,,,43066-027-10,limited availability
9131,Rosuvastatin Calcium Tablets,Sandoz,5 mg (NDC 0781-5400-92),New,6/16/22,,,,,Cardiovascular,To be Discontinued,,,0781-5400-92,discontinued
9132,Rosuvastatin Calcium Tablets,Sandoz,10 mg (NDC 0781-5401-92),New,6/16/22,,,,,Cardiovascular,To be Discontinued,,,0781-5401-92,discontinued
9133,Rosuvastatin Calcium Tablets,Sandoz,20 mg (NDC 0781-5402-92),New,6/16/22,,,,,Cardiovascular,To be Discontinued,,,0781-5402-92,discontinued
9134,Rosuvastatin Calcium Tablets,Sandoz,40 mg (NDC 0781-5403-31),New,6/16/22,,,,,Cardiovascular,To be Discontinued,,,0781-5403-31,discontinued
9135,Samarium SM 153 Lexidronam  (Quadramet) Injection,Lantheus Medical Imaging INC,150mCi (NDC 11994-016-01),New,10/28/21,,,,,Oncology,To be Discontinued,,,11994-016-01,discontinued
9136,Saquinavir Mesylate (Invirase) 200mg Capsules,"Genentech, Inc",200 mg capsules (NDC 0004-0245-15),New,2/6/18,,,,,Antiviral,To be Discontinued,,,0004-0245-15,discontinued
9137,Sclerosol Intrapleural Aerosol,Lymol Medical Corp.,Sclerosol 4 GM (NDC 63256-100-30),Revised,6/14/22,,,,,Pulmonary/Allergy,To be Discontinued,,,63256-100-30,discontinued
9138,Scopolamine Transdermal System,Mylan Pharmaceuticals Inc.,1 mg/3 days 24s (NDC 0378-6470-44),Revised,12/10/19,,,,,Endocrinology/Metabolism;Neurology,Resolved,,,0378-6470-44,
9139,"Selenium Sulfide Lotion, 2.5%",Wockhardt,4 fl oz (118 mL) (NDC 60432-528-04),New,6/13/22,,,,,Dermatology,To be Discontinued,,,60432-528-04,discontinued
9140,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",0.25 mg / 0.5mg (NDC 0169-4132-12),Revised,10/3/22,Limited availability; Intermittent supply disruption will continue through November 2022,Localized short term stock outages in pharmacies,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4132-12,limited availability
9141,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",1 mg (NDC 0169-4130-13),Revised,10/3/22,Currently available,,,,Endocrinology/Metabolism,Current,,,0169-4130-13,available
9142,Semaglutide (Ozempic) Injection,"Novo Nordisk, Inc.",2 mg (NDC 0169-4772-12),Revised,10/3/22,Limited availability; Intermittent supply disruption will continue through October 2022,Localized short term stock outages in pharmacies,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4772-12,limited availability
9143,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",0.25 mg / 0.5mL (NDC 0169-4525-14),Revised,9/14/22,"Distribution of this dose temporarily paused, resumption of supply expected towards the end of 2022.",,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,0169-4525-14,not available
9144,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",0.5 mg / 0.5mL (NDC 0169-4505-14),Revised,9/14/22,"Distribution of this dose temporarily paused, resumption of supply expected towards the end of 2022.",,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,0169-4505-14,not available
9145,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",1 mg / 0.5mL (NDC 0169-4501-14),Revised,9/14/22,Currently unavailable; Resumption of supply expected towards the end of 2022.,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,0169-4501-14,not available
9146,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",1.7 mg / 0.75mL (NDC 0169-4517-14),Revised,9/14/22,Currently available,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,0169-4517-14,available
9147,Semaglutide (WEGOVY®) Injection,"Novo Nordisk, Inc.",2.4 mg / 0.75mL (NDC 0169-4524-14),Revised,9/14/22,Currently available,,,Requirements related to complying with good manufacturing practices.,Endocrinology/Metabolism,Current,,,0169-4524-14,available
9148,"Sertraline Hydrochloride Oral Solution, USP",Aurobindo Pharma,"20mg/ml, 60ml  (NDC 16714-601-02)",Revised,4/13/21,,,Northstar Rx label. Product Distributed by McKesson:  +1 (972) 446-4800,,Psychiatry,Resolved,,,16714-601-02,
9149,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 30 count (NDC 16729-215-10)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-215-10,
9150,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 90 count (NDC 16729-215-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-215-15,
9151,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"25 mg, 500 count (NDC 16729-215-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-215-16,
9152,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 90 count (NDC 16729-216-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-216-15,
9153,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"50 mg, 500 count (NDC 16729-216-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-216-16,
9154,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 90 count (NDC 16729-217-15)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-217-15,
9155,Sertraline Hydrochloride Tablets,Accord Healthcare Inc.,"100 mg, 500 count (NDC 16729-217-16)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16729-217-16,
9156,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 65862-011-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-011-30,
9157,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 65862-011-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-011-01,
9158,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 65862-011-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-011-05,
9159,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 65862-012-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-012-30,
9160,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 65862-012-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-012-01,
9161,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 65862-012-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-012-05,
9162,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 65862-013-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-013-30,
9163,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 65862-013-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-013-01,
9164,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 65862-013-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,65862-013-05,
9165,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 30 count (NDC 16714-611-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-611-01,
9166,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 100 count (NDC 16714-611-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-611-04,
9167,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 500 count (NDC 16714-611-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-611-05,
9168,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"25 mg, 1000 count (NDC 16714-611-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-611-06,
9169,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 30 count (NDC 16714-612-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-612-01,
9170,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 100 count (NDC 16714-612-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-612-04,
9171,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 500 count (NDC 16714-612-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-612-05,
9172,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"50 mg, 1000 count (NDC 16714-612-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-612-06,
9173,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 30 count (NDC 16714-613-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-613-01,
9174,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 100 count (NDC 16714-613-04)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-613-04,
9175,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 500 count (NDC 16714-613-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-613-05,
9176,Sertraline Hydrochloride Tablets,Aurobindo Pharma,"100 mg, 1000 count (NDC 16714-613-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,16714-613-06,
9177,Sertraline Hydrochloride Tablets,Viatris,Zoloft 25 mg; Bottle of 30 tablets (NDC 0049-4960-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,0049-4960-30,
9178,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Bottle of 30 tablets (NDC 0049-4900-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,0049-4900-30,
9179,Sertraline Hydrochloride Tablets,Viatris,Zoloft 50 mg; Blister of 10 tablets (NDC 0049-4900-41); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,0049-4900-41,
9180,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Bottle of 30 tablets (NDC 0049-4910-30); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,0049-4910-30,
9181,Sertraline Hydrochloride Tablets,Viatris,Zoloft 100 mg; Blister of 10 tablets (NDC 0049-4910-41); Pfizer label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,0049-4910-41,
9182,Sertraline Hydrochloride Tablets,Viatris,25 mg; Bottle of 30 tablets (NDC 59762-6347-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,59762-6347-1,
9183,Sertraline Hydrochloride Tablets,Viatris,50 mg; Bottle of 30 tablets (NDC 59762-6443-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,59762-6443-1,
9184,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 30 tablets (NDC 59762-5160-1); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,59762-5160-1,
9185,Sertraline Hydrochloride Tablets,Viatris,100 mg; Bottle of 100 tablets (NDC 59762-5160-2); Greenstone label,Revised,3/15/21,,,"To order these products, contact Pfizer at 800-553-4535",,Pediatric;Psychiatry,Resolved,,,59762-5160-2,
9186,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 30 count (NDC 68180-351-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-351-06,
9187,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 90 count  (NDC 68180-351-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-351-09,
9188,Sertraline Hydrochloride Tablets,Lupin,"25 mg, 1000 count (NDC 68180-351-03)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-351-03,
9189,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 30 count (NDC 68180-352-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-352-06,
9190,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 90 count (NDC 68180-352-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-352-09,
9191,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 500 count (NDC 68180-352-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-352-02,
9192,Sertraline Hydrochloride Tablets,Lupin,"50 mg, 5000 count (NDC 68180-352-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-352-05,
9193,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 30 count (NDC 68180-353-06)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-353-06,
9194,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 90 count (NDC 68180-353-09)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-353-09,
9195,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 500 count (NDC 68180-353-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-353-02,
9196,Sertraline Hydrochloride Tablets,Lupin,"100 mg, 5000 count (NDC 68180-353-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,68180-353-05,
9197,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 69097-833-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-833-02,
9198,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 69097-833-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-833-05,
9199,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 69097-833-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-833-12,
9200,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 69097-834-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-834-02,
9201,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 69097-834-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-834-12,
9202,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 69097-835-02)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-835-02,
9203,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 69097-835-12)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,69097-835-12,
9204,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 30 count (NDC 76282-212-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-30,
9205,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 60 count (NDC 76282-212-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-60,
9206,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 90 count (NDC 76282-212-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-90,
9207,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 100 count (NDC 76282-212-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-01,
9208,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 180 count (NDC 76282-212-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-18,
9209,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"25 mg, 500 count (NDC 76282-212-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-212-05,
9210,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 30 count (NDC 76282-213-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-30,
9211,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 60 count (NDC 76282-213-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-60,
9212,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 90 count (NDC 76282-213-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-90,
9213,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 100 count (NDC 76282-213-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-01,
9214,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 180 count (NDC 76282-213-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-18,
9215,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"50 mg, 500 count (NDC 76282-213-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-213-05,
9216,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 30 count (NDC 76282-214-30)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-30,
9217,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 60 count (NDC 76282-214-60)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-60,
9218,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 90 count (NDC 76282-214-90)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-90,
9219,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 100 count (NDC 76282-214-01)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-01,
9220,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 180 count (NDC 76282-214-18)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-18,
9221,Sertraline Hydrochloride Tablets,InvaGen Pharmaceuticals (a subsidiary of Cipla Ltd),"100 mg, 500 count (NDC 76282-214-05)",Revised,3/9/21,,,,,Pediatric;Psychiatry,Resolved,,,76282-214-05,
9222,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/12.5 mL; vial (NDC 0069-0338-01),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,0069-0338-01,
9223,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,20 mg; tablets (NDC 0069-4190-68),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,0069-4190-68,
9224,Sildenafil Citrate (REVATIO),Pfizer Pharmaceuticals,10 mg/mL (powder); bottle (NDC 0069-0336-21),Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,0069-0336-21,
9225,Sildenafil Citrate (REVATIO),Novitium Pharma LLC,"10 mg/mL, (NDC 70954-168-10)",Revised,10/24/19,,,,,Cardiovascular;Pediatric;Pulmonary/Allergy,Resolved,,,70954-168-10,
9226,Simeprevir Capsules,Janssen Pharmaceuticals,150mg capsules (NDC 59676-225-28),New,5/23/18,,,,,Antiviral,To be Discontinued,,,59676-225-28,discontinued
9227,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,5 mg (NDC 0093-7152-98),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,0093-7152-98,discontinued
9228,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,10 mg (NDCs 0093-7153-93 / 0093-7153-56 / 0093-7153-19 / 0093-7153-31 / 0093-7153-10),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,,discontinued
9229,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,20 mg (NDCs 0093-7154-93 / 0093-7154-56 / 0093-7154-31 / 0093-7154-19 / 0093-7154-10),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,,discontinued
9230,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,40 mg (NDCs 0093-7155-93 / 0093-7155-56 / 0093-7155-31 / 0093-7155-19 / 0093-7155-10),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,,discontinued
9231,Simvastatin (Zocor) Tablets,Teva Pharmaceuticals,80 mg (NDCs 0093-7156-98 / 0093-7156-93 / 0093-7156-56 / 0093-7156-19 / 0093-7156-10),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,,discontinued
9232,Simvastatin (Zocor) Tablets,Merck Sharp & Dohme Corp.,5 mg Tablets bottles of 30 (NDC 0006-0726-31),New,2/6/18,,,,,Cardiovascular,To be Discontinued,,,0006-0726-31,discontinued
9233,Simvastatin Tablets,Merck Sharp & Dohme Corp.,80 mg (NDCs 0006-0543-31 and 0006-0543-54),New,7/27/21,,,,,Cardiovascular,To be Discontinued,,,,discontinued
9234,Sincalide (Kinevac) Lyophilized Powder for Injection,Bracco Diagnostics,Supplied in packages of 10 single dose vials containing 5 mcg of sincalide per vial (NDC 0270-0556-15),Reverified,7/16/21,Available,,,Delay in shipping of the drug,Medical Imaging;Other,Current,,,0270-0556-15,available
9235,Sodium Acetate Injection,"Hospira, Inc.",100 mEq/50 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3299-05),Revised,9/12/22,Next Delivery and Estimated Recovery: November 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-3299-05,not available
9236,Sodium Acetate Injection,"Hospira, Inc.",200 mEq/100 mL (2 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 0409-3299-06),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-3299-06,not available
9237,Sodium Acetate Injection,"Hospira, Inc.",40 mEq/20 mL (2 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 0409-7299-73),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: January 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7299-73,not available
9238,Sodium Acetate Injection,"Fresenius Kabi USA, LLC",32.8% 400 mEq 100mL PBP (NDC 63323-0032-00),Reverified,9/14/22,Backordered. Next release not available at this time.,,,Manufacturing delay,Total Parenteral Nutrition,Current,,,63323-0032-00,not available
9239,Sodium Acetate Injection,Milla Pharmaceuticals,100 mEq/50 mL (2 mEq/mL) (NDC 69784-230-20),Reverified,12/3/21,Available,,,Other,Total Parenteral Nutrition,Current,,,69784-230-20,available
9240,Sodium Acetate Injection,Milla Pharmaceuticals,200 mEq/100 mL (2 mEq/mL) (NDC 69784-231-20),Reverified,12/3/21,Available,,,Other,Total Parenteral Nutrition,Current,,,69784-231-20,available
9241,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial (4.2% Concentration) (NDC 0409-5555-02),Revised,9/30/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-5555-02,limited availability
9242,Sodium Bicarbonate Injection,"Hospira, Inc.",2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial Novaplus®  (4.2% Concentration) (NDC 0409-5555-01),Revised,9/30/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-5555-01,available
9243,Sodium Bicarbonate Injection,"Hospira, Inc.",44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (7.5% concentration) (NDC 0409-4916-14),Revised,9/30/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-4916-14,available
9244,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) (NDC 0409-6625-14) (old NDC 0409-6625-02),Revised,9/30/22,Limited Supply Available. Next Delivery and Estimated Recovery: September 2022,,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6625-14,limited availability
9245,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) Single Dose Vial Novaplus® (8.4% concentration) (NDC 0409-6625-35),Revised,9/30/22,Available,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6625-35,available
9246,Sodium Bicarbonate Injection,"Hospira, Inc.",Pediatric 10 mEq/10 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-4900-14),Revised,9/30/22,Limited Supply Available. Next Delivery: November 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-4900-14,limited availability
9247,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC",10 mEq/10 mL (NDC 2551754-5011-04),New,1/31/22,Currently on backorder,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,2551754-5011-04,not available
9248,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","5 mEq/10 mL, 4.2%, (NDC 51754-5012-04)",New,1/31/22,On backorder,,,,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,51754-5012-04,not available
9249,Sodium Bicarbonate Injection,"Hospira, Inc.",Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02),Revised,9/30/22,Discontinued,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6609-02,discontinued
9250,Sodium Bicarbonate Injection,"Hospira, Inc.",Infant 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe (4.2% Concentration) (NDC 0409-5534-14) (old NDC 0409-5534-34),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-5534-14,not available
9251,Sodium Bicarbonate Injection,"Hospira, Inc.",50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-6637-14),Revised,9/30/22,Next Delivery: September 2022; Estimated Recovery: June 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0409-6637-14,not available
9252,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc./IMS","Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1)",Reverified,8/12/22,Backorder due to the increase in demands,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,0548-3352-00,not available
9253,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05)",Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-083-05,available
9254,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL)  (84 mg per mL)(NDC 63323-089-50)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,63323-089-50,not available
9255,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","8.4%, 50mL (NDC 51754-5001-05)",Revised,1/31/22,Available,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric,Current,,,51754-5001-05,available
9256,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 50 mL (Legacy Hospira NDC 0409-7984-13)(ICU Medical NDC 0990-7984-13)",Reverified,10/3/22,Allocated to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,0409-7984-13,limited availability
9257,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 50 mL 4-1 (Legacy Hospira NDC 0409-7984-36)(ICU Medical NDC 0990-7984-36)",Reverified,10/3/22,Available to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,0409-7984-36,limited availability
9258,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 100 mL (Legacy Hospira NDC 0409-7984-37)(ICU Medical NDC 0990-7984-37)",Reverified,10/3/22,Allocated to Contracted Customers Only,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,0409-7984-37,limited availability
9259,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 100 mL (Legacy Hospira NDC 0409-7984-23)(ICU Medical NDC 0990-7984-23)",Reverified,10/3/22,Allocated to Contracted Customers Only,,,Other,Gastroenterology;Other;Pediatric,Current,,,0409-7984-23,limited availability
9260,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 25 mL (Legacy Hospira NDC 0409-7984-20)(ICU Medical NDC 0990-7984-20)",Reverified,10/3/22,Available,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,0409-7984-20,available
9261,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,1000 mL Excel Bag L8000 (NDC 0264-7800-00),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-7800-00,limited availability
9262,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,500 mL Excel Bag L8001 (NDC 0264-7800-10),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-7800-10,limited availability
9263,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,250 mL Excel Bag L8002 (NDC 0264-7800-20),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-7800-20,limited availability
9264,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,1000 mL E3 Bag E8000 (NDC 0264-7800-09),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-7800-09,limited availability
9265,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,100 mL PAB Bag S8004-5264 (NDC 0264-1800-32),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-1800-32,limited availability
9266,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,50 mL PAB Bag S8004-5384 (NDC 0264-1800-31),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-1800-31,limited availability
9267,Sodium Chloride 0.9% Injection Bags,B. Braun Medical Inc.,25 mL PAB Bag S8004-5410 (NDC 0264-1800-36),New,12/10/21,Product available for contracted customers,,,Other,Gastroenterology;Other;Pediatric,Current,,,0264-1800-36,limited availability
9268,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",50 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-66),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Other;Pediatric,Current,,,00409-7101-66,limited availability
9269,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",100 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-67),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: October 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Gastroenterology;Other;Pediatric,Current,,,00409-7101-67,limited availability
9270,Sodium Chloride 0.9% Injection Bags,"Hospira, Inc.",250 mL ADD-Vantage™ Flexible Container (NDC 00409-7101-02),Revised,9/12/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,00409-7101-02,available
9271,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 76297-001-21)",New,3/16/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,76297-001-21,available
9272,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 76297-001-31)",New,3/16/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,76297-001-31,available
9273,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC NDC 76297-001-01)",New,3/16/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,76297-001-01,available
9274,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC NDC 76297-001-41)",New,3/16/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,76297-001-41,available
9275,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 76297-001-11)",New,3/16/22,Available,,,Other,Gastroenterology;Other;Pediatric,Current,,,76297-001-11,available
9276,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (450 mg per 50 mL), (9 mg per mL), Single Dose freeflex bag, 50 mL, (NDC: 63323-623-53)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,not available
9277,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (900 mg per 100 mL), (9 mg per mL), Single Dose freeflex bag, 100 mL, (NDC: 63323-623-61)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,not available
9278,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (2,250 mg per 250 mL), (9 mg per mL), Single dose freeflex bag, 250 mL, (NDC: 63323-623-74)",Revised,9/14/22,Backordered. Next release August 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,not available
9279,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (4,500 mg per 500 mL), (9 mg per mL), Single dose freeflex bag, 500 mL, (NDC: 63323-623-75)",Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,not available
9280,Sodium Chloride 0.9% Injection Bags,"Fresenius Kabi USA, LLC","0.9% (9,000 mg per 1,000 mL), (9 mg per mL), Single dose freeflex bag, 1,000 mL, (NDC: 63323-623-76)",Revised,9/14/22,Backordered. Next release August 2022.,Check wholesaler inventory,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,,not available
9281,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Quad Pack; Product Code 2B1302; (NDC 0338-0049-18)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-0049-18,available
9282,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Product Code 2B1306 (NDC 0338-0049-41)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-0049-41,available
9283,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Product Code 2B1307 (NDC 0338-0049-48)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0049-48,available
9284,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B1308 (NDC 0338-0049-31)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0049-31,available
9285,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLEX Plastic Container, Product Code 2B1322Q (NDC 0338-0049-02)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0049-02,available
9286,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLEX Plastic Container, Product Code 2B1323Q (NDC 0338-0049-03)",Reverified,9/28/22,Limited supply; Recovery August,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0049-03,limited availability
9287,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLEX Plastic Container, Product Code 2B1324X (NDC 0338-0049-04)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-0049-04,available
9288,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"25 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B1300 (NDC 0338-0049-10)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-0049-10,available
9289,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL VIAFLEX Plastic Container, Quad Pack, Product Code 2B1301 (NDC 0338-0049-11)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-0049-11,available
9290,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL VIAFLEX Plastic Container, Multi Pack, Product Code 2B1309 (NDC 0338-0049-38)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0049-38,available
9291,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLO Plastic Container, Product Code UE1322D (NDC 0338-9543-02)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9543-02,available
9292,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLO Plastic Container, Product Code UE1324D (NDC 0338-9543-06)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9543-06,available
9293,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLO Plastic Container, Product Code UE1323D (NDC 0338-9543-04)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9543-04,available
9294,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL MINI-BAG Plus Container, Quad Pack, Product Code 2B0042 (NDC 0338-0553-11)",Reverified,9/28/22,Available,,,Manufacturing delay,Gastroenterology;Other;Pediatric,Current,,,0338-0553-11,available
9295,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"50 mL MINI-BAG Plus Container, Single Pack, Product Code EZPB0042 (NDC 0338-9151-30)",Reverified,9/28/22,Supply available on allocation,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9151-30,limited availability
9296,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL MINI-BAG Plus Container, Single Pack, Product Code EZPB0043 (NDC 0338-9159-30)",Reverified,9/28/22,"Limited Supply on Allocation, Recovery 2023",,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-9159-30,limited availability
9297,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"100 mL MINI-BAG Plus Container, Quad Pack, Product Code 2B 0043 (NDC 0338-0553-18)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-0553-18,available
9298,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"250 mL VIAFLO Plastic Container, Product Code UE1322D (NDC 0338-9543-02)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9543-02,available
9299,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"500 mL VIAFLO Plastic Container, Product Code UE1323D (NDC 0338-9543-04)",Reverified,9/28/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0338-9543-04,available
9300,Sodium Chloride 0.9% Injection Bags,Baxter Healthcare,"1000 mL VIAFLO Plastic Container, Product Code UE1324D (NDC 0338-9543-06)",Reverified,9/28/22,Available,,,Demand increase,Gastroenterology;Other;Pediatric,Current,,,0338-9543-06,available
9301,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 50 mL Fleboflex Plastic Container (115 units/carton)(NDC 79672-613-01)",New,3/16/22,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,79672-613-01,limited availability
9302,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 100 mL Fleboflex Plastic Container (70 units/carton)(NDC 79672-613-02)",New,3/16/22,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,79672-613-02,limited availability
9303,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 250 mL Fleboflex Plastic Container (28 units/carton)(NDC 79672-613-03)",New,3/16/22,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,79672-613-03,limited availability
9304,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 500 mL Fleboflex Plastic Container (20 units/carton)(NDC 79672-613-04)",New,3/16/22,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,79672-613-04,limited availability
9305,Sodium Chloride 0.9% Injection Bags,"Laboratorios Grifols, S.A.","0.9% Sodium Chloride Injection, USP 1000 mL Fleboflex Plastic Container (10 units/carton)(NDC 79672-613-05)",New,3/16/22,Product available for contracted customers.,,,Other,Gastroenterology;Other;Pediatric,Current,,,79672-613-05,limited availability
9306,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 500 mL (Legacy Hospira (NDC 0409-7983-03)(ICU Medical NDC 0990-7983-03)",Reverified,10/3/22,Available,,,,Gastroenterology;Other;Pediatric,Current,,,0409-7983-03,available
9307,Sodium Chloride 0.9% Injection Bags,"ICU Medical, Inc.","0.9% Sodium Chloride, USP 1000 mL (Legacy Hospira NDC 0409-7983-09)(ICU Medical NDC 0990-7983-09)",Reverified,10/3/22,Allocation,,,Demand increase for the drug,Gastroenterology;Other;Pediatric,Current,,,0409-7983-09,limited availability
9308,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","50 mEq per 20 mL (2.5 mEq per mL), Single dose plastic flip top vial, (NDC 63323-090-20)",New,4/5/22,Backordered. Next release June 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-090-20,not available
9309,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","100 mEq per 40 mL (2.5 mEq per mL), Single dose plastic flip top vial, (NDC 63323-090-40)",New,4/5/22,Backordered. Next release June 2022.,,,Increase in Demand,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-090-40,not available
9310,Sodium Chloride 14.6% Injection,"Hospira, Inc.",14.6% 100 mEq/40 mL (2.5 mEq/mL); Single Dose Plastic Fliptop Vial (NDC 00409-6660-75),Reverified,9/12/22,Next Delivery and Estimated Recovery: March 2023,,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,00409-6660-75,not available
9311,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",100 mL vials (NDC 63323-0095-61),Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0095-61,not available
9312,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",200 mL vials (NDC 63323-0088-63),Revised,9/14/22,Backordered. Next release October 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0088-63,not available
9313,Sodium Chloride 23.4% Injection,"Hospira, Inc.",400 mEq/100 mL (4 mEq/mL); Pharmacy Bulk Package Glass Fliptop Vial (NDC 00409-1141-02),Revised,9/12/22,Next Delivery: October 2022; Estimated Recovery: March 2023,,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,00409-1141-02,not available
9314,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC",30 mL vials (NDC 63323-0093-30),Revised,9/14/22,Backordered. Next release September 2022.,Check wholesaler inventory,,Demand increase for the drug,Gastroenterology;Endocrinology/Metabolism;Total Parenteral Nutrition;Pediatric,Current,,,63323-0093-30,not available
9315,"Sodium Chloride Injection, 0.9% Vials and Syringes","Medefil, Inc.","Sodium Chloride Injection, USP, 0.9%, in a plastic syringe (10 mL) (NDC 64253-202-30)",Revised,10/3/22,Available,,,Available,Other,Current,,,64253-202-30,available
9316,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose plastic vial, 0.9%, (18 mg per 2 mL)(9 mg per mL) (NDC 63323-186-02)",Revised,10/3/22,Backordered. Next release Q4-2022.,,,Increase in Demand,Other,Current,,,63323-186-02,not available
9317,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (90 mg per 10 mL)(9 mg per mL) (NDC 63323-186-10)",Revised,10/3/22,Backordered. Next release October 2022.,Check wholesalers for inventory,,Demand increase,Other,Current,,,63323-186-10,not available
9318,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP,  Single dose plastic vial, 0.9%, (180 mg per 20 mL)(9 mg per mL) (NDC 63323-186-20)",Revised,10/3/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase,Other,Current,,,63323-186-20,not available
9319,"Sodium Chloride Injection, 0.9% Vials and Syringes","Fresenius Kabi USA, LLC","Sodium Chloride Injection USP, Single dose tear top vial, 0.9%, (900 mg per 100 mL)(9 mg per mL) (NDC 63323-186-00)",Revised,10/3/22,Backordered.  Next release date not available at this time.,,,Increase in Demand,Other,Current,,,63323-186-00,not available
9320,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose Plastic Fliptop Vial (NDC 00409-4888-10),Revised,10/3/22,Available,,,Demand increase for the drug,Other,Current,,,00409-4888-10,available
9321,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",10 mL (0.9%); Single Dose LifeShield Plastic Fliptop Vial (NDC 00409-4888-12),Revised,10/3/22,Next Delivery: October 2022; Estimated Recovery: December 2022,,,Demand increase for the drug,Other,Current,,,00409-4888-12,not available
9322,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-20),Revised,10/3/22,Available,,,Other,Other,Current,,,00409-4888-20,available
9323,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Single Dose Plastic Fliptop Vial (NDC 00409-4888-50),Revised,10/3/22,Next Delivery: October 2022; Estimated Recovery: August 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Other,Current,,,00409-4888-50,not available
9324,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-32),Revised,10/3/22,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-32,discontinued
9325,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-33),Revised,10/3/22,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-33,discontinued
9326,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hospira, Inc.",0.9%; Carpuject Luer Lock Glass Syringe (NDC 00409-1918-35),Revised,10/3/22,Discontinued,,,Discontinuation of the manufacture of the drug,Other,Current,,,00409-1918-35,discontinued
9327,"Sodium Chloride Injection, 0.9% Vials and Syringes","Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","0.9%, 2 mL vial (NDC 0641-0497-25)",Revised,10/3/22,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Other,Current,,,0641-0497-25,not available
9328,"Sodium Chloride Injection, 0.9% Vials and Syringes","Spectra Medical Devices, Inc.",0.9% 10mL Ampule (NDC 65282-1510-1),Revised,10/3/22,"Currently available, in stock, Production is ongoing",,,Other,Other,Current,,,65282-1510-1,available
9329,"Sodium Chloride Injection, 0.9% Vials and Syringes","Spectra Medical Devices, Inc.",0.9% 5mL Ampule (NDC 65282-1505-1),Revised,10/3/22,"Currently available, in stock, Production is ongoing",,,Other,Other,Current,,,65282-1505-1,available
9330,"Sodium Chloride Injection, 0.9% Vials and Syringes",Guerbet LLC,125 mL PFS (NDC 0019-1188-81),Revised,10/3/22,"On backorder. Next batch will be available in April 2022, and the current demand can be fulfilled by May 2022.",,,Other,Other,Current,,,0019-1188-81,not available
9331,"Sodium Chloride Injection, 0.9% Vials and Syringes",Guerbet LLC,125 mL PFS RFID Tag (NDC 0019-1188-27),Revised,10/3/22,Available; Next batch will be available May 2022.,,,Other,Other,Current,,,0019-1188-27,limited availability
9332,Sodium Phosphates Injection,"Hospira, Inc.","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 0409-7391-72)",Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: December 2022,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,0409-7391-72,limited availability
9333,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 15 mmol/5 mL, Sodium 20 mEq/5 mL, vial (NDC 63323-170-05)",Revised,9/14/22,Available,Check wholesaler inventory,,Other,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-170-05,available
9334,Sodium Phosphates Injection,"Fresenius Kabi USA, LLC","Phosphorus 45 mmol/15 mL, Sodium 60 mEq/15 mL, vial (NDC 63323-881-16)",Revised,9/14/22,Available,Check wholesaler inventory,,Demand increase for the drug,Endocrinology/Metabolism;Gastroenterology;Pediatric;Total Parenteral Nutrition,Current,,,63323-881-16,available
9335,Somatropin Recombinant (Humatrope) Injection,Eli Lilly and Co.,5 mg kit (NDC 0002-7335-11) contains 5 mg/mL in 1 vial (NDC 0002-7349-01) of Humatrope and 5 mL in 1 vial (NDC 0002-7336-01) of Sterile Diluent,New,7/7/20,,,,,Hematology,To be Discontinued,,,0002-7335-11,discontinued
9336,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 100 (NDC 0228-2803-11)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2803-11,discontinued
9337,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"25mg tablets, bottle of 500 (NDC 0228-2803-50)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2803-50,discontinued
9338,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 100 (NDC 0228-2672-11)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2672-11,discontinued
9339,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"50mg tablets, bottle of 500 (NDC 0228-2672-50)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2672-50,discontinued
9340,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 100 (NDC 0228-2673-11)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2673-11,discontinued
9341,Spironolactone Tablets,Actavis Elizabeth LLC an indirect wholly owned subsidiary of Teva Pharmaceuticals USA Inc.,"100mg tablets, bottle of 500 (NDC 0228-2673-50)",New,5/22/18,,,,,Renal,To be Discontinued,,,0228-2673-50,discontinued
9342,Stavudine Capsules,Mylan Pharmaceuticals Inc.,20mg capsules (NDC 0378-5041-91),New,4/30/18,,,,,Antiviral,To be Discontinued,,,0378-5041-91,discontinued
9343,Sterile Water for Injection,"Medefil, Inc.",10 mL in plastic syringe (NDC 64253-020-30),Revised,3/1/22,Available,,,Available; Demand Increase for the drug,Other,Current,,,64253-020-30,available
9344,Sterile Water for Injection,"Fresenius Kabi USA, LLC","Single Dose free flex bag, 1,000 mL fill, (NDC 63323-178-76)",Revised,9/14/22,Backordered. Next release October 2022.,,,,Other,Current,,,63323-178-76,not available
9345,Sterile Water for Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",10 mL vial (NDC 0641-6147-10),Revised,6/3/22,This presentation is temporarily on backorder.,,,Demand increase for the drug,Other,Current,,,0641-6147-10,not available
9346,Sterile Water for Injection,"Hospira, Inc.",10 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-10),Revised,9/12/22,Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: May 2023,,,Demand increase for the drug,Other,Current,,,00409-4887-10,limited availability
9347,Sterile Water for Injection,"Hospira, Inc.",20 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-20),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: October 2022,,,Demand increase for the drug,Other,Current,,,00409-4887-20,not available
9348,Sterile Water for Injection,"Hospira, Inc.",50 mL Single Dose Plastic Fliptop Vial (NDC 00409-4887-50),Revised,9/12/22,Next Delivery: September 2022; Estimated Recovery: October 2023,,,Demand increase for the drug,Other,Current,,,00409-4887-50,not available
9349,Sterile Water for Injection,"Hospira, Inc.",100 mL Single Dose Glass Fliptop Vial (NDC 00409-4887-99),Revised,9/12/22,Next Delivery: February 2023; Estimated Recovery: March 2023,,,Demand increase for the drug,Other,Current,,,00409-4887-99,not available
9350,Sterile Water for Injection,"Fresenius Kabi USA, LLC",10 mL Vial (NDC 63323-0185-10),Revised,9/14/22,Available,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,63323-0185-10,available
9351,Sterile Water for Injection,"Fresenius Kabi USA, LLC",20 mL Vial (NDC 63323-0185-20),Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,63323-0185-20,not available
9352,Sterile Water for Injection,"Fresenius Kabi USA, LLC",50 mL Vial (NDC 63323-0185-50),Revised,9/14/22,Backordered. Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,63323-0185-50,not available
9353,Sterile Water for Injection,Nephron Pharmaceuticals Corporation,5 mL Plastic Vials (NDC 0487-6105-01),New,2/22/22,Available,,,Other,Other,Current,,,0487-6105-01,available
9354,Sterile Water for Injection,American Regent/Luitpold,10mL Vial (NDC 0517-3010-25),New,5/26/22,"Backordered, Next release August 2022",,,Demand increase for the drug,Other,Current,,,0517-3010-25,not available
9355,Sterile Water for Injection,American Regent/Luitpold,20mL Vial (NDC 0517-3020-25),New,5/26/22,Backordered Next release July 2022,,,Demand increase for the drug,Other,Current,,,0517-3020-25,not available
9356,Streptozocin (Zanosar) Sterile Powder,Teva Pharmaceuticals,Streptozocin (Zanosar®) Sterile Powder: (NDC 0703-4636-01) (1 gram Single Dose Vial),Reverified,10/5/22,"Backorder, Recovery expected TBD",,,Other,Oncology,Current,,,0703-4636-01,not available
9357,Streptozocin (Zanosar) Sterile Powder,Teva,NDC 0703-4636-01 (1 gram Single Dose Vial),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4636-01,discontinued
9358,Succimer (Chemet) Capsules,Recordati Rare Diseases,100 mg capsules (NDC 55292-201-11),Revised,9/14/21,,,Available,,Hematology,Resolved,,,55292-201-11,
9359,Sufentanil Citrate Injection,"Hospira, Inc.",50 mcg/mL Single Dose Glass Fliptop Vial (NDC 0409-3382-21),Reverified,9/12/22,Next Delivery and Estimated Recovery: March 2023,Shortage per Manufacturer: Manufacturing Delay,,Other,Analgesia/Addiction;Pediatric,Current,,,0409-3382-21,not available
9360,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-01), 1mL vial, 10 pack",Revised,5/4/22,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,17478-050-01,not available
9361,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)",Information pending,New,5/3/22,Information pending,,,Information pending,Analgesia/Addiction;Pediatric,Current,,,,unclear
9362,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-02), 2mL vial, 10 pack",New,5/4/22,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,17478-050-02,not available
9363,Sufentanil Citrate Injection,Akorn Pharmaceuticals,"50 mcg/mL (NDC 17478-050-05), 5mL vial, 10 pack",New,5/4/22,On backorder,,,Availability of API,Analgesia/Addiction;Pediatric,Current,,,17478-050-05,not available
9364,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide (prednisolone acetate; sulfacetamide sodium) (NDC 11980-022-05) - 5 mL in 10 mL bottle,New,6/9/22,,,,,Ophthalmology,To be Discontinued,,,11980-022-05,discontinued
9365,Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment,Abbvie,Blephamide S.O.P. (sulfacetamide sodium 10% and prednisolone acetate 0.2%) 1 TUBE in 1 CARTON 3.5 g in 1 TUBE (NDC 0023-0313-04),New,9/13/21,,,,,Ophthalmology,To be Discontinued,,,0023-0313-04,discontinued
9366,Sulfacetamide Sodium Solution,Abbvie,Bleph-10® (sulfacetamide sodium) (NDC 11980-011-05) - 5 mL in 10 mL bottle,New,6/9/22,,,,,Ophthalmology,To be Discontinued,,,11980-011-05,discontinued
9367,Sulfasalazine Tablets,Chartwell Pharma,500 mg tablets; Bottle of 100 (NDC 23155-019-01),Revised,9/7/22,"Product Available. Distributed by Chartwell. For inquiries, call Customer Service number 845-268-5000  Ext: 510.",,,Other,Gastroenterology,Current,,,23155-019-01,available
9368,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 100 (NDC 0013-0101-10),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,0013-0101-10,available
9369,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE (Sulfasalazine tablets) 500 mg tablets; Bottle of 300 (NDC 0013-0101-20/0013-0101-30),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,0013-0101-20,available
9370,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 100 (NDC 0013-0102-50),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,0013-0102-50,available
9371,Sulfasalazine Tablets,Pfizer Pharmaceuticals,AZULFIDINE EN-tabs® (Sulfasalazine delayed release tablets) 500 mg Delayed-Release tablets; Bottle of 300 (NDC 0013-0102-20/0013-0102-60),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,0013-0102-20,available
9372,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 100 (NDC 59762-0104-1/59762-0104-5),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,59762-0104-1,available
9373,Sulfasalazine Tablets,Pfizer Pharmaceuticals,Sulfasalazine Delayed-Release Tablets 500 mg Delayed-Release tablets; bottle of 300 (NDC 59762-0104-6),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,59762-0104-6,available
9374,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 100 (NDC 59762-5000-1/59762-5000-5),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,59762-5000-1,available
9375,Sulfasalazine Tablets,Pfizer Pharmaceuticals,500 mg tablets; bottle of 300 (NDC 59762-5000-6),Reverified,9/12/22,Available,,,Other,Gastroenterology,Current,,,59762-5000-6,available
9376,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 100 Count (NDC 00591-0796-01),Revised,10/5/22,Allocation,,,,Gastroenterology,Current,,,00591-0796-01,limited availability
9377,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 1000 Count (NDC 00591-0796-10),Revised,10/5/22,Allocation,,,,Gastroenterology,Current,,,00591-0796-10,limited availability
9378,Sulfasalazine Tablets,Teva Pharmaceuticals,500 mg 500 Count (NDC 00591-0796-05),Revised,10/5/22,Allocation,,,,Gastroenterology,Current,,,00591-0796-05,limited availability
9379,Sumatriptan (Sumavel DosePro) Injection,"Endo Pharmaceuticals, Inc.",Sumavel DosePro (sumatriptan injection) 6mg/0.5mL (NDC 63481-367-06),New,2/27/18,,,,,Neurology,To be Discontinued,,,63481-367-06,discontinued
9380,Sumatriptan Succinate Injection,Teva Pharmaceuticals,6 mg/0.5 mL  (NDC 0703-7351-01),New,12/5/19,,,,,Neurology,To be Discontinued,,,0703-7351-01,discontinued
9381,Synercid Injection,Pfizer,500 mg; 10 mL Single Dose Glass Vial  (NDC 61570-260-10),New,8/30/22,,Discontinuation of the manufacture of the drug.,,,Antibiotic,To be Discontinued,8/30/22,8/30/22,61570-260-10,discontinued
9382,Tacrolimus Capsules,Ascend Laboratories LLC.,0.5 mg 100’s count (NDC 67877-278-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,67877-278-01,
9383,Tacrolimus Capsules,Ascend Laboratories LLC.,1 mg 100’s count (NDC 67877-279-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,67877-279-01,
9384,Tacrolimus Capsules,Ascend Laboratories LLC.,5 mg 100’s count (NDC 67877-280-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,67877-280-01,
9385,Tacrolimus Capsules,Glenmark Pharmaceuticals,0.5 mg 100 count bottles (NDC 68462-685-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68462-685-01,
9386,Tacrolimus Capsules,Glenmark Pharmaceuticals,1 mg 100 count bottles (NDC 68462-686-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68462-686-01,
9387,Tacrolimus Capsules,Glenmark Pharmaceuticals,5 mg 100 count bottles (NDC 68462-687-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68462-687-01,
9388,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",0.5 mg (NDC 55111-525-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,55111-525-01,
9389,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",1 mg (NDC 55111-526-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,55111-526-01,
9390,Tacrolimus Capsules,"Dr. Reddy's Laboratories, Inc.",5 mg (NDC 55111-527-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,55111-527-01,
9391,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","0.5 mg, 100s (NDC 0378-2045-01)",Revised,5/2/22,,,Available,,Transplant,Resolved,,,0378-2045-01,
9392,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100s (NDC 0378-2046-01)",Revised,5/2/22,,,Available,,Transplant,Resolved,,,0378-2046-01,
9393,Tacrolimus Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100s (NDC 0378-2047-01)",Revised,5/2/22,,,Available,,Transplant,Resolved,,,0378-2047-01,
9394,Tacrolimus Capsules,Accord Healthcare Inc.,0.5 mg 100 count (NDC 1672904101),Revised,5/2/22,,,Available,,Transplant,Resolved,,,1672904101,
9395,Tacrolimus Capsules,Accord Healthcare Inc.,1 mg 100 count (NDC 1672904201),Revised,5/2/22,,,Available,,Transplant,Resolved,,,1672904201,
9396,Tacrolimus Capsules,Accord Healthcare Inc.,5 mg 100 count (NDC 1672904301),Revised,5/2/22,,,Available,,Transplant,Resolved,,,1672904301,
9397,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 30 count (NDC 68992-3075-3),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3075-3,
9398,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 0.75 mg Extended-Release Tablets 100 count (NDC 68992-3075-1),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3075-1,
9399,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 30 count (NDC 68992-3010-3),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3010-3,
9400,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 1 mg Extended-Release Tablets 100 count (NDC 68992-3010-1),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3010-1,
9401,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 30 count (NDC 68992-3040-3),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3040-3,
9402,Tacrolimus Capsules,"Veloxis Pharmaceuticals, Inc.",Envarsus XR 4 mg Extended-Release Tablets 100 count (NDC 68992-3040-1),Revised,5/2/22,,,Available,,Transplant,Resolved,,,68992-3040-1,
9403,Tacrolimus Capsules,Strides Pharma Inc.,1 mg 100 count bottles (NDC 64338-721-06),Revised,5/2/22,,,Available,,Transplant,Resolved,,,64338-721-06,
9404,Tacrolimus Capsules,Strides Pharma Inc.,0.5 mg 100 count bottles (NDC 64380-720-06),Revised,5/2/22,,,Available,,Transplant,Resolved,,,64380-720-06,
9405,Tacrolimus Capsules,Strides Pharma Inc.,5 mg 100 count bottles (NDC 64380-722-06),Revised,5/2/22,,,Available,,Transplant,Resolved,,,64380-722-06,
9406,Tacrolimus Capsules,Sandoz,0.5 mg 100 count bottle (NDC 0781-2102-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0781-2102-01,
9407,Tacrolimus Capsules,Sandoz,1 mg 100 count bottle (NDC 0781-2103-04),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0781-2103-04,
9408,Tacrolimus Capsules,Sandoz,5 mg 100 count bottle (NDC 0781-2104-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0781-2104-01,
9409,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 0.5 mg 100 count bottle (NDC 0469-0607-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0607-73,
9410,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 5 mg 100 count bottle (NDC 0469-0657-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0657-73,
9411,Tacrolimus Capsules,Astellas,PROGRAF® (tacrolimus) capsules 1 mg 100 count bottle (NDC 0469-0617-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0617-73,
9412,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 0.5 mg 30 count bottle (NDC 0469-0647-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0647-73,
9413,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 1 mg 30 count bottle (NDC 0469-0677-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0677-73,
9414,Tacrolimus Capsules,Astellas,ASTAGRAF XL® (tacrolimus extended release capsules) 5 mg 30 count bottle (NDC 0469-0687-73),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-0687-73,
9415,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 0.2 mg unit dose packets (NDC 0469-1230-50),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-1230-50,
9416,Tacrolimus Capsules,Astellas,PROGRAF® Granules (tacrolimus for oral suspension) 1 mg unit dose packets (NDC 0469-1330-50),Revised,5/2/22,,,Available,,Transplant,Resolved,,,0469-1330-50,
9417,Tacrolimus Capsules,"BPI Labs, LLC",1 mg 100 count bottle (NDC 54288-135-01),Revised,5/2/22,,,Available,,Transplant,Resolved,,,54288-135-01,
9418,"Talwin (Pentazocine Lactate Injection, USP, CIV)","Hospira, Inc.",30 mg/mL; 1 mL glass ampul (NDC 00409-1941-01),New,4/16/18,,,,,Analgesia/Addiction,To be Discontinued,,,00409-1941-01,discontinued
9419,Technetium Tc 99m Sulfur Colloid Injection,Sun Pharmaceutical Industries Inc.,5 Vial Kit (NDC 45567-0030-1),Revised,4/29/22,,,Available,,Medical Imaging,Resolved,,,45567-0030-1,
9420,Technetium TC-99M Mebrofenin Injection,Sun Pharmaceutical Industries Inc.,5 vial kit (NDC 45567-0455-1),Revised,6/28/22,On backorder.,,,Other,Medical Imaging,Current,,,45567-0455-1,not available
9421,Technetium TC-99M Mebrofenin Injection,Sun Pharmaceutical Industries Inc.,30 vial kit (NDC 45567-0455-2),Revised,6/28/22,On backorder.,,,Other,Medical Imaging,Current,,,45567-0455-2,not available
9422,Technetium TC-99M Mebrofenin Injection,Bracco Diagnostics,"CHOLETEC- mebrofenin injection, powder, lyophilized, for solution; Kit for the Preparation of Technetium Tc 99m Mebrofenin, supplied as 10 sterile multidose reaction vials per kit. (NDC 0270-0083-20)",Reverified,9/13/22,Available,,,Delay in shipping of the drug,Medical Imaging,Current,,,0270-0083-20,available
9423,Technetium Tc99m Succimer Injection (DMSA),Theragnostics Inc.,ROTOP DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection). One vial contains 1.74 mg powder with the active substance: 1.0 mg succimer.  Five vials included in a carton (NDC 71647-001-01),Revised,1/7/21,Available,,,Other,Medical Imaging,Current,,,71647-001-01,available
9424,Telmisartan and Amlodipine (Twynsta) Tablets,"Boehringer Ingelheim Pharmaceuticals, Inc.","Telmisartan and Amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister (NDC 0597-0127-37)",New,3/6/18,,,,,Cardiovascular,To be Discontinued,,,0597-0127-37,discontinued
9425,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",5mg capsules (NDCs 62559-920-51 and 62559-920-14),New,4/12/22,,,,,Oncology,To be Discontinued,,,,discontinued
9426,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",20mg capsules (NDCs 62559-921-51 and 62559-921-14),New,4/12/22,,,,,Oncology,To be Discontinued,,,,discontinued
9427,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",100mg capsules (NDCs 62559-922-51 and 62559-922-14),New,4/12/22,,,,,Oncology,To be Discontinued,,,,discontinued
9428,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",140mg capsules (NDCs 62559-923-51 and 62559-923-14),New,4/12/22,,,,,Oncology,To be Discontinued,,,,discontinued
9429,Temozolomide Capsules,"ANI Pharmaceuticals, Inc.",180mg capsules (NDCs 62559-924-51 and 62559-924-14),New,4/12/22,,,,,Oncology,To be Discontinued,,,,discontinued
9430,Teprotumumab-trbw,Horizon Therapeutics,500 mg lyophilized powder (NDC 75987-130-15),Revised,3/31/21,Product available.,,,Other,Ophthalmology,Current,,,75987-130-15,available
9431,Testosterone Transdermal Gel,"Endo Pharmaceuticals, Inc.",25mg/2.5g  (NDC 49884-418-72),New,8/29/22,,,,,Urology,To be Discontinued,8/29/22,8/29/22,49884-418-72,discontinued
9432,Testosterone Transdermal Gel,"Endo Pharmaceuticals, Inc.",50mg/5g  (NDC 49884-510-72),New,8/29/22,,,,,Urology,To be Discontinued,8/29/22,8/29/22,49884-510-72,discontinued
9433,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","1 mg, 100 count bottle (NDC 0378-1001-01)",Revised,7/1/22,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,0378-1001-01,limited availability
9434,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","2 mg, 100 count bottle (NDC 0378-2002-01)",Revised,7/1/22,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,0378-2002-01,limited availability
9435,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","5 mg, 100 count bottle (NDC 0378-3005-01)",Revised,7/1/22,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,0378-3005-01,limited availability
9436,Thiothixene Capsules,"Mylan Pharmaceuticals Inc., a Viatris Company","10 mg, 100 count bottle (NDC 0378-5010-01)",Revised,7/1/22,Limited Availability (until 6.30.22),,,Other,Psychiatry,Current,,,0378-5010-01,limited availability
9437,Thiothixene Capsules,Novitium Pharma LLC,"1 mg, 100 count bottle (NDC 70954-014-10)",Reverified,3/16/22,Available,,,,Psychiatry,Current,,,70954-014-10,available
9438,Thiothixene Capsules,Novitium Pharma LLC,"2 mg, 100 count bottle (NDC 70954-015-10)",Reverified,3/16/22,Available,,,,Psychiatry,Current,,,70954-015-10,available
9439,Thiothixene Capsules,Novitium Pharma LLC,"5 mg, 100 count bottle (NDC 70954-016-10)",Reverified,3/16/22,Available,,,,Psychiatry,Current,,,70954-016-10,available
9440,Thiothixene Capsules,Novitium Pharma LLC,"10 mg, 100 count bottle (NDC 70954-017-10)",Reverified,3/16/22,Available,,,,Psychiatry,Current,,,70954-017-10,available
9441,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 2.5mL bottle (NDC 60505-1005-04),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60505-1005-04,
9442,Timolol Maleate Ophthalmic Solution,Apotex Corp.,Timolol Maleate Ophthalmic Solution 0.5% 5mL bottle (NDC 60505-1005-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60505-1005-01,
9443,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 7.5 mL bottle (NDC 24208-004-01)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,24208-004-01,
9444,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Istalol, Timolol Maleate Ophthalmic solution 0.5% in a 10 ml bottle (NDC 24208-004-03)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,24208-004-03,
9445,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%,  2.5ml (NDC 68682-045-25)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,68682-045-25,
9446,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","Timolol Maleate Ophthalmic Solution 0.5%, 5ml (NDC 68682-045-50)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,68682-045-50,
9447,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 5mL (NDC 64980-513-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-513-05,
9448,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25%  10 mL (NDC 64980-513-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-513-01,
9449,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.25% 15 mL (NDC 64980-513-15),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-513-15,
9450,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 5mL (NDC 64980-514-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-514-05,
9451,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 10mL (NDC 64980-514-01),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-514-01,
9452,Timolol Maleate Ophthalmic Solution,FDC Limited,TIMOLOL MALEATE OPHTHAMIC SOLUTION 0.5% 15mL (NDC 64980-514-15),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,64980-514-15,
9453,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x5ml BTL (NDC 60758-802-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60758-802-05,
9454,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.25% OS 1x10ml BTL (NDC 60758-802-10),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60758-802-10,
9455,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x5ml BTL (NDC 60758-801-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60758-801-05,
9456,Timolol Maleate Ophthalmic Solution,Allergan,Timolol Maleate 0.5% OS 1x10ml BTL (NDC 60758-801-10),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,60758-801-10,
9457,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5% 5mg/mL, 5mL, 1 Bottle/EA (NDC 17478-0288-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,17478-0288-10,
9458,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 10mL, 1 Bottle / EA (NDC 17478-0288-11)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,17478-0288-11,
9459,Timolol Maleate Ophthalmic Solution,Akorn Pharmaceuticals,"Timolol Maleate Ophth Sol 0.5%, 15mL, 1 Bottle / EA (NDC 17478-0288-12)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,17478-0288-12,
9460,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 5 mL bottle, (NDC 61314-227-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-227-05,
9461,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 10 mL bottle (NDC 61314-227-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-227-10,
9462,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.5%, 15 mL bottle (NDC 61314-227-15)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-227-15,
9463,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 5 mL bottle, ()NDC 61314-226-05",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-226-05,
9464,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 10 mL bottle, (NDC 61314-226-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-226-10,
9465,Timolol Maleate Ophthalmic Solution,Sandoz,"Timolol Maleate Ophthalmic Solution, USP 0.25%, 15 mL bottle, (NDC 61314-226-15)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,61314-226-15,
9466,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.25%, 5 mL in a 7.5 mL bottle (NDC 24208-812-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,24208-812-05,
9467,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 5 mL in a 7.5 mL bottle (NDC 24208-813-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,24208-813-05,
9468,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® (timolol maleate ophthalmic solution), 0.5%, 10 mL in a 10 mL bottle (NDC 24208-813-10)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,24208-813-10,
9469,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.",Authorized Generic Timolol Maleate Ophthalmic Solution 0.5% 5 mL in a 7.5 mL bottle (NDC 68682-813-05),Revised,4/16/21,,,,,Ophthalmology,Resolved,,,68682-813-05,
9470,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE® (timolol maleate) Sterile Ophthalmic Solution, 0.25% 0.3 mL in 60 individual doses (NDC 0187-1498-25)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,0187-1498-25,
9471,Timolol Maleate Ophthalmic Solution,"Bausch Health Americas, Inc.","TIMOPTIC® in OCUDOSE®  (timolol maleate) Sterile Ophthalmic Solution, 0.5% 0.3 mL in 60 individual doses (NDC 0187-1496-05)",Revised,4/16/21,,,,,Ophthalmology,Resolved,,,0187-1496-05,
9472,Tipranavir Oral Solution,"Boehringer Ingelheim Pharmaceuticals, Inc.",100mg/mL (NDC 0597-0002-01),New,6/29/21,,,,,Antiviral,To be Discontinued,,,0597-0002-01,discontinued
9473,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",2 mg  (NDC 49884-611-53),New,6/30/21,,,,,Neurology,To be Discontinued,,,49884-611-53,discontinued
9474,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",4 mg (NDC 49884-719-53),New,6/30/21,,,,,Neurology,To be Discontinued,,,49884-719-53,discontinued
9475,Tizanidine Hydrochloride Capsules,"Endo Pharmaceuticals, Inc.",6 mg (NDC 49884-765-53),New,6/30/21,,,,,Neurology,To be Discontinued,,,49884-765-53,discontinued
9476,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,4 mg (NDC 0378-0724-19),New,11/21/19,,,,,Neurology,To be Discontinued,,,0378-0724-19,discontinued
9477,Tizanidine Hydrochloride Tablets,Mylan Pharmaceuticals Inc.,2 mg (NDC 0378-0722-19),New,11/21/19,,,,,Neurology,To be Discontinued,,,0378-0722-19,discontinued
9478,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-51)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,,,63323-303-51,
9479,Tobramycin Lyophilized Powder for Injection,"Fresenius Kabi USA, LLC","1.2 g, pharmacy bulk package, tray of 6 vials (NDC 63323-303-55), Novaplus",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,,,63323-303-55,
9480,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, bottle (NDC 39822-0412-1)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,,,39822-0412-1,
9481,Tobramycin Lyophilized Powder for Injection,"X-GEN Pharmaceuticals, Inc.","1.2 g, pharmacy bulk package, pack of 6 bottles (NDC 39822-0412-6)",Revised,4/12/21,,,,,Anti-Infective;Pediatric,Resolved,,,39822-0412-6,
9482,Tocilizumab Injection,"Genentech, Inc","200mg/10mL, (NDC 50242-0136-01)",Revised,3/30/22,,,Available,,Rheumatology,Resolved,,,50242-0136-01,
9483,Tocilizumab Injection,"Genentech, Inc","400mg/20mL, (NDC 50242-0137-01)",Revised,3/30/22,,,Available,,Rheumatology,Resolved,,,50242-0137-01,
9484,Tocilizumab Injection,"Genentech, Inc","80mg/4mL, (NDC 50242-0135-01)",Revised,3/30/22,,,Available,,Rheumatology,Resolved,,,50242-0135-01,
9485,Topotecan Injection,Teva,NDC 0703-4714-01 (4 mg/4 mL (1 mg/mL) Single-Dose Vial),New,8/11/22,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4714-01,discontinued
9486,Trandolapril Tablets,Teva Pharmaceuticals,"4 mg tablets, 100 count (NDC 16252-543-90)",New,4/18/18,,,,,Cardiovascular,To be Discontinued,,,16252-543-90,discontinued
9487,Trandolapril Tablets,Teva Pharmaceuticals,"2 mg tablets, 100 count (NDC 16252-542-90)",New,4/18/18,,,,,Cardiovascular,To be Discontinued,,,16252-542-90,discontinued
9488,Trandolapril Tablets,Teva Pharmaceuticals,"1 mg tablets, 100 count (NDC 16252-541-30)",New,4/18/18,,,,,Cardiovascular,To be Discontinued,,,16252-541-30,discontinued
9489,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 30 Tablets per Bottle,  (NDC 60505-3638-3)",New,12/4/19,,,,,Hematology,To be Discontinued,,,60505-3638-3,discontinued
9490,Tranexamic Acid Tablets,Apotex Corp.,"Tranexamic Acid 650 mg per Tablet, 100 Tablets per Bottle,  (NDC 60505-3638-1)",New,12/4/19,,,,,Hematology,To be Discontinued,,,60505-3638-1,discontinued
9491,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1 mg/1g (NDC 40085-029-80),New,3/20/18,,,,,Dermatology,To be Discontinued,,,40085-029-80,discontinued
9492,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,1mg/1g (NDC 40085-029-16),New,3/20/18,,,,,Dermatology,To be Discontinued,,,40085-029-16,discontinued
9493,Triamcinolone Acetonide Cream,Mylan Pharmaceuticals Inc.,0.25mg/1g (NDC 40085-028-80),New,3/20/18,,,,,Dermatology,To be Discontinued,,,40085-028-80,discontinued
9494,Triamcinolone Acetonide Injectable Suspension,Novartis,"40mg/mL vial, 1mL in 1 vial (NDC 0065-0543-01)",Reverified,9/30/22,Availability through wholesalers: not available. Estimated duration of supply shortage: 3-18 months.,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0065-0543-01,not available
9495,Triamcinolone Hexacetonide Injectable suspension,Medexus,"Hexatrione 2% (triamcinolone hexacetonide) Injectable suspension, 20mg/ml, 2-mL glass ampoule (NDC 59137-570-01)",Revised,12/8/21,Available,,,,Rheumatology,Current,,,59137-570-01,available
9496,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 0781-5068-01)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0781-5068-01,discontinued
9497,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 0781-5068-05)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0781-5068-05,discontinued
9498,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 0781-5067-01)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0781-5067-01,discontinued
9499,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 0781-5067-05)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,0781-5067-05,discontinued
9500,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 100 count bottle (NDC 68001-0216-00)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,68001-0216-00,discontinued
9501,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 37.5 mg/25 mg, 500 count bottle (NDC 68001-0216-03)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,68001-0216-03,discontinued
9502,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 100 count bottle (NDC 68001-0215-00)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,68001-0215-00,discontinued
9503,Triamterene and Hydrochlorothiazide Tablets,Sandoz,"Triamterene and Hydrochlorothiazide tablets, 75 mg/50 mg, 500 count bottle (NDC 68001-0215-03)",New,2/23/18,,,,,Cardiovascular,To be Discontinued,,,68001-0215-03,discontinued
9504,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 30 (NDC 43386-660-03)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-03,not available
9505,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 100 (NDC 43386-660-24)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-24,not available
9506,Trimethobenzamide Hydrochloride Capsules,Lupin,"300 mg, bottle of 500 (NDC 43386-660-26)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,Shortage of an active ingredient.,Gastroenterology,Current,,,43386-660-26,not available
9507,Trimethobenzamide Hydrochloride Capsules,Pfizer Pharmaceuticals,"300 mg, bottle of 100 (NDC 61570-079-01)",Reverified,9/12/22,Discontinued,,,Discontinuation of the manufacture of the drug.,Gastroenterology,Current,,,61570-079-01,discontinued
9508,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",Revised,10/26/21,Unavailable,,,Shortage of an active ingredient.,Gastroenterology,Current,,,53489-376-01,not available
9509,Trimethobenzamide Hydrochloride Capsules,Sun Pharmaceutical Industries Inc.,"300 mg, bottle of 100 (NDC 53489-376-01)",New,10/26/21,,,,,Gastroenterology,To be Discontinued,,,53489-376-01,discontinued
9510,Umbrasilib Tosylate Tablets,"TG Therapeutics, Inc.","Umbralisib Tosylate (Ukoniq) Tablets, 200 mg (free base), 120 Tablets per bottle (NDC 73150-200-12)",Revised,5/31/22,,,,,Oncology,To be Discontinued,,,73150-200-12,discontinued
9511,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","100 mg/mL, 5 mL vial (NDC 0143-9785-10)",Reverified,8/26/22,Currently on backorder.,,,Demand increase for the drug,Neurology,Current,,,0143-9785-10,not available
9512,Valproate Sodium Injection,"Fresenius Kabi USA, LLC",500 mg per 5 mL (100 mg per mL) (NDC 63323-494-05),Reverified,8/13/22,Backordered. Next release Q4 - 2022.,,,Manufacturing delays,Neurology,Current,,,63323-494-05,not available
9513,Valproic Acid Oral Solution,Wockhardt,"250mg/5mL, 473mL (NDC 60432-0621-16)",New,4/11/22,,,,,Neurology,To be Discontinued,,,60432-0621-16,discontinued
9514,Vancomycin Hydrochloride for Injection,"Mylan Institutional, a Viatris company",Vancomycin Hydrochloride Injection (Lyophilisate in Single Dose Vials) [250 mg] (NDC 67457-822-99),New,7/26/21,,,,,Anti-Infective,To be Discontinued,,,67457-822-99,discontinued
9515,Vandetanib Tablets,Sanofi,Vandetanib (Caprelsa) 100mg Tablets (NDC 58468-7820-3),Revised,9/9/22,Available,,,Shortage of an active ingredient,Oncology,Current,,,58468-7820-3,available
9516,Vandetanib Tablets,Sanofi,Vandetanib (Caprelsa) 300mg Tablets (NDC 58468-7840-3),Revised,9/9/22,Out of stock.,,,Shortage of an active ingredient,Oncology,Current,,,58468-7840-3,not available
9517,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,Starter Pack (NDC 49884-944-99),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,49884-944-99,
9518,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,60505-4765-5,
9519,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,60505-4766-6,
9520,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,60505-4767-0,
9521,Varenicline Tartrate (Chantix) Tablets,Apotex Corp.,Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,60505-4766-5,
9522,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"0.5 mg, 56 ‘s count bottle pack (NDC 49884-155-76)",Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,49884-155-76,
9523,Varenicline Tartrate (Chantix) Tablets,Par Pharmaceutical,"1 mg, 56 ‘s count bottle pack (NDC 49884-156-76)",Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,49884-156-76,
9524,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 0.5 mg; bottle of 56 (NDC 0069-0468-56),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,0069-0468-56,
9525,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix 1 mg; bottle of 56 (NDC 0069-0469-56),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,0069-0469-56,
9526,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Starting wallet; 0.5 mg 1x11 1 mg FCT 3x14 BLS WL US (NDC 0069-0471-03),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,0069-0471-03,
9527,Varenicline Tartrate (Chantix) Tablets,Pfizer Pharmaceuticals,Chantix Continuing wallet; 1 mg FCT 4x14 BLS WL US (NDC 0069-0469-03),Revised,5/26/22,,,,,Analgesia/Addiction,Resolved,,,0069-0469-03,
9528,Vecuronium Bromide for Injection,Teva Pharmaceuticals,NDC 0703-2914-03 (10 mg (1 mg/ml when reconstituted to 10 mL) 10 x 10 mL Vials),Revised,7/20/22,,Product is temporarily unavailable and no future production expected for an extended period.,,,Anesthesia,To be Discontinued,7/20/22,7/20/22,0703-2914-03,discontinued
9529,Vecuronium Bromide for Injection,"Hospira, Inc.",10 mg Single Dose Glass Fliptop Vial (NDC 00409-1632-01),Reverified,9/12/22,Available,,,Other,Anesthesia,Current,,,00409-1632-01,available
9530,Vecuronium Bromide for Injection,"Hospira, Inc.",20 mg Single Dose Glass Fliptop Vial (NDC 00409-1634-01),Revised,8/30/22,,,,,Anesthesia,To be Discontinued,8/30/22,8/30/22,00409-1634-01,discontinued
9531,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [10 mg](NDC 67457-438-10),Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-438-10,available
9532,Vecuronium Bromide for Injection,"Mylan Institutional, a Viatris company",Vecuronium Bromide Injection (Lyophilizate in Single Dose Vials) [20 mg](NDC 67457-475-20),Reverified,9/28/22,Backordered,Re-supply October 2022.,,Demand increase for the drug,Anesthesia,Current,,,67457-475-20,not available
9533,Vecuronium Bromide for Injection,Fresenius Kabi,10 mg/vial (NDC 63323-781-10),Revised,9/28/22,Available,,,,Anesthesia,Current,,,63323-781-10,available
9534,Vecuronium Bromide for Injection,Fresenius Kabi,20 mg/vial (NDC 63323-782-20),Revised,9/28/22,Available,,,,Anesthesia,Current,,,63323-782-20,available
9535,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,10 mg (NDC 47335-931-44),Reverified,9/23/22,Available,,,,Anesthesia,Current,,,47335-931-44,available
9536,Vecuronium Bromide for Injection,Sun Pharmaceutical Industries Inc.,20 mg (NDC 47335-932-44),Reverified,9/23/22,Available,,,,Anesthesia,Current,,,47335-932-44,available
9537,Vecuronium Bromide for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"10 mg/vial, packages of 10 (NDC 55150-235-10)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-235-10,available
9538,Vecuronium Bromide for Injection,Eugia Pharma Specialties LTD. (formerly Aurobindo),"20 mg/vial, packages of 10 (NDC 55150-236-20)",Reverified,9/28/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,55150-236-20,available
9539,Vecuronium Bromide Injection,Teva,NDC 0703-2914-03 (10 mg (1 mg/mL when reconstituted to 10 mL) 10 x 10 mL Vials),New,8/11/22,,Product is currently unavailable and no future production expected for an extended period.,,,Anesthesia,To be Discontinued,8/11/22,8/11/22,0703-2914-03,discontinued
9540,Verapamil Hydrochloride Tablets,Pfizer,240 mg; Bottle of 100 caplets (NDC 0025-1891-31),New,9/8/22,,Supply expected to exhaust late September 2022; Discontinuation of the manufacture of the drug.,,,Cardiovascular,To be Discontinued,9/8/22,9/8/22,0025-1891-31,discontinued
9541,Vibramycin Hyclate (Doxycycline Hyclate) for Suspension,Pfizer Pharmaceuticals,25 mg/5 mL oral suspension; 1 x 60 mL bottle (NDC 0069-0970-65),New,11/16/21,,,,,Anti-Infective,To be Discontinued,,,0069-0970-65,discontinued
9542,Vincristine Sulfate (Vincasar PFS) Injection,Teva,NDC 0703-4402-11 (1 mg/mL 1 mL Single-Dose Vial),New,8/11/22,,Product is available with an expected supply duration until AUG 2022.  No future production expected for an extended period.,,,Oncology,To be Discontinued,8/11/22,8/11/22,0703-4402-11,discontinued
9543,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-06),New,4/16/18,,,,,Oncology,To be Discontinued,,,61703-0341-06,discontinued
9544,Vinorelbine Tartrate Injection,"Hospira, Inc.",10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial (NDC 61703-0341-09),New,4/16/18,,,,,Oncology,To Be Discontinued,,,61703-0341-09,discontinued
9545,Vitamin A Palmitate (Aquasol A) Injection,"Casper Pharma, LLC","50,000 USP units/mL (15 mg retinol), single dose vial (NDC 70199-0026-11)",Revised,4/14/22,,,Available,,Endocrinology/Metabolism;Gastroenterology,Resolved,,,70199-0026-11,
9546,Zafirlukast Oral Tablets,Par Pharmaceutical,"Zafirlukast 10 mg Tablets, (NDC 49884-549-02)",New,3/17/22,,,,,Pulmonary/Allergy,To be Discontinued,,,49884-549-02,discontinued
9547,Zafirlukast Oral Tablets,Par Pharmaceutical,"Zafirlukast 20 mg Tablets, (NDC 49884-554-02)",New,3/17/22,,,,,Pulmonary/Allergy,To be Discontinued,,,49884-554-02,discontinued
9548,Zafirlukast Oral Tablets,Par Pharmaceutical,"Accolate® Zafirlukast 10 mg Tablets, (NDC 49884-589-02)",New,3/17/22,,,,,Pulmonary/Allergy,To be Discontinued,,,49884-589-02,discontinued
9549,Zafirlukast Oral Tablets,Par Pharmaceutical,"Accolate® Zafirlukast 20 mg Tablets, (NDC 49884-590-02)",New,3/17/22,,,,,Pulmonary/Allergy,To be Discontinued,,,49884-590-02,discontinued
9550,Zinc Acetate Capsules,Teva Pharmaceuticals,"25 mg, bottle of 250 (NDC 57844-215-52)",Revised,5/18/21,,,Available,,Other;Pediatric,Resolved,,,57844-215-52,
9551,Zinc Acetate Capsules,Teva Pharmaceuticals,"50 mg, bottle of 250 (NDC 57844-208-52)",Revised,5/18/21,,,Available,,Other;Pediatric,Resolved,,,57844-208-52,
9552,Zolpidem Tartrate (Edluar) Sublingual Tablets,Mylan Pharmaceuticals Inc.,10 mg (NDC 0037-6010-30),Revised,11/21/18,,,Available,,Psychiatry,Resolved,,,0037-6010-30,
9553,Zolpidem Tartrate Oral Spray,Aytu BioPharma,5 mg per spray (NDCs 69654-510-30 and 69654-510-60),New,6/13/22,,,,,Psychiatry,To be Discontinued,,,,discontinued
9554,,Etomidate Injection,"2 mg/mL, 20 mL vial (NDC 25021-674-20)",New,10/5/22,Available,Marketed by Sagent,,,Anesthesiology,Current,,,25021-674-20,available
9555,"Abacavir Sulfate Tablet, Film Coated",GlaxoSmithKline,"Ziagen, Tablet, Film Coated, 300 mg (NDC 49702-221-18)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately November 27, 2023. Ziagen Oral Solution (49702-222-48) will still be available.",,Discontinuation of the manufacture of the drug,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-221-18,discontinued
9556,"Abacavir Sulfate, Lamivudine Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Epzicom, Tablet, Film Coated, 600 mg; 300 mg (NDC 49702-206-13)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-206-13,discontinued
9557,"Abacavir Sulfate, Lamivudine, Zidovudine Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Trizivir, Tablet, Film Coated, 300 mg; 150 mg; 300 mg (NDC 49702-217-18)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately November 27, 2023.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-217-18,discontinued
9558,"Albuterol Sulfate Aerosol, Metered",Sandoz Inc.,"Proventil-hfa, Aerosol, Metered, 108 ug (NDC 66758-959-85)",New,4/13/23,,,,,Pulmonary/Allergy,To Be Discontinued,4/13/23,4/13/23,66758-959-85,discontinued
9559,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Revised,12/20/23,"This product is currently available on allocation., At least 6 months until it is off allocation",,,Demand increase for the drug,Pulmonary/Allergy; Pediatric,Current,,,0487-9901-30,limited availability
9560,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-60)",New,11/27/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-60,discontinued
9561,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-45)",New,11/27/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-45,discontinued
9562,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 mg/1 g (NDC 0168-0263-15)",New,11/27/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-15,discontinued
9563,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-15)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0264-15,discontinued
9564,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-45)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0264-45,discontinued
9565,Alclometasone Dipropionate Ointment,Sandoz Inc.,"Alclometasone Dipropionate, Ointment, .5 mg/1 g (NDC 0168-0264-60)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0264-60,discontinued
9566,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 250 ug (NDC 0037-8120-06)",Reverified,12/21/23,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,0037-8120-06,not available
9567,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 500 ug (NDC 0037-8130-06)",Reverified,12/21/23,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,0037-8130-06,not available
9568,Alprostadil Suppository,"Mylan Institutional, a Viatris Company","Muse, Suppository, 1000 ug (NDC 0037-8140-06)",Reverified,12/21/23,Out of stock; Estimated release dates to be determined,,,Delay in shipping of the drug,Urology,Current,,,0037-8140-06,not available
9569,Alvimopan Capsule,Merck Sharp & Dohme LLC,"Entereg, Capsule, 12 mg (NDC 67919-020-10)",New,3/2/23,,"To be discontinued May 31, 2023",,,Gastroenterology,To Be Discontinued,3/2/23,3/2/23,67919-020-10,discontinued
9570,Amifostine Injection,"Clinigen, Inc.","Ethyol, Injection, 500 mg/10 mL (NDC 76310-017-50)",Reverified,5/16/22,Shortage anticipated from June 2020; Estimated shortage duration:  Unknown,,,,Oncology; Other,Current,,,76310-017-50,limited availability
9571,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0264-4500-00,available
9572,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7171-17",,,Gastroenterology,Current,,,0990-7171-17,available
9573,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7172-17",,,Gastroenterology,Current,,,0990-7172-17,available
9574,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,12/20/23,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4178-03",,Shortage of an active ingredient,Gastroenterology,Current,,,0990-4178-03,not available
9575,Amino Acid Injection,"ICU Medical, Inc.","Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,12/20/23,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4179-05",,Shortage of an active ingredient,Gastroenterology,Current,,,0990-4179-05,not available
9576,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,12/21/23,Available,,,,Gastroenterology,Current,,,0338-0502-06,available
9577,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0264-4500-05,available
9578,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,12/21/23,Available,,,,Gastroenterology,Current,,,0338-0502-03,available
9579,Aminocaproic Acid Solution,VistaPharm,"Aminocaproic Acid, Solution, .25 g/1 mL (NDC 66689-330-08)",New,3/8/23,,,,,Hematology,To Be Discontinued,3/8/23,3/8/23,66689-330-08,discontinued
9580,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 50 mg (NDC 0591-5714-01)",Revised,12/6/23,Available,,,,Psychiatry,Current,,,0591-5714-01,available
9581,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 25 mg (NDC 0591-5713-01)",Revised,12/6/23,Available,,,,Psychiatry,Current,,,0591-5713-01,available
9582,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0591-5715-01)",Revised,12/6/23,Allocation,,,Demand increase for the drug,Psychiatry,Current,,,0591-5715-01,limited availability
9583,Amoxapine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 150 mg (NDC 0591-5716-30)",Revised,12/6/23,Available,,,,Psychiatry,Current,,,0591-5716-30,available
9584,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-706-01,limited availability
9585,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-070-01,limited availability
9586,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-707-01,limited availability
9587,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-071-01,limited availability
9588,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-01,available
9589,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-01,available
9590,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-01,available
9591,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-01,available
9592,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-46,available
9593,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-55,available
9594,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-58,available
9595,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6156-46,available
9596,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6156-52,limited availability
9597,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6156-57,limited availability
9598,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6157-46,limited availability
9599,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6157-52,limited availability
9600,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6157-57,limited availability
9601,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6041-46,limited availability
9602,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6041-55,available
9603,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0781-6041-58,limited availability
9604,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4155-73,available
9605,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4155-80,available
9606,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4155-79,available
9607,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4160-73,available
9608,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4160-76,available
9609,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4160-78,available
9610,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,0093-4161-73,available
9611,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4161-76,available
9612,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4161-78,available
9613,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-706-55,limited availability
9614,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-706-80,limited availability
9615,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-070-50,limited availability
9616,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-070-75,limited availability
9617,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-707-55,limited availability
9618,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-707-80,limited availability
9619,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-071-50,limited availability
9620,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)",Revised,12/19/23,On allocation.,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,65862-071-75,limited availability
9621,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-15,available
9622,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-80,available
9623,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-50,available
9624,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-75,available
9625,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-15,available
9626,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-80,available
9627,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-50,available
9628,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)",Revised,12/19/23,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-75,available
9629,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,70010-111-01,available
9630,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Reverified,12/19/23,Unavailable. Estimated availability: February 2024,,,Demand increase for the drug,Psychiatry,Current,,,70010-112-01,not available
9631,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,70010-113-01,available
9632,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Reverified,12/19/23,Unavailable. Estimated availability: February 2024,,,Demand increase for the drug,Psychiatry,Current,,,70010-114-01,not available
9633,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,70010-115-01,available
9634,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,70010-116-01,available
9635,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,70010-117-01,available
9636,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-500-01,available
9637,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-501-01,available
9638,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-502-01,available
9639,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-503-01,available
9640,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-504-01,available
9641,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-505-01,available
9642,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,64850-506-01,available
9643,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8884-01,available
9644,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8885-01,available
9645,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8891-01,available
9646,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8892-01,available
9647,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8893-01,available
9648,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0406-8894-01,available
9649,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Revised,12/20/23,Available,,,,Psychiatry,Current,,,42806-344-01,available
9650,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Revised,12/20/23,Available,,,,Psychiatry,Current,,,42806-341-01,available
9651,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Revised,12/20/23,Available,,,,Psychiatry,Current,,,42806-343-01,available
9652,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Revised,12/20/23,Available,,,,Psychiatry,Current,,,42806-345-01,available
9653,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Revised,12/20/23,Available,,,,Psychiatry,Current,,,42806-339-01,available
9654,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Reverified,12/19/23,Available,Supporting contracted business only,,,Psychiatry,Current,,,47781-174-01,available
9655,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Reverified,12/19/23,Available,Supporting contracted business only,,,Psychiatry,Current,,,47781-176-01,available
9656,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Reverified,12/19/23,Available,Supporting contracted business only,,,Psychiatry,Current,,,47781-178-01,available
9657,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Reverified,12/19/23,Available,Supporting contracted business only,,,Psychiatry,Current,,,47781-179-01,available
9658,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Reverified,12/19/23,Available,Supporting contracted business only,,,Psychiatry,Current,,,47781-180-01,available
9659,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-190-01,available
9660,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-192-01,available
9661,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-191-01,available
9662,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-193-01,available
9663,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-194-01,available
9664,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-195-01,available
9665,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,11534-196-01,available
9666,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,72516-016-01,available
9667,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,72516-014-01,available
9668,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,72516-013-01,available
9669,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,72516-012-01,available
9670,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",USPHARMA WINDLAS,"Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,72516-011-01,available
9671,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-068-01,not available
9672,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-069-01,not available
9673,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-070-01,not available
9674,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-072-01,not available
9675,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-073-01,not available
9676,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Reverified,12/19/23,Estimated availability December 2023,,,,Psychiatry,Current,,,13107-074-01,not available
9677,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-0760-37,available
9678,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-0761-37,available
9679,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-1502-37,available
9680,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-0763-37,available
9681,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-0764-37,available
9682,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-1505-37,available
9683,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0527-0766-37,available
9684,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0185-2099-01,available
9685,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0185-0853-01,available
9686,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0185-0842-01,available
9687,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,0185-2098-01,available
9688,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-110-01,available
9689,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-112-01,available
9690,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-115-01,available
9691,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-120-01,available
9692,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-130-01,available
9693,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-105-01,available
9694,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,57844-117-01,available
9695,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0776-02,available
9696,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0777-02,available
9697,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0775-02,available
9698,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Reverified,12/19/23,Unavailable,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0972-02,not available
9699,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Reverified,12/19/23,Limited supply available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0973-02,limited availability
9700,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Reverified,12/19/23,Limited supply available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0974-02,limited availability
9701,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Reverified,12/19/23,Available,Teva is manufacturing and distributing consistent with historic levels. We continue to see unprecedented demand.,,Demand increase for the drug,Psychiatry,Current,,,0555-0971-02,available
9702,"Atropa Belladonna, Opium Suppository",Padagis US LLC,"Belladonna And Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12)",Reverified,12/19/23,Currently out of stock. No estimated release date available.,,,Regulatory delay,Urology,Current,,,0574-7040-12,not available
9703,"Atropa Belladonna, Opium Suppository",Padagis US LLC,"Belladonna And Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04)",Reverified,12/19/23,Currently out of stock. No estimated release date available.,,,Regulatory delay,Urology,Current,,,0574-7040-04,not available
9704,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 mg/1 mL (NDC 16729-525-08)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-525-08,available
9705,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 mg/1 mL (NDC 16729-512-43)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-512-43,available
9706,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, 1 mg/1 mL (NDC 16729-526-08)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-526-08,available
9707,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .05 mg/1 mL (NDC 16729-483-03)",Reverified,12/19/23,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,16729-483-03,available
9708,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-45)",Reverified,12/19/23,Inventory on hold pending further assessment,Inventory on hold pending further assessment,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-484-45,unclear
9709,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 mg/1 mL (NDC 16729-484-90)",Reverified,12/19/23,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,16729-484-90,available
9710,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, .4 mg/1 mL (NDC 63323-580-20)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology; Pediatric,Current,,,63323-580-20,available
9711,Atropine Sulfate Injection,"American Regent, Inc.","Injection, .4 mg/1 mL (NDC 0517-1004-25)",Reverified,12/8/23,Available,old NDC 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1004-25,available
9712,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 mg/1 mL (NDC 76329-3340-1)",Reverified,12/19/23,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,76329-3340-1,available
9713,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-1630-10)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,0409-1630-10,not available
9714,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .05 mg/1 mL (NDC 0409-9630-05)",Revised,9/11/23,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0409-9630-05,available
9715,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",Revised,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,0409-4910-34,limited availability
9716,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4911-34)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology; Pediatric,Current,,,0409-4911-34,not available
9717,Atropine Sulfate Injection,"American Regent, Inc.","Injection, 1 mg/1 mL (NDC 0517-1001-25)",Reverified,12/8/23,Available,old NDC 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1001-25,available
9718,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, .4 mg/1 mL (NDC 0641-6251-10)",Reverified,12/19/23,Inventory is currently available.,Additional lots are scheduled for manufacturing.  Product will be made available as it is released.,,,Anesthesia; Neurology; Pediatric,Current,,,0641-6251-10,available
9719,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",New,6/15/23,Available,,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,64253-400-91,available
9720,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Injection, 0.1 mg/mL, 10 mL (NDC 0409-4911-11)",Reverified,12/19/23,Next Delivery: August 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia; Neurology; Pediatric,Current,,,0409-4911-11,not available
9721,Atropine Sulfate Ointment,Bausch & Lomb Incorporated,"Ointment, 10 mg/1 g (NDC 24208-825-55)",New,12/6/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,To Be Discontinued,,12/6/23,24208-825-55,discontinued
9722,Azacitidine Injection,Cipla Limited,"Azacitidine, Injection, 100 mg (NDC 69097-805-40)",New,8/3/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,8/3/23,8/3/23,69097-805-40,discontinued
9723,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 0781-9253-94)",New,8/3/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,8/3/23,8/3/23,0781-9253-94,discontinued
9724,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 0781-3253-94)",Revised,12/19/23,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,12/19/23,12/19/23,0781-3253-94,discontinued
9725,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg, Powder, Lyoph (NDC 0781-9253-94)",Revised,12/19/23,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,12/19/23,12/19/23,0781-9253-94,discontinued
9726,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Reverified,12/19/23,Available,,,Demand increase for the drug,Oncology,Current,,,59572-102-01,available
9727,Azacitidine Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/30 mL (NDC 63323-771-39)",Reverified,12/20/23,Available,,,,Oncology,Current,,,63323-771-39,available
9728,Azacitidine Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 100 mg/ Vial (NDC 0143-9606-01)",Reverified,12/19/23,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Oncology,Current,,,0143-9606-01,available
9729,Azacitidine Injection,"Dr. Reddy's Laboratories, Inc.","Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Revised,9/28/23,Available,,,Demand increase for the drug,Oncology,Current,,,43598-305-62,available
9730,Azacitidine Injection,Armas Pharmaceuticals Inc,"Injection, 100 mg (NDC 72485-201-01)",Revised,11/2/23,Available,Armas can provide product immediately,,,Oncology,Current,,,72485-201-01,available
9731,Azacitidine Injection,Accord Healthcare Inc.,"Injection, 100 mg (NDC 16729-306-10)",Revised,11/2/23,Unavailable,Back in Stock the Week of Nov. 06 - Nov. 10,,Delay in shipping of the drug,Oncology,Current,,,16729-306-10,not available
9732,Azacitidine Injection,Cipla Limited,"Azacitidine, Injection, 100 mg (NDC 69097-805-40)",Revised,8/3/23,Discontinuation,,,Discontinuation of the manufacture of the drug,Oncology,Current,,,69097-805-40,discontinued
9733,Azacitidine Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg (NDC 68001-313-56)",Reverified,12/6/23,MADE TO ORDER PRODUCT; Estimated Supply December 2023,Product is manufactured and labeled  for Blue Point Laboratories on a made to order basis,,Demand increase for the drug,Oncology,Current,,,68001-313-56,limited availability
9734,Azacitidine Injection,"Breckenridge Pharmaceutical, Inc.","Injection, 100 mg/50 mL (NDC 51991-797-98)",Reverified,12/19/23,Unavailable,No longer marketed. Expiry of last lot marketed: 01/31/2024,,Demand increase for the drug,Oncology,Current,,,51991-797-98,not available
9735,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 100 mg/30 mL (NDC 71288-115-30)",Reverified,12/19/23,Available,,,Demand increase for the drug,Oncology,Current,,,71288-115-30,available
9736,Azacitidine Injection,Eugia US LLC,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Reverified,12/19/23,Available,,,,Oncology,Current,,,55150-393-01,available
9737,AZITHROMYCIN FOR SUSPENSION,Pfizer Inc.,"FOR SUSPENSION, 200 mg/5 mL (NDC 0069-3140-19)",New,9/28/23,,,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,,0069-3140-19,discontinued
9738,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 300 mg/15mL (NDC 0069-3110-19)",New,9/29/23,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/23,0069-3110-19,discontinued
9739,AZITHROMYCIN FOR SUSPENSION,Pfizer Inc.,"ZITHROMAX, FOR SUSPENSION, 1 g (NDC 0069-3051-07)",New,9/29/23,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/23,0069-3051-07,discontinued
9740,Azithromycin Monohydrate Solution/ Drops,Thea Pharma Inc.,"Azasite, Solution/ Drops, 10 mg/1 mL (NDC 82584-307-03)",Revised,8/3/23,,,Available,,Ophthalmology,Resolved,8/3/23,,82584-307-03,
9741,"Bazedoxifene Acetate, Estrogens, Conjugated Tablet",Pfizer Inc.,"Duavee, Tablet, 20 mg; .45 mg (NDC 0008-1123-12)",Reverified,12/19/23,Available,,,Demand increase for the drug,Reproductive,Current,,,0008-1123-12,available
9742,"Beclomethasone Dipropionate Monohydrate Spray, Suspension",GlaxoSmithKline,"Beconase Aq, Spray, Suspension, 42 ug (NDC 0173-0388-79)",New,7/21/23,,The anticipated date that GSK will cease distribution of the product is approximately November 2023.,,,Pulmonary/Allergy,To Be Discontinued,7/21/23,7/21/23,0173-0388-79,discontinued
9743,Belantamab Mafodotin Injection,GlaxoSmithKline,"Blenrep, Injection, 50 mg/1 mL (NDC 0173-0896-01)",New,2/10/23,,The product is no longer available as the BLA has been withdrawn.,,,Oncology,To Be Discontinued,2/10/23,2/10/23,0173-0896-01,discontinued
9744,Belatacept Injection,Bristol Myers Squibb Co.,"Nulojix, Injection, 250 mg (NDC 0003-0371-13)",Revised,9/12/23,,,"Available. BMS will no longer limit distribution of NULOJIXÂ® (belatacept) for appropriate patients as of 1-October-2023. However, physicians must continue to register new patients via the US NULOJIX Distribution Program. This will enable BMS to closely monitor demand and ensure supply. For further information, contact BMS Medical Information at 800-321-1335.",,Transplant,Resolved,9/12/23,,0003-0371-13,
9745,"Betamethasone Dipropionate Cream, Augmented",Sandoz Inc.,"Betamethasone Dipropionate, Cream, Augmented, .5 mg/1 g (NDC 0168-0265-50)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0265-50,discontinued
9746,"Betamethasone Dipropionate Cream, Augmented",Sandoz Inc.,"Betamethasone Dipropionate, Cream, Augmented, .5 mg/1 g (NDC 0168-0265-15)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0265-15,discontinued
9747,"Betamethasone Dipropionate, Calcipotriene Ointment","Tolmar, Inc.","Calcipotriene And Betamethasone Dipropionate, Ointment, .5 mg/1 g; 50 ug/1 g (NDC 0781-7165-35)",New,3/2/23,,,,,Dermatology,To Be Discontinued,3/2/23,3/2/23,0781-7165-35,discontinued
9748,"Betamethasone Dipropionate, Calcipotriene Ointment","Tolmar, Inc.","Calcipotriene And Betamethasone Dipropionate, Ointment, .5 mg/1 g; 50 ug/1 g (NDC 0781-7165-95)",Revised,6/8/23,,,,,Dermatology,To Be Discontinued,3/2/23,3/2/23,0781-7165-95,discontinued
9749,Bivalirudin Injection,Pfizer Inc.,"Bivalirudin, Injection, 250 mg (NDC 0409-8300-15)",New,7/24/23,,Supply expected to exhaust late September 2023; Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,7/24/23,7/24/23,0409-8300-15,discontinued
9750,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-22)",New,9/19/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/23,0054-0521-22,discontinued
9751,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-21)",New,9/19/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/23,0054-0521-21,discontinued
9752,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 125 mg (NDC 0054-0521-18)",New,9/19/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/23,0054-0521-18,discontinued
9753,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 62.5 mg (NDC 0054-0520-21)",New,9/19/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/23,0054-0520-21,discontinued
9754,BOSENTAN TABLET,"Hikma Pharmaceuticals USA, Inc.","BOSENTAN, TABLET, 62.5 mg (NDC 0054-0520-18)",New,9/19/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,9/19/23,0054-0520-18,discontinued
9755,Bumetanide Injection,MSN Laboratories Private Limited,"Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,72205-101-01,available
9756,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,72205-101-07,available
9757,Bumetanide Injection,MSN Laboratories Private Limited,"Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,72205-102-01,available
9758,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,72205-102-07,available
9759,Bumetanide Injection,"Fresenius Kabi USA, LLC","Injection, .25 mg/1 mL (NDC 65219-570-04)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,65219-570-04,available
9760,Bumetanide Injection,"Fresenius Kabi USA, LLC","Injection, .25 mg/1 mL (NDC 65219-572-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,65219-572-10,available
9761,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 70860-405-04)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-405-04,available
9762,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 70860-406-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-406-10,available
9763,Bumetanide Injection,"Hospira, Inc., a Pfizer Company","Injection, .25 mg/1 mL (NDC 0409-1412-04)",Revised,11/3/23,,Discontinued,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,12/1/23,11/3/23,0409-1412-04,discontinued
9764,Bumetanide Injection,"Hospira, Inc., a Pfizer Company","Injection, .25 mg/1 mL (NDC 0409-1412-10)",Revised,11/3/23,,Discontinued,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,12/1/23,11/3/23,0409-1412-10,discontinued
9765,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Revised,12/19/23,Inventory is currently available,Additional lots are scheduled for manufacturing and will be available. Product will be made available as it is released.,,,Cardiovascular,Current,,,0641-6008-10,available
9766,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Revised,12/19/23,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Delay in shipping of the drug,Cardiovascular,Current,,,0641-6007-10,not available
9767,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1159-01)",Revised,9/11/23,Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,0409-1159-01,not available
9768,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1159-02)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1159-02,limited availability
9769,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-1160-01)",Revised,9/11/23,Next Delivery: March 2024; Estimated Recovery: December 2024,,,,Anesthesia,Current,,,0409-1160-01,not available
9770,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1162-01)",Revised,9/11/23,Next Delivery: September 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1162-01,not available
9771,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1162-02)",Revised,9/11/23,Next Delivery: October 2023; Estimated Recovery: March 2024,,,,Anesthesia,Current,,,0409-1162-02,not available
9772,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-1163-01)",Revised,9/11/23,Next Delivery: January 2024; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1163-01,not available
9773,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Revised,9/11/23,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1165-01,limited availability
9774,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-02)",Revised,9/11/23,Available,,,,Anesthesia,Current,,,0409-1165-02,available
9775,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-3613-01)",Revised,9/11/23,Depleted,,,,Anesthesia,Current,,,0409-3613-01,not available
9776,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1559-10)",Revised,9/11/23,Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,0409-1559-10,not available
9777,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1559-30)",Revised,9/11/23,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,0409-1559-30,limited availability
9778,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 2.5 mg/1 mL (NDC 0409-1587-50)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,0409-1587-50,available
9779,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1560-10)",Revised,9/11/23,Next Delivery: November 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1560-10,not available
9780,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1560-29)",Revised,9/11/23,Limited Supply Available. Next Delivery: January 2024; Estimated Recovery: June 2024,,,,Anesthesia,Current,,,0409-1560-29,limited availability
9781,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 5 mg/1 mL (NDC 0409-1610-50)",Reverified,12/19/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-1610-50,limited availability
9782,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 7.5 mg/1 mL (NDC 0409-1582-10)",Revised,9/11/23,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1582-10,limited availability
9783,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 7.5 mg/1 mL (NDC 0409-1582-29)",Revised,9/11/23,Available,,,,Anesthesia,Current,,,0409-1582-29,available
9784,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Revised,11/29/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-465-57,available
9785,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-467-57,available
9786,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Revised,11/29/23,Unavailable,Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-17,not available
9787,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-464-37,available
9788,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Revised,11/29/23,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
9789,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Revised,11/29/23,Unavailable,Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-17,not available
9790,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-466-37,available
9791,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-466-31,not available
9792,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-472-17,available
9793,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-472-37,available
9794,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-167-10,available
9795,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-168-30,available
9796,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 55150-169-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-169-10,available
9797,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 55150-170-30)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-170-30,available
9798,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-171-10,available
9799,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-172-30,available
9800,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Reverified,12/19/23,Currently on backorder - next shipment November 2023,,,Demand increase for the drug,Anesthesia,Current,,,55150-249-50,not available
9801,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Reverified,12/19/23,Currently on backorder - next shipment November 2023,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-250-50,not available
9802,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,73293-0002-2,available
9803,Bupivacaine Hydrochloride Injection,Baxter Healthcare,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 36000-092-10)",Revised,8/1/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,To Be Discontinued,8/1/23,8/1/23,36000-092-10,discontinued
9804,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 59923-717-05)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,59923-717-05,available
9805,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 59923-719-10)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,59923-719-10,available
9806,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 59923-718-05)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,59923-718-05,available
9807,Bupivacaine Hydrochloride Injection,"Areva Pharmaceuticals, Inc.","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 59923-720-10)",Reverified,12/19/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,59923-720-10,available
9808,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Reverified,12/19/23,Available,Meitheal Pharmaceuticals is distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,71288-723-52,available
9809,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Reverified,12/19/23,Available,Meitheal Pharmaceuticals is distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,71288-726-52,available
9810,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-461-57,not available
9811,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-463-57,not available
9812,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-17,not available
9813,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-468-37,not available
9814,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-17,not available
9815,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-37,not available
9816,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Revised,11/29/23,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-462-31,not available
9817,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Revised,11/29/23,Unavailable,Next release Q3-2024. Not available to order at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-460-37,not available
9818,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9042-01)",Revised,9/11/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-9042-01,not available
9819,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9042-17)",Revised,9/11/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-9042-17,not available
9820,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 2.5 mg/1 mL; 5 ug/1 mL (NDC 0409-9043-01)",Reverified,12/19/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9043-01,not available
9821,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9045-01)",Revised,9/11/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-9045-01,not available
9822,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9045-17)",Revised,9/11/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-9045-17,not available
9823,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 5 mg/1 mL; 5 ug/1 mL (NDC 0409-9046-01)",Reverified,12/19/23,Next Delivery and Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9046-01,not available
9824,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1746-10)",Revised,9/11/23,Next Delivery: October 2023; Estimated Recovery: March 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1746-10,not available
9825,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1746-30)",Revised,9/11/23,Next Delivery: October 2023; Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1746-30,not available
9826,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1749-10)",Revised,9/11/23,Next Delivery: September 2023; Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1749-10,not available
9827,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1749-29)",Revised,9/11/23,Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-1749-29,not available
9828,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 2.5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1752-50)",Reverified,12/19/23,Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-1752-50,not available
9829,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, 5 mg/1 mL; .0091 mg/1 mL (NDC 0409-1755-50)",Reverified,12/19/23,Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-1755-50,not available
9830,"Bupropion Hydrochloride Tablet, Extended Release",Endo Pharmaceuticals. Inc.,"Tablet, Extended Release, 150 mg (NDC 10370-101-03)",New,10/2/23,,Discontinued due to business reasons,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/2/23,10370-101-03,discontinued
9831,"Bupropion Hydrochloride Tablet, Extended Release",Endo Pharmaceuticals. Inc.,"Tablet, Extended Release, 150 mg (NDC 10370-101-50)",New,10/2/23,,Discontinued due to business reasons,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,,10370-101-50,discontinued
9832,Calcium Acetate Solution,Fresenius Medical Care North America,"Phoslyra, Solution, 667 mg/5 mL (NDC 49230-643-31)",New,4/5/23,,FMCNA Customer Service Call: 1-800-323-5188 Hours of Operation: 7:00 a.m. – 6:00 p.m. (CT),,Discontinuation of the manufacture of the drug,Renal,To Be Discontinued,4/5/23,4/5/23,49230-643-31,discontinued
9833,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 20 mg/1 mL (NDC 44567-620-24)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-620-24,
9834,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 20 mg/1 mL (NDC 44567-621-24)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-621-24,
9835,Calcium Gluconate Injection,HQ Specialty Pharma,"Calcium Gluconate In Sodium Chloride, Injection, 10 mg/1 mL (NDC 44567-622-24)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-622-24,
9836,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-19)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-19,
9837,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-59)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-59,
9838,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 63323-360-61)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-61,
9839,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 20 mg/1 mL (NDC 65219-162-10)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,65219-162-10,
9840,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Calcium Gluconate, Injection, 20 mg/1 mL (NDC 65219-164-50)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,65219-164-50,
9841,Calcium Gluconate Injection,"Nivagen Pharmaceuticals, Inc.","Calcium Gluconate, Injection, 98 mg/1 mL (NDC 75834-171-19)",Revised,9/7/23,,,Available,Demand increase for the drug,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,75834-171-19,
9842,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-01)",Revised,9/7/23,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-01,
9843,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-03)",Revised,9/7/23,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-03,
9844,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/mL (NDC 63323-360-05)",Revised,9/7/23,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,63323-360-05,
9845,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 20 mg/mL (NDC 44567-620-01)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-620-01,
9846,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 20 mg/mL (NDC 44567-621-01)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-621-01,
9847,Calcium Gluconate Injection,HQ Specialty Pharma,"Injection, 10 mg/mL (NDC 44567-622-01)",Revised,9/7/23,,,"Available; Marketed by WG Critical Care, LLC",,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,44567-622-01,
9848,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 20 mg/mL (NDC 65219-162-01)",Revised,9/7/23,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,65219-162-01,
9849,Calcium Gluconate Injection,"Fresenius Kabi USA, LLC","Injection, 20 mg/mL (NDC 65219-164-01)",Revised,9/7/23,,,Available,,Cardiovascular; Endocrinology/Metabolism; Gastroenterology; Other; Pediatric; Pulmonary/Allergy,Resolved,9/7/23,,65219-164-01,
9850,Capecitabine Tablet,Accord Healthcare Inc.,"Tablet, 500 mg (NDC 16729-073-29)",Revised,12/20/23,"Stock Available; Inventory allocating to orders, 111 days coverage","Manufacturing resumed, manufacturing and packaging plans being put together.",,,Oncology,Current,,,16729-073-29,limited availability
9851,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 150 mg (NDC 0004-1100-20)",Revised,12/19/23,Limited supply available,,,Demand increase for the drug,Oncology,Current,,,0004-1100-20,limited availability
9852,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 500 mg (NDC 0004-1101-50)",Revised,12/19/23,Available,,,,Oncology,Current,,,0004-1101-50,available
9853,Capecitabine Tablet,Novadoz Pharmaceuticals LLC,"Capecitabine, Tablet, 500 mg (NDC 72205-007-92)",Revised,12/19/23,Available,Manufactured by MSN Laboratories Private Limited (Formulation Division),,Demand increase for the drug,Oncology,Current,,,72205-007-92,available
9854,Capecitabine Tablet,Novadoz Pharmaceuticals LLC,"Capecitabine, Tablet, 150 mg (NDC 72205-006-60)",Revised,12/19/23,Available,Manufactured by MSN Laboratories Private Limited (Formulation Division),,Demand increase for the drug,Oncology,Current,,,72205-006-60,available
9855,Capecitabine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 150 mg (NDC 0093-7473-06)",Revised,12/19/23,Available,,,,Oncology,Current,,,0093-7473-06,available
9856,Capecitabine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-7474-89)",Revised,12/19/23,Available,,,,Oncology,Current,,,0093-7474-89,available
9857,Capecitabine Tablet,Eugia US LLC,"Tablet, 150 mg (NDC 59651-204-60)",Reverified,12/20/23,On allocation,Intermittent availability expected,,Demand increase for the drug,Oncology,Current,,,59651-204-60,limited availability
9858,Capecitabine Tablet,Eugia US LLC,"Tablet, 500 mg (NDC 59651-205-08)",Reverified,12/20/23,On allocation,Intermittent availability expected,,Demand increase for the drug,Oncology,Current,,,59651-205-08,limited availability
9859,Capecitabine Tablet,"Dr. Reddy's Laboratories, Inc.","Capecitabine, Tablet, 150 mg (NDC 55111-496-60)",Revised,12/19/23,Available,,,Demand increase for the drug,Oncology,Current,,,55111-496-60,available
9860,Capecitabine Tablet,"Dr. Reddy's Laboratories, Inc.","Capecitabine, Tablet, 500 mg (NDC 55111-497-04)",Revised,12/19/23,Available,,,,Oncology,Current,,,55111-497-04,available
9861,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 100 mg (NDC 0781-8016-01)",New,10/23/23,,"Novartis Pharmaceuticals’ brand product, Tegretol XR 100 mg (NDC 0078-0510-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/23,0781-8016-01,discontinued
9862,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 200 mg (NDC 0781-5987-01)",New,10/23/23,,"Novartis Pharmaceuticals’ brand product, Tegretol XR, 200 mg (NDC 0078-0511-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/23,0781-5987-01,discontinued
9863,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 400 mg (NDC 0781-5988-01)",New,10/23/23,,"Novartis Pharmaceuticals’ brand product, Tegretol XR, 400 mg, (NDC 0078-0512-05), will continue to be manufactured and available.",,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,10/23/23,0781-5988-01,discontinued
9864,Carboplatin Injection,Gland Pharma Limited,"Injection, 50mg/5mL (NDC 54288-164-01)",Reverified,12/19/23,Available,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,54288-164-01,available
9865,Carboplatin Injection,Gland Pharma Limited,"Injection, 150mg/15mL (NDC 54288-165-01)",Revised,12/19/23,Available,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,54288-165-01,available
9866,Carboplatin Injection,Gland Pharma Limited,"Injection, 450mg/45mL (NDC 54288-166-01)",Reverified,12/19/23,On allocation; full availability in November 2023,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,54288-166-01,limited availability
9867,Carboplatin Injection,Gland Pharma Limited,"Injection, 600 mg/65 mL (NDC 54288-167-01)",Revised,12/19/23,On allocation; full availability in November 2023,"Distributed by BPI Labs, LLC",,,Oncology,Current,,,54288-167-01,limited availability
9868,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Injection, 600 mg/60 mL (NDC 50742-448-60)",Reverified,12/19/23,,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,,Oncology,Current,,,50742-448-60,
9869,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Reverified,12/19/23,Available,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,,Oncology,Current,,,50742-447-45,available
9870,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Reverified,12/19/23,Currently on backorder - next shipment in November 2023,,,Demand increase for the drug,Oncology,Current,,,55150-335-01,not available
9871,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Reverified,12/19/23,Currently on backorder - next shipment in November 2023,,,Demand increase for the drug,Oncology,Current,,,55150-386-01,not available
9872,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-295-34)",Reverified,12/19/23,"Unavailable, 75 days","Manufacturing resumed, manufacturing and packaging plans being put together.",,Requirements related to complying with good manufacturing practices,Oncology,Current,,,16729-295-34,not available
9873,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-295-12)",Reverified,12/19/23,"Unavailable, 75 days","Manufacturing resumed, manufacturing and packaging plans being put together.",,Requirements related to complying with good manufacturing practices,Oncology,Current,,,16729-295-12,not available
9874,Carboplatin Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-172-60)",Reverified,12/20/23,Limited availability. Next release December 2023.,Check wholesaler inventory,,Demand increase for the drug,Oncology,Current,,,63323-172-60,limited availability
9875,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4239-01)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Oncology,Current,,,0703-4239-01,not available
9876,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-18)",Reverified,12/19/23,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-339-18,not available
9877,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-360-18)",Reverified,12/19/23,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-360-18,not available
9878,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-22)",Reverified,12/19/23,Next delivery: October 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-339-22,not available
9879,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-150-05)",Reverified,12/19/23,Next delivery: October 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-150-05,not available
9880,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-50)",Reverified,12/19/23,Limited Supply Available. Next delivery: November 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-339-50,limited availability
9881,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-262-05)",Reverified,12/19/23,Next delivery: November 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-262-05,not available
9882,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-339-56)",Reverified,12/19/23,Limited Supply Available. Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-339-56,limited availability
9883,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 10 mg/1 mL (NDC 61703-600-05)",Reverified,12/19/23,Next delivery: September 2023; Estimated recovery: December 2023,,,Demand increase for the drug,Oncology,Current,,,61703-600-05,not available
9884,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4244-01)",Reverified,12/19/23,Available,,,,Oncology,Current,,,0703-4244-01,available
9885,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4246-01)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Oncology,Current,,,0703-4246-01,not available
9886,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-4248-01)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Oncology,Current,,,0703-4248-01,not available
9887,Cefixime Capsule,"Ascend Laboratories, LLC","Capsule, 400 mg (NDC 67877-584-50)",Revised,11/2/23,Available,,,,Anti-Infective,Current,,,67877-584-50,available
9888,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 mg (NDC 68180-423-08)",Reverified,11/18/22,"Limited availability, Manufacturing and distribution is ongoing.",,,,Anti-Infective,Current,,,68180-423-08,limited availability
9889,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 mg (NDC 68180-423-11)",Reverified,12/19/23,"Limited availability, Manufacturing and distribution is ongoing.",,,Demand increase for the drug,Anti-Infective,Current,,,68180-423-11,limited availability
9890,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 500 mg (NDC 0143-9930-10)",Revised,10/13/22,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9930-10,not available
9891,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 1 g (NDC 0143-9931-25)",Revised,10/13/22,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9931-25,not available
9892,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Cefotaxime, Injection, 2 g (NDC 0143-9933-25)",Revised,10/13/22,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9933-25,not available
9893,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Cefotaxime, Injection, 10 g (NDC 0143-9935-01)",Revised,10/13/22,Currently unavailable,On backorder. Shortage duration is unknown at this time.,,,Anti-Infective; Pediatric,Current,,,0143-9935-01,not available
9894,Cefotaxime Sodium Injection,"SteriMax, Inc.","Cefotaxime, Injection, 2 g (NDC 21586-012-02)",Revised,6/6/23,Available,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,21586-012-02,available
9895,Cefotaxime Sodium Injection,"SteriMax, Inc.","Cefotaxime, Injection, 1 g (NDC 21586-011-02)",Revised,6/6/23,Available,,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,21586-011-02,available
9896,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 1 g/10 mL (NDC 63323-385-10)",Reverified,12/20/23,4 & 8 months dating available (03/31/2024 & 07/31/2024 expiry) upon request.  Check wholesalers for inventory.,Check wholesaler for inventory,,Demand increase for the drug,Anti-Infective,Current,,,63323-385-10,limited availability
9897,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 2 g/20 mL (NDC 63323-386-20)",Reverified,12/20/23,4 & 8 months dating available (03/31/2024 & 07/31/2024 expiry) upon request.  Check wholesalers for inventory.,Check wholesaler for inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-386-20,limited availability
9898,Cefotetan Disodium Injection,"Fresenius Kabi USA, LLC","Injection, 10 g (NDC 63323-396-61)",Reverified,12/20/23,No release date available at this time.,,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-396-61,not available
9899,Cefotetan Disodium Injection,"Teligent Pharma, Inc.","Cefotan, Injection, 2 g/20 mL (NDC 52565-053-10)",Reverified,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,52565-053-10,discontinued
9900,Chloramphenicol Sodium Succinate Injection,"Fresenius Kabi USA, LLC","Injection, 1 g/10 mL (NDC 63323-011-15)",Revised,12/11/23,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,12/11/23,12/11/23,63323-011-15,discontinued
9901,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal, Injection, 10 mg/mL (NDC 0264-7055-05)",Revised,11/2/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,To Be Discontinued,11/2/23,11/2/23,0264-7055-05,discontinued
9902,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 10 mg/1 mL (NDC 63323-475-37)",Reverified,12/20/23,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-475-37,available
9903,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 20 mg/1 mL (NDC 63323-476-37)",Reverified,12/20/23,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-476-37,available
9904,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 20 mg/1 mL (NDC 63323-477-27)",Reverified,12/20/23,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-477-27,available
9905,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Nesacaine, Injection, 30 mg/1 mL (NDC 63323-478-27)",Reverified,12/20/23,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-478-27,available
9906,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Chloroprocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9209-10)",Reverified,5/16/23,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9209-10,available
9907,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Chloroprocaine Hydrochloride, Injection, 30 mg/1 mL (NDC 0143-9210-10)",Reverified,5/16/23,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9210-10,available
9908,Chlorothiazide Suspension,"Salix Pharmaceuticals, Inc.","Diuril, Suspension, 250 mg/5 mL (NDC 65649-311-12)",Revised,9/13/23,,,Available,,Cardiovascular,Resolved,9/13/23,,65649-311-12,
9909,"Ciprofloxacin Hydrochloride, Dexamethasone Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Ciprodex, Suspension/ Drops, 3 mg/1 mL; 1 mg/1 mL (NDC 0078-0799-75)",New,6/26/23,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue CIPRODEX (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension.Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, NDC 0781-6186-67, will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Anti-Infective,To Be Discontinued,6/26/23,6/26/23,0078-0799-75,discontinued
9910,Ciprofloxacin Injection,Baxter Healthcare,"Ciprofloxacin In Dextrose 5% In Plastic Container, Injection, 2 mg/1 mL (NDC 36000-008-24)",New,1/31/23,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,1/31/23,1/31/23,36000-008-24,discontinued
9911,Ciprofloxacin Injection,Baxter Healthcare,"Ciprofloxacin In Dextrose 5% In Plastic Container, Injection, 2 mg/1 mL (NDC 36000-009-24)",New,1/31/23,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,1/31/23,1/31/23,36000-009-24,discontinued
9912,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 2 mg/1 mL (NDC 0074-4378-05)",New,9/11/23,,,,,Analgesia/Addiction,To Be Discontinued,9/11/23,9/11/23,0074-4378-05,discontinued
9913,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 2 mg/1 mL (NDC 0074-4380-10)",New,9/11/23,,,,,Analgesia/Addiction,To Be Discontinued,9/11/23,9/11/23,0074-4380-10,discontinued
9914,Cisatracurium Besylate Injection,AbbVie Inc.,"Nimbex, Injection, 10 mg/1 mL (NDC 0074-4382-20)",New,9/11/23,,,,,Analgesia/Addiction,To Be Discontinued,9/11/23,9/11/23,0074-4382-20,discontinued
9915,Cisplatin Injection,Gland Pharma Limited,"Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-50)",Reverified,12/19/23,On backorder; Estimated recovery: October 2023,Marketed by Sagent. New launch.,,Demand increase for the drug,Oncology; Pediatric,Current,,,25021-253-50,not available
9916,Cisplatin Injection,Gland Pharma Limited,"Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-51)",Reverified,12/19/23,Available. On allocation due to high demand,Marketed by Sagent. New launch.,,Demand increase for the drug,Oncology; Pediatric,Current,,,25021-253-51,limited availability
9917,Cisplatin Injection,"Qilu Pharmaceutical Co., Ltd.","Cisplatin, Injection, 50 mg/50 mL (NDC 60505-6277-0)",Reverified,12/19/23,Not available. All imported product has been distributed.,"Qilu Pharmaceutical Co., Ltd., in coordination with the U.S. FDA and Apotex Corp., has initiated temporary importation of CISplatin Injection 50 mg/50 mL (1 mg/mL) vials into the U.S. market to address a drug shortage of CISplatin. Product is available via Apotex Corp.â€™s authorized distributors. Contact your primary wholesaler/distributor to place orders.",,Demand increase for the drug,Oncology; Pediatric,Current,,,60505-6277-0,not available
9918,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-11)",Revised,11/13/23,Available with intermittent releases under allocation,Marketed by Accord Healthcare. Manufacturing has resumed and new batches are being planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,16729-288-11,limited availability
9919,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-38)",Revised,11/13/23,Available with intermittent releases under allocation,Marketed by Accord Healthcare. Manufacturing has resumed and new batches are being planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,16729-288-38,limited availability
9920,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-27)",Revised,11/13/23,Not available,Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,68001-283-27,not available
9921,Cisplatin Injection,Accord Healthcare Inc.,"Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-32)",Revised,11/13/23,Not available,Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned.,,Requirements related to complying with good manufacturing practices,Oncology; Pediatric,Current,,,68001-283-32,not available
9922,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-51)",Reverified,12/20/23,Backordered. Next release October 2023.,,,Demand increase for the drug,Oncology; Pediatric,Current,,,63323-103-51,not available
9923,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-65)",Reverified,12/20/23,Backordered. Next release October 2023.,Check wholesalers for inventory,,Demand increase for the drug,Oncology; Pediatric,Current,,,63323-103-65,not available
9924,Cisplatin Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-103-64)",Reverified,12/20/23,Backordered. Next release October 2023.,,,Demand increase for the drug,Oncology; Pediatric,Current,,,63323-103-64,not available
9925,Cisplatin Injection,"Hikma Pharmaceuticals USA, Inc.","Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9504-01)",Reverified,12/19/23,Temporarily on backorder.,Additional lots will be available in the August 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9504-01,not available
9926,Cisplatin Injection,"Hikma Pharmaceuticals USA, Inc.","Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9505-01)",Reverified,12/19/23,Temporarily on backorder.,Additional lots will be available in the September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9505-01,not available
9927,Cisplatin Injection,HQ Specialty Pharma,"Injection, 1 mg/1 mL (NDC 44567-511-01)",Reverified,12/20/23,Available on allocation,Marketed by WG Critical Care,,Demand increase for the drug,Oncology; Pediatric,Current,,,44567-511-01,limited availability
9928,Cisplatin Injection,HQ Specialty Pharma,"Injection, 1 mg/1 mL (NDC 44567-530-01)",Reverified,12/20/23,Available on allocation,Marketed by WG Critical Care,,Demand increase for the drug,Oncology; Pediatric,Current,,,44567-530-01,limited availability
9929,Cisplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/50 mL (NDC 0703-5747-11)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,0703-5747-11,available
9930,Cisplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg/100 mL (NDC 0703-5748-11)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,0703-5748-11,available
9931,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-3051-02)",Revised,12/19/23,Next Delivery and Estimated Recovery: November 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-3051-02,not available
9932,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-5095-06)",Revised,12/19/23,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-5095-06,not available
9933,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-4073-04)",Revised,12/19/23,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-4073-04,not available
9934,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0870-26)",Revised,12/19/23,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-0870-26,not available
9935,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0775-26)",Revised,12/19/23,Estimated Recovery: November 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-0775-26,not available
9936,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0728-09)",Revised,12/19/23,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-0728-09,not available
9937,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 150 mg/1 mL (NDC 0009-0902-18)",Revised,12/19/23,Estimated Recovery: December 2023,,,Demand increase for the drug,Anti-Infective,Current,,,0009-0902-18,not available
9938,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-02)",Reverified,12/19/23,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,25021-115-02,not available
9939,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-04)",Reverified,12/19/23,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,25021-115-04,not available
9940,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 mg/1 mL (NDC 25021-115-06)",Reverified,12/19/23,Backorder. Estimated availability TBD,,,Demand increase for the drug,Anti-Infective,Current,,,25021-115-06,not available
9941,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-9545-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-9545-50,limited availability
9942,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-9549-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-9549-50,limited availability
9943,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 900 mg/50 mL (NDC 0338-9553-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-9553-50,limited availability
9944,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 300 mg/50 mL (NDC 0338-3410-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-3410-50,limited availability
9945,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 600 mg/50 mL (NDC 0338-3612-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-3612-50,limited availability
9946,Clindamycin Phosphate Injection,Baxter Healthcare,"Injection, 900 mg/50 mL (NDC 0338-3814-50)",Reverified,12/19/23,Available on Allocation; Recovery December 2023,,,Delay in shipping of the drug,Anti-Infective,Current,,,0338-3814-50,limited availability
9947,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Revised,12/19/23,Unavailable,,,Demand increase for the drug,Anti-Infective,Current,,,0781-3288-09,not available
9948,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective,Current,,,0781-3289-09,limited availability
9949,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Revised,12/19/23,Limited Availability,,,Demand increase for the drug,Anti-Infective,Current,,,0781-3290-09,limited availability
9950,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Revised,12/19/23,Unavailable,Civica Label,,Demand increase for the drug,Anti-Infective,Current,,,72572-074-24,not available
9951,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Revised,12/19/23,Unavailable,Civica Label,,Demand increase for the drug,Anti-Infective,Current,,,72572-076-24,not available
9952,Clobazam Tablet,"Breckenridge Pharmaceutical, Inc.","Clobazam, Tablet, 20 mg (NDC 51991-901-01)",New,2/17/23,,Business decision to discontinue product from the commercial market,,,Neurology,To Be Discontinued,2/17/23,2/17/23,51991-901-01,discontinued
9953,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-93)",New,10/18/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-93,discontinued
9954,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-75)",New,10/18/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-75,discontinued
9955,Clocortolone Pivalate Cream,EPI Health,"Cream, 1 mg/g (NDC 71403-804-45)",New,10/18/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-45,discontinued
9956,Clofarabine Injection,Apotex Corp.,"Injection, 20 mg/20 ml (1mg/ml) (NDC 60505-6166-0)",New,10/26/23,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/26/23,60505-6166-0,discontinued
9957,Clomipramine Hydrochloride Capsule,Sandoz Inc.,"Clomipramine Hydrochloride, Capsule, 25 mg (NDC 0781-2027-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-2027-01,discontinued
9958,Clomipramine Hydrochloride Capsule,Sandoz Inc.,"Clomipramine Hydrochloride, Capsule, 50 mg (NDC 0781-2037-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-2037-01,discontinued
9959,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-136-00,not available
9960,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-136-16,not available
9961,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-00,not available
9962,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-16,not available
9963,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-138-00,not available
9964,Clonazepam Tablet,"Accord Healthcare, Inc.","Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",New,3/10/23,Not available. Shortage duration not available.,Inventory on hold pending further assessment.,,,Neurology; Pediatric; Psychiatry,Current,,,16729-138-16,not available
9965,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",New,3/10/23,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-605-10,available
9966,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",New,3/10/23,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-610-10,available
9967,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",New,3/10/23,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-620-10,available
9968,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-10,available
9969,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-11,available
9970,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-50,available
9971,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-10,available
9972,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-11,available
9973,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-50,available
9974,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-10,available
9975,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",New,3/10/23,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-50,available
9976,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, .5 mg (NDC 0093-0832-01)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-01,available
9977,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, .5 mg (NDC 0093-0832-05)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-05,available
9978,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 mg (NDC 0093-3212-01)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-01,available
9979,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 mg (NDC 0093-3212-05)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-05,available
9980,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2 mg (NDC 0093-3213-01)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-01,available
9981,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2 mg (NDC 0093-3213-05)",Revised,12/6/23,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-05,available
9982,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-30,available
9983,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-01,available
9984,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-05,available
9985,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-30,available
9986,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-01,available
9987,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-05,available
9988,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-30,available
9989,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-01,available
9990,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Revised,4/12/23,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-05,available
9991,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 g/5 g (NDC 0009-0260-01)",Revised,3/30/23,,Supply expected to exhaust late May 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/23,3/30/23,0009-0260-01,discontinued
9992,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 g/5 g (NDC 59762-0260-2)",Revised,3/30/23,,Discontinuation of the manufacture of the drug. This product is distributed by Viatris.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/23,3/30/23,59762-0260-2,discontinued
9993,Colestipol Hydrochloride Granule,Pfizer Inc.,"Flavored Colestid, Granule, 5 g/7.5 g (NDC 0009-0370-05)",Revised,3/30/23,,Supply expected to exhaust early July 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/23,3/30/23,0009-0370-05,discontinued
9994,Colestipol Hydrochloride Granule,Pfizer Inc.,"Flavored Colestid, Granule, 5 g/7.5 g (NDC 0009-0370-03)",Revised,3/30/23,,Supply expected to exhaust late August 2023. Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,3/30/23,3/30/23,0009-0370-03,discontinued
9995,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 g/5 g (NDC 59762-0260-1)",New,10/17/23,,Supply expected to exhaust early November 2023. Discontinuation of the manufacture of the drug. This product distributed by Viatris.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/23,59762-0260-1,discontinued
9996,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 g/5 g (NDC 0009-0260-04)",New,11/9/23,,Supply expected to exhaust December 2023,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/23,0009-0260-04,discontinued
9997,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [arb'U]/1 g (NDC 50484-010-30)",Reverified,12/19/23,Product is available.,,,,Dermatology,Current,,,50484-010-30,available
9998,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [arb'U]/1 g (NDC 50484-010-90)",Reverified,12/19/23,Product is currently on back order with Smith and Nephew. Shortage duration is unknown at this time.,,,Delay in shipping of the drug,Dermatology,Current,,,50484-010-90,not available
9999,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",New,3/14/22,Next delivery April 2022.  Estimated recovery 3Q 2022.,,,,Cardiovascular,Current,,,66220-160-10,not available
10000,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 mg/5 mL (NDC 69784-200-96)",Reverified,12/19/23,Product is available. Additional volumes expected to early 2024.,Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2,,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,69784-200-96,available
10001,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 mg/5 mL (NDC 76204-025-96)",Reverified,12/19/23,Product is available. Additional volumes expected to early 2024.,"Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300",,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,76204-025-96,available
10002,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Reverified,12/21/23,Unavailable; Anticipate availability January  2024,,,Delay in shipping of the drug,Pulmonary/Allergy,Current,,,16571-600-96,not available
10003,Cromolyn Sodium Concentrate,Micro Labs LTD,"Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Reverified,12/20/23,Available. On allocation due to high demand,,,Demand increase for the drug,Pulmonary/Allergy,Current,,,42571-132-52,limited availability
10004,Cromolyn Sodium Concentrate,"Mylan Specialty, a Viatris Company","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Reverified,12/19/23,Available,,,,Pulmonary/Allergy,Current,,,0037-0678-96,available
10005,Cromolyn Sodium Oral Solution,"Mylan Institutional, a Viatris Company","Oral Solution, 100mg/5mL (NDC 51525-0470-9)",New,11/1/23,,Gastrocrom 100mg/5mL Oral Concentrate 96s (NDC: 0037-0678-96) will remain available,,Discontinuation of the manufacture of the drug,Pulmonary/Allergy,To Be Discontinued,,11/1/23,51525-0470-9,discontinued
10006,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 mg/1 mL (NDC 24208-735-06)",Reverified,12/19/23,Limited availability,Restock projected Q1 2024,,Demand increase for the drug,Ophthalmology,Current,,,24208-735-06,limited availability
10007,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 5 mg/1 mL (NDC 0065-0395-15)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0395-15,available
10008,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 0065-0396-02)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0396-02,available
10009,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 0065-0396-05)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0396-05,available
10010,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-02)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0397-02,available
10011,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-05)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0397-05,available
10012,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 mg/1 mL (NDC 0065-0397-15)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0397-15,available
10013,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 61314-396-01)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,61314-396-01,available
10014,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 mg/1 mL (NDC 61314-396-03)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,61314-396-03,available
10015,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 mg/1 mL (NDC 24208-735-01)",Reverified,12/19/23,Limited availability,Restock projected Q1 2024,,Demand increase for the drug,Ophthalmology,Current,,,24208-735-01,limited availability
10016,"Cyclopentolate Hydrochloride, Phenylephrine Hydrochloride Ophthalmic Solution",Alcon,"Cyclomydril, Ophthalmic Solution, 2 mg/1 mL; 10 mg/1 mL (NDC 0065-0359-02)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0359-02,available
10017,"Cyclopentolate Hydrochloride, Phenylephrine Hydrochloride Ophthalmic Solution",Alcon,"Cyclomydril, Ophthalmic Solution, 2 mg/1 mL; 10 mg/1 mL (NDC 0065-0359-05)",Reverified,12/19/23,"Available, We have adequate inventory to support demand",,,,Ophthalmology,Current,,,0065-0359-05,available
10018,Cyclosporine Injection,Padagis US LLC,"Injection, 250 mg/5 mL (50 mg/mL) in 5 mL Ampule (NDC 0574-0866-10)",New,9/29/23,,Discontinuation of the manufacture of the product.,,Discontinuation of the manufacture of the drug,Transplant,To Be Discontinued,,9/29/23,0574-0866-10,discontinued
10019,Cytarabine Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/1 mL (NDC 63323-120-20)",Reverified,12/20/23,Limited Availability,"2, 3, & 4 month expiry (1/31/2024, 2/29/2024, 3/31/2024  expiry) dating available by request. Next release December 2023.",,Regulatory delay,Oncology; Pediatric,Current,,,63323-120-20,limited availability
10020,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-305-38)",Reverified,9/11/23,Limited Supply Available. Next delivery: November 2023; Estimated recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Oncology; Pediatric,Current,,,61703-305-38,limited availability
10021,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 100 mg/1 mL (NDC 61703-319-22)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,61703-319-22,available
10022,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-304-36)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,61703-304-36,available
10023,Cytarabine Injection,"Hospira, Inc., a Pfizer Company","Cytarabine, Injection, 20 mg/1 mL (NDC 61703-303-46)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,61703-303-46,available
10024,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 2 g/20 mL (NDC 71288-109-20)",Reverified,12/19/23,Available,,,,Oncology; Pediatric,Current,,,71288-109-20,available
10025,Dacarbazine Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-127-10)",Reverified,12/20/23,Next release December 2023.,Check wholesaler inventory,,Regulatory delay,Oncology,Current,,,63323-127-10,not available
10026,Dacarbazine Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-128-20)",Reverified,12/20/23,Backordered.  Next release December 2023.,Check wholesaler inventory,,Regulatory delay,Oncology,Current,,,63323-128-20,not available
10027,Dacarbazine Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 200 mg per Vial (NDC 0143-9245-10)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots will be available in the December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology,Current,,,0143-9245-10,not available
10028,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Cosmegen, Injection, .5 mg/1 mL (NDC 55292-811-55)",New,10/16/23,,,,,Oncology,To Be Discontinued,,10/16/23,55292-811-55,discontinued
10029,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 mg/1 mL (NDC 66993-489-35)",New,10/16/23,,Authorized generic distributed by Prasco Laboratories,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/16/23,66993-489-35,discontinued
10030,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 mg/1 mL (NDC 66993-489-83)",New,10/16/23,,Authorized generic distributed by Prasco Laboratories,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/16/23,66993-489-83,discontinued
10031,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0781-8218-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8218-01,discontinued
10032,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 25 mg (NDC 0781-8972-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8972-01,discontinued
10033,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 50 mg (NDC 0781-8973-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8973-01,discontinued
10034,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 75 mg (NDC 0781-8974-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8974-01,discontinued
10035,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 100 mg (NDC 0781-8975-01)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8975-01,discontinued
10036,"Desipramine Hydrochloride Tablet, Film Coated",Sandoz Inc.,"Desipramine Hydrochloride, Tablet, Film Coated, 150 mg (NDC 0781-8976-50)",New,2/14/23,,,,,Psychiatry,To Be Discontinued,2/14/23,2/14/23,0781-8976-50,discontinued
10037,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Reverified,12/20/23,Available,,,,Hematology,Current,,,60505-0815-0,available
10038,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Hematology,Current,,,55566-2500-0,not available
10039,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Hematology,Current,,,0053-6871-00,not available
10040,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Hematology,Current,,,69918-501-05,not available
10041,Desmopressin Acetate Tablet,"Teva Pharmaceuticals USA, Inc.","Desmopressin Acetate, Tablet, .1 mg (NDC 0591-2464-01)",New,3/14/23,,,,,Gastroenterology,To Be Discontinued,3/14/23,3/14/23,0591-2464-01,discontinued
10042,Desmopressin Acetate Tablet,"Teva Pharmaceuticals USA, Inc.","Desmopressin Acetate, Tablet, .2 mg (NDC 0591-2465-01)",New,3/14/23,,,,,Gastroenterology,To Be Discontinued,3/14/23,3/14/23,0591-2465-01,discontinued
10043,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 100 mg (NDC 59762-1222-3)",New,6/20/23,,Discontinuation of the manufacture of the drug; Supply expected to exhaust late July 2023,,,Psychiatry,To Be Discontinued,6/20/23,6/20/23,59762-1222-3,discontinued
10044,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 50 mg (NDC 59762-1211-3)",New,6/20/23,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,6/20/23,6/20/23,59762-1211-3,discontinued
10045,"Desvenlafaxine Succinate Tablet, Extended Release",Pfizer Inc.,"Pristiq, Tablet, Extended Release, 25 mg (NDC 59762-1210-3)",New,9/11/23,,Discontinuation of the manufacture of the drug; Supply expected to exhaust November 2023,,,Psychiatry,To Be Discontinued,9/11/23,9/11/23,59762-1210-3,discontinued
10046,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-304-25)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-304-25,available
10047,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-305-10)",Revised,12/20/23,Currently on backorder - next shipment Jan,Intermittent availability expected,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-305-10,not available
10048,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 76045-106-10)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-106-10,available
10049,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 76045-109-10)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-109-10,available
10050,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-423-12)",Reverified,12/21/23,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-423-12,available
10051,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-422-54)",Reverified,12/21/23,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-422-54,available
10052,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 4 mg/1 mL (NDC 67457-421-30)",Reverified,12/21/23,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-421-30,available
10053,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Injection, 10 mg/1 mL (NDC 67457-420-10)",Reverified,12/21/23,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-420-10,available
10054,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-237-01)",Reverified,12/20/23,On long-term backorder,Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-237-01,not available
10055,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-238-05)",Reverified,12/20/23,On long-term backorder,Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-238-05,not available
10056,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Injection, 4 mg/1 mL (NDC 55150-239-30)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-239-30,available
10057,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,70069-021-25,limited availability
10058,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-05)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-05,available
10059,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-516-10)",Reverified,12/20/23,Next release not available at this time.,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-516-10,not available
10060,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-30)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-30,available
10061,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-165-01)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-01,available
10062,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-506-01,available
10063,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May - June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6145-25,not available
10064,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and will be available in the June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6146-25,not available
10065,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Revised,12/19/23,Inventory is currently available,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-0367-25,available
10066,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-40)",New,6/26/23,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/23,6/26/23,0078-0953-40,discontinued
10067,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-25)",New,6/26/23,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/23,6/26/23,0078-0953-25,discontinued
10068,"Dexamethasone, Tobramycin Suspension/ Drops",Novartis Pharmaceuticals Corporation,"Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-26)",New,6/26/23,,"Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEXÂ® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.  Product will be available until approximately September 2023.  The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz.  Other generic equivalents are also available.",,,Ophthalmology,To Be Discontinued,6/26/23,6/26/23,0078-0953-26,discontinued
10069,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,70121-1388-1,available
10070,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,70121-1389-1,available
10071,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 ug/1 mL (NDC 42023-186-20)",Revised,11/1/23,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-186-20,available
10072,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 ug/1 mL (NDC 42023-187-10)",Revised,11/1/23,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-187-10,available
10073,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Reverified,9/12/23,Available,,,,Anesthesia,Current,,,67457-924-50,available
10074,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Reverified,9/12/23,Available,,,,Anesthesia,Current,,,67457-925-10,available
10075,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 ug/1 mL (NDC 70121-1388-8)",Revised,11/2/23,Available,,,,Anesthesia,Current,,,70121-1388-8,available
10076,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 ug/1 mL (NDC 70121-1389-7)",Revised,11/2/23,Available,,,,Anesthesia,Current,,,70121-1389-7,available
10077,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Reverified,5/16/23,Inventory is currently available,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9532-25,available
10078,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Reverified,5/9/23,Inventory available,,,Demand increase for the drug,Anesthesia,Current,,,43598-976-58,available
10079,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Reverified,5/9/23,Inventory available,,,Demand increase for the drug,Anesthesia,Current,,,43598-975-58,available
10080,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-296-10,available
10081,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-297-10,available
10082,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Reverified,4/21/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,16729-239-93,available
10083,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Reverified,4/21/22,Available,,,Demand increase for the drug,Anesthesia,Current,,,16729-432-93,available
10084,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Reverified,12/19/23,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Delay in shipping of the drug,Anesthesia,Current,,,55150-209-02,not available
10085,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,0338-9555-24,available
10086,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,0338-9557-12,available
10087,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,43066-555-24,available
10088,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,43066-557-12,available
10089,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-20)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-671-20,not available
10090,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-50)",Revised,11/29/23,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-671-50,not available
10091,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 ug/1 mL (NDC 63323-671-00)",Revised,11/29/23,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-671-00,not available
10092,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 100 ug/1 mL (NDC 63323-421-02)",Revised,11/29/23,Available,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,63323-421-02,available
10093,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 100 ug/1 mL (NDC 44567-600-04)",Reverified,12/20/23,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-600-04,available
10094,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 100 ug/1 mL (NDC 44567-601-04)",Reverified,12/20/23,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-601-04,available
10095,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 4 ug/1 mL (NDC 44567-602-24)",Reverified,12/20/23,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-602-24,available
10096,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Injection, 4 ug/1 mL (NDC 44567-603-24)",Reverified,12/20/23,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-603-24,available
10097,Dexmedetomidine Hydrochloride Injection,Jiangsu Hengrui Medicine Co. Ltd.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70860-605-03)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,70860-605-03,available
10098,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Reverified,9/12/23,Available,,,,Anesthesia,Current,,,67457-251-02,available
10099,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 100 ug/1 mL (NDC 42023-146-25)",Revised,11/1/23,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-146-25,available
10100,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-20)",Revised,9/11/23,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,,,,Anesthesia,Current,,,0409-1660-20,limited availability
10101,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-50)",Revised,9/11/23,Available,,,,Anesthesia,Current,,,0409-1660-50,available
10102,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 4 ug/1 mL (NDC 0409-1660-10)",Revised,9/11/23,Available,,,,Anesthesia,Current,,,0409-1660-10,available
10103,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 100 ug/1 mL (NDC 0409-1638-02)",Revised,9/11/23,Limited Supply Available,Limited Supply Available. Check Wholesaler for Availability,,,Anesthesia,Current,,,0409-1638-02,limited availability
10104,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Reverified,12/28/22,Available,,,,Anesthesia,Current,,,71225-126-05,available
10105,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Reverified,12/28/22,Available,,,,Anesthesia,Current,,,71225-126-06,available
10106,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Revised,2/13/23,Available on allocation.,,,Demand increase for the drug,Anesthesia,Current,,,71288-505-03,limited availability
10107,Dextrose Monohydrate Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Reverified,12/19/23,Backorder due to increase in demand,old NDC 76329-3301-1,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3302-1,not available
10108,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-7517-16)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-7517-16,not available
10109,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-4902-34)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4902-34,not available
10110,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 25 g/50 mL (NDC 0409-6648-02)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6648-02,not available
10111,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-10)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-10,available
10112,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-00)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-00,available
10113,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 g/100 mL (NDC 0264-7510-20)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-20,available
10114,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-32,available
10115,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-31,available
10116,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-00,available
10117,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-10,available
10118,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-20,available
10119,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-03,available
10120,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-55",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-55,available
10121,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-09,available
10122,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-02,available
10123,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-03,available
10124,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-04,available
10125,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-00,available
10126,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-10,available
10127,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-20,available
10128,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Reverified,12/20/23,Next release March 2024.,Check wholesalers for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-74,not available
10129,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-75,available
10130,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-76,available
10131,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-02)",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-02,available
10132,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-03,available
10133,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-09,available
10134,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Reverified,12/19/23,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7938-19",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7938-19,not available
10135,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose, Injection, 250 mg/1 mL (NDC 0409-1775-10)",Reverified,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-1775-10,limited availability
10136,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-66)",Reverified,9/11/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-66,available
10137,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-67)",Reverified,9/11/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-67,available
10138,Dextrose Monohydrate Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0409-7100-02)",Reverified,9/11/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-02,available
10139,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-61)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-61,available
10140,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-74)",Reverified,12/20/23,Next release date not available at this time. Check wholesaler inventory.,Check wholesaler inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-74,unclear
10141,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-75)",Reverified,12/20/23,Available. Check wholesaler for inventory,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-75,available
10142,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-10)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-10,available
10143,Dextrose Monohydrate Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 63323-624-50)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-50,available
10144,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-02,available
10145,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-61",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-61,available
10146,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-13",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-13,available
10147,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-20",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-20,available
10148,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-23",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-23,available
10149,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-36",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-36,available
10150,Dextrose Monohydrate Injection,"ICU Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-37",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-37,available
10151,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-10,available
10152,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-41,available
10153,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-11,available
10154,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-31,available
10155,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-48,available
10156,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-18,available
10157,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-38,available
10158,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-11,available
10159,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Reverified,12/21/23,Available on allocation,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9143-30,limited availability
10160,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Reverified,12/19/23,Available on allocation,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9147-30,limited availability
10161,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-18,available
10162,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0070-10,available
10163,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-02,available
10164,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0062-30,available
10165,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Reverified,9/27/23,Available,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-03,available
10166,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0066-20,available
10167,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,0264-9598-20,available
10168,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,0264-9594-20,available
10169,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,0264-9594-10,available
10170,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 20 mg/4 mL (NDC 68682-655-20)",Reverified,12/21/23,Available,,,,Neurology,Current,,,68682-655-20,available
10171,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 10 mg/2 mL (NDC 68682-652-20)",Reverified,12/21/23,Available,,,,Neurology,Current,,,68682-652-20,available
10172,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 2.5 mg/.5 mL (NDC 68682-650-20)",Reverified,12/19/23,"Currently unavailable, delayed until November 8th",Estimated availability September 2023,,Delay in shipping of the drug,Neurology,Current,,,68682-650-20,not available
10173,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 10 mg/2 g (NDC 43386-280-01)",New,11/6/23,Available,,,,Neurology,Current,,,43386-280-01,available
10174,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 20 mg/4 g (NDC 43386-281-01)",Reverified,12/19/23,Available,,,,Neurology,Current,,,43386-281-01,available
10175,Diclofenac Sodium Gel,Amneal Pharmaceuticals,"Diclofenac Sodium, Gel, 10 mg/1 g (NDC 65162-833-66)",New,8/1/23,,,,,Analgesia/Addiction,To Be Discontinued,8/1/23,8/1/23,65162-833-66,discontinued
10176,Dicyclomine Hydrochloride Injection,"Allergan, Inc.","Bentyl, Injection, 20 mg/2 mL (NDC 58914-080-52)",New,7/31/23,,Discontinuation of the manufacture of the drug,,,Gastroenterology,To Be Discontinued,7/31/23,7/31/23,58914-080-52,discontinued
10177,"Diflunisal Tablet, Film Coated","Avet Pharmaceuticals, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 14539-673-06)",Revised,8/4/23,,,Available,,Analgesia/Addiction,Resolved,8/4/23,,14539-673-06,
10178,"Diflunisal Tablet, Film Coated","Avet Pharmaceuticals, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 14539-673-01)",Revised,8/4/23,,,Available,,Analgesia/Addiction,Resolved,8/4/23,,14539-673-01,
10179,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-01)",Revised,8/4/23,,,Available,,Analgesia/Addiction,Resolved,8/4/23,,0093-9222-01,
10180,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-05)",Revised,8/4/23,,,Available,,Analgesia/Addiction,Resolved,8/4/23,,0093-9222-05,
10181,"Diflunisal Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Diflunisal, Tablet, Film Coated, 500 mg (NDC 0093-9222-06)",Revised,8/4/23,,,Available,,Analgesia/Addiction,Resolved,8/4/23,,0093-9222-06,
10182,Difluprednate Emulsion,Amneal Pharmaceuticals,"Emulsion, .5 mg/1 mL (NDC 69238-1380-3)",Reverified,12/19/23,Available,,,,Ophthalmology,Current,,,69238-1380-3,available
10183,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 mg/1 mL (NDC 0078-0862-25)",Reverified,12/19/23,"Unavailable; Resupply November 20, 2023",,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0078-0862-25,not available
10184,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 mg/1 mL (NDC 0781-6000-78)",Reverified,12/19/23,Available; Currently have 7.5 months of coverage,,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0781-6000-78,available
10185,Difluprednate Emulsion,Cipla Limited,"Difluprednate, Emulsion, .5 mg/1 mL (NDC 69097-341-35)",Reverified,12/19/23,Currently unavailable,,,Demand increase for the drug,Ophthalmology,Current,,,69097-341-35,not available
10186,Digoxin Injection,"Hikma Pharmaceuticals USA, Inc.","Digoxin, Injection, .25 mg/1 mL (NDC 0641-1410-35)",Reverified,4/8/22,Inventory is currently available,,,Demand increase for the drug,Cardiovascular,Current,,,0641-1410-35,available
10187,Digoxin Injection,Sandoz Inc.,"Injection, 250 ug/1 mL (NDC 0781-3059-95)",Revised,11/1/23,Available,,,,Cardiovascular,Current,,,0781-3059-95,available
10188,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 ug/1 mL (NDC 70515-260-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70515-260-10,available
10189,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 ug/1 mL (NDC 70515-261-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70515-261-10,available
10190,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 ug/1 mL (NDC 70515-262-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70515-262-10,available
10191,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 ug/1 mL (NDC 70515-263-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70515-263-10,available
10192,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-05)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-301-05,available
10193,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-301-10,available
10194,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 mg/1 mL (NDC 70860-301-25)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-301-25,available
10195,Diltiazem Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Diltiazem Hydrochloride, Injection, 100 mg (NDC 0409-4350-03)",Revised,12/19/23,Limited Supply Available.  Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,0409-4350-03,limited availability
10196,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6013-10)",Revised,12/19/23,This presentation is temporarily on backorder.,Product will be made available as it is released.,,Delay in shipping of the drug,Cardiovascular,Current,,,0641-6013-10,not available
10197,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6014-10)",Revised,12/19/23,Inventory is currently available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,0641-6014-10,available
10198,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Diltiazem Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6015-10)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots will be scheduled for manufacturing and will be available in the June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0641-6015-10,not available
10199,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 125mg/ 25mL (NDC 55150-427-10)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,55150-427-10,available
10200,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 25mg/ 5mL (NDC 55150-425-10)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,55150-425-10,available
10201,Diltiazem Hydrochloride Injection,Eugia US LLC,"Injection, 50mg/10mL (NDC 55150-426-10)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,55150-426-10,available
10202,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 25 mg (NDC 62559-235-01)",New,5/1/23,,,,,Cardiovascular,To Be Discontinued,5/1/23,5/1/23,62559-235-01,discontinued
10203,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 50 mg (NDC 62559-236-01)",New,5/1/23,,,,,Cardiovascular,To Be Discontinued,5/1/23,5/1/23,62559-236-01,discontinued
10204,"Dipyridamole Tablet, Film Coated",ANI Pharmaceuticals,"Dipyridamole, Tablet, Film Coated, 75 mg (NDC 62559-237-01)",New,5/1/23,,,,,Cardiovascular,To Be Discontinued,5/1/23,5/1/23,62559-237-01,discontinued
10205,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 100 mg (NDC 59762-0386-1)",Reverified,9/11/23,Available,,,,Cardiovascular,Current,,,59762-0386-1,available
10206,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 150 mg (NDC 59762-0400-1)",Reverified,9/11/23,Next Delivery & Estimated Recovery: September 2023,Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular,Current,,,59762-0400-1,not available
10207,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 100 mg (NDC 0093-3127-01)",Reverified,12/6/23,Available,,,,Cardiovascular,Current,,,0093-3127-01,available
10208,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 150 mg (NDC 0093-3129-01)",Reverified,12/6/23,Available,,,,Cardiovascular,Current,,,0093-3129-01,available
10209,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace Cr, Capsule, 100 mg, Extended Release (NDC 0025-2732-31)",Reverified,9/11/23,Available,,,,Cardiovascular,Current,,,0025-2732-31,available
10210,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace Cr, Capsule, 150 mg, Extended Release (NDC 0025-2742-31)",Reverified,9/11/23,Available,,,,Cardiovascular,Current,,,0025-2742-31,available
10211,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 100 mg (NDC 0025-2752-31)",Reverified,9/11/23,Available,,,,Cardiovascular,Current,,,0025-2752-31,available
10212,Disopyramide Phosphate Capsule,Pfizer Inc.,"Norpace, Capsule, 150 mg (NDC 0025-2762-31)",Reverified,9/11/23,Next Delivery and Estimated Recovery: September 2023,Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular,Current,,,0025-2762-31,not available
10213,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0054-0357-25)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0357-25,discontinued
10214,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0054-0357-13)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0357-13,discontinued
10215,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 250 mg (NDC 0054-0356-25)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0356-25,discontinued
10216,Disulfiram Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 250 mg (NDC 0054-0356-13)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0356-13,discontinued
10217,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Reverified,12/19/23,Available on Allocation,,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0338-1075-02,limited availability
10218,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1077-02,limited availability
10219,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",Revised,12/19/23,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-88,available
10220,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 250 mg/20 mL (NDC 70436-203-80)",Reverified,12/19/23,Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,70436-203-80,available
10221,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 500 mg/40 mL (NDC 70436-204-80)",Revised,11/1/23,Unavailable,,,Discontinuation of the manufacture of the drug,Cardiovascular; Pediatric; Renal,To Be Discontinued,11/1/23,11/1/23,70436-204-80,not available
10222,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1073-02,limited availability
10223,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0409-2346-32)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2346-32,not available
10224,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0409-2347-32)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2347-32,not available
10225,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0409-3724-32)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-3724-32,not available
10226,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-01)",Reverified,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-01,limited availability
10227,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-02)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-02,limited availability
10228,"Dolutegravir Sodium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Tivicay, Tablet, Film Coated, 10 mg (NDC 49702-226-13)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Tivicay 50 mg tablets (49702-228-13) will still be available as well as Tivicay PD 5 mg (49702-255-37).",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-226-13,discontinued
10229,"Dolutegravir Sodium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Tivicay, Tablet, Film Coated, 25 mg (NDC 49702-227-13)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Tivicay 50 mg tablets (49702-228-13) will still be available as well as Tivicay PD 5 mg (49702-255-37).",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-227-13,discontinued
10230,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1.6 mg/1 mL (NDC 0409-7809-22)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,0409-7809-22,not available
10231,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1.6 mg/1 mL (NDC 0409-7809-24)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,0409-7809-24,limited availability
10232,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 3.2 mg/1 mL (NDC 0409-7810-22)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,0409-7810-22,not available
10233,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0409-5820-01)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,0409-5820-01,limited availability
10234,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0409-9104-20)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Cardiovascular,Current,,,0409-9104-20,limited availability
10235,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular,Current,,,0338-1005-02,limited availability
10236,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9252-25)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024  timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9252-25,not available
10237,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9254-25)",Reverified,12/19/23,Inventory is currently available.,Additional lots will be scheduled for manufacturing.  Product will be made available as it is released.,,,Cardiovascular,Current,,,0143-9254-25,available
10238,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular,Current,,,0338-1005-03,limited availability
10239,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular,Current,,,0338-1007-02,limited availability
10240,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Reverified,12/21/23,Available on Allocation,,,,Cardiovascular,Current,,,0338-1007-03,limited availability
10241,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, .5 ug (NDC 0955-1720-50)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,0955-1720-50,discontinued
10242,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, 1 ug (NDC 0955-1721-50)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,0955-1721-50,discontinued
10243,Doxercalciferol Capsule,Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, 2.5 ug (NDC 0955-1722-50)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,0955-1722-50,discontinued
10244,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, .5 ug (NDC 58468-0120-1)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,58468-0120-1,discontinued
10245,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, 1 ug (NDC 58468-0124-1)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,58468-0124-1,discontinued
10246,"Doxercalciferol Capsule, Liquid Filled",Sanofi-Aventis U.S. LLC,"Hectorol, Capsule, Liquid Filled, 2.5 ug (NDC 58468-0121-1)",New,5/19/23,,,,,Endocrinology/Metabolism,To Be Discontinued,5/19/23,5/19/23,58468-0121-1,discontinued
10247,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Reverified,12/12/23,Limited Availability through January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0002-1433-80,limited availability
10248,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Reverified,12/19/23,Limited Availability through March 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0002-1434-80,limited availability
10249,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Reverified,12/19/23,Limited Availability through January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0002-2236-80,limited availability
10250,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Reverified,12/19/23,Limited Availability mid-December 2023 to January 2024.,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0002-3182-80,limited availability
10251,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125%  (NDC 48102-053-05)",Revised,12/11/23,Available through limited distribution by AllianceRx Walgreens Specialty Pharmacy.,,,Delay in shipping of the drug,Ophthalmology,Current,,,48102-053-05,limited availability
10252,Edetate Calcium Disodium Injection,"Casper Pharma, LLC","Injection, 200 mg/mL; 5 mL in 1 VIAL (NDC 64980-588-05)",Revised,10/24/23,Available,Available,Available,,Other,Resolved,10/24/23,,64980-588-05,available
10253,Edetate Calcium Disodium Injection,"Casper Pharma, LLC","Injection, 200 mg/mL; 5 VIAL in 1 CARTON (NDC 64980-588-51)",Revised,10/24/23,Available,Available,Available,,Other,Resolved,10/24/23,,64980-588-51,available
10254,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 2.5 mg/2 mL (NDC 0143-9786-10)",Reverified,12/19/23,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,0143-9786-10,available
10255,Enalaprilat Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1.25 mg/1 mL (NDC 0143-9787-10)",Reverified,12/19/23,This presentation is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Cardiovascular,Current,,,0143-9787-10,available
10256,Epinastine Hydrochloride Solution/ Drops,"Breckenridge Pharmaceutical, Inc.","Epinastine Hydrochloride, Solution/ Drops, .5 mg/1 mL (NDC 51991-836-75)",New,4/12/23,,,,,Ophthalmology,To Be Discontinued,4/12/23,4/12/23,51991-836-75,discontinued
10257,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Revised,11/29/23,Available,Available. Check wholesaler for inventory,,,Anesthesia; Pediatric,Current,,,63323-481-57,available
10258,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Revised,11/29/23,Limited Availability,Next release December 2023. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-482-27,limited availability
10259,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Revised,11/29/23,Limited Availability,Next release December 2023. Check wholesaler for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-482-57,limited availability
10260,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Revised,11/29/23,Unavailable,Next release December 2023. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-483-27,not available
10261,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,63323-483-57,available
10262,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Revised,11/29/23,Limited Availability,Next release December 2023. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-487-37,limited availability
10263,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Revised,11/29/23,Available,Available - Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,63323-488-37,available
10264,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-489-27,available
10265,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Revised,11/29/23,Backordered. Next release not available at this time.,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-482-17,not available
10266,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Revised,11/29/23,Backordered. Next release not available at this time.,,,Delay in shipping of the drug,Anesthesia; Pediatric,Current,,,63323-487-17,not available
10267,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia; Pediatric,Current,,,63323-488-17,not available
10268,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Revised,11/29/23,Unavailable,Next release December 2023.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-489-17,not available
10269,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 5 mg/1 mL (NDC 0409-3177-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3177-01,not available
10270,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3178-01,not available
10271,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-02)",Reverified,9/11/23,Next Delivery: January 2024; Estimated Recovery: September 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3178-02,not available
10272,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 10 mg/1 mL (NDC 0409-3178-03)",Reverified,9/11/23,Depleted,,,,Anesthesia; Pediatric,Current,,,0409-3178-03,not available
10273,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 15 mg/1 mL (NDC 0409-1209-01)",Reverified,9/11/23,Next Delivery: July 2024; Estimated Recovery: September 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-1209-01,not available
10274,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 15 mg/1 mL (NDC 0409-3181-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3181-01,not available
10275,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3182-01,not available
10276,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-02)",Reverified,9/11/23,Depleted,,,,Anesthesia; Pediatric,Current,,,0409-3182-02,not available
10277,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 10 ug/1 mL; 20 mg/1 mL (NDC 0409-3182-03)",Reverified,9/11/23,Next Delivery: January 2024; Estimated Recovery: September 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3182-03,not available
10278,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 5 ug/1 mL; 20 mg/1 mL (NDC 0409-3183-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-3183-01,not available
10279,Epinephrine Injection,"Hospira, Inc., a Pfizer Company","Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)",Reverified,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Cardiovascular; Pulmonary/Allergy,Current,,,0409-4933-01,limited availability
10280,Epinephrine Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 mg/1 mL (NDC 76329-3318-1)",Reverified,12/19/23,Backorder due to the increase in demands,,,Demand increase for the drug,Cardiovascular; Pulmonary/Allergy,Current,,,76329-3318-1,not available
10281,EPINEPHRINE SOLUTION,Adamis Pharmaceuticals Corporation,"SYMJEPI, SOLUTION, 0.15 mg/0.3 mL  (NDC 78670-131-02)",New,9/18/23,,,,Discontinuation of the manufacture of the drug,Pulmonary/Allergy,To Be Discontinued,,9/18/23,78670-131-02,discontinued
10282,Erythromycin Ointment,Fera Pharmaceuticals,"Ointment, 5 mg/g (NDC 48102-057-11)",Reverified,12/19/23,Available,,,,Ophthalmology; Pediatric,Current,,,48102-057-11,available
10283,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-50)",Reverified,12/19/23,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,0574-4024-50,limited availability
10284,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-35)",Reverified,12/19/23,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,0574-4024-35,limited availability
10285,Erythromycin Ointment,"Bausch Health Americas, Inc.","Ointment, 5 mg/1 g (NDC 24208-910-55)",Reverified,12/21/23,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Delay in shipping of the drug,Ophthalmology; Pediatric,Current,,,24208-910-55,limited availability
10286,Erythromycin Ointment,Padagis US LLC,"Ointment, 5 mg/1 g (NDC 0574-4024-39)",Reverified,12/19/23,"Product available until Mid-November, no availability after November 2023: Estimated Shortage duration TBD",,,Demand increase for the drug,Ophthalmology; Pediatric,Current,,,0574-4024-39,limited availability
10287,Erythromycin Ointment,"Bausch Health Americas, Inc.","Ointment, 5 mg/1 g (NDC 24208-910-19)",Reverified,12/21/23,Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.,,,Delay in shipping of the drug,Ophthalmology; Pediatric,Current,,,24208-910-19,limited availability
10288,Estramustine Phosphate Sodium Capsule,Pfizer Inc.,"Emcyt, Capsule, 140 mg (NDC 0013-0132-02)",New,5/18/23,,Supply expected to exhaust late January 2024,,,Oncology,To Be Discontinued,5/18/23,5/18/23,0013-0132-02,discontinued
10289,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 68682-012-27)",New,2/24/23,,"Marketed by Oceanside Pharmaceuticals, a division of Bausch Health U.S.  Current Inventory run out 4/1/23. No further manufacturing is scheduled.",,,Cardiovascular; Pediatric,To Be Discontinued,2/24/23,2/24/23,68682-012-27,discontinued
10290,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 68682-012-50)",New,2/24/23,,"Marketed by Oceanside Pharmaceuticals, a division of Bausch Health U.S.  Current Inventory run out 4/1/23. No further manufacturing is scheduled.",,,Cardiovascular; Pediatric,To Be Discontinued,2/24/23,2/24/23,68682-012-50,discontinued
10291,"Ethacrynate Sodium Powder, For Solution","Bausch Health Americas, Inc.","Edecrin, Powder, For Solution, 50 mg/50 mL (NDC 25010-210-27)",New,2/24/23,,Current Inventory run out 4/1/23. No further manufacturing is scheduled.,,,Cardiovascular; Pediatric,To Be Discontinued,2/24/23,2/24/23,25010-210-27,discontinued
10292,Ethinyl Estradiol/Norethindrone/Ferrous Fumarate Tablet,"Allergan Sales, LLC","Minastrin 24 Fe, Tablet, 1 mg/0.02 mg (NDC 0430-0540-50)",New,4/5/23,,,,,Reproductive,To Be Discontinued,4/5/23,4/5/23,0430-0540-50,discontinued
10293,"Etodolac Tablet, Coated",Sandoz Inc.,"Etodolac, Tablet, Coated, 400 mg (NDC 0185-0675-01)",New,2/14/23,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,2/14/23,2/14/23,0185-0675-01,discontinued
10294,"Etodolac Tablet, Coated",Sandoz Inc.,"Etodolac, Tablet, Coated, 400 mg (NDC 0185-0675-10)",New,2/14/23,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,2/14/23,2/14/23,0185-0675-10,discontinued
10295,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 65219-445-10)",Revised,11/2/23,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,65219-445-10,available
10296,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 40 mg/20 mL (NDC 65219-445-20)",Revised,11/2/23,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,65219-445-20,available
10297,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 25021-674-10)",Reverified,12/19/23,Available,Marketed by Sagent,,,Anesthesia,Current,,,25021-674-10,available
10298,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 25021-674-20)",Reverified,12/19/23,Available,Marketed by Sagent,,,Anesthesia,Current,,,25021-674-20,available
10299,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Revised,8/22/23,Pending information,Distributed by Civica,,,Anesthesia,Current,,,72572-160-10,unclear
10300,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Revised,8/22/23,Pending information,Distributed by Civica,,,Anesthesia,Current,,,72572-161-10,unclear
10301,Etomidate Injection,Eugia US LLC,"Injection, 20 mg/10 mL (NDC 55150-221-10)",Reverified,12/19/23,Available,"Manufactured by Eugia Pharma Specialties, Ltd.",,,Anesthesia,Current,,,55150-221-10,available
10302,Etomidate Injection,Eugia US LLC,"Injection, 40 mg/20 mL (NDC 55150-222-20)",Reverified,12/19/23,Available,"Manufactured by Eugia Pharma Specialties, Ltd.",,,Anesthesia,Current,,,55150-222-20,available
10303,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Revised,8/22/23,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Demand increase for the drug,Anesthesia,Current,,,72266-146-10,available
10304,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Revised,8/22/23,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Demand increase for the drug,Anesthesia,Current,,,72266-147-10,available
10305,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Revised,8/22/23,Currently on backorder,,,Demand increase for the drug,Anesthesia,Current,,,0143-9506-10,not available
10306,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Revised,8/22/23,Currently on backorder,,,Demand increase for the drug,Anesthesia,Current,,,0143-9507-10,not available
10307,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Revised,8/22/23,Pending information,,,,Anesthesia,Current,,,0143-9310-10,unclear
10308,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Revised,8/22/23,Pending information,,,,Anesthesia,Current,,,0143-9311-10,unclear
10309,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Reverified,9/12/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-902-10,available
10310,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Reverified,9/12/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-903-20,available
10311,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-6695-01,not available
10312,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-02)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia,Current,,,0409-6695-02,not available
10313,"Exemestane Tablet, Film Coated","Hikma Pharmaceuticals USA, Inc.","Exemestane, Tablet, Film Coated, 25 mg (NDC 0054-0080-13)",New,6/28/23,,,,,Oncology,To Be Discontinued,6/28/23,6/28/23,0054-0080-13,discontinued
10314,"Famotidine, Ibuprofen Tablet, Coated",Horizon Therapeutics,"Duexis, Tablet, Coated, 26.6 mg; 800 mg (NDC 70748-312-09)",New,8/17/23,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,8/17/23,8/17/23,70748-312-09,discontinued
10315,"Famotidine, Ibuprofen Tablet, Coated",Horizon Therapeutics,"Duexis, Tablet, Coated, 26.6 mg; 800 mg (NDC 75987-010-03)",New,8/17/23,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,8/17/23,8/17/23,75987-010-03,discontinued
10316,"Famotidine, Ibuprofen Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Ibuprofen And Famotidine, Tablet, Film Coated, 26.6 mg; 800 mg (NDC 0093-8107-98)",New,1/25/23,,Business decision to discontinue manufacture of the drug product,,,Analgesia/Addiction,To Be Discontinued,1/25/23,1/25/23,0093-8107-98,discontinued
10317,Felbamate Oral Suspension,"Mylan Specialty, a Viatris Company","Felbatol® , Oral Suspension, 8 oz Each 5 mL contains 600 mg felbamate (NDC 0037-0442-67)",New,11/27/23,,,,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,11/27/23,0037-0442-67,discontinued
10318,Felbamate Oral Suspension,"Mylan Specialty, a Viatris Company","Felbatol®, Oral Suspension, 32 oz Each 5 mL contains 600 mg felbamate (NDC 0037-0442-17)",New,11/27/23,,,,Discontinuation of the manufacture of the drug,Neurology,To Be Discontinued,,11/27/23,0037-0442-17,discontinued
10319,Fenofibrate Tablet,Viatris,"Tablet, 160 mg (NDC 0378-7101-77)",New,10/16/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/23,0378-7101-77,discontinued
10320,Fenofibrate Tablet,Viatris,"Tablet, 54 mg (NDC 0378-7100-77)",New,10/16/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/23,0378-7100-77,discontinued
10321,Fenofibrate Tablet,AbbVie Inc.,"Tricor, Tablet, 145 mg (NDC 0074-3189-90)",New,10/16/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/16/23,0074-3189-90,discontinued
10322,Fenofibrate Tablet,AbbVie Inc.,"Tricor, Tablet, 48 mg (NDC 0074-3173-90)",New,10/16/23,,,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,10/16/23,10/16/23,0074-3173-90,discontinued
10323,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6247-25)",Revised,12/19/23,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6247-25,available
10324,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Injection, 50 ug/1 mL (NDC 63323-808-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-808-11,available
10325,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-20,available
10326,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-50,available
10327,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-01,available
10328,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-02,available
10329,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-05,available
10330,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate Preservative Free, Injection, 50 ug/1 mL (NDC 0409-1276-32)",Revised,12/19/23,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,0409-1276-32,not available
10331,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9093-32)",Revised,12/19/23,Next Delivery: January 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,0409-9093-32,not available
10332,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9093-35)",Revised,12/19/23,Limited Supply Available. Next Delivery: February 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,0409-9093-35,limited availability
10333,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-22)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction; Pediatric,Current,,,0409-9094-22,limited availability
10334,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-25)",Revised,12/19/23,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-25,available
10335,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-28)",Revised,12/19/23,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-28,available
10336,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-31)",Revised,12/19/23,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-31,available
10337,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0409-9094-61)",Revised,12/19/23,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-61,available
10338,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Revised,12/19/23,Unavailable,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0641-6024-10,not available
10339,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Revised,12/19/23,Unavailable,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0641-6025-10,not available
10340,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Revised,12/19/23,Currently not available,Inventory available in vial presentations.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0641-6026-05,not available
10341,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6027-25)",Revised,12/19/23,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0641-6027-25,available
10342,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6028-25)",Revised,12/19/23,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0641-6028-25,available
10343,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6029-25)",Revised,12/19/23,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6029-25,available
10344,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6030-01)",Revised,12/19/23,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6030-01,available
10345,Fluconazole Injection,Sagent Pharmaceuticals,"Fluconazole In Sodium Chloride 0.9% In Plastic Container, Injection, 2 mg/1 mL (NDC 25021-113-82)",Revised,9/18/23,Backorder. Estimated availability October 2023,,,Regulatory delay,Anti-Infective,Current,,,25021-113-82,not available
10346,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 50 mg  (NDC 0049-3410-30)",New,10/24/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/24/23,0049-3410-30,discontinued
10347,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 mg (NDC 59762-5018-1)",New,8/31/23,,Supply expected to exhaust September 2023; Discontinuation of the manufacture of the drug.,,,Anti-Infective,To Be Discontinued,8/31/23,8/31/23,59762-5018-1,discontinued
10348,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 mg (NDC 59762-5016-1)",New,6/20/23,,Discontinuation of the manufacture of the drug; Supply expected to exhaust August 2023,,,Anti-Infective,To Be Discontinued,6/20/23,6/20/23,59762-5016-1,discontinued
10349,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 150 mg (NDC 59762-5017-1)",New,6/20/23,,Discontinuation of the manufacture of the drug; Supply expected to exhaust June 2023,,,Anti-Infective,To Be Discontinued,6/20/23,6/20/23,59762-5017-1,discontinued
10350,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 25 mg/1 mL (NDC 45963-621-51)",Reverified,12/19/23,Temporarily Unavailable,,,Demand increase for the drug,Oncology,Current,,,45963-621-51,not available
10351,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 25 mg/1 mL (NDC 0480-9772-01)",Reverified,12/19/23,Available,,,,Oncology,Current,,,0480-9772-01,available
10352,Fludarabine Phosphate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/2 mL (NDC 45963-609-55)",Reverified,12/19/23,Available,,,,Oncology,Current,,,45963-609-55,available
10353,Fludarabine Phosphate Injection,"Fresenius Kabi USA, LLC","Injection, 25 mg/1 mL (NDC 63323-192-02)",Reverified,12/20/23,Available. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,63323-192-02,available
10354,Fludarabine Phosphate Injection,"Areva Pharmaceuticals, Inc.","Fludarabine Phosphate, Injection, 25 mg/1 mL (NDC 59923-604-02)",Reverified,12/19/23,"Available, To order call 1-812-399-0479",,,,Oncology,Current,,,59923-604-02,available
10355,Fluorescein Sodium Injection,Long Grove Pharmaceuticals LLC,"Ak-fluor, Injection, 100 mg/1 mL (NDC 17478-253-10)",Revised,12/5/23,,,Available,,Ophthalmology,Resolved,12/5/23,,17478-253-10,
10356,Fluorescein Sodium Injection,Long Grove Pharmaceuticals LLC,"Ak-fluor, Injection, 250 mg/1 mL (NDC 17478-250-20)",Revised,12/5/23,,,Available,,Ophthalmology,Resolved,12/5/23,,17478-250-20,
10357,Fluorescein Sodium Injection,"Nexus Pharmaceuticals, LLC","Injection, 500 mg/1 mL (NDC 14789-122-05)",New,12/5/23,Available,,Available,,Ophthalmology,Resolved,12/5/23,,14789-122-05,available
10358,Fluorescein Sodium Injection,"Nexus Pharmaceuticals, LLC","Injection, 250 mg/1 mL (NDC 14789-123-05)",Revised,12/5/23,,,Available,,Ophthalmology,Resolved,12/5/23,,14789-123-05,
10359,Fluorescein Sodium Injection,Alcon,"Fluorescite, Injection, 100 mg/1 mL (NDC 0065-0092-65)",Revised,12/5/23,,,Available,,Ophthalmology,Resolved,,,0065-0092-65,
10360,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 20 mg (NDC 0093-0807-01)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-0807-01,discontinued
10361,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 20 mg (NDC 0093-0807-56)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-0807-56,discontinued
10362,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 60 mg (NDC 0093-5262-56)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-5262-56,discontinued
10363,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-01)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-7188-01,discontinued
10364,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-10)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-7188-10,discontinued
10365,"Fluoxetine Hydrochloride Tablet, Film Coated","Teva Pharmaceuticals USA, Inc.","Fluoxetine Hydrochloride, Tablet, Film Coated, 10 mg (NDC 0093-7188-56)",New,2/8/23,,Business Decision to Discontinue,,,Psychiatry,To Be Discontinued,2/8/23,2/8/23,0093-7188-56,discontinued
10366,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 15 mg (NDC 0378-4415-01)",Reverified,12/21/23,Anticipated availability: June 2024,Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,0378-4415-01,not available
10367,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 30 mg (NDC 0378-4430-01)",Reverified,12/21/23,Anticipated availability: June 2024,Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,0378-4430-01,not available
10368,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Capsule, 15 mg (NDC 62135-736-90)",Reverified,12/20/23,Product available through all wholesalers,,,,Oncology; Other,Current,,,62135-736-90,available
10369,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Capsule, 30 mg (NDC 62135-737-90)",Reverified,12/20/23,Product available through all wholesalers,,,,Neurology; Other,Current,,,62135-737-90,available
10370,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 44 ug (NDC 0173-0718-20)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0718-20,discontinued
10371,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 110 ug (NDC 0173-0719-20)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0719-20,discontinued
10372,"Fluticasone Propionate Aerosol, Metered",GlaxoSmithKline,"Flovent Hfa, Aerosol, Metered, 220 ug (NDC 0173-0720-20)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0720-20,discontinued
10373,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-15)",New,8/7/23,,,,,Dermatology,To Be Discontinued,8/7/23,8/7/23,0168-0332-15,discontinued
10374,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-30)",New,8/7/23,,,,,Dermatology,To Be Discontinued,8/7/23,8/7/23,0168-0332-30,discontinued
10375,Fluticasone Propionate Cream,Sandoz Inc.,"Fluticasone Propionate, Cream, .5 mg/1 g (NDC 0168-0332-60)",New,8/7/23,,,,,Dermatology,To Be Discontinued,8/7/23,8/7/23,0168-0332-60,discontinued
10376,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 50 ug (NDC 0173-0600-02)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0600-02,discontinued
10377,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 100 ug (NDC 0173-0602-02)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0602-02,discontinued
10378,"Fluticasone Propionate Powder, Metered",GlaxoSmithKline,"Flovent, Powder, Metered, 250 ug (NDC 0173-0601-02)",New,6/2/23,,"The last date the product will be available for ordering is December 31, 2023.",,,Pulmonary/Allergy,To Be Discontinued,6/2/23,6/2/23,0173-0601-02,discontinued
10379,Fosamprenavir Calcium Suspension,GlaxoSmithKline (ViiV Healthcare),"Lexiva, Suspension, 50 mg/1 mL (NDC 49702-208-53)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-208-53,discontinued
10380,"Fosamprenavir Calcium Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Lexiva, Tablet, Film Coated, 700 mg (NDC 49702-207-18)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-207-18,discontinued
10381,Fulvestrant Solution,"Teva Pharmaceuticals USA, Inc.","Solution, 250 mg/5 mL (NDC 0591-5019-02)",New,10/26/23,,Business Decision to Discontinue.,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,10/26/23,0591-5019-02,discontinued
10382,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-02)",Revised,12/19/23,Available,Use Sagent NDC 25021-311-02,,Demand increase for the drug,Cardiovascular,Current,,,70860-302-02,available
10383,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-04)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-302-04,available
10384,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 70860-302-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,70860-302-10,available
10385,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-500-08)",Revised,12/19/23,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,16729-500-08,not available
10386,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-501-43)",Revised,12/19/23,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,16729-501-43,not available
10387,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 mg/1 mL (NDC 16729-502-43)",Revised,12/19/23,Unavailable,Inventory on hold pending further assessment.,,Regulatory delay,Cardiovascular,Current,,,16729-502-43,not available
10388,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-27)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,0409-6102-27,available
10389,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Reverified,2/13/23,Available,,,,Cardiovascular,Current,,,71288-205-03,available
10390,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-203-05)",Revised,12/19/23,Available,,,Demand increase for the drug,Cardiovascular,Current,,,71288-203-05,available
10391,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-203-11)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,71288-203-11,available
10392,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 2 mL (NDC 70860-302-41)",Revised,12/19/23,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,70860-302-41,discontinued
10393,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 4 mL (NDC 70860-302-42)",Revised,12/19/23,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,70860-302-42,discontinued
10394,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/mL, 10 mL (NDC 70860-302-43)",Revised,12/19/23,No longer ordering APD NDC,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,70860-302-43,discontinued
10395,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-02)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,63323-280-02,available
10396,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-04)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,63323-280-04,available
10397,Furosemide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-280-10)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Cardiovascular,Current,,,63323-280-10,available
10398,Furosemide Injection,Eugia US LLC,"Injection, 20 mg/2 mL (NDC 55150-322-25)",Revised,12/19/23,Currently on backorder - next shipment TBD,Check wholesalers for inventory,,Demand increase for the drug,Cardiovascular,Current,,,55150-322-25,not available
10399,Furosemide Injection,Eugia US LLC,"Injection, 40 mg/4 mL (NDC 55150-323-25)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,55150-323-25,available
10400,Furosemide Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-324-25)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,55150-324-25,available
10401,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,36000-284-25,available
10402,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,36000-282-25,available
10403,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,36000-283-25,available
10404,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-41)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,23155-473-41,available
10405,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-42)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,23155-473-42,available
10406,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 23155-473-44)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,23155-473-44,available
10407,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-02)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,0409-6102-02,limited availability
10408,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-04)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,0409-6102-04,limited availability
10409,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-10)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,0409-6102-10,available
10410,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-25)",Revised,12/19/23,Available,,,,Cardiovascular,Current,,,0409-6102-25,available
10411,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 10 mg/1 mL (NDC 0409-6102-26)",Revised,12/19/23,Limited Supply Available. Next Delivery: February 2024; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Cardiovascular,Current,,,0409-6102-26,limited availability
10412,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,12/19/23,Available.,,,,Cardiovascular,Current,,,25021-311-02,available
10413,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,12/19/23,Available.,,,,Cardiovascular,Current,,,25021-311-04,available
10414,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,12/19/23,Available,,,,Cardiovascular,Current,,,25021-311-10,available
10415,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,12/19/23,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-02,available
10416,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,12/19/23,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-04,available
10417,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,12/19/23,Available,,,Demand increase for the drug,Cardiovascular,Current,,,25021-311-10,available
10418,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 0023-3615-25)",New,3/10/23,,Labeler Allergan. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/23,3/10/23,0023-3615-25,discontinued
10419,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 0023-3615-01)",New,3/10/23,,Labeler Allergan. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/23,3/10/23,0023-3615-01,discontinued
10420,Gatifloxacin Solution/ Drops,Abbvie,"Zymaxid, Solution/ Drops, 5 mg/1 mL (NDC 60758-615-25)",New,3/10/23,,Labeler Pacific Pharma. Business decision to discontinue product,,,Ophthalmology,To Be Discontinued,3/10/23,3/10/23,60758-615-25,discontinued
10421,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg/1 mL (NDC 63323-010-02)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anti-Infective,Current,,,63323-010-02,available
10422,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg/1 mL (NDC 63323-010-20)",Revised,11/29/23,"Available, Available. Check wholesaler for inventory.",Check wholesaler inventory,,,Anti-Infective,Current,,,63323-010-20,available
10423,Gentamicin Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-173-02)",Revised,11/29/23,Available,,,,Anti-Infective,Current,,,63323-173-02,available
10424,Gentamicin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Gentamicin Sulfate, Injection, 40 mg/1 mL (NDC 0409-1207-03)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anti-Infective,Current,,,0409-1207-03,not available
10425,Gentamicin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Gentamicin Sulfate, Injection, 40 mg/1 mL (NDC 0409-1207-25)",Reverified,9/11/23,Discontinued,,,,Anti-Infective,Current,,,0409-1207-25,discontinued
10426,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 mg/50 mL (NDC 0338-0507-41)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0507-41,available
10427,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 mg/50 mL (NDC 0338-0509-41)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0509-41,available
10428,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-0503-48)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0503-48,available
10429,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 mg/50 mL (NDC 0338-0511-41)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0511-41,available
10430,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-0505-48)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0505-48,available
10431,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 mg/50 mL (NDC 0338-0507-48)",Reverified,9/27/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,0338-0507-48,available
10432,Gentamicin Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 40 mg/1 mL (NDC 0143-9128-25)",Reverified,12/19/23,"This presentation is on backorder., Recovery date TBD",Recovery date has not been determined at this time.,,Demand increase for the drug,Anti-Infective,Current,,,0143-9128-25,not available
10433,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 1 mg (NDC 0039-0221-10)",New,6/20/23,,"Discontinued due to a business decision. 1mg last lot expires June 30, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/23,6/20/23,0039-0221-10,discontinued
10434,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 2 mg (NDC 0039-0222-10)",New,6/20/23,,"Discontinued due to a business decision. 2mg last lot expires August 31, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/23,6/20/23,0039-0222-10,discontinued
10435,Glimepiride Tablet,Sanofi-Aventis U.S. LLC,"Amaryl, Tablet, 4 mg (NDC 0039-0223-10)",New,6/20/23,,"Discontinued due to a business decision. 4mg last lot expires August 31, 2023",,,Endocrinology/Metabolism,To Be Discontinued,6/20/23,6/20/23,0039-0223-10,discontinued
10436,"Glipizide  TABLET, EXTENDED RELEASE",Pfizer Inc.,"Glucotrol XL , TABLET, EXTENDED RELEASE, 2.5 mg tablet (NDC 0049-0170-01)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,To Be Discontinued,,,0049-0170-01,discontinued
10437,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 2.5 mg (NDC 59762-0540-1)",New,8/9/23,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,59762-0540-1,discontinued
10438,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 5 mg (NDC 59762-0541-1)",New,8/9/23,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,59762-0541-1,discontinued
10439,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 10 mg (NDC 59762-0542-1)",New,8/9/23,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,59762-0542-1,discontinued
10440,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol XL, Tablet, Extended Release, 10 mg (NDC 0049-0178-07)",New,8/9/23,,Supply expected to exhaust November 2023,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,0049-0178-07,discontinued
10441,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 5 mg (NDC 59762-0541-2)",New,8/9/23,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,59762-0541-2,discontinued
10442,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glipizide XL, Tablet, Extended Release, 10 mg (NDC 59762-0542-2)",New,8/9/23,,Supply expected to exhaust October 2023,,,Endocrinology/Metabolism,To Be Discontinued,8/9/23,8/9/23,59762-0542-2,discontinued
10443,Glucagon Hydrochloride Injection,Novo Nordisk,"Glucagen, Injection, 1 mg/1 mL (NDC 0169-7065-15)",New,11/15/23,,"Will be unavailable after July 1, 2024",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,To Be Discontinued,,11/18/22,0169-7065-15,discontinued
10444,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 1.5 mg (NDC 0009-0341-01)",New,1/3/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/23,1/3/23,0009-0341-01,discontinued
10445,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 3 mg (NDC 0009-0352-01)",New,1/3/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early November 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/23,1/3/23,0009-0352-01,discontinued
10446,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 6 mg (NDC 0009-3449-01)",New,1/3/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/23,1/3/23,0009-3449-01,discontinued
10447,Glyburide Tablet,Pfizer Inc.,"Glynase, Tablet, 6 mg (NDC 0009-3449-03)",New,1/3/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust early February 2023.,,,Endocrinology/Metabolism,To Be Discontinued,1/3/23,1/3/23,0009-3449-03,discontinued
10448,Glycopyrrolate Inhalation Solution,"Sunovion Pharmaceuticals, Inc.","Inhalation Solution, 25 mcg/mL (NDC 63402-201-01)",New,4/3/23,,,,,Pulmonary/Allergy,To Be Discontinued,4/3/23,4/3/23,63402-201-01,discontinued
10449,Glycopyrrolate Solution,"Sunovion Pharmaceuticals, Inc.","Lonhala Magnair Kit, Solution, 25 ug/1 mL (NDC 63402-201-00)",New,4/3/23,,,,,Pulmonary/Allergy,To Be Discontinued,4/3/23,4/3/23,63402-201-00,discontinued
10450,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 1 mg (NDC 65162-711-10)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,65162-711-10,available
10451,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-10)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,65162-713-10,available
10452,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-50)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,65162-713-50,available
10453,Guanfacine Hydrochloride Tablet,"Epic Pharma, LLC","Guanfacine Hydrochloride, Tablet, 1 mg (NDC 42806-048-01)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,42806-048-01,available
10454,Guanfacine Hydrochloride Tablet,"Epic Pharma, LLC","Guanfacine Hydrochloride, Tablet, 2 mg (NDC 42806-296-01)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,42806-296-01,available
10455,Guanfacine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Guanfacine Hydrochloride, Tablet, 1 mg (NDC 0591-0444-01)",Revised,10/10/23,Product available with short expiration,,1 mg available with short expiration,,Cardiovascular,Resolved,10/10/23,,0591-0444-01,available
10456,Guanfacine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Guanfacine Hydrochloride, Tablet, 2 mg (NDC 0591-0453-01)",Revised,10/10/23,Available,,2 mg available,,Cardiovascular,Resolved,10/10/23,,0591-0453-01,available
10457,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 1 mg (NDC 65162-711-03)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,65162-711-03,available
10458,Guanfacine Hydrochloride Tablet,Amneal Pharmaceuticals,"Guanfacine Hydrochloride, Tablet, 2 mg (NDC 65162-713-03)",Revised,10/10/23,Available,,Available,,Cardiovascular,Resolved,10/10/23,,65162-713-03,available
10459,Halobetasol Propionate Cream,Sandoz Inc.,"Halobetasol Propionate, Cream, .5 mg/1 g (NDC 0168-0355-15)",New,8/7/23,,,,,Dermatology,To Be Discontinued,8/7/23,8/7/23,0168-0355-15,discontinued
10460,Halobetasol Propionate Cream,Sandoz Inc.,"Halobetasol Propionate, Cream, .5 mg/1 g (NDC 0168-0355-50)",New,8/7/23,,,,,Dermatology,To Be Discontinued,8/7/23,8/7/23,0168-0355-50,discontinued
10461,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Reverified,12/21/23,Available on Allocation,,,,Hematology,Current,,,0338-0433-04,limited availability
10462,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Reverified,12/21/23,Unavailable,,,Regulatory delay,Hematology,Current,,,0338-0431-03,not available
10463,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 0409-7620-03)",Revised,12/19/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Hematology,Current,,,0409-7620-03,limited availability
10464,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 0409-7620-59)",Revised,12/19/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Hematology,Current,,,0409-7620-59,limited availability
10465,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Reverified,12/21/23,Available on allocation.,Product code AHB0953U replaces code 2B0953,,,Hematology,Current,,,0338-0424-18,limited availability
10466,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Reverified,12/20/23,Next release December 2023. Check wholesalers for inventory.,Check wholesaler for inventory,,Delay in shipping of the drug,Hematology,Current,,,63323-519-77,not available
10467,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Reverified,12/20/23,Available. Check wholesaler for inventory,Check wholesaler inventory,,Demand increase for the drug,Hematology,Current,,,63323-519-10,available
10468,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Reverified,12/19/23,"Available, N/A",,,,Hematology,Current,,,0264-9872-10,unclear
10469,"Hyaluronidase, Ovine Injection",Bausch & Lomb Incorporated,"Vitrase, Injection, 200 USP U/mL (NDC 24208-002-02)",New,8/28/23,,Discontinuing manufacture of the product.,,,Ophthalmology; Other,To Be Discontinued,8/28/23,8/28/23,24208-002-02,discontinued
10470,"Hyaluronidase, Ovine Injection",Bausch & Lomb Incorporated,"Vitrase, Injection, 200USP U/ml  (NDC 24208-002-03)",New,8/28/23,,Discontinuing manufacture of the product.,,,Ophthalmology; Other,To Be Discontinued,8/28/23,8/28/23,24208-002-03,discontinued
10471,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 12.5 mg; 20 mg (NDC 59762-0220-1)",New,10/2/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/2/23,59762-0220-1,discontinued
10472,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 12.5 mg; 10 mg (NDC 59762-0222-1)",New,10/2/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/2/23,59762-0222-1,discontinued
10473,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET,Pfizer Inc.,"ACCURETIC, TABLET, 25 mg; 20 mg (NDC 59762-0223-1)",New,10/2/23,,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Antibiotic; Cardiovascular,To Be Discontinued,,10/2/23,59762-0223-1,discontinued
10474,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 1000 mg/8 mL (NDC 0009-0005-01)",Revised,12/20/23,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0005-01,available
10475,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/2 mL (NDC 0009-0825-01)",Revised,12/20/23,"Limited Supply Available
Next Delivery: December 2023;
Estimated Recovery: March 2024",,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0825-01,
10476,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/2 mL (NDC 0009-0011-04)",Revised,12/20/23,Next Delivery: Dec 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0011-04,not available
10477,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-Cortef, Injection, 100 mg/mL (NDC 0009-0011-03)",Revised,12/20/23,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0011-03,not available
10478,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/2 mL (NDC 0009-0013-06)",Revised,12/20/23,Next Delivery: January 2024; Estimated Recovery: April 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-06,not available
10479,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/2 mL (NDC 0009-0013-05)",Revised,12/20/23,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-05,available
10480,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 500 mg/4 mL (NDC 0009-0016-12)",Revised,12/20/23,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0016-12,not available
10481,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-121-11,available
10482,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-010-11,available
10483,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-11,available
10484,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0110-03)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0703-0110-03,available
10485,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0113-03)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0703-0113-03,available
10486,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 10 mg/1 mL (NDC 0703-0018-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0703-0018-01,available
10487,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Revised,12/19/23,Inventory is currently available.,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-0121-25,available
10488,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-2341-41)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-2341-41,available
10489,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-05)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1283-05,discontinued
10490,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-31)",Revised,12/19/23,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-1283-31,available
10491,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-30)",Revised,12/19/23,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-1312-30,available
10492,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 0409-1304-31)",Revised,12/19/23,Available,,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-1304-31,available
10493,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-2552-01)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-2552-01,not available
10494,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Revised,12/19/23,Limited Supply Available. Next Delivery: April 2024; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-2634-01,limited availability
10495,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-05)",Revised,12/19/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-2634-05,limited availability
10496,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-50)",Reverified,12/19/23,Next Delivery: September 2023; Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,0409-2634-50,not available
10497,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-852-25)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-852-25,available
10498,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 63323-853-25)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-853-25,available
10499,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-854-10)",Reverified,12/20/23,Available - Check wholesaler for inventory,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-854-10,unclear
10500,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-851-10,available
10501,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-15)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-851-15,available
10502,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-851-50)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-851-50,available
10503,"Hydroxyamphetamine Hydrobromide, Tropicamide Solution",Akorn Pharmaceuticals,"Paremyd, Solution, 10 mg/1 mL; 2.5 mg/1 mL (NDC 17478-704-12)",New,1/31/23,,Business decision to discontinue product.,,,Ophthalmology,To Be Discontinued,1/31/23,1/31/23,17478-704-12,discontinued
10504,"Hydroxychloroquine Sulfate Tablet, Film Coated",Sandoz Inc.,"Hydroxychloroquine Sulfate, Tablet, Film Coated, 200 mg (NDC 0781-5994-01)",New,2/14/23,,,,,Rheumatology; Anti-Infective,To Be Discontinued,2/14/23,2/14/23,0781-5994-01,discontinued
10505,"Hydroxychloroquine Sulfate Tablet, Film Coated",Sandoz Inc.,"Hydroxychloroquine Sulfate, Tablet, Film Coated, 200 mg (NDC 0781-5994-05)",New,2/14/23,,,,,Rheumatology; Anti-Infective,To Be Discontinued,,2/14/23,0781-5994-05,discontinued
10506,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Reverified,12/19/23,"Unavailable, Resupply expected January 2024, Mar-25",Techinical transfer of drug product,,Regulatory delay,Ophthalmology,Current,,,24208-800-60,not available
10507,Hydroxyzine Pamoate Capsule,Pfizer Inc.,"Vistaril, Capsule, 25 mg (NDC 0069-5410-66)",New,3/28/23,,To be discontinued upon stop sale date May 2025,,,Psychiatry; Analgesia/Addiction,To Be Discontinued,3/28/23,3/28/23,0069-5410-66,discontinued
10508,Hydroxyzine Pamoate Capsule,Pfizer Inc.,"Vistaril, Capsule, 50 mg (NDC 0069-5420-66)",New,3/28/23,,To be discontinued upon stop sale date April 2023,,,Psychiatry; Analgesia/Addiction,To Be Discontinued,3/28/23,3/28/23,0069-5420-66,discontinued
10509,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Emulsion, 20 g/100 mL (NDC 0264-4460-00)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0264-4460-00,available
10510,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Emulsion, 20 g/100 mL (NDC 0264-4460-10)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0264-4460-10,available
10511,I.V. Fat Emulsion,B. Braun Medical Inc.,"Nutrilipid I.v. Fat Emulsion, Solution, Emulsion, 20 g/100 mL (NDC 0264-4460-30)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0264-4460-30,available
10512,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-00)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,63323-820-00,available
10513,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-74)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,63323-820-74,available
10514,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-50)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,63323-820-50,available
10515,I.V. Fat Emulsion,"Fresenius Kabi USA, LLC","Smoflipid 20%, Emulsion, 3 g/100 mL; 6 g/100 mL; 5 g/100 mL; 6 g/100 mL (NDC 63323-820-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,63323-820-10,available
10516,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-05)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-9540-05,available
10517,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-08)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-9540-08,available
10518,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-06)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-9540-06,available
10519,I.V. Fat Emulsion,Baxter Healthcare,"Clinolipid 20%, Emulsion, 16 g/100 mL; 4 g/100 mL (NDC 0338-9540-07)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-9540-07,available
10520,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-58)",Reverified,12/21/23,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-0519-58,limited availability
10521,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-09)",Reverified,12/21/23,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-0519-09,limited availability
10522,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-14)",Reverified,12/21/23,Stocked Out,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-0519-14,not available
10523,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 20%, Emulsion, 20 g/100 mL (NDC 0338-0519-13)",Reverified,12/21/23,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-0519-13,limited availability
10524,I.V. Fat Emulsion,Baxter Healthcare,"Intralipid 30%, Emulsion, 30 g/100 mL (NDC 0338-0520-13)",Reverified,12/21/23,Limited supply,,,Regulatory delay,Endocrinology/Metabolism; Gastroenterology; Total Parenteral Nutrition,Current,,,0338-0520-13,limited availability
10525,"Ibrutinib Tablet, Film Coated",AbbVie Inc.,"Imbruvica, Tablet, Film Coated, 560 mg (NDC 57962-560-28)",New,5/22/23,,No other NDCs are impacted. All other NDCs are still available.,,,Hematology; Oncology,To Be Discontinued,5/22/23,5/22/23,57962-560-28,discontinued
10526,Ibutilide Fumarate Injection,"Mylan Institutional, a Viatris Company","Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",Revised,9/14/23,,,Available,,Cardiovascular,Resolved,9/14/23,,67457-366-10,
10527,Ibutilide Fumarate Injection,Pfizer Inc.,"Corvert, Injection, .1 mg/1 mL (NDC 0009-3794-01)",Revised,9/14/23,,,Available,,Cardiovascular,Resolved,9/14/23,,0009-3794-01,
10528,Ibutilide Fumarate Injection,Pfizer Inc.,"Corvert, Injection, .1 mg/1 mL (NDC 0009-3794-22)",Revised,9/14/23,,,Available,,Cardiovascular,Resolved,9/14/23,,0009-3794-22,
10529,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 mg (NDC 49884-056-01)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-056-01,discontinued
10530,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 mg (NDC 49884-056-10)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-056-10,discontinued
10531,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 mg (NDC 49884-055-10)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-055-10,discontinued
10532,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 mg (NDC 49884-055-01)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-055-01,discontinued
10533,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 mg (NDC 49884-054-01)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-054-01,discontinued
10534,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 mg (NDC 49884-054-10)",Revised,9/15/23,,ANDA ownership transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-054-10,discontinued
10535,Indigotindisulfonate Sodium Injection,"American Regent, Inc.","Indigo Carmine, Injection, 8 mg/1 mL (NDC 0517-0375-05)",Revised,11/1/23,,,,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,11/1/23,11/1/23,0517-0375-05,discontinued
10536,Indigotindisulfonate Sodium Injection,Provepharm SAS,"Bludigo, Injection, 8 mg/1 mL (NDC 81284-315-05)",Revised,11/3/23,Available,,,,Medical Imaging,Current,12/6/23,,81284-315-05,available
10537,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [iU]/1 mL (NDC 0169-6432-10)",New,11/8/23,,"Supply disruptions for Levemir® FlexPen® anticipated to start in mid-January 2024 followed by discontinuation on April 1, 2024",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/23,0169-6432-10,discontinued
10538,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [iU]/1 mL (NDC 0169-3687-12)",New,11/8/23,,"Levemir® vials will be available until the end of 2024. Full brand discontinuation, including Levemir® vials, will occur on December 31, 2024.",,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/23,0169-3687-12,discontinued
10539,Interferon Beta-1b Injection,Novartis Pharmaceuticals Corporation,"Extavia, Injection, 0.3 mg/mL (NDC 0078-0569-12)",New,6/23/23,,,,,Neurology,To Be Discontinued,6/23/23,6/23/23,0078-0569-12,discontinued
10540,Iobenguane I-131 Injection,Progenics Pharmaceuticals Inc.,"Azedra, Injection, 15 mCi/1 mL (NDC 71258-015-02)",New,8/23/23,,This product is being discontinued for lack of commercial demand.,,,Oncology,To Be Discontinued,8/23/23,8/23/23,71258-015-02,discontinued
10541,Iobenguane I-131 Injection,Progenics Pharmaceuticals Inc.,"Azedra, Injection, 15 mCi/1 mL (NDC 71258-015-22)",New,8/23/23,,This product is being discontinued for lack of commercial demand.,,,Oncology,To Be Discontinued,8/23/23,8/23/23,71258-015-22,discontinued
10542,Isoniazid Injection,Sandoz Inc.,"Isoniazid, Injection, 100 mg/1 mL (NDC 0781-3056-70)",Revised,9/20/23,,,Available,,Anti-Infective,Resolved,9/20/23,,0781-3056-70,
10543,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0555-0066-02)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,0555-0066-02,available
10544,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-02)",Revised,12/19/23,Limited Supply Available,,,Demand increase for the drug,Anti-Infective,Current,,,0555-0071-02,limited availability
10545,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-01)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,0555-0071-01,available
10546,Itraconazole Capsule,"Par Pharmaceutical, Inc.","Itraconazole, Capsule, 100 mg (NDC 49884-239-11)",New,9/14/23,,Business decision to discontinue manufacturing of the drug,,,Anti-Infective; Other,To Be Discontinued,9/14/23,9/14/23,49884-239-11,discontinued
10547,Itraconazole Solution,Janssen Research and Development,"Sporanox, Solution, 10 mg/1 mL (NDC 50458-295-15)",New,3/21/23,,Business decision to discontinue manufacturing of this product.,,,Anti-Infective; Other,To Be Discontinued,3/21/23,3/21/23,50458-295-15,discontinued
10548,Itraconazole Solution,Janssen Research and Development,"Sporanox, Solution, 10 mg/1 mL (NDC 10147-0150-1)",New,3/21/23,,Distributed by Patriot Pharmaceuticals. Business decision to discontinue manufacturing of this product.,,,Anti-Infective; Other,To Be Discontinued,3/21/23,3/21/23,10147-0150-1,discontinued
10549,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 25021-682-20)",Reverified,12/19/23,Tentatively available by end of October 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,25021-682-20,not available
10550,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 25021-683-10)",Reverified,12/19/23,Available by September 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,25021-683-10,not available
10551,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 25021-684-05)",Reverified,12/19/23,Tentatively available by end of October 2023,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,Regulatory delay,Anesthesia,Current,,,25021-684-05,not available
10552,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0143-9508-10)",Revised,12/19/23,This presentation is on backorder.,Recovery: TBD,,Demand increase for the drug,Anesthesia,Current,,,0143-9508-10,not available
10553,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 0143-9509-10)",Revised,12/19/23,This presentation is on backorder.,Recovery: TBD,,Demand increase for the drug,Anesthesia,Current,,,0143-9509-10,not available
10554,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 mg/1 mL (NDC 42023-113-10)",Revised,12/19/23,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,42023-113-10,not available
10555,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 mg/1 mL (NDC 42023-115-10)",Revised,12/19/23,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,42023-115-10,not available
10556,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 mg/1 mL (NDC 42023-114-10)",Revised,12/19/23,This presentation is on backorder.,Recovery: TBD,,Shortage of an active ingredient,Anesthesia,Current,,,42023-114-10,not available
10557,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-438-10)",Revised,12/20/23,Currently on backorder - next shipment Jan,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,55150-438-10,not available
10558,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 50 mg/1 mL (NDC 55150-439-10)",Revised,12/20/23,Currently on backorder - next shipment TBD,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,55150-439-10,not available
10559,Ketamine Hydrochloride Injection,Eugia US LLC,"Injection, 100 mg/1 mL (NDC 55150-440-10)",Revised,12/20/23,Currently on backorder - next shipment TBD,Intermittent availability expected,,Demand increase for the drug,Anesthesia,Current,,,55150-440-10,not available
10560,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Injection, 100 mg/1 mL (NDC 0409-2051-05)",Reverified,12/19/23,Next Delivery and Estimated Recovery: December 2023,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-2051-05,not available
10561,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0409-2053-10)",Reverified,12/19/23,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-2053-10,not available
10562,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 15 mg/1 mL (NDC 63323-161-01)",Reverified,12/20/23,Available. Check wholesaler for inventory,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,63323-161-01,available
10563,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 63323-162-01)",Reverified,12/20/23,Backordered. Next release December 2023. Check wholesaler for inventory.,Check wholesaler for inventory.,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,63323-162-01,not available
10564,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 63323-162-02)",Reverified,12/20/23,Available,Check wholesaler for inventory.,,,Analgesia/Addiction,Current,,,63323-162-02,available
10565,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 15 mg/1 mL (NDC 70860-700-01)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-700-01,available
10566,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-01)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-01,available
10567,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-02)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-02,available
10568,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 15 mg/1 mL (NDC 25021-700-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,25021-700-01,available
10569,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 25021-701-02)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,25021-701-02,available
10570,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 25021-701-01)",Reverified,12/19/23,Available,,,,Analgesia/Addiction,Current,,,25021-701-01,available
10571,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,0409-3793-01,not available
10572,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,0409-3795-01,not available
10573,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 0409-3796-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Analgesia/Addiction,Current,,,0409-3796-01,not available
10574,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Reverified,12/19/23,Limited Supply; Recovery: May 2024,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0338-0069-10,limited availability
10575,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Reverified,5/16/23,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6041-25,unclear
10576,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Reverified,5/16/23,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6042-25,unclear
10577,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Reverified,5/16/23,"Unavailable, shortage recovery TBD.",,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6043-25,unclear
10578,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Reverified,12/19/23,Limited supply; Recovery: June 2024,FOR INTRAVENOUS AND INTRAMUSCULAR USE. 30mg/mL (1 mL fill volume/ 2 mL container),,Demand increase for the drug,Analgesia/Addiction,Current,,,0338-0072-25,limited availability
10579,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 15 mg/1 mL (NDC 76045-107-10)",Reverified,12/20/23,Not available at this time.,Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-107-10,not available
10580,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 30 mg/1 mL (NDC 76045-104-10)",Reverified,12/20/23,RFID NDC 76045-0209-10 release January 2024.,Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,76045-104-10,not available
10581,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Injection, 60 mg/2 mL (NDC 76045-105-20)",Reverified,12/20/23,Available,Check wholesaler for inventory,,,Analgesia/Addiction,Current,,,76045-105-20,available
10582,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 72266-118-25)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-118-25,available
10583,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 72266-119-25)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,72266-119-25,available
10584,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 15 mg/1 mL (NDC 62332-599-25)",Revised,12/19/23,Product available,,,,Analgesia/Addiction,Current,,,62332-599-25,available
10585,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 30 mg/1 mL (NDC 62332-600-25)",Revised,12/19/23,Product available,,,,Analgesia/Addiction,Current,,,62332-600-25,available
10586,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 60 mg/2 mL (NDC 62332-601-25)",Revised,12/19/23,Product available,,,,Analgesia/Addiction,Current,,,62332-601-25,available
10587,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-03)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-03,available
10588,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 15 mg/1 mL (NDC 70860-700-02)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-700-02,available
10589,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Injection, 30 mg/1 mL (NDC 70860-701-04)",Revised,12/19/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,70860-701-04,available
10590,"Ketorolac Tromethamine Tablet, Film Coated",Virtus Pharmaceuticals,"Ketorolac Tromethamine, Tablet, Film Coated, 10 mg (NDC 69543-388-10)",Revised,6/6/23,Available,,,,Analgesia/Addiction,Current,,,69543-388-10,available
10591,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Revised,12/19/23,Replenishment due in January,,,Demand increase for the drug,Oncology; Pediatric,Current,,,25021-828-50,not available
10592,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mg/5 mL (NDC 0143-9555-01)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9555-01,not available
10593,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 100 mg/10 mL (NDC 0143-9554-01)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9554-01,not available
10594,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 200 mg/20 mL (NDC 0143-9553-01)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9553-01,not available
10595,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Reverified,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the December 2023 - January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Oncology; Pediatric,Current,,,0143-9552-01,not available
10596,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Reverified,12/20/23,Next release February 2024.  Check wholesalers for inventory.,Check wholesalers for inventory.,,Delay in shipping of the drug,Oncology; Pediatric,Current,,,63323-631-10,not available
10597,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Reverified,12/20/23,Next release January 2024. Check wholesaler for inventory.,Check wholesalers for inventory.,,Delay in shipping of the drug,Oncology; Pediatric,Current,,,63323-631-50,not available
10598,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Reverified,12/21/23,Re-supply in January 2024,,,Demand increase for the drug,Oncology; Pediatric,Current,,,67457-528-10,not available
10599,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Reverified,12/21/23,Available,,,Demand increase for the drug,Oncology; Pediatric,Current,,,67457-529-20,available
10600,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Reverified,12/21/23,Available,,,Demand increase for the drug,Oncology; Pediatric,Current,,,67457-530-35,available
10601,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-256-50)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-256-50,available
10602,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 15 mg/1 mL (NDC 0409-4776-01)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4776-01,available
10603,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/mL (NDC 55150-251-10)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-251-10,available
10604,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/mL (NDC 55150-252-20)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-252-20,available
10605,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-254-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-254-10,available
10606,Lidocaine Hydrochloride Injection,Eugia US LLC,"Injection, 20 mg/mL (NDC 55150-255-20)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-255-20,available
10607,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Revised,3/24/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9595-25,not available
10608,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Revised,3/24/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9594-25,not available
10609,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Revised,3/24/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the May timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9577-10,not available
10610,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Revised,3/24/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the April timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9575-10,not available
10611,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, LLC","Injection, 10 mg/1 mL (NDC 65282-1605-1)",Reverified,12/20/23,Available,,,,Anesthesia,Current,,,65282-1605-1,available
10612,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/mL (NDC 55150-158-72)",Reverified,12/19/23,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,not available
10613,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-159-74)",Revised,11/1/23,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,not available
10614,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 55150-160-72)",Reverified,12/19/23,On long term backorder,Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,not available
10615,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-161-02)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-161-02,available
10616,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-162-05)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-162-05,available
10617,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 55150-163-30)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-163-30,available
10618,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/mL (NDC 55150-164-02)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-164-02,available
10619,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 55150-165-05)",Reverified,12/19/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-165-05,available
10620,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Revised,11/29/23,Not available at this time.,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-492-31,not available
10621,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Reverified,12/20/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-484-57,not available
10622,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-491-57,available
10623,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-201-02,available
10624,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-201-10,available
10625,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-485-27,available
10626,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-485-57,available
10627,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-27,available
10628,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-57,available
10629,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-37,available
10630,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-9137-05)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-9137-05,not available
10631,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0409-4713-32)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-32,available
10632,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-4276-01)",Revised,9/11/23,Limited Supply Available. Next Delivery: October 2023; Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4276-01,limited availability
10633,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-4279-02)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: March 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4279-02,limited availability
10634,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 0409-4276-02)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia; Pediatric,Current,,,0409-4276-02,limited availability
10635,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4282-01)",Revised,9/11/23,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4282-01,limited availability
10636,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4282-02)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4282-02,available
10637,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-4904-34)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4904-34,not available
10638,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-4903-34)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4903-34,not available
10639,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0409-2066-05)",Revised,9/11/23,Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anesthesia; Pediatric,Current,,,0409-2066-05,not available
10640,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-4277-01)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4277-01,available
10641,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-4277-02)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4277-02,not available
10642,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 40 mg/1 mL (NDC 0409-4283-01)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4283-01,available
10643,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 20 mg/1 mL (NDC 0409-1323-05)",Revised,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-1323-05,not available
10644,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Reverified,12/19/23,Available,old NDC 0548-3390-00,,,Anesthesia; Pediatric,Current,,,76329-3390-1,available
10645,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-493-97,not available
10646,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-493-91,not available
10647,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-202-02,available
10648,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-208-05,available
10649,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-486-17,available
10650,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-486-27,available
10651,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-486-57,available
10652,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-495-27,available
10653,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Revised,11/29/23,Available,,,,Anesthesia; Pediatric,Current,,,63323-495-07,available
10654,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Revised,11/29/23,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-496-97,not available
10655,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 5 mg/1 mL (NDC 0409-4275-01)",Revised,9/11/23,Next Delivery: October 2024; Estimated Recovery: December 2024,Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Pediatric,Current,,,0409-4275-01,not available
10656,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-4278-01)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4278-01,available
10657,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,0338-0409-03,available
10658,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Reverified,12/21/23,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
10659,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 10 mg/1 mL (NDC 0409-4713-02)",Revised,9/11/23,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-02,available
10660,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-001-10,available
10661,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-002-10,available
10662,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-003-10,available
10663,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-004-10,available
10664,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-005-10,available
10665,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-006-10,available
10666,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Revised,3/29/23,Available,,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,83090-007-10,available
10667,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Revised,10/3/23,Available,,,,Anesthesia,Current,,,73293-0001-2,available
10668,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Injection, 10 mg/1 mL (NDC 50102-400-10)",New,11/2/23,Available,"Inventory available through ANDA, ASD Healthcare, Henry Schein, McKesson Medical-Surgical and R&S",,,Anesthesia; Pediatric,Current,,,50102-400-10,available
10669,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous, Solution, 20 mg/1 mL (NDC 0054-3500-49)",Reverified,12/19/23,Available to current customers,,,Demand increase for the drug,Anesthesia,Current,,,0054-3500-49,limited availability
10670,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous, Solution, 20 mg/1 mL (NDC 0054-0548-44)",Reverified,12/19/23,Available to current customers,,,Demand increase for the drug,Anesthesia,Current,,,0054-0548-44,limited availability
10671,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings LLC,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Reverified,11/2/23,Available,Product available in all wholesalers,,,Anesthesia,Current,,,62135-712-42,available
10672,Lidocaine Patch,Endo Pharmaceuticals. Inc.,"Lidoderm, Patch, 50 mg/1 g (NDC 63481-687-06)",New,1/25/23,,Permanent discontinuation on 1/18/2023,,,Analgesia/Addiction,To Be Discontinued,1/25/23,1/25/23,63481-687-06,discontinued
10673,"Linezolid Tablet, Film Coated",Pfizer Inc.,"Zyvox, Tablet, Film Coated, 600 mg (NDC 0009-5138-02)",New,8/3/23,,Supply expected to exhaust late September 2023; Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,8/3/23,8/3/23,0009-5138-02,discontinued
10674,Liothyronine Sodium Injection,Par Sterile Products LLC,"Triostat, Injection, 10 ug/1 mL (NDC 42023-120-01)",Revised,2/23/23,,,,,Endocrinology/Metabolism,To Be Discontinued,2/23/23,2/23/23,42023-120-01,discontinued
10675,Liothyronine Sodium Injection,Par Sterile Products LLC,"Triostat, Injection, 10 ug/1 mL (NDC 42023-120-06)",New,2/23/23,,,,,Endocrinology/Metabolism,To Be Discontinued,2/23/23,2/23/23,42023-120-06,discontinued
10676,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Revised,12/11/23,Limited availability,Limited availability through the end of 2023,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-2800-15,limited availability
10677,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-101-10,available
10678,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-102-10,available
10679,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-103-10,available
10680,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-104-10,available
10681,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-105-10,available
10682,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-106-10,available
10683,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-107-10,available
10684,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 10 mg (NDC 60505-4739-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4739-1,limited availability
10685,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 20 mg (NDC 60505-4740-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4740-1,limited availability
10686,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 30 mg (NDC 60505-4741-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4741-1,limited availability
10687,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 40 mg (NDC 60505-4742-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4742-1,limited availability
10688,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 50 mg (NDC 60505-4743-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4743-1,limited availability
10689,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 60 mg (NDC 60505-4744-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4744-1,limited availability
10690,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 70 mg (NDC 60505-4745-1)",Reverified,12/20/23,Currently available in limited quantities,,,Shortage of an active ingredient,Psychiatry,Current,,,60505-4745-1,limited availability
10691,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 10 mg (NDC 0378-6854-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6854-77,limited availability
10692,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 20 mg (NDC 0378-6855-77)",Reverified,12/21/23,Allocating limited inventory,Allocating limited inventory,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6855-77,limited availability
10693,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 30 mg (NDC 0378-6856-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6856-77,limited availability
10694,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 40 mg (NDC 0378-6857-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6857-77,limited availability
10695,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 50 mg (NDC 0378-6858-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6858-77,limited availability
10696,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 60 mg (NDC 0378-6859-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6859-77,limited availability
10697,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Capsule, 70 mg (NDC 0378-6860-77)",Reverified,12/21/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0378-6860-77,limited availability
10698,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 10 mg (NDC 57664-046-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-046-88,available
10699,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 mg (NDC 57664-048-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-048-88,available
10700,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 mg (NDC 57664-048-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-048-88,available
10701,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 40 mg (NDC 57664-049-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-049-88,available
10702,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 50 mg (NDC 57664-050-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-050-88,available
10703,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 60 mg (NDC 57664-051-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-051-88,available
10704,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 70 mg (NDC 57664-052-88)",Reverified,12/19/23,Available,,,Demand increase for the drug,Psychiatry,Current,,,57664-052-88,available
10705,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 10 mg (NDC 0406-5111-01)",Reverified,12/19/23,Available,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5111-01,available
10706,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 20 mg (NDC 0406-5112-01)",Reverified,12/19/23,Available; Shortage anticipated in December 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5112-01,limited availability
10707,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 30 mg (NDC 0406-5113-01)",Reverified,12/19/23,Available; Shortage anticipated in January 2024,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5113-01,limited availability
10708,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 40 mg (NDC 0406-5114-01)",Reverified,12/19/23,Available; Shortage anticipated in October 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5114-01,limited availability
10709,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 50 mg (NDC 0406-5115-01)",Revised,12/19/23,"On backorder, Estimated shortage duration December 2023",,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5115-01,not available
10710,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 60 mg (NDC 0406-5116-01)",Reverified,12/19/23,Available; Shortage anticipated in September 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5116-01,limited availability
10711,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Capsule, 70 mg (NDC 0406-5117-01)",Reverified,12/19/23,Available; Shortage anticipated in December 2023,,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5117-01,limited availability
10712,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 20 mg (NDC 0054-0370-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0370-25,limited availability
10713,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 30 mg (NDC 0054-0371-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0371-25,limited availability
10714,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 40 mg (NDC 0054-0372-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0372-25,limited availability
10715,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 50 mg (NDC 0054-0373-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0373-25,limited availability
10716,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 60 mg (NDC 0054-0374-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0374-25,limited availability
10717,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Capsule, 70 mg (NDC 0054-0375-25)",Reverified,12/19/23,Allocating limited supply,,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0375-25,limited availability
10718,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 10 mg (NDC 0527-4661-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4661-37,limited availability
10719,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 20 mg (NDC 0527-4662-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4662-37,limited availability
10720,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 30 mg (NDC 0527-4663-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4663-37,limited availability
10721,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 40 mg (NDC 0527-4664-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4664-37,limited availability
10722,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 50 mg (NDC 0527-4665-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4665-37,limited availability
10723,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 60 mg (NDC 0527-4666-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4666-37,limited availability
10724,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 70 mg (NDC 0527-4667-37)",Reverified,12/19/23,Allocating limited inventory,,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4667-37,limited availability
10725,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 20 mg (NDC 65162-023-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-023-09,limited availability
10726,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 30 mg (NDC 65162-024-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-024-09,limited availability
10727,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 40 mg (NDC 65162-025-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-025-09,limited availability
10728,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 50 mg (NDC 65162-026-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-026-09,limited availability
10729,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 60 mg (NDC 65162-027-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-027-09,limited availability
10730,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 70 mg (NDC 65162-028-09)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,65162-028-09,limited availability
10731,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 10 mg (NDC 43547-602-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-602-10,limited availability
10732,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 20 mg (NDC 43547-603-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-603-10,limited availability
10733,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 30 mg (NDC 43547-604-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-604-10,limited availability
10734,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 40 mg (NDC 43547-605-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-605-10,limited availability
10735,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 50 mg (NDC 43547-606-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-606-10,limited availability
10736,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 60 mg (NDC 43547-607-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-607-10,limited availability
10737,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Capsule, 70 mg (NDC 43547-608-10)",Reverified,12/19/23,On allocation,,,Shortage of an active ingredient,Psychiatry,Current,,,43547-608-10,limited availability
10738,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 10 mg (NDC 57664-083-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-083-88,available
10739,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 20 mg (NDC 57664-084-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-084-88,available
10740,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 30 mg (NDC 57664-085-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-085-88,available
10741,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 50 mg (NDC 57664-087-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-087-88,available
10742,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 60 mg (NDC 57664-088-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-088-88,available
10743,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 40 mg (NDC 57664-086-88)",Reverified,12/19/23,Available,,,,Psychiatry,Current,,,57664-086-88,available
10744,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-115-01,available
10745,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-116-01,available
10746,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-117-01,available
10747,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-118-01,available
10748,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-119-01,available
10749,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,59417-120-01,available
10750,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 mg (NDC 0378-1300-01)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1300-01,discontinued
10751,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 mg (NDC 0378-1300-05)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1300-05,discontinued
10752,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Lithium Carbonate, Tablet, Extended Release, 450 mg (NDC 0378-1450-01)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1450-01,discontinued
10753,Lithium Citrate Solution,"Hikma Pharmaceuticals USA, Inc. (formerly West-Ward)","Lithium Citrate, Solution, 8 meq/5 mL (NDC 0054-3527-63)",Revised,1/30/23,,Discontinued,,,Psychiatry,To Be Discontinued,1/30/23,1/30/23,0054-3527-63,discontinued
10754,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5745-02)",Revised,2/3/23,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/23,2/3/23,0024-5745-02,discontinued
10755,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection, 100 ug/1 mL (NDC 0024-5747-02)",Revised,2/3/23,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/23,2/3/23,0024-5747-02,discontinued
10756,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5741-01)",Revised,2/3/23,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/23,2/3/23,0024-5741-01,discontinued
10757,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5740-00)",Revised,2/3/23,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/23,2/3/23,0024-5740-00,discontinued
10758,Lixisenatide Injection,Sanofi-Aventis U.S. LLC,"Adlyxin, Injection,  (NDC 0024-5740-00)",Revised,2/3/23,,Product expiry date is 9/30/2023 (Marketing End Date),,,Endocrinology/Metabolism,To Be Discontinued,2/3/23,2/3/23,0024-5740-00,discontinued
10759,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-6778-02)",New,7/18/23,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,7/18/23,7/18/23,0409-6778-02,discontinued
10760,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Revised,11/9/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the November - December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6001-25,not available
10761,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Revised,11/9/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6000-10,not available
10762,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Revised,11/9/23,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,0641-6003-25,available
10763,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,11/9/23,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,0641-6002-10,available
10764,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Revised,11/9/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the November - December 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6044-25,not available
10765,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Revised,11/9/23,This presentation is temporarily on backorder.,Additional lots are scheduled for manufacturing and will be available in the January 2024 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Neurology,Current,,,0641-6046-10,not available
10766,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Revised,11/9/23,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,0641-6045-25,available
10767,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,11/9/23,Inventory is currently available.,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Neurology,Current,,,0641-6002-10,available
10768,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-1985-30)",Reverified,9/11/23,Available,,,,Neurology,Current,,,0409-1985-30,available
10769,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL (NDC 0409-6778-02)",Reverified,9/11/23,Discontinued,,,,Neurology,Current,,,0409-6778-02,discontinued
10770,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 2 mg/1 mL (NDC 76329-8261-1)",Reverified,12/19/23,Available,,,,Neurology,Current,,,76329-8261-1,available
10771,Lutetium Lu-177 Vipivotide Tetraxetan Injection,"Advanced Accelerator Applications USA, Inc.","Pluvicto, Injection, 27 mCi/1 mL (NDC 69488-010-61)",Revised,10/25/23,Available,Available,Available,,Oncology,Resolved,10/25/23,,69488-010-61,available
10772,Mafenide Acetate Solution,"Par Pharmaceutical, Inc.","Solution, 50 g (NDC 49884-902-78)",New,11/30/23,,,,Discontinuation of the manufacture of the drug,Dermatology,To Be Discontinued,,11/30/23,49884-902-78,discontinued
10773,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 20 g/100 mL (NDC 0338-0357-02)",Reverified,12/21/23,Available,,,,Renal,Current,,,0338-0357-02,available
10774,Mannitol Injection,B. Braun Medical Inc.,"Injection, 20 g/100 mL (NDC 0264-7578-20)",Reverified,12/19/23,Available,,,,Renal,Current,,,0264-7578-20,available
10775,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 0.1 (NDC 0338-0535-03)",Reverified,12/19/23,Available,,,,Renal,Current,,,0338-0535-03,available
10776,Mannitol Injection,Baxter Healthcare,"Osmitrol, Injection, 20 g/100 mL (NDC 0338-0357-03)",Reverified,12/21/23,Available,,,,Renal,Current,,,0338-0357-03,available
10777,Mannitol Injection,"ICU Medical, Inc.","Mannitol 20% In Plastic Container, Injection, 20 g/100 mL (NDC 0990-7715-03)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7715-03",,,Renal,Current,,,0990-7715-03,available
10778,Mannitol Injection,"ICU Medical, Inc.","Mannitol 20% In Plastic Container, Injection, 20 g/100 mL (NDC 0990-7715-02)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7715-02",,,Renal,Current,,,0990-7715-02,available
10779,Mannitol Injection,"Fresenius Kabi USA, LLC","Mannitol 25%, Injection, 250 mg/1 mL (NDC 63323-024-25)",Reverified,12/20/23,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Renal,Current,,,63323-024-25,not available
10780,Mannitol Injection,"Hospira, Inc., a Pfizer Company","Mannitol, Injection, 12.5 g/50 mL (NDC 0409-4031-01)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Renal,Current,,,0409-4031-01,not available
10781,"Maraviroc Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Selzentry, Tablet, Film Coated, 25 mg (NDC 49702-233-08)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Selzentry 150mg (49702-223-18), Selzentry 300 mg (49702-224-18) and Selzentry Oral Solution (49702-260-55) will still be available.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-233-08,discontinued
10782,"Maraviroc Tablet, Film Coated",GlaxoSmithKline (ViiV Healthcare),"Selzentry, Tablet, Film Coated, 75 mg (NDC 49702-235-08)",New,1/3/23,,"The anticipated date that GSK will cease distribution of the product is approximately January 1, 2024.  Selzentry 150mg (49702-223-18), Selzentry 300 mg (49702-224-18) and Selzentry Oral Solution (49702-260-55) will still be available.",,,Antiviral,To Be Discontinued,1/3/23,1/3/23,49702-235-08,discontinued
10783,Mebrofenin Injection,"Sun Pharmaceutical Industries, Inc.","Technetium Tc-99m Mebrofenin, Injection, 45 mg/10 mL (NDC 45567-0455-1)",Revised,8/10/23,,,Available,,Medical Imaging,Resolved,8/10/23,,45567-0455-1,
10784,Mebrofenin Injection,"Sun Pharmaceutical Industries, Inc.","Technetium Tc-99m Mebrofenin, Injection, 45 mg/10 mL (NDC 45567-0455-2)",Revised,8/10/23,,,Available,,Medical Imaging,Resolved,8/10/23,,45567-0455-2,
10785,Mebrofenin Injection,Bracco Diagnostics,"Choletec, Injection, 45 mg (NDC 0270-0083-20)",Revised,8/10/23,,,Available,,Medical Imaging,Resolved,8/10/23,,0270-0083-20,
10786,Memantine Hydrochloride Capsule,AbbVie Inc.,"Namenda, Capsule, 7 mg/14 mg/21 mg/28 mg (NDC 0456-3200-14)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3200-14,discontinued
10787,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 7 mg (NDC 0456-3407-33)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3407-33,discontinued
10788,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 14 mg (NDC 0456-3414-33)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3414-33,discontinued
10789,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 14 mg (NDC 0456-3414-90)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3414-90,discontinued
10790,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 21 mg (NDC 0456-3421-33)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3421-33,discontinued
10791,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 28 mg (NDC 0456-3428-33)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3428-33,discontinued
10792,"Memantine Hydrochloride Capsule, Extended Release",AbbVie Inc.,"Namenda Xr, Capsule, Extended Release, 28 mg (NDC 0456-3428-90)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3428-90,discontinued
10793,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 5 mg (NDC 0456-3205-63)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3205-63,discontinued
10794,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 10 mg (NDC 0456-3210-60)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3210-60,discontinued
10795,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 10 mg (NDC 0456-3210-63)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3210-63,discontinued
10796,Memantine Hydrochloride Tablet,AbbVie Inc.,"Namenda, Tablet, 5 mg/10 mg (NDC 0456-3200-14)",New,7/11/23,,,,,Neurology,To Be Discontinued,7/11/23,7/11/23,0456-3200-14,discontinued
10797,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine, Injection, 10 mg/1 mL (NDC 63323-283-57)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-283-57,available
10798,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine, Injection, 20 mg/1 mL (NDC 63323-296-57)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-296-57,available
10799,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 10 mg/1 mL (NDC 63323-260-37)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-260-37,available
10800,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 15 mg/1 mL (NDC 63323-293-37)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-293-37,available
10801,Mepivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Polocaine-mpf, Injection, 20 mg/1 mL (NDC 63323-294-27)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-294-27,available
10802,"Mesalamine Capsule, Delayed Release",AbbVie Inc.,"Delzicol, Capsule, Delayed Release, 400 mg (NDC 0023-5853-18)",New,10/25/23,,Sales expected to last until June 2024,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,10/25/23,0023-5853-18,discontinued
10803,"Mesalamine Capsule, Delayed Release",AbbVie Inc.,"Capsule, Delayed Release, 400 mg (NDC 59762-0117-1)",New,10/25/23,,Sales expected to last until June 2024,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,10/25/23,59762-0117-1,discontinued
10804,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 2.5 mg (NDC 0310-6125-60)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6125-60,discontinued
10805,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 500 mg; 5 mg (NDC 0310-6135-30)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6135-30,discontinued
10806,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 5 mg (NDC 0310-6145-30)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6145-30,discontinued
10807,"Metformin Hydrochloride, Saxagliptin Hydrochloride Tablet, Film Coated, Extended Release",AstraZeneca Pharmaceuticals LP,"Kombiglyze Xr, Tablet, Film Coated, Extended Release, 1000 mg; 5 mg (NDC 0310-6145-95)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6145-95,discontinued
10808,Methamphetamine Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 5 mg (NDC 68308-115-01)",Revised,12/19/23,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,68308-115-01,not available
10809,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 5 mg (NDC 0054-0389-25)",Revised,12/19/23,Currently unavailable,,,,Psychiatry,Current,,,0054-0389-25,not available
10810,Methamphetamine Hydrochloride Tablet,"Key Therapeutics, Inc.","Desoxyn, Tablet, 5 mg (NDC 70868-820-05)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,70868-820-05,available
10811,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 15 mg/.6 mL (NDC 66220-815-22)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-815-22,discontinued
10812,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 15 mg/0.6 mL (NDC 66220-815-11)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-815-11,discontinued
10813,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 20 mg/.8 mL (NDC 66220-820-22)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-820-22,discontinued
10814,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 20 mg/0.8 mL (NDC 66220-820-11)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-820-11,discontinued
10815,Methotrexate Injection,Nordic Group BV,"Reditrex, Injection, 25 mg/1 mL (NDC 66220-825-22)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,Discontinuation of the manufacture of the drug,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-825-22,discontinued
10816,Methotrexate Injection,Nordic Group BV,"RediTrex, Injection, 25 mg/mL (NDC 66220-825-11)",New,6/13/23,,Expiry of last lot marketed: 2023-10-31,,,Dermatology; Rheumatology,To Be Discontinued,6/13/23,6/13/23,66220-825-11,discontinued
10817,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Reverified,12/19/23,Temporarily on backorder.,Additional lots will be available in the September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Rheumatology; Oncology,Current,,,0143-9830-01,not available
10818,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Reverified,12/19/23,Temporarily on backorder.,Additional lots will be available in the August â€“ September 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Rheumatology; Oncology,Current,,,0143-9519-10,not available
10819,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Reverified,12/19/23,Available,,,,Rheumatology; Oncology,Current,,,0703-3671-01,available
10820,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Reverified,12/19/23,Available,,,,Rheumatology; Oncology,Current,,,0703-3675-01,available
10821,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Reverified,12/19/23,Available,,,,Rheumatology; Oncology,Current,,,0703-3678-01,available
10822,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-38)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Rheumatology; Oncology,Current,,,61703-350-38,limited availability
10823,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-10)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023Estimated recovery: September 2023,,,,Rheumatology; Oncology,Current,,,61703-350-10,limited availability
10824,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-41)",Reverified,12/19/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,61703-408-41,limited availability
10825,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-25)",Reverified,12/19/23,Next Delivery: September 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,61703-408-25,not available
10826,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate, Injection, 25 mg/1 mL (NDC 61703-124-40)",Reverified,12/19/23,Next Delivery: October 2023; Estimated Recovery: December 2023,,,Demand increase for the drug,Rheumatology; Oncology,Current,,,61703-124-40,not available
10827,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Reverified,12/20/23,Available,Available. Check wholesaler for inventory,,,Rheumatology; Oncology,Current,,,63323-122-50,available
10828,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 25 mg/1 mL (NDC 63323-123-10)",Reverified,12/20/23,Available,Available. Check wholesaler for inventory.,,,Rheumatology; Oncology,Current,,,63323-123-10,available
10829,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Revised,11/7/23,"Limited Availability, Manufacturing resumed",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,16729-277-30,available
10830,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-03)",Reverified,12/19/23,"Not Available, Manufacturing pending",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,16729-277-03,not available
10831,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Revised,11/7/23,"Limited Availability, Manufacturing resumed",,,Demand increase for the drug,Rheumatology; Oncology,Current,,,16729-277-35,available
10832,Methotrexate Sodium Tablet,Eugia US LLC,"Methotrexate Sodium, Tablet, 2.5 mg (NDC 59651-182-01)",Revised,12/20/23,On allocation,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,59651-182-01,limited availability
10833,Methotrexate Sodium Tablet,Accord Healthcare Inc.,"Tablet, 2.5 mg (NDC 16729-486-01)",Revised,12/20/23,"Stock Available; Inventory allocating to orders, > 365 days coverage","Manufacturing resumed, manufacturing and packaging plans being put together.",,,Rheumatology; Dermatology; Dental; Oncology,Current,,,16729-486-01,limited availability
10834,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 mg (NDC 47335-235-83)",Revised,12/19/23,Limited Availability. Additional POâ€™s are in the pipeline,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,47335-235-83,limited availability
10835,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 mg (NDC 47335-235-96)",Revised,12/19/23,Limited Availability. Additional POâ€™s are in the pipeline,,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,47335-235-96,limited availability
10836,Methotrexate Sodium Tablet,"Hikma Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0054-4550-25)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,0054-4550-25,available
10837,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0555-0572-02)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,0555-0572-02,available
10838,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 2.5 mg (NDC 0555-0572-35)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,0555-0572-35,available
10839,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 5 mg (NDC 51285-366-01)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,51285-366-01,available
10840,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 7.5 mg (NDC 51285-367-01)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,51285-367-01,available
10841,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 10 mg (NDC 51285-368-01)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,51285-368-01,available
10842,Methotrexate Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Trexall, Tablet, 15 mg (NDC 51285-369-01)",Revised,12/19/23,Available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,51285-369-01,available
10843,Methotrexate Sodium Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Tablet, 2.5 mg (NDC 0378-0014-01)",Reverified,12/21/23,Available on allocation,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,0378-0014-01,limited availability
10844,Methotrexate Sodium Tablet,Zydus Pharmaceuticals USA Inc.,"Tablet, 2.5 mg (NDC 68382-775-01)",Revised,12/19/23,Currently available,,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,68382-775-01,available
10845,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 69238-1423-6)",Reverified,12/19/23,"Not commercialized, N/A",Non-preferred customer packaging configuration,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,69238-1423-6,not available
10846,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 69238-1423-1)",Reverified,12/19/23,Supplying existing customers with possibility to expand mid-Novemebr 2023,Supplying existing customers with possibility to expand mid-Novemebr 2023,,,Rheumatology; Dermatology; Dental; Oncology,Current,,,69238-1423-1,limited availability
10847,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 42291-505-01)",Reverified,12/19/23,"Not commercialized, N/A",Labeler is AvKARE,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,42291-505-01,not available
10848,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 mg (NDC 50268-527-15)",Reverified,12/19/23,"Not commercialized, N/A",Labeler is AvPAK,,Demand increase for the drug,Rheumatology; Dermatology; Dental; Oncology,Current,,,50268-527-15,not available
10849,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 mg (NDC 16729-030-01)",Revised,11/2/23,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,16729-030-01,unclear
10850,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 mg (NDC 16729-030-16)",Revised,11/2/23,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,16729-030-16,unclear
10851,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 mg (NDC 16729-031-01)",Revised,11/2/23,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,16729-031-01,unclear
10852,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 mg (NDC 16729-031-16)",Revised,11/2/23,No additional lots are anticipated at this time.,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,16729-031-16,unclear
10853,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,62175-310-37,available
10854,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Revised,12/19/23,Out of Stock; new lot available in December 2023,,,Demand increase for the drug,Psychiatry,Current,,,62175-311-37,not available
10855,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Revised,12/19/23,Out of Stock; new lot available in December 2023,,,Demand increase for the drug,Psychiatry,Current,,,62175-312-37,not available
10856,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Revised,12/19/23,Out of Stock; new lot available in November 2023,,,Demand increase for the drug,Psychiatry,Current,,,62175-313-37,not available
10857,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,62037-725-01,available
10858,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,62037-734-01,available
10859,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,62037-726-01,available
10860,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,62037-727-01,available
10861,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Revised,12/19/23,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,43598-438-01,not available
10862,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Revised,12/19/23,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,43598-439-01,not available
10863,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Revised,12/19/23,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,43598-440-01,not available
10864,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Revised,12/19/23,"Unavailable, Currently unavailable. Estimated shortage duration is January 2024",,,Shortage of an active ingredient,Psychiatry,Current,,,43598-441-01,not available
10865,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-706-10,available
10866,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-707-10,available
10867,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-708-10,available
10868,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Relexxii, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-711-30,available
10869,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-709-10,available
10870,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Relexxii, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-700-30,available
10871,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,13811-710-30,available
10872,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,50458-585-01,available
10873,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,50458-588-01,available
10874,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,50458-586-01,available
10875,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Revised,12/19/23,Available,,,,Psychiatry,Current,,,50458-587-01,available
10876,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Revised,12/19/23,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,57664-606-88,discontinued
10877,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Revised,12/19/23,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,57664-607-88,discontinued
10878,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Revised,12/19/23,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,57664-608-88,discontinued
10879,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Revised,12/19/23,Not currently marketing,,,Delay in shipping of the drug,Psychiatry,Current,,,57664-609-88,discontinued
10880,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Revised,12/19/23,On backorder through November 2023,,,Demand increase for the drug,Psychiatry,Current,,,0406-1445-01,not available
10881,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Revised,12/19/23,Supply available to current customers only,,,,Psychiatry,Current,,,0406-1473-01,limited availability
10882,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Revised,12/19/23,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,0406-0127-01,limited availability
10883,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Revised,12/19/23,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,0406-0136-01,limited availability
10884,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Revised,12/19/23,Available; Shipping on allocation to all customers,,,,Psychiatry,Current,,,0406-0154-01,limited availability
10885,Methylprednisolone Acetate Injection,Eugia US LLC,"Injection, 40 mg/1 mL (NDC 55150-313-01)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Rheumatology,Current,,,55150-313-01,available
10886,Methylprednisolone Acetate Injection,Eugia US LLC,"Injection, 80 mg/1 mL (NDC 55150-314-01)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Rheumatology,Current,,,55150-314-01,available
10887,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 mg/1 mL (NDC 25021-820-10)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,25021-820-10,available
10888,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 mg/1 mL (NDC 25021-820-05)",Reverified,12/19/23,Available.,,,,Rheumatology,Current,,,25021-820-05,available
10889,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 80 mg/1 mL (NDC 25021-821-05)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,25021-821-05,available
10890,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Injection, 80 mg/1 mL (NDC 42023-240-01)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,42023-240-01,available
10891,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,70121-1573-1,available
10892,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,70121-1573-5,available
10893,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,70121-1574-1,available
10894,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,70121-1574-5,available
10895,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-0274-01,available
10896,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-0280-02,available
10897,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Revised,12/19/23,Available,,,,Rheumatology,Current,,,0009-0280-03,available
10898,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-0280-51,available
10899,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-0280-52,available
10900,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Revised,12/19/23,Available,,,,Rheumatology,Current,,,0009-0306-02,available
10901,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-0306-12,available
10902,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3073-01,available
10903,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3073-03,available
10904,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3073-22,available
10905,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3073-23,available
10906,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3475-01,available
10907,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Reverified,12/19/23,Available,,,,Rheumatology,Current,,,0009-3475-03,available
10908,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-22)",Reverified,12/19/23,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing delay,,Demand increase for the drug,Rheumatology,Current,,,0009-3475-22,not available
10909,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-23)",Reverified,12/19/23,Next Delivery: February 2025; Estimated Recovery: March 2025,Shortage per Manufacturer: Manufacturing delay,,Demand increase for the drug,Rheumatology,Current,,,0009-3475-23,not available
10910,Methylprednisolone Tablet,Sandoz Inc.,"Methylprednisolone, Tablet, 4 mg (NDC 0781-5022-01)",New,2/14/23,,,,,Neurology,To Be Discontinued,2/14/23,2/14/23,0781-5022-01,discontinued
10911,Methylprednisolone Tablet,Sandoz Inc.,"Methylprednisolone, Tablet, 4 mg (NDC 0781-5022-07)",New,2/14/23,,,,,Neurology,To Be Discontinued,2/14/23,2/14/23,0781-5022-07,discontinued
10912,Metronidazole Gel,"Tolmar, Inc.","Metronidazole, Gel, 10 mg/1 g (NDC 0781-7080-35)",New,2/16/23,,,,,Dermatology,To Be Discontinued,2/16/23,2/16/23,0781-7080-35,discontinued
10913,Metronidazole Gel,"Tolmar, Inc.","Metronidazole, Gel, 10 mg/1 g (NDC 0781-7080-55)",New,2/16/23,,,,,Dermatology,To Be Discontinued,2/16/23,2/16/23,0781-7080-55,discontinued
10914,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Reverified,12/19/23,Available. On allocation.,,,Demand increase for the drug,Anti-Infective,Current,,,0264-5535-32,limited availability
10915,Metronidazole Injection,Baxter Healthcare,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Reverified,12/21/23,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
10916,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Reverified,12/19/23,Lots are anticipated in April; with additional inventory arriving in May.,,,Demand increase for the drug,Anti-Infective,Current,,,47335-993-01,limited availability
10917,Metronidazole Injection,"Hospira, Inc., a Pfizer Company","Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 0409-7811-37)",Revised,9/11/23,Discontinued,,,,Anti-Infective,Current,,,0409-7811-37,discontinued
10918,Metronidazole Injection,"Hospira, Inc., a Pfizer Company","Metronidazole In Plastic Container, Injection, 5 mg/1 mL (NDC 0409-0152-24)",Revised,9/11/23,Limited Supply Available. Next Delivery: September 2023; Estimated Recovery: December 2023,,,,Anti-Infective,Current,,,0409-0152-24,limited availability
10919,Metronidazole Injection,Pfizer Inc.,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 0409-7811-37)",New,4/6/23,,Supply expected to exhaust late May/early June 2023; Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,4/6/23,4/6/23,0409-7811-37,discontinued
10920,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Revised,11/2/23,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,44567-610-10,available
10921,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Revised,11/2/23,Available,,,,Anesthesia; Neurology,Current,,,44567-611-10,available
10922,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,70860-601-10,available
10923,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,70860-601-05,available
10924,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Reverified,3/10/23,No stock available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,47781-589-17,not available
10925,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,47781-589-91,available
10926,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,70860-600-02,available
10927,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Reverified,3/10/23,Available,,,Demand increase for the drug,Anesthesia; Neurology,Current,,,47781-588-68,available
10928,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-411-10,available
10929,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-001-20)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,76045-001-20,available
10930,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-12)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-411-12,available
10931,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-411-25)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-411-25,available
10932,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-25)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-412-25,available
10933,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-412-10,available
10934,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-412-02)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-412-02,available
10935,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0641-6056-10)",Revised,11/2/23,Available,,,,Anesthesia; Neurology,Current,,,0641-6056-10,available
10936,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0641-6057-25)",Revised,11/2/23,Available,,,,Anesthesia; Neurology,Current,,,0641-6057-25,available
10937,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/mL, 5 mL (NDC 0641-6059-25)",Revised,11/2/23,Available,,,,Anesthesia; Neurology,Current,,,0641-6059-25,available
10938,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/1 mL (NDC 0641-6061-25)",Revised,11/2/23,Unavailable,This presentation is temporarily on backorder.,,Demand increase for the drug,Anesthesia; Neurology,Current,,,0641-6061-25,not available
10939,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/1 mL (NDC 0641-6060-10)",Revised,11/2/23,Available,,,,Anesthesia; Neurology,Current,,,0641-6060-10,available
10940,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 1 mg/1 mL (NDC 0409-2305-17)",Reverified,9/11/23,Limited Supply Available.,,,,Anesthesia; Neurology,Current,,,0409-2305-17,limited availability
10941,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 1 mg/1 mL (NDC 0409-2305-05)",Reverified,9/11/23,Available,,,,Anesthesia; Neurology,Current,,,0409-2305-05,available
10942,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 0409-2308-01)",Reverified,9/11/23,Depleted,,,,Anesthesia; Neurology,Current,,,0409-2308-01,not available
10943,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-2596-05)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology,Current,,,0409-2596-05,not available
10944,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/1 mL (NDC 0409-2308-02)",Reverified,9/11/23,Depleted,,,,Anesthesia; Neurology,Current,,,0409-2308-02,not available
10945,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0409-2596-03)",Reverified,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Anesthesia; Neurology,Current,,,0409-2596-03,limited availability
10946,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-2587-05)",Reverified,9/11/23,Depleted,,,,Anesthesia; Neurology,Current,,,0409-2587-05,not available
10947,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 mg/1 mL (NDC 23155-601-42)",Revised,11/1/23,Available,,,,Anesthesia; Neurology,Current,,,23155-601-42,available
10948,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 mg/1 mL (NDC 23155-601-41)",Revised,11/1/23,Available,,,,Anesthesia; Neurology,Current,,,23155-601-41,available
10949,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 1 mg/1 mL (NDC 23155-600-41)",Revised,11/1/23,Available,,,,Anesthesia; Neurology,Current,,,23155-600-41,available
10950,Minocycline Extended Release Tablet,EPI Health,"Minolira, Extended Release Tablet, 135 mg (NDC 71403-102-30)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/2/23,71403-102-30,discontinued
10951,Minocycline Extended Release Tablets,EPI Health,"Minolira, Extended Release Tablets, 105mg (NDC 71403-101-30)",New,11/2/23,,,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/2/23,71403-101-30,discontinued
10952,"MINOCYCLINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE",Journey Medical Corporation,"XIMINO, CAPSULE, EXTENDED RELEASE, 45 mg (NDC 69489-121-30)",New,9/29/23,,Discontinuation due to business reasons.,,Discontinuation of the manufacture of the drug,Antibiotic,To Be Discontinued,,9/29/23,69489-121-30,discontinued
10953,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 45 mg (NDC 0781-5385-31)",New,6/28/23,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/23,6/28/23,0781-5385-31,discontinued
10954,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 90 mg (NDC 0781-5386-31)",New,6/28/23,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/23,6/28/23,0781-5386-31,discontinued
10955,"Minocycline Hydrochloride Tablet, Extended Release",Sandoz Inc.,"Minocycline Hydrochloride, Tablet, Extended Release, 135 mg (NDC 0781-5387-31)",New,6/28/23,,Discontinuing due to a business decision.,,,Anti-Infective,To Be Discontinued,6/28/23,6/28/23,0781-5387-31,discontinued
10956,Montelukast Sodium Granule,"Teva Pharmaceuticals USA, Inc.","Montelukast Sodium, Granule, 4 mg (NDC 0093-7487-56)",New,6/6/23,,,,,Pulmonary/Allergy,To Be Discontinued,6/6/23,6/6/23,0093-7487-56,discontinued
10957,Montelukast Sodium Granules,"Teva Pharmaceuticals USA, Inc.","Granules, 4 mg (NDC 0093-7487-19)",New,6/6/23,,,,,Pulmonary/Allergy,To Be Discontinued,6/6/23,6/6/23,0093-7487-19,discontinued
10958,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 1 mg/30 mL (NDC 76329-1912-1)",Reverified,12/19/23,Available,,,,Analgesia/Addiction,Current,,,76329-1912-1,available
10959,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled to be manufactured in the May 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6019-10,available
10960,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6020-10,available
10961,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 200, Injection, 10 mg/1 mL (NDC 0641-6039-01)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6039-01,available
10962,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 500, Injection, 25 mg/1 mL (NDC 0641-6040-01)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6040-01,available
10963,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 63323-452-01)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-452-01,available
10964,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 63323-454-01)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-454-01,available
10965,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 5 mg/1 mL (NDC 63323-455-01)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-455-01,available
10966,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-451-01)",Reverified,12/20/23,Next release not available at this time.,Check wholesalers for inventory,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,63323-451-01,not available
10967,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0409-1890-01,available
10968,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0409-1891-01,available
10969,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0409-1892-01,available
10970,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",Revised,12/19/23,Available,,,,Analgesia/Addiction,Current,,,0409-1893-01,available
10971,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, .5 mg/1 mL (NDC 0409-3814-12)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-3814-12,limited availability
10972,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 0409-3815-12)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction,Current,,,0409-3815-12,limited availability
10973,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-03)",Reverified,12/19/23,Next Delivery and Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,0409-1134-03,not available
10974,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Reverified,12/19/23,Next Delivery and Estimated Recovery: December 2023,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Analgesia/Addiction,Current,,,0409-1134-05,not available
10975,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6125-25,available
10976,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots are scheduled to be manufactured in the May - June 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,not available
10977,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Revised,12/19/23,Inventory is currently available.,Additional lots are scheduled for manufacturing and will be available in the May - June 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6127-25,available
10978,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 2 mg/1 mL (NDC 76045-004-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-004-11,available
10979,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 4 mg/1 mL (NDC 76045-005-11)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-11,available
10980,Moxetumomab Pasudotox Injection,AstraZeneca Pharmaceuticals LP,"Lumoxiti, Injection, 1 mg/1 mL (NDC 0310-4700-01)",New,1/10/23,,"The planned permanent discontinuation of moxetumomab pasudotox-tdfk) for injection from the U.S. market is August 31, 2023.",,,Oncology,To Be Discontinued,1/10/23,1/10/23,0310-4700-01,discontinued
10981,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-30)",New,3/28/23,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/23,3/28/23,13668-201-30,discontinued
10982,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-01)",New,3/28/23,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/23,3/28/23,13668-201-01,discontinued
10983,Moxifloxacin Hydrochloride Tablet,Torrent Pharmaceuticals Limited,"Moxifloxacin Hydrochloride, Tablet, 400 mg (NDC 13668-201-05)",New,3/28/23,,Business decision to discontinue manufacture of this product.,,,Anti-Infective,To Be Discontinued,3/28/23,3/28/23,13668-201-05,discontinued
10984,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-66)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-66,discontinued
10985,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-01)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-01,discontinued
10986,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-05)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-05,discontinued
10987,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 400 mg (NDC 55111-112-66)",New,10/4/23,,Discontinuance of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-66,discontinued
10988,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, 1 [iU]/1 mL; 20 [iU]/1 mL; 15 ug/1 mL; 330 [iU]/1 mL (NDC 65219-335-82)",Revised,12/20/23,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,65219-335-82,available
10989,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, .7 [iU]/1 mL; 40 [iU]/1 mL; 20 ug/1 mL; 230 [iU]/1 mL (NDC 65219-337-62)",Revised,12/20/23,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,65219-337-62,available
10990,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Fresenius Kabi USA, LLC","Vitalipid N, Injection, .7 [iU]/1 mL; 40 [iU]/1 mL; 20 ug/1 mL; 230 [iU]/1 mL (NDC 65219-339-64)",Revised,12/20/23,Available for direct orders.,,,Demand increase for the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,65219-339-64,available
10991,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Adult, Injection, 10 Kit In 1 Package (61703-434-82) (NDC 61703-434-82)",Revised,10/30/23,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-434-82,discontinued
10992,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Adult, Injection, 2 Box In 1 Case (61703-422-83)  (NDC 61703-422-83)",Revised,10/30/23,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-422-83,discontinued
10993,Multi-Vitamin Infusion (Adult and Pediatric) Injection,"Hospira, Inc., a Pfizer Company","M.v.i. Pediatric, Injection, 7 mg/5 mL; 80 mg/5 mL; 20 ug/5 mL; 1 ug/5 mL; 5 mg/5 mL; 10 ug/5 mL; 140 ug/5 mL; 17 mg/5 mL; 200 ug/5 mL; 1 mg/5 mL; .7 mg/5 mL; 1.4 mg/5 mL; 1.2 mg/5 mL (NDC 61703-421-53)",Revised,10/30/23,Discontinued,,,Discontinuation of the manufacture of the drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-421-53,discontinued
10994,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Pediatric Infuvite Multiple Vitamins For Infusion, Injection, 7 [iU]/5 mL; 80 mg/5 mL; 20 ug/5 mL; 400 [iU]/5 mL; 1 ug/5 mL; 5 mg/5 mL; 140 ug/5 mL; 17 mg/5 mL; .2 mg/5 mL; 1 mg/5 mL; 1.4 mg/5 mL; 1.2 mg/5 mL; 2300 [iU]/5 mL (NDC 54643-5646-1)",Reverified,12/19/23,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,54643-5646-1,available
10995,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Infuvite Adult, Injection, 10 [iU]/10 mL; 200 mg/10 mL; 60 ug/10 mL; 200 [iU]/10 mL; 5 ug/10 mL; 15 mg/10 mL; 600 ug/10 mL; 40 mg/10 mL; 150 ug/10 mL; 6 mg/10 mL; 3.6 mg/10 mL; 6 mg/10 mL; 3300 [iU]/10 mL (NDC 54643-5649-1)",Reverified,12/19/23,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,54643-5649-1,available
10996,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Infuvite Adult Multiple Vitamins, Injection, 10 [iU]/10 mL; 200 mg/10 mL; 60 ug/10 mL; 200 [iU]/10 mL; 5 ug/10 mL; 15 mg/10 mL; 600 ug/10 mL; 40 mg/10 mL; 150 ug/10 mL; 6 mg/10 mL; 3.6 mg/10 mL; 6 mg/10 mL; 3300 [iU]/10 mL (NDC 54643-5650-2)",Reverified,12/19/23,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,54643-5650-2,available
10997,Multi-Vitamin Infusion (Adult and Pediatric) Injection,Sandoz Inc.,"Pediatric Infuvite Multiple Vitamins, Injection, 40 mL in 1 VIAL * 10 mL in 1 VIAL (NDC 54643-5647-0)",Reverified,12/19/23,Available,Distributed by BaxterCustomer Service Number 888-229-0001,,,Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,54643-5647-0,available
10998,"Mycophenolate Sodium Tablet, Delayed Release","Lupin Pharmaceuticals, Inc.","Mycophenolic Sodium, Tablet, Delayed Release, 180 mg (NDC 70748-217-16)",New,4/6/23,,,,,Anti-Infective,To Be Discontinued,4/6/23,4/6/23,70748-217-16,discontinued
10999,"Mycophenolate Sodium Tablet, Delayed Release","Lupin Pharmaceuticals, Inc.","Mycophenolic Sodium, Tablet, Delayed Release, 360 mg (NDC 70748-218-16)",New,4/6/23,,,,,Anti-Infective,To Be Discontinued,4/6/23,4/6/23,70748-218-16,discontinued
11000,Neomycin Sulfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-1177-01)",Reverified,12/6/23,Available,,,,Anti-Infective,Current,,,0093-1177-01,available
11001,Neomycin Sulfate Tablet,"XGen Pharmaceuticals DJB, Inc.","Neomycin Sulfate, Tablet, 500 mg (NDC 39822-0310-5)",Revised,10/12/23,Available,,,,Anti-Infective,Current,,,39822-0310-5,available
11002,Nicotine Inhalant,Pfizer Inc.,"Nicotrol, Inhalant, 4 mg (NDC 0009-5400-01)",New,4/26/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust late August 2023,,,Other,To Be Discontinued,4/26/23,4/26/23,0009-5400-01,discontinued
11003,Nifedipine Capsule,Pfizer Inc.,"Capsule, 10 mg (NDC 59762-1004-1)",New,10/26/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust November 2023.,,Discontinuation of the manufacture of the drug,Cardiovascular,To Be Discontinued,,10/26/23,59762-1004-1,discontinued
11004,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Reverified,12/19/23,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/23,,0338-1049-02,limited availability
11005,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Reverified,12/19/23,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/23,,0338-1051-02,limited availability
11006,Nitroglycerin Injection,Baxter Healthcare,"NITROGLYCERIN IN DEXTROSE 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Reverified,12/19/23,"On Allocation, Recovery late November",,,Demand increase for the drug,Cardiovascular,Current,10/3/23,,0338-1047-02,limited availability
11007,Nitroglycerin Injection,"American Regent, Inc.","Injection, 5 mg/1 mL (NDC 0517-4810-25)",Reverified,12/19/23,"Check wholesaler, ETA January 2024",,,Regulatory delay,Cardiovascular,Current,10/3/23,,0517-4810-25,not available
11008,Nizatidine Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 300 mg (NDC 0591-3138-30)",Revised,12/19/23,Available,,,,Gastroenterology,Current,,,0591-3138-30,available
11009,Nizatidine Capsule,"Teva Pharmaceuticals USA, Inc.","Capsule, 150 mg (NDC 0591-3137-60)",Revised,12/19/23,Available,,,,Gastroenterology,Current,,,0591-3137-60,available
11010,Nystatin Ointment,Torrent Pharmaceuticals Limited,"Nystatin, Ointment, 100000 U/1 g (NDC 13668-534-01)",New,3/21/23,,,,,Dermatology,To Be Discontinued,3/21/23,3/21/23,13668-534-01,discontinued
11011,Nystatin Ointment,Torrent Pharmaceuticals Limited,"Nystatin, Ointment, 100000 U/1 g (NDC 13668-534-02)",Revised,3/21/23,,,,,Dermatology,To Be Discontinued,3/21/23,3/21/23,13668-534-02,discontinued
11012,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 mg/1 mL (NDC 0078-0669-13)",New,11/3/23,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,11/3/23,0078-0669-13,discontinued
11013,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 mg/1 mL (NDC 0078-0690-61)",New,11/3/23,,,,Discontinuation of the manufacture of the drug,Oncology,To Be Discontinued,,11/3/23,0078-0690-61,discontinued
11014,Omacetaxine Mepesuccinate Injection,"Teva Pharmaceuticals USA, Inc.","Synribo, Injection, 3.5 mg/1 mL (NDC 63459-177-14)",New,6/13/23,,,,,Hematology; Oncology,To Be Discontinued,6/13/23,6/13/23,63459-177-14,discontinued
11015,Omeprazole; Sodium Bicarbonate	 For Suspension,"Par Pharmaceutical, Inc.","For Suspension, 20 mg; 1680 mg (NDC 49884-268-11)",New,12/7/23,,,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,12/7/23,49884-268-11,discontinued
11016,Omeprazole; Sodium Bicarbonate Suspension,"Par Pharmaceutical, Inc.","Suspension, 40 mg; 1680 mg (NDC 49884-269-11)",New,12/7/23,,,,Discontinuation of the manufacture of the drug,Gastroenterology,To Be Discontinued,,12/7/23,49884-269-11,discontinued
11017,Oxandrolone Tablet,Endo Pharmaceuticals. Inc.,"Oxandrolone, Tablet, 2.5 mg (NDC 49884-301-01)",New,7/10/23,,,,,Endocrinology/Metabolism,To Be Discontinued,7/10/23,7/10/23,49884-301-01,discontinued
11018,Oxandrolone Tablet,Endo Pharmaceuticals. Inc.,"Oxandrolone, Tablet, 10 mg (NDC 49884-302-02)",New,7/10/23,,,,,Endocrinology/Metabolism,To Be Discontinued,7/10/23,7/10/23,49884-302-02,discontinued
11019,Oxaprozin Tablet,Sandoz Inc.,"Oxaprozin, Tablet, 600 mg (NDC 0185-0141-01)",New,3/17/23,,Discontinuation of the manufacture of the product,,,Analgesia/Addiction,To Be Discontinued,3/17/23,3/17/23,0185-0141-01,discontinued
11020,Oxybutynin Chloride Gel,AbbVie Inc.,"Gelnique, Gel, 100 mg/1 g (NDC 0023-5861-11)",New,6/14/23,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,6/14/23,6/14/23,0023-5861-11,discontinued
11021,Oxybutynin Chloride Gel,AbbVie Inc.,"Gel, 100 mg/g (NDC 0023-5861-10)",New,6/14/23,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,6/14/23,6/14/23,0023-5861-10,discontinued
11022,Oxybutynin Chloride Syrup,Chartwell Molecular Holdings LLC,"Syrup, 5 mg/5 mL (NDC 62135-520-47)",Reverified,12/20/23,Product available in all wholesalers,,,,Urology,Current,,,62135-520-47,available
11023,Oxybutynin Chloride Syrup,"Lannett Company, Inc.","Syrup, 5 mg/5 mL (NDC 54838-510-80)",Revised,12/19/23,Limited Availability,Estimated Delivery: December 2023,,Shortage of an active ingredient,Urology,Current,,,54838-510-80,limited availability
11024,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 30 mg (NDC 0228-2879-11)",New,5/9/23,,,,,,To Be Discontinued,5/9/23,5/9/23,0228-2879-11,discontinued
11025,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 15 mg (NDC 0228-2878-11)",New,5/9/23,,,,,,To Be Discontinued,5/9/23,5/9/23,0228-2878-11,discontinued
11026,Oxycodone Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Oxycodone Hydrochloride, Tablet, 5 mg (NDC 0228-2876-11)",New,5/9/23,,,,,,To Be Discontinued,5/9/23,5/9/23,0228-2876-11,discontinued
11027,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-11)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,63323-012-11,
11028,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-10)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,63323-012-10,
11029,Oxytocin Injection,"Fresenius Kabi USA, LLC","Oxytocin, Injection, 10 [USP'U]/1 mL (NDC 63323-012-30)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,63323-012-30,
11030,Oxytocin Injection,"Fresenius Kabi USA, LLC","Injection, 10 USP units (NDC 63323-112-01)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,63323-112-01,
11031,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-130-06)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,42023-130-06,
11032,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-116-25)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,42023-116-25,
11033,Oxytocin Injection,"Par Pharmaceutical, Inc.","Pitocin, Injection, 10 [iU]/1 mL (NDC 42023-116-02)",Revised,8/14/23,,,Available,,Anesthesia; Urology; Other,Resolved,8/14/23,,42023-116-02,
11034,Palifermin Injection,Swedish Orphan Biovitrum AB,"Kepivance, Injection, 6.25 mg/1.2 mL (NDC 66658-112-03)",Revised,10/18/23,Available,,Available,,Other,Resolved,10/18/23,,66658-112-03,available
11035,Palifermin Injection,Swedish Orphan Biovitrum AB,"Kepivance, Injection, 6.25 mg/1.2 mL (NDC 66658-112-06)",Revised,10/18/23,Available,,Available,,Other,Resolved,10/18/23,,66658-112-06,available
11036,"Paliperidone Tablet, Extended Release",Janssen Research and Development,"Invega, Tablet, Extended Release, 1.5 mg (NDC 50458-554-01)",New,2/3/23,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To Be Discontinued,2/3/23,2/3/23,50458-554-01,discontinued
11037,"Paliperidone Tablet, Extended Release",Janssen Research and Development,"Invega, Tablet, Extended Release, 1.5 mg (NDC 50458-554-10)",New,2/3/23,,Discontinuation of the manufacture of the drug.,,,Psychiatry,To Be Discontinued,2/3/23,2/3/23,50458-554-10,discontinued
11038,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 65219-433-15)",Revised,9/15/23,,Marketed by Fresenius Kabi,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/23,,65219-433-15,
11039,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 72572-550-10)",Revised,9/15/23,,,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/23,,72572-550-10,
11040,Pantoprazole Sodium Injection,Sandoz Inc.,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 0781-3232-95)",Revised,9/15/23,,,Available. NDC 72572-550-10 marketed by Civica. NDC 65219-433-15 marketed by Fresenius Kabi.,,Gastroenterology,Resolved,9/15/23,,0781-3232-95,
11041,Pantoprazole Sodium Injection,Eugia US LLC,"Pantoprazole Sodium, Injection, 40 mg (NDC 55150-202-10)",Revised,9/15/23,,,Available,,Gastroenterology,Resolved,9/15/23,,55150-202-10,
11042,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-55)",Revised,9/15/23,,,Available,,Gastroenterology,Resolved,9/15/23,,0008-0923-55,
11043,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-60)",Revised,9/15/23,,,Available,,Gastroenterology,Resolved,9/15/23,,0008-0923-60,
11044,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-4001-10)",Revised,9/15/23,,,Available,,Gastroenterology,Resolved,9/15/23,,0008-4001-10,
11045,Pantoprazole Sodium Injection,"Hospira, Inc., a Pfizer Company","Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-4001-25)",Revised,9/15/23,,,Available,,Gastroenterology,Resolved,9/15/23,,0008-4001-25,
11046,Pantoprazole Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Pantoprazole Sodium, Injection, 40 mg (NDC 0143-9284-10)",Revised,9/15/23,,,Limited availability,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,0143-9284-10,
11047,Pantoprazole Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Pantoprazole Sodium, Injection, 40 mg (NDC 0143-9300-10)",Revised,9/15/23,,,Limited availability,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,0143-9300-10,
11048,Pantoprazole Sodium Injection,"ACIC Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 67850-150-10)",Revised,9/15/23,,,"Available. Marketed by Methapharm, Inc.",Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,67850-150-10,
11049,Pantoprazole Sodium Injection,"ACIC Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 67850-150-25)",Revised,9/15/23,,,"Available. Marketed by Methapharm, Inc.",Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,67850-150-25,
11050,Pantoprazole Sodium Injection,"Meitheal Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 71288-600-11)",Revised,9/15/23,,,Available. NDC 72603-128-10 marketed by Northstar Rx.,,Gastroenterology,Resolved,9/15/23,,71288-600-11,
11051,Pantoprazole Sodium Injection,"Meitheal Pharmaceuticals, Inc.","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 72603-128-10)",Revised,9/15/23,,,Available. NDC 72603-128-10 marketed by Northstar Rx.,,Gastroenterology,Resolved,9/15/23,,72603-128-10,
11052,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 25021-751-10)",Revised,9/15/23,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,25021-751-10,
11053,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 25021-751-11)",Revised,9/15/23,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,25021-751-11,
11054,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 70095-024-02)",Revised,9/15/23,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,70095-024-02,
11055,Pantoprazole Sodium Injection,Gland Pharma Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 70095-024-03)",Revised,9/15/23,,,Available. NDCs 25021-751-10 and 25021-751-11 marketed by Sagent. NDCs 70095-024-02 and 70095-024-03 marketed by Sun.,Demand increase for the drug,Gastroenterology,Resolved,9/15/23,,70095-024-03,
11056,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Revised,12/21/23,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0203-2,discontinued
11057,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Revised,12/21/23,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0204-2,discontinued
11058,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Revised,12/21/23,The 100 mcg cartridge is no longer available and Takeda is unable to resupply prior to ceasing of manufacturing of Natpara at the end of 2024. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0205-2,discontinued
11059,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Revised,12/21/23,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details â€“ https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/,,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0202-2,discontinued
11060,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Revised,9/11/23,Next delivery: TBD; Estimated recovery 2024,,,,Anti-Infective,Current,,,60793-700-10,unclear
11061,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Revised,9/11/23,Limited Supply. Next delivery: September 2023; Estimated recovery: Q2 2024,On allocation. Check Wholesaler for Availability,,,Anti-Infective,Current,,,60793-701-10,limited availability
11062,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-a, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Revised,9/11/23,Limited Supply. Next delivery: September 2023; Estimated recovery: Q2 2024,On allocation. Check Wholesaler for Availability,,,Anti-Infective,Current,,,60793-702-10,limited availability
11063,Penicillin G Procaine Injection,Pfizer Inc.,"Penicillin G Procaine, Injection, 600000 [iU]/1 mL (NDC 60793-130-10)",New,6/13/23,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,6/13/23,6/13/23,60793-130-10,discontinued
11064,Penicillin G Procaine Injection,Pfizer Inc.,"Penicillin G Procaine, Injection, 1200000 [iU]/2 mL (NDC 60793-131-10)",New,6/13/23,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,6/13/23,6/13/23,60793-131-10,discontinued
11065,Piroxicam Capsule,Pfizer Inc.,"Feldene, Capsule, 10 mg (NDC 0069-3220-66)",New,4/4/23,,Supply expected to exhaust late May 2023; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,4/4/23,4/4/23,0069-3220-66,discontinued
11066,Piroxicam Capsule,Pfizer Inc.,"Feldene, Capsule, 20 mg (NDC 0069-3230-66)",New,8/24/23,,Supply expected to exhaust late October 2023; Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,8/24/23,8/24/23,0069-3230-66,discontinued
11067,Podofilox Solution,"Teva Pharmaceuticals USA, Inc.","Condylox, Solution, 5 mg/1 mL (NDC 0591-3204-13)",New,5/9/23,,Business decision:  Discontinuation of the manufacture of the drug,,,Dermatology,To Be Discontinued,5/9/23,5/9/23,0591-3204-13,discontinued
11068,Posaconazole Oral Suspension,Merck Sharp & Dohme LLC,"Noxafil, Oral Suspension, 40MG/ML (NDC 0085-1328-01)",New,11/15/23,,"To be discontinued 
on December 18th, 2023.",,Discontinuation of the manufacture of the drug,Anti-Infective,To Be Discontinued,,11/15/23,0085-1328-01,discontinued
11069,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 196.3 mg/1 mL (NDC 0409-3294-51)",Reverified,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3294-51,limited availability
11070,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 3.93 g/20 mL (NDC 0409-8183-01)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-8183-01,not available
11071,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 196.3 mg/1 mL (NDC 0409-3294-25)",Reverified,9/11/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3294-25,available
11072,Potassium Acetate Injection,"Hospira, Inc., a Pfizer Company","Potassium Acetate, Injection, 3.93 g/20 mL (NDC 0409-8183-25)",Reverified,9/11/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-8183-25,not available
11073,Potassium Acetate Injection,"Exela Pharma Sciences, LLC","Injection, 3.93 g/20 mL (NDC 51754-2001-4)",Revised,11/2/23,Limited Availability,Batch released 10/25. Seven Additional batches pending packaging and release; Recovery estimated by Nov 15,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,51754-2001-4,limited availability
11074,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 20mEq In Plastic Container, Injection, 400 meq/1000 mL (NDC 0990-7077-14)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7077-14",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0990-7077-14,available
11075,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 10mEq In Plastic Container, Injection, 10 meq/100 mL (NDC 0990-7074-26)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7074-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0990-7074-26,available
11076,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 10mEq In Plastic Container, Injection, 200 meq/1000 mL (NDC 0990-7075-14)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7075-14",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0990-7075-14,available
11077,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 20mEq In Plastic Container, Injection, 200 meq/1000 mL (NDC 0990-7075-26)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7075-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0990-7075-26,available
11078,Potassium Chloride Injection,"ICU Medical, Inc.","Potassium Chloride 40mEq In Plastic Container, Injection, 400 meq/1000 mL (NDC 0990-7077-26)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7077-26",,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0990-7077-26,available
11079,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 20 mEq (NDC 14789-107-08)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,14789-107-08,available
11080,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 40 mEq (NDC 14789-107-16)",Reverified,12/19/23,Unavailable,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,14789-107-16,not available
11081,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 20 mEq (NDC 14789-108-16)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,14789-108-16,available
11082,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 10 mEq (NDC 14789-108-08)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,14789-108-08,available
11083,Potassium Chloride Injection,"Nexus Pharmaceuticals, LLC","Injection, 10 mEq (NDC 14789-109-16)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,14789-109-16,available
11084,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 g/100 mL (NDC 0264-1944-20)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0264-1944-20,available
11085,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 7.46 g/1000 mL (NDC 0338-0709-48)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0338-0709-48,available
11086,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 g/1000 mL (NDC 0338-0705-41)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0338-0705-41,available
11087,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 g/1000 mL (NDC 0338-0705-48)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0338-0705-48,available
11088,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 g/1000 mL (NDC 0338-0703-41)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0338-0703-41,available
11089,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 g/1000 mL (NDC 0338-0703-48)",Reverified,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0338-0703-48,available
11090,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6635-01)",Revised,9/11/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6635-01,available
11091,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6651-06)",Revised,9/11/23,Depleted,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6651-06,not available
11092,Potassium Chloride Injection,"Hospira, Inc., a Pfizer Company","Potassium Chloride, Injection, 149 mg/1 mL (NDC 0409-6653-05)",Revised,9/11/23,Limited Supply Available. Next Delivery and Estimated Recovery: December 2023,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6653-05,limited availability
11093,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-967-30)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-967-30,available
11094,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-05)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-965-05,available
11095,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-10)",Reverified,12/20/23,Available. Check wholesaler for inventory.,Check wholesalers for inventory,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-965-10,available
11096,Potassium Chloride Injection,"Fresenius Kabi USA, LLC","Potassium Chloride In Plastic Container, Injection, 2 meq/1 mL (NDC 63323-965-20)",Reverified,12/20/23,Next release not available at this time.,Check wholesalers for inventory,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-965-20,not available
11097,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 g/100 mL (NDC 0264-1940-20)",Reverified,12/19/23,Inventory depleted.,Discontinuation of manufacturing,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0264-1940-20,not available
11098,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 1.5 mg (NDC 0597-0113-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0113-30,discontinued
11099,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 4.5 mg (NDC 0597-0116-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0116-30,discontinued
11100,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 3.75 mg (NDC 0597-0287-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0287-30,discontinued
11101,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, 2.25 mg (NDC 0597-0286-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0286-30,discontinued
11102,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, .75 mg (NDC 0597-0285-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0285-30,discontinued
11103,"Pramipexole Dihydrochloride Tablet, Extended Release","Boehringer Ingelheim Pharmaceuticals, Inc.","Mirapex Er, Tablet, Extended Release, .375 mg (NDC 0597-0109-30)",New,8/1/23,,,,,Neurology,To Be Discontinued,8/1/23,8/1/23,0597-0109-30,discontinued
11104,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4310-71,discontinued
11105,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4370-71,discontinued
11106,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4380-71,discontinued
11107,Prednicarbate Ointment,Sandoz Inc.,"Prednicarbate, Ointment, 1 mg/1 g (NDC 0168-0410-15)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0410-15,discontinued
11108,Prednicarbate Ointment,Sandoz Inc.,"Prednicarbate, Ointment, 1 mg/1 g (NDC 0168-0410-60)",Revised,3/16/23,,,,,Dermatology,To Be Discontinued,3/16/23,3/16/23,0168-0410-60,discontinued
11109,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Reverified,12/19/23,Product Expected January 2024,,,Delay in shipping of the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5525-3,not available
11110,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Reverified,12/19/23,Product Expected January 2024,,,Delay in shipping of the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5550-6,not available
11111,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,12/1/22,,0641-0928-25,not available
11112,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-0929-25,not available
11113,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-1495-35,not available
11114,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-1496-35,not available
11115,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-6084-25,not available
11116,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)",New,11/21/23,Inventory is currently available,Additional lots will be available in the December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-6085-25,available
11117,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)",New,11/21/23,Product is temporarily on backorder,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-6082-25,not available
11118,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)",New,11/21/23,Inventory is currently available,Additional lots will be available in the November - December 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,11/21/23,,0641-6083-25,available
11119,Propranolol Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-604-01)",Reverified,12/20/23,Backordered. Next release January 2024.,Backordered. Next release January 2024.,,Shortage of an active ingredient,Cardiovascular,Current,,,63323-604-01,not available
11120,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,12/19/23,This presentation is currently unavailable.,This presentation is currently unavailable.,,Shortage of an active ingredient,Cardiovascular,Current,,,0143-9872-10,not available
11121,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,12/19/23,,This presentation is currently unavailable.,,Shortage of an active ingredient,Cardiovascular,Current,,,0143-9872-10,
11122,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 5 1 (NDC 43547-410-09)",Revised,12/19/23,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-410-09,not available
11123,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 10 mg (NDC 43547-411-09)",Revised,12/19/23,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-411-09,not available
11124,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 20 mg (NDC 43547-412-09)",Revised,12/19/23,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-412-09,not available
11125,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Tablet, 40 mg (NDC 43547-413-09)",Revised,12/19/23,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-413-09,not available
11126,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Revised,12/19/23,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-556-09,not available
11127,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Revised,12/19/23,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-557-09,not available
11128,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Revised,12/19/23,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-558-09,not available
11129,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Revised,12/19/23,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-554-09,not available
11130,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-617-90,discontinued
11131,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-618-90,discontinued
11132,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-618-90,discontinued
11133,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-620-90,discontinued
11134,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Reverified,12/19/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0535-23,unclear
11135,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Reverified,12/19/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0530-23,unclear
11136,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Reverified,12/19/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0532-23,unclear
11137,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Reverified,12/19/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0527-23,unclear
11138,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Reverified,9/11/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,,Cardiovascular,Current,,,0071-0222-23,unclear
11139,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Reverified,9/11/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,,Cardiovascular,Current,,,0071-0220-23,unclear
11140,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 mg; 20 mg (NDC 0071-0223-23)",Revised,12/19/23,Next Delivery and Estimated Recovery: TBD,Shortage per Manufacturer: Product manufacturing and release delay due to product/ingredient testing,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0223-23,unclear
11141,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-161-90,discontinued
11142,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-162-90,discontinued
11143,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Revised,12/19/23,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-163-90,discontinued
11144,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-1)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1003-1,discontinued
11145,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-1)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1004-1,discontinued
11146,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-2)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1003-2,discontinued
11147,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 500 mg (NDC 61958-1003-3)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1003-3,discontinued
11148,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-2)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1004-2,discontinued
11149,"Ranolazine Tablet, Film Coated, Extended Release","Gilead Sciences, Inc.","Ranexa, Tablet, Film Coated, Extended Release, 1000 mg (NDC 61958-1004-3)",Revised,12/22/22,,,,,Cardiovascular,To Be Discontinued,12/22/22,12/22/22,61958-1004-3,discontinued
11150,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Reverified,12/21/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,72078-034-01,available
11151,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Reverified,12/21/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,72078-035-02,available
11152,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 5 mg (NDC 67457-198-10)",Reverified,12/21/23,Available,,,Demand increase for the drug,Analgesia/Addiction,Current,,,67457-198-10,available
11153,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 1 mg/1 mL (NDC 0143-9391-10)",Revised,12/19/23,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0143-9391-10,available
11154,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 2 mg/2 mL (NDC 0143-9392-10)",Revised,12/19/23,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0143-9392-10,available
11155,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 5 mg/5 mL (NDC 0143-9393-10)",Revised,12/19/23,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0143-9393-10,available
11156,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-723-03)",Reverified,12/20/23,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-723-03,available
11157,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-724-05)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,63323-724-05,available
11158,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-725-10)",Reverified,12/20/23,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-725-10,available
11159,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 150 mg (NDC 42806-801-30)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-801-30,available
11160,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 150 mg (NDC 42806-801-01)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-801-01,available
11161,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-30)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-799-30,available
11162,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-60)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-799-60,available
11163,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-01)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-799-01,available
11164,Rifampin Capsule,"Epic Pharma, LLC","Capsule, 300 mg (NDC 42806-799-05)",Revised,12/20/23,Available,,,,Anti-Infective,Current,,,42806-799-05,available
11165,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,68180-658-06,available
11166,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,68180-659-06,available
11167,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Revised,12/19/23,Available,,,,Anti-Infective,Current,,,68180-659-07,available
11168,Rifampin Injection,"Fresenius Kabi USA, LLC","Injection, 600 mg (NDC 63323-351-20)",Reverified,12/20/23,Available. Check wholesaler for inventory.,Check wholesaler inventory,,Delay in shipping of the drug,Anti-Infective,Current,,,63323-351-20,available
11169,Rifampin Injection,Sanofi-Aventis U.S. LLC,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Reverified,12/19/23,Available,,,,Anti-Infective,Current,,,0068-0597-01,available
11170,Rifampin Injection,"Mylan Institutional, a Viatris Company","Injection, 600 mg/10 mL (NDC 67457-445-60)",Reverified,12/21/23,Available,,,Demand increase for the drug,Anti-Infective,Current,,,67457-445-60,available
11171,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. LLC,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Reverified,12/19/23,Available,,,,Anti-Infective,Current,,,0088-2102-24,available
11172,Ritonavir Solution,AbbVie Inc.,"Norvir, Solution, 80 mg/1 mL (NDC 0074-1940-63)",New,2/1/23,,Discontinuation,,,Antiviral,To Be Discontinued,2/1/23,2/1/23,0074-1940-63,discontinued
11173,"Rivaroxaban Granule, For Suspension",Janssen Pharmaceuticals,"Xarelto, Granule, For Suspension, 155 mg (NDC 50458-575-01)",Revised,7/12/23,,,Available,,Hematology,Resolved,7/12/23,,50458-575-01,
11174,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-700-06)",Revised,12/19/23,Available,,,,Anesthesia,Current,,,71288-700-06,available
11175,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 mg/1 mL (NDC 71288-718-11)",Revised,12/19/23,Available,,,,Anesthesia,Current,,,71288-718-11,available
11176,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,67457-228-10,available
11177,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 65219-065-05)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,65219-065-05,available
11178,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Reverified,12/21/23,Available,,,,Anesthesia,Current,,,67457-228-05,available
11179,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 mg/1 mL (NDC 0781-3220-95)",Revised,12/19/23,Available,,,,Anesthesia,Current,,,0781-3220-95,available
11180,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 mg/1 mL (NDC 0781-3220-92)",Revised,12/19/23,Available,,,,Anesthesia,Current,,,0781-3220-92,available
11181,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-05)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9558-05,limited availability
11182,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-49)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9558-49,limited availability
11183,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-10)",Revised,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9558-10,limited availability
11184,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0409-9558-50)",Revised,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Anesthesia,Current,,,0409-9558-50,not available
11185,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-426-05)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,63323-426-05,available
11186,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 10 mg/1 mL (NDC 63323-426-10)",Reverified,12/20/23,Available,Check wholesalers for inventory.,,,Anesthesia,Current,,,63323-426-10,available
11187,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Injection, 50 mg/5 mL (NDC 39822-4200-2)",Revised,12/19/23,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,39822-4200-2,available
11188,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Injection, 100 mg/10 mL (NDC 39822-4200-6)",Revised,12/19/23,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,39822-4200-6,available
11189,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-662-05)",Revised,12/19/23,Available in January as NDC 25021-687-05,,,Demand increase for the drug,Anesthesia,Current,,,25021-662-05,available
11190,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 mg/1 mL (NDC 25021-662-10)",Reverified,12/19/23,Not currently offered,,,Demand increase for the drug,Anesthesia,Current,,,25021-662-10,not available
11191,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Reverified,12/21/23,Available,Tamarang is the application holder and Baxter is the distributor/labeler,,,Anesthesia,Current,,,43066-007-10,available
11192,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Reverified,12/19/23,Limited supply; Recovery: February 2024,Tamarang is the application holder and Baxter is the distributor/labeler,,Demand increase for the drug,Anesthesia,Current,,,43066-013-10,limited availability
11193,Rocuronium Bromide Injection,Eugia US LLC,"Injection, 100 mg/10 mL (NDC 55150-226-10)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-226-10,available
11194,Rocuronium Bromide Injection,Eugia US LLC,"Injection, 50 mg/5 mL (NDC 55150-225-05)",Revised,12/20/23,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-225-05,available
11195,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots will be available in the March 2023 timeframe. Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9250-10,not available
11196,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Revised,12/19/23,This presentation is temporarily on backorder.,Additional lots will be available in the March - April 2023 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9251-10,not available
11197,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-061-10,limited availability
11198,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-061-25,limited availability
11199,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-062-10,limited availability
11200,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-062-25,limited availability
11201,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-064-01,limited availability
11202,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-064-10,limited availability
11203,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Reverified,12/19/23,Limited Availability,,,Demand increase for the drug,Anesthesia,Current,,,70069-064-25,limited availability
11204,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-66,available
11205,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-67,available
11206,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-82,available
11207,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-87,available
11208,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-82,available
11209,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Reverified,12/19/23,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-87,available
11210,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 2 mg/1 mL (NDC 43066-015-10)",Revised,11/2/23,Limited supply; Recovery: April 2024,,,Demand increase for the drug,Anesthesia,Current,,,43066-015-10,limited availability
11211,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 mg/1 mL (NDC 43066-019-10)",Revised,11/2/23,Available,,,,Anesthesia,Current,,,43066-019-10,available
11212,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 mg/1 mL (NDC 43066-023-10)",Revised,11/2/23,Limited supply; Recovery: April 2024,,,Demand increase for the drug,Anesthesia,Current,,,43066-023-10,limited availability
11213,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 10 mg/1 mL (NDC 43066-027-10)",Revised,11/2/23,Available,,,,Anesthesia,Current,,,43066-027-10,available
11214,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 2 mg/1 mL (NDC 55150-195-20)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-195-20,available
11215,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 2 mg/1 mL (NDC 55150-196-99)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-196-99,available
11216,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 5 mg/1 mL (NDC 55150-197-20)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-197-20,available
11217,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 5 mg/1 mL (NDC 55150-198-30)",Reverified,12/19/23,Available,,,,Anesthesia,Current,,,55150-198-30,available
11218,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-199-20,available
11219,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-200-10)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-200-10,available
11220,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Injection, 10 mg/1 mL (NDC 55150-201-20)",Reverified,12/19/23,Currently on backorder - next shipment TBD,,,Demand increase for the drug,Anesthesia,Current,,,55150-201-20,not available
11221,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-285-10,not available
11222,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-285-20,not available
11223,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-286-20,not available
11224,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-287-20,available
11225,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-288-10,not available
11226,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-288-20,not available
11227,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-285-61,not available
11228,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-285-63,not available
11229,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-285-65,available
11230,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Revised,11/29/23,Available,Available. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-285-64,available
11231,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-286-00,available
11232,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Revised,11/29/23,Available,Available. Check wholesaler for inventory,,,Anesthesia,Current,,,63323-286-63,available
11233,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-285-13,available
11234,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-285-23,available
11235,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-286-35,available
11236,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-286-23,available
11237,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Revised,11/29/23,Available,Available. Check wholesaler for inventory,,,Anesthesia,Current,,,63323-287-21,available
11238,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-288-11,available
11239,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Revised,11/29/23,Available,,,,Anesthesia,Current,,,63323-288-21,available
11240,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Revised,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-286-31,not available
11241,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-30)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6100-30,discontinued
11242,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-90)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6100-90,discontinued
11243,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 2.5 mg (NDC 0310-6100-95)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6100-95,discontinued
11244,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-30)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6105-30,discontinued
11245,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-90)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6105-90,discontinued
11246,"Saxagliptin Hydrochloride Tablet, Film Coated",AstraZeneca Pharmaceuticals LP,"Onglyza, Tablet, Film Coated, 5 mg (NDC 0310-6105-95)",New,3/21/23,,"The reason for the permanent discontinuation is an AZ business decision, and not due to any safety or efficacy-related concerns for the drug.",,,Endocrinology/Metabolism,To Be Discontinued,3/21/23,3/21/23,0310-6105-95,discontinued
11247,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, .68 mg/1 mL (NDC 0169-4181-13)",Revised,12/11/23,Currently available,,44796,,Endocrinology/Metabolism,Current,,,0169-4181-13,available
11248,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .25 mg/.5 mL (NDC 0169-4525-14)",Revised,12/11/23,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4525-14,limited availability
11249,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .5 mg/.5 mL (NDC 0169-4505-14)",Revised,12/11/23,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4505-14,limited availability
11250,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1 mg/.5 mL (NDC 0169-4501-14)",Revised,12/11/23,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4501-14,limited availability
11251,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1.7 mg/.75 mL (NDC 0169-4517-14)",Revised,12/11/23,Limited availability.  Estimated shortage duration TBD,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4517-14,limited availability
11252,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 2.4 mg/.75 mL (NDC 0169-4524-14)",Revised,12/11/23,Available,,,,Endocrinology/Metabolism,Current,,,0169-4524-14,available
11253,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 1.34 mg/1 mL (NDC 0169-4130-13)",Revised,12/11/23,Currently available,,,,Endocrinology/Metabolism,Current,,,0169-4130-13,available
11254,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 2.68 mg/1 mL (NDC 0169-4772-12)",Revised,12/11/23,Limited availability through end of 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0169-4772-12,limited availability
11255,Sincalide Injection,Bracco Diagnostics,"Kinevac, Injection, 5 ug/5 mL (NDC 0270-0556-15)",Revised,7/11/23,,,Available,,Medical Imaging; Other,Resolved,7/11/23,,0270-0556-15,
11256,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-05)",Revised,9/18/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-05,limited availability
11257,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-06)",Revised,9/18/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-06,not available
11258,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 3.28 g/20 mL (NDC 0409-7299-73)",Revised,9/18/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-73,not available
11259,Sodium Acetate Injection,"Fresenius Kabi USA, LLC","Injection, 4 meq/100 mL (NDC 63323-032-00)",Reverified,11/29/23,Unavailable,Next release not available at this time.,,Demand increase for the drug,Total Parenteral Nutrition,Current,,,63323-032-00,not available
11260,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 164 mg/1 mL (NDC 69784-230-10)",Revised,12/21/23,Available,,,,Total Parenteral Nutrition,Current,,,69784-230-10,available
11261,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 164 mg/1 mL (NDC 69784-231-10)",Revised,12/21/23,Available,,,,Total Parenteral Nutrition,Current,,,69784-231-10,available
11262,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-25)",Revised,9/18/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-25,limited availability
11263,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 164 mg/1 mL (NDC 0409-3299-26)",Revised,9/18/23,Next Delivery and Estimated Recovery: June 2024,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-26,not available
11264,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 3.28 g/20 mL (NDC 0409-7299-25)",Revised,9/18/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-25,not available
11265,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 328 mg/1 mL (NDC 69784-232-01)",New,12/21/23,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,69784-232-01,available
11266,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 84 mg/1 mL (NDC 51754-5011-4)",Revised,12/19/23,Unavailable,"On backorder, anticipated release Jan 15, 2024",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5011-4,not available
11267,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 42 mg/1 mL (NDC 51754-5012-4)",Revised,12/19/23,Unavailable,"On backorder, anticipated release Jan 15, 2024",,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5012-4,not available
11268,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5534-14)",Reverified,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5534-14,not available
11269,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6637-14)",Reverified,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6637-14,not available
11270,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 84 mg/1 mL (NDC 76329-3352-1)",Reverified,12/19/23,"Backorder due to the increase in demands, We are regularly releasing this product but demands are higher than what we can supply. We put this product under allocation program.",old NDC 0548-3352-00,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3352-1,limited availability
11271,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Injection, 42 mg/1 mL (NDC 63323-083-05)",Reverified,12/20/23,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-083-05,not available
11272,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Injection, 84 mg/1 mL (NDC 63323-089-50)",Reverified,12/20/23,Next release December 2023. Check wholesaler for inventory.,Check wholesalers for inventory,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-089-50,not available
11273,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5555-02)",Reverified,12/19/23,Limited Supply Available.,,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5555-02,limited availability
11274,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 42 mg/1 mL (NDC 0409-5555-01)",Reverified,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5555-01,limited availability
11275,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 75 mg/1 mL (NDC 0409-4916-14)",Reverified,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4916-14,not available
11276,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6625-14)",Reverified,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6625-14,limited availability
11277,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-6625-35)",Reverified,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6625-35,limited availability
11278,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Injection, 84 mg/1 mL (NDC 0409-4900-14)",Reverified,12/19/23,Depleted,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4900-14,not available
11279,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Injection, 84 mg/1 mL (NDC 51754-5001-5)",Reverified,12/19/23,Available,Available in NDC 51754-5001-4,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5001-5,available
11280,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals USA, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Reverified,12/1/23,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,,Demand increase for the drug,Other,Current,,,0641-0497-25,not available
11281,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9%, Injection, 234 mg/1 mL (NDC 0409-1141-02)",Revised,9/28/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,0409-1141-02,limited availability
11282,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride, Injection, 4 meq/1 mL (NDC 63323-095-61)",Reverified,12/20/23,Available,Check wholesaler inventory; old NDC 63323-088-61,,Demand increase for the drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-095-61,available
11283,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Other,Current,,,63323-186-02,available
11284,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Other,Current,,,63323-186-10,available
11285,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Reverified,12/20/23,Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,63323-186-20,not available
11286,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride, Injection, 9 mg/1 mL (NDC 63323-186-00)",Reverified,12/20/23,Next release date not available at this time.,,,Demand increase for the drug,Other,Current,,,63323-186-00,not available
11287,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-10)",Revised,9/28/23,Available,,,Demand increase for the drug,Other,Current,,,0409-4888-10,available
11288,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-12)",Revised,9/28/23,Available,,,Demand increase for the drug,Other,Current,,,0409-4888-12,available
11289,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-20)",Revised,9/28/23,Available,,,Demand increase for the drug,Other,Current,,,0409-4888-20,available
11290,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-4888-50)",Revised,9/28/23,Available,,,Demand increase for the drug,Other,Current,,,0409-4888-50,available
11291,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Reverified,12/20/23,Available,,,,Other,Current,,,64253-202-30,available
11292,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9%, Injection, 5.84 g/40 mL (NDC 0409-6660-75)",Revised,9/28/23,Next Delivery and Estimated Recovery: June 2024,Shortage per Manufacturer: Manufacturing Delay,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6660-75,not available
11293,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-03",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-03,available
11294,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-09",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-09,available
11295,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Reverified,12/20/23,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-01,limited availability
11296,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Reverified,12/20/23,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-02,limited availability
11297,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Reverified,12/20/23,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-03,limited availability
11298,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Reverified,12/20/23,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-04,limited availability
11299,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Reverified,12/20/23,Product available for contracted customers.,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-05,limited availability
11300,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-00)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-00,available
11301,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-10)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-10,available
11302,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-20)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-20,available
11303,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 g/100 mL (NDC 0264-7800-09)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-09,available
11304,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-32,available
11305,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-31,available
11306,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-36,available
11307,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-66)",Revised,9/28/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-7101-66,available
11308,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-67)",Revised,9/28/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-7101-67,available
11309,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0409-7101-02)",Revised,9/28/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-7101-02,available
11310,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Revised,11/15/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-21,available
11311,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Revised,11/15/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-31,available
11312,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Revised,11/15/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-01,available
11313,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Revised,11/15/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-41,available
11314,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Revised,11/15/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,76297-001-11,available
11315,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-623-53)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,63323-623-53,available
11316,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-623-61)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,63323-623-61,available
11317,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Reverified,12/20/23,Available,Check wholesaler inventory; old NDC 63323-623-75,,,Gastroenterology; Other; Pediatric,Current,,,65219-472-20,available
11318,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Reverified,12/20/23,Available,Check wholesaler inventory; old NDC 63323-623-76,,,Gastroenterology; Other; Pediatric,Current,,,65219-474-10,available
11319,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-18,available
11320,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-41,available
11321,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-48,available
11322,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-31,available
11323,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-0049-02,available
11324,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-0049-03,available
11325,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-0049-04,available
11326,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-10,available
11327,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-11,available
11328,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Reverified,12/21/23,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-38,available
11329,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-02,available
11330,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-06,available
11331,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-04,available
11332,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Revised,9/27/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0553-11,available
11333,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Revised,9/27/23,Limited supply on allocation; Recovery: December 2024,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-9151-30,limited availability
11334,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Revised,9/27/23,Available on Allocation,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-9159-30,limited availability
11335,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Revised,9/27/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0553-18,available
11336,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-02,available
11337,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-04,available
11338,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,9/27/23,Available,,,Regulatory delay,Gastroenterology; Other; Pediatric,Current,,,0338-9543-06,available
11339,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Reverified,12/19/23,Product is not available as of today,,,Delay in shipping of the drug,Other,Current,,,0019-1188-81,not available
11340,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Reverified,12/19/23,Sodium Chloride Injection in RFID presentation is not available and the plan is to discontinue this presentation from sales,,,Discontinuation of the manufacture of the drug,Other,Current,,,0019-1188-27,discontinued
11341,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,63323-924-30,available
11342,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Gastroenterology; Other; Pediatric,Current,,,63323-924-10,available
11343,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-12)",Revised,9/28/23,Depleted,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-1966-12,not available
11344,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-05)",Revised,9/28/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-1966-05,available
11345,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0409-1966-07)",Revised,9/28/23,Available,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0409-1966-07,available
11346,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-13",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-13,available
11347,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-36",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-36,available
11348,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-37",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-37,available
11349,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-23",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-23,available
11350,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7984-20",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-20,available
11351,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Reverified,12/20/23,"Currently available, in stock, Production is ongoing",,,,Other,Current,,,65282-1510-1,available
11352,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Reverified,12/20/23,"Currently available, in stock, Production is ongoing",,,,Other,Current,,,65282-1505-1,available
11353,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-61",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-61,available
11354,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-02",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-02,available
11355,Sodium Chloride 0.9% Injection,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Reverified,12/20/23,Available,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7983-55",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-55,available
11356,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 g/100 mL (NDC 0264-7802-00)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7802-00,available
11357,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 g/100 mL (NDC 0264-7802-10)",Reverified,12/19/23,Product available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7802-10,available
11358,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-7388-60)",Revised,12/1/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-7388-60,limited availability
11359,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-7388-50)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-7388-50,limited availability
11360,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-2201-10)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2201-10,limited availability
11361,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 g/100mL (NDC 0264-2201-00)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2201-00,limited availability
11362,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Reverified,12/21/23,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-02,limited availability
11363,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Reverified,12/21/23,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-03,limited availability
11364,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Reverified,12/21/23,"Limited Supply On Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-04,limited availability
11365,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6138-22",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-6138-22,limited availability
11366,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6138-03",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-6138-03,limited availability
11367,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7138-09",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-7138-09,limited availability
11368,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Reverified,12/20/23,Unavailable,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7138-36",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-7138-36,not available
11369,Sodium Chloride 14.6% Injection,"Hospira, Inc., a Pfizer Company","Injection, 100 mEq/40 mL (2.5 mEq/mL) (NDC 0409-6660-75)",New,12/12/23,"Next Delivery and Estimated Recovery: January 2024, Shortage per Manufacturer: Manufacturing Delays",,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6660-75,limited availability
11370,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 14.6%, Injection, 2.5 meq/1 mL (NDC 63323-090-20)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-090-20,available
11371,Sodium Chloride 14.6% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 14.6%, Injection, 2.5 meq/1 mL (NDC 63323-090-40)",Reverified,12/20/23,Available,Check wholesaler inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-090-40,available
11372,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Reverified,12/20/23,Available,Check wholesaler inventory; old NDC 63323-088-63,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-099-63,available
11373,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Reverified,12/20/23,Available,Check wholesaler inventory; old NDC 63323-187-30,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-093-30,available
11374,Sodium Chloride 23.4% Injection,"Hospira, Inc., a Pfizer Company","Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",New,12/12/23,"Next Delivery: April 2024
Estimated Recovery: May 2024
, Shortage per Manufacturer: Manufacturing Delays",,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-1141-02,
11375,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-886-56)",Revised,11/29/23,Unavailable,Backordered. Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-886-56,not available
11376,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Hospira, Inc., a Pfizer Company","Sodium Phosphates In Plastic Container, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 0409-7391-72)",Revised,9/11/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7391-72,limited availability
11377,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-884-06)",Revised,11/29/23,Unavailable,Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-884-06,not available
11378,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi USA, LLC","Sodium Phosphates, Injection, 142 mg/1 mL; 276 mg/1 mL (NDC 63323-881-16)",Revised,11/29/23,Unavailable,Next release January 2024. Check wholesaler for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-881-16,not available
11379,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Revised,12/19/23,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-7704-21,limited availability
11380,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Revised,12/19/23,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-7705-21,limited availability
11381,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Revised,12/19/23,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-7708-21,limited availability
11382,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Revised,12/19/23,Intermittent supply until end of Q1 2024,,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-7703-21,limited availability
11383,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0781-3001-07,available
11384,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0781-3004-07,available
11385,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 12 mg/vial (NDC 0002-8148-01)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-8148-01,available
11386,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 24 mg/vial (NDC 0002-8149-01)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-8149-01,available
11387,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 mg/mL (NDC 0013-2626-81)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0013-2626-81,available
11388,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 mg/vial (NDC 0013-2646-81)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0013-2646-81,available
11389,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 mg/vial (NDC 0013-2649-02)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0013-2649-02,available
11390,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 mg/vial (NDC 0013-2650-02)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0013-2650-02,available
11391,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 mg/vial (NDC 0013-2651-02)",Reverified,12/19/23,Next Delivery: September 2023; Estimated Recovery: Q1 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2651-02,not available
11392,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 mg/vial (NDC 0013-2652-02)",Reverified,12/19/23,Next Delivery and Estimated Recovery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2652-02,not available
11393,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 mg/vial (NDC 0013-2653-02)",Reverified,12/19/23,Next Delivery and Estimated Recovery: January 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2653-02,not available
11394,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 mg/vial (NDC 0013-2654-02)",Reverified,12/19/23,Next Delivery and Estimated Recover: January 2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2654-02,not available
11395,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 mg/vial (NDC 0013-2655-02)",Reverified,12/19/23,Next Delivery and Estimated Recvoery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2655-02,not available
11396,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 mg/vial (NDC 0013-2656-02)",Reverified,12/19/23,Next Delivery and Estimated Recvoery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2656-02,not available
11397,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 mg/vial (NDC 0013-2657-02)",Reverified,12/19/23,Next Delivery and Estimated Recovery: December 2023,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,0013-2657-02,not available
11398,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 mg/vial (NDC 0013-2658-02)",Reverified,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0013-2658-02,available
11399,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 mg/2 mL (NDC 50242-074-01)",New,12/19/23,"Limited Supply, expected supply stability mid-2024",,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,50242-074-01,limited availability
11400,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 mg/2 mL (NDC 50242-075-01)",New,12/19/23,Not Available.  Next supply expected in Feb 2024 with supply stability by mid-2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,50242-075-01,not available
11401,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 mg/2 mL (NDC 50242-076-01)",New,12/19/23,Not Available.  Next supply expected in Jan 2024 with supply stability by mid-2024,,,Demand increase for the drug,Endocrinology/Metabolism,Current,,,50242-076-01,not available
11402,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 5 mg/vial (NDC 44087-1005-2)",Revised,1/9/23,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/23,1/9/23,44087-1005-2,discontinued
11403,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 8.8 mg/vial (NDC 44087-1088-1)",Revised,1/9/23,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/23,1/9/23,44087-1088-1,discontinued
11404,Somatropin Injection,"EMD Serono, Inc.","Saizen, Injection, 8.8 mg/vial (NDC 44087-0016-1)",Revised,1/9/23,,Discontinuation of the manufacture of the product,,,Endocrinology/Metabolism,To Be Discontinued,1/9/23,1/9/23,44087-0016-1,discontinued
11405,Sterile Water Injection,"Hikma Pharmaceuticals USA, Inc.","Sterile Water For Injection, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Revised,9/18/23,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Other,Current,,,0641-6147-10,available
11406,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-10)",Revised,9/11/23,Available,,,,Other,Current,,,0409-4887-10,available
11407,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-20)",Revised,9/11/23,Available,,,,Other,Current,,,0409-4887-20,available
11408,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-50)",Revised,9/11/23,Limited Supply Available. Next Delivery and Estimated Recovery: September 2023,,,,Other,Current,,,0409-4887-50,limited availability
11409,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mL/1 mL (NDC 0409-4887-99)",Revised,9/11/23,Available,,,,Other,Current,,,0409-4887-99,available
11410,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Other,Current,,,63323-185-10,available
11411,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Reverified,12/20/23,Next release not available at this time.,Check wholesalers for inventory,,Demand increase for the drug,Other,Current,,,63323-185-20,not available
11412,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Other,Current,,,63323-185-50,available
11413,Sterile Water Injection,"Medefil, Inc.","Injection, 100 mL/100 mL (NDC 64253-020-30)",Reverified,12/20/23,Available,,,,Other,Current,,,64253-020-30,available
11414,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Reverified,12/19/23,Available,,,,Other,Current,,,0409-3977-03,available
11415,Sterile Water Injection,"Fresenius Kabi USA, LLC","Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Reverified,12/20/23,Available,Check wholesalers for inventory,,,Other,Current,,,63323-178-76,available
11416,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Injection, 1 mL/1 mL (NDC 0487-6105-01)",Reverified,12/19/23,Available,,,,Other,Current,,,0487-6105-01,available
11417,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2101-10,limited availability
11418,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2101-00,limited availability
11419,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-22",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-6139-22,limited availability
11420,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-03",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-6139-03,limited availability
11421,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-09",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-7139-09,limited availability
11422,Sterile Water Irrigant,"ICU Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Reverified,12/20/23,Allocated to Contracted Customers Only,"ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-36",,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0990-7139-36,limited availability
11423,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Reverified,12/19/23,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-02,limited availability
11424,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Reverified,12/21/23,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-03,limited availability
11425,Sterile Water Irrigant,Baxter Healthcare,"Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Reverified,12/21/23,"Limited Supply on Allocation, Recovery Q1 2024",,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-04,limited availability
11426,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2101-10,limited availability
11427,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,12/19/23,Product on allocation for contracted customers,,,Demand increase for the drug,Gastroenterology; Other; Pediatric,Current,,,0264-2101-00,limited availability
11428,"Streptozocin Powder, For Solution","Teva Pharmaceuticals USA, Inc.","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)",Revised,12/19/23,Temporarily Unavailable,,,Demand increase for the drug,Oncology,Current,,,0703-4636-01,not available
11429,"Streptozocin Powder, For Solution","ESTEVE PHARMACEUTICALS, S.A.","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)",Reverified,12/19/23,Available,,,,Oncology,Current,,,68118-100-01,available
11430,Sucralfate Tablet,Amneal Pharmaceuticals,"Tablet, 1 g (NDC 69238-1656-1)",Revised,11/2/23,Available,Supplying existing customers with possibility to expand mid-November 2023,,,Gastroenterology,Current,,,69238-1656-1,available
11431,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 g (NDC 29033-003-01)",Reverified,11/2/23,Available,,,,Gastroenterology,Current,,,29033-003-01,available
11432,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 g (NDC 29033-003-05)",Reverified,11/2/23,Available,,,,Gastroenterology,Current,,,29033-003-05,available
11433,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-01)",Revised,12/6/23,Limited Supply Available,,,Demand increase for the drug,Gastroenterology,Current,,,0093-2210-01,limited availability
11434,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-05)",Revised,12/6/23,Limited Supply Available,,,Demand increase for the drug,Gastroenterology,Current,,,0093-2210-05,limited availability
11435,Sucralfate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 1 g (NDC 0093-2210-98)",Revised,12/6/23,Available,,,,Gastroenterology,Current,,,0093-2210-98,available
11436,Sucralfate Tablet,"Allergan, Inc.","Carafate, Tablet, 1 g (NDC 58914-171-10)",Revised,11/2/23,Available,Healthy inventory for demand of the Brand,,,Gastroenterology,Current,,,58914-171-10,available
11437,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 g (NDC 59762-040-11)",Revised,11/2/23,Unavailable,Recovery in December 2023,,Delay in shipping of the drug,Gastroenterology,Current,,,59762-040-11,not available
11438,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 g (NDC 59762-040-15)",Revised,11/2/23,Unavailable,Recovery in December 2023,,Delay in shipping of the drug,Gastroenterology,Current,,,59762-040-15,not available
11439,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-02)",Reverified,12/19/23,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-02,not available
11440,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-05)",Reverified,12/19/23,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-05,not available
11441,Sufentanil Citrate Injection,"Hospira, Inc., a Pfizer Company","Injection, 50 ug/1 mL (NDC 0409-3382-21)",Reverified,12/19/23,Limited Supply Available.,Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,0409-3382-21,limited availability
11442,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Injection, 50 mcg/1 mL (NDC 17478-050-01)",Reverified,12/19/23,Unavailable,Not currently manufactured,,Delay in shipping of the drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-01,not available
11443,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-01)",Revised,12/20/23,Available,,,,Gastroenterology,Current,,,62135-960-01,available
11444,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-05)",Revised,12/20/23,Available,,,,Gastroenterology,Current,,,62135-960-05,available
11445,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-10)",Revised,12/20/23,Available,,,,Gastroenterology,Current,,,62135-960-10,available
11446,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 62135-960-31)",Revised,12/20/23,Available,,,,Gastroenterology,Current,,,62135-960-31,available
11447,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-10)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0013-0101-10,available
11448,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-20)",Revised,12/19/23,Available,,,Demand increase for the drug,Gastroenterology,Current,,,0013-0101-20,available
11449,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-50)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0013-0102-50,available
11450,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-20)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0013-0102-20,available
11451,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-1)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,59762-0104-1,available
11452,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-6)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,59762-0104-6,available
11453,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-1)",Revised,12/19/23,Available,,,Demand increase for the drug,Gastroenterology,Current,,,59762-5000-1,available
11454,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-6)",Reverified,12/19/23,Next Delivery: September 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Gastroenterology,Current,,,59762-5000-6,not available
11455,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-01)",Revised,12/19/23,Available,NDC: 0591-0796-01 has been changed to NDC: 0093-3234-01,,,Gastroenterology,Current,,,0093-3234-01,available
11456,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-10)",Revised,12/19/23,Available,NDC: 0591-0796-10 has been changed to NDC: 0093-3234-10,,,Gastroenterology,Current,,,0093-3234-10,available
11457,Sulfasalazine Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 500 mg (NDC 0093-3234-05)",Revised,12/19/23,Available,NDC: 0591-0796-05 has been changed to NDC: 0093-3234-05,,,Gastroenterology,Current,,,0093-3234-05,available
11458,Sulfasalazine Tablet,Chartwell Molecular Holdings LLC,"Tablet, 500 mg (NDC 23155-019-01)",Revised,12/20/23,"Product Available. Distributed by Chartwell. For inquiries, call Customer Service number 845-268-5000  Ext: 510.",,,,Gastroenterology,Current,,,23155-019-01,available
11459,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0101-30)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0013-0101-30,available
11460,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 mg (NDC 0013-0102-60)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,0013-0102-60,available
11461,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 mg (NDC 59762-0104-5)",Reverified,12/19/23,Available,,,,Gastroenterology,Current,,,59762-0104-5,available
11462,Sulfasalazine Tablet,Pfizer Inc.,"Sulfasalazine, Tablet, 500 mg (NDC 59762-5000-5)",Reverified,12/19/23,Next Delivery: September 2023; Estimated Recovery: January 2024,,,Demand increase for the drug,Gastroenterology,Current,,,59762-5000-5,not available
11463,Sumatriptan Spray,GlaxoSmithKline,"Imitrex, Spray, 5 mg (NDC 0173-0524-00)",New,8/8/23,,"The last date the product will be available for ordering is January 31, 2024.",,,Neurology,To Be Discontinued,8/8/23,8/8/23,0173-0524-00,discontinued
11464,Sumatriptan Spray,GlaxoSmithKline,"Imitrex, Spray, 20 mg (NDC 0173-0523-00)",New,8/8/23,,"The last date the product will be available for ordering is January 31, 2024.",,,Neurology,To Be Discontinued,8/8/23,8/8/23,0173-0523-00,discontinued
11465,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 7.5 Ci/7.5 Ci (NDC 71612-075-02)",New,10/17/23,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution; The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-075-02,discontinued
11466,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 12 Ci/12 Ci (NDC 71612-120-02)",New,10/17/23,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution. The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-120-02,discontinued
11467,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 19 Ci/19 Ci (NDC 71612-190-02)",New,10/17/23,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution. The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-190-02,discontinued
11468,Technetium Tc-99m Sodium Pertechnetate Generator,"NorthStar Medical Radioisotopes, LLC","RadioGenix® System, Generator, 15 Ci/15 Ci (NDC 71612-150-02)",New,10/17/23,,"The RadioGenix System is a technetium Tc 99m generator that produces Sodium Pertechnetate Tc 99m Injection, USP from a non-uranium potassium molybdate Mo-99 source solution, which is shielded within a source container that completely encases a vial containing 22-30 mL of solution; The company has made a business decision to discontinue production and distribution. The production date for the last batch of Mo-99 source vessels is October 30, 2023 with an expiration date of November 20, 2023.",,Discontinuation of the manufacture of the drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-150-02,discontinued
11469,Testosterone Cypionate Injection,"Teva Pharmaceuticals USA, Inc.","Testosterone Cypionate, Injection, 200 mg/1 mL (NDC 0591-4128-79)",New,4/18/23,,,,,Urology,To Be Discontinued,4/18/23,4/18/23,0591-4128-79,discontinued
11470,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-18)",New,12/7/23,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/23,63481-183-18,discontinued
11471,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-17)",New,12/7/23,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/23,63481-183-17,discontinued
11472,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 63481-183-16)",New,12/7/23,,,,Discontinuation of the manufacture of the drug,Urology,To Be Discontinued,,12/7/23,63481-183-16,discontinued
11473,"Testosterone Gel, Metered",Endo Pharmaceuticals. Inc.,"Fortesta, Gel, Metered, 10 mg/.5 g (NDC 0603-7831-88)",New,8/25/23,,,,,Urology,To Be Discontinued,8/25/23,8/25/23,0603-7831-88,discontinued
11474,Testosterone Patch,AbbVie Inc.,"Androderm, Patch, 2 mg/1 d (NDC 0023-5990-60)",New,1/10/23,,The discontinuation is limited to only the NDCs listed.  Other NDCs of the same or similar products will continue to be available.,,,Urology,To Be Discontinued,1/10/23,1/10/23,0023-5990-60,discontinued
11475,Testosterone Patch,AbbVie Inc.,"Androderm, Patch, 4 mg/1 d (NDC 0023-5992-30)",New,1/10/23,,The discontinuation is limited to only the NDCs listed.  Other NDCs of the same or similar products will continue to be available.,,,Urology,To Be Discontinued,1/10/23,1/10/23,0023-5992-30,discontinued
11476,Tirofiban Hydrochloride Injection,Medicure Pharma Inc.,"Aggrastat, Injection, 5 mg/100 mL (NDC 25208-002-03)",New,2/24/23,,"The discontinuation is limited to only the NDC listed.  Tirofiban hydrochloride injection 5 mg/100 mL bag, 50 mcg/mL (NDC 25208-002-01) will continue to be available",,,Cardiovascular,To Be Discontinued,2/24/23,2/24/23,25208-002-03,discontinued
11477,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 2.5 mg/.5 mL (NDC 0002-1506-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1506-80,available
11478,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 7.5 mg/.5 mL (NDC 0002-1484-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1484-80,available
11479,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 12.5 mg/.5 mL (NDC 0002-1460-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1460-80,available
11480,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 15 mg/.5 mL (NDC 0002-1457-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1457-80,available
11481,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 10 mg/.5 mL (NDC 0002-1471-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1471-80,available
11482,Tirzepatide Injection,Eli Lilly and Co.,"Mounjaro, Injection, 5 mg/.5 mL (NDC 0002-1495-80)",Revised,12/19/23,Available,,,,Endocrinology/Metabolism,Current,,,0002-1495-80,available
11483,Triamcinolone Acetonide Injection,Novartis Pharmaceuticals Corporation,"Triesence, Injection, 40 mg/1 mL (NDC 0065-0543-01)",Revised,11/1/23,"Availability through wholesalers: Unavailable,  3-18 months",There are no therapeutic equivalents.,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,0065-0543-01,not available
11484,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Reverified,12/19/23,Unavailable,,,Delay in shipping of the drug,Rheumatology,Current,,,59137-570-01,not available
11485,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-03)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,43386-660-03,not available
11486,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-24)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,43386-660-24,not available
11487,Trimethobenzamide Hydrochloride Capsule,"Lupin Pharmaceuticals, Inc.","Trimethobenzamide Hydrochloride, Capsule, 300 mg (NDC 43386-660-26)",Reverified,10/25/21,Currently unavailable. Estimated shortage duration: TBD,,,,Gastroenterology,Current,,,43386-660-26,not available
11488,Trimethobenzamide Hydrochloride Capsule,Pfizer Inc.,"Tigan, Capsule, 300 mg (NDC 61570-079-01)",Reverified,11/28/22,Discontinued,,,,Gastroenterology,Current,,,61570-079-01,discontinued
11489,Trimethobenzamide Hydrochloride Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 300 mg (NDC 53489-376-01)",Revised,11/1/23,Unavailable,,,Shortage of an active ingredient,Gastroenterology,Current,,,53489-376-01,not available
11490,Ursodiol Tablet,AbbVie Inc.,"Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",New,6/23/23,,,,,Other,To Be Discontinued,6/23/23,6/23/23,0591-3005-01,discontinued
11491,Ursodiol Tablet,AbbVie Inc.,"Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",New,6/23/23,,,,,Other,To Be Discontinued,6/23/23,6/23/23,0591-2998-01,discontinued
11492,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso 250, Tablet, Film Coated, 250 mg (NDC 58914-785-10)",New,6/23/23,,,,,Other,To Be Discontinued,6/23/23,6/23/23,58914-785-10,discontinued
11493,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso Forte, Tablet, Film Coated, 500 mg (NDC 58914-790-01)",New,6/23/23,,,,,Other,To Be Discontinued,6/23/23,6/23/23,58914-790-01,discontinued
11494,"Ursodiol Tablet, Film Coated",AbbVie Inc.,"Urso Forte, Tablet, Film Coated, 500 mg (NDC 58914-790-10)",New,6/23/23,,,,,Other,To Be Discontinued,6/23/23,6/23/23,58914-790-10,discontinued
11495,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Revised,5/16/23,Inventory is currently available.,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Neurology,Current,,,0143-9785-10,available
11496,Valproate Sodium Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg/1 mL (NDC 63323-494-05)",Reverified,12/20/23,Next release not available at this time.,Check wholesaler inventory,,Demand increase for the drug,Neurology,Current,,,63323-494-05,not available
11497,Valproate Sodium Injection,Sagent Pharmaceuticals,"Injection, 100 mg/mL, 5 mL (NDC 70860-784-41)",Revised,10/31/23,Available,,,,Neurology,Current,,,70860-784-41,available
11498,Vecuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 0409-1632-01)",Reverified,9/11/23,Available,,,,Anesthesia,Current,,,0409-1632-01,available
11499,Vecuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Injection, 1 mg/1 mL (NDC 67457-438-10)",Reverified,12/21/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-438-10,available
11500,Vecuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Injection, 1 mg/1 mL (NDC 67457-475-20)",Reverified,12/21/23,Available,,,Demand increase for the drug,Anesthesia,Current,,,67457-475-20,available
11501,Vecuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-781-10)",Reverified,12/20/23,6 month expiry (4/30/2024 expiry) dating available by request.,Check wholesaler inventory,,Delay in shipping of the drug,Anesthesia,Current,,,63323-781-10,limited availability
11502,Vecuronium Bromide Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-782-20)",Reverified,12/20/23,Not available at this time.,,,Delay in shipping of the drug,Anesthesia,Current,,,63323-782-20,not available
11503,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 47335-931-44)",Reverified,9/23/22,Available,,,,Anesthesia,Current,,,47335-931-44,available
11504,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 mg/1 mL (NDC 47335-932-44)",Reverified,9/23/22,Available,,,,Anesthesia,Current,,,47335-932-44,available
11505,Vecuronium Bromide Injection,Eugia US LLC,"Injection, 10 mg (NDC 55150-235-10)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-235-10,available
11506,Vecuronium Bromide Injection,Eugia US LLC,"Injection, 20 mg (NDC 55150-236-20)",Revised,11/1/23,Available,Sporadic availability expected.,,,Anesthesia,Current,,,55150-236-20,available
11507,Vinblastine Sulfate Injection,"Fresenius Kabi USA, LLC","Injection, 1 mg/1 mL (NDC 63323-278-10)",Reverified,12/20/23,Backordered. Next release expected December 2023.,Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,63323-278-10,not available
11508,Voriconazole Injection,"XGen Pharmaceuticals DJB, Inc.","Voriconazole, Injection, 10 mg/1 mL (NDC 39822-1077-1)",New,5/19/23,,Final lot to be received for distribution in May/June 2023; anticipated inventory depletion by end of year 2023,,,Anti-Infective,To Be Discontinued,5/19/23,5/19/23,39822-1077-1,discontinued
11509,"Voriconazole Tablet, Film Coated",Pfizer Inc.,"Vfend, Tablet, Film Coated, 200 mg (NDC 0049-3180-30)",New,5/10/23,,Discontinuation of the manufacture of the drug; Supply expected to exhaust late June 2023,,,Anti-Infective,To Be Discontinued,5/10/23,5/10/23,0049-3180-30,discontinued
11510,Zoledronic Acid Injection,"Hospira, Inc., a Pfizer Company","Zoledronic Acid, Injection, 4 mg/5 mL (NDC 0409-4215-01)",New,5/4/23,,Discontinuation of the manufacture of the drug,,,Oncology; Endocrinology/Metabolism,To Be Discontinued,5/4/23,5/4/23,0409-4215-01,discontinued
11511,Zolmitriptan Tablet,IPR PHARMACEUTICALS INC,"Zomig, Tablet, 2.5 mg (NDC 64896-671-51)",New,3/3/23,,,,,Neurology,To Be Discontinued,3/3/23,3/3/23,64896-671-51,discontinued
11512,Zolmitriptan Tablet,IPR PHARMACEUTICALS INC,"Zomig, Tablet, 5 mg (NDC 64896-672-50)",New,3/3/23,,,,,Neurology,To Be Discontinued,3/3/23,3/3/23,64896-672-50,discontinued
11513,"Zolmitriptan Tablet, Orally Disintegrating",AstraZeneca Pharmaceuticals LP,"Zomig-zmt, Tablet, Orally Disintegrating, 2.5 mg (NDC 64896-691-51)",New,3/3/23,,,,,Neurology,To Be Discontinued,3/3/23,3/3/23,64896-691-51,discontinued
11514,"Zolmitriptan Tablet, Orally Disintegrating",AstraZeneca Pharmaceuticals LP,"Zomig-zmt, Tablet, Orally Disintegrating, 5 mg (NDC 64896-692-50)",New,3/3/23,,,,,Neurology,To Be Discontinued,3/3/23,3/3/23,64896-692-50,discontinued
11515,Acyclovir Tablet,Apotex Corp.,"Tablet, 400 Mg/1 (NDC 60505-5306-1)",New,4/26/24,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/24,60505-5306-1,discontinued
11516,Acyclovir Tablet,Apotex Corp.,"Tablet, 400 Mg/1 (NDC 60505-5306-8)",New,4/26/24,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/24,60505-5306-8,discontinued
11517,Acyclovir Tablet,Apotex Corp.,"Tablet, 800 Mg/1 (NDC 60505-5307-1)",New,4/26/24,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/24,60505-5307-1,discontinued
11518,Acyclovir Tablet,Apotex Corp.,"Tablet, 800 Mg/1 (NDC 60505-5307-5)",New,4/26/24,,Business Related Decision To Discontinue The Product,,,Antiviral,To Be Discontinued,,4/26/24,60505-5307-5,discontinued
11519,"Albuterol Sulfate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Proair Digihaler, Powder, Metered, 90 Ug (NDC 59310-117-20)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-117-20,discontinued
11520,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 Mg/.5 Ml (NDC 0487-9901-30)",Revised,7/17/24,Available,,,,Pulmonary/Allergy; Pediatric,Current,,,0487-9901-30,available
11521,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-15)",New,11/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-15,discontinued
11522,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-45)",New,11/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-45,discontinued
11523,Alclometasone Dipropionate Cream,Sandoz Inc.,"Cream, .5 Mg/1 G (NDC 0168-0263-60)",New,11/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/27/23,0168-0263-60,discontinued
11524,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 1000 Ug (NDC 0037-8140-06)",Revised,8/12/24,,,,,Urology,To Be Discontinued,8/12/24,8/12/24,0037-8140-06,discontinued
11525,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 500 Ug (NDC 0037-8130-06)",Revised,8/12/24,,,,,Urology,To Be Discontinued,8/12/24,8/12/24,0037-8130-06,discontinued
11526,Alprostadil Suppository,"Mylan Institutional, A Viatris Company","Muse, Suppository, 250 Ug (NDC 0037-8120-06)",Revised,8/12/24,,,,,Urology,To Be Discontinued,8/12/24,8/12/24,0037-8120-06,discontinued
11527,Amifostine Injection,"Clinigen, Inc.","Ethyol, Injection, 500 Mg/10 Ml (NDC 76310-017-50)",Revised,4/18/24,Unavailable,Temporary Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Oncology; Other,Current,,,76310-017-50,not available
11528,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,9/5/24,Available,,,,Gastroenterology,Current,,,0338-0502-03,available
11529,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,9/3/24,Available,,,,Gastroenterology,Current,,,0264-4500-05,available
11530,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,9/5/24,Available,,,,Gastroenterology,Current,,,0338-0502-06,available
11531,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn-Pf 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,9/4/24,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-4179-05",,Shortage Of An Active Ingredient,Gastroenterology,Current,,,0990-4179-05,not available
11532,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn-Pf 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,9/4/24,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-4178-03",,Shortage Of An Active Ingredient,Gastroenterology,Current,,,0990-4178-03,not available
11533,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn Ii 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7172-17",,,Gastroenterology,Current,,,0990-7172-17,available
11534,Amino Acid Injection,"Icu Medical, Inc.","Aminosyn Ii 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7171-17",,,Gastroenterology,Current,,,0990-7171-17,available
11535,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,9/3/24,Available,,,,Gastroenterology,Current,,,0264-4500-00,available
11536,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 150 Mg (NDC 0591-5716-30)",Revised,9/4/24,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,0591-5716-30,not available
11537,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 100 Mg (NDC 0591-5715-01)",Revised,9/4/24,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,0591-5715-01,not available
11538,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 25 Mg (NDC 0591-5713-01)",Revised,9/4/24,Unavailable,Estimated Recovery October 2024,,Other,Psychiatry,Current,,,0591-5713-01,not available
11539,Amoxapine Tablet,"Teva Pharmaceuticals Usa, Inc.","Amoxapine Tablets, Usp, Tablet, 50 Mg (NDC 0591-5714-01)",Reverified,9/4/24,Unavailable,Estimated Recovery September 2024,,Other,Psychiatry,Current,,,0591-5714-01,not available
11540,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-75)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-75,available
11541,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-50)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-50,available
11542,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-80)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-80,available
11543,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Amoxicillin, Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-15)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-15,available
11544,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-75)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-75,available
11545,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-50)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-50,available
11546,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-80)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-80,available
11547,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-15)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-15,available
11548,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-75)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-071-75,available
11549,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-50)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-071-50,available
11550,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-80)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-707-80,available
11551,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-55)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-707-55,available
11552,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-75)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-070-75,available
11553,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-50)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-070-50,available
11554,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-80)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-706-80,available
11555,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-55)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-706-55,available
11556,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-78)",Revised,9/4/24,Available,Estimated Recovery May 2025,,,Anti-Infective; Pediatric,Current,,,0093-4161-78,available
11557,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-76)",Revised,9/4/24,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4161-76,available
11558,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 400 Mg/5 Ml (NDC 0093-4161-73)",Reverified,9/4/24,Available,Estimated Recovery December 2024,,Demand Increase For The Drug,Anti-Infective,Current,,,0093-4161-73,available
11559,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-78)",Revised,9/4/24,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,0093-4160-78,available
11560,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-76)",Revised,9/4/24,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4160-76,available
11561,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 200 Mg/5 Ml (NDC 0093-4160-73)",Revised,9/4/24,Available,,,,Anti-Infective; Pediatric,Current,,,0093-4160-73,available
11562,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-79)",Reverified,9/4/24,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,0093-4155-79,available
11563,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-80)",Reverified,9/4/24,Available,Estimated Recovery November 2024,,,Anti-Infective; Pediatric,Current,,,0093-4155-80,available
11564,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals Usa, Inc.","Amoxicillin For Oral Suspension, Usp, Powder, For Suspension, 250 Mg/5 Ml (NDC 0093-4155-73)",Reverified,9/4/24,Available,Estimated Recovery January 2025,,,Anti-Infective; Pediatric,Current,,,0093-4155-73,available
11565,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-58)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6041-58,limited availability
11566,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-55)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6041-55,available
11567,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 250 Mg/5 Ml (NDC 0781-6041-46)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6041-46,limited availability
11568,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-57)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6157-57,limited availability
11569,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-52)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6157-52,limited availability
11570,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 400 Mg/5 Ml (NDC 0781-6157-46)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6157-46,limited availability
11571,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-57)",Reverified,8/5/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0781-6156-57,limited availability
11572,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-52)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6156-52,available
11573,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 200 Mg/5 Ml (NDC 0781-6156-46)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6156-46,available
11574,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-58)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-58,available
11575,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-55)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-55,available
11576,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Powder, For Suspension, 125 Mg/5 Ml (NDC 0781-6039-46)",Reverified,8/5/24,Available,,,,Anti-Infective; Pediatric,Current,,,0781-6039-46,available
11577,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 400 Mg/5 Ml (NDC 0143-9887-01)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9887-01,available
11578,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 250 Mg/5 Ml (NDC 0143-9889-01)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9889-01,available
11579,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 200 Mg/5 Ml (NDC 0143-9886-01)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9886-01,available
11580,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals Usa, Inc.","Powder, For Suspension, 125 Mg/5 Ml (NDC 0143-9888-01)",Reverified,8/28/24,Available,,,,Anti-Infective; Pediatric,Current,,,0143-9888-01,available
11581,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 400 Mg/5 Ml (NDC 65862-071-01)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-071-01,available
11582,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 250 Mg/5 Ml (NDC 65862-707-01)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-707-01,available
11583,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 200 Mg/5 Ml (NDC 65862-070-01)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-070-01,available
11584,"Amoxicillin Powder, For Suspension",Aurobindo Pharma Usa,"Powder, For Suspension, 125 Mg/5 Ml (NDC 65862-706-01)",Revised,5/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,65862-706-01,available
11585,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 70010-117-01)",Reverified,8/26/24,Available,,,,Psychiatry,Current,,,70010-117-01,available
11586,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 70010-116-01)",Reverified,8/26/24,Available,,,,Psychiatry,Current,,,70010-116-01,available
11587,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 70010-115-01)",Reverified,8/26/24,Available,,,,Psychiatry,Current,,,70010-115-01,available
11588,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 70010-114-01)",Reverified,7/23/24,Unavailable,Estimated Availability: July 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,70010-114-01,not available
11589,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 70010-113-01)",Reverified,8/26/24,Available,,,,Psychiatry,Current,,,70010-113-01,available
11590,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 70010-112-01)",Reverified,7/23/24,Unavailable,Estimated Availability: July 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,70010-112-01,not available
11591,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 70010-111-01)",Reverified,8/26/24,Available,,,,Psychiatry,Current,,,70010-111-01,available
11592,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 64850-506-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-506-01,available
11593,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 64850-505-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-505-01,available
11594,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 64850-504-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-504-01,available
11595,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 64850-503-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-503-01,available
11596,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 64850-502-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-502-01,available
11597,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 64850-501-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-501-01,available
11598,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 64850-500-01)",Reverified,9/2/24,Available,,,,Psychiatry,Current,,,64850-500-01,available
11599,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 13107-070-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-070-01,not available
11600,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 13107-069-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-069-01,not available
11601,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 13107-068-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-068-01,not available
11602,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0527-0766-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-0766-37,available
11603,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0527-1505-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-1505-37,available
11604,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0527-0764-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-0764-37,available
11605,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 0527-0763-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-0763-37,available
11606,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0527-1502-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-1502-37,available
11607,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0527-0761-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-0761-37,available
11608,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0527-0760-37)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,0527-0760-37,available
11609,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 13107-074-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-074-01,not available
11610,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 13107-073-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-073-01,not available
11611,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma Usa,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 13107-072-01)",Revised,1/31/24,Estimated Availability: September 2024,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,13107-072-01,not available
11612,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 11534-196-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-196-01,available
11613,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 11534-195-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-195-01,available
11614,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 11534-194-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-194-01,available
11615,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 11534-193-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-193-01,available
11616,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 11534-191-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-191-01,available
11617,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 11534-192-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-192-01,available
11618,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 11534-190-01)",Reverified,5/1/24,Available,,,,Psychiatry,Current,,,11534-190-01,available
11619,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 47781-180-01)",Reverified,5/18/24,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,47781-180-01,available
11620,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 47781-179-01)",Reverified,7/2/24,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,47781-179-01,available
11621,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 47781-178-01)",Reverified,8/16/24,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,47781-178-01,available
11622,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 47781-176-01)",Reverified,9/4/24,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,47781-176-01,available
11623,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 47781-174-01)",Reverified,7/2/24,Available,Supporting Contracted Business Only,,,Psychiatry,Current,,,47781-174-01,available
11624,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 42806-339-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,42806-339-01,available
11625,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 42806-345-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,42806-345-01,available
11626,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 42806-343-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,42806-343-01,available
11627,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 42806-341-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,42806-341-01,available
11628,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, Llc","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 42806-344-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,42806-344-01,available
11629,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0406-8894-01)",Revised,8/15/24,Limited Availability,Available To Primary Customers Only. Next Release Late Aug With Intermittent Backorder Through Oct 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-8894-01,limited availability
11630,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0406-8893-01)",Revised,8/15/24,Limited Availability,Available For Primary Customers Only. Backorder Projected In November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-8893-01,limited availability
11631,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0406-8892-01)",Revised,8/15/24,Limited Availability,Available For Primary Customers Only. Backorder Projected In November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-8892-01,limited availability
11632,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0406-8891-01)",Revised,8/15/24,Limited Availability,Available To Primary Customers Only.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-8891-01,limited availability
11633,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0406-8885-01)",Revised,8/15/24,Limited Availability,Available For Primary Customers Only; Backorder Expected In August 2024 With Recovery Late Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-8885-01,limited availability
11634,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Specgx Llc,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0406-8884-01)",Revised,8/15/24,Available,Available For Primary Customers,,,Psychiatry,Current,,,0406-8884-01,available
11635,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 72516-011-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,72516-011-01,available
11636,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 72516-012-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,72516-012-01,available
11637,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 72516-013-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,72516-013-01,available
11638,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 72516-014-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,72516-014-01,available
11639,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Uspharma Windlas,"Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 72516-016-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,72516-016-01,available
11640,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0555-0971-02)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,0555-0971-02,available
11641,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0555-0974-02)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,0555-0974-02,available
11642,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0555-0973-02)",Revised,8/23/24,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,0555-0973-02,available
11643,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0555-0972-02)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,0555-0972-02,available
11644,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 0555-0775-02)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,0555-0775-02,available
11645,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 0555-0777-02)",Revised,8/23/24,Limited Availability,Estimated Recovery September 2024,,Demand Increase For The Drug,Psychiatry,Current,,,0555-0777-02,limited availability
11646,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 0555-0776-02)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,0555-0776-02,available
11647,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 1.875 Mg; 1.875 Mg; 1.875 Mg; 1.875 Mg (NDC 57844-117-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-117-01,available
11648,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 57844-105-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-105-01,available
11649,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 57844-130-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-130-01,available
11650,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 57844-120-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-120-01,available
11651,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 3.75 Mg; 3.75 Mg; 3.75 Mg; 3.75 Mg (NDC 57844-115-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-115-01,available
11652,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 3.125 Mg; 3.125 Mg; 3.125 Mg; 3.125 Mg (NDC 57844-112-01)",Reverified,9/4/24,Available,Estimated Recovery September 2024,,,Psychiatry,Current,,,57844-112-01,available
11653,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals Usa, Inc.","Adderall, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 57844-110-01)",Revised,8/23/24,Available,,,,Psychiatry,Current,,,57844-110-01,available
11654,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 Mg; 1.25 Mg; 1.25 Mg; 1.25 Mg (NDC 0185-2098-01)",Reverified,8/5/24,Available,,,,Psychiatry,Current,,,0185-2098-01,available
11655,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 Mg; 2.5 Mg; 2.5 Mg; 2.5 Mg (NDC 0185-0842-01)",Revised,8/5/24,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,0185-0842-01,limited availability
11656,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 Mg; 5 Mg; 5 Mg; 5 Mg (NDC 0185-0853-01)",Revised,8/5/24,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,0185-0853-01,limited availability
11657,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 Mg; 7.5 Mg; 7.5 Mg; 7.5 Mg (NDC 0185-2099-01)",Revised,8/5/24,Limited Availability,Intermittent Backorders Through Oct 2024,,Other,Psychiatry,Current,,,0185-2099-01,limited availability
11658,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 125 Mg (NDC 0781-9401-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-9401-95,discontinued
11659,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-9250-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-9250-95,discontinued
11660,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 250 Mg (NDC 0781-9242-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-9242-95,discontinued
11661,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 125 Mg (NDC 0781-3400-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-3400-95,discontinued
11662,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-9407-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-9407-95,discontinued
11663,Ampicillin Sodium Injection,Sandoz Inc.,"Injection, 250 Mg (NDC 0781-9402-95)",New,3/4/24,,Other Ndcs Are Available,,,Antibiotic,To Be Discontinued,,3/4/24,0781-9402-95,discontinued
11664,"Atropa Belladonna, Opium Suppository",Padagis Us Llc,"Belladonna And Opium, Suppository, 16.2 Mg; 60 Mg (NDC 0574-7040-04)",Revised,7/1/24,Available,,,,Urology,Current,,,0574-7040-04,available
11665,"Atropa Belladonna, Opium Suppository",Padagis Us Llc,"Belladonna And Opium, Suppository, 16.2 Mg; 60 Mg (NDC 0574-7040-12)",Revised,7/1/24,Available,,,,Urology,Current,,,0574-7040-12,available
11666,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 Mg/1 Ml (NDC 64253-400-91)",Revised,9/3/24,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,64253-400-91,available
11667,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .05 Mg/1 Ml (NDC 16729-483-03)",Reverified,8/19/24,Unavailable,Temporarily Discontinued,,Other,Anesthesia; Neurology; Pediatric,Current,,,16729-483-03,not available
11668,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 Mg/1 Ml (NDC 16729-484-90)",Reverified,8/19/24,Unavailable,Temporarily Discontinued,,Other,Anesthesia; Neurology; Pediatric,Current,,,16729-484-90,not available
11669,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .1 Mg/1 Ml (NDC 16729-484-45)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,16729-484-45,not available
11670,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, 1 Mg/1 Ml (NDC 16729-526-08)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,16729-526-08,not available
11671,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 Mg/1 Ml (NDC 16729-512-43)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,16729-512-43,not available
11672,Atropine Sulfate Injection,Accord Healthcare Inc.,"Injection, .4 Mg/1 Ml (NDC 16729-525-08)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia; Neurology; Pediatric,Current,,,16729-525-08,not available
11673,Atropine Sulfate Injection,"American Regent, Inc.","Injection, .4 Mg/1 Ml (NDC 0517-1004-25)",Reverified,7/15/24,Available,Old Ndc 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1004-25,available
11674,Atropine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, .4 Mg/1 Ml (NDC 63323-580-20)",Revised,9/4/24,Limited Availability,2 Month Dating Available On Request. Next Release September 2024.,,Other,Anesthesia; Neurology; Pediatric,Current,,,63323-580-20,limited availability
11675,Atropine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Atropine Sulfate Injection, Usp, Injection, 0.4 Mg/1 Ml (NDC 0641-6251-10)",Reverified,8/28/24,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0641-6251-10,available
11676,Atropine Sulfate Injection,"American Regent, Inc.","Injection, 1 Mg/1 Ml (NDC 0517-1001-25)",Reverified,7/15/24,Available,Old Ndc 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1001-25,available
11677,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 1 Mg/10 Ml (0.1 Mg/Ml) Syringes (NDC 0409-4911-34)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,0409-4911-34,not available
11678,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 0.5 Mg/5 Ml (0.1 Mg/Ml) Syringes (NDC 0409-4910-34)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,0409-4910-34,not available
11679,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 0.25 Mg/5 Ml (0.05 Mg/Ml) Syringes (NDC 0409-9630-05)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0409-9630-05,available
11680,Atropine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Atropine Sulfate, Injection, 1 Mg/10 Ml (0.1 Mg/Ml) Syringes (NDC 0409-1630-10)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0409-1630-10,available
11681,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, .1 Mg/1 Ml (NDC 76329-3340-1)",Reverified,8/20/24,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,76329-3340-1,available
11682,Atropine Sulfate Ointment,Bausch & Lomb Incorporated,"Ointment, 10 Mg/1 G (NDC 24208-825-55)",New,12/6/23,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia; Neurology; Pediatric,To Be Discontinued,,12/6/23,24208-825-55,discontinued
11683,Azacitidine Injection,Eugia Us Llc,"Injection, 100 Mg/4 Ml (NDC 55150-393-01)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,55150-393-01,available
11684,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 100 Mg/30 Ml (NDC 71288-115-30)",Reverified,7/3/24,Available,,,,Oncology,Current,,,71288-115-30,available
11685,Azacitidine Injection,Cipla Limited,"Injection, 100 Mg (NDC 69097-805-40)",Reverified,3/5/24,,This Presentation Has Been Discontinued.,,,Oncology,To Be Discontinued,3/5/24,3/5/24,69097-805-40,discontinued
11686,Azacitidine Injection,Accord Healthcare Inc.,"Injection, 100 Mg (NDC 16729-306-10)",Revised,8/19/24,"Unavailable, 45-60 Days",Manufacturing Capacity,,Other,Oncology,Current,,,16729-306-10,not available
11687,Azacitidine Injection,Armas Pharmaceuticals Inc,"Injection, 100 Mg (NDC 72485-201-01)",Reverified,7/15/24,Available,,,,Oncology,Current,,,72485-201-01,available
11688,Azacitidine Injection,"Dr. Reddy'S Laboratories, Inc.","Injection, 100 Mg (NDC 43598-305-62)",Reverified,7/23/24,Available,,,,Oncology,Current,,,43598-305-62,available
11689,Azacitidine Injection,"Hikma Pharmaceuticals Usa, Inc.","Azacitidine For Injection, Injection, 100 Mg/ Vial (NDC 0143-9606-01)",Reverified,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Oncology,Current,,,0143-9606-01,available
11690,Azacitidine Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Mg/30 Ml (NDC 63323-771-39)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Oncology,Current,,,63323-771-39,available
11691,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg (NDC 59572-102-01)",Reverified,5/27/24,Available,,,,Oncology,Current,,,59572-102-01,available
11692,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg, Powder, Lyoph (NDC 0781-9253-94)",Revised,12/19/23,Discontinuation,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,12/19/23,12/19/23,0781-9253-94,discontinued
11693,Azacitidine Injection,Celgene Corporation,"Vidaza, Injection, 100 Mg (NDC 0781-3253-94)",Revised,12/19/23,Discontinuation,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,12/19/23,12/19/23,0781-3253-94,discontinued
11694,Azacitidine Injection,"Teva Pharmaceuticals Usa, Inc.","Azacitidine For Injection, Injection, 100 Mg (NDC 68001-313-56)",Revised,9/4/24,Available,,,,Oncology,Current,,,68001-313-56,available
11695,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-75)",New,7/26/24,,,,,Anti-Infective,To Be Discontinued,,7/26/24,0069-3051-75,discontinued
11696,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 59762-3051-1)",New,5/17/24,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/24,59762-3051-1,discontinued
11697,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 59762-3051-2)",New,5/17/24,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/24,59762-3051-2,discontinued
11698,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 200 Mg/5 Ml (NDC 59762-3120-1)",New,5/17/24,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/24,59762-3120-1,discontinued
11699,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 900 Mg/22.5 Ml (NDC 59762-3130-1)",New,5/17/24,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/24,59762-3130-1,discontinued
11700,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1200 Mg/30 Ml (NDC 59762-3140-1)",New,5/17/24,,Discontinuation Of The Manufacture Of The Drug.,,,Antiviral,To Be Discontinued,,5/17/24,59762-3140-1,discontinued
11701,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-75)",New,3/26/24,,Discontinuation Due To Business Reasons.,,,Anti-Infective,To Be Discontinued,,3/26/24,0069-3051-75,discontinued
11702,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 200 Mg/5 Ml (NDC 0069-3140-19)",New,9/28/23,,,,,Antibiotic,To Be Discontinued,,2/28/24,0069-3140-19,discontinued
11703,Azithromycin For Suspension,Pfizer Inc.,"For Suspension, 300 Mg/15ml (NDC 0069-3110-19)",New,9/28/23,,Discontinuation Due To Business Reasons.,,,Antibiotic,To Be Discontinued,,9/28/23,0069-3110-19,discontinued
11704,Azithromycin For Suspension,Pfizer Inc.,"Zithromax, For Suspension, 1 G (NDC 0069-3051-07)",New,9/28/23,,Discontinuation Due To Business Reasons.,,,Antibiotic,To Be Discontinued,,9/28/23,0069-3051-07,discontinued
11705,Barium Sulfate Cream,Bracco Diagnostics,"E-Z-Paste, Cream, .6 G/1 G (NDC 32909-770-01)",New,3/26/24,,Discontinued Due To Business Reasons.,,,Medical Imaging,To Be Discontinued,,3/26/24,32909-770-01,discontinued
11706,Barium Sulfate Suspension,Bracco Diagnostics,"Neulumex, Suspension, 1 Mg/1 Ml (NDC 32909-927-03)",New,5/2/24,,Discontinued Due To Business Reasons.,,,Cardiovascular,To Be Discontinued,,5/2/24,32909-927-03,discontinued
11707,Barium Sulfate Suspension,Bracco Diagnostics,"Liquid Polibar Plus, Suspension, 1.05 G/1 Ml (NDC 32909-167-55)",New,5/2/24,,Discontinued Due To Business Reasons.,,,Medical Imaging,To Be Discontinued,,5/2/24,32909-167-55,discontinued
11708,Betaxolol Hydrochloride Ophthalmic Suspension,Novartis Pharmaceuticals Corporation,"Betoptic S, Ophthalmic Suspension, 2.8 Mg/1 Ml (NDC 0078-0729-10)",New,7/2/24,,"Novartis Has Made A Business Decision To Permanently Discontinue Betoptic S® (Betaxolol Hydrochloride Ophthalmic Suspension), 0.25% As Base.Discontinuation Of The Product Is Not Due To Manufacturing, Product Quality, Safety, Or Efficacy Concerns.",,,Ophthalmology,To Be Discontinued,,7/2/24,0078-0729-10,discontinued
11709,Betaxolol Hydrochloride Ophthalmic Suspension,Novartis Pharmaceuticals Corporation,"Betoptic S, Ophthalmic Suspension, 2.8 Mg/1 Ml (NDC 0078-0729-15)",New,7/2/24,,"Novartis Has Made A Business Decision To Permanently Discontinue Betoptic S® (Betaxolol Hydrochloride Ophthalmic Suspension), 0.25% As Base.Discontinuation Of The Product Is Not Due To Manufacturing, Product Quality, Safety, Or Efficacy Concerns.",,,Ophthalmology,To Be Discontinued,,7/2/24,0078-0729-15,discontinued
11710,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 10 Mg; 6.25 Mg (NDC 51285-040-01)",New,7/26/24,,,,,Cardiovascular,To Be Discontinued,,7/26/24,51285-040-01,discontinued
11711,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 2.5 Mg; 6.25 Mg (NDC 51285-047-02)",New,7/26/24,,,,,Cardiovascular,To Be Discontinued,,7/26/24,51285-047-02,discontinued
11712,Bisoprolol Fumarate; Hydrochlorothiazide Tablet,"Teva Pharmaceuticals Usa, Inc.","Ziac, Tablet, 5 Mg; 6.25 Mg (NDC 51285-050-02)",New,7/26/24,,,,,Cardiovascular,To Be Discontinued,,7/26/24,51285-050-02,discontinued
11713,Bromocriptine Mesylate Tablet,Sandoz Inc.,"Tablet, 2.5 Mg (NDC 0781-5325-01)",New,8/8/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,8/8/24,0781-5325-01,discontinued
11714,Bromocriptine Mesylate Tablet,Sandoz Inc.,"Tablet, 2.5 Mg (NDC 0781-5325-31)",New,8/8/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,8/8/24,0781-5325-31,discontinued
11715,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 72205-102-07)",Reverified,7/18/24,Available,,,,Cardiovascular,Current,,,72205-102-07,available
11716,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, 0.25 Mg/Ml, 10 Ml (NDC 72205-102-01)",Revised,7/18/24,Available,,,,Cardiovascular,Current,,,72205-102-01,available
11717,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 72205-101-07)",Reverified,7/18/24,Available,,,,Cardiovascular,Current,,,72205-101-07,available
11718,Bumetanide Injection,Msn Laboratories Private Limited,"Bumetanide, Injection, 0.25 Mg/Ml, 4ml (NDC 72205-101-01)",Revised,7/18/24,Available,,,,Cardiovascular,Current,,,72205-101-01,available
11719,Bumetanide Injection,"Fresenius Kabi Usa, Llc","Injection, .25 Mg/1 Ml (NDC 65219-572-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,65219-572-10,available
11720,Bumetanide Injection,"Fresenius Kabi Usa, Llc","Injection, .25 Mg/1 Ml (NDC 65219-570-04)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,65219-570-04,available
11721,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 70860-406-10)",Reverified,7/1/24,Available,,,,Cardiovascular,Current,,,70860-406-10,available
11722,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 Mg/1 Ml (NDC 70860-405-04)",Reverified,7/1/24,Available,,,,Cardiovascular,Current,,,70860-405-04,available
11723,Bumetanide Injection,"Hikma Pharmaceuticals Usa, Inc.","Bumetanide Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-6007-10)",Reverified,8/28/24,Available,,,,Cardiovascular,Current,,,0641-6007-10,available
11724,Bumetanide Injection,"Hikma Pharmaceuticals Usa, Inc.","Bumetanide Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-6008-10)",Reverified,8/28/24,Available,,,,Cardiovascular,Current,,,0641-6008-10,available
11725,Bumetanide Injection,"Hospira, Inc., A Pfizer Company","Injection, .25 Mg/1 Ml (NDC 0409-1412-10)",Revised,11/3/23,,Discontinued,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,12/1/23,11/3/23,0409-1412-10,discontinued
11726,Bumetanide Injection,"Hospira, Inc., A Pfizer Company","Injection, .25 Mg/1 Ml (NDC 0409-1412-04)",Revised,11/3/23,,Discontinued,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,12/1/23,11/3/23,0409-1412-04,discontinued
11727,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 5 Mg/1 Ml (NDC 71288-726-52)",Reverified,7/11/24,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,71288-726-52,available
11728,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 2.5 Mg/1 Ml (NDC 71288-723-52)",Reverified,7/11/24,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,71288-723-52,available
11729,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 Mg/1 Ml (NDC 73293-0002-2)",Reverified,8/5/24,Available,,,,Anesthesia,Current,,,73293-0002-2,available
11730,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 Mg/1 Ml (NDC 55150-167-10)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-167-10,available
11731,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 225 Mg/30 Ml (7.5 Mg/Ml) (NDC 0409-1582-29)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1582-29,available
11732,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 75 Mg/10 Ml (7.5 Mg/Ml) (NDC 0409-1582-10)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1582-10,available
11733,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-1610-50)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: December 2027,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1610-50,limited availability
11734,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-1560-29)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1560-29,available
11735,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-1560-10)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1560-10,available
11736,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-1587-50)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1587-50,available
11737,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1559-30)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1559-30,available
11738,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, Marcaine 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-1559-10)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1559-10,available
11739,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 Mg/2 Ml (7.5 Mg/Ml In 8.25% Dextrose) (NDC 0409-3613-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-3613-01,available
11740,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 225 Mg/30 Ml (7.5 Mg/Ml) (NDC 0409-1165-02)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1165-02,available
11741,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 Mg/1 Ml (NDC 0409-1165-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1165-01,available
11742,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-1163-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1163-01,available
11743,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-1162-02)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1162-02,available
11744,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-1162-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1162-01,available
11745,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-1160-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1160-01,available
11746,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1159-02)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1159-02,available
11747,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride, Injection, 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-1159-01)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1159-01,available
11748,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml (NDC 63323-472-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-472-37,available
11749,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml (NDC 63323-472-17)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-472-17,available
11750,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-31)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-466-31,not available
11751,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-466-37,available
11752,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-466-17)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-466-17,available
11753,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-31)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Demand Increase For The Drug,Anesthesia,Current,,,63323-464-31,not available
11754,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-464-37,available
11755,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-464-17)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-464-17,available
11756,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml (NDC 63323-467-57)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-467-57,available
11757,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 55150-250-50)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-250-50,available
11758,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride, Injection, 2.5 Mg/1 Ml (NDC 55150-249-50)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-249-50,available
11759,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 Mg/1 Ml (NDC 55150-172-30)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-172-30,not available
11760,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 7.5 Mg/1 Ml (NDC 55150-171-10)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-171-10,not available
11761,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 Mg/1 Ml (NDC 55150-170-30)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-170-30,not available
11762,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 5 Mg/1 Ml (NDC 55150-169-10)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-169-10,available
11763,Bupivacaine Hydrochloride Injection,Eugia Us Llc,"Bupivacaine Hydrochloride Preservative Free, Injection, 2.5 Mg/1 Ml (NDC 55150-168-30)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-168-30,available
11764,Bupivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml (NDC 63323-465-57)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-465-57,available
11765,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, 0.75% 15 Mg/2 Ml (NDC 0409-1761-62)",Revised,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1761-62,available
11766,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 0.25%; 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-1159-10)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1159-10,available
11767,Bupivacaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Marcaine, Injection, 0.75% 15 Mg/2 Ml (7.5 Mg/Ml) In Dextrose 8.25% (NDC 0409-1761-10)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,0409-1761-10,available
11768,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-753-25)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-753-25,available
11769,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2.5 Mg/1 Ml (NDC 70069-752-25)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-752-25,available
11770,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 5 Mg/1 Ml (NDC 71288-725-32)",Reverified,7/11/24,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,71288-725-32,available
11771,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 7.5 Mg/1 Ml (NDC 71288-728-32)",Reverified,7/11/24,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,71288-728-32,available
11772,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 2.5 Mg/1 Ml (NDC 71288-722-32)",Reverified,7/11/24,Available,Meitheal Pharmaceuticals Is Distributor/Labeler; Product Is Available,,,Anesthesia,Current,,,71288-722-32,available
11773,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 250 Mg/50 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1755-50)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1755-50,limited availability
11774,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 125 Mg/50 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1752-50)",Revised,8/26/24,Limited Availability,Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1752-50,limited availability
11775,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 150 Mg/30 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1749-29)",Revised,8/26/24,Limited Availability,Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1749-29,limited availability
11776,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 50 Mg/10 Ml (5 Mg/Ml 1:200,000) (NDC 0409-1749-10)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1749-10,limited availability
11777,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 75 Mg/30 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1746-30)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1746-30,limited availability
11778,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine With Epinephrine 1:200,000 As The Bitartrate 25 Mg/10 Ml (2.5 Mg/Ml 1:200,000) (NDC 0409-1746-10)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: September 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-1746-10,limited availability
11779,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 Mg/50 Ml (5 Mg/Ml) (NDC 0409-9046-01)",Revised,8/26/24,Unavailable,Next Delivery: April 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9046-01,not available
11780,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 150 Mg/30 Ml (5 Mg/Ml) (NDC 0409-9045-17)",Revised,8/26/24,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9045-17,not available
11781,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-9045-01)",Revised,8/26/24,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9045-01,not available
11782,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 125 Mg/50 Ml (2.5 Mg/Ml) (NDC 0409-9043-01)",Revised,8/26/24,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9043-01,not available
11783,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 Mg/30 Ml (2.5 Mg/Ml) (NDC 0409-9042-17)",Revised,8/26/24,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9042-17,not available
11784,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., A Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 Mg/10 Ml (2.5 Mg/Ml) (NDC 0409-9042-01)",Revised,8/26/24,Unavailable,Next Delivery: June 2025; Estimated Recovery: December 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-9042-01,not available
11785,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 7.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-460-37)",Revised,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Anesthesia,Current,,,63323-460-37,not available
11786,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-31)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-462-31,not available
11787,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-37)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-462-37,available
11788,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-462-17)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-462-17,available
11789,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-468-37)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-468-37,available
11790,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-468-17)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-468-17,available
11791,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-463-57)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-463-57,available
11792,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi Usa, Llc","Sensorcaine, Injection, 2.5 Mg/1 Ml; .005 Mg/1 Ml (NDC 63323-461-57)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Anesthesia,Current,,,63323-461-57,available
11793,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 300 Mg (NDC 10370-102-03)",New,12/28/23,,,,,Psychiatry,To Be Discontinued,,12/28/23,10370-102-03,discontinued
11794,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 300 Mg (NDC 10370-102-50)",New,12/28/23,,,,,Psychiatry,To Be Discontinued,,12/28/23,10370-102-50,discontinued
11795,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 150 Mg (NDC 10370-101-03)",New,10/2/23,,,,,Psychiatry,To Be Discontinued,,10/2/23,10370-101-03,discontinued
11796,"Bupropion Hydrochloride Tablet, Extended Release","Endo Pharmaceuticals, Inc.","Tablet, Extended Release, 150 Mg (NDC 10370-101-50)",New,10/2/23,,,,,Psychiatry,To Be Discontinued,,,10370-101-50,discontinued
11797,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 1.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-206-20)",New,3/21/24,,,,,Renal,To Be Discontinued,,3/21/24,49230-206-20,discontinued
11798,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 2.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-209-23)",New,3/21/24,,,,,Renal,To Be Discontinued,,3/21/24,49230-209-23,discontinued
11799,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Delflex, Peritoneal Dialysis Solution, 18.4 Mg/100 Ml; 4.25 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-212-23)",New,3/21/24,,,,,Renal,To Be Discontinued,,3/21/24,49230-212-23,discontinued
11800,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 25.7 Mg/100 Ml; 1.5 G/100 Ml; 15.2 Mg/100 Ml; 567 Mg/100 Ml; 392 Mg/100 Ml (NDC 49230-188-50)",New,6/4/24,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/24,49230-188-50,discontinued
11801,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 25.7 Mg/100 Ml; 2.5 G/100 Ml; 15.2 Mg/100 Ml; 567 Mg/100 Ml; 392 Mg/100 Ml (NDC 49230-191-50)",New,6/4/24,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/24,49230-191-50,discontinued
11802,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 1.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-206-50)",New,6/4/24,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/24,49230-206-50,discontinued
11803,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 2.5 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-209-50)",New,6/4/24,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/24,49230-209-50,discontinued
11804,Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Solution,Fresenius Medical Care North America,"Delflex, Solution, 18.4 Mg/100 Ml; 4.25 G/100 Ml; 5.08 Mg/100 Ml; 538 Mg/100 Ml; 448 Mg/100 Ml (NDC 49230-212-50)",New,6/4/24,,"As Part Of Fresenius Medical Care North America’S (Fmcna) Overall Strategy To Replace Delflex Pvc With Biofine, We Are Temporarily Discontinuing The Delflex 5l Product In A Pvc Container.",,,Renal,To Be Discontinued,,6/4/24,49230-212-50,discontinued
11805,Capecitabine Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 500 Mg (NDC 55111-497-04)",Revised,6/27/24,,,Available,,Oncology,Resolved,6/27/24,,55111-497-04,
11806,Capecitabine Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 150 Mg (NDC 55111-496-60)",Revised,6/27/24,,,Available,,Oncology,Resolved,6/27/24,,55111-496-60,
11807,Capecitabine Tablet,Eugia Us Llc,"Tablet, 500 Mg (NDC 59651-205-08)",Revised,5/21/24,,,,,Oncology,Resolved,5/21/24,,59651-205-08,
11808,Capecitabine Tablet,Eugia Us Llc,"Tablet, 150 Mg (NDC 59651-204-60)",Revised,5/21/24,,,,,Oncology,Resolved,5/21/24,,59651-204-60,
11809,Capecitabine Tablet,"Teva Pharmaceuticals Usa, Inc.","Capecitabine Tablets Usp, Tablet, 500 Mg (NDC 0093-7474-89)",Revised,5/21/24,,,,,Oncology,Resolved,5/21/24,,0093-7474-89,
11810,Capecitabine Tablet,"Teva Pharmaceuticals Usa, Inc.","Capecitabine Tablets Usp, Tablet, 150 Mg (NDC 0093-7473-06)",Revised,5/21/24,,,,,Oncology,Resolved,5/21/24,,0093-7473-06,
11811,Capecitabine Tablet,Novadoz Pharmaceuticals Llc,"Capecitabine, Tablet, 150 Mg (NDC 72205-006-60)",Revised,5/21/24,,,Manufactured By Msn Laboratories Private Limited (Formulation Division),,Oncology,Resolved,5/21/24,,72205-006-60,
11812,Capecitabine Tablet,Novadoz Pharmaceuticals Llc,"Capecitabine, Tablet, 500 Mg (NDC 72205-007-92)",Revised,5/21/24,,,Manufactured By Msn Laboratories Private Limited (Formulation Division),,Oncology,Resolved,5/21/24,,72205-007-92,
11813,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 500 Mg (NDC 0004-1101-50)",Revised,1/23/24,,Product Was Discontinued In March 2023.,,,Oncology,To Be Discontinued,1/23/24,1/23/24,0004-1101-50,discontinued
11814,Capecitabine Tablet,"Genentech, Inc","Xeloda, Tablet, 150 Mg (NDC 0004-1100-20)",Revised,1/23/24,,Product Was Discontinued In March 2023.,,,Oncology,To Be Discontinued,1/23/24,1/23/24,0004-1100-20,discontinued
11815,Capecitabine Tablet,Accord Healthcare Inc.,"Tablet, 500 Mg (NDC 16729-073-29)",Revised,6/27/24,,,Available,,Oncology,Resolved,6/27/24,,16729-073-29,
11816,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 300 Mg (NDC 66993-409-32)",New,2/6/24,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/24,66993-409-32,discontinued
11817,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 100 Mg (NDC 66993-407-32)",New,2/6/24,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/24,66993-407-32,discontinued
11818,"Carbamazepine Capsule, Extended Release",Takeda Pharmaceuticals Usa Inc.,"Capsule, Extended Release, 200 Mg (NDC 66993-408-32)",New,2/6/24,,The Brand Carbatrol Will Continue To Be Available.,,,Neurology,To Be Discontinued,,2/6/24,66993-408-32,discontinued
11819,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 200 Mg (NDC 0781-5987-01)",New,10/23/23,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr, 200 Mg (Ndc 0078-0511-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/23,0781-5987-01,discontinued
11820,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 400 Mg (NDC 0781-5988-01)",New,10/23/23,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr, 400 Mg, (Ndc 0078-0512-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/23,0781-5988-01,discontinued
11821,"Carbamazepine Tablet, Extended Release",Novartis Pharmaceuticals Corporation,"Tablet, Extended Release, 100 Mg (NDC 0781-8016-01)",New,10/23/23,,"Novartis Pharmaceuticals’ Brand Product, Tegretol Xr 100 Mg (Ndc 0078-0510-05), Will Continue To Be Manufactured And Available.",,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,10/23/23,0781-8016-01,discontinued
11822,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 25/250 Mg (NDC 0378-1133-01)",New,3/26/24,,,,,Neurology,To Be Discontinued,,3/26/24,0378-1133-01,discontinued
11823,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 25/100 Mg (NDC 0378-0085-01)",New,3/26/24,,,,,Neurology,To Be Discontinued,,3/26/24,0378-0085-01,discontinued
11824,Carbidopa And Levodopa Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 10/100 Mg (NDC 0378-0078-01)",New,3/26/24,,,,,Neurology,To Be Discontinued,,3/26/24,0378-0078-01,discontinued
11825,Carboplatin Injection,Ingenus Pharmaceuticals Llc,"Injection, 450 Mg/45 Ml (NDC 50742-447-45)",Reverified,6/24/24,Available,"For Any Other Information, Please Contact The Ingenus Customer Service Team At 866-321-5031.",,,Oncology,Current,,,50742-447-45,available
11826,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4248-01)",Revised,8/23/24,Limited Availability,,,Demand Increase For The Drug,Oncology,Current,,,0703-4248-01,limited availability
11827,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4246-01)",Revised,8/23/24,Available,,,,Oncology,Current,,,0703-4246-01,available
11828,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4244-01)",Revised,8/23/24,Available,,,,Oncology,Current,,,0703-4244-01,available
11829,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 600 Mg/60 Ml (10 Mg/Ml) (NDC 61703-600-05)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Oncology,Current,,,61703-600-05,limited availability
11830,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 600 Mg/60 Ml (10 Mg/Ml) (NDC 61703-339-56)",Reverified,8/26/24,Available,,,,Oncology,Current,,,61703-339-56,available
11831,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 450 Mg/45 Ml (10 Mg/Ml) (NDC 61703-262-05)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Oncology,Current,,,61703-262-05,limited availability
11832,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 450 Mg/45 Ml (10 Mg/Ml) (NDC 61703-339-50)",Reverified,8/26/24,Available,,,,Oncology,Current,,,61703-339-50,available
11833,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 150 Mg/15 Ml (10 Mg/Ml) (NDC 61703-150-05)",Reverified,8/26/24,Available,,,,Oncology,Current,,,61703-150-05,available
11834,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 150 Mg/15 Ml (10 Mg/Ml) (NDC 61703-339-22)",Reverified,8/26/24,Available,,,,Oncology,Current,,,61703-339-22,available
11835,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 61703-360-18)",Revised,8/26/24,Available,,,,Oncology,Current,,,61703-360-18,available
11836,Carboplatin Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 61703-339-18)",Reverified,8/26/24,Available,,,,Oncology,Current,,,61703-339-18,available
11837,Carboplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Carboplatin Injection, Injection, 10 Mg/1 Ml (NDC 0703-4239-01)",Revised,8/23/24,Available,,,,Oncology,Current,,,0703-4239-01,available
11838,Carboplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-172-60)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,63323-172-60,available
11839,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-12)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,16729-295-12,not available
11840,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-34)",Revised,8/19/24,"Unavailable, 15-30 Days",Inventory At Dc; Awaiting Quality Review,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,16729-295-34,not available
11841,Carboplatin Injection,Eugia Us Llc,"Carboplatin, Injection, 600 Mg/60 Ml (NDC 55150-386-01)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,55150-386-01,available
11842,Carboplatin Injection,Eugia Us Llc,"Carboplatin, Injection, 450 Mg/45 Ml (NDC 55150-335-01)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,55150-335-01,available
11843,Carboplatin Injection,Teyro Labs,"Injection, 600 Mg/60 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-7)",Reverified,9/3/24,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-7,available
11844,Carboplatin Injection,Teyro Labs,"Injection, 50 Mg/5 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-1)",Reverified,9/3/24,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-1,available
11845,Carboplatin Injection,Teyro Labs,"Injection, 450 Mg/45 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-6)",Reverified,9/3/24,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-6,available
11846,Carboplatin Injection,Teyro Labs,"Injection, 150 Mg/15 Ml (10 Mg/Ml) Multiple Dose Vial (NDC 60505-6282-3)",Reverified,9/3/24,Available,Wholesaler & Distributor Through Marketing Partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-3,available
11847,Carboplatin Injection,Ingenus Pharmaceuticals Llc,"Injection, 600 Mg/60 Ml (NDC 50742-448-60)",Reverified,6/24/24,Available,"For Any Other Information, Please Contact The Ingenus Customer Service Team At 866-321-5031.",,,Oncology,Current,,,50742-448-60,available
11848,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 50mg/5ml (NDC 54288-164-01)",Revised,7/15/24,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,54288-164-01,available
11849,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 450mg/45ml (NDC 54288-166-01)",Revised,7/15/24,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,54288-166-01,available
11850,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 150mg/15ml (NDC 54288-165-01)",Revised,7/15/24,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,54288-165-01,available
11851,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 600 Mg/65 Ml (NDC 54288-167-01)",Revised,7/15/24,Available,"Distributed By Bpi Labs, Llc",,,Oncology,Current,,,54288-167-01,available
11852,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-31)",Revised,8/19/24,Unavailable,Temporarily Discontinued,,Other,Oncology,Current,,,16729-295-31,not available
11853,Carboplatin Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-295-33)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Oncology,Current,,,16729-295-33,not available
11854,Caspofungin Acetate Injection,Merck Sharp & Dohme Corp.,"Cancidas, Injection, 7 Mg/1 Ml (NDC 0006-3823-10)",New,6/27/24,,,,,Anti-Infective,To Be Discontinued,,6/27/24,0006-3823-10,discontinued
11855,Cefazolin Sodium Injection,Sandoz Inc.,"Injection, 500 Mg (NDC 0781-3450-95)",New,12/12/23,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,12/12/23,0781-3450-95,discontinued
11856,Cefazolin Sodium Injection,Sandoz Inc.,"Injection, 10 G (NDC 0781-3452-95)",New,12/12/23,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,12/12/23,0781-3452-95,discontinued
11857,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 Mg (NDC 68180-423-11)",Revised,3/19/24,,,Available,,Anti-Infective,Resolved,3/19/24,,68180-423-11,
11858,Cefixime Capsule,"Lupin Pharmaceuticals, Inc.","Suprax, Capsule, 400 Mg (NDC 68180-423-08)",Revised,3/19/24,,,Available,,Anti-Infective,Resolved,3/19/24,,68180-423-08,
11859,Cefixime Capsule,"Ascend Laboratories, Llc","Capsule, 400 Mg (NDC 67877-584-50)",Revised,3/19/24,,,Available,,Anti-Infective,Resolved,3/19/24,,67877-584-50,
11860,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 10 G (NDC 0143-9935-01)",Reverified,8/28/24,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0143-9935-01,not available
11861,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 2 G (NDC 0143-9933-25)",Reverified,8/28/24,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0143-9933-25,not available
11862,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 1 G (NDC 0143-9931-25)",Reverified,8/28/24,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0143-9931-25,not available
11863,Cefotaxime Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Cefotaxime For Injection, Usp, Injection, 500 Mg (NDC 0143-9930-10)",Reverified,8/28/24,Unavailable,Shortage Duration Is Unknown At This Time.,,Demand Increase For The Drug,Anti-Infective; Pediatric,Current,,,0143-9930-10,not available
11864,Cefotaxime Sodium Injection,"Sterimax, Inc.","Injection, 1 G (NDC 21586-011-02)",Reverified,3/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,21586-011-02,available
11865,Cefotaxime Sodium Injection,"Sterimax, Inc.","Cefotaxime, Injection, 2 G (NDC 21586-012-02)",Revised,3/15/24,Available,,,,Anti-Infective; Pediatric,Current,,,21586-012-02,available
11866,Cefotetan Disodium Injection,"Teligent Pharma, Inc.","Cefotan, Injection, 2 G/20 Ml (NDC 52565-053-10)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,52565-053-10,
11867,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 10 G (NDC 63323-396-61)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,63323-396-61,
11868,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 2 G/20 Ml (NDC 63323-386-20)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,63323-386-20,
11869,Cefotetan Disodium Injection,"Fresenius Kabi Usa, Llc","Injection, 1 G/10 Ml (NDC 63323-385-10)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,63323-385-10,
11870,Cefotetan Disodium Injection,Pai Pharma,"Cefotan, Injection, 1 G/10 Ml (NDC 0121-0976-10)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,0121-0976-10,
11871,Cefotetan Disodium Injection,Pai Pharma,"Cefotan, Injection, 2 G/20 Ml (NDC 0121-0977-10)",Revised,9/10/24,,,Available,,Anti-Infective,Resolved,9/10/24,,0121-0977-10,
11872,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 Mg (NDC 60505-3849-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3849-5,discontinued
11873,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 Mg (NDC 60505-3849-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3849-1,discontinued
11874,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 Mg (NDC 60505-3848-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3848-5,discontinued
11875,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 Mg (NDC 60505-3848-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3848-1,discontinued
11876,Celecoxib Capsule,Apotex Corp.,"Capsule, 50 Mg (NDC 60505-3847-6)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3847-6,discontinued
11877,Chloramphenicol Sodium Succinate Injection,"Fresenius Kabi Usa, Llc","Injection, 1 G/10 Ml (NDC 63323-011-15)",Revised,12/11/23,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,12/11/23,12/11/23,63323-011-15,discontinued
11878,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Chloroprocaine Hcl Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0143-9210-10)",Reverified,8/28/24,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia,Current,,,0143-9210-10,not available
11879,Chloroprocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Chloroprocaine Hcl Injection, Usp, Injection, 20 Mg/1 Ml (NDC 0143-9209-10)",Reverified,8/28/24,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia,Current,,,0143-9209-10,not available
11880,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 30 Mg/1 Ml (NDC 63323-478-27)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-478-27,available
11881,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 20 Mg/1 Ml (NDC 63323-477-27)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,63323-477-27,available
11882,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 20 Mg/1 Ml (NDC 63323-476-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,63323-476-37,available
11883,Chloroprocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Nesacaine, Injection, 10 Mg/1 Ml (NDC 63323-475-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Anesthesia,Current,,,63323-475-37,available
11884,Chloroprocaine Hydrochloride Injection,B. Braun Medical Inc.,"Clorotekal, Injection, 10 Mg/Ml (NDC 0264-7055-05)",Revised,11/2/23,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia,To Be Discontinued,11/2/23,11/2/23,0264-7055-05,discontinued
11885,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 30 Mg (NDC 65862-831-05)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-831-05,discontinued
11886,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 30 Mg (NDC 65862-831-30)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-831-30,discontinued
11887,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 60 Mg (NDC 65862-832-05)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-832-05,discontinued
11888,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 60 Mg (NDC 65862-832-30)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-832-30,discontinued
11889,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 90 Mg (NDC 65862-833-05)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-833-05,discontinued
11890,Cinacalcet Hydrochloride Tablet,Aurobindo Pharma Usa,"Tablet, 90 Mg (NDC 65862-833-30)",New,4/29/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,4/29/24,65862-833-30,discontinued
11891,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/1 Ml (NDC 0409-3670-10)",New,4/15/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/15/24,0409-3670-10,discontinued
11892,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/5ml (2 Mg/Ml) Single Dose Vial Premierprorx® (NDC 0409-5547-10)",New,4/15/24,,Supply Expected To Exhaust July 2024,,,Analgesia/Addiction,To Be Discontinued,,4/15/24,0409-5547-10,discontinued
11893,Cisatracurium Besylate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-7083-10)",New,4/15/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/15/24,0409-7083-10,discontinued
11894,Cisplatin Injection,Gland Pharma Limited,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 25021-253-51)",Revised,6/27/24,,,Available.  Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals.  Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,6/27/24,,25021-253-51,
11895,Cisplatin Injection,Gland Pharma Limited,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 25021-253-50)",Revised,6/27/24,,,Available.  Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals.  Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,6/27/24,,25021-253-50,
11896,Cisplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 0703-5748-11)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,0703-5748-11,
11897,Cisplatin Injection,"Teva Pharmaceuticals Usa, Inc.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 0703-5747-11)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,0703-5747-11,
11898,Cisplatin Injection,Hq Specialty Pharma,"Injection, 50 Mg (NDC 44567-530-01)",Revised,6/27/24,,,Available. Marketed By Wg Critical Care.,,Oncology; Pediatric,Resolved,6/27/24,,44567-530-01,
11899,Cisplatin Injection,Hq Specialty Pharma,"Injection, 200 Ml Vial, 1 Mg/Ml (NDC 44567-511-01)",Revised,6/27/24,,,Available. Marketed By Wg Critical Care.,,Oncology; Pediatric,Resolved,6/27/24,,44567-511-01,
11900,Cisplatin Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 0143-9505-01)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,0143-9505-01,
11901,Cisplatin Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 0143-9504-01)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,0143-9504-01,
11902,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 200 Ml Vial, 1 Mg/Ml (NDC 63323-103-64)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,63323-103-64,
11903,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Ml Vial, 1 Mg/Ml (NDC 63323-103-65)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,63323-103-65,
11904,Cisplatin Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 63323-103-51)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,63323-103-51,
11905,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 68001-283-32)",Revised,6/27/24,,Marketed By Bluepoint Laboratories,,,Oncology; Pediatric,To Be Discontinued,6/27/24,6/27/24,68001-283-32,discontinued
11906,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 68001-283-27)",Revised,6/27/24,,Marketed By Bluepoint Laboratories,,,Oncology; Pediatric,To Be Discontinued,6/27/24,6/27/24,68001-283-27,discontinued
11907,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 16729-288-38)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,16729-288-38,
11908,Cisplatin Injection,Accord Healthcare Inc.,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 16729-288-11)",Revised,6/27/24,,,Available,,Oncology; Pediatric,Resolved,6/27/24,,16729-288-11,
11909,Cisplatin Injection,Gland Pharma Limited,"Injection, 100 Ml Vial, 1 Mg/Ml (NDC 72266-253-01)",Revised,6/27/24,,,Available. Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals. Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,,,72266-253-01,
11910,Cisplatin Injection,"Qilu Pharmaceutical Co., Ltd.","Injection, 50 Ml Vial, 1 Mg/Ml (NDC 60505-6279-0)",Revised,6/27/24,,,Estimated Availability August 2024. Marketed By Apotex Corp.,,Oncology; Pediatric,Resolved,,,60505-6279-0,
11911,Cisplatin Injection,Gland Pharma Limited,"Injection, 50 Ml Vial, 1 Mg/Ml (NDC 72266-252-01)",Revised,6/27/24,,,Available. Ndc 25021-253-50 And Ndc 25021-253-51 Marketed By Sagent Pharmaceuticals. Ndc 72266-252-01 And Ndc 72266-253-01) Marketed By Fosun Pharma Usa Inc.,,Oncology; Pediatric,Resolved,,,72266-252-01,
11912,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 600 Mg/4 Ml (150 Mg/Ml) (NDC 0009-4073-04)",Revised,8/26/24,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Anti-Infective,Current,,,0009-4073-04,limited availability
11913,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 900 Mg/6 Ml (150 Mg/Ml) (NDC 0009-5095-06)",Reverified,8/26/24,Available,,,,Anti-Infective,Current,,,0009-5095-06,available
11914,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 300 Mg/2 Ml (150 Mg/Ml) (NDC 0009-3051-02)",Revised,8/26/24,Available,,,,Anti-Infective,Current,,,0009-3051-02,available
11915,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 Mg/1 Ml (NDC 72572-074-24)",Reverified,8/5/24,Available,Civica Label,,,Anti-Infective,Current,,,72572-074-24,available
11916,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-06)",Reverified,7/1/24,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,25021-115-06,not available
11917,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-04)",Reverified,7/1/24,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,25021-115-04,not available
11918,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Injection, 150 Mg/1 Ml (NDC 25021-115-02)",Reverified,7/1/24,Unavailable,Backorder. Estimated Availability Tbd,,Demand Increase For The Drug,Anti-Infective,Current,,,25021-115-02,not available
11919,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 Mg/6 Ml (150 Mg/Ml) (NDC 0009-0902-18)",Reverified,8/26/24,Available,,,,Anti-Infective,Current,,,0009-0902-18,available
11920,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 G/60 Ml (150 Mg/Ml) (NDC 0009-0728-09)",Reverified,8/26/24,Available,,,,Anti-Infective,Current,,,0009-0728-09,available
11921,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 Mg/4 Ml (150 Mg/Ml) (NDC 0009-0775-26)",Reverified,8/26/24,Available,,,,Anti-Infective,Current,,,0009-0775-26,available
11922,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 Mg/2 Ml (150 Mg/Ml) (NDC 0009-0870-26)",Reverified,8/26/24,Available,,,,Anti-Infective,Current,,,0009-0870-26,available
11923,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 Mg/1 Ml (NDC 72572-076-24)",Reverified,8/5/24,Available,Civica Label,,,Anti-Infective,Current,,,72572-076-24,available
11924,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 Mg/1 Ml (NDC 0781-3290-09)",Reverified,8/5/24,Available,,,,Anti-Infective,Current,,,0781-3290-09,available
11925,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 Mg/1 Ml (NDC 0781-3289-09)",Reverified,8/5/24,Available,,,,Anti-Infective,Current,,,0781-3289-09,available
11926,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 Mg/1 Ml (NDC 0781-3288-09)",Reverified,8/5/24,Available,,,,Anti-Infective,Current,,,0781-3288-09,available
11927,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 Mg/50 Ml (NDC 0338-3814-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-3814-50,available
11928,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 600 Mg/50 Ml (NDC 0338-3612-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-3612-50,available
11929,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-3410-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-3410-50,available
11930,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 Mg/50 Ml (NDC 0338-9553-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-9553-50,available
11931,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-9549-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-9549-50,available
11932,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 Mg/50 Ml (NDC 0338-9545-50)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,0338-9545-50,available
11933,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-15)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0163-15,discontinued
11934,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-30)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0163-30,discontinued
11935,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-46)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0163-46,discontinued
11936,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0163-60)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0163-60,discontinued
11937,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-15)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0293-15,discontinued
11938,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-30)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0293-30,discontinued
11939,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Cream, .5 Mg/1 G (NDC 0168-0293-60)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0293-60,discontinued
11940,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Clobetasol Propionate (Emollient), Cream, .5 Mg/1 G (NDC 0168-0301-30)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0301-30,discontinued
11941,Clobetasol Propionate Cream,Fougera (A Sandoz Company),"Clobetasol Propionate (Emollient), Cream, .5 Mg/1 G (NDC 0168-0301-60)",New,4/3/24,,,,,Dermatology,To Be Discontinued,,4/3/24,0168-0301-60,discontinued
11942,Clobetasol Propionate Spray,"Actavis Pharma, Inc.","Clobex, Spray, .05 G/1 Ml (NDC 0591-4039-46)",New,8/28/24,,,,,Dermatology,To Be Discontinued,,8/28/24,0591-4039-46,discontinued
11943,Clobetasol Propionate Spray,"Actavis Pharma, Inc.","Clobex, Spray, .05 G/1 Ml (NDC 0591-4039-74)",New,8/28/24,,,,,Dermatology,To Be Discontinued,,8/28/24,0591-4039-74,discontinued
11944,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-45)",New,10/18/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-45,discontinued
11945,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-75)",New,10/18/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-75,discontinued
11946,Clocortolone Pivalate Cream,Epi Health,"Cream, 1 Mg/G (NDC 71403-804-93)",New,10/18/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,10/18/23,71403-804-93,discontinued
11947,Clofarabine Injection,Apotex Corp.,"Injection, 20 Mg/20 Ml (1mg/Ml) (NDC 60505-6166-0)",New,10/26/23,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/26/23,60505-6166-0,discontinued
11948,Clomipramine Hydrochloride Capsule,Amneal Pharmaceuticals,"Capsule, 50 Mg (NDC 69238-1109-9)",New,4/30/24,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/24,69238-1109-9,discontinued
11949,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-05)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-05,available
11950,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-01)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-01,available
11951,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 Mg (NDC 72888-154-30)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-30,available
11952,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-05)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-05,available
11953,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-01)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-01,available
11954,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 Mg (NDC 72888-153-30)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-30,available
11955,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-05)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-05,available
11956,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-01)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-01,available
11957,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 Mg (NDC 72888-152-30)",Reverified,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-30,available
11958,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 2 Mg (NDC 0093-3213-05)",Revised,9/4/24,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-05,available
11959,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 2 Mg (NDC 0093-3213-01)",Revised,9/4/24,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-01,available
11960,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 1 Mg (NDC 0093-3212-05)",Revised,9/4/24,Limited Availability,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-05,limited availability
11961,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, 1 Mg (NDC 0093-3212-01)",Revised,9/4/24,Available,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-01,available
11962,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, .5 Mg (NDC 0093-0832-05)",Revised,9/4/24,Limited Availability,Estimated Recovery November 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-05,limited availability
11963,Clonazepam Tablet,"Teva Pharmaceuticals Usa, Inc.","Clonazepam Tablets, Usp Civ, Tablet, .5 Mg (NDC 0093-0832-01)",Revised,9/4/24,Limited Availability,Estimated Recovery October 2024,,Demand Increase For The Drug,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-01,limited availability
11964,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 Mg (NDC 43547-408-50)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-50,available
11965,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 Mg (NDC 43547-408-10)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-10,available
11966,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-50)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-50,available
11967,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-11)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-11,available
11968,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 Mg (NDC 43547-407-10)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-10,available
11969,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-50)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-50,available
11970,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-11)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-11,available
11971,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 Mg (NDC 43547-406-10)",Reverified,6/18/24,Available,Marketed By Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-10,available
11972,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, 2 Mg (NDC 61269-620-10)",Reverified,9/4/24,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-620-10,available
11973,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, 1 Mg (NDC 61269-610-10)",Reverified,9/4/24,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-610-10,available
11974,Clonazepam Tablet,Cheplapharm Arzneimittel Gmbh,"Klonopin, Tablet, .5 Mg (NDC 61269-605-10)",Reverified,9/4/24,Available,Marketed By H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-605-10,available
11975,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 2 Mg (NDC 16729-138-16)",Revised,8/19/24,"Unavailable, 30 Days",Batches Ready At Manufacturing Facilty Awaiting Qa Release,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,16729-138-16,not available
11976,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 2 Mg (NDC 16729-138-00)",Revised,8/19/24,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,16729-138-00,not available
11977,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 1 Mg (NDC 16729-137-16)",Reverified,8/19/24,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-16,available
11978,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, 1 Mg (NDC 16729-137-00)",Reverified,8/19/24,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-00,available
11979,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, .5 Mg (NDC 16729-136-16)",Reverified,8/19/24,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-136-16,available
11980,Clonazepam Tablet,Accord Healthcare Inc.,"Tablet, .5 Mg (NDC 16729-136-00)",Revised,8/19/24,"Unavailable, 30 Days",Batches Ready At Manufacturing Facilty Awaiting Qa Release,,Requirements Related To Complying With Good Manufacturing Practices,Neurology; Pediatric; Psychiatry,Current,,,16729-136-00,not available
11981,"Clonidine Hydrochloride Tablet, Extended Release",Concordia Pharmaceuticals Inc.,"Kapvay, Tablet, Extended Release, .1 Mg (NDC 59212-658-13)",New,12/13/23,,,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,12/13/23,59212-658-13,discontinued
11982,"Clonidine Hydrochloride Tablet, Extended Release",Concordia Pharmaceuticals Inc.,"Kapvay, Tablet, Extended Release, .1 Mg (NDC 59212-658-60)",New,12/13/23,,"A Business Decision Was Made To Discontinue Manufacture And Supply Of Kapvay® (Clonidine Hydrochloride) Extended Release Tablets, 0.1 Mg. This Product Discontinuation Is Not Related To Product Quality, Safety, Or Efficacy.  All Existing Lots On The Market Are Already Expired.",,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,12/13/23,59212-658-60,discontinued
11983,Colestipol Hydrochloride Granule,Pfizer Inc.,"Colestid, Granule, 5 G/5 G (NDC 0009-0260-04)",New,11/9/23,,Supply Expected To Exhaust December 2023,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/23,0009-0260-04,discontinued
11984,Colestipol Hydrochloride Granule,Pfizer Inc.,"Granule, 5 G/5 G (NDC 59762-0260-1)",New,10/17/23,,Supply Expected To Exhaust Early November 2023. Discontinuation Of The Manufacture Of The Drug. This Product Distributed By Viatris.,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,To Be Discontinued,,3/30/23,59762-0260-1,discontinued
11985,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [Arb'U]/1 G (NDC 50484-010-90)",Revised,4/8/24,,,Available,,Dermatology,Resolved,4/8/24,,50484-010-90,
11986,Collagenase Clostridium Histolyticum Ointment,"Smith & Nephew, Inc.","Santyl, Ointment, 250 [Arb'U]/1 G (NDC 50484-010-30)",Revised,4/8/24,,,Available,,Dermatology,Resolved,4/8/24,,50484-010-30,
11987,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 Mg/100 Ml (NDC 66220-160-10)",Reverified,9/3/24,Unavailable,,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,66220-160-10,not available
11988,Cromolyn Sodium Concentrate,"Mylan Specialty, A Viatris Company","Gastrocrom, Concentrate, 20 Mg/1 Ml (NDC 0037-0678-96)",Reverified,9/5/24,Available,,,,Pulmonary/Allergy,Current,,,0037-0678-96,available
11989,Cromolyn Sodium Concentrate,Micro Labs Ltd,"Concentrate, 100 Mg/5 Ml (NDC 42571-132-52)",Reverified,9/4/24,Available,,,,Pulmonary/Allergy,Current,,,42571-132-52,available
11990,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Concentrate, 100 Mg/5 Ml (NDC 16571-600-96)",Revised,7/2/24,Limited Availability,Shipping Limited Quantities.,,Demand Increase For The Drug,Pulmonary/Allergy,Current,,,16571-600-96,limited availability
11991,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 Mg/5 Ml (NDC 76204-025-96)",Reverified,7/15/24,Available,"Distributed By Ritedose Pharmaceuticals, Llc (855) 806 3300",,,Pulmonary/Allergy,Current,,,76204-025-96,available
11992,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Concentrate, 100 Mg/5 Ml (NDC 69784-200-96)",Reverified,7/15/24,Available,Distributed By Woodward Pharma Services Llc (248) 308-1120 Ext 2,,,Pulmonary/Allergy,Current,,,69784-200-96,available
11993,Cromolyn Sodium Oral Solution,"Mylan Institutional, A Viatris Company","Oral Solution, 100mg/5ml (NDC 51525-0470-9)",New,11/1/23,,Gastrocrom 100mg/5ml Oral Concentrate 96s (Ndc: 0037-0678-96) Will Remain Available,,Discontinuation Of The Manufacture Of The Drug,Pulmonary/Allergy,To Be Discontinued,,11/1/23,51525-0470-9,discontinued
11994,Cyanocobalamin Spray,"Endo Pharmaceuticals, Inc.","Nascobal, Spray, 500 Ug (NDC 49884-270-82)",New,7/12/24,,,,,Hematology,To Be Discontinued,,7/12/24,49884-270-82,discontinued
11995,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 Mg/1 Ml (NDC 24208-735-06)",Reverified,9/4/24,Available,,,,Ophthalmology,Current,,,24208-735-06,available
11996,Cyclopentolate Hydrochloride Ophthalmic Solution,Bausch & Lomb Incorporated,"Pentolair, Ophthalmic Solution, 10 Mg/1 Ml (NDC 24208-735-01)",Reverified,9/4/24,Available,,,,Ophthalmology,Current,,,24208-735-01,available
11997,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclopentolate Hydrochloride Ophthalmic Solution, Usp 1%, Ophthalmic Solution, 10 Mg/1 Ml (NDC 61314-396-03)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,61314-396-03,available
11998,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclopentolate Hydrochloride Ophthalmic Solution, Usp 1%, Ophthalmic Solution, 10 Mg/1 Ml (NDC 61314-396-01)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,61314-396-01,available
11999,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-15)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0397-15,available
12000,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-05)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0397-05,available
12001,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 20 Mg/1 Ml (NDC 0065-0397-02)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0397-02,available
12002,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 Mg/1 Ml (NDC 0065-0396-05)",Revised,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0396-05,available
12003,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 10 Mg/1 Ml (NDC 0065-0396-02)",Revised,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0396-02,available
12004,Cyclopentolate Hydrochloride Ophthalmic Solution,Alcon,"Cyclogyl, Ophthalmic Solution, 5 Mg/1 Ml (NDC 0065-0395-15)",Reverified,8/27/24,Available,,,,Ophthalmology,Current,,,0065-0395-15,available
12005,Cyclosporine Injection,Padagis Us Llc,"Injection, 250 Mg/5 Ml (50 Mg/Ml) In 5 Ml Ampule (NDC 0574-0866-10)",New,9/29/23,,Discontinuation Of The Manufacture Of The Product.,,Discontinuation Of The Manufacture Of The Drug,Transplant,To Be Discontinued,,9/29/23,0574-0866-10,discontinued
12006,Cyclosporine Solution,Novartis Pharmaceuticals Corporation,"Sandimmune, Solution, 100 Mg/1 Ml (NDC 0078-0110-22)",New,8/20/24,,"Novartis Pharmaceuticals Has Made A Business Decision To Permanently Discontinue Sandimmune® Oral Solution (Cyclosporine Oral Solution, Usp).The Product Is Not Available.",,,Transplant,To Be Discontinued,,8/20/24,0078-0110-22,discontinued
12007,Cytarabine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 2 G/20 Ml (NDC 71288-109-20)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,71288-109-20,
12008,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 50 Ml Vial, 20 Mg/Ml (NDC 61703-303-46)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,61703-303-46,
12009,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 25 Ml Vial, 20 Mg/Ml (NDC 61703-304-36)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,61703-304-36,
12010,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 20 Ml Vial, 100 Mg/Ml (NDC 61703-319-22)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,61703-319-22,
12011,Cytarabine Injection,"Hospira, Inc., A Pfizer Company","Cytarabine, Injection, 5 Ml Vial, 20 Mg/Ml (NDC 61703-305-38)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,61703-305-38,
12012,Cytarabine Injection,"Fresenius Kabi Usa, Llc","Injection, 20 Ml Vial, 100 Mg/Ml (NDC 63323-120-20)",Revised,7/12/24,,,Available,,Oncology; Pediatric,Resolved,7/12/24,,63323-120-20,
12013,Cytarabine Injection,Gland Pharma Limited,"Injection, 5 Ml Vial, 20 Mg/Ml (NDC 25021-229-05)",Revised,7/12/24,,,Available. Marketed By Sagent Pharmaceuticals.,,Oncology; Pediatric,Resolved,7/12/24,,25021-229-05,
12014,Cytarabine Injection,Gland Pharma Limited,"Injection, 20 Ml Vial, 100 Mg/Ml (NDC 25021-223-20)",Revised,7/12/24,,,Available. Marketed By Sagent Pharmaceuticals.,,Oncology; Pediatric,Resolved,7/12/24,,25021-223-20,
12015,Dacarbazine Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-127-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,63323-127-10,available
12016,Dacarbazine Injection,"Hikma Pharmaceuticals Usa, Inc.","Dacarbazine For Injection, Usp, Injection, 200 Mg Per Vial (NDC 0143-9245-10)",Revised,7/25/24,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Oncology,Current,,,0143-9245-10,not available
12017,Dacarbazine Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-128-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,63323-128-20,available
12018,Dacarbazine Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 200 Mg/20 Ml (NDC 71288-174-21)",New,7/22/24,Available,New Launch,,,Oncology,Current,,,71288-174-21,available
12019,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 Mg/1 Ml (NDC 66993-489-35)",New,10/16/23,,Authorized Generic Distributed By Prasco Laboratories,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/16/23,66993-489-35,discontinued
12020,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Cosmegen, Injection, .5 Mg/1 Ml (NDC 55292-811-55)",New,10/16/23,,,,,Oncology,To Be Discontinued,,10/16/23,55292-811-55,discontinued
12021,Dactinomycin Injection,Recordati Rare Diseases Inc.,"Injection, .5 Mg/1 Ml (NDC 66993-489-83)",New,10/16/23,,Authorized Generic Distributed By Prasco Laboratories,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/16/23,66993-489-83,discontinued
12022,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 Ug/.1 Ml (NDC 69918-501-05)",Reverified,3/15/24,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,69918-501-05,not available
12023,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (Needs No Refrigeration), Spray, 10 Ug (NDC 60505-0815-0)",Reverified,9/3/24,Available,,,,Hematology,Current,,,60505-0815-0,available
12024,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 Ug/1 Ml (NDC 55566-2500-0)",Reverified,3/15/24,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,55566-2500-0,not available
12025,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 Mg/1 Ml (NDC 0053-6871-00)",Reverified,3/15/24,Unavailable,,,Demand Increase For The Drug,Hematology,Current,,,0053-6871-00,not available
12026,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 76045-109-10)",Revised,9/4/24,Limited Availability,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-109-10,limited availability
12027,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 76045-106-10)",Revised,9/4/24,Unavailable,Not Available At This Time.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-106-10,not available
12028,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-305-10)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-305-10,not available
12029,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-304-25)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-304-25,not available
12030,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0641-0367-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing.  Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-0367-25,available
12031,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6146-25)",Reverified,8/28/24,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6146-25,available
12032,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexamethasone Sodium Phosphate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6145-25)",Reverified,8/28/24,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6145-25,available
12033,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 Mg/1 Ml (NDC 63323-506-01)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-506-01,not available
12034,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-01)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-01,available
12035,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-30)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-30,available
12036,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-516-10)",Revised,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-516-10,not available
12037,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-165-05)",Reverified,9/4/24,Available,Check Wholesalers For Inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-05,available
12038,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, Llc","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 Mg/1 Ml (NDC 70069-021-25)",Reverified,8/30/24,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,70069-021-25,available
12039,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-239-30)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-239-30,not available
12040,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-238-05)",Revised,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-238-05,not available
12041,Dexamethasone Sodium Phosphate Injection,Eugia Us Llc,"Injection, 4 Mg/1 Ml (NDC 55150-237-01)",Revised,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-237-01,not available
12042,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 10 Mg/1 Ml (NDC 67457-420-10)",Reverified,9/5/24,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-420-10,available
12043,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-421-30)",Reverified,9/5/24,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-421-30,available
12044,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-422-54)",Reverified,9/5/24,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-422-54,available
12045,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, A Viatris Company","Injection, 4 Mg/1 Ml (NDC 67457-423-12)",Reverified,9/5/24,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-423-12,available
12046,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Mcg/Ml, 100 Ml (NDC 70121-1389-1)",Revised,7/9/24,Available,Sufficient Inventory Available (20 To 25 Wk) As Per Current Demand,,,Anesthesia,Current,,,70121-1389-1,available
12047,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Mcg/Ml, 50 Ml (NDC 70121-1388-1)",Revised,7/9/24,Available,Sufficient Inventory Available (16 To 20 Wk) As Per Current Demand,,,Anesthesia,Current,,,70121-1388-1,available
12048,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 71288-505-03)",Revised,7/3/24,Available,Estimated Recovery End Of August 2024,,Demand Increase For The Drug,Anesthesia,Current,,,71288-505-03,available
12049,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Ug/1 Ml (NDC 70121-1389-7)",Reverified,7/9/24,Available,,,,Anesthesia,Current,,,70121-1389-7,available
12050,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Injection, 4 Ug/1 Ml (NDC 70121-1388-8)",Reverified,7/9/24,Available,,,,Anesthesia,Current,,,70121-1388-8,available
12051,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 55150-297-10)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-297-10,available
12052,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 55150-296-10)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-296-10,available
12053,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 67457-925-10)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-925-10,available
12054,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 67457-924-50)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-924-50,available
12055,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 Ug/1 Ml (NDC 42023-187-10)",Revised,9/3/24,Available,Please Check Wholesalers For Inventory,,Other,Anesthesia,Current,,,42023-187-10,available
12056,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 4 Ug/1 Ml (NDC 42023-186-20)",Reverified,9/3/24,Limited Availability,Please Check Wholesalers For Inventory,,Other,Anesthesia,Current,,,42023-186-20,limited availability
12057,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 43598-975-58)",Revised,7/15/24,Available,,,,Anesthesia,Current,,,43598-975-58,available
12058,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 43598-976-58)",Revised,7/15/24,Available,,,,Anesthesia,Current,,,43598-976-58,available
12059,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 0143-9532-25)",Reverified,8/28/24,Available,,,,Anesthesia,Current,,,0143-9532-25,available
12060,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 71225-126-06)",Revised,1/15/24,Available,,,,Anesthesia,Current,,,71225-126-06,available
12061,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 Ug/1 Ml (NDC 71225-126-05)",Revised,1/15/24,Available,,,,Anesthesia,Current,,,71225-126-05,available
12062,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/2 Ml (100 Mcg/Ml) (NDC 0409-1638-02)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1638-02,available
12063,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-1596-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1596-10,available
12064,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-1660-50)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1660-50,available
12065,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 Mcg/20 Ml (4 Mcg/Ml) (NDC 0409-1660-20)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: June 2025,,Other,Anesthesia,Current,,,0409-1660-20,limited availability
12066,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Injection, 100 Ug/1 Ml (NDC 42023-146-25)",Reverified,9/3/24,Unavailable,Recovery: Tbd,,Other,Anesthesia,Current,,,42023-146-25,not available
12067,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 67457-251-02)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-251-02,available
12068,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 4 Ug/1 Ml (NDC 44567-603-24)",Reverified,5/18/24,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,44567-603-24,available
12069,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 4 Ug/1 Ml (NDC 44567-602-24)",Reverified,5/18/24,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,44567-602-24,available
12070,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 100 Ug/1 Ml (NDC 44567-601-04)",Reverified,5/18/24,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,44567-601-04,available
12071,Dexmedetomidine Hydrochloride Injection,Hq Specialty Pharma,"Injection, 100 Ug/1 Ml (NDC 44567-600-04)",Reverified,5/18/24,Available,Marketed By Wg Critical Care,,,Anesthesia,Current,,,44567-600-04,available
12072,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Ug/1 Ml (NDC 63323-421-02)",Revised,9/4/24,Unavailable,Backordered. Next Release November 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,63323-421-02,not available
12073,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-00)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-671-00,not available
12074,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-50)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-671-50,not available
12075,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Ug/1 Ml (NDC 63323-671-20)",Revised,9/4/24,Unavailable,Not Available At This Time.,,Other,Anesthesia,Current,,,63323-671-20,not available
12076,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 43066-557-12)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,43066-557-12,available
12077,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 43066-555-24)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,43066-555-24,available
12078,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 Ug/100 Ml (NDC 0338-9557-12)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,0338-9557-12,available
12079,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 Ug/50 Ml (NDC 0338-9555-24)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,0338-9555-24,available
12080,Dexmedetomidine Hydrochloride Injection,Eugia Us Llc,"Dexmedetomidine Hydrochloride, Injection, 100 Ug/1 Ml (NDC 55150-209-02)",Reverified,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-209-02,not available
12081,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Injection, 100 Ug/1 Ml (NDC 16729-432-93)",Reverified,8/19/24,Unavailable,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anesthesia,Current,,,16729-432-93,not available
12082,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Injection, 100 Ug/1 Ml (NDC 16729-239-93)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Anesthesia,Current,,,16729-239-93,not available
12083,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 400 Mcg/100 Ml (NDC 0781-3495-95)",Revised,7/11/24,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,0781-3495-95,available
12084,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 80 Mcg/20 Ml  (NDC 0781-3493-95)",Revised,7/11/24,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,0781-3493-95,available
12085,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Injection, 200 Mcg/50 Ml  (NDC 0781-3494-95)",Revised,7/11/24,Available,Marketed By Sandoz Inc.; Customer Service: 800-525-8747,,,Anesthesia,Current,,,0781-3494-95,available
12086,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 Mcg/250 Ml Glass Bottle Novaplus (NDC 0409-2815-01)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-2815-01,available
12087,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-4596-20)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-4596-20,available
12088,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 Mcg/250 Ml Single Dose Glass Bottle (NDC 0409-1434-01)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1434-01,available
12089,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 Mcg/50 Ml (4 Mcg/Ml) (NDC 0409-1454-20)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1454-20,available
12090,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 Mcg/20 Ml (4 Mcg/Ml) (NDC 0409-3301-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-3301-10,available
12091,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-1174-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1174-10,available
12092,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 Mcg/100 Ml (4 Mcg/Ml) (NDC 0409-0155-02)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-0155-02,available
12093,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Injection, 200 Ug/2 Ml (NDC 66794-230-42)",Revised,7/15/24,Available,Marketed By Piramal Critical Care Inc.: 800-414-1901,,,Anesthesia,Current,,,66794-230-42,available
12094,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7938-19)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7938-19",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7938-19,available
12095,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-13)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-13",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-13,available
12096,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-10)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-10,available
12097,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-09)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-09,available
12098,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-03)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-03,available
12099,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 10% In Plastic Container, Injection, 10 G/100 Ml (NDC 0990-7930-02)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7930-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-02,available
12100,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-76)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-76,available
12101,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-75)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-75,available
12102,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 10% In Plastic Container, Injection, 100 Mg/1 Ml (NDC 63323-824-74)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-74,available
12103,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-20)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-20,available
12104,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-10)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-10,available
12105,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 10 G/100 Ml (NDC 0264-7520-00)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-00,available
12106,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-04)",Revised,6/21/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-04,available
12107,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-03)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-03,available
12108,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 G/1000 Ml (NDC 0338-0023-02)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-02,available
12109,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-09)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-09",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-09,available
12110,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-55)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-55",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-55,available
12111,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-03)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-03",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-03,available
12112,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 0264-1510-31)",Reverified,9/3/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-31,available
12113,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 0264-1510-32)",Reverified,9/3/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-32,available
12114,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-20)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-20,available
12115,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-00)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-00,available
12116,Dextrose Monohydrate Injection,B. Braun Medical Inc.,"Injection, 5 G/100 Ml (NDC 0264-7510-10)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-10,available
12117,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0066-20)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0066-20,available
12118,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-03)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-03,available
12119,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0062-30)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0062-30,available
12120,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-02)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-02,available
12121,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0070-10)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0070-10,available
12122,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0551-18)",Reverified,9/5/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-18,available
12123,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-9147-30)",Reverified,9/5/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9147-30,available
12124,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 G/50 Ml (NDC 0338-9143-30)",Reverified,9/5/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9143-30,available
12125,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0338-0551-11)",Reverified,9/5/24,Available,On Allocation,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-11,available
12126,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-38)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-38,available
12127,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-18)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-18,available
12128,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-48)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-48,available
12129,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-31)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-31,available
12130,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-11)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-11,available
12131,Dextrose Monohydrate Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 G/1000 Ml (NDC 0338-0017-41)",Reverified,9/5/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-41,available
12132,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) (NDC 0409-6648-02)",Revised,8/26/24,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6648-02,not available
12133,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) Syringes (NDC 0409-4902-34)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4902-34,not available
12134,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 25 G/50 Ml (50%, 0.5 G/Ml) Syringes (NDC 0409-7517-16)",Revised,8/26/24,Unavailable,Estimated Recovery: March 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-7517-16,not available
12135,Dextrose Monohydrate Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose 50%, Injection, 25 G/50 Ml (NDC 76329-3302-1)",Reverified,8/20/24,Limited Availability,On Allocation,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3302-1,limited availability
12136,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose, Injection, 2.5 G/10ml (25%, 250 Mg/ Ml) Syringes (NDC 0409-1775-10)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-1775-10,limited availability
12137,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-37)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-37",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-37,available
12138,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-36)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-36",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-36,available
12139,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-23)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-23",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-23,available
12140,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7923-20)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7923-20",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-20,available
12141,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-61)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-61",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-61,available
12142,Dextrose Monohydrate Injection,"Icu Medical, Inc.","Dextrose 5% In Plastic Container, Injection, 5 G/100 Ml (NDC 0990-7922-02)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7922-02",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-02,available
12143,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-50)",Revised,9/4/24,Limited Availability,7 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-50,limited availability
12144,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-10)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-10,available
12145,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-75)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-75,available
12146,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-74)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-74,available
12147,Dextrose Monohydrate Injection,"Fresenius Kabi Usa, Llc","Dextrose 5% In Plastic Container, Injection, 50 Mg/1 Ml (NDC 63323-624-61)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-624-61,available
12148,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 12.5 G/250ml (5%) (NDC 0409-7100-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-02,available
12149,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 5 G/100ml (5%) Plastic (NDC 0409-7100-67)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-67,available
12150,Dextrose Monohydrate Injection,"Hospira, Inc., A Pfizer Company","Dextrose 5% In Plastic Container, Injection, 2.5 G/50ml (5%, 50mg/Ml) (NDC 0409-7100-66)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-66,available
12151,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .4 G/100 Ml (NDC 0264-9594-10)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,0264-9594-10,available
12152,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .4 G/100 Ml (NDC 0264-9594-20)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,0264-9594-20,available
12153,"Dextrose Monohydrate, Lidocaine Hydrochloride Anhydrous Injection",B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 G/100 Ml; .8 G/100 Ml (NDC 0264-9598-20)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,0264-9598-20,available
12154,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 2.5 Mg/.5 Ml (NDC 68682-650-20)",Revised,4/19/24,,,Available,,Neurology,Resolved,4/19/24,,68682-650-20,
12155,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 10 Mg/2 Ml (NDC 68682-652-20)",Revised,4/19/24,,,Available,,Neurology,Resolved,4/19/24,,68682-652-20,
12156,Diazepam Gel,"Bausch Health Americas, Inc.","Gel, 20 Mg/4 Ml (NDC 68682-655-20)",Revised,4/19/24,,,Available,,Neurology,Resolved,4/19/24,,68682-655-20,
12157,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 20 Mg/4 G (NDC 43386-281-01)",Revised,4/19/24,,,Available,,Neurology,Resolved,4/19/24,,43386-281-01,
12158,Diazepam Gel,"Lupin Pharmaceuticals, Inc.","Gel, 10 Mg/2 G (NDC 43386-280-01)",Revised,4/19/24,,,Available,,Neurology,Resolved,4/19/24,,43386-280-01,
12159,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 Mg/1 Ml (NDC 0078-0862-25)",Revised,4/24/24,,,Available,,Ophthalmology,Resolved,4/24/24,,0078-0862-25,
12160,Difluprednate Emulsion,Amneal Pharmaceuticals,"Difluprednate Ophthalmic Emulsion, Emulsion, .5 Mg/1 Ml (NDC 69238-1380-3)",Revised,4/24/24,,,Available,,Ophthalmology,Resolved,4/24/24,,69238-1380-3,
12161,Difluprednate Emulsion,Cipla Limited,"Emulsion, .5 Mg/1 Ml (NDC 69097-341-35)",Revised,4/24/24,,,Available,,Ophthalmology,Resolved,4/24/24,,69097-341-35,
12162,Difluprednate Emulsion,Sandoz Inc.,"Durezol, Emulsion, .5 Mg/1 Ml (NDC 0781-6000-78)",Revised,4/24/24,,,Available,,Ophthalmology,Resolved,4/24/24,,0781-6000-78,
12163,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 Ug/1 Ml (NDC 70515-263-10)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,70515-263-10,
12164,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 100 Ug/1 Ml (NDC 70515-262-10)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,70515-262-10,
12165,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 Ug/1 Ml (NDC 70515-261-10)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,70515-261-10,
12166,Digoxin Injection,Covis Pharma,"Lanoxin, Injection, 250 Ug/1 Ml (NDC 70515-260-10)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,70515-260-10,
12167,Digoxin Injection,Sandoz Inc.,"Injection, 250 Ug/1 Ml (NDC 0781-3059-95)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,0781-3059-95,
12168,Digoxin Injection,"Hikma Pharmaceuticals Usa, Inc.","Digoxin Injection, Usp, Injection, .25 Mg/1 Ml (NDC 0641-1410-35)",Revised,5/2/24,,,Available,,Cardiovascular,Resolved,5/2/24,,0641-1410-35,
12169,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 50mg/10ml (NDC 55150-426-10)",Revised,5/22/24,,,Available,,Cardiovascular,Resolved,5/22/24,,55150-426-10,
12170,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 25mg/ 5ml (NDC 55150-425-10)",Revised,5/22/24,,,Available,,Cardiovascular,Resolved,5/22/24,,55150-425-10,
12171,Diltiazem Hydrochloride Injection,Eugia Us Llc,"Injection, 125mg/ 25ml (NDC 55150-427-10)",Revised,5/22/24,,,Available,,Cardiovascular,Resolved,5/22/24,,55150-427-10,
12172,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-25)",Reverified,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,70860-301-25,
12173,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-10)",Reverified,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,70860-301-10,
12174,Diltiazem Hydrochloride Injection,Sagent Pharmaceuticals,"Injection, 5 Mg/1 Ml (NDC 70860-301-05)",Reverified,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,70860-301-05,
12175,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6015-10)",Revised,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,0641-6015-10,
12176,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6014-10)",Revised,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,0641-6014-10,
12177,Diltiazem Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 5 Mg/1 Ml (NDC 0641-6013-10)",Revised,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,0641-6013-10,
12178,Diltiazem Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Diltiazem Hydrochloride, Injection, 100 Mg (NDC 0409-4350-03)",Revised,5/22/24,,,,,Cardiovascular,Resolved,5/22/24,,0409-4350-03,
12179,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Ir, 150 Mg  (NDC 0025-2762-31)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,0025-2762-31,
12180,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Ir, 100 Mg (NDC 0025-2752-31)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,0025-2752-31,
12181,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, 100 Mg (NDC 59762-0386-1)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,59762-0386-1,
12182,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Cr, 150 Mg Extended Release (NDC 0025-2742-31)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,0025-2742-31,
12183,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, Norpace Cr, 100 Mg Extended Release (NDC 0025-2732-31)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,0025-2732-31,
12184,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals Usa, Inc.","Capsule, 150 Mg (NDC 0093-3129-01)",Revised,6/4/24,,,Available,,Cardiovascular,Resolved,6/4/24,,0093-3129-01,
12185,Disopyramide Phosphate Capsule,"Teva Pharmaceuticals Usa, Inc.","Capsule, 100 Mg (NDC 0093-3127-01)",Revised,6/4/24,,,Available,,Cardiovascular,Resolved,6/4/24,,0093-3127-01,
12186,Disopyramide Phosphate Capsule,Pfizer Inc.,"Capsule, 150 Mg (NDC 59762-0400-1)",Revised,6/4/24,,,Available; Greenstone Brand (Ndc 59762-0386-1 And Ndc 59762-0400-1) Marketed By Viatris,,Cardiovascular,Resolved,6/4/24,,59762-0400-1,
12187,Disopyramide Phosphate Capsule,"Dr. Reddy'S Laboratories, Inc.","Capsule, 150 Mg (NDC 51862-096-01)",Revised,6/4/24,,,Available. Marketed By Mayne Pharmaceuticals.,,Cardiovascular,Resolved,,,51862-096-01,
12188,Disopyramide Phosphate Capsule,"Dr. Reddy'S Laboratories, Inc.","Capsule, 100 Mg (NDC 51862-095-01)",Revised,6/4/24,,,Available. Marketed By Mayne Pharmaceuticals.,,Cardiovascular,Resolved,,,51862-095-01,
12189,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0054-0356-13)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0356-13,discontinued
12190,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0054-0356-25)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0356-25,discontinued
12191,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 500 Mg (NDC 0054-0357-13)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0357-13,discontinued
12192,Disulfiram Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 500 Mg (NDC 0054-0357-25)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Analgesia/Addiction,To Be Discontinued,,11/2/23,0054-0357-25,discontinued
12193,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-02)",Reverified,8/26/24,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-02,available
12194,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 Mg/100 Ml (NDC 0338-1077-02)",Revised,7/17/24,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1077-02,available
12195,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 Mg/100 Ml (NDC 0338-1075-02)",Reverified,9/5/24,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1075-02,available
12196,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Injection, 500 Mg/40 Ml (NDC 70436-204-80)",Revised,11/1/23,Unavailable,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular; Pediatric; Renal,To Be Discontinued,11/1/23,11/1/23,70436-204-80,not available
12197,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Dobutamine Hydrochloride, Injection, 250 Mg/20 Ml (NDC 70436-203-80)",Revised,7/15/24,"Available, Not Applicable","Distributed By Slate Run Pharmaceuticals, Llc, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,70436-203-80,available
12198,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-88)",Reverified,8/26/24,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-88,available
12199,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride, Injection, 250 Mg/20ml (12.5 Mg/1 Ml) (NDC 0409-2344-01)",Reverified,8/26/24,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-01,available
12200,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 Mg/250ml (400 Mg/Ml) (NDC 0409-3724-32)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,0409-3724-32,not available
12201,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 Mg/250ml (200 Mg/Ml) (NDC 0409-2347-32)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2347-32,limited availability
12202,Dobutamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 Mg/250ml (100 Mg/Ml) (NDC 0409-2346-32)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2346-32,not available
12203,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 Mg/100 Ml (NDC 0338-1073-02)",Reverified,9/5/24,Available,On Allocation,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1073-02,available
12204,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .125 Mg (NDC 0069-5800-43)",New,4/23/24,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/24,0069-5800-43,discontinued
12205,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .25 Mg (NDC 0069-5810-43)",New,4/23/24,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/24,0069-5810-43,discontinued
12206,Dofetilide Capsule,Pfizer Inc.,"Tikosyn, Capsule, .5 Mg (NDC 0069-5820-43)",New,4/23/24,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,4/23/24,0069-5820-43,discontinued
12207,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 Mg/100 Ml (NDC 0338-1007-03)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1007-03,available
12208,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 Mg/100 Ml (NDC 0338-1007-02)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1007-02,available
12209,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-1005-03)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1005-03,available
12210,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dopamine Hcl Injection, Usp, Injection, 40 Mg/1 Ml (NDC 0143-9254-25)",Reverified,8/28/24,Available,,,,Cardiovascular,Current,,,0143-9254-25,available
12211,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Dopamine Hcl Injection, Usp, Injection, 40 Mg/1 Ml (NDC 0143-9252-25)",Revised,7/25/24,Unavailable,Additional Lots Will Be Available In The October 2024 Timeframe.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Cardiovascular,Current,,,0143-9252-25,not available
12212,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 Mg/500 Ml (1.6 Mg/1 Ml) (NDC 0409-7809-24)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,0409-7809-24,not available
12213,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 Mg/250 Ml (1.6 Mg/1 Ml) (NDC 0409-7809-22)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,0409-7809-22,limited availability
12214,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-1005-02)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
12215,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride, Injection, 400 Mg/10ml (40 Mg/1 Ml) (NDC 0409-9104-20)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-9104-20,available
12216,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride, Injection, 200 Mg/5ml (40 Mg/1 Ml) (NDC 0409-5820-01)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-5820-01,available
12217,Dopamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 Mg/250 Ml (3.2 Mg/1 Ml) (NDC 0409-7810-22)",Revised,8/26/24,Available,,,,Cardiovascular,Current,,,0409-7810-22,available
12218,Doxycycline Hyclate Capsule,Pfizer Inc.,"Vibramycin, Capsule, 100 Mg (NDC 0069-0950-50)",New,2/1/24,,Supply Expected To Exhaust Early April 2024,,,Anti-Infective,To Be Discontinued,,,0069-0950-50,discontinued
12219,Doxycycline Hyclate Tablet,Apotex Corp.,"Tablet, 75 Mg (NDC 60505-4382-6)",New,4/30/24,,,,,Anti-Infective,To Be Discontinued,,4/30/24,60505-4382-6,discontinued
12220,Doxycycline Hyclate Tablet,Apotex Corp.,"Tablet, 150 Mg (NDC 60505-4384-6)",New,4/30/24,,,,,Anti-Infective,To Be Discontinued,,4/30/24,60505-4384-6,discontinued
12221,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 4.5 Mg/.5 Ml (NDC 0002-3182-80)",Revised,9/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-3182-80,available
12222,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 3 Mg/.5 Ml (NDC 0002-2236-80)",Revised,9/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2236-80,available
12223,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, 1.5 Mg/.5 Ml (NDC 0002-1434-80)",Revised,9/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1434-80,available
12224,Dulaglutide Injection,Eli Lilly And Co.,"Trulicity, Injection, .75 Mg/.5 Ml (NDC 0002-1433-80)",Revised,9/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1433-80,available
12225,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Reverified,1/15/24,Available Through Limited Distribution By Alliancerx Walgreens Specialty Pharmacy.,,,Delay In Shipping Of The Drug,Ophthalmology,Current,,,48102-053-05,limited availability
12226,Enalaprilat Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 1.25 Mg/1 Ml (NDC 0143-9787-10)",Revised,6/26/24,,,Available,,Cardiovascular,Resolved,6/26/24,,0143-9787-10,
12227,Enalaprilat Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 2.5 Mg/2 Ml (NDC 0143-9786-10)",Revised,6/26/24,,,Available,,Cardiovascular,Resolved,6/26/24,,0143-9786-10,
12228,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-489-27)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-489-27,available
12229,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 15 Mg/1 Ml (NDC 63323-488-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-488-37,available
12230,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-487-37)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-487-37,available
12231,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-483-57)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-483-57,available
12232,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-483-27)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-483-27,available
12233,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-57)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-482-57,available
12234,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-27)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-482-27,available
12235,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 5 Mg/1 Ml (NDC 63323-481-57)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-481-57,available
12236,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 Mg/20 Ml (2%; 1:200,000) (NDC 0409-3183-01)",Revised,8/26/24,Unavailable,Next Delivery: February 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3183-01,not available
12237,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 1 G/50 Ml (2%; 1:100,000) (NDC 0409-3182-03)",Revised,8/26/24,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3182-03,not available
12238,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 600 Mg/30 Ml (2%; 1:100,000) (NDC 0409-3182-02)",Revised,8/26/24,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3182-02,not available
12239,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 Mg/20 Ml (2%; 1:100,000) (NDC 0409-3182-01)",Revised,8/26/24,Unavailable,Next Delivery: July 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3182-01,not available
12240,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 450 Mg/30 Ml (1.5%; 1:200,000) (NDC 0409-3181-01)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3181-01,not available
12241,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 75 Mg/5 Ml (1.5%; 1:200,000) (NDC 0409-1209-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-1209-01,available
12242,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 500 Mg/50 Ml (1%; 1:100,000) (NDC 0409-3178-03)",Revised,8/26/24,Unavailable,Next Delivery: February 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3178-03,not available
12243,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 300 Mg/30 Ml (1%; 1:100,000) (NDC 0409-3178-02)",Revised,8/26/24,Unavailable,Next Delivery: November 2024; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3178-02,not available
12244,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 200 Mg/20 Ml (1%; 1:100,000) (NDC 0409-3178-01)",Revised,8/26/24,Unavailable,Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3178-01,not available
12245,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 G/50 Ml (0.5%; 1:200,000) (NDC 0409-3177-01)",Revised,8/26/24,Unavailable,Next Delivery: April 2025; Estimated Recovery: September 2025,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-3177-01,not available
12246,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 20 Mg/1 Ml (NDC 63323-489-17)",Revised,9/4/24,Available,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,,Anesthesia; Pediatric,Current,,,63323-489-17,available
12247,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 15 Mg/1 Ml (NDC 63323-488-17)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-488-17,available
12248,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .005 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-487-17)",Revised,9/4/24,Available,8 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,,Anesthesia; Pediatric,Current,,,63323-487-17,available
12249,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi Usa, Llc","Xylocaine, Injection, .01 Mg/1 Ml; 10 Mg/1 Ml (NDC 63323-482-17)",Revised,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-482-17,available
12250,"Epinephrine Injection, Syringes","Amphastar Pharmaceuticals, Inc.","Injection, Syringes, 0.1 Mg/Ml (NDC 76329-3318-1)",Revised,8/20/24,Available,Available On Allocation,,,Cardiovascular; Pulmonary/Allergy,Current,,,76329-3318-1,available
12251,"Epinephrine Injection, Syringes","Hospira, Inc., A Pfizer Company","Injection, Syringes, 1 Mg/10 Ml (0.1 Mg/1 Ml) (NDC 0409-4933-01)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Cardiovascular; Pulmonary/Allergy,Current,,,0409-4933-01,not available
12252,Epinephrine Solution,Adamis Pharmaceuticals Corporation,"Symjepi, Solution, 0.15 Mg/0.3 Ml  (NDC 78670-131-02)",New,9/18/23,,,,,Pulmonary/Allergy,To Be Discontinued,,9/18/23,78670-131-02,discontinued
12253,Erythromycin Ointment,Bausch & Lomb Incorporated,"Erythromycin, Ointment, 5 Mg/1 G (NDC 24208-910-19)",Revised,7/2/24,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/24,,24208-910-19,
12254,Erythromycin Ointment,Bausch & Lomb Incorporated,"Erythromycin, Ointment, 5 Mg/1 G (NDC 24208-910-55)",Revised,7/2/24,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/24,,24208-910-55,
12255,Erythromycin Ointment,Armas Pharmaceuticals Inc,"Ointment, 0.5% 1 -Gram Tube (NDC 72485067031)",Revised,7/2/24,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/24,,72485067031,
12256,Erythromycin Ointment,Armas Pharmaceuticals Inc,"Ointment, 0.5% 3.5-Gram Tubes (NDC 72485067035)",Revised,7/2/24,,,Available,,Ophthalmology; Pediatric,Resolved,7/2/24,,72485067035,
12257,Estradiol Valerate Injection,"Par Pharmaceutical, Inc.","Delestrogen, Injection, 40 Mg/1 Ml (NDC 42023-112-01)",New,6/4/24,,,,,Reproductive,To Be Discontinued,,6/4/24,42023-112-01,discontinued
12258,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 72572-161-10)",Reverified,8/28/24,Pending Information,Distributed By Civica,,,Anesthesia,Current,,,72572-161-10,unclear
12259,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 72572-160-10)",Reverified,8/28/24,Pending Information,Distributed By Civica,,,Anesthesia,Current,,,72572-160-10,unclear
12260,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 40 Mg/20 Ml (NDC 65219-445-20)",Reverified,7/16/24,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,65219-445-20,available
12261,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 65219-445-10)",Reverified,7/16/24,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,65219-445-10,available
12262,Etomidate Injection,"Hospira, Inc., A Pfizer Company","Amidate, Injection, 2 Mg/Ml (NDC 0409-6695-02)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-6695-02,available
12263,Etomidate Injection,"Hospira, Inc., A Pfizer Company","Amidate, Injection, 2 Mg/1 Ml (NDC 0409-6695-01)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-6695-01,available
12264,Etomidate Injection,"Mylan Institutional, A Viatris Company","Etomidate, Injection, 2 Mg/1 Ml (NDC 67457-903-20)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-903-20,available
12265,Etomidate Injection,"Mylan Institutional, A Viatris Company","Etomidate, Injection, 2 Mg/1 Ml (NDC 67457-902-10)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-902-10,available
12266,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9311-10)",Reverified,8/28/24,Pending Information,Novaplus,,,Anesthesia,Current,,,0143-9311-10,unclear
12267,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9310-10)",Reverified,8/28/24,Pending Information,Novaplus,,,Anesthesia,Current,,,0143-9310-10,unclear
12268,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9507-10)",Reverified,8/28/24,Available,Additional Lots Will Be Available.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9507-10,available
12269,Etomidate Injection,"Hikma Pharmaceuticals Usa, Inc.","Etomidate Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0143-9506-10)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9506-10,available
12270,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 Mg/1 Ml (NDC 72266-147-10)",Reverified,7/15/24,Available,"Distributed By Fosun Pharma Usa, Inc.. To Order, Contact: 833-291-9645.",,,Anesthesia,Current,,,72266-147-10,available
12271,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 Mg/1 Ml (NDC 72266-146-10)",Reverified,7/15/24,Available,"Distributed By Fosun Pharma Usa, Inc.. To Order, Contact: 833-291-9645.",,,Anesthesia,Current,,,72266-146-10,available
12272,Etomidate Injection,Eugia Us Llc,"Injection, 40 Mg/20 Ml (NDC 55150-222-20)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-222-20,available
12273,Etomidate Injection,Eugia Us Llc,"Injection, 20 Mg/10 Ml (NDC 55150-221-10)",Reverified,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-221-10,not available
12274,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 65219-447-20)",Revised,8/14/24,Available,Check Wholesalers For Inventory; Marketed By Fresenius Kabi,,,Anesthesia,Current,,,65219-447-20,available
12275,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 72485-508-10)",Revised,8/14/24,Available,"Check Wholesalers For Inventory; Marketed By Armas Pharmaceuticals, Inc.",,,Anesthesia,Current,,,72485-508-10,available
12276,Etomidate Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 72485-509-10)",Revised,8/14/24,Available,"Check Wholesalers For Inventory; Marketed By Armas Pharmaceuticals, Inc.",,,Anesthesia,Current,,,72485-509-10,available
12277,Evolocumab Injection,Amgen Inc.,"Repatha, Injection, 1 Kit In 1 Carton (55513-770-01) * 1 Cartridge In 1 Tray / 3.5 Ml In 1 Cartridge (NDC 55513-770-01)",New,4/12/24,,,,,Cardiovascular,To Be Discontinued,,4/12/24,55513-770-01,discontinued
12278,Evolocumab Injection,Amgen Inc.,"Repatha, Injection, 1 Kit In 1 Carton (72511-770-01) * 1 Cartridge In 1 Tray / 3.5 Ml In 1 Cartridge (NDC 72511-770-01)",New,4/12/24,,,,,Cardiovascular,To Be Discontinued,,4/12/24,72511-770-01,discontinued
12279,Felbamate Oral Suspension,"Mylan Specialty, A Viatris Company","Felbatol®, Oral Suspension, 32 Oz Each 5 Ml Contains 600 Mg Felbamate (NDC 0037-0442-17)",New,11/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,11/27/23,0037-0442-17,discontinued
12280,Felbamate Oral Suspension,"Mylan Specialty, A Viatris Company","Felbatol® , Oral Suspension, 8 Oz Each 5 Ml Contains 600 Mg Felbamate (NDC 0037-0442-67)",New,11/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,,11/27/23,0037-0442-67,discontinued
12281,Fenofibrate Tablet,Viatris,"Tablet, 54 Mg (NDC 0378-7100-77)",New,10/16/23,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/23,0378-7100-77,discontinued
12282,Fenofibrate Tablet,Viatris,"Tablet, 160 Mg (NDC 0378-7101-77)",New,10/16/23,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/23,0378-7101-77,discontinued
12283,Fenofibrate Tablet,Abbvie Inc.,"Tricor, Tablet, 48 Mg (NDC 0074-3173-90)",New,10/16/23,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,10/16/23,10/16/23,0074-3173-90,discontinued
12284,Fenofibrate Tablet,Abbvie Inc.,"Tricor, Tablet, 145 Mg (NDC 0074-3189-90)",New,10/16/23,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/16/23,0074-3189-90,discontinued
12285,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6247-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6247-25,available
12286,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Ug/1 Ml (NDC 63323-808-11)",Reverified,8/15/24,Unavailable,Backordered. Next Releast August 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,63323-808-11,not available
12287,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-05)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-05,available
12288,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-02)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-02,available
12289,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-01)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-01,available
12290,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-50)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-50,available
12291,Fentanyl Citrate Injection,"Fresenius Kabi Usa, Llc","Fentanyl Citrate Preservative Free, Injection, .05 Mg/1 Ml (NDC 63323-806-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-20,available
12292,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6030-01)",Reverified,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6030-01,available
12293,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6029-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6029-25,available
12294,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6028-25)",Reverified,7/25/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6028-25,available
12295,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 0641-6027-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6027-25,available
12296,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6026-05)",Reverified,8/28/24,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6026-05,not available
12297,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6025-10)",Reverified,8/28/24,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6025-10,not available
12298,Fentanyl Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Fentanyl Citrate Injection, Usp, Injection, 50 Ug/1 Ml (NDC 0641-6024-10)",Reverified,8/28/24,Unavailable,Inventory Available In Vial Presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6024-10,not available
12299,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 2500 Mcg/50 Ml (50 Ug/1 Ml) (NDC 0409-9094-61)",Reverified,8/26/24,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-61,available
12300,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 1000 Mcg/20 Ml (50 Ug/1 Ml) (NDC 0409-9094-31)",Reverified,8/26/24,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-31,available
12301,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 500 Mcg/10 Ml (50 Ug/1 Ml) (NDC 0409-9094-28)",Reverified,8/26/24,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-28,available
12302,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 250 Mcg/5 Ml (50 Ug/1 Ml) (NDC 0409-9094-25)",Reverified,8/26/24,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-25,available
12303,Fentanyl Citrate Injection,"Hospira, Inc., A Pfizer Company","Fentanyl Citrate, Injection, 100 Mcg/2 Ml (50 Ug/1 Ml) (NDC 0409-9094-22)",Reverified,8/26/24,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-22,available
12304,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 8 Mg (NDC 62559-376-90)",New,4/30/24,,,,,Urology,To Be Discontinued,,4/30/24,62559-376-90,discontinued
12305,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 8 Mg (NDC 62559-376-30)",New,4/30/24,,,,,Urology,To Be Discontinued,,4/30/24,62559-376-30,discontinued
12306,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 4 Mg (NDC 62559-375-30)",New,4/30/24,,,,,Urology,To Be Discontinued,,4/30/24,62559-375-30,discontinued
12307,"Fesoterodine Fumarate  Tablet, Extended Release",Ani Pharmaceuticals,"Tablet, Extended Release, 4 Mg (NDC 62559-375-90)",New,4/30/24,,,,,Urology,To Be Discontinued,,4/30/24,62559-375-90,discontinued
12308,Fluconazole Injection,Sagent Pharmaceuticals,"Fluconazole In Sodium Chloride 0.9% In Plastic Container, Injection, 2 Mg/1 Ml (NDC 25021-184-82)",Reverified,5/21/24,,,,,Anti-Infective,Resolved,5/21/24,,25021-184-82,
12309,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 50 Mg  (NDC 0049-3410-30)",Revised,10/24/23,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,10/24/23,0049-3410-30,discontinued
12310,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 Mg (NDC 0049-3420-41)",New,6/14/24,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,6/14/24,0049-3420-41,discontinued
12311,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 Mf (NDC 0049-3430-41)",New,3/28/24,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,3/28/24,0049-3430-41,discontinued
12312,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Cytostatikum Fludarabin Actavis 25 Mg/Ml, Injection, 25 Mg/1 Ml (NDC 0480-9772-01)",Revised,4/17/24,,,Available,,Oncology,Resolved,4/17/24,,0480-9772-01,
12313,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Fludarabine Phosphate For Injection, Usp (Lyophilized), Injection, 25 Mg/1 Ml (NDC 45963-621-51)",Revised,4/17/24,,,Available,,Oncology,Resolved,4/17/24,,45963-621-51,
12314,Fludarabine Phosphate Injection,Accord Healthcare Inc.,"Fludarabine Phosphate, Injection, 25 Mg/1 Ml (NDC 16729-131-30)",Revised,11/14/22,Product Anticipated 11/21/2022,,,,Oncology,Current,,,16729-131-30,not available
12315,Fludarabine Phosphate Injection,"Fresenius Kabi Usa, Llc","Injection, 25 Mg/1 Ml (NDC 63323-192-02)",Revised,4/17/24,,,Available,,Oncology,Resolved,4/17/24,,63323-192-02,
12316,Fludarabine Phosphate Injection,"Teva Pharmaceuticals Usa, Inc.","Fludarabine Phosphate For Injection, Usp (Lyophilized), Injection, 50 Mg/2 Ml (NDC 45963-609-55)",Revised,4/17/24,,,Available,,Oncology,Resolved,4/17/24,,45963-609-55,
12317,Fludarabine Phosphate Injection,"Areva Pharmaceuticals, Inc.","Injection, 25 Mg/1 Ml (NDC 59923-604-02)",Revised,4/17/24,,,Available,,Oncology,Resolved,4/17/24,,59923-604-02,
12318,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Flurazepam Hydrochloride, Capsule, 30 Mg (NDC 62135-737-90)",Reverified,9/2/24,Available,,,,Neurology; Other,Current,,,62135-737-90,available
12319,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Flurazepam Hydrochloride, Capsule, 15 Mg (NDC 62135-736-90)",Reverified,9/2/24,Available,,,,Oncology; Other,Current,,,62135-736-90,available
12320,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 30 Mg (NDC 0378-4430-01)",Revised,7/2/24,Unavailable,Anticipated Availability: Q1 2025; Delay Is Due To Manufacturing Delays At The Contract Manufacturing Facility.,,Regulatory Delay,Neurology; Other,Current,,,0378-4430-01,not available
12321,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Capsule, 15 Mg (NDC 0378-4415-01)",Revised,7/2/24,Unavailable,Anticipated Availability: Q1 2025; Delay Is Due To Manufacturing Delays At The Contract Manufacturing Facility.,,Regulatory Delay,Neurology; Other,Current,,,0378-4415-01,not available
12322,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Capsule, 30 Mg (NDC 62135-737-30)",Reverified,9/2/24,Available,,,,Neurology; Other,Current,,,62135-737-30,available
12323,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings Llc,"Capsule, 15 Mg (NDC 62135-736-30)",Reverified,9/2/24,Available,,,,Neurology; Other,Current,,,62135-736-30,available
12324,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 55 Ug (NDC 59310-114-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-114-06,discontinued
12325,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 113 Ug/1 (NDC 59310-200-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-200-06,discontinued
12326,"Fluticasone Propionate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Armonair Digihaler, Powder, Metered, 232 Ug/1 (NDC 59310-311-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-311-06,discontinued
12327,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 55 Ug; 14 Ug (NDC 59310-111-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-111-06,discontinued
12328,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 113 Ug; 14 Ug (NDC 59310-129-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-129-06,discontinued
12329,"Fluticasone Propionate; Salmeterol Xinafoate Powder, Metered","Teva Pharmaceuticals Usa, Inc.","Airduo Digihaler, Powder, Metered, 232 Ug; 14 Ug (NDC 59310-136-06)",New,4/30/24,,,,,Pulmonary/Allergy,To Be Discontinued,,4/30/24,59310-136-06,discontinued
12330,Fulvestrant Solution,"Teva Pharmaceuticals Usa, Inc.","Solution, 250 Mg/5 Ml (NDC 0591-5019-02)",New,10/26/23,,Business Decision To Discontinue.,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,10/26/23,0591-5019-02,discontinued
12331,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-10)",Revised,7/30/24,Unavailable,Use Sagent Ndc 25021-311-10,,Other,Cardiovascular,Current,,,70860-302-10,not available
12332,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-04)",Revised,7/30/24,Unavailable,Use Sagent Ndc 25021-311-04,,Other,Cardiovascular,Current,,,70860-302-04,not available
12333,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 70860-302-02)",Revised,7/30/24,Unavailable,Use Sagent Ndc 25021-311-02,,Other,Cardiovascular,Current,,,70860-302-02,not available
12334,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-203-11)",Reverified,7/3/24,Available,,,,Cardiovascular,Current,,,71288-203-11,available
12335,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-203-05)",Reverified,7/3/24,Available,,,,Cardiovascular,Current,,,71288-203-05,available
12336,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/Ml, 2 Ml (NDC 71288-205-03)",Reverified,7/3/24,Available,,,,Cardiovascular,Current,,,71288-205-03,available
12337,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Mg/ 10ml (10 Mg/1 Ml) (NDC 0409-6102-27)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-27,available
12338,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-502-43)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,16729-502-43,not available
12339,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-501-43)",Reverified,8/19/24,Available,,,,Cardiovascular,Current,,,16729-501-43,available
12340,Furosemide Injection,Accord Healthcare Inc.,"Injection, 10 Mg/1 Ml (NDC 16729-500-08)",Revised,8/19/24,Unavailable,Resupply Tbd,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,16729-500-08,not available
12341,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 10 Ml (NDC 70860-302-43)",Revised,3/6/24,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/24,3/6/24,70860-302-43,discontinued
12342,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 4 Ml (NDC 70860-302-42)",Revised,3/6/24,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/24,3/6/24,70860-302-42,discontinued
12343,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/Ml, 2 Ml (NDC 70860-302-41)",Revised,3/6/24,,This Presentation Has Been Discontinued,,,Cardiovascular,To Be Discontinued,3/6/24,3/6/24,70860-302-41,discontinued
12344,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-10)",Reverified,7/1/24,Available,,,,Cardiovascular,Current,,,25021-311-10,available
12345,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-04)",Reverified,7/1/24,Available,,,,Cardiovascular,Current,,,25021-311-04,available
12346,Furosemide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-311-02)",Reverified,7/1/24,Available,,,,Cardiovascular,Current,,,25021-311-02,available
12347,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-10)",Revised,7/15/24,Available,,,,Cardiovascular,Current,,,25021-311-10,available
12348,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-04)",Revised,7/15/24,Available,,,,Cardiovascular,Current,,,25021-311-04,available
12349,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 Mg/1 Ml (NDC 25021-311-02)",Revised,7/15/24,Available,,,,Cardiovascular,Current,,,25021-311-02,available
12350,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-283-25)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,36000-283-25,available
12351,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-282-25)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,36000-282-25,available
12352,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 Mg/1 Ml (NDC 36000-284-25)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,36000-284-25,available
12353,Furosemide Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-324-25)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,55150-324-25,available
12354,Furosemide Injection,Eugia Us Llc,"Injection, 40 Mg/4 Ml (NDC 55150-323-25)",Reverified,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,55150-323-25,not available
12355,Furosemide Injection,Eugia Us Llc,"Injection, 20 Mg/2 Ml (NDC 55150-322-25)",Reverified,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,55150-322-25,not available
12356,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-10)",Reverified,8/15/24,Available,Check Wholesalers For Inventory.,,,Cardiovascular,Current,,,63323-280-10,available
12357,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-04)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,63323-280-04,not available
12358,Furosemide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-280-02)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Cardiovascular,Current,,,63323-280-02,available
12359,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Mg/4 Ml (10 Mg/1 Ml) (NDC 0409-6102-26)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-26,available
12360,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Furosemide, Injection, 20 Mg/2 Ml (10 Mg/1 Ml) (NDC 0409-6102-25)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-25,available
12361,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Furosemide, Injection, 100 Mg/ 10ml (10 Mg/1 Ml) (NDC 0409-6102-10)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-10,available
12362,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Mg/4 Ml (10 Mg/1 Ml) (NDC 0409-6102-04)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-04,available
12363,Furosemide Injection,"Hospira, Inc., A Pfizer Company","Injection, 20 Mg/2 Ml (10 Mg/1 Ml) (NDC 0409-6102-02)",Reverified,8/26/24,Available,,,,Cardiovascular,Current,,,0409-6102-02,available
12364,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-44)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,23155-473-44,available
12365,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-42)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,23155-473-42,available
12366,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 23155-473-41)",Reverified,9/3/24,Available,,,,Cardiovascular,Current,,,23155-473-41,available
12367,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml; 4ml Vial (NDC 83634-302-04)",Revised,9/3/24,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-04,available
12368,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml; 2ml Vial (NDC 83634-302-02)",Revised,9/3/24,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-02,available
12369,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 83634-302-10)",Reverified,9/3/24,Available,Distributed By Avenacy; Contact Information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-10,available
12370,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 Mg/50 Ml (NDC 0338-0507-48)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0507-48,
12371,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 Mg/100 Ml (NDC 0338-0505-48)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0505-48,
12372,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 100 Mg/50 Ml (NDC 0338-0511-41)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0511-41,
12373,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 Mg/100 Ml (NDC 0338-0503-48)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0503-48,
12374,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 80 Mg/50 Ml (NDC 0338-0509-41)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0509-41,
12375,Gentamicin Sulfate Injection,Baxter Healthcare,"Gentamicin Sulfate In Sodium Chloride 0.9% In Plastic Container, Injection, 60 Mg/50 Ml (NDC 0338-0507-41)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0338-0507-41,
12376,Gentamicin Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Injection, 40 Mg/1 Ml (NDC 0143-9128-25)",Revised,7/24/24,,,,,Anti-Infective,Resolved,7/24/24,,0143-9128-25,
12377,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 40 Mg/1 Ml (NDC 63323-010-02)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,63323-010-02,
12378,Gentamicin Sulfate Injection,"Hospira, Inc., A Pfizer Company","Gentamicin Sulfate, Injection, 40 Mg/1 Ml (NDC 0409-1207-25)",Revised,3/29/24,,,,,Anti-Infective,To Be Discontinued,3/29/24,3/29/24,0409-1207-25,discontinued
12379,Gentamicin Sulfate Injection,"Hospira, Inc., A Pfizer Company","Injection, 80 Mg/2 Ml (40 Mg/Ml) (NDC 0409-1207-03)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,0409-1207-03,
12380,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-173-02)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,63323-173-02,
12381,Gentamicin Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 40 Mg/1 Ml (NDC 63323-010-20)",Revised,7/24/24,,,Available,,Anti-Infective,Resolved,7/24/24,,63323-010-20,
12382,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol Xl, Tablet, Extended Release, 5 Mg (NDC 0049-0174-02)",New,8/5/24,,Supply Expected To Exhaust Mid September 2024; Discontinuation Of The Manufacture Of The Drug,,,Endocrinology/Metabolism,To Be Discontinued,,8/5/24,0049-0174-02,discontinued
12383,Glucagon Hydrochloride Injection,Novo Nordisk,"Glucagen, Injection, 1 Mg/1 Ml (NDC 0169-7065-15)",New,11/15/23,,"Will Be Unavailable After July 1, 2024",,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,To Be Discontinued,,11/18/22,0169-7065-15,discontinued
12384,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [Usp'U]/100 Ml (NDC 0264-9872-10)",Reverified,9/3/24,Available,,,,Hematology,Current,,,0264-9872-10,available
12385,Heparin Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 [Usp'U]/100 Ml (NDC 63323-519-10)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Hematology,Current,,,63323-519-10,available
12386,Heparin Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 [Usp'U]/100 Ml (NDC 63323-519-77)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Hematology,Current,,,63323-519-77,available
12387,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0424-18)",Reverified,9/5/24,Available,On Allocation; Product Code Ahb0953u Replaces Code 2b0953,,,Hematology,Current,,,0338-0424-18,available
12388,Heparin Sodium Injection,"Hospira, Inc., A Pfizer Company","Heparin Sodium, Injection, 2,000 Units/1,000 Ml (2 Units/Ml) (NDC 0409-7620-59)",Revised,8/26/24,Limited Availability,Estimated Recovery: September 2024,,Other,Hematology,Current,,,0409-7620-59,limited availability
12389,Heparin Sodium Injection,"Hospira, Inc., A Pfizer Company","Heparin Sodium, Injection, 1,000 Units/500 Ml (2 Units/Ml) (NDC 0409-7620-03)",Reverified,8/26/24,Available,,,,Hematology,Current,,,0409-7620-03,available
12390,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0431-03)",Reverified,9/5/24,Unavailable,,,,Hematology,Current,,,0338-0431-03,not available
12391,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [Usp'U]/100 Ml (NDC 0338-0433-04)",Revised,5/13/24,Limited Availability,On Allocation; Recovery June 2024,,Demand Increase For The Drug,Hematology,Current,,,0338-0433-04,limited availability
12392,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 Mg; 20 Mg (NDC 59762-0223-1)",New,10/2/23,,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Antibiotic; Cardiovascular,To Be Discontinued,,10/2/23,59762-0223-1,discontinued
12393,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 12.5 Mg; 10 Mg (NDC 59762-0222-1)",New,10/2/23,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,10/2/23,59762-0222-1,discontinued
12394,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accuretic, Tablet, 12.5 Mg; 20 Mg (NDC 59762-0220-1)",New,10/2/23,,Discontinuation Of The Manufacture Of The Drug,,,Cardiovascular,To Be Discontinued,,10/2/23,59762-0220-1,discontinued
12395,Hydrocortisone Probutate Cream,Ani Pharmaceuticals,"Pandel, Cream, 1 Mg/1 G (NDC 62559-325-26)",New,8/21/24,,"Business Decision To Discontinue Product Manufacturing. Ani Anticipates Ceasing Distribution Of All Configurations On September 30, 2024.",,,Dermatology,To Be Discontinued,,8/21/24,62559-325-26,discontinued
12396,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 500 Mg/Vial (NDC 0009-0016-12)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0016-12,available
12397,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 250 Mg/Vial (NDC 0009-0013-05)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-05,available
12398,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 250 Mg/Vial (NDC 0009-0013-06)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-06,available
12399,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0011-03)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0011-03,available
12400,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0011-04)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0011-04,available
12401,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 100 Mg/Vial (NDC 0009-0825-01)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0825-01,limited availability
12402,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., A Pfizer Company","Solu-Cortef, Injection, 1000 Mg/Vial (NDC 0009-0005-01)",Reverified,8/26/24,Available,,,,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0005-01,available
12403,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 2 Mg/1 Ml (NDC 76045-010-11)",Reverified,9/4/24,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,76045-010-11,not available
12404,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, .2 Mg/1 Ml (NDC 76045-121-11)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,76045-121-11,available
12405,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 1 Mg/1 Ml (NDC 76045-009-11)",Revised,8/21/24,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,76045-009-11,not available
12406,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-50)",Reverified,9/4/24,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-851-50,not available
12407,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-15)",Reverified,8/15/24,Unavailable,Backordered. Next Release August 2024; Check Wholesalers For Inventory.,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,63323-851-15,not available
12408,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-851-10)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-851-10,not available
12409,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-854-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,63323-854-10,available
12410,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 63323-853-25)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024;  Check Wholesalers For Inventory,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-853-25,not available
12411,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-852-25)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-852-25,not available
12412,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Hydromorphone Hcl Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-2341-41)",Reverified,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-2341-41,available
12413,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Hydromorphone Hcl Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-0121-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-0121-25,available
12414,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0018-01)",Revised,8/23/24,Unavailable,Estimated Recovery Tbd,,Other,Analgesia/Addiction,Current,,,0703-0018-01,not available
12415,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0113-03)",Revised,8/23/24,Unavailable,Estimated Recovery Tbd,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0703-0113-03,not available
12416,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals Usa, Inc.","Hydromorphone Hydrochloride Injection, Usp Cii, Injection, 10 Mg/1 Ml (NDC 0703-0110-03)",Revised,8/23/24,Unavailable,Estimated Recovery Tbd,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0703-0110-03,not available
12417,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 Mg/1 Ml (NDC 0409-2552-01)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: June 2025,,Other,Analgesia/Addiction,Current,,,0409-2552-01,not available
12418,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 500 Mg/50 Ml (10 Mg/Ml) (NDC 0409-2634-50)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,0409-2634-50,not available
12419,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-2634-05)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,0409-2634-05,not available
12420,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 Mg/1 Ml (NDC 0409-2634-01)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,0409-2634-01,not available
12421,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 Mg/1 Ml Syringes (NDC 0409-1304-31)",Revised,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1304-31,available
12422,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 Mg/1 Ml Syringes (NDC 0409-1312-30)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: September 2024,,Other,Analgesia/Addiction,Current,,,0409-1312-30,limited availability
12423,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 Mg/1 Ml Syringes (NDC 0409-1283-31)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,0409-1283-31,limited availability
12424,Hydromorphone Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Dilaudid, Injection, 1 Mg/1 Ml (NDC 76045-009-06)",Revised,8/21/24,Unavailable,Backordered. Next Release August 2024.  Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,76045-009-06,not available
12425,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-1312-36)",Revised,8/26/24,Unavailable,Next Delivery: November 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,0409-1312-36,not available
12426,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Mg/1 Ml (NDC 0409-1283-37)",Revised,8/26/24,Unavailable,Next Delivery: October 2024; Estimated Recovery: December 2024,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,0409-1283-37,not available
12427,Hydromorphone Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml (NDC 0409-3365-10)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Analgesia/Addiction,Current,,,0409-3365-10,not available
12428,Hydroxocobalamin Injection,"Teva Pharmaceuticals Usa, Inc.","Hydroxocobalamin Injection Usp, Injection, 1000 Ug/1 Ml (NDC 0591-2888-30)",Revised,9/12/24,,,,,Endocrinology/Metabolism,Resolved,9/12/24,,0591-2888-30,
12429,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 Mg (NDC 24208-800-60)",Reverified,9/4/24,Unavailable,Discontinuation Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Ophthalmology,Current,,,24208-800-60,not available
12430,Iloprost Solution,Actelion Pharmaceuticals,"Ventavis, Solution, 10 Ug/1 Ml (NDC 66215-302-30)",New,5/9/24,,"Philips Respironics Has Decided To Discontinue The I-Neb® Aad® System And Its Associated Supplies, Including The Medication Discs Required For Administering Ventavis® Inhalation Solution.",,,Pulmonary/Allergy,To Be Discontinued,,5/9/24,66215-302-30,discontinued
12431,Iloprost Solution,Actelion Pharmaceuticals,"Ventavis, Solution, 20 Ug/1 Ml (NDC 66215-303-30)",New,5/9/24,,"Philips Respironics Has Decided To Discontinue The I-Neb® Aad® System And Its Associated Supplies, Including The Medication Discs Required For Administering Ventavis® Inhalation Solution.",,,Pulmonary/Allergy,To Be Discontinued,,5/9/24,66215-303-30,discontinued
12432,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 Mg (NDC 49884-054-10)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-054-10,discontinued
12433,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 10 Mg (NDC 49884-054-01)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-054-01,discontinued
12434,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 Mg (NDC 49884-055-01)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-055-01,discontinued
12435,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 25 Mg (NDC 49884-055-10)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-055-10,discontinued
12436,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 Mg (NDC 49884-056-10)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-056-10,discontinued
12437,Imipramine Hydrochloride Tablet,"Par Pharmaceutical, Inc.","Imipramine Hydrochloride, Tablet, 50 Mg (NDC 49884-056-01)",Revised,9/15/23,,Anda Ownership Transferred,,,Psychiatry,To Be Discontinued,9/14/23,9/14/23,49884-056-01,discontinued
12438,Indigotindisulfonate Sodium Injection,"American Regent, Inc.","Indigo Carmine, Injection, 8 Mg/1 Ml (NDC 0517-0375-05)",Revised,11/1/23,,,,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,11/1/23,11/1/23,0517-0375-05,discontinued
12439,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"Injection, 25 Mg (NDC 70100-424-02)",Reverified,9/5/24,Limited Availability,Limited Availability Through December 2024,,Delay In Shipping Of The Drug,Medical Imaging; Ophthalmology; Other,Current,,,70100-424-02,limited availability
12440,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-937-26)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-937-26,available
12441,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-937-16)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-937-16,available
12442,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-306-23)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-306-23,available
12443,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-903-24)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-903-24,available
12444,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-936-25)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-936-25,available
12445,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-306-13)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-306-13,available
12446,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-903-14)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-903-14,available
12447,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 Mg (NDC 66259-936-15)",Revised,8/26/24,Available,,,,Medical Imaging; Ophthalmology; Other,Current,,,66259-936-15,available
12448,Insulin (Human) Injection,Eli Lilly And Co.,"Humulin-R, Injection, 100 [Iu]/1 Ml, 3ml Vial (NDC 0002-0213-01)",New,3/1/24,,Humulin R U-100 Will Continue To Be Available In 10ml Vials.,,,Endocrinology/Metabolism,To Be Discontinued,,3/1/24,0002-0213-01,discontinued
12449,Insulin (Human) Injection,Eli Lilly And Co.,"Humulin-R, Injection, 100 [Iu]/1 Ml, 3 Ml Vial (NDC 0002-8215-17)",New,3/1/24,,Humulin R U-100 Will Continue To Be Available In 10ml Vials.,,,Endocrinology/Metabolism,To Be Discontinued,,3/1/24,0002-8215-17,discontinued
12450,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [Iu]/1 Ml (NDC 0169-3687-12)",New,11/8/23,,"Levemir® Vials Will Be Available Until The End Of 2024. Full Brand Discontinuation Will Occur On December 31, 2024.",,,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/23,0169-3687-12,discontinued
12451,Insulin Detemir Injection,Novo Nordisk,"Levemir, Injection, 100 [Iu]/1 Ml (NDC 0169-6432-10)",New,11/8/23,,"Limited Supply Of Levemir® Flexpen® Through The End Of 2024. Full Brand Discontinuation Will Occur On December 31, 2024.",,,Endocrinology/Metabolism; Other,To Be Discontinued,,11/8/23,0169-6432-10,discontinued
12452,Insulin Glargine Injection,Sanofi-Aventis U.S. Llc,"Insulin Glargine Solostar, Injection, 100 [Iu]/Ml (NDC 0955-1728-05)",New,5/24/24,,Sanofi Has Discontinued This Product Due To A Business Decision.,,,Endocrinology/Metabolism; Other,To Be Discontinued,,5/24/24,0955-1728-05,discontinued
12453,Insulin Glargine Injection,Sanofi-Aventis U.S. Llc,"Insulin Glargine, Injection, 100 [Iu]/Ml (NDC 0955-1729-01)",New,5/24/24,,Sanofi Has Discontinued This Product Due To A Business Decision.,,,Endocrinology/Metabolism; Other,To Be Discontinued,,5/24/24,0955-1729-01,discontinued
12454,Insulin Lispro Injection,Eli Lilly And Co.,"Humalog, Injection, 3ml Vial (NDC 0002-7510-17)",New,3/27/24,,Alternatives Include 10 Ml Vial And Kwikpen Presentations Of Humalog And Insulin Lispro Injection,,,Endocrinology/Metabolism,To Be Discontinued,,3/27/24,0002-7510-17,discontinued
12455,Insulin Lispro Injection,Eli Lilly And Co.,"Humalog, Injection, 3ml Vial (NDC 0002-7533-01)",New,3/27/24,,Alternatives Include 10 Ml Vial And Kwikpen Presentations Of Humalog And Insulin Lispro Injection,,,Endocrinology/Metabolism,To Be Discontinued,,3/27/24,0002-7533-01,discontinued
12456,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 300 Mg (NDC 0555-0071-01)",Revised,9/4/24,Available,,,,Anti-Infective,Current,,,0555-0071-01,available
12457,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 300 Mg (NDC 0555-0071-02)",Revised,9/4/24,Available,,,Demand Increase For The Drug,Anti-Infective,Current,,,0555-0071-02,available
12458,Isoniazid Tablet,"Teva Pharmaceuticals Usa, Inc.","Isoniazid Tablets, Usp, Tablet, 100 Mg (NDC 0555-0066-02)",Revised,9/4/24,Available,,,,Anti-Infective,Current,,,0555-0066-02,available
12459,Isoniazid Tablet,Chartwell Molecular Holdings Llc,"Laniazid, Tablet, 300 Mg (NDC 62135-709-90)",Reverified,9/2/24,Available,,,,Anti-Infective,Current,,,62135-709-90,available
12460,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 Mg/1 Ml (NDC 25021-684-05)",Revised,7/15/24,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,25021-684-05,available
12461,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 Mg/1 Ml (NDC 25021-683-10)",Revised,7/15/24,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,25021-683-10,available
12462,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 25021-682-20)",Revised,7/15/24,Available,Distributed By Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia,Current,,,25021-682-20,available
12463,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketamine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0143-9508-10)",Reverified,8/28/24,Available,,,,Anesthesia,Current,,,0143-9508-10,available
12464,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketamine Hcl Injection, Usp, Injection, 100 Mg/1 Ml (NDC 0143-9509-10)",Reverified,8/28/24,Available,,,,Anesthesia,Current,,,0143-9509-10,available
12465,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 Mg/1 Ml (NDC 42023-114-10)",Reverified,9/3/24,Unavailable,Recovery: Tbd,,Shortage Of An Active Ingredient,Anesthesia,Current,,,42023-114-10,not available
12466,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 Mg/1 Ml (NDC 42023-115-10)",Reverified,9/3/24,Unavailable,Recovery: Tbd,,Shortage Of An Active Ingredient,Anesthesia,Current,,,42023-115-10,not available
12467,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 Mg/1 Ml (NDC 42023-113-10)",Reverified,9/3/24,Available,,,,Anesthesia,Current,,,42023-113-10,available
12468,Ketamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Ketamine Hydrochloride, Injection, 500 Mg/10 Ml (50 Mg/Ml) (NDC 0409-2053-10)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: March 2025,,Delay In Shipping Of The Drug,Anesthesia,Current,,,0409-2053-10,not available
12469,Ketamine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 500 Mg/5 Ml (100 Mg/Ml) (NDC 0409-0040-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-0040-10,available
12470,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 100 Mg/1 Ml (NDC 55150-440-10)",Reverified,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,55150-440-10,not available
12471,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 50 Mg/1 Ml (NDC 55150-439-10)",Reverified,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,55150-439-10,not available
12472,Ketamine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-438-10)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-438-10,available
12473,Ketamine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 65219-184-20)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Anesthesia,Current,,,65219-184-20,available
12474,Ketamine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 50 Mg/1 Ml (NDC 65219-188-10)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Anesthesia,Current,,,65219-188-10,available
12475,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-04)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-701-04,available
12476,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 70860-700-02)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-700-02,available
12477,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-03)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-701-03,available
12478,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 60 Mg/2 Ml (NDC 62332-601-25)",Reverified,9/4/24,Available,,,,Analgesia/Addiction,Current,,,62332-601-25,available
12479,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 62332-600-25)",Reverified,9/4/24,Available,,,,Analgesia/Addiction,Current,,,62332-600-25,available
12480,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Injection, 15 Mg/1 Ml (NDC 62332-599-25)",Reverified,9/4/24,Available,,,,Analgesia/Addiction,Current,,,62332-599-25,available
12481,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 0338-0069-10)",Revised,7/17/24,Limited Availability,Recovery September 2024,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0338-0069-10,limited availability
12482,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 60 Mg/2 Ml (NDC 76045-105-20)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,76045-105-20,available
12483,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 76045-104-10)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Other,Analgesia/Addiction,Current,,,76045-104-10,not available
12484,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 15 Mg/1 Ml (NDC 76045-107-10)",Reverified,9/4/24,Unavailable,Not Available At This Time.,,Other,Analgesia/Addiction,Current,,,76045-107-10,not available
12485,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 0338-0072-25)",Reverified,9/5/24,Available,For Intravenous And Intramuscular Use. 30mg/Ml (1 Ml Fill Volume/ 2 Ml Container),,,Analgesia/Addiction,Current,,,0338-0072-25,available
12486,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 72266-119-25)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,72266-119-25,available
12487,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 72266-118-25)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,72266-118-25,available
12488,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0641-6043-25)",Reverified,8/28/24,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,0641-6043-25,not available
12489,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 30 Mg/1 Ml (NDC 0641-6042-25)",Reverified,8/28/24,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,0641-6042-25,not available
12490,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals Usa, Inc.","Ketorolac Tromethamine Injection, Usp, Injection, 15 Mg/1 Ml (NDC 0641-6041-25)",Reverified,8/28/24,Unavailable,Shortage Recovery: Tbd,,Other,Analgesia/Addiction,Current,,,0641-6041-25,not available
12491,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 60 Mg/2 Ml (30 Mg/Ml) (NDC 0409-3796-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-3796-01,available
12492,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 30 Mg/1 Ml (NDC 0409-3795-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-3795-01,available
12493,Ketorolac Tromethamine Injection,"Hospira, Inc., A Pfizer Company","Injection, 15 Mg/1 Ml (NDC 0409-3793-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-3793-01,available
12494,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 25021-701-01)",Reverified,7/1/24,Available,,,,Analgesia/Addiction,Current,,,25021-701-01,available
12495,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 30 Mg/1 Ml (NDC 25021-701-02)",Reverified,7/1/24,Available,,,,Analgesia/Addiction,Current,,,25021-701-02,available
12496,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Injection, 15 Mg/1 Ml (NDC 25021-700-01)",Reverified,7/1/24,Available,,,,Analgesia/Addiction,Current,,,25021-700-01,available
12497,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-02)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-701-02,available
12498,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 Mg/1 Ml (NDC 70860-701-01)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-701-01,available
12499,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 Mg/1 Ml (NDC 70860-700-01)",Revised,7/15/24,Available,,,,Analgesia/Addiction,Current,,,70860-700-01,available
12500,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 63323-162-02)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,63323-162-02,available
12501,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 30 Mg/1 Ml (NDC 63323-162-01)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,63323-162-01,available
12502,Ketorolac Tromethamine Injection,"Fresenius Kabi Usa, Llc","Injection, 15 Mg/1 Ml (NDC 63323-161-01)",Reverified,9/4/24,Available,Check Wholesaler Inventory,,,Analgesia/Addiction,Current,,,63323-161-01,available
12503,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 100 Mg (NDC 0591-0605-01)",New,3/11/24,,,,,Cardiovascular,To Be Discontinued,,3/11/24,0591-0605-01,discontinued
12504,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 100 Mg (NDC 0591-0605-05)",New,3/11/24,,,,,Cardiovascular,To Be Discontinued,,3/11/24,0591-0605-05,discontinued
12505,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 200 Mg (NDC 0591-0606-01)",New,3/11/24,,,,,Cardiovascular,To Be Discontinued,,3/11/24,0591-0606-01,discontinued
12506,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 200 Mg (NDC 0591-0606-05)",New,3/11/24,,,,,Cardiovascular,To Be Discontinued,,3/11/24,0591-0606-05,discontinued
12507,Labetalol Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 300 Mg (NDC 0591-0607-01)",New,3/11/24,,,,,Cardiovascular,To Be Discontinued,,3/11/24,0591-0607-01,discontinued
12508,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 50 Mg (NDC 65162-923-06)",New,4/15/24,,,,,Neurology,To Be Discontinued,,4/15/24,65162-923-06,discontinued
12509,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 100 Mg (NDC 65162-924-06)",New,4/15/24,,,,,Neurology,To Be Discontinued,,4/15/24,65162-924-06,discontinued
12510,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 150 Mg (NDC 65162-925-06)",New,4/15/24,,,,,Neurology,To Be Discontinued,,4/15/24,65162-925-06,discontinued
12511,Lacosamide Tablet,Amneal Pharmaceuticals,"Tablet, 200 Mg (NDC 65162-926-06)",New,4/15/24,,,,,Neurology,To Be Discontinued,,4/15/24,65162-926-06,discontinued
12512,Lanadelumab-Flyo Injection,Takeda Pharmaceuticals Usa Inc.,"Takhzyro, Injection, 300 Mg/2 Ml (NDC 47783-644-01)",New,9/4/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/4/24,47783-644-01,discontinued
12513,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 500 Mg (NDC 66993-422-85)",New,2/6/24,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/24,66993-422-85,discontinued
12514,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 750 Mg (NDC 66993-423-85)",New,2/6/24,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/24,66993-423-85,discontinued
12515,"Lanthanum Carbonate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Tablet, Chewable, 1000 Mg (NDC 66993-424-85)",New,2/6/24,,30 Apr 2024; Branded Fosrenol Will Continue To Be Available,,,Renal,To Be Discontinued,,2/6/24,66993-424-85,discontinued
12516,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 Mg/17.5 Ml (NDC 67457-530-35)",Reverified,9/5/24,Available,,,,Oncology; Pediatric,Current,,,67457-530-35,available
12517,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 Mg/20 Ml (NDC 67457-529-20)",Reverified,9/5/24,Available,,,,Oncology; Pediatric,Current,,,67457-529-20,available
12518,Leucovorin Calcium Injection,"Mylan Institutional, A Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 Mg/10 Ml (NDC 67457-528-10)",Reverified,9/5/24,Available,,,,Oncology; Pediatric,Current,,,67457-528-10,available
12519,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium, Injection, 10 Mg/1 Ml (NDC 63323-631-50)",Reverified,8/15/24,Available,Check Wholesaler Inventory,,,Oncology; Pediatric,Current,,,63323-631-50,available
12520,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium, Injection, 10 Mg/1 Ml (NDC 63323-631-10)",Reverified,8/15/24,Available,Check Wholesaler Inventory,,,Oncology; Pediatric,Current,,,63323-631-10,available
12521,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 350 Mg/17.5 Ml (NDC 0143-9552-01)",Reverified,8/28/24,Available,,,,Oncology; Pediatric,Current,,,0143-9552-01,available
12522,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 200 Mg/20 Ml (NDC 0143-9553-01)",Reverified,8/28/24,Available,,,,Oncology; Pediatric,Current,,,0143-9553-01,available
12523,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 100 Mg/10 Ml (NDC 0143-9554-01)",Reverified,8/28/24,Available,,,,Oncology; Pediatric,Current,,,0143-9554-01,available
12524,Leucovorin Calcium Injection,"Hikma Pharmaceuticals Usa, Inc.","Leucovorin Calcium For Injection, Usp, Injection, 50 Mg/5 Ml (NDC 0143-9555-01)",Reverified,8/28/24,Available,,,,Oncology; Pediatric,Current,,,0143-9555-01,available
12525,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 Mg/50 Ml (NDC 25021-828-50)",Reverified,7/1/24,Out Of Stock,Estimated Delivery August 2024,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,25021-828-50,not available
12526,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 100 Mg (NDC 70436-117-80)",Reverified,8/15/24,Available,,,,Oncology; Pediatric,Current,,,70436-117-80,available
12527,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 200 Mg (NDC 70436-118-80)",Reverified,8/15/24,Available,,,,Oncology; Pediatric,Current,,,70436-118-80,available
12528,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 500 Mg (NDC 70436-120-80)",Reverified,8/15/24,Available,,,,Oncology; Pediatric,Current,,,70436-120-80,available
12529,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 200 Mg/20 Ml (NDC 25021-815-30)",Reverified,7/1/24,Available,,,,Oncology; Pediatric,Current,,,25021-815-30,available
12530,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 100 Mg/10 Ml (NDC 25021-814-30)",Reverified,7/1/24,Available,,,,Oncology; Pediatric,Current,,,25021-814-30,available
12531,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 50 Mg/5 Ml (NDC 25021-813-10)",Reverified,7/1/24,Limited Availability,,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,25021-813-10,limited availability
12532,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Injection, 50 Mg (NDC 70436-116-82)",Reverified,8/15/24,Available,,,,Oncology; Pediatric,Current,,,70436-116-82,available
12533,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Injection, 350 Mg/17.5 Ml (NDC 25021-816-30)",Reverified,7/1/24,Available,,,,Oncology; Pediatric,Current,,,25021-816-30,available
12534,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 500 Mg/50 Ml (NDC 71288-164-50)",Revised,7/30/24,Available,"Estimated Recovery October 2024; Marketed By Meitheal Pharmaceuticals, Inc.",,Demand Increase For The Drug,Oncology; Pediatric,Current,,,71288-164-50,available
12535,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 350 Mg/17.5 Ml (NDC 71288-163-30)",Revised,7/11/24,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,71288-163-30,available
12536,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 100 Mg/10 Ml (NDC 71288-161-20)",Revised,7/11/24,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,71288-161-20,available
12537,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 200 Mg/20 Ml (NDC 71288-162-30)",Revised,7/11/24,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,71288-162-30,available
12538,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Injection, 50 Mg/5 Ml (NDC 71288-160-10)",Revised,7/30/24,Available,"Marketed By Meitheal Pharmaceuticals, Inc.",,,Oncology; Pediatric,Current,,,71288-160-10,available
12539,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Injection, 200 Mg/20 Ml (NDC 63323-710-50)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Oncology; Pediatric,Current,,,63323-710-50,available
12540,Leucovorin Calcium Injection,"Fresenius Kabi Usa, Llc","Leucovorin Calcium Preservative Free, Injection, 500 Mg/50 Ml (NDC 63323-711-00)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Oncology; Pediatric,Current,,,63323-711-00,not available
12541,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Injection, 10 Mg/1 Ml (NDC 50102-400-10)",Reverified,7/15/24,Available,"Inventory Available Through Anda, Asd Healthcare, Henry Schein, Mckesson Medical-Surgical And R&S",,,Anesthesia; Pediatric,Current,,,50102-400-10,available
12542,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 40 Mg/1 Ml (NDC 83090-007-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 4% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-007-10,available
12543,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-006-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x10ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-006-10,available
12544,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-005-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-005-10,available
12545,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 83090-004-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 2% 10x2ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-004-10,available
12546,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-003-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x10ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-003-10,available
12547,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-002-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x5ml)  Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-002-10,available
12548,Lidocaine Hydrochloride Injection,Sintetica Us,"Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 83090-001-10)",Reverified,9/3/24,Available,"Inventory Available At Cardinal Health, Mckesson, Cencora (Fka Amerisource Bergen). Product (Lidocaine Hcl 1% 10x2ml) Is Preservative Free.",,,Anesthesia; Pediatric,Current,,,83090-001-10,available
12549,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 73293-0001-2)",Reverified,8/5/24,Available,,,,Anesthesia,Current,,,73293-0001-2,available
12550,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-256-50)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-256-50,available
12551,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, Llc","Injection, 10 Mg/1 Ml (NDC 65282-1605-1)",Reverified,6/26/24,Available,,,,Anesthesia,Current,,,65282-1605-1,available
12552,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp, Injection, 20 Mg/1 Ml (NDC 0143-9575-10)",Revised,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9575-10,available
12553,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0143-9577-10)",Revised,8/28/24,Available,Additional Lots Are Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9577-10,available
12554,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp Preservative Free, Injection, 20 Mg/1 Ml (NDC 0143-9594-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9594-25,available
12555,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Hcl Injection, Usp Preservative Free, Injection, 10 Mg/1 Ml (NDC 0143-9595-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9595-25,available
12556,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-255-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-255-20,available
12557,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 20 Mg/Ml (NDC 55150-254-10)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-254-10,available
12558,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/Ml (NDC 55150-252-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-252-20,available
12559,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/Ml (NDC 55150-251-10)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-251-10,not available
12560,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 300 Mg/20 Ml (1.5%; 15 Mg/Ml) (NDC 0409-4776-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4776-01,available
12561,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 55150-165-05)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-165-05,available
12562,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/Ml (NDC 55150-164-02)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-164-02,available
12563,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-163-30)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-163-30,available
12564,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-162-05)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-162-05,available
12565,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-161-02)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-161-02,available
12566,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 55150-160-72)",Revised,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,55150-160-72,not available
12567,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/1 Ml (NDC 55150-159-74)",Revised,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,55150-159-74,not available
12568,Lidocaine Hydrochloride Injection,Eugia Us Llc,"Lidocaine Hydrochloride Preservative Free, Injection, 10 Mg/Ml (NDC 55150-158-72)",Revised,8/5/24,Unavailable,Intermittent Availability Expected,,Demand Increase For The Drug,Anesthesia,Current,,,55150-158-72,not available
12569,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 Mg/1 Ml (NDC 0338-0411-02)",Reverified,7/17/24,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
12570,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 Mg/1 Ml (NDC 0338-0409-03)",Reverified,7/17/24,Available,,,,Cardiovascular,Current,,,0338-0409-03,available
12571,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 50 Mg/5 Ml (1%; 10 Mg/Ml) (NDC 0409-4713-02)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-02,available
12572,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 250 Mg/50 Ml (0.5%; 5 Mg/Ml) (NDC 0409-4278-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4278-01,available
12573,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 250 Mg/50 Ml (0.5%; 5 Mg/Ml) (NDC 0409-4275-01)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: December 2026,,,Anesthesia; Pediatric,Current,,,0409-4275-01,not available
12574,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-496-97)",Reverified,9/4/24,Unavailable,Next Release Date Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-496-97,not available
12575,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-495-07)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-495-07,available
12576,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-495-27)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-495-27,available
12577,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-57)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-486-57,available
12578,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-27)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-486-27,available
12579,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 20 Mg/1 Ml (NDC 63323-486-17)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Pediatric,Current,,,63323-486-17,available
12580,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride Preservative Free, Injection, 20 Mg/1 Ml (NDC 63323-208-05)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-208-05,available
12581,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 63323-202-02)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-202-02,available
12582,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 15 Mg/1 Ml (NDC 63323-493-91)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-493-91,not available
12583,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 15 Mg/1 Ml (NDC 63323-493-97)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-493-97,not available
12584,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 Mg/1 Ml (NDC 76329-3390-1)",Reverified,8/20/24,Available,Old Ndc 0548-3390-00,,,Anesthesia; Pediatric,Current,,,76329-3390-1,available
12585,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 Mg/5ml (2%,20 Mg/1 Ml) Syringes (NDC 0409-1323-05)",Revised,8/26/24,Unavailable,Next Delivery: November 2024; Estimated Recovery: March 2025,,,Anesthesia; Pediatric,Current,,,0409-1323-05,not available
12586,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 Mg/5 Ml (4%; 40 Mg/Ml) (NDC 0409-4283-01)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: October 2024; Estimated Recovery: December 2024,,,Anesthesia; Pediatric,Current,,,0409-4283-01,limited availability
12587,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 Mg/50 Ml (2%; 20 Mg/Ml) (NDC 0409-4277-02)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4277-02,available
12588,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 400 Mg/20 Ml (2%; 20 Mg/Ml) (NDC 0409-4277-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4277-01,available
12589,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 100 Mg/5 Ml (2%; 20 Mg/Ml) (NDC 0409-2066-05)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-2066-05,available
12590,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 100 Mg/5ml (2%, 20 Mg/1 Ml) Syringes (NDC 0409-4903-34)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-4903-34,not available
12591,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 50 Mg/5ml (1%,10 Mg/1 Ml) Syringes (NDC 0409-4904-34)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Delay In Shipping Of The Drug,Anesthesia; Pediatric,Current,,,0409-4904-34,not available
12592,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 200 Mg/10 Ml (2%; 20 Mg/Ml) (NDC 0409-4282-02)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4282-02,available
12593,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 40 Mg/2 Ml (2%; 20 Mg/Ml) (NDC 0409-4282-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4282-01,available
12594,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 500 Mg/50 Ml (1%; 10 Mg/Ml) (NDC 0409-4276-02)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4276-02,available
12595,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride, Injection, 300 Mg/30 Ml (1%; 10 Mg/Ml) (NDC 0409-4279-02)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4279-02,available
12596,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 200 Mg/20 Ml (1%; 10 Mg/Ml) (NDC 0409-4276-01)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4276-01,available
12597,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 Mg/2 Ml (1%; 10 Mg/Ml) (NDC 0409-4713-32)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-32,available
12598,Lidocaine Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 Mg/5ml (1%, 10 Mg/1 Ml) Syringes (NDC 0409-9137-05)",Reverified,8/26/24,Available,,,,Anesthesia; Pediatric,Current,,,0409-9137-05,available
12599,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-31)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-492-31,not available
12600,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-37)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-37,available
12601,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-57)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-57,available
12602,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/Ml, 5 Ml (NDC 63323-492-89)",Revised,10/13/23,Not Available At This Time.,,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-492-89,not available
12603,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/Ml, 2 Ml (NDC 63323-492-80)",Revised,10/13/23,Not Available At This Time.,,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-492-80,not available
12604,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-492-27)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-492-27,available
12605,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-485-57)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-485-57,available
12606,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 10 Mg/1 Ml (NDC 63323-485-27)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-485-27,available
12607,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride, Injection, 10 Mg/1 Ml (NDC 63323-201-10)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-201-10,available
12608,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Lidocaine Hydrochloride In Plastic Container, Injection, 10 Mg/1 Ml (NDC 63323-201-02)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-201-02,available
12609,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 5 Mg/1 Ml (NDC 63323-491-57)",Reverified,9/4/24,Available,,,,Anesthesia; Pediatric,Current,,,63323-491-57,available
12610,Lidocaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Xylocaine, Injection, 5 Mg/1 Ml (NDC 63323-484-57)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia; Pediatric,Current,,,63323-484-57,not available
12611,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings Llc,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 62135-712-42)",Reverified,9/2/24,Available,,,,Anesthesia,Current,,,62135-712-42,available
12612,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride Oral Topical Solution, Usp), Solution, 20 Mg/1 Ml (NDC 0054-0548-44)",Reverified,8/28/24,Limited Availability,Available To Current Customers.,,Demand Increase For The Drug,Anesthesia,Current,,,0054-0548-44,limited availability
12613,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals Usa, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride Oral Topical Solution, Usp), Solution, 20 Mg/1 Ml (NDC 0054-3500-49)",Reverified,8/28/24,Limited Availability,Available To Current Customers.,,Demand Increase For The Drug,Anesthesia,Current,,,0054-3500-49,limited availability
12614,Lidocaine Hydrochloride Solution,Pai Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 0121-0950-03)",Revised,6/24/24,Available,,,,Anesthesia,Current,,,0121-0950-03,available
12615,Lidocaine Hydrochloride Solution,Pai Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 Mg/1 Ml (NDC 0121-4950-40)",Revised,6/24/24,Available,,,,Anesthesia,Current,,,0121-4950-40,available
12616,Lidocaine Hydrochloride Solution,Rubicon Research Private Limited,"Solution, 20 Mg/1 Ml (NDC 72888-125-26)",Revised,6/18/24,Available,Marketed By Advagen Pharma Ltd.,,,Anesthesia,Current,,,72888-125-26,available
12617,Linezolid Tablet,Pfizer Inc.,"Zyvox, Tablet, 600 Mg (NDC 0009-5138-03)",New,3/28/24,,Discontinuation Of The Manufacture Of The Drug.,,,Anti-Infective,To Be Discontinued,,3/28/24,0009-5138-03,discontinued
12618,Liothyronine Sodium Injectable,"Xgen Pharmaceuticals Djb, Inc.","Injectable, 10 Ug/1 Ml (NDC 39822-0151-1)",New,10/19/23,Available,"Even Though We Requested New Posting Information, We Did Not Post It And It'S Resolved Now.",Please Do Not Publish. Obsolete And Needs To Be Deleted.,Regulatory Delay,Endocrinology/Metabolism,Resolved,12/1/23,,39822-0151-1,available
12619,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 Mg/1 Ml (NDC 0169-2800-15)",Revised,9/6/24,Limited Availability,Estimated Shortage Duration Tbd,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,0169-2800-15,limited availability
12620,Liraglutide Injection,"Novo Nordisk, Inc.","Injection, 6 Mg/1 Ml (NDC 0480-3667-22)",Revised,9/6/24,Available,Distributed By Teva,,,Endocrinology/Metabolism,Current,,,0480-3667-22,available
12621,Liraglutide Injection,"Novo Nordisk, Inc.","Injection, 6 Mg/1 Ml (NDC 0480-3667-20)",Revised,9/6/24,Available,Distributed By Teva,,,Endocrinology/Metabolism,Current,,,0480-3667-20,available
12622,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 Mg/1 Ml (NDC 0169-4060-13)",Revised,9/6/24,Limited Availability,Estimated Shortage Duration Tbd,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,0169-4060-13,limited availability
12623,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 Mg/1 Ml (NDC 0169-4060-12)",Revised,9/6/24,Limited Availability,Estimated Shortage Duration Tbd,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,0169-4060-12,limited availability
12624,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 70 Mg (NDC 59417-107-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-107-10,available
12625,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 60 Mg (NDC 59417-106-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-106-10,available
12626,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 50 Mg (NDC 59417-105-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-105-10,available
12627,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 40 Mg (NDC 59417-104-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-104-10,available
12628,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 30 Mg (NDC 59417-103-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-103-10,available
12629,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 20 Mg (NDC 59417-102-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-102-10,available
12630,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Capsule, 10 Mg (NDC 59417-101-10)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-101-10,available
12631,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 70 Mg (NDC 47781-568-01)",Revised,5/7/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-568-01,limited availability
12632,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 60 Mg (NDC 47781-567-01)",Revised,5/7/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-567-01,limited availability
12633,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 10 Mg (NDC 47781-562-01)",Revised,5/7/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-562-01,not available
12634,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 10 Mg (NDC 42858-161-01)",Reverified,8/15/24,Available,,,,Psychiatry,Current,,,42858-161-01,available
12635,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 50 Mg (NDC 47781-566-01)",Reverified,4/17/24,Unavailable,Resupply End Of April 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-566-01,not available
12636,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 40 Mg (NDC 47781-565-01)",Reverified,4/17/24,Unavailable,Resupply End Of April 2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-565-01,not available
12637,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 70 Mg (NDC 42858-167-01)",Revised,8/15/24,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,42858-167-01,not available
12638,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 60 Mg (NDC 42858-166-01)",Revised,8/15/24,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,42858-166-01,not available
12639,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 50 Mg (NDC 42858-165-01)",Revised,8/15/24,"Unavailable, Unknown",,,Shortage Of An Active Ingredient,Psychiatry,Current,,,42858-165-01,not available
12640,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 20 Mg (NDC 42858-162-01)",Reverified,8/15/24,Available,,,,Psychiatry,Current,,,42858-162-01,available
12641,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 40 Mg (NDC 42858-164-01)",Reverified,8/15/24,Available,,,,Psychiatry,Current,,,42858-164-01,available
12642,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Capsule, 30 Mg (NDC 42858-163-01)",Revised,8/15/24,Available,,,,Psychiatry,Current,,,42858-163-01,available
12643,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 30 Mg (NDC 47781-564-01)",Revised,5/7/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-564-01,limited availability
12644,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Capsule, 20 Mg (NDC 47781-563-01)",Revised,5/7/24,Limited Availability,Resupply End Of April2024,,Shortage Of An Active Ingredient,Psychiatry,Current,,,47781-563-01,limited availability
12645,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 10 Mg (NDC 60505-4739-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4739-1,not available
12646,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 50 Mg (NDC 60505-4743-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4743-1,not available
12647,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 20 Mg (NDC 60505-4740-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4740-1,not available
12648,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 70 Mg (NDC 60505-4745-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4745-1,not available
12649,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 60 Mg (NDC 60505-4744-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4744-1,not available
12650,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 40 Mg (NDC 60505-4742-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4742-1,not available
12651,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Capsule, 30 Mg (NDC 60505-4741-1)",Revised,7/16/24,Unavailable,Next Resupply Expected Aug 2024; Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,60505-4741-1,not available
12652,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 60 Mg (NDC 65162-027-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-027-09,not available
12653,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-024-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-024-09,not available
12654,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 50 Mg (NDC 65162-026-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-026-09,not available
12655,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 70 Mg (NDC 65162-028-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-028-09,not available
12656,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 20 Mg (NDC 65162-023-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-023-09,not available
12657,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Capsule, 40 Mg (NDC 65162-025-09)",Reverified,7/9/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,65162-025-09,not available
12658,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 10 Mg (NDC 57664-046-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-046-88,limited availability
12659,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 50 Mg (NDC 57664-050-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-050-88,limited availability
12660,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 60 Mg (NDC 57664-051-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-051-88,limited availability
12661,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 40 Mg (NDC 57664-049-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-049-88,limited availability
12662,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 70 Mg (NDC 57664-052-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-052-88,limited availability
12663,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 Mg (NDC 57664-048-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-048-88,limited availability
12664,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Capsule, 30 Mg (NDC 57664-048-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-048-88,limited availability
12665,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 50 Mg (NDC 0378-6858-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6858-77,limited availability
12666,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 10 Mg (NDC 0378-6854-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6854-77,limited availability
12667,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 70 Mg (NDC 0378-6860-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6860-77,limited availability
12668,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 60 Mg (NDC 0378-6859-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6859-77,limited availability
12669,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 30 Mg (NDC 0378-6856-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6856-77,limited availability
12670,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 40 Mg (NDC 0378-6857-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6857-77,limited availability
12671,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 30 Mg (NDC 0378-6857-77)",Revised,9/20/23,Available On Allocation,,,Demand Increase For The Drug,Psychiatry,Current,,,0378-6857-77,limited availability
12672,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 40 Mg (NDC 0378-6857-77)",Revised,9/20/23,Available On Allocation,,,Demand Increase For The Drug,Psychiatry,Current,,,0378-6857-77,limited availability
12673,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., A Viatris Company","Capsule, 20 Mg (NDC 0378-6855-77)",Reverified,9/5/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0378-6855-77,limited availability
12674,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 50 Mg (NDC 0054-0373-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0373-25,limited availability
12675,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 30 Mg (NDC 0054-0371-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0371-25,limited availability
12676,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 60 Mg (NDC 0054-0374-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0374-25,limited availability
12677,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 20 Mg (NDC 0054-0370-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0370-25,limited availability
12678,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 40 Mg (NDC 0054-0372-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0372-25,limited availability
12679,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals Usa, Inc.","Capsule, 70 Mg (NDC 0054-0375-25)",Reverified,8/28/24,Limited Availability,Available On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0375-25,limited availability
12680,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 40 Mg (NDC 0406-5114-01)",Revised,8/15/24,Unavailable,Backorder. Next Release Mid August. Backorder Expected Again In September,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5114-01,not available
12681,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 60 Mg (NDC 0406-5116-01)",Revised,8/15/24,Unavailable,On Backorder,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5116-01,not available
12682,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 10 Mg (NDC 0406-5111-01)",Revised,8/15/24,Unavailable,Allocations To All Customers. Backorder Projected In October,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5111-01,not available
12683,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 30 Mg (NDC 0406-5113-01)",Revised,8/15/24,Limited Availability,Available To Primary Customers Only. Backorder Projected In Mid August,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5113-01,limited availability
12684,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 50 Mg (NDC 0406-5115-01)",Revised,8/15/24,Unavailable,Backorder. Next Release Mid August. Backorder Expected Again In October,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5115-01,not available
12685,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 70 Mg (NDC 0406-5117-01)",Revised,8/15/24,Unavailable,On Backorder,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5117-01,not available
12686,Lisdexamfetamine Dimesylate Capsule,Specgx Llc,"Capsule, 20 Mg (NDC 0406-5112-01)",Revised,8/15/24,Limited Availability,Available To Primary Customers Only. Intermittent Backorder Expected Through Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-5112-01,limited availability
12687,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 30 Mg (NDC 43547-604-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-604-10,limited availability
12688,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 20 Mg (NDC 43547-603-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-603-10,limited availability
12689,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 60 Mg (NDC 43547-607-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-607-10,limited availability
12690,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 10 Mg (NDC 43547-602-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-602-10,limited availability
12691,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 70 Mg (NDC 43547-608-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-608-10,limited availability
12692,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 50 Mg (NDC 43547-606-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-606-10,limited availability
12693,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare Us, Llc","Capsule, 40 Mg (NDC 43547-605-10)",Reverified,9/3/24,Limited Availability,On Allocation,,Shortage Of An Active Ingredient,Psychiatry,Current,,,43547-605-10,limited availability
12694,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 60 Mg (NDC 0527-4666-37)",Reverified,9/3/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4666-37,not available
12695,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 20 Mg (NDC 0527-4662-37)",Revised,9/3/24,Unavailable,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4662-37,not available
12696,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 40 Mg (NDC 0527-4664-37)",Reverified,9/3/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4664-37,limited availability
12697,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 50 Mg (NDC 0527-4665-37)",Revised,9/3/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4665-37,limited availability
12698,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 30 Mg (NDC 0527-4663-37)",Reverified,9/3/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4663-37,limited availability
12699,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 10 Mg (NDC 0527-4661-37)",Revised,9/3/24,Unavailable,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4661-37,not available
12700,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Capsule, 70 Mg (NDC 0527-4667-37)",Reverified,9/3/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0527-4667-37,not available
12701,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 60 Mg (NDC 59417-120-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-120-01,available
12702,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 50 Mg (NDC 59417-119-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-119-01,available
12703,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 40 Mg (NDC 59417-118-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-118-01,available
12704,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 30 Mg (NDC 59417-117-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-117-01,available
12705,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 20 Mg (NDC 59417-116-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-116-01,available
12706,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals Usa Inc.,"Vyvanse, Tablet, Chewable, 10 Mg (NDC 59417-115-01)",Reverified,9/3/24,Available,,,,Psychiatry,Current,,,59417-115-01,available
12707,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 Mg (NDC 72205-132-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-132-91,available
12708,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 Mg (NDC 72205-137-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-137-91,available
12709,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 Mg (NDC 72205-136-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-136-91,available
12710,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 Mg (NDC 72205-135-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-135-91,available
12711,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 Mg (NDC 72205-134-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-134-91,available
12712,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals Llc,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 Mg (NDC 72205-133-91)",Revised,7/18/24,Available,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,72205-133-91,available
12713,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 40 Mg (NDC 57664-086-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-086-88,limited availability
12714,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 60 Mg (NDC 57664-088-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-088-88,limited availability
12715,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 50 Mg (NDC 57664-087-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-087-88,limited availability
12716,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 30 Mg (NDC 57664-085-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-085-88,limited availability
12717,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 20 Mg (NDC 57664-084-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-084-88,limited availability
12718,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Tablet, Chewable, 10 Mg (NDC 57664-083-88)",Revised,8/26/24,Limited Availability,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-083-88,limited availability
12719,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 Mg (NDC 0378-1300-01)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1300-01,discontinued
12720,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 450 Mg (NDC 0378-1450-01)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1450-01,discontinued
12721,"Lithium Carbonate Tablet, Extended Release","Mylan Pharmaceuticals Inc., A Viatris Company","Lithium Carbonate, Tablet, Extended Release, 300 Mg (NDC 0378-1300-05)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,To Be Discontinued,,10/4/23,0378-1300-05,discontinued
12722,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6045-25)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6045-25,not available
12723,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-6046-10)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6046-10,not available
12724,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Lorazepam Injection, Usp, Injection, 2 Mg/1 Ml (NDC 0641-6044-25)",Reverified,8/28/24,Unavailable,Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6044-25,not available
12725,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 4 Mg/1 Ml (NDC 0641-6002-10)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6002-10,not available
12726,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 4 Mg/1 Ml (NDC 0641-6003-25)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6003-25,not available
12727,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 2 Mg/1 Ml (NDC 0641-6000-10)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6000-10,not available
12728,Lorazepam Injection,"Hikma Pharmaceuticals Usa, Inc.","Ativan Injection (Lorazepam Injection, Usp), Injection, 2 Mg/1 Ml (NDC 0641-6001-25)",Reverified,8/28/24,Unavailable,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Neurology,Current,,,0641-6001-25,not available
12729,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 2 Mg/1 Ml (NDC 76329-8261-1)",Reverified,8/20/24,Limited Availability,,,Demand Increase For The Drug,Neurology,Current,,,76329-8261-1,limited availability
12730,Lorazepam Injection,"Hospira, Inc., A Pfizer Company","Injection, 2 Mg/1 Ml Syringes (NDC 0409-1985-30)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,,Demand Increase For The Drug,Neurology,Current,,,0409-1985-30,limited availability
12731,Mafenide Acetate Solution,"Par Pharmaceutical, Inc.","Solution, 50 G (NDC 49884-902-78)",New,11/30/23,,,,Discontinuation Of The Manufacture Of The Drug,Dermatology,To Be Discontinued,,11/30/23,49884-902-78,discontinued
12732,Mefloquine Hydrochloride Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 250 Mg (NDC 0555-0171-78)",Revised,8/23/24,Unavailable,Estimated Recovery November 2024,,Delay In Shipping Of The Drug,Anti-Infective,Current,,,0555-0171-78,not available
12733,Melphalan Tablet,Alvogen,"Tablet, 2 Mg (NDC 47781-200-50)",New,2/23/24,,"Discontinuation Due To Low Sales Volume.   Supply Currently Available With April, 2024 Expiry Dating.",,,Oncology,To Be Discontinued,,2/23/24,47781-200-50,discontinued
12734,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 28 Mg (NDC 0456-3428-90)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3428-90,discontinued
12735,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 14mg (NDC 0456-3414-90)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3414-90,discontinued
12736,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 7mg +14 Mg+21 Mg+28mg (NDC 0456-3400-29)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3400-29,discontinued
12737,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 28 Mg (NDC 0456-3428-33)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3428-33,discontinued
12738,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 21 Mg (NDC 0456-3421-33)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3421-33,discontinued
12739,"Memantine Hydrochloride Capsule, Extended Release",Abbvie Inc.,"Namenda Xr, Capsule, Extended Release, 14 Mg (NDC 0456-3414-33)",New,8/7/24,,"Distributed By Allergan, Inc.",,,Neurology,To Be Discontinued,,8/7/24,0456-3414-33,discontinued
12740,"Mesalamine Capsule, Delayed Release",Abbvie Inc.,"Delzicol, Capsule, Delayed Release, 400 Mg (NDC 0023-5853-18)",New,10/25/23,,Sales Expected To Last Until June 2024,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,10/25/23,0023-5853-18,discontinued
12741,"Mesalamine Capsule, Delayed Release",Abbvie Inc.,"Capsule, Delayed Release, 400 Mg (NDC 59762-0117-1)",New,10/25/23,,Sales Expected To Last Until June 2024,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,10/25/23,59762-0117-1,discontinued
12742,"Mesalamine Tablet, Delayed Release",Takeda Pharmaceuticals Usa Inc.,"Tablet, Delayed Release, 1.2 G (NDC 54092-100-01)",New,2/6/24,,The Brand Lialda Will Continue To Be Available,,,Gastroenterology,To Be Discontinued,,2/6/24,54092-100-01,discontinued
12743,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 5 Mg (NDC 0054-0389-25)",Reverified,8/28/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0054-0389-25,not available
12744,Methamphetamine Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 5 Mg (NDC 68308-115-01)",Reverified,7/23/24,Available,Available To Existing Customers,,Shortage Of An Active Ingredient,Psychiatry,Current,,,68308-115-01,available
12745,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-35)",Revised,8/19/24,"Limited Availability, 30 Days",Short Dated Inventory Available; Fresh Manufacturing In Process At Plant Site,,Requirements Related To Complying With Good Manufacturing Practices,Rheumatology; Oncology,Current,,,16729-277-35,limited availability
12746,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-03)",Revised,2/5/24,,,,,Rheumatology; Oncology,To Be Discontinued,2/5/24,2/5/24,16729-277-03,discontinued
12747,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 16729-277-30)",Revised,8/19/24,"Limited Availability, 30 Days",Short Dated Inventory Available; Inventory On Hold Pending Further Assessment,,Requirements Related To Complying With Good Manufacturing Practices,Rheumatology; Oncology,Current,,,16729-277-30,limited availability
12748,Methotrexate Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 25 Mg/1 Ml (NDC 63323-123-10)",Revised,9/4/24,Available,"6, 7 & 8 Month Expiry Available.  Check Wholesalers For Inventory.",,,Rheumatology; Oncology,Current,,,63323-123-10,available
12749,Methotrexate Sodium Injection,"Fresenius Kabi Usa, Llc","Methotrexate Preservative Free, Injection, 1 G (NDC 63323-122-50)",Reverified,9/4/24,Available,Check Wholesaler For Inventory,,,Rheumatology; Oncology,Current,,,63323-122-50,available
12750,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-124-40)",Reverified,8/26/24,Available,,,,Rheumatology; Oncology,Current,,,61703-124-40,available
12751,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3678-01)",Revised,9/4/24,Available,Estimated Recovery January 2025,,,Rheumatology; Oncology,Current,,,0703-3678-01,available
12752,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3675-01)",Revised,9/4/24,Available,,,Demand Increase For The Drug,Rheumatology; Oncology,Current,,,0703-3675-01,available
12753,Methotrexate Sodium Injection,"Teva Pharmaceuticals Usa, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 Mg/1 Ml (NDC 0703-3671-01)",Revised,9/4/24,Available,,,,Rheumatology; Oncology,Current,,,0703-3671-01,available
12754,Methotrexate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Methotrexate Injection,Usp Preservative Free, Injection, 25 Mg/1 Ml (NDC 0143-9519-10)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Rheumatology; Oncology,Current,,,0143-9519-10,available
12755,Methotrexate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Methotrexate Injection, Usp Preservative Free, Injection, 1 G (NDC 0143-9830-01)",Reverified,8/28/24,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Rheumatology; Oncology,Current,,,0143-9830-01,available
12756,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-408-25)",Reverified,8/26/24,Available,,,,Rheumatology; Oncology,Current,,,61703-408-25,available
12757,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 1 G/40 Ml (25 Mg/Ml) (NDC 61703-408-41)",Reverified,8/26/24,Available,,,,Rheumatology; Oncology,Current,,,61703-408-41,available
12758,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 50 Mg/2 Ml  (25 Mg/Ml) (NDC 61703-350-10)",Revised,8/26/24,Available,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,,Rheumatology; Oncology,Current,,,61703-350-10,available
12759,Methotrexate Sodium Injection,"Hospira, Inc., A Pfizer Company","Methotrexate, Injection, 50 Mg/2 Ml (25 Mg/Ml) (NDC 61703-350-38)",Revised,8/26/24,Limited Availability,Estimated Recovery: December 2024,,Demand Increase For The Drug,Rheumatology; Oncology,Current,,,61703-350-38,limited availability
12760,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 Mg (NDC 69238-1423-1)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,69238-1423-1,
12761,Methotrexate Sodium Tablet,Amneal Pharmaceuticals,"Tablet, 2.5 Mg (NDC 69238-1423-6)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,69238-1423-6,
12762,Methotrexate Sodium Tablet,Zydus Pharmaceuticals Usa Inc.,"Tablet, 2.5 Mg (NDC 68382-775-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,68382-775-01,
12763,Methotrexate Sodium Tablet,"Mylan Pharmaceuticals Inc., A Viatris Company","Tablet, 2.5 Mg (NDC 0378-0014-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,0378-0014-01,
12764,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 15 Mg (NDC 51285-369-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,51285-369-01,
12765,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 10 Mg (NDC 51285-368-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,51285-368-01,
12766,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 7.5 Mg (NDC 51285-367-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,51285-367-01,
12767,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Trexall, Tablet, 5 Mg (NDC 51285-366-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,51285-366-01,
12768,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0555-0572-35)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,0555-0572-35,
12769,Methotrexate Sodium Tablet,"Teva Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0555-0572-02)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,0555-0572-02,
12770,Methotrexate Sodium Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, 2.5 Mg (NDC 0054-4550-25)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,0054-4550-25,
12771,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 Mg (NDC 47335-235-96)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,47335-235-96,
12772,Methotrexate Sodium Tablet,"Sun Pharmaceutical Industries, Inc.","Methotrexate Sodium, Tablet, 2.5 Mg (NDC 47335-235-83)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,47335-235-83,
12773,Methotrexate Sodium Tablet,Accord Healthcare Inc.,"Tablet, 2.5 Mg (NDC 16729-486-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,16729-486-01,
12774,Methotrexate Sodium Tablet,Eugia Us Llc,"Tablet, 2.5 Mg (NDC 59651-182-01)",Revised,6/27/24,,,Available,,Rheumatology; Dermatology; Dental; Oncology,Resolved,6/27/24,,59651-182-01,
12775,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 Mg (NDC 16729-030-01)",Revised,2/5/24,,,,,Cardiovascular,To Be Discontinued,2/5/24,2/5/24,16729-030-01,discontinued
12776,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 Mg (NDC 16729-031-16)",Revised,2/5/24,,,,,Cardiovascular,To Be Discontinued,2/5/24,2/5/24,16729-031-16,discontinued
12777,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 500 Mg (NDC 16729-031-01)",Revised,2/5/24,,,,,Cardiovascular,To Be Discontinued,2/5/24,2/5/24,16729-031-01,discontinued
12778,"Methyldopa Tablet, Film Coated",Accord Healthcare Inc.,"Tablet, Film Coated, 250 Mg (NDC 16729-030-16)",Revised,2/5/24,,,,,Cardiovascular,To Be Discontinued,2/5/24,2/5/24,16729-030-16,discontinued
12779,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 18 Mg (NDC 62037-725-01)",Revised,8/23/24,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,62037-725-01,available
12780,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 54 Mg (NDC 62175-313-37)",Reverified,9/3/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,62175-313-37,not available
12781,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 36 Mg (NDC 62175-312-37)",Reverified,9/3/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,62175-312-37,not available
12782,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 27 Mg (NDC 62175-311-37)",Reverified,9/3/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,62175-311-37,not available
12783,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Tablet, Extended Release, 18 Mg (NDC 62175-310-37)",Reverified,9/3/24,Limited Availability,Allocating Limited Inventory,,Shortage Of An Active Ingredient,Psychiatry,Current,,,62175-310-37,limited availability
12784,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 54 Mg (NDC 0406-0154-01)",Revised,8/15/24,Limited Availability,Backorder. Next Release Mid Sept. Intermittent Backorder Through November.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-0154-01,limited availability
12785,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 36 Mg (NDC 0406-0136-01)",Revised,8/15/24,Unavailable,Backorder. Next Release Mid Sept. Intermittent Backorder Through November,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-0136-01,not available
12786,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Tablet, Extended Release, 27 Mg (NDC 0406-0127-01)",Revised,8/15/24,Limited Availability,Allocation To All Customers.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-0127-01,limited availability
12787,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Methylin Er, Tablet, Extended Release, 20 Mg (NDC 0406-1473-01)",Revised,8/15/24,Limited Availability,Allocation To All Customers; Expected Backorder Late Sept.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-1473-01,limited availability
12788,"Methylphenidate Hydrochloride Tablet, Extended Release",Specgx Llc,"Methylin Er, Tablet, Extended Release, 10 Mg (NDC 0406-1445-01)",Revised,8/15/24,Limited Availability,Allocations To All Customers. Backorder Projected October.,,Shortage Of An Active Ingredient,Psychiatry,Current,,,0406-1445-01,limited availability
12789,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 Mg (NDC 57664-609-88)",Reverified,8/26/24,Unavailable,Currently Not Marketed,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,Current,,,57664-609-88,not available
12790,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 Mg (NDC 57664-608-88)",Reverified,8/26/24,Unavailable,Currently Not Marketed,,Discontinuation Of The Manufacture Of The Drug,Psychiatry,Current,,,57664-608-88,not available
12791,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 Mg (NDC 57664-607-88)",Reverified,8/26/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-607-88,not available
12792,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 Mg (NDC 57664-606-88)",Reverified,8/26/24,Unavailable,,,Shortage Of An Active Ingredient,Psychiatry,Current,,,57664-606-88,not available
12793,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 27 Mg (NDC 62037-734-01)",Revised,8/23/24,Available,,,Demand Increase For The Drug,Psychiatry,Current,,,62037-734-01,available
12794,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 Mg (NDC 13811-710-30)",Revised,3/7/24,Available,,,,Psychiatry,Current,,,13811-710-30,available
12795,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 Mg (NDC 50458-587-01)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,50458-587-01,available
12796,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 Mg (NDC 50458-586-01)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,50458-586-01,available
12797,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 Mg (NDC 50458-588-01)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,50458-588-01,available
12798,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 Mg (NDC 50458-585-01)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,50458-585-01,available
12799,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 Mg (NDC 13811-700-30)",Revised,3/7/24,Available,,,,Psychiatry,Current,,,13811-700-30,available
12800,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 Mg (NDC 13811-709-10)",Revised,3/7/24,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,13811-709-10,available
12801,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 Mg (NDC 13811-711-30)",Revised,3/7/24,Available,,,,Psychiatry,Current,,,13811-711-30,available
12802,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 Mg (NDC 13811-708-10)",Revised,3/7/24,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,13811-708-10,available
12803,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 Mg (NDC 13811-707-10)",Revised,3/7/24,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,13811-707-10,available
12804,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, Llc","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 Mg (NDC 13811-706-10)",Revised,3/7/24,Available,Allocation To Current Contracted Customers,,Demand Increase For The Drug,Psychiatry,Current,,,13811-706-10,available
12805,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 54 Mg (NDC 43598-441-01)",Revised,7/23/24,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,43598-441-01,not available
12806,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 36 Mg (NDC 43598-440-01)",Revised,7/23/24,Unavailable,Unavailable. Estimated Limited Supplies From Aug 2024,,Other,Psychiatry,Current,,,43598-440-01,not available
12807,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 27 Mg (NDC 43598-439-01)",Revised,7/23/24,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,43598-439-01,not available
12808,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy'S Laboratories, Inc.","Tablet, Extended Release, 18 Mg (NDC 43598-438-01)",Revised,7/23/24,Unavailable,Estimated Availability Tbd,,Other,Psychiatry,Current,,,43598-438-01,not available
12809,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 54 Mg (NDC 62037-727-01)",Revised,8/23/24,Limited Availability,Estimated Recovery October 2024,,Demand Increase For The Drug,Psychiatry,Current,,,62037-727-01,limited availability
12810,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, Usp   Cii, Tablet, Extended Release, 36 Mg (NDC 62037-726-01)",Revised,8/23/24,Limited Availability,Estimated Recovery 'October 2024,,Demand Increase For The Drug,Psychiatry,Current,,,62037-726-01,limited availability
12811,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 36 Mg (NDC 68025-097-10)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-097-10,available
12812,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 18 Mg (NDC 68025-095-10)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-095-10,available
12813,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 72 Mg (NDC 68025-084-30)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-084-30,available
12814,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 45 Mg (NDC 68025-088-30)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-088-30,available
12815,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 54 Mg (NDC 68025-098-10)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-098-10,available
12816,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 27 Mg (NDC 68025-096-10)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-096-10,available
12817,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, Llc","Relexxii, Tablet, Extended Release, 63 Mg (NDC 68025-089-30)",Reverified,9/4/24,Available,,,,Psychiatry,Current,,,68025-089-30,available
12818,Methylprednisolone Acetate Injection,Eugia Us Llc,"Injection, 80 Mg/1 Ml (NDC 55150-314-01)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Rheumatology,Current,,,55150-314-01,not available
12819,Methylprednisolone Acetate Injection,Eugia Us Llc,"Injection, 40 Mg/1 Ml (NDC 55150-313-01)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Rheumatology,Current,,,55150-313-01,available
12820,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Injection, 80 Mg/1 Ml (NDC 42023-240-01)",Revised,9/3/24,Unavailable,Recovery: Nov 2024,,Other,Rheumatology,Current,,,42023-240-01,not available
12821,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 25021-821-05)",Reverified,7/1/24,Available,,,,Rheumatology,Current,,,25021-821-05,available
12822,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 25021-820-05)",Reverified,7/1/24,Available,,,,Rheumatology,Current,,,25021-820-05,available
12823,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 25021-820-10)",Reverified,7/1/24,Available,,,,Rheumatology,Current,,,25021-820-10,available
12824,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-3475-03)",Revised,8/26/24,Next Delivery: August 2024; Estimated Recovery: September 2024,Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Rheumatology,Current,,,0009-3475-03,not available
12825,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-3475-01)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-3475-01,available
12826,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-23)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-3073-23,available
12827,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-22)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-3073-22,available
12828,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-03)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-3073-03,available
12829,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 70121-1574-1)",Revised,7/9/24,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 7th July-24,,,Rheumatology,Current,,,70121-1574-1,available
12830,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 70121-1573-5)",Revised,7/9/24,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 7th July-24,,,Rheumatology,Current,,,70121-1573-5,available
12831,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 40 Mg/1 Ml (NDC 70121-1573-1)",Revised,7/9/24,Available,Sufficient Inventory Available (02 To 04 Wk) As Per Current Demand.Next Supply From Wk. Of 14th July-24,,,Rheumatology,Current,,,70121-1573-1,available
12832,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-3073-01)",Revised,8/26/24,Limited Supply Available. Next Delivery: August 2024; Estimated Recovery: September 2024,Check Wholesaler For Availability Shortage Per Manufacturer: Manufacturing Delay,,Delay In Shipping Of The Drug,Rheumatology,Current,,,0009-3073-01,limited availability
12833,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-0306-12)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0306-12,available
12834,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 80 Mg/1 Ml (NDC 0009-0306-02)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0306-02,available
12835,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-52)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0280-52,available
12836,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-51)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0280-51,available
12837,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-03)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0280-03,available
12838,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 40 Mg/1 Ml (NDC 0009-0280-02)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0280-02,available
12839,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-Medrol, Injection, 20 Mg/1 Ml (NDC 0009-0274-01)",Reverified,8/26/24,Available,,,,Rheumatology,Current,,,0009-0274-01,available
12840,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Injection, 80 Mg/1 Ml (NDC 70121-1574-5)",Revised,7/9/24,Available,Available Inventory For 1 Week As Per Current Demand.Next Supply From Wk. Of 14th July-24,,,Rheumatology,Current,,,70121-1574-5,available
12841,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 Mg/100 Ml (NDC 47335-993-01)",Reverified,7/15/24,Limited Availability,,,Demand Increase For The Drug,Anti-Infective,Current,,,47335-993-01,limited availability
12842,Metronidazole Injection,Baxter Healthcare,"Flagyl I.V. Rtu In Plastic Container, Injection, 500 Mg/100 Ml (NDC 0338-1055-48)",Reverified,7/17/24,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
12843,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.V. In Plastic Container, Injection, 500 Mg/100 Ml (NDC 0264-5535-32)",Reverified,9/3/24,Available,On Allocation,,,Anti-Infective,Current,,,0264-5535-32,available
12844,Midazolam Hydrochloride Injection,Wg Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 Mg/1 Ml (NDC 44567-611-10)",Reverified,9/1/24,Available,Please Check Wholesalers And Distributors For Inventory.,,,Anesthesia; Neurology,Current,,,44567-611-10,available
12845,Midazolam Hydrochloride Injection,Wg Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 Mg/1 Ml (NDC 44567-610-10)",Reverified,9/1/24,Available,Please Check Wholesalers And Distributors For Inventory.,,,Anesthesia; Neurology,Current,,,44567-610-10,available
12846,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 1 Mg/1 Ml (NDC 23155-600-41)",Reverified,9/3/24,Available,,,,Anesthesia; Neurology,Current,,,23155-600-41,available
12847,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 Mg/1 Ml (NDC 23155-601-41)",Revised,9/3/24,Available,,,,Anesthesia; Neurology,Current,,,23155-601-41,available
12848,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Injection, 5 Mg/1 Ml (NDC 23155-601-42)",Revised,9/3/24,Available,,,,Anesthesia; Neurology,Current,,,23155-601-42,available
12849,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Mg/10 Ml (1 Mg/Ml) (NDC 0409-2587-05)",Revised,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2587-05,available
12850,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 25 Mg/5 Ml (5 Mg/Ml) (NDC 0409-2596-03)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2596-03,available
12851,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 10 Mg/2 Ml (5 Mg/Ml) (NDC 0409-2308-02)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2308-02,available
12852,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/10 Ml (5 Mg/Ml) (NDC 0409-2596-05)",Revised,8/26/24,Unavailable,Next Delivery: July 2026; Estimated Recovery: September 2026,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,0409-2596-05,not available
12853,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 Mg/Ml (5 Mg/Ml) (NDC 0409-2308-01)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2308-01,available
12854,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 Mg/5 Ml (1 Mg/Ml) (NDC 0409-2305-05)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2305-05,available
12855,Midazolam Hydrochloride Injection,"Hospira, Inc., A Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 2 Mg/2ml (1 Mg/Ml) (NDC 0409-2305-17)",Reverified,8/26/24,Available,,,,Anesthesia; Neurology,Current,,,0409-2305-17,available
12856,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 5 Mg/1 Ml (NDC 0641-6060-10)",Revised,8/28/24,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,0641-6060-10,not available
12857,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 5 Mg/1 Ml (NDC 0641-6061-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,0641-6061-25,available
12858,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6059-01)",Revised,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,0641-6059-01,available
12859,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6057-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,0641-6057-25,available
12860,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Midazolam Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0641-6056-10)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Anesthesia; Neurology,Current,,,0641-6056-10,available
12861,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-02)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,63323-412-02,available
12862,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,63323-412-10,available
12863,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-412-25)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,63323-412-25,available
12864,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-25)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,63323-411-25,available
12865,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-12)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,63323-411-12,available
12866,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Midazolam Hydrochloride Preservative Free, Injection, 2 Mg/2 Ml (NDC 76045-001-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia; Neurology,Current,,,76045-001-20,available
12867,Midazolam Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-411-10)",Revised,9/4/24,Limited Availability,3 & 6 Mos Dating Available For Wholesalers. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,63323-411-10,limited availability
12868,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 Mg/2 Ml (NDC 47781-588-68)",Revised,7/15/24,Available,,,,Anesthesia; Neurology,Current,,,47781-588-68,available
12869,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 Mg/2 Ml (NDC 70860-600-02)",Revised,7/15/24,Available,,,,Anesthesia; Neurology,Current,,,70860-600-02,available
12870,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 47781-589-91)",Revised,7/15/24,Available,,,,Anesthesia; Neurology,Current,,,47781-589-91,available
12871,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 47781-589-17)",Revised,7/15/24,Unavailable,,,Demand Increase For The Drug,Anesthesia; Neurology,Current,,,47781-589-17,not available
12872,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 70860-601-05)",Revised,7/15/24,Available,,,,Anesthesia; Neurology,Current,,,70860-601-05,available
12873,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 Mg/1 Ml (NDC 70860-601-10)",Revised,7/15/24,Available,,,,Anesthesia; Neurology,Current,,,70860-601-10,available
12874,Minocycline Extended Release Tablet,Epi Health,"Minolira, Extended Release Tablet, 135 Mg (NDC 71403-102-30)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/2/23,71403-102-30,discontinued
12875,Minocycline Extended Release Tablets,Epi Health,"Minolira, Extended Release Tablets, 105mg (NDC 71403-101-30)",New,11/2/23,,,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/2/23,71403-101-30,discontinued
12876,"Minocycline Hydrochloride Capsule, Extended Release",Journey Medical Corporation,"Ximino, Capsule, Extended Release, 45 Mg (NDC 69489-121-30)",New,9/29/23,,Discontinuation Due To Business Reasons.,,Discontinuation Of The Manufacture Of The Drug,Antibiotic,To Be Discontinued,,9/29/23,69489-121-30,discontinued
12877,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 76045-005-11)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,76045-005-11,available
12878,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 76045-004-11)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,76045-004-11,available
12879,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 Mg/1 Ml (NDC 0641-6040-01)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6040-01,available
12880,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 Mg/1 Ml (NDC 0641-6039-01)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6039-01,available
12881,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Duramorph (Morphine Sulfate Injection, Usp), Injection, .5 Mg/1 Ml (NDC 0641-6020-10)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6020-10,available
12882,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Duramorph (Morphine Sulfate Injection, Usp), Injection, 1 Mg/1 Ml (NDC 0641-6019-10)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6019-10,available
12883,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-451-01)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,63323-451-01,available
12884,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 5 Mg/1 Ml (NDC 63323-455-01)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,63323-455-01,available
12885,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Mg/1 Ml (NDC 63323-454-01)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,63323-454-01,available
12886,Morphine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 2 Mg/1 Ml (NDC 63323-452-01)",Revised,8/2/24,Available,Check Wholesalers For Inventory,,,Analgesia/Addiction,Current,,,63323-452-01,available
12887,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 1 Mg/1 Ml (NDC 76329-1912-1)",Reverified,8/20/24,Available,,,,Analgesia/Addiction,Current,,,76329-1912-1,available
12888,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 8 Mg/1 Ml Syringes (NDC 0409-1892-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1892-01,available
12889,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 10 Mg/1 Ml (NDC 0641-6127-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6127-25,available
12890,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 8 Mg/1 Ml (NDC 0641-6126-25)",Reverified,8/28/24,Available,Currently Available.  Additional Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6126-25,available
12891,Morphine Sulfate Injection,"Hikma Pharmaceuticals Usa, Inc.","Morphine Sulfate Injection, Usp, Injection, 4 Mg/1 Ml (NDC 0641-6125-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction,Current,,,0641-6125-25,available
12892,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 50 Mg/1 Ml (NDC 0409-1134-05)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,0409-1134-05,not available
12893,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 50 Mg/1 Ml (NDC 0409-1896-20)",Revised,8/26/24,Unavailable,Next Delivery: December 2024; Estimated Recovery: March 2025,,Other,Analgesia/Addiction,Current,,,0409-1896-20,not available
12894,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 10 Mg/10 Ml (1 Mg/Ml) (NDC 0409-3815-12)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: September 2024,,Other,Analgesia/Addiction,Current,,,0409-3815-12,limited availability
12895,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 5 Mg/10 Ml (0.5 Mg/Ml) (NDC 0409-3814-12)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Analgesia/Addiction,Current,,,0409-3814-12,limited availability
12896,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 10 Mg/1 Ml Syringes (NDC 0409-1893-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1893-01,available
12897,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 4 Mg/1 Ml Syringes (NDC 0409-1891-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1891-01,available
12898,Morphine Sulfate Injection,"Hospira, Inc., A Pfizer Company","Morphine Sulfate, Injection, 2 Mg/1 Ml Syringes (NDC 0409-1890-01)",Reverified,8/26/24,Available,,,,Analgesia/Addiction,Current,,,0409-1890-01,available
12899,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, Usp), Injection, 500 Mg/20 Ml (NDC 66794-162-02)",Revised,6/19/24,Limited Availability,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,66794-162-02,limited availability
12900,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, Usp), Injection, 200 Mg/20 Ml (NDC 66794-160-02)",Revised,6/26/24,Available,,,,Analgesia/Addiction,Current,,,66794-160-02,available
12901,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 15 Mg (NDC 0228-4270-11)",New,4/3/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/24,0228-4270-11,discontinued
12902,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 15 Mg (NDC 0228-4270-11)",New,3/5/24,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/24,0228-4270-11,discontinued
12903,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 30 Mg (NDC 0228-4271-11)",New,4/3/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/24,0228-4271-11,discontinued
12904,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 30 Mg (NDC 0228-4271-11)",New,3/5/24,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/24,0228-4271-11,discontinued
12905,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 60 Mg (NDC 0228-4311-11)",New,4/3/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/24,0228-4311-11,discontinued
12906,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 60 Mg (NDC 0228-4311-11)",New,3/5/24,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/24,0228-4311-11,discontinued
12907,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 100 Mg (NDC 0228-4323-11)",New,4/3/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/24,0228-4323-11,discontinued
12908,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 100 Mg (NDC 0228-4323-11)",New,3/5/24,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/24,0228-4323-11,discontinued
12909,"Morphine Sulfate Tablet, Extended Release","Teva Pharmaceuticals Usa, Inc.","Tablet, Extended Release, 200 Mg (NDC 0228-4347-11)",New,4/3/24,,,,,Analgesia/Addiction,To Be Discontinued,,4/3/24,0228-4347-11,discontinued
12910,"Morphine Sulfate Tablet, Extended Release","Actavis Pharma, Inc.","Tablet, Extended Release, 200 Mg (NDC 0228-4347-11)",New,3/5/24,,,,,Analgesia/Addiction,To Be Discontinued,,3/5/24,0228-4347-11,discontinued
12911,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-01)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-01,discontinued
12912,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-05)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-05,discontinued
12913,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-66)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-66,discontinued
12914,Moxifloxacin Hydrochloride Tablet,"Dr. Reddy'S Laboratories, Inc.","Tablet, 400 Mg (NDC 55111-112-66)",New,10/4/23,,Discontinuance Of The Manufacture Of The Drug,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,10/4/23,55111-112-66,discontinued
12915,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Pediatric, Injection, 7 Mg/5 Ml; 80 Mg/5 Ml; 20 Ug/5 Ml; 1 Ug/5 Ml; 5 Mg/5 Ml; 10 Ug/5 Ml; 140 Ug/5 Ml; 17 Mg/5 Ml; 200 Ug/5 Ml; 1 Mg/5 Ml; .7 Mg/5 Ml; 1.4 Mg/5 Ml; 1.2 Mg/5 Ml (NDC 61703-421-53)",Revised,10/30/23,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-421-53,discontinued
12916,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Adult, Injection, 2 Box In 1 Case (61703-422-83)  (NDC 61703-422-83)",Revised,10/30/23,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-422-83,discontinued
12917,Multi-Vitamin Infusion (Adult And Pediatric) Injection,"Hospira, Inc., A Pfizer Company","M.V.I. Adult, Injection, 10 Kit In 1 Package (61703-434-82) (NDC 61703-434-82)",Revised,10/30/23,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,10/30/23,10/30/23,61703-434-82,discontinued
12918,Naltrexone Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Tablet, 50 Mg (NDC 62135-242-60)",Reverified,9/2/24,Available,,,,Analgesia/Addiction,Current,,,62135-242-60,available
12919,Naltrexone Hydrochloride Tablet,Specgx Llc,"Tablet, 50 Mg (NDC 0406-1170-03)",Revised,8/15/24,Limited Availability,Long Term Allocations To Primary Customers With Intermittent Backorder Expected Through Mid 2025.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0406-1170-03,limited availability
12920,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-08)",Reverified,8/26/24,Unavailable,Currently Not Marketed,,Other,Analgesia/Addiction,Current,,,47335-326-08,not available
12921,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-83)",Reverified,8/26/24,Limited Availability,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,47335-326-83,limited availability
12922,Naltrexone Hydrochloride Tablet,Specgx Llc,"Tablet, 50 Mg (NDC 0406-1170-01)",Revised,8/15/24,Limited Availability,Long Term Allocations To Primary Customers With Intermittent Backorder Expected Through Mid 2025.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0406-1170-01,limited availability
12923,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-18)",Reverified,8/26/24,Unavailable,Currently Not Marketed,,Other,Analgesia/Addiction,Current,,,47335-326-18,not available
12924,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Tablet, 50 Mg (NDC 47335-326-88)",Reverified,8/26/24,Limited Availability,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,47335-326-88,limited availability
12925,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 51224-206-30)",Reverified,9/2/24,Available,Marketed By Tagi Pharma,,,Analgesia/Addiction,Current,,,51224-206-30,available
12926,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 51224-206-50)",Reverified,9/2/24,Available,Marketed By Tagi Pharma,,,Analgesia/Addiction,Current,,,51224-206-50,available
12927,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 68094-909-30)",Reverified,9/2/24,Available,Marketed By Precision Dose,,,Analgesia/Addiction,Current,,,68094-909-30,available
12928,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Tablet, 50 Mg (NDC 68094-909-50)",Reverified,9/2/24,Available,Marketed By Precision Dose,,,Analgesia/Addiction,Current,,,68094-909-50,available
12929,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Tablet, 50 Mg (NDC 16729-081-10)",Revised,7/23/24,Limited Availability,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,16729-081-10,limited availability
12930,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Tablet, 50 Mg (NDC 16729-081-01)",Revised,7/23/24,Unavailable,,,Shortage Of An Active Ingredient,Analgesia/Addiction,Current,,,16729-081-01,not available
12931,Neomycin Sulfate Tablet,"Xgen Pharmaceuticals Djb, Inc.","Tablet, 500 Mg (NDC 39822-0310-5)",Revised,5/17/24,,,Available,,Anti-Infective,Resolved,5/17/24,,39822-0310-5,
12932,Neomycin Sulfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Neomycin Sulfate Tablets, Usp, Tablet, 500 Mg (NDC 0093-1177-01)",Revised,5/17/24,,,Available,,Anti-Infective,Resolved,5/17/24,,0093-1177-01,
12933,Nifedipine Capsule,Pfizer Inc.,"Procardia, Capsule, 10 Mg (NDC 59762-1004-1)",New,12/27/23,,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,11/26/23,59762-1004-1,discontinued
12934,Nifedipine Capsule,Pfizer Inc.,"Capsule, 10 Mg (NDC 59762-1004-1)",New,10/26/23,,Discontinuation Of The Manufacture Of The Drug. Supply Expected To Exhaust November 2023.,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,To Be Discontinued,,10/26/23,59762-1004-1,discontinued
12935,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 40 Mg/100 Ml (NDC 0338-1051-02)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1051-02,available
12936,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 20 Mg/100 Ml (NDC 0338-1049-02)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1049-02,available
12937,Nitroglycerin Injection,"American Regent, Inc.","Injection, 5 Mg/1 Ml (NDC 0517-4810-25)",Reverified,7/15/24,Unavailable,Estimated Availability: Q3 2024,,Demand Increase For The Drug,Cardiovascular,Current,,,0517-4810-25,not available
12938,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin In Dextrose 5%, Injection, 10 Mg/100 Ml (NDC 0338-1047-02)",Reverified,9/5/24,Available,,,,Cardiovascular,Current,,,0338-1047-02,available
12939,Norethindrone Acetate / Ethinyl Estradiol / Ferrous Fumarate Capsule,Amneal Pharmaceuticals,"Taysofy™, Capsule, 1mg/20mcg  (NDC 1111-1111-11)",New,2/6/24,,,,,Reproductive,To Be Discontinued,,2/6/24,1111-1111-11,discontinued
12940,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 Mg/1 Ml (NDC 0078-0669-13)",New,11/3/23,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,11/3/23,0078-0669-13,discontinued
12941,Ofatumumab Injection,Novartis Pharmaceuticals Corporation,"Arzerra, Injection, 20 Mg/1 Ml (NDC 0078-0690-61)",New,11/3/23,,,,Discontinuation Of The Manufacture Of The Drug,Oncology,To Be Discontinued,,11/3/23,0078-0690-61,discontinued
12942,Omeprazole; Sodium Bicarbonate	 For Suspension,"Par Pharmaceutical, Inc.","For Suspension, 20 Mg; 1680 Mg (NDC 49884-268-11)",New,12/7/23,,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,12/7/23,49884-268-11,discontinued
12943,Omeprazole; Sodium Bicarbonate Suspension,"Par Pharmaceutical, Inc.","Suspension, 40 Mg; 1680 Mg (NDC 49884-269-11)",New,12/7/23,,,,Discontinuation Of The Manufacture Of The Drug,Gastroenterology,To Be Discontinued,,12/7/23,49884-269-11,discontinued
12944,Oxaliplatin Injection,"Actavis Pharma, Inc.","Injection, 5 Mg/1 Ml (NDC 45963-611-53)",New,3/25/24,,,,,Oncology,To Be Discontinued,,3/25/24,45963-611-53,discontinued
12945,Oxaliplatin Injection,"Actavis Pharma, Inc.","Injection, 5 Mg/1 Ml (NDC 45963-611-59)",New,3/25/24,,,,,Oncology,To Be Discontinued,,3/25/24,45963-611-59,discontinued
12946,Oxybutynin Chloride Syrup,"Lannett Company, Inc.","Syrup, 5 Mg/5 Ml (NDC 54838-510-80)",Revised,8/29/24,,,Available,,Urology,Resolved,8/29/24,,54838-510-80,
12947,Oxybutynin Chloride Syrup,Chartwell Molecular Holdings Llc,"Syrup, 5 Mg/5 Ml (NDC 62135-520-47)",Revised,8/29/24,,,Available,,Urology,Resolved,8/29/24,,62135-520-47,
12948,Pantoprazole Sodium Injection,Aspiro Pharma Ltd.,"Pantoprazole Sodium, Injection, 40 Mg (NDC 31722-204-10)",Revised,9/15/23,,,"Available. Marketed By Camber Pharmaceuticals, Inc.",,Gastroenterology,Resolved,9/15/23,,31722-204-10,
12949,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 100 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Reverified,9/3/24,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,68875-0205-2,not available
12950,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 75 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Reverified,9/3/24,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,68875-0204-2,not available
12951,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 50 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Reverified,9/3/24,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,68875-0203-2,not available
12952,Parathyroid Hormone Injection,Takeda Pharmaceuticals Usa Inc.,"Natpara, Injection, 25 Ug/.08 Ml, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Reverified,9/3/24,Unavailable,Takeda Will Be Ceasing Manufacturing Of Natpara At The End Of 2024 With A Priority To Maintain Treatment Continuity For Patients Enrolled In The U.S. Special Use Program Until Inventory Is Depleted Or Expired. Please Refer To The Following Link For More Details Â€“ Https://Www.Takeda.Com/En-Us/Newsroom/Statements/2022/Takeda-To-Discontinue-Manufacturing-Of-Natpar-Natpara/,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,68875-0202-2,not available
12953,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 2400000 [Iu]/4 Ml (NDC 60793-702-10)",Revised,9/6/24,Available,,,,Anti-Infective,Current,,,60793-702-10,available
12954,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 1200000 [Iu]/2 Ml (NDC 60793-701-10)",Revised,9/6/24,Available,,,,Anti-Infective,Current,,,60793-701-10,available
12955,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 600000 [Iu]/1 Ml (NDC 60793-700-10)",Revised,9/6/24,Unavailable,"Next Delivery And Estimated Recovery:  Q1, 2025",,Delay In Shipping Of The Drug,Anti-Infective,Current,,,60793-700-10,not available
12956,Penicillin G Benzathine Injection,Laboratorios Atral,"Lentocilin, Injection, 1200000 U/4 Ml (NDC 84383-110-01)",Revised,9/3/24,Available,,,,Anti-Infective,Current,,,84383-110-01,available
12957,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 1,200,000 Units (NDC 81284-521-01)",Revised,7/24/24,Available,,,,Anti-Infective,Current,,,81284-521-01,available
12958,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 2,400,000 Units (NDC 81284-522-01)",Revised,7/24/24,Available,,,,Anti-Infective,Current,,,81284-522-01,available
12959,Phenytoin Oral Suspension,Vistapharm,"Oral Suspension, 125 Mg/5 Ml (NDC 66689-036-50)",New,2/28/24,,,,,Neurology,To Be Discontinued,,2/28/24,66689-036-50,discontinued
12960,Phenytoin Oral Suspension,Vistapharm,"Oral Suspension, 125 Mg/5 Ml (NDC 66689-775-08)",New,2/28/24,,,,,Neurology,To Be Discontinued,,2/28/24,66689-775-08,discontinued
12961,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-10)",New,3/21/24,,,,,Neurology,To Be Discontinued,,3/21/24,65162-212-10,discontinued
12962,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-11)",New,3/21/24,,,,,Neurology,To Be Discontinued,,3/21/24,65162-212-11,discontinued
12963,Phenytoin Sodium Extended-Release Capsule,Amneal Pharmaceuticals,"Extended-Release Capsule, 100 Mg (NDC 65162-212-50)",New,3/21/24,,,,,Neurology,To Be Discontinued,,3/21/24,65162-212-50,discontinued
12964,Posaconazole Oral Suspension,Merck Sharp & Dohme Llc,"Noxafil, Oral Suspension, 40mg/Ml (NDC 0085-1328-01)",New,11/15/23,,"To Be Discontinued On December 18th, 2023.",,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/15/23,0085-1328-01,discontinued
12965,Posaconazole Suspension,Merck Sharp & Dohme Llc,"Noxafil, Suspension, 40 Mg/1 Ml (NDC 0085-1328-01)",New,11/27/23,,To Be Discontinued On18 Dec 2023.,,Discontinuation Of The Manufacture Of The Drug,Anti-Infective,To Be Discontinued,,11/27/23,0085-1328-01,discontinued
12966,"Posaconazole Tablet, Delayed Release","Merck Sharp & Dohme Corp., A Subsidiary Of Merck And Co., Inc.","Noxafil, Tablet, Delayed Release, 100 Mg (NDC 0085-4324-02)",New,7/22/24,,,,,Anti-Infective,To Be Discontinued,,7/22/24,0085-4324-02,discontinued
12967,Potassium Acetate Injection,"Exela Pharma Sciences, Llc","Injection, 3.93 G/20 Ml (NDC 51754-2001-4)",Revised,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,51754-2001-4,available
12968,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-8183-25)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-8183-25,available
12969,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3294-25)",Revised,8/26/24,Unavailable,Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3294-25,not available
12970,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-8183-01)",Revised,8/26/24,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-8183-01,not available
12971,Potassium Acetate Injection,"Hospira, Inc., A Pfizer Company","Potassium Acetate, Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3294-51)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3294-51,limited availability
12972,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 G/100 Ml (NDC 0264-1944-20)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0264-1944-20,
12973,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 G/1000 Ml (NDC 0338-0703-41)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0338-0703-41,
12974,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 G/1000 Ml (NDC 0338-0705-48)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0338-0705-48,
12975,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 14.9 G/1000 Ml (NDC 0338-0705-41)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0338-0705-41,
12976,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 7.46 G/1000 Ml (NDC 0338-0709-48)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0338-0709-48,
12977,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 10 Meq (NDC 14789-109-16)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,14789-109-16,
12978,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 10 Meq (NDC 14789-108-08)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,14789-108-08,
12979,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 20 Meq (NDC 14789-108-16)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,14789-108-16,
12980,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 40 Meq (NDC 14789-107-16)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,14789-107-16,
12981,Potassium Chloride Injection,"Nexus Pharmaceuticals, Llc","Injection, 20 Meq (NDC 14789-107-08)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,14789-107-08,
12982,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 40meq In Plastic Container, Injection, 400 Meq/1000 Ml (NDC 0990-7077-26)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0990-7077-26,
12983,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 20meq In Plastic Container, Injection, 200 Meq/1000 Ml (NDC 0990-7075-26)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0990-7075-26,
12984,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 10meq In Plastic Container, Injection, 200 Meq/1000 Ml (NDC 0990-7075-14)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0990-7075-14,
12985,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 10meq In Plastic Container, Injection, 10 Meq/100 Ml (NDC 0990-7074-26)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0990-7074-26,
12986,Potassium Chloride Injection,"Icu Medical, Inc.","Potassium Chloride 20meq In Plastic Container, Injection, 400 Meq/1000 Ml (NDC 0990-7077-14)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0990-7077-14,
12987,Potassium Chloride Injection,Baxter Healthcare,"Potassium Chloride, Injection, 29.8 G/1000 Ml (NDC 0338-0703-48)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0338-0703-48,
12988,Potassium Chloride Injection,B. Braun Medical Inc.,"Injection, 14.9 G/100 Ml (NDC 0264-1940-20)",Revised,2/2/24,,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,To Be Discontinued,2/6/24,2/2/24,0264-1940-20,discontinued
12989,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-20)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,63323-965-20,
12990,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-10)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,63323-965-10,
12991,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-965-05)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,63323-965-05,
12992,Potassium Chloride Injection,"Fresenius Kabi Usa, Llc","Potassium Chloride In Plastic Container, Injection, 2 Meq/1 Ml (NDC 63323-967-30)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,63323-967-30,
12993,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6653-05)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0409-6653-05,
12994,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6651-06)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0409-6651-06,
12995,Potassium Chloride Injection,"Hospira, Inc., A Pfizer Company","Injection, 149 Mg/1 Ml (NDC 0409-6635-01)",Revised,5/7/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,5/7/24,,0409-6635-01,
12996,Pralatrexate Solution,"Fresenius Kabi Usa, Llc","Folotyn, Solution, 20 Mg/1 Ml (NDC 65219-550-01)",New,3/21/24,,,,,Hematology; Oncology,To Be Discontinued,,3/21/24,65219-550-01,discontinued
12997,Pralatrexate Solution,"Fresenius Kabi Usa, Llc","Folotyn, Solution, 40 Mg/2 Ml (NDC 65219-552-02)",New,3/21/24,,,,,Hematology; Oncology,To Be Discontinued,,3/21/24,65219-552-02,discontinued
12998,Praziquantel Tablet,Bayer Healthcare Pharmaceuticals Inc.,"Biltricide, Tablet, 600 Mg (NDC 50419-747-01)",New,3/5/24,,,,,Anti-Infective,To Be Discontinued,,3/5/24,50419-747-01,discontinued
12999,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 50 Mg/1 Ml (NDC 0641-6085-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6085-25,available
13000,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 50 Mg/1 Ml (NDC 0641-6083-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6083-25,available
13001,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 25 Mg/1 Ml (NDC 0641-6082-25)",Revised,8/28/24,Unavailable,Additional Lots Will Be Available In The September - October 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6082-25,not available
13002,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Phenergan Injection (Promethazine Hcl Injection,Usp, Injection, 25 Mg/1 Ml (NDC 0641-6084-25)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing To Meet Demand.  Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6084-25,available
13003,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0641-1496-35)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-1496-35,available
13004,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 25 Mg/1 Ml (NDC 0641-1495-35)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-1495-35,available
13005,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 50 Mg/1 Ml (NDC 0641-0929-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-0929-25,available
13006,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Promethazine Hcl Injection, Usp, Injection, 25 Mg/1 Ml (NDC 0641-0928-25)",Reverified,8/28/24,Available,Additional Lots Are Scheduled To Be Manufactured. Product Will Be Made Available As It Is Released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-0928-25,available
13007,Promethazine Hydrochloride Injection,"Xgen Pharmaceuticals Djb, Inc.","Promethazine Hydrochloride, Injection, 25 Mg/1 Ml (NDC 39822-5525-3)",Reverified,7/16/24,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5525-3,available
13008,Promethazine Hydrochloride Injection,"Xgen Pharmaceuticals Djb, Inc.","Promethazine Hydrochloride, Injection, 50 Mg/1 Ml (NDC 39822-5550-6)",Reverified,7/16/24,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5550-6,available
13009,Propranolol Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-604-01)",Revised,8/15/24,Unavailable,Backordered. Next Release August 2024; Check Wholesalers For Inventory,,Demand Increase For The Drug,Cardiovascular,Current,,,63323-604-01,not available
13010,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Propranolol Hcl Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0143-9872-10)",Reverified,8/28/24,Unavailable,,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,0143-9872-10,not available
13011,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Propranolol Hcl Injection, Usp, Injection, 1 Mg/1 Ml (NDC 0143-9872-10)",Reverified,8/28/24,Unavailable,,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,0143-9872-10,not available
13012,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 65862-618-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-618-90,discontinued
13013,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 Mg (NDC 68180-557-09)",Reverified,8/19/24,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,68180-557-09,not available
13014,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 40 Mg (NDC 43547-413-09)",Reverified,9/3/24,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,43547-413-09,not available
13015,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 Mg (NDC 0071-0527-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0527-23,not available
13016,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 Mg (NDC 0071-0532-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0532-23,not available
13017,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 Mg (NDC 0071-0530-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0530-23,not available
13018,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 Mg (NDC 0071-0535-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0535-23,not available
13019,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 40 Mg (NDC 65862-620-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-620-90,discontinued
13020,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 65862-618-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-618-90,discontinued
13021,Quinapril Hydrochloride Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride, Tablet, 5 Mg (NDC 65862-617-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-617-90,discontinued
13022,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 Mg (NDC 68180-554-09)",Reverified,8/19/24,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,68180-554-09,not available
13023,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 Mg (NDC 68180-558-09)",Reverified,8/19/24,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,68180-558-09,not available
13024,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 Mg (NDC 68180-556-09)",Reverified,8/19/24,Unavailable,,,Requirements Related To Complying With Good Manufacturing Practices,Cardiovascular,Current,,,68180-556-09,not available
13025,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 20 Mg (NDC 43547-412-09)",Reverified,9/3/24,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,43547-412-09,not available
13026,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 10 Mg (NDC 43547-411-09)",Reverified,9/3/24,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,43547-411-09,not available
13027,Quinapril Hydrochloride Tablet,"Solco Healthcare Us, Llc","Tablet, 5 Mg (NDC 43547-410-09)",Reverified,9/3/24,Unavailable,Not Available. Long-Term Backorder For All Ndcs. No Estimated Release Date At This Time.,,Shortage Of An Active Ingredient,Cardiovascular,Current,,,43547-410-09,not available
13028,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 5 Mg (NDC 62135-484-60)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-484-60,available
13029,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 10 Mg (NDC 62135-485-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-485-90,available
13030,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 20 Mg (NDC 62135-486-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-486-90,available
13031,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings Llc,"Quinapril Hydrochloride, Tablet, 40 Mg (NDC 62135-487-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-487-90,available
13032,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 Mg; 20 Mg (NDC 65862-163-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-163-90,discontinued
13033,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 Mg; 20 Mg (NDC 65862-162-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-162-90,discontinued
13034,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma Usa,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 Mg; 10 Mg (NDC 65862-161-90)",Reverified,7/2/24,Discontinued,,,Discontinuation Of The Manufacture Of The Drug,Cardiovascular,Current,,,65862-161-90,discontinued
13035,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 Mg/20 Mg (NDC 0071-0223-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0223-23,not available
13036,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 Mg/12.5 Mg (NDC 0071-0220-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0220-23,not available
13037,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 Mg/12.5 Mg (NDC 0071-0222-23)",Reverified,8/26/24,Unavailable,Next Delivery And Estimated Recovery: Tbd,,Delay In Shipping Of The Drug,Cardiovascular,Current,,,0071-0222-23,not available
13038,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 Mg; 10 Mg (NDC 62135-667-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-667-90,available
13039,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 Mg; 20 Mg (NDC 62135-668-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-668-90,available
13040,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings Llc,"Quinapril/Hydrochlorothiazide, Tablet, 25 Mg; 20 Mg (NDC 62135-669-90)",Reverified,9/2/24,Available,,,,Cardiovascular,Current,,,62135-669-90,available
13041,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 1 Mg/1 Ml (NDC 72078-034-01)",Reverified,9/5/24,Available,,,,Analgesia/Addiction,Current,,,72078-034-01,available
13042,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-725-10)",Reverified,9/4/24,Unavailable,Backordered. Next Release Not Available At This Time; Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-725-10,not available
13043,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-724-05)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-724-05,not available
13044,Remifentanil Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-723-03)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,63323-723-03,not available
13045,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 5 Mg Per Vial (NDC 0143-9393-10)",Revised,7/25/24,Unavailable,,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0143-9393-10,not available
13046,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 2 Mg Per Vial (NDC 0143-9392-10)",Revised,7/25/24,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0143-9392-10,not available
13047,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals Usa, Inc.","Remifentanil Hcl For Injection, Injection, 1 Mg Per Vial (NDC 0143-9391-10)",Revised,7/25/24,Unavailable,Additional Lots Will Be Available In The August 2024 Timeframe. Product Will Be Made Available As It Is Released.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,0143-9391-10,not available
13048,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 5 Mg (NDC 67457-198-10)",Reverified,9/5/24,Unavailable,Next Supply In Q4-2024.,,Demand Increase For The Drug,Analgesia/Addiction,Current,,,67457-198-10,not available
13049,Remifentanil Hydrochloride Injection,"Mylan Institutional, A Viatris Company","Ultiva, Injection, 2 Mg (NDC 72078-035-02)",Reverified,9/5/24,Available,,,,Analgesia/Addiction,Current,,,72078-035-02,available
13050,Reteplase Injection,"Chiesi Usa, Inc.","Retavase, Injection, 10 Ml/Vial (NDC 10122-143-01)",New,9/5/24,,,,,Cardiovascular,To Be Discontinued,,9/5/24,10122-143-01,discontinued
13051,Reteplase Injection,"Chiesi Usa, Inc.","Retavase, Injection, 10 Ml/Vial (NDC 10122-141-02)",New,9/5/24,,,,,Cardiovascular,To Be Discontinued,,9/5/24,10122-141-02,discontinued
13052,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 Mg (NDC 68180-659-07)",Reverified,8/19/24,Available,,,,Anti-Infective,Current,,,68180-659-07,available
13053,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 Mg (NDC 68180-659-06)",Reverified,8/19/24,Available,,,,Anti-Infective,Current,,,68180-659-06,available
13054,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 Mg (NDC 68180-658-06)",Reverified,8/19/24,Available,,,,Anti-Infective,Current,,,68180-658-06,available
13055,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-05)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-799-05,available
13056,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-01)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-799-01,available
13057,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-60)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-799-60,available
13058,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 300 Mg (NDC 42806-799-30)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-799-30,available
13059,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 150 Mg (NDC 42806-801-01)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-801-01,available
13060,Rifampin Capsule,"Epic Pharma, Llc","Capsule, 150 Mg (NDC 42806-801-30)",Reverified,9/3/24,Available,,,,Anti-Infective,Current,,,42806-801-30,available
13061,Rifampin Injection,"Mylan Institutional, A Viatris Company","Injection, 600 Mg/10 Ml (NDC 67457-445-60)",Reverified,9/5/24,Available,,,,Anti-Infective,Current,,,67457-445-60,available
13062,Rifampin Injection,Sanofi-Aventis U.S. Llc,"Rifadin, Injection, 600 Mg/10 Ml (NDC 0068-0597-01)",Reverified,7/1/24,Available,,,,Anti-Infective,Current,,,0068-0597-01,available
13063,Rifampin Injection,"Fresenius Kabi Usa, Llc","Injection, 600 Mg (NDC 63323-351-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anti-Infective,Current,,,63323-351-20,available
13064,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. Llc,"Priftin, Tablet, Film Coated, 150 Mg (NDC 0088-2102-24)",Reverified,7/1/24,Available,,,,Anti-Infective,Current,,,0088-2102-24,available
13065,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0306-1)",Reverified,9/3/24,Available,,,,Neurology,Current,,,70726-0306-1,available
13066,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0305-1)",Reverified,9/3/24,Available,,,,Neurology,Current,,,70726-0305-1,available
13067,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 Mg/1 Ml (NDC 70726-0304-1)",Reverified,9/3/24,Available,,,,Neurology,Current,,,70726-0304-1,available
13068,Riluzole Oral Suspension,"Edw Pharma, Inc. (Formerly Italfarmaco Pharma, Inc.)","Tiglutik, Oral Suspension, 50 Mg/10 Ml (NDC 70726-0303-2)",Reverified,9/3/24,Unavailable,Next Release Not Available At This Time; Shortage Per Manufacturer: Product Manufacturing Interrupted Due To Viscosity Testing,,Requirements Related To Complying With Good Manufacturing Practices,Neurology,Current,,,70726-0303-2,not available
13069,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-718-11)",Reverified,7/3/24,Available,,,,Anesthesia,Current,,,71288-718-11,available
13070,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Injection, 10 Mg/1 Ml (NDC 71288-700-06)",Reverified,7/3/24,Available,,,,Anesthesia,Current,,,71288-700-06,available
13071,Rocuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Rocuronium Bromide, Injection, 10 Mg/1 Ml (NDC 67457-228-10)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-228-10,available
13072,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 65219-065-05)",Revised,9/4/24,Limited Availability,5 Month Expiry Available Upon Request; Check Wholesalers For Inventory,,Delay In Shipping Of The Drug,Anesthesia,Current,,,65219-065-05,limited availability
13073,Rocuronium Bromide Injection,"Hikma Pharmaceuticals Usa, Inc.","Rocuronium Bromide Injection, Injection, 10 Mg/1 Ml (NDC 0143-9251-10)",Reverified,8/28/24,Available,,,,Anesthesia,Current,,,0143-9251-10,available
13074,Rocuronium Bromide Injection,"Hikma Pharmaceuticals Usa, Inc.","Rocuronium Bromide Injection, Injection, 10 Mg/1 Ml (NDC 0143-9250-10)",Reverified,8/28/24,Available,Additional Lots Will Be Available.  Product Will Be Made Available As It Is Released.,,,Anesthesia,Current,,,0143-9250-10,available
13075,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 Mg/10 Ml (NDC 43066-013-10)",Reverified,9/5/24,Available,Tamarang Is The Application Holder And Baxter Is The Distributor/Labeler,,,Anesthesia,Current,,,43066-013-10,available
13076,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 Mg/5 Ml (NDC 43066-007-10)",Reverified,9/5/24,Available,Tamarang Is The Application Holder And Baxter Is The Distributor/Labeler,,,Anesthesia,Current,,,43066-007-10,available
13077,Rocuronium Bromide Injection,Eugia Us Llc,"Injection, 50 Mg/5 Ml (NDC 55150-225-05)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-225-05,not available
13078,Rocuronium Bromide Injection,Eugia Us Llc,"Injection, 100 Mg/10 Ml (NDC 55150-226-10)",Revised,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-226-10,not available
13079,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Rocuronium Bromide, Injection, 100 Mg/10 Ml (10 Mg/Ml) (NDC 0409-5160-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-5160-10,available
13080,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Mg/10 Ml (10 Mg/Ml) (NDC 0409-7037-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-7037-10,available
13081,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-1403-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-1403-10,available
13082,Rocuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Mg/5 Ml (10 Mg/Ml) (NDC 0409-3189-10)",Reverified,8/26/24,Available,,,,Anesthesia,Current,,,0409-3189-10,available
13083,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 Mg/1 Ml (NDC 0781-3220-92)",Reverified,8/5/24,Available,,,,Anesthesia,Current,,,0781-3220-92,available
13084,Rocuronium Bromide Injection,Sandoz Inc.,"Injection, 10 Mg/1 Ml (NDC 0781-3220-95)",Reverified,8/5/24,Available,,,,Anesthesia,Current,,,0781-3220-95,available
13085,Rocuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Rocuronium Bromide, Injection, 10 Mg/1 Ml (NDC 67457-228-05)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-228-05,available
13086,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Injection, 10 Mg/1 Ml (NDC 25021-687-05)",Reverified,7/1/24,Available,,,,Anesthesia,Current,,,25021-687-05,available
13087,Rocuronium Bromide Injection,"Xgen Pharmaceuticals Djb, Inc.","Injection, 100 Mg/10 Ml (NDC 39822-4200-6)",Reverified,7/16/24,Available,Tamarang Is The Application Holder And X-Gen Is The Distributor/Labeler,,,Anesthesia,Current,,,39822-4200-6,available
13088,Rocuronium Bromide Injection,"Xgen Pharmaceuticals Djb, Inc.","Injection, 50 Mg/5 Ml (NDC 39822-4200-2)",Reverified,7/16/24,Available,Tamarang Is The Application Holder And X-Gen Is The Distributor/Labeler,,,Anesthesia,Current,,,39822-4200-2,available
13089,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-426-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-426-10,available
13090,Rocuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 10 Mg/1 Ml (NDC 63323-426-05)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,63323-426-05,available
13091,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Injection, 50 Mg/5 Ml (NDC 66794-228-41)",Revised,6/26/24,Limited Availability,,,Demand Increase For The Drug,Anesthesia,Current,,,66794-228-41,limited availability
13092,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Injection, 100 Mg/10 Ml (NDC 66794-229-41)",Revised,6/26/24,Available,,,,Anesthesia,Current,,,66794-229-41,available
13093,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-67)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-67,available
13094,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-66)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-66,available
13095,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-25)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-064-25,available
13096,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-10)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-064-10,available
13097,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 5 Mg/1 Ml (NDC 70069-064-01)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-064-01,available
13098,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-062-25)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-062-25,available
13099,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-062-10)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-062-10,available
13100,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-061-25)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-061-25,available
13101,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, Llc","Injection, 2 Mg/1 Ml (NDC 70069-061-10)",Reverified,8/30/24,Available,,,,Anesthesia,Current,,,70069-061-10,available
13102,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 10 Mg/1 Ml (NDC 43066-027-10)",Reverified,7/16/24,Available,Check Wholesalers For Inventory; Marketed By Baxter,,,Anesthesia,Current,,,43066-027-10,available
13103,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 Mg/1 Ml (NDC 43066-023-10)",Reverified,7/16/24,Limited Availability,Limited Supply; Check Wholesalers For Inventory; Marketed By Baxter,,Demand Increase For The Drug,Anesthesia,Current,,,43066-023-10,limited availability
13104,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 5 Mg/1 Ml (NDC 43066-019-10)",Reverified,7/16/24,Available,Check Wholesalers For Inventory; Marketed By Baxter,,,Anesthesia,Current,,,43066-019-10,available
13105,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Injection, 2 Mg/1 Ml (NDC 43066-015-10)",Reverified,7/16/24,Limited Availability,Check Wholesalers For Inventory; Marketed By Baxter,,Demand Increase For The Drug,Anesthesia,Current,,,43066-015-10,limited availability
13106,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 25021-652-87)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-87,available
13107,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 5 Mg/1 Ml (NDC 25021-652-82)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-82,available
13108,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-87)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-87,available
13109,Ropivacaine Hydrochloride Injection,Inforlife Sa,"Ropivacaine Hydrochloride, Injection, 2 Mg/1 Ml (NDC 25021-671-82)",Reverified,7/1/24,Available,Marketed By Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-82,available
13110,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-31)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-286-31,not available
13111,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-21)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-288-21,available
13112,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-11)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-288-11,available
13113,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 7.5 Mg/1 Ml (NDC 63323-287-21)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-287-21,available
13114,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-23)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-286-23,available
13115,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-35)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-286-35,available
13116,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-23)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-285-23,available
13117,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-13)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-285-13,available
13118,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-63)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-286-63,available
13119,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-00)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-286-00,available
13120,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-64)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-285-64,available
13121,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-65)",Reverified,9/4/24,Available,,,,Anesthesia,Current,,,63323-285-65,available
13122,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-63)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-285-63,not available
13123,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-61)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-285-61,not available
13124,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-20)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-288-20,not available
13125,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 10 Mg/1 Ml (NDC 63323-288-10)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-288-10,not available
13126,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 7.5 Mg/1 Ml (NDC 63323-287-20)",Revised,9/4/24,Limited Availability,7 Month Expiry Availabe Upon Request. Check Wholesaler Inventory.,,Demand Increase For The Drug,Anesthesia,Current,,,63323-287-20,limited availability
13127,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 5 Mg/1 Ml (NDC 63323-286-20)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-286-20,not available
13128,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-20)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Delay In Shipping Of The Drug,Anesthesia,Current,,,63323-285-20,not available
13129,Ropivacaine Hydrochloride Injection,"Fresenius Kabi Usa, Llc","Naropin, Injection, 2 Mg/1 Ml (NDC 63323-285-10)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Anesthesia,Current,,,63323-285-10,not available
13130,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-201-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-201-20,available
13131,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 10 Mg/1 Ml (NDC 55150-200-10)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-200-10,available
13132,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 7.5 Mg/1 Ml (NDC 55150-199-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-199-20,available
13133,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 5 Mg/1 Ml (NDC 55150-198-30)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-198-30,available
13134,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 5 Mg/1 Ml (NDC 55150-197-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-197-20,available
13135,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 2 Mg/1 Ml (NDC 55150-196-99)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-196-99,available
13136,Ropivacaine Hydrochloride Injection,Eugia Us Llc,"Injection, 2 Mg/1 Ml (NDC 55150-195-20)",Revised,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-195-20,available
13137,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 2.68 Mg/1 Ml (NDC 0169-4772-12)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4772-12,available
13138,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, 1.34 Mg/1 Ml (NDC 0169-4130-13)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4130-13,available
13139,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 2.4 Mg/.75 Ml (NDC 0169-4524-14)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4524-14,available
13140,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1.7 Mg/.75 Ml (NDC 0169-4517-14)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4517-14,available
13141,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, 1 Mg/.5 Ml (NDC 0169-4501-14)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4501-14,available
13142,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .5 Mg/.5 Ml (NDC 0169-4505-14)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4505-14,available
13143,Semaglutide Injection,"Novo Nordisk, Inc.","Wegovy, Injection, .25 Mg/.5 Ml (NDC 0169-4525-14)",Revised,8/6/24,Limited Availability,Estimated Shortage Duration Tbd,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,0169-4525-14,limited availability
13144,Semaglutide Injection,"Novo Nordisk, Inc.","Ozempic, Injection, .68 Mg/1 Ml (NDC 0169-4181-13)",Revised,8/6/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-4181-13,available
13145,"Sildenafil Powder, For Suspension","Mylan Specialty, A Viatris Company","Revatio 10mg/Ml Pos 1x1 Gbtl Us, Powder, For Suspension, 10mg/Ml (NDC 0069-0336-21)",New,8/14/24,,,,,Cardiovascular,To Be Discontinued,,8/14/24,0069-0336-21,discontinued
13146,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-7299-25)",Revised,8/26/24,Unavailable,Estimated Recovery: September 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-25,not available
13147,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3299-26)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-26,not available
13148,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 200 Meq/100 Ml (2 Meq/Ml) (NDC 0409-3299-25)",Revised,8/26/24,Unavailable,Next Delivery: December 2024; Estimated Recovery: March 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-25,not available
13149,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 200 Meq/100ml (2 Meq/Ml) (NDC 69784-231-10)",Reverified,9/3/24,Available,,,,Total Parenteral Nutrition,Current,,,69784-231-10,available
13150,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 100 Meq/50ml (2 Meq/Ml) (NDC 69784-230-10)",Reverified,9/3/24,Available,,,,Total Parenteral Nutrition,Current,,,69784-230-10,available
13151,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 100 Meq/50 Ml (2 Meq/Ml) (NDC 0409-3299-05)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-05,limited availability
13152,Sodium Acetate Injection,"Fresenius Kabi Usa, Llc","Injection, 4 Meq/100 Ml (NDC 63323-032-00)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Total Parenteral Nutrition,Current,,,63323-032-00,available
13153,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 40 Meq/20 Ml (2 Meq/Ml) (NDC 0409-7299-73)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-73,limited availability
13154,Sodium Acetate Injection,"Hospira, Inc., A Pfizer Company","Injection, 200 Meq/100 Ml (2 Meq/Ml) (NDC 0409-3299-06)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-06,limited availability
13155,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 40 Meq/20ml (2 Meq/Ml) (NDC 69784-229-10)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,69784-229-10,available
13156,Sodium Acetate Injection,Milla Pharmaceuticals,"Injection, 400 Meq/100ml (4 Meq/Ml) (NDC 69784-232-01)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,69784-232-01,available
13157,Sodium Benzoate; Sodium Phenylacetate Injection,"Bausch Health Americas, Inc.","Ammonul, Injection, 100 Mg/1 Ml; 100 Mg/1 Ml (NDC 0187-0010-50)",New,7/3/24,,Discontinuation Due To Business Decision,,,Inborn Errors; Other,To Be Discontinued,,7/3/24,0187-0010-50,discontinued
13158,Sodium Benzoate; Sodium Phenylacetate Injection,"Bausch Health Americas, Inc.","Ammonul, Injection, 100 Mg/1 Ml; 100 Mg/1 Ml (NDC 68682-001-50)",New,7/3/24,,Discontinuation Due To Business Decision,,,Inborn Errors; Other,To Be Discontinued,,7/3/24,68682-001-50,discontinued
13159,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 42 Mg/1 Ml (NDC 51754-5012-4)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5012-4,available
13160,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 84 Mg/1 Ml (NDC 51754-5011-4)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5011-4,available
13161,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 10 Meq/10 Ml (8.4%, 1 Meq/Ml) Syringes (NDC 0409-4900-14)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4900-14,not available
13162,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) (NDC 0409-6625-35)",Revised,8/26/24,Unavailable,Next Delivery: April 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6625-35,not available
13163,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) (NDC 0409-6625-14)",Revised,8/26/24,Limited Availability,Limited Supply Available; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6625-14,limited availability
13164,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 44.6 Meq/50 Ml (7.5%, 0.9 Meq/Ml) Syringes (NDC 0409-4916-14)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4916-14,not available
13165,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2.5 Meq/5 Ml (4.2%, 0.5 Meq/Ml) (NDC 0409-5555-01)",Revised,8/26/24,Unavailable,Next Delivery: April 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5555-01,not available
13166,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Injection, 2.5 Meq/5 Ml (4.2%, 0.5 Meq/Ml) (NDC 0409-5555-02)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5555-02,limited availability
13167,Sodium Bicarbonate Injection,"Exela Pharma Sciences, Llc","Injection, 84 Mg/1 Ml (NDC 51754-5001-5)",Reverified,9/3/24,Available,Available In Ndc 51754-5001-4 Which Is Carton Of 25 Vials. The 521754-5001-05 Was Discontinued Over A Year Ago.,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5001-5,available
13168,Sodium Bicarbonate Injection,"Fresenius Kabi Usa, Llc","Injection, 84 Mg/1 Ml (NDC 63323-089-50)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-089-50,available
13169,Sodium Bicarbonate Injection,"Fresenius Kabi Usa, Llc","Injection, 42 Mg/1 Ml (NDC 63323-083-05)",Reverified,9/4/24,Unavailable,Backordered. Next Release September 2024. Check Wholesalers For Inventory,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-083-05,not available
13170,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Injection, 84 Mg/1 Ml (NDC 76329-3352-1)",Reverified,8/20/24,Limited Availability,On Allocation,,Demand Increase For The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3352-1,limited availability
13171,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Sodium Bicarbonate, Injection, 50 Meq/50 Ml (8.4%, 1 Meq/Ml) Syringes (NDC 0409-6637-14)",Revised,8/26/24,Unavailable,Next Delivery: January 2025; Estimated Recovery: June 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6637-14,not available
13172,Sodium Bicarbonate Injection,"Hospira, Inc., A Pfizer Company","Sodium Bicarbonate, Injection, 5 Meq/10 Ml (4.2%, 0.5 Meq/Ml) Syringes (NDC 0409-5534-14)",Revised,8/26/24,Unavailable,Next Delivery: January 2026; Estimated Recovery: June 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-5534-14,not available
13173,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-23)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-23",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-23,available
13174,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 G/100 Ml (NDC 0264-7802-10)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7802-10,available
13175,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .45 G/100 Ml (NDC 0264-7802-00)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7802-00,available
13176,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-09)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-09",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-09,available
13177,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-03)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-03",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-03,available
13178,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-55)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-55",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-55,available
13179,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-02)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-02",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-02,available
13180,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7983-61)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7983-61",,,Gastroenterology; Other; Pediatric,Current,,,0990-7983-61,available
13181,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Reverified,5/18/24,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-05,available
13182,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Reverified,5/18/24,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-04,available
13183,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Reverified,5/18/24,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-03,available
13184,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Reverified,5/18/24,Available,Product Available For Contracted Customers.,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-02,available
13185,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 Ml Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Revised,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,79672-613-01,available
13186,Sodium Chloride 0.9% Injection,Guerbet Llc,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 Mg/1 Ml (NDC 0019-1188-27)",Reverified,5/31/24,Unavailable,Sodium Chloride Injection In Rfid Presentation Is Not Available And The Plan Is To Discontinue This Presentation From Sales,,Discontinuation Of The Manufacture Of The Drug,Other,Current,,,0019-1188-27,not available
13187,Sodium Chloride 0.9% Injection,Guerbet Llc,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 Mg/1 Ml (NDC 0019-1188-81)",Revised,5/31/24,Available,,,,Other,Current,,,0019-1188-81,available
13188,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-20)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-20",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-20,available
13189,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-37)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-37",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-37,available
13190,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-36)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-36",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-36,available
13191,Sodium Chloride 0.9% Injection,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0990-7984-13)",Reverified,9/4/24,Available,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7984-13",,,Gastroenterology; Other; Pediatric,Current,,,0990-7984-13,available
13192,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, Llc","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 65282-1505-1)",Reverified,6/26/24,Available,,,,Other,Current,,,65282-1505-1,available
13193,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, Llc","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 65282-1510-1)",Reverified,6/26/24,Available,,,,Other,Current,,,65282-1510-1,available
13194,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-623-61)",Revised,9/4/24,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,63323-623-61,available
13195,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-623-53)",Reverified,9/4/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,63323-623-53,available
13196,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-11)",Reverified,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-11,available
13197,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-41)",Reverified,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-41,available
13198,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-01)",Reverified,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-01,available
13199,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-31)",Reverified,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-31,available
13200,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 76297-001-21)",Reverified,5/18/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,76297-001-21,available
13201,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-02)",Reverified,8/26/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0409-7101-02,available
13202,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-67)",Reverified,8/26/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0409-7101-67,available
13203,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (9%, 9mg/Ml) (NDC 0409-7101-66)",Reverified,8/26/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0409-7101-66,available
13204,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-36)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-36,available
13205,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-31)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-31,available
13206,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 0264-1800-32)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-1800-32,available
13207,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-09)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-09,available
13208,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-20)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-20,available
13209,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-10)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-10,available
13210,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride, Injection, .9 G/100 Ml (NDC 0264-7800-00)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7800-00,available
13211,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-07)",Reverified,8/26/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0409-1966-07,available
13212,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-05)",Reverified,8/26/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0409-1966-05,available
13213,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-1966-12)",Revised,8/26/24,Unavailable,Next Delivery And Estimated Recovery: September 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0409-1966-12,not available
13214,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-924-10)",Reverified,9/4/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,63323-924-10,available
13215,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-924-30)",Reverified,9/4/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,63323-924-30,available
13216,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-06)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-06,available
13217,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-04)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-04,available
13218,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-02)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-02,available
13219,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-0553-18)",Reverified,7/17/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0338-0553-18,available
13220,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-9159-30)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-9159-30,limited availability
13221,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 Mg/100 Ml (NDC 0338-9151-30)",Reverified,9/5/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0338-9151-30,available
13222,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 Mg/100 Ml (NDC 0338-0553-11)",Reverified,9/5/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0338-0553-11,available
13223,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-04)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-04,available
13224,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-06)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-06,available
13225,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-9543-02)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-9543-02,available
13226,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-38)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-38,available
13227,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-11)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-11,available
13228,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-10)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-10,available
13229,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-04)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-04,available
13230,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-03)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-03,available
13231,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-02)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-02,available
13232,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-31)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-31,available
13233,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-48)",Revised,6/21/24,Limited Availability,Recovery Late July 2024,,Delay In Shipping Of The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0049-48,limited availability
13234,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-41)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-41,available
13235,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 G/1000 Ml (NDC 0338-0049-18)",Reverified,9/5/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0049-18,available
13236,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 65219-474-10)",Reverified,9/4/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,65219-474-10,available
13237,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 65219-472-20)",Reverified,9/4/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,65219-472-20,available
13238,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 Mg/1 Ml (NDC 64253-202-30)",Revised,9/3/24,Available,,,,Other,Current,,,64253-202-30,available
13239,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-50)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4888-50,available
13240,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-20)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4888-20,available
13241,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-12)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery And Estimated Recovery: December 2024,,Demand Increase For The Drug,Other,Current,,,0409-4888-12,limited availability
13242,Sodium Chloride 0.9% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 Mg/1 Ml) (NDC 0409-4888-10)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4888-10,available
13243,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride, Injection, 9 Mg/1 Ml (NDC 63323-186-00)",Reverified,9/4/24,Unavailable,Next Release Not Available At This Time.,,Demand Increase For The Drug,Other,Current,,,63323-186-00,not available
13244,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Other,Current,,,63323-186-20,available
13245,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Other,Current,,,63323-186-10,available
13246,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 0.9% In Plastic Container, Injection, 9 Mg/1 Ml (NDC 63323-186-02)",Revised,9/4/24,Limited Availability,1 & 4 Month Expiry Available Upon Request; Check Wholesalers For Inventory,,Demand Increase For The Drug,Other,Current,,,63323-186-02,limited availability
13247,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals Usa, Inc.","Sodium Chloride Injection Usp, 0.9%, Injection, 9 Mg/1 Ml (NDC 0641-0497-25)",Reverified,8/28/24,Unavailable,This Presentation Is Temporarily On Backorder.  Recovery Is Tbd At This Time.,,Demand Increase For The Drug,Other,Current,,,0641-0497-25,not available
13248,Sodium Chloride 0.9% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride, Injection, 4 Meq/1 Ml (NDC 63323-095-61)",Revised,9/4/24,Available,Check Wholesalers For Inventory,,Demand Increase For The Drug,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-095-61,available
13249,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-7138-09)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7138-09",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7138-09,limited availability
13250,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-6138-03)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6138-03",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6138-03,limited availability
13251,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-6138-22)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6138-22",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6138-22,limited availability
13252,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-04)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-04,limited availability
13253,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-03)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-03,limited availability
13254,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0338-0048-02)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0048-02,limited availability
13255,Sodium Chloride 0.9% Irrigation,"Icu Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 Mg/100 Ml (NDC 0990-7138-36)",Reverified,9/4/24,Unavailable,"Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7138-36",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7138-36,not available
13256,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-2201-10)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-2201-10,available
13257,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-7388-50)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7388-50,available
13258,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-2201-00)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-2201-00,available
13259,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Irrigation, .9 G/100ml (NDC 0264-7388-60)",Reverified,9/3/24,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-7388-60,available
13260,Sodium Chloride 14.6% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 14.6%, Injection, 2.5 Meq/1 Ml (NDC 63323-090-40)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-090-40,available
13261,Sodium Chloride 14.6% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 14.6%, Injection, 2.5 Meq/1 Ml (NDC 63323-090-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,63323-090-20,available
13262,Sodium Chloride 14.6% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride, Injection, 14.6% 100 Meq/40 Ml (2.5 Meq/Ml) (NDC 0409-6660-75)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-6660-75,available
13263,Sodium Chloride 23.4% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 23.4%, Injection, 4 Meq/1 Ml (NDC 63323-099-63)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-099-63,available
13264,Sodium Chloride 23.4% Injection,"Fresenius Kabi Usa, Llc","Sodium Chloride 23.4%, Injection, 4 Meq/1 Ml (NDC 63323-093-30)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Current,,,63323-093-30,available
13265,Sodium Chloride 23.4% Injection,"Hospira, Inc., A Pfizer Company","Sodium Chloride, Injection, 400 Meq/100 Ml (4 Meq/Ml) (NDC 0409-1141-02)",Revised,8/26/24,Limited Availability,Estimated Recovery: September 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-1141-02,limited availability
13266,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 50 Ml Vial (NDC 63323-886-56)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,63323-886-56,
13267,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 15 Ml Vial (NDC 63323-881-16)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,63323-881-16,
13268,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Fresenius Kabi Usa, Llc","Injection, 5 Ml Vial (NDC 63323-884-06)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,63323-884-06,
13269,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","Hospira, Inc., A Pfizer Company","Injection, 15 Ml Vial (NDC 0409-7391-72)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,0409-7391-72,
13270,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 50 Ml Vial (NDC 0517-7350-25)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,0517-7350-25,
13271,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 5 Ml Vial (NDC 0517-7305-25)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,0517-7305-25,
13272,"Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection","American Regent, Inc.","Injection, 15 Ml Vial (NDC 0517-7315-25)",Revised,8/2/24,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,8/2/24,,0517-7315-25,
13273,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 Mg/2 Ml (NDC 50242-076-01)",Revised,3/22/24,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,50242-076-01,limited availability
13274,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 Mg/2 Ml (NDC 50242-075-01)",Revised,3/22/24,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,50242-075-01,limited availability
13275,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 Mg/2 Ml (NDC 50242-074-01)",Revised,3/22/24,Limited Availability,,,Discontinuation Of The Manufacture Of The Drug,Endocrinology/Metabolism,Current,,,50242-074-01,limited availability
13276,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 Mg Preservative Free (NDC 0013-2658-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2658-02,available
13277,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 Mg Preservative Free (NDC 0013-2657-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2657-02,available
13278,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 Mg Preservative Free (NDC 0013-2656-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2656-02,available
13279,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 Mg Preservative Free (NDC 0013-2655-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2655-02,available
13280,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 Mg/Ml, W/ Preservative (NDC 0013-2626-81)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2626-81,available
13281,Somatropin Injection,Eli Lilly And Co.,"Humatrope, Injection, 24 Mg/Vial (NDC 0002-8149-01)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-8149-01,available
13282,Somatropin Injection,Eli Lilly And Co.,"Humatrope, Injection, 12 Mg/Vial (NDC 0002-8148-01)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-8148-01,available
13283,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 Mg/1.5 Ml (NDC 0781-3004-07)",Reverified,8/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0781-3004-07,available
13284,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 Mg/1.5 Ml (NDC 0781-3001-07)",Reverified,8/5/24,Available,,,,Endocrinology/Metabolism,Current,,,0781-3001-07,available
13285,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 Mg/3 Ml (NDC 0169-7703-21)",Revised,7/31/24,Unavailable,Unavailable Until End Of 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,0169-7703-21,not available
13286,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 Mg/1.5 Ml (NDC 0169-7708-21)",Revised,7/31/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-7708-21,available
13287,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 Mg/1.5 Ml (NDC 0169-7705-21)",Revised,7/31/24,Available,,,,Endocrinology/Metabolism,Current,,,0169-7705-21,available
13288,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 Mg/1.5 Ml (NDC 0169-7704-21)",Revised,7/31/24,Limited Availability,Intermittent Supply Until End Of Q2 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism,Current,,,0169-7704-21,limited availability
13289,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 Mg Preservative Free (NDC 0013-2654-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2654-02,available
13290,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 Mg Preservative Free (NDC 0013-2653-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2653-02,available
13291,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 Mg Preservative Free (NDC 0013-2652-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2652-02,available
13292,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 Mg Preservative Free (NDC 0013-2651-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2651-02,available
13293,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 Mg Preservative Free (NDC 0013-2650-02)",Reverified,8/26/24,Unavailable,Next Delivery: September 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Endocrinology/Metabolism,Current,,,0013-2650-02,not available
13294,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 Mg Preservative Free (NDC 0013-2649-02)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2649-02,available
13295,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 Mg/Ml, W/ Preservative (NDC 0013-2646-81)",Reverified,8/26/24,Available,,,,Endocrinology/Metabolism,Current,,,0013-2646-81,available
13296,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 10 Mg/2 Ml (NDC 50242-074-01)",New,3/22/24,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/24,50242-074-01,discontinued
13297,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 5 Mg/2 Ml (NDC 50242-075-01)",New,3/22/24,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/24,50242-075-01,discontinued
13298,Somatropin Injection,"Genentech, Inc","Nutropin Aq, Injection, 20 Mg/2 Ml (NDC 50242-076-01)",New,3/22/24,,"The Decision To Discontinue Commercial Distribution Of Nutropin Aq In The United States Is A Business Decision, Taken In View Of The Availability Of Generic And Alternative Treatments For Patients, And Is Not Related To Any Quality, Safety Or Efficacy Concerns With The Product.",,,Endocrinology/Metabolism,To Be Discontinued,,3/22/24,50242-076-01,discontinued
13299,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Injection, 1 Ml/1 Ml (NDC 0487-6105-01)",Reverified,7/17/24,"Product Will Be Made Available As It Is Released, Tbd",,,Requirements Related To Complying With Good Manufacturing Practices,Other,Current,,,0487-6105-01,unclear
13300,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Injection, 1000 Ml/1000 Ml (NDC 63323-178-76)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Other,Current,,,63323-178-76,available
13301,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 0409-3977-03)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-3977-03,available
13302,Sterile Water Injection,"Medefil, Inc.","Injection, 10 Ml/10 Ml (NDC 64253-020-30)",Revised,9/3/24,Available,,,,Other,Current,,,64253-020-30,available
13303,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-50)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Other,Current,,,63323-185-50,available
13304,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-20)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Other,Current,,,63323-185-20,available
13305,Sterile Water Injection,"Fresenius Kabi Usa, Llc","Sterile Water For Injection In Plastic Container, Injection, 1 Ml/1 Ml (NDC 63323-185-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Other,Current,,,63323-185-10,available
13306,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-99)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4887-99,available
13307,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-50)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4887-50,available
13308,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-20)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4887-20,available
13309,Sterile Water Injection,"Hospira, Inc., A Pfizer Company","Injection, 1 Ml/1 Ml (NDC 0409-4887-10)",Reverified,8/26/24,Available,,,,Other,Current,,,0409-4887-10,available
13310,Sterile Water Injection,"Hikma Pharmaceuticals Usa, Inc.","Sterile Water For Injection, Injection, 1 Ml/1 Ml (NDC 0641-6147-10)",Reverified,8/28/24,Available,,,,Other,Current,,,0641-6147-10,available
13311,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0264-2101-00)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-2101-00,available
13312,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0264-2101-10)",Reverified,9/3/24,Available,On Allocation,,,Gastroenterology; Other; Pediatric,Current,,,0264-2101-10,available
13313,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-04)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-04,limited availability
13314,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-03)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-03,limited availability
13315,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 Ml/100 Ml (NDC 0338-0004-02)",Reverified,6/21/24,Limited Availability,On Allocation; Recovery Q3 2024,,Demand Increase For The Drug,Gastroenterology; Other; Pediatric,Current,,,0338-0004-02,limited availability
13316,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-7139-36)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7139-36",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7139-36,limited availability
13317,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-7139-09)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-7139-09",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7139-09,limited availability
13318,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-6139-22)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6139-22",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6139-22,limited availability
13319,Sterile Water Irrigant,"Icu Medical, Inc.","Sterile Water In Plastic Container, Irrigant, 1 Ml/1 Ml (NDC 0990-6139-03)",Reverified,9/4/24,Limited Availability,"Allocated To Contracted Customers Only. Icu Medical Acquired These Products From Hospira, A Pfizer Company. For Questions Or Inquiries Regarding These Hospira Labeled Products, Please Contact Icu Medical. Legacy Hospira Ndc 0409-6139-03",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6139-03,limited availability
13320,"Streptozocin Powder, For Solution","Esteve Pharmaceuticals, S.A.","Zanosar, Powder, For Solution, 1 G/10 Ml (NDC 68118-100-01)",Reverified,1/15/24,Available,,,,Oncology,Current,,,68118-100-01,available
13321,"Streptozocin Powder, For Solution","Teva Pharmaceuticals Usa, Inc.","Zanosar, Powder, For Solution, 100 Mg/1 Ml (NDC 0703-4636-01)",Reverified,9/4/24,Unavailable,Estimated Recovery Tbd,,Other,Oncology,Current,,,0703-4636-01,not available
13322,Sucralfate Tablet,Amneal Pharmaceuticals,"Tablet, 1 G (NDC 69238-1656-1)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,69238-1656-1,
13323,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 G (NDC 59762-040-15)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,59762-040-15,
13324,Sucralfate Tablet,"Allergan, Inc.","Tablet, 1 G (NDC 59762-040-11)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,59762-040-11,
13325,Sucralfate Tablet,"Allergan, Inc.","Carafate, Tablet, 1 G (NDC 58914-171-10)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,58914-171-10,
13326,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-98)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,0093-2210-98,
13327,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-05)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,0093-2210-05,
13328,Sucralfate Tablet,"Teva Pharmaceuticals Usa, Inc.","Sucralfate Tablets, Usp, Tablet, 1 G (NDC 0093-2210-01)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,0093-2210-01,
13329,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 G (NDC 29033-003-05)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,29033-003-05,
13330,Sucralfate Tablet,"Nostrum Laboratories, Inc.","Tablet, 1 G (NDC 29033-003-01)",Revised,7/15/24,,,Available,,Gastroenterology,Resolved,7/15/24,,29033-003-01,
13331,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-01)",Reverified,8/28/24,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-01,not available
13332,Sufentanil Citrate Injection,"Hospira, Inc., A Pfizer Company","Injection, 50 Ug/1 Ml (NDC 0409-3382-21)",Revised,8/26/24,Limited Availability,Limited Supply Available. Next Delivery: November 2024; Estimated Recovery: December 2024,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,0409-3382-21,limited availability
13333,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-05)",Reverified,8/28/24,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-05,not available
13334,Sufentanil Citrate Injection,"Hikma Pharmaceuticals Usa, Inc.","Sufentanil Citrate Injection, Usp, Injection, 50 Mcg/1 Ml (NDC 17478-050-02)",Reverified,8/28/24,Unavailable,Not Currently Manufactured,,Demand Increase For The Drug,Analgesia/Addiction; Pediatric,Current,,,17478-050-02,not available
13335,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-5)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-5000-5,
13336,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-5)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-0104-5,
13337,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-60)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0102-60,
13338,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-30)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0101-30,
13339,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-31)",Revised,5/21/24,,,Available,,Gastroenterology,Resolved,5/21/24,,62135-960-31,
13340,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-10)",Revised,5/21/24,,,Available,,Gastroenterology,Resolved,5/21/24,,62135-960-10,
13341,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-05)",Revised,5/21/24,,,Available,,Gastroenterology,Resolved,5/21/24,,62135-960-05,
13342,Sulfasalazine Tablet,Chartwell Molecular Holdings Llc,"Sulfasalazine, Tablet, 500 Mg (NDC 62135-960-01)",Revised,5/21/24,,,Available,,Gastroenterology,Resolved,5/21/24,,62135-960-01,
13343,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-05)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0093-3234-05,
13344,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-10)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0093-3234-10,
13345,Sulfasalazine Tablet,"Teva Pharmaceuticals Usa, Inc.","Sulfasalazine Tablets, Usp, Tablet, 500 Mg (NDC 0093-3234-01)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0093-3234-01,
13346,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-6)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-5000-6,
13347,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-5000-1)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-5000-1,
13348,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-6)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-0104-6,
13349,Sulfasalazine Tablet,Pfizer Inc.,"Tablet, 500 Mg (NDC 59762-0104-1)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,59762-0104-1,
13350,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-20)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0102-20,
13351,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0102-50)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0102-50,
13352,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-20)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0101-20,
13353,Sulfasalazine Tablet,Pfizer Inc.,"Azulfidine, Tablet, 500 Mg (NDC 0013-0101-10)",Revised,5/21/24,,,,,Gastroenterology,Resolved,5/21/24,,0013-0101-10,
13354,Technetium Tc-99m Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","Cis-Pyro, Injection, 12 Mg/10 Ml (NDC 45567-0060-1)",Revised,8/26/24,Unavailable,Estimated Return Of Supply: October'2024,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,45567-0060-1,not available
13355,Technetium Tc-99m Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","Cis-Pyro, Injection, 12 Mg/10 Ml (NDC 45567-0060-2)",Revised,8/26/24,Unavailable,Estimated Return Of Supply: October'2024,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,45567-0060-2,not available
13356,Technetium Tc-99m Pyrophosphate Kit Injection,Curium Us Llc,"Technescan Pyp, Injection, 11.9 Mg/10 Ml; 3.2 Mg/10 Ml (NDC 69945-094-20)",Reverified,9/2/24,Unavailable,,,Shortage Of An Active Ingredient,Medical Imaging,Current,,,69945-094-20,not available
13357,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 12 Ci/12 Ci (NDC 71612-120-02)",New,10/17/23,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution. The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-120-02,discontinued
13358,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 7.5 Ci/7.5 Ci (NDC 71612-075-02)",New,10/17/23,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution; The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-075-02,discontinued
13359,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 15 Ci/15 Ci (NDC 71612-150-02)",New,10/17/23,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution; The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-150-02,discontinued
13360,Technetium Tc-99m Sodium Pertechnetate Generator,"Northstar Medical Radioisotopes, Llc","Radiogenix® System, Generator, 19 Ci/19 Ci (NDC 71612-190-02)",New,10/17/23,,"The Radiogenix System Is A Technetium Tc 99m Generator That Produces Sodium Pertechnetate Tc 99m Injection, Usp From A Non-Uranium Potassium Molybdate Mo-99 Source Solution, Which Is Shielded Within A Source Container That Completely Encases A Vial Containing 22-30 Ml Of Solution. The Company Has Made A Business Decision To Discontinue Production And Distribution. The Production Date For The Last Batch Of Mo-99 Source Vessels Is October 30, 2023 With An Expiration Date Of November 20, 2023.",,Discontinuation Of The Manufacture Of The Drug,Medical Imaging,To Be Discontinued,,10/17/23,71612-190-02,discontinued
13361,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 15 Mg (NDC 65162-556-10)",New,4/30/24,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/24,65162-556-10,discontinued
13362,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 15 Mg (NDC 65162-556-50)",New,4/30/24,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/24,65162-556-50,discontinued
13363,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-557-10)",New,4/30/24,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/24,65162-557-10,discontinued
13364,Temazepam Capsule,Amneal Pharmaceuticals,"Capsule, 30 Mg (NDC 65162-557-50)",New,4/30/24,,Business-Related Decision To Discontinue The Product.,,,Psychiatry,To Be Discontinued,,4/30/24,65162-557-50,discontinued
13365,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-16)",New,12/7/23,,,,,Urology,To Be Discontinued,,12/7/23,63481-183-16,discontinued
13366,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-17)",New,12/7/23,,,,,Urology,To Be Discontinued,,12/7/23,63481-183-17,discontinued
13367,"Testosterone Gel, Metered","Endo Pharmaceuticals, Inc.","Fortesta, Gel, Metered, 10 Mg/.5 G (NDC 63481-183-18)",New,12/7/23,,,,,Urology,To Be Discontinued,,12/7/23,63481-183-18,discontinued
13368,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 5 Mg/.5 Ml (NDC 0002-1495-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1495-80,available
13369,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 15 Mg/.5 Ml (NDC 0002-1457-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1457-80,available
13370,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 12.5 Mg/.5 Ml (NDC 0002-1460-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1460-80,available
13371,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 7.5 Mg/.5 Ml (NDC 0002-1484-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1484-80,available
13372,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 2.5 Mg/.5 Ml (NDC 0002-1506-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1506-80,available
13373,Tirzepatide Injection,Eli Lilly And Co.,"Mounjaro, Injection, 10 Mg/.5 Ml (NDC 0002-1471-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-1471-80,available
13374,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 7.5 Mg/.5 Ml (NDC 0002-2484-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2484-80,available
13375,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 2.5 Mg/.5 Ml (NDC 0002-2506-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2506-80,available
13376,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 10 Mg/.5 Ml (NDC 0002-2471-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2471-80,available
13377,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 15 Mg/.5 Ml (NDC 0002-2457-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2457-80,available
13378,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 12.5 Mg/.5 Ml (NDC 0002-2460-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2460-80,available
13379,Tirzepatide Injection,Eli Lilly And Co.,"Zepbound, Injection, 5 Mg/.5 Ml (NDC 0002-2495-80)",Reverified,9/3/24,Available,,,,Endocrinology/Metabolism,Current,,,0002-2495-80,available
13380,Tobramycin Sulfate Injection,"Fresenius Kabi Usa, Llc","Tobramycin Sulfate, Injection, 1200 Mg/30 Ml (NDC 63323-303-55)",Revised,4/12/21,,,,,Anti-Infective; Pediatric,Resolved,,,63323-303-55,
13381,Tobramycin Sulfate Injection,"Fresenius Kabi Usa, Llc","Tobramycin Sulfate, Injection, 1200 Mg/30 Ml (NDC 63323-303-51)",Revised,4/12/21,,,,,Anti-Infective; Pediatric,Resolved,,,63323-303-51,
13382,Triamcinolone Acetonide Injection,"Harrow Eye, Llc","Triesence, Injection, 40 Mg/1 Ml (NDC 0065-0543-01)",Revised,8/14/24,Unavailable,Supply Expected To Be Available October 2024. There Are No Therapeutic Equivalents.,,Requirements Related To Complying With Good Manufacturing Practices,Ophthalmology,Current,,,0065-0543-01,not available
13383,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 Mg/2 Ml (NDC 59137-570-01)",Reverified,12/19/23,Unavailable,,,Delay In Shipping Of The Drug,Rheumatology,Current,,,59137-570-01,not available
13384,Triazolam Tablet,Pfizer Inc.,"Halcion, Tablet, .25 Mg (NDC 0009-0017-55)",New,6/27/24,,,,,Psychiatry,To Be Discontinued,,6/27/24,0009-0017-55,discontinued
13385,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .125 Mg (NDC 0054-4858-25)",New,1/30/24,,,,,Psychiatry,To Be Discontinued,,1/30/24,0054-4858-25,discontinued
13386,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .25 Mg (NDC 0054-4859-25)",New,1/30/24,,,,,Psychiatry,To Be Discontinued,,1/30/24,0054-4859-25,discontinued
13387,Triazolam Tablet,"Hikma Pharmaceuticals Usa, Inc.","Tablet, .25 Mg (NDC 0054-4859-29)",New,1/30/24,,,,,Psychiatry,To Be Discontinued,,1/30/24,0054-4859-29,discontinued
13388,Valproate Sodium Injection,Sagent Pharmaceuticals,"Injection, 100 Mg/Ml, 5 Ml (NDC 70860-784-41)",Revised,1/9/24,,No Longer Ordering Apd Ndc,,Discontinuation Of The Manufacture Of The Drug,Neurology,To Be Discontinued,1/9/24,1/9/24,70860-784-41,discontinued
13389,Valproate Sodium Injection,"Fresenius Kabi Usa, Llc","Injection, 100 Mg/1 Ml (NDC 63323-494-05)",Revised,9/4/24,Unavailable,Backordered. Next Release Not Available At This Time. Check Wholesaler For Inventory.,,Demand Increase For The Drug,Neurology,Current,,,63323-494-05,not available
13390,Valproate Sodium Injection,"Hikma Pharmaceuticals Usa, Inc.","Valproate Sodium Injection, Usp, Injection, 500 Mg/5 Ml (NDC 0143-9785-10)",Reverified,8/28/24,Available,Additional Lots Will Be Scheduled For Manufacturing. Product Will Be Made Available As It Is Released.,,,Neurology,Current,,,0143-9785-10,available
13391,Vecuronium Bromide Injection,Eugia Us Llc,"Injection, 20 Mg (NDC 55150-236-20)",Reverified,8/5/24,Available,Check Wholesalers For Inventory,,,Anesthesia,Current,,,55150-236-20,available
13392,Vecuronium Bromide Injection,Eugia Us Llc,"Injection, 10 Mg (NDC 55150-235-10)",Reverified,8/5/24,Unavailable,On Backorder. Recovery: Tbd. Check Wholesalers For Inventory,,Demand Increase For The Drug,Anesthesia,Current,,,55150-235-10,not available
13393,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 47335-932-44)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,47335-932-44,available
13394,Vecuronium Bromide Injection,"Sun Pharmaceutical Industries, Inc.","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 47335-931-44)",Revised,8/26/24,Available,,,,Anesthesia,Current,,,47335-931-44,available
13395,Vecuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-782-20)",Revised,3/22/24,,,,,Anesthesia,To Be Discontinued,3/22/24,3/22/24,63323-782-20,discontinued
13396,Vecuronium Bromide Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-781-10)",Revised,3/22/24,,,,,Anesthesia,To Be Discontinued,3/22/24,3/22/24,63323-781-10,discontinued
13397,Vecuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Injection, 1 Mg/1 Ml (NDC 67457-475-20)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-475-20,available
13398,Vecuronium Bromide Injection,"Mylan Institutional, A Viatris Company","Injection, 1 Mg/1 Ml (NDC 67457-438-10)",Reverified,9/5/24,Available,,,,Anesthesia,Current,,,67457-438-10,available
13399,Vecuronium Bromide Injection,"Hospira, Inc., A Pfizer Company","Vecuronium Bromide, Injection, 1 Mg/1 Ml (NDC 0409-1632-01)",Revised,3/22/24,,,,,Anesthesia,To Be Discontinued,3/22/24,3/22/24,0409-1632-01,discontinued
13400,Verteporfin Injection,Bausch & Lomb Incorporated,"Visudyne, Injection, 15 Mg (NDC 0187-5600-15)",Revised,2/9/23,,,Available,,Ophthalmology,Resolved,2/9/23,,0187-5600-15,
13401,Vinblastine Sulfate Injection,"Fresenius Kabi Usa, Llc","Injection, 1 Mg/1 Ml (NDC 63323-278-10)",Reverified,9/4/24,Available,Check Wholesalers For Inventory,,,Oncology,Current,,,63323-278-10,available
13402,Vitamin A Palmitate Injection,"Casper Pharma, Llc","Aquasol A, Injection, 15 Mg/1 Ml (NDC 70199-026-11)",New,6/10/24,Unavailable,Next Delivery And Estimated Recovery: August 2024,,Delay In Shipping Of The Drug,Endocrinology/Metabolism; Ophthalmology,Current,,,70199-026-11,not available
13403,"Zolpidem Tartrate Tablet, Extended Release",Sandoz Inc.,"Tablet, Extended Release, 6.25 Mg (NDC 0781-5315-01)",New,1/26/24,,,,,Psychiatry,To Be Discontinued,,1/26/24,0781-5315-01,discontinued
13404,"Zolpidem Tartrate Tablet, Extended Release",Sandoz Inc.,"Tablet, Extended Release, 12.5 Mg (NDC 0781-5316-01)",New,1/26/24,,,,,Psychiatry,To Be Discontinued,,1/26/24,0781-5316-01,discontinued
13405,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 15gram Tube, Ointment, 5% 15gram (NDC 0378-8700-06)",New,9/16/24,,,,,Dermatology,To Be Discontinued,,9/16/24,0378-8700-06,discontinued
13406,Acyclovir Ointment,"Mylan Institutional, a Viatris Company","Acyclovir Ointment 5% 5g 2pk, Ointment, 5% 5g (NDC 51079-550-68)",New,9/16/24,,,,,Dermatology,To Be Discontinued,,9/16/24,51079-550-68,discontinued
13407,Acyclovir Ointment,"Actavis Pharma, Inc.","Zovirax, Ointment, 50 mg/1 g (NDC 0591-1159-30)",New,3/3/25,,,,,Dermatology,To Be Discontinued,,3/3/25,0591-1159-30,discontinued
13408,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25,61314-454-20,discontinued
13409,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25,61314-476-64,discontinued
13410,Adalimumab-adaz Injection,Sandoz Inc.,"Hyrimoz, Injection, 10 mg/.1 mL (NDC 61314-509-64)",New,4/14/25,,,,,Rheumatology,To Be Discontinued,,4/14/25,61314-509-64,discontinued
13411,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-16)",New,3/3/25,,,,,Rheumatology,To Be Discontinued,,3/3/25,0597-0375-16,discontinued
13412,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0375-23)",New,3/3/25,,,,,Rheumatology,To Be Discontinued,,3/3/25,0597-0375-23,discontinued
13413,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-40)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0495-40,discontinued
13414,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0495-60)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0495-60,discontinued
13415,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-40)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0575-40,discontinued
13416,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0575-60)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0575-60,discontinued
13417,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-44)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0545-44,discontinued
13418,Adalimumab-adbm Injection,"Boehringer Ingelheim Pharmaceuticals, Inc.","Cyltezo, Injection, Kit (NDC 0597-0545-66)",New,1/6/25,,,,,Rheumatology,To Be Discontinued,,1/6/25,0597-0545-66,discontinued
13419,Adefovir Dipivoxil Tablet,Apotex Corp.,"Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/29/25,60505-3947-3,discontinued
13420,Albendazole Tablet,Strides Pharma Inc.,"Tablet, 200 mg (NDC 31722-935-02)",New,9/16/24,,Current Product distributor: Camber Pharmaceuticals. Product temporarily discontinued due to business related reasons.,,,Anti-Infective,To Be Discontinued,,9/16/24,31722-935-02,discontinued
13421,Albuterol Sulfate Solution,Nephron Pharmaceuticals Corporation,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Revised,7/2/25,Available,"Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.",,Other,Pulmonary/Allergy; Pediatric,Current,,,0487-9901-30,available
13422,Albuterol Sulfate Solution,"Rising Pharma Holdings, Inc.","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)",Reverified,8/15/25,Available,,,,Pediatric; Pulmonary/Allergy,Current,,,64980-642-03,available
13423,Albuterol Sulfate Solution,"Ritedose Pharmaceuticals, LLC","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)",Reverified,8/15/25,Available,,,,Pediatric; Pulmonary/Allergy,Current,,,76204-027-01,available
13424,Albuterol Sulfate Syrup,"Actavis Pharma, Inc.","Syrup, 2 mg/5 mL (NDC 0472-0825-16)",New,11/4/24,,,,,Pulmonary/Allergy,To Be Discontinued,,11/4/24,0472-0825-16,discontinued
13425,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-01)",New,2/5/25,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/25,0591-4920-01,discontinued
13426,Amantadine Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-05)",New,2/5/25,,A business decision was made to discontinue manufacture of the drug.,,,Antiviral; Neurology,To Be Discontinued,,2/5/25,0591-4920-05,discontinued
13427,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-01)",New,2/12/25,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/25,42543-493-01,discontinued
13428,Amantadine Hydrochloride Capsule,Strides Pharma Inc.,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-05)",New,2/12/25,,Discontinuation of manufacture of drug based on business decision,,,Antiviral; Neurology,To Be Discontinued,,2/12/25,42543-493-05,discontinued
13429,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25,0832-1015-00,discontinued
13430,Amantadine Hydrochloride Capsule,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25,0832-1015-50,discontinued
13431,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25,0832-0111-00,discontinued
13432,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25,0832-0111-03,discontinued
13433,Amantadine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Antiviral; Neurology,To Be Discontinued,,7/23/25,0832-0111-50,discontinued
13434,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 5 mg (NDC 60505-4552-3)",New,1/14/25,,,,,Cardiovascular,To Be Discontinued,,1/14/25,60505-4552-3,discontinued
13435,Ambrisentan Tablet,Apotex Corp.,"Ambrisentan, Tablet, 10 mg (NDC 60505-4553-3)",New,1/14/25,,,,,Cardiovascular,To Be Discontinued,,1/14/25,60505-4553-3,discontinued
13436,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-1130-03,available
13437,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-1130-04,available
13438,Amino Acid Injection,Baxter Healthcare,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-1130-06,available
13439,Amino Acid Injection,Baxter Healthcare,"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-0499-06,available
13440,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)",Revised,9/3/25,Limited Availability,Capacity constraint - Recovery in November 2025,,Other,Gastroenterology,Current,,,0338-0644-03,limited availability
13441,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)",Reverified,9/3/25,Unavailable,Capacity constraint - Recovery in October 2025,,Other,Gastroenterology,Current,,,0338-0644-04,not available
13442,Amino Acid Injection,Baxter Healthcare,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-0644-06,available
13443,Amino Acid Injection,B. Braun Medical Inc.,"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,0264-1933-10,available
13444,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,0264-4500-05,available
13445,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-0502-03,available
13446,Amino Acid Injection,B. Braun Medical Inc.,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Reverified,8/21/25,Available,On allocation. Manufacturing delay.,,Other,Gastroenterology,Current,,,0264-4500-00,available
13447,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,,0990-7171-17,available
13448,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Gastroenterology,Current,,,0990-7172-17,available
13449,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,,0990-4178-03,not available
13450,Amino Acid Injection,Otsuka ICU Medical LLC,"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Shortage of an active ingredient,Gastroenterology,Current,,,0990-4179-05,not available
13451,Amino Acid Injection,Baxter Healthcare,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Reverified,9/3/25,Available,,,,Gastroenterology,Current,,,0338-0502-06,available
13452,Aminocaproic Acid Tablet,ANI Pharmaceuticals,"Tablet, 500 mg (NDC 62559-225-30)",New,11/7/24,,"ANI anticipates ceasing distribution on November 30, 2024.",,,Cardiovascular; Hematology; Other,To Be Discontinued,,11/7/24,62559-225-30,discontinued
13453,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 2.5 mg; 10 mg (NDC 65862-582-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-582-01,discontinued
13454,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-583-01,discontinued
13455,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-583-05,discontinued
13456,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-584-01,discontinued
13457,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-584-05,discontinued
13458,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-585-01,discontinued
13459,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-585-05,discontinued
13460,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-586-01,discontinued
13461,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-05)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-586-05,discontinued
13462,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Aurobindo Pharma USA,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 40 mg (NDC 65862-587-01)",New,3/4/25,,,,,Cardiovascular,To Be Discontinued,,3/4/25,65862-587-01,discontinued
13463,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25,0078-0364-05,discontinued
13464,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25,0078-0379-05,discontinued
13465,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25,0078-0405-05,discontinued
13466,Amlodipine Besylate; Benazepril Hydrochloride Capsule,Novartis Pharmaceuticals Corporation,"Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)",New,6/24/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/24/25,0078-0406-05,discontinued
13467,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-382-05,discontinued
13468,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-382-30,discontinued
13469,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-382-90,discontinued
13470,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-383-05,discontinued
13471,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-383-30,discontinued
13472,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-383-90,discontinued
13473,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-385-05,discontinued
13474,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-385-30,discontinued
13475,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-385-90,discontinued
13476,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-386-05,discontinued
13477,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-386-30,discontinued
13478,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-386-90,discontinued
13479,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-397-05,discontinued
13480,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-397-30,discontinued
13481,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,Torrent Pharma Inc.,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)",New,6/13/25,,A business decision was made to discontinue manufacture of the product.,,,Cardiovascular,To Be Discontinued,,6/13/25,13668-397-90,discontinued
13482,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4160-73,
13483,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4160-76,
13484,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4160-78,
13485,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)",Revised,5/2/25,,,Available,,Anti-Infective,Resolved,5/2/25,,0093-4161-73,
13486,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4161-76,
13487,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4161-78,
13488,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-706-55,
13489,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-706-80,
13490,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-070-50,
13491,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-070-75,
13492,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-707-55,
13493,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-707-80,
13494,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-071-50,
13495,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-071-75,
13496,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9888-15,
13497,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9888-80,
13498,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9886-50,
13499,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9886-75,
13500,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9889-15,
13501,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9889-80,
13502,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9887-50,
13503,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9887-75,
13504,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-706-01,
13505,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-070-01,
13506,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-707-01,
13507,"Amoxicillin Powder, For Suspension",Aurobindo Pharma USA,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,65862-071-01,
13508,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9888-01,
13509,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9886-01,
13510,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9889-01,
13511,"Amoxicillin Powder, For Suspension","Hikma Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0143-9887-01,
13512,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6039-46,
13513,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6039-55,
13514,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6039-58,
13515,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6156-46,
13516,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6156-52,
13517,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6156-57,
13518,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6157-46,
13519,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6157-52,
13520,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6157-57,
13521,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6041-46,
13522,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6041-55,
13523,"Amoxicillin Powder, For Suspension",Sandoz Inc.,"Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0781-6041-58,
13524,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4155-73,
13525,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4155-80,
13526,"Amoxicillin Powder, For Suspension","Teva Pharmaceuticals USA, Inc.","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)",Revised,5/2/25,,,Available,,Anti-Infective; Pediatric,Resolved,5/2/25,,0093-4155-79,
13527,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8884-01,available
13528,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8885-01,available
13529,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8891-01,available
13530,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8892-01,available
13531,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8893-01,available
13532,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",SpecGx LLC,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0406-8894-01,available
13533,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,42806-344-01,limited availability
13534,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,42806-341-01,limited availability
13535,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,42806-343-01,limited availability
13536,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,42806-345-01,limited availability
13537,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Epic Pharma, LLC","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Reverified,9/2/25,Limited Availability,Limited availability until end of September 2025,,Shortage of an active ingredient,Psychiatry,Current,,,42806-339-01,limited availability
13538,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-174-01,available
13539,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-176-01,available
13540,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-178-01,available
13541,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Reverified,9/2/25,Unavailable,Supporting contracted business only; Resupply Q3 2025,,Other,Psychiatry,Current,,,47781-179-01,not available
13542,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Alvogen,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-180-01,available
13543,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-190-01,available
13544,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-192-01,available
13545,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-191-01,available
13546,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-193-01,available
13547,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-194-01,available
13548,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-195-01,available
13549,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Sunrise Pharmaceutical, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,11534-196-01,available
13550,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-0760-37,available
13551,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-0761-37,available
13552,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-1502-37,available
13553,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-0763-37,available
13554,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-0764-37,available
13555,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-1505-37,available
13556,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Lannett Company, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,0527-0766-37,available
13557,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Reverified,8/19/25,Available,,,,Psychiatry,Current,,,72516-016-01,available
13558,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,72516-014-01,limited availability
13559,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Revised,8/19/25,Unavailable,Estimated availability October 2025,,Shortage of an active ingredient,Psychiatry,Current,,,72516-013-01,not available
13560,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,72516-012-01,limited availability
13561,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Oryza Pharmaceuticals Inc.,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Revised,8/19/25,Limited Availability,Allocating to customers,,Other,Psychiatry,Current,,,72516-011-01,limited availability
13562,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-068-01,not available
13563,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-069-01,not available
13564,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-070-01,not available
13565,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-072-01,not available
13566,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-073-01,not available
13567,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Aurobindo Pharma USA,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Reverified,6/25/25,Unavailable,Estimated availability December 2025,,Shortage of an active ingredient,Psychiatry,Current,,,13107-074-01,not available
13568,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-111-01,available
13569,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-112-01,available
13570,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-113-01,available
13571,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-114-01,available
13572,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-115-01,available
13573,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-116-01,available
13574,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Granules Pharmaceuticals Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Reverified,8/12/25,Available,,,,Psychiatry,Current,,,70010-117-01,available
13575,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-500-01,limited availability
13576,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-501-01,limited availability
13577,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-502-01,limited availability
13578,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-503-01,limited availability
13579,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-504-01,limited availability
13580,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-505-01,limited availability
13581,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Elite Laboratories, Inc.","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Reverified,9/2/25,Limited Availability,3 months,,Shortage of an active ingredient,Psychiatry,Current,,,64850-506-01,limited availability
13582,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,0185-2099-01,available
13583,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,0185-0853-01,available
13584,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,0185-0842-01,available
13585,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",Sandoz Inc.,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,0185-2098-01,available
13586,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-110-01,available
13587,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-112-01,available
13588,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-115-01,available
13589,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-120-01,available
13590,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-130-01,available
13591,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-105-01,available
13592,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,57844-117-01,available
13593,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Revised,8/19/25,Available,Estimated recovery: December 2025,,Other,Psychiatry,Current,,,0555-0776-02,available
13594,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0555-0777-02,available
13595,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0555-0775-02,available
13596,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Revised,8/19/25,Limited Availability,Estimated recovery: October 2025,,Other,Psychiatry,Current,,,0555-0972-02,limited availability
13597,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Revised,8/19/25,Limited Availability,Estimated recovery: August 2025,,Other,Psychiatry,Current,,,0555-0973-02,limited availability
13598,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Revised,8/19/25,Limited Availability,Estimated recovery: November 2025,,Other,Psychiatry,Current,,,0555-0974-02,limited availability
13599,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","Teva Pharmaceuticals USA, Inc.","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0555-0971-02,available
13600,Amphotericin B Injection,"Leadiant Biosciences, Inc.","Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)",New,8/8/25,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,8/8/25,57665-101-41,discontinued
13601,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 200 mg (NDC 0003-3631-12)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25,0003-3631-12,discontinued
13602,Atazanavir Sulfate Capsule,Bristol Myers Squibb Co.,"Reyataz, Capsule, 300 mg (NDC 0003-3622-12)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25,0003-3622-12,discontinued
13603,Atazanavir Sulfate Oral Powder,Bristol Myers Squibb Co.,"Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)",New,6/4/25,,Permanent discontinuation,,,Antiviral,To Be Discontinued,,6/4/25,0003-3638-10,discontinued
13604,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 10 mg (NDC 0002-3227-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3227-30,discontinued
13605,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 25 mg (NDC 0002-3228-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3228-30,discontinued
13606,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 40 mg (NDC 0002-3229-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3229-30,discontinued
13607,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 18 mg (NDC 0002-3238-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3238-30,discontinued
13608,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 60 mg (NDC 0002-3239-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3239-30,discontinued
13609,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 80 mg (NDC 0002-3250-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3250-30,discontinued
13610,Atomoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Strattera, Capsule, 100 mg (NDC 0002-3251-30)",New,10/22/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/22/24,0002-3251-30,discontinued
13611,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",New,2/19/25,,,,,Anesthesia; Neurology; Pediatric,To Be Discontinued,,2/19/25,0409-4910-34,discontinued
13612,Atropine Sulfate Injection,"Fresenius Kabi USA, LLC","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology; Pediatric,Current,,,63323-580-20,available
13613,Atropine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)",Reverified,8/19/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,76329-3340-1,available
13614,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0409-1630-10,available
13615,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0409-9630-05,available
13616,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 0.5 mg/5 mL (0.1 mg/mL) Syringes (NDC 0409-4910-34)",Revised,8/19/25,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia; Neurology; Pediatric,Current,,,0409-4910-34,not available
13617,Atropine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-4911-34)",Revised,8/15/25,Unavailable.,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Neurology; Pediatric,Current,,,0409-4911-34,not available
13618,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)",Reverified,8/19/25,Available,old NDC 0517-1010-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1001-25,available
13619,Atropine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)",Reverified,7/23/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,0641-6251-10,available
13620,Atropine Sulfate Injection,"American Regent, Inc.","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)",Reverified,8/19/25,Available,old NDC 0517-0401-25,,,Anesthesia; Neurology; Pediatric,Current,,,0517-1004-25,available
13621,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,16729-525-08,
13622,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)",Reverified,8/19/25,Unavailable,Resupply TBD,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,16729-512-43,not available
13623,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,16729-526-08,
13624,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-483-03,not available
13625,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)",Revised,8/19/25,"Unavailable, 90 days",Manufacturing in process,,Requirements related to complying with good manufacturing practices,Anesthesia; Neurology; Pediatric,Current,,,16729-484-45,
13626,Atropine Sulfate Injection,Accord Healthcare Inc.,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia; Neurology; Pediatric,Current,,,16729-484-90,not available
13627,Atropine Sulfate Injection,"Medefil, Inc.","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology; Pediatric,Current,,,64253-400-91,available
13628,Azacitidine Injection,Eugia US LLC,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Oncology,Current,,,55150-393-01,available
13629,Azacitidine Injection,"Meitheal Pharmaceuticals, Inc.","Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)",Reverified,8/19/25,Available,,,,Oncology,Current,,,71288-115-30,available
13630,Azacitidine Injection,Bristol Myers Squibb Co.,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Reverified,9/3/25,Available,,,,Oncology,Current,,,59572-102-01,available
13631,Azacitidine Injection,"Fresenius Kabi USA, LLC","Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Oncology,Current,,,63323-771-39,available
13632,Azacitidine Injection,"Hikma Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)",Reverified,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Oncology,Current,,,0143-9606-01,available
13633,Azacitidine Injection,"Dr. Reddy's Laboratories, Inc.","Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Reverified,8/15/25,Available,Available to existing customers,,,Oncology,Current,,,43598-305-62,available
13634,Azacitidine Injection,Armas Pharmaceuticals Inc,"Azacitidine, Injection, 100 mg (NDC 72485-201-01)",Reverified,8/19/25,Available,,,,Oncology,Current,,,72485-201-01,available
13635,Azacitidine Injection,Accord Healthcare Inc.,"Azacitidine, Injection, 100 mg (NDC 16729-306-10)",Revised,8/19/25,Limited Availability,TBD,,Regulatory delay,Oncology,Current,,,16729-306-10,limited availability
13636,Azacitidine Injection,"Teva Pharmaceuticals USA, Inc.","Azacitidine, Injection, 100 mg (NDC 68001-313-56)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,,68001-313-56,not available
13637,Azelaic Acid Gel,Leo Pharma Inc.,"Finacea, Gel, .15 g/1 g (NDC 50222-505-50)",New,1/13/25,,,,,Dermatology,To Be Discontinued,,1/13/25,50222-505-50,discontinued
13638,Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray,"Mylan Pharmaceuticals Inc., a Viatris Company","Dymista, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)",New,9/4/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,9/4/25,0378-3458-23,discontinued
13639,Azithromycin for Suspension,Pfizer Inc.,"Zithromax, for Suspension, 100 mg/5 mL (NDC 59762-3110-1)",New,10/15/24,,,,,Anti-Infective,To Be Discontinued,,10/15/24,59762-3110-1,discontinued
13640,Bacitracin Ophthalmic Ointment,Padagis US LLC,"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)",Revised,7/2/25,Unavailable,Shortage is estimated for 18 months,,Discontinuation of the manufacture of the drug,Anti-Infective; Ophthalmology,Current,,,0574-4022-35,not available
13641,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-10)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1054-10,discontinued
13642,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-11)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1054-11,discontinued
13643,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-15)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1054-15,discontinued
13644,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 0832-1054-90)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1054-90,discontinued
13645,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-10)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1055-10,discontinued
13646,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-11)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1055-11,discontinued
13647,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-15)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1055-15,discontinued
13648,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 20 mg (NDC 0832-1055-90)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,0832-1055-90,discontinued
13649,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-0)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,50090-6868-0,discontinued
13650,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-1)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,50090-6868-1,discontinued
13651,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6868-3)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,50090-6868-3,discontinued
13652,Baclofen Tablet,"Upsher-Smith Laboratories, LLC","Baclofen, Tablet, 10 mg (NDC 50090-6869-0)",New,4/23/25,,,,,Neurology,To Be Discontinued,,4/23/25,50090-6869-0,discontinued
13653,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 10 mg (NDC 65862-116-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25,65862-116-01,discontinued
13654,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 20 mg (NDC 65862-117-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25,65862-117-01,discontinued
13655,Benazepril Hydrochloride Tablet,Aurobindo Pharma USA,"Benazepril Hydrochloride, Tablet, 40 mg (NDC 65862-118-01)",New,2/7/25,,,,,Cardiovascular,To Be Discontinued,,2/7/25,65862-118-01,discontinued
13656,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 25 mg (NDC 60505-6095-0)",New,1/27/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/25,60505-6095-0,discontinued
13657,Bendamustine Hydrochloride Injection,Apotex Corp.,"Bendamustine Hydrochloride, Injection, 100 mg (NDC 60505-6096-0)",New,1/27/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/27/25,60505-6096-0,discontinued
13658,Bezlotoxumab Injection,Merck Sharp & Dohme LLC,"Zinplava, Injection, 25 mg/1 mL (NDC 0006-3025-00)",New,12/23/24,,"To be discontinued on January 31, 2025",,,Anti-Infective,To Be Discontinued,,12/23/24,0006-3025-00,discontinued
13659,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)",New,6/13/25,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/25,0409-0323-20,discontinued
13660,Bleomycin Sulfate Injection,"Hospira, Inc., a Pfizer Company","Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)",New,6/13/25,,Discontinuation of the manufacture of the drug,,,Hematology; Oncology; Pediatric,To Be Discontinued,,6/13/25,0409-0332-20,discontinued
13661,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)",New,6/9/25,,,,,Cardiovascular,To Be Discontinued,,6/9/25,66215-101-03,discontinued
13662,Bosentan Tablet,Actelion Pharmaceuticals,"Tracleer, Tablet, 125 mg (NDC 66215-102-03)",New,6/9/25,,,,,Cardiovascular,To Be Discontinued,,6/9/25,66215-102-03,discontinued
13663,Brexanolone Solution,"Sage Therapeutics, Inc.","Zulresso, Solution, 5 mg/1 mL (NDC 72152-547-20)",New,10/29/24,,,,,Psychiatry,To Be Discontinued,,10/29/24,72152-547-20,discontinued
13664,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)",New,8/25/25,Available,,,,Cardiovascular,Current,,,25021-321-04,available
13665,Bumetanide Injection,Sagent Pharmaceuticals,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)",New,8/25/25,Available,,,,Cardiovascular,Current,,,25021-321-10,available
13666,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Reverified,7/23/25,Available,,,,Cardiovascular,Current,,,0641-6008-10,available
13667,Bumetanide Injection,"Hikma Pharmaceuticals USA, Inc.","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Reverified,7/23/25,Available,,,,Cardiovascular,Current,,,0641-6007-10,available
13668,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,65219-570-04,available
13669,Bumetanide Injection,"Fresenius Kabi USA, LLC","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,65219-572-10,available
13670,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,,72205-101-01,available
13671,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,,72205-101-07,available
13672,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,,72205-102-01,available
13673,Bumetanide Injection,MSN Laboratories Private Limited,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Revised,8/8/25,Available,,,,Cardiovascular,Current,,,72205-102-07,available
13674,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, .5 mg (NDC 0832-0540-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25,0832-0540-11,discontinued
13675,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-10)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25,0832-0541-10,discontinued
13676,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 1 mg (NDC 0832-0541-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25,0832-0541-11,discontinued
13677,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-10)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25,0832-0542-10,discontinued
13678,Bumetanide Tablet,"Upsher-Smith Laboratories, LLC","Bumetanide, Tablet, 2 mg (NDC 0832-0542-11)",New,5/2/25,,,,,Cardiovascular,To Be Discontinued,,5/2/25,0832-0542-11,discontinued
13679,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10)",New,1/10/25,,Discontinuation of the manufacture of the drug,,,Anesthesia,To Be Discontinued,,1/10/25,0409-1159-10,discontinued
13680,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1610-50)",New,1/10/25,,"Discontinuation of the manufacture of the drug.
Replaced with NDC 0409-0525-01",,,Anesthesia,To Be Discontinued,,1/10/25,0409-1610-50,discontinued
13681,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,71288-723-52,available
13682,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,71288-726-52,available
13683,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2028,,Other,Anesthesia,Current,,,0409-1159-10,not available
13684,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-1761-10,limited availability
13685,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,,0409-1761-62,available
13686,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-752-25,available
13687,Bupivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-753-25,available
13688,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,71288-722-32,available
13689,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,71288-725-32,available
13690,Bupivacaine Hydrochloride Injection,Kindos Pharmaceuticals Co. Ltd.,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)",Reverified,8/19/25,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,,,Anesthesia,Current,,,71288-728-32,available
13691,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-465-57,available
13692,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-467-57,available
13693,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-464-17,available
13694,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-464-37,available
13695,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-464-31,not available
13696,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-466-17,available
13697,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-466-37,available
13698,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-466-31,not available
13699,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-472-17,available
13700,Bupivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-472-37,available
13701,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-167-10,available
13702,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-168-30,available
13703,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-169-10,available
13704,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-170-30,available
13705,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-171-10,available
13706,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-172-30,not available
13707,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-249-50,not available
13708,Bupivacaine Hydrochloride Injection,Eugia US LLC,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-250-50,not available
13709,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1159-01,available
13710,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1159-02,available
13711,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1160-01,available
13712,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1162-01,available
13713,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)",Revised,8/15/25,Limited Available,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,,0409-1162-02,
13714,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1163-01,available
13715,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1165-01,available
13716,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1165-02,available
13717,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-3613-01,available
13718,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Demand increase for the drug,Anesthesia,Current,,,0409-1559-10,limited availability
13719,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1559-30,available
13720,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-1587-50,not available
13721,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1560-10,available
13722,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-1560-29,limited availability
13723,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 250 mg/50 mL (5 mg/mL) (NDC 0409-1610-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1610-50,available
13724,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-1582-10,limited availability
13725,Bupivacaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1582-29,available
13726,Bupivacaine Hydrochloride Injection,"Huons Co., Ltd","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,73293-0002-2,available
13727,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-9042-01,not available
13728,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-9042-17,not available
13729,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,12/19/24,,0409-9043-01,not available
13730,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-9045-01,not available
13731,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-9045-17,not available
13732,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anesthesia,Current,,,0409-9046-01,not available
13733,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1746-10,available
13734,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia,Current,,,0409-1746-30,limited availability
13735,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1749-10,available
13736,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1749-29,available
13737,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1752-50,available
13738,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Hospira, Inc., a Pfizer Company","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1755-50,available
13739,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-461-57,available
13740,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Anesthesia,Current,,,63323-463-57,available
13741,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-468-17,available
13742,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-468-37,available
13743,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-462-17,available
13744,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-462-37,available
13745,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-462-31,not available
13746,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","Fresenius Kabi USA, LLC","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-460-37,available
13747,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 4 mg (NDC 49884-658-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24,49884-658-09,discontinued
13748,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 8 mg (NDC 49884-659-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24,49884-659-09,discontinued
13749,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 16 mg (NDC 49884-660-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24,49884-660-09,discontinued
13750,Candesartan Cilexetil Tablet,"Par Pharmaceutical, Inc.","Atacand, Tablet, 32 mg (NDC 49884-661-09)",New,10/15/24,,,,,Cardiovascular,To Be Discontinued,,10/15/24,49884-661-09,discontinued
13751,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0090-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25,0093-0090-01,discontinued
13752,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25,0093-0109-01,discontinued
13753,Carbamazepine Tablet,"Teva Pharmaceuticals USA, Inc.","Epitol, Tablet, 200 mg (NDC 0093-0109-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/10/25,0093-0109-10,discontinued
13754,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-3)",New,3/28/25,,Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/25,60505-6282-3,discontinued
13755,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-1)",New,3/28/25,,Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,To Be Discontinued,,3/28/25,60505-6282-1,discontinued
13756,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)",Reverified,8/19/25,Unavailable,Pending discontinuation of the manufacture of the drug,,Requirements related to complying with good manufacturing practices,Oncology,Current,,,16729-295-33,not available
13757,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Oncology,Current,,,16729-295-31,not available
13758,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)",Reverified,7/24/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,,60505-6282-1,not available
13759,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)",Reverified,7/24/25,Limited Availability,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Oncology,Current,,,60505-6282-3,limited availability
13760,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)",Reverified,7/24/25,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-6,available
13761,Carboplatin Injection,Teyro Labs,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)",Reverified,7/24/25,Available,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,,Oncology,Current,,,60505-6282-7,available
13762,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Reverified,9/2/25,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,,50742-447-45,not available
13763,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)",Revised,7/28/25,Unavailable,"Discontinued; Distributed by BPI Labs, LLC",,Discontinuation of the manufacture of the drug,Oncology,Current,,,54288-164-01,not available
13764,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,54288-165-01,limited availability
13765,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,54288-166-01,limited availability
13766,Carboplatin Injection,Gland Pharma Limited,"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)",Revised,7/28/25,Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,Demand increase for the drug,Oncology,Current,,,54288-167-01,limited availability
13767,Carboplatin Injection,Ingenus Pharmaceuticals LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)",Reverified,9/2/25,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,Other,Oncology,Current,,,50742-448-60,not available
13768,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Oncology,Current,,,55150-335-01,not available
13769,Carboplatin Injection,Eugia US LLC,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Oncology,Current,,,55150-386-01,available
13770,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)",Revised,8/19/25,Limited Availability,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Oncology,Current,,,16729-295-34,limited availability
13771,Carboplatin Injection,Accord Healthcare Inc.,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)",Reverified,8/19/25,Available,,,,Oncology,Current,,,16729-295-12,available
13772,Carboplatin Injection,"Fresenius Kabi USA, LLC","Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Oncology,Current,,,63323-172-60,available
13773,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)",Revised,8/19/25,Limited Availability,,,Delay in shipping of the drug,Oncology,Current,,,0703-4239-01,limited availability
13774,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-339-18,available
13775,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-360-18,available
13776,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-339-22,available
13777,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-150-05,available
13778,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-339-50,available
13779,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-262-05,available
13780,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-339-56,available
13781,Carboplatin Injection,"Hospira, Inc., a Pfizer Company","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)",Reverified,8/15/25,Available,,,,Oncology,Current,,,61703-600-05,available
13782,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)",Revised,8/19/25,Available,,,,Oncology,Current,,,0703-4244-01,available
13783,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)",Revised,8/19/25,Available,,,,Oncology,Current,,,0703-4246-01,available
13784,Carboplatin Injection,"Teva Pharmaceuticals USA, Inc.","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)",Revised,8/19/25,Limited Availability,Estimated recovery: September 2025,,Other,Oncology,Current,,,0703-4248-01,limited availability
13785,Caspofungin Acetate Injection,Merck Sharp & Dohme Corp.,"Cancidas, Injection, 5 mg/1 mL (NDC 0006-3822-10)",New,9/26/24,,"To be discontinued on October 31, 2024",,,Anti-Infective,To Be Discontinued,,9/26/24,0006-3822-10,discontinued
13786,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)",Reverified,8/19/25,Available,,,,Anti-Infective; Pediatric,Current,,,21586-012-02,available
13787,"Cefotaxime Sodium Powder, for Solution","SteriMax, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)",Reverified,8/19/25,Available,,,,Anti-Infective; Pediatric,Current,,,21586-011-02,available
13788,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9930-10,not available
13789,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9931-25,not available
13790,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9933-25,not available
13791,"Cefotaxime Sodium Powder, for Solution","Hikma Pharmaceuticals USA, Inc.","Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anti-Infective; Pediatric,Current,,,0143-9935-01,not available
13792,Celecoxib Capsule,Apotex Corp.,"Capsule, 50 mg (NDC 60505-3847-6)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3847-6,discontinued
13793,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3848-1,discontinued
13794,Celecoxib Capsule,Apotex Corp.,"Capsule, 100 mg (NDC 60505-3848-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3848-5,discontinued
13795,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-1)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3849-1,discontinued
13796,Celecoxib Capsule,Apotex Corp.,"Capsule, 200 mg (NDC 60505-3849-5)",New,9/9/24,,,,,Analgesia/Addiction,To Be Discontinued,,9/9/24,60505-3849-5,discontinued
13797,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3982-60,discontinued
13798,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3983-01,discontinued
13799,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3983-05,discontinued
13800,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3984-01,discontinued
13801,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3984-05,discontinued
13802,Celecoxib Capsule,"Teva Pharmaceuticals USA, Inc.","Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)",New,8/15/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,8/15/25,0591-3985-60,discontinued
13803,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-23)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0245-0036-23,discontinued
13804,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-42)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0245-0036-42,discontinued
13805,Cholestyramine Powder,"Upsher-Smith Laboratories, LLC","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0245-0036-60,discontinued
13806,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 10 mg/5 mL (NDC 0703-2033-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25,0703-2033-03,discontinued
13807,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25,0703-2045-03,discontinued
13808,Cisatracurium Besylate Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 20 mg/10 mL (NDC 0703-2056-03)",New,1/6/25,,,,,Anesthesia,To Be Discontinued,,1/6/25,0703-2056-03,discontinued
13809,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-01)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-692-01,discontinued
13810,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-03)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-692-03,discontinued
13811,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-05)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-692-05,discontinued
13812,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-77)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-692-77,discontinued
13813,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-01)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-01,discontinued
13814,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-03)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-03,discontinued
13815,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-05)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-05,discontinued
13816,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-11)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-11,discontinued
13817,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-16)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-16,discontinued
13818,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-62)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-62,discontinued
13819,Clindamycin Hydrochloride Capsule,Sun Pharmaceutical Industries Limited,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-77)",New,12/5/24,,Discontinuing for business reasons,,,Anti-Infective,To Be Discontinued,,12/5/24,63304-693-77,discontinued
13820,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,0009-3051-02,not available
13821,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: June 2026,,Other,Anti-Infective,Current,,,0009-5095-06,limited availability
13822,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)",Revised,8/15/25,Available,,,,Anti-Infective,Current,,,0009-4073-04,available
13823,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)",Revised,8/15/25,Available,,,,Anti-Infective,Current,,,0009-0870-26,available
13824,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,0009-0775-26,not available
13825,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 g/60 mL (150 mg/mL) (NDC 0009-0728-09)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Demand increase for the drug,Anti-Infective,Current,,,0009-0728-09,not available
13826,Clindamycin Phosphate Injection,Pfizer Inc.,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Anti-Infective,Current,,,0009-0902-18,limited availability
13827,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,,25021-115-02,available
13828,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,,25021-115-04,available
13829,Clindamycin Phosphate Injection,Sagent Pharmaceuticals,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)",Reverified,8/26/25,Available,,,,Anti-Infective,Current,,,25021-115-06,available
13830,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)",Reverified,8/15/25,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,,0338-9545-50,not available
13831,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)",Revised,8/15/25,Limited Availability,Estimated recovery: October 2025,,Other,Anti-Infective,Current,,,0338-9549-50,limited availability
13832,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,,0338-9553-50,available
13833,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)",Reverified,9/3/25,Unavailable,Estimated recovery: September 2025,,Demand increase for the drug,Anti-Infective,Current,,,0338-3410-50,not available
13834,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,,0338-3612-50,available
13835,Clindamycin Phosphate Injection,Baxter Healthcare,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)",Revised,8/15/25,Unavailable,Estimated recovery: November 2025,,Demand increase for the drug,Anti-Infective,Current,,,0338-3814-50,not available
13836,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,,0781-3288-09,available
13837,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,,0781-3289-09,available
13838,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Reverified,8/15/25,Available,,,,Anti-Infective,Current,,,0781-3290-09,available
13839,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Reverified,8/15/25,Available,Civica Label,,,Anti-Infective,Current,,,72572-074-24,available
13840,Clindamycin Phosphate Injection,Sandoz Inc.,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Reverified,8/15/25,Available,Civica Label,,,Anti-Infective,Current,,,72572-076-24,available
13841,Clindamycin Phosphate; Benzoyl Peroxide Gel,"Teva Pharmaceuticals USA, Inc.","Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)",New,8/1/25,,A business decision was made to discontinue manufacture of the product.,,,Dermatology,To Be Discontinued,,8/1/25,0591-3916-68,discontinued
13842,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)",Reverified,8/19/25,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-00,unclear
13843,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)",Reverified,8/19/25,Information pending,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-00,unclear
13844,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-722-01,available
13845,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-722-99,available
13846,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-723-01,available
13847,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-723-99,available
13848,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-724-01,available
13849,Clonazepam Tablet,Aurobindo Pharma USA,"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,59651-724-05,available
13850,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-136-00,available
13851,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-136-16,available
13852,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-00,available
13853,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-137-16,available
13854,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-138-00,available
13855,Clonazepam Tablet,Accord Healthcare Inc.,"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,16729-138-16,available
13856,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-605-10,available
13857,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-610-10,available
13858,Clonazepam Tablet,Cheplapharm Arzneimittel GmbH,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",Reverified,9/3/25,Available,Marketed by H2-Pharma,,,Neurology; Pediatric; Psychiatry,Current,,,61269-620-10,available
13859,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-10,available
13860,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-11,available
13861,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-406-50,available
13862,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-10,available
13863,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-11,available
13864,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-407-50,available
13865,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-10,available
13866,Clonazepam Tablet,"Prinston Pharmaceutical, Inc.","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",Reverified,8/19/25,Available,Marketed by Solco Healthcare,,,Neurology; Pediatric; Psychiatry,Current,,,43547-408-50,available
13867,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-01,available
13868,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-0832-05,available
13869,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-01,available
13870,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3212-05,available
13871,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)",Reverified,8/19/25,Limited Availability,Estimated recovery: September 2025,,Other,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-01,limited availability
13872,Clonazepam Tablet,"Teva Pharmaceuticals USA, Inc.","Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)",Reverified,8/19/25,Available,,,,Neurology; Pediatric; Psychiatry,Current,,,0093-3213-05,available
13873,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-30,available
13874,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-01,available
13875,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-152-05,available
13876,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-30,available
13877,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-01,available
13878,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-153-05,available
13879,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-30,available
13880,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-01,available
13881,Clonazepam Tablet,Rubicon Research Private Limited,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Reverified,8/19/25,Available,Marketed by Advagen Pharma Ltd.,,,Neurology; Pediatric; Psychiatry,Current,,,72888-154-05,available
13882,Conivaptan Hydrochloride Injection,Cumberland Pharmaceuticals Inc.,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",Reverified,8/15/25,Unavailable,,,Delay in shipping of the drug,Cardiovascular,Current,,,66220-160-10,not available
13883,Cromolyn Sodium Concentrate,"Rising Pharma Holdings, Inc.","Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Revised,8/15/25,Available,,,,Pulmonary/Allergy,Current,,,16571-600-96,available
13884,Cromolyn Sodium Concentrate,Micro Labs LTD,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Reverified,9/2/25,Available,,,,Pulmonary/Allergy,Current,,,42571-132-52,available
13885,Cromolyn Sodium Concentrate,"Mylan Specialty, a Viatris Company","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Reverified,9/3/25,Available,,,,Pulmonary/Allergy,Current,,,0037-0678-96,available
13886,Cromolyn Sodium Concentrate,Ailex Pharmaceuticals,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)",Revised,8/15/25,Available,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195,,,Pulmonary/Allergy,Current,,,81665-104-96,available
13887,Cyanocobalamin Injection,Accord Healthcare Inc.,"Dodex, Injection, 1000 ug/1 mL (NDC 16729-533-08)",New,1/17/25,,Permanent discontinuation in the manufacturing of the drug.,,,Hematology,To Be Discontinued,,1/17/25,16729-533-08,discontinued
13888,Cyclosporine Oral Solution,AbbVie Inc.,"Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50)",New,12/5/24,,"Abbvie has made a business decision to permanently discontinue GENGRAF Oral Solution (cyclosporine oral solution, USP) 100 mg/mL .",,,Transplant,To Be Discontinued,,12/5/24,0074-7269-50,discontinued
13889,"Dalfampridine Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Tablet, Extended Release, 10 mg (NDC 62756-429-86)",New,9/20/24,,,,,Neurology,To Be Discontinued,,9/20/24,62756-429-86,discontinued
13890,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 5 mg; 5 mg (NDC 0310-6770-30)",New,3/3/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,,0310-6770-30,discontinued
13891,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,AstraZeneca AB,"Qtern, Tablet, 10 mg; 5 mg (NDC 0310-6780-30)",New,3/3/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/3/25,0310-6780-30,discontinued
13892,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0897-13,discontinued
13893,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0897-56,discontinued
13894,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0903-13,discontinued
13895,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0903-56,discontinued
13896,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0906-13,discontinued
13897,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0906-56,discontinued
13898,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0911-13,discontinued
13899,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0911-56,discontinued
13900,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-13)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0914-13,discontinued
13901,Daprodustat Tablet,GlaxoSmithKline,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-56)",New,11/21/24,,Discontinuing for Business Reasons.,,,Hematology,To Be Discontinued,,11/21/24,0173-0914-56,discontinued
13902,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-578-01,discontinued
13903,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-579-01,discontinued
13904,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-580-01,discontinued
13905,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-581-01,discontinued
13906,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-582-01,discontinued
13907,Desipramine Hydrochloride Tablet,"Avet Pharmaceuticals, Inc.","Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)",New,8/12/25,,Discontinuation of the manufacture of the drug,,,Psychiatry,To Be Discontinued,,8/12/25,23155-583-25,discontinued
13908,Desmopressin Acetate Injection,Sun Pharmaceutical Industries Limited,"Desmopressin Acetate, Injection, 4 ug/1 mL (NDC 62756-529-40)",New,12/5/24,,Discontinuing for business reasons,,,Endocrinology/Metabolism,To Be Discontinued,,12/5/24,62756-529-40,discontinued
13909,Desmopressin Acetate Spray,Ferring,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,69918-501-05,not available
13910,Desmopressin Acetate Spray,Ferring,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,55566-2500-0,not available
13911,Desmopressin Acetate Spray,Apotex Corp.,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Reverified,7/24/25,Available,,,,Hematology,Current,,,60505-0815-0,available
13912,Desmopressin Acetate Spray,Ferring,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Reverified,6/27/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Hematology,Current,,,0053-6871-00,not available
13913,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)",New,5/28/25,,,,,Dermatology,To Be Discontinued,,5/28/25,0472-0804-15,discontinued
13914,Desonide Cream,"Actavis Pharma, Inc.","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)",New,5/28/25,,,,,Dermatology,To Be Discontinued,,5/28/25,0472-0804-60,discontinued
13915,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-106-10,not available
13916,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,76045-109-10,available
13917,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-304-25,available
13918,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 100 mg/10 mL (NDC 55150-305-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-305-10,not available
13919,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-423-12,available
13920,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-422-54,available
13921,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-421-30,available
13922,Dexamethasone Sodium Phosphate Injection,"Mylan Institutional, a Viatris Company","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)",Reverified,9/3/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,67457-420-10,available
13923,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-237-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-237-01,not available
13924,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-238-05)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-238-05,not available
13925,Dexamethasone Sodium Phosphate Injection,Eugia US LLC,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-239-30)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,55150-239-30,not available
13926,Dexamethasone Sodium Phosphate Injection,"Somerset Therapeutics, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Reverified,8/19/25,Available,,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,70069-021-25,available
13927,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)",Reverified,9/2/25,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-05,available
13928,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-516-10,available
13929,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-30,available
13930,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)",Reverified,9/2/25,Available,Check wholesalers for inventory.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-165-01,available
13931,Dexamethasone Sodium Phosphate Injection,"Fresenius Kabi USA, LLC","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,63323-506-01,available
13932,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6145-25,available
13933,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Reverified,7/23/25,Unavailable,Additional lots will be available in the April 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-6146-25,not available
13934,Dexamethasone Sodium Phosphate Injection,"Hikma Pharmaceuticals USA, Inc.","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Reverified,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology,Current,,,0641-0367-25,available
13935,Dexmedetomidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Reverified,7/23/25,Unavailable,Shortage duration is unknown at this time.,,Demand increase for the drug,Anesthesia,Current,,,0143-9532-25,not available
13936,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-186-20,available
13937,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-187-10,available
13938,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-924-50,available
13939,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-925-10,available
13940,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,70121-1388-8,available
13941,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,70121-1389-7,available
13942,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-296-10,available
13943,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-297-10,available
13944,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Anesthesia,Current,,,16729-239-93,not available
13945,Dexmedetomidine Hydrochloride Injection,Accord Healthcare Inc.,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Reverified,8/19/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Anesthesia,Current,,,16729-432-93,not available
13946,Dexmedetomidine Hydrochloride Injection,Eugia US LLC,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-209-02,available
13947,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,0338-9555-24,available
13948,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Revised,9/3/25,Limited Availability,Recovery in November 2025,,Demand increase for the drug,Anesthesia,Current,,,0338-9557-12,limited availability
13949,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,43066-555-24,available
13950,Dexmedetomidine Hydrochloride Injection,Baxter Healthcare,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,43066-557-12,available
13951,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Anesthesia,Current,,,63323-671-20,not available
13952,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-671-50,not available
13953,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-671-00,not available
13954,Dexmedetomidine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)",Reverified,9/2/25,Available,Short-dated supply (8 months from expiry) available upon request. Check wholesaler for inventory.,,,Anesthesia,Current,,,63323-421-02,available
13955,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-600-04,available
13956,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-601-04,available
13957,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-602-24,available
13958,Dexmedetomidine Hydrochloride Injection,HQ Specialty Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)",Reverified,7/16/25,Available,Marketed by WG Critical Care,,,Anesthesia,Current,,,44567-603-24,available
13959,Dexmedetomidine Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-251-02,available
13960,Dexmedetomidine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)",Reverified,9/2/25,Available,Please check wholesalers for inventory,,,Anesthesia,Current,,,42023-146-25,available
13961,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1660-20,available
13962,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1660-50,available
13963,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1596-10,available
13964,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1638-02,available
13965,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,71225-126-05,available
13966,Dexmedetomidine Hydrochloride Injection,Slayback Pharma,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,71225-126-06,available
13967,Dexmedetomidine Hydrochloride Injection,"Meitheal Pharmaceuticals, Inc.","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,71288-505-03,available
13968,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Reverified,7/28/25,Available,Distributed by DRL,,,Anesthesia,Current,,,43598-976-58,available
13969,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Reverified,7/28/25,Available,Distributed by DRL,,,Anesthesia,Current,,,43598-975-58,available
13970,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,70121-1388-1,available
13971,Dexmedetomidine Hydrochloride Injection,Amneal Pharmaceuticals,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,70121-1389-1,available
13972,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,0781-3493-95,available
13973,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,0781-3494-95,available
13974,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)",Reverified,9/2/25,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,,Anesthesia,Current,,,0781-3495-95,available
13975,Dexmedetomidine Hydrochloride Injection,Gland Pharma Limited,"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)",Reverified,7/28/25,Available,Marketed by Piramal Critical Care Inc.: 800-414-1901,,,Anesthesia,Current,,,66794-230-42,available
13976,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-3301-10,available
13977,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-4596-20,available
13978,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-0155-02,available
13979,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1174-10,available
13980,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)",Revised,8/15/25,Unavailable,Unavailable. Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-1434-01,not available
13981,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,,Other,Anesthesia,Current,,,0409-2815-01,limited availability
13982,Dexmedetomidine Hydrochloride Injection,Pfizer Inc.,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1454-20,available
13983,Dexmedetomidine Hydrochloride Injection,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)",Reverified,9/2/25,Unavailable,Distributed by Avenacy; Contact information: 877-283-6229,,Demand increase for the drug,Anesthesia,Current,,,83634-600-02,not available
13984,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-02,available
13985,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-03,available
13986,Dextrose Monohydrate 10% Injection,Baxter Healthcare,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0023-04,available
13987,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-00,available
13988,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-10,available
13989,Dextrose Monohydrate 10% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7520-20,available
13990,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-74,available
13991,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-75,not available
13992,Dextrose Monohydrate 10% Injection,"Fresenius Kabi USA, LLC","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,63323-824-76,available
13993,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-02,available
13994,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-03,available
13995,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7930-09,available
13996,Dextrose Monohydrate 10% Injection,Otsuka ICU Medical LLC,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7938-19,available
13997,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 2.5 g/50mL (5%, 50mg/mL) (NDC 0409-7100-66)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-66,available
13998,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-67,available
13999,Dextrose Monohydrate 5% Injection,"Hospira, Inc., a Pfizer Company","Dextrose 5% In Plastic Container, Injection, 12.5 g/250mL (5%) (NDC 0409-7100-02)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0409-7100-02,available
14000,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,65219-464-50,available
14001,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,65219-458-30,available
14002,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,65219-460-20,available
14003,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,65219-462-10,available
14004,Dextrose Monohydrate 5% Injection,"Fresenius Kabi USA, LLC","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)",Reverified,9/2/25,Available,Check wholealers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,65219-456-60,available
14005,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-02,available
14006,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-61,available
14007,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-13,available
14008,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-20,available
14009,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-23,available
14010,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-36,available
14011,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7923-37,available
14012,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-10,available
14013,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-41,available
14014,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-11,available
14015,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-31,available
14016,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-48,available
14017,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-18,available
14018,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-38,available
14019,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-11,available
14020,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9143-30,available
14021,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-9147-30,available
14022,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0551-18,available
14023,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0070-10,available
14024,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-02,available
14025,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0062-30,available
14026,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0017-03,available
14027,Dextrose Monohydrate 5% Injection,Baxter Healthcare,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0066-20,available
14028,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-10,available
14029,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-00,available
14030,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7510-20,available
14031,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-32,available
14032,Dextrose Monohydrate 5% Injection,B. Braun Medical Inc.,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-1510-31,available
14033,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-03,available
14034,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-55,available
14035,Dextrose Monohydrate 5% Injection,Otsuka ICU Medical LLC,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7922-09,available
14036,Dextrose Monohydrate 50% Injection,"Amphastar Pharmaceuticals, Inc.","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3302-1,available
14037,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)",Revised,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-7517-16,available
14038,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-4902-34,not available
14039,Dextrose Monohydrate 50% Injection,"Hospira, Inc., a Pfizer Company","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6648-02,available
14040,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7120-07,available
14041,Dextrose Monohydrate 70% Injection,B. Braun Medical Inc.,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0264-7387-50,available
14042,Dextrose Monohydrate 70% Injection,Otsuka ICU Medical LLC,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0990-7918-19,available
14043,Dextrose Monohydrate 70% Injection,Baxter Healthcare,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other; Pediatric,Current,,,0338-0719-06,available
14044,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-88)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24,57664-437-88,discontinued
14045,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 125 ug (NDC 57664-437-18)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24,57664-437-18,discontinued
14046,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-18)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24,57664-441-18,discontinued
14047,Digoxin Tablet,Sun Pharmaceutical Industries Limited,"Digoxin, Tablet, 250 ug (NDC 57664-441-88)",New,12/5/24,,Discontinuing for business reasons,,,Cardiovascular,To Be Discontinued,,12/5/24,57664-441-88,discontinued
14048,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-05)",New,9/16/24,,,,,Neurology,To Be Discontinued,,9/16/24,0574-0850-05,discontinued
14049,Dihydroergotamine Mesylate Injection,Padagis US LLC,"Injection, 1 mg/1 mL (NDC 0574-0850-10)",New,9/16/24,,,,,Neurology,To Be Discontinued,,9/16/24,0574-0850-10,discontinued
14050,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7122-11,discontinued
14051,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7122-15,discontinued
14052,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-01)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7123-01,discontinued
14053,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7123-11,discontinued
14054,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7123-15,discontinued
14055,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-01)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7124-01,discontinued
14056,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-11)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7124-11,discontinued
14057,"Divalproex Sodium Tablet, Delayed Release","Upsher-Smith Laboratories, LLC","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-15)",New,4/28/25,,Discontinuation of manufacture of drug based on business decision.,,,Neurology,To Be Discontinued,,4/28/25,0832-7124-15,discontinued
14058,Dobutamine Hydrochloride Injection,Pfizer Inc.,"Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",New,8/27/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular; Pediatric; Renal,To Be Discontinued,,8/27/25,0409-2344-88,discontinued
14059,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1075-02,available
14060,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1077-02,available
14061,Dobutamine Hydrochloride Injection,"Hainan Poly Pharm. Co., Ltd.","Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)",Reverified,9/3/25,Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,,Cardiovascular; Pediatric; Renal,Current,,,70436-203-80,available
14062,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular; Pediatric; Renal,Current,,,0409-2344-88,not available
14063,Dobutamine Hydrochloride Injection,Baxter Healthcare,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Reverified,9/3/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,,,0338-1073-02,available
14064,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,,,0409-2346-32,not available
14065,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/24,,0409-2347-32,not available
14066,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)",Revised,8/15/25,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular; Pediatric; Renal,Current,12/19/24,,0409-3724-32,not available
14067,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)",Revised,8/15/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/24,,0409-2344-01,available
14068,Dobutamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)",Revised,8/15/25,Available,,,,Cardiovascular; Pediatric; Renal,Current,12/19/24,,0409-2344-02,available
14069,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-0016-01)",New,6/24/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/25,0409-0016-01,discontinued
14070,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN‚Äö√Ñ√∂‚àö√´¬¨¬¢ Glass Fliptop Vial Novaplus¬¨¬®‚àö√ú  (NDC 0409-2026-01)",New,6/24/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,6/24/25,0409-2026-01,discontinued
14071,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-1732-01)",New,1/15/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/25,0409-1732-01,discontinued
14072,Docetaxel Injection,Pfizer Inc.,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-7870-01)",New,1/15/25,,Discontinuation of the manufacture of the drug,,,Oncology,To Be Discontinued,,1/15/25,0409-7870-01,discontinued
14073,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-01)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-127-01,discontinued
14074,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-03)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-127-03,discontinued
14075,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-05)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-127-05,discontinued
14076,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-06)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-127-06,discontinued
14077,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-01)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-128-01,discontinued
14078,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-03)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-128-03,discontinued
14079,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-05)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-128-05,discontinued
14080,Donepezil Hydrochloride Tablet,Strides Pharma Inc.,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-06)",New,1/28/25,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,,Neurology,To Be Discontinued,,1/28/25,71093-128-06,discontinued
14081,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)",New,8/27/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,,0409-7809-24,discontinued
14082,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Cardiovascular,Current,,,0409-7809-22,not available
14083,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Cardiovascular,Current,,,0409-7809-24,not available
14084,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,,0409-7810-22,not available
14085,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)",Revised,8/15/25,Available,,,,Cardiovascular,Current,,,0409-5820-01,available
14086,Dopamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)",Revised,8/15/25,Available,,,,Cardiovascular,Current,,,0409-9104-20,available
14087,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-1005-02,available
14088,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9252-25,not available
14089,Dopamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Cardiovascular,Current,,,0143-9254-25,not available
14090,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-1005-03,available
14091,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-1007-02,available
14092,Dopamine Hydrochloride Injection,Baxter Healthcare,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-1007-03,available
14093,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,5/2/25,,,,,Anti-Infective,To Be Discontinued,,,0591-5553-05,discontinued
14094,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,5/2/25,,,,,Anti-Infective,To Be Discontinued,,5/2/25,0591-5553-50,discontinued
14095,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",New,6/13/25,,,,,Anti-Infective,To Be Discontinued,,6/13/25,0591-5553-05,discontinued
14096,Doxycycline Hyclate Tablet,"Teva Pharmaceuticals USA, Inc.","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",New,6/13/25,,,,,Anti-Infective,To Be Discontinued,,6/13/25,0591-5553-50,discontinued
14097,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Yasmin, Tablet, Kit (NDC 0555-9131-67)",New,6/13/25,,,,,Reproductive,To Be Discontinued,,6/13/25,0555-9131-67,discontinued
14098,Drospirenone; Ethinyl Estradiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ocella, Tablet, Kit (NDC 0555-9131-67)",New,5/2/25,,,,,Reproductive,To Be Discontinued,,5/2/25,0555-9131-67,discontinued
14099,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,,0002-1433-80,
14100,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,,0002-1434-80,
14101,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,,0002-2236-80,
14102,Dulaglutide Injection,Eli Lilly and Co.,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Revised,6/13/25,,,Available,,Endocrinology/Metabolism,Resolved,6/13/25,,0002-3182-80,
14103,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 20 mg (NDC 0002-3235-60)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24,0002-3235-60,discontinued
14104,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-30)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24,0002-3240-30,discontinued
14105,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-90)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24,0002-3240-90,discontinued
14106,"Duloxetine Hydrochloride Capsule, Delayed Release",Eli Lilly and Co.,"Cymbalta, Capsule, Delayed Release, 60 mg (NDC 0002-3270-30)",New,10/18/24,,Business decision to discontinue,,,Psychiatry,To Be Discontinued,,10/18/24,0002-3270-30,discontinued
14107,Echothiophate Iodide Ophthalmic Solution,Fera Pharmaceuticals,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Reverified,6/27/25,Available,Available through limited distribution by Walgreens Specialty Pharmacy.,,,Ophthalmology,Current,,,48102-053-05,available
14108,Edaravone Injection,"Mitsubishi Tanabe Pharma America, Inc.","Radicava, Injection, 30 mg/100 mL (NDC 70510-2171-2)",New,12/5/24,,"A business decision was made to discontinue manufacture of this product. Distribution will end as early as April 1, 2025. The discontinuation of Radicava (edaravone) injection will not impact the commercial availability of Radicava ORS (edaravone) oral suspension.",,,Neurology,To Be Discontinued,,12/5/24,70510-2171-2,discontinued
14109,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-482-17,available
14110,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-487-17,not available
14111,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-488-17,available
14112,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-489-17,available
14113,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,,0409-3177-01,available
14114,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3178-01,available
14115,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3178-02,available
14116,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,,0409-3178-03,available
14117,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-1209-01,available
14118,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3181-01,available
14119,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3182-01,available
14120,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,,0409-3182-02,available
14121,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3182-03,available
14122,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-3183-01,available
14123,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-481-57,available
14124,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-482-27,available
14125,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-482-57,available
14126,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,63323-483-27,available
14127,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-483-57,available
14128,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-487-37,available
14129,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Reverified,9/2/25,Available,8 mos expiry available upon request. Check wholesaler for inventory.,,,Anesthesia; Pediatric,Current,,,63323-488-37,available
14130,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","Fresenius Kabi USA, LLC","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-489-27,available
14131,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, .5 mg (NDC 0173-0517-00)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25,0173-0517-00,discontinued
14132,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1.5 mg (NDC 0173-0519-00)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25,0173-0519-00,discontinued
14133,Epoprostenol Sodium Injection,GlaxoSmithKline,"Flolan, Injection, 1 mL/1 mL (NDC 0173-0857-02)",New,1/31/25,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,,Cardiovascular,To Be Discontinued,,1/31/25,0173-0857-02,discontinued
14134,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-60)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25,0378-8075-60,discontinued
14135,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25,0378-8075-93,discontinued
14136,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-60)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25,0378-8212-60,discontinued
14137,Erythromycin  Topical Gel,"Mylan Pharmaceuticals Inc., a Viatris Company","Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-93)",New,2/14/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,2/14/25,0378-8212-93,discontinued
14138,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .3 mg (NDC 61570-072-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25,61570-072-01,discontinued
14139,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, .625 mg (NDC 61570-073-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25,61570-073-01,discontinued
14140,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 1.25 mg (NDC 61570-074-01)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25,61570-074-01,discontinued
14141,Esterified Estrogens Tablet,Pfizer Inc.,"Menest, Tablet, 2.5 mg (NDC 61570-075-50)",New,7/29/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/29/25,61570-075-50,discontinued
14142,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25,0093-5537-56,discontinued
14143,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25,0093-5538-01,discontinued
14144,Eszopiclone Tablet,"Teva Pharmaceuticals USA, Inc.","Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)",New,6/26/25,,Discontinuation of the manufacture of the drug,,,Neurology,To Be Discontinued,,6/26/25,0093-5539-01,discontinued
14145,Ethinyl Estradiol; Ethinyl Diacetate Tablet,"Teva Pharmaceuticals USA, Inc.","Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)",New,6/13/25,,,,,Reproductive,To Be Discontinued,,6/13/25,0093-8073-16,discontinued
14146,Ethinyl Estradiol; Etonogestrel Ring,"Teva Pharmaceuticals USA, Inc.","Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Reproductive,To Be Discontinued,,6/16/25,0093-7679-02,discontinued
14147,"Ethinyl Estradiol; Norethindrone Tablet, Chewable","Teva Pharmaceuticals USA, Inc.","Tablet, Chewable, Kit (NDC 52544-064-31)",New,1/10/25,,,,,Reproductive,To Be Discontinued,,1/10/25,52544-064-31,discontinued
14148,Ethionamide Tablet,Pfizer Inc.,"Trecator, Tablet, 250 mg (NDC 0008-4117-01)",New,7/16/25,,"Discontinuation of the manufacture of the drug.

Supply expected to exhaust September 2025",,,Anti-Infective,To Be Discontinued,,7/16/25,0008-4117-01,discontinued
14149,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,65219-445-10,available
14150,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,,,Anesthesia,Current,,,65219-445-20,available
14151,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Revised,7/23/25,Available,Distributed by Civica,,,Anesthesia,Current,,,72572-160-10,available
14152,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Revised,7/23/25,Available,Distributed by Civica,,,Anesthesia,Current,,,72572-161-10,available
14153,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176,,,Anesthesia,Current,,,65219-447-20,available
14154,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)",Reverified,9/2/25,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,,72485-508-10,available
14155,Etomidate Injection,"Caplin Steriles, Ltd.","Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)",Reverified,9/2/25,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,,Anesthesia,Current,,,72485-509-10,available
14156,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)",Reverified,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-221-10,available
14157,Etomidate Injection,Eugia US LLC,"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)",Reverified,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-222-20,not available
14158,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,,72266-146-10,available
14159,Etomidate Injection,Gland Pharma Limited,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Anesthesia,Current,,,72266-147-10,available
14160,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Revised,7/23/25,Unavailable,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Anesthesia,Current,,,0143-9506-10,not available
14161,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Anesthesia,Current,,,0143-9507-10,available
14162,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Revised,7/23/25,Available,Novaplus,,,Anesthesia,Current,,,0143-9310-10,available
14163,Etomidate Injection,"Hikma Pharmaceuticals USA, Inc.","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Revised,7/23/25,Available,Novaplus,,,Anesthesia,Current,,,0143-9311-10,available
14164,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-902-10,available
14165,Etomidate Injection,"Mylan Institutional, a Viatris Company","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-903-20,available
14166,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-6695-01,available
14167,Etomidate Injection,"Hospira, Inc., a Pfizer Company","Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Anesthesia,Current,,,0409-6695-02,not available
14168,"Exenatide Synthetic Injectable Suspension, Extended Release",AstraZeneca AB,"Bydureon BCise, Injectable Suspension, Extended Release, 2 mg/.85 mL (NDC 0310-6540-04)",New,10/28/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/28/24,0310-6540-04,discontinued
14169,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 300MCG/1.2ML (250MCG/ML) (NDC 0310-6512-01)",New,10/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/24,0310-6512-01,discontinued
14170,Exenatide Synthetic Injection,AstraZeneca AB,"Byetta, Injection, 600MCG/2.4ML (250MCG/ML) (NDC 0310-6524-01)",New,10/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,10/25/24,0310-6524-01,discontinued
14171,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25,0591-3713-05,discontinued
14172,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25,0591-3713-19,discontinued
14173,Ezetimibe Tablet,"Actavis Pharma, Inc.","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)",New,6/27/25,,A business decision was made to discontinue manufacture of the product,,,Cardiovascular,To Be Discontinued,,6/27/25,0591-3713-30,discontinued
14174,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-565-08,discontinued
14175,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-565-30,discontinued
14176,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-566-08,discontinued
14177,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-566-30,discontinued
14178,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-567-08,discontinued
14179,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-567-30,discontinued
14180,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-08)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-568-08,discontinued
14181,Ezetimibe; Simvastatin Tablet,"Teva Pharmaceuticals USA, Inc.","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-30)",New,1/6/25,,,,,Cardiovascular,To Be Discontinued,,1/6/25,45963-568-30,discontinued
14182,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 80 mg (NDC 64764-677-30)",New,1/22/25,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/25,64764-677-30,discontinued
14183,Febuxostat Tablet,Takeda Pharmaceuticals USA Inc.,"Uloric, Tablet, 40 mg (NDC 64764-918-30)",New,1/22/25,,Anticipate continued distribution to wholesalers until March 2026,,,Other,To Be Discontinued,,1/22/25,64764-918-30,discontinued
14184,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,63323-806-20,not available
14185,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,63323-806-50,not available
14186,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-01,available
14187,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction; Pediatric,Current,,,63323-806-02,not available
14188,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-806-05,available
14189,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6247-25,available
14190,Fentanyl Citrate Injection,"Fresenius Kabi USA, LLC","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction; Pediatric,Current,,,63323-808-11,available
14191,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-22,available
14192,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-25,available
14193,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,1/2/25,,0409-9094-28,available
14194,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-31,available
14195,Fentanyl Citrate Injection,"Hospira, Inc., a Pfizer Company","Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)",Reverified,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-9094-61,available
14196,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6024-10,not available
14197,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6025-10,not available
14198,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Revised,7/23/25,Unavailable,Inventory available in vial presentations.,,Other,Analgesia/Addiction; Pediatric,Current,,,0641-6026-05,not available
14199,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6027-25,available
14200,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6028-25,available
14201,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6029-25,available
14202,Fentanyl Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Pediatric,Current,,,0641-6030-01,available
14203,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 100 ug (NDC 63459-541-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,63459-541-28,discontinued
14204,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 200 ug (NDC 63459-542-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,63459-542-28,discontinued
14205,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 400 ug (NDC 63459-544-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,63459-544-28,discontinued
14206,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 600 ug (NDC 63459-546-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,63459-546-28,discontinued
14207,Fentanyl Citrate Tablet,"Teva Pharmaceuticals USA, Inc.","Fentora, Tablet, 800 ug (NDC 63459-548-28)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,63459-548-28,discontinued
14208,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 200 ug (NDC 0093-7865-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7865-65,discontinued
14209,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 400 ug (NDC 0093-7866-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7866-65,discontinued
14210,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 600 ug (NDC 0093-7867-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7867-65,discontinued
14211,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 800 ug (NDC 0093-7868-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7868-65,discontinued
14212,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1200 ug (NDC 0093-7869-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7869-65,discontinued
14213,Fentanyl Citrate Troche/Lozenge,"Teva Pharmaceuticals USA, Inc.","Actiq, Troche/Lozenge, 1600 ug (NDC 0093-7870-65)",New,9/24/24,,Company Decision to Discontinue the Product,,,Analgesia/Addiction,To Be Discontinued,,9/24/24,0093-7870-65,discontinued
14214,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-05)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25,0093-7355-05,discontinued
14215,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-56)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25,0093-7355-56,discontinued
14216,Finasteride Tablet,"Teva Pharmaceuticals USA, Inc.","Finasteride, Tablet, 5 mg (NDC 0093-7355-98)",New,8/19/25,,Discontinuation of the manufacture of the drug product,,,Urology,To Be Discontinued,,8/19/25,0093-7355-98,discontinued
14217,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 100 mg (NDC 0049-3420-30)",New,9/27/24,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/24,0049-3420-30,discontinued
14218,Fluconazole Tablet,Pfizer Inc.,"Diflucan, Tablet, 200 mg (NDC 0049-3430-30)",New,9/27/24,,Discontinuation Of The Manufacture Of The Drug,,,Anti-Infective,To Be Discontinued,,9/27/24,0049-3430-30,discontinued
14219,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 10 mg (NDC 0777-3104-02)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24,0777-3104-02,discontinued
14220,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-02)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24,0777-3105-02,discontinued
14221,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 20 mg (NDC 0777-3105-30)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24,0777-3105-30,discontinued
14222,Fluoxetine Hydrochloride Capsule,Eli Lilly and Co.,"Prozac, Capsule, 40 mg (NDC 0777-3107-30)",New,10/3/24,,,,,Psychiatry,To Be Discontinued,,10/3/24,0777-3107-30,discontinued
14223,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,,62135-736-30,available
14224,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,,62135-737-30,available
14225,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)",Reverified,8/19/25,Available,,,,Oncology; Other,Current,,,62135-736-90,available
14226,Flurazepam Hydrochloride Capsule,Chartwell Molecular Holdings LLC,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)",Reverified,8/19/25,Available,,,,Neurology; Other,Current,,,62135-737-90,available
14227,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)",Reverified,8/19/25,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,0378-4415-01,not available
14228,Flurazepam Hydrochloride Capsule,"Rising Pharma Holdings, Inc.","Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)",Reverified,8/19/25,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,Regulatory delay,Neurology; Other,Current,,,0378-4430-01,not available
14229,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-01)",New,11/13/24,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/24,0093-0711-01,discontinued
14230,Flurbiprofen Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0093-0711-05)",New,11/13/24,,A business decision was made to discontinue manufacture of the product.,,,Analgesia/Addiction,To Be Discontinued,,11/13/24,0093-0711-05,discontinued
14231,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25,59310-805-06,discontinued
14232,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25,59310-812-06,discontinued
14233,Fluticasone Propionate; Salmeterol Xinafoate Powder,"Teva Pharmaceuticals USA, Inc.","AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)",New,6/13/25,,,,,Pulmonary/Allergy,To Be Discontinued,,6/13/25,59310-822-06,discontinued
14234,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,0409-6102-27,limited availability
14235,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,71288-205-03,available
14236,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,71288-203-05,available
14237,Furosemide Injection,"Meitheal Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,71288-203-11,available
14238,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,16729-500-08,not available
14239,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,16729-501-43,not available
14240,Furosemide Injection,Accord Healthcare Inc.,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,16729-502-43,not available
14241,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-02,available
14242,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-04,available
14243,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)",Reverified,9/3/25,Available,Distributed by Avenacy; Contact information: 877-283-6229,,,Cardiovascular,Current,,,83634-302-10,available
14244,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-02)",Reverified,8/26/25,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-02,,Other,Cardiovascular,Current,,,70860-302-02,
14245,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-04)",Reverified,8/26/25,Unavailable,Use Sagent NDC 25021-311-04,,Other,Cardiovascular,Current,,,70860-302-04,not available
14246,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-10)",Reverified,8/26/25,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-10,,Other,Cardiovascular,Current,,,70860-302-10,
14247,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,,25021-311-02,available
14248,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,,25021-311-04,available
14249,Furosemide Injection,Sagent Pharmaceuticals,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,8/26/25,Available,,,,Cardiovascular,Current,,,25021-311-10,available
14250,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,63323-280-02,available
14251,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,63323-280-04,available
14252,Furosemide Injection,"Fresenius Kabi USA, LLC","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,63323-280-10,available
14253,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,55150-322-25,available
14254,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,55150-323-25,available
14255,Furosemide Injection,Eugia US LLC,"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,55150-324-25,available
14256,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Reverified,9/3/25,Unavailable,Estimated recovery: end of 2025,,Other,Cardiovascular,Current,,,36000-284-25,not available
14257,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,36000-282-25,available
14258,Furosemide Injection,Baxter Healthcare,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Reverified,9/3/25,Limited Availability,On allocation through Q3 2025,,Other,Cardiovascular,Current,,,36000-283-25,limited availability
14259,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,23155-473-41,available
14260,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,23155-473-42,available
14261,Furosemide Injection,"Avet Pharmaceuticals, Inc.","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,23155-473-44,available
14262,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Cardiovascular,Current,,,0409-6102-02,limited availability
14263,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,Other,Cardiovascular,Current,,,0409-6102-04,limited availability
14264,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)",Reverified,8/15/25,Available,,,,Cardiovascular,Current,,,0409-6102-10,available
14265,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,0409-6102-25,limited availability
14266,Furosemide Injection,"Hospira, Inc., a Pfizer Company","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,Other,Cardiovascular,Current,,,0409-6102-26,limited availability
14267,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,25021-311-02,available
14268,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,25021-311-04,available
14269,Furosemide Injection,Gland Pharma Limited,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Cardiovascular,Current,,,25021-311-10,available
14270,Gefitinib Tablet,Apotex Corp.,"Gefitinib, Tablet, 250 mg (NDC 60505-4512-3)",New,2/5/25,,,,,Oncology,To Be Discontinued,,2/5/25,60505-4512-3,discontinued
14271,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-01)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25,0591-0844-01,discontinued
14272,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-10)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25,0591-0844-10,discontinued
14273,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-01)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25,0591-0845-01,discontinued
14274,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-10)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25,0591-0845-10,discontinued
14275,"Glipizide Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Glipizide, Tablet, Extended Release, 2.5 mg (NDC 0591-0900-30)",New,2/6/25,,A business decision was made to discontinue manufacture of the drug.,,,Endocrinology/Metabolism,To Be Discontinued,,2/6/25,0591-0900-30,discontinued
14276,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucotrol XL, Tablet, Extended Release, 5 mg (NDC 0049-0174-03)",New,3/17/25,,Supply expected to exhaust early April 2025,,,Endocrinology/Metabolism,To Be Discontinued,,3/17/25,0049-0174-03,discontinued
14277,"Glipizide Tablet, Extended Release",Pfizer Inc.,"Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)",New,7/24/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/24/25,0049-0178-08,discontinued
14278,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25,0093-8034-01,discontinued
14279,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25,0093-8035-01,discontinued
14280,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25,0093-8035-05,discontinued
14281,Glyburide Tablet,"Teva Pharmaceuticals USA, Inc.","Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,6/10/25,0093-8036-01,discontinued
14282,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 10147-0921-3)",New,4/7/25,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25,10147-0921-3,discontinued
14283,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haloperidol Decanoate, Injection, 100 mg/1 mL (NDC 10147-0922-5)",New,4/7/25,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25,10147-0922-5,discontinued
14284,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 50 mg/1 mL (NDC 50458-253-03)",New,4/7/25,,Last batch expiration date 5/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25,50458-253-03,discontinued
14285,Haloperidol Decanoate Injection,Janssen Pharmaceuticals,"Haldol, Injection, 100 mg/1 mL (NDC 50458-254-14)",New,4/7/25,,Last batch expiration date 8/31/2025,,,Psychiatry,To Be Discontinued,,4/7/25,50458-254-14,discontinued
14286,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 5000 [USP'U]/1 mL (NDC 0409-1402-12)",New,4/29/25,,Discontinuation of the manufacture of the drug.,,,Hematology,To Be Discontinued,,4/29/25,0409-1402-12,discontinued
14287,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)",Reverified,8/21/25,Available,,,,Hematology,Current,,,0264-9872-00,available
14288,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Hematology,Current,,,63323-519-77,available
14289,Heparin Sodium Injection,"Fresenius Kabi USA, LLC","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Hematology,Current,,,63323-519-10,available
14290,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Reverified,9/3/25,Unavailable,Product Discontinued - Product code AHB0953U replaced by Product Code 2B0953,,Discontinuation of the manufacture of the drug,Hematology,Current,,,0338-0424-18,not available
14291,Heparin Sodium Injection,B. Braun Medical Inc.,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Reverified,8/21/25,Available,,,,Hematology,Current,,,0264-9872-10,available
14292,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Reverified,9/3/25,Available,,,,Hematology,Current,,,0338-0433-04,available
14293,Heparin Sodium Injection,Baxter Healthcare,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Reverified,9/3/25,Limited Availability,Recovery TBD,,Demand increase for the drug,Hematology,Current,,,0338-0431-03,limited availability
14294,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)",Reverified,8/15/25,Available,,,,Hematology,Current,1/2/25,,0409-7620-03,available
14295,Heparin Sodium Injection,"Hospira, Inc., a Pfizer Company","Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)",Reverified,8/15/25,Available,,,,Hematology,Current,1/2/25,,0409-7620-59,available
14296,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 10 mg/1 g (NDC 0472-0321-26)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25,0472-0321-26,discontinued
14297,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-20)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25,0472-0337-20,discontinued
14298,Hydrocortisone Cream,"Teva Pharmaceuticals USA, Inc.","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-30)",New,3/24/25,,A business decision was made to discontinue.,,,Dermatology,To Be Discontinued,,3/24/25,0472-0337-30,discontinued
14299,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0005-01,limited availability
14300,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0825-01,limited availability
14301,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/24,,0009-0011-04,limited availability
14302,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,12/19/24,,0009-0011-03,limited availability
14303,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-06,limited availability
14304,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0013-05,limited availability
14305,Hydrocortisone Sodium Succinate Injection,"Hospira, Inc., a Pfizer Company","Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Pulmonary/Allergy; Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Pediatric; Renal; Rheumatology,Current,,,0009-0016-12,limited availability
14306,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,,0409-3365-10,available
14307,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)",Revised,8/15/25,Unavailable,Next Delivery: February 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,,0409-1283-37,not available
14308,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Analgesia/Addiction,Current,,,0409-1312-36,limited availability
14309,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,76045-009-06,not available
14310,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0703-0110-03,available
14311,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0703-0113-03,available
14312,Hydromorphone Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)",Revised,8/19/25,Available,Estimated recovery: November 2025,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0703-0018-01,available
14313,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,1/3/25,,0641-0121-25,available
14314,Hydromorphone Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6254-01,available
14315,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,1/2/25,,0409-1283-31,limited availability
14316,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,,0409-1312-30,available
14317,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,,0409-1304-31,available
14318,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Injection, 1 mg/1 mL (NDC 0409-2552-01)",Revised,1/13/25,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,1/13/25,1/13/25,0409-2552-01,discontinued
14319,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,,0409-2634-01,available
14320,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,,0409-2634-05,available
14321,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/2/25,,0409-2634-50,available
14322,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-852-25,available
14323,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,63323-853-25,not available
14324,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,,63323-854-10,not available
14325,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-851-10,not available
14326,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Other,Analgesia/Addiction,Current,,,63323-851-15,not available
14327,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,63323-851-50,not available
14328,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-009-11,available
14329,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Revised,9/2/25,Available,Check wholesalers for inventory,,Other,Analgesia/Addiction,Current,,,76045-121-11,available
14330,Hydromorphone Hydrochloride Injection,"Fresenius Kabi USA, LLC","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-010-11,available
14331,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,,0409-4264-01,not available
14332,Hydromorphone Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect‚Äö√Ñ√∂‚àö√´¬¨¬¢ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,,0409-1805-01,available
14333,Hydroxocobalamin Injection,BTG International Inc.,"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)",Revised,8/5/25,Limited Availability,"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.",,Requirements related to complying with good manufacturing practices,Other,Current,,,50633-310-11,limited availability
14334,Hydroxypropyl Cellulose (1600000 Wamw) Insert,Bausch & Lomb Incorporated,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Revised,7/16/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Ophthalmology,Current,,,24208-800-60,not available
14335,Ibandronate Sodium Injection,Norvium Bioscience LLC,"Ibandronate Sodium, Injection, 3 mg/3 mL (NDC 67457-524-33)",New,3/5/25,,,,,Endocrinology/Metabolism,To Be Discontinued,,3/5/25,67457-524-33,discontinued
14336,Ibutilide Fumarate Injection,Norvium Bioscience LLC,"Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",New,3/5/25,,,,,Cardiovascular,To Be Discontinued,,3/5/25,67457-366-10,discontinued
14337,Idarubicin Hydrochloride Injection,Pfizer Inc.,"Idamycin, Injection, 1 mg/1 mL (NDC 0013-2576-91)",New,2/6/25,,Replaced with NDC 0013-2576-05,,,Oncology,To Be Discontinued,,2/6/25,0013-2576-91,discontinued
14338,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-13)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-472-13,discontinued
14339,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-81)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-472-81,discontinued
14340,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-83)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-472-83,discontinued
14341,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-88)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-472-88,discontinued
14342,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-13)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-475-13,discontinued
14343,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-64)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-475-64,discontinued
14344,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-83)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-475-83,discontinued
14345,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-88)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,47335-475-88,discontinued
14346,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 100 mg (NDC 68001-490-05)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,68001-490-05,discontinued
14347,Imatinib Mesylate Tablet,Sun Pharmaceutical Industries Limited,"Imatinib Mesylate, Tablet, 400 mg (NDC 68001-491-04)",New,12/5/24,,Discontinuing for business reasons,,,Hematology,To Be Discontinued,,12/5/24,68001-491-04,discontinued
14348,Indium In-111 Chloride  Injection,Curium US LLC,"Injection, 0.5 mL/vial (5 mCi at time of calibration) (NDC 69945-132-06)",New,9/24/24,,Product discontinued due to business related reasons,,,Medical Imaging,To Be Discontinued,,9/24/24,69945-132-06,discontinued
14349,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"Indocyanine Green, Injection, 25 mg (NDC 70100-424-02)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,70100-424-02,
14350,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-15)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-936-15,
14351,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-14)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-903-14,
14352,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-13)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-306-13,
14353,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-25)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-936-25,
14354,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-24)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-903-24,
14355,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-23)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-306-23,
14356,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-16)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-937-16,
14357,Indocyanine Green Injection,Novadaq Technologies,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-26)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,66259-937-26,
14358,Indocyanine Green Injection,Renew Pharmaceuticals Limited,"IC-GREEN, Injection, 25 mg (NDC 70100-825-02)",Revised,8/26/25,,,Available,,Medical Imaging; Ophthalmology; Other,Resolved,8/26/25,,70100-825-02,
14359,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)",New,7/21/25,,"Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-100-11,discontinued
14360,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill¬¨¬®‚àö√ú cartridge (NDC 73070-102-15)",New,7/21/25,,"Unbranded Insulin Aspart 3 mL PenFill¬¨¬®‚àö√ú cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-102-15,discontinued
14361,Insulin Aspart Injection,"Novo Nordisk, Inc.","Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen¬¨¬®‚àö√ú (NDC 73070-103-15)",New,7/21/25,,"Unbranded Insulin Aspart 3 mL FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-103-15,discontinued
14362,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)",New,7/21/25,,"Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-200-11,discontinued
14363,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"Novo Nordisk, Inc.","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen¬¨¬®‚àö√ú (NDC 73070-203-15)",New,7/21/25,,"Unbranded Insulin aspart protamine and insulin aspart FlexPen¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-203-15,discontinued
14364,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)",New,7/21/25,,"Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-400-11,discontinued
14365,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch¬¨¬®‚àö√ú (NDC 73070-403-15)",New,7/21/25,,"Unbranded Insulin Degludec 3 mL U-100 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-403-15,discontinued
14366,Insulin Degludec Injection,"Novo Nordisk, Inc.","Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch¬¨¬®‚àö√ú (NDC 73070-503-15)",New,7/21/25,,"Unbranded Insulin Degludec 3 mL U-200 FlexTouch¬¨¬®‚àö√ú will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,,Endocrinology/Metabolism,To Be Discontinued,,7/21/25,73070-503-15,discontinued
14367,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-49)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24,47335-706-49,discontinued
14368,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-52)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24,47335-706-52,discontinued
14369,Ipratropium Bromide Solution,"Sun Pharmaceutical Industries, Inc.","Solution, .5 mg/2.5 mL (NDC 47335-706-54)",New,9/20/24,,,,,Pulmonary/Allergy,To Be Discontinued,,9/20/24,47335-706-54,discontinued
14370,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)",New,8/4/25,,Product not anticipated to be available beyond mid-late October 2025,,,Oncology,To Be Discontinued,,8/4/25,45963-614-51,discontinued
14371,Irinotecan Hydrochloride Injection,"Teva Pharmaceuticals USA, Inc.","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)",New,8/4/25,,Product not anticipated to be available beyond mid-late September 2025,,,Oncology,To Be Discontinued,,8/4/25,45963-614-55,discontinued
14372,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 40 mg per 2 mL (20mg per mL) (NDC 63323-193-52)",New,9/30/24,,,,,Oncology,To Be Discontinued,,9/30/24,63323-193-52,discontinued
14373,Irinotecan Hydrochloride Injection,"Fresenius Kabi USA, LLC","Injection, 100 mg per 5 mL (20mg per mL) (NDC 63323-193-55)",New,9/30/24,,,,,Oncology,To Be Discontinued,,9/30/24,63323-193-55,discontinued
14374,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 100 mg (NDC 0555-0066-02)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24,0555-0066-02,discontinued
14375,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-01)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24,0555-0071-01,discontinued
14376,Isoniazid Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 300 mg (NDC 0555-0071-02)",New,11/21/24,,Product available through 12/03/2024,,,Anti-Infective,To Be Discontinued,,11/21/24,0555-0071-02,discontinued
14377,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-03)",New,7/1/25,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/25,64950-217-03,discontinued
14378,Isoniazid Tablet,Genus Lifesciences,"Isoniazid, Tablet, 300 mg (NDC 64950-217-10)",New,7/1/25,,Product expected to be available until August 2025.,,,Anti-Infective,To Be Discontinued,,7/1/25,64950-217-10,discontinued
14379,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 20 mg (NDC 0228-2620-11)",New,11/13/24,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/24,0228-2620-11,discontinued
14380,Isosorbide Mononitrate Tablet,"Teva Pharmaceuticals USA, Inc.","Tablet, 10 mg (NDC 0228-2631-11)",New,11/13/24,,A business decision was made to discontinue manufacture of this product.,,,Cardiovascular,To Be Discontinued,,11/13/24,0228-2631-11,discontinued
14381,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-2051-05)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,0409-2051-05,
14382,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 65219-184-20)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,65219-184-20,
14383,Ketamine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 65219-188-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,65219-188-10,
14384,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 25021-682-20)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,25021-682-20,
14385,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 25021-683-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,25021-683-10,
14386,Ketamine Hydrochloride Injection,Gland Pharma Limited,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 25021-684-05)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,25021-684-05,
14387,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-438-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,55150-438-10,
14388,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 55150-439-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,55150-439-10,
14389,Ketamine Hydrochloride Injection,Eugia US LLC,"Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 55150-440-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,55150-440-10,
14390,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL) (NDC 0409-0040-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,0409-0040-10,
14391,Ketamine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Ketamine Hydrochloride, Injection, 500 mg/10 mL (50 mg/mL) (NDC 0409-2053-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,0409-2053-10,
14392,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 100 mg/1 mL (NDC 0143-9509-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,0143-9509-10,
14393,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 10 mg/1 mL (NDC 42023-113-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,42023-113-10,
14394,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 100 mg/1 mL (NDC 42023-115-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,42023-115-10,
14395,Ketamine Hydrochloride Injection,"Par Pharmaceutical, Inc.","Ketalar, Injection, 50 mg/1 mL (NDC 42023-114-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,42023-114-10,
14396,Ketamine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Ketamine Hydrochloride, Injection, 50 mg/1 mL (NDC 0143-9508-10)",Revised,4/2/25,,,Available,,Anesthesia,Resolved,4/2/25,,0143-9508-10,
14397,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,,25021-700-01,available
14398,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,,25021-701-02,available
14399,Ketorolac Tromethamine Injection,Sagent Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)",Reverified,8/26/25,Available,,,,Analgesia/Addiction,Current,,,25021-701-01,available
14400,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,,0409-3793-01,limited availability
14401,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,,0409-3795-01,available
14402,Ketorolac Tromethamine Injection,"Hospira, Inc., a Pfizer Company","Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Analgesia/Addiction,Current,,,0409-3796-01,limited availability
14403,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,0641-6041-25,not available
14404,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,0641-6042-25,not available
14405,Ketorolac Tromethamine Injection,"Hikma Pharmaceuticals USA, Inc.","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Revised,7/23/25,Unavailable,Shortage recovery: TBD,,Other,Analgesia/Addiction,Current,,,0641-6043-25,not available
14406,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,63323-161-01,available
14407,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,63323-162-01,available
14408,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)",Reverified,9/2/25,Available,Check wholesaler inventory,,,Analgesia/Addiction,Current,,,63323-162-02,available
14409,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,,0338-0069-10,available
14410,Ketorolac Tromethamine Injection,Baxter Healthcare,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,,0338-0072-25,available
14411,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,76045-107-10,not available
14412,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,76045-104-10,not available
14413,Ketorolac Tromethamine Injection,"Fresenius Kabi USA, LLC","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)",Reverified,9/2/25,Unavailable,Not available at this time.,,Other,Analgesia/Addiction,Current,,,76045-105-20,not available
14414,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,,72266-118-25,available
14415,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)",Reverified,7/28/25,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,,Analgesia/Addiction,Current,,,72266-119-25,available
14416,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,,62332-599-25,available
14417,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,,62332-600-25,available
14418,Ketorolac Tromethamine Injection,Alembic Pharmaceuticals,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)",Reverified,6/27/25,Available,,,,Analgesia/Addiction,Current,,,62332-601-25,available
14419,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-01",,,Analgesia/Addiction,Current,,,70860-701-03,available
14420,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC  25021-700-01",,,Analgesia/Addiction,Current,,,70860-700-02,available
14421,Ketorolac Tromethamine Injection,Gland Pharma Limited,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)",Reverified,7/28/25,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-02",,,Analgesia/Addiction,Current,,,70860-701-04,available
14422,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-02)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0990-7953-02,available
14423,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-03)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0990-7953-03,available
14424,Lactated Ringers Injection,Otsuka ICU Medical LLC,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-09)",Reverified,8/20/25,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0990-7953-09,available
14425,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0117-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0338-0117-04,available
14426,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 250 mL bag, 36 count (NDC 0338-0117-02)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0338-0117-02,available
14427,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 500 mL bag, 24 count (NDC 0338-0117-03)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0338-0117-03,available
14428,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-04)",Reverified,9/3/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0338-0125-04,available
14429,Lactated Ringers Injection,Baxter Healthcare,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-03)",Reverified,9/3/25,Unavailable,Product Discontinued,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0338-0125-03,not available
14430,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7500-00)",Reverified,8/21/25,Unavailable,Product not yet launched,,Other,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7500-00,not available
14431,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-00)",Revised,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7750-00,available
14432,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7750-10,available
14433,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-20)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7750-20,available
14434,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-00)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7751-00,available
14435,Lactated Ringers Injection,B. Braun Medical Inc.,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-10)",Reverified,8/21/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Other,Current,,,0264-7751-10,available
14436,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg (NDC 70436-119-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,70436-119-80,
14437,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg (NDC 70436-116-82)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,70436-116-82,
14438,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg (NDC 70436-117-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,70436-117-80,
14439,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg (NDC 70436-118-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,70436-118-80,
14440,Leucovorin Calcium Injection,Slate Run Pharmaceuticals,"Leucovorin Calcium, Injection, 500 mg (NDC 70436-120-80)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,70436-120-80,
14441,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 25021-813-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,25021-813-10,
14442,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 25021-814-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,25021-814-30,
14443,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 25021-815-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,25021-815-30,
14444,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 25021-816-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,25021-816-30,
14445,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 63323-710-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,63323-710-50,
14446,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 63323-711-00)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,63323-711-00,
14447,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 71288-160-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,71288-160-10,
14448,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 71288-161-20)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,71288-161-20,
14449,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 71288-162-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,71288-162-30,
14450,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 71288-163-30)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,71288-163-30,
14451,Leucovorin Calcium Injection,Kindos Pharmaceuticals Co. Ltd.,"Leucovorin Calcium, Injection, 500 mg/50 mL (NDC 71288-164-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,71288-164-50,
14452,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 0143-9555-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,0143-9555-01,
14453,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 0143-9554-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,0143-9554-01,
14454,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 0143-9553-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,0143-9553-01,
14455,Leucovorin Calcium Injection,"Hikma Pharmaceuticals USA, Inc.","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,0143-9552-01,
14456,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,63323-631-10,
14457,Leucovorin Calcium Injection,"Fresenius Kabi USA, LLC","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,63323-631-50,
14458,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,67457-528-10,
14459,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,67457-529-20,
14460,Leucovorin Calcium Injection,"Mylan Institutional, a Viatris Company","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,67457-530-35,
14461,Leucovorin Calcium Injection,Sagent Pharmaceuticals,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Revised,7/8/25,,,Available,,Oncology; Pediatric,Resolved,7/8/25,,25021-828-50,
14462,Levalbuterol Hydrochloride Solution,"Teva Pharmaceuticals USA, Inc.","Solution, 1.25 mg/.5 mL (NDC 0093-4147-56)",New,10/15/24,,,,,Pulmonary/Allergy,To Be Discontinued,,10/15/24,0093-4147-56,discontinued
14463,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-025-30,discontinued
14464,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 25 ug (NDC 72305-025-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-025-90,discontinued
14465,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-050-30,discontinued
14466,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 50 ug (NDC 72305-050-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-050-90,discontinued
14467,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-075-30,discontinued
14468,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 75 ug (NDC 72305-075-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-075-90,discontinued
14469,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-088-30,discontinued
14470,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 88 ug (NDC 72305-088-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-088-90,discontinued
14471,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-100-30,discontinued
14472,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 100 ug (NDC 72305-100-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-100-90,discontinued
14473,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-112-30,discontinued
14474,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 112 ug (NDC 72305-112-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-112-90,discontinued
14475,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-125-30,discontinued
14476,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 125 ug (NDC 72305-125-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-125-90,discontinued
14477,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-137-30,discontinued
14478,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 137 ug (NDC 72305-137-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-137-90,discontinued
14479,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-150-30,discontinued
14480,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 150 ug (NDC 72305-150-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-150-90,discontinued
14481,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-175-30,discontinued
14482,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 175 ug (NDC 72305-175-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-175-90,discontinued
14483,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-30)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-200-30,discontinued
14484,Levothyroxine Sodium Tablet,"EMD Serono, Inc.","Euthyrox, Tablet, 200 ug (NDC 72305-200-90)",New,7/10/25,,Discontinuation of the manufacture of the drug,,,Endocrinology/Metabolism,To Be Discontinued,,7/10/25,72305-200-90,discontinued
14485,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-251-10,available
14486,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-252-20,available
14487,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-254-10,available
14488,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-255-20,available
14489,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9595-25,available
14490,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9594-25,available
14491,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9577-10,available
14492,Lidocaine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Revised,7/23/25,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9575-10,available
14493,Lidocaine Hydrochloride Injection,"Spectra Medical Devices, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,65282-1605-1,available
14494,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,,0409-4776-01,limited availability
14495,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-492-31,not available
14496,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-0409-03,available
14497,Lidocaine Hydrochloride Injection,Baxter Healthcare,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Reverified,9/3/25,Available,,,,Cardiovascular,Current,,,0338-0411-02,available
14498,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,,0264-9598-20,available
14499,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,,0264-9594-20,available
14500,Lidocaine Hydrochloride Injection,B. Braun Medical Inc.,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Reverified,8/21/25,Available,,,,Cardiovascular,Current,,,0264-9594-10,available
14501,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-158-72)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-158-72,not available
14502,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-159-74,not available
14503,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-160-72)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-160-72,not available
14504,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-161-02,available
14505,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-162-05,available
14506,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-163-30,available
14507,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-164-02,available
14508,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-165-05,available
14509,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-484-57,not available
14510,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-491-57,available
14511,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-201-02,available
14512,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-201-10,available
14513,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-485-27,available
14514,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-485-57,available
14515,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-492-27,available
14516,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-492-57,available
14517,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-492-37,available
14518,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-9137-05,available
14519,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-32,available
14520,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4276-01,available
14521,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4279-02,available
14522,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4276-02,available
14523,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,0409-4282-01,limited availability
14524,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4282-02,available
14525,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/24,,0409-4904-34,not available
14526,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Anesthesia; Pediatric,Current,12/19/24,,0409-4903-34,not available
14527,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,12/19/24,,0409-2066-05,available
14528,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4277-01,available
14529,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,,,0409-4277-02,limited availability
14530,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4283-01,available
14531,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-1323-05,available
14532,Lidocaine Hydrochloride Injection,"Amphastar Pharmaceuticals, Inc.","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Reverified,8/19/25,Available,old NDC 0548-3390-00,,,Anesthesia; Pediatric,Current,,,76329-3390-1,available
14533,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-493-97,not available
14534,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Reverified,9/2/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-493-91,not available
14535,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-202-02,available
14536,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-208-05,available
14537,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-486-17,available
14538,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-486-27,available
14539,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-486-57,available
14540,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-495-27,available
14541,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Pediatric,Current,,,63323-495-07,available
14542,Lidocaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Reverified,9/2/25,Unavailable,Next release date not available at this time.,,Demand increase for the drug,Anesthesia; Pediatric,Current,,,63323-496-97,not available
14543,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Anesthesia; Pediatric,Current,12/19/24,,0409-4275-01,not available
14544,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4278-01,available
14545,Lidocaine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)",Reverified,8/15/25,Available,,,,Anesthesia; Pediatric,Current,,,0409-4713-02,available
14546,Lidocaine Hydrochloride Injection,Eugia US LLC,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-256-50,not available
14547,Lidocaine Hydrochloride Injection,Afaxys Pharma,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 50102-400-10)",Revised,3/5/25,,,,,Anesthesia; Pediatric,To Be Discontinued,3/5/25,3/5/25,50102-400-10,discontinued
14548,Lidocaine Hydrochloride Injection,"Huons Co., Ltd. (South Korea)","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Reverified,6/27/25,Available,,,,Anesthesia,Current,,,73293-0001-2,available
14549,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-001-10,available
14550,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-002-10,available
14551,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-003-10,available
14552,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-004-10,available
14553,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-005-10,available
14554,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-006-10,available
14555,Lidocaine Hydrochloride Injection,Sintetica US,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Reverified,8/19/25,Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.",,,Anesthesia; Pediatric,Current,,,83090-007-10,available
14556,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-3500-49)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,0054-3500-49,
14557,Lidocaine Hydrochloride Solution,"Hikma Pharmaceuticals USA, Inc.","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-0548-44)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,0054-0548-44,
14558,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-4950-40)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,0121-4950-40,
14559,Lidocaine Hydrochloride Solution,Rubicon Research Private Limited,"Lidocaine Hydrochloride, Solution, 20 mg/1 mL (NDC 72888-125-26)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,72888-125-26,
14560,Lidocaine Hydrochloride Solution,PAI Pharma,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-0950-03)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,0121-0950-03,
14561,Lidocaine Hydrochloride Solution,Chartwell Molecular Holdings LLC,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Revised,8/29/25,,,Available,,Anesthesia,Resolved,8/29/25,,62135-712-42,
14562,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 30 gram tubes (NDC 64380-789-23)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25,64380-789-23,discontinued
14563,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 35.44 gram tubes (NDC 64380-789-32)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25,64380-789-32,discontinued
14564,Lidocaine Ointment,Strides Pharma Inc.,"Lidocaine, Ointment, 5%, 50 gram jar (NDC 64380-789-33)",New,1/28/25,,,,,Anesthesia,To Be Discontinued,,1/28/25,64380-789-33,discontinued
14565,Lidocaine Patch,"Actavis Pharma, Inc.","Lidocaine, Patch, 5% (NDC 0591-2679-30)",New,7/17/25,,Discontinuation is for the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´NovaPlus‚Äö√Ñ√∂‚àö√ë‚àöœÄ label product only.,,,Analgesia/Addiction,To Be Discontinued,,7/17/25,0591-2679-30,discontinued
14566,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 600 mg/300 mL (NDC 0009-4992-02)",New,10/11/24,,,,,Anti-Infective,To Be Discontinued,,10/11/24,0009-4992-02,discontinued
14567,Linezolid Solution,Pfizer Inc.,"Zyvox, Solution, 200 mg/100 mL (NDC 0009-5137-04)",New,10/11/24,,,,,Anti-Infective,To Be Discontinued,,10/11/24,0009-5137-04,discontinued
14568,Liraglutide Injection,"Novo Nordisk, Inc.","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Reverified,7/15/25,Available,,,,Endocrinology/Metabolism,Current,,,0169-2800-15,available
14569,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)",Reverified,7/23/25,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,,0143-9144-03,available
14570,Liraglutide Injection,"Hikma Pharmaceuticals USA, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)",Reverified,7/23/25,Available,Product will be made available as it is released.,,,Endocrinology/Metabolism,Current,,,0143-9144-02,available
14571,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism,Current,,,71288-563-84,available
14572,Liraglutide Injection,"Meitheal Pharmaceuticals, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism,Current,,,71288-563-85,available
14573,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)",Reverified,7/15/25,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,,0480-3667-20,available
14574,Liraglutide Injection,"Novo Nordisk, Inc.","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)",Reverified,7/15/25,Available,Distributed by Teva,,,Endocrinology/Metabolism,Current,,,0480-3667-22,available
14575,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)",Reverified,7/15/25,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-4060-12,limited availability
14576,Liraglutide Injection,"Novo Nordisk, Inc.","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)",Reverified,7/15/25,Limited Availability,Estimated shortage duration TBD,,Delay in shipping of the drug,Endocrinology/Metabolism,Current,,,0169-4060-13,limited availability
14577,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-161-01,available
14578,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-162-01,available
14579,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-163-01,available
14580,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-164-01,available
14581,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-166-01,available
14582,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-165-01,available
14583,Lisdexamfetamine Dimesylate Capsule,Rhodes Pharmaceuticals L.P.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)",Reverified,8/5/25,Available,,,,Psychiatry,Current,,,42858-167-01,available
14584,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-562-01,available
14585,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-563-01,available
14586,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-564-01,available
14587,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-565-01,available
14588,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-566-01,available
14589,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-567-01,available
14590,Lisdexamfetamine Dimesylate Capsule,Alvogen,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,47781-568-01,available
14591,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,,60505-4739-1,available
14592,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,,60505-4740-1,available
14593,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,,60505-4741-1,available
14594,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,,60505-4742-1,available
14595,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)",Reverified,7/24/25,Available,Product currently available,,,Psychiatry,Current,,,60505-4743-1,available
14596,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)",Reverified,7/24/25,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,,60505-4744-1,limited availability
14597,Lisdexamfetamine Dimesylate Capsule,Apotex Corp.,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)",Reverified,7/24/25,Limited Availability,"Limited quantity available, next resupply in late July 2025",,Other,Psychiatry,Current,,,60505-4745-1,limited availability
14598,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6854-77,available
14599,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6855-77,available
14600,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6856-77,available
14601,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6857-77,available
14602,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6858-77,available
14603,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6859-77,available
14604,Lisdexamfetamine Dimesylate Capsule,"Mylan Pharmaceuticals Inc., a Viatris Company","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-6860-77,available
14605,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-046-88,limited availability
14606,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-048-88,limited availability
14607,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-048-88,limited availability
14608,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-049-88,limited availability
14609,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-050-88,limited availability
14610,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-051-88,limited availability
14611,Lisdexamfetamine Dimesylate Capsule,"Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Shortage of an active ingredient,Psychiatry,Current,,,57664-052-88,limited availability
14612,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5111-01,limited availability
14613,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5112-01,limited availability
14614,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5113-01,limited availability
14615,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5114-01,limited availability
14616,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5115-01,limited availability
14617,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5116-01,limited availability
14618,Lisdexamfetamine Dimesylate Capsule,SpecGx LLC,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-5117-01,limited availability
14619,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0370-25,limited availability
14620,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0371-25,limited availability
14621,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0372-25,limited availability
14622,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0373-25,limited availability
14623,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0374-25,limited availability
14624,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)",Reverified,7/23/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0375-25,limited availability
14625,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4661-37,limited availability
14626,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4662-37,limited availability
14627,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)",Revised,9/2/25,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4663-37,not available
14628,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)",Revised,9/2/25,Unavailable,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4664-37,not available
14629,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4665-37,limited availability
14630,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)",Reverified,9/2/25,Limited Availability,Limited Availability,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4666-37,limited availability
14631,Lisdexamfetamine Dimesylate Capsule,"Lannett Company, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)",Reverified,9/2/25,Unavailable,Unavailable,,Shortage of an active ingredient,Psychiatry,Current,,,0527-4667-37,not available
14632,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-023-09,not available
14633,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-024-09,not available
14634,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-025-09,not available
14635,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-026-09,not available
14636,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-027-09,not available
14637,Lisdexamfetamine Dimesylate Capsule,Amneal Pharmaceuticals,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)",Reverified,8/5/25,Unavailable,Shortage of an active ingredient,,Shortage of an active ingredient,Psychiatry,Current,,,65162-028-09,not available
14638,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-602-10,limited availability
14639,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-603-10,limited availability
14640,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-604-10,limited availability
14641,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-605-10,limited availability
14642,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-606-10,limited availability
14643,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-607-10,limited availability
14644,Lisdexamfetamine Dimesylate Capsule,"Solco Healthcare US, LLC","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)",Reverified,8/5/25,Limited Availability,On allocation,,Shortage of an active ingredient,Psychiatry,Current,,,43547-608-10,limited availability
14645,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-101-10,available
14646,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-102-10,available
14647,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-103-10,available
14648,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-104-10,available
14649,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-105-10,available
14650,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-106-10,available
14651,Lisdexamfetamine Dimesylate Capsule,Takeda Pharmaceuticals USA Inc.,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-107-10,available
14652,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-550-01,limited availability
14653,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-551-01,limited availability
14654,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-552-01,limited availability
14655,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-553-01,limited availability
14656,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-554-01,limited availability
14657,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-555-01,limited availability
14658,Lisdexamfetamine Dimesylate Capsule,"Elite Laboratories, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)",Reverified,9/2/25,Limited Availability,,,Shortage of an active ingredient,Psychiatry,Current,,,64850-556-01,limited availability
14659,Lisdexamfetamine Dimesylate Capsule,"Hikma Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)",Revised,8/1/25,Limited Availability,Available on allocation,,Shortage of an active ingredient,Psychiatry,Current,,,0054-0660-25,limited availability
14660,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3565-01,available
14661,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3566-01,available
14662,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3567-01,available
14663,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3568-01,available
14664,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)",Revised,8/19/25,Limited Availability,Estimated recovery: August 2025,,Shortage of an active ingredient,Psychiatry,Current,,,0480-3569-01,limited availability
14665,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3570-01,available
14666,Lisdexamfetamine Dimesylate Capsule,"Teva Pharmaceuticals USA, Inc.","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,0480-3564-01,available
14667,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-115-01,available
14668,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-116-01,available
14669,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-117-01,available
14670,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-118-01,available
14671,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-119-01,available
14672,"Lisdexamfetamine Dimesylate Tablet, Chewable",Takeda Pharmaceuticals USA Inc.,"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Reverified,8/15/25,Available,,,,Psychiatry,Current,,,59417-120-01,available
14673,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-083-88,limited availability
14674,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-084-88,limited availability
14675,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-085-88,limited availability
14676,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-087-88,limited availability
14677,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-088-88,limited availability
14678,"Lisdexamfetamine Dimesylate Tablet, Chewable","Sun Pharmaceutical Industries, Inc.","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Psychiatry,Current,,,57664-086-88,limited availability
14679,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-132-91,available
14680,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-133-91,available
14681,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-134-91,available
14682,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-135-91,available
14683,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-136-91,available
14684,"Lisdexamfetamine Dimesylate Tablet, Chewable",Novadoz Pharmaceuticals LLC,"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)",Revised,7/16/25,Available,Limited supply,,Shortage of an active ingredient,Psychiatry,Current,,,72205-137-91,available
14685,Lodoxamide Tromethamine Solution,Novartis Pharmaceuticals Corporation,"Alomide, Solution, 1 mg/1 mL (NDC 0078-0736-10)",New,12/9/24,,"Novartis has made a business decision to permanently discontinue ALOMIDE¬¨¬®‚àö√ú (lodoxamide tromethamine) ophthalmic solution, 0.1%

Discontinuation of the product is due in part to manufacturing concerns.

Short-dated material is available until January 2025.",,,Ophthalmology,To Be Discontinued,,12/9/24,0078-0736-10,discontinued
14686,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6047-10,not available
14687,Lorazepam Injection,"Hospira, Inc., a Pfizer Company","Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Neurology,Current,,,0409-1985-30,not available
14688,Lorazepam Injection,"Amphastar Pharmaceuticals, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)",Reverified,8/19/25,Limited Availability,,,Demand increase for the drug,Neurology,Current,,,76329-8261-1,limited availability
14689,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6001-25,not available
14690,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6000-10,not available
14691,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6003-25,not available
14692,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6002-10,not available
14693,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6044-25,not available
14694,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6046-10,not available
14695,Lorazepam Injection,"Hikma Pharmaceuticals USA, Inc.","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Revised,7/23/25,Unavailable,Shortage duration unknown,,Regulatory delay,Neurology,Current,,,0641-6045-25,not available
14696,Mefloquine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Mefloquine Hydrochloride, Tablet, 250 mg (NDC 0555-0171-78)",Revised,8/21/25,,,Available,,Anti-Infective,Resolved,8/21/25,,0555-0171-78,
14697,Mefloquine Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Mefloquine Hydrochloride, Tablet, 250 mg (NDC 62135-973-25)",Revised,8/21/25,,,Available,,Anti-Infective,Resolved,8/21/25,,62135-973-25,
14698,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 5 mg (NDC 0832-1112-60)",New,4/28/25,,,,,Neurology,To Be Discontinued,,4/28/25,0832-1112-60,discontinued
14699,Memantine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Memantine Hydrochloride, Tablet, 10 mg (NDC 0832-1113-60)",New,4/28/25,,,,,Neurology,To Be Discontinued,,4/28/25,0832-1113-60,discontinued
14700,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-44)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24,0591-3870-44,discontinued
14701,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 5 mg (NDC 0591-3870-60)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24,0591-3870-60,discontinued
14702,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-44)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24,0591-3875-44,discontinued
14703,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, 10 mg (NDC 0591-3875-60)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24,0591-3875-60,discontinued
14704,Memantine Hydrochloride Tablet,"Actavis Pharma, Inc.","Namenda, Tablet, Kit (NDC 0591-3900-87)",New,11/21/24,,,,,Neurology,To Be Discontinued,,11/21/24,0591-3900-87,discontinued
14705,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0641-6052-25,not available
14706,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0641-6053-25,not available
14707,Meperidine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,Shortage of an active ingredient,Analgesia/Addiction,Current,,,0641-6054-25,not available
14708,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,0409-1176-30,not available
14709,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,0409-1178-30,not available
14710,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Analgesia/Addiction,Current,,,0409-1181-30,not available
14711,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1179-30,not available
14712,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1180-69,not available
14713,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1362-01,not available
14714,Meperidine Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1418-01,not available
14715,Methamphetamine Hydrochloride Tablet,"Dr. Reddy's Laboratories, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)",Reverified,8/15/25,Available,Available to existing customers,,,Psychiatry,Current,,,68308-115-01,available
14716,Methamphetamine Hydrochloride Tablet,"Hikma Pharmaceuticals USA, Inc.","Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)",Revised,8/1/25,Available,,,,Psychiatry,Current,,,0054-0389-25,available
14717,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-010-04,discontinued
14718,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-012-04,discontinued
14719,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-015-04,discontinued
14720,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-017-04,discontinued
14721,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-020-04,discontinued
14722,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-022-04,discontinued
14723,Methotrexate Injection,"Assertio Specialty Pharmaceuticals, LLC","Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)",New,8/29/25,,Discontinuation of the manufacture of the drug,,,Rheumatology,To Be Discontinued,,8/29/25,82497-025-04,discontinued
14724,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Injection, 25 mg/1 mL (NDC 61703-161-05)",New,1/8/25,,Discontinuation of the manufacture of the drug,,,Oncology; Rheumatology,To Be Discontinued,,1/8/25,61703-161-05,discontinued
14725,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Reverified,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Rheumatology; Oncology,Current,,,0143-9830-01,available
14726,Methotrexate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Rheumatology; Oncology,Current,,,0143-9519-10,available
14727,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Revised,8/19/25,Available,Estimated recovery: December 2025,,Other,Rheumatology; Oncology,Current,,,0703-3671-01,available
14728,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Revised,8/19/25,Unavailable,Estimated recovery: October 2025,,Other,Rheumatology; Oncology,Current,,,0703-3675-01,not available
14729,Methotrexate Sodium Injection,"Teva Pharmaceuticals USA, Inc.","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Revised,8/19/25,Limited Availability,Estimated recovery: January 2026,,Other,Rheumatology; Oncology,Current,,,0703-3678-01,limited availability
14730,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,,61703-350-38,available
14731,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Rheumatology; Oncology,Current,,,61703-350-10,limited availability
14732,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,,61703-408-41,available
14733,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,,61703-408-25,available
14734,Methotrexate Sodium Injection,"Hospira, Inc., a Pfizer Company","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)",Reverified,8/15/25,Available,,,,Rheumatology; Oncology,Current,,,61703-124-40,available
14735,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Reverified,9/2/25,Available,Check wholesaler for inventory,,,Rheumatology; Oncology,Current,,,63323-122-50,available
14736,Methotrexate Sodium Injection,"Fresenius Kabi USA, LLC","Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)",Reverified,9/2/25,Available,Check whlolesaler for inventory,,,Rheumatology; Oncology,Current,,,63323-123-10,available
14737,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Revised,8/19/25,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,,16729-277-30,not available
14738,Methotrexate Sodium Injection,Accord Healthcare Inc.,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Revised,8/19/25,Unavailable,Resupply: estimated 14 days,,Shortage of an active ingredient,Rheumatology; Oncology,Current,,,16729-277-35,not available
14739,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 10 mg (NDC 68968-5552-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,68968-5552-3,not available
14740,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 15 mg (NDC 68968-5553-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,68968-5553-3,not available
14741,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 20 mg (NDC 68968-5554-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,68968-5554-3,not available
14742,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Daytrana, Film, Extended Release, 30 mg (NDC 68968-5555-3)",Reverified,8/19/25,Unavailable,Estimated availability TBD,,Shortage of an active ingredient,Psychiatry,Current,,,68968-5555-3,not available
14743,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)",Revised,8/19/25,Available,Available. Distributed by Padagis US LLC,,,Psychiatry,Current,,,0574-2410-65,available
14744,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)",Revised,8/19/25,Unavailable,Estimated availability: end October 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,0574-2415-65,not available
14745,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)",Revised,8/19/25,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,0574-2420-65,not available
14746,"Methylphenidate Film, Extended Release","Noven Pharmaceuticals, Inc.","Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)",Revised,8/19/25,Unavailable,Estimated availability: early September 2025. Distributed by Padagis US LLC,,Shortage of an active ingredient,Psychiatry,Current,,,0574-2430-65,not available
14747,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 10mg/9hrs (NDC 0378-8260-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-8260-93,available
14748,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 15mg/9hrs (NDC 0378-8261-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-8261-93,available
14749,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 20mg/9hrs (NDC 0378-8262-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-8262-93,available
14750,"Methylphenidate Film, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Methylphenidate, Film, Extended Release, 30mg/9hrs (NDC 0378-8263-93)",Reverified,9/3/25,Available,,,,Psychiatry,Current,,,0378-8263-93,available
14751,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-095-30,available
14752,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-096-30,available
14753,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-097-30,available
14754,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-098-30,available
14755,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,68025-095-10,not available
14756,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,68025-096-10,not available
14757,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,68025-097-10,not available
14758,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-088-30,available
14759,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)",Reverified,9/4/25,Unavailable,Estimated recovery: TBD,,Other,Psychiatry,Current,,,68025-098-10,not available
14760,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-089-30,available
14761,"Methylphenidate Hydrochloride Tablet, Extended Release","Vertical Pharmaceuticals, LLC","Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)",Reverified,9/4/25,Available,,,,Psychiatry,Current,,,68025-084-30,available
14762,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-1445-01,limited availability
14763,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-1473-01,limited availability
14764,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Revised,9/2/25,Unavailable,Backorder expected with next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-0127-01,not available
14765,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Reverified,9/2/25,Limited Availability,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-0136-01,limited availability
14766,"Methylphenidate Hydrochloride Tablet, Extended Release",SpecGx LLC,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Reverified,9/2/25,Unavailable,Backorder. Next release expected in October 2025.,,Shortage of an active ingredient,Psychiatry,Current,,,0406-0154-01,not available
14767,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,62175-310-37,available
14768,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,62175-311-37,available
14769,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Reverified,9/2/25,Unavailable,other,,Other,Psychiatry,Current,,,62175-312-37,not available
14770,"Methylphenidate Hydrochloride Tablet, Extended Release","Lannett Company, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,62175-313-37,available
14771,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,62037-725-01,available
14772,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,62037-734-01,available
14773,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,62037-726-01,available
14774,"Methylphenidate Hydrochloride Tablet, Extended Release","Teva Pharmaceuticals USA, Inc.","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Revised,8/19/25,Available,,,,Psychiatry,Current,,,62037-727-01,available
14775,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,43598-438-01,not available
14776,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,43598-439-01,not available
14777,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Reverified,8/15/25,Available,Available to existing customers,,,Psychiatry,Current,,,43598-440-01,available
14778,"Methylphenidate Hydrochloride Tablet, Extended Release","Dr. Reddy's Laboratories, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Reverified,8/15/25,Unavailable,Estimated availability TBD,,Other,Psychiatry,Current,,,43598-441-01,not available
14779,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-706-10,limited availability
14780,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-707-10,limited availability
14781,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-708-10,limited availability
14782,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-711-30,limited availability
14783,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-709-10,limited availability
14784,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-700-30,limited availability
14785,"Methylphenidate Hydrochloride Tablet, Extended Release","Trigen Laboratories, LLC","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Reverified,9/4/25,Limited Availability,Allocation to current contracted customers,,Demand increase for the drug,Psychiatry,Current,,,13811-710-30,limited availability
14786,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,50458-585-01,available
14787,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,50458-588-01,available
14788,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,50458-586-01,available
14789,"Methylphenidate Hydrochloride Tablet, Extended Release",Janssen Pharmaceuticals,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Reverified,9/2/25,Available,,,,Psychiatry,Current,,,50458-587-01,available
14790,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,57664-606-88,not available
14791,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,57664-607-88,not available
14792,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,57664-608-88,not available
14793,"Methylphenidate Hydrochloride Tablet, Extended Release","Sun Pharmaceutical Industries, Inc.","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Revised,8/20/25,Unavailable,Currently not marketed,,Discontinuation of the manufacture of the drug,Psychiatry,Current,,,57664-609-88,not available
14794,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,,55150-313-01,not available
14795,Methylprednisolone Acetate Injection,Eugia US LLC,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Rheumatology,Current,,,55150-314-01,not available
14796,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,,25021-820-10,available
14797,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,,25021-820-05,available
14798,Methylprednisolone Acetate Injection,Sagent Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)",Reverified,8/26/25,Available,,,,Rheumatology,Current,,,25021-821-05,available
14799,Methylprednisolone Acetate Injection,"Par Pharmaceutical, Inc.","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)",Reverified,9/2/25,Available,,,,Rheumatology,Current,,,42023-240-01,available
14800,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,,70121-1573-1,available
14801,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,,70121-1573-5,available
14802,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,,70121-1574-1,available
14803,Methylprednisolone Acetate Injection,Amneal Pharmaceuticals,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Reverified,6/27/25,Available,,,,Rheumatology,Current,,,70121-1574-5,available
14804,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,,0009-0274-01,available
14805,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Rheumatology,Current,,,0009-0280-02,limited availability
14806,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Revised,8/15/25,Available,,,,Rheumatology,Current,,,0009-0280-03,available
14807,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,,0009-0280-51,not available
14808,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,,0009-0280-52,available
14809,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,,0009-0306-02,available
14810,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: March 2026,,Demand increase for the drug,Rheumatology,Current,,,0009-0306-12,not available
14811,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,,0009-3073-01,available
14812,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: September 2025,,Demand increase for the drug,Rheumatology,Current,,,0009-3073-03,not available
14813,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Reverified,8/15/25,Available,,,,Rheumatology,Current,,,0009-3073-22,available
14814,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Revised,8/15/25,Available,,,,Rheumatology,Current,,,0009-3073-23,available
14815,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Revised,8/15/25,Available,,,,Rheumatology,Current,,,0009-3475-01,available
14816,Methylprednisolone Acetate Injection,Pfizer Inc.,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Revised,8/15/25,Unavailable,Next Delivery: September 2025; Estimated Recovery: June 2026,,Demand increase for the drug,Rheumatology,Current,,,0009-3475-03,not available
14817,Methylprednisolone Sodium Succinate Injection,Pfizer Inc.,"Solu-Medrol, Injection, 1 g/1 mL (NDC 0009-0698-02)",New,10/10/24,,,,,Rheumatology,To Be Discontinued,,10/10/24,0009-0698-02,discontinued
14818,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-062-01,discontinued
14819,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-062-99,discontinued
14820,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-063-01,discontinued
14821,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-063-59,discontinued
14822,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-063-99,discontinued
14823,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-064-01,discontinued
14824,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-064-39,discontinued
14825,Metoprolol Tartrate Tablet,Aurobindo Pharma USA,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)",New,6/3/25,,Permanent discontinuation in the manufacturing of the drug,,,Cardiovascular,To Be Discontinued,,6/3/25,65862-064-99,discontinued
14826,Metronidazole Injection,InfoRLife SA,"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)",Reverified,8/26/25,Limited Availability,Labeler: Hospira Inc.,,Other,Anti-Infective,Current,,,0409-0152-24,limited availability
14827,Metronidazole Injection,InfoRLife SA,"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)",Reverified,8/26/25,Available,Labeler: Sagent Pharmaceuticals,,,Anti-Infective,Current,,,25021-131-82,available
14828,Metronidazole Injection,B. Braun Medical Inc.,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Reverified,8/21/25,Limited Availability,Temporary discontinuation of the manufacture of the drug. Some lots are available through exhaustion of inventory,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,0264-5535-32,limited availability
14829,Metronidazole Injection,Baxter Healthcare,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,,0338-1055-48,available
14830,Metronidazole Injection,Gland Pharma Limited,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Reverified,7/28/25,Unavailable,,,Shortage of an active ingredient,Anti-Infective,Current,,,47335-993-01,not available
14831,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Reverified,7/16/25,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,44567-610-10,available
14832,Midazolam Hydrochloride Injection,WG Critical Care,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Reverified,7/16/25,Available,Please check wholesalers and distributors for inventory.,,,Anesthesia; Neurology,Current,,,44567-611-10,available
14833,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,,23155-601-42,available
14834,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,,23155-601-41,available
14835,Midazolam Hydrochloride Injection,"Avet Pharmaceuticals, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)",Reverified,9/3/25,Available,,,,Anesthesia; Neurology,Current,,,23155-600-41,available
14836,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia; Neurology,Current,,,63323-411-10,not available
14837,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,76045-211-20,available
14838,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-411-12,available
14839,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-411-25,available
14840,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-412-25,available
14841,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia; Neurology,Current,,,63323-412-10,not available
14842,Midazolam Hydrochloride Injection,"Fresenius Kabi USA, LLC","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia; Neurology,Current,,,63323-412-02,available
14843,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,0641-6056-10,available
14844,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,0641-6057-25,available
14845,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,0641-6059-01,available
14846,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,0641-6061-25,available
14847,Midazolam Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Anesthesia; Neurology,Current,,,0641-6060-10,available
14848,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,,0409-2305-17,available
14849,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,Demand increase for the drug,Anesthesia; Neurology,Current,,,0409-2305-05,limited availability
14850,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,,0409-2308-01,available
14851,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,,0409-2596-05,available
14852,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,,0409-2308-02,available
14853,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)",Revised,8/15/25,Unavailable,Next Delivery: August 2025; Estimated Recovery: September 2025,,Other,Anesthesia; Neurology,Current,,,0409-2596-03,not available
14854,Midazolam Hydrochloride Injection,"Hospira, Inc., a Pfizer Company","Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)",Reverified,8/15/25,Available,,,,Anesthesia; Neurology,Current,,,0409-2587-05,available
14855,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,70860-601-10,available
14856,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,70860-601-05,available
14857,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Reverified,7/28/25,Unavailable,Alvogen,,Demand increase for the drug,Anesthesia; Neurology,Current,,,47781-589-17,not available
14858,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,47781-589-91,available
14859,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,70860-600-02,available
14860,Midazolam Hydrochloride Injection,Gland Pharma Limited,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Reverified,7/28/25,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,Anesthesia; Neurology,Current,,,47781-588-68,available
14861,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0211-01,discontinued
14862,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0211-11,discontinued
14863,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0212-01,discontinued
14864,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 0245-0212-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0212-11,discontinued
14865,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-01)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0213-01,discontinued
14866,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 10 mg (NDC 0245-0213-11)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,0245-0213-11,discontinued
14867,Midodrine Hydrochloride Tablet,"Upsher-Smith Laboratories, LLC","Orvaten, Tablet, 5 mg (NDC 55154-5623-0)",New,4/28/25,,,,,Cardiovascular,To Be Discontinued,,4/28/25,55154-5623-0,discontinued
14868,Minocycline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)",New,5/23/25,,Permanent discontinuation of manufacture due to business decision.,,,Anti-Infective,To Be Discontinued,,5/23/25,0591-3153-01,discontinued
14869,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 50 mg (NDC 64380-154-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25,64380-154-01,discontinued
14870,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 75 mg (NDC 64380-155-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25,64380-155-01,discontinued
14871,Minocycline Hydrochloride Tablet,Strides Pharma Inc.,"Minocycline Hydrochloride, Tablet, 100 mg (NDC 64380-156-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Antiviral,To Be Discontinued,,1/22/25,64380-156-01,discontinued
14872,Mitomycin Injection,Accord Healthcare Inc.,"Mitomycin, Injection, 20 mg/40 mL (NDC 16729-108-11)",New,1/17/25,,Permanent discontinuation in the manufacturing of the drug.,,,Anti-Infective,To Be Discontinued,,1/17/25,16729-108-11,discontinued
14873,Montelukast Sodium Granule,Organon,"Singulair, Granule, 4 mg (NDC 78206-171-01)",New,3/24/25,,,,,Pulmonary/Allergy,To Be Discontinued,,3/24/25,78206-171-01,discontinued
14874,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25,0409-1891-23,discontinued
14875,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25,0409-1892-01,discontinued
14876,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Analgesia/Addiction,To Be Discontinued,,7/8/25,0409-1893-01,discontinued
14877,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)",Revised,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,76045-004-11,not available
14878,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,76045-005-11,available
14879,Morphine Sulfate Injection,"Amphastar Pharmaceuticals, Inc.","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,,76329-1912-1,available
14880,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)",Reverified,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-452-01,not available
14881,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)",Revised,9/2/25,Unavailable,Backordered. Next release September 2025. Check wholesalers for inventory.,,Other,Analgesia/Addiction,Current,,,63323-454-01,not available
14882,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)",Reverified,9/2/25,Unavailable,Not available at this time.,,Demand increase for the drug,Analgesia/Addiction,Current,,,63323-455-01,not available
14883,Morphine Sulfate Injection,"Fresenius Kabi USA, LLC","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-451-01,available
14884,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, 1 mg/1 mL (NDC 0641-6019-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6019-10,available
14885,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Duramorph (Morphine Sulfate Injection, USP), Injection, .5 mg/1 mL (NDC 0641-6020-10)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6020-10,available
14886,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6039-01,available
14887,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6040-01,available
14888,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)",Revised,8/15/25,Unavailable,Next Delivery: September 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,0409-1890-01,not available
14889,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)",Revised,8/15/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Other,Analgesia/Addiction,Current,,,0409-1891-01,not available
14890,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)",Revised,8/15/25,Unavailable,,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,1/3/25,,0409-1892-01,not available
14891,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)",Reverified,8/15/25,Unavailable,Discontinuation of the manufacture of the drug,,Discontinuation of the manufacture of the drug,Analgesia/Addiction,Current,,,0409-1893-01,not available
14892,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,,,0409-3814-12,available
14893,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,,0409-3815-12,available
14894,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,,0409-1896-20,available
14895,Morphine Sulfate Injection,"Hospira, Inc., a Pfizer Company","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Reverified,8/15/25,Available,,,,Analgesia/Addiction,Current,1/3/25,,0409-1134-05,available
14896,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6125-25,available
14897,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Reverified,7/23/25,Unavailable,Additional lots will be available in the May 2025 timeframe.  Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0641-6126-25,not available
14898,Morphine Sulfate Injection,"Hikma Pharmaceuticals USA, Inc.","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Reverified,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction,Current,,,0641-6127-25,available
14899,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 200 mg/20 mL (NDC 66794-160-02)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,,66794-160-02,limited availability
14900,Morphine Sulfate Injection,Piramal Critical Care Inc.,"Mitigo (Morphine Sulfate Injection, USP), Injection, 500 mg/20 mL (NDC 66794-162-02)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Analgesia/Addiction,Current,,,66794-162-02,limited availability
14901,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,,16729-081-01,available
14902,Naltrexone Hydrochloride Tablet,Accord Healthcare Inc.,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,,16729-081-10,available
14903,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)",Reverified,9/2/25,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,,51224-206-50,available
14904,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)",Reverified,9/2/25,Available,Marketed by Tagi Pharma,,,Analgesia/Addiction,Current,,,51224-206-30,available
14905,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)",Reverified,9/2/25,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,,68094-909-50,available
14906,Naltrexone Hydrochloride Tablet,"Elite Laboratories, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)",Reverified,9/2/25,Available,Marketed by Precision Dose,,,Analgesia/Addiction,Current,,,68094-909-30,available
14907,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,,47335-326-88,limited availability
14908,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)",Revised,8/20/25,Limited Availability,Q3 2025,,Other,Analgesia/Addiction,Current,,,47335-326-83,limited availability
14909,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)",Revised,8/20/25,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,,47335-326-08,not available
14910,Naltrexone Hydrochloride Tablet,"Sun Pharmaceutical Industries, Inc.","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)",Revised,8/20/25,Unavailable,Currently not marketed,,Other,Analgesia/Addiction,Current,,,47335-326-18,not available
14911,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)",Revised,9/2/25,Limited Availability,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0406-1170-01,limited availability
14912,Naltrexone Hydrochloride Tablet,SpecGx LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)",Revised,9/2/25,Available,Long term allocations to all customers with intermittent backorder expected through 2025.,,Demand increase for the drug,Analgesia/Addiction,Current,,,0406-1170-03,available
14913,Naltrexone Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)",Reverified,8/19/25,Available,,,,Analgesia/Addiction,Current,,,62135-242-60,available
14914,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Revised,9/3/25,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,,0338-1049-02,not available
14915,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Revised,9/3/25,Unavailable,Manufacturing delay; Recovery in September 2025,,Other,Cardiovascular,Current,,,0338-1051-02,not available
14916,Nitroglycerin Injection,Baxter Healthcare,"Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Reverified,9/3/25,Unavailable,Manufacturing delay; Recovery in October 2025,,Other,Cardiovascular,Current,,,0338-1047-02,not available
14917,Nitroglycerin Injection,"American Regent, Inc.","Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,0517-4810-25,available
14918,Norepinephrine Bitartrate Injection,"Sun Pharmaceutical Industries, Inc.","Injection, 1 mg/1 mL (NDC 47335-615-44)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24,47335-615-44,discontinued
14919,Nortriptyline Hydrochloride Capsule,"Teva Pharmaceuticals USA, Inc.","Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)",New,5/23/25,,Permanent discontinuation of specific package size/ SKU for business reasons.,,,Psychiatry,To Be Discontinued,,5/23/25,0093-0813-05,discontinued
14920,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-15)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25,0832-0465-15,discontinued
14921,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-30)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25,0832-0465-30,discontinued
14922,Nystatin Topical Powder,"Upsher-Smith Laboratories, LLC","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-60)",New,4/28/25,,,,,Anti-Infective; Dermatology,To Be Discontinued,,4/28/25,0832-0465-60,discontinued
14923,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 4 mg (NDC 45963-538-30)",New,11/4/24,,,,,Gastroenterology,To Be Discontinued,,11/4/24,45963-538-30,discontinued
14924,Ondansetron Hydrochloride Tablet,"Actavis Pharma, Inc.","Tablet, 8 mg (NDC 45963-539-30)",New,11/4/24,,,,,Gastroenterology,To Be Discontinued,,11/4/24,45963-539-30,discontinued
14925,Oseltamivir Phosphate Capsule,"Genentech, Inc","Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)",New,7/8/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,7/8/25,0004-0802-85,discontinued
14926,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)",New,4/22/25,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/25,50742-405-10,discontinued
14927,Oxaliplatin Injection,Novast Labs,"Oxaliplatin, Injection, 100 mg/20 mL (NDC 50742-406-20)",New,4/22/25,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,,Oncology,To Be Discontinued,,4/22/25,50742-406-20,discontinued
14928,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 50 mg/10 mL (NDC 0703-3985-01)",New,10/11/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/24,0703-3985-01,discontinued
14929,Oxaliplatin Injection,"Teva Pharmaceuticals USA, Inc.","Injection, 100 mg/20 mL (NDC 0703-3986-01)",New,10/11/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/11/24,0703-3986-01,discontinued
14930,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9315-70)",New,10/16/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/24,0781-9315-70,discontinued
14931,Oxaliplatin Injection,Sandoz Inc.,"Injection, 5 mg/1 mL (NDC 0781-9317-80)",New,10/16/24,,A business decision was made to discontinue this product.,,,Oncology,To Be Discontinued,,10/16/24,0781-9317-80,discontinued
14932,Oxaprozin Tablet,"Hospira, Inc., a Pfizer Company","Daypro, Tablet, 600 mg (NDC 0025-1381-31)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Analgesia/Addiction,To Be Discontinued,,7/17/25,0025-1381-31,discontinued
14933,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 10 mg (NDC 0228-2067-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,,0228-2067-10,
14934,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 15 mg (NDC 0228-2069-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,,0228-2069-10,
14935,Oxazepam Capsule,"Teva Pharmaceuticals USA, Inc.","Oxazepam, Capsule, 30 mg (NDC 0228-2073-10)",Revised,7/3/25,,,Available,,Neurology; Psychiatry,Resolved,7/3/25,,0228-2073-10,
14936,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-00)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25,0832-0038-00,discontinued
14937,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-01)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25,0832-0038-01,discontinued
14938,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-10)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25,0832-0038-10,discontinued
14939,Oxybutynin Chloride Tablet,"Upsher-Smith Laboratories, LLC","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-50)",New,5/14/25,,,,,Renal,To Be Discontinued,,5/14/25,0832-0038-50,discontinued
14940,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)",New,8/13/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/25,66658-230-01,discontinued
14941,Palivizumab Injection,Swedish Orphan Biovitrum AB,"Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)",New,8/13/25,,Discontinuation of the manufacture of the drug,,,Antiviral,To Be Discontinued,,8/13/25,66658-231-01,discontinued
14942,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24,62756-129-40,discontinued
14943,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24,62756-129-44,discontinued
14944,Pantoprazole Sodium Injection,Sun Pharmaceutical Industries Limited,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45)",New,12/5/24,,Discontinuing for business reasons,,,Gastroenterology,To Be Discontinued,,12/5/24,62756-129-45,discontinued
14945,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0203-2,limited availability
14946,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0204-2,limited availability
14947,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Reverified,8/15/25,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0205-2,not available
14948,Parathyroid Hormone Injection,Takeda Pharmaceuticals USA Inc.,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Reverified,8/15/25,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,Discontinuation of the manufacture of the drug,Endocrinology/Metabolism,Current,,,68875-0202-2,limited availability
14949,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)",Revised,8/19/25,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,,82154-0449-1,limited availability
14950,Peginterferon alfa-2a Injection,pharmaand GmbH (pharma&),"Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)",Revised,8/19/25,Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Shortage of an active ingredient,Antiviral,Current,,,82154-0451-4,limited availability
14951,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/25,0409-1060-01,discontinued
14952,Pemetrexed Ditromethamine Injection,Pfizer Inc.,"Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)",New,7/17/25,,Discontinuation of the manufacture of the drug.,,,Oncology,To Be Discontinued,,7/17/25,0409-1061-01,discontinued
14953,Penicillin G Benzathine Injection,Laboratorios Atral,"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,,84383-110-01,available
14954,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 1,200,000 units (NDC 81284-521-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,,81284-521-01,available
14955,Penicillin G Benzathine Injection,Laboratoires Delbert,"Extencilline, Injection, 2,400,000 units (NDC 81284-522-01)",Reverified,7/18/25,Available,,,,Anti-Infective,Current,,,81284-522-01,available
14956,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Revised,8/25/25,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,,Demand increase for the drug,Anti-Infective,Current,,,60793-700-10,not available
14957,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Revised,8/25/25,Limited Availability,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,60793-701-10,limited availability
14958,Penicillin G Benzathine Injection,Pfizer Inc.,"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Revised,8/25/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Anti-Infective,Current,,,60793-702-10,not available
14959,Peritoneal Dialysis Solution,Baxter Healthcare,"Peritoneal Dialysis, Solution, Various NDCs (NDC 0941-0679-05)",Revised,7/7/25,,,Available,,Renal,Resolved,7/7/25,,0941-0679-05,
14960,Peritoneal Dialysis Solution,Fresenius Medical Care North America,"Peritoneal Dialysis, Solution, Various NDCs (NDC 46163-206-94)",Revised,7/7/25,,,Available,,Renal,Resolved,7/7/25,,46163-206-94,
14961,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)",New,6/13/25,,,,,Other,To Be Discontinued,,6/13/25,57844-140-01,discontinued
14962,Phentermine Hydrochloride Tablet,"Teva Pharmaceuticals USA, Inc.","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)",New,6/13/25,,,,,Other,To Be Discontinued,,6/13/25,57844-140-56,discontinued
14963,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 30gm (NDC 0187-5100-01)",New,2/28/25,,Authorized generic is still marketed and available under NDC 68682-110-01,,,Dermatology,To Be Discontinued,,2/28/25,0187-5100-01,discontinued
14964,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 60gm (NDC 0187-5101-02)",New,2/28/25,,Authorized generics is still marketed and available under NDC 68682-111-02,,,Dermatology,To Be Discontinued,,2/28/25,0187-5101-02,discontinued
14965,Pimecrolimus Cream,"Bausch Health Americas, Inc.","Elidel, Cream, 100gm (NDC 0187-5102-03)",New,2/28/25,,Authorized generics is still marketed and available under NDC 68682-112-03,,,Dermatology,To Be Discontinued,,2/28/25,0187-5102-03,discontinued
14966,Pirfenidone Capsule,"Genentech, Inc","Esbriet, Capsule, 267 mg (NDC 50242-121-01)",New,2/5/25,,,,,Pulmonary/Allergy,To Be Discontinued,,2/5/25,50242-121-01,discontinued
14967,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-559-01,discontinued
14968,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-559-05,discontinued
14969,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-560-01,discontinued
14970,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-560-05,discontinued
14971,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-560-10,discontinued
14972,"Potassium Chloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)",New,5/19/25,,,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,5/19/25,62037-560-90,discontinued
14973,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0832-5322-11,discontinued
14974,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0832-5322-10,discontinued
14975,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0832-5323-11,discontinued
14976,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0832-5323-10,discontinued
14977,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5315-01,discontinued
14978,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5315-11,discontinued
14979,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5315-15,discontinued
14980,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5316-01,discontinued
14981,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5316-15,discontinued
14982,"Potassium Chloride Tablet, Extended Release","Upsher-Smith Laboratories, LLC","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)",New,7/23/25,,Discontinuation of the manufacture of the drug product,,,Endocrinology/Metabolism; Gastroenterology,To Be Discontinued,,7/23/25,0245-5316-11,discontinued
14983,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25,0591-2682-01,discontinued
14984,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25,0591-2729-01,discontinued
14985,"Potassium Citrate Tablet, Extended Release",Watson Pharma Private Limited,"Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)",New,7/17/25,,A business decision was made to discontinue.,,,Renal,To Be Discontinued,,7/17/25,0591-2742-01,discontinued
14986,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-0771-10,discontinued
14987,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-0771-98,discontinued
14988,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-7201-10,discontinued
14989,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-7201-98,discontinued
14990,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-7202-10,discontinued
14991,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0093-7202-98,discontinued
14992,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0480-7270-10,discontinued
14993,Pravastatin Sodium Tablet,"Teva Pharmaceuticals USA, Inc.","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)",New,6/13/25,,,,,Cardiovascular,To Be Discontinued,,6/13/25,0480-7270-98,discontinued
14994,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4310-71,discontinued
14995,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4370-71,discontinued
14996,Prazosin Hydrochloride Capsule,Pfizer Inc.,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",New,4/28/23,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,,,Cardiovascular,To Be Discontinued,4/28/23,4/28/23,0069-4380-71,discontinued
14997,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Reverified,8/4/25,Unavailable,Next lots scheduled for release August 2025.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5525-3,not available
14998,Promethazine Hydrochloride Injection,"XGen Pharmaceuticals DJB, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Reverified,8/4/25,Available,,,,Analgesia/Addiction; Gastroenterology; Other; Pulmonary/Allergy,Current,,,39822-5550-6,available
14999,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-0928-25,not available
15000,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-0929-25,not available
15001,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",Revised,7/23/25,Unavailable,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,Demand increase for the drug,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-1495-35,not available
15002,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",Revised,7/23/25,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-1496-35,available
15003,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 25 mg/1 mL (NDC 0641-6084-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6084-25,not available
15004,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6085-25)",Revised,7/23/25,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,Other,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6085-25,not available
15005,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6082-25)",Revised,7/23/25,Available,Currently available.  Additional product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6082-25,available
15006,Promethazine Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6083-25)",Revised,7/23/25,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,,Analgesia/Addiction; Gastroenterology; Pediatric; Pulmonary/Allergy,Current,,,0641-6083-25,available
15007,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 225 mg (NDC 0832-0740-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0832-0740-60,discontinued
15008,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 325 mg (NDC 0832-0741-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0832-0741-60,discontinued
15009,"Propafenone Hydrochloride Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Propafenone Hydrochloride, Capsule, Extended Release, 425 mg (NDC 0832-0742-60)",New,5/14/25,,A business decision was made to discontinue the product.,,,Cardiovascular,To Be Discontinued,,5/14/25,0832-0742-60,discontinued
15010,Propranolol Hydrochloride Injection,"Fresenius Kabi USA, LLC","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Cardiovascular,Current,,,63323-604-01,available
15011,Propranolol Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)",Reverified,7/23/25,Unavailable,,,Shortage of an active ingredient,Cardiovascular,Current,,,0143-9872-10,not available
15012,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-484-60,available
15013,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-485-90,available
15014,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-486-90,available
15015,Quinapril Hydrochloride Tablet,Chartwell Molecular Holdings LLC,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-487-90,available
15016,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-410-09,not available
15017,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-411-09,not available
15018,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-412-09,not available
15019,Quinapril Hydrochloride Tablet,"Solco Healthcare US, LLC","Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)",Reverified,6/27/25,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,Shortage of an active ingredient,Cardiovascular,Current,,,43547-413-09,not available
15020,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-556-09,not available
15021,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-557-09,not available
15022,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-558-09,not available
15023,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Reverified,8/19/25,Unavailable,,,Requirements related to complying with good manufacturing practices,Cardiovascular,Current,,,68180-554-09,not available
15024,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-617-90,discontinued
15025,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-618-90,discontinued
15026,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-618-90,discontinued
15027,Quinapril Hydrochloride Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-620-90,discontinued
15028,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0535-23,not available
15029,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0530-23,not available
15030,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0532-23,not available
15031,Quinapril Hydrochloride Tablet,Pfizer Inc.,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0527-23,not available
15032,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0222-23,not available
15033,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0220-23,not available
15034,Quinapril/Hydrochlorothiazide Tablet,Pfizer Inc.,"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)",Reverified,8/15/25,Unavailable,Next Delivery and Estimated Recovery: TBD,,Delay in shipping of the drug,Cardiovascular,Current,,,0071-0223-23,not available
15035,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-161-90,discontinued
15036,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-162-90,discontinued
15037,Quinapril/Hydrochlorothiazide Tablet,Aurobindo Pharma USA,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Reverified,6/25/25,Discontinued,,,Discontinuation of the manufacture of the drug,Cardiovascular,Current,,,65862-163-90,discontinued
15038,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-669-90,available
15039,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-668-90,available
15040,Quinapril/Hydrochlorothiazide Tablet,Chartwell Molecular Holdings LLC,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)",Reverified,8/19/25,Available,,,,Cardiovascular,Current,,,62135-667-90,available
15041,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-01)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25,43598-741-01,discontinued
15042,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-10)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25,43598-741-10,discontinued
15043,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 43598-741-30)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25,43598-741-30,discontinued
15044,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 50268-708-15)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25,50268-708-15,discontinued
15045,Ramelteon Tablet,"Dr. Reddy's Laboratories, Inc.","Tablet, 8 mg (NDC 72162-2169-3)",New,1/8/25,,,,,Other,To Be Discontinued,,1/8/25,72162-2169-3,discontinued
15046,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 2.5 mg (NDC 61570-111-01)",New,1/30/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/25,61570-111-01,discontinued
15047,Ramipril Capsule,Pfizer Inc.,"Altace, Capsule, 10 mg (NDC 61570-120-01)",New,1/30/25,,Discontinuation of the manufacture of the drug,,,Cardiovascular,To Be Discontinued,,1/30/25,61570-120-01,discontinued
15048,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 500 mg (NDC 47335-624-60)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24,47335-624-60,discontinued
15049,"Ranolazine Granules, Extended Release","Sun Pharmaceutical Industries, Inc.","Aspruzyo Sprinkle, Granules, Extended Release, 1000 mg (NDC 47335-625-60)",New,9/20/24,,,,,Cardiovascular,To Be Discontinued,,9/20/24,47335-625-60,discontinued
15050,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,,72078-035-02,available
15051,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 5 mg (NDC 72078-036-05)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,,72078-036-05,available
15052,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9391-10,not available
15053,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9392-10,not available
15054,Remifentanil Hydrochloride Injection,"Hikma Pharmaceuticals USA, Inc.","Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)",Reverified,7/23/25,Unavailable,,,Demand increase for the drug,Analgesia/Addiction,Current,,,0143-9393-10,not available
15055,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-723-03,available
15056,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-724-05,available
15057,Remifentanil Hydrochloride Injection,"Fresenius Kabi USA, LLC","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Analgesia/Addiction,Current,,,63323-725-10,available
15058,Remifentanil Hydrochloride Injection,"Mylan Institutional, a Viatris Company","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Reverified,9/3/25,Available,,,,Analgesia/Addiction,Current,,,72078-034-01,available
15059,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-30)",Reverified,9/2/25,Available,,,,Anti-Infective,Current,,,42806-801-30,available
15060,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 150 mg (NDC 42806-801-01)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,42806-801-01,not available
15061,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-30)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,42806-799-30,not available
15062,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-60)",Reverified,9/2/25,Available,,,,Anti-Infective,Current,,,42806-799-60,available
15063,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-01)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,42806-799-01,not available
15064,Rifampin Capsule,"Epic Pharma, LLC","Rifampin, Capsule, 300 mg (NDC 42806-799-05)",Reverified,9/2/25,Unavailable,Discontinuation of the manufacture of the drug.,,Discontinuation of the manufacture of the drug,Anti-Infective,Current,,,42806-799-05,not available
15065,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,,68180-658-06,available
15066,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,,68180-659-06,available
15067,Rifampin Capsule,"Lupin Pharmaceuticals, Inc.","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Reverified,8/19/25,Available,,,,Anti-Infective,Current,,,68180-659-07,available
15068,Rifampin Injection,"Fresenius Kabi USA, LLC","Rifampin, Injection, 600 mg (NDC 63323-351-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anti-Infective,Current,,,63323-351-20,available
15069,Rifampin Injection,Sanofi-Aventis U.S. LLC,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Reverified,6/27/25,Available,,,,Anti-Infective,Current,,,0068-0597-01,available
15070,Rifampin Injection,"Mylan Institutional, a Viatris Company","Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)",Reverified,9/3/25,Available,,,,Anti-Infective,Current,,,67457-445-60,available
15071,"Rifapentine Tablet, Film Coated",Sanofi-Aventis U.S. LLC,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Reverified,6/27/25,Available,,,,Anti-Infective,Current,,,0088-2102-24,available
15072,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,,70726-0305-1,available
15073,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,,70726-0306-1,available
15074,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)",Reverified,9/2/25,Unavailable,Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to viscosity testing,,Requirements related to complying with good manufacturing practices,Neurology,Current,,,70726-0303-2,not available
15075,Riluzole Oral Suspension,"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)","Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)",Reverified,9/2/25,Available,,,,Neurology,Current,,,70726-0304-1,available
15076,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)",Reverified,8/19/25,Limited Availability,On allocation,,Demand increase for the drug,Anesthesia,Current,,,66794-228-41,limited availability
15077,Rocuronium Bromide Injection,Piramal Critical Care Inc.,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,66794-229-41,available
15078,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,71288-700-06,available
15079,Rocuronium Bromide Injection,"Meitheal Pharmaceuticals, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,71288-718-11,available
15080,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)",Reverified,9/2/25,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,,65219-065-05,not available
15081,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-226-10,not available
15082,Rocuronium Bromide Injection,Eugia US LLC,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-225-05,available
15083,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-228-10,available
15084,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,43066-007-10,available
15085,Rocuronium Bromide Injection,Baxter Healthcare,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,43066-013-10,available
15086,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Reverified,7/23/25,Available,Additional lots will be available.  Product will be made available as it is released.,,,Anesthesia,Current,,,0143-9250-10,available
15087,Rocuronium Bromide Injection,"Hikma Pharmaceuticals USA, Inc.","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Reverified,7/23/25,Available,,,,Anesthesia,Current,,,0143-9251-10,available
15088,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-426-05,available
15089,Rocuronium Bromide Injection,"Fresenius Kabi USA, LLC","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)",Reverified,9/2/25,Unavailable,Backordered. Next release October 2025. Check wholesaers for inventory.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-426-10,not available
15090,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)",Reverified,9/4/25,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,39822-4200-2,available
15091,Rocuronium Bromide Injection,"XGen Pharmaceuticals DJB, Inc.","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)",Reverified,9/4/25,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,,,Anesthesia,Current,,,39822-4200-6,available
15092,Rocuronium Bromide Injection,Sagent Pharmaceuticals,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)",Reverified,8/26/25,Available,,,,Anesthesia,Current,,,25021-687-05,available
15093,Rocuronium Bromide Injection,"Mylan Institutional, a Viatris Company","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Reverified,9/3/25,Available,,,,Anesthesia,Current,,,67457-228-05,available
15094,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0781-3220-95,available
15095,Rocuronium Bromide Injection,Sandoz Inc.,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0781-3220-92,available
15096,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-3189-10,available
15097,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-1403-10,available
15098,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-7037-10,available
15099,Rocuronium Bromide Injection,"Hospira, Inc., a Pfizer Company","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)",Reverified,8/15/25,Available,,,,Anesthesia,Current,,,0409-5160-10,available
15100,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-66,available
15101,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-67,available
15102,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-064-01,available
15103,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-064-10,available
15104,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-064-25,available
15105,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-061-10,available
15106,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-061-25,available
15107,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-062-10,available
15108,Ropivacaine Hydrochloride Injection,"Somerset Therapeutics, LLC","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Reverified,8/19/25,Available,,,,Anesthesia,Current,,,70069-062-25,available
15109,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-82,available
15110,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-671-87,available
15111,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-82,available
15112,Ropivacaine Hydrochloride Injection,InfoRLife SA,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Reverified,8/26/25,Available,Marketed by Sagent Pharmaceuticals,,,Anesthesia,Current,,,25021-652-87,available
15113,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)",Reverified,9/2/25,Limited Availability,Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,,43066-015-10,limited availability
15114,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,,43066-019-10,available
15115,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)",Reverified,9/2/25,Limited Availability,Limited supply; Check wholesalers for inventory; Marketed by Baxter,,Other,Anesthesia,Current,,,43066-023-10,limited availability
15116,Ropivacaine Hydrochloride Injection,"Caplin Steriles, Ltd.","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)",Reverified,9/2/25,Available,Check wholesalers for inventory; Marketed by Baxter,,,Anesthesia,Current,,,43066-027-10,available
15117,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-195-20,available
15118,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-196-99,not available
15119,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-197-20,available
15120,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-198-30,available
15121,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-199-20,not available
15122,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)",Revised,8/21/25,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,,Demand increase for the drug,Anesthesia,Current,,,55150-200-10,not available
15123,Ropivacaine Hydrochloride Injection,Eugia US LLC,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)",Revised,8/21/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,55150-201-20,available
15124,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-285-10,not available
15125,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-285-20,not available
15126,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Revised,9/3/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-286-20,not available
15127,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Revised,9/3/25,Unavailable,Not available at this time.,,Demand increase for the drug,Anesthesia,Current,,,63323-287-20,not available
15128,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-288-10,not available
15129,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-288-20,not available
15130,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-285-61,not available
15131,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Revised,9/3/25,Unavailable,Next release not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-285-63,not available
15132,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Revised,9/3/25,Available,Check wholesalers for inventory,,,Anesthesia,Current,,,63323-285-65,available
15133,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-285-64,available
15134,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-286-00,available
15135,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-286-63,available
15136,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-285-13,available
15137,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-285-23,available
15138,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-286-35,available
15139,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-286-23,available
15140,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-287-21,available
15141,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-288-11,available
15142,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,63323-288-21,available
15143,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Revised,9/3/25,Unavailable,Not available at this time.,,Delay in shipping of the drug,Anesthesia,Current,,,63323-286-31,not available
15144,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,65219-632-10,available
15145,Ropivacaine Hydrochloride Injection,"Fresenius Kabi USA, LLC","Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)",Revised,9/3/25,Available,,,,Anesthesia,Current,,,65219-632-20,available
15146,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-129-01,discontinued
15147,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-129-03,discontinued
15148,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-129-05,discontinued
15149,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-130-01,discontinued
15150,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-130-03,discontinued
15151,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-130-05,discontinued
15152,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-01)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-131-01,discontinued
15153,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-03)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-131-03,discontinued
15154,Sertraline Hydrochloride Tablet,Strides Pharma Inc.,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-05)",New,1/22/25,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,,Psychiatry,To Be Discontinued,,1/22/25,71093-131-05,discontinued
15155,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 4 mg (NDC 0023-6147-30)",New,2/20/25,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/25,0023-6147-30,discontinued
15156,Silodosin Capsule,AbbVie Inc.,"Rapaflo, Capsule, 8 mg (NDC 0023-6142-30)",New,2/20/25,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,,Urology,To Be Discontinued,,2/20/25,0023-6142-30,discontinued
15157,Silver Nitrate Solution,"Teva Pharmaceuticals USA, Inc.","Solution, .005 g/1 mL (NDC 0093-9614-13)",New,10/15/24,,,,,Dermatology,To Be Discontinued,,10/15/24,0093-9614-13,discontinued
15158,Sodium Acetate Injection,"Fresenius Kabi USA, LLC","Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Total Parenteral Nutrition,Current,,,63323-032-00,available
15159,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-05,available
15160,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-06,available
15161,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-73,available
15162,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)",Reverified,9/2/25,Available,,,,Total Parenteral Nutrition,Current,,,71357-007-10,available
15163,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)",Reverified,9/2/25,Available,,,,Total Parenteral Nutrition,Current,,,71357-008-10,available
15164,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-25,available
15165,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-3299-26,available
15166,Sodium Acetate Injection,"Hospira, Inc., a Pfizer Company","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,0409-7299-25,available
15167,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 69784-232-01)",Reverified,9/2/25,Limited Availability,Limited Availability,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,69784-232-01,limited availability
15168,Sodium Acetate Injection,Milla Pharmaceuticals,"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 69784-229-10)",Reverified,9/2/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Current,,,69784-229-10,available
15169,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)",Revised,9/2/25,Available,Next batch release expected in 2 weeks.,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5011-4,available
15170,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)",Reverified,9/2/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5012-4,available
15171,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-5555-02,limited availability
15172,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-5555-01,available
15173,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-4916-14,not available
15174,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)",Reverified,8/15/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,0409-6625-14,available
15175,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-6625-35,not available
15176,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)",Revised,8/15/25,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-4900-14,not available
15177,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)",Revised,8/15/25,Unavailable,Next Delivery and Estimated Recovery: December 2025,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-5534-14,not available
15178,Sodium Bicarbonate Injection,"Hospira, Inc., a Pfizer Company","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)",Revised,8/15/25,Unavailable,Shortage per Manufacturer: Manufacturing Delay,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,1/3/25,,0409-6637-14,not available
15179,Sodium Bicarbonate Injection,"Amphastar Pharmaceuticals, Inc.","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)",Reverified,8/19/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,76329-3352-1,available
15180,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-083-05,available
15181,Sodium Bicarbonate Injection,"Fresenius Kabi USA, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)",Reverified,9/2/25,Unavailable,Backordered. Next release October 2025. Check wholesalers for inventory.,,Other,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,63323-089-50,not available
15182,Sodium Bicarbonate Injection,"Exela Pharma Sciences, LLC","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)",Revised,9/2/25,Limited Availability,Over 3 weeks in Channel. Next release 9/8/25,,Demand increase for the drug,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,51754-5001-5,limited availability
15183,Sodium Bicarbonate Injection,Long Grove Pharmaceuticals LLC,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)",Reverified,6/27/25,Available,,,,Endocrinology/Metabolism; Gastroenterology; Pediatric,Current,,,81298-7620-3,available
15184,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-00)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0264-5802-00,
15185,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0264-5802-10,
15186,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/25,46163-300-10,discontinued
15187,Sodium Chloride 0.9% Injection,Fresenius Medical Care North America,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)",New,6/10/25,,Discontinuation of the manufacture of the drug,,,Gastroenterology; Renal,To Be Discontinued,,6/10/25,49230-300-10,discontinued
15188,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,63323-186-02,
15189,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,63323-186-10,
15190,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,63323-186-20,
15191,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 63323-186-00)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,63323-186-00,
15192,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-10)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0409-4888-10,
15193,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-12)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0409-4888-12,
15194,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-20)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0409-4888-20,
15195,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-50)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0409-4888-50,
15196,Sodium Chloride 0.9% Injection,"Medefil, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,64253-202-30,
15197,Sodium Chloride 0.9% Injection,"Hikma Pharmaceuticals USA, Inc.","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0641-0497-25,
15198,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9%, Injection, 4 meq/1 mL (NDC 63323-095-61)",Revised,8/8/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,8/8/25,,63323-095-61,
15199,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7984-13,
15200,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7984-36,
15201,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7984-37,
15202,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7984-23,
15203,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7984-20,
15204,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0019-1188-81,
15205,Sodium Chloride 0.9% Injection,Guerbet LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,0019-1188-27,
15206,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,63323-924-30,
15207,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,63323-924-10,
15208,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-12)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-1966-12,
15209,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-05)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-1966-05,
15210,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-07)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-1966-07,
15211,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,65282-1510-1,
15212,Sodium Chloride 0.9% Injection,"Spectra Medical Devices, LLC","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Revised,8/8/25,,,Available,,Other,Resolved,8/8/25,,65282-1505-1,
15213,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-00)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7800-00,
15214,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7800-10,
15215,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7800-20,
15216,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-09)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7800-09,
15217,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-1800-32,
15218,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-1800-31,
15219,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-1800-36,
15220,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-66)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-7101-66,
15221,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-67)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-7101-67,
15222,Sodium Chloride 0.9% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0409-7101-02,
15223,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,76297-001-21,
15224,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,76297-001-31,
15225,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,76297-001-01,
15226,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,76297-001-41,
15227,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,76297-001-11,
15228,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-466-60)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,65219-466-60,
15229,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-468-50)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,65219-468-50,
15230,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,65219-472-20,
15231,Sodium Chloride 0.9% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,65219-474-10,
15232,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-18,
15233,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-41,
15234,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-48,
15235,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-31,
15236,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-02,
15237,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-03,
15238,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-04,
15239,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-10,
15240,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-11,
15241,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0049-38,
15242,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-02,
15243,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-06,
15244,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-04,
15245,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0553-11,
15246,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9151-30,
15247,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9159-30,
15248,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-0553-18,
15249,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-02,
15250,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-04,
15251,Sodium Chloride 0.9% Injection,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0338-9543-06,
15252,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-00)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7802-00,
15253,Sodium Chloride 0.9% Injection,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-10)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0264-7802-10,
15254,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7983-03,
15255,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7983-09,
15256,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,79672-613-01,
15257,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,79672-613-02,
15258,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,79672-613-03,
15259,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,79672-613-04,
15260,Sodium Chloride 0.9% Injection,"Laboratorios Grifols, S.A.","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,79672-613-05,
15261,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7983-61,
15262,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7983-02,
15263,Sodium Chloride 0.9% Injection,Otsuka ICU Medical LLC,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Revised,8/8/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,8/8/25,,0990-7983-55,
15264,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0338-0048-02,
15265,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0338-0048-03,
15266,Sodium Chloride 0.9% Irrigation,Baxter Healthcare,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Revised,7/2/25,,,,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0338-0048-04,
15267,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0990-6138-22,
15268,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0990-6138-03,
15269,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0990-7138-09,
15270,Sodium Chloride 0.9% Irrigation,"ICU Medical, Inc.","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0990-7138-36,
15271,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-60)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0264-7388-60,
15272,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-50)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0264-7388-50,
15273,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-10)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0264-2201-10,
15274,Sodium Chloride 0.9% Irrigation,B. Braun Medical Inc.,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-00)",Revised,7/2/25,,,Available,,Gastroenterology; Other; Pediatric,Resolved,7/2/25,,0264-2201-00,
15275,Sodium Chloride 23.4% Injection,"Hospira, Inc., a Pfizer Company","Sodium Chloride, Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",Revised,7/2/25,,,Available,,Endocrinology/Metabolism; Gastroenterology; Pediatric; Total Parenteral Nutrition,Resolved,7/2/25,,0409-1141-02,
15276,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Revised,7/2/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/25,,63323-099-63,
15277,Sodium Chloride 23.4% Injection,"Fresenius Kabi USA, LLC","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Revised,7/2/25,,,Available,,Gastroenterology; Endocrinology/Metabolism; Total Parenteral Nutrition; Pediatric,Resolved,7/2/25,,63323-093-30,
15278,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0169-7704-21,
15279,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0169-7705-21,
15280,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0169-7708-21,
15281,Somatropin Injection,"Novo Nordisk, Inc.","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0169-7703-21,
15282,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0781-3001-07,
15283,Somatropin Injection,Sandoz Inc.,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0781-3004-07,
15284,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 12 mg/cartridge (NDC 0002-8148-01)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0002-8148-01,
15285,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, 24 mg/cartridge (NDC 0002-8149-01)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0002-8149-01,
15286,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 5 mg/mL, w/ preservative (NDC 0013-2626-81)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2626-81,
15287,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 12 mg/mL, w/ preservative (NDC 0013-2646-81)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2646-81,
15288,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.2 mg preservative free (NDC 0013-2649-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2649-02,
15289,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.4 mg preservative free (NDC 0013-2650-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2650-02,
15290,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.6 mg preservative free (NDC 0013-2651-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2651-02,
15291,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 0.8 mg preservative free (NDC 0013-2652-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2652-02,
15292,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.0 mg preservative free (NDC 0013-2653-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2653-02,
15293,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.2 mg preservative free (NDC 0013-2654-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2654-02,
15294,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.4 mg preservative free (NDC 0013-2655-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2655-02,
15295,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.6 mg preservative free (NDC 0013-2656-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2656-02,
15296,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 1.8 mg preservative free (NDC 0013-2657-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2657-02,
15297,Somatropin Injection,Pfizer Inc.,"Genotropin, Injection, 2.0 mg preservative free (NDC 0013-2658-02)",Revised,8/28/25,,,Available,,Endocrinology/Metabolism,Resolved,8/28/25,,0013-2658-02,
15298,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 6 mg (0002-8147-01): 1 TRAY in 1 CARTON (0002-8147-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7554-01) * 2.88 mL in 1 SYRINGE (0002-7618-01) (NDC 0002-8147-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24,0002-8147-01,discontinued
15299,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 12 mg (0002-8148-01): 1 TRAY in 1 CARTON (0002-8148-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7555-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8148-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24,0002-8148-01,discontinued
15300,Somatropin Injection,Eli Lilly and Co.,"Humatrope, Injection, Humatrope Kit 24 mg (0002-8149-01): 1 TRAY in 1 CARTON (0002-8149-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7556-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8149-01)",New,10/29/24,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,Endocrinology/Metabolism,To Be Discontinued,,10/29/24,0002-8149-01,discontinued
15301,Sterile Water Injection,"Hikma Pharmaceuticals USA, Inc.","Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Reverified,7/23/25,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,,Other,Current,,,0641-6147-10,available
15302,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)",Reverified,8/15/25,Available,,,,Other,Current,,,0409-4887-10,available
15303,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)",Reverified,8/15/25,Available,,,,Other,Current,,,0409-4887-20,available
15304,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)",Reverified,8/15/25,Available,,,,Other,Current,,,0409-4887-50,available
15305,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)",Reverified,8/15/25,Available,,,,Other,Current,,,0409-4887-99,available
15306,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,,63323-185-10,available
15307,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,,63323-185-20,available
15308,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,,63323-185-50,available
15309,Sterile Water Injection,"Medefil, Inc.","Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)",Reverified,8/15/25,Available,,,,Other,Current,,,64253-020-30,available
15310,Sterile Water Injection,"Hospira, Inc., a Pfizer Company","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Revised,8/15/25,Limited Availability,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,Other,Other,Current,,,0409-3977-03,limited availability
15311,Sterile Water Injection,"Fresenius Kabi USA, LLC","Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Reverified,9/2/25,Available,Check wholesalers for inventory,,,Other,Current,,,63323-178-76,available
15312,Sterile Water Injection,Nephron Pharmaceuticals Corporation,"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)",Reverified,7/2/25,Unavailable,Product can be manufactured as requested,,Other,Other,Current,,,0487-6105-01,not available
15313,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Reverified,8/20/25,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6139-22,not available
15314,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-6139-03,limited availability
15315,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7139-09,limited availability
15316,Sterile Water Irrigant,Otsuka ICU Medical LLC,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Reverified,8/20/25,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,Other,Gastroenterology; Other; Pediatric,Current,,,0990-7139-36,limited availability
15317,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0004-02,available
15318,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0004-03,available
15319,Sterile Water Irrigant,Baxter Healthcare,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Reverified,9/3/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0338-0004-04,available
15320,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Reverified,8/21/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-2101-10,available
15321,Sterile Water Irrigant,B. Braun Medical Inc.,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Reverified,8/21/25,Available,,,,Gastroenterology; Other; Pediatric,Current,,,0264-2101-00,available
15322,"Streptozocin Powder, For Solution","ESTEVE PHARMACEUTICALS, S.A.","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)",Revised,6/30/25,Available,,,,Oncology,Current,,,68118-100-01,available
15323,"Streptozocin Powder, For Solution","Teva Pharmaceuticals USA, Inc.","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)",Revised,8/19/25,Unavailable,Estimated recovery: TBD,,Other,Oncology,Current,,,0703-4636-01,not available
15324,Sufentanil Citrate Injection,"Hospira, Inc., a Pfizer Company","Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)",Revised,8/15/25,Available,,,,Analgesia/Addiction; Pediatric,Current,,,0409-3382-21,available
15325,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)",Reverified,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,17478-050-01,not available
15326,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)",Revised,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,17478-050-02,not available
15327,Sufentanil Citrate Injection,"Hikma Pharmaceuticals USA, Inc.","Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)",Revised,7/23/25,Unavailable,Not currently manufactured,,Other,Analgesia/Addiction; Pediatric,Current,,,17478-050-05,not available
15328,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .25 mg (NDC 0069-0296-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0353-30",,,Oncology,To Be Discontinued,,1/13/25,0069-0296-30,discontinued
15329,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .1 mg (NDC 0069-1031-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0252-30",,,Oncology,To Be Discontinued,,1/13/25,0069-1031-30,discontinued
15330,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, 1 mg (NDC 0069-1195-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0757-30",,,Oncology,To Be Discontinued,,1/13/25,0069-1195-30,discontinued
15331,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .35 mg (NDC 0069-1235-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0454-30",,,Oncology,To Be Discontinued,,1/13/25,0069-1235-30,discontinued
15332,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .5 mg (NDC 0069-1501-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0546-30",,,Oncology,To Be Discontinued,,1/13/25,0069-1501-30,discontinued
15333,Talazoparib Tosylate Capsule,Pfizer Inc.,"Talzenna, Capsule, .75 mg (NDC 0069-1751-30)",New,1/13/25,,"Supply expected to exhaust late February 2025

Replaced with Soft Gel NDC 0069-0655-30",,,Oncology,To Be Discontinued,,1/13/25,0069-1751-30,discontinued
15334,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-01)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25,0781-2076-01,discontinued
15335,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-10)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25,0781-2076-10,discontinued
15336,Tamsulosin Hydrochloride Capsule,Sandoz Inc.,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-92)",New,4/10/25,,,,,Urology,To Be Discontinued,,4/10/25,0781-2076-92,discontinued
15337,Tbo-filgrastim Injection,"Cephalon, LLC","Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)",New,6/13/25,,,,,Hematology,To Be Discontinued,,6/13/25,63459-920-59,discontinued
15338,Technetium TC-99M Pyrophosphate Kit Injection,Curium US LLC,"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)",Reverified,9/2/25,Unavailable,Unavailable,,Shortage of an active ingredient,Medical Imaging,Current,,,69945-094-20,not available
15339,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)",Revised,8/20/25,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,,45567-0060-1,limited availability
15340,Technetium TC-99M Pyrophosphate Kit Injection,"Sun Pharmaceutical Industries, Inc.","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)",Revised,8/20/25,Limited Availability,Additional supply anticipated early 2026,,Shortage of an active ingredient,Medical Imaging,Current,,,45567-0060-2,limited availability
15341,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 20 mg (NDC 0597-0039-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24,0597-0039-37,discontinued
15342,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 40 mg (NDC 0597-0040-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24,0597-0040-37,discontinued
15343,Telmisartan Tablet,"Boehringer Ingelheim Pharmaceuticals, Inc.","Micardis, Tablet, 80 mg (NDC 0597-0041-37)",New,10/22/24,,Discontinued for business reasons,,,Cardiovascular,To Be Discontinued,,10/22/24,0597-0041-37,discontinued
15344,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 7 mg (NDC 60505-4477-3)",New,1/28/25,,,,,Neurology,To Be Discontinued,,1/28/25,60505-4477-3,discontinued
15345,Teriflunomide Tablet,Apotex Corp.,"Teriflunomide, Tablet, 14 mg (NDC 60505-4478-3)",New,1/28/25,,,,,Neurology,To Be Discontinued,,1/28/25,60505-4478-3,discontinued
15346,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0009-0086-10)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24,0009-0086-10,discontinued
15347,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-02)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24,0409-6562-02,discontinued
15348,Testosterone Cypionate Injection,Pfizer Inc.,"Depo-Testosterone, Injection, 200 mg/1 mL (NDC 0409-6562-22)",New,9/25/24,,,,,Endocrinology/Metabolism,To Be Discontinued,,9/25/24,0409-6562-22,discontinued
15349,"Testosterone Gel; Gel, Metered","Actavis Pharma, Inc.","Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Urology,To Be Discontinued,,6/16/25,0591-2925-30,discontinued
15350,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-83)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24,62756-200-83,discontinued
15351,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-18)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/5/24,62756-200-18,discontinued
15352,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-83)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24,62756-224-83,discontinued
15353,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-88)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24,62756-224-88,discontinued
15354,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-08)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24,62756-224-08,discontinued
15355,Tiagabine Hydrochloride Tablet,Sun Pharmaceutical Industries Limited,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-18)",New,12/9/24,,Discontinuing for business reasons,,,Neurology,To Be Discontinued,,12/9/24,62756-224-18,discontinued
15356,Tigecycline Injection,"Fresenius Kabi USA, LLC","Injection, 50 mg/5 mL (NDC 63323-960-10)",New,12/9/24,,Check wholesalers for inventory.,,,Anti-Infective,To Be Discontinued,,12/9/24,63323-960-10,discontinued
15357,Tigecycline Injection,Sandoz Inc.,"Tigecycline, Injection, 50 mg/10 mL (NDC 0781-3481-92)",New,1/17/25,,,,,Anti-Infective,To Be Discontinued,,1/17/25,0781-3481-92,discontinued
15358,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25,0093-3750-28,discontinued
15359,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25,0093-3750-63,discontinued
15360,Tobramycin Solution,"Teva Pharmaceuticals USA, Inc.","Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)",New,6/16/25,,Discontinuation of the manufacture of the drug,,,Pulmonary/Allergy,To Be Discontinued,,6/16/25,0093-4085-63,discontinued
15361,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-77)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-103-77,discontinued
15362,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-93)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-103-93,discontinued
15363,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-77)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-104-77,discontinued
15364,"Tolterodine Tartrate Capsule, Extended Release","Mylan Pharmaceuticals Inc., a Viatris Company","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-93)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-104-93,discontinued
15365,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 1 mg (NDC 58151-098-91)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-098-91,discontinued
15366,Tolterodine Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Detrol, Tablet, 2 mg (NDC 58151-099-91)",New,2/26/25,,,,,Urology,To Be Discontinued,,2/26/25,58151-099-91,discontinued
15367,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 25 mg (NDC 0245-1071-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25,0245-1071-30,discontinued
15368,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25,0245-1072-30,discontinued
15369,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 200 mg (NDC 0245-1073-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25,0245-1073-30,discontinued
15370,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 100 mg (NDC 0245-1074-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25,0245-1074-30,discontinued
15371,"Topiramate Capsule, Extended Release","Upsher-Smith Laboratories, LLC","Qudexy XR, Capsule, Extended Release, 150 mg (NDC 0245-1075-30)",New,4/24/25,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,,Neurology,To Be Discontinued,,4/24/25,0245-1075-30,discontinued
15372,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 2.5 mL (NDC 0781-6185-56)",New,3/18/25,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/25,0781-6185-56,discontinued
15373,Travoprost Solution/Drops,Sandoz Inc.,"Travatan Z, Solution/Drops, 5 mL (NDC 0781-6185-75)",New,3/18/25,,Business related decision to discontinue the product,,,Ophthalmology,To Be Discontinued,,3/18/25,0781-6185-75,discontinued
15374,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-20)",New,2/4/25,,,,,Dermatology,To Be Discontinued,,2/4/25,0472-0117-20,discontinued
15375,Tretinoin Cream,"Mylan Pharmaceuticals Inc., a Viatris Company","Avita, Cream, .25 mg/1 g (NDC 0472-0117-45)",New,2/4/25,,,,,Dermatology,To Be Discontinued,,2/4/25,0472-0117-45,discontinued
15376,Triamcinolone Acetonide Injection,"Harrow Eye, LLC","Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)",Reverified,6/27/25,Limited Availability,Estimated duration: 12 months,,Requirements related to complying with good manufacturing practices,Ophthalmology,Current,,,82667-800-01,limited availability
15377,Triamcinolone Hexacetonide Injection,Medexus,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Reverified,6/27/25,Unavailable,,,Delay in shipping of the drug,Rheumatology,Current,,,59137-570-01,not available
15378,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",New,3/28/25,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/25,0591-2998-01,discontinued
15379,Ursodiol Tablet,"Teva Pharmaceuticals USA, Inc.","Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",New,3/28/25,,A business decision was made to discontinue manufacture of the drug.,,,Other,To Be Discontinued,,3/28/25,0591-3005-01,discontinued
15380,Valproate Sodium Injection,"Hikma Pharmaceuticals USA, Inc.","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Revised,7/23/25,Unavailable,Additional Lots scheduled to be available in the October 2025 timeframe.,,Demand increase for the drug,Neurology,Current,,,0143-9785-10,not available
15381,Valproate Sodium Injection,"Fresenius Kabi USA, LLC","Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)",Reverified,9/2/25,Available,Checkwholesalers for inventory,,,Neurology,Current,,,63323-494-05,available
15382,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, .5 mg (NDC 0378-5089-73)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25,0378-5089-73,discontinued
15383,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 1 mg (NDC 0378-5090-73)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25,0378-5090-73,discontinued
15384,Varenicline Tartrate Tablet,"Mylan Pharmaceuticals Inc., a Viatris Company","Varenicline Tartrate, Tablet, 0.5mg/1mg  (NDC 0378-5091-85)",New,2/6/25,,Permanent discontinuation in the manufacturing of the drug,,,Analgesia/Addiction,To Be Discontinued,,2/6/25,0378-5091-85,discontinued
15385,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 120 mg (NDC 0591-2880-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25,0591-2880-01,discontinued
15386,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 180 mg (NDC 0591-2882-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25,0591-2882-01,discontinued
15387,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 240 mg (NDC 0591-2884-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25,0591-2884-01,discontinued
15388,"Verapamil Hydrochloride Capsule, Extended Release","Teva Pharmaceuticals USA, Inc.","Verelan, Capsule, Extended Release, 360 mg (NDC 0591-2886-01)",New,1/23/25,,,,,Cardiovascular,To Be Discontinued,,1/23/25,0591-2886-01,discontinued
15389,Voriconazole Tablet,Pfizer Inc.,"Vfend, Tablet, 50 mg (NDC 0049-3170-30)",New,7/28/25,,Discontinuation of the manufacture of the drug,,,Anti-Infective,To Be Discontinued,,7/28/25,0049-3170-30,discontinued
15390,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 500 mg (NDC 72786-101-01)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24,72786-101-01,discontinued
15391,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-02)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24,72786-102-02,discontinued
15392,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-102-03)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24,72786-102-03,discontinued
15393,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-03)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24,72786-111-03,discontinued
15394,Voxelotor Tablet,Pfizer Inc.,"Oxbryta, Tablet, 300 mg (NDC 72786-111-02)",New,9/27/24,,,,,Hematology,To Be Discontinued,,9/27/24,72786-111-02,discontinued
15395,Zileuton Tablet,"Chiesi USA, Inc.","Zyflo, Tablet, 600 mg (NDC 10122-901-12)",New,4/1/25,,,,,Pulmonary/Allergy,To Be Discontinued,,4/1/25,10122-901-12,discontinued
